,Unnamed: 0,Patient ID,Prompts,Outcome,Prognosis
0,0,P0001,"Age: 58
Gender: Male 
Weight: 83 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 110/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 42,4
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,4
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,36
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1834.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,02
Urea (mg/dL): 7,12
LVEF (%): 35.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 58-year-old male with a history of idiopathic dilated cardiomyopathy, a condition characterized by a weakened heart muscle leading to decreased left ventricular ejection fraction (LVEF). The patient's current LVEF of 35% indicates a significant impairment of the heart's pumping ability. 

The patient's NYHA Class III classification indicates that he experiences symptoms of heart failure with moderate limitation in physical activity. The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG suggests an increased risk of sudden cardiac death. However, the patient's overall condition does not indicate an immediate risk of life-threatening arrhythmias.

The patient is on a regimen of beta blockers, digoxin, loop diuretics, and an ACE inhibitor, which are standard treatments for heart failure and arrhythmias. These medications help manage symptoms, improve heart function, and reduce the risk of arrhythmias.

The patient's laboratory results, including normal liver enzymes (ALT and AST), normal kidney function (creatinine and urea), and normal electrolyte levels (potassium and sodium), suggest that the patient does not have any acute liver or kidney damage. The low T3 and normal T4 levels indicate that the patient does not have hyperthyroidism, which can exacerbate heart failure.

The patient's high Pro-BNP level (1834.0 ng/L) is indicative of heart failure, but the patient's symptoms and ECG findings do not suggest an acute decompensation of heart failure. The patient's hemoglobin level is within the normal range, and the patient's glucose level is slightly elevated but not indicative of diabetes mellitus.

Given the patient's overall clinical picture, it appears that the patient is being effectively managed for his heart failure and arrhythmias. The patient's medications are likely helping to control symptoms and prevent complications, and the patient is able to survive with a reduced LVEF."
1,1,P0002,"Age: 58
Gender: Male 
Weight: 74 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 40,4
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 6,18
Creatinine (mmol/L): 121.0
Gamma-glutamil transpeptidase (IU/L): 44
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 126.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,6
LDL (mmol/L): 4,06
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 570.0
Protein (g/L): 75
T3 (pg/dL): 0,04
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,27
Urea (mg/dL): 10,47
LVEF (%): 35.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 58-year-old male with a history of ischemic dilated cardiomyopathy, dyslipemia, and myocardial infarction. Despite these significant cardiac conditions, the patient has been receiving optimal medical management with Angiotensin II Receptor Blocker, Beta Blockers, and Statins. 

The patient's LVEF (Left Ventricular Ejection Fraction) is 35%, which is significantly reduced, indicating a compromised cardiac function. However, the patient's Pro-BNP (Brain Natriuretic Peptide) level is elevated at 570.0 ng/L, which suggests that the patient's heart is experiencing increased stress and pressure, but this is not uncommon in patients with reduced LVEF. 

The patient's creatinine level is slightly elevated at 121.0 mmol/L, which may indicate some degree of kidney impairment, but it is not severe enough to be a major concern. The patient's potassium level is within the normal range, and the hemoglobin level is slightly elevated, which is not uncommon in patients with heart failure.

The patient's TSH level is within the normal range, indicating that the thyroid function is not contributing to the cardiac condition. The T3 and T4 levels are also within the normal range, which rules out hypothyroidism as a contributing factor.

The patient's ECG shows a monomorphic ventricular extrasystole, which is a common finding in patients with cardiomyopathy. However, there is no evidence of sustained ventricular tachycardia or other serious arrhythmias.

Considering the patient's age, medical history, and the current laboratory results, it is likely that the patient's cardiac condition is stable and manageable with ongoing medical therapy. The patient's ability to survive despite these significant cardiac conditions suggests that the treatment plan is effective in controlling the disease progression. Therefore, the patient outcome is survivor."
2,2,P0003,"Age: 69
Gender: Male 
Weight: 83 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 100/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40,1
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 5,3
Creatinine (mmol/L): 87.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 132.0
HDL (mmol/L): 2,04
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,97
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 403.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,93
Urea (mg/dL): 10,02
LVEF (%): 39.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient's age of 69 and NYHA Class II classification indicate that he has mild to moderate heart failure symptoms, which is manageable with medication. The patient's current medications, including Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, and Loop Diuretics, are standard treatments for heart failure and idiopathic dilated cardiomyopathy. 

The patient's LVEF (Left Ventricular Ejection Fraction) of 39% is below the normal range, indicating left ventricular dysfunction, which is consistent with his diagnosis of idiopathic dilated cardiomyopathy. However, his Pro-BNP level of 403 ng/L is elevated, which suggests that he has some degree of heart failure, but it is not severe.

The patient's ECG findings of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia indicate that he has some degree of arrhythmia, but it is not life-threatening. The absence of sustained ventricular tachycardia and the fact that the patient is still alive suggest that his heart function is stable, and he is not in immediate danger.

The patient's laboratory results, including normal liver enzymes, normal kidney function, and normal electrolytes, indicate that he does not have any other underlying conditions that could contribute to his heart failure. His low T3 level and normal T4 level suggest that he does not have hypothyroidism, which is a common cause of heart failure.

Overall, the patient's stable medication regimen, manageable heart failure symptoms, and absence of life-threatening arrhythmias suggest that he is likely to survive with proper medical management."
3,3,P0004,"Age: 56
Gender: Female 
Weight: 84 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 155/75 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 40,9
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 6,21
Creatinine (mmol/L): 77.0
Gamma-glutamil transpeptidase (IU/L): 37
Glucose (mmol/L): 17,8
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,49
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 695.0
Protein (g/L): 72
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,07
Urea (mg/dL): 8,91
LVEF (%): 38.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient's outcome is a survivor, which is a positive outcome given the patient's severe underlying conditions. The patient has a history of Hypertensive cardiomyopathy, which is a condition where the heart muscle becomes weakened and enlarged due to high blood pressure, leading to reduced heart function. The patient's Left Ventricular Ejection Fraction (LVEF) of 38% is below the normal range (50-70%), indicating reduced heart function.

The patient's blood pressure is elevated at 155/75 mmHg, and the patient is on medications such as Angiotensin II Receptor Blocker, Beta Blockers, and Loop Diuretics, which are commonly used to manage hypertension and heart failure.

The patient's Pro-BNP level of 695.0 ng/L is elevated, which is a biomarker for heart failure. However, the patient's Troponin level is within normal limits, indicating that there is no acute myocardial infarction.

The patient's ECG shows ventricular extrasystole, but no sustained ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia. The presence of ventricular extrasystole may be a sign of underlying cardiac disease, but it is not an immediate life-threatening condition.

Given the patient's severe underlying conditions, including heart failure and hypertension, the patient's survival can be attributed to the effective management of their medications and the absence of acute cardiac events such as myocardial infarction. The patient's outcome is a testament to the importance of ongoing medical management and monitoring of patients with severe cardiac conditions."
4,4,P0005,"Age: 70
Gender: Male 
Weight: 97 kg
Height: 183 cm
NYHA Class: II
Blood Pressure: 125/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 45,3
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,72
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 7,8
Hemoglobin (g/L): 159.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,28
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 456.0
Protein (g/L): 82
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,01
Urea (mg/dL): 10,91
LVEF (%): 34.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient, a 70-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction, has been managed with a comprehensive medication regimen, including beta blockers, loop diuretics, statins, ACE inhibitors, and nitrovasodilators. His current medications likely aim to control his heart failure symptoms, manage his blood pressure, and reduce his risk of further cardiovascular events.

The patient's left ventricular ejection fraction (LVEF) is 34%, indicating severe left ventricular dysfunction. However, the patient's New York Heart Association (NYHA) class is II, suggesting that he is experiencing some limitations in physical activity but is still able to perform daily tasks without significant symptoms. This discrepancy between LVEF and NYHA class may indicate that the patient has adapted to his condition over time or has developed compensatory mechanisms to maintain a relatively stable clinical status.

The patient's biomarkers, including troponin, pro-BNP, and TSH, are within relatively normal ranges, indicating that there is no acute myocardial infarction, heart failure exacerbation, or thyroid dysfunction. The patient's lipid profile is also well-controlled, with an LDL level of 3.28 mmol/L, which is below the target for secondary prevention of cardiovascular disease.

The patient's creatinine level is slightly elevated at 88.0 μmol/L, which may indicate some degree of renal impairment. However, the patient's urea level is within a relatively normal range, and his potassium level is not significantly abnormal. These findings suggest that the patient's renal function is not severely compromised.

The patient's albumin level is slightly low at 45.3 g/L, which may indicate some degree of malnutrition or liver dysfunction. However, the patient's AST and ALT levels are within relatively normal ranges, suggesting that liver function is not significantly impaired.

In summary, the patient's outcome as a survivor is likely due to the effective management of his underlying conditions, including his heart failure, diabetes, and dyslipemia, as well as his adaptation to his condition over time. The patient's relatively stable clinical status, well-controlled biomarkers, and lack of acute complications all contribute to his favorable outcome."
5,5,P0006,"Age: 70
Gender: Male 
Weight: 83 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 105/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 44,1
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,8
LDL (mmol/L): 3
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 3437.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,88
Urea (mg/dL): 8,46
LVEF (%): 34.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type I
            ",survivor,"REASONING: The patient is a 70-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, and myocardial infarction. He has a low left ventricular ejection fraction (LVEF) of 34%, indicating reduced cardiac function. However, despite these risk factors, the patient's blood pressure is well-controlled at 105/75 mmHg, and his creatinine levels are slightly elevated but not severely so (101.0 mmol/L).

The patient's medication regimen, including beta blockers, loop diuretics, spironolactone, ACE inhibitor, and nitrovasodilator, suggests that he is receiving appropriate management for heart failure and hypertension. The presence of spironolactone, an aldosterone antagonist, also indicates that the patient is at risk for heart failure with reduced ejection fraction (HFrEF).

The elevated Pro-BNP level (3437.0 ng/L) is consistent with heart failure, but the patient's overall clinical presentation and medication regimen suggest that his condition is being managed.

The patient's ECG shows a second-degree AV block, type I, which can be a complication of his heart failure and may require further monitoring but is not an immediate cause for concern.

Given the patient's age, comorbidities, and medication regimen, it is not surprising that he has survived. The combination of medications and the absence of severe complications such as ventricular tachycardia or bradycardia suggest that the patient is receiving effective care for his condition."
6,6,P0007,"Age: 52
Gender: Male 
Weight: 71 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 125/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 49,69
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 34.0
Total Cholesterol (mmol/L): 5,79
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 90
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 4
LDL (mmol/L): 3,83
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 140.0
Protein (g/L): 73
T3 (pg/dL): 0,06
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,979
Urea (mg/dL): 7,8
LVEF (%): 39.0
Medications: Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient, a 52-year-old male with a history of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipemia, presented with a reduced left ventricular ejection fraction (LVEF) of 39%, indicating impaired heart function. The patient's current medications, beta blockers and statins, are standard treatments for heart failure and dyslipidemia, respectively.

The patient's laboratory results show elevated levels of troponin (0.01 ng/mL), indicating minimal myocardial damage, but still within a relatively normal range. The patient's creatinine level of 97.0 mmol/L is within the normal range, suggesting that kidney function is not significantly impaired at this time. The patient's pro-BNP level of 140.0 ng/L is elevated, indicating increased ventricular wall stress, but not at a level that would suggest severe heart failure.

The patient's ECG shows non-sustained ventricular tachycardia, which is a common finding in patients with heart failure. However, the absence of sustained ventricular tachycardia, paroxysmal supraventricular tachyarrhythmia, and bradycardia suggests that the patient's heart rhythm is generally stable.

Given the patient's current clinical status, medications, and laboratory results, the patient's outcome of survival is likely due to the following factors:

1. Effective medical management: The patient is on standard medications for heart failure and dyslipidemia, which have helped to stabilize his condition.
2. Mild disease severity: The patient's LVEF is reduced, but not severely so, and his troponin levels are within a relatively normal range.
3. Absence of severe complications: The patient does not have severe kidney dysfunction, electrolyte imbalances, or other complications that would increase his risk of mortality.
4. Stable heart rhythm: The patient's ECG shows no signs of sustained ventricular tachycardia, paroxysmal supraventricular tachyarrhythmia, or bradycardia, suggesting that his heart rhythm is generally stable.

Overall, the combination of effective medical management, mild disease severity, absence of severe complications, and stable heart rhythm likely contributed to the patient's outcome of survival."
7,7,P0009,"Age: 64
Gender: Female 
Weight: 68 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 160/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 41,4
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,53
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 7,2
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,44
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 211.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,88
Urea (mg/dL): 7,8
LVEF (%): 24.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient's outcome of survival can be attributed to a combination of factors, including:

1.  Optimal medical management: The patient is on a comprehensive treatment regimen consisting of medications for diabetes, hypertension, heart failure (Beta Blockers, ACE Inhibitor, Loop Diuretics), and dyslipidemia (Statins). These medications are crucial in managing the underlying conditions that contributed to the patient's ischemic dilated cardiomyopathy.

2.  Early detection and monitoring: The patient's Pro-BNP level is elevated at 211.0 ng/L, indicating heart failure, but the Troponin level is low at 0.01 ng/mL, suggesting minimal cardiac damage. This suggests that the patient's condition is being closely monitored, and the treatment plan is adjusted accordingly.

3.  Close blood pressure control: The patient's blood pressure is well-managed at 160/70 mmHg, which is relatively low for someone with hypertension. This is crucial in reducing the strain on the heart and preventing further cardiac damage.

4.  Regular monitoring of cardiac function: The patient's LVEF (Left Ventricular Ejection Fraction) is 24.0%, indicating severely reduced cardiac function. However, the patient is still alive, suggesting that the treatment plan is effective in slowing down the progression of the disease.

5.  Supportive care: The patient's electrolyte levels, including potassium and sodium, are within normal limits, which is essential for maintaining proper cardiac function.

6.  Nutritional status: The patient's albumin level is 41.4 g/L, which is within the normal range, indicating adequate nutrition and hydration.

7.  Absence of acute cardiac events: The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia on the ECG suggests that the patient is not experiencing any acute cardiac events that could compromise their survival.

In conclusion, the patient's survival can be attributed to a combination of optimal medical management, early detection and monitoring, close blood pressure control, regular monitoring of cardiac function, supportive care, nutritional status, and the absence of acute cardiac events."
8,8,P0010,"Age: 54
Gender: Male 
Weight: 88 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 38,7
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 89.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 3,9
LDL (mmol/L): 3,26
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 361.0
Protein (g/L): 71
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,02
Urea (mg/dL): 7,57
LVEF (%): 22.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 54-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and a previous myocardial infarction. Despite these significant risk factors and a severely reduced left ventricular ejection fraction (LVEF) of 22%, the patient survived. 

Several factors contributed to this outcome:

1. Current medications: The patient is on beta blockers and an ACE inhibitor, which are standard treatments for heart failure and hypertension. These medications likely helped to reduce the patient's heart rate, lower blood pressure, and decrease the strain on the heart, contributing to his survival.

2. Stable vital signs: The patient's blood pressure is 140/90 mmHg, which is within a relatively normal range, considering his age and medical history. This suggests that his blood pressure is being adequately controlled, reducing the strain on the heart.

3. Lack of severe electrolyte imbalance: The patient's potassium level is 3.9 mEq/L, which is within a relatively normal range. Potassium imbalances can lead to arrhythmias and cardiac arrest, so the patient's stable potassium levels likely contributed to his survival.

4. Low troponin levels: The patient's troponin level is 0.01 ng/mL, which is within a normal range. Elevated troponin levels indicate cardiac damage, so the patient's low troponin levels suggest that he did not experience significant cardiac damage during the current episode.

5. Reasonable renal function: The patient's creatinine level is 89.0 μmol/L, which is within a relatively normal range, considering his age and medical history. Adequate renal function is essential for eliminating waste products and maintaining electrolyte balance, which contributed to the patient's survival.

6. No evidence of severe anemia: The patient's hemoglobin level is 142 g/L, which is within a relatively normal range. Anemia can lead to reduced oxygen delivery to the heart, exacerbating cardiac dysfunction.

7. Thyroid function within normal limits: The patient's TSH level is 2.02 mIU/L, which is within a normal range. Thyroid dysfunction can affect cardiac function, and the patient's normal TSH levels suggest that his thyroid function is not contributing to his cardiac condition.

8. No signs of severe liver dysfunction: The patient's albumin and liver enzyme levels are within relatively normal ranges, indicating that his liver function is not significantly impaired.

9. No evidence of severe respiratory distress: The patient's oxygenation status is not mentioned, but the lack of severe respiratory distress or hypoxia likely contributed to his survival.

10. Non-sustained ventricular tachycardia: The patient's ECG shows non-sustained ventricular tachycardia, but this is a common finding in patients with heart failure and is not typically a life-threatening condition.

In summary, the patient's survival can be attributed to a combination of his current medications, stable vital signs, lack of severe electrolyte imbalance, low troponin levels, reasonable renal function, no evidence of severe anemia, normal thyroid function, no signs of severe liver dysfunction, and no evidence of severe respiratory distress."
9,9,P0013,"Age: 71
Gender: Female 
Weight: 70 kg
Height: 152 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension
Albumin (g/L): 41,4
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 118.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4
LDL (mmol/L): 2,56
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 653.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,53
Urea (mg/dL): 9,8
LVEF (%): 39.0
Medications: Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient is a 71-year-old female with a history of ischemic dilated cardiomyopathy and hypertension. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 39%, indicating systolic heart failure. The elevated Pro-BNP (brain natriuretic peptide) level of 653.0 ng/L also supports the diagnosis of heart failure.

Despite the patient's history and reduced LVEF, the patient is on appropriate medical therapy, including beta blockers, statins, ACE inhibitors, and nitrovasodilators. These medications are standard treatments for heart failure and ischemic cardiomyopathy, and their use suggests that the patient is receiving evidence-based care.

The patient's blood pressure is within a relatively normal range (140/80 mmHg), which is a good indicator of blood pressure control. The patient's lipid profile is also relatively well-managed, with a total cholesterol of 4.29 mmol/L and an LDL of 2.56 mmol/L.

The patient's kidney function is also relatively preserved, with a creatinine level of 80.0 umol/L. This suggests that the patient's kidney function is not significantly impaired, which is a good prognostic sign.

The patient's ECG shows polymorphic ventricular extrasystoles, but no sustained ventricular tachycardia or other significant arrhythmias. This finding is not uncommon in patients with heart failure and may not necessarily impact the patient's outcome.

The patient's hemoglobin level is slightly low at 118 g/L, but this is not significantly low and may not be a major concern. The patient's electrolyte levels are also within a relatively normal range.

Overall, the patient's treatment regimen, blood pressure control, and preserved kidney function suggest that the patient is receiving appropriate care for their heart failure and ischemic cardiomyopathy. The patient's outcome of survivorship is likely due to the combination of their medical therapy, relatively well-managed blood pressure and lipid profile, and preserved kidney function."
10,10,P0014,"Age: 50
Gender: Male 
Weight: 51 kg
Height: 164 cm
NYHA Class: III
Blood Pressure: 90/60 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Peripheral vascular disease
Albumin (g/L): 42
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4
LDL (mmol/L): 3,23
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 577.0
Protein (g/L): 64
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,77
Urea (mg/dL): 8,69
LVEF (%): 22.0
Medications: Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient's outcome of survival can be attributed to several factors based on the provided data. 

1. Optimal Medication Management: The patient is taking Spironolactone and an ACE Inhibitor, which are commonly used to manage heart failure and reduce mortality in patients with heart failure. These medications are likely contributing to the patient's survival.

2. LVEF of 22%: Although the patient has a low left ventricular ejection fraction (LVEF), which indicates significant left ventricular dysfunction, the patient has managed to survive. This suggests that the patient's heart is still functioning to some extent, allowing for sufficient blood circulation and oxygenation of vital organs.

3. No evidence of severe electrolyte imbalance: The patient's potassium levels are within the normal range (4 mEq/L), which is crucial for maintaining proper cardiac function. Severe electrolyte imbalances, particularly hyperkalemia or hypokalemia, can be life-threatening and contribute to cardiac arrhythmias and sudden death.

4. Normal glucose levels: The patient's glucose level is within the normal range (4.2 mmol/L), which is essential for maintaining proper cardiac function and overall health. Hyperglycemia or hypoglycemia can have adverse effects on the heart and contribute to poor outcomes.

5. No evidence of acute coronary syndrome: The patient's troponin level is within the normal range (0.01 ng/mL), indicating that there is no acute myocardial infarction or cardiac damage.

6. Mildly elevated BNP: The patient's B-type natriuretic peptide (BNP) level is elevated at 577.0 ng/L, which is consistent with heart failure. However, the level is not excessively high, suggesting that the patient's heart is not under extreme stress.

7. Normal TSH and T3/T4 levels: The patient's thyroid function is within the normal range, which is essential for maintaining proper cardiac function and overall health.

Considering these factors, the patient's survival is likely due to a combination of optimal medication management, a low but functional LVEF, absence of severe electrolyte imbalances, normal glucose levels, no evidence of acute coronary syndrome, mildly elevated BNP, and normal thyroid function."
11,11,P0015,"Age: 40
Gender: Male 
Weight: 98 kg
Height: 180 cm
NYHA Class: III
Blood Pressure: 100/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 39
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 6,13
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 179.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,93
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 670.0
Protein (g/L): 69
T3 (pg/dL): 0,06
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,83
Urea (mg/dL): 3,79
LVEF (%): 20.0
Medications: Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 40-year-old male with a history of idiopathic dilated cardiomyopathy, which is a condition where the heart's left ventricle becomes enlarged and weakened, reducing its ability to pump blood effectively. The patient's left ventricular ejection fraction (LVEF) is 20.0%, which is significantly below the normal range of 50-70%, indicating severe heart failure.

The patient's blood work shows elevated levels of troponin (0.01 ng/mL), which is a biomarker of cardiac injury. However, this level is not extremely high, suggesting that the patient has not experienced a recent acute myocardial infarction. The elevated Pro-BNP (670.0 ng/L) level indicates that the patient is experiencing heart failure, and the elevated creatinine (88.0 umol/L) level suggests that the patient's kidneys are being affected by the heart failure.

The patient is taking a combination of medications, including digoxin, loop diuretics, spironolactone, statins, and an ACE inhibitor, which are all standard treatments for heart failure. The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG suggests that the patient has arrhythmias, which are common in patients with heart failure.

Despite the severity of the patient's condition, the fact that the patient is a survivor suggests that the patient has been receiving effective treatment and has a good response to therapy. The patient's LVEF is still quite low, but it is not as low as it could be, and the patient's creatinine level is not extremely high, indicating that the patient's kidneys are not being severely affected.

It is likely that the patient's survival is due to the combination of his medications, a relatively low level of troponin, and the fact that the patient has not experienced a recent acute myocardial infarction. The patient's survival is a testament to the effectiveness of modern heart failure treatment and the importance of ongoing medical management and monitoring for patients with heart failure."
12,12,P0017,"Age: 58
Gender: Female 
Weight: 89 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43,8
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,54
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 161.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,9
LDL (mmol/L): 4,09
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1108.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,14
Urea (mg/dL): 8,02
LVEF (%): 21.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 58-year-old female with a history of ischemic dilated cardiomyopathy, dyslipemia, hypertension, and myocardial infarction, has been prescribed a comprehensive medication regimen including amiodarone, an angiotensin II receptor blocker, beta blockers, statins, and a nitrovasodilator. 

The patient's laboratory results show a low LVEF of 21%, indicating severely reduced left ventricular function, which is consistent with her ischemic dilated cardiomyopathy. However, her blood pressure is well-controlled at 110/80 mmHg, and her electrolyte levels are within normal limits, which is crucial in managing heart failure.

The patient's Pro-BNP level of 1108 ng/L is elevated, which is indicative of heart failure. However, her troponin level is within normal limits, suggesting that there is no ongoing myocardial infarction. Her TSH level is within the normal range, and her thyroid function is well-managed.

The patient's medication regimen is aimed at reducing the risk of sudden cardiac death, managing heart failure symptoms, and controlling blood pressure. The beta blockers and angiotensin II receptor blocker are used to reduce the workload on the heart, while the statins help to manage dyslipemia. The nitrovasodilator is used to reduce blood pressure and improve cardiac output.

Given the patient's comprehensive treatment plan and the absence of any acute cardiac events, the patient is able to survive with a relatively stable condition."
13,13,P0019,"Age: 74
Gender: Male 
Weight: 95 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 46,3
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 6,08
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 48
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 160.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 3,8
LDL (mmol/L): 3,88
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1596.0
Protein (g/L): 80
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,99
Urea (mg/dL): 7,8
LVEF (%): 50.0
Medications: Calcium Channel Blocker, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

This patient, a 74-year-old male, has a complex medical history of hypertensive cardiomyopathy and hypertension, which are likely contributing factors to his current cardiac condition. His low LVEF of 50% indicates reduced left ventricular function, which increases his risk of cardiac complications. The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG suggests underlying cardiac arrhythmias, which may be related to his cardiomyopathy.

The patient's medications, including calcium channel blockers, beta blockers, digoxin, loop diuretics, ACE inhibitors, and nitrovasodilators, are consistent with the management of heart failure and hypertension. The use of these medications suggests that the patient is receiving appropriate treatment for his condition.

The patient's laboratory results, including elevated Pro-BNP (1596.0 ng/L) and normal troponin levels (0.01 ng/mL), indicate that he is experiencing cardiac stress, but not acute myocardial infarction. The slightly elevated gamma-glutamil transpeptidase (48 IU/L) and normal liver enzymes (AST and ALT) suggest that there is no significant liver damage.

The patient's blood work also shows a slightly elevated glucose level (4.9 mmol/L), which may be related to his age and the use of certain medications. His electrolyte levels, including potassium (3.8 mEq/L), are within normal limits.

The patient's TSH level is slightly elevated (2.99 mIU/L), but his T3 and T4 levels are within normal limits. This may indicate subclinical hypothyroidism, which can be a contributing factor to cardiac disease.

The patient's urea level is slightly elevated (7.8 mg/dL), which may be related to his heart failure and reduced renal function.

Considering the patient's complex medical history, his cardiac medications, and the laboratory results, it is likely that he is being managed for heart failure and hypertension. The presence of cardiac arrhythmias and reduced LVEF increases his risk of cardiac complications, but the fact that he is on appropriate medications and has not had an acute myocardial infarction suggests that he is being effectively managed. The patient's outcome of survivor suggests that he is able to tolerate his current treatment regimen and is not experiencing any life-threatening complications at this time."
14,14,P0020,"Age: 48
Gender: Male 
Weight: 77 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 145/80 mmHg
Past Medical History: Post-myocardial dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 45,5
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,44
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 52
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,5
LDL (mmol/L): 4,22
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 322.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,25
Urea (mg/dL): 6,45
LVEF (%): 28.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 48-year-old male with a history of post-myocardial dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and enlarged, leading to poor heart function. The patient's left ventricular ejection fraction (LVEF) is severely reduced at 28%, indicating a significant impairment in heart function.

The patient's medication regimen includes Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, and Loop Diuretics, which are commonly used to manage heart failure and reduce symptoms. The patient's blood pressure is within a relatively normal range, and the absence of significant electrolyte imbalances suggests that the medications are being effective in managing his heart condition.

The patient's laboratory results show elevated levels of Pro-BNP (Brain Natriuretic Peptide), which is a biomarker for heart failure. However, the levels are not extremely high, suggesting that the patient is not in acute heart failure. The patient's glucose, hemoglobin, and electrolyte levels are within normal limits, which suggests that the patient's kidney function is relatively preserved.

The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG indicates some degree of arrhythmia, but the absence of sustained ventricular tachycardia and bradycardia suggests that the patient's heart rhythm is not significantly unstable.

Given the patient's age, sex, and medical history, the patient's survival outcome can be attributed to the effective management of his heart failure symptoms with medication and the absence of significant acute complications. The patient's relatively preserved kidney function and normal electrolyte levels also suggest that his overall condition is stable."
15,15,P0021,"Age: 67
Gender: Female 
Weight: 56 kg
Height: 146 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 38,19
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,11
Creatinine (mmol/L): 72.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 6,4
Hemoglobin (g/L): 121.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 6,1
LDL (mmol/L): 1,06
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 568.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,98
Urea (mg/dL): 5,79
LVEF (%): 36.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient outcome is a survivor due to a combination of factors that suggest a relatively stable and manageable condition, despite the presence of significant comorbidities. 

Firstly, the patient's NYHA Class II classification indicates that the patient has mild to moderate symptoms of heart failure, which is a positive sign. The presence of beta blockers, digoxin, loop diuretics, statins, and ACE inhibitors in the patient's medication list suggests that the patient is receiving appropriate treatment for heart failure and other comorbid conditions such as hypertension and dyslipidemia.

The patient's LVEF (Left Ventricular Ejection Fraction) of 36% is below the normal range, indicating systolic dysfunction, but it is not severely low. The patient's pro-BNP (brain natriuretic peptide) level of 568.0 ng/L is elevated, which is consistent with heart failure, but it is not extremely high, suggesting that the patient's condition is not in an acute decompensated state.

The patient's blood pressure is within a relatively normal range, and the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG suggests that the patient's heart rhythm is relatively stable.

The patient's laboratory results show a slightly elevated glucose level, which is consistent with the patient's diabetes diagnosis. However, the patient's kidney function, as indicated by the creatinine level, is relatively preserved, which suggests that the patient's kidney function is not severely impaired.

The patient's thyroid function, as indicated by the TSH and T4 levels, is within a normal range, which suggests that the patient's thyroid function is not contributing to the patient's heart failure.

Overall, the patient's stable medication regimen, relatively preserved kidney function, and stable heart rhythm, combined with the absence of severe symptoms or laboratory abnormalities, suggest that the patient is a survivor."
16,16,P0022,"Age: 43
Gender: Male 
Weight: 130 kg
Height: 179 cm
NYHA Class: II
Blood Pressure: 140/100 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 46,5
ALT or GPT (IU/L): 100.0
AST or GOT (IU/L): 49.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 83.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,9
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 195.0
Protein (g/L): 75
T3 (pg/dL): 0,03
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,46
Urea (mg/dL): 5,79
LVEF (%): 40.0
Medications: Angiotensin II Receptor Blocker, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient, a 43-year-old male with a history of idiopathic dilated cardiomyopathy and hypertension, has been diagnosed with heart failure (NYHA Class II) and is on medications for angiotensin II receptor blocker and spironolactone. 

The patient's laboratory results show elevated liver enzymes (ALT and AST), which may indicate liver dysfunction or potential side effects of medications. The patient also has elevated creatinine levels (83.0 mmol/L), which suggests impaired kidney function. 

However, the patient's low levels of T3 (0.03 pg/dL) and T4 (13 ng/L) indicate hypothyroidism, which may contribute to his heart failure symptoms. The patient's low HDL (1.22 mmol/L) and high LDL (2.9 mmol/L) levels suggest dyslipidemia, which may also contribute to his heart disease.

The patient's LVEF (40%) is significantly reduced, indicating systolic heart failure. The presence of polymorphic ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG further indicate arrhythmias, which may be contributing to his heart failure symptoms.

Despite these findings, the patient's overall outcome is a survivor, which suggests that his current treatment regimen is effective in managing his symptoms and slowing disease progression. The patient's medications, including the angiotensin II receptor blocker and spironolactone, are likely contributing to his improved outcome by reducing blood pressure, improving cardiac function, and managing fluid overload.

Additionally, the patient's low levels of BNP (195.0 ng/L) suggest that his heart failure is being well-managed, as BNP is a marker of heart failure severity. The patient's hemoglobin level (146.0 g/L) is within the normal range, indicating that his kidney function is not significantly impairing his red blood cell production.

Overall, the patient's outcome is a survivor due to the combination of his treatment regimen, which is effectively managing his heart failure and other comorbidities, and his relatively stable laboratory results, which indicate that his heart function is not deteriorating rapidly."
17,17,P0023,"Age: 76
Gender: Male 
Weight: 73 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 36,6
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 5,87
Creatinine (mmol/L): 136.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,5
LDL (mmol/L): 4,22
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 188.0
Protein (g/L): 65
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,53
Urea (mg/dL): 11,13
LVEF (%): 37.0
Medications: Calcium Channel Blocker, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

Given the patient's profile, the outcome of survival is likely due to a combination of factors:

1.  Optimal Medication Management: The patient is on a Calcium Channel Blocker, ACE Inhibitor, and Nitrovasodilator, which are commonly used to manage heart failure symptoms and reduce the risk of cardiac arrhythmias. These medications have likely helped to control the patient's heart rate and blood pressure, thereby reducing the strain on the heart.

2.  LVEF of 37%: Although the patient's Left Ventricular Ejection Fraction (LVEF) is low, indicating reduced cardiac function, it is not as low as some other cases of idiopathic dilated cardiomyopathy. This relatively preserved LVEF may have contributed to the patient's survival.

3.  Absence of Severe Electrocardiographic Abnormalities: The patient's ECG shows ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia, but these are not severe or life-threatening. The absence of severe ECG abnormalities suggests that the patient's cardiac function is not significantly compromised.

4.  Normal Blood Pressure: The patient's blood pressure is within a relatively normal range (140/80 mmHg), which may indicate that the patient's cardiac function is not significantly impaired by hypertension.

5.  Reasonable Renal Function: The patient's creatinine level is elevated, but not severely so (136.0 mmol/L). This suggests that the patient's kidneys are functioning reasonably well, which is important for overall health and cardiac function.

6.  Limited Metabolic Abnormalities: The patient's glucose, potassium, sodium, and TSH levels are within relatively normal ranges, indicating that the patient's metabolic function is not severely impaired.

7.  Absence of Severe Cardiac Biomarkers: The patient's troponin level is low (0.01 ng/mL), indicating minimal cardiac damage, and the Pro-BNP level is elevated but not severely so (188.0 ng/L), which may indicate some cardiac stress but not severe cardiac dysfunction.

Considering these factors, the patient's survival is likely due to a combination of optimal medication management, relatively preserved LVEF, absence of severe ECG abnormalities, normal blood pressure, reasonable renal function, limited metabolic abnormalities, and absence of severe cardiac biomarkers."
18,18,P0024,"Age: 58
Gender: Male 
Weight: 94 kg
Height: 188 cm
NYHA Class: II
Blood Pressure: 130/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 44,5
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,48
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,37
Potassium (mEq/L): 4
LDL (mmol/L): 3,62
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 492.0
Protein (g/L): 68
T3 (pg/dL): 0,06
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,75
Urea (mg/dL): 7,12
LVEF (%): 37.0
Medications: Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's comprehensive medical history, laboratory results, and ECG findings, the patient's outcome of survival is likely due to a combination of factors. 

The patient's ischemic dilated cardiomyopathy, as indicated by a left ventricular ejection fraction (LVEF) of 37%, suggests significant left ventricular dysfunction. However, the patient is currently on beta blockers and loop diuretics, which are standard treatments for heart failure and may be contributing to the patient's survival. The use of statins to manage dyslipemia is also beneficial in reducing cardiovascular risk.

The patient's blood pressure of 130/75 mmHg is within a relatively normal range, indicating effective blood pressure control. The absence of significant elevation in troponin levels (0.01 ng/mL) and normal potassium levels (4 mEq/L) suggest that the patient is not experiencing acute coronary syndrome or significant electrolyte imbalances.

The patient's Pro-BNP level of 492.0 ng/L is elevated, which is consistent with heart failure, but it is not extremely high. The patient's albumin level of 44.5 g/L is within a relatively normal range, which suggests that the patient does not have significant liver dysfunction.

The patient's TSH level of 2.75 mIU/L is within a normal range, indicating that the patient's thyroid function is not contributing to their cardiac condition.

The presence of polymorphic ventricular extrasystoles on the ECG is a benign finding in this case, as it is not associated with any other concerning cardiac arrhythmias. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia suggests that the patient's heart rhythm is relatively stable.

In conclusion, the patient's survival is likely due to the combination of their ongoing medical treatment, relatively controlled blood pressure, and the absence of acute cardiac complications."
19,19,P0029,"Age: 58
Gender: Male 
Weight: 90 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 45,59
ALT or GPT (IU/L): 45.0
AST or GOT (IU/L): 36.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 176.0
Gamma-glutamil transpeptidase (IU/L): 50
Glucose (mmol/L): 9,1
Hemoglobin (g/L): 157.0
HDL (mmol/L): 0,59
Potassium (mEq/L): 4
LDL (mmol/L): 2,38
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 453.0
Protein (g/L): 72
T3 (pg/dL): 0,05
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 24,3
Urea (mg/dL): 16,03
LVEF (%): 36.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient, a 58-year-old male with a history of hypertensive cardiomyopathy, diabetes, dyslipemia, and hypertension, has a complex medical profile. Despite his comorbidities, the patient has been managed with a comprehensive treatment plan consisting of beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor.

The patient's current hemodynamic status is reflected in his LVEF (Left Ventricular Ejection Fraction) of 36%, which indicates a reduced ejection fraction, a hallmark of heart failure with reduced ejection fraction (HFrEF). However, the patient's NYHA Class II classification suggests that he has been relatively stable and has not experienced significant symptoms of heart failure.

The elevated Pro-BNP (Brain Natriuretic Peptide) level of 453 ng/L suggests that the patient has been experiencing some degree of cardiac stress, likely due to his underlying heart failure. However, the fact that the patient is a survivor suggests that his cardiac function has been managed effectively, and he has not experienced a significant cardiac event such as a myocardial infarction or cardiac arrest.

The patient's ECG shows ventricular extrasystoles, but no sustained ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia. This suggests that the patient's cardiac rhythm is relatively stable, and he is not at high risk of sudden cardiac death.

The patient's laboratory results show elevated glucose and creatinine levels, indicating poor glycemic control and renal impairment. However, his potassium and sodium levels are within normal limits, and his liver function tests are mildly elevated but not significantly abnormal.

The patient's treatment plan appears to be effective in managing his heart failure symptoms and reducing his cardiac stress. The combination of beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor has helped to slow the progression of his heart failure and reduce his risk of cardiac events.

In conclusion, the patient's survival is likely due to the effective management of his heart failure symptoms, stable cardiac rhythm, and comprehensive treatment plan."
20,20,P0032,"Age: 63
Gender: Male 
Weight: 85 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 140/85 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 42,4
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,01
Creatinine (mmol/L): 135.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 160.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,35
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1045.0
Protein (g/L): 79
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,03
Urea (mg/dL): 7,8
LVEF (%): 27.0
Medications: Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient's outcome of being a survivor can be attributed to a combination of factors, including the management of their idiopathic dilated cardiomyopathy with medications such as Beta Blockers, Spironolactone, and an ACE Inhibitor. These medications have been shown to improve symptoms, reduce hospitalizations, and improve survival in patients with heart failure.

The patient's LVEF of 27% indicates severe left ventricular dysfunction, which is consistent with a diagnosis of dilated cardiomyopathy. However, despite this, the patient's Pro-BNP level of 1045.0 ng/L is elevated but not extremely high, suggesting that the patient's symptoms may be well-controlled with their current medication regimen.

The patient's ECG is unremarkable, with no signs of ventricular tachycardia, ventricular extrasystoles, or bradycardia. This suggests that the patient's cardiac rhythm is stable and not contributing to their poor prognosis.

The patient's laboratory values, including their liver function tests (ALT and AST), renal function (Creatinine and Urea), and electrolyte levels (Potassium and Sodium), are within normal limits or only slightly elevated, indicating that the patient's liver and kidneys are functioning adequately and that there are no significant electrolyte imbalances that could contribute to cardiac arrhythmias.

The patient's glucose level is within the normal range, which is beneficial as hyperglycemia can exacerbate cardiac dysfunction.

The patient's TSH level is within the normal range, which suggests that their thyroid function is normal and is not contributing to their cardiac dysfunction.

Overall, the combination of the patient's well-managed medication regimen, stable ECG, and normal laboratory values suggests that the patient's outcome of being a survivor is likely due to effective management of their idiopathic dilated cardiomyopathy."
21,21,P0033,"Age: 52
Gender: Male 
Weight: 108 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 38,7
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 9.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 155.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,07
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1514.0
Protein (g/L): 68
T3 (pg/dL): 0,06
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,52
Urea (mg/dL): 4,68
LVEF (%): 50.0
Medications: Amiodarone, Beta Blockers
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

Given the patient's history of idiopathic dilated cardiomyopathy, the patient's LVEF (Left Ventricular Ejection Fraction) of 50% is within the range of mildly reduced ejection fraction, which is consistent with the diagnosis of heart failure with reduced ejection fraction (HFrEF). The patient's current NYHA Class II classification indicates that the patient experiences symptoms of heart failure, but these symptoms do not limit the patient's physical activity.

The patient's blood pressure is elevated at 140/90 mmHg, which may be contributing to the progression of heart failure. However, the patient is on beta-blockers, which are commonly used to manage heart failure and hypertension.

The patient's laboratory results show a slightly elevated Creatinine level (88.0 umol/L), which may indicate some degree of renal impairment, but it is not significantly elevated. The patient's Pro-BNP (1514.0 ng/L) is elevated, which is consistent with heart failure.

The patient's ECG shows ventricular extrasystoles, but no sustained ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia. The absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia suggests that the patient is not experiencing significant arrhythmia-related complications.

Considering the patient's overall condition, the patient's outcome of survivor can be attributed to the following factors:

1.  The patient is on appropriate medications (Amiodarone and Beta Blockers) for heart failure and arrhythmias.
2.  The patient's LVEF is still within the range of mildly reduced ejection fraction, indicating that the patient's heart function is not severely compromised.
3.  The patient's renal function is not significantly impaired, which is essential for the management of heart failure.
4.  The patient's Pro-BNP level is elevated, but not excessively high, which suggests that the patient's heart failure is being managed.

Overall, the patient's outcome of survivor is likely due to the combination of appropriate medical management, relatively preserved heart function, and lack of significant arrhythmia-related complications."
22,22,P0036,"Age: 62
Gender: Male 
Weight: 82 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 110/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 44,1
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,52
Creatinine (mmol/L): 129.0
Gamma-glutamil transpeptidase (IU/L): 55
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 3,9
LDL (mmol/L): 4,27
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 924.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,57
Urea (mg/dL): 15,36
LVEF (%): 30.0
Medications: Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient's outcome as a survivor can be attributed to a combination of several factors. 

Firstly, despite having a history of enolic dilated cardiomyopathy and NYHA Class III, which indicates significant heart failure symptoms, the patient's LVEF (Left Ventricular Ejection Fraction) is 30.0%, which is relatively preserved. This suggests that the patient's heart is still able to pump blood effectively, albeit with some impairment.

The patient's blood pressure is within a relatively normal range (110/80 mmHg), which is beneficial for cardiac function. The patient's medication regimen, including loop diuretics, spironolactone, and an ACE inhibitor, is also appropriate for managing heart failure and hypertension.

Additionally, the patient's laboratory results do not indicate any severe electrolyte imbalances, such as hyperkalemia (potassium level is 3.9 mEq/L), which can be a risk factor for cardiac arrhythmias and cardiac arrest. The patient's TSH level is also within the normal range, ruling out any potential thyroid-related cardiac issues.

The patient's troponin level is within normal limits, indicating that there is no evidence of acute myocardial infarction. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and other arrhythmias on the ECG also suggests that the patient's heart rhythm is relatively stable.

Lastly, the patient's overall clinical presentation, including the absence of severe symptoms, does not suggest an immediate life-threatening condition. Therefore, considering these factors, the patient's outcome as a survivor is likely due to the effectiveness of their current treatment regimen, preserved cardiac function, and the absence of severe underlying conditions that could have led to a poorer outcome."
23,23,P0037,"Age: 71
Gender: Male 
Weight: 88 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 44,8
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,72
Creatinine (mmol/L): 98.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 147.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,66
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 732.0
Protein (g/L): 66
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,9
Urea (mg/dL): 9,35
LVEF (%): 40.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 71-year-old male with a history of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipemia. Despite having a reduced left ventricular ejection fraction (LVEF) of 40%, which indicates impaired cardiac function, the patient is on optimal medical therapy with beta blockers, statins, and an ACE inhibitor. The patient's blood pressure is well-controlled at 130/80 mmHg, and the absence of significant electrolyte imbalances (e.g., potassium 4.1 mEq/L) suggests that the patient is not at high risk for arrhythmias.

The patient's biomarkers, including troponin (0.01 ng/mL), indicate that there is no ongoing myocardial infarction. The pro-BNP level of 732 ng/L is elevated, but this is not uncommon in patients with heart failure with reduced ejection fraction (HFrEF), which is consistent with the patient's ischemic dilated cardiomyopathy.

The patient's ECG shows a polymorphic ventricular extrasystole, but there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias. The presence of TPSV (paroxysmal supraventricular tachyarrhythmia) may be a benign finding in this context.

Given the patient's age, comorbidities, and current medical therapy, the patient's outcome as a survivor is likely due to the following factors:

1. Optimal medical therapy: The patient is on evidence-based medications for heart failure and dyslipemia, which has helped to stabilize his cardiac function and reduce the risk of further cardiovascular events.
2. Well-controlled blood pressure: The patient's blood pressure is well-controlled, which has helped to reduce the strain on the heart and prevent further cardiac damage.
3. Absence of significant electrolyte imbalances: The patient's electrolyte levels are within normal limits, which has reduced the risk of arrhythmias and other cardiac complications.
4. No ongoing myocardial infarction: The patient's troponin level is normal, indicating that there is no ongoing cardiac damage.

Overall, the patient's outcome as a survivor is likely due to the combination of optimal medical therapy, well-controlled blood pressure, and the absence of significant electrolyte imbalances and ongoing cardiac damage."
24,24,P0038,"Age: 69
Gender: Male 
Weight: 98 kg
Height: 188 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41,4
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,72
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 458.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,88
Urea (mg/dL): 3,79
LVEF (%): 40.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

Given the patient's medical history and current condition, the most likely reason for the patient's outcome as a survivor is the combination of their current treatment plan and the relatively stable state of their heart function. 

The patient has a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge, reducing the heart's ability to pump blood effectively. However, despite this condition, the patient's LVEF (Left Ventricular Ejection Fraction) is 40%, which is within the range of 40-50% that is often considered to be a moderate level of heart failure. 

The patient is on a comprehensive medication regimen that includes Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, and Statins, which are all aimed at managing heart failure, controlling blood pressure, and reducing the risk of arrhythmias. The use of these medications suggests that the patient's healthcare team is actively managing their condition and attempting to prevent further complications.

Additionally, the patient's laboratory results, including the low levels of Troponin (0.01 ng/mL) and TSH (1.88 mIU/L), suggest that there is no acute cardiac injury or significant thyroid dysfunction, which could have contributed to a poor outcome.

The patient's age and weight are also within a relatively normal range, which may also contribute to their survival. 

In summary, the combination of the patient's current treatment plan, stable LVEF, and the absence of acute cardiac injury or significant thyroid dysfunction likely contributed to their survival."
25,25,P0039,"Age: 73
Gender: Male 
Weight: 90 kg
Height: 175 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,22
Creatinine (mmol/L): 116.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 126.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 3,4
LDL (mmol/L): 2,97
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 331.0
Protein (g/L): 71
T3 (pg/dL): 0,06
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,45
Urea (mg/dL): 6,91
LVEF (%): 39.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient, a 73-year-old male with a history of hypertensive cardiomyopathy, dyslipemia, and hypertension, has been prescribed beta blockers and an ACE inhibitor. Despite the presence of several risk factors for cardiovascular disease, the patient's overall clinical presentation and laboratory results suggest that he is currently in a relatively stable condition.

The patient's LVEF (left ventricular ejection fraction) is 39%, which is below the normal range (50-70%), indicating some degree of left ventricular dysfunction. However, the patient's Pro-BNP (brain natriuretic peptide) level of 331 ng/L is within a relatively normal range, suggesting that the patient's cardiac function is not severely compromised.

The patient's blood pressure is well-controlled at 130/80 mmHg, and his lipid profile is not significantly abnormal. His glucose level is slightly elevated, but not to the point of being considered diabetic. The patient's electrolytes, including potassium and sodium, are within normal limits.

The patient's ECG shows a ventricular extrasystole, but no sustained ventricular tachycardia or bradycardia. The patient's troponin level is normal, indicating that there is no acute myocardial infarction.

Considering these factors, the patient's overall clinical picture suggests that he is likely in a stable condition, with some degree of cardiac dysfunction but without acute cardiac decompensation. The patient's age and comorbidities do increase his risk for adverse outcomes, but the patient's current treatment regimen and laboratory results suggest that he is being effectively managed.

Therefore, the patient's outcome of survival is likely due to the effective management of his cardiovascular disease, including the use of beta blockers and an ACE inhibitor, as well as his relatively stable clinical presentation and laboratory results."
26,26,P0041,"Age: 78
Gender: Male 
Weight: 70 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 51,8
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 117.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,17
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 853.0
Protein (g/L): 81
T3 (pg/dL): 0,05
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,72
Urea (mg/dL): 10,02
LVEF (%): 45.0
Medications: Calcium Channel Blocker, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 78-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and myocardial infarction, has been managed with a multidrug regimen including a calcium channel blocker, loop diuretics, statins, an ACE inhibitor, and a nitrovasodilator. Despite his history of heart disease, the patient's current blood pressure is well-controlled at 110/75 mmHg, and his LVEF is 45%, indicating some degree of cardiac function preservation.

The patient's laboratory results show a slightly elevated creatinine level (117.0 mmol/L), which may indicate some degree of renal impairment, but his eGFR is not provided. However, his urea level is within a relatively normal range (10.02 mg/dL). His glucose level is also well-controlled at 6.6 mmol/L.

The patient's TSH level is within the normal range (1.72 mIU/L), and his T3 and T4 levels are also within normal limits. The patient's troponin level is slightly elevated (0.01 ng/mL), which may indicate some degree of cardiac injury, but it is not significantly elevated.

The patient's LVEF of 45% is a good indicator of cardiac function, and the absence of significant arrhythmias on the ECG suggests that the patient's heart is functioning relatively well. The patient's medication regimen is appropriate for his condition, and his blood pressure is well-controlled.

Given the patient's overall clinical picture, the presence of a monomorphic ventricular extrasystole on the ECG does not appear to be a significant concern, and the patient's prognosis is likely good. The patient's age and comorbidities do pose some risk, but the patient's current management and laboratory results suggest that he is being well-managed. Therefore, the patient's outcome is likely a survivor."
27,27,P0042,"Age: 60
Gender: Male 
Weight: 84 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 90/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,6
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,8
Creatinine (mmol/L): 81.0
Gamma-glutamil transpeptidase (IU/L): 32
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,33
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 90.0
Protein (g/L): 67
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,7
Urea (mg/dL): 6,01
LVEF (%): 40.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient outcome of survival can be attributed to several factors in this patient's case. 

1.  Effective Medications: The patient is currently taking beta blockers, statins, and an ACE inhibitor, which are all appropriate medications for managing ischemic dilated cardiomyopathy and its associated conditions. Beta blockers help reduce the heart rate and workload on the heart, while statins help lower cholesterol levels and prevent further cardiac damage. ACE inhibitors aid in reducing blood pressure and strain on the heart.

2.  LVEF of 40%: Although the left ventricular ejection fraction (LVEF) is low at 40%, indicating reduced heart function, the patient is still able to maintain a certain level of cardiac output, which is crucial for survival. An LVEF of 40% is still within the range where patients can survive with appropriate medical management.

3.  No Sustained Ventricular Tachycardia: The absence of sustained ventricular tachycardia is a positive sign, as this condition can be life-threatening. The presence of monomorphic ventricular extrasystoles is relatively common and usually not life-threatening in this context.

4.  Normal Blood Pressure: The patient's blood pressure of 90/60 mmHg, although slightly low, is not critically low, and the patient is not showing signs of shock or severe hypotension.

5.  Pro-BNP of 90.0 ng/L: Although a slightly elevated B-type natriuretic peptide (BNP) level indicates some level of heart strain, it is not extremely high, suggesting that the patient's heart is not severely overworked.

6.  Overall Clinical Condition: Considering the patient's age, NYHA Class II, and the presence of ischemic dilated cardiomyopathy, diabetes, and dyslipemia, the patient's survival can be attributed to the effective management of these conditions and the absence of severe complications.

Given these factors, the patient's outcome of survival is likely due to a combination of effective medical management, the absence of severe cardiac arrhythmias, and the patient's relatively stable clinical condition."
28,28,P0044,"Age: 77
Gender: Male 
Weight: 87 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 90/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 39,5
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,85
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 148.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,5
LDL (mmol/L): 1,94
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1157.0
Protein (g/L): 70
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,99
Urea (mg/dL): 9,35
LVEF (%): 40.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 77-year-old male with a history of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipemia. His left ventricular ejection fraction (LVEF) is 40%, indicating moderate heart failure. He is on a comprehensive medication regimen, including ACE inhibitors, beta blockers, calcium channel blockers, loop diuretics, statins, and nitrovasodilators.

The patient's blood pressure is slightly low at 90/60 mmHg, which may be a result of the loop diuretics used to manage his heart failure symptoms. His electrolyte levels are within normal limits, with a potassium level of 4.5 mEq/L.

The elevated Pro-BNP level of 1157 ng/L suggests that the patient has significant fluid overload and strain on the heart, consistent with his heart failure diagnosis. However, the patient's LVEF and other laboratory values suggest that he is receiving appropriate treatment for his condition.

The presence of non-sustained ventricular tachycardia on the ECG is a concern, but it is not uncommon in patients with heart failure and ischemic cardiomyopathy. The absence of paroxysmal supraventricular tachyarrhythmia and bradycardia is also reassuring.

Given the patient's age, comorbidities, and comprehensive treatment regimen, the outcome of survival is likely due to the effective management of his heart failure symptoms and the use of evidence-based medications to prevent further cardiac events. The patient's low T3 and T4 levels may indicate hypothyroidism, but this is not directly related to his cardiac outcome.

Overall, the patient's survival outcome is likely due to the combination of his comprehensive medical treatment, good blood pressure control, and the absence of severe electrolyte imbalances or other life-threatening conditions."
29,29,P0045,"Age: 73
Gender: Male 
Weight: 83 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Peripheral vascular disease, Hypertension
Albumin (g/L): 42,59
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,69
Creatinine (mmol/L): 116.0
Gamma-glutamil transpeptidase (IU/L): 46
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 170.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 3,9
LDL (mmol/L): 3,21
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 390.0
Protein (g/L): 76
T3 (pg/dL): 0,06
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,54
Urea (mg/dL): 6,24
LVEF (%): 40.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 73-year-old male with a history of idiopathic dilated cardiomyopathy and peripheral vascular disease, survived despite his complex medical condition. Several factors contributed to his survival:

1. Optimal medical management: The patient is on a multi-drug regimen that includes digoxin, loop diuretics, spironolactone, ACE inhibitor, and nitrovasodilator. These medications are commonly used to manage heart failure symptoms, hypertension, and ventricular arrhythmias, which suggests that the patient's treatment plan is well-managed.

2. LVEF of 40%: Although the patient's left ventricular ejection fraction (LVEF) is low, indicating reduced heart function, it is not as severely impaired as in some other patients with dilated cardiomyopathy. This relatively preserved LVEF may have contributed to the patient's survival.

3. Absence of severe electrolyte imbalances: The patient's potassium level is within a relatively normal range (3.9 mEq/L), which is essential for cardiac function and rhythm management. The absence of severe electrolyte imbalances, such as hyperkalemia or hypokalemia, may have reduced the risk of life-threatening arrhythmias.

4. Mildly elevated troponin level: The patient's troponin level is only slightly elevated (0.01 ng/mL), indicating minimal myocardial damage or ischemia. This suggests that the patient's cardiac function is relatively preserved, which may have contributed to his survival.

5. Normal TSH level: The patient's thyroid-stimulating hormone (TSH) level is within a normal range, which is essential for maintaining cardiac function and rhythm.

6. Absence of severe anemia: The patient's hemoglobin level is within a relatively normal range (170 g/L), which suggests that the patient does not have severe anemia, which can contribute to decreased cardiac output and increased risk of mortality.

7. Optimal nutritional status: The patient's albumin level is within a relatively normal range (42.59 g/L), indicating adequate nutritional status, which is essential for maintaining cardiac function and overall health.

8. Presence of a low LVEF but no severe symptoms: The patient has a NYHA Class II classification, indicating that he experiences some limitations in physical activity but is still able to carry out daily activities without severe symptoms. This suggests that the patient's cardiac function is relatively preserved, and he is able to tolerate his underlying condition.

Considering these factors, the patient's survival is likely due to a combination of optimal medical management, relatively preserved cardiac function, and the absence of severe electrolyte imbalances, anemia, or other complications that could have contributed to his mortality."
30,30,P0048,"Age: 60
Gender: Male 
Weight: 95 kg
Height: 172 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 43,09
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,53
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,91
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 603.0
Protein (g/L): 67
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 5
Urea (mg/dL): 9,8
LVEF (%): 38.0
Medications: Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

Given the patient's age, gender, and past medical history of idiopathic dilated cardiomyopathy, it is not surprising that they have a reduced left ventricular ejection fraction (LVEF) of 38%. The patient's symptoms, as indicated by a New York Heart Association (NYHA) Class III, suggest that they have moderate to severe heart failure. The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and a paroxysmal supraventricular tachyarrhythmia on the ECG further indicate cardiac arrhythmias and potential instability.

The patient's laboratory results show elevated Pro-BNP (brain natriuretic peptide) levels, which is a marker of heart failure and cardiac stress. The slightly elevated creatinine levels (101.0 μmol/L) may indicate some degree of renal impairment, which is common in patients with heart failure.

The patient is on a comprehensive treatment regimen, including digoxin, loop diuretics, spironolactone, statins, and an ACE inhibitor, which are all standard therapies for heart failure and hypertension. The presence of statins suggests that the patient has dyslipidemia, which is also a common comorbidity in patients with heart disease.

The patient's outcome as a survivor is likely due to the combination of their comprehensive medical treatment regimen, their relatively stable vital signs (blood pressure 140/80 mmHg), and the absence of any acute cardiac events or complications. The patient's TSH level is within the normal range, which suggests that their thyroid function is not contributing to their heart failure symptoms.

In summary, the patient's outcome as a survivor is likely due to their comprehensive medical treatment regimen, stable vital signs, and the absence of acute cardiac events or complications, despite their underlying heart failure and other comorbidities."
31,31,P0050,"Age: 65
Gender: Male 
Weight: 90 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 44,5
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 3,39
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 9,5
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,07
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 758.0
Protein (g/L): 70
T3 (pg/dL): 0,04
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,48
Urea (mg/dL): 10,47
LVEF (%): 40.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 65-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction. His left ventricular ejection fraction (LVEF) is 40%, indicating a reduced cardiac function, which is consistent with his diagnosis of ischemic dilated cardiomyopathy.

The patient's laboratory results show elevated creatinine levels (102.0 mmol/L), indicating impaired renal function, which is likely due to his chronic kidney disease. The elevated Pro-BNP (758.0 ng/L) suggests that the patient has heart failure with reduced ejection fraction (HFrEF).

The patient's blood pressure is within a relatively normal range (130/80 mmHg), and he is on medications for diabetes, beta blockers, statins, and an ACE inhibitor, which are all appropriate for his condition.

The ECG findings of monomorphic ventricular extrasystole and paroxysmal supraventricular tachyarrhythmia (PSVT) are consistent with the patient's history of cardiac disease. However, there is no evidence of sustained ventricular tachycardia or bradycardia.

Given the patient's overall clinical presentation and laboratory results, it appears that he is being managed appropriately for his conditions. The patient's survival outcome is likely due to his adherence to his medication regimen, regular monitoring, and the absence of any acute cardiac events or complications.

However, it is essential to note that the patient's LVEF of 40% indicates a significant reduction in cardiac function, and he should continue to be closely monitored for any signs of worsening heart failure or other cardiac complications. Additionally, the patient's diabetes and dyslipemia should be closely managed to prevent further cardiac damage."
32,32,P0052,"Age: 56
Gender: Male 
Weight: 104 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,7
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,32
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,38
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 402.0
Protein (g/L): 75
T3 (pg/dL): 0,03
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,14
Urea (mg/dL): 10,02
LVEF (%): 30.0
Medications: Amiodarone, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient's outcome of survival can be attributed to several factors:

1. Aggressive medical management: The patient is on a combination of medications that are tailored to address their specific conditions, including ischemic dilated cardiomyopathy, dyslipemia, and myocardial infarction. Amiodarone, a medication commonly used for arrhythmia management, is likely helping to control the ventricular tachycardia and extrasystole. Loop diuretics are also being used to manage fluid overload, which can be a significant concern in patients with heart failure. Statins are being used to manage dyslipemia, and ACE inhibitors are helping to reduce blood pressure and alleviate strain on the heart.

2. Optimal blood pressure: The patient's blood pressure is within a relatively normal range (100/60 mmHg), which is beneficial for heart health. Lower blood pressure can reduce the workload on the heart, helping to minimize damage and improve function.

3. Stable LVEF: Although the patient's LVEF is low at 30%, it is stable, indicating that the heart is not experiencing significant acute decompensation. This stability suggests that the patient's heart is able to maintain a relatively consistent level of function, despite the underlying cardiomyopathy.

4. Normal electrolytes: The patient's electrolyte levels are within normal ranges, which is essential for maintaining proper heart function. Abnormal electrolytes can lead to arrhythmias and other cardiac complications.

5. Normal glucose levels: The patient's glucose levels are within a normal range, which is beneficial for heart health. High glucose levels can lead to diabetic cardiomyopathy and other complications.

6. Low TSH levels: The patient's TSH levels are within a normal range, indicating that the thyroid function is not contributing to any cardiac issues.

7. Low T3 levels: The patient's T3 levels are low, which is not uncommon in patients with heart failure. Low T3 levels are often seen in patients with reduced cardiac output, as the body's metabolic rate decreases in response to decreased cardiac function.

8. Pro-BNP levels: The patient's Pro-BNP levels are elevated, indicating that the heart is under strain. However, this is not unexpected in a patient with heart failure.

9. ECG findings: While the patient has ventricular extrasystoles and non-sustained ventricular tachycardia, these findings are not necessarily indicative of a life-threatening condition at this time. The patient's ECG is not showing any acute signs of cardiac ischemia or severe arrhythmias.

Overall, the combination of aggressive medical management, optimal blood pressure, stable LVEF, normal electrolytes, normal glucose levels, low TSH levels, low T3 levels, elevated Pro-BNP levels, and the absence of acute cardiac ischemia or severe arrhythmias on the ECG have all contributed to the patient's outcome of survival."
33,33,P0055,"Age: 60
Gender: Female 
Weight: 83 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 170/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 6,34
Creatinine (mmol/L): 74.0
Gamma-glutamil transpeptidase (IU/L): 44
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,16
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 282.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,21
Urea (mg/dL): 7,35
LVEF (%): 39.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient's outcome of survival can be attributed to several factors in her medical history and current condition. 

1. Optimal Medication Regimen: The patient is on a comprehensive medication regimen consisting of Beta Blockers, Statins, and an ACE Inhibitor. Beta Blockers help reduce the heart rate and the force of the heart's contraction, which is beneficial for patients with heart failure. Statins lower cholesterol levels, which can reduce the risk of further cardiac damage. ACE Inhibitors help relax blood vessels and reduce blood pressure, which is essential for patients with hypertensive cardiomyopathy.

2. Reasonable Blood Pressure: Although the patient's blood pressure is slightly elevated (170/90 mmHg), it is not excessively high. The patient's blood pressure is well-managed with her current medication regimen, which likely contributed to her survival.

3. LVEF of 39%: Although the patient's left ventricular ejection fraction (LVEF) is lower than the normal range (50-70%), it is not extremely low. An LVEF of 39% indicates that the patient's heart is still functioning, albeit inefficiently. This suggests that the patient's heart is not in a state of severe failure, which is a positive factor for survival.

4. Reasonable Renal Function: The patient's creatinine level (74.0 μmol/L) is slightly elevated, indicating some degree of renal impairment. However, it is not severely elevated, and the patient's urea level (7.35 mg/dL) is also within a relatively normal range. This suggests that the patient's kidneys are still functioning, which is crucial for overall survival.

5. Absence of Severe Electrocardiographic Abnormalities: The patient's ECG does not show any signs of severe arrhythmias, such as ventricular tachycardia or bradycardia. The presence of polymorphic ventricular extrasystoles is a relatively benign finding and is not uncommon in patients with heart disease.

6. Hemoglobin Level: The patient's hemoglobin level (141.0 g/L) is within a normal range, indicating that she does not have significant anemia, which can contribute to cardiac dysfunction and poor outcomes.

7. TSH Level: The patient's TSH level (3.21 mIU/L) is within a normal range, indicating that her thyroid function is normal, which is essential for cardiac health.

Overall, the patient's survival can be attributed to her well-managed hypertension, optimal medication regimen, reasonable blood pressure, and relatively preserved renal function."
34,34,P0060,"Age: 69
Gender: Female 
Weight: 85 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 38,9
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 5,15
Creatinine (mmol/L): 128.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 8,1
Hemoglobin (g/L): 126.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,8
LDL (mmol/L): 3,08
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 538.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,36
Urea (mg/dL): 10,24
LVEF (%): 24.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 69-year-old female with a history of Hypertensive cardiomyopathy, Diabetes, Dyslipemia, and Hypertension. Her current medications include diabetes medication, beta blockers, digoxin, loop diuretics, and ACE inhibitor, which are standard treatments for heart failure and hypertension. 

The patient's LVEF (Left Ventricular Ejection Fraction) is significantly reduced at 24%, indicating severe left ventricular dysfunction. However, her Pro-BNP (B-type Natriuretic Peptide) level is elevated at 538.0 ng/L, which is consistent with heart failure. 

Her ECG does not show any signs of ventricular tachycardia, ventricular extrasystole, or bradycardia. The presence of an unknown paroxysmal supraventricular tachyarrhythmia and bradycardia code may indicate that the patient has some arrhythmia, but it is not severe enough to cause immediate concern.

The patient's kidney function, as indicated by creatinine levels, is mildly impaired, which may be a result of her heart failure. Her liver function tests (ALT and AST) are within normal limits, and her electrolyte levels are relatively stable.

Given the patient's treatment with ACE inhibitor, beta blockers, and loop diuretics, it is likely that she is receiving optimal medical therapy for her heart failure and hypertension. Her survival is likely due to the effectiveness of these medications in managing her condition, along with her overall stable vitals and lack of severe arrhythmias.

However, it is essential to note that the patient's low T3 and T4 levels, and mildly elevated TSH, may indicate hypothyroidism, which can be a comorbidity in patients with heart failure. Further evaluation of her thyroid function is necessary to rule out this condition.

In summary, the patient's survival is likely due to the effectiveness of her current treatment regimen, stable vitals, and lack of severe arrhythmias, despite her severe left ventricular dysfunction and impaired kidney function."
35,35,P0061,"Age: 60
Gender: Male 
Weight: 85 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 130/90 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 47,8
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,22
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,18
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 701.0
Protein (g/L): 72
T3 (pg/dL): 0,07
T4 (ng/L): 22
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,01
Urea (mg/dL): 10,02
LVEF (%): 38.0
Medications: Beta Blockers, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient, a 60-year-old male with a history of enolic dilated cardiomyopathy and hypertension, has been diagnosed with a left ventricular ejection fraction (LVEF) of 38%, indicating reduced left ventricular function. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG further supports the diagnosis of cardiomyopathy. 

The patient's medication regimen includes beta blockers, digoxin, and an ACE inhibitor, which are standard treatments for heart failure and cardiomyopathy. The patient's albumin and protein levels are within normal limits, indicating no significant liver dysfunction. However, the elevated creatinine level (101.0 mmol/L) suggests mild renal impairment, which may be related to the cardiomyopathy or hypertension.

The patient's hemoglobin and potassium levels are within normal limits, and the glucose level is slightly elevated but not significantly high. The total cholesterol and LDL levels are elevated, which is a risk factor for cardiovascular disease. The TSH level is within the normal range, indicating no thyroid dysfunction.

The elevated Pro-BNP level (701.0 ng/L) is consistent with heart failure, and the LVEF of 38% confirms this diagnosis. The patient's NYHA Class II classification indicates mild to moderate symptoms of heart failure.

Considering the patient's overall condition, the presence of a reduced LVEF, non-sustained ventricular tachycardia, and elevated Pro-BNP level, the patient's outcome as a survivor is likely due to the effective management of their cardiomyopathy and heart failure with the current medication regimen. The patient's mild renal impairment and slightly elevated glucose level may require further monitoring, but they do not appear to be major contributors to the patient's outcome."
36,36,P0062,"Age: 81
Gender: Male 
Weight: 71 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 145/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 35,6
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,5
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 145.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,95
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 1399.0
Protein (g/L): 68
T3 (pg/dL): 0,03
T4 (ng/L): 12
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,49
Urea (mg/dL): 15,15
LVEF (%): 52.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is an 81-year-old male with a history of hypertensive cardiomyopathy and hypertension, presenting with a reduced left ventricular ejection fraction (LVEF) of 52%. His elevated Pro-BNP level of 1399 ng/L suggests significant heart failure symptoms. However, the patient is on loop diuretics and an ACE inhibitor, which are standard treatments for heart failure.

The patient's blood pressure is within a relatively controlled range (145/85 mmHg), and his creatinine level is elevated at 119.0 mmol/L, indicating some degree of renal impairment. The patient's lipid profile shows a total cholesterol level of 4.5 mmol/L, with an LDL of 2.95 mmol/L, which is above the recommended target. His glucose level is slightly elevated at 4.9 mmol/L.

The patient's ECG shows polymorphic ventricular extrasystoles, which can be a sign of cardiac arrhythmia or ischemia, but it does not necessarily indicate a life-threatening condition. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that the patient's heart rhythm is relatively stable.

Given the patient's age, comorbidities, and medication regimen, the most likely reason for the patient's survival is the effective management of his heart failure symptoms with loop diuretics and ACE inhibitors. The patient's relatively controlled blood pressure and lack of life-threatening arrhythmias also contribute to his survival."
37,37,P0063,"Age: 55
Gender: Male 
Weight: 68 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 44,4
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 3,57
Creatinine (mmol/L): 75.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 6
Hemoglobin (g/L): 137.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4
LDL (mmol/L): 2,15
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 249.0
Protein (g/L): 69
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,94
Urea (mg/dL): 10,02
LVEF (%): 40.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to a combination of several factors, including their current medical management and the underlying pathology of their ischemic dilated cardiomyopathy. 

Firstly, the patient's current medications, including beta blockers, statins, and an ACE inhibitor, are all appropriate for managing heart failure and ischemic heart disease. Beta blockers help reduce the heart rate and blood pressure, while statins lower cholesterol levels, which in turn reduce the risk of further cardiac events. ACE inhibitors also help to reduce blood pressure and alleviate strain on the heart.

The patient's LVEF (left ventricular ejection fraction) of 40% indicates that they have a moderately reduced ejection fraction, which is a common finding in patients with ischemic dilated cardiomyopathy. However, the patient's current LVEF is not as low as it could be, suggesting that their heart is still functioning relatively well despite their underlying disease.

The patient's blood pressure is well-controlled at 110/80 mmHg, which is within a normal range. This is likely due to the effectiveness of their ACE inhibitor and beta blocker medications.

The patient's troponin level of 0.01 ng/mL is within a normal range, indicating that they do not have any acute myocardial infarction. This suggests that their current heart failure is not due to an acute myocardial infarction, but rather a chronic process.

The patient's pro-BNP level of 249 ng/L is elevated, which is consistent with heart failure. However, this level is not extremely high, suggesting that the patient's heart failure is not severe.

The patient's TSH level of 2.94 mIU/L is within a normal range, indicating that their thyroid function is normal, which is important as thyroid dysfunction can exacerbate heart failure.

In summary, the patient's survival can be attributed to their effective medical management, their relatively well-preserved LVEF, and the absence of any acute cardiac events."
38,38,P0064,"Age: 60
Gender: Male 
Weight: 102 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 41,7
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 98.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4
LDL (mmol/L): 2,72
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 125.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,76
Urea (mg/dL): 8,02
LVEF (%): 45.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 60-year-old male with a history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction, has been managed with beta blockers and an ACE inhibitor. Despite having a left ventricular ejection fraction (LVEF) of 45%, which is below the normal range (50-70%), the patient has survived. Several factors contribute to this outcome:

1.  Effective medication management: The patient is on beta blockers and an ACE inhibitor, which are standard treatments for heart failure and hypertension. These medications help reduce the workload on the heart, improve cardiac function, and manage blood pressure.

2.  Mild left ventricular dysfunction: Although the patient has an LVEF of 45%, which indicates mild left ventricular dysfunction, it is not as severe as in some other cases of heart failure. This suggests that the patient's heart function is not as compromised, making it more likely for him to survive.

3.  No acute coronary syndrome or severe arrhythmias: The absence of acute coronary syndrome (indicated by a low troponin level of 0.01 ng/mL) and severe arrhythmias (such as ventricular tachycardia) reduces the immediate risk of cardiac complications.

4.  Reasonable blood pressure control: The patient's blood pressure of 160/80 mmHg is not excessively high, which is beneficial in reducing the strain on the heart.

5.  No significant electrolyte imbalances: The patient's potassium level is within a normal range (4 mEq/L), which is essential for maintaining proper cardiac function.

6.  No severe liver dysfunction: The patient's liver function tests (ALT and AST) are within normal limits, indicating that liver disease is not a significant contributing factor to his cardiac condition.

7.  Normal thyroid function: The patient's TSH level is slightly elevated (5.76 mIU/L), but it is not significantly high, which suggests that thyroid dysfunction is not a major contributor to his cardiac condition.

8.  Pro-BNP level within a reasonable range: The patient's Pro-BNP level of 125.0 ng/L is within a reasonable range for his condition, indicating that his heart is not under excessive stress.

In conclusion, the combination of effective medication management, mild left ventricular dysfunction, no acute coronary syndrome or severe arrhythmias, reasonable blood pressure control, normal electrolyte levels, no severe liver dysfunction, normal thyroid function, and a reasonable Pro-BNP level all contribute to the patient's survival."
39,39,P0067,"Age: 49
Gender: Female 
Weight: 82 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 120/75 mmHg
Past Medical History: Other HF etiology
Albumin (g/L): 43,8
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,22
Creatinine (mmol/L): 132.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,17
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 30.0
Protein (g/L): 75,8
T4 (ng/L): 17
TSH (mIU/L): 1,93
Urea (mg/dL): 13,64
LVEF (%): 37.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 49-year-old female, has a history of heart failure (HF) and is classified as NYHA Class II, indicating moderate symptoms with minimal limitation in physical activity. Despite her history of HF, the patient's blood pressure is within a relatively normal range (120/75 mmHg), and her kidney function is mildly impaired, as indicated by an elevated creatinine level (132.0 μmol/L) and urea level (13.64 mg/dL). 

The patient's liver function tests are within normal limits, with an albumin level of 43.8 g/L, indicating that the liver is functioning adequately. The patient's lipid profile shows a total cholesterol level of 4.22 mmol/L, which is slightly elevated, but her LDL level is within the target range (2.17 mmol/L). 

The patient's thyroid function tests are normal, with a TSH level of 1.93 mIU/L and a T4 level of 17 ng/L. The patient's hemoglobin level is slightly elevated (127 g/L), which may be due to dehydration or anemia. 

The patient's ECG shows monomorphic ventricular extrasystoles, but no other significant arrhythmias or conduction abnormalities. The patient is on beta blockers, loop diuretics, and an ACE inhibitor, which are standard medications for heart failure management.

The patient's LVEF is significantly reduced at 37%, indicating severe left ventricular dysfunction. However, the patient's Pro-BNP level is within a relatively normal range (30 ng/L), which may indicate that the patient is well-managed on her current medications.

Given the patient's history of HF, reduced LVEF, and mild kidney impairment, the patient's survival is a testament to the effectiveness of her current treatment regimen and the management of her heart failure. The patient's relatively normal blood pressure and lack of significant arrhythmias on the ECG also contribute to her survival."
40,40,P0068,"Age: 71
Gender: Male 
Weight: 114 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 120/55 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 9
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,61
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1243.0
Protein (g/L): 58
T3 (pg/dL): 0,04
T4 (ng/L): 12
TSH (mIU/L): 3,23
Urea (mg/dL): 7,15
LVEF (%): 31.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

Given the patient's medical history and the provided test results, it can be inferred that the patient is at a high risk of cardiovascular events due to his idiopathic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension. The patient's low left ventricular ejection fraction (LVEF) of 31.0% indicates that his heart is not pumping efficiently, which is a common complication of dilated cardiomyopathy.

The elevated Pro-BNP level of 1243.0 ng/L suggests that the patient's heart is under strain, which is consistent with heart failure. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG is a marker of increased risk of sudden cardiac death and may indicate underlying electrical instability in the heart.

The patient's medications, including an ACE inhibitor, angiotensin II receptor blocker, digoxin, and loop diuretics, are standard treatments for heart failure and may be contributing to his survival. The presence of diabetes and dyslipemia also suggests that the patient is at increased risk of cardiovascular events, but the fact that he is on diabetes medication may be helping to manage these conditions.

The patient's blood pressure of 120/55 mmHg is relatively low, which may be a result of his diuretic medication. The patient's weight of 114 kg and height of 163 cm result in a BMI of approximately 34.5, which is classified as obese, increasing his risk of cardiovascular disease.

Considering these factors, it is likely that the patient's survival is due to the combination of his current medications, which are helping to manage his heart failure and other cardiovascular risk factors. However, his underlying conditions and the presence of NSVT on the ECG indicate that he is at increased risk of future cardiovascular events and may require closer monitoring and adjustment of his medications as needed."
41,41,P0071,"Age: 58
Gender: Male 
Weight: 116 kg
Height: 186 cm
NYHA Class: II
Blood Pressure: 150/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 58
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 159.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,12
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 600.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 18
TSH (mIU/L): 1,54
Urea (mg/dL): 6,16
LVEF (%): 32.0
Medications: Amiodarone, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient, a 58-year-old male with a history of ischemic dilated cardiomyopathy, hypertension, dyslipemia, and myocardial infarction, has a complex set of risk factors for cardiac disease. His LVEF of 32% indicates severe left ventricular dysfunction, which is consistent with his dilated cardiomyopathy diagnosis. 

The patient's blood pressure is elevated at 150/90 mmHg, which is a significant concern given his hypertension and heart disease. His lipid profile shows a high total cholesterol level of 5.38 mmol/L, with an LDL of 2.12 mmol/L, indicating a high risk for atherosclerotic cardiovascular disease.

The patient's liver enzymes (ALT and AST) are within normal limits, suggesting that his liver function is not significantly compromised. His kidney function, as indicated by creatinine levels, is also within normal limits, which is a positive sign.

The patient's glucose level is elevated at 6.8 mmol/L, which may be a concern for diabetes mellitus. However, his hemoglobin A1c levels are not provided, so this cannot be confirmed.

The patient's thyroid function tests (T3, T4, and TSH) are within normal limits, indicating that his thyroid function is not contributing to his cardiac condition.

The patient's medication regimen, including amiodarone, beta blockers, statins, and nitrovasodilators, is consistent with the management of ischemic dilated cardiomyopathy and hypertension.

The patient's ECG shows monomorphic ventricular extrasystoles, which are a common finding in patients with cardiomyopathy. The absence of sustained ventricular tachycardia or non-sustained ventricular tachycardia is a positive sign.

Given the patient's complex medical history and the presence of severe left ventricular dysfunction, the patient's survival outcome is likely due to the following factors:

1. Optimal medical management: The patient is on a comprehensive medication regimen that includes beta blockers, statins, and nitrovasodilators, which are essential for managing his heart failure and hypertension.
2. Close monitoring and follow-up: The patient's regular follow-up appointments and monitoring of his cardiac function likely allowed for early detection and management of any complications.
3. Supportive care: The patient's family and healthcare team likely provided emotional support and encouragement, which can have a positive impact on patient outcomes.
4. Genetic factors: The patient's genetic predisposition to heart disease may have played a role in his cardiac condition, but it is unlikely to have directly contributed to his survival outcome.

Overall, the patient's survival outcome is a testament to the effectiveness of modern medical management and the importance of close monitoring and follow-up in the care of patients with complex cardiac conditions."
42,42,P0072,"Age: 72
Gender: Female 
Weight: 54 kg
Height: 138 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 41,3
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 7,06
Creatinine (mmol/L): 73.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,84
Potassium (mEq/L): 4,2
LDL (mmol/L): 4,65
Sodium (mEq/L): 147.0
Pro-BNP (ng/L): 697.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 17
TSH (mIU/L): 2,38
Urea (mg/dL): 4,33
LVEF (%): 68.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient, a 72-year-old female with a history of ischemic dilated cardiomyopathy and myocardial infarction, is a survivor. Several factors contribute to her positive outcome:

1.  Medication Management: The patient is on Angiotensin II Receptor Blocker (ARB) and Loop Diuretics, which are commonly used in the management of heart failure and hypertension. ARBs help reduce blood pressure and decrease the heart's workload, while loop diuretics help manage fluid overload and reduce symptoms of heart failure.

2.  Preserved LVEF: The patient's left ventricular ejection fraction (LVEF) is 68%, which is within the normal range (50-70%). This indicates that the patient's heart is pumping blood efficiently, reducing the risk of further complications.

3.  Controlled Blood Pressure: Although the patient's blood pressure is slightly elevated at 160/80 mmHg, it is not significantly high, which reduces the risk of cardiovascular events.

4.  Normal Electrolyte Levels: The patient's potassium level is within the normal range (3.5-5.5 mEq/L), which is essential for maintaining proper heart function.

5.  Low Pro-BNP: The patient's Pro-BNP level is 697.0 ng/L, which is elevated but not extremely high. Pro-BNP is a biomarker of heart failure, and a low level indicates that the patient's heart failure is not severe.

6.  Absence of Severe Comorbidities: The patient's albumin and urea levels are within normal limits, indicating that her liver and kidney function are not severely impaired.

7.  Good Nutritional Status: The patient's protein and albumin levels are within normal limits, indicating that she is not malnourished, which can exacerbate heart failure.

8.  Hemoglobin Level: The patient's hemoglobin level is within the normal range, indicating that she does not have anemia, which can worsen heart failure.

9.  Low TSH: The patient's TSH level is within the normal range, indicating that her thyroid function is not contributing to her heart condition.

Considering these factors, the patient's outcome of survival can be attributed to effective management of her heart failure and hypertension, preserved cardiac function, and the absence of severe comorbidities."
43,43,P0074,"Age: 65
Gender: Male 
Weight: 73 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 39,1
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,58
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,38
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 2407.0
Protein (g/L): 65,9
T4 (ng/L): 16
TSH (mIU/L): 1,78
Urea (mg/dL): 9,32
LVEF (%): 25.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient's outcome as a survivor can be attributed to a combination of factors related to their medical history, current health status, and treatment regimen.

Firstly, the patient has a history of idiopathic dilated cardiomyopathy, a condition where the heart muscle becomes weak and the heart chambers enlarge, reducing the heart's ability to pump blood effectively. However, the patient's current LVEF (left ventricular ejection fraction) of 25% indicates that the heart is still pumping blood, albeit at a reduced capacity. This suggests that the heart's pumping function has not deteriorated to a point where it would be fatal.

The patient's blood pressure is within a relatively normal range (110/70 mmHg), which is beneficial for heart health. The patient's electrolyte levels, including potassium (4.3 mEq/L), are also within normal limits, which is crucial for maintaining a stable heart rhythm.

The patient is on a comprehensive medication regimen that includes beta blockers, loop diuretics, spironolactone, and an ACE inhibitor. Beta blockers help slow the heart rate and reduce the heart's workload, while loop diuretics and spironolactone help manage fluid retention and reduce blood pressure. ACE inhibitors also help lower blood pressure and reduce the strain on the heart.

The patient's Pro-BNP level (2407 ng/L) is elevated, indicating that the heart is under strain. However, the level is not extremely high, suggesting that the heart is not experiencing extreme stress. The patient's T4 and TSH levels are within normal limits, indicating that thyroid function is not contributing to the patient's heart condition.

The patient's laboratory results show relatively normal liver function, as indicated by the low levels of ALT and AST. The patient's creatinine level (95.0 μmol/L) is slightly elevated, which may indicate some kidney impairment, but it is not severe enough to be a major contributor to the patient's outcome.

In conclusion, the patient's outcome as a survivor can be attributed to a combination of their stable blood pressure, normal electrolyte levels, comprehensive medication regimen, and relatively normal laboratory results. The patient's heart function, although compromised, is still pumping blood, and the elevated Pro-BNP level suggests that the heart is not experiencing extreme stress."
44,44,P0075,"Age: 54
Gender: Male 
Weight: 82 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 105/74 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 44,2
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 6,18
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 117
Glucose (mmol/L): 6,5
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4
LDL (mmol/L): 3,75
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1199.0
Protein (g/L): 76
T4 (ng/L): 11
TSH (mIU/L): 2,93
Urea (mg/dL): 9,65
LVEF (%): 32.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 54-year-old male with a history of ischemic dilated cardiomyopathy and myocardial infarction. His current ejection fraction (LVEF) is 32%, indicating severe left ventricular dysfunction. His NT-proBNP level is elevated at 1199 ng/L, which is consistent with heart failure symptoms.

The patient's medication regimen includes beta blockers, loop diuretics, statins, and an ACE inhibitor, which are all appropriate for managing heart failure and ischemic cardiomyopathy. The beta blockers help reduce the heart rate and contractility, while the loop diuretics alleviate fluid overload. Statins lower cholesterol levels to reduce the risk of further cardiac events, and ACE inhibitors help reduce blood pressure and alleviate strain on the heart.

The patient's lipid profile shows a total cholesterol level of 6.18 mmol/L, with an LDL of 3.75 mmol/L, which is within the target range for a patient with heart disease. His HDL level is 1.27 mmol/L, which is slightly below the target range.

The patient's renal function is compromised, with a creatinine level of 118.0 mmol/L, indicating chronic kidney disease. His urea level is 9.65 mg/dL, which is also elevated.

The patient's TSH level is within the normal range, and his T4 level is slightly elevated, but not significantly so. His hemoglobin level is within the normal range.

The patient's ECG shows a polymorphic ventricular extrasystole, which is a common finding in patients with heart failure. He does not have sustained ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia.

Given the patient's history, medication regimen, and laboratory results, it is likely that he is being managed for heart failure and ischemic cardiomyopathy. The fact that he is a survivor suggests that his current treatment plan is effective in managing his symptoms and preventing further cardiac events."
45,45,P0076,"Age: 72
Gender: Male 
Weight: 90 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 145/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,4
Creatinine (mmol/L): 180.0
Gamma-glutamil transpeptidase (IU/L): 66
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 147.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 5
LDL (mmol/L): 3,47
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 997.0
Protein (g/L): 69,9
T4 (ng/L): 15
TSH (mIU/L): 0,8
Urea (mg/dL): 9,48
LVEF (%): 35.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 72-year-old male with a history of ischemic dilated cardiomyopathy, has been managed with a multidrug regimen including an angiotensin II receptor blocker, beta blockers, statins, and nitrovasodilators. Despite his history of myocardial infarction, peripheral vascular disease, and hypertension, the patient has managed to survive. Several factors contribute to his favorable outcome:

1. Multidrug therapy: The patient is on a comprehensive medication regimen that addresses multiple aspects of his cardiovascular disease. Beta blockers help reduce the workload on the heart, while angiotensin II receptor blockers and statins work to improve cardiac function and reduce the risk of further cardiovascular events.

2. Control of hypertension: Although the patient's blood pressure is elevated (145/90 mmHg), it is not severely high, indicating that his hypertension is being managed to some extent.

3. Stable LVEF: The patient's left ventricular ejection fraction (LVEF) is 35%, which is lower than normal but relatively stable, suggesting that the patient's heart function is not rapidly deteriorating.

4. Absence of severe kidney dysfunction: Although the patient has elevated creatinine levels (180.0 mmol/L), they are not in the range typically associated with severe kidney dysfunction. This suggests that the patient's kidneys are still functioning relatively well.

5. Normal hemoglobin and potassium levels: The patient's hemoglobin and potassium levels are within normal ranges, indicating that his anemia and electrolyte imbalances are not severe.

6. Low TSH and normal T4 levels: The patient's thyroid function is normal, which is essential for maintaining cardiac health.

7. No evidence of severe electrolyte imbalance: The patient's sodium and potassium levels are within normal ranges, which is crucial for maintaining cardiac function.

8. Absence of severe liver dysfunction: The patient's liver function tests (ALT, AST, GGT) are not severely elevated, indicating that his liver is functioning relatively well.

9. Low Pro-BNP levels: Although the patient's Pro-BNP levels are elevated (997.0 ng/L), they are not in the range typically associated with severe heart failure.

Considering these factors, the patient's survival is likely due to the effectiveness of his multidrug regimen, relatively controlled hypertension, stable LVEF, and the absence of severe kidney dysfunction, anemia, electrolyte imbalances, or liver dysfunction."
46,46,P0077,"Age: 63
Gender: Female 
Weight: 65 kg
Height: 152 cm
NYHA Class: III
Blood Pressure: 105/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 41
ALT or GPT (IU/L): 7.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 111.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,63
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,39
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 2093.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,05
Urea (mg/dL): 11,58
LVEF (%): 30.0
Medications: Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient, a 63-year-old female with a history of idiopathic dilated cardiomyopathy, has a relatively poor prognosis based on her current clinical presentation. Her left ventricular ejection fraction (LVEF) is severely impaired at 30%, indicating significant systolic dysfunction. The patient is also classified as NYHA Class III, indicating moderate to severe symptoms of heart failure.

The elevated Pro-BNP level (2093.0 ng/L) further supports the presence of heart failure, as this biomarker is often used to diagnose and monitor heart failure. The patient's high creatinine level (111.0 umol/L) and low albumin level (41 g/L) suggest renal impairment, which is common in patients with heart failure.

The patient is on appropriate medications for heart failure, including loop diuretics, spironolactone, statins, and an ACE inhibitor. These medications are standard treatments for heart failure with reduced ejection fraction (HFrEF).

The ECG findings of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles are concerning and may indicate underlying cardiac instability. However, the patient's overall clinical presentation and the fact that she is being treated with appropriate medications suggest that she is being managed for these conditions.

Given the patient's advanced heart failure and impaired renal function, her survival is a testament to the effectiveness of her current treatment regimen and management. Her ability to survive suggests that she is tolerating her medications and is receiving adequate care for her condition."
47,47,P0080,"Age: 72
Gender: Male 
Weight: 66 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 38,9
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 6,21
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 49
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,88
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 183.0
Protein (g/L): 65
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,11
Urea (mg/dL): 7,57
LVEF (%): 38.0
Medications: Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 72-year-old male with a history of idiopathic dilated cardiomyopathy, dyslipemia, and hypertension, has a reduced left ventricular ejection fraction (LVEF) of 38%. Despite this, the patient is a survivor, indicating that they have not experienced a fatal outcome.

Several factors may have contributed to the patient's survival:

1.  Stable Blood Pressure: The patient's blood pressure is within a relatively normal range (120/60 mmHg), which suggests that their cardiovascular system is not under excessive strain.
2.  Optimal Medications: The patient is on loop diuretics and spironolactone, which are commonly used to manage heart failure and reduce fluid overload. These medications may have helped to alleviate symptoms and improve the patient's cardiac function.
3.  Lack of Significant Arrhythmias: Although the patient has polymorphic ventricular extrasystoles, there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias. This suggests that the patient's cardiac rhythm is relatively stable.
4.  Mild Kidney Function Impairment: The patient's creatinine level is elevated (103.0 mmol/L), indicating mild kidney function impairment. However, this is not severe enough to suggest that the patient is at high risk for acute kidney injury or failure.
5.  Normal TSH and T4 Levels: The patient's thyroid function is within normal limits, which is important for maintaining cardiac function and overall health.
6.  Low Pro-BNP Levels: The patient's B-type natriuretic peptide (BNP) level is elevated (183.0 ng/L), which suggests that the patient's heart is under strain. However, the level is not extremely high, which may indicate that the patient is not experiencing severe heart failure.
7.  Absence of Severe Electrolyte Imbalances: The patient's potassium level is within a relatively normal range (4.2 mEq/L), which is important for maintaining cardiac function.

Overall, while the patient has a history of idiopathic dilated cardiomyopathy and other cardiovascular risk factors, their current clinical status suggests that they are stable and not at high risk for a fatal outcome at this time."
48,48,P0082,"Age: 71
Gender: Male 
Weight: 70 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 44,8
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,6
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,66
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 430.0
Protein (g/L): 70
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,77
Urea (mg/dL): 7,57
LVEF (%): 24.0
Medications: Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to a combination of factors, including the effectiveness of the current medication regimen, the patient's overall clinical condition, and the presence of certain biomarkers. 

The patient is taking Digoxin and an ACE Inhibitor, which are both commonly used in the management of heart failure and cardiomyopathy. The patient's LVEF (Left Ventricular Ejection Fraction) of 24% indicates severe heart failure, but the fact that they are still alive suggests that the medications are helping to stabilize the patient's condition.

The low levels of T3 and T4 (thyroid hormones) may also be a contributing factor to the patient's survival. Hypothyroidism can be associated with heart failure, but in this case, the TSH level is within the normal range, indicating that the patient's thyroid function is not significantly impaired.

The patient's Pro-BNP (B-type Natriuretic Peptide) level of 430.0 ng/L is elevated, which is consistent with heart failure. However, the fact that the patient is still alive suggests that the elevated BNP level is not indicative of an acute decompensation of heart failure.

The patient's troponin level is within normal limits, which suggests that there is no acute myocardial infarction or significant cardiac damage.

The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG may be a concern, but the fact that they are non-sustained suggests that they are not causing significant hemodynamic instability.

Overall, the combination of effective medical therapy, the patient's overall clinical condition, and the presence of certain biomarkers that are not indicative of acute cardiac damage or instability have contributed to the patient's survival."
49,49,P0084,"Age: 75
Gender: Male 
Weight: 83 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 47,19
ALT or GPT (IU/L): 52.0
AST or GOT (IU/L): 35.0
Total Cholesterol (mmol/L): 3,93
Creatinine (mmol/L): 149.0
Gamma-glutamil transpeptidase (IU/L): 40
Glucose (mmol/L): 14,7
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,59
Potassium (mEq/L): 5,2
LDL (mmol/L): 1,32
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 671.0
Protein (g/L): 68
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,04
Urea (mg/dL): 14,69
LVEF (%): 28.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient is a 75-year-old male with a history of idiopathic dilated cardiomyopathy, diabetes, and multiple comorbidities. His left ventricular ejection fraction (LVEF) is significantly reduced at 28%, indicating severe heart failure. The patient's pro-BNP level of 671 ng/L is elevated, which is consistent with heart failure.

The patient's laboratory results show evidence of liver dysfunction (elevated ALT and AST), renal impairment (elevated creatinine and urea), and electrolyte imbalance (hypokalemia). His glucose level is also elevated, indicating poor glucose control.

Despite these complications, the patient is on a comprehensive treatment regimen, including diabetes medication, beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor. These medications are standard treatments for heart failure and diabetes.

The patient's ECG does not show any acute arrhythmias, but there are unknown paroxysmal supraventricular tachyarrhythmia and bradycardia codes. However, these are not specified, so it is unclear if they are present or not.

Given the patient's advanced age, multiple comorbidities, and comprehensive treatment regimen, the most likely reason for the patient's outcome is that he is a survivor, indicating that he has survived the acute event or exacerbation of his heart failure. The patient's treatment plan and medical history suggest that he is receiving appropriate care for his conditions, and his outcome is likely due to the effectiveness of his treatment and his body's resilience."
50,50,P0086,"Age: 30
Gender: Male 
Weight: 103 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 50,8
ALT or GPT (IU/L): 191.0
AST or GOT (IU/L): 146.0
Total Cholesterol (mmol/L): 5,97
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 700
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,39
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 763.0
Protein (g/L): 80
T3 (pg/dL): 0,06
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,78
Urea (mg/dL): 4,46
LVEF (%): 39.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 30-year-old male with a history of enolic dilated cardiomyopathy, which is a condition where the heart's ability to pump blood is impaired due to a weakening of the heart muscle. The patient's left ventricular ejection fraction (LVEF) is 39%, indicating a significant reduction in cardiac function. However, the patient is a survivor, indicating that he has not experienced a fatal cardiac event such as a heart attack or sudden cardiac death.

Several factors contribute to the patient's survival:

1.  Medications: The patient is on a combination of beta blockers, digoxin, loop diuretics, spironolactone, and ACE inhibitors, which are commonly used to manage heart failure and dilated cardiomyopathy. These medications help to reduce symptoms, slow the progression of the disease, and improve survival.
2.  Pro-BNP levels: The patient's pro-BNP (brain natriuretic peptide) level is elevated at 763.0 ng/L, which is a marker of heart failure. However, the fact that the patient is a survivor suggests that the level is not so high that it would indicate a catastrophic cardiac event.
3.  ECG findings: Although the patient has polymorphic ventricular extrasystoles, there is no evidence of ventricular tachycardia, non-sustained ventricular tachycardia, or paroxysmal supraventricular tachyarrhythmia. These findings suggest that the patient's cardiac rhythm is not severely abnormal.
4.  Laboratory results: The patient's liver function tests (ALT and AST) are elevated, which may indicate liver damage or inflammation, but this is not directly related to the patient's cardiac survival.
5.  Hemoglobin and electrolytes: The patient's hemoglobin level is within a normal range, and electrolyte levels (potassium, sodium) are also within normal limits, which reduces the risk of arrhythmias and cardiac arrest.

In summary, the patient's survival can be attributed to the combination of his medications, relatively stable cardiac rhythm, and the absence of severe cardiac abnormalities."
51,51,P0088,"Age: 62
Gender: Male 
Weight: 74 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 111.0
Gamma-glutamil transpeptidase (IU/L): 46
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,9
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 720.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,997
Urea (mg/dL): 8,02
LVEF (%): 36.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient's outcome is a survivor, which can be attributed to several factors based on the provided data. 

Firstly, the patient's ejection fraction (LVEF) is 36%, which indicates that the patient has a reduced left ventricular function. However, this patient is on optimal medical therapy with Digoxin, Loop Diuretics, and an ACE Inhibitor, which are standard treatments for heart failure with reduced ejection fraction (HFrEF). These medications aim to improve symptoms, slow disease progression, and reduce hospitalizations.

The patient's blood pressure is within a relatively normal range (120/80 mmHg), which is beneficial for heart failure management. The patient's total cholesterol level is elevated (4.78 mmol/L), but HDL cholesterol is relatively low (1.22 mmol/L). The patient is not on a statin, which is a common medication used to lower cholesterol levels. However, the patient's LDL level is within a relatively acceptable range (2.9 mmol/L).

The patient's Pro-BNP level is elevated (720.0 ng/L), which is consistent with heart failure. However, the patient's troponin level is normal (0.01 ng/mL), indicating that there is no acute coronary syndrome. The patient's potassium level is slightly low (3.9 mEq/L), which may be due to the use of diuretics.

The patient's TSH level is within a normal range (0.997 mIU/L), indicating that there is no evidence of hypothyroidism, which can contribute to heart failure.

The patient's creatinine level is elevated (111.0 umol/L), indicating impaired renal function, which is common in patients with heart failure. However, the patient's urea level is relatively normal (8.02 mg/dL), which suggests that the renal impairment is not severe.

Considering the patient's age, reduced ejection fraction, and optimal medical therapy, the patient's outcome as a survivor can be attributed to the effectiveness of the treatment plan, relatively controlled blood pressure, and the absence of acute coronary syndrome. The patient's overall clinical picture suggests that the heart failure is well-managed, and the patient is likely to continue to survive with ongoing medical management and lifestyle modifications."
52,52,P0089,"Age: 69
Gender: Male 
Weight: 84 kg
Height: 172 cm
NYHA Class: III
Blood Pressure: 100/60 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 46,9
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,61
Creatinine (mmol/L): 116.0
Gamma-glutamil transpeptidase (IU/L): 50
Glucose (mmol/L): 5
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,9
LDL (mmol/L): 4,03
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 5432.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,55
Urea (mg/dL): 7,8
LVEF (%): 18.0
Medications: Beta Blockers, Digoxin, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 69-year-old male with a history of hypertensive cardiomyopathy and hypertension. He is classified as NYHA Class III, indicating moderate to severe heart failure symptoms. His low left ventricular ejection fraction (LVEF) of 18% suggests significant left ventricular dysfunction. 

The patient's blood pressure is 100/60 mmHg, which is low and may be indicative of orthostatic hypotension. His creatinine level of 116.0 mmol/L suggests impaired renal function, which is a common complication of heart failure.

The patient's elevated Pro-BNP (Brain Natriuretic Peptide) level of 5432.0 ng/L is consistent with heart failure, particularly left ventricular dysfunction. His troponin level of 0.01 ng/mL is slightly elevated, which may indicate myocardial injury or ischemia.

The patient's lipid profile shows elevated total cholesterol and LDL levels, which are risk factors for cardiovascular disease. His HDL level is low, which is a risk factor for atherosclerosis.

The patient's TSH level is within the normal range, which suggests that his thyroid function is not contributing to his heart failure symptoms. His T3 and T4 levels are also within the normal range, which suggests that his thyroid function is not contributing to his heart failure symptoms.

The patient is on beta blockers, digoxin, spironolactone, and an ACE inhibitor, which are standard treatments for heart failure and hypertension.

Given the patient's history, physical examination, and laboratory results, it is likely that his outcome as a survivor is due to the following factors:

1. Optimal medical management: The patient is on a comprehensive treatment plan that includes beta blockers, digoxin, spironolactone, and an ACE inhibitor, which are all evidence-based treatments for heart failure and hypertension.
2. Low blood pressure: The patient's low blood pressure may have reduced his cardiac workload and prevented further cardiac damage.
3. Renal function: Although the patient's creatinine level is elevated, his renal function is not severely impaired, which may have allowed his body to clear waste products and maintain homeostasis.
4. Low troponin level: The patient's troponin level is only slightly elevated, which suggests that his myocardial injury is not severe.
5. Normal thyroid function: The patient's thyroid function is within the normal range, which suggests that his thyroid function is not contributing to his heart failure symptoms.

In conclusion, the patient's outcome as a survivor is likely due to a combination of optimal medical management, low blood pressure, preserved renal function, low troponin level, and normal thyroid function."
53,53,P0090,"Age: 58
Gender: Female 
Weight: 67 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 105/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 6,4
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,88
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1486.0
Protein (g/L): 63
T3 (pg/dL): 0,04
T4 (ng/L): 17
TSH (mIU/L): 1,18
Urea (mg/dL): 10,98
LVEF (%): 20.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 58-year-old female with a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge, leading to reduced heart function. The patient's left ventricular ejection fraction (LVEF) is severely reduced at 20%, indicating poor heart function.

Despite the patient's poor heart function, she is classified as NYHA Class II, which means she experiences some limitations in physical activity but is still able to perform daily activities without significant discomfort. This suggests that the patient's symptoms are not severe enough to limit her daily life, and she is likely able to manage her condition with medication.

The patient's blood pressure is within a relatively normal range, and her lipid profile shows elevated total cholesterol and LDL levels, which are risk factors for cardiovascular disease. However, her HDL level is also elevated, which is a protective factor against cardiovascular disease.

The patient's kidney function is slightly impaired, as indicated by elevated creatinine levels. This could be a result of her heart failure or other underlying conditions.

The patient's thyroid function tests (T3, T4, and TSH) are within normal limits, ruling out thyroid dysfunction as a contributing factor to her heart failure.

The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are common in patients with dilated cardiomyopathy. However, there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias.

The patient is on a regimen of beta blockers, digoxin, loop diuretics, spironolactone, and ACE inhibitors, which are standard medications for heart failure management. The use of these medications likely helped to stabilize the patient's condition and improve her symptoms.

Considering the patient's age, sex, and comorbidities, as well as her current medication regimen, the most likely reason for the patient's outcome is that she is able to manage her condition effectively with medication and lifestyle modifications. The patient's heart function is severely impaired, but she is able to survive with supportive care and close monitoring."
54,54,P0091,"Age: 53
Gender: Male 
Weight: 105 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 47
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 5,77
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 157.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,88
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 24.0
Protein (g/L): 79
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,26
Urea (mg/dL): 6,16
LVEF (%): 36.0
Medications: Calcium Channel Blocker, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 53-year-old male with a history of hypertensive cardiomyopathy and hypertension, which is a significant risk factor for heart failure. His NYHA Class II classification indicates that he experiences some limitations in physical activity but is still able to perform daily tasks without symptoms. The patient's LVEF of 36% suggests that he has a reduced left ventricular ejection fraction, which is consistent with heart failure with reduced ejection fraction (HFrEF).

The patient's blood pressure is within a relatively controlled range, which is a positive sign given his history of hypertension. However, his total cholesterol and LDL levels are elevated, which may contribute to his cardiovascular risk.

The patient's liver enzymes (ALT and AST) are within normal limits, indicating no significant liver dysfunction. His creatinine level is elevated at 80.0 umol/L, suggesting some degree of renal impairment, which is not uncommon in patients with heart failure.

The patient's potassium level is within the normal range, which is a good sign given his heart failure diagnosis. His TSH level is within the normal range, indicating no apparent thyroid dysfunction.

The patient's Troponin level is low, which suggests that he does not have an acute myocardial infarction. His Pro-BNP level is also low, which is a good sign, as elevated levels are associated with heart failure.

The patient is on a combination of medications, including calcium channel blockers, beta blockers, digoxin, loop diuretics, and ACE inhibitors, which is a standard treatment regimen for heart failure with reduced ejection fraction.

Given the patient's stable medication regimen, controlled blood pressure, and relatively low Pro-BNP level, it is likely that the patient's heart failure is being well-managed. The patient's overall condition is stable, and he is able to tolerate his daily activities without significant symptoms, which suggests that he is a survivor."
55,55,P0092,"Age: 50
Gender: Female 
Weight: 108 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,49
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 88
Glucose (mmol/L): 19,7
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 5,1
LDL (mmol/L): 3,96
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 350.0
Protein (g/L): 67
T3 (pg/dL): 0,06
T4 (ng/L): 14
Troponin (ng/mL): 0,02
TSH (mIU/L): 4,3
Urea (mg/dL): 9,15
LVEF (%): 27.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

This patient, a 50-year-old female with a history of Hypertensive cardiomyopathy, Diabetes, Dyslipemia, and Hypertension, has been managed with a combination of medications including Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, and ACE Inhibitor. 

The patient's LVEF (Left Ventricular Ejection Fraction) is significantly reduced at 27%, indicating severe left ventricular dysfunction. The elevated Pro-BNP (B-type natriuretic peptide) level of 350.0 ng/L further supports the presence of heart failure, which is consistent with the patient's NYHA Class II classification.

The patient's blood pressure is well-controlled at 130/70 mmHg, and the medications seem to be effective in managing her hypertension. The presence of ventricular extrasystoles on the ECG is a common finding in patients with cardiomyopathy, but it does not appear to be causing any significant arrhythmia.

The patient's laboratory results show a slightly elevated glucose level (19.7 mmol/L) and total cholesterol level (6.49 mmol/L), which are consistent with her diabetes and dyslipemia. The liver function tests are within normal limits, and the kidney function is relatively preserved, with a creatinine level of 80.0 μmol/L.

The patient's TSH level is within the normal range, and the T3 and T4 levels are low, which is consistent with the use of beta blockers and possibly other medications that can affect thyroid function.

Given the patient's complex medical history and the presence of severe left ventricular dysfunction, it is likely that she is being managed in a hospital setting to monitor her condition closely. The fact that she is a survivor suggests that her treatment plan is effective in managing her symptoms and preventing further cardiac decompensation. However, close monitoring and adjustments to her medications may be necessary to prevent further cardiac events."
56,56,P0093,"Age: 40
Gender: Female 
Weight: 67 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 38
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 62.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,52
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 152.0
Protein (g/L): 65
T3 (pg/dL): 0,03
T4 (ng/L): 16
Troponin (ng/mL): 0,005
TSH (mIU/L): 2,23
Urea (mg/dL): 4,49
LVEF (%): 60.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 40-year-old female with a history of idiopathic dilated cardiomyopathy, has been treated with a comprehensive medication regimen consisting of beta blockers, loop diuretics, spironolactone, and an ACE inhibitor. These medications are standard treatments for heart failure and are aimed at reducing symptoms, improving cardiac function, and preventing complications.

The patient's current left ventricular ejection fraction (LVEF) is 60%, which indicates that the heart is pumping blood efficiently enough to meet the body's needs. This is a significant improvement from the underlying condition of idiopathic dilated cardiomyopathy, which is characterized by a decreased LVEF.

The patient's blood pressure is within a relatively normal range (100/60 mmHg), and her laboratory results show no signs of significant organ damage or dysfunction. The creatinine level is within normal limits, indicating that kidney function is preserved. The pro-BNP level is slightly elevated at 152.0 ng/L, which may indicate some degree of heart failure, but it is not excessively high.

The absence of significant arrhythmias on the ECG, such as ventricular tachycardia or bradycardia, is a positive sign. The presence of monomorphic ventricular extrasystoles is common and not typically a cause for concern in this context.

Given the patient's stable clinical status, preserved kidney function, and effective medication regimen, the patient's outcome of survival is likely due to the successful management of her idiopathic dilated cardiomyopathy and heart failure. Regular follow-up and monitoring of her condition will be essential to prevent complications and ensure continued improvement."
57,57,P0094,"Age: 31
Gender: Male 
Weight: 79 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 105/60 mmHg
Past Medical History: Post-myocardial dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 47
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,51
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 951.0
Protein (g/L): 80
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,79
Urea (mg/dL): 5,16
LVEF (%): 35.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's medical history of post-myocardial dilated cardiomyopathy and myocardial infarction, it is not surprising that the patient has a left ventricular ejection fraction (LVEF) of 35%, which indicates a reduced left ventricular function. The patient's current medication regimen, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, suggests that the patient is being managed for heart failure symptoms.

The patient's albumin level of 47 g/L is within the normal range, which suggests that the liver function is likely not significantly impaired. The low levels of AST and ALT suggest that the liver is not experiencing significant damage.

The patient's lipid profile shows elevated total cholesterol (4.29 mmol/L) and LDL (2.51 mmol/L) levels, which are risk factors for cardiovascular disease. However, the HDL level of 1.24 mmol/L is within the normal range, which is beneficial.

The patient's creatinine level of 97.0 umol/L is elevated, which suggests impaired kidney function. This is consistent with the patient's history of heart failure, as decreased kidney function is a common complication of heart failure.

The patient's pro-BNP level of 951.0 ng/L is elevated, which is consistent with heart failure. The patient's TSH level of 1.79 mIU/L is within the normal range, which suggests that thyroid function is not significantly impaired.

The patient's troponin level of 0.03 ng/mL is within the normal range, which suggests that there is no ongoing myocardial damage.

The patient's ECG shows a monomorphic ventricular extrasystole, which is a common finding in patients with heart failure. However, there is no evidence of sustained ventricular tachycardia, paroxysmal supraventricular tachyarrhythmia, or bradycardia.

Considering the patient's overall medical history, laboratory results, and ECG findings, the patient's outcome as a survivor is likely due to the effective management of their heart failure symptoms with their current medication regimen and close monitoring by their healthcare team. The patient's reduced LVEF and elevated pro-BNP level indicate that the patient still has heart failure, but the patient's overall clinical status suggests that they are stable and able to survive with ongoing medical management."
58,58,P0095,"Age: 50
Gender: Female 
Weight: 77 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 120/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 38
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 6,08
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 5
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 3,9
LDL (mmol/L): 3,1
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 40.0
Protein (g/L): 67
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,27
Urea (mg/dL): 6,49
LVEF (%): 50.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient's outcome of survival can be attributed to a combination of factors, including her current medical management and the underlying characteristics of her idiopathic dilated cardiomyopathy. 

Firstly, the patient is on loop diuretics and an ACE inhibitor, which are standard medications for managing heart failure symptoms and improving cardiac function in patients with dilated cardiomyopathy. The use of these medications suggests that her condition has been adequately managed, contributing to her survival.

The patient's LVEF (Left Ventricular Ejection Fraction) is 50%, which indicates that her heart is still pumping efficiently to some extent. Although it is below the normal range, it is not severely impaired, which may have contributed to her ability to survive.

Additionally, the patient's Pro-BNP (Brain Natriuretic Peptide) level is 40.0 ng/L, which is elevated but not excessively high. Elevated Pro-BNP levels are associated with heart failure, but a moderate level like this may indicate that her condition is being managed effectively.

The patient's laboratory results also show relatively normal liver function (ALT, AST, GGT) and electrolyte levels (Potassium, Sodium), which are essential for maintaining cardiac function. Her TSH (Thyroid-Stimulating Hormone) level is within the normal range, indicating that her thyroid function is not contributing to her cardiac condition.

The patient's low T3 level may indicate a euthyroid sick syndrome, which is a common condition in patients with heart failure. This condition does not necessarily indicate a poor prognosis.

The absence of severe abnormalities in the ECG, such as sustained ventricular tachycardia or bradycardia, also suggests that the patient's heart rhythm is stable, contributing to her survival.

In summary, the patient's survival can be attributed to her current medical management, relatively preserved cardiac function (LVEF 50%), and the absence of severe abnormalities in her laboratory and ECG results."
59,59,P0096,"Age: 68
Gender: Male 
Weight: 71 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,97
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 5,7
LDL (mmol/L): 2,4
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 675.0
Protein (g/L): 65
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,16
TSH (mIU/L): 3,73
Urea (mg/dL): 12,15
LVEF (%): 31.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 68-year-old male with a history of hypertensive cardiomyopathy and hypertension, which is a significant risk factor for heart failure. His low left ventricular ejection fraction (LVEF) of 31% indicates severe left ventricular dysfunction, consistent with heart failure with reduced ejection fraction (HFrEF).

The patient's laboratory results show elevated creatinine levels (133.0 mmol/L) and a high pro-BNP level (675.0 ng/L), both of which are indicative of decreased renal function and increased cardiac stress, respectively. His low hemoglobin (133.0 g/L) may be a sign of anemia, which can contribute to decreased oxygen delivery to the tissues and exacerbate heart failure symptoms.

The patient's lipid profile shows elevated total cholesterol (4.97 mmol/L) and LDL (2.4 mmol/L) levels, which are risk factors for atherosclerotic cardiovascular disease. His low HDL (1.5 mmol/L) level further increases his cardiovascular risk.

The patient's medications, including an angiotensin II receptor blocker, loop diuretics, spironolactone, and an ACE inhibitor, are standard treatments for heart failure with reduced ejection fraction. The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and unknown paroxysmal supraventricular tachyarrhythmia on the ECG suggests underlying cardiac arrhythmias, which can be a complication of heart failure.

Despite these risk factors and complications, the patient survived, likely due to the aggressive management of his heart failure symptoms with medications and possibly other supportive care measures. His low TSH level (3.73 mIU/L) suggests that his thyroid function is within normal limits, which can help explain why he did not have a more severe outcome.

In conclusion, the patient's survival is likely due to the combination of his medication regimen, underlying cardiac function, and the absence of other complicating factors such as severe renal failure or severe anemia, which would have increased his risk of mortality."
60,60,P0097,"Age: 68
Gender: Female 
Weight: 78 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,45
Potassium (mEq/L): 5
LDL (mmol/L): 2,59
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1284.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,03
TSH (mIU/L): 4,53
Urea (mg/dL): 7,49
LVEF (%): 35.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 68-year-old female with a history of idiopathic dilated cardiomyopathy, hypertension, and a left ventricular ejection fraction (LVEF) of 35%, indicating severe systolic heart failure. Despite these significant comorbidities, the patient is a survivor, which suggests that she has been receiving appropriate medical management and treatment.

The patient's current medications, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, are consistent with standard treatment for heart failure and hypertension. Beta blockers help reduce the heart rate and contractility, digoxin increases the strength of the heart contractions, loop diuretics reduce fluid overload, spironolactone helps to reduce the effects of aldosterone, and ACE inhibitors reduce the heart's workload.

The patient's ECG results indicate non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death, but the absence of sustained ventricular tachycardia or bradycardia suggests that the patient's heart is not in a life-threatening rhythm. The presence of polymorphic ventricular extrasystoles is a common finding in patients with heart failure and is not typically a predictor of poor outcome.

The patient's laboratory results, including normal liver enzymes (ALT and AST), normal electrolytes (potassium and sodium), and normal glucose levels, suggest that the patient is not experiencing significant metabolic derangements that could contribute to cardiac instability.

The patient's TSH and T4 levels are within normal limits, indicating that there is no apparent thyroid dysfunction contributing to her cardiac condition.

The patient's B-type natriuretic peptide (BNP) level is elevated at 1284 pg/L, which is consistent with heart failure. However, the patient's creatinine level is within normal limits, suggesting that there is no significant renal impairment contributing to her cardiac condition.

The patient's hemoglobin level is within normal limits, which suggests that there is no significant anemia contributing to her cardiac condition.

In summary, the patient's survival is likely due to the effective management of her heart failure and hypertension with standard medications and close monitoring of her cardiac function and rhythm."
61,61,P0098,"Age: 56
Gender: Female 
Weight: 60 kg
Height: 140 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 66.0
AST or GOT (IU/L): 66.0
Total Cholesterol (mmol/L): 5,64
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 5,2
LDL (mmol/L): 3,96
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 2081.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 19
TSH (mIU/L): 5,52
Urea (mg/dL): 4,99
LVEF (%): 38.0
Medications: Diabetes Medication, Amiodarone, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient, a 56-year-old female with a history of idiopathic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension, has a complex medical profile. Despite her multiple comorbidities, she is able to survive. Several factors contribute to her survival:

1.  Optimal Medication Management: The patient is on a multidrug regimen, including beta blockers, digoxin, loop diuretics, and an ACE inhibitor, which are all commonly used to manage heart failure and its associated conditions. These medications help control symptoms, reduce morbidity, and potentially slow disease progression.
2.  Control of Blood Pressure: Her blood pressure is within a relatively normal range (140/80 mmHg), which is beneficial for patients with heart failure. Elevated blood pressure can exacerbate heart failure symptoms and worsen prognosis.
3.  Stable Renal Function: Although her creatinine level is slightly elevated (80.0 mmol/L), it is not indicative of severe kidney impairment. This suggests that her kidneys are functioning relatively well, which is essential for removing waste products and excess fluids that can strain the heart.
4.  Appropriate Lipid Management: Her total cholesterol and LDL levels are high, but her HDL level is relatively low. The use of lipid-lowering medications, such as statins, is often recommended for patients with heart failure to reduce cardiovascular risk.
5.  Monitoring and Follow-up: The patient's Pro-BNP level is elevated (2081.0 ng/L), which indicates some degree of heart failure severity. However, her LVEF (left ventricular ejection fraction) is 38%, which, while low, is not extremely low. This suggests that her heart is still pumping some blood efficiently.
6.  No Recent Sudden Cardiac Death or Cardiac Arrest: The patient's ECG shows monomorphic ventricular extrasystoles, but no ventricular tachycardia or sustained arrhythmias. This suggests that her heart rhythm is relatively stable, which is a positive prognostic indicator.
7.  No Recent Hospitalization or Cardiac Event: The fact that the patient is able to survive suggests that she has not experienced a recent cardiac event, such as a heart attack or stroke, which could have contributed to her current condition.

Considering these factors, the patient's survival is likely due to a combination of her medical management, relatively stable renal function, and the absence of recent cardiac events."
62,62,P0100,"Age: 68
Gender: Female 
Weight: 70 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 150/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 47,1
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,83
Creatinine (mmol/L): 82.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 7,4
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,76
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 200.0
Protein (g/L): 80
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,21
Urea (mg/dL): 6,01
LVEF (%): 27.0
Medications: Calcium Channel Blocker, Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 68-year-old female with a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and enlarged due to a heart attack or reduced blood flow. Despite this, the patient has a relatively preserved hemoglobin level (141.0 g/L) and a normal sodium level (140.0 mEq/L), indicating that the patient is not experiencing severe anemia or hyponatremia.

The patient's LVEF (left ventricular ejection fraction) is severely reduced at 27.0%, indicating poor heart function. However, the patient is on a combination of medications that are standard for managing heart failure, including a calcium channel blocker, angiotensin II receptor blocker, digoxin, loop diuretics, spironolactone, and nitrovasodilator. These medications are likely helping to manage the patient's symptoms and improve heart function to some extent.

The patient's creatinine level is elevated at 82.0 umol/L, which may indicate some degree of kidney dysfunction. However, the urea level is only slightly elevated at 6.01 mg/dL, suggesting that the patient's kidney function is not severely impaired.

The patient's troponin level is normal (0.01 ng/mL), which suggests that there is no acute myocardial infarction. The TSH level is within the normal range (2.21 mIU/L), indicating that the patient's thyroid function is not contributing to the patient's cardiac condition.

The patient's Pro-BNP level is elevated at 200.0 ng/L, which is a marker of heart failure. However, this is not unexpected given the patient's history of heart failure.

The patient's T3 and T4 levels are within the normal range, and the patient's HDL and LDL cholesterol levels are relatively well-controlled. The patient's potassium level is slightly low (4.1 mEq/L), which may be related to the use of loop diuretics.

Given the patient's medication regimen and the lack of acute cardiac events, the patient's ability to survive suggests that the treatment plan is effective in managing the patient's heart failure symptoms and preventing further cardiac complications. The patient's overall clinical picture suggests that the patient is stable and being well-managed for her condition."
63,63,P0101,"Age: 56
Gender: Male 
Weight: 72 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/50 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,55
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,74
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 3566.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,02
TSH (mIU/L): 0,904
Urea (mg/dL): 6,32
LVEF (%): 17.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's medical history of idiopathic dilated cardiomyopathy, the low left ventricular ejection fraction (LVEF) of 17% indicates severe systolic dysfunction. The patient's high levels of B-type natriuretic peptide (BNP) at 3566 ng/L also suggest significant heart failure. However, despite these factors, the patient has been managed with a combination of beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are standard treatments for heart failure with reduced ejection fraction (HFrEF).

The patient's vital signs, including blood pressure and heart rate, do not indicate acute decompensation or severe hemodynamic instability. The absence of symptoms such as dyspnea, orthopnea, or syncope also suggests that the patient's condition is stable.

The ECG findings of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia are concerning but not uncommon in patients with cardiomyopathy. However, the patient's overall clinical picture and the absence of acute symptoms or signs of hemodynamic compromise suggest that these findings are likely not the primary cause of the patient's outcome.

Given the patient's stable clinical condition, management with standard heart failure therapies, and the absence of acute decompensation or severe hemodynamic instability, the patient's survival can be attributed to the effectiveness of the current treatment regimen and close monitoring of the patient's condition."
64,64,P0102,"Age: 63
Gender: Male 
Weight: 102 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 37
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 11,5
Hemoglobin (g/L): 128.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 5,3
LDL (mmol/L): 2,66
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 346.0
Protein (g/L): 67
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,06
TSH (mIU/L): 2,34
Urea (mg/dL): 6,99
LVEF (%): 43.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 63-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction, has been managed with a multidrug regimen including beta blockers, calcium channel blockers, loop diuretics, statins, and ACE inhibitors. The patient's ejection fraction (LVEF) is 43%, indicating a reduced left ventricular function, which is a common complication of ischemic cardiomyopathy.

The patient's blood pressure is well-controlled at 110/70 mmHg, and the glucose level is within the target range for diabetes management. The lipid profile shows a total cholesterol of 4.65 mmol/L, with an HDL of 0.88 mmol/L and an LDL of 2.66 mmol/L, indicating some room for improvement in lipid management.

The patient's kidney function, as indicated by the creatinine level of 124.0 mmol/L, is slightly elevated, suggesting some degree of renal impairment. However, the urea level of 6.99 mg/dL is within the normal range, which may indicate that the renal impairment is not severe.

The patient's thyroid function is within the normal range, with a TSH level of 2.34 mIU/L and a T4 level of 15 ng/L.

The patient's ECG shows evidence of ventricular extrasystoles and non-sustained ventricular tachycardia, which are common findings in patients with ischemic cardiomyopathy. However, the patient does not have any sustained ventricular tachycardia or bradycardia.

Given the patient's overall clinical picture, including the presence of ischemic cardiomyopathy, reduced LVEF, and evidence of ventricular arrhythmias, it is likely that the patient is being managed in a way that is tailored to their specific needs. The patient's survival is likely due to the combination of their medication regimen, which includes beta blockers and ACE inhibitors that are known to improve survival in patients with heart failure and ischemic cardiomyopathy. Additionally, the patient's well-controlled blood pressure and glucose levels may also contribute to their survival."
65,65,P0103,"Age: 50
Gender: Male 
Weight: 81 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,65
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 144.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,09
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 526.0
Protein (g/L): 68
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,05
Urea (mg/dL): 8,49
LVEF (%): 24.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's profile, the outcome of survival is likely due to a combination of factors, including the patient's current treatment regimen and the presence of certain biomarkers. 

1. Optimal Medications: The patient is on beta blockers, statins, and an ACE inhibitor, which are all standard treatments for heart failure and ischemic dilated cardiomyopathy. Beta blockers help reduce the heart rate and workload, while statins lower cholesterol levels, and ACE inhibitors reduce blood pressure and improve cardiac function.

2. Low TSH Level: The patient's TSH (Thyroid-Stimulating Hormone) level is within the normal range (2.05 mIU/L). This suggests that the patient does not have hypothyroidism, which is a common comorbidity in heart failure patients. Adequate thyroid function is crucial for maintaining cardiac health.

3. Low T3 and T4 Levels: Although the T3 and T4 levels are slightly below the normal range, they are not significantly low. This might be due to the patient's age or other underlying conditions. However, the low levels do not seem to be causing significant harm, and the patient is still on the path of survival.

4. Pro-BNP Level: The Pro-BNP (N-terminal pro-b-type natriuretic peptide) level is elevated at 526.0 ng/L, which is a marker of heart failure. However, despite this, the patient is still alive, suggesting that the heart failure is being managed effectively.

5. LVEF: The left ventricular ejection fraction (LVEF) is severely reduced at 24.0%, indicating significant left ventricular dysfunction. However, the patient's survival suggests that the heart is still functioning, albeit inefficiently.

6. ECG Findings: The presence of non-sustained ventricular tachycardia (VT) and polymorphic ventricular extrasystoles indicates some level of cardiac electrical instability. However, the patient's survival suggests that these arrhythmias are not causing significant harm.

7. Albumin and Creatinine Levels: The patient's albumin level is slightly low (43 g/L), which might indicate mild malnutrition or liver dysfunction. However, the creatinine level is within the normal range, suggesting that renal function is preserved.

In summary, the patient's survival is likely due to a combination of optimal medical treatment, preserved thyroid function, and the absence of significant electrolyte imbalances or other life-threatening conditions."
66,66,P0104,"Age: 51
Gender: Male 
Weight: 75 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 39
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,26
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 7,6
Hemoglobin (g/L): 145.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4
LDL (mmol/L): 1,5
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 405.0
Protein (g/L): 66
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 2,63
Urea (mg/dL): 8,65
LVEF (%): 31.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 51-year-old male with a history of idiopathic dilated cardiomyopathy, diabetes, and dyslipemia. He has a low left ventricular ejection fraction (LVEF) of 31%, indicating significant left ventricular dysfunction. However, despite this, the patient is a survivor, which can be attributed to several factors.

Firstly, the patient's blood pressure is within a relatively normal range (120/70 mmHg), which is beneficial for cardiac function. His medications, including beta blockers, loop diuretics, and an ACE inhibitor, are appropriate for managing heart failure and hypertension, and are likely contributing to his stable condition.

The patient's glucose level (7.6 mmol/L) is slightly elevated but not significantly high, suggesting that his diabetes is well-controlled. His lipid profile shows a high total cholesterol level (3.26 mmol/L), but his low-density lipoprotein (LDL) cholesterol is relatively low (1.5 mmol/L), which is a good sign.

The patient's renal function, as indicated by his creatinine level (106.0 μmol/L), is slightly elevated, which may be a consequence of his heart failure. However, his urea level (8.65 mg/dL) is within a relatively normal range.

The patient's thyroid function tests (TSH, T3, and T4) are within normal limits, which is essential for maintaining cardiac function.

The patient's troponin level (0.03 ng/mL) is within a normal range, indicating no acute myocardial infarction. His pro-BNP level (405.0 ng/L) is elevated, which is consistent with heart failure, but not unexpectedly given his low LVEF.

The absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia on the ECG is a positive sign, indicating that the patient is not experiencing any life-threatening arrhythmias.

Considering these factors, the patient's survival can be attributed to his well-managed heart failure, controlled diabetes, and relatively stable renal function. His medication regimen is also likely contributing to his stable condition."
67,67,P0105,"Age: 75
Gender: Female 
Weight: 77 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 130/88 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 40,4
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 131.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 11,4
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,51
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 2176.0
Protein (g/L): 71
T4 (ng/L): 16
TSH (mIU/L): 1,48
Urea (mg/dL): 10,82
LVEF (%): 39.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient, a 75-year-old female with a history of ischemic dilated cardiomyopathy, diabetes, and hypertension, has been managed with a comprehensive treatment regimen including diabetes medication, angiotensin II receptor blocker, beta blockers, loop diuretics, and spironolactone. Her current medication regimen is likely aimed at controlling her heart failure symptoms, managing her blood pressure, and regulating her diabetes.

The patient's LVEF (left ventricular ejection fraction) of 39% indicates a reduced cardiac function, consistent with her diagnosis of ischemic dilated cardiomyopathy. However, her Pro-BNP level of 2176.0 ng/L, which is elevated, suggests that she is experiencing some degree of heart failure, but the fact that she is a survivor indicates that her current treatment plan is effective in managing her symptoms and preventing further decompensation.

The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG indicates that she is at risk for arrhythmias, but the fact that she is a survivor suggests that these arrhythmias are not severe enough to cause cardiac arrest or sudden cardiac death.

The patient's lab results, including a slightly elevated creatinine level of 131.0 mmol/L, suggest that she may have some degree of renal impairment, which is a common comorbidity in patients with heart failure. However, her hemoglobin level of 135.0 g/L is within the normal range, indicating that she does not have significant anemia.

The patient's lipid profile shows a total cholesterol level of 4.68 mmol/L, which is slightly elevated, but her HDL level of 1.42 mmol/L is within the normal range. Her LDL level of 2.51 mmol/L is also within the target range for patients with heart failure.

Overall, the patient's outcome as a survivor suggests that her treatment plan is effective in managing her heart failure and preventing further complications. However, close monitoring of her cardiac function, renal function, and arrhythmias is necessary to prevent further decompensation and optimize her treatment plan."
68,68,P0106,"Age: 56
Gender: Female 
Weight: 55 kg
Height: 148 cm
NYHA Class: II
Blood Pressure: 125/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 8.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,41
Creatinine (mmol/L): 66.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,16
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1160.0
Protein (g/L): 74,9
T4 (ng/L): 15
TSH (mIU/L): 0,65
Urea (mg/dL): 6,99
LVEF (%): 26.0
Medications: Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 56-year-old female with idiopathic dilated cardiomyopathy, has a relatively favorable outcome despite her advanced heart failure condition. Several factors contribute to this outcome:

1.  Optimal medical management: The patient is on a multidrug regimen that includes loop diuretics, spironolactone, and an ACE inhibitor, which are standard treatments for heart failure with reduced ejection fraction (HFrEF). These medications help manage symptoms, reduce fluid overload, and slow disease progression.

2.  Close monitoring and early intervention: The patient's regular follow-up and monitoring allowed for early detection of potential complications, such as non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles, which can be indicative of arrhythmias and other cardiac issues. This close monitoring enabled timely interventions to prevent potential complications.

3.  Low blood pressure: The patient's blood pressure of 125/80 mmHg is within a relatively normal range, which may indicate effective management of hypertension, a common comorbidity in heart failure patients. Maintaining optimal blood pressure can help reduce cardiac workload and slow disease progression.

4.  Renal function: The patient's creatinine level of 66.0 μmol/L is slightly elevated, indicating mild renal impairment. However, her urea level of 6.99 mg/dL is within a relatively normal range, suggesting that her kidneys are still functioning adequately.

5.  Hemoglobin and anemia management: The patient's hemoglobin level of 127 g/L is within the normal range, indicating that her anemia is well-managed. Anemia is a common comorbidity in heart failure patients, and maintaining adequate hemoglobin levels is essential for optimal cardiac function.

6.  Pro-BNP levels: The patient's Pro-BNP level of 1160 ng/L is elevated, indicating increased ventricular wall stress, but it is not excessively high, suggesting that the patient's heart failure is being managed effectively.

7.  ECG findings: While the patient has non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles, these are not indicative of a poor outcome in this case. The absence of sustained ventricular tachycardia and bradycardia suggests that the patient's cardiac rhythm is relatively stable.

In summary, the patient's favorable outcome can be attributed to her optimal medical management, close monitoring, and effective management of comorbidities, such as hypertension, anemia, and renal function."
69,69,P0110,"Age: 67
Gender: Female 
Weight: 69 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 98/52 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 41
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 5
LDL (mmol/L): 2,43
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 125.0
Protein (g/L): 71
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,72
Urea (mg/dL): 8,32
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 67-year-old female with a history of idiopathic dilated cardiomyopathy, a condition characterized by a weakened heart muscle that impairs its ability to pump blood effectively. Despite this, the patient has been on a treatment regimen that includes diabetes medication, beta blockers, spironolactone, and an ACE inhibitor, which are commonly used to manage heart failure and reduce the risk of complications.

The patient's laboratory results show elevated levels of pro-BNP (125.0 ng/L), which is a biomarker for heart failure, but the troponin level is within normal limits (0.01 ng/mL), indicating that there is no acute myocardial infarction. The patient's left ventricular ejection fraction (LVEF) is 30.0%, which is significantly reduced, indicating a poor heart function.

The patient's blood pressure is within a relatively normal range (98/52 mmHg), and the hemoglobin level is within the normal range (117 g/L). However, the patient's glucose level is elevated (5.8 mmol/L), which may be a concern for diabetes management.

The patient's ECG shows a monomorphic ventricular extrasystole, which is a common finding in patients with heart failure, but there is no evidence of sustained ventricular tachycardia or other arrhythmias.

Given the patient's history of idiopathic dilated cardiomyopathy, the patient's reduced LVEF, and the elevated pro-BNP levels, the patient's outcome as a survivor suggests that the treatment regimen is effective in managing the patient's heart failure symptoms and preventing further complications. The patient's relatively stable vital signs and lack of acute myocardial infarction also support this outcome."
70,70,P0111,"Age: 60
Gender: Male 
Weight: 85 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 115/68 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 40
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,09
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 349.0
Protein (g/L): 76
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,19
Urea (mg/dL): 7,49
LVEF (%): 25.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient's outcome of survival can be attributed to several factors. Firstly, the patient is on appropriate medical therapy for heart failure, including beta blockers and ACE inhibitors, which are known to improve survival and reduce morbidity in patients with heart failure. The patient's LVEF of 25% indicates reduced ejection fraction, a hallmark of heart failure with reduced ejection fraction (HFrEF). Despite this, the patient's low blood pressure (115/68 mmHg) suggests that the medications are effectively managing the patient's blood pressure, which is a critical factor in reducing the risk of cardiovascular events.

The patient's lipid profile, although not ideal, shows a high total cholesterol level, but the LDL level is relatively well-controlled at 2.09 mmol/L, which is below the target for patients with cardiovascular disease. The patient's statin therapy is likely contributing to this.

The patient's troponin level of 0.01 ng/mL indicates that there is no ongoing myocardial infarction, and the low level suggests that the patient is not experiencing acute coronary syndrome.

The patient's kidney function, as indicated by the creatinine level of 97.0 mmol/L, is within normal limits, which suggests that the patient's kidney function is not significantly compromised.

The patient's hemoglobin level of 144.0 g/L is within the normal range, indicating that the patient is not anemic, which can be a factor in patients with heart failure.

The patient's TSH level of 1.19 mIU/L is within the normal range, indicating that the patient's thyroid function is not contributing to their heart failure.

The patient's Pro-BNP level of 349.0 ng/L is elevated, which is consistent with heart failure, but the patient's symptoms and medical history suggest that they are being effectively managed.

In summary, the combination of appropriate medical therapy, controlled blood pressure, well-managed lipid profile, lack of acute coronary syndrome, preserved kidney function, and absence of anemia, all contribute to the patient's survival outcome."
71,71,P0113,"Age: 63
Gender: Male 
Weight: 66 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 105/68 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 43
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,71
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,9
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 290.0
Protein (g/L): 66
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,8
Urea (mg/dL): 9,65
LVEF (%): 25.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to several factors:

1.  Timely and appropriate medical management: The patient is on a combination of medications that are crucial for managing heart failure and cardiomyopathy, including beta blockers, digoxin, loop diuretics, statins, and ACE inhibitors. These medications help control symptoms, improve cardiac function, and reduce the risk of complications.

2.  Monitoring and management of blood pressure: The patient's blood pressure is well-controlled at 105/68 mmHg, which is within the target range for patients with heart failure. Effective blood pressure control is essential in managing heart failure and preventing further strain on the heart.

3.  Low troponin levels: The patient's troponin level is 0.01 ng/mL, which is within the normal range. Elevated troponin levels can indicate cardiac damage, but in this case, the patient's low troponin levels suggest minimal cardiac damage.

4.  Pro-BNP levels: The patient's Pro-BNP level is 290.0 ng/L, which is elevated but not extremely high. Pro-BNP is a marker of heart failure severity, and while an elevated level indicates some level of heart failure, it does not necessarily predict a poor outcome.

5.  LVEF: Although the patient's LVEF is low at 25%, it is not the lowest possible value, indicating that the heart still has some pumping function. A low LVEF can be managed with medical therapy, and the patient's survival suggests that the current treatment plan is effective.

6.  ECG findings: While the patient has some ECG abnormalities, including ventricular extrasystoles and non-sustained ventricular tachycardia, these are not necessarily predictors of poor outcome. In fact, the patient's survival suggests that these findings are not significantly impacting cardiac function.

7.  Patient's overall health: The patient's age, weight, and hemoglobin levels are within relatively normal ranges, which suggests that the patient does not have significant comorbidities that would impact survival.

In conclusion, the combination of timely and effective medical management, controlled blood pressure, low troponin levels, and relatively preserved LVEF, along with the absence of severe comorbidities, likely contributed to the patient's survival."
72,72,P0115,"Age: 67
Gender: Female 
Weight: 65 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 105/59 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,81
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,97
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,59
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 984.0
Protein (g/L): 61
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,16
Urea (mg/dL): 6,99
LVEF (%): 35.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 67-year-old female with a history of ischemic dilated cardiomyopathy, dyslipemia, and myocardial infarction, indicating a compromised cardiac function. Her left ventricular ejection fraction (LVEF) of 35% suggests severe heart failure. Despite this, the patient is on optimal medical therapy with an Angiotensin II Receptor Blocker, Beta Blockers, and Statins, which are standard treatments for heart failure and dyslipidemia.

The patient's laboratory results show a slightly elevated creatinine level (80.0 μmol/L), which may indicate mild renal impairment. However, her eGFR (estimated glomerular filtration rate) is not provided, so it's difficult to assess the severity of renal impairment.

The patient's troponin level is within normal limits (0.01 ng/mL), indicating no recent myocardial infarction. Her pro-BNP (brain natriuretic peptide) level is elevated (984.0 ng/L), which is consistent with heart failure.

The patient's ECG shows ventricular extrasystoles, but no sustained ventricular tachycardia or other concerning arrhythmias. The absence of significant arrhythmias and the patient's stable blood pressure (105/59 mmHg) suggest that the patient is not experiencing acute cardiac instability.

Considering the patient's overall clinical presentation, laboratory results, and ECG findings, the most likely reason for the patient's survival is the effective management of her heart failure and dyslipidemia with optimal medical therapy. The patient's renal function, although slightly impaired, is not severe enough to impact her survival. The absence of acute cardiac instability and arrhythmias also contributes to her survival."
73,73,P0116,"Age: 64
Gender: Male 
Weight: 98 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 15,3
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,17
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 575.0
Protein (g/L): 67
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,88
Urea (mg/dL): 9,32
LVEF (%): 30.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 64-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and myocardial infarction, has a complex medical profile. Despite his history of heart disease, the patient has been on a multidrug regimen consisting of diabetes medication, angiotensin II receptor blocker, beta blockers, loop diuretics, statins, and nitrovasodilators. 

The patient's LVEF (Left Ventricular Ejection Fraction) is 30%, which is significantly reduced and indicates a poor heart function. However, the patient's Pro-BNP (B-type natriuretic peptide) level of 575 ng/L is within the normal range, which may indicate that the patient is not experiencing severe heart failure symptoms at the moment.

The patient's medication regimen is aimed at managing his heart failure, diabetes, and dyslipidemia. The use of beta blockers, ACE inhibitors (angiotensin II receptor blocker), and statins suggests that the patient is being treated for heart failure and cardiovascular risk reduction. The presence of nitrovasodilators may be used to manage symptoms of heart failure or angina.

The patient's ECG shows polymorphic ventricular extrasystoles, which are abnormal heartbeats that can be a sign of underlying cardiac disease. However, there is no evidence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, or paroxysmal supraventricular tachyarrhythmia, which are more concerning signs of cardiac arrhythmias.

Considering the patient's complex medical profile and the multidrug regimen, it is likely that the patient's outcome of survival is due to the effective management of his heart failure and cardiovascular risk factors. The combination of medications and the patient's lack of severe symptoms, as indicated by the normal Pro-BNP level, suggest that the patient is being well-managed and is likely to survive with continued medical treatment and monitoring."
74,74,P0118,"Age: 61
Gender: Male 
Weight: 60 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 124/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,78
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,61
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 709.0
Protein (g/L): 66
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,49
Urea (mg/dL): 7,32
LVEF (%): 35.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 61-year-old male with a history of ischemic dilated cardiomyopathy, has survived despite his poor cardiac function, as indicated by a left ventricular ejection fraction (LVEF) of 35%. This suggests that the patient's heart is not pumping efficiently, which can increase the risk of complications and mortality.

Several factors contribute to the patient's survival:

1.  Optimal Medication Management: The patient is on beta blockers, spironolactone, statins, and an ACE inhibitor, which are all evidence-based treatments for heart failure and cardiomyopathy. These medications help reduce symptoms, slow disease progression, and improve survival.
2.  Low Troponin Levels: The patient's troponin level is within normal limits (0.01 ng/mL), indicating that there is no acute myocardial infarction or significant cardiac damage at the time of evaluation.
3.  Normal Electrolytes: The patient's potassium level (4.2 mEq/L) is within the normal range, which is essential for maintaining proper heart function. Hypokalemia can lead to cardiac arrhythmias and worsen heart failure.
4.  Stable Blood Pressure: The patient's blood pressure (124/55 mmHg) is within a relatively normal range, which reduces the risk of cardiac complications and allows for more efficient blood flow to vital organs.
5.  Low Pro-BNP Levels: Although the patient's Pro-BNP level (709.0 ng/L) is elevated, it is not excessively high. Pro-BNP is a marker of heart failure severity, and a moderate elevation suggests that the patient's condition is being managed effectively.
6.  Normal Hemoglobin and Protein Levels: The patient's hemoglobin (130.0 g/L) and protein (66 g/L) levels are within normal limits, indicating that there is no significant anemia or malnutrition, which can contribute to cardiac decompensation.
7.  Optimal Lipid Profile: The patient's lipid profile, particularly his HDL (1.78 mmol/L) and LDL (2.61 mmol/L) levels, is well-managed, which reduces the risk of cardiovascular events and progression of atherosclerosis.

Considering these factors, the patient's survival can be attributed to a combination of effective medical management, stable cardiac function, and absence of acute cardiac damage or other complicating factors."
75,75,P0119,"Age: 58
Gender: Male 
Weight: 73 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 145/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 49
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 9,7
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,07
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 397.0
Protein (g/L): 75
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,42
Urea (mg/dL): 7,49
LVEF (%): 23.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"REASONING: 

The patient's outcome of survival can be attributed to a combination of factors. Firstly, the patient's blood pressure is well-controlled at 145/70 mmHg, which reduces the risk of cardiovascular complications. The patient is also on beta blockers, which are commonly used to manage heart rate and blood pressure in patients with heart failure and ischemic cardiomyopathy.

The patient's medication regimen includes diabetes medication, statins, and an ACE inhibitor, which are all evidence-based treatments for managing diabetes, dyslipemia, and heart failure. The statins are likely helping to manage the patient's dyslipemia, and the ACE inhibitor is likely helping to reduce the patient's blood pressure and alleviate symptoms of heart failure.

The patient's LVEF (Left Ventricular Ejection Fraction) is 23%, which is low, indicating reduced cardiac function. However, the patient's LVEF has not decreased significantly over time, suggesting that the patient's cardiac function is relatively stable.

The patient's troponin level is 0.01 ng/mL, which is within normal limits, indicating that there is no acute myocardial infarction. The patient's pro-BNP level is 397.0 ng/L, which is elevated, indicating that the patient has heart failure. However, the patient's pro-BNP level is not extremely high, suggesting that the patient's heart failure is not severe.

The patient's ECG shows ventricular extrasystoles and non-sustained ventricular tachycardia, but these are not life-threatening arrhythmias. The patient's TSH level is 2.42 mIU/L, which is within the normal range, indicating that the patient's thyroid function is normal.

The patient's albumin level is 49 g/L, which is low, indicating that the patient has malnutrition or liver disease. However, the patient's AST and ALT levels are within normal limits, suggesting that the patient's liver function is not significantly impaired.

Overall, the patient's outcome of survival can be attributed to a combination of their well-controlled blood pressure, evidence-based medication regimen, stable cardiac function, and absence of acute myocardial infarction."
76,76,P0120,"Age: 61
Gender: Female 
Weight: 58 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 128/67 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 9.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 62.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,33
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 822.0
Protein (g/L): 70
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,07
Urea (mg/dL): 5,83
LVEF (%): 30.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 61-year-old female with a history of idiopathic dilated cardiomyopathy, dyslipemia, and hypertension. Despite her complex medical history, the patient has been on optimal medical therapy with beta blockers, statins, and an ACE inhibitor, which are standard treatments for heart failure and hypertension.

The patient's left ventricular ejection fraction (LVEF) is 30%, indicating significant left ventricular dysfunction, but it is still within the range of some preserved ejection fraction, which is a positive prognostic sign.

The elevated pro-BNP (brain natriuretic peptide) level of 822 ng/L suggests increased ventricular wall stress, but it is not excessively high, indicating that the patient's heart failure is not severely decompensated.

The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, but no sustained ventricular tachycardia or bradycardia. These findings are concerning for arrhythmia, but the fact that they are non-sustained suggests that they are not life-threatening.

The patient's laboratory results show slightly elevated liver enzymes (ALT and AST), but they are not excessively high, indicating that the patient's liver function is not significantly compromised.

The patient's lipid profile shows elevated total cholesterol and LDL, but the patient is on statins, which should help to manage these levels.

The patient's blood glucose level is slightly elevated, but it is not excessively high, and the patient does not have a history of diabetes.

The patient's kidney function is within normal limits, with a creatinine level of 62.0 μmol/L.

Given the patient's complex medical history and the presence of ventricular extrasystoles and non-sustained ventricular tachycardia, the patient's survival can be attributed to the following factors:

1. Optimal medical therapy: The patient is on standard treatments for heart failure and hypertension, which have likely helped to slow the progression of her disease.
2. Preserved LVEF: The patient's LVEF is still within a range that suggests some preserved cardiac function, which is a positive prognostic sign.
3. Non-sustained arrhythmias: The patient's arrhythmias are not life-threatening, and the fact that they are non-sustained suggests that they are not a significant concern at this time.
4. Good kidney function: The patient's kidney function is within normal limits, which suggests that the patient is not experiencing significant renal impairment.

Overall, the patient's survival can be attributed to a combination of optimal medical therapy, preserved cardiac function, and the absence of severe arrhythmias or renal impairment."
77,77,P0121,"Age: 41
Gender: Female 
Weight: 97 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 5,4
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 9,8
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,05
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 642.0
Protein (g/L): 70
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,87
Urea (mg/dL): 6,99
LVEF (%): 35.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 41-year-old female with a complex medical history, including idiopathic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension. Despite the presence of these comorbidities, the patient's blood pressure is well-controlled at 120/70 mmHg, and her glucose level is slightly elevated but not severely so (9.8 mmol/L). 

The patient's kidney function, as indicated by creatinine levels (88.0 mmol/L), is mildly impaired. However, her albumin levels are within the normal range (38 g/L), which suggests that her kidney function is not severely compromised.

The patient's cardiac function is significantly impaired, as evidenced by a left ventricular ejection fraction (LVEF) of 35.0%, which is below the normal range. However, her troponin levels are within the normal range (0.01 ng/mL), indicating that she does not have acute myocardial infarction.

The patient is on a multidrug regimen that includes an angiotensin II receptor blocker, loop diuretics, statins, ACE inhibitor, and nitrovasodilator, which are all appropriate for managing heart failure and hypertension.

The ECG shows polymorphic ventricular extrasystoles, but no other significant arrhythmias. This finding is not uncommon in patients with heart failure and may be a benign variant.

Given the patient's complex medical history and the presence of heart failure, it is not surprising that she is classified as NYHA Class II. However, her overall prognosis is guarded due to her low LVEF and impaired kidney function. Nevertheless, the fact that she is a survivor suggests that her current treatment regimen is effective in managing her symptoms and preventing further cardiac deterioration.

It is likely that the patient's survival is due to the combination of her medication regimen, lifestyle modifications, and close monitoring by her healthcare team. Regular follow-up and adjustments to her treatment plan as needed will be crucial to maintaining her current level of function and preventing further cardiac complications."
78,78,P0122,"Age: 65
Gender: Female 
Weight: 62 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 130/54 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 35
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,47
Creatinine (mmol/L): 62.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,5
LDL (mmol/L): 1,86
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 173.0
Protein (g/L): 62
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,03
Urea (mg/dL): 6,99
LVEF (%): 30.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 65-year-old female with a history of idiopathic dilated cardiomyopathy, dyslipemia, and hypertension, has a complex medical profile. Despite her severe heart condition, characterized by a left ventricular ejection fraction (LVEF) of 30%, she has been on optimal medical therapy, including beta blockers, statins, and an ACE inhibitor.

The patient's low blood pressure (130/54 mmHg) and low heart rate suggest that her beta blockers are effective in controlling her heart rate and blood pressure. The absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG further supports the effectiveness of her medication regimen.

The patient's laboratory results show a slightly elevated creatinine level (62.0 mmol/L), which may indicate some degree of renal impairment, but it is not severe enough to be a major concern at this time. Her liver enzymes (ALT and AST) are within normal limits, indicating that her liver function is preserved.

The patient's lipid profile shows a total cholesterol level of 3.47 mmol/L, which is elevated, but her LDL cholesterol level is 1.86 mmol/L, which is within the target range for patients with cardiovascular disease. Her HDL cholesterol level is 1.09 mmol/L, which is low, but her medication regimen includes statins, which should help to improve her lipid profile.

The patient's thyroid function is within normal limits, with a TSH level of 1.03 mIU/L and a T4 level of 13 ng/L. Her hemoglobin level is 117.0 g/L, which is within the normal range.

The patient's Pro-BNP level is 173.0 ng/L, which is elevated, indicating some degree of heart failure. However, her LVEF of 30% and her symptoms (NYHA Class II) suggest that she has mild to moderate heart failure.

In summary, the patient's optimal medical therapy, combined with her relatively mild symptoms and preserved liver and kidney function, have contributed to her survival. Her low blood pressure and absence of ventricular arrhythmias on the ECG further support her favorable outcome."
79,79,P0124,"Age: 80
Gender: Male 
Weight: 109 kg
Height: 178 cm
NYHA Class: III
Blood Pressure: 150/95 mmHg
Past Medical History: Hypertropic cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,75
Creatinine (mmol/L): 177.0
Gamma-glutamil transpeptidase (IU/L): 32
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 100.0
HDL (mmol/L): 0,8
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,35
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1475.0
Protein (g/L): 64
T3 (pg/dL): 0,02
T4 (ng/L): 9
Troponin (ng/mL): 0,05
TSH (mIU/L): 1,38
Urea (mg/dL): 23,13
LVEF (%): 62.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome is a survivor due to several factors that indicate a relatively stable cardiac condition, despite having a history of hypertrophic cardiomyopathy and other comorbidities. 

The patient's LVEF (Left Ventricular Ejection Fraction) is 62%, which is within the normal range (50-70%), indicating that the patient's heart is still pumping blood efficiently. The patient's Troponin level is also within the normal range, which suggests that there is no acute myocardial infarction.

The patient's Pro-BNP (B-type Natriuretic Peptide) level is elevated at 1475.0 ng/L, which can indicate heart failure or stress on the heart. However, the patient's NYHA Class III classification suggests that the patient has some limitations in physical activity but is still able to perform daily activities.

The patient's ECG shows monomorphic ventricular extrasystoles, which are common in patients with hypertrophic cardiomyopathy. However, there is no indication of sustained ventricular tachycardia or other life-threatening arrhythmias.

The patient's medication regimen, including Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins, and Nitrovasodilator, is consistent with the treatment of hypertrophic cardiomyopathy and related conditions. These medications help to reduce symptoms, slow the heart rate, and improve cardiac function.

Overall, while the patient has a complex medical history and several comorbidities, the combination of a relatively preserved LVEF, normal troponin level, and absence of acute arrhythmias, along with an appropriate medication regimen, suggest that the patient is likely to survive with proper management and follow-up."
80,80,P0125,"Age: 76
Gender: Male 
Weight: 79 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 37.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,47
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 54
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 122.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,66
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 303.0
Protein (g/L): 74
T3 (pg/dL): 0,06
T4 (ng/L): 13
Troponin (ng/mL): 0,02
TSH (mIU/L): 12,9
Urea (mg/dL): 6,16
LVEF (%): 54.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"REASONING: The patient, a 76-year-old male with a history of enolic dilated cardiomyopathy and hypertension, has a favorable outcome despite his complex medical history. Several factors contribute to this outcome:

1.  Effective Medication Management: The patient is on a comprehensive treatment regimen that includes Amiodarone, Beta Blockers, Loop Diuretics, and an ACE Inhibitor. This combination is likely helping to manage his heart failure, hypertension, and arrhythmias.

2.  Reasonable Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 54.0%, which is above the critical threshold of 30% but below the normal range of 55-70%. This suggests that the patient's heart is functioning relatively well, considering his history of dilated cardiomyopathy.

3.  Mildly Elevated Pro-BNP: The patient's Pro-BNP level is 303.0 ng/L, which is mildly elevated. Elevated Pro-BNP levels can indicate heart failure, but in this case, the level is not extremely high, suggesting that the patient's heart failure is not severe.

4.  No Significant Abnormalities in Liver Function Tests: The patient's liver function tests (ALT, AST, and GGT) are within normal limits, which suggests that there is no significant liver dysfunction contributing to his overall condition.

5.  Good Kidney Function: The patient's creatinine level is 115.0 μmol/L, which is within the normal range. This indicates that his kidney function is not significantly impaired.

6.  No Evidence of Malnutrition: The patient's albumin and protein levels are within normal limits, which suggests that he is not malnourished.

7.  No Severe Thyroid Dysfunction: The patient's TSH level is slightly elevated at 12.9 mIU/L, but his T3 and T4 levels are within normal limits. This suggests that his thyroid function is not significantly impaired.

8.  No Severe Electrolyte Imbalance: The patient's potassium level is within normal limits, which suggests that he does not have a severe electrolyte imbalance.

9.  Absence of Severe Arrhythmias: Although the patient has ventricular extrasystoles and non-sustained ventricular tachycardia, they are not severe or sustained, which reduces the risk of sudden cardiac death.

Considering these factors, the patient's favorable outcome is likely due to the effectiveness of his medication regimen, his relatively well-preserved cardiac function, and the absence of significant comorbidities."
81,81,P0126,"Age: 77
Gender: Female 
Weight: 70 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 36
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,35
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 237
Glucose (mmol/L): 7,2
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,28
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 4117.0
Protein (g/L): 66
T3 (pg/dL): 0,04
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,42
Urea (mg/dL): 8,49
LVEF (%): 56.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 77-year-old female with a history of hypertensive cardiomyopathy and hypertension. The patient's current medications, including an Angiotensin II Receptor Blocker, Loop Diuretics, and Spironolactone, suggest that she is being managed for heart failure symptoms. 

The patient's LVEF (Left Ventricular Ejection Fraction) is 56%, which indicates mildly reduced left ventricular function, consistent with heart failure with reduced ejection fraction (HFrEF). The elevated Pro-BNP (Brain Natriuretic Peptide) level of 4117.0 ng/L further supports the presence of heart failure.

The patient's ECG shows monomorphic ventricular extrasystoles, which are common in patients with heart disease, particularly in the context of heart failure. However, the absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that the patient's cardiac rhythm is relatively stable.

The patient's liver function tests (ALT and AST) are within normal limits, and her kidney function, as indicated by creatinine levels, is mildly impaired but not significantly abnormal. The patient's glucose level is slightly elevated, but not to the extent that would suggest diabetes as a contributing factor to her heart disease.

Considering the patient's age, comorbidities, and current medications, the most likely reason for her survival is that she is being effectively managed for her heart failure symptoms. The combination of medications, including the Angiotensin II Receptor Blocker, Loop Diuretics, and Spironolactone, is likely contributing to her improved cardiac function and reduced symptoms. The mildly reduced LVEF and elevated Pro-BNP level suggest that the patient is still experiencing some degree of heart failure, but the fact that she is alive and not experiencing acute cardiac decompensation suggests that her current treatment regimen is effective in managing her condition."
82,82,P0128,"Age: 72
Gender: Male 
Weight: 74 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 45.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,65
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 38
Glucose (mmol/L): 15,2
Hemoglobin (g/L): 132.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4,9
LDL (mmol/L): 1,91
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 208.0
Protein (g/L): 75
T3 (pg/dL): 0,02
T4 (ng/L): 26
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,68
Urea (mg/dL): 6,82
LVEF (%): 36.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Paroxysmal AVB
            ",survivor,"REASONING: 

Given the patient's medical history and current condition, the outcome of survival can be attributed to a combination of several factors. 

Firstly, the patient's current medications, including beta blockers, digoxin, loop diuretics, spironolactone, statins, and ACE inhibitors, are all aimed at managing the patient's heart failure and related conditions such as hypertension and ischemic dilated cardiomyopathy. These medications have likely contributed to the patient's survival by reducing symptoms and slowing the progression of the disease.

The patient's LVEF (left ventricular ejection fraction) of 36% is relatively low, indicating some degree of heart failure, but it is not severely impaired. The patient's Pro-BNP (B-type natriuretic peptide) level of 208.0 ng/L is elevated, which is consistent with heart failure, but it is not excessively high, suggesting that the patient's condition is being managed.

The patient's ECG shows a paroxysmal AV block, which is a type of bradycardia, but this is not considered a life-threatening condition in this context. The presence of monomorphic ventricular extrasystoles is also relatively benign and not typically associated with a poor prognosis.

The patient's laboratory results show elevated glucose and creatinine levels, indicating some degree of diabetes and renal impairment, respectively. However, these values are not excessively high, and the patient's hemoglobin and albumin levels are within relatively normal ranges, suggesting that the patient's nutritional status and liver function are not severely compromised.

Overall, while the patient has a complex medical history and several comorbidities, the combination of appropriate medical management, relatively stable laboratory values, and the absence of severe cardiac arrhythmias or other life-threatening conditions have likely contributed to the patient's survival."
83,83,P0130,"Age: 48
Gender: Male 
Weight: 74 kg
Height: 182 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 5,1
LDL (mmol/L): 3,15
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 677.0
Protein (g/L): 74
T3 (pg/dL): 0,06
T4 (ng/L): 11
Troponin (ng/mL): 0,37
TSH (mIU/L): 2,4
Urea (mg/dL): 6,82
LVEF (%): 29.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 48-year-old male with a history of idiopathic dilated cardiomyopathy, has a poor left ventricular ejection fraction (LVEF) of 29%, indicating significant heart failure. However, despite this, the patient is classified as NYHA Class II, which suggests that he is experiencing some symptoms of heart failure but is able to perform most physical activities without significant limitations.

The patient's laboratory results show elevated levels of Pro-BNP (677 ng/L), which is a biomarker for heart failure and can indicate fluid overload. His creatinine level is also elevated at 106.0 mmol/L, suggesting impaired renal function, which can be a complication of heart failure. Additionally, his total cholesterol level is elevated at 4.84 mmol/L, which can contribute to the progression of his heart disease.

The patient is on a multidrug regimen, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, which are all standard treatments for heart failure. The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG indicates that the patient has some arrhythmias, but the fact that they are non-sustained suggests that they are not life-threatening at this time.

Given the patient's overall condition, including his LVEF, elevated Pro-BNP, and renal impairment, it is likely that the patient's outcome is a survivor due to the following reasons:

1. The patient is on appropriate medical therapy for heart failure, which is helping to manage his symptoms and slow the progression of his disease.
2. The patient's NYHA Class II classification indicates that he is still able to perform most physical activities without significant limitations, suggesting that his heart failure is not severe enough to cause significant functional impairment.
3. The patient's arrhythmias are non-sustained, which reduces the risk of sudden cardiac death.
4. The patient's renal function, although impaired, is not severe enough to cause significant morbidity.

Overall, while the patient's heart disease is significant, his current treatment regimen and relatively stable clinical status suggest that he is likely to survive with continued medical management."
84,84,P0131,"Age: 66
Gender: Male 
Weight: 95 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 130/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 6,03
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 120.0
HDL (mmol/L): 1,71
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,72
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 481.0
Protein (g/L): 65
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,05
TSH (mIU/L): 2,63
Urea (mg/dL): 9,32
LVEF (%): 40.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Parosysmal AF
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 66-year-old male with a history of ischemic dilated cardiomyopathy, dyslipemia, hypertension, and myocardial infarction, has been managed with a multidrug regimen including beta blockers, ACE inhibitors, angiotensin II receptor blockers, statins, and loop diuretics, which are standard treatments for heart failure and coronary artery disease. The patient's left ventricular ejection fraction (LVEF) is 40%, indicating moderate to severe left ventricular dysfunction.

The patient's blood pressure is within a relatively normal range (130/60 mmHg), and the serum creatinine level is slightly elevated at 106.0 umol/L, which may indicate mild renal impairment. However, the patient's eGFR (estimated glomerular filtration rate) is not provided, and this would be an important factor in assessing renal function.

The patient's troponin level is slightly elevated at 0.05 ng/mL, which may indicate ongoing myocardial ischemia or infarction. However, the patient's symptoms and ECG findings do not suggest acute coronary syndrome.

The patient's thyroid function tests (T3 and T4) are within normal limits, and the TSH level is slightly elevated at 2.63 mIU/L, which may indicate subclinical hypothyroidism. However, this is not a significant concern in the context of the patient's overall cardiovascular disease.

The patient's ECG shows a polymorphic ventricular extrasystole, which is a common finding in patients with heart failure and may not be a significant concern. The presence of paroxysmal atrial fibrillation (AF) is noted, which is a common arrhythmia in patients with heart failure.

Considering the patient's overall clinical picture, the patient's prognosis is guarded. However, the patient's ability to survive with a combination of medications and close monitoring suggests that the patient's condition is stable at this time. The patient's LVEF is relatively well-managed, and the patient's blood pressure is controlled. The patient's renal function is mildly impaired, but not significantly impacting the patient's survival.

The patient's overall survival is likely due to the aggressive management of their heart failure and coronary artery disease, as well as the use of evidence-based medications. The patient's survival is a testament to the effectiveness of modern cardiovascular medicine in managing complex cardiac conditions."
85,85,P0132,"Age: 46
Gender: Female 
Weight: 53 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 90/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,55
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 133.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,62
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 64.0
Protein (g/L): 76
T3 (pg/dL): 0,06
T4 (ng/L): 14
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,07
Urea (mg/dL): 4,33
LVEF (%): 34.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 46-year-old female with a history of idiopathic dilated cardiomyopathy, has been managed with a combination of medications including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 34%, indicating severe heart failure.

The patient's blood pressure is low at 90/60 mmHg, which may be a result of the diuretic therapy used to manage fluid overload. The albumin level is slightly low, which can be a sign of malnutrition or liver dysfunction, but the liver enzymes (ALT and AST) are within normal limits. The patient's lipid profile shows a high total cholesterol level, but the LDL is not extremely high.

The patient's kidney function, as indicated by the creatinine level, is slightly elevated, which may be a result of the heart failure itself or the medications used to manage it. The patient's electrolyte levels are within normal limits, and the potassium level is slightly low, which may be a result of the diuretic therapy.

The patient's BNP level is elevated, indicating heart failure, but not extremely high. The patient's TSH level is within normal limits, indicating that the thyroid function is normal. The troponin level is slightly elevated, which may indicate some cardiac damage, but the level is not extremely high.

The ECG shows polymorphic ventricular extrasystoles, which can be a sign of cardiac ischemia or arrhythmia, but there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias.

Given the patient's severe heart failure and reduced LVEF, the patient is at risk for sudden cardiac death. However, the patient has been managed with a combination of medications and has not experienced any life-threatening arrhythmias or cardiac events. The patient's survival outcome is likely due to the effective management of the heart failure and the patient's overall good clinical condition.

The patient's age and gender are also favorable factors for survival. The patient's weight and height are within a normal range, and the patient's hemoglobin level is within normal limits, indicating that the patient is not anemic.

In conclusion, the patient's survival outcome is likely due to the effective management of the heart failure and the patient's overall good clinical condition, despite the presence of severe heart failure and reduced LVEF."
86,86,P0133,"Age: 36
Gender: Female 
Weight: 81 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 48
ALT or GPT (IU/L): 130.0
AST or GOT (IU/L): 89.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 142
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,8
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,05
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 57.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,06
TSH (mIU/L): 3,53
Urea (mg/dL): 6,32
LVEF (%): 24.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's medical history of idiopathic dilated cardiomyopathy, a condition characterized by a weakened heart muscle leading to poor heart function, the patient's outcome of being a survivor is likely due to a combination of factors.

Firstly, the patient is receiving appropriate medical treatment for heart failure, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor. These medications are standard treatments for heart failure and are aimed at improving heart function, reducing symptoms, and slowing disease progression.

The patient's laboratory results also suggest that the liver function is mildly elevated, as indicated by the increased levels of AST, ALT, and gamma-glutamil transpeptidase. However, the liver function is not severely impaired, and the patient's albumin levels are within a relatively normal range, which suggests that the liver is still functioning adequately.

The patient's LVEF (left ventricular ejection fraction) of 24% is low, indicating poor heart function. However, the patient's pro-BNP (brain natriuretic peptide) level of 57.0 ng/L is within a relatively normal range, which may indicate that the patient's heart is not under extreme stress, and the patient is not experiencing severe heart failure.

Additionally, the patient's TSH (thyroid-stimulating hormone) level is within a normal range, which suggests that the patient's thyroid function is not contributing to the heart failure.

The patient's ECG shows monomorphic ventricular extrasystoles, which are common in patients with heart failure and are not typically a cause for concern.

In conclusion, the patient's outcome of being a survivor is likely due to the combination of appropriate medical treatment, relatively normal liver function, and the absence of severe heart failure symptoms, as indicated by the patient's laboratory results and ECG."
87,87,P0137,"Age: 58
Gender: Male 
Weight: 70 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 6,44
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 61
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 160.0
HDL (mmol/L): 2,51
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,39
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 320.0
Protein (g/L): 67
T3 (pg/dL): 0,06
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,19
Urea (mg/dL): 6,16
LVEF (%): 53.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient, a 58-year-old male with a history of enolic dilated cardiomyopathy, has a favorable outcome despite his underlying condition. Several factors contribute to this outcome:

1.  Current Medications: The patient is on a comprehensive treatment regimen, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor. These medications are standard for managing heart failure and dilated cardiomyopathy, suggesting that the patient is receiving optimal care for his condition.

2.  LVEF (Left Ventricular Ejection Fraction) of 53%: Although the patient's LVEF is below the normal range (typically > 55%), it is not severely decreased, indicating that the heart is still pumping blood effectively enough to maintain adequate circulation.

3.  Troponin levels: The patient's troponin level of 0.01 ng/mL is within the normal range, suggesting that there is no significant myocardial infarction or acute coronary syndrome contributing to the patient's condition.

4.  Pro-BNP (B-type natriuretic peptide) levels: The patient's Pro-BNP level of 320 ng/L is elevated, indicating that the heart is under stress and possibly experiencing fluid overload. However, this is not uncommon in patients with heart failure and dilated cardiomyopathy.

5.  ECG findings: The presence of ventricular extrasystoles and non-sustained ventricular tachycardia is concerning, but the patient's overall ECG impression does not indicate any acute or severe arrhythmias that would significantly impact his outcome.

6.  Blood work: The patient's electrolyte levels, liver function tests, and renal function tests are relatively stable, indicating that there are no acute complications or organ dysfunction that would negatively impact his outcome.

Considering these factors, the patient's outcome as a survivor is likely due to the effectiveness of his treatment regimen, the relatively preserved LVEF, and the absence of acute complications or severe arrhythmias."
88,88,P0142,"Age: 67
Gender: Female 
Weight: 98 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 120/85 mmHg
Past Medical History: Valvular cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 40,8
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,8
Creatinine (mmol/L): 73.0
Gamma-glutamil transpeptidase (IU/L): 257
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,13
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,81
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 683.0
Protein (g/L): 68,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,3
Urea (mg/dL): 7,5
LVEF (%): 55.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to several factors in her medical history and current condition. 

Firstly, despite having a history of valvular cardiomyopathy, the patient's LVEF (Left Ventricular Ejection Fraction) is 55%, which is within the normal range (>50%). This suggests that the patient's heart function is relatively preserved, and the valvular cardiomyopathy may not be significantly impairing her cardiac function at this time.

The patient's current medications, including digoxin, loop diuretics, statins, and ACE inhibitor, are also contributing to her survival. Digoxin is a heart medication that can help regulate heart rhythm and improve heart function, while loop diuretics are helping to manage fluid overload and reduce blood pressure. Statins are lowering her cholesterol levels, which is beneficial for reducing the risk of cardiovascular disease, and ACE inhibitors are helping to manage her hypertension.

The patient's blood pressure is well-controlled at 120/85 mmHg, which is within the normal range, further reducing her risk of cardiovascular events.

Additionally, the patient's laboratory results, such as her normal hemoglobin and potassium levels, suggest that her overall metabolic and electrolyte balance is stable.

The presence of ventricular extrasystoles on the ECG is a common finding in many patients and is not typically a cause for concern unless it is sustained or frequent. In this case, it is described as monomorphic, which means that it is likely a benign finding.

The patient's troponin level is within the normal range, indicating that there is no evidence of acute myocardial infarction.

Lastly, the patient's pro-BNP level is elevated at 683.0 ng/L, which is a marker of heart failure and can indicate fluid overload or strain on the heart. However, the patient's LVEF is within the normal range, and her other cardiac function parameters are also stable, suggesting that the elevated pro-BNP may not be indicative of severe heart failure.

Overall, the combination of the patient's stable cardiac function, controlled blood pressure, and effective medical management contribute to her survival outcome."
89,89,P0145,"Age: 57
Gender: Male 
Weight: 106 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 170/100 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension
Albumin (g/L): 40,2
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,76
Creatinine (mmol/L): 83.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 6
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,07
Potassium (mEq/L): 3,44
LDL (mmol/L): 3,09
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 431.0
Protein (g/L): 68,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,73
Urea (mg/dL): 5,7
LVEF (%): 25.0
Medications: Diabetes Medication, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient survived, likely due to the combination of optimal medical management and supportive care. The patient's LVEF of 25% indicates severe left ventricular dysfunction, which is a hallmark of advanced heart failure. However, the patient's NYHA Class II classification suggests that they are still able to perform some physical activity without experiencing significant symptoms.

The patient's blood pressure is elevated at 170/100 mmHg, which is a concern for cardiovascular disease progression. However, the use of an ACE inhibitor, a medication that helps to lower blood pressure and reduce strain on the heart, is noted in the patient's medication list. This suggests that the patient is receiving appropriate treatment for their hypertension.

The patient's laboratory results show elevated creatinine levels (83.0 μmol/L), which indicates impaired kidney function. This is likely due to the patient's diabetes and hypertension, both of which can cause kidney damage. The patient's albumin levels are also slightly low, which may indicate some degree of kidney damage.

The patient's Pro-BNP level is elevated at 431.0 ng/L, which is consistent with heart failure. However, the patient's troponin level is low (0.01 ng/mL), which suggests that there is no significant acute myocardial infarction.

The patient's ECG shows non-sustained ventricular tachycardia, which is a type of abnormal heart rhythm that can be a sign of heart disease. However, the patient does not have a history of sustained ventricular tachycardia, which is a more severe and potentially life-threatening condition.

Overall, the patient's survival is likely due to the combination of their medical treatment, including ACE inhibitors, loop diuretics, and diabetes medication, as well as supportive care. The patient's ability to manage their symptoms and maintain a relatively stable condition despite their severe heart failure suggests that they are receiving effective treatment and care."
90,90,P0146,"Age: 49
Gender: Male 
Weight: 85 kg
Height: 169 cm
NYHA Class: III
Blood Pressure: 90/60 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 40,1
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,07
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 40
Glucose (mmol/L): 5
Hemoglobin (g/L): 128.0
Potassium (mEq/L): 4,31
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 3021.0
Protein (g/L): 65,8
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,34
Urea (mg/dL): 5,2
LVEF (%): 19.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 49-year-old male with a history of enolic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge, leading to reduced heart function. The patient's left ventricular ejection fraction (LVEF) is severely reduced at 19%, indicating poor heart function.

The patient's current medications, including beta blockers, loop diuretics, statins, and ACE inhibitors, are standard treatments for heart failure and dilated cardiomyopathy. Beta blockers help slow the heart rate and reduce the heart's workload, while loop diuretics help reduce fluid buildup in the body. Statins lower cholesterol levels to reduce the risk of heart disease, and ACE inhibitors help reduce blood pressure and strain on the heart.

The patient's blood pressure is low at 90/60 mmHg, which may be a result of the medications or the heart failure itself. The patient's creatinine level is elevated at 102.0 mmol/L, indicating impaired kidney function, which is a common complication of heart failure.

The patient's troponin level is within normal limits, indicating no acute myocardial infarction (heart attack). The pro-BNP level is elevated at 3021.0 ng/L, which is consistent with heart failure.

The patient's ECG shows ventricular extrasystoles and non-sustained ventricular tachycardia, which are abnormal heart rhythms that can be a concern in patients with heart failure. However, the patient does not have a history of sustained ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia.

Given the patient's medical history, current medications, and laboratory results, the patient's outcome as a survivor is likely due to the effective management of his heart failure and dilated cardiomyopathy with medications and close monitoring. The patient's low blood pressure and impaired kidney function may require further monitoring and adjustment of medications as needed."
91,91,P0147,"Age: 81
Gender: Female 
Weight: 50 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 120/75 mmHg
Past Medical History: Hypertropic cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 39,7
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 16,2
Hemoglobin (g/L): 131.0
Potassium (mEq/L): 3,93
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 2167.0
Protein (g/L): 67,4
T3 (pg/dL): 0,07
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,1
Urea (mg/dL): 13,1
LVEF (%): 40.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome is a survivor due to a combination of factors that contributed to her resilience and effective management of her conditions. 

Firstly, the patient's ejection fraction (LVEF) is 40%, which is below the normal range (50-70%), indicating left ventricular systolic dysfunction. However, it is not severely decreased, and the patient is still on medications that support heart function, such as ACE inhibitors and nitrovasodilators. 

The patient's blood pressure is within a relatively normal range (120/75 mmHg), which is beneficial for heart health. The patient's creatinine level (96.0 μmol/L) is slightly elevated, but not significantly so, suggesting that her kidney function is still relatively preserved. 

The patient's glucose level (16.2 mmol/L) is elevated, indicating uncontrolled diabetes, which is a significant risk factor for cardiovascular disease. However, the patient is on diabetes medication, which is likely helping to manage her condition.

The patient's troponin level (0.01 ng/mL) is within normal limits, indicating that there is no acute myocardial infarction. The patient's TSH level (0.1 mIU/L) is within the normal range, suggesting that her thyroid function is well-managed.

The patient's Pro-BNP level (2167.0 ng/L) is elevated, which is consistent with heart failure, but it is not extremely high. This suggests that the patient's heart failure is not severe, and she is likely being effectively managed with her current medications.

The patient's ECG shows non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles, which are abnormal heart rhythms that can be associated with heart failure and cardiomyopathy. However, the patient is on amiodarone, which is an anti-arrhythmic medication that is often used to manage abnormal heart rhythms.

Overall, the patient's outcome as a survivor is likely due to a combination of her relatively preserved kidney function, effective management of her diabetes and heart failure, and the use of appropriate medications to manage her abnormal heart rhythms."
92,92,P0150,"Age: 73
Gender: Female 
Weight: 79 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 95/50 mmHg
Past Medical History: Valvular cardiomyopathy, Hypertension
Albumin (g/L): 43,8
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 4,7
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 6,5
Hemoglobin (g/L): 135.0
Potassium (mEq/L): 3,64
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 6343.0
Protein (g/L): 63,6
T4 (ng/L): 15,5
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,78
Urea (mg/dL): 13,9
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 73-year-old female with a history of valvular cardiomyopathy and hypertension, presenting with a New York Heart Association (NYHA) class III, indicating severe symptoms of heart failure. Her laboratory results and ECG findings suggest a high risk of cardiac complications.

Her low left ventricular ejection fraction (LVEF) of 20% indicates severe left ventricular dysfunction, which is consistent with her valvular cardiomyopathy. The elevated Pro-BNP level of 6343.0 ng/L is a marker of heart failure and suggests that the patient's heart is under strain.

The patient's blood pressure is low, with a systolic pressure of 95 mmHg, which may be a result of her medications, including beta blockers and loop diuretics, which can cause orthostatic hypotension. However, the low blood pressure may also be a sign of heart failure with reduced ejection fraction (HFrEF), a condition where the heart is unable to pump enough blood to meet the body's needs.

The patient's creatinine level of 95.0 μmol/L indicates impaired renal function, which is a common complication of heart failure. The low hemoglobin level of 135 g/L may be a sign of anemia, which can further exacerbate heart failure.

Despite the patient's high risk factors, she is still a survivor. This may be due to several factors:

1.  The patient is on appropriate medical therapy, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are all evidence-based treatments for heart failure.
2.  The patient's troponin level is normal, indicating that there is no acute myocardial infarction.
3.  The patient's TSH level is within the normal range, indicating that her thyroid function is not contributing to her heart failure.
4.  The patient's potassium level is low, which may be a sign of diuretic therapy, but it is not a contraindication to treatment.

In summary, the patient's survival is likely due to a combination of her appropriate medical therapy, the absence of acute myocardial infarction, and the lack of any other life-threatening conditions."
93,93,P0152,"Age: 64
Gender: Female 
Weight: 90 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 160/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40,5
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,48
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 38
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 135.0
Potassium (mEq/L): 4,04
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1312.0
Protein (g/L): 68,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,95
Urea (mg/dL): 9,8
LVEF (%): 40.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient is a 64-year-old female with a complex medical history, including ischemic dilated cardiomyopathy, diabetes, peripheral vascular disease, hypertension, and a history of myocardial infarction. Despite these comorbidities, the patient has been managed with a multi-drug regimen consisting of diabetes medication, an angiotensin II receptor blocker, beta blockers, loop diuretics, statins, and nitrovasodilators.

The patient's left ventricular ejection fraction (LVEF) is 40%, which indicates reduced cardiac function. However, the patient's Pro-BNP level is 1312.0 ng/L, which is elevated but not excessively high, suggesting that the patient is not experiencing acute heart failure. The patient's troponin level is within normal limits, indicating no acute myocardial infarction.

The patient's blood pressure is 160/70 mmHg, which is elevated but not extremely high. The patient's weight is 90 kg, which is within the normal range for her height. The patient's albumin level is slightly low, which may indicate mild malnutrition or liver dysfunction, but the AST and ALT levels are within normal limits.

The patient's electrolytes are within normal limits, and her hemoglobin level is slightly elevated. The patient's creatinine level is elevated at 104.0 mmol/L, indicating impaired renal function, but the urea level is within normal limits.

The patient's ECG shows polymorphic ventricular extrasystoles, which is a common finding in patients with ischemic cardiomyopathy. However, there is no evidence of ventricular tachycardia or other life-threatening arrhythmias.

Given the patient's complex medical history, reduced LVEF, and elevated Pro-BNP level, the patient is at risk for adverse cardiac events. However, the patient's current medication regimen and lack of acute symptoms suggest that the patient is being effectively managed. The patient's survival is likely due to the comprehensive management of her cardiovascular disease and comorbidities, as well as her relatively stable cardiac function."
94,94,P0154,"Age: 59
Gender: Male 
Weight: 96 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 90/60 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 42,1
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 71
Glucose (mmol/L): 7,4
Hemoglobin (g/L): 127.0
Potassium (mEq/L): 4,28
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 706.0
Protein (g/L): 73,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,8
Urea (mg/dL): 6,3
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's complex medical history, including enolic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, and myocardial infarction, it is not surprising that the patient's left ventricular ejection fraction (LVEF) is severely impaired at 25%. This indicates that the patient's heart is not pumping efficiently, which can lead to symptoms such as shortness of breath, fatigue, and swelling in the legs.

The patient's blood pressure is low at 90/60 mmHg, which may be contributing to the decreased cardiac output. The use of beta blockers and diuretics may be contributing to this hypotension. The patient's creatinine level of 113.0 μmol/L suggests that there may be some renal impairment, which could be related to the patient's underlying cardiovascular disease or the use of certain medications.

The patient's Pro-BNP level of 706.0 ng/L is elevated, indicating increased ventricular stress and potential heart failure. However, the troponin level is normal, suggesting that there is no acute myocardial infarction.

The patient's medications, including calcium channel blockers, beta blockers, loop diuretics, statins, ACE inhibitors, and nitrovasodilators, are appropriate for a patient with heart failure and coronary artery disease. The patient's diabetes is being managed with medication.

Given the patient's complex medical history and the presence of heart failure, it is likely that the patient's survival is due to the effective management of their cardiovascular disease with medication and close monitoring. The patient's low blood pressure may be a concern, but it is likely being closely monitored and managed by the healthcare team.

The patient's survival is a testament to the effectiveness of modern cardiovascular medicine and the importance of early intervention and management of cardiovascular disease."
95,95,P0156,"Age: 53
Gender: Male 
Weight: 82 kg
Height: 182 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 40,3
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,77
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 11,6
Hemoglobin (g/L): 153.0
Potassium (mEq/L): 3,41
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 157.0
Protein (g/L): 66,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,79
Urea (mg/dL): 5,3
LVEF (%): 35.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to several factors, including the patient's current treatment regimen and the absence of severe complications. 

The patient has been prescribed Beta Blockers, which are commonly used to reduce the risk of sudden cardiac death and improve survival in patients with heart failure. Digoxin is also being used to slow the heart rate and increase the strength of the heart's contractions, which can help to improve the patient's cardiac function. Loop Diuretics are being used to reduce fluid buildup in the body, which can help to alleviate symptoms of heart failure. Finally, the ACE Inhibitor is being used to reduce the strain on the heart by lowering blood pressure and reducing the heart's workload.

The patient's LVEF (Left Ventricular Ejection Fraction) of 35% indicates that the heart is not pumping efficiently, but it is still functioning. The patient's Pro-BNP (Brain Natriuretic Peptide) level of 157.0 ng/L is elevated, which indicates that the heart is experiencing stress, but it is not at a critically high level. The patient's Troponin level of 0.01 ng/mL is within normal limits, indicating that there is no acute myocardial infarction.

The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, but these are not life-threatening and are not uncommon in patients with heart failure. The patient's blood pressure is within a relatively normal range, and their kidney function is also within normal limits.

Overall, while the patient has a history of enolic dilated cardiomyopathy and is experiencing heart failure, their current treatment regimen and the absence of severe complications suggest that they are likely to survive."
96,96,P0158,"Age: 65
Gender: Female 
Weight: 96 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 140/85 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 45,3
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 6,16
Creatinine (mmol/L): 86.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 125.0
Potassium (mEq/L): 4,73
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 288.0
Protein (g/L): 76,8
T4 (ng/L): 18,8
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,18
Urea (mg/dL): 8,5
LVEF (%): 39.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 65-year-old female with a history of idiopathic dilated cardiomyopathy, hypertension, and dyslipemia, has been managed with a comprehensive treatment regimen including Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, and Statins. The patient's left ventricular ejection fraction (LVEF) is 39%, indicating a reduced ejection fraction, but still within the range that may be managed medically.

The patient's blood pressure is well-controlled at 140/85 mmHg, and the laboratory results show a slightly elevated creatinine level (86.0 mmol/L), which may indicate mild renal impairment, but the urea level is within the normal range. The liver enzymes (ALT and AST) are within normal limits, and the total cholesterol level is slightly elevated, which is consistent with the patient's history of dyslipemia.

The patient's B-type natriuretic peptide (BNP) level is elevated at 288.0 ng/L, which is consistent with heart failure with reduced ejection fraction (HFrEF). However, the patient's hemoglobin level is within the normal range, and the TSH level is within the normal range, indicating no evidence of thyroid dysfunction.

The ECG shows a monomorphic ventricular extrasystole, which is a common finding in patients with dilated cardiomyopathy, but there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias.

Given the patient's age, comorbidities, and current treatment regimen, the most likely reason for the patient's outcome is the effective management of her heart failure and other comorbidities, which has allowed her to survive with a reduced ejection fraction. The patient's well-controlled blood pressure, normal hemoglobin level, and lack of evidence of thyroid dysfunction or other life-threatening conditions all contribute to her favorable outcome."
97,97,P0162,"Age: 76
Gender: Female 
Weight: 71 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 150/100 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 37,7
ALT or GPT (IU/L): 85.0
AST or GOT (IU/L): 63.0
Total Cholesterol (mmol/L): 4,47
Creatinine (mmol/L): 105.0
Gamma-glutamil transpeptidase (IU/L): 199
Glucose (mmol/L): 8,8
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1
Potassium (mEq/L): 3,84
LDL (mmol/L): 2,85
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 6915.0
Protein (g/L): 69,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,09
Urea (mg/dL): 8,1
LVEF (%): 30.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to several factors:

1.  Optimal Medication Management: The patient is on a combination of medications that are commonly used to manage heart failure and hypertension, including digoxin, loop diuretics, and an ACE inhibitor. These medications are likely helping to manage the patient's symptoms and slow the progression of the disease.

2.  Early Detection and Treatment of Complications: The patient's elevated Pro-BNP level (6915.0 ng/L) indicates that the patient's heart failure is being closely monitored. Elevated Pro-BNP levels are associated with increased risk of mortality and morbidity in patients with heart failure. The patient's elevated Pro-BNP level suggests that the patient's heart failure is being closely monitored, and appropriate treatment is being administered.

3.  Low Troponin Level: The patient's troponin level is within the normal range (0.01 ng/mL), which suggests that there is no acute myocardial infarction. This is a positive sign, as it indicates that the patient's heart muscle is not experiencing acute damage.

4.  Maintained Hemoglobin Level: The patient's hemoglobin level is within the normal range (150.0 g/L), which suggests that the patient is not experiencing significant anemia. Anemia is a common comorbidity in patients with heart failure, and maintaining a normal hemoglobin level is essential for optimal oxygen delivery to the tissues.

5.  Normal TSH Level: The patient's TSH level is within the normal range (1.09 mIU/L), which suggests that the patient's thyroid function is normal. Hypothyroidism is a common comorbidity in patients with heart failure, and maintaining a normal TSH level is essential for optimal cardiovascular function.

6.  Monitoring of Electrocardiogram: The patient's ECG shows evidence of ventricular extrasystole, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia. However, the patient's heart rate is not significantly elevated, and there is no evidence of bradycardia. This suggests that the patient's cardiac rhythm is being closely monitored, and any arrhythmias are being managed appropriately.

7.  Monitoring of Renal Function: The patient's creatinine level is elevated (105.0 mmol/L), which suggests that the patient's renal function is impaired. However, the patient's urea level is within the normal range (8.1 mg/dL), which suggests that the patient's renal function is not significantly impaired. This is a positive sign, as it indicates that the patient's kidneys are still functioning adequately.

In conclusion, the patient's outcome of survival can be attributed to optimal medication management, early detection and treatment of complications, low troponin level, maintained hemoglobin level, normal TSH level, monitoring of electrocardiogram, and monitoring of renal function."
98,98,P0163,"Age: 71
Gender: Female 
Weight: 70 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 150/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 40,5
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 6,43
Creatinine (mmol/L): 89.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,3
Potassium (mEq/L): 3,82
LDL (mmol/L): 4,43
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 469.0
Protein (g/L): 72,8
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,7
Urea (mg/dL): 4,8
LVEF (%): 55.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

Given the patient's age of 71, she is considered elderly and at higher risk for cardiovascular events. Her past medical history of hypertensive cardiomyopathy and hypertension suggests that she has a compromised heart function, which is further supported by her reduced left ventricular ejection fraction (LVEF) of 55%. However, this is not extremely low, and her heart function is still relatively preserved.

The patient's blood pressure is elevated at 150/90 mmHg, which is consistent with her history of hypertension. Her albumin level is slightly elevated at 40.5 g/L, which may indicate some degree of liver dysfunction or kidney impairment, as seen by her elevated creatinine level of 89.0 μmol/L. However, her glomerular filtration rate (GFR) is not explicitly mentioned, so it is difficult to assess the severity of kidney impairment.

The patient's lipid profile shows a total cholesterol of 6.43 mmol/L, with an LDL of 4.43 mmol/L, which is slightly elevated. Her HDL is low at 1.3 mmol/L, which is a risk factor for cardiovascular disease. Her glucose level is slightly elevated at 6.9 mmol/L, which may indicate impaired glucose regulation.

The patient's pro-BNP level is elevated at 469.0 ng/L, which suggests some degree of heart failure or cardiac stress. However, her troponin level is normal, which suggests that there is no acute myocardial infarction.

The patient's ECG shows no evidence of ventricular extrasystoles, ventricular tachycardia, or non-sustained ventricular tachycardia. However, the presence of an unknown paroxysmal supraventricular tachyarrhythmia or bradycardia code is noted, but the exact type and severity are not specified.

Considering the patient's age, history of hypertensive cardiomyopathy, and compromised heart function, it is likely that she has a high risk for cardiovascular events. However, her relatively preserved LVEF and the absence of acute myocardial infarction or severe kidney impairment suggest that she may be a candidate for medical management and lifestyle modifications to reduce her risk.

The patient's current medications, including beta blockers, loop diuretics, and ACE inhibitors, are appropriate for managing her hypertension and heart failure. The patient's survival outcome is likely due to the effectiveness of these medications and her relatively stable cardiovascular condition.

However, it is essential to note that the patient's kidney function and liver function should be closely monitored, and her lipid profile and glucose levels should be optimized to reduce her risk for cardiovascular events. A more detailed evaluation of her kidney function and liver function, as well as further optimization of her medications and lifestyle modifications, may be necessary to improve her long-term outcomes."
99,99,P0164,"Age: 78
Gender: Male 
Weight: 92 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 34,4
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,58
Creatinine (mmol/L): 82.0
Gamma-glutamil transpeptidase (IU/L): 133
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,25
Potassium (mEq/L): 4,44
LDL (mmol/L): 1,89
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 2104.0
Protein (g/L): 62,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,84
Urea (mg/dL): 8,1
LVEF (%): 35.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient is a 78-year-old male with a history of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipemia. His current medical condition is likely a result of the progression of his underlying heart disease. The patient's LVEF of 35% indicates severe left ventricular dysfunction, which is consistent with his NYHA Class II classification. His elevated Pro-BNP level (2104.0 ng/L) also suggests heart failure with reduced ejection fraction.

The patient's current medications, including beta blockers, digoxin, loop diuretics, statins, and ACE inhibitors, are standard treatments for heart failure and ischemic cardiomyopathy. The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and unknown paroxysmal supraventricular tachyarrhythmia on the ECG indicates arrhythmias, which are common in patients with heart failure.

The patient's laboratory results show elevated liver enzymes (ALT and GGT), which could be related to his statin medication or underlying liver disease. His total cholesterol and LDL levels are within acceptable ranges, but his HDL level is low, which is a risk factor for cardiovascular disease.

The patient's blood pressure is within a relatively normal range (140/90 mmHg), and his hemoglobin level is within a normal range. His urea level is slightly elevated, which may indicate mild kidney dysfunction.

Considering the patient's age, underlying medical conditions, and current medications, the most likely reason for the patient's outcome is the effective management of his heart failure and ischemic cardiomyopathy with his current medication regimen. The combination of beta blockers, digoxin, loop diuretics, statins, and ACE inhibitors likely helped to stabilize his heart function and prevent further complications. Additionally, the patient's relatively normal blood pressure and hemoglobin levels suggest that his medications are well-tolerated and effective in managing his symptoms."
100,100,P0165,"Age: 76
Gender: Female 
Weight: 70 kg
Height: 153 cm
NYHA Class: II
Blood Pressure: 213/110 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41,6
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 5,67
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,28
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,2
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 366.0
Protein (g/L): 75,6
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,92
Urea (mg/dL): 8,4
LVEF (%): 45.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient's outcome of survival can be attributed to a combination of several factors:

1. Timely medical intervention: The patient is already on a comprehensive treatment plan, including medications such as an Angiotensin II Receptor Blocker, Loop Diuretics, Statins, and ACE Inhibitor. These medications are crucial in managing hypertension, heart failure, and dyslipidemia, which are key components of the patient's condition.

2. Optimal blood pressure control: Although the patient's blood pressure is elevated (213/110 mmHg), it is not extremely high, and the patient is already on medications to manage hypertension. This suggests that the patient's blood pressure is being effectively controlled, which reduces the risk of cardiac complications.

3. Moderate left ventricular ejection fraction (LVEF): The patient's LVEF is 45%, which is lower than the normal range (50-70%), indicating some degree of left ventricular dysfunction. However, it is not severely compromised, and the patient is not in cardiac failure.

4. Low troponin levels: The patient's troponin level is 0.01 ng/mL, which is within the normal range. This suggests that there is no significant acute myocardial infarction or cardiac damage.

5. Normal hemoglobin levels: The patient's hemoglobin level is 130 g/L, which is within the normal range. This suggests that the patient does not have significant anemia, which can contribute to cardiac complications.

6. Low pro-BNP levels: The patient's pro-BNP level is 366 ng/L, which is slightly elevated but not extremely high. This suggests that the patient's heart is not under excessive strain, and the risk of cardiac failure is not high.

7. Absence of severe comorbidities: The patient does not have severe comorbidities such as kidney failure (Creatinine 93.0 μmol/L is slightly elevated but not extremely high) or severe liver dysfunction (ALT and AST levels are within normal limits).

Overall, the patient's outcome of survival can be attributed to a combination of timely medical intervention, optimal blood pressure control, moderate left ventricular dysfunction, low troponin levels, normal hemoglobin levels, low pro-BNP levels, and the absence of severe comorbidities."
101,101,P0166,"Age: 75
Gender: Female 
Weight: 68 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 190/80 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 42,8
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,16
Creatinine (mmol/L): 82.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 131.0
Potassium (mEq/L): 4,08
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 746.0
Protein (g/L): 75,9
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,18
Urea (mg/dL): 7,9
LVEF (%): 69.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient, a 75-year-old female, has been diagnosed with valvular cardiomyopathy, a condition that affects the heart's ability to pump blood efficiently. Despite this, her left ventricular ejection fraction (LVEF) is 69%, indicating that her heart is still functioning relatively well. The patient is on a regimen of beta blockers, digoxin, loop diuretics, and ACE inhibitors, which are standard treatments for heart failure and valvular cardiomyopathy.

The patient's blood pressure is elevated at 190/80 mmHg, but this is not uncommon in patients with heart failure, as the body often compensates for decreased cardiac output by increasing peripheral resistance. The patient's kidney function, as indicated by creatinine levels, is within the normal range, suggesting that her kidneys are functioning adequately.

The patient's liver function tests, including ALT and AST, are within normal limits, indicating that her liver is functioning properly. Her total cholesterol level is elevated, but this is not uncommon in patients with heart failure, as the body often produces more cholesterol as a response to inflammation and oxidative stress.

The patient's hemoglobin level is within the normal range, and her potassium and sodium levels are also within normal limits. Her pro-BNP level is elevated, indicating that her heart is under stress, but this is consistent with her diagnosis of heart failure.

The patient's ECG shows polymorphic ventricular extrasystoles, which are abnormal heartbeats that can be a sign of underlying heart disease. However, the absence of ventricular tachycardia and non-sustained ventricular tachycardia is reassuring. The unknown paroxysmal supraventricular tachyarrhythmia and bradycardia codes on the ECG do not provide any clear indication of a life-threatening arrhythmia.

Given the patient's age, comorbidities, and treatment regimen, it is likely that she is being managed for heart failure and valvular cardiomyopathy. The fact that she is a survivor suggests that her treatment plan is effective in managing her symptoms and preventing complications. However, ongoing monitoring and adjustment of her treatment plan may be necessary to ensure optimal outcomes."
102,102,P0167,"Age: >89
Gender: Male 
Weight: 78 kg
Height: 164 cm
NYHA Class: III
Blood Pressure: 150/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 2,92
Creatinine (mmol/L): 129.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 114.0
Potassium (mEq/L): 4,2
Sodium (mEq/L): 147.0
Pro-BNP (ng/L): 3724.0
Protein (g/L): 65
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,45
Urea (mg/dL): 9,6
LVEF (%): 60.0
Medications: Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient, a 89-year-old male with a history of ischemic dilated cardiomyopathy and myocardial infarction, has been prescribed medications such as loop diuretics, ACE inhibitors, and nitrovasodilators. The patient's current LVEF (Left Ventricular Ejection Fraction) is 60%, indicating that the heart is pumping blood efficiently, albeit not at the optimal level. 

The patient's BNP (Brain Natriuretic Peptide) level of 3724 ng/L is elevated, which is consistent with heart failure. However, the absence of other severe biomarkers such as troponin (0.01 ng/mL) suggests that the patient is not experiencing an acute myocardial infarction. The patient's potassium level is within the normal range (4.2 mEq/L), which is a good sign, as hypokalemia can exacerbate heart failure. 

The patient's albumin level is slightly low (38 g/L), which may indicate malnutrition or liver disease, but the AST and ALT levels are within normal limits, suggesting that liver function is not significantly impaired. The patient's creatinine level is elevated (129.0 umol/L), indicating mild kidney dysfunction, but the urea level is within normal limits, which suggests that the kidneys are still functioning adequately. 

The patient's hemoglobin level is slightly elevated (114 g/L), which may be due to dehydration or polycythemia. The patient's sodium level is within the normal range (147 mEq/L), and the TSH level is within normal limits (1.45 mIU/L), indicating that the patient's thyroid function is not significantly abnormal.

Considering the patient's age, medical history, and the current lab results, the patient's outcome of survival is likely due to the following factors:

1.  The patient is on appropriate medications for heart failure, including loop diuretics, ACE inhibitors, and nitrovasodilators, which are helping to manage symptoms and improve cardiac function.
2.  The patient's LVEF is 60%, which is not optimal but not severely impaired, indicating that the heart is still able to pump blood efficiently.
3.  The absence of severe biomarkers such as troponin and the patient's relatively stable clinical condition suggest that the patient is not experiencing an acute cardiac event.
4.  The patient's kidney function is mildly impaired, but the urea level is within normal limits, indicating that the kidneys are still functioning adequately.

Overall, the patient's outcome of survival is likely due to the combination of effective medical management, relatively preserved cardiac function, and the absence of severe biomarkers indicating acute cardiac events."
103,103,P0168,"Age: 88
Gender: Female 
Weight: 66 kg
Height: 153 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 37,9
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,07
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 137.0
Potassium (mEq/L): 3,2
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 237.0
Protein (g/L): 70,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,36
Urea (mg/dL): 14,1
LVEF (%): 60.0
Medications: Calcium Channel Blocker, Angiotensin II Receptor Blocker, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, an 88-year-old female, has been diagnosed with hypertensive cardiomyopathy and is being treated with a combination of medications including a calcium channel blocker, angiotensin II receptor blocker, loop diuretics, and an ACE inhibitor. Her current medications are likely aimed at managing her hypertension, reducing cardiac workload, and improving heart function.

Her current NYHA Class II classification indicates that she experiences some limitation in physical activity, but she is still able to perform everyday tasks without symptoms. This suggests that her cardiac condition is relatively well-managed.

The patient's blood pressure is within a relatively normal range, at 120/60 mmHg, and her LVEF (Left Ventricular Ejection Fraction) is 60%, indicating that her heart is pumping efficiently. Her troponin levels are within normal limits, suggesting that there is no acute myocardial damage.

The patient's laboratory results show that her albumin levels are slightly elevated, which can be seen in heart failure or liver disease. However, her AST and ALT levels are within normal limits, suggesting that liver function is intact. Her total cholesterol and glucose levels are also within normal limits.

The patient's Pro-BNP (Brain Natriuretic Peptide) level is elevated at 237.0 ng/L, which is a marker of heart failure. However, this is not unexpected given her history of hypertensive cardiomyopathy.

The patient's ECG shows polymorphic ventricular extrasystoles, which are premature ventricular contractions that can be seen in patients with heart disease. However, there is no evidence of sustained ventricular tachycardia or other serious arrhythmias.

Overall, the patient's outcome of survivorship suggests that her cardiac condition is being managed effectively with her current treatment regimen, and she is able to tolerate her medications without significant adverse effects. Her relatively well-controlled blood pressure, normal LVEF, and lack of acute myocardial damage all contribute to her favorable outcome."
104,104,P0169,"Age: 49
Gender: Male 
Weight: 69 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 115/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,74
Creatinine (mmol/L): 273.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 113.0
Potassium (mEq/L): 4,63
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 17620.0
Protein (g/L): 70
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,49
Urea (mg/dL): 24,2
LVEF (%): 23.0
Medications: Loop Diuretics, Statins, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 49-year-old male with a history of ischemic dilated cardiomyopathy, has been treated with a combination of medications, including loop diuretics, statins, hydralazine, and nitrovasodilators. His left ventricular ejection fraction (LVEF) is significantly reduced at 23%, indicating a compromised heart function.

Despite these challenges, the patient has survived, which can be attributed to several factors:

1.  Aggressive medical management: The patient is on a regimen of loop diuretics, which helps alleviate fluid overload and reduce symptoms of heart failure. Statins are also being used to manage dyslipemia, a common comorbidity in patients with ischemic cardiomyopathy. Hydralazine and nitrovasodilators are likely being used to manage hypertension and reduce afterload, thereby improving cardiac output.

2.  Low troponin levels: The troponin level of 0.02 ng/mL suggests that there has been minimal cardiac muscle damage in recent days, which is a positive sign. This indicates that the patient's heart is not currently experiencing significant ischemia, which could be a contributing factor to their survival.

3.  Normal glucose levels: The patient's glucose level is within the normal range, which is beneficial for heart health. High glucose levels can exacerbate cardiac damage and worsen outcomes in patients with heart failure.

4.  Low creatinine levels: The patient's creatinine level is 2.73 mmol/L, which is slightly elevated but not alarmingly high. This suggests that the patient's kidneys are functioning relatively well, which is essential for removing waste products and excess fluids from the body.

5.  Lack of severe electrolyte imbalances: The patient's potassium and sodium levels are within the normal range, which is crucial for maintaining cardiac function and preventing arrhythmias.

6.  Normal TSH levels: The patient's thyroid-stimulating hormone (TSH) level is within the normal range, which is essential for maintaining a healthy metabolism and heart function.

7.  No signs of severe malnutrition: The patient's albumin level is 40 g/L, which is within the normal range. This suggests that the patient is not malnourished, which can exacerbate heart failure and worsen outcomes.

In conclusion, the patient's survival can be attributed to a combination of aggressive medical management, low troponin levels, normal glucose levels, low creatinine levels, lack of severe electrolyte imbalances, normal TSH levels, and the absence of severe malnutrition."
105,105,P0170,"Age: 73
Gender: Female 
Weight: 64 kg
Height: 152 cm
NYHA Class: II
Blood Pressure: 210/110 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 39,2
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 4,9
Creatinine (mmol/L): 82.0
Gamma-glutamil transpeptidase (IU/L): 60
Glucose (mmol/L): 10,9
Hemoglobin (g/L): 107.0
HDL (mmol/L): 1,04
Potassium (mEq/L): 4,03
LDL (mmol/L): 2,96
Sodium (mEq/L): 139.0
Protein (g/L): 74,8
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,19
Urea (mg/dL): 8,4
LVEF (%): 70.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 73-year-old female with a history of hypertensive cardiomyopathy, diabetes, and hypertension, presented with a complex clinical profile. Despite the presence of several risk factors, including high blood pressure (210/110 mmHg), elevated glucose levels (10.9 mmol/L), and impaired renal function (creatinine 82.0 mmol/L), the patient's left ventricular ejection fraction (LVEF) was preserved at 70%.

The patient's medication regimen, including diabetes medication, beta blockers, loop diuretics, ACE inhibitors, and nitrovasodilators, suggests a comprehensive management approach to control her hypertension and diabetes. The use of beta blockers and ACE inhibitors is particularly relevant in this context, as they are known to reduce morbidity and mortality in patients with heart failure and hypertension.

The ECG findings, while indicating some arrhythmias, including ventricular extrasystoles and paroxysmal supraventricular tachycardia, do not suggest any acute cardiac ischemia or severe arrhythmia burden, which would have increased the risk of mortality.

The patient's albumin level (39.2 g/L) is within the normal range, suggesting that her liver function is not significantly impaired, which is consistent with the mildly elevated liver enzymes (ALT 32.0 IU/L and AST 27.0 IU/L).

The patient's troponin level (0.01 ng/mL) is within the normal range, indicating that there is no evidence of acute myocardial infarction.

Considering the patient's overall clinical profile, the preserved LVEF, and the absence of acute cardiac ischemia or severe arrhythmia, the patient's outcome as a survivor is likely due to the effective management of her hypertension and diabetes, as well as the use of appropriate medications to control her heart failure symptoms."
106,106,P0171,"Age: 75
Gender: Male 
Weight: 76 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Toxic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 36
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 121.0
Potassium (mEq/L): 4,43
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 10060.0
Protein (g/L): 67,9
Troponin (ng/mL): 0,14
TSH (mIU/L): 0,74
Urea (mg/dL): 9
LVEF (%): 20.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 75-year-old male with a history of toxic dilated cardiomyopathy, dyslipemia, and hypertension. His current medical condition is characterized by a low left ventricular ejection fraction (LVEF) of 20%, which is a strong indicator of heart failure. The patient's blood work shows elevated levels of B-type natriuretic peptide (BNP) at 10060 ng/L, which is consistent with heart failure. 

Despite the severe cardiac dysfunction, the patient is on loop diuretics and an ACE inhibitor, which are standard treatments for heart failure. The patient's blood pressure is 140/90 mmHg, which is slightly elevated but not excessively high.

The patient's ECG shows a polymorphic ventricular extrasystole, which is a common finding in patients with cardiomyopathy. There is no evidence of sustained ventricular tachycardia or bradycardia. The presence of paroxysmal supraventricular tachyarrhythmia (PSVT) is also noted, which can be managed with medication or ablation.

Given the patient's age and the severity of his cardiac dysfunction, it is not surprising that he survived the episode. The fact that he is on appropriate medical therapy and does not have any life-threatening arrhythmias or other complications that would suggest a poor prognosis, supports the outcome of survival."
107,107,P0173,"Age: 83
Gender: Female 
Weight: 69 kg
Height: 151 cm
NYHA Class: II
Blood Pressure: 105/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 39,7
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 3,65
Creatinine (mmol/L): 108.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 112.0
Potassium (mEq/L): 4,49
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 3532.0
Protein (g/L): 65,4
T4 (ng/L): 23,5
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,1
Urea (mg/dL): 8,4
LVEF (%): 28.0
Medications: Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is an 83-year-old female with a history of ischemic dilated cardiomyopathy and myocardial infarction, which are significant risk factors for heart failure. Her low left ventricular ejection fraction (LVEF) of 28% indicates severe systolic dysfunction, consistent with her diagnosis of ischemic dilated cardiomyopathy.

The patient's elevated Pro-BNP level of 3532 ng/L suggests that she is experiencing significant cardiac stress and strain, likely due to her heart failure. However, her blood pressure of 105/70 mmHg is within a relatively normal range, which may indicate that her heart is adapting to compensate for the decreased ejection fraction by increasing peripheral resistance.

The patient's laboratory results show mild elevations in liver enzymes (ALT and AST), which may indicate some degree of liver dysfunction, but this is not likely to be a significant contributor to her cardiac outcome. Her lipid profile is within a relatively normal range, and her glucose level is slightly elevated but not significantly so.

The patient's medication regimen, including loop diuretics, ACE inhibitor, and nitrovasodilator, is consistent with standard treatment for heart failure and may be contributing to her survival. The presence of a TPSV (paroxysmal supraventricular tachyarrhythmia) on the ECG may be a benign finding in this context, and the absence of ventricular tachycardia or sustained ventricular tachycardia is a positive sign.

Overall, the patient's survival outcome is likely due to a combination of her adapted compensatory mechanisms, effective medical management, and the absence of severe acute cardiac events or complications."
108,108,P0174,"Age: 79
Gender: Female 
Weight: 66 kg
Height: 150 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 37
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 3,98
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 10
Hemoglobin (g/L): 111.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 5,6
LDL (mmol/L): 2,02
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 505.0
Protein (g/L): 81
T3 (pg/dL): 0,03
T4 (ng/L): 27
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,16
Urea (mg/dL): 21,63
LVEF (%): 70.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",survivor,"REASONING: The patient's age of 79 years and past medical history of Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, and Myocardial Infarction indicate a high risk for cardiovascular events. However, the patient's LVEF of 70% suggests that the left ventricle is still functioning relatively well, which is a positive prognostic indicator.

The patient's current medications, including Beta Blockers, Loop Diuretics, Statins, and ACE Inhibitor, are appropriate for managing hypertension, heart failure, and dyslipidemia. The absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG is also a positive sign.

The elevated Pro-BNP level of 505.0 ng/L suggests that the patient has some degree of heart failure, but the level is not extremely high, which may indicate that the heart failure is not severe.

The patient's blood pressure of 140/70 mmHg is within a relatively normal range, and the absence of bradycardia or other severe arrhythmias is a positive sign.

Considering the patient's overall condition, the presence of a first-degree Atrioventricular block (AVB) on the ECG may be a consequence of the patient's age and past medical history, rather than an acute event. The patient's other laboratory values, including electrolyte levels and liver function tests, are within normal limits.

Overall, the patient's outcome as a survivor can be attributed to the effective management of their cardiovascular risk factors, the relatively preserved LVEF, and the absence of severe arrhythmias or other acute complications."
109,109,P0175,"Age: 48
Gender: Female 
Weight: 69 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,83
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,86
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 572.0
Protein (g/L): 71
T3 (pg/dL): 0,03
T4 (ng/L): 27
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,91
Urea (mg/dL): 3,66
LVEF (%): 42.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 48-year-old female with a history of ischemic dilated cardiomyopathy and myocardial infarction, has been managed with a multidrug regimen including beta blockers, loop diuretics, statins, and ACE inhibitors. Her current ejection fraction (LVEF) of 42% indicates a moderately reduced left ventricular function, which is consistent with her past medical history of heart failure.

The patient's blood pressure is well-controlled at 110/65 mmHg, which is within a relatively normal range. Her laboratory results show a slightly elevated troponin level (0.01 ng/mL), but this is likely due to previous myocardial infarction rather than an acute event. The elevated Pro-BNP level (572.0 ng/L) is consistent with heart failure, but it is not extremely high, suggesting that the patient's condition is being managed.

The patient's lipid profile shows a high total cholesterol level (3.83 mmol/L), but this is being addressed with statin therapy. Her potassium level is slightly low (4.4 mEq/L), which may be related to diuretic use.

The patient's thyroid function tests (T3, T4, and TSH) are within normal limits, indicating no apparent thyroid dysfunction.

The patient's ECG shows monomorphic ventricular extrasystoles, but no sustained ventricular tachycardia or other significant arrhythmias.

Given the patient's stable medical history, controlled blood pressure, and well-managed heart failure symptoms (NYHA Class II), it is likely that the patient's outcome as a survivor is due to the effectiveness of her current treatment regimen and close monitoring. The patient's moderately reduced ejection fraction and elevated Pro-BNP level suggest that she still requires ongoing management and follow-up to prevent further cardiac complications."
110,110,P0177,"Age: 76
Gender: Male 
Weight: 90 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 110/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,69
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 57
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 110.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,65
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 948.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 26
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,29
Urea (mg/dL): 6,82
LVEF (%): 43.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 76-year-old male with a history of ischemic dilated cardiomyopathy, myocardial infarction, and hypertension, which are significant risk factors for cardiac complications. However, despite these risk factors, the patient's current outcome is a survivor.

Several factors contributed to this outcome:

1.  Optimal Medication Management: The patient is on a comprehensive regimen of beta blockers, digoxin, loop diuretics, spironolactone, ACE inhibitors, and nitrovasodilators, which are all evidence-based treatments for heart failure and hypertension. These medications likely helped to manage the patient's symptoms and slow disease progression.
2.  Monitoring and Follow-up: The patient's regular follow-up appointments and monitoring allowed for timely adjustments to their treatment plan, which may have helped to prevent further cardiac events.
3.  Good Blood Pressure Control: The patient's blood pressure is well-controlled at 110/55 mmHg, which is below the target for patients with heart failure. This suggests that the patient's hypertension is well-managed, reducing the risk of further cardiac damage.
4.  Low Troponin Levels: The patient's troponin levels are within normal limits, indicating that there is no ongoing myocardial damage or infarction.
5.  LVEF of 43%: Although the patient's left ventricular ejection fraction (LVEF) is below the normal range, it is not severely impaired. This suggests that the patient's heart is still functioning relatively well, and the patient is likely experiencing some degree of compensation.
6.  Normal Hemoglobin and Potassium Levels: The patient's hemoglobin and potassium levels are within normal limits, indicating that there are no significant electrolyte imbalances or anemia, which could contribute to cardiac complications.
7.  Pro-BNP Levels: The patient's pro-BNP levels are elevated, which is consistent with heart failure. However, the level is not extremely high, suggesting that the patient's heart failure is not severely decompensated.
8.  ECG Findings: Although the patient has some arrhythmias on their ECG, none of these findings are life-threatening or indicative of an acute cardiac event.

Considering these factors, the patient's outcome of survival is likely due to a combination of optimal medical management, regular monitoring, and a relatively stable cardiac condition."
111,111,P0179,"Age: 74
Gender: Male 
Weight: 98 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,85
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 38
Glucose (mmol/L): 9,4
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,69
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 408.0
Protein (g/L): 75
T3 (pg/dL): 0,03
T4 (ng/L): 26
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,02
Urea (mg/dL): 6,32
LVEF (%): 29.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome as a survivor can be attributed to a combination of factors, including the effective management of their ischemic dilated cardiomyopathy, hypertension, and myocardial infarction through the use of medications such as beta blockers, loop diuretics, statins, and an ACE inhibitor. These medications have likely contributed to the stabilization of the patient's cardiac function, as indicated by the relatively low levels of troponin (0.01 ng/mL) and the presence of a left ventricular ejection fraction (LVEF) of 29%, which is still within a relatively stable range.

The patient's current NYHA Class II classification suggests that they are experiencing some limitations in their physical activity but are still able to perform everyday tasks without severe symptoms. This classification, combined with the patient's age and past medical history, suggests that the patient has been living with their heart condition for some time and has adapted to their limitations.

The laboratory results, such as the normal levels of troponin, low levels of T3 (0.03 pg/dL), and a normal TSH (1.02 mIU/L), suggest that the patient's cardiac function is not currently under significant stress or strain. The patient's LVEF of 29% indicates that the heart is still pumping blood effectively, albeit at a reduced capacity.

The patient's weight of 98 kg and height of 172 cm indicate that they are overweight, which may be a contributing factor to their hypertension and ischemic dilated cardiomyopathy. However, the patient's blood pressure of 140/70 mmHg is within a relatively normal range, suggesting that their hypertension is well-managed.

In summary, the patient's outcome as a survivor can be attributed to the effective management of their heart condition through medication, a stable NYHA Class II classification, and relatively normal laboratory results."
112,112,P0181,"Age: 69
Gender: Male 
Weight: 100 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 110/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,84
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 273.0
Protein (g/L): 67
T3 (pg/dL): 0,03
T4 (ng/L): 24
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,83
Urea (mg/dL): 8,49
LVEF (%): 39.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 69-year-old male with a history of ischemic dilated cardiomyopathy, survived due to a combination of his current treatment regimen and relatively stable clinical condition. 

Several factors contributed to his survival:

1.  Optimal Medication Adherence: The patient is taking medications that are crucial for managing his ischemic dilated cardiomyopathy, including beta blockers, statins, and an ACE inhibitor. These medications help reduce the risk of cardiac complications, improve heart function, and manage symptoms.

2.  Stable Blood Pressure: The patient's blood pressure of 110/50 mmHg is within a relatively normal range, indicating that his blood pressure is being effectively managed. This is crucial for patients with heart disease, as uncontrolled hypertension can lead to further cardiac damage.

3.  Low Creatinine Levels: The patient's creatinine level of 97.0 mmol/L is within a relatively normal range, suggesting that his kidney function is preserved. Elevated creatinine levels can indicate kidney damage, which can be a complication of heart failure.

4.  LVEF of 39%: Although the patient's left ventricular ejection fraction (LVEF) is low at 39%, indicating some degree of heart failure, it is not extremely low. This suggests that the patient's heart is still functioning to some extent, allowing him to survive.

5.  Normal Troponin Levels: The patient's troponin level of 0.01 ng/mL is within a normal range, indicating that there is no acute myocardial infarction (heart attack) occurring at the time of testing.

6.  Normal TSH and T3/T4 Levels: The patient's thyroid function tests are within a normal range, which is essential for maintaining a stable heart rhythm and overall cardiac function.

7.  Low Pro-BNP Levels: The patient's pro-BNP level of 273.0 ng/L is relatively low, indicating that his heart is not experiencing excessive stress or strain, which is a good sign for survival.

In summary, the patient's survival can be attributed to his adherence to medication, stable blood pressure, preserved kidney function, relatively preserved LVEF, normal troponin levels, normal thyroid function, and low pro-BNP levels."
113,113,P0182,"Age: 76
Gender: Male 
Weight: 90 kg
Height: 181 cm
NYHA Class: III
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 35
ALT or GPT (IU/L): 37.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,72
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 140.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,4
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 859.0
Protein (g/L): 67
T3 (pg/dL): 0,03
T4 (ng/L): 27
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,56
Urea (mg/dL): 8,15
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome is likely due to a combination of factors, including the effectiveness of their current medication regimen and their overall cardiac function.

1.  The patient is on a standard treatment regimen for heart failure, including beta blockers, loop diuretics, statins, and an ACE inhibitor, which are all evidence-based therapies that have been shown to improve outcomes in patients with heart failure.

2.  The patient's LVEF (Left Ventricular Ejection Fraction) is 40%, which indicates that the left ventricle is pumping at a reduced efficiency. However, this is not as low as some other patients with ischemic dilated cardiomyopathy, and the patient is still alive, which suggests that their heart function is relatively well-preserved.

3.  The patient's Pro-BNP (B-type natriuretic peptide) level is elevated at 859.0 ng/L, which is a marker of heart failure and can indicate the severity of the condition. However, this level is not extremely high, which may suggest that the patient's heart failure is not as severe as some other patients.

4.  The patient's blood pressure is within a relatively normal range (130/70 mmHg), which is likely due to the effect of their beta blockers and ACE inhibitor. Well-controlled blood pressure is an important factor in preventing further cardiac damage.

5.  The patient's lipid profile is within a relatively normal range, with a total cholesterol level of 3.72 mmol/L and an LDL level of 2.4 mmol/L. This suggests that the patient's statin therapy is effective in managing their cholesterol levels.

6.  The patient's kidney function, as indicated by their creatinine level (88.0 mmol/L), is within a relatively normal range, which is important for patients with heart failure, as kidney function can be affected by the condition.

7.  The patient's troponin level (0.01 ng/mL) is within a normal range, which suggests that there is no acute myocardial infarction or ongoing cardiac damage.

8.  The patient's ECG shows a polymorphic ventricular extrasystole, which is a type of abnormal heart rhythm, but it is not a life-threatening arrhythmia.

Considering these factors, the patient's outcome as a survivor is likely due to a combination of their effective medication regimen, relatively preserved cardiac function, and well-controlled blood pressure and lipid levels."
114,114,P0184,"Age: 77
Gender: Male 
Weight: 84 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 130/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 45
ALT or GPT (IU/L): 48.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 9,4
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,64
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 525.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 24
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,13
Urea (mg/dL): 7,32
LVEF (%): 37.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 77-year-old male with a history of idiopathic dilated cardiomyopathy, diabetes, and dyslipemia, has a relatively favorable outcome despite his advanced age and significant cardiac impairment. Several factors contribute to this outcome:

1.  Optimal Medication Management: The patient is on a comprehensive medication regimen, including diabetes medication, digoxin, loop diuretics, statins, and nitrovasodilators. This combination helps control his symptoms, manage his comorbidities, and prevent further cardiac deterioration.

2.  Monitoring and Management of Cardiac Function: The patient's left ventricular ejection fraction (LVEF) of 37% indicates moderate to severe left ventricular dysfunction. However, the fact that he has not required more aggressive interventions, such as an implantable cardioverter-defibrillator (ICD) or heart transplantation, suggests that his cardiac function is stable, and his symptoms are well-managed.

3.  Absence of Acute Coronary Syndrome: The patient's troponin level is within normal limits, indicating that he has not experienced a recent myocardial infarction. This absence of acute coronary syndrome reduces the risk of sudden cardiac death and improves his prognosis.

4.  Control of Blood Pressure: The patient's blood pressure is well-controlled at 130/60 mmHg, which is beneficial for patients with heart failure. High blood pressure can exacerbate cardiac dysfunction, so maintaining optimal blood pressure levels is crucial.

5.  Low Levels of Pro-BNP: The patient's pro-BNP level is elevated at 525.0 ng/L, which suggests that he has some degree of cardiac dysfunction. However, it is not excessively high, indicating that his cardiac function is not severely compromised.

6.  Stable Electrocardiogram (ECG) Findings: The patient's ECG shows polymorphic ventricular extrasystoles but no evidence of sustained ventricular tachycardia or bradycardia. This suggests that his cardiac rhythm is relatively stable, and there is no immediate need for more aggressive rhythm management.

Considering these factors, the patient's outcome as a survivor is likely due to the combination of his comprehensive medication regimen, stable cardiac function, absence of acute coronary syndrome, well-controlled blood pressure, and stable ECG findings."
115,115,P0189,"Age: 83
Gender: Female 
Weight: 58 kg
Height: 148 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 6,7
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 24,6
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,49
LDL (mmol/L): 2,77
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1094.0
Protein (g/L): 77
T3 (pg/dL): 0,0609
T4 (ng/L): 17,03
Troponin (ng/mL): 0,4
TSH (mIU/L): 0,51
Urea (mg/dL): 11,3
LVEF (%): 50.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome is a survivor, which can be attributed to several factors from the provided data.

1. Age and Comorbidities: Although the patient is 83 years old, which is a significant risk factor for mortality, her comorbidities, such as hypertension and hypertensive cardiomyopathy, are being well-managed with medications like ACE inhibitors, loop diuretics, and spironolactone. This suggests that the patient's heart failure symptoms are being effectively controlled.

2. Medications: The patient is on a comprehensive regimen of medications, including digoxin, loop diuretics, spironolactone, ACE inhibitors, and nitrovasodilators. These medications are commonly used to manage heart failure symptoms, hypertension, and arrhythmias, which is consistent with her NYHA Class III classification.

3. ECG Findings: The presence of monomorphic ventricular extrasystoles and non-sustained ventricular tachycardia (VT) on the ECG is concerning, but the fact that they are non-sustained suggests that they are not causing significant hemodynamic instability. Additionally, the absence of bradycardia and paroxysmal supraventricular tachyarrhythmia indicates that the patient's heart rate is within a relatively stable range.

4. Laboratory Results: The patient's laboratory results, including her creatinine levels (118.0 mmol/L), indicate that she has mild kidney dysfunction, which is consistent with her age and comorbidities. However, her hemoglobin levels are within the normal range (130 g/L), which suggests that her kidney function is not severely impaired.

5. LVEF and Pro-BNP: The patient's left ventricular ejection fraction (LVEF) is 50%, which is within the normal range. This suggests that her heart function is relatively preserved. The elevated pro-BNP level (1094.0 ng/L) indicates that the patient's heart is under stress, but it is not a predictor of mortality in this context.

Considering these factors, the patient's outcome as a survivor can be attributed to the effective management of her comorbidities, comprehensive medication regimen, and relatively preserved heart function."
116,116,P0190,"Age: 58
Gender: Male 
Weight: 103 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,33
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 3,88
LDL (mmol/L): 3,52
Sodium (mEq/L): 147.0
Pro-BNP (ng/L): 761.0
Protein (g/L): 72,9
T3 (pg/dL): 0,0636
T4 (ng/L): 15,97
Troponin (ng/mL): 0,2
TSH (mIU/L): 1,66
Urea (mg/dL): 7,6
LVEF (%): 50.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 58-year-old male with ischemic dilated cardiomyopathy, diabetes, and hypertension, has a complex medical history that contributes to his current condition. The patient's LVEF (Left Ventricular Ejection Fraction) of 50% indicates moderate heart failure, which is consistent with his NYHA Class II classification. The patient's medications, including beta blockers, loop diuretics, ACE inhibitors, and nitrovasodilators, are standard treatments for heart failure and hypertension.

The patient's laboratory results show elevated creatinine levels (133.0 mmol/L), indicating impaired renal function, which is a common complication in patients with heart failure. The patient's glucose level is slightly elevated (6.6 mmol/L), which may be related to his diabetes. The low HDL level (1.06 mmol/L) and high LDL level (3.52 mmol/L) suggest dyslipidemia, which is a risk factor for cardiovascular disease.

The patient's troponin level is mildly elevated (0.2 ng/mL), indicating some degree of myocardial damage. However, the level is not extremely high, suggesting that the patient may not have had a recent myocardial infarction.

The patient's TSH level is within the normal range (1.66 mIU/L), indicating that his thyroid function is normal. The patient's T3 and T4 levels are also within the normal range, which suggests that his thyroid function is not contributing to his cardiac condition.

The patient's Pro-BNP level is elevated (761.0 ng/L), which is consistent with heart failure. However, the level is not extremely high, suggesting that the patient's heart failure is not severe.

The patient's ECG shows ventricular extrasystoles and non-sustained ventricular tachycardia, which are common findings in patients with heart failure. However, the patient does not have any sustained ventricular tachycardia or bradycardia.

Given the patient's complex medical history and laboratory results, it is likely that the patient's outcome is a survivor due to the following reasons:

1. The patient's medications are optimized to manage his heart failure and hypertension.
2. The patient's LVEF is 50%, which is a moderate level of heart failure, but not severe enough to be life-threatening.
3. The patient's renal function is impaired, but not severely so.
4. The patient's glucose level is slightly elevated, but not extremely high.
5. The patient's lipid profile is not ideal, but not extremely abnormal.
6. The patient's troponin level is mildly elevated, but not extremely high.
7. The patient's thyroid function is normal.
8. The patient's Pro-BNP level is elevated, but not extremely high.
9. The patient's ECG findings are consistent with heart failure, but not severe enough to be life-threatening.

Overall, the patient's outcome as a survivor is likely due to a combination of his optimized medications, moderate level of heart failure, and relatively mild laboratory abnormalities."
117,117,P0191,"Age: 56
Gender: Male 
Weight: 67 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 130/75 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,37
Creatinine (mmol/L): 138.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 7,7
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,73
Potassium (mEq/L): 5,8
LDL (mmol/L): 2,09
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 341.0
Protein (g/L): 73
T3 (pg/dL): 0,0594
T4 (ng/L): 19,91
TSH (mIU/L): 1,12
Urea (mg/dL): 18,3
LVEF (%): 60.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 56-year-old male with a history of hypertensive cardiomyopathy, diabetes, and hypertension, has been managed with a combination of medications including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor. The patient's left ventricular ejection fraction (LVEF) is 60%, indicating preserved systolic function.

The patient's ECG shows monomorphic ventricular extrasystoles, which are common in patients with cardiomyopathy. However, the absence of non-sustained ventricular tachycardia and other significant arrhythmias suggests that the patient's cardiac function is relatively stable.

The patient's laboratory results show elevated creatinine levels (138.0 μmol/L), indicating chronic kidney disease, but the glomerular filtration rate (GFR) is not provided. The patient's albumin levels are within the normal range, suggesting that the kidney function is not severely impaired.

The patient's glucose level (7.7 mmol/L) is within the target range for diabetes management, and the patient is on diabetes medication, which is likely contributing to the controlled glucose levels.

The patient's lipid profile shows elevated total cholesterol (4.37 mmol/L) and LDL (2.09 mmol/L) levels, but the HDL level is also elevated (1.73 mmol/L), which is a good prognostic sign.

The patient's thyroid function tests are within the normal range, with a TSH level of 1.12 mIU/L, which suggests that the patient is euthyroid.

The patient's BNP level is elevated (341.0 ng/L), which is consistent with heart failure, but the patient's symptoms and ECG findings suggest that the patient is stable and not experiencing acute decompensation.

Considering the patient's overall clinical presentation, laboratory results, and ECG findings, the patient's outcome as a survivor is likely due to the following factors:

1.  Effective management of hypertension and diabetes, which has helped to slow the progression of cardiomyopathy.
2.  The use of beta blockers, digoxin, and loop diuretics, which have helped to control symptoms of heart failure and improve cardiac function.
3.  The patient's relatively preserved LVEF (60%) and absence of significant arrhythmias suggest that the patient's cardiac function is relatively stable.
4.  The patient's elevated BNP level may indicate some degree of heart failure, but the patient's symptoms and ECG findings suggest that the patient is not experiencing acute decompensation.

Overall, the patient's outcome as a survivor is likely due to a combination of effective medical management and the patient's relatively stable cardiac function."
118,118,P0193,"Age: 55
Gender: Female 
Weight: 100 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,27
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 5,32
LDL (mmol/L): 2,15
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 281.0
Protein (g/L): 78
T3 (pg/dL): 0,0321
T4 (ng/L): 17,73
Troponin (ng/mL): 0,6
TSH (mIU/L): 0,94
Urea (mg/dL): 14,4
LVEF (%): 40.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

Given the patient's medical history and current laboratory results, it is not surprising that she is a survivor. Here's a breakdown of the key factors contributing to her outcome:

1.  Ischemic dilated cardiomyopathy: Despite having a reduced left ventricular ejection fraction (LVEF) of 40%, the patient's heart condition is managed with optimal medical therapy, including beta blockers, ACE inhibitors, and spironolactone. This suggests that her condition is being effectively managed, which contributed to her survival.

2.  Medications: The patient is on a comprehensive regimen of medications that address her multiple comorbidities, including diabetes, hypertension, and dyslipidemia. This polypharmacy suggests that her healthcare team is taking a proactive approach to managing her conditions, which likely contributed to her survival.

3.  ECG findings: The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia indicates that the patient does not have any acute cardiac arrhythmias that could have led to sudden cardiac death.

4.  Hemoglobin and creatinine levels: The patient's hemoglobin level is within the normal range, indicating adequate oxygen delivery to tissues. Her creatinine level is elevated, but it is not significantly elevated, suggesting that her kidney function is not severely compromised.

5.  Pro-BNP level: The patient's Pro-BNP level is elevated at 281.0 ng/L, which is consistent with heart failure. However, this level is not excessively high, indicating that the patient's heart failure is not acutely decompensated.

6.  TSH and T4 levels: The patient's thyroid function is within the normal range, which is essential for maintaining cardiac function and overall well-being.

7.  Medication adherence: The patient is on a complex regimen of medications, which suggests that she is likely adherent to her treatment plan, which contributed to her survival.

Considering these factors, it is likely that the patient's survival is due to the comprehensive management of her multiple comorbidities, optimal medication therapy, and the absence of acute cardiac arrhythmias."
119,119,P0195,"Age: 62
Gender: Female 
Weight: 60 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 6.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 109.0
Gamma-glutamil transpeptidase (IU/L): 7,4
Glucose (mmol/L): 4,1
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,11
LDL (mmol/L): 2,35
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 237.0
Protein (g/L): 66,8
T3 (pg/dL): 0,0402
T4 (ng/L): 13,59
TSH (mIU/L): 1,6
Urea (mg/dL): 8
LVEF (%): 25.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of being a survivor can be attributed to several factors. 

1. Optimal medical management: The patient is on a comprehensive treatment regimen that includes beta blockers, loop diuretics, and an ACE inhibitor, which are all standard therapies for heart failure management. These medications have likely helped to control the patient's symptoms and slow the progression of the disease.

2. NYHA Class II classification: The patient's New York Heart Association (NYHA) classification of II indicates that she experiences some limitations in physical activity, but is still able to perform everyday tasks without significant symptoms. This suggests that her heart failure is not severe, and she is not in an advanced stage of the disease.

3. LVEF of 25%: Although the patient's left ventricular ejection fraction (LVEF) is severely reduced, indicating significant left ventricular dysfunction, it is not the lowest possible value. An LVEF of 25% is still compatible with survival, especially with optimal medical management.

4. Normal electrolyte levels: The patient's potassium and sodium levels are within normal limits, which is essential for optimal cardiac function. Hypokalemia or hyperkalemia can exacerbate heart failure symptoms and potentially lead to life-threatening arrhythmias.

5. Normal TSH and T3/T4 levels: The patient's thyroid function tests are within normal limits, which is crucial for maintaining cardiac function. Hypothyroidism or hyperthyroidism can lead to heart failure symptoms and worsen the patient's prognosis.

6. Absence of severe comorbidities: The patient does not have any severe comorbidities, such as renal failure (creatinine level is slightly elevated but not severely abnormal) or liver dysfunction (ALT and AST levels are within normal limits), which can complicate heart failure management and worsen the prognosis.

7. Pro-BNP level: The patient's Pro-BNP level is elevated, indicating increased ventricular stretch and potential heart failure. However, the level is not extremely high, which may indicate that the patient's condition is being managed effectively.

Considering these factors, the patient's outcome of being a survivor can be attributed to a combination of optimal medical management, relatively mild heart failure symptoms, and the absence of severe comorbidities."
120,120,P0196,"Age: 71
Gender: Male 
Weight: 65 kg
Height: 167 cm
NYHA Class: III
Blood Pressure: 90/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 187.0
Gamma-glutamil transpeptidase (IU/L): 137
Glucose (mmol/L): 7,1
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 6,1
LDL (mmol/L): 3,34
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 7460.0
Protein (g/L): 78,899
T3 (pg/dL): 0,0315
T4 (ng/L): 15,28
Troponin (ng/mL): 0,7
TSH (mIU/L): 3,14
Urea (mg/dL): 24,46
LVEF (%): 30.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 71-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, and myocardial infarction, has a complex medical profile. His New York Heart Association (NYHA) Class III classification indicates that he experiences symptoms of heart failure with limited physical activity.

The patient's low blood pressure (90/55 mmHg) may be a concern, but it could be a result of his heart failure and diuretic therapy, which can cause dehydration and electrolyte imbalances. His creatinine level of 187.0 μmol/L suggests impaired kidney function, likely due to his heart failure and potential renal artery stenosis.

The patient's high troponin level of 0.7 ng/mL indicates some degree of myocardial damage, but it's not extremely elevated. His low LVEF (left ventricular ejection fraction) of 30% indicates significant left ventricular dysfunction.

The patient is on optimal heart failure medications, including digoxin, loop diuretics, spironolactone, and an ACE inhibitor, which are commonly used to manage heart failure and reduce mortality.

The patient's high Pro-BNP (brain natriuretic peptide) level of 7460.0 ng/L suggests significant heart failure and increased ventricular wall stress. However, his TSH level is within the normal range, which is a good sign.

Considering the patient's complex medical profile, his current medications, and the presence of a non-sustained ventricular tachycardia, it is surprising that the patient is a survivor. However, it's essential to consider the following factors:

1. The patient's LVEF has not decreased significantly in recent years, suggesting that his heart failure is not rapidly progressive.
2. His medications are optimized, which may be contributing to his survival.
3. The patient's high Pro-BNP level may indicate that his heart failure is being managed, and his symptoms are not worsening rapidly.

In conclusion, the patient's survival is likely due to his optimized medical therapy, relatively stable LVEF, and the absence of significant acute changes in his cardiac function."
121,121,P0197,"Age: 71
Gender: Male 
Weight: 73 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Peripheral vascular disease
Albumin (g/L): 41
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 6,78
Creatinine (mmol/L): 145.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,78
Potassium (mEq/L): 4,9
LDL (mmol/L): 4,37
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1367.0
Protein (g/L): 74,5
T3 (pg/dL): 0,0384
T4 (ng/L): 17,4
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,14
Urea (mg/dL): 13,4
LVEF (%): 40.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient, a 71-year-old male with a history of idiopathic dilated cardiomyopathy and peripheral vascular disease, has been managed with a combination of medications including digoxin, loop diuretics, and an ACE inhibitor. His current LVEF (Left Ventricular Ejection Fraction) is 40%, indicating a reduced cardiac function. However, the patient's Pro-BNP level is elevated at 1367 ng/L, which suggests that despite the reduced LVEF, the patient's heart is not in severe distress.

The patient's blood pressure is within a relatively normal range (110/60 mmHg), and his glucose and lipid profiles are well-controlled. His creatinine level is elevated at 145.0 mmol/L, indicating some degree of renal impairment, but it is not severe.

The patient's ECG shows a monomorphic ventricular extrasystole, which is a common finding in patients with dilated cardiomyopathy. The absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia suggests that the patient is not experiencing significant arrhythmia-related complications.

Considering the patient's age, comorbidities, and current medication regimen, it is likely that the patient is being managed conservatively to prevent further cardiac decompensation. The patient's ability to survive suggests that the current treatment plan is effective in controlling symptoms and preventing cardiac complications.

The patient's low T3 and T4 levels, with a normal TSH, indicate that the thyroid function is well-controlled. The patient's hemoglobin level is within a normal range, indicating adequate iron stores and no significant anemia.

In summary, the patient's survival is likely due to the effective management of his cardiomyopathy and other comorbidities, as well as his relatively stable cardiac function and well-controlled medication regimen."
122,122,P0198,"Age: 53
Gender: Male 
Weight: 77 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 46
ALT or GPT (IU/L): 49.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,15
Creatinine (mmol/L): 90.0
Gamma-glutamil transpeptidase (IU/L): 69
Glucose (mmol/L): 19,2
Hemoglobin (g/L): 144.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,48
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 41.0
Protein (g/L): 81,8
T3 (pg/dL): 0,0522
T4 (ng/L): 18,6
Troponin (ng/mL): 0,4
TSH (mIU/L): 1,79
Urea (mg/dL): 6,7
LVEF (%): 40.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's medical history of enolic dilated cardiomyopathy, which is a condition characterized by the enlargement of the left ventricle, leading to reduced left ventricular ejection fraction (LVEF), the patient is at a higher risk of heart failure. The patient's LVEF of 40% is within the range of heart failure with reduced ejection fraction (HFrEF). 

The patient's current medications, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, are appropriate for managing heart failure and dilated cardiomyopathy. Beta blockers reduce the heart rate and contractility, digoxin increases the contractility of the heart, loop diuretics help reduce fluid overload, spironolactone is an aldosterone antagonist that helps to reduce fluid retention, and ACE inhibitors help to reduce the workload on the heart.

The patient's laboratory results show elevated levels of troponin, which is a marker of cardiac damage, but the level is not extremely high (0.4 ng/mL). The patient's TSH is within the normal range, indicating that there is no evidence of hypothyroidism, which can sometimes contribute to cardiomyopathy. The patient's T3 and T4 levels are also within the normal range.

The patient's blood pressure is within the normal range, and the patient does not have any signs of acute coronary syndrome or other acute cardiac conditions. The patient's creatinine level is elevated, which may indicate some degree of renal impairment, but it is not severe.

Given the patient's overall clinical picture and the management of their heart failure, it is likely that the patient will survive with appropriate medical management. The patient's outcome of survival is likely due to the effectiveness of their current treatment regimen and the absence of any acute cardiac events."
123,123,P0201,"Age: 48
Gender: Male 
Weight: 96 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,17
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 66
Glucose (mmol/L): 7,8
Hemoglobin (g/L): 179.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 5,09
LDL (mmol/L): 3,59
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1176.0
Protein (g/L): 72,3
T3 (pg/dL): 0,03
T4 (ng/L): 15,92
Troponin (ng/mL): 0,2
TSH (mIU/L): 0,88
Urea (mg/dL): 5,7
LVEF (%): 25.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient, a 48-year-old male with a history of enolic dilated cardiomyopathy, has been receiving appropriate medical management with beta blockers, digoxin, loop diuretics, and an ACE inhibitor. His LVEF of 25% indicates severe left ventricular dysfunction, which is consistent with his diagnosis of dilated cardiomyopathy. 

The patient's elevated Pro-BNP level of 1176.0 ng/L suggests increased ventricular wall stress, which is also consistent with his heart failure symptoms. His elevated creatinine level of 113.0 μmol/L indicates impaired renal function, likely due to his heart failure and potential chronic kidney disease.

The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG indicates ventricular arrhythmias, which are common in patients with dilated cardiomyopathy. However, the fact that these arrhythmias are non-sustained suggests that they are not currently causing hemodynamic instability.

Given the patient's overall clinical presentation and the fact that he is receiving appropriate medical management, the patient's survival is likely due to the effectiveness of his treatment regimen and the absence of acute decompensation. The patient's NYHA class II classification indicates that he has mild to moderate symptoms of heart failure, which is consistent with his ability to survive with medical management.

It is also worth noting that the patient's TSH level is within the normal range, which suggests that his thyroid function is not contributing to his heart failure symptoms. Additionally, his low T3 level may be a reflection of his heart failure and impaired renal function, as T3 is often decreased in patients with chronic kidney disease."
124,124,P0202,"Age: 75
Gender: Male 
Weight: 77 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 160/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,83
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 13,2
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,32
LDL (mmol/L): 2,22
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 918.0
Protein (g/L): 71,6
T3 (pg/dL): 0,0585
T4 (ng/L): 12,73
Troponin (ng/mL): 0,2
TSH (mIU/L): 1,16
Urea (mg/dL): 8,3
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 75-year-old male with a history of hypertensive cardiomyopathy, diabetes, dyslipemia, and hypertension, has a complex medical profile. His LVEF of 45% indicates reduced left ventricular function, which is a risk factor for adverse cardiac events. However, the patient's current medications, including beta blockers, loop diuretics, statins, and ACE inhibitors, are appropriate for managing his conditions.

The patient's blood pressure is well-controlled at 160/85 mmHg, which is within a relatively acceptable range for a patient with hypertension. His glucose level is elevated at 13.2 mmol/L, but his diabetes medication is likely managing his blood sugar levels effectively.

The patient's troponin level is slightly elevated at 0.2 ng/mL, which may indicate myocardial ischemia or minor cardiac damage, but it is not significantly elevated to indicate acute coronary syndrome.

The patient's BNP level of 918 ng/L is elevated, indicating increased ventricular wall stress, which is consistent with his reduced LVEF and history of cardiomyopathy.

The patient's ECG shows monomorphic ventricular extrasystoles, which are common in patients with cardiomyopathy and are often benign. There is no evidence of sustained ventricular tachycardia, paroxysmal supraventricular tachyarrhythmia, or bradycardia.

Considering the patient's overall medical profile and the fact that his medications are well-managed, the most likely reason for the patient's outcome is that he has survived his current episode of reduced cardiac function and is likely receiving effective treatment for his conditions. The patient's survival is likely due to the combination of his current medications, his relatively well-controlled blood pressure, and the fact that his cardiac function has not deteriorated to a point where it would lead to a fatal outcome."
125,125,P0203,"Age: 78
Gender: Female 
Weight: 90 kg
Height: 157 cm
NYHA Class: III
Blood Pressure: 150/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,97
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 3,8
LDL (mmol/L): 3,44
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 491.0
Protein (g/L): 80
T3 (pg/dL): 0,0363
T4 (ng/L): 16,39
Troponin (ng/mL): 0,1
TSH (mIU/L): 2,19
Urea (mg/dL): 18,8
LVEF (%): 30.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient outcome of survival is likely due to a combination of factors, including the patient's current medical treatment and the absence of severe acute cardiac decompensation. The patient is already on loop diuretics and an ACE inhibitor, which are standard treatments for heart failure and hypertension. The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG suggests that the patient has a high risk of arrhythmias, but the fact that they are not experiencing sustained ventricular tachycardia or ventricular fibrillation at the time of the ECG suggests that their heart function is not severely compromised.

The patient's LVEF (Left Ventricular Ejection Fraction) of 30% is significantly decreased, indicating severe left ventricular dysfunction, but the fact that they are still alive suggests that their heart is still able to pump enough blood to meet their body's needs, albeit with significant impairment. The patient's high Pro-BNP (B-type natriuretic peptide) level of 491 ng/L suggests that they have heart failure, but the fact that they are not experiencing severe symptoms or acute decompensation suggests that their condition is being well-managed.

The patient's other laboratory values, including their electrolytes, liver function tests, and renal function tests, are within relatively normal limits, which suggests that they do not have any other underlying conditions that would increase their risk of death. Overall, while the patient has a significant cardiac condition, their current medical treatment and the absence of severe acute cardiac decompensation suggest that they are likely to survive."
126,126,P0204,"Age: 69
Gender: Male 
Weight: 69 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 8.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 4,24
Creatinine (mmol/L): 152.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 6,4
Hemoglobin (g/L): 115.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,4
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 7794.0
Protein (g/L): 77
T3 (pg/dL): 0,0351
T4 (ng/L): 18,87
Troponin (ng/mL): 0,7
TSH (mIU/L): 1,89
Urea (mg/dL): 11
LVEF (%): 40.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's medical history and the provided test results, the patient's outcome of survival can be attributed to several factors. 

1. Optimal Medical Management: The patient is on a comprehensive regimen of medications, including an Angiotensin II Receptor Blocker, Loop Diuretics, Statins, and Nitrovasodilators. These medications are crucial in managing heart failure, hypertension, and dyslipidemia. The patient's diabetes is also being managed with medication, which is essential in preventing further cardiac damage.

2. Stable Blood Pressure: The patient's blood pressure is within a relatively normal range (120/80 mmHg), which is a good indicator of controlled hypertension. Uncontrolled hypertension can exacerbate heart failure and lead to further complications.

3. Moderate LVEF: Although the patient's left ventricular ejection fraction (LVEF) is 40%, which is lower than the normal range (50-70%), it is not severely impaired. This suggests that the patient's heart is still functioning to some extent, allowing them to survive.

4. Reasonable Electrocardiogram (ECG) Findings: While the patient has non-sustained ventricular tachycardia and ventricular extrasystoles, these are not severe indicators of cardiac instability. The presence of paroxysmal supraventricular tachycardia (PSVT) may be a concern, but it is not life-threatening in this context.

5. TSH and T4 Levels: The patient's thyroid hormone levels are within the normal range, which is essential for maintaining cardiac function and overall health.

6. Glucose and Lipid Profile: The patient's glucose level is relatively well-controlled, and their lipid profile shows a relatively low LDL cholesterol level, which is beneficial for preventing further cardiac damage.

7. Kidney Function: Although the patient has elevated creatinine levels, indicating some degree of kidney impairment, it is not severe enough to compromise their overall survival.

8. Pro-BNP Level: The patient's Pro-BNP level is elevated (7794.0 ng/L), which is consistent with heart failure. However, this does not necessarily indicate a poor prognosis, as it can be elevated in patients with heart failure who are being treated effectively.

Considering these factors, the patient's survival can be attributed to the effectiveness of their medical management, stable blood pressure, moderate LVEF, reasonable ECG findings, and relatively well-controlled glucose and lipid profiles."
127,127,P0206,"Age: 80
Gender: Male 
Weight: 88 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,51
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,57
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 3087.0
Protein (g/L): 62,3
T3 (pg/dL): 0,0444
T4 (ng/L): 13,71
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,46
Urea (mg/dL): 8,5
LVEF (%): 45.0
Medications: Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient's outcome of being a survivor can be attributed to a combination of factors, including the patient's current medical management and the presence of certain biomarkers that indicate a relatively stable cardiac condition.

Firstly, the patient is on loop diuretics, which are commonly used to manage heart failure symptoms and reduce fluid overload, a common complication of dilated cardiomyopathy. This medication is likely helping to control the patient's symptoms and prevent further decompensation.

The patient's LVEF (Left Ventricular Ejection Fraction) is 45%, which is below the normal range (50-70%), indicating some degree of left ventricular dysfunction. However, it is not severely impaired, and the patient is still able to maintain a relatively stable condition.

The patient's Pro-BNP (N-terminal pro b-type natriuretic peptide) level is elevated at 3087.0 ng/L, which is consistent with heart failure. However, the level is not extremely high, suggesting that the patient is not in acute heart failure.

The patient's TSH (thyroid-stimulating hormone) level is within the normal range, which is important because thyroid dysfunction can exacerbate heart failure symptoms.

The patient's Troponin level is within the normal range, which suggests that there is no acute myocardial infarction (heart attack).

The patient's ECG shows non-sustained ventricular tachycardia, which is a common finding in patients with heart failure. However, the presence of polymorphic ventricular extrasystoles and unknown paroxysmal supraventricular tachyarrhythmia may indicate some degree of arrhythmia burden, but it is not severe enough to cause significant harm.

Overall, the patient's stable condition, current medical management, and the presence of biomarkers that indicate a relatively stable cardiac condition suggest that the patient is likely to survive with appropriate management and follow-up."
128,128,P0208,"Age: 63
Gender: Male 
Weight: 83 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 160/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,31
Creatinine (mmol/L): 87.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 160.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,19
LDL (mmol/L): 4,53
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 520.0
Protein (g/L): 73,6
T3 (pg/dL): 0,0618
T4 (ng/L): 15,21
Troponin (ng/mL): 0,1
TSH (mIU/L): 1,43
Urea (mg/dL): 5,9
LVEF (%): 15.0
Medications: Calcium Channel Blocker, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome is a survivor, which can be attributed to several factors based on the provided information. 

Firstly, the patient's current medications, Calcium Channel Blocker and ACE Inhibitor, are appropriate for managing hypertension and heart failure symptoms. These medications can help control blood pressure and reduce the strain on the heart.

Secondly, despite having a history of idiopathic dilated cardiomyopathy, the patient's LVEF (Left Ventricular Ejection Fraction) is 15%, which is relatively low but not extremely low. This indicates that the heart is still pumping some blood, albeit inefficiently.

Thirdly, the patient's Pro-BNP (Brain Natriuretic Peptide) level is elevated at 520.0 ng/L, which is often associated with heart failure. However, the patient's overall clinical presentation and laboratory values do not suggest severe heart failure.

Fourthly, the patient's creatinine level is 87.0 mmol/L, indicating some kidney impairment, which is likely related to the patient's peripheral vascular disease and hypertension. However, the patient's urea level is only 5.9 mg/dL, which is not significantly elevated, suggesting that the kidney impairment is not severe.

Lastly, the patient's ECG shows polymorphic ventricular extrasystoles, but no sustained ventricular tachycardia or other life-threatening arrhythmias. This suggests that the patient's heart is still functioning, albeit with some arrhythmias.

Considering these factors, the patient's outcome as a survivor is likely due to the effectiveness of their current medications, the relatively stable and not extremely low LVEF, and the absence of severe heart failure or life-threatening arrhythmias."
129,129,P0209,"Age: 55
Gender: Male 
Weight: 84 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 5,28
Creatinine (mmol/L): 74.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 4,1
Hemoglobin (g/L): 160.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 5,1
LDL (mmol/L): 3,7
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 149.0
Protein (g/L): 71,5
T3 (pg/dL): 0,06
T4 (ng/L): 15,82
TSH (mIU/L): 1,64
Urea (mg/dL): 5,4
LVEF (%): 30.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's medical history, the patient is a 55-year-old male with ischemic dilated cardiomyopathy, hypertension, and a history of myocardial infarction. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 30%, indicating a poor heart function.

The patient's current medications, including beta blockers, digoxin, loop diuretics, ACE inhibitors, and nitrovasodilators, are aimed at managing heart failure symptoms, controlling blood pressure, and improving cardiac function. The presence of these medications suggests that the patient is receiving appropriate treatment for heart failure.

The laboratory results show elevated levels of creatinine (74.0 mmol/L), indicating impaired kidney function, which is common in patients with heart failure. The patient's total cholesterol level is elevated (5.28 mmol/L), which may be a contributing factor to the development of atherosclerosis and subsequent ischemic dilated cardiomyopathy.

The patient's NT-proBNP level is elevated at 149.0 ng/L, which is consistent with heart failure. However, the patient's T3 and T4 levels are within normal limits, and the TSH level is also within the normal range, indicating no evidence of thyroid dysfunction.

The ECG shows a monomorphic ventricular extrasystole, which is a benign finding in this context. There is no evidence of sustained or non-sustained ventricular tachycardia, paroxysmal supraventricular tachyarrhythmia, or bradycardia.

Considering the patient's overall clinical presentation, laboratory results, and ECG findings, the most likely reason for the patient's survival is the effectiveness of the current treatment regimen, which includes medications aimed at managing heart failure, controlling blood pressure, and improving cardiac function. The patient's reduced LVEF and elevated creatinine levels indicate ongoing cardiac dysfunction, but the absence of severe symptoms and the presence of supportive medications likely contributed to the patient's survival."
130,130,P0210,"Age: 75
Gender: Male 
Weight: 80 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 180/95 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 5,61
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 7,8
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,45
Potassium (mEq/L): 3,78
LDL (mmol/L): 3,78
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 308.0
Protein (g/L): 70
T3 (pg/dL): 0,0597
T4 (ng/L): 19,3
Troponin (ng/mL): 0,5
TSH (mIU/L): 0,69
Urea (mg/dL): 8,3
LVEF (%): 70.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient, a 75-year-old male, has a complex medical history that includes hypertension, cardiomyopathy, diabetes, dyslipidemia, and hypertension. His blood pressure is elevated at 180/95 mmHg, which is a significant risk factor for cardiovascular disease. However, his left ventricular ejection fraction (LVEF) is 70%, indicating that his heart function is relatively preserved.

The patient's laboratory results show evidence of kidney impairment, with elevated creatinine levels (88.0 mmol/L) and urea (8.3 mg/dL). This suggests that his kidney function is compromised, which can be a contributing factor to his cardiovascular disease.

Despite these risk factors, the patient's ECG shows only a monomorphic ventricular extrasystole, which is a relatively benign finding. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and other arrhythmias suggests that his cardiac function is not severely compromised.

The patient is on a regimen of angiotensin II receptor blocker, loop diuretics, and ACE inhibitor, which are all standard treatments for hypertension and heart failure. These medications are likely contributing to his relatively good outcome.

The patient's low TSH level (0.69 mIU/L) suggests that his thyroid function is within normal limits, which is important for cardiovascular health.

In conclusion, this patient's outcome as a survivor is likely due to a combination of factors, including:

1. Preserved left ventricular function (LVEF 70%)
2. Effective management of hypertension with medications
3. Absence of severe cardiac arrhythmias
4. Normal thyroid function
5. Presence of kidney impairment, which may be a contributing factor to his cardiovascular disease, but not severe enough to compromise his survival.

Overall, this patient's outcome as a survivor is a testament to the effectiveness of modern cardiovascular management and the importance of timely medical intervention."
131,131,P0214,"Age: 50
Gender: Female 
Weight: 77 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 81.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 126.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,32
LDL (mmol/L): 2,3
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 327.0
Protein (g/L): 69
T3 (pg/dL): 0,051
T4 (ng/L): 14,1
TSH (mIU/L): 1,38
Urea (mg/dL): 5,5
LVEF (%): 50.0
Medications: Beta Blockers, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome as a survivor can be attributed to several factors based on the provided data. 

1.  Optimal Medication Management: The patient is on a combination of beta blockers, ACE inhibitors, and nitrovasodilators, which are standard medications for managing ischemic dilated cardiomyopathy and heart failure. These medications likely helped to control the patient's symptoms and reduce the risk of further cardiac complications.

2.  Stable LVEF (Left Ventricular Ejection Fraction): The patient's LVEF is 50%, which is relatively stable and not significantly decreased. An LVEF of 50% indicates that the heart is pumping blood efficiently enough to meet the body's needs, although it's not at optimal levels. This stability suggests that the patient's cardiac function has not significantly deteriorated.

3.  Normal Blood Pressure: The patient's blood pressure is within a normal range (130/80 mmHg), which is a positive indicator of cardiovascular health. Maintaining normal blood pressure helps reduce the strain on the heart and minimizes the risk of cardiac complications.

4.  Low Pro-BNP Levels: The patient's Pro-BNP level is 327.0 ng/L, which is slightly elevated but not excessively high. B-type natriuretic peptide (BNP) is a hormone produced by the heart in response to increased wall stress. Elevated BNP levels can indicate heart failure, but a relatively low level in this case suggests that the patient's heart function is not severely compromised.

5.  Stable Electrocardiogram (ECG) Results: The ECG results do not indicate any severe arrhythmias or cardiac abnormalities that could have led to a poor outcome.

6.  Absence of Severe Comorbidities: The patient does not have severe comorbidities such as severe kidney disease (elevated creatinine levels are within a relatively normal range), or severe electrolyte imbalances (potassium levels are within a normal range).

Considering these factors, the patient's stable condition, optimal medication management, and relatively stable cardiac function contributed to their survival."
132,132,P0216,"Age: 79
Gender: Male 
Weight: 73 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 150/90 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 33
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 46.0
Total Cholesterol (mmol/L): 3,26
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 149
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,73
Potassium (mEq/L): 4,58
LDL (mmol/L): 1,71
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 5971.0
Protein (g/L): 66,3
T3 (pg/dL): 0,0642
T4 (ng/L): 19,53
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,68
Urea (mg/dL): 7,2
LVEF (%): 30.0
Medications: Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient's outcome is a survivor, which is a positive outcome. Several factors contribute to this outcome, despite the patient's advanced age and multiple comorbidities. 

1.  Optimal Medication Management: The patient is on a comprehensive regimen of medications, including an Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, ACE Inhibitor, and Nitrovasodilator. These medications are crucial in managing heart failure symptoms, hypertension, and arrhythmias. The patient's LVEF (Left Ventricular Ejection Fraction) of 30% suggests a significant impairment in cardiac function, but the medication regimen is likely helping to mitigate this condition.

2.  Proper Monitoring and Management of Heart Failure: The patient's NYHA Class II classification indicates that the patient has mild to moderate symptoms of heart failure. The patient's Pro-BNP (B-type Natriuretic Peptide) level of 5971.0 ng/L is elevated, which is consistent with heart failure. However, the patient's creatinine level of 119.0 umol/L suggests that the patient does not have significant renal impairment, which is a common complication in patients with heart failure.

3.  Control of Blood Pressure: The patient's blood pressure of 150/90 mmHg is not optimally controlled, but it is not severely elevated. The patient's hypertension is being managed with an Angiotensin II Receptor Blocker and an ACE Inhibitor, which are both effective in controlling blood pressure and reducing the progression of heart failure.

4.  Lack of Significant Arrhythmias: Although the patient has non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles, these arrhythmias are not severe enough to compromise the patient's survival. The patient's TSH level of 1.68 mIU/L is within the normal range, which suggests that the patient's thyroid function is not contributing to arrhythmias.

5.  Patient's Age and Comorbidities: The patient's age of 79 is a significant risk factor for mortality, but the patient's overall condition and comorbidities are being managed effectively. The patient's weight of 73 kg and height of 161 cm are within a normal range for his age, which suggests that the patient is not malnourished or dehydrated.

In conclusion, the patient's survivor outcome is likely due to the comprehensive management of their heart failure, hypertension, and arrhythmias, as well as the absence of significant renal impairment and other comorbidities."
133,133,P0219,"Age: 61
Gender: Male 
Weight: 84 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 49.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 4,95
Creatinine (mmol/L): 136.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 7,74
Hemoglobin (g/L): 167.0
HDL (mmol/L): 1,1
Potassium (mEq/L): 4,46
LDL (mmol/L): 2,77
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 165.0
Protein (g/L): 75,5
T3 (pg/dL): 0,0204
T4 (ng/L): 13,65
Troponin (ng/mL): 0,8
TSH (mIU/L): 1,19
Urea (mg/dL): 7,8
LVEF (%): 40.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient, a 61-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension, has been managed with a multi-faceted treatment plan that likely contributed to his favorable outcome. The patient's current medications, including an angiotensin II receptor blocker, digoxin, loop diuretics, and statins, are all standard treatments for heart failure with reduced ejection fraction (HFrEF) and are likely aimed at managing his ischemic dilated cardiomyopathy.

The patient's left ventricular ejection fraction (LVEF) is 40%, indicating systolic heart failure, but it is not severely impaired. His Pro-BNP level of 165 ng/L suggests some degree of heart failure, but it is not excessively elevated, indicating that the patient's heart failure is not severe.

The patient's blood pressure is controlled at 140/90 mmHg, which is within the target range for most patients with heart failure. His lipid profile is also well-managed, with a total cholesterol of 4.95 mmol/L and an LDL of 2.77 mmol/L, which are both within the target range.

The patient's glucose level is 7.74 mmol/L, which is within the normal range, indicating good control of his diabetes. His kidney function is also preserved, with a creatinine level of 136.0 μmol/L, which is within the normal range.

The patient's ECG shows ventricular extrasystoles and non-sustained ventricular tachycardia, which are common findings in patients with heart failure. However, there is no evidence of sustained ventricular tachycardia, bradycardia, or paroxysmal supraventricular tachyarrhythmia.

Overall, the patient's combination of medications, controlled blood pressure, well-managed diabetes and lipid profile, preserved kidney function, and absence of severe ECG abnormalities all contributed to his favorable outcome."
134,134,P0220,"Age: 44
Gender: Male 
Weight: 106 kg
Height: 181 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Valvular cardiomyopathy, Dyslipemia
Albumin (g/L): 46
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 6,21
Creatinine (mmol/L): 128.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 5,02
Hemoglobin (g/L): 111.0
HDL (mmol/L): 0,8
Potassium (mEq/L): 4,59
LDL (mmol/L): 4,19
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 1057.0
Protein (g/L): 82,4
T3 (pg/dL): 0,0339
T4 (ng/L): 20,91
Troponin (ng/mL): 0,6
TSH (mIU/L): 1,55
Urea (mg/dL): 19,2
LVEF (%): 20.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the provided patient data, the patient is a 44-year-old male with a history of valvular cardiomyopathy, dyslipemia, and a severely reduced left ventricular ejection fraction (LVEF) of 20%. He is on a regimen of beta blockers, digoxin, loop diuretics, and an ACE inhibitor, indicating a treatment plan for heart failure and potential arrhythmias.

The patient's elevated Pro-BNP level (1057 ng/L) is indicative of heart failure with preserved ejection fraction or reduced ejection fraction, suggesting that the patient's heart is not functioning properly. His low hemoglobin level (111 g/L) may indicate anemia, which can further compromise cardiac function.

The patient's lipid profile shows high total cholesterol (6.21 mmol/L) and LDL levels (4.19 mmol/L), which are risk factors for coronary artery disease and potential worsening of heart failure. His low HDL level (0.8 mmol/L) is also a risk factor for cardiovascular disease.

The patient's ECG shows ventricular extrasystoles, which are common in patients with cardiomyopathy, but no sustained ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia. His blood pressure is low (100/60 mmHg), which may be due to the use of loop diuretics.

Considering the patient's overall condition, his survival is likely due to the following factors:

1.  Aggressive treatment of heart failure with beta blockers, digoxin, and ACE inhibitors.
2.  The presence of a treatment plan to manage dyslipemia, which may help slow the progression of cardiovascular disease.
3.  The patient's relatively low level of troponin (0.6 ng/mL), indicating minimal myocardial damage.
4.  The absence of sustained ventricular tachycardia or other severe arrhythmias on the ECG.

However, the patient's prognosis remains guarded due to his severely reduced LVEF and the presence of valvular cardiomyopathy, which may require further intervention, such as cardiac transplantation or mechanical circulatory support."
135,135,P0222,"Age: 57
Gender: Female 
Weight: 47 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 41
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,39
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 4,74
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,2
Potassium (mEq/L): 4,17
LDL (mmol/L): 3,63
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1537.0
Protein (g/L): 64
T3 (pg/dL): 0,054
T4 (ng/L): 16,68
Troponin (ng/mL): 0,5
TSH (mIU/L): 0,09
Urea (mg/dL): 8
LVEF (%): 35.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type I
            ",survivor,"REASONING: The patient is a 57-year-old female with a history of ischemic dilated cardiomyopathy, which is a condition where the heart's pumping ability is reduced due to a heart attack or coronary artery disease. Her left ventricular ejection fraction (LVEF) is 35%, indicating severe left ventricular dysfunction. However, the patient has been on a comprehensive treatment regimen, including beta blockers, digoxin, loop diuretics, spironolactone, statins, and ACE inhibitors, which are all standard medications for managing heart failure and reducing the risk of complications.

The patient's blood work shows elevated troponin levels (0.5 ng/mL), indicating some level of myocardial injury, but not to the extent that would cause immediate cardiac arrest. The pro-BNP level is elevated at 1537 ng/L, which is consistent with heart failure. Her TSH level is within the normal range, indicating no thyroid dysfunction.

The ECG shows polymorphic ventricular extrasystoles, which are premature ventricular contractions that can be a sign of heart disease, but they are not life-threatening in this case. The second-degree atrioventricular block (type I) is a type of heart rhythm disorder, but it is not a critical finding in this patient's outcome.

Given the patient's age, gender, and comprehensive treatment regimen, the patient's survival outcome is likely due to the effectiveness of her current treatment plan and the absence of any acute life-threatening conditions. The patient's weight and height are not indicative of malnutrition or severe wasting, which is consistent with her protein and albumin levels. The patient's hemoglobin level is within the normal range, indicating no significant anemia. The creatinine level is slightly elevated, but not to the extent that would indicate severe kidney dysfunction.

Overall, the patient's survival outcome is likely due to a combination of her treatment plan, the absence of acute life-threatening conditions, and her relatively stable laboratory results."
136,136,P0224,"Age: 76
Gender: Male 
Weight: 94 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,2
Creatinine (mmol/L): 183.0
Gamma-glutamil transpeptidase (IU/L): 8
Glucose (mmol/L): 3,96
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,1
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,25
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 211.0
Protein (g/L): 71
T3 (pg/dL): 0,0282
T4 (ng/L): 12,07
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,85
Urea (mg/dL): 12,1
LVEF (%): 70.0
Medications: Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient, a 76-year-old male with a history of hypertensive cardiomyopathy, dyslipemia, and hypertension, has a favorable outcome despite his complex medical history. Several factors contribute to this outcome:

1.  LVEF of 70%: This indicates that the patient's left ventricular ejection fraction is within the normal range, suggesting that the heart is pumping efficiently and effectively, which is a good sign for survival.
2.  Blood pressure: The patient's blood pressure is well-controlled at 110/80 mmHg, which is within a healthy range, reducing the risk of cardiovascular events.
3.  Medications: The patient is on loop diuretics, spironolactone, statins, and nitrovasodilators, which are all appropriate for managing heart failure and hypertension. These medications help to control symptoms, improve cardiac function, and reduce the risk of complications.
4.  ECG findings: Although the patient has ventricular extrasystoles and non-sustained ventricular tachycardia, these are not life-threatening and are being managed with medication.
5.  Lab results: The patient's electrolytes, including potassium and sodium, are within normal limits, which is essential for maintaining cardiac function. The patient's creatinine level is slightly elevated, but it is not significantly high, indicating that kidney function is not severely compromised.
6.  Hemoglobin and protein levels: The patient's hemoglobin and protein levels are within normal limits, indicating that there is no significant anemia or malnutrition.
7.  TSH and T3/T4 levels: The patient's thyroid function is within normal limits, which is essential for maintaining cardiac function and overall health.
8.  Pro-BNP level: The patient's pro-BNP level is elevated at 211.0 ng/L, which indicates that the patient has some degree of heart failure, but it is not severe.

Considering these factors, the patient's outcome is likely due to the effectiveness of his current treatment regimen, his relatively well-controlled blood pressure, and his normal LVEF. The presence of non-sustained ventricular tachycardia and ventricular extrasystoles is not life-threatening, and the patient's overall cardiac function is preserved."
137,137,P0225,"Age: 79
Gender: Male 
Weight: 71 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 3,38
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 5,17
Hemoglobin (g/L): 153.0
HDL (mmol/L): 1
Potassium (mEq/L): 3,5
LDL (mmol/L): 1,94
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 2070.0
Protein (g/L): 64
T3 (pg/dL): 0,0318
T4 (ng/L): 18,1
TSH (mIU/L): 0,88
Urea (mg/dL): 5,7
LVEF (%): 70.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient's age of 79 and NYHA Class II classification indicate that the patient has some limitations in physical activity due to heart disease, but is still relatively stable. The patient's LVEF of 70% suggests that the heart is functioning within a relatively normal range, which is a positive prognostic indicator.

The patient's blood pressure is well-controlled at 120/80 mmHg, and they are on medications such as ACE inhibitors and loop diuretics, which are commonly used to manage hypertension and heart failure. The patient's creatinine level of 106.0 μmol/L is slightly elevated, but not significantly so, indicating that kidney function is still relatively preserved.

The patient's lipid profile shows a total cholesterol of 3.38 mmol/L, which is within the target range for primary prevention of cardiovascular disease. However, their HDL (good) cholesterol is low at 1 mmol/L, which may be a concern for cardiovascular risk.

The patient's TSH level of 0.88 mIU/L is within the normal range, indicating that thyroid function is not a contributing factor to their cardiac condition. The patient's T3 and T4 levels are also within normal ranges.

The patient's Pro-BNP level of 2070.0 ng/L is elevated, which may indicate some degree of cardiac strain or stress. However, this is not uncommon in patients with heart failure and may not necessarily be a cause for concern in this context.

The patient's ECG shows monomorphic ventricular extrasystoles, but no sustained ventricular tachycardia or non-sustained ventricular tachycardia. This suggests that the patient's heart rhythm is relatively stable, despite some occasional abnormal beats.

Overall, the patient's stable medication regimen, controlled blood pressure, and relatively preserved LVEF suggest that they are being effectively managed for their heart condition. The patient's age and comorbidities do increase their risk for adverse outcomes, but their current clinical status and lack of acute decompensation suggest that they are likely to survive."
138,138,P0227,"Age: 73
Gender: Male 
Weight: 86 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,33
Creatinine (mmol/L): 128.0
Gamma-glutamil transpeptidase (IU/L): 8
Glucose (mmol/L): 5,24
Hemoglobin (g/L): 116.0
HDL (mmol/L): 1,1
Potassium (mEq/L): 4,5
LDL (mmol/L): 1,9
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 1184.0
Protein (g/L): 75
T3 (pg/dL): 0,0273
T4 (ng/L): 13,94
Troponin (ng/mL): 0,1
TSH (mIU/L): 1,07
Urea (mg/dL): 6,5
LVEF (%): 70.0
Medications: Diabetes Medication, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

Given the patient's age (73 years) and past medical history of Hypertensive cardiomyopathy, Diabetes, Dyslipemia, and Peripheral vascular disease, the patient is at a high risk for cardiovascular events. However, the patient's left ventricular ejection fraction (LVEF) is 70%, which indicates preserved systolic function. 

The patient's blood pressure is 150/80 mmHg, which is slightly elevated but not excessively high, and is likely being managed with medication. The patient's medications, including ACE inhibitor, statins, and nitrovasodilator, are appropriate for managing hypertension, dyslipidemia, and heart failure symptoms.

The patient's troponin level is 0.1 ng/mL, which is within the normal range, indicating no acute myocardial infarction. The pro-BNP level is 1184.0 ng/L, which is elevated, suggesting heart failure, but the patient's LVEF is preserved, indicating that the heart is still functioning adequately.

The patient's ECG shows polymorphic ventricular extrasystole, which is a common finding in patients with heart failure and hypertension. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that the patient's heart rhythm is relatively stable.

The patient's laboratory results show elevated creatinine levels (128.0 mmol/L), which indicates impaired renal function, likely due to the patient's diabetes and hypertension. However, the patient's urea level is within the normal range, suggesting that the kidney function is still relatively preserved.

The patient's TSH level is within the normal range, indicating euthyroidism. The patient's T3 and T4 levels are also within the normal range, suggesting that the patient's thyroid function is normal.

Given the patient's age, comorbidities, and laboratory results, the patient's outcome as a survivor is likely due to the effectiveness of their current treatment regimen, including their medications and lifestyle modifications. The patient's preserved LVEF and relatively stable heart rhythm suggest that the patient's heart is functioning adequately, despite the presence of heart failure and other comorbidities."
139,139,P0228,"Age: 77
Gender: Female 
Weight: 62 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 160/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 46
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 4,46
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 10,22
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,7
Potassium (mEq/L): 4,27
LDL (mmol/L): 2,35
Sodium (mEq/L): 146.0
Pro-BNP (ng/L): 1951.0
Protein (g/L): 79,5
T3 (pg/dL): 0,0288
T4 (ng/L): 16,13
Troponin (ng/mL): 1,6
TSH (mIU/L): 0,87
Urea (mg/dL): 10
LVEF (%): 25.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient's outcome is a survivor, which is a positive outcome for a patient with a complex medical history and multiple comorbidities. Several factors contribute to this outcome:

1.  Optimal Medication Management: The patient is on a combination of medications that are appropriate for her condition, including an angiotensin II receptor blocker (ARB), loop diuretics, statins, and a nitrovasodilator. These medications help manage her heart failure, hypertension, and lipid levels, which are all contributing factors to her ischemic dilated cardiomyopathy.

2.  Monitoring and Management of Heart Failure: The patient has a low left ventricular ejection fraction (LVEF) of 25%, indicating severe heart failure. However, her NT-proBNP level is elevated at 1951.0 ng/L, which is a marker of heart failure severity. Despite this, her LVEF is not significantly decreased, indicating that her heart failure is being managed effectively.

3.  Control of Hypertension: The patient's blood pressure is 160/70 mmHg, which is well-controlled for someone with hypertension. This is likely due to the use of her ARB medication.

4.  Management of Diabetes: The patient is on diabetes medication, which is helping to control her glucose levels. Her glucose level is 10.22 mmol/L, which is within a relatively normal range.

5.  Lack of Acute Complications: There is no indication of acute coronary syndrome or other acute complications, such as acute heart failure exacerbation or severe arrhythmias.

6.  ECG Findings: While the patient has ventricular extrasystoles and non-sustained ventricular tachycardia, these are not severe enough to indicate a life-threatening arrhythmia.

7.  Laboratory Results: The patient's liver enzymes are within normal limits, indicating that her liver function is not significantly compromised. Her electrolyte levels are also within normal limits, which is important for managing her heart rhythm.

Overall, the patient's outcome is a survivor due to the combination of optimal medication management, effective management of her heart failure and hypertension, and the lack of acute complications."
140,140,P0230,"Age: 84
Gender: Female 
Weight: 67 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 135/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,25
Creatinine (mmol/L): 117.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 105.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 4,72
LDL (mmol/L): 2,35
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 308.0
Protein (g/L): 71,3
T3 (pg/dL): 0,0348
T4 (ng/L): 14,23
Troponin (ng/mL): 0,4
TSH (mIU/L): 2,54
Urea (mg/dL): 8,3
LVEF (%): 70.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome as a survivor can be attributed to several factors:

1.  Optimal Medication Management: The patient is on a comprehensive medication regimen, including Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, and Nitrovasodilator. These medications are aimed at managing hypertension, heart failure symptoms, and controlling heart rate and rhythm. This suggests that the patient's condition has been well-managed, contributing to a positive outcome.

2.  Good Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 70%, which is within the normal range (50-70%). This indicates that the left ventricle is functioning effectively, pumping blood efficiently, and supporting the patient's survival.

3.  Low Troponin Levels: The patient's troponin level is 0.4 ng/mL, which is within the normal range. Elevated troponin levels are indicative of myocardial infarction (heart attack), but in this case, the low levels suggest that the patient has not experienced a recent heart attack.

4.  Normal TSH and T4 Levels: The patient's thyroid function, as indicated by TSH (2.54 mIU/L) and T4 (14.23 ng/L) levels, is within the normal range. Thyroid dysfunction can impact heart function, but in this case, the patient's thyroid function appears to be normal.

5.  Absence of Significant ECG Abnormalities: The patient's ECG does not show any significant abnormalities, such as ventricular tachycardia, non-sustained ventricular tachycardia, or bradycardia. This suggests that the patient's heart rhythm is stable.

6.  Reasonable Blood Pressure: The patient's blood pressure is within the normal range (135/70 mmHg), which is controlled by the patient's medication regimen.

7.  Reasonable Kidney Function: The patient's creatinine level (117.0 mmol/L) is slightly elevated, but not significantly so. This suggests that the patient's kidney function is compromised, but not severely.

8.  Reasonable Cholesterol Levels: The patient's total cholesterol level (4.25 mmol/L) is within the normal range, which is a positive factor for cardiovascular health.

Considering these factors, the patient's outcome as a survivor can be attributed to a combination of optimal medication management, good LVEF, low troponin levels, normal thyroid function, absence of significant ECG abnormalities, reasonable blood pressure, and reasonable kidney function."
141,141,P0231,"Age: 78
Gender: Male 
Weight: 80 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 130/65 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 6,07
Creatinine (mmol/L): 140.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 5,55
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,49
LDL (mmol/L): 4,1
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 5910.0
Protein (g/L): 70
T3 (pg/dL): 0,0168
T4 (ng/L): 13,49
Troponin (ng/mL): 0,4
TSH (mIU/L): 1,27
Urea (mg/dL): 9
LVEF (%): 25.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's medical history and the current data, the patient's outcome of survival is likely due to a combination of factors:

1. Current Medications: The patient is on loop diuretics and an ACE inhibitor, which are standard treatments for heart failure and hypertension. These medications are likely helping to manage the patient's symptoms and slowing the progression of the disease.
2. Low TSH Level: The patient's TSH level is within the normal range (1.27 mIU/L), indicating that the thyroid function is not contributing to the patient's cardiac condition.
3. Normal Hemoglobin Level: The patient's hemoglobin level is within the normal range (133.0 g/L), indicating that anemia is not a contributing factor to the patient's condition.
4. Low Pro-BNP Level: Although the patient's Pro-BNP level is elevated (5910.0 ng/L), it is not extremely high, indicating that the patient is not in acute heart failure.
5. LVEF of 25%: Although the patient's left ventricular ejection fraction (LVEF) is severely reduced (25%), it is not the lowest possible value, indicating that the heart is still functioning to some extent.
6. No History of Cardiac Arrest or Sudden Cardiac Death: The patient has not experienced any cardiac arrest or sudden cardiac death, which suggests that the patient's condition is stable and manageable.
7. Current Blood Pressure: The patient's blood pressure is within the normal range (130/65 mmHg), which is a positive sign for the patient's cardiovascular health.

Considering these factors, it is likely that the patient's outcome of survival is due to the effective management of their condition through medications and the absence of any acute complications or severe underlying conditions that would have led to a worse outcome."
142,142,P0234,"Age: 67
Gender: Male 
Weight: 69 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 46
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 4,41
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 57
Glucose (mmol/L): 7
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,16
LDL (mmol/L): 1,5
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 2129.0
Protein (g/L): 76,5
T3 (pg/dL): 0,0471
T4 (ng/L): 15,02
Troponin (ng/mL): 0,9
TSH (mIU/L): 1,05
Urea (mg/dL): 7,2
LVEF (%): 20.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient, a 67-year-old male, has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack, leading to a reduced left ventricular ejection fraction (LVEF) of 20%. Despite this, the patient is classified as NYHA Class II, indicating that he experiences some limitation of physical activity but is still able to perform daily tasks without severe symptoms.

The patient's current medications, including Calcium Channel Blocker, Beta Blockers, Statins, ACE Inhibitor, and Nitrovasodilator, are aimed at managing his heart failure and reducing the risk of further cardiac events. The patient's blood pressure is well-controlled at 120/80 mmHg, and his lipid profile is being managed with statins.

The patient's liver enzymes, including ALT, AST, and GGT, are within normal limits, indicating that there is no significant liver dysfunction. His renal function, as indicated by creatinine levels, is also within normal limits. However, his total cholesterol level is elevated at 4.41 mmol/L, which may require further management.

The patient's troponin level is slightly elevated at 0.9 ng/mL, indicating some degree of myocardial damage. However, this is not significantly elevated, and the patient's symptoms do not suggest an acute myocardial infarction.

The patient's thyroid function, as indicated by TSH and T4 levels, is within normal limits, and his T3 level is slightly low. The patient's hemoglobin level is within normal limits, and his potassium level is slightly low at 4.16 mEq/L.

The patient's pro-BNP level is elevated at 2129 ng/L, which is consistent with heart failure. However, the patient's LVEF is only 20%, indicating a significant reduction in cardiac function.

Considering the patient's overall condition, the combination of his medications, and the lack of acute symptoms, it is likely that the patient's outcome is a survivor. The patient's heart failure is being managed, and his cardiac function is being supported by his medications. The patient's other medical conditions, including hypertension and dyslipidemia, are also being managed."
143,143,P0235,"Age: 76
Gender: Female 
Weight: 92 kg
Height: 153 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 107.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 7,07
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,84
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1309.0
Protein (g/L): 67
T3 (pg/dL): 0,0441
T4 (ng/L): 22,35
Troponin (ng/mL): 0,7
TSH (mIU/L): 1,62
Urea (mg/dL): 8,4
LVEF (%): 40.0
Medications: Diabetes Medication, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 76-year-old female with a complex medical history, including ischemic dilated cardiomyopathy, diabetes, peripheral vascular disease, hypertension, and a history of myocardial infarction. Despite this, the patient has survived, which can be attributed to several factors:

1. Effective Medication Management: The patient is on a regimen of diabetes medication, loop diuretics, ACE inhibitor, and nitrovasodilator, which are all relevant to managing heart failure, hypertension, and diabetes. The use of ACE inhibitors, in particular, has been shown to improve survival in patients with heart failure and reduced ejection fraction.

2. Reasonable Blood Pressure: The patient's blood pressure of 120/70 mmHg is within a relatively normal range, which is a positive factor in reducing the risk of cardiovascular events.

3. Stable Renal Function: The patient's creatinine level of 107.0 mmol/L is within the normal range, indicating stable renal function, which is crucial for patients with heart failure and diabetes.

4. Low Troponin Level: The troponin level of 0.7 ng/mL is low, indicating minimal myocardial damage, which is a good sign for the patient's cardiac health.

5. Normal Hemoglobin and Potassium Levels: The patient's hemoglobin level of 130.0 g/L and potassium level of 3.9 mEq/L are within normal ranges, which are essential for maintaining cardiac function.

6. Pro-BNP Level: Although the patient's Pro-BNP level is elevated at 1309.0 ng/L, indicating some degree of heart failure, it is not excessively high, which suggests that the patient's condition is being managed.

7. ECG Findings: While the ECG shows ventricular extrasystoles and an unknown ventricular tachycardia code, there is no indication of sustained ventricular tachycardia, which is a more serious condition.

8. LVEF of 40%: The patient's left ventricular ejection fraction (LVEF) of 40% is lower than normal, indicating heart failure, but the patient's overall clinical picture suggests that the condition is being managed.

In conclusion, the patient's survival can be attributed to a combination of effective medication management, stable blood pressure, renal function, low troponin levels, normal hemoglobin and potassium levels, and the absence of severe ECG abnormalities."
144,144,P0236,"Age: 74
Gender: Female 
Weight: 87 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 180/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,41
Creatinine (mmol/L): 130.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 5,68
Hemoglobin (g/L): 120.0
HDL (mmol/L): 1,2
Potassium (mEq/L): 3,9
LDL (mmol/L): 1,71
Sodium (mEq/L): 146.0
Pro-BNP (ng/L): 1176.0
Protein (g/L): 72,9
T3 (pg/dL): 0,0312
T4 (ng/L): 14,43
Troponin (ng/mL): 0,5
TSH (mIU/L): 5,19
Urea (mg/dL): 13
LVEF (%): 50.0
Medications: Amiodarone, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome is likely due to a combination of factors related to her medical history, current health status, and treatment plan. 

Firstly, the patient's age and NYHA Class II classification indicate that she has some limitations in physical activity but is still able to perform everyday activities without severe symptoms. This suggests that her heart function is still relatively preserved.

The patient's blood pressure is elevated (180/90 mmHg), which is a risk factor for cardiovascular disease. However, she is already on an ACE inhibitor, which is an appropriate medication for hypertension management. The presence of hypertensive cardiomyopathy in her past medical history also indicates that her heart has been affected by high blood pressure in the past.

The patient's laboratory results show elevated creatinine levels (130.0 mmol/L), which suggests impaired kidney function. This is a concern, as it may indicate that the patient's heart failure is affecting her kidneys, or vice versa. However, her LVEF (left ventricular ejection fraction) is 50%, which is within the normal range, indicating that her heart function is still relatively preserved.

The patient's glucose level (5.68 mmol/L) is slightly elevated, which may indicate that she has poorly controlled diabetes. However, her HbA1c level is not provided, so it is unclear how well-controlled her diabetes is.

The patient's lipid profile shows elevated total cholesterol (3.41 mmol/L) and LDL (1.71 mmol/L) levels, which are risk factors for cardiovascular disease. However, she is on statins, which are appropriate for managing high cholesterol.

The patient's Pro-BNP level (1176.0 ng/L) is elevated, which is a marker of heart failure. However, her troponin level (0.5 ng/mL) is within the normal range, indicating that she does not have acute myocardial infarction.

The patient's ECG shows ventricular extrasystoles, but no other significant abnormalities. This suggests that her heart rhythm is generally stable.

Considering all these factors, the patient's outcome as a survivor is likely due to a combination of her relatively preserved heart function, appropriate medical management, and the absence of acute cardiac events. However, it is essential to continue monitoring her kidney function, glucose levels, and lipid profile to prevent further complications."
145,145,P0237,"Age: 54
Gender: Male 
Weight: 92 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 194.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 7,4
Hemoglobin (g/L): 141.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 5,1
LDL (mmol/L): 1,03
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 986.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,23
TSH (mIU/L): 0,87
Urea (mg/dL): 11,48
LVEF (%): 25.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type I
            ",survivor,"REASONING: 

The patient, a 54-year-old male with a history of ischemic dilated cardiomyopathy, myocardial infarction, and hypertension, is a survivor. Several factors contributed to this outcome:

1.  Optimal Medication Regimen: The patient is on a comprehensive medication regimen, including an Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor, and Nitrovasodilator. This combination is crucial in managing heart failure and preventing further cardiac complications.

2.  Close Monitoring of Cardiac Function: The patient's Left Ventricular Ejection Fraction (LVEF) of 25% indicates reduced cardiac function. However, the presence of a comprehensive treatment plan and the patient's survival suggest that the current medications are effectively managing the condition, at least in the short term.

3.  Blood Pressure Control: The patient's blood pressure of 120/70 mmHg is within a healthy range, which is essential for reducing the strain on the heart.

4.  Electrocardiogram (ECG) Findings: While the patient has non-sustained ventricular tachycardia, this is not uncommon in patients with heart failure. The presence of a second-degree AV block type I indicates some degree of conduction system disease, but the patient is still alive, suggesting that this is being managed effectively.

5.  Low Troponin Levels: The patient's troponin level of 0.23 ng/mL is within a normal range, indicating that there is no ongoing myocardial infarction.

6.  Normal Hemoglobin and Potassium Levels: The patient's hemoglobin and potassium levels are within normal ranges, which is crucial for maintaining cardiac function and preventing arrhythmias.

7.  Low Pro-BNP Levels: The patient's Pro-BNP level of 986 ng/L is elevated but not extremely high. This indicates some degree of heart failure, but it is not severe enough to indicate a poor prognosis.

Overall, the combination of optimal medication management, close monitoring, and controlled blood pressure, along with the absence of severe cardiac complications, contributed to the patient's survival."
146,146,P0238,"Age: 53
Gender: Male 
Weight: 66 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 130/50 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 27
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,15
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 48
Glucose (mmol/L): 3,8
Hemoglobin (g/L): 83.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 5,6
LDL (mmol/L): 1,71
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 137.0
Protein (g/L): 60
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,04
TSH (mIU/L): 2,4
Urea (mg/dL): 11,32
LVEF (%): 55.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 53-year-old male with a history of hypertensive cardiomyopathy and hypertension, has been managed with beta blockers, loop diuretics, and an ACE inhibitor. His current condition is stable, as indicated by a left ventricular ejection fraction (LVEF) of 55%, which is within the normal range (>45-52%). The presence of polymorphic ventricular extrasystoles on the ECG is a common finding in patients with cardiomyopathy and may not necessarily indicate a high risk of sudden cardiac death.

The patient's blood pressure is controlled at 130/50 mmHg, and his heart rate is not excessively high or low, suggesting that his beta blockers are effective in managing his heart rate. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia on the ECG also suggests that his cardiac rhythm is stable.

The patient's laboratory results show mild elevations in liver enzymes (ALT and AST) and gamma-glutamil transpeptidase, which may indicate some degree of liver dysfunction, but these are not severe enough to suggest significant liver disease. The patient's kidney function is also relatively preserved, with a creatinine level of 124.0 μmol/L, which is within the normal range for his sex and weight.

The patient's electrolyte levels are within normal limits, with a potassium level of 5.6 mEq/L, which is not excessively high or low. The patient's thyroid function is also within normal limits, with a TSH level of 2.4 mIU/L.

The patient's hemoglobin level is slightly low at 83.0 g/L, but this is not severe enough to suggest anemia. The patient's lipid profile shows a total cholesterol level of 3.15 mmol/L, which is within the normal range.

Overall, the patient's clinical and laboratory findings suggest that he is stable and that his current medications are effective in managing his hypertension and cardiomyopathy. Therefore, the patient outcome is a survivor, indicating that he is likely to continue living with his condition without significant progression or complications."
147,147,P0240,"Age: 54
Gender: Male 
Weight: 103 kg
Height: 179 cm
NYHA Class: II
Blood Pressure: 130/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 44
ALT or GPT (IU/L): 137.0
AST or GOT (IU/L): 119.0
Total Cholesterol (mmol/L): 6,62
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 378
Glucose (mmol/L): 16,8
Hemoglobin (g/L): 149.0
HDL (mmol/L): 2,22
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,9
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 18.0
Protein (g/L): 84
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,04
TSH (mIU/L): 1,47
Urea (mg/dL): 8,32
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 54-year-old male with a history of idiopathic dilated cardiomyopathy, diabetes, and several other comorbidities. His left ventricular ejection fraction (LVEF) is 45%, indicating mildly reduced left ventricular function. He is on a regimen of medications that include beta blockers, digoxin, loop diuretics, and an ACE inhibitor, which are standard treatments for heart failure and cardiomyopathy.

The patient's blood work shows elevated liver enzymes (ALT and AST), which could indicate liver dysfunction or chronic hepatitis, but the gamma-glutamil transpeptidase (GGT) is also elevated, suggesting possible alcohol use or bile duct obstruction. However, the patient's T3 and T4 levels are within normal limits, indicating no signs of hyperthyroidism or hypothyroidism.

The patient's glucose level is elevated at 16.8 mmol/L, indicating poor control of his diabetes. His total cholesterol is high at 6.62 mmol/L, with an LDL of 3.9 mmol/L, which is a risk factor for cardiovascular disease. However, his HDL is low at 2.22 mmol/L, which is a risk factor for atherosclerosis.

The patient's potassium level is slightly low at 4.9 mEq/L, which could be a concern, but his pro-BNP level is low at 18 ng/L, indicating reduced stress on the heart. His troponin level is normal at 0.04 ng/mL, indicating no acute myocardial infarction.

The patient's ECG shows monomorphic ventricular extrasystoles, which are common in patients with heart failure and cardiomyopathy. However, there are no signs of sustained ventricular tachycardia, paroxysmal supraventricular tachyarrhythmia, or bradycardia.

Considering the patient's overall clinical presentation and laboratory results, the most likely reason for his survival is the effectiveness of his current treatment regimen, including beta blockers, digoxin, loop diuretics, and an ACE inhibitor, which are all aimed at managing his heart failure and cardiomyopathy. Additionally, his low pro-BNP level suggests that his heart is not under significant stress, and his low troponin level indicates no acute myocardial infarction."
148,148,P0241,"Age: 35
Gender: Female 
Weight: 76 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 115/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 46
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 6,15
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 134.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,2
LDL (mmol/L): 4,47
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 35070.0
Protein (g/L): 79
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,32
Urea (mg/dL): 3,16
LVEF (%): 50.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient, a 35-year-old female with a history of idiopathic dilated cardiomyopathy, has a relatively stable condition as indicated by her NYHA Class II classification. Despite having a low left ventricular ejection fraction (LVEF) of 50%, which is below the normal range (50-70%), she is not in heart failure, as evidenced by her relatively normal creatinine levels (88.0 μmol/L) and lack of symptoms.

The patient's laboratory results show elevated liver enzymes (ALT and AST), which could be indicative of liver dysfunction or secondary to her heart failure. However, the lack of significant elevation in bilirubin or albumin levels suggests that liver dysfunction is not severe.

Her lipid profile indicates high total cholesterol and LDL levels, which are risk factors for cardiovascular disease. However, her HDL level is also low, which is a negative prognostic indicator.

The patient's T3 and T4 levels are within the normal range, indicating that her thyroid function is normal. Her TSH level is also within the normal range, indicating that her thyroid function is not contributing to her heart condition.

The patient's troponin level is normal, indicating that there is no acute myocardial infarction. Her pro-BNP level is elevated, which is consistent with heart failure, but not to an extent that would indicate severe heart failure.

The patient's medication regimen, which includes an angiotensin II receptor blocker, beta blockers, loop diuretics, and spironolactone, is appropriate for heart failure management.

Overall, the patient's stable condition and relatively well-controlled heart failure symptoms, combined with her current medication regimen, suggest that she is likely to survive and continue to manage her condition effectively with ongoing medical management.

However, it is essential to note that the patient's elevated pro-BNP level and low LVEF indicate that her heart condition is not fully resolved, and she requires ongoing monitoring and management to prevent progression of her heart disease."
149,149,P0244,"Age: 36
Gender: Male 
Weight: 94 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 49.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 53
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,28
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 164.0
Protein (g/L): 79
T3 (pg/dL): 0,02
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,41
Urea (mg/dL): 4,82
LVEF (%): 43.0
Medications: None reported.
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient's age and gender are within the range where heart disease is more common, but the patient's NYHA Class II classification indicates that the patient is experiencing some symptoms of heart failure, but is still able to perform everyday activities without significant limitation. The patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which are risk factors for heart failure and poor cardiac function.

The patient's laboratory results show elevated levels of troponin (0.01 ng/mL), which is a marker of cardiac damage, but the level is relatively low. The patient's LVEF (43.0%) is below the normal range (50-60%), indicating some degree of left ventricular dysfunction. The patient's pro-BNP level (164.0 ng/L) is elevated, which is a marker of heart failure.

The patient's lipid profile shows high total cholesterol and LDL levels, which are risk factors for cardiovascular disease. The patient's potassium level is within the normal range, and the patient is not taking any medications, which may indicate that the patient is not being managed for their heart condition.

The ECG shows polymorphic ventricular extrasystoles, which can be a sign of cardiac stress or abnormal heart rhythm. However, there is no evidence of sustained ventricular tachycardia or other severe arrhythmias.

Considering the patient's history, laboratory results, and ECG findings, the patient's outcome of survival is likely due to the following factors:

1. The patient's LVEF is not severely impaired (43%), which suggests that the patient's heart is still functioning to some extent.
2. The patient's troponin level is relatively low, indicating minimal cardiac damage.
3. The patient is not experiencing severe symptoms of heart failure, as indicated by the NYHA Class II classification.
4. The patient is not taking any medications, which may indicate that the patient is not receiving optimal management for their heart condition.

However, the patient's outcome of survival is also likely due to the fact that the patient has not experienced any severe cardiac events, such as a myocardial infarction or cardiac arrest, during the follow-up period. The patient's overall condition is stable, and the patient is likely being monitored closely by a cardiologist to manage their heart condition and prevent further complications."
150,150,P0247,"Age: 72
Gender: Male 
Weight: 67 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 46
ALT or GPT (IU/L): 49.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 4,42
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 5
LDL (mmol/L): 2,64
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 455.0
Protein (g/L): 82
T3 (pg/dL): 0,04
T4 (ng/L): 25
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,27
Urea (mg/dL): 11,15
LVEF (%): 34.0
Medications: Calcium Channel Blocker, Diabetes Medication, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 72-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension, has a complex medical profile that could potentially lead to a poor outcome. However, the patient's outcome is a survivor, which can be attributed to several factors.

Firstly, the patient's left ventricular ejection fraction (LVEF) is 34%, which is within the range for heart failure with reduced ejection fraction (HFrEF). Despite this, the patient's New York Heart Association (NYHA) class is II, indicating that the patient's symptoms are relatively mild, and they are able to perform most daily activities without significant limitation.

The patient's blood pressure is well-controlled at 120/60 mmHg, which is within the normal range. The patient is also on a combination of medications that are commonly used to treat heart failure, including a calcium channel blocker, diabetes medication, digoxin, loop diuretics, spironolactone, and an ACE inhibitor. These medications are likely contributing to the patient's stable condition.

The patient's laboratory results show elevated levels of troponin (0.01 ng/mL), which is a marker of cardiac damage, but the level is relatively low. The patient's pro-BNP (brain natriuretic peptide) level is elevated at 455 ng/L, which is consistent with heart failure. However, the patient's T3 and T4 levels are within the normal range, indicating that the patient's thyroid function is normal.

The patient's ECG shows polymorphic ventricular extrasystoles, but no sustained ventricular tachycardia or bradycardia. The presence of TPSV (paroxysmal supraventricular tachyarrhythmia) may indicate some arrhythmia, but it is not a major concern in this case.

Considering the patient's overall medical profile and laboratory results, it is likely that the patient's outcome as a survivor is due to the combination of effective medication management, relatively mild symptoms, and a low level of cardiac damage. The patient's age and comorbidities may also have contributed to the patient's outcome, but the patient's overall health status and treatment plan have helped to mitigate these risks."
151,151,P0249,"Age: 48
Gender: Male 
Weight: 65 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 200/100 mmHg
Past Medical History: Toxic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 61.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 6,75
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 194
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 150.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 3,6
LDL (mmol/L): 4,14
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 320.0
Protein (g/L): 79
T3 (pg/dL): 0,03
T4 (ng/L): 22
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,21
Urea (mg/dL): 3,66
LVEF (%): 44.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient outcome of survival can be attributed to a combination of factors, including the patient's current treatment regimen and the relatively stable condition of his heart function. 

The patient has been prescribed Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, and Loop Diuretics, which are standard medications for managing heart failure and dilated cardiomyopathy. These medications are likely helping to manage the patient's blood pressure, reduce the heart's workload, and prevent further cardiac damage.

The patient's LVEF (Left Ventricular Ejection Fraction) is 44%, which is slightly below the normal range but not severely impaired. This indicates that the patient's heart is still pumping blood effectively, albeit not at optimal levels. The patient's Pro-BNP (B-type natriuretic peptide) level of 320.0 ng/L is elevated, which is consistent with heart failure, but not excessively high, suggesting that the patient's condition is being managed.

The patient's ECG results show polymorphic ventricular extrasystoles, which are common in patients with dilated cardiomyopathy. However, there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias, which is a positive sign.

The patient's laboratory results show elevated liver enzymes (ALT and GGT), which may indicate ongoing liver damage or stress, possibly related to the patient's dilated cardiomyopathy or other underlying conditions. However, this is not a critical factor in the patient's immediate outcome.

The patient's blood glucose level is slightly elevated (6.8 mmol/L), which may be a concern for future cardiovascular risk, but it is not a critical factor in the patient's current outcome.

Overall, the patient's survival can be attributed to the effectiveness of his current treatment regimen, the relatively stable condition of his heart function, and the absence of life-threatening arrhythmias or other complications."
152,152,P0252,"Age: 73
Gender: Male 
Weight: 83 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 3,03
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,94
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1070.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 27
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,55
Urea (mg/dL): 6,66
LVEF (%): 38.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 73-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction, indicating a high risk of cardiovascular disease. His NYHA Class III classification suggests that he has severe symptoms of heart failure, including shortness of breath, fatigue, and limitation in physical activity.

The patient's laboratory results show elevated levels of pro-BNP (1070.0 ng/L), which is a biomarker of heart failure and cardiac stress. His LVEF (Left Ventricular Ejection Fraction) is 38%, which is significantly below the normal range (50-70%), indicating impaired left ventricular function and a high risk of heart failure.

However, the patient's troponin level is within the normal range (0.01 ng/mL), indicating that he is not experiencing an acute myocardial infarction. His TSH level is within the normal range (2.55 mIU/L), suggesting that his thyroid function is not contributing to his cardiac condition.

The patient is on a multidrug regimen, including a calcium channel blocker, diabetes medication, angiotensin II receptor blocker, and statins, which are all appropriate for managing his conditions. The medications are likely contributing to the stabilization of his cardiac function.

Given the patient's age, comorbidities, and the presence of heart failure, the patient's outcome as a survivor suggests that his current treatment plan is effective in managing his condition. The patient's LVEF of 38% indicates that he still has some cardiac function, and his pro-BNP level has not reached a critical level that would suggest an acute decompensation of heart failure. Therefore, the patient's survival can be attributed to the effectiveness of his current treatment regimen and the absence of acute cardiac events."
153,153,P0253,"Age: 59
Gender: Female 
Weight: 80 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 5,04
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,26
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 824.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,005
TSH (mIU/L): 3,37
Urea (mg/dL): 7,32
LVEF (%): 40.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 59-year-old female with a history of idiopathic dilated cardiomyopathy, a condition characterized by the enlargement of the heart's chambers, reducing its ability to pump blood effectively. Despite this, the patient has been managed with a combination of medications, including Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, and Spironolactone. These medications are aimed at reducing the heart's workload, improving its pumping efficiency, and managing symptoms.

The patient's LVEF (Left Ventricular Ejection Fraction) is 40%, which is below the normal range (50-70%), indicating a reduced pumping efficiency of the left ventricle. However, the patient's blood pressure is within a relatively normal range (110/75 mmHg), suggesting that the medications are effective in managing hypertension.

The patient's laboratory results show elevated Pro-BNP (B-type natriuretic peptide) levels (824.0 ng/L), which is a biomarker of heart failure and congestion. However, the patient's creatinine levels (106.0 umol/L) are slightly elevated, indicating some degree of renal impairment, which is not uncommon in patients with heart failure.

The patient's ECG shows evidence of ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia. These arrhythmias are not uncommon in patients with heart failure and can be managed with medications or other interventions.

Given the patient's complex medical history and the presence of multiple comorbidities, it is remarkable that the patient has survived. The combination of medications and close monitoring have likely contributed to the patient's survival, as well as the patient's overall resilience.

In conclusion, the patient's survival can be attributed to the effective management of her heart failure symptoms, the use of medications to manage her arrhythmias and hypertension, and her overall resilience as a patient."
154,154,P0254,"Age: 49
Gender: Male 
Weight: 65 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 100/50 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 36.0
AST or GOT (IU/L): 49.0
Total Cholesterol (mmol/L): 5,53
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 465
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 166.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,1
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 194.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,38
Urea (mg/dL): 5,99
LVEF (%): 23.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's profile, the outcome of survival is likely due to a combination of factors, including the patient's current treatment regimen and the absence of severe acute decompensation. The patient has a history of enolic dilated cardiomyopathy, which is a condition where the left ventricle of the heart is weakened and cannot pump blood effectively. However, the patient's LVEF (Left Ventricular Ejection Fraction) is 23%, which is relatively low but not extremely low. The patient is on medications such as beta blockers, digoxin, loop diuretics, spironolactone, statins, and an ACE inhibitor, which are commonly used to manage heart failure and its complications.

The patient's blood pressure is within a relatively normal range, considering their history of hypertension, and their creatinine level is elevated but not severely so. The patient's albumin level is slightly low, which may indicate some degree of liver dysfunction or malnutrition, but it is not a critical finding. The patient's liver function tests (ALT, AST) are mildly elevated, which may indicate some degree of liver injury, but it is not severe.

The patient's glucose level is slightly elevated, which may be a concern for diabetes, but it is not extremely high. The patient's lipid profile shows a high total cholesterol and LDL, which is a concern for cardiovascular disease, but the patient is on statins, which should help manage this.

The patient's TSH level is within the normal range, which suggests that the patient's thyroid function is normal. The patient's T3 and T4 levels are also within normal ranges, which suggests that the patient's thyroid function is normal.

The patient's ECG shows polymorphic ventricular extrasystoles, which can be a sign of underlying cardiac disease, but it is not a critical finding. The patient does not have any sustained ventricular tachycardia or bradycardia.

Overall, the patient's outcome of survival is likely due to the combination of their current treatment regimen and the absence of severe acute decompensation. The patient's relatively low LVEF and history of myocardial infarction make them a high-risk patient, but the patient's current medications and lack of severe acute complications suggest that they are being effectively managed."
155,155,P0255,"Age: 41
Gender: Male 
Weight: 81 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 13,3
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4
LDL (mmol/L): 3,88
Sodium (mEq/L): 130.0
Protein (g/L): 68
T3 (pg/dL): 0,02
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,28
Urea (mg/dL): 6,66
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 41-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and myocardial infarction, has been managed with a comprehensive treatment plan that includes diabetes medication, angiotensin II receptor blocker, beta blockers, loop diuretics, spironolactone, and statins. Despite his complex medical history, the patient has demonstrated resilience and survived.

Several factors contributed to this positive outcome:

1.  Multidisciplinary treatment approach: The patient's treatment plan involves a combination of medications that target different aspects of his cardiovascular disease, such as hypertension, heart failure, and dyslipidemia. This comprehensive approach likely helped to stabilize his condition and prevent further complications.
2.  Control of blood pressure: The patient's blood pressure is well-controlled at 140/80 mmHg, which is within the target range for most adults. Effective blood pressure management is crucial in preventing cardiovascular events and progression of heart failure.
3.  Management of dyslipidemia: The patient's total cholesterol level is 4.63 mmol/L, which is slightly elevated but not excessively high. His LDL level is 3.88 mmol/L, and HDL level is 0.91 mmol/L, indicating a favorable lipid profile. Statin therapy is likely contributing to the control of his dyslipidemia.
4.  Stable LVEF: The patient's left ventricular ejection fraction (LVEF) is 35%, which indicates a reduced but stable cardiac function. This suggests that the patient's heart is adapting to the damage caused by his myocardial infarction, and the treatment plan is helping to slow disease progression.
5.  Electrocardiogram (ECG) findings: The ECG does not show any signs of life-threatening arrhythmias, such as ventricular tachycardia or bradycardia, which is a positive sign.

However, the patient still faces challenges due to his underlying conditions, including:

1.  Ischemic dilated cardiomyopathy: The patient's heart muscle is still weakened, and his LVEF is reduced, indicating ongoing cardiac damage.
2.  Diabetes: The patient's glucose level is 13.3 mmol/L, which is higher than the target range for most adults. Uncontrolled diabetes can exacerbate cardiovascular disease and increase the risk of complications.
3.  Kidney function: The patient's creatinine level is 106.0 μmol/L, indicating some degree of kidney impairment. This may be related to his diabetes or heart failure.

In conclusion, the patient's survival is likely due to a combination of his comprehensive treatment plan, effective blood pressure and lipid management, and stable LVEF. However, ongoing management and monitoring are essential to prevent further complications and improve his quality of life."
156,156,P0257,"Age: 76
Gender: Male 
Weight: 84 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 105/55 mmHg
Past Medical History: Other HF etiology, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 7,73
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 120.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,6
LDL (mmol/L): 5,79
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1876.0
Protein (g/L): 68
T3 (pg/dL): 0,02
T4 (ng/L): 25
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,44
Urea (mg/dL): 7,15
LVEF (%): 42.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

Given the patient's data, the outcome of survival can be attributed to several factors:

1.  Optimal Medication Regimen: The patient is on a comprehensive regimen of medications, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor. These medications are crucial in managing heart failure (HF) and reducing the risk of sudden cardiac death. Beta blockers help slow the heart rate and reduce the heart's workload, while loop diuretics and spironolactone help alleviate fluid overload and reduce mortality in HF patients.

2.  LVEF of 42%: Although the patient's left ventricular ejection fraction (LVEF) is mildly reduced at 42%, it is still within a range that may not immediately necessitate advanced heart failure therapies. A mildly reduced LVEF can be managed with optimal medical therapy, and the patient's survival suggests that the current treatment plan is effective in stabilizing the condition.

3.  Low Pro-BNP Levels: The patient's brain natriuretic peptide (BNP) level is 1876.0 ng/L, which, although elevated, is not excessively high. Elevated BNP levels are associated with increased mortality and morbidity in HF patients. However, the patient's survival suggests that the BNP level is not a strong predictor of mortality in this case.

4.  Normal Hemoglobin and Potassium Levels: The patient's hemoglobin and potassium levels are within normal ranges, indicating that there are no significant electrolyte imbalances that could contribute to cardiac arrhythmias or other complications.

5.  No Recent Myocardial Infarction or Sudden Cardiac Death: The patient's troponin level is 0.01 ng/mL, indicating that there is no recent myocardial infarction. The absence of a recent myocardial infarction or sudden cardiac death suggests that the patient's cardiac function is relatively stable.

6.  Low TSH and Normal T4 Levels: The patient's thyroid function tests are within normal ranges, indicating that there is no underlying thyroid dysfunction contributing to cardiac complications.

7.  No Indication of Malnutrition: The patient's albumin and protein levels are within normal ranges, indicating that there is no indication of malnutrition, which can exacerbate cardiac conditions.

Considering these factors, the patient's survival can be attributed to the effectiveness of the current treatment plan, the mildly reduced LVEF, and the absence of significant electrolyte imbalances, recent myocardial infarction, or thyroid dysfunction."
157,157,P0258,"Age: 59
Gender: Male 
Weight: 80 kg
Height: 173 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 37
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,03
Creatinine (mmol/L): 239.0
Gamma-glutamil transpeptidase (IU/L): 58
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 108.0
HDL (mmol/L): 0,39
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,91
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 709.0
Protein (g/L): 72
T3 (pg/dL): 0,03
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,01
Urea (mg/dL): 20,3
LVEF (%): 48.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's comprehensive data, it is evident that they are a 59-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, and myocardial infarction. These conditions indicate a high risk of cardiovascular events and complications. 

The patient's NYHA Class III classification suggests that they experience symptoms of heart failure with activity limitation, such as shortness of breath or fatigue, which may be a result of their reduced left ventricular ejection fraction (LVEF) of 48%. However, their blood pressure is within a relatively normal range, which is beneficial for their cardiovascular health.

Their laboratory results show elevated levels of creatinine (239.0 mmol/L), indicating renal impairment, which may be related to their diabetes and cardiovascular disease. The high Pro-BNP level (709.0 ng/L) suggests increased stress on the heart, possibly due to heart failure or other cardiac conditions. 

The patient's lipid profile shows high total cholesterol and LDL levels, which are being managed with statins. Their TSH level is within the normal range, indicating that their thyroid function is not contributing to their cardiovascular condition. 

The patient's ECG results show monomorphic ventricular extrasystoles, which are common in patients with heart disease, but there is no indication of sustained ventricular tachycardia or other severe arrhythmias.

Considering the patient's medications, they are on a regimen that includes beta blockers, loop diuretics, statins, and an ACE inhibitor, which are all appropriate for managing heart failure, hypertension, and dyslipidemia. 

Given the patient's complex medical history and current condition, their survival can be attributed to their comprehensive treatment plan, which includes medications to manage their heart failure, hypertension, and dyslipidemia, as well as regular monitoring of their renal function and cardiac health."
158,158,P0259,"Age: 55
Gender: Male 
Weight: 94 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 180/80 mmHg
Past Medical History: Hypertropic cardiomyopathy, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 35.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,97
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 161.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,65
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 102.0
Protein (g/L): 69
T3 (pg/dL): 0,02
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,25
Urea (mg/dL): 9,65
LVEF (%): 70.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 55-year-old male, with a history of hypertrophic cardiomyopathy, peripheral vascular disease, hypertension, and myocardial infarction, is classified as NYHA Class III, indicating severe symptoms of heart failure. Despite this, the patient's left ventricular ejection fraction (LVEF) is 70%, which is within the normal range. The patient's blood pressure is 180/80 mmHg, which is elevated but not extremely high. 

The patient is on a comprehensive treatment plan that includes beta blockers, loop diuretics, statins, ACE inhibitors, and nitrovasodilators. These medications are effective in managing heart failure symptoms, hypertension, and lipid profiles.

The patient's liver function tests (ALT and AST) are within normal limits, indicating that the liver is functioning properly. The patient's kidney function, as indicated by creatinine levels, is also within normal limits. The patient's total cholesterol and LDL levels are well-managed with statin therapy. The patient's TSH and T4 levels are within normal limits, indicating normal thyroid function.

The patient's troponin level is 0.01 ng/mL, which is within normal limits, indicating that there is no acute myocardial infarction. The patient's pro-BNP level is 102 ng/L, which is slightly elevated but not extremely high, indicating some level of heart failure but not severe.

Considering the patient's comprehensive treatment plan, stable LVEF, and normal kidney and liver function, the patient's outcome of being a survivor can be attributed to the effective management of their cardiovascular disease and heart failure symptoms. The patient's age, gender, and comorbidities also suggest a higher risk of mortality, but the patient's treatment plan and relatively stable condition contribute to their survival."
159,159,P0267,"Age: 42
Gender: Female 
Weight: 78 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 130/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 37,4
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,13
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 162
Glucose (mmol/L): 19,7
Hemoglobin (g/L): 125.0
HDL (mmol/L): 0,58
Potassium (mEq/L): 3,95
LDL (mmol/L): 1,96
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 2237.0
Protein (g/L): 71,8
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,22
Urea (mg/dL): 14,99
LVEF (%): 28.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"REASONING: The patient, a 42-year-old female with a history of ischemic dilated cardiomyopathy, myocardial infarction, hypertension, and diabetes, has a complex clinical presentation. Despite her multiple comorbidities, the patient's outcome is a survivor. Several factors contribute to this outcome:

1. Optimal Medical Management: The patient is on a comprehensive medication regimen, including diabetes medication, an angiotensin II receptor blocker, loop diuretics, spironolactone, an ACE inhibitor, and a nitrovasodilator. These medications are tailored to address her hypertension, heart failure, and diabetes, suggesting that her condition is being effectively managed.

2. Low Troponin Levels: The patient's troponin level of 0.01 ng/mL indicates that there is minimal ongoing myocardial damage, which is a positive sign. This suggests that the patient's heart is not experiencing significant ischemia or infarction at the moment.

3. LVEF of 28%: Although the patient's left ventricular ejection fraction (LVEF) is severely reduced, indicating significant left ventricular dysfunction, it is not the lowest possible value. This suggests that the patient's heart is still functioning to some extent, which may be contributing to her survival.

4. No Indication of Acute Coronary Syndrome: The absence of elevated troponin levels and the patient's stable blood pressure suggest that there is no acute coronary syndrome, which is a significant risk factor for mortality in patients with heart failure.

5. Low Creatinine Levels: The patient's creatinine level of 84.0 mmol/L is within a relatively normal range, indicating that her kidney function is not significantly impaired. This is a positive sign, as kidney dysfunction is a common complication of heart failure and can increase the risk of mortality.

6. Stable Hemoglobin Levels: The patient's hemoglobin level of 125 g/L is within a normal range, indicating that her anemia, if present, is not severe. Anemia is a common complication of heart failure and can increase the risk of mortality.

7. Stable Electrocardiogram (ECG) Findings: The patient's ECG shows ventricular extrasystoles and non-sustained ventricular tachycardia, which are common findings in patients with heart failure. However, the absence of sustained ventricular tachycardia and bradycardia suggests that her cardiac rhythm is relatively stable.

Considering these factors, the patient's outcome as a survivor can be attributed to the combination of optimal medical management, minimal ongoing myocardial damage, relatively preserved left ventricular function, and stable kidney and hemoglobin levels."
160,160,P0268,"Age: 76
Gender: Female 
Weight: 71 kg
Height: 151 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 47,8
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,61
Creatinine (mmol/L): 112.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,65
Potassium (mEq/L): 4,24
LDL (mmol/L): 3,3
Sodium (mEq/L): 139.0
Protein (g/L): 74,3
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,69
Urea (mg/dL): 11,9
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient, a 76-year-old female with a history of valvular cardiomyopathy, diabetes, dyslipemia, and hypertension, has a complex set of risk factors and comorbidities that contribute to her overall clinical outcome. Despite these challenges, her survival is likely due to a combination of factors.

Firstly, her blood pressure is well-controlled at 120/70 mmHg, which is within a relatively normal range. This is crucial, as uncontrolled hypertension can exacerbate heart failure and increase the risk of cardiovascular events.

Secondly, her medication regimen is comprehensive and tailored to her specific conditions. She is on diabetes medication, beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor, which are all evidence-based treatments for her conditions. These medications likely help to manage her symptoms, slow disease progression, and reduce the risk of complications.

Thirdly, her laboratory results indicate that her liver function is relatively preserved, with normal levels of albumin, AST, and ALT. This suggests that her liver is not significantly compromised, which is important given her history of dyslipemia and potential for liver disease.

Fourthly, her kidney function, as indicated by her creatinine levels, is also relatively preserved, with a level of 112.0 μmol/L, which is within a relatively normal range. This is crucial, as kidney disease can be a significant contributor to cardiovascular morbidity and mortality.

Fifthly, her LVEF (Left Ventricular Ejection Fraction) is 30%, which is significantly reduced, indicating left ventricular dysfunction. However, her troponin levels are normal, suggesting that there is no acute myocardial infarction or ischemia.

Lastly, her ECG results show ventricular extrasystoles and non-sustained ventricular tachycardia, but no sustained ventricular tachycardia or bradycardia. While these findings are concerning, they are not necessarily indicative of a life-threatening condition.

Considering these factors, the patient's survival is likely due to a combination of her well-managed medical conditions, comprehensive medication regimen, preserved liver and kidney function, and the absence of acute myocardial infarction or ischemia."
161,161,P0272,"Age: 80
Gender: Female 
Weight: 76 kg
Height: 152 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,12
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 7,8
Hemoglobin (g/L): 120.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,29
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 918.0
Protein (g/L): 68,6
T3 (pg/dL): 0,0477
T4 (ng/L): 16,39
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,42
Urea (mg/dL): 7,1
LVEF (%): 60.0
Medications: Calcium Channel Blocker, Diabetes Medication, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient is an 80-year-old female with a history of hypertensive cardiomyopathy, diabetes, dyslipemia, and hypertension. Her current medications include a calcium channel blocker, diabetes medication, loop diuretics, spironolactone, statins, and an ACE inhibitor, which suggests that her condition is being managed with a comprehensive treatment plan. 

The patient's LVEF (Left Ventricular Ejection Fraction) is 60%, which indicates that her heart is functioning within a relatively normal range, considering her age and medical history. However, her elevated Pro-BNP (B-type natriuretic peptide) level of 918.0 ng/L suggests that her heart is under strain and may be experiencing some degree of heart failure.

The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG indicates that the patient is at risk for arrhythmias, but the fact that the arrhythmias are non-sustained suggests that they are not currently causing significant hemodynamic instability.

The patient's laboratory results show mild elevations in liver enzymes (ALT and AST), which could be indicative of mild liver dysfunction or a side effect of medications. However, the total cholesterol and LDL levels are within a relatively acceptable range, and the patient is on statins, which are helping to manage her dyslipemia.

The patient's blood glucose level is slightly elevated, but her diabetes is being managed with medication. Her hemoglobin level is within a normal range, and her TSH level is slightly elevated, but not significantly so.

Given the patient's overall clinical picture, it appears that she is being effectively managed for her chronic conditions, and her medications are helping to control her symptoms and prevent complications. The presence of non-sustained arrhythmias and elevated Pro-BNP level suggest that she is at risk for heart failure and arrhythmias, but the fact that she is a survivor suggests that her treatment plan is effective in preventing adverse outcomes.

The patient's age and NYHA Class II classification also indicate that she is experiencing some symptoms of heart failure, but they are not severe enough to significantly impact her daily activities. Overall, the patient's outcome of survival suggests that her treatment plan is effective in managing her chronic conditions and preventing adverse outcomes."
162,162,P0273,"Age: 75
Gender: Male 
Weight: 77 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 4,54
LDL (mmol/L): 2,87
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 5435.0
Protein (g/L): 75,199
T3 (pg/dL): 0,0249
T4 (ng/L): 20,99
Troponin (ng/mL): 0,5
TSH (mIU/L): 0,3
Urea (mg/dL): 9,1
LVEF (%): 45.0
Medications: Calcium Channel Blocker, Amiodarone, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of survival is attributed to a combination of several factors, including the effective management of his cardiovascular conditions and the optimization of his medication regimen. The patient's age and comorbidities, such as ischemic dilated cardiomyopathy and peripheral vascular disease, place him at high risk for adverse cardiovascular events. However, the patient's left ventricular ejection fraction (LVEF) of 45% indicates that his heart is still functioning, albeit at a reduced capacity.

The patient's blood pressure is well-controlled at 120/80 mmHg, which is beneficial for reducing the risk of cardiovascular events. His medication regimen, including beta blockers, ACE inhibitors, and spironolactone, is consistent with guidelines for managing heart failure and reducing the risk of adverse outcomes. The use of a calcium channel blocker and nitrovasodilator also helps to manage his hypertension and angina symptoms.

The patient's electrolyte levels, including potassium and sodium, are within normal limits, which is essential for maintaining proper cardiac function. His TSH level is also within the normal range, indicating that his thyroid function is not contributing to his cardiovascular condition.

The patient's troponin level of 0.5 ng/mL is slightly elevated, which may indicate some degree of cardiac injury or stress. However, this level is not alarmingly high, and the patient's overall clinical picture suggests that he is stable.

The patient's Pro-BNP level of 5435.0 ng/L is elevated, which is consistent with heart failure. However, this level is not excessively high, and the patient's symptoms and clinical findings do not suggest acute decompensation.

In summary, the patient's outcome of survival is likely due to the effective management of his cardiovascular conditions, the optimization of his medication regimen, and the absence of any acute decompensation or severe cardiac dysfunction."
163,163,P0274,"Age: 68
Gender: Female 
Weight: 74 kg
Height: 153 cm
NYHA Class: II
Blood Pressure: 170/75 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,81
Creatinine (mmol/L): 105.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 7,5
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 3,6
LDL (mmol/L): 1,63
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 149.0
Protein (g/L): 75
T3 (pg/dL): 0,0267
T4 (ng/L): 18,16
Troponin (ng/mL): 0,3
TSH (mIU/L): 2,4
Urea (mg/dL): 9,2
LVEF (%): 70.0
Medications: Calcium Channel Blocker, Diabetes Medication, Amiodarone, Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 68-year-old female with a history of hypertensive cardiomyopathy, diabetes, dyslipemia, and hypertension, has been managed with a combination of medications including calcium channel blockers, diabetes medication, amiodarone, angiotensin II receptor blockers, digoxin, loop diuretics, and statins. Despite the presence of several risk factors and comorbidities, the patient has a relatively preserved left ventricular ejection fraction (LVEF) of 70% and a normal troponin level, indicating minimal myocardial damage.

The patient's blood pressure is elevated at 170/75 mmHg, but it is well-controlled with medications. The patient's glucose level is slightly elevated at 7.5 mmol/L, but it is likely under control with diabetes medication. The patient's lipid profile shows elevated total cholesterol and LDL levels, but statin therapy is in place.

The patient's liver function tests are within normal limits, and her kidney function, as indicated by creatinine and urea levels, is also preserved. The patient's albumin level is slightly low, but this may be related to nephrotic syndrome or liver disease, which is not evident in this case.

The patient's thyroid function tests are within normal limits, and her T3 and T4 levels are within normal ranges. The patient's TSH level is slightly elevated, but it is within the normal range.

The patient's ECG shows monomorphic ventricular extrasystoles, but no sustained ventricular tachycardia or other arrhythmias. This finding is relatively benign and may not be clinically significant.

Given the patient's overall clinical picture, it is likely that the patient's medications and management plan are effective in controlling her symptoms and preventing complications. The patient's preserved LVEF and lack of significant myocardial damage suggest that she is at low risk for adverse cardiac events. Therefore, the patient outcome of survivor is likely due to the effective management of her comorbidities and risk factors."
164,164,P0276,"Age: 37
Gender: Male 
Weight: 103 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 140/100 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,27
Creatinine (mmol/L): 116.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,9
Potassium (mEq/L): 4,06
LDL (mmol/L): 2,36
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 308.0
Protein (g/L): 79,6
T3 (pg/dL): 0,0402
T4 (ng/L): 15,66
TSH (mIU/L): 0,41
Urea (mg/dL): 6
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Paroxysmal AVB
            ",survivor,"REASONING: 

The patient, a 37-year-old male with a history of enolic dilated cardiomyopathy and hypertension, has a complex medical profile. Despite the presence of significant cardiac dysfunction (LVEF 30.0%), the patient is classified as NYHA Class II, indicating moderate symptoms with minimal limitations in physical activity. This suggests that the patient is currently tolerating their cardiac condition relatively well, likely due to the ongoing medical management with beta blockers, loop diuretics, and an ACE inhibitor.

The elevated Pro-BNP level (308.0 ng/L) indicates increased ventricular wall stress, which is consistent with the patient's dilated cardiomyopathy. However, the absence of other adverse biomarkers such as elevated troponin levels or significant arrhythmias on the ECG suggests that the patient is not experiencing acute cardiac decompensation at the time of evaluation.

The patient's lipid profile shows elevated total cholesterol and LDL levels, which may contribute to the progression of atherosclerotic cardiovascular disease. However, the current treatment regimen likely includes statin therapy to manage these lipid abnormalities.

The patient's thyroid function tests are within normal limits, ruling out hypothyroidism as a contributing factor to the cardiomyopathy.

The patient's creatinine level is elevated at 116.0 umol/L, indicating mild renal impairment. This may be a consequence of the patient's hypertension and cardiomyopathy.

The patient's potassium level is slightly low at 4.06 mEq/L, which may be related to the diuretic therapy. Monitoring of electrolytes is essential to prevent hypokalemia.

In summary, the patient's outcome as a survivor is likely due to the ongoing medical management of their cardiomyopathy and hypertension, as well as the absence of acute cardiac decompensation or other adverse events. However, close monitoring of the patient's renal function, electrolytes, and cardiac status is necessary to prevent potential complications."
165,165,P0277,"Age: 75
Gender: Male 
Weight: 89 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 4,4
Creatinine (mmol/L): 177.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,77
LDL (mmol/L): 2,61
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 410.0
Protein (g/L): 68,6
T3 (pg/dL): 0,039
T4 (ng/L): 15,86
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,23
Urea (mg/dL): 11,9
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's age, history of ischemic dilated cardiomyopathy, and reduced left ventricular ejection fraction (LVEF) of 30% suggest a high risk of heart failure. However, the patient's overall clinical presentation and laboratory results indicate that the patient is being effectively managed with appropriate medications, including beta blockers, statins, and an ACE inhibitor. The patient's blood pressure is within a relatively normal range, and there is no indication of severe electrolyte imbalances or acute coronary syndrome (troponin is slightly elevated but not significantly).

The patient's T3 and T4 levels are within the normal range, indicating that thyroid function is not contributing to the patient's cardiac condition. The patient's pro-BNP level is elevated at 410.0 ng/L, which is consistent with heart failure, but the patient's overall clinical presentation and laboratory results suggest that the patient is being effectively managed.

The presence of polymorphic ventricular extrasystoles on the ECG may be a benign finding in this patient, especially given the absence of other concerning ECG abnormalities. The patient's LVEF of 30% is a significant reduction, but the patient's overall clinical presentation and laboratory results suggest that the patient is being effectively managed, and the patient is likely a survivor due to the combination of optimal medical therapy and likely a low risk of acute cardiac events.

Therefore, the patient's outcome is likely due to effective management of their underlying cardiac condition, including the use of appropriate medications, and a low risk of acute cardiac events."
166,166,P0278,"Age: 82
Gender: Female 
Weight: 79 kg
Height: 144 cm
NYHA Class: III
Blood Pressure: 160/60 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 42.0
Total Cholesterol (mmol/L): 7,06
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 50
Glucose (mmol/L): 3,9
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,91
Potassium (mEq/L): 4,47
LDL (mmol/L): 4,22
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 710.0
Protein (g/L): 75,9
T3 (pg/dL): 0,045
T4 (ng/L): 23,19
Troponin (ng/mL): 0,3
TSH (mIU/L): 0,07
Urea (mg/dL): 11,2
LVEF (%): 67.0
Medications: Amiodarone, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient outcome of survival is likely due to a combination of factors, including the patient's current medical treatment regimen and her overall physiological condition.

Firstly, the patient is being treated with Amiodarone, a medication commonly used to treat arrhythmias, particularly ventricular extrasystoles and tachycardias. The presence of Amiodarone suggests that the patient's cardiomyopathy and hypertension have been managed to some extent, which may have contributed to her survival.

Additionally, the patient is taking Loop Diuretics, which are often used to manage fluid overload in patients with heart failure. The patient's NYHA Class III classification indicates that she has severe symptoms of heart failure, but the use of Loop Diuretics may have helped alleviate some of these symptoms, contributing to her survival.

The patient is also on an ACE Inhibitor, which is a standard treatment for hypertension and heart failure. ACE Inhibitors work by reducing blood pressure and decreasing the workload on the heart, which may have helped to slow the progression of her cardiomyopathy.

The patient's laboratory results show a relatively well-managed metabolic profile, with normal or near-normal levels of electrolytes, liver enzymes, and kidney function. Her glucose and lipid profiles are also within relatively normal limits, which may indicate that her diabetes and lipid disorders are under control.

The patient's ECG results show a polymorphic ventricular extrasystole, which is a type of irregular heartbeat. However, the absence of sustained ventricular tachycardia and other arrhythmias suggests that her cardiac rhythm is relatively stable, which is a positive prognostic sign.

The patient's low TSH level (0.07 mIU/L) suggests that her thyroid function is well-managed, which is important for cardiac health. Her low T3 level (0.045 pg/dL) may indicate a mild hypothyroidism, but this is not likely to have a significant impact on her cardiac function.

The patient's LVEF (Left Ventricular Ejection Fraction) of 67% is within the normal range, indicating that her heart is pumping blood efficiently. Her Pro-BNP level of 710.0 ng/L is elevated, but this is not uncommon in patients with heart failure and may not necessarily indicate a poor prognosis.

In summary, the combination of the patient's current medical treatment regimen, her relatively well-managed metabolic profile, and her stable cardiac rhythm have likely contributed to her survival."
167,167,P0281,"Age: 50
Gender: Male 
Weight: 91 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 160/100 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 9
Hemoglobin (g/L): 148.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 3,41
LDL (mmol/L): 3,4
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1825.0
Protein (g/L): 66,2
T3 (pg/dL): 0,0402
T4 (ng/L): 17,78
Troponin (ng/mL): 0,3
TSH (mIU/L): 0,95
Urea (mg/dL): 3,9
LVEF (%): 60.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 50-year-old male with a history of enolic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension, has a complex medical profile. Despite the presence of several risk factors for poor cardiovascular outcomes, including reduced left ventricular ejection fraction (LVEF) at 60% and elevated B-type natriuretic peptide (BNP) levels at 1825 ng/L, the patient has survived.

Several factors may have contributed to this outcome:

1. Optimal medical management: The patient is on a multidisciplinary regimen of medications, including beta blockers, digoxin, loop diuretics, statins, and an ACE inhibitor, which have likely helped to manage his heart failure and control his blood pressure.

2. LVEF of 60%: Although the patient's LVEF is reduced, it is not severely impaired, which suggests that the heart is still functioning relatively well. This may indicate that the patient's heart is resilient and able to adapt to his disease state.

3. No acute cardiovascular events: The patient does not have evidence of acute coronary syndrome, myocardial infarction, or other acute cardiovascular events that could have led to a poor outcome.

4. Stable hemodynamics: The patient's blood pressure is well-controlled, and his electrolyte levels are within a relatively normal range, which suggests that his cardiac function is not being significantly compromised by electrolyte imbalances.

5. Good renal function: The patient's creatinine level is elevated, but not severely so, which suggests that his renal function is not significantly impaired. This is important, as patients with heart failure and renal impairment often have a worse prognosis.

6. No severe electrolyte imbalances: The patient's potassium level is slightly low, but not severely so, which may be a result of the diuretic therapy. This is a common side effect of loop diuretics, and it is not typically a cause for concern.

In conclusion, the combination of optimal medical management, a relatively preserved LVEF, stable hemodynamics, good renal function, and the absence of acute cardiovascular events have likely contributed to the patient's survival."
168,168,P0282,"Age: 58
Gender: Male 
Weight: 87 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 135/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 8,1
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 3,82
LDL (mmol/L): 2,2
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 165.0
Protein (g/L): 69,8
T3 (pg/dL): 0,0339
T4 (ng/L): 17,8
Troponin (ng/mL): 0,6
TSH (mIU/L): 1,62
Urea (mg/dL): 8,9
LVEF (%): 40.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"REASONING: 

The patient is a 58-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, and myocardial infarction. Despite these comorbidities, the patient has been on a treatment regimen consisting of diabetes medication, beta blockers, loop diuretics, statins, and ACE inhibitor, which suggests a multidisciplinary approach to managing his cardiovascular and metabolic conditions.

The patient's laboratory results show elevated levels of creatinine (99.0 mmol/L) and pro-BNP (165.0 ng/L), indicating possible renal impairment and heart failure. However, the patient's LVEF is 40.0%, which is within the range of heart failure with reduced ejection fraction (HFrEF). The patient's blood pressure is well-controlled at 135/80 mmHg, and his glucose level is slightly elevated at 8.1 mmol/L, but not significantly high.

The patient's ECG shows polymorphic ventricular extrasystole and sinus node dysfunction, but no sustained ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia. The presence of polymorphic ventricular extrasystole may be a sign of underlying cardiac arrhythmias, but it is not uncommon in patients with heart failure.

Considering the patient's overall clinical picture, the most likely reason for the patient's outcome is the effective management of his cardiovascular and metabolic conditions. The patient's treatment regimen appears to be addressing his comorbidities, and his blood pressure and glucose levels are well-controlled. The patient's renal function is impaired, but not severely so, and his LVEF is within the range of HFrEF. Therefore, the patient's survival is likely due to the multidisciplinary approach to his care and the effective management of his underlying conditions."
169,169,P0283,"Age: 80
Gender: Female 
Weight: 87 kg
Height: 150 cm
NYHA Class: III
Blood Pressure: 160/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,58
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 3,52
LDL (mmol/L): 2,48
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 4058.0
Protein (g/L): 67,699
T3 (pg/dL): 0,0354
T4 (ng/L): 17,65
Troponin (ng/mL): 0,4
TSH (mIU/L): 2,07
Urea (mg/dL): 12,1
LVEF (%): 70.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's data, it is not surprising that they are a survivor. Here are the key factors contributing to this outcome:

1. Stable LVEF (Left Ventricular Ejection Fraction) of 70%: This indicates that the patient's heart is pumping blood effectively, which is crucial for survival in a patient with a history of hypertensive cardiomyopathy.

2. Current Medications: The patient is on beta blockers, loop diuretics, and an ACE inhibitor, which are standard treatments for heart failure and hypertension. These medications have helped to manage the patient's condition and prevent further complications.

3. No Evidence of Sustained Ventricular Tachycardia: The absence of sustained ventricular tachycardia on the ECG is a good sign, indicating that the patient's heart rhythm is stable.

4. Low Troponin Levels: The troponin level of 0.4 ng/mL is within normal limits, indicating that there is no acute myocardial infarction (heart attack) or significant cardiac damage.

5. Normal Hemoglobin and Urea Levels: The patient's hemoglobin and urea levels are within normal limits, indicating that their kidneys are functioning adequately, and there is no significant anemia or renal impairment.

6. TSH Level within Normal Limits: The TSH level of 2.07 mIU/L is within the normal range, indicating that the patient's thyroid function is normal, which is essential for overall cardiovascular health.

7. Patient's Age and NYHA Class III: While the patient is 80 years old and classified as NYHA Class III, which indicates some limitations in physical activity, their overall condition is stable, and they are not in an advanced stage of heart failure.

Considering these factors, the patient's survival is likely due to the effective management of their hypertension and cardiomyopathy, along with the use of appropriate medications and a stable heart rhythm."
170,170,P0284,"Age: 80
Gender: Female 
Weight: 54 kg
Height: 143 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 35
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 57.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 75
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 118.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,63
LDL (mmol/L): 2,37
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1057.0
Protein (g/L): 76,8
T3 (pg/dL): 0,0726
T4 (ng/L): 14,63
Troponin (ng/mL): 0,6
TSH (mIU/L): 6,19
Urea (mg/dL): 6,7
LVEF (%): 45.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient, an 80-year-old female, has a complex medical history that includes hypertensive cardiomyopathy, hypertension, and myocardial infarction. The patient's New York Heart Association (NYHA) class of III indicates that she experiences symptoms of heart failure during ordinary physical activity but is comfortable at rest. 

The laboratory results show elevated levels of creatinine (80.0 mmol/L), indicating impaired renal function, which is consistent with her history of hypertension and potential chronic kidney disease. The patient's low LVEF (45%) suggests that she has significant left ventricular dysfunction. The elevated Pro-BNP (1057.0 ng/L) level is indicative of heart failure.

The patient is on a combination of medications, including beta blockers, loop diuretics, ACE inhibitors, and nitrovasodilators, which are standard treatments for heart failure and hypertension. The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and possible paroxysmal supraventricular tachyarrhythmia on the ECG suggests that the patient has arrhythmias, which can be a complication of heart failure.

Given the patient's age, complex medical history, and the presence of heart failure and arrhythmias, the fact that she is a survivor is likely due to the aggressive management of her heart failure and hypertension with a combination of medications. The patient's ability to survive is also likely due to the support of her healthcare team and her own resilience."
171,171,P0288,"Age: 80
Gender: Female 
Weight: 81 kg
Height: 161 cm
NYHA Class: III
Blood Pressure: 150/65 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 114.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,53
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 195.0
Protein (g/L): 69,2
T3 (pg/dL): 0,0327
T4 (ng/L): 13,05
TSH (mIU/L): 1,05
Urea (mg/dL): 15,7
LVEF (%): 70.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"REASONING: 

The patient is an 80-year-old female with a history of valvular cardiomyopathy, diabetes, dyslipemia, and hypertension. She is on a comprehensive medication regimen, including diabetes medication, angiotensin II receptor blocker, beta blockers, loop diuretics, statins, and nitrovasodilators. 

The patient's New York Heart Association (NYHA) class III classification indicates that she experiences symptoms of heart failure with minimal physical activity, such as walking on the level or climbing stairs, but is comfortable at rest. 

Her laboratory results show elevated total cholesterol (4.91 mmol/L) and low HDL (1.32 mmol/L) levels, indicating dyslipemia. Her glucose level is elevated (4.8 mmol/L), consistent with diabetes. Her creatinine level is mildly elevated (118.0 μmol/L), suggesting some degree of renal impairment. 

Her left ventricular ejection fraction (LVEF) is within a relatively normal range (70.0%), indicating preserved cardiac function. The Pro-BNP level is mildly elevated (195.0 ng/L), suggesting some degree of heart failure, but not severe. 

The ECG shows ventricular extrasystoles, but no sustained ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia. The presence of sinus node dysfunction suggests some degree of autonomic dysfunction.

Considering the patient's age, comorbidities, and medication regimen, the patient's outcome of survival is likely due to the following factors:

1. Comprehensive medication management: The patient is on a comprehensive regimen of medications that target her comorbidities, including heart failure, diabetes, and hypertension.
2. Preserved cardiac function: The patient's LVEF is within a relatively normal range, indicating that her heart function is preserved, which is a positive prognostic factor.
3. Mild elevation of Pro-BNP: The mildly elevated Pro-BNP level suggests some degree of heart failure, but not severe, which is a positive prognostic factor.
4. No severe cardiac arrhythmias: The absence of sustained ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia suggests that the patient's cardiac rhythm is relatively stable.
5. Sinus node dysfunction: The presence of sinus node dysfunction may indicate some degree of autonomic dysfunction, but it is not a contraindication to survival.

Overall, the patient's outcome of survival is likely due to a combination of her comprehensive medication regimen, preserved cardiac function, and the absence of severe cardiac arrhythmias."
172,172,P0292,"Age: 64
Gender: Male 
Weight: 75 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,4
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 4,11
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 3,9
LDL (mmol/L): 3,88
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1363.0
Protein (g/L): 67
T3 (pg/dL): 0,0426
T4 (ng/L): 14,2
TSH (mIU/L): 0,96
Urea (mg/dL): 7,1
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 64-year-old male with a history of idiopathic dilated cardiomyopathy, dyslipemia, peripheral vascular disease, and hypertension. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 30%, indicating severe systolic heart failure. However, the patient is being managed with appropriate medications, including beta blockers, loop diuretics, statins, and an ACE inhibitor, which are standard treatments for heart failure with reduced ejection fraction.

The patient's biomarkers, such as elevated pro-BNP (1363.0 ng/L), suggest increased ventricular wall stress and potential fluid overload, which are consistent with heart failure. The patient's albumin level is within the normal range, but the creatinine level is elevated at 118.0 μmol/L, indicating mild renal impairment, which is not uncommon in patients with heart failure.

The patient's lipid profile shows a high total cholesterol level and low HDL cholesterol level, which are risk factors for cardiovascular disease. However, the patient is on statins, which are likely helping to manage these lipid levels.

The patient's TSH level is within the normal range, indicating that hypothyroidism is unlikely to be contributing to the patient's symptoms. The patient's T3 and T4 levels are also within the normal range, which further supports this conclusion.

The ECG findings of polymorphic ventricular extrasystoles and TPSV are concerning, but the absence of sustained ventricular tachycardia or non-sustained ventricular tachycardia suggests that the patient is not at high risk of sudden cardiac death.

Given the patient's age, comorbidities, and current treatment regimen, the patient's outcome of survival is likely due to the effective management of their heart failure symptoms with medications and the absence of any acute complications or severe arrhythmias."
173,173,P0295,"Age: 37
Gender: Male 
Weight: 94 kg
Height: 174 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 154.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,8
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3232.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 27
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,17
Urea (mg/dL): 6,99
LVEF (%): 21.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 37-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, hypertension, and myocardial infarction, has been prescribed a comprehensive treatment regimen including diabetes medication, beta blockers, loop diuretics, statins, ACE inhibitors, and nitrovasodilators. Despite the severity of his conditions, the patient has survived.

The patient's left ventricular ejection fraction (LVEF) is 21%, indicating severe left ventricular dysfunction, which is a strong predictor of poor outcomes in heart failure patients. However, the patient's survival suggests that his treatment plan is effective in managing his symptoms and slowing disease progression.

The patient's elevated pro-BNP (brain natriuretic peptide) level of 3232 ng/L indicates that his heart is under significant stress, consistent with heart failure. However, the fact that he has survived despite this high level suggests that his treatment plan is adequate in managing his condition.

The patient's blood pressure is within a relatively normal range (140/80 mmHg), which may indicate effective management of his hypertension. His glucose level is slightly elevated (5.6 mmol/L), but this is likely well-managed by his diabetes medication.

The patient's ECG shows evidence of ventricular extrasystoles and non-sustained ventricular tachycardia, which are common in patients with heart failure. However, the absence of sustained ventricular tachycardia and bradycardia suggests that his treatment plan is effective in managing his arrhythmias.

Overall, the patient's survival can be attributed to his comprehensive treatment plan, which includes medications that target his multiple comorbidities and symptoms. His healthcare team's efforts to manage his heart failure, hypertension, and diabetes have likely contributed to his survival."
174,174,P0296,"Age: 69
Gender: Female 
Weight: 55 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,84
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 13,9
Glucose (mmol/L): 5,03
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,95
Potassium (mEq/L): 4,74
LDL (mmol/L): 3,09
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 267.0
Protein (g/L): 80
T3 (pg/dL): 0,0432
T4 (ng/L): 13,91
TSH (mIU/L): 1,51
Urea (mg/dL): 9
LVEF (%): 25.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient, a 69-year-old female with a history of idiopathic dilated cardiomyopathy, has a relatively favorable outcome given her advanced heart failure symptoms and reduced left ventricular ejection fraction (LVEF) of 25%. Several factors contribute to her survival:

1. Optimal Medical Management: The patient is on appropriate medications for heart failure, including digoxin, loop diuretics, and an ACE inhibitor. These medications help manage symptoms, improve heart function, and reduce mortality.

2. Mild Hypertension: The patient's blood pressure is well-controlled at 120/70 mmHg, which is beneficial for heart health. Elevated blood pressure can exacerbate heart failure.

3. Normal Electrolytes: The patient's potassium level is within the normal range (4.74 mEq/L), which is essential for proper cardiac function. Hypokalemia can worsen heart failure symptoms and increase the risk of arrhythmias.

4. Normal Thyroid Function: The patient's thyroid function tests (T3, T4, and TSH) are within normal limits, which is crucial for heart health. Hypothyroidism can contribute to heart failure.

5. No Sustained Arrhythmias: The ECG does not show sustained ventricular tachycardia or other life-threatening arrhythmias, which can be a significant risk factor for mortality in heart failure patients.

6. Low Pro-BNP: The patient's pro-B-type natriuretic peptide (pro-BNP) level is elevated at 267.0 ng/L, indicating heart failure, but not excessively high, suggesting that the patient's condition is being managed effectively.

7. No Severe Liver or Renal Dysfunction: The patient's liver and renal function tests (ALT, AST, GGT, creatinine, and urea) are relatively normal, indicating that there is no significant organ dysfunction contributing to her heart failure.

8. Appropriate Nutritional Status: The patient's albumin and protein levels are within normal limits, indicating adequate nutrition and no significant malnutrition, which can worsen heart failure outcomes.

Considering these factors, the patient's survival outcome is likely due to a combination of optimal medical management, favorable laboratory results, and the absence of significant comorbidities that could have contributed to a poorer outcome."
175,175,P0297,"Age: 73
Gender: Male 
Weight: 82 kg
Height: 159 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 15,7
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 3,79
LDL (mmol/L): 2,07
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 678.0
Protein (g/L): 65
T3 (pg/dL): 0,0396
T4 (ng/L): 13,66
Troponin (ng/mL): 0,1
TSH (mIU/L): 1,3
Urea (mg/dL): 3,4
LVEF (%): 25.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 73-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and myocardial infarction. His NYHA Class III classification indicates that he has severe symptoms of heart failure, including shortness of breath and fatigue, but he is still able to perform daily activities with some limitation.

The patient's laboratory results show elevated levels of troponin (0.1 ng/mL), indicating myocardial damage, and a low left ventricular ejection fraction (LVEF) of 25%, which is consistent with heart failure. The elevated Pro-BNP level (678.0 ng/L) also supports the diagnosis of heart failure.

The patient's medications, including beta blockers, loop diuretics, statins, ACE inhibitors, and nitrovasodilators, are consistent with standard treatment for heart failure and ischemic cardiomyopathy.

The patient's ECG shows polymorphic ventricular extrasystoles, but no sustained ventricular tachycardia or other arrhythmias. This suggests that the patient's heart rhythm is relatively stable, despite the presence of ventricular extrasystoles.

The patient's overall clinical presentation and laboratory results suggest that he is at high risk for adverse outcomes, including mortality. However, the fact that he is still alive and receiving treatment suggests that he has received appropriate medical care and has been able to manage his condition.

The most likely reason for the patient's survival is the comprehensive medical treatment he is receiving, including medications and lifestyle modifications, which are helping to manage his heart failure and reduce the risk of adverse outcomes. Additionally, the patient's relatively stable ECG and lack of severe arrhythmias also contribute to his survival."
176,176,P0298,"Age: 86
Gender: Male 
Weight: 90 kg
Height: 190 cm
NYHA Class: III
Blood Pressure: 125/80 mmHg
Past Medical History: Other HF etiology, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,32
Creatinine (mmol/L): 62.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,53
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 851.0
Protein (g/L): 71
T3 (pg/dL): 0,03
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,59
Urea (mg/dL): 3,5
LVEF (%): 37.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome is likely due to a combination of factors, including the presence of a preserved ejection fraction (LVEF of 37%), which suggests that the heart is still pumping blood effectively, albeit at a reduced capacity. The use of evidence-based medications such as ACE inhibitor, statins, and digoxin, as well as loop diuretics, is also a contributing factor to the patient's survival. The patient's blood pressure is well-controlled at 125/80 mmHg, which reduces the strain on the heart. Additionally, the absence of severe electrolyte imbalances (e.g., potassium level of 3.8 mEq/L) and a relatively normal liver function (ALT and AST levels) suggests that the patient's organs are functioning adequately.

The patient's Pro-BNP level of 851 ng/L indicates some degree of heart failure, but the fact that it is not extremely high suggests that the patient's condition is being managed effectively. The patient's low T3 level (0.03 pg/dL) and normal T4 level (16 ng/L) suggest that there is no significant thyroid dysfunction contributing to the patient's condition.

The patient's recent troponin level of 0.01 ng/mL is within normal limits, indicating that there is no acute myocardial infarction. The absence of ventricular tachycardia and the presence of a polymorphic ventricular extrasystole on the ECG suggests that the patient's heart rhythm is relatively stable.

Overall, the patient's outcome is likely due to a combination of effective medical management, preserved cardiac function, and the absence of severe comorbidities or acute cardiac events."
177,177,P0299,"Age: 71
Gender: Female 
Weight: 95 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,07
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 5,9
LDL (mmol/L): 3,26
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3233.0
Protein (g/L): 72
T3 (pg/dL): 0,03
T4 (ng/L): 20
Troponin (ng/mL): 0,04
TSH (mIU/L): 2,86
Urea (mg/dL): 6,16
LVEF (%): 17.0
Medications: Amiodarone, Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

This patient, a 71-year-old female with a history of idiopathic dilated cardiomyopathy and hypertension, has a complex clinical presentation. The patient's left ventricular ejection fraction (LVEF) is severely impaired at 17%, indicating significant left ventricular dysfunction. The elevated Pro-BNP level of 3233 ng/L further supports the presence of heart failure.

The patient is on a comprehensive medication regimen, including Amiodarone, Beta Blockers, Spironolactone, and an ACE Inhibitor, which are standard treatments for heart failure and arrhythmias. The presence of non-sustained ventricular tachycardia (VT) and polymorphic ventricular extrasystoles on the ECG indicates that the patient is at risk for sudden cardiac death. However, the fact that the patient has survived suggests that the medications are likely effective in managing these arrhythmias.

The patient's laboratory results show mild elevation in liver enzymes (ALT and AST) and gamma-glutamyl transpeptidase (GGT), which may be related to the use of Amiodarone. The low T3 level (0.03 pg/dL) and high TSH level (2.86 mIU/L) suggest subclinical hypothyroidism, which is a common side effect of Amiodarone.

The patient's renal function is impaired, with a creatinine level of 97.0 μmol/L, which may be contributing to the patient's overall morbidity. However, the patient's blood pressure is well-controlled at 120/70 mmHg, and the patient's hemoglobin level is within the normal range.

Overall, the patient's survival is likely due to the comprehensive medical management of her heart failure and arrhythmias, as well as the absence of any acute cardiac events such as myocardial infarction or cardiac arrest. The patient's suboptimal renal function and subclinical hypothyroidism may be contributing factors to her overall morbidity, but they do not appear to have negatively impacted her survival."
178,178,P0301,"Age: 76
Gender: Male 
Weight: 83 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 150.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 7,6
Hemoglobin (g/L): 124.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,38
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3182.0
Protein (g/L): 68
T3 (pg/dL): 0,03
T4 (ng/L): 20
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,07
Urea (mg/dL): 17,14
LVEF (%): 12.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient's outcome of survival is likely due to a combination of factors, including the comprehensive treatment plan and the patient's current clinical status. 

Firstly, the patient is on a multidrug regimen consisting of Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, and Nitrovasodilator, which are all evidence-based treatments for heart failure and ischemic dilated cardiomyopathy. Beta blockers help reduce the heart rate and the force of contraction, while loop diuretics help manage fluid overload. Statins improve lipid profiles and reduce the risk of further cardiovascular events. ACE inhibitors help reduce afterload and improve cardiac output. Nitrovasodilators also help reduce afterload and improve cardiac output.

The patient's current clinical status also plays a significant role in their survival. Although the patient has a low left ventricular ejection fraction (LVEF) of 12%, which indicates severe heart failure, the patient's blood pressure is relatively well-managed at 100/60 mmHg, which suggests that the patient is not experiencing severe hypertension. The patient's glucose level is also well-controlled at 7.6 mmol/L, which reduces the risk of cardiovascular complications.

Additionally, the patient's TSH level is within the normal range, indicating that the patient's thyroid function is well-managed, which is essential for cardiac function. The patient's troponin level is also within the normal range, indicating that the patient is not experiencing acute myocardial infarction.

However, the patient's Pro-BNP level is elevated at 3182.0 ng/L, which indicates that the patient is experiencing heart failure symptoms. The patient's creatinine level is also elevated at 150.0 mmol/L, which suggests that the patient has chronic kidney disease, which is a common comorbidity in patients with heart failure.

In summary, the patient's survival is likely due to the combination of their comprehensive treatment plan and their current clinical status, which includes well-managed blood pressure, glucose, and thyroid function, as well as the absence of acute myocardial infarction."
179,179,P0302,"Age: 67
Gender: Male 
Weight: 80 kg
Height: 175 cm
NYHA Class: III
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 16
Hemoglobin (g/L): 134.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 5,8
LDL (mmol/L): 2,97
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 589.0
Protein (g/L): 74
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,09
Urea (mg/dL): 11,48
LVEF (%): 48.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to a combination of several factors. 

Firstly, the patient's current blood pressure of 130/70 mmHg is within a relatively normal range, indicating that the patient's blood pressure is being effectively managed with medication. The use of beta blockers, which are commonly prescribed for patients with heart failure, is also a contributing factor to the patient's survival.

The patient's left ventricular ejection fraction (LVEF) of 48% indicates that the heart is still pumping blood efficiently, albeit not at its optimal level. The LVEF is a critical indicator of heart function, and a value of 48% suggests that the patient's heart is still functioning adequately to meet the body's needs.

The patient's troponin level of 0.01 ng/mL is within a normal range, indicating that there is no significant cardiac damage or ongoing myocardial infarction. This is a positive sign, as elevated troponin levels are often associated with cardiac damage or infarction.

The patient's pro-BNP level of 589.0 ng/L is elevated, which is consistent with heart failure. However, the fact that the patient is still alive suggests that the heart failure is being effectively managed with medication, including loop diuretics and spironolactone.

The patient's creatinine level of 115.0 μmol/L is slightly elevated, indicating some degree of renal impairment. However, this is not uncommon in patients with heart failure and diabetes. The patient's urea level of 11.48 mg/dL is also elevated, which is consistent with renal impairment.

The patient's medication regimen, which includes diabetes medication, beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, is likely contributing to the patient's survival. These medications are all commonly used to manage heart failure and diabetes, and are likely helping to control the patient's symptoms and slow the progression of the disease.

In summary, the patient's survival can be attributed to a combination of effective blood pressure management, adequate heart function, lack of significant cardiac damage, effective management of heart failure, and a comprehensive medication regimen."
180,180,P0304,"Age: 75
Gender: Female 
Weight: 64 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 5,04
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 14,7
Hemoglobin (g/L): 133.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,23
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3866.0
Protein (g/L): 70
T3 (pg/dL): 0,02
T4 (ng/L): 22
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,14
Urea (mg/dL): 5,99
LVEF (%): 42.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 75-year-old female with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and a previous myocardial infarction. Her current medications include diabetes medication, beta blockers, loop diuretics, statins, ACE inhibitors, and nitrovasodilators, which suggest that she has a history of heart failure and is being managed accordingly.

The patient's blood pressure is 150/80 mmHg, which is elevated but not severely so, given her age and comorbidities. Her LVEF (left ventricular ejection fraction) is 42%, indicating that she has a reduced ejection fraction, which is a hallmark of heart failure.

The patient's laboratory results show elevated levels of pro-BNP (3866 ng/L), which is a biomarker for heart failure and cardiac stress. Her creatinine level is slightly elevated at 106.0 μmol/L, indicating some degree of kidney dysfunction, which is common in patients with heart failure.

The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are indicative of arrhythmias and cardiac electrical instability. However, the fact that she has a non-sustained ventricular tachycardia with a cycle length > 10 seconds suggests that she is not in a life-threatening arrhythmia at the moment.

Given the patient's age, comorbidities, and current medications, it is likely that she has been managed for heart failure and is being treated to reduce her symptoms and prevent further complications. The fact that she is a survivor suggests that her treatment plan is effective in managing her condition, and she is able to tolerate her medications and manage her symptoms.

The patient's TSH level is slightly elevated at 2.14 mIU/L, which may indicate subclinical hypothyroidism, but it is not likely to be the primary cause of her heart failure. Her T3 and T4 levels are within normal limits, and her glucose level is elevated at 14.7 mmol/L, which is consistent with her diabetes diagnosis.

In conclusion, the patient's outcome as a survivor is likely due to the effectiveness of her current treatment plan, which includes medications for heart failure, diabetes, and hypertension, as well as lifestyle modifications. Her laboratory results and ECG findings suggest that she has a complex cardiac condition, but her ability to survive suggests that she is being managed effectively."
181,181,P0305,"Age: 52
Gender: Male 
Weight: 71 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 160/100 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 141.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,8
LDL (mmol/L): 1,58
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 89.0
Protein (g/L): 67
T3 (pg/dL): 0,03
T4 (ng/L): 21
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,53
Urea (mg/dL): 3,99
LVEF (%): 66.0
Medications: Calcium Channel Blocker, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient's age and gender suggest that he is at an increased risk for cardiovascular events due to his sex and the fact that he is over 50 years old. His NYHA Class II classification indicates that he experiences some symptoms of heart failure, such as shortness of breath, but is still able to perform light physical activity.

The patient's blood pressure of 160/100 mmHg is elevated, which is consistent with his history of hypertension. His past medical history of ischemic dilated cardiomyopathy, myocardial infarction, and peripheral vascular disease further increases his risk of cardiovascular events. 

However, his LVEF of 66% is relatively preserved, indicating that his heart is still functioning relatively well. The patient's medications, including a calcium channel blocker, statins, and an ACE inhibitor, are appropriate for managing his hypertension and dyslipidemia, and are likely contributing to his relatively stable cardiac function.

The patient's laboratory results show elevated levels of creatinine, which may indicate kidney dysfunction, but this is not severe enough to cause significant impairment. His liver enzymes are within normal limits, and his glucose and lipid profiles are being managed with medication.

The patient's thyroid function tests are within normal limits, and his troponin level is low, indicating that he is not experiencing an acute myocardial infarction. His pro-BNP level is also within normal limits, indicating that he is not experiencing significant cardiac stress.

Given the patient's overall clinical picture, it appears that he is being effectively managed with his current medications and lifestyle modifications. His preserved LVEF and lack of acute cardiac stressors suggest that he is at low risk for immediate cardiac complications, and his survival outcome is likely due to his effective management of his cardiovascular risk factors."
182,182,P0306,"Age: 55
Gender: Male 
Weight: 78 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,04
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,88
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 453.0
Protein (g/L): 70
T3 (pg/dL): 0,03
T4 (ng/L): 22
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,52
Urea (mg/dL): 6,99
LVEF (%): 51.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's data, the patient's outcome of survival is likely due to a combination of several factors. 

1.  Optimal Medication Management: The patient is on a comprehensive medication regimen, including an Angiotensin II Receptor Blocker, Beta Blockers, Statins, and a Nitrovasodilator. These medications are commonly used to manage heart failure, hypertension, and dyslipidemia, which are all relevant to the patient's past medical history.

2.  Reasonable Left Ventricular Ejection Fraction (LVEF): Although the patient's LVEF is slightly below the normal range (LVEF > 55%), it is not severely impaired, which may indicate that the patient's heart function is still relatively preserved.

3.  Absence of Severe Electrocardiographic Abnormalities: The ECG results do not show any signs of severe arrhythmias, such as ventricular tachycardia, which could potentially lead to sudden cardiac death.

4.  Relatively Normal Renal Function: The patient's creatinine level is slightly elevated (106.0 μmol/L), but not severely impaired, indicating that the patient's kidneys are functioning reasonably well.

5.  Low Troponin Levels: The patient's troponin level is within the normal range, which suggests that there is no acute myocardial infarction occurring at the time of the assessment.

6.  Well-Controlled Blood Pressure: The patient's blood pressure is within the normal range, which is beneficial for reducing the risk of cardiovascular events.

7.  Reasonable Thyroid Function: The patient's thyroid function tests (TSH and T4) are within the normal range, which is essential for maintaining cardiac function and overall health.

Considering these factors, the patient's outcome of survival is likely due to a combination of optimal medication management, relatively preserved cardiac function, and absence of severe cardiac complications."
183,183,P0307,"Age: 51
Gender: Male 
Weight: 112 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 120/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 82.0
AST or GOT (IU/L): 37.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 13,6
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,21
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 128.0
Protein (g/L): 80
T3 (pg/dL): 0,03
T4 (ng/L): 22
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,45
Urea (mg/dL): 5,32
LVEF (%): 50.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 51-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, hypertension, and myocardial infarction, has been prescribed a comprehensive regimen of medications including calcium channel blockers, diabetes medication, beta blockers, loop diuretics, statins, ACE inhibitors, and nitrovasodilators. 

The patient's current LVEF (left ventricular ejection fraction) is 50%, indicating a mildly reduced ejection fraction, which is consistent with the diagnosis of ischemic dilated cardiomyopathy. However, the patient's LVEF is still within the range that can be managed medically, and the patient has not experienced any recent acute myocardial infarctions or decompensated heart failure episodes.

The patient's blood pressure is well-controlled at 120/75 mmHg, and the patient's glucose levels are under control with diabetes medication. The patient's lipid profile is also being managed with statins, with a total cholesterol level of 4.94 mmol/L and an LDL level of 3.21 mmol/L.

The patient's Pro-BNP level is 128 ng/L, which is elevated but not excessively high, indicating some degree of heart failure but not severe. The patient's creatinine level is within normal limits, and the patient's electrolyte levels, including potassium and sodium, are also within normal limits.

The patient's ECG shows a ventricular extrasystole, which is a common finding in patients with heart disease but not indicative of acute cardiac ischemia or arrhythmia.

Considering the patient's overall clinical picture, it appears that the patient is being effectively managed with their current medication regimen and lifestyle modifications. The patient's symptoms are likely being controlled, and the patient is at a low risk of acute cardiac events. Therefore, the patient's outcome is likely to be a survivor."
184,184,P0309,"Age: 51
Gender: Male 
Weight: 97 kg
Height: 182 cm
NYHA Class: III
Blood Pressure: 160/100 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 60.0
AST or GOT (IU/L): 50.0
Total Cholesterol (mmol/L): 5,12
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 60
Glucose (mmol/L): 10,3
Hemoglobin (g/L): 144.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 3,9
LDL (mmol/L): 3,1
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1185.0
Protein (g/L): 85
T3 (pg/dL): 0,02
T4 (ng/L): 23
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,99
Urea (mg/dL): 7,49
LVEF (%): 36.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient's outcome as a survivor is likely due to a combination of factors, including the patient's current treatment regimen and the presence of certain biomarkers that indicate a relatively stable cardiac condition. 

The patient is taking beta blockers, statins, and an ACE inhibitor, which are all standard treatments for heart failure and hypertension. Beta blockers are used to reduce the workload on the heart, statins help lower cholesterol levels, and ACE inhibitors help reduce blood pressure and alleviate strain on the heart. The patient's use of these medications suggests that they are receiving appropriate treatment for their ischemic dilated cardiomyopathy, hypertension, and dyslipemia.

The patient's LVEF (left ventricular ejection fraction) is 36%, which is lower than the normal range (50-70%), indicating some degree of heart failure. However, the patient's Pro-BNP (B-type natriuretic peptide) level is 1185.0 ng/L, which is elevated but not extremely high (normal range is < 100 ng/L). Elevated Pro-BNP levels are associated with heart failure, but a level of 1185.0 ng/L is not typically indicative of severe heart failure.

Additionally, the patient's troponin level is 0.01 ng/mL, which is within the normal range, indicating that there is no evidence of ongoing myocardial infarction. The patient's TSH (thyroid-stimulating hormone) level is 1.99 mIU/L, which is within the normal range, indicating that thyroid dysfunction is unlikely to be contributing to the patient's cardiac condition.

The patient's ECG does not show any signs of life-threatening arrhythmias, such as ventricular tachycardia or fibrillation. While the patient has a history of myocardial infarction, the current ECG and troponin level suggest that there is no ongoing cardiac ischemia.

Overall, the patient's stable medication regimen, relatively low LVEF, and lack of evidence of ongoing cardiac ischemia or arrhythmias suggest that they are likely a survivor of their cardiac condition, with a focus on ongoing management and monitoring to prevent further cardiac events."
185,185,P0310,"Age: 58
Gender: Male 
Weight: 87 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 158.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,1
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 14.0
Protein (g/L): 72
T3 (pg/dL): 0,02
T4 (ng/L): 22
Troponin (ng/mL): 0,03
TSH (mIU/L): 2,05
Urea (mg/dL): 5,83
LVEF (%): 60.0
Medications: Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 58-year-old male with a history of ischemic dilated cardiomyopathy, dyslipemia, hypertension, and myocardial infarction, has survived despite the severity of his condition. Several factors contribute to this outcome:

1.  Optimal Medication Management: The patient is on beta blockers and statins, which are essential medications for managing heart failure and reducing the risk of cardiovascular events. Beta blockers help slow the heart rate and reduce the workload on the heart, while statins lower cholesterol levels, which is crucial for preventing further cardiac damage.

2.  Normal Blood Pressure: The patient's blood pressure is within a relatively normal range (130/80 mmHg), which is beneficial for heart health. Elevated blood pressure can exacerbate heart failure and increase the risk of cardiovascular events.

3.  Slightly Elevated Creatinine: The patient's creatinine level is slightly elevated (97.0 mmol/L), indicating mild kidney impairment. However, this is not significantly impacting the patient's survival, as his kidney function is still relatively preserved.

4.  Normal TSH and T3/T4 Levels: The patient's thyroid function is within normal limits, which is crucial for maintaining heart health. Thyroid disorders can exacerbate heart failure and increase the risk of cardiovascular events.

5.  Low Pro-BNP Level: The patient's Pro-BNP level is low (14.0 ng/L), which is a good prognostic indicator for heart failure. Elevated Pro-BNP levels are associated with increased mortality and morbidity in patients with heart failure.

6.  Moderate LVEF: The patient's left ventricular ejection fraction (LVEF) is 60.0%, which is within the moderate range. While it is not ideal, an LVEF of 60% is not typically associated with severe heart failure symptoms or a high risk of mortality.

7.  Absence of Severe Arrhythmias: The patient's ECG shows no signs of severe arrhythmias, such as ventricular tachycardia or bradycardia, which can increase the risk of sudden cardiac death.

8.  Stable Hemoglobin and Electrolyte Levels: The patient's hemoglobin and electrolyte levels are within normal limits, which is essential for maintaining proper cardiac function.

Considering these factors, the patient's survival can be attributed to a combination of optimal medication management, relatively normal blood pressure, preserved kidney function, normal thyroid function, low Pro-BNP levels, moderate LVEF, and the absence of severe arrhythmias."
186,186,P0311,"Age: 64
Gender: Male 
Weight: 107 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 53.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,82
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 254
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,36
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 208.0
Protein (g/L): 73
T3 (pg/dL): 0,02
T4 (ng/L): 22
Troponin (ng/mL): 0,02
TSH (mIU/L): 3,26
Urea (mg/dL): 8,32
LVEF (%): 45.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 64-year-old male with a history of ischemic dilated cardiomyopathy, dyslipemia, hypertension, and myocardial infarction. Despite these significant cardiovascular risk factors, the patient's current medications, including beta blockers, statins, and an ACE inhibitor, are evidence-based treatments that have likely contributed to his survival. The patient's LVEF (Left Ventricular Ejection Fraction) of 45% indicates that he has some degree of left ventricular dysfunction, but it is not severe enough to be classified as heart failure. 

The patient's current blood pressure is within a relatively normal range (130/70 mmHg), which is likely a result of the ACE inhibitor therapy. The patient's lipid profile shows elevated total cholesterol and LDL levels, but the statin therapy has likely helped to reduce these levels. The patient's creatinine level is slightly elevated, which may indicate some degree of renal impairment, but it is not severe enough to be a major concern.

The patient's ECG shows evidence of ventricular extrasystoles, which can be a sign of underlying cardiac disease, but it is not a life-threatening condition. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia suggests that the patient's cardiac rhythm is relatively stable.

The patient's BNP (B-type natriuretic peptide) level is elevated at 208.0 ng/L, which can indicate heart failure or cardiac stress, but in this case, it may also be a reflection of the patient's underlying cardiac disease.

Considering these factors, the patient's survival is likely due to the combination of his current medications, his relatively stable cardiac rhythm, and the fact that his cardiac dysfunction is not severe enough to cause significant symptoms or life-threatening complications."
187,187,P0312,"Age: 69
Gender: Male 
Weight: 84 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,17
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4
LDL (mmol/L): 3,67
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 164.0
Protein (g/L): 70
T3 (pg/dL): 0,03
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,95
Urea (mg/dL): 7,49
LVEF (%): 51.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 69-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, hypertension, and myocardial infarction. Despite these comorbidities, the patient's current blood pressure is within a relatively normal range (120/70 mmHg), and his LVEF (Left Ventricular Ejection Fraction) is 51%, which is above the threshold for severe heart failure. 

The patient's laboratory results show elevated total cholesterol (5.17 mmol/L), LDL (3.67 mmol/L), and glucose levels (8.3 mmol/L), which are all risk factors for cardiovascular disease. However, the patient is on statins and diabetes medication, which suggests that these factors are being actively managed.

The patient's Pro-BNP (B-type natriuretic peptide) level is elevated at 164.0 ng/L, which is consistent with heart failure. However, the patient's LVEF is not severely reduced, and the patient is on medications that are commonly used in heart failure management, such as ACE inhibitors and beta blockers.

The ECG shows a monomorphic ventricular extrasystole, but there is no indication of sustained ventricular tachycardia or other severe arrhythmias.

Given these factors, it is likely that the patient's outcome as a survivor is due to the combination of his relatively well-managed comorbidities, the effectiveness of his current medications, and the fact that his LVEF is not severely reduced. The patient's overall health status and the fact that he is alive suggest that he is receiving appropriate care and management for his cardiovascular conditions."
188,188,P0314,"Age: 56
Gender: Male 
Weight: 62 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 55.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,66
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 133.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 23
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,12
Urea (mg/dL): 8,32
LVEF (%): 50.0
Medications: Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 56-year-old male with a history of ischemic dilated cardiomyopathy, dyslipemia, hypertension, and myocardial infarction, had a relatively favorable outcome despite his complex medical history. Several factors contributed to this outcome:

1. Current medications: The patient is on beta blockers and statins, which are crucial for managing heart failure and reducing the risk of further cardiovascular events. Beta blockers help slow the heart rate and reduce the workload on the heart, while statins lower cholesterol levels and reduce inflammation.

2. LVEF of 50%: Although the patient's left ventricular ejection fraction (LVEF) is slightly below the normal range (50-70%), it is still within the moderate range. This suggests that the patient's heart function is not severely compromised, which may have contributed to his survival.

3. Low levels of troponin: The patient's troponin level is 0.01 ng/mL, which is within the normal range. Elevated troponin levels are a marker of cardiac damage, so this low level suggests that the patient's heart has not suffered significant damage recently.

4. Normal potassium and sodium levels: The patient's potassium and sodium levels are within the normal range, which is essential for maintaining proper heart function. Electrolyte imbalances can lead to arrhythmias and other cardiac complications.

5. Pro-BNP level: The patient's pro-BNP level is 133 ng/L, which is elevated but not extremely high. Elevated BNP levels are associated with heart failure, but this level may indicate mild to moderate heart failure rather than severe heart failure.

6. ECG findings: The patient's ECG shows ventricular extrasystoles, but no signs of sustained ventricular tachycardia or bradycardia. The presence of paroxysmal supraventricular tachyarrhythmia (PSVT) is a type of abnormal heart rhythm, but it is not typically life-threatening.

7. Albumin and protein levels: The patient's albumin and protein levels are within the normal range, which suggests that his liver function is not significantly impaired.

Considering these factors, the patient's survival is likely due to a combination of his current medical treatment, relatively preserved heart function, and the absence of severe cardiac damage or electrolyte imbalances. However, it is essential to continue monitoring his condition and adjusting his treatment plan as needed to prevent further cardiac complications."
189,189,P0315,"Age: 71
Gender: Male 
Weight: 76 kg
Height: 173 cm
NYHA Class: III
Blood Pressure: 115/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 47,8
ALT or GPT (IU/L): 44.0
AST or GOT (IU/L): 51.0
Total Cholesterol (mmol/L): 3,47
Creatinine (mmol/L): 109.0
Gamma-glutamil transpeptidase (IU/L): 112
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,68
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 5342.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,02
TSH (mIU/L): 3,26
Urea (mg/dL): 4,23
LVEF (%): 22.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient's survival outcome can be attributed to a combination of factors, including the current management of his ischemic dilated cardiomyopathy and the presence of supportive medications. 

The patient's LVEF (Left Ventricular Ejection Fraction) of 22% indicates severe left ventricular dysfunction, which is a hallmark of advanced heart failure. However, the patient's current medications, including Beta Blockers, Loop Diuretics, Spironolactone, Statins, and ACE Inhibitor, are all evidence-based treatments for heart failure and have likely contributed to the patient's survival. Beta Blockers help reduce the workload on the heart, while Loop Diuretics and Spironolactone help alleviate fluid overload and reduce mortality. Statins have been shown to improve outcomes in patients with heart failure by reducing inflammation and improving cardiac function. ACE Inhibitors also help reduce afterload and improve cardiac function.

Additionally, the patient's blood pressure is well-controlled at 115/80 mmHg, which is within a normal range, further supporting the effectiveness of his current management plan. The absence of severe electrolyte imbalances, such as hypokalemia or hyperkalemia, also suggests that his current medications are not causing significant adverse effects.

The patient's low T3 and T4 levels may indicate a euthyroid state, which is not likely to have a significant impact on his cardiac function. The elevated Pro-BNP level is consistent with heart failure, but the patient's current management plan appears to be effective in managing his symptoms.

While the patient has a history of myocardial infarction, peripheral vascular disease, and non-sustained ventricular tachycardia, these conditions are being managed with his current medications, and there is no indication that they have significantly contributed to his mortality. Overall, the patient's survival outcome is likely due to the effectiveness of his current management plan and the absence of any acute or severe complications."
190,190,P0316,"Age: 71
Gender: Male 
Weight: 61 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Peripheral vascular disease, Hypertension
Albumin (g/L): 40,7
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,12
Creatinine (mmol/L): 110.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 5
LDL (mmol/L): 3,36
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1903.0
Protein (g/L): 76
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,42
Urea (mg/dL): 9,13
LVEF (%): 39.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 71-year-old male, has a history of hypertensive cardiomyopathy, peripheral vascular disease, and hypertension, which are all contributing factors to his current heart condition. The patient's ejection fraction (LVEF) is 39%, indicating reduced left ventricular function, which is a common complication of hypertensive cardiomyopathy.

The patient's Pro-BNP level is elevated at 1903.0 ng/L, which is indicative of heart failure. However, the patient is being treated with beta blockers, loop diuretics, and ACE inhibitors, which are standard treatments for heart failure and hypertension.

The patient's ECG shows polymorphic ventricular extrasystoles, which can be a sign of abnormal heart rhythm but is not typically a life-threatening condition in this context. The absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia suggests that the patient's heart rhythm is relatively stable.

The patient's laboratory results show a slightly elevated creatinine level (110.0 umol/L), which may indicate mild kidney dysfunction, but this is not uncommon in patients with heart failure and hypertension. The patient's glucose level is within the normal range, and the liver function tests (ALT and AST) are within normal limits.

Considering the patient's overall clinical picture, the patient's age, and the presence of heart failure, the most likely reason for the patient's survival is the effective management of his heart failure and hypertension with his current medication regimen. The patient's symptoms and laboratory results suggest that he is receiving adequate treatment, and his survival outcome is likely due to the timely and appropriate management of his condition."
191,191,P0318,"Age: 55
Gender: Male 
Weight: 63 kg
Height: 149 cm
NYHA Class: II
Blood Pressure: 105/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 48,3
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 6,67
Creatinine (mmol/L): 155.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 5,4
LDL (mmol/L): 3,1
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 142.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,729
Urea (mg/dL): 15,15
LVEF (%): 39.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 55-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, and dyslipemia, has been managed with a multidisciplinary approach, including medications such as beta blockers, angiotensin II receptor blockers, loop diuretics, spironolactone, and digoxin. The patient's left ventricular ejection fraction (LVEF) of 39% indicates a reduced ejection fraction, which is consistent with heart failure with reduced ejection fraction (HFrEF).

The patient's blood pressure is well-controlled at 105/70 mmHg, which is beneficial for patients with heart failure. The patient's serum creatinine level of 155.0 mmol/L indicates some degree of renal impairment, but it is not severe. The patient's glucose level is slightly elevated at 6.8 mmol/L, which is consistent with his diabetes diagnosis.

The patient's troponin level is within normal limits, indicating that there is no acute myocardial infarction. The patient's TSH level is slightly low at 0.729 mIU/L, but this is not likely to be clinically significant.

The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, but these findings are not uncommon in patients with heart failure and are not necessarily indicative of poor prognosis.

Given the patient's overall management and the absence of acute cardiac events, the patient's outcome of survival is likely due to the effectiveness of his current treatment regimen and the absence of significant acute cardiac decompensation. The patient's LVEF of 39% indicates that he still has some degree of cardiac function, which is a positive prognostic indicator. Overall, the patient's outcome of survival suggests that he is stable and well-managed, with a reasonable quality of life and a good prognosis."
192,192,P0319,"Age: 52
Gender: Male 
Weight: 89 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 44,69
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 6,31
Creatinine (mmol/L): 86.0
Gamma-glutamil transpeptidase (IU/L): 37
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 155.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,3
LDL (mmol/L): 4,68
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 984.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,39
Urea (mg/dL): 9,57
LVEF (%): 30.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient is a 52-year-old male with a history of idiopathic dilated cardiomyopathy, a condition characterized by a weakened heart muscle that impairs the heart's ability to pump blood efficiently. The patient's left ventricular ejection fraction (LVEF) of 30% indicates severe left ventricular dysfunction. 

Despite the severe heart condition, the patient is on a comprehensive treatment plan that includes medications such as ACE inhibitors, loop diuretics, and digoxin, which are commonly used to manage heart failure symptoms and improve cardiac function. The patient is also on diabetes medication, suggesting that the patient's diabetes is being managed.

The patient's blood work shows elevated levels of pro-BNP (B-type natriuretic peptide), a hormone produced by the heart in response to increased wall stress, which is consistent with heart failure. However, the patient's blood pressure is well-controlled at 100/70 mmHg, which is within the normal range.

The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are arrhythmias that can be associated with heart failure. However, the absence of sustained ventricular tachycardia and other severe arrhythmias suggests that the patient's cardiac function is not severely compromised at this time.

The patient's glucose level is slightly elevated at 6.9 mmol/L, but it is not significantly high, indicating that the diabetes is being managed. The patient's lipid profile shows a high total cholesterol level, but the LDL (bad cholesterol) level is not excessively high.

Considering the patient's comprehensive treatment plan, well-controlled blood pressure, and absence of severe arrhythmias, the patient's survival can be attributed to the effective management of their heart failure and diabetes. The patient's medication regimen and overall medical care have likely contributed to their survival."
193,193,P0323,"Age: 62
Gender: Male 
Weight: 108 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43,9
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 32.0
Total Cholesterol (mmol/L): 5,07
Creatinine (mmol/L): 139.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 176.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,92
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 535.0
Protein (g/L): 81
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,69
Urea (mg/dL): 12,03
LVEF (%): 38.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient, a 62-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction, has been managed with a multidrug regimen including beta blockers, angiotensin II receptor blockers, calcium channel blockers, loop diuretics, and nitrovasodilators. Despite these treatments, his left ventricular ejection fraction (LVEF) is severely reduced at 38%, indicating a poor cardiac function.

The patient's NT-proBNP level is elevated at 535.0 ng/L, which is consistent with heart failure symptoms and supports the diagnosis of heart failure with reduced ejection fraction (HFrEF). The presence of polymorphic ventricular extrasystoles on the ECG suggests that the patient may be experiencing arrhythmia-related complications.

However, the patient's blood pressure is well-controlled at 130/80 mmHg, which is a positive sign. His kidney function is also relatively preserved, with a creatinine level of 139.0 umol/L, and his hemoglobin level is within the normal range.

The patient's survival can be attributed to the comprehensive management of his cardiovascular disease, including the use of evidence-based medications and close monitoring. The patient's ability to tolerate his medication regimen and the absence of severe symptoms, despite his poor LVEF, also contribute to his survival."
194,194,P0324,"Age: 63
Gender: Male 
Weight: 78 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 45,59
ALT or GPT (IU/L): 40.0
AST or GOT (IU/L): 42.0
Total Cholesterol (mmol/L): 4,53
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 104
Glucose (mmol/L): 8,8
Hemoglobin (g/L): 113.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,59
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 1148.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,61
Urea (mg/dL): 7,57
LVEF (%): 34.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 63-year-old male with a history of enolic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, and hypertension. He is currently taking a combination of medications, including an angiotensin II receptor blocker, beta blockers, digoxin, loop diuretics, and spironolactone, which suggests that he is being managed for heart failure.

The patient's laboratory results indicate elevated levels of troponin (0.02 ng/mL), which may suggest some degree of cardiac injury or stress, but it is not significantly elevated. His LVEF (Left Ventricular Ejection Fraction) is 34%, which is below the normal range (50-70%), indicating left ventricular dysfunction.

The patient's Pro-BNP (brain natriuretic peptide) level is elevated at 1148 ng/L, which is consistent with heart failure. His creatinine level is elevated at 94.0 mmol/L, suggesting some degree of renal impairment, which is not uncommon in patients with heart failure.

Despite these findings, the patient is classified as NYHA Class II, indicating that he is experiencing some symptoms of heart failure but is able to perform most of his daily activities without significant limitation.

The patient's ECG shows evidence of ventricular extrasystole, non-sustained ventricular tachycardia, and unknown paroxysmal supraventricular tachyarrhythmia. However, these findings are not uncommon in patients with heart failure and are not necessarily indicative of a poor prognosis.

Given the patient's history, laboratory results, and ECG findings, it is likely that he is being managed for heart failure, and his medications are aimed at reducing symptoms, improving cardiac function, and preventing further cardiac complications. The fact that he is classified as a survivor suggests that his current management plan is effective in managing his condition, and he is able to tolerate his medications without significant adverse effects.

However, it is essential to continue monitoring his condition closely, adjusting his medications as needed, and addressing any potential complications that may arise. Regular follow-up appointments with his cardiologist and other healthcare providers will be crucial in ensuring that his condition remains stable and that he continues to have a good quality of life."
195,195,P0325,"Age: 53
Gender: Male 
Weight: 99 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 125/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 48,8
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,58
Creatinine (mmol/L): 83.0
Gamma-glutamil transpeptidase (IU/L): 230
Glucose (mmol/L): 11,5
Hemoglobin (g/L): 153.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,15
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 171.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,09
Urea (mg/dL): 5,79
LVEF (%): 50.0
Medications: Diabetes Medication, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient's outcome of survival can be attributed to several factors, both positive and negative, as seen in the provided data. 

Positive factors contributing to the patient's survival include:

1. Current Medications: The patient is on a combination of diabetes medication, loop diuretics, statins, and nitrovasodilators, which are all aimed at managing the patient's underlying conditions. The use of these medications suggests that the patient has been receiving appropriate care for their ischemic dilated cardiomyopathy, diabetes, and hypertension.

2. LVEF (Left Ventricular Ejection Fraction): Although the patient's LVEF is slightly below the normal range (50%), it is still within a range that can be managed with medical therapy. An LVEF of 50% indicates that the heart is still pumping blood effectively, which is a positive sign for survival.

3. TSH (Thyroid-Stimulating Hormone): The patient's TSH level is within the normal range, indicating that the thyroid function is not contributing to any cardiac issues.

4. Glucose Control: The patient's glucose level is slightly elevated (11.5 mmol/L), but it is not severely high. Good glucose control is essential for patients with diabetes, and this level suggests that the patient's diabetes is being managed.

Negative factors that could have contributed to a worse outcome include:

1. Ischemic Dilated Cardiomyopathy: The patient's history of ischemic dilated cardiomyopathy increases their risk of heart failure and arrhythmias. However, the fact that they are still alive suggests that their condition is being managed effectively.

2. Myocardial Infarction: The patient's history of myocardial infarction increases their risk of future cardiovascular events. However, the fact that they have survived this long suggests that their heart has adapted to the damage.

3. Ventricular Extrasystole: The presence of ventricular extrasystoles on the ECG can be a sign of underlying cardiac disease, but in this case, it is not severe enough to suggest a worse outcome.

4. Hypertension: The patient's blood pressure is within a relatively normal range (125/85 mmHg), which is a positive sign for survival.

5. Creatinine Level: The patient's creatinine level is elevated (83.0 mmol/L), which suggests some degree of renal impairment. However, this is not severe enough to suggest a worse outcome.

6. Gamma-glutamil transpeptidase (GGT): The patient's GGT level is elevated (230 IU/L), which can indicate liver disease or alcohol use. However, this is not directly related to the patient's cardiac outcome.

In summary, the combination of the patient's current medications, relatively good LVEF, and normal TSH level, along with the lack of severe cardiac arrhythmias or significantly elevated creatinine level, all contribute to the patient's survival."
196,196,P0326,"Age: 67
Gender: Male 
Weight: 78 kg
Height: 157 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease
Albumin (g/L): 52,4
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,09
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,89
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 298.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,29
Urea (mg/dL): 4,9
LVEF (%): 34.0
Medications: Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 67-year-old male, has a history of idiopathic dilated cardiomyopathy, which is a condition characterized by the enlargement and weakening of the heart muscle, leading to reduced heart function. The patient's left ventricular ejection fraction (LVEF) of 34% is significantly below the normal range (50-70%), indicating severe heart failure.

The patient's blood pressure is within a relatively normal range (140/80 mmHg), but the elevated levels of natriuretic peptides (Pro-BNP 298.0 ng/L) suggest that the patient's heart is under strain, likely due to the underlying cardiomyopathy.

The patient's lipid profile shows high levels of LDL cholesterol (1.89 mmol/L) and low levels of HDL cholesterol (1.29 mmol/L), which is a risk factor for cardiovascular disease. However, the patient is on statin therapy, which helps to manage cholesterol levels.

The patient's liver function tests (ALT and AST) are within normal limits, which suggests that the liver is functioning properly and not contributing to the patient's condition.

The patient's kidney function, as indicated by the creatinine level (106.0 μmol/L), is slightly elevated, which may be a sign of mild kidney impairment. However, the urea level (4.9 mg/dL) is within normal limits.

The patient's thyroid function tests (TSH 2.29 mIU/L, T3 0.05 pg/dL, T4 19 ng/L) are within normal limits, which suggests that the thyroid is functioning properly and not contributing to the patient's condition.

The patient's ECG shows monomorphic ventricular extrasystoles, which are premature heartbeats originating from the ventricles. However, this finding is not uncommon in patients with heart failure and is not a significant concern in this case.

Considering the patient's overall clinical presentation, including the history of idiopathic dilated cardiomyopathy, reduced LVEF, elevated natriuretic peptides, and normal kidney and liver function, the patient's outcome of survival is likely due to the following factors:

1.  Optimal medical therapy: The patient is on spironolactone, statins, and ACE inhibitors, which are all evidence-based treatments for heart failure and cardiomyopathy.
2.  Mild kidney function impairment: The patient's kidney function is not severely impaired, which reduces the risk of complications and allows the patient to tolerate the medication regimen.
3.  Normal thyroid function: The patient's thyroid function is normal, which reduces the risk of thyroid-related complications.
4.  Absence of severe arrhythmias: The patient does not have severe arrhythmias, such as ventricular tachycardia, which can increase the risk of sudden cardiac death.

Overall, the patient's survival is likely due to a combination of optimal medical therapy, mild kidney function impairment, normal thyroid function, and the absence of severe arrhythmias."
197,197,P0328,"Age: 64
Gender: Male 
Weight: 84 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 48,7
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 6,21
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,8
LDL (mmol/L): 4,42
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 511.0
Protein (g/L): 76
T3 (pg/dL): 0,03
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,22
Urea (mg/dL): 6,68
LVEF (%): 35.0
Medications: Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 64-year-old male with a history of ischemic dilated cardiomyopathy, dyslipemia, peripheral vascular disease, hypertension, and myocardial infarction. His current NYHA Class II classification indicates that he has some limitations in physical activity, but he is still able to perform everyday activities without severe symptoms.

The patient's laboratory results show elevated levels of troponin (0.01 ng/mL), indicating previous myocardial damage, but it is within a non-significant range. The elevated Pro-BNP (511.0 ng/L) suggests increased stress on the heart, which is consistent with his history of heart disease. However, the patient's hemoglobin (148.0 g/L) is within a normal range, indicating adequate oxygen delivery to tissues.

The patient's lipid profile shows elevated total cholesterol (6.21 mmol/L) and LDL (4.42 mmol/L) levels, which are above the recommended levels. His HDL (1.16 mmol/L) is low, indicating a higher risk of cardiovascular disease. The patient is already on statins, which should help manage his lipid profile.

The patient's kidney function, as indicated by creatinine (93.0 mmol/L), is slightly elevated, but not significantly abnormal. His urea (6.68 mg/dL) is within a normal range.

The patient's TSH (1.22 mIU/L) is within a normal range, indicating that his thyroid function is normal. His T3 (0.03 pg/dL) and T4 (14 ng/L) levels are also within normal ranges.

The patient's ECG shows a monomorphic ventricular extrasystole, which is a common finding in patients with heart disease. There is no evidence of sustained ventricular tachycardia or other serious arrhythmias.

Considering the patient's history, laboratory results, and ECG findings, it is likely that the patient is a survivor because:

1. He has a history of heart disease, but his current medications (beta blockers, statins, and nitrovasodilators) are likely helping to manage his symptoms and prevent further cardiac events.
2. His laboratory results indicate that his kidney function is not significantly impaired, which suggests that he does not have severe cardiac failure.
3. His hemoglobin level is within a normal range, indicating that his oxygen delivery to tissues is adequate.
4. His lipid profile is being managed with statins, which should help reduce his risk of cardiovascular events.
5. His ECG findings are not indicative of a serious cardiac arrhythmia, and his TSH and thyroid function are normal, indicating that there is no underlying thyroid disease contributing to his cardiac condition.

Overall, the patient's current treatment plan and laboratory results suggest that he is being managed effectively for his heart disease, and his outcome as a survivor is likely due to the effectiveness of his treatment and his overall health status."
198,198,P0331,"Age: 52
Gender: Female 
Weight: 82 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 125/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,28
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 720.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,74
Urea (mg/dL): 8,02
LVEF (%): 37.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient outcome of survival can be attributed to several factors based on the provided data.

Firstly, the patient's current medications, including Angiotensin II Receptor Blocker, Beta Blockers, and Statins, are evidence-based treatments for ischemic dilated cardiomyopathy, hypertension, and dyslipemia. These medications have been shown to improve cardiac function, reduce symptoms, and decrease the risk of adverse outcomes in patients with heart failure.

The patient's LVEF (Left Ventricular Ejection Fraction) of 37% indicates that the heart is still functioning, albeit with reduced efficiency. This suggests that the patient's cardiomyopathy is not in an advanced stage, and there is still some residual cardiac function.

The patient's blood pressure of 125/70 mmHg is within a relatively normal range, which is beneficial for heart health. Additionally, the patient's low levels of Troponin (0.01 ng/mL) indicate that there is no ongoing myocardial infarction, which is a positive sign.

The patient's TSH (2.74 mIU/L) is within the normal range, indicating that there are no signs of thyroid dysfunction, which can sometimes contribute to cardiac issues.

The patient's Pro-BNP (720.0 ng/L) is elevated, but not excessively high, which may indicate some degree of heart failure, but not to a severe extent.

The patient's albumin and protein levels are within normal ranges, which suggests that there is no significant malnutrition or liver dysfunction contributing to the patient's condition.

Overall, while the patient has a history of ischemic dilated cardiomyopathy, myocardial infarction, and other comorbidities, the combination of evidence-based medications, relatively preserved cardiac function, and absence of acute myocardial infarction or severe thyroid dysfunction likely contributed to the patient's survival."
199,199,P0334,"Age: 52
Gender: Male 
Weight: 83 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 50,09
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,92
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 136.0
Protein (g/L): 78
T3 (pg/dL): 0,04
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,36
Urea (mg/dL): 9,8
LVEF (%): 32.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 52-year-old male with a history of ischemic dilated cardiomyopathy, dyslipemia, hypertension, and myocardial infarction, has a relatively favorable outcome. Several factors contribute to this outcome:

1. Effective Medication Adherence: The patient is on a comprehensive medication regimen, including a calcium channel blocker, beta blockers, statins, and an ACE inhibitor, which are all standard treatments for heart failure and cardiovascular disease. This suggests that the patient is receiving appropriate medical care.

2. Controlled Blood Pressure: The patient's blood pressure is within a relatively normal range (120/80 mmHg), which is essential for patients with cardiovascular disease.

3. LVEF (Left Ventricular Ejection Fraction) of 32%: Although the patient has a reduced LVEF, indicating impaired left ventricular function, it is not extremely low. The patient's LVEF is still within the range where medical management can be effective in managing heart failure symptoms and preventing further deterioration.

4. Low Pro-BNP (Brain Natriuretic Peptide) Levels: The patient's Pro-BNP level is 136.0 ng/L, which is relatively low. Elevated Pro-BNP levels are often associated with heart failure and poor prognosis. A low level suggests that the patient's heart function is not severely compromised.

5. Absence of Severe Electrocardiogram (ECG) Abnormalities: The ECG findings of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia are concerning but not severe. The absence of paroxysmal supraventricular tachyarrhythmia and bradycardia suggests that the patient's cardiac rhythm is relatively stable.

6. Hemoglobin and Potassium Levels: The patient's hemoglobin level is within the normal range, and his potassium level is slightly low but not critically low. Both of these factors are important for cardiac function.

7. Absence of Severe Liver Function Abnormalities: The patient's liver function tests (ALT, AST, GGT, and Albumin) are within relatively normal ranges, indicating that liver function is not severely compromised.

8. Glucose and Lipid Levels: The patient's glucose and lipid profiles are not severely abnormal, which is important for cardiovascular health.

Considering these factors, the patient's outcome can be attributed to a combination of effective medical management, relatively controlled blood pressure, and the absence of severe cardiac and liver function abnormalities."
200,200,P0335,"Age: 44
Gender: Male 
Weight: 90 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 42,8
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 3,41
Creatinine (mmol/L): 78.0
Gamma-glutamil transpeptidase (IU/L): 38
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 161.0
HDL (mmol/L): 0,57
Potassium (mEq/L): 4,3
LDL (mmol/L): 1,55
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 522.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,03
Urea (mg/dL): 7,35
LVEF (%): 25.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's survival can be attributed to a combination of factors, including the presence of a well-managed medical regimen, the patient's overall physiological reserve, and the absence of severe comorbidities. 

Firstly, the patient is on a comprehensive treatment plan consisting of beta blockers, spironolactone, statins, and an ACE inhibitor, which are all standard therapies for managing idiopathic dilated cardiomyopathy, hypertension, and dyslipidemia. These medications help to reduce the workload on the heart, lower blood pressure, and prevent further cardiac damage.

Secondly, despite having a low left ventricular ejection fraction (LVEF) of 25%, the patient's overall physiological reserve appears to be relatively preserved. The patient's hemoglobin level is within a normal range, and there is no indication of severe anemia or malnutrition, which are often associated with poor outcomes in heart failure patients. Additionally, the patient's serum albumin and protein levels are within normal limits, indicating adequate nutritional status.

Thirdly, the patient's blood pressure is well-controlled, with a systolic blood pressure of 100 mmHg, which is lower than the typical target of 120-130 mmHg for patients with heart failure. This suggests that the patient's blood pressure is being effectively managed, reducing the risk of further cardiac damage.

Lastly, the absence of severe comorbidities, such as severe kidney disease (creatinine 78.0 μmol/L), electrolyte imbalances (potassium 4.3 mEq/L), or severe anemia (hemoglobin 161.0 g/L), also contributes to the patient's survival.

However, it is essential to note that the patient's Pro-BNP level is elevated at 522.0 ng/L, which suggests that the patient still has significant cardiac stress and may require further optimization of their medical regimen or consideration of more advanced therapies, such as cardiac resynchronization therapy or an implantable cardioverter-defibrillator."
201,201,P0337,"Age: 55
Gender: Male 
Weight: 88 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 160/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 48,7
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 6,54
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 60
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 157.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 3,6
LDL (mmol/L): 4,03
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 209.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,544
Urea (mg/dL): 10,24
LVEF (%): 67.0
Medications: Calcium Channel Blocker, Angiotensin II Receptor Blocker, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient survived despite having multiple risk factors for cardiovascular disease and heart failure. Several factors contributed to this outcome:

1. Effective Medication Management: The patient is on a comprehensive regimen of medications, including a calcium channel blocker, angiotensin II receptor blocker, beta blockers, and statins. These medications are commonly used to manage hypertension, heart failure, and dyslipidemia, which are all relevant to this patient's condition. The use of these medications likely helped to stabilize the patient's cardiovascular system and prevent further deterioration.

2. Preserved LVEF: The patient's left ventricular ejection fraction (LVEF) is 67%, which is within the normal range (50-70%). This suggests that the patient's heart is still functioning relatively well, and the patient is not in advanced heart failure.

3. Mild Hypertension: The patient's blood pressure is 160/85 mmHg, which is considered mildly elevated but not severely hypertensive. This may indicate that the patient's hypertension is under control with medication.

4. No Indication of Severe Cardiac Damage: The patient's troponin level is 0.01 ng/mL, which is within the normal range. This suggests that there is no indication of recent cardiac damage or myocardial infarction.

5. No Sustained Ventricular Tachycardia: The ECG does not show any indication of sustained ventricular tachycardia, which is a significant risk factor for sudden cardiac death.

6. Normal Thyroid Function: The patient's thyroid-stimulating hormone (TSH) level is within the normal range, which suggests that the patient's thyroid function is not contributing to any cardiac issues.

7. No Severe Kidney Dysfunction: The patient's creatinine level is 96.0 μmol/L, which is slightly elevated but not severely abnormal. This suggests that the patient's kidney function is not significantly impaired.

8. Pro-BNP Level: The patient's pro-B-type natriuretic peptide (pro-BNP) level is 209.0 ng/L, which is slightly elevated but not severely abnormal. This suggests that the patient's heart is under some stress, but not to the extent that would indicate severe heart failure.

Overall, the combination of effective medication management, preserved LVEF, mild hypertension, and no indication of severe cardiac damage or kidney dysfunction contributed to the patient's survival."
202,202,P0338,"Age: 75
Gender: Male 
Weight: 63 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 52,19
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,3
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 38
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 145.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,31
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1121.0
Protein (g/L): 79
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,43
Urea (mg/dL): 5,79
LVEF (%): 39.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient, a 75-year-old male with a history of enolic dilated cardiomyopathy, myocardial infarction, dyslipemia, and hypertension, presents with several factors that contribute to his outcome as a survivor. 

1. Current Medications: The patient is on a comprehensive regimen of medications, including Digoxin, Loop Diuretics, Statins, and an ACE Inhibitor. These medications are aimed at managing heart failure symptoms, reducing blood pressure, and lowering cholesterol levels. The use of ACE inhibitors, in particular, is beneficial in patients with heart failure as it has been shown to improve survival and reduce hospitalization rates.

2. NYHA Class II: The patient's New York Heart Association (NYHA) functional classification of II indicates that he has mild symptoms of heart failure, such as shortness of breath when walking up stairs or on level ground, but is comfortable at rest. This classification suggests that the patient's heart failure is not severe and is manageable with current treatment.

3. LVEF of 39%: Although the patient's left ventricular ejection fraction (LVEF) is low at 39%, indicating impaired heart function, it is not as low as expected in a patient with dilated cardiomyopathy. An LVEF of 39% suggests that the patient's heart is still pumping some blood efficiently, which contributes to his survival.

4. Pro-BNP levels: The patient's Pro-BNP (brain natriuretic peptide) level of 1121.0 ng/L is elevated, which is indicative of heart failure. However, the level is not extremely high, suggesting that the patient's heart failure is not severe.

5. ECG findings: The patient has several ECG abnormalities, including ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia. While these findings indicate some cardiac electrical instability, they are not life-threatening in this context.

6. Laboratory results: The patient's laboratory results, including normal hemoglobin, potassium, and urea levels, suggest that his kidney function is relatively preserved. The patient's total cholesterol and LDL levels are also under control with statin therapy.

Considering these factors, the patient's survival outcome is likely due to the combination of his current medications, relatively well-managed heart failure symptoms, and preserved kidney function."
203,203,P0341,"Age: 61
Gender: Female 
Weight: 85 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 47
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 32.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 89.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 146.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,4
LDL (mmol/L): 3
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 485.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,706
Urea (mg/dL): 7,12
LVEF (%): 30.0
Medications: Angiotensin II Receptor Blocker, Digoxin, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient is a 61-year-old female with a history of hypertensive cardiomyopathy and hypertension. The patient has a reduced left ventricular ejection fraction (LVEF) of 30%, indicating systolic heart failure. However, the patient's condition is well-managed with medications such as an Angiotensin II Receptor Blocker, Digoxin, and Statins, which are commonly used to treat heart failure and hypertension.

The patient's blood pressure is within a relatively normal range (140/80 mmHg), and the absence of sustained ventricular tachycardia and bradycardia on the ECG suggests that the patient's cardiac rhythm is relatively stable.

The patient's laboratory results show mild elevations in liver enzymes (ALT and AST), but these are not significantly elevated, suggesting that the liver is not severely affected. The patient's total cholesterol and LDL levels are within relatively normal ranges, indicating that the patient is receiving effective treatment for hyperlipidemia.

The patient's Pro-BNP level is elevated at 485.0 ng/L, which is consistent with heart failure, but the patient's overall clinical picture and laboratory results suggest that the patient is being effectively managed for heart failure.

The patient's TSH level is within a normal range, indicating that the patient's thyroid function is not significantly abnormal. The patient's Troponin level is normal, suggesting that there is no acute myocardial infarction.

The patient's LVEF of 30% indicates that the patient has a reduced ejection fraction, but the patient's overall clinical picture and laboratory results suggest that the patient is being effectively managed for heart failure, and the patient's survival outcome is likely due to the effectiveness of the patient's treatment regimen.

Therefore, the patient's survival outcome can be attributed to the effective management of their heart failure and hypertension, as well as the use of appropriate medications to manage their condition."
204,204,P0342,"Age: 66
Gender: Male 
Weight: 75 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 42,9
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,93
Creatinine (mmol/L): 143.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 11,9
Hemoglobin (g/L): 123.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,42
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 2416.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 19,55
Urea (mg/dL): 12,69
LVEF (%): 50.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient's survival can be attributed to several factors despite having a complex medical history and current condition. 

1.  Optimal Medication Regimen: The patient is on a comprehensive medication regimen, which includes a Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, and Statins. This combination of medications helps to manage hypertension, diabetes, heart failure, and dyslipidemia, which are all contributing factors to his condition.

2.  Early Detection and Management of Ischemic Dilated Cardiomyopathy: The patient has been diagnosed with ischemic dilated cardiomyopathy, a condition that can lead to heart failure. Early detection and management of this condition through medication and lifestyle changes have likely contributed to his survival.

3.  Regular Monitoring and Follow-up: The patient's medical history and lab results suggest regular monitoring and follow-up with his healthcare provider, which is crucial in managing chronic conditions such as heart failure and diabetes.

4.  Good Hemoglobin Levels: The patient's hemoglobin level is within a normal range (123 g/L), which is essential for maintaining adequate oxygen delivery to tissues and organs.

5.  Moderate Creatinine Levels: Although the patient has a slightly elevated creatinine level (143.0 mmol/L), it is not significantly high, indicating that his kidney function is still relatively preserved. This suggests that the patient's medications, such as the Angiotensin II Receptor Blocker, are helping to manage his kidney function.

6.  Low TSH Levels: The patient's TSH level is elevated (19.55 mIU/L), but not excessively high. This suggests that his thyroid function is being monitored, and any potential thyroid-related issues are being addressed.

7.  Low T3 Levels: The patient's T3 level is low (0.05 pg/dL), which may be a result of his medication regimen, particularly the beta blockers, which can affect thyroid function.

8.  Pro-BNP Levels: The patient's Pro-BNP level is elevated (2416.0 ng/L), indicating that his heart failure is being monitored and managed.

9.  ECG Findings: Although the patient has various ECG abnormalities, including ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia, they are not life-threatening and are being managed through medication.

In summary, the patient's survival can be attributed to a combination of optimal medication management, regular monitoring, and follow-up, as well as good hemoglobin and kidney function levels."
205,205,P0344,"Age: 56
Gender: Male 
Weight: 110 kg
Height: 176 cm
NYHA Class: III
Blood Pressure: 180/100 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 43,9
ALT or GPT (IU/L): 135.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 7,34
Creatinine (mmol/L): 98.0
Gamma-glutamil transpeptidase (IU/L): 95
Glucose (mmol/L): 6
Hemoglobin (g/L): 170.0
HDL (mmol/L): 1,94
Potassium (mEq/L): 4,5
LDL (mmol/L): 4,45
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 466.0
Protein (g/L): 78
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,55
Urea (mg/dL): 6,68
LVEF (%): 35.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 56-year-old male with a history of enolic dilated cardiomyopathy and hypertension, has a complex set of clinical and laboratory findings. His NYHA Class III classification indicates that he has severe symptoms of heart failure, such as shortness of breath, fatigue, and swelling, which significantly limit his physical activity.

The patient's laboratory results show elevated levels of liver enzymes (ALT and GGT), which may indicate liver dysfunction or fatty liver disease. His total cholesterol level is elevated, which is a risk factor for cardiovascular disease. The patient's creatinine level is slightly elevated, indicating mild kidney impairment. His hemoglobin level is slightly elevated, which may be a sign of dehydration or anemia. His potassium level is within the normal range, which is good.

The patient's LVEF (left ventricular ejection fraction) is severely reduced at 35%, indicating that his heart is not pumping efficiently. His Pro-BNP level is elevated, which is consistent with heart failure. His TSH level is within the normal range, and his T3 and T4 levels are within the normal range, indicating that his thyroid function is normal.

The patient's ECG shows polymorphic ventricular extrasystoles, which are abnormal heartbeats that can be a sign of cardiac arrhythmia. However, there is no evidence of sustained ventricular tachycardia or other serious arrhythmias.

Given the patient's complex medical history, laboratory results, and ECG findings, the most likely reason for his survival is that he is receiving appropriate medical treatment for his enolic dilated cardiomyopathy and hypertension. His medications, including angiotensin II receptor blockers, beta blockers, and loop diuretics, are likely helping to manage his symptoms and slow the progression of his heart disease.

Additionally, the patient's survival may be attributed to his relatively high hemoglobin level, which may be a sign of good cardiac output and adequate oxygen delivery to his tissues. His normal TSH and T3/T4 levels also suggest that his thyroid function is not contributing to his heart failure.

Overall, the patient's survival is likely due to a combination of his medical treatment, his relatively stable laboratory results, and the absence of any acute cardiac events or other serious complications."
206,206,P0347,"Age: 65
Gender: Male 
Weight: 69 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 46
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 14,5
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,46
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 500.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,05
Urea (mg/dL): 10,47
LVEF (%): 40.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 65-year-old male with a complex medical history, including ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, and a previous myocardial infarction. His current medications include a calcium channel blocker, diabetes medication, beta blockers, statins, ACE inhibitor, and nitrovasodilator, which suggests that he is being managed for his heart failure and cardiovascular risk factors.

The patient's left ventricular ejection fraction (LVEF) is 40%, indicating that he has systolic heart failure. His elevated pro-BNP (brain natriuretic peptide) level of 500.0 ng/L further supports the presence of heart failure.

The patient's ECG shows polymorphic ventricular extrasystoles, which are abnormal heartbeats originating in the ventricles. However, there is no evidence of sustained ventricular tachycardia, which is a more serious arrhythmia.

The patient's laboratory results show:

* Elevated total cholesterol (4.45 mmol/L) and LDL (2.46 mmol/L) levels, indicating dyslipemia.
* Elevated glucose (14.5 mmol/L) level, indicating uncontrolled diabetes.
* Normal potassium (4.2 mEq/L) and sodium (140.0 mEq/L) levels.
* Elevated creatinine (94.0 μmol/L) level, indicating impaired renal function.
* Elevated urea (10.47 mg/dL) level, indicating impaired renal function.
* Normal liver function tests (ALT, AST, GGT).

Given the patient's complex medical history, the presence of heart failure, and the current medications, the patient's outcome as a survivor can be attributed to the following factors:

1.  The patient is receiving appropriate medical therapy for his heart failure and cardiovascular risk factors, including beta blockers, ACE inhibitors, and statins.
2.  The patient's LVEF of 40% is not as low as it could be, indicating that the patient's heart function is still relatively preserved.
3.  The patient's ECG does not show any signs of life-threatening arrhythmias, such as sustained ventricular tachycardia.
4.  The patient's laboratory results do not show any acute kidney injury or liver dysfunction, which could have contributed to a poorer outcome.

In summary, the patient's outcome as a survivor can be attributed to the effectiveness of his current medical therapy, the relatively preserved left ventricular function, and the absence of life-threatening arrhythmias or acute organ dysfunction."
207,207,P0348,"Age: 60
Gender: Male 
Weight: 79 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 54,4
ALT or GPT (IU/L): 55.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 3,47
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 7,4
Hemoglobin (g/L): 160.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,84
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 266.0
Protein (g/L): 74
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,01
Urea (mg/dL): 7,8
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient outcome is a survivor due to a combination of factors, including the patient's current medical management and the severity of their underlying heart condition. 

Firstly, the patient's ischemic dilated cardiomyopathy is a significant concern, with a left ventricular ejection fraction (LVEF) of 35%, indicating reduced heart function. However, the patient is currently on beta blockers and statins, which are standard treatments for heart failure and high cholesterol, respectively. These medications likely contribute to the patient's improved survival.

The patient's glucose level is well-controlled at 7.4 mmol/L, which is within the target range for diabetes management. This suggests that the patient's diabetes is under control, reducing the risk of complications.

The patient's electrolyte levels, including potassium (4.7 mEq/L) and sodium (140 mEq/L), are within the normal range. This is crucial for maintaining proper heart function.

The patient's troponin level is 0.01 ng/mL, which is within the normal range, indicating that there is no ongoing myocardial infarction or acute cardiac injury.

The patient's TSH level is 3.01 mIU/L, which is within the normal range, indicating that the patient's thyroid function is normal.

The patient's pro-BNP level is 266.0 ng/L, which is elevated but not extremely high. Elevated pro-BNP levels are often seen in patients with heart failure, but this level is not so high that it would suggest severe heart failure.

The patient's ECG is normal, with no signs of ventricular extrasystole, ventricular tachycardia, non-sustained ventricular tachycardia, paroxysmal supraventricular tachyarrhythmia, or bradycardia.

Considering these factors, the patient's outcome as a survivor is likely due to the effectiveness of their current medical management, including their medications and controlled glucose levels. The patient's reduced LVEF and elevated pro-BNP level suggest that they still require close monitoring and management of their heart failure, but the patient's current condition does not suggest an immediate life-threatening outcome."
208,208,P0350,"Age: 76
Gender: Female 
Weight: 89 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 37,2
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,35
Creatinine (mmol/L): 125.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 120.0
HDL (mmol/L): 1,53
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,03
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 480.0
Protein (g/L): 69
T3 (pg/dL): 0,03
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,25
Urea (mg/dL): 16,03
LVEF (%): 32.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 76-year-old female with a history of Hypertensive cardiomyopathy and hypertension. She is currently on a treatment regimen consisting of an Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, and Spironolactone, which is appropriate for her condition.

Her NYHA Class III classification indicates that she experiences symptoms of heart failure, such as shortness of breath and fatigue, when performing moderate physical activity. However, her LVEF of 32% is relatively low, indicating significant left ventricular dysfunction.

The patient's laboratory results show elevated Creatinine levels (125.0 mmol/L), indicating renal impairment. Her Pro-BNP level of 480.0 ng/L is also elevated, which is consistent with heart failure. However, her Troponin level is within normal limits, suggesting that she does not have acute coronary syndrome.

The patient's ECG shows monomorphic ventricular extrasystoles, but no signs of sustained ventricular tachycardia or other life-threatening arrhythmias. Her TSH level is slightly elevated, but not significantly so, and her T4 level is within normal limits.

Given the patient's age, comorbidities, and treatment regimen, it is not surprising that she is a survivor. The combination of medications she is taking, including Beta Blockers and Loop Diuretics, is likely helping to manage her symptoms and slow the progression of her heart failure. Additionally, her low LVEF and renal impairment suggest that she may be at higher risk for complications, but her survival suggests that her treatment plan is effective in managing her condition."
209,209,P0352,"Age: 51
Gender: Male 
Weight: 85 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 46,3
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,72
Creatinine (mmol/L): 109.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 148.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,88
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 239.0
Protein (g/L): 80
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,66
Urea (mg/dL): 8,24
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 51-year-old male with a history of ischemic dilated cardiomyopathy and myocardial infarction, has a relatively favorable outcome despite a low left ventricular ejection fraction (LVEF) of 35%. This suggests that the patient's heart is still pumping efficiently enough to maintain adequate blood flow and oxygenation to vital organs. 

Several factors contribute to the patient's survival:

1.  Current Medications: The patient is on a combination of calcium channel blockers, beta blockers, and an ACE inhibitor, which are standard treatments for heart failure and ischemic cardiomyopathy. These medications help to reduce blood pressure, slow the heart rate, and improve cardiac output.

2.  Blood Pressure and Electrolytes: The patient's blood pressure is within a relatively normal range (110/70 mmHg), and his potassium levels are also within the normal range (4.3 mEq/L). This suggests that the patient's cardiac function is not significantly compromised by electrolyte imbalances.

3.  Lack of Complications: The ECG does not show any signs of ventricular arrhythmias, bradycardia, or other potentially life-threatening cardiac conditions. This indicates that the patient's heart is not experiencing any acute or chronic arrhythmias that could compromise cardiac function.

4.  Minimal Organ Dysfunction: The patient's creatinine level is elevated (109.0 μmol/L), but not significantly, suggesting that renal function is not severely impaired. His albumin and protein levels are also within normal limits, indicating that liver function is not significantly compromised.

5.  TSH and Thyroid Function: The patient's thyroid-stimulating hormone (TSH) level is within the normal range (1.66 mIU/L), indicating that thyroid function is not a contributing factor to the patient's cardiac condition.

6.  Low Troponin Levels: The patient's troponin level is low (0.01 ng/mL), indicating that there is no evidence of ongoing myocardial infarction or ischemia.

Considering these factors, the patient's survival can be attributed to the effectiveness of his current treatment regimen, the absence of acute or chronic complications, and the relatively preserved cardiac function despite a low LVEF."
210,210,P0353,"Age: 78
Gender: Male 
Weight: 75 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,71
Creatinine (mmol/L): 140.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,9
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 4518.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,63
Urea (mg/dL): 14,92
LVEF (%): 15.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Digoxin, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient's outcome of survival is likely due to a combination of several factors:

1. Optimal medical management: The patient is on a regimen of medications that are commonly used to manage heart failure and hypertension, including an angiotensin II receptor blocker, digoxin, spironolactone, and a nitrovasodilator. These medications are likely helping to manage the patient's symptoms and slow the progression of the disease.

2. Low troponin levels: The patient's troponin level is within normal limits (0.01 ng/mL), which suggests that there is no ongoing myocardial infarction or significant cardiac damage.

3. Moderate NYHA class: The patient's New York Heart Association (NYHA) class is II, indicating that they have some symptoms of heart failure, but are still able to perform light physical activity without significant limitation. This suggests that the patient's heart function is not severely impaired.

4. Reasonable LVEF: The patient's left ventricular ejection fraction (LVEF) is 15%, which is a significant impairment, but not as severe as some other patients with ischemic dilated cardiomyopathy. The LVEF is still within the range of patients who can survive with medical management.

5. No acute decompensation: The patient's laboratory values, such as creatinine and urea levels, are not significantly elevated, which suggests that there is no acute decompensation of the heart failure.

6. No severe electrolyte imbalance: The patient's potassium level is within normal limits, which is important for maintaining proper cardiac function.

7. Appropriate medication adjustments: The patient's medications have been adjusted to manage their symptoms and slow the progression of the disease. The presence of spironolactone and digoxin suggests that the patient's heart failure is being managed, and the nitrovasodilator is helping to reduce the workload on the heart.

8. TSH and T4 levels within normal limits: The patient's thyroid function is within normal limits, which is important for maintaining proper cardiac function.

Overall, the patient's survival is likely due to a combination of optimal medical management, low troponin levels, moderate NYHA class, reasonable LVEF, no acute decompensation, no severe electrolyte imbalance, and appropriate medication adjustments."
211,211,P0354,"Age: 54
Gender: Male 
Weight: 61 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 120/78 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 43,5
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 6,39
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 159.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,5
LDL (mmol/L): 4,06
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 123.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,442
Urea (mg/dL): 8,91
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type II
            ",survivor,"REASONING: 

Given the patient's medical history and the provided data, the patient outcome of survival can be attributed to several factors:

1. Aggressive management of cardiovascular risk factors: The patient is on a statin, which suggests that the management of dyslipemia is being addressed. Additionally, the patient is on beta blockers, which are effective in reducing the risk of myocardial infarction and mortality in patients with ischemic heart disease.

2. Optimal blood pressure control: The patient's blood pressure is within a normal range (120/78 mmHg), which is crucial in preventing further cardiovascular events and reducing the strain on the heart.

3. Control of heart rate: The patient is on a calcium channel blocker and a nitrovasodilator, which suggests that the heart rate is being controlled, reducing the workload on the heart.

4. Monitoring and management of cardiac function: The patient's LVEF (Left Ventricular Ejection Fraction) is 35%, indicating that the heart is still pumping effectively, albeit at a reduced capacity. This suggests that the patient's cardiac function is being closely monitored and managed.

5. Absence of severe electrolyte imbalances: The patient's potassium level is within a normal range (4.5 mEq/L), which is essential for maintaining cardiac function and preventing arrhythmias.

6. Absence of severe renal impairment: The patient's creatinine level is within a normal range (93.0 μmol/L), indicating that the kidneys are functioning adequately, and the patient is not at risk of further cardiac damage due to renal impairment.

7. Presence of a stable and supportive medical regimen: The patient is on a combination of medications that are effective in managing heart failure, ischemic heart disease, and dyslipemia. This suggests that the patient is receiving optimal medical care.

8. Limited evidence of acute cardiac injury: The patient's troponin level is within a normal range (0.01 ng/mL), indicating that there is no evidence of acute cardiac injury or myocardial infarction.

Considering these factors, the patient's survival can be attributed to a combination of optimal medical management, close monitoring of cardiovascular risk factors, and effective control of cardiac function."
212,212,P0355,"Age: 48
Gender: Male 
Weight: 78 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 48,2
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4
LDL (mmol/L): 2,53
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 325.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,12
Urea (mg/dL): 6,68
LVEF (%): 28.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 48-year-old male with a history of ischemic dilated cardiomyopathy and myocardial infarction, has a complex set of clinical and laboratory findings. Despite these challenges, the patient's outcome is a survivor, which can be attributed to several factors:

1.  Optimal Medical Management: The patient is on beta-blockers and an ACE inhibitor, which are standard treatments for heart failure and hypertension. These medications have likely helped control the patient's heart rate and blood pressure, reducing the strain on the heart.

2.  Low Troponin Levels: The patient's troponin level is 0.01 ng/mL, which is within the normal range. This suggests that the myocardial infarction may not have caused significant ongoing cardiac damage, contributing to the patient's survival.

3.  Normal TSH and T4 Levels: The patient's thyroid function is within the normal range, which is crucial for maintaining cardiac function. Hypothyroidism can exacerbate heart failure, so the patient's euthyroid state is beneficial for their overall cardiac health.

4.  LVEF of 28%: Although the patient's left ventricular ejection fraction (LVEF) is severely reduced, indicating significant heart failure, it is not as low as some patients with similar conditions. This may indicate that the patient's heart has adapted to some extent, allowing them to survive.

5.  Albumin and Protein Levels: The patient's albumin and protein levels are within the normal range, which suggests that they do not have significant liver dysfunction or nephrotic syndrome, which could have contributed to their mortality.

6.  ECG Findings: The patient's ECG shows polymorphic ventricular extrasystoles, but no sustained ventricular tachycardia or bradycardia. This suggests that the patient's heart rhythm is relatively stable, which is beneficial for survival.

7.  Hemoglobin and Glucose Levels: The patient's hemoglobin and glucose levels are within the normal range, indicating that they do not have significant anemia or diabetes, which could have increased their risk of mortality.

Considering these factors, the patient's survival can be attributed to optimal medical management, a relatively stable heart rhythm, and the absence of significant underlying conditions that could have contributed to mortality."
213,213,P0357,"Age: 69
Gender: Female 
Weight: 80 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 135/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 11,5
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,76
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,4
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 875.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,05
TSH (mIU/L): 1,16
Urea (mg/dL): 7,99
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 69-year-old female with a history of idiopathic dilated cardiomyopathy, diabetes, and hypertension. Her current medications include diabetes medication, beta blockers, digoxin, loop diuretics, and an ACE inhibitor, which are all appropriate for her conditions.

Her LVEF (left ventricular ejection fraction) is 45%, indicating that she has a reduced ejection fraction, which is a hallmark of heart failure. However, the fact that she is a survivor suggests that her current treatment regimen is effective in managing her condition.

The patient's blood pressure is well-controlled at 135/75 mmHg, which is within a normal range. Her glucose level is slightly elevated at 11.5 mmol/L, but this is likely due to her diabetes.

The patient's electrolytes are within normal limits, with a potassium level of 4.7 mEq/L, which is within the normal range. Her liver enzymes, including ALT and AST, are within normal limits, indicating that her liver function is not significantly compromised.

The patient's troponin level is slightly elevated at 0.05 ng/mL, but this is not indicative of acute coronary syndrome. Her BNP (B-type natriuretic peptide) level is elevated at 875.0 ng/L, which is consistent with heart failure.

The patient's TSH level is within normal limits, indicating that her thyroid function is normal. Her T3 and T4 levels are also within normal limits, which suggests that her thyroid hormone levels are within a normal range.

The patient's ECG shows ventricular extrasystoles, but no evidence of ventricular tachycardia or non-sustained ventricular tachycardia. The presence of ventricular extrasystoles is not uncommon in patients with heart failure.

Overall, the patient's outcome as a survivor suggests that her current treatment regimen is effective in managing her conditions, and she is likely experiencing a stable phase of her disease."
214,214,P0358,"Age: 53
Gender: Male 
Weight: 71 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 110/65 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,16
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 126
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 161.0
HDL (mmol/L): 1,76
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,09
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 3068.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,35
Urea (mg/dL): 5,66
LVEF (%): 21.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 53-year-old male with a history of enolic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge, reducing the heart's ability to pump blood effectively. The patient's left ventricular ejection fraction (LVEF) is severely reduced at 21%, indicating a significant impairment in cardiac function.

The patient's current medications, including beta blockers, digoxin, loop diuretics, and an ACE inhibitor, are standard treatments for heart failure and are aimed at managing symptoms, reducing hospitalizations, and improving quality of life. The patient's low pro-BNP (brain natriuretic peptide) level of 3068 ng/L is within the range of expected values for a patient with heart failure, indicating that the treatment is effective in managing the condition.

The patient's ECG shows evidence of ventricular extrasystoles and non-sustained ventricular tachycardia, which are common in patients with dilated cardiomyopathy. The presence of these arrhythmias may indicate a higher risk of sudden cardiac death, but the fact that they are non-sustained suggests that the patient's cardiac function is not severely compromised.

The patient's laboratory results show elevated levels of gamma-glutamyl transferase (GGT), which may indicate liver dysfunction or bile duct obstruction, but this is not directly related to the patient's cardiac outcome. The patient's glucose level is elevated, which may be related to insulin resistance or diabetes, but this is not a direct contributor to the patient's cardiac outcome.

The patient's TSH level is within the normal range, indicating that thyroid function is not a contributing factor to the patient's cardiac condition.

Considering the patient's severe cardiac dysfunction, the presence of ventricular arrhythmias, and the current treatment regimen, the patient's outcome as a survivor is likely due to the effective management of the condition through medications and close monitoring. The patient's low LVEF and the presence of arrhythmias indicate a high risk of cardiac complications, but the fact that the patient is alive suggests that the treatment is effective in managing the condition and preventing adverse outcomes."
215,215,P0360,"Age: 64
Gender: Female 
Weight: 52 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 50.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 10,8
Hemoglobin (g/L): 108.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 3,7
LDL (mmol/L): 2,09
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 1314.0
Protein (g/L): 67
T3 (pg/dL): 0,06
T4 (ng/L): 18
TSH (mIU/L): 3,01
Urea (mg/dL): 5,16
LVEF (%): 25.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 64-year-old female with a history of idiopathic dilated cardiomyopathy, diabetes, and hypertension. Despite her multiple comorbidities, the patient is currently a survivor, which suggests that her treatment plan has been effective in managing her condition.

Several factors contribute to her positive outcome:

1.  Optimal Medication Regimen: The patient is on a comprehensive medication regimen, including diabetes medication, an angiotensin II receptor blocker, beta blockers, loop diuretics, spironolactone, and statins. This combination of medications is aimed at managing her heart failure, hypertension, and diabetes, which are all contributing factors to her cardiomyopathy.

2.  Control of Blood Pressure: The patient's blood pressure is well-controlled at 110/70 mmHg, which is within the target range for someone with heart failure. This suggests that her antihypertensive medication is effective in controlling her blood pressure, reducing the strain on her heart.

3.  Low Pro-BNP Levels: The patient's Pro-BNP level is 1314.0 ng/L, which is elevated but not extremely high. Pro-BNP is a biomarker of heart failure severity, and a lower level suggests that her heart failure is not as severe as it could be.

4.  Good Electrocardiogram (ECG) Results: The ECG shows a polymorphic ventricular extrasystole, but no signs of sustained ventricular tachycardia or bradycardia. This suggests that her heart rhythm is relatively stable, and there is no indication of severe arrhythmias.

5.  Low LVEF: The patient's left ventricular ejection fraction (LVEF) is 25.0%, which is low, indicating that her heart is not pumping efficiently. However, this is consistent with her diagnosis of dilated cardiomyopathy, and her medication regimen is likely aimed at improving her LVEF over time.

6.  Good Renal Function: The patient's creatinine level is 97.0 umol/L, which is within the normal range. This suggests that her kidneys are functioning well, and there is no indication of acute kidney injury.

In conclusion, the patient's survivor outcome is likely due to her comprehensive treatment plan, well-controlled blood pressure, low Pro-BNP levels, good ECG results, low LVEF, and good renal function."
216,216,P0361,"Age: 72
Gender: Male 
Weight: 83 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 35,7
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 8,4
Glucose (mmol/L): 6,36
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,87
LDL (mmol/L): 2,16
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 864.0
Protein (g/L): 64
T3 (pg/dL): 0,0489
T4 (ng/L): 16,17
Troponin (ng/mL): 0,4
TSH (mIU/L): 1,54
Urea (mg/dL): 20,49
LVEF (%): 20.0
Medications: Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's extensive medical history, including ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction, it is not surprising that the patient's left ventricular ejection fraction (LVEF) is severely impaired at 20%. This suggests that the patient has significant heart failure, which is a common complication of ischemic cardiomyopathy.

The patient's high pro-BNP level (864 ng/L) further supports the presence of heart failure, as elevated BNP levels are often associated with increased ventricular wall stress and poor cardiac function. The patient's weight of 83 kg and height of 160 cm also indicate a high body mass index (BMI), which can exacerbate heart failure symptoms.

The patient's blood pressure is within a relatively normal range (100/70 mmHg), which may be a result of the patient's current medication regimen, including loop diuretics and ACE inhibitors, which are commonly used to manage hypertension and heart failure.

The patient's laboratory results, including elevated creatinine (133.0 mmol/L) and urea (20.49 mg/dL), suggest that the patient has some degree of renal impairment, which is a common comorbidity in patients with heart failure. The patient's low hemoglobin level (130.0 g/L) may be due to anemia, which is often seen in patients with heart failure.

The patient's ECG results show polymorphic ventricular extrasystoles, which can be a benign finding in some cases, but in the context of the patient's other medical history, it may be a sign of underlying cardiac disease.

Considering the patient's overall clinical picture, the most likely reason for the patient's outcome is that they are a survivor of heart failure, likely due to the effective management of their symptoms with medication and possibly some degree of compensation of their cardiac function. The patient's low TSH level (1.54 mIU/L) and normal T3 and T4 levels suggest that the patient's thyroid function is within a normal range, which is a good prognostic sign.

Overall, the patient's outcome is likely due to a combination of factors, including effective medical management, a relatively stable clinical course, and some degree of cardiac compensation."
217,217,P0365,"Age: 54
Gender: Male 
Weight: 69 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Other HF etiology, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,97
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,89
Potassium (mEq/L): 4
LDL (mmol/L): 3,85
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 46.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,16
Urea (mg/dL): 6,16
LVEF (%): 65.0
Medications: Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 54-year-old male, has been classified as a survivor, indicating that he has survived a cardiac event or has not experienced a fatal outcome. Several factors from the provided data suggest a favorable prognosis for this patient:

1.  Low LVEF (65.0%): Although the patient has reduced left ventricular ejection fraction (LVEF), which is often a marker of heart failure, the level is not critically low. An LVEF of 65% is still within the normal range, indicating that the patient's heart function is relatively preserved.

2.  Hemoglobin (g/L): 129.0: The patient's hemoglobin level is within the normal range, indicating adequate oxygen delivery to tissues. This suggests that the heart's ability to pump blood effectively is sufficient to meet the body's needs.

3.  Pro-BNP (ng/L): 46.0: The brain natriuretic peptide (BNP) level is elevated, which is often associated with heart failure. However, the level is not extremely high, suggesting that the patient's heart failure is not in an advanced stage.

4.  ECG Impression: The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and other serious arrhythmias suggests that the patient's cardiac rhythm is relatively stable.

5.  Medications: The patient is taking loop diuretics, which are commonly used to manage heart failure symptoms. The fact that the patient is on this medication suggests that his heart failure is being managed, contributing to his survival.

6.  Other lab values: The patient's albumin, ALT, AST, total cholesterol, creatinine, and glucose levels are within or near the normal range, indicating that his liver function, kidney function, and blood glucose control are relatively well-managed.

Considering these factors, the patient's overall clinical picture suggests that he has a relatively stable and manageable heart condition, contributing to his survival."
218,218,P0366,"Age: 59
Gender: Male 
Weight: 100 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 165/110 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 5,46
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 6,5
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,59
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,05
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1477.0
Protein (g/L): 65
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,15
TSH (mIU/L): 0,76
Urea (mg/dL): 8,49
LVEF (%): 37.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient survived due to a combination of effective management of his comorbidities and the presence of a relatively preserved LVEF (Left Ventricular Ejection Fraction) of 37%, which is not severely decreased. Although the patient has ischemic dilated cardiomyopathy, his LVEF is still within the range of moderate dysfunction. The use of beta blockers and ACE inhibitors suggests that the patient is being treated for heart failure and hypertension, which is likely contributing to the stabilization of his condition.

The patient's blood pressure is well-controlled at 165/110 mmHg, which is slightly elevated but not excessively high. His diabetes is being managed with medication, and his lipid profile is being monitored with statins. The patient's renal function, as indicated by his creatinine level, is also relatively preserved.

The absence of significant electrolyte imbalances, such as hypokalemia or hyperkalemia, is another factor that contributed to the patient's survival. His potassium level of 4.6 mEq/L is within the normal range.

The elevated Pro-BNP level of 1477.0 ng/L indicates that the patient has some degree of heart failure, but the fact that it is not extremely high suggests that the patient's condition is not in acute decompensation. The presence of a normal TSH level also suggests that the patient's thyroid function is within the normal range, which is important for maintaining a stable cardiovascular system.

Overall, the combination of effective management of the patient's comorbidities, relatively preserved LVEF, and absence of severe electrolyte imbalances likely contributed to the patient's survival."
219,219,P0367,"Age: 63
Gender: Male 
Weight: 82 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 102/75 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 10.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 131.0
HDL (mmol/L): 0,54
Potassium (mEq/L): 5,3
LDL (mmol/L): 2,74
Sodium (mEq/L): 139.0
Protein (g/L): 67
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,06
TSH (mIU/L): 0,92
Urea (mg/dL): 15,31
LVEF (%): 55.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient's age of 63 and NYHA Class II classification indicate that the patient has mild heart failure symptoms, which is a good prognostic sign. The patient's LVEF (Left Ventricular Ejection Fraction) of 55% is within the normal range, indicating that the patient's heart is pumping efficiently. The patient's blood pressure is within the normal range, which is also a positive indicator.

The patient's medication regimen includes Amiodarone, Beta Blockers, Loop Diuretics, and ACE Inhibitor, which are all standard treatments for hypertensive cardiomyopathy and heart failure. The use of Amiodarone and Beta Blockers suggests that the patient is at risk for arrhythmias, but the absence of sustained ventricular tachycardia or non-sustained ventricular tachycardia on the ECG is a positive sign.

The patient's laboratory results show normal or near-normal values for most parameters, including albumin, ALT, AST, total cholesterol, creatinine, gamma-glutamil transpeptidase, glucose, hemoglobin, HDL, LDL, potassium, sodium, protein, T3, T4, and TSH. The slightly elevated urea level is within the normal range for the patient's age and sex.

The presence of ventricular extrasystole on the ECG is a common finding in patients with cardiomyopathy, but it is not a significant predictor of mortality. The patient's troponin level is normal, indicating that there is no acute myocardial infarction.

Overall, the patient's combination of a normal LVEF, absence of sustained arrhythmias, and normal laboratory results, along with the use of appropriate medications, suggest that the patient is at low risk for cardiac complications and is likely to survive."
220,220,P0371,"Age: 61
Gender: Female 
Weight: 73 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 84.0
AST or GOT (IU/L): 68.0
Total Cholesterol (mmol/L): 6,67
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 89
Glucose (mmol/L): 11,7
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,27
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 27434.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 20
TSH (mIU/L): 1,25
Urea (mg/dL): 7,82
LVEF (%): 26.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 61-year-old female with a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge, reducing its ability to pump blood effectively. Despite having a low left ventricular ejection fraction (LVEF) of 26%, indicating severe heart failure, the patient has been managed with a combination of medications, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor.

The patient's laboratory results show elevated liver enzymes (ALT and AST), which may indicate liver dysfunction, but the patient's albumin and protein levels are within normal limits, suggesting that the liver impairment is not severe. The patient's blood glucose level is elevated at 11.7 mmol/L, which may be a contributing factor to her heart failure, as hyperglycemia can exacerbate cardiac dysfunction.

The patient's serum creatinine level is slightly elevated at 71.0 umol/L, indicating mild renal impairment. However, the patient's urea level is within normal limits, suggesting that the renal impairment is not severe.

The patient's thyroid function tests (T3, T4, and TSH) are within normal limits, indicating that thyroid dysfunction is unlikely to be a contributing factor to her heart failure.

The patient's brain natriuretic peptide (BNP) level is elevated at 27434 pg/L, which is consistent with heart failure.

The patient's ECG shows polymorphic ventricular extrasystoles, which may be a sign of abnormal heart rhythm, but there is no evidence of sustained ventricular tachycardia or other serious arrhythmias.

Given the patient's severe heart failure symptoms (NYHA Class III), the patient's treatment plan is likely focused on optimizing her heart failure management, including adjusting her medications and monitoring her symptoms and laboratory results closely.

The patient's outcome of survival is likely due to the following factors:

1. Effective management of her heart failure symptoms with a combination of medications.
2. Mild renal impairment, which is not severe enough to significantly impact her prognosis.
3. Normal thyroid function, which reduces the likelihood of thyroid-related cardiac complications.
4. No evidence of severe liver dysfunction or other significant comorbidities that could impact her prognosis.
5. Close monitoring and management of her heart failure symptoms and laboratory results.

Overall, the patient's survival outcome is likely due to a combination of effective medical management and the absence of severe comorbidities that could impact her prognosis."
221,221,P0372,"Age: 60
Gender: Male 
Weight: 77 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 185.0
AST or GOT (IU/L): 154.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 188
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 121.0
HDL (mmol/L): 2,04
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,38
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 186.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 13
Troponin (ng/mL): 0,04
TSH (mIU/L): 1,7
Urea (mg/dL): 5,66
LVEF (%): 70.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to several factors, despite the presence of multiple comorbidities and laboratory abnormalities. 

Firstly, the patient's left ventricular ejection fraction (LVEF) is 70%, which is within the normal range. This suggests that the patient's heart function is relatively preserved, given their history of ischemic dilated cardiomyopathy. The patient's current treatment regimen, including beta blockers, ACE inhibitors, and statins, is likely contributing to the maintenance of their cardiac function.

The patient's blood pressure is well-controlled at 130/70 mmHg, which is within the target range for most patients with heart disease. The absence of significant left ventricular dysfunction and controlled blood pressure reduces the risk of adverse cardiac events.

The patient's laboratory values, although not entirely normal, are not indicative of severe organ dysfunction. The elevated liver enzymes (ALT and AST) may suggest some degree of liver dysfunction, but this is likely related to the patient's dyslipidemia and diabetes rather than a direct consequence of their cardiac disease. The patient's glucose level is also well-controlled, which is essential for preventing diabetic complications.

The patient's troponin level is within the normal range, indicating that there is no evidence of acute myocardial infarction. The absence of significant troponin elevation, along with the preserved LVEF, suggests that the patient's ischemic dilated cardiomyopathy is not actively causing significant cardiac damage.

The patient's TSH level is within the normal range, indicating that their thyroid function is not contributing to their cardiac disease. The patient's T3 and T4 levels are also within the normal range, which is consistent with euthyroidism.

The patient's pro-BNP level is elevated, which may indicate some degree of cardiac stress or strain. However, this is likely a chronic adaptation to their underlying cardiac disease rather than an acute decompensation.

Overall, the patient's combination of preserved cardiac function, controlled blood pressure, well-managed diabetes, and absence of acute cardiac damage contribute to their survival."
222,222,P0373,"Age: 41
Gender: Male 
Weight: 70 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 180/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 32.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 212.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,89
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,07
Sodium (mEq/L): 132.0
Pro-BNP (ng/L): 5017.0
Protein (g/L): 87
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,09
TSH (mIU/L): 2,27
Urea (mg/dL): 12,48
LVEF (%): 29.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 41-year-old male with a history of hypertensive cardiomyopathy and hypertension, presenting with a reduced left ventricular ejection fraction (LVEF) of 29.0%, indicating severe heart failure. Despite this, the patient is classified as NYHA Class II, which suggests that the patient's symptoms are mild and only appear with strenuous physical activity.

The patient's blood pressure is elevated at 180/90 mmHg, which is a concern for uncontrolled hypertension. However, the patient is already on a combination of medications, including a calcium channel blocker, beta blockers, loop diuretics, and an ACE inhibitor, which are commonly used to manage hypertension and heart failure.

The patient's laboratory results show elevated creatinine levels (212.0 μmol/L), indicating impaired renal function, which is likely a result of chronic kidney disease secondary to hypertension. The elevated Pro-BNP level (5017.0 ng/L) suggests that the patient has significant cardiac stress and is at risk for heart failure hospitalization.

The patient's ECG shows polymorphic ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachycardia, which are all indicators of cardiac arrhythmias. However, the patient's troponin level is within normal limits, indicating that there is no acute myocardial infarction.

Given the patient's complex medical history and the presence of multiple comorbidities, it is likely that the patient's outcome is a result of the combined effects of hypertension, heart failure, and renal impairment. Despite these challenges, the patient is able to survive, likely due to the comprehensive management of his medications and close monitoring.

The patient's survival can be attributed to the following factors:

1.  Effective management of hypertension and heart failure with a combination of medications.
2.  Close monitoring and management of renal function.
3.  Presence of a healthcare team that is able to provide ongoing care and adjust treatment as needed.
4.  The patient's relatively young age, which may have contributed to his ability to tolerate the underlying disease process.

In conclusion, the patient's survival is a testament to the importance of comprehensive management of complex medical conditions and the role of a multidisciplinary healthcare team in achieving optimal patient outcomes."
223,223,P0374,"Age: 74
Gender: Male 
Weight: 73 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,6
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 28
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 3,5
LDL (mmol/L): 2,61
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1414.0
Protein (g/L): 66
T3 (pg/dL): 0,04
T4 (ng/L): 23
Troponin (ng/mL): 0,023
TSH (mIU/L): 0,565
Urea (mg/dL): 6,99
LVEF (%): 43.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome is a survivor due to a combination of several factors that indicate a relatively stable cardiac condition. 

1.  NYHA Class II: The patient's functional capacity is still relatively preserved, as indicated by their New York Heart Association (NYHA) classification of II, which suggests that they can still perform everyday activities without significant limitations.

2.  LVEF of 43%: Although the patient has idiopathic dilated cardiomyopathy, their left ventricular ejection fraction (LVEF) is still relatively high, indicating that the heart is still pumping blood efficiently. This suggests that the patient's heart function is not severely compromised.

3.  Medications: The patient is on a regimen of amiodarone, beta blockers, loop diuretics, and ACE inhibitors, which are all commonly used to manage heart failure and arrhythmias. These medications are likely contributing to the patient's stable condition.

4.  ECG findings: Although the patient has polymorphic ventricular extrasystoles, this is not a life-threatening arrhythmia, and the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that their cardiac rhythm is generally stable.

5.  Lab results: The patient's lab results, including their blood work and troponin levels, do not indicate any acute myocardial infarction or severe cardiac damage. The elevated Pro-BNP level is a marker of heart failure, but the patient's overall clinical picture suggests that their heart failure is well-managed.

6.  Age and comorbidities: The patient is 74 years old and has a history of idiopathic dilated cardiomyopathy, which is a chronic condition. However, their age and comorbidities do not necessarily preclude them from surviving with proper medical management.

In conclusion, the patient's outcome is a survivor due to a combination of their relatively preserved functional capacity, stable LVEF, effective medication regimen, stable ECG findings, and well-managed lab results."
224,224,P0375,"Age: 69
Gender: Male 
Weight: 80 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,42
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 5
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 5
LDL (mmol/L): 2,66
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 2834.0
Protein (g/L): 67
T3 (pg/dL): 0,04
T4 (ng/L): 20
Troponin (ng/mL): 0,03
TSH (mIU/L): 4,09
Urea (mg/dL): 8,15
LVEF (%): 37.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient's outcome as a survivor can be attributed to several factors:

1. Optimal Medication Management: The patient is on a comprehensive regimen of medications, including Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, and Spironolactone, which are all standard treatments for idiopathic dilated cardiomyopathy and heart failure. These medications likely helped to manage the patient's symptoms and slow disease progression.

2. Stable Blood Pressure: The patient's blood pressure is within a relatively normal range (110/60 mmHg), which suggests that the medications are effectively controlling hypertension and reducing the strain on the heart.

3. Limited Evidence of Organ Dysfunction: Although the patient has elevated creatinine levels (115.0 mmol/L), which indicates some degree of renal impairment, it is not severe enough to suggest acute kidney injury or failure. Additionally, the patient's urea levels (8.15 mg/dL) are also within a relatively normal range, suggesting that the kidneys are still functioning adequately.

4. Mild Anemia: The patient's hemoglobin level (150.0 g/L) is slightly elevated, which may be a compensatory response to chronic disease. However, it is not severe enough to cause significant anemia-related symptoms or complications.

5. Low T3 and T4 Levels: The patient's thyroid function tests (T3 and T4) are within a relatively normal range, which suggests that hypothyroidism is unlikely to be a contributing factor to the patient's cardiac condition.

6. Low Troponin Levels: The patient's troponin levels (0.03 ng/mL) are within a normal range, indicating that there is no acute myocardial infarction or significant cardiac injury.

7. Low Pro-BNP Levels: The patient's Pro-BNP levels (2834.0 ng/L) are elevated, but not extremely high, which suggests that the patient is not in acute heart failure or decompensation.

8. NYHA Class II: The patient's New York Heart Association (NYHA) functional class is II, which indicates that the patient is experiencing mild to moderate symptoms of heart failure, such as fatigue, shortness of breath, or angina, but is still able to perform daily activities with some limitation.

Overall, the patient's outcome as a survivor can be attributed to the effective management of their idiopathic dilated cardiomyopathy, hypertension, and other comorbidities, as well as the absence of severe organ dysfunction or acute cardiac injury."
225,225,P0376,"Age: 51
Gender: Male 
Weight: 80 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,53
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,82
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 727.0
Protein (g/L): 71
T3 (pg/dL): 0,07
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,39
Urea (mg/dL): 4,99
LVEF (%): 20.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient is a 51-year-old male with a history of idiopathic dilated cardiomyopathy, which is a condition characterized by a weakened heart muscle that cannot pump blood effectively. The patient's left ventricular ejection fraction (LVEF) is severely impaired at 20%, indicating that his heart is not pumping blood efficiently.

Despite the patient's poor heart function, he is on a comprehensive treatment regimen consisting of beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, which are all standard medications used to manage heart failure symptoms and improve cardiac function. The patient's blood pressure is well-controlled at 130/70 mmHg, which is within a normal range.

The patient's electrolyte levels, including potassium and sodium, are within normal limits, which is essential for maintaining proper heart function. The patient's liver function tests (ALT, AST, and GGT) are also within normal limits, indicating that his liver is functioning properly.

The patient's pro-BNP level is elevated at 727.0 ng/L, which is consistent with heart failure. However, the patient's troponin level is within normal limits, indicating that there is no evidence of acute myocardial infarction.

The patient's thyroid function tests (TSH, T3, and T4) are within normal limits, indicating that his thyroid function is normal.

The patient's ECG shows polymorphic ventricular extrasystoles, which are abnormal heart rhythms that can be a sign of underlying cardiac disease. However, the patient does not have any sustained ventricular tachycardia or bradycardia.

Considering the patient's comprehensive treatment regimen, controlled blood pressure, normal electrolyte levels, and absence of acute myocardial infarction, it is likely that the patient's heart failure is being well-managed, and he is able to survive with his current condition."
226,226,P0378,"Age: 45
Gender: Male 
Weight: 82 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 141.0
HDL (mmol/L): 2,61
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,13
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 236.0
Protein (g/L): 68
T3 (pg/dL): 0,06
T4 (ng/L): 21
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,75
Urea (mg/dL): 5,83
LVEF (%): 29.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient, a 45-year-old male with a history of idiopathic dilated cardiomyopathy, has a left ventricular ejection fraction (LVEF) of 29%, indicating severe systolic heart failure. Despite this, the patient is on optimal medical therapy with beta blockers, loop diuretics, and an ACE inhibitor, which suggests that the treatment is aimed at managing symptoms and slowing disease progression.

The patient's blood pressure is well-controlled at 120/70 mmHg, and the absence of significant elevations in liver enzymes (ALT and AST) suggests that the patient's liver function is preserved. The patient's kidney function is also relatively preserved, with a creatinine level of 88.0 μmol/L, which is within the normal range.

The patient's lipid profile shows a total cholesterol level of 4.65 mmol/L, which is elevated, but the LDL level of 3.13 mmol/L is not excessively high. The patient's HDL level is 2.61 mmol/L, which is slightly low. The patient's glucose level is within the normal range.

The patient's thyroid function is normal, with a TSH level of 2.75 mIU/L, and a normal T4 level. The patient's troponin level is 0.02 ng/mL, which is within the normal range, indicating no acute myocardial infarction.

The patient's ECG shows polymorphic ventricular extrasystoles, which are common in patients with heart failure and may be related to the underlying cardiomyopathy. There is no evidence of sustained ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia.

Considering the patient's overall clinical presentation, the patient's outcome of survival is likely due to the following factors:

1. Optimal medical therapy: The patient is on a combination of beta blockers, loop diuretics, and an ACE inhibitor, which are all evidence-based treatments for heart failure.
2. Preserved kidney function: The patient's creatinine level is within the normal range, indicating that the patient's kidney function is preserved, which is a good prognostic factor for patients with heart failure.
3. Normal thyroid function: The patient's TSH and T4 levels are normal, which is important for maintaining optimal cardiac function.
4. Absence of acute myocardial infarction: The patient's troponin level is within the normal range, indicating no acute myocardial infarction.
5. Mild electrolyte imbalance: The patient's potassium level is within the normal range, which is important for maintaining cardiac function.

Overall, the patient's survival outcome is likely due to a combination of optimal medical therapy, preserved kidney function, normal thyroid function, absence of acute myocardial infarction, and mild electrolyte imbalance."
227,227,P0379,"Age: 49
Gender: Male 
Weight: 88 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,31
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,5
LDL (mmol/L): 1,76
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1517.0
Protein (g/L): 72
T3 (pg/dL): 0,05
T4 (ng/L): 16
TSH (mIU/L): 2,05
Urea (mg/dL): 5,66
LVEF (%): 67.0
Medications: Calcium Channel Blocker, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 49-year-old male with a history of hypertensive cardiomyopathy and hypertension, has been managed with a combination of calcium channel blockers, loop diuretics, and ACE inhibitors. The patient's current medications are likely aimed at controlling his blood pressure and reducing the strain on the heart. 

The patient's laboratory results show elevated levels of creatinine (133.0 mmol/L), indicating impaired renal function, which is a common complication of hypertensive cardiomyopathy. However, the patient's ejection fraction (LVEF) is relatively preserved at 67%, suggesting that the heart is still functioning relatively well despite the cardiomyopathy.

The patient's pro-BNP level is elevated at 1517.0 ng/L, which is a marker of cardiac stress and potential heart failure. However, the patient's symptoms and overall clinical picture do not suggest acute heart failure, and the patient's NYHA class is II, indicating mild symptoms of heart failure.

The patient's T3 and T4 levels are within normal limits, and the TSH level is slightly elevated at 2.05 mIU/L, which may indicate subclinical hypothyroidism. However, this is not directly related to the patient's cardiac outcome.

The patient's lipid profile shows elevated LDL levels (1.76 mmol/L), which is a risk factor for cardiovascular disease. However, the patient's HDL level is low at 1.14 mmol/L, which is also a risk factor for cardiovascular disease.

The patient's potassium level is slightly low at 4.5 mEq/L, which may be related to the use of loop diuretics.

Considering the patient's overall clinical picture, it appears that the patient's medications and management plan have been effective in controlling his blood pressure and reducing the strain on the heart. The patient's relatively preserved LVEF and lack of acute symptoms suggest that he is likely to survive with continued management and monitoring."
228,228,P0380,"Age: 59
Gender: Male 
Weight: 88 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 120/65 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,81
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 62
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,18
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 105.0
Protein (g/L): 68
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,51
Urea (mg/dL): 4,16
LVEF (%): 32.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

This patient, a 59-year-old male with a history of enolic dilated cardiomyopathy and hypertension, presented with several risk factors for cardiac complications. The patient's low left ventricular ejection fraction (LVEF) of 32% indicates significant left ventricular dysfunction, which is a hallmark of dilated cardiomyopathy. The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG further suggest an increased risk of arrhythmias.

The patient's laboratory results show elevated levels of Troponin, indicating myocardial injury or stress, although the level is very low (0.005 ng/mL). The high levels of Pro-BNP (105.0 ng/L) also suggest heart failure, which is consistent with the patient's NYHA Class II classification.

The patient is on a treatment regimen that includes beta blockers, digoxin, loop diuretics, and an ACE inhibitor, which is typical for managing heart failure and dilated cardiomyopathy. The patient's blood pressure is well-controlled at 120/65 mmHg, and the potassium level is within the normal range.

Considering the patient's clinical presentation, laboratory results, and treatment regimen, the most likely reason for the patient's survival is the effective management of their heart failure and arrhythmias through their current medications. The combination of beta blockers, digoxin, and ACE inhibitors has likely helped to reduce the patient's symptoms and slow the progression of their heart failure. The loop diuretics have also helped to manage fluid overload and reduce the patient's risk of heart failure exacerbation.

Additionally, the patient's low TSH level (1.51 mIU/L) suggests that the thyroid function is within the normal range, which is important for the management of heart failure. The patient's T3 and T4 levels are also within the normal range, indicating that there is no evidence of hypothyroidism or hyperthyroidism, which can affect heart function.

In conclusion, the patient's survival can be attributed to the effective management of their heart failure and arrhythmias through their current treatment regimen, as well as the absence of any other significant comorbidities or complications that could have contributed to their outcome."
229,229,P0381,"Age: 70
Gender: Male 
Weight: 58 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 96/57 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 37
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 8,8
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,35
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 434.0
Protein (g/L): 61
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,67
Urea (mg/dL): 5,49
LVEF (%): 40.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 70-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction, has a complex medical profile. Despite this, the patient is a survivor, which can be attributed to several factors.

Firstly, the patient's blood pressure is within a relatively normal range (96/57 mmHg), which is lower than expected for someone with a history of hypertension. This may indicate effective management of hypertension with the Angiotensin II Receptor Blocker and possibly the Beta Blockers.

Secondly, the patient's Pro-BNP level of 434.0 ng/L is elevated, which is often seen in patients with heart failure. However, the patient's LVEF (Left Ventricular Ejection Fraction) of 40% is not extremely low, indicating some preserved cardiac function.

Thirdly, the patient's Troponin level of 0.01 ng/mL is within normal limits, suggesting that there is no ongoing myocardial infarction or acute coronary syndrome.

Fourthly, the patient's medication regimen is comprehensive, including Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Spironolactone, Statins, and Nitrovasodilator, which are all aimed at managing the patient's multiple comorbidities.

Lastly, the ECG findings, although abnormal, do not indicate any life-threatening arrhythmias, and the presence of polymorphic ventricular extrasystoles may not necessarily be a cause for concern in this context.

Considering these factors, the patient's survival can be attributed to the effective management of his comorbidities, the presence of preserved cardiac function, and the absence of any acute cardiac events."
230,230,P0384,"Age: 71
Gender: Male 
Weight: 91 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 185/110 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 40
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 107.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,25
Sodium (mEq/L): 142.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,72
Urea (mg/dL): 7,82
LVEF (%): 28.0
Medications: Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 71-year-old male with a history of ischemic dilated cardiomyopathy, dyslipemia, and hypertension, which are all significant risk factors for heart failure and cardiac complications. However, the patient's LVEF (Left Ventricular Ejection Fraction) is 28%, indicating a severely reduced cardiac function, which is a strong indicator of heart failure.

Despite the patient's poor cardiac function, the patient is on appropriate medications for heart failure, including loop diuretics, statins, and nitrovasodilators, which are commonly used to manage symptoms, improve cardiac function, and reduce the risk of further cardiac complications.

The patient's blood pressure is elevated at 185/110 mmHg, which is concerning for hypertensive urgency or emergency, but it is not the primary reason for the patient's poor cardiac function. The patient's troponin level is within normal limits, indicating that there is no evidence of acute myocardial infarction.

The patient's ECG shows monomorphic ventricular extrasystoles, but there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias. The patient's TSH level is within normal limits, indicating that there is no evidence of hypothyroidism, which can contribute to heart failure.

The patient's lab results show slightly elevated liver enzymes, which may indicate some degree of liver dysfunction, but this is not a primary concern in this patient.

Given the patient's age, comorbidities, and cardiac function, the patient's survival is a positive outcome, indicating that the patient's treatment plan and management have been effective in stabilizing their cardiac function and preventing further complications."
231,231,P0386,"Age: 52
Gender: Female 
Weight: 69 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 105/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 108.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,3
LDL (mmol/L): 4,24
Sodium (mEq/L): 138.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 22
Troponin (ng/mL): 0,005
TSH (mIU/L): 3,45
Urea (mg/dL): 7,99
LVEF (%): 45.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to a combination of factors, including their current medical management and the presence of certain favorable clinical indicators. 

Firstly, the patient's current medications, including Amiodarone, Beta Blockers, Loop Diuretics, and ACE Inhibitor, are all relevant to the management of idiopathic dilated cardiomyopathy. Amiodarone is an anti-arrhythmic medication that can help prevent arrhythmias, while Beta Blockers are used to reduce the workload on the heart and slow the heart rate. Loop Diuretics help to reduce fluid buildup in the body, which can alleviate symptoms of heart failure. ACE Inhibitors are used to reduce blood pressure and strain on the heart.

The patient's LVEF (Left Ventricular Ejection Fraction) of 45% is below the normal range (50-70%), indicating that the patient has a reduced heart function. However, the patient's current medications and management plan are likely helping to stabilize their condition and prevent further deterioration.

The patient's laboratory results also indicate that their liver function is relatively preserved (ALT 12.0 IU/L, AST 14.0 IU/L), and their electrolyte levels are within normal limits (Potassium 4.3 mEq/L). The patient's TSH level is also within the normal range (3.45 mIU/L), indicating that their thyroid function is not contributing to their cardiac condition.

The patient's ECG results show a polymorphic ventricular extrasystole, which is a type of abnormal heart rhythm, but it is not a life-threatening arrhythmia. The absence of non-sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia also suggests that the patient's heart rhythm is relatively stable.

Overall, while the patient has a history of idiopathic dilated cardiomyopathy and reduced LVEF, their current medical management and favorable laboratory results suggest that they are stable and likely to survive with continued treatment and follow-up."
232,232,P0387,"Age: 37
Gender: Male 
Weight: 110 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 125/95 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 42
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 141.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,49
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 577.0
Protein (g/L): 74
T3 (pg/dL): 0,06
T4 (ng/L): 27
Troponin (ng/mL): 0,03
TSH (mIU/L): 5,15
Urea (mg/dL): 9,15
LVEF (%): 50.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient's outcome as a survivor can be attributed to several factors based on the provided data. Firstly, the patient's left ventricular ejection fraction (LVEF) is 50%, which indicates a reduced but not severely impaired cardiac function, allowing the heart to continue pumping blood effectively. The presence of idiopathic dilated cardiomyopathy, a condition characterized by a weakened heart muscle, is well-managed with medications such as Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, and ACE Inhibitor. These medications have helped to alleviate symptoms, slow disease progression, and improve cardiac function.

Additionally, the patient's blood pressure is controlled at 125/95 mmHg, which is within a relatively normal range, reducing the risk of further strain on the heart. The patient's serum creatinine level is 97.0 mmol/L, indicating a normal kidney function, which is essential for the proper metabolism and excretion of medications.

The patient's laboratory results, including normal liver function tests (ALT and AST), normal electrolyte levels (potassium and sodium), and a normal hemoglobin level, suggest that the patient is not experiencing significant organ dysfunction.

The presence of ventricular extrasystole, a common finding in patients with heart disease, is not a significant concern in this case, as it is not accompanied by other arrhythmias such as ventricular tachycardia or non-sustained ventricular tachycardia.

Furthermore, the patient's TSH level is within the normal range, indicating that the thyroid function is not contributing to the patient's cardiac condition.

The patient's Pro-BNP level is elevated at 577.0 ng/L, which is consistent with heart failure. However, the patient's overall clinical picture and medication regimen suggest that the heart failure is well-managed, contributing to the patient's survival.

In conclusion, the combination of effective medication management, controlled blood pressure, and relatively preserved cardiac function, along with normal organ function and lack of significant arrhythmias, have contributed to the patient's survival."
233,233,P0388,"Age: 58
Gender: Female 
Weight: 87 kg
Height: 149 cm
NYHA Class: II
Blood Pressure: 155/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 9.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 17,8
Hemoglobin (g/L): 117.0
HDL (mmol/L): 0,62
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,15
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 881.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 11
Troponin (ng/mL): 0,05
TSH (mIU/L): 2,19
Urea (mg/dL): 6,99
LVEF (%): 65.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's medical history and current condition, the outcome of survival can be attributed to several factors:

1.  Optimal Medication Management: The patient is on a comprehensive regimen of medications that effectively manage their conditions, including hypertension, diabetes, and dyslipidemia. The use of a calcium channel blocker, angiotensin II receptor blocker, loop diuretics, statins, and nitrovasodilators suggests that their cardiomyopathy, hypertension, and peripheral vascular disease are being well-controlled.

2.  Reasonable Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 65%, which is within the normal range. This indicates that the heart is pumping blood efficiently, and the cardiomyopathy has not significantly impaired the heart's function.

3.  Moderate Blood Pressure: Although the patient's blood pressure is elevated at 155/80 mmHg, it is not severely high, which reduces the risk of cardiovascular complications.

4.  Normal Electrocardiogram (ECG) Parameters: The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and other arrhythmias in the ECG suggests that the heart is not experiencing significant arrhythmic disturbances.

5.  Low Pro-BNP Levels: The patient's Pro-BNP level is 881.0 ng/L, which is within a range that indicates mild to moderate heart failure. This suggests that the heart is not under extreme stress, which could contribute to the patient's survival.

6.  Limited Organ Dysfunction: The patient's kidney function, as indicated by the creatinine level of 88.0 μmol/L, is not severely impaired, and the liver function, as indicated by the AST and ALT levels, is within normal limits. This suggests that the patient's organs are not experiencing significant damage due to their conditions.

7.  Hemoglobin Level: The patient's hemoglobin level is 117.0 g/L, which is within the normal range. This suggests that the patient's anemia is not severe, which can be a risk factor for cardiovascular events.

8.  Thyroid Function: The patient's TSH level is within the normal range, which suggests that thyroid dysfunction is not contributing to their cardiovascular condition.

Considering these factors, the patient's survival can be attributed to the effective management of their conditions, the absence of severe organ dysfunction, and the presence of a reasonable LVEF."
234,234,P0389,"Age: 52
Gender: Male 
Weight: 90 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 135/100 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 6,7
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 44
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 132.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 3,9
LDL (mmol/L): 4,63
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 315.0
Protein (g/L): 67
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,73
Urea (mg/dL): 8,65
LVEF (%): 45.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient's outcome as a survivor is attributed to several factors, including the patient's age, comorbidities, and current treatment regimen. 

Firstly, the patient's age of 52 is considered relatively young for a patient with hypertensive cardiomyopathy, which is a condition where the heart muscle becomes weakened due to high blood pressure. This suggests that the patient may have been diagnosed and treated for the condition early, potentially slowing the progression of the disease.

The patient's NYHA Class II classification indicates that the patient experiences some limitations in physical activity but is still able to perform daily activities without experiencing symptoms. This suggests that the patient's heart condition is not severe at this point.

The patient's current medications, including beta blockers, loop diuretics, and an ACE inhibitor, are all appropriate for managing hypertension and heart failure. Beta blockers are used to reduce the heart rate and blood pressure, while loop diuretics help to remove excess fluid from the body, reducing the workload on the heart. ACE inhibitors help to relax blood vessels, reducing blood pressure and strain on the heart.

The patient's laboratory results, such as a normal hemoglobin level and a slightly elevated creatinine level, suggest that the patient's kidneys are functioning relatively well, which is important for patients with heart failure.

Additionally, the patient's low TSH level (1.73 mIU/L) suggests that the patient's thyroid function is within the normal range, which is important for maintaining a healthy heart rate and blood pressure.

The patient's low T3 level (0.05 pg/dL) and normal T4 level (15 ng/L) suggest that the patient does not have hypothyroidism, which is a condition where the thyroid gland does not produce enough thyroid hormones. This is important because hypothyroidism can exacerbate heart failure.

The patient's troponin level (0.005 ng/mL) is within the normal range, indicating that there is no acute myocardial infarction.

The patient's LVEF (45%) is slightly below the normal range (50-70%), indicating that the patient has some degree of left ventricular dysfunction. However, the patient's overall clinical presentation and laboratory results suggest that the patient's condition is not severe.

In conclusion, the patient's outcome as a survivor is likely due to a combination of early diagnosis and treatment of hypertensive cardiomyopathy, appropriate medication regimen, and relatively well-controlled kidney function."
235,235,P0392,"Age: 48
Gender: Female 
Weight: 60 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 130/85 mmHg
Past Medical History: Valvular cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,15
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 3,5
LDL (mmol/L): 3,39
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 768.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 7,85
Urea (mg/dL): 8,15
LVEF (%): 48.0
Medications: Amiodarone, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 48-year-old female with a history of valvular cardiomyopathy, dyslipemia, and hypertension. Despite her past medical history, she has been on a treatment regimen consisting of amiodarone, loop diuretics, and statins. The patient's laboratory results show elevated levels of troponin (0.03 ng/mL), which indicates some degree of cardiac injury, but it is not significantly high. Her LVEF (left ventricular ejection fraction) is 48%, which is below the normal range (50-70%), indicating some degree of left ventricular dysfunction.

However, her overall clinical condition does not indicate an immediate life-threatening situation. Her blood pressure is well-controlled (130/85 mmHg), and she does not have any signs of acute coronary syndrome or severe cardiac failure. The presence of paroxysmal supraventricular tachycardia (PSVT) on the ECG is a benign arrhythmia that is not life-threatening.

The patient's BNP (brain natriuretic peptide) level is elevated at 768 ng/L, which is a marker of heart failure, but it is not extremely high. Her creatinine level is slightly elevated at 97.0 umol/L, which may indicate some degree of renal impairment, but it is not severe.

Considering her overall clinical condition, laboratory results, and ECG findings, the patient's outcome is likely due to the combination of her chronic valvular cardiomyopathy and mild heart failure, which is being managed with her current medication regimen. The patient's age, weight, and height are not particularly concerning, and her hemoglobin level is within a normal range. The patient's TSH level is slightly elevated at 7.85 mIU/L, but it is not indicative of a life-threatening condition.

In conclusion, the patient's outcome is likely a result of her chronic valvular cardiomyopathy and mild heart failure, which is being managed with her current medication regimen."
236,236,P0395,"Age: 70
Gender: Male 
Weight: 73 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 40
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,15
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 107
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 120.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,9
LDL (mmol/L): 2,97
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 329.0
Protein (g/L): 68
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,03
Urea (mg/dL): 9,48
LVEF (%): 27.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient, a 70-year-old male with a history of idiopathic dilated cardiomyopathy, has a relatively favorable outcome. This can be attributed to several factors:

1.  Optimal Medical Management: The patient is on a comprehensive regimen of medications, including beta blockers, digoxin, loop diuretics, statins, and ACE inhibitors, which are standard treatments for heart failure and dilated cardiomyopathy. These medications have likely helped to control symptoms, slow disease progression, and improve quality of life.

2.  Low Troponin Levels: The patient's troponin level is 0.03 ng/mL, which is within the normal range. Elevated troponin levels are indicative of cardiac damage, and the low level suggests that there has been minimal cardiac injury.

3.  Normal Blood Pressure: The patient's blood pressure is 130/80 mmHg, which is within the normal range. Well-controlled blood pressure is essential for patients with heart failure, as uncontrolled hypertension can exacerbate the condition.

4.  Normal LVEF: The patient's left ventricular ejection fraction (LVEF) is 27%, which is low but not extremely low. LVEF is a critical indicator of heart function, and an LVEF of 27% suggests that the patient's heart is still pumping some blood effectively.

5.  Absence of Sustained Ventricular Tachycardia: The ECG report does not indicate sustained ventricular tachycardia, which is a potentially life-threatening arrhythmia that can be a complication of heart failure.

6.  Absence of Bradycardia: Although the ECG report mentions unknown bradycardia, the patient's heart rate is not significantly low, which suggests that the bradycardia may not be causing significant symptoms.

7.  Stable Kidney Function: The patient's creatinine level is 97.0 umol/L, which is within the normal range. This suggests that the patient's kidney function is stable, and there is no evidence of acute kidney injury.

8.  Absence of Severe Liver Enzyme Elevation: The patient's liver enzymes (ALT and AST) are within the normal range, which suggests that the patient's liver function is stable and not significantly affected by the disease.

Considering these factors, the patient's outcome can be attributed to effective medical management, stable cardiac function, and the absence of severe complications."
237,237,P0398,"Age: 72
Gender: Male 
Weight: 77 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,18
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 40
Glucose (mmol/L): 6
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,84
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 551.0
Protein (g/L): 63
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,78
Urea (mg/dL): 6,99
LVEF (%): 27.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Parosysmal AF
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

Given the patient's profile, the outcome of survival is likely due to a combination of factors, including the following:

1. Optimal medical management: The patient is on beta blockers, statins, and ACE inhibitors, which are standard treatments for ischemic dilated cardiomyopathy, hypertension, and dyslipemia. These medications are likely helping to manage the patient's condition and prevent further cardiac damage.

2. Low troponin levels: The patient's troponin level is 0.01 ng/mL, which is within the normal range. This suggests that the patient has not experienced a recent myocardial infarction, and the heart muscle is not currently experiencing significant damage.

3. LVEF of 27%: Although the patient's left ventricular ejection fraction (LVEF) is low, indicating reduced heart function, it is not extremely low. The LVEF is still above the threshold for severe heart failure, and the patient may be able to tolerate the current level of cardiac dysfunction.

4. Pro-BNP level: The patient's Pro-BNP level is 551.0 ng/L, which is elevated but not extremely high. This suggests that the patient's heart is under some stress, but not to the point of severe heart failure.

5. ECG findings: While the patient has several ECG abnormalities, including polymorphic ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal atrial fibrillation, these are not typically life-threatening in isolation. The presence of unknown bradycardia is concerning, but its impact is unclear without further information.

6. Age and comorbidities: The patient is 72 years old, which is a significant risk factor for cardiovascular disease. However, the presence of comorbidities such as hypertension, dyslipemia, and myocardial infarction suggests that the patient's cardiovascular system is already compromised.

Considering these factors, the patient's outcome of survival is likely due to a combination of optimal medical management, the absence of recent cardiac damage, and the patient's ability to tolerate the current level of cardiac dysfunction. However, close monitoring and further management are still necessary to prevent further cardiac deterioration."
238,238,P0399,"Age: 56
Gender: Male 
Weight: 68 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 130/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,98
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 5
LDL (mmol/L): 2,38
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1192.0
Protein (g/L): 72
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,21
Urea (mg/dL): 7,82
LVEF (%): 20.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to several factors based on the provided data. 

Firstly, the patient's current medications, including beta blockers, statins, and an ACE inhibitor, are consistent with standard treatment for ischemic dilated cardiomyopathy and hypertension. These medications help to reduce the workload on the heart, lower cholesterol levels, and prevent further cardiac damage.

The patient's LVEF (Left Ventricular Ejection Fraction) of 20% indicates severe left ventricular dysfunction, but it is not a contraindication for survival. In fact, with appropriate medical management, patients with LVEF as low as 20% can still survive for extended periods.

The patient's blood pressure of 130/55 mmHg is within a relatively normal range, which suggests that the ACE inhibitor is effectively controlling blood pressure. The absence of significant electrolyte imbalances (e.g., potassium levels are within normal range) and liver enzyme elevations (e.g., ALT and AST are within normal range) also suggests that the patient is not experiencing significant organ dysfunction.

Furthermore, the patient's troponin level of 0.01 ng/mL is within normal range, indicating that there is no ongoing myocardial infarction. The pro-BNP level of 1192.0 ng/L is elevated, but not excessively high, which may indicate some degree of heart failure but not to the extent that it would be life-threatening.

The patient's TSH level of 2.21 mIU/L is within the normal range, which suggests that thyroid function is not contributing to the patient's cardiac condition.

Overall, while the patient has severe heart failure and a history of myocardial infarction, the combination of appropriate medical management, relatively stable vital signs, and absence of significant organ dysfunction all contribute to the patient's survival."
239,239,P0400,"Age: 58
Gender: Male 
Weight: 82 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 95/63 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,83
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,91
Sodium (mEq/L): 132.0
Pro-BNP (ng/L): 867.0
Protein (g/L): 67
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,17
Urea (mg/dL): 10,15
LVEF (%): 35.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 58-year-old male with a history of ischemic dilated cardiomyopathy and myocardial infarction, has a complex medical profile. Despite these risk factors, the patient has been able to survive, likely due to a combination of factors.

Firstly, the patient's blood pressure is within a relatively normal range (95/63 mmHg), which suggests that the patient's cardiovascular system is not under excessive stress. The use of beta blockers, statins, and ACE inhibitors, which are standard medications for heart failure and coronary artery disease, also likely played a crucial role in stabilizing the patient's cardiovascular system.

The patient's LVEF (left ventricular ejection fraction) of 35% indicates that the heart is still pumping blood effectively, albeit at a reduced capacity. This suggests that the patient's heart has adapted to the damage caused by the myocardial infarction and is still able to meet the body's basic needs.

The patient's troponin level of 0.01 ng/mL is also within a normal range, indicating that there is no ongoing myocardial damage or infarction. The absence of ventricular tachycardia and other arrhythmias on the ECG further supports this conclusion.

The patient's kidney function, as indicated by the creatinine level of 133.0 μmol/L, is slightly elevated, but not severely impaired. This suggests that the patient's kidneys are still able to filter waste products from the blood, albeit at a reduced capacity.

The patient's laboratory results also indicate that the liver function is relatively preserved, with normal levels of ALT and AST. The patient's lipid profile is also well-managed, with a total cholesterol level of 3.83 mmol/L and an LDL level of 1.91 mmol/L.

Overall, while the patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, a combination of effective medication management, relatively normal blood pressure, and preserved kidney and liver function have contributed to the patient's ability to survive."
240,240,P0401,"Age: 54
Gender: Male 
Weight: 72 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 113/66 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 43
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,28
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 82
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,03
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 47.0
Protein (g/L): 69
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,42
Urea (mg/dL): 6,82
LVEF (%): 43.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome is a survivor due to a combination of factors that suggest a relatively stable and manageable condition. 

1.  Idiopathic dilated cardiomyopathy with an LVEF of 43%: The patient has a reduced left ventricular ejection fraction (LVEF), which indicates a reduced heart function. However, the LVEF is not extremely low, and the patient is being managed with medications such as beta blockers, loop diuretics, statins, and ACE inhibitors, which are standard treatments for heart failure.

2.  Normal blood pressure: The patient's blood pressure is within a normal range (113/66 mmHg), which is a good sign, as uncontrolled hypertension can exacerbate heart failure.

3.  Mild elevation in troponin: The patient's troponin level is slightly elevated (0.01 ng/mL), but not significantly high, which suggests that the patient is not experiencing an acute myocardial infarction or severe cardiac damage.

4.  Normal TSH and T4 levels: The patient's thyroid function is within a normal range, which is essential for heart health, as thyroid disorders can impact heart function.

5.  No signs of severe electrolyte imbalance: The patient's potassium and sodium levels are within normal ranges, which is crucial for maintaining proper heart function.

6.  Low pro-BNP level: The patient's pro-BNP level is 47.0 ng/L, which is relatively low. Pro-BNP is a marker of heart failure, and a low level suggests that the patient is not experiencing severe heart failure symptoms.

7.  ECG findings: While the patient has non-sustained ventricular tachycardia, this is not an uncommon finding in patients with heart failure, and the patient is being managed with medications that can help prevent arrhythmias.

Overall, the patient's stable medical history, normal vital signs, and effective medication regimen suggest that the patient is being effectively managed for their heart condition, and the outcome is a survivor."
241,241,P0402,"Age: 50
Gender: Male 
Weight: 75 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 42.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 7,21
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 53
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 160.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,1
LDL (mmol/L): 4,91
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 708.0
Protein (g/L): 78
T3 (pg/dL): 0,06
T4 (ng/L): 17
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,07
Urea (mg/dL): 7,32
LVEF (%): 36.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome as a survivor can be attributed to a combination of factors, including the management of his underlying idiopathic dilated cardiomyopathy and the use of appropriate medications. 

The patient's ejection fraction (LVEF) of 36% indicates a reduced left ventricular function, which is consistent with his diagnosis of dilated cardiomyopathy. However, the fact that he is on beta blockers, loop diuretics, spironolactone, and an ACE inhibitor suggests that his condition is being actively managed. Beta blockers help to slow the heart rate and reduce the force of contraction, which can reduce the workload on the heart and improve symptoms. Loop diuretics help to reduce fluid overload and alleviate symptoms of congestion. Spironolactone is an aldosterone antagonist that helps to reduce fluid retention and has been shown to improve survival in patients with heart failure. ACE inhibitors also help to reduce blood pressure and reduce the strain on the heart.

The patient's laboratory results also suggest that he is not experiencing significant kidney dysfunction, as indicated by a creatinine level of 106.0 μmol/L, which is within the normal range. His electrolyte levels, including potassium and sodium, are also within normal limits. His TSH level is slightly elevated, but not significantly, indicating that there is no apparent thyroid dysfunction.

The patient's troponin level is normal, indicating that he is not experiencing any acute myocardial infarction. His BNP level is elevated, which is consistent with heart failure, but not to an extent that would suggest severe decompensation.

The absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG suggests that the patient is not experiencing any life-threatening arrhythmias. The presence of polymorphic ventricular extrasystoles may be a benign finding and does not necessarily indicate poor prognosis.

Overall, the patient's outcome as a survivor can be attributed to the effective management of his underlying condition and the use of appropriate medications, as well as the absence of any acute complications or life-threatening arrhythmias."
242,242,P0404,"Age: 68
Gender: Male 
Weight: 80 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 135/84 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,66
Creatinine (mmol/L): 256.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,54
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1858.0
Protein (g/L): 69
T4 (ng/L): 15
TSH (mIU/L): 0,6
Urea (mg/dL): 13,48
LVEF (%): 20.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome as a survivor can be attributed to a combination of factors, including the timely and appropriate management of his underlying conditions, the effectiveness of his current medication regimen, and the presence of certain physiological adaptations.

Firstly, the patient's current medications, including Calcium Channel Blockers, Beta Blockers, Loop Diuretics, and Statins, are likely contributing to his survival. Calcium Channel Blockers and Beta Blockers are effective in reducing the heart rate and blood pressure, which can decrease the workload on the heart and reduce the risk of further cardiac complications. Loop Diuretics help to manage fluid overload, which is common in patients with heart failure, and Statins help to lower cholesterol levels, reducing the risk of further cardiac events.

Secondly, the patient's physiological adaptations, such as a low LVEF (20%) and elevated Pro-BNP levels (1858.0 ng/L), indicate that he has been living with heart failure for some time. His body has likely adapted to this condition, and his heart has become more efficient at pumping blood despite the reduced ejection fraction.

Thirdly, the patient's NYHA Class II classification indicates that he has mild to moderate symptoms of heart failure, which suggests that his condition is not severe enough to prevent him from performing everyday activities. This classification also implies that he is likely receiving adequate treatment and is being closely monitored.

Lastly, the patient's overall health status, as indicated by his blood pressure, hemoglobin, and urea levels, suggests that he is not in a state of acute distress or failure. His blood pressure is well-controlled, his hemoglobin levels are within a normal range, and his urea levels are not elevated, indicating that his kidneys are functioning adequately.

In conclusion, the combination of effective medical management, physiological adaptations, and the patient's overall health status have contributed to his survival. However, it is essential to continue monitoring his condition closely and adjusting his treatment plan as needed to prevent further cardiac complications."
243,243,P0406,"Age: 55
Gender: Male 
Weight: 95 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 41
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 106
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,77
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 162.0
Protein (g/L): 65
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,29
Urea (mg/dL): 5,83
LVEF (%): 22.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient, a 55-year-old male with a history of idiopathic dilated cardiomyopathy, has a low left ventricular ejection fraction (LVEF) of 22%, indicating significant left ventricular dysfunction. The patient is on a treatment regimen consisting of Amiodarone, Beta Blockers, Loop Diuretics, and ACE Inhibitor, which suggests that the patient is being managed for heart failure and arrhythmia prevention.

The patient's blood pressure is within a relatively normal range (100/60 mmHg), but the low diastolic blood pressure may indicate orthostatic hypotension, which can be a complication of heart failure. The patient's creatinine level is elevated (124.0 μmol/L), suggesting impaired renal function, which is a common comorbidity in patients with heart failure.

The patient's liver enzymes (ALT and AST) are mildly elevated, which may indicate some degree of liver dysfunction, potentially related to the use of Amiodarone. The total cholesterol and LDL levels are elevated, which is a risk factor for cardiovascular disease.

The patient's TSH level is within the normal range, and the T4 level is slightly elevated, but not significantly abnormal. The low T3 level is not uncommon in patients with heart failure.

The patient's pro-BNP level is elevated (162.0 ng/L), which is consistent with heart failure.

The patient's LVEF of 22% indicates that the patient is in NYHA Class III or IV heart failure, despite being classified as NYHA Class II. This discrepancy may be due to the patient's ability to tolerate physical activity and symptoms of heart failure.

Considering the patient's age, comorbidities, and treatment regimen, the most likely reason for the patient's survival is the comprehensive management of heart failure and arrhythmia prevention. The patient's medications, including ACE inhibitors, beta blockers, and loop diuretics, have likely helped to manage symptoms and slow disease progression. Additionally, the patient's social and family support, as well as access to medical care, have likely contributed to their survival."
244,244,P0407,"Age: 76
Gender: Male 
Weight: 84 kg
Height: 175 cm
NYHA Class: III
Blood Pressure: 110/65 mmHg
Past Medical History: Other HF etiology, Diabetes, Dyslipemia
Albumin (g/L): 38
ALT or GPT (IU/L): 35.0
AST or GOT (IU/L): 36.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 300
Glucose (mmol/L): 5
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,04
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 1733.0
Protein (g/L): 72
T3 (pg/dL): 0,02
T4 (ng/L): 24
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,58
Urea (mg/dL): 8,32
LVEF (%): 26.0
Medications: Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 76-year-old male with a history of heart failure (HF), diabetes, and dyslipemia, who presented with a severely reduced left ventricular ejection fraction (LVEF) of 26%. This suggests significant left ventricular dysfunction, which is consistent with the patient's NYHA Class III classification, indicating moderate to severe symptoms of heart failure.

The elevated Pro-BNP (brain natriuretic peptide) level of 1733 ng/L is indicative of heart failure with reduced ejection fraction (HFrEF), which is consistent with the patient's symptoms and reduced LVEF.

The patient's blood pressure is within a relatively normal range (110/65 mmHg), which may be a result of the beta-blocker and loop diuretic medications. However, the patient's total cholesterol level is elevated (3.88 mmol/L), and the low HDL level (1.5 mmol/L) may indicate a higher risk of cardiovascular events.

The patient's liver function tests (ALT and AST) are slightly elevated, which could indicate some degree of liver dysfunction. However, the gamma-glutamyl transpeptidase (GGT) level is significantly elevated (300 IU/L), which suggests some degree of liver damage, possibly related to alcohol use or other liver diseases.

The patient's glucose level is elevated (5 mmol/L), indicating diabetes mellitus. The hemoglobin level is within a relatively normal range, but the urea level is slightly elevated (8.32 mg/dL), which may indicate some degree of renal impairment.

The patient's ECG shows polymorphic ventricular extrasystoles, but no sustained ventricular tachycardia or bradycardia. This suggests that the patient's heart rhythm is relatively stable, despite the presence of ventricular extrasystoles.

Considering the patient's overall clinical presentation, laboratory results, and ECG findings, it appears that the patient has a complex set of comorbidities, including heart failure, diabetes, dyslipemia, and possible liver damage. However, the patient's vital signs and laboratory results indicate that he is stable and not experiencing any acute cardiac or renal emergencies.

The patient's survival outcome is likely due to the following factors:

1.  Effective management of heart failure symptoms with beta-blockers and loop diuretics.
2.  The use of statins to manage dyslipemia.
3.  The patient's relatively stable vital signs, including blood pressure and heart rate.
4.  The absence of acute cardiac or renal emergencies, such as acute myocardial infarction or acute kidney injury.
5.  The patient's relatively stable ECG findings, despite the presence of ventricular extrasystoles.

Overall, the patient's survival outcome is likely a result of the effective management of his comorbidities and the absence of acute cardiac or renal emergencies."
245,245,P0408,"Age: 52
Gender: Female 
Weight: 64 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,17
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 13,9
Hemoglobin (g/L): 133.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,88
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 14.0
Protein (g/L): 70
T3 (pg/dL): 0,02
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,34
Urea (mg/dL): 4,66
LVEF (%): 52.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's age, gender, and past medical history suggest a high risk for cardiovascular disease. The patient has a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction, all of which contribute to a high risk for adverse cardiac outcomes.

The patient's current medications, including beta blockers, loop diuretics, statins, ACE inhibitors, and nitrovasodilators, are appropriate for managing heart failure and reducing the risk of further cardiac events. The patient's LVEF of 52% indicates that the patient has some degree of left ventricular dysfunction, but it is not severely impaired, which is consistent with the patient's NYHA Class II classification.

The patient's laboratory results show elevated glucose and cholesterol levels, which are being managed with diabetes medication and statins. The patient's creatinine level is elevated, but not significantly, which may indicate some degree of kidney impairment due to the patient's history of diabetes and hypertension. The patient's troponin level is within normal limits, indicating that there is no acute myocardial infarction.

The patient's ECG shows monomorphic ventricular extrasystoles, which are common in patients with heart failure and can be a benign finding. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that the patient does not have a high risk for sudden cardiac death.

Overall, the patient's current management plan and laboratory results suggest that the patient is being well-managed for their cardiac condition. The patient's survival outcome is likely due to the effective management of their cardiac condition and the absence of any acute cardiac events or complications."
246,246,P0411,"Age: 75
Gender: Male 
Weight: 70 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 100/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 34
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,59
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 46
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 81.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,04
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 859.0
Protein (g/L): 63
T4 (ng/L): 23
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,1
Urea (mg/dL): 9,32
LVEF (%): 25.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

This patient, a 75-year-old male with a history of ischemic dilated cardiomyopathy and myocardial infarction, has a complex clinical picture that suggests a high risk of cardiac complications. The patient's left ventricular ejection fraction (LVEF) is severely reduced at 25%, indicating significant left ventricular dysfunction. This, combined with a history of ischemic dilated cardiomyopathy and myocardial infarction, suggests that the patient has had significant myocardial damage.

The patient is on a comprehensive treatment regimen, including amiodarone, beta blockers, loop diuretics, statins, and an ACE inhibitor, which are all appropriate for managing heart failure and arrhythmias. The patient's blood pressure is within a relatively normal range, and the low levels of troponin indicate that there is no acute myocardial infarction.

The patient's high level of pro-BNP (859 ng/L) is consistent with heart failure, and the elevated creatinine level (124.0 umol/L) suggests impaired renal function, which is common in patients with heart failure.

Despite these risk factors, the patient's outcome is a survivor. There are several possible reasons for this:

1. Effective medical management: The patient's comprehensive treatment regimen appears to be well-managed, and the patient is likely receiving optimal medical therapy for heart failure and arrhythmias.
2. Compensatory mechanisms: The patient's body may have developed compensatory mechanisms to adapt to the reduced LVEF, such as increased sympathetic tone or fluid retention, which may have helped to maintain cardiac output.
3. Limited disease progression: Despite the patient's history of ischemic dilated cardiomyopathy and myocardial infarction, the patient's cardiac function may not have progressed as rapidly as expected, allowing the patient to survive.
4. Good support system: The patient may have a supportive social network, access to healthcare, and a good living situation, which can contribute to improved outcomes.

In summary, the patient's outcome as a survivor is likely due to a combination of effective medical management, compensatory mechanisms, limited disease progression, and a good support system."
247,247,P0412,"Age: 41
Gender: Male 
Weight: 80 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 115/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 36
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,12
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 286.0
Protein (g/L): 65
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,4
Urea (mg/dL): 6,16
LVEF (%): 40.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 41-year-old male with a history of ischemic dilated cardiomyopathy, dyslipemia, hypertension, and myocardial infarction. Despite having a reduced left ventricular ejection fraction (LVEF) of 40%, which indicates systolic heart failure, the patient's overall condition is relatively stable. 

The patient's current medications, including beta blockers, statins, and an ACE inhibitor, are appropriate for managing heart failure and reducing the risk of further cardiovascular events. The low troponin level (0.01 ng/mL) suggests that there is no current acute myocardial infarction.

The patient's blood pressure is within a relatively normal range (115/55 mmHg), and his creatinine level is elevated at 88.0 μmol/L, indicating some degree of renal impairment, which is not uncommon in patients with heart failure. However, the patient's urea level is within a relatively normal range (6.16 mg/dL).

The patient's ejection fraction of 40% is below the normal range, indicating systolic dysfunction, but the patient's New York Heart Association (NYHA) functional class is II, indicating that the patient's symptoms are relatively mild. The patient's pro-BNP level is elevated at 286.0 ng/L, which is consistent with heart failure, but not excessively high.

Considering the patient's stable condition, the lack of acute myocardial infarction, and the relatively mild symptoms, the patient's outcome of survival is likely due to the effective management of their heart failure and cardiovascular risk factors through their current medication regimen and lifestyle modifications."
248,248,P0413,"Age: 76
Gender: Male 
Weight: 84 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 133/88 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 36,5
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,6
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,3
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,87
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 870.0
Protein (g/L): 67
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,72
Urea (mg/dL): 8,49
LVEF (%): 37.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

Given the patient's data, the outcome of survival is likely due to a combination of factors. 

Firstly, the patient is on beta blockers and ACE inhibitors, which are standard medications for managing heart failure and hypertension. Beta blockers help slow the heart rate and reduce the heart's workload, while ACE inhibitors help reduce blood pressure and decrease the heart's workload. These medications are likely contributing to the patient's survival.

The patient's LVEF (Left Ventricular Ejection Fraction) is 37%, which is low but not extremely low. While it indicates some degree of heart dysfunction, it is not so severe that it would be expected to lead to immediate cardiac arrest or death. 

Additionally, the patient's Troponin level is within normal limits (0.01 ng/mL), which suggests that there is no acute myocardial infarction (heart attack). This is a positive sign, as it reduces the risk of cardiac complications.

The patient's Pro-BNP level is elevated at 870.0 ng/L, which is a marker of heart failure. However, it is not at the extremely high levels that are typically seen in patients with severe heart failure.

The patient's NYHA Class II classification indicates that they have some symptoms of heart failure, but they are still able to perform everyday activities without significant limitation.

Considering these factors, the patient's survival is likely due to the combination of their ongoing medical treatment, the relatively mild severity of their heart failure, and the absence of acute cardiac complications."
249,249,P0414,"Age: 72
Gender: Male 
Weight: 74 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 112/78 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 36
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 4,09
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 50
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,04
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 161.0
Protein (g/L): 73
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,61
Urea (mg/dL): 9,15
LVEF (%): 45.0
Medications: Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient, a 72-year-old male with a history of idiopathic dilated cardiomyopathy and hypertension, has been prescribed a comprehensive treatment regimen consisting of beta blockers, spironolactone, and an ACE inhibitor. His current medications are likely aimed at managing his heart failure symptoms, reducing blood pressure, and alleviating symptoms of his cardiomyopathy.

The patient's current LVEF (Left Ventricular Ejection Fraction) is 45%, which indicates a mildly reduced ejection fraction, a common finding in patients with dilated cardiomyopathy. His Pro-BNP (Brain Natriuretic Peptide) level of 161.0 ng/L is elevated, suggesting that the patient is experiencing some degree of heart failure. However, his blood pressure is within a relatively normal range (112/78 mmHg), which is a positive sign.

The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, but no sustained ventricular tachycardia or significant bradycardia. These findings are not uncommon in patients with cardiomyopathy and are likely related to the underlying heart disease.

Given the patient's relatively stable condition, treatment with his current medications, and the absence of any acute cardiac events or severe symptoms, it is reasonable to conclude that the patient is a survivor. The patient's age and comorbidities do increase his risk for cardiac events, but his current treatment plan and stable condition suggest that he is managing his heart disease effectively."
250,250,P0415,"Age: 28
Gender: Male 
Weight: 95 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 90/50 mmHg
Past Medical History: Other HF etiology
Albumin (g/L): 44
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,27
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 5
LDL (mmol/L): 2,64
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 38.0
Protein (g/L): 75
T3 (pg/dL): 0,04
T4 (ng/L): 21
Troponin (ng/mL): 0,062
TSH (mIU/L): 1,97
Urea (mg/dL): 3,83
LVEF (%): 59.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 28-year-old male with a history of heart failure (HF) of other etiology, as indicated by a New York Heart Association (NYHA) Class II classification. He has a relatively low left ventricular ejection fraction (LVEF) of 59%, which suggests some degree of left ventricular dysfunction.

The patient's vital signs show a low blood pressure (90/50 mmHg), which may be indicative of hypotension, possibly related to his heart failure or other underlying conditions. His creatinine level of 88.0 μmol/L suggests impaired renal function, which is consistent with heart failure.

The laboratory results show elevated levels of troponin (0.062 ng/mL), indicating myocardial injury or stress. However, the level is not extremely high, which may suggest that the myocardial damage is not severe.

The patient is on angiotensin II receptor blocker, beta blockers, and digoxin, which are commonly used medications for heart failure management. The presence of these medications suggests that the patient's heart failure is being actively managed.

The ECG shows a monomorphic ventricular extrasystole, which is a common finding in patients with heart failure. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia suggests that the patient's heart rhythm is relatively stable.

Given the patient's age, relatively preserved LVEF, and the presence of heart failure management medications, it is likely that the patient's heart failure is being managed effectively, and he is at lower risk of severe cardiac complications. Therefore, the patient outcome of ""survivor"" is likely due to the effective management of his heart failure and the absence of severe cardiac complications."
251,251,P0417,"Age: 45
Gender: Male 
Weight: 72 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 35.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 5,92
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 85
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,9
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 197.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 15
Troponin (ng/mL): 0,005
TSH (mIU/L): 2,37
Urea (mg/dL): 6,82
LVEF (%): 38.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 45-year-old male with a history of enolic dilated cardiomyopathy, has been prescribed a comprehensive treatment regimen consisting of beta blockers, loop diuretics, spironolactone, and an ACE inhibitor. 

The patient's left ventricular ejection fraction (LVEF) of 38% is within the range typically associated with heart failure with reduced ejection fraction (HFrEF). The presence of non-sustained ventricular tachycardia (VT) on the ECG suggests that the patient is at risk of arrhythmias, which can further compromise cardiac function. However, the fact that the patient's troponin levels are within normal limits (<0.01 ng/mL) and the absence of symptoms of acute coronary syndrome or myocardial infarction suggest that the patient's current condition is not due to acute coronary artery disease.

The patient's low T3 level (0.06 pg/dL) and TSH level (2.37 mIU/L) suggest that the patient may be experiencing subclinical hypothyroidism, which can be associated with heart failure and reduced cardiac function. However, the T4 level (15 ng/L) is within the normal range, indicating that the patient's thyroid function is not significantly impaired.

The patient's high Pro-BNP level (197.0 ng/L) is consistent with heart failure, and the patient's low LVEF and elevated creatinine level (88.0 μmol/L) suggest that the patient has chronic kidney disease (CKD) secondary to heart failure.

Given the patient's complex medical history and treatment regimen, the patient's ability to survive can be attributed to the following factors:

1.  Effective management of heart failure symptoms with beta blockers, loop diuretics, and spironolactone.
2.  The absence of acute coronary syndrome or myocardial infarction.
3.  The presence of a comprehensive treatment regimen that addresses the patient's heart failure and CKD.
4.  The patient's relatively young age and absence of other high-risk factors for mortality.

Overall, the patient's survival can be attributed to the effective management of their heart failure and CKD, as well as the absence of acute coronary syndrome or myocardial infarction."
252,252,P0420,"Age: 82
Gender: Female 
Weight: 64 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 36.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 6,23
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,53
Potassium (mEq/L): 4,5
LDL (mmol/L): 4,34
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 616.0
Protein (g/L): 82
T3 (pg/dL): 0,03
T4 (ng/L): 22
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,91
Urea (mg/dL): 11,65
LVEF (%): 38.0
Medications: Calcium Channel Blocker, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's age of 82 and NYHA Class II, which indicates some limitations in physical activity but still able to carry on light physical activity, the patient's overall outcome as a survivor can be attributed to several factors.

Firstly, despite having a history of hypertensive cardiomyopathy and hypertension, the patient's blood pressure is well-controlled at 140/80 mmHg, which is within the normal range. This suggests effective management of her blood pressure, which is crucial in preventing further cardiac damage.

The patient's laboratory results show a slightly elevated creatinine level (141.0 mmol/L), which may indicate some degree of renal impairment. However, the patient's urea level (11.65 mg/dL) is within a relatively normal range, suggesting that the renal function is not severely compromised.

The patient's cardiac function, as indicated by the LVEF of 38%, is slightly below the normal range (50-70%). However, this is not unexpected given her age and history of cardiomyopathy. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG suggests some degree of cardiac arrhythmia, but the patient's overall cardiac function is still compensating.

The patient's medication regimen, which includes a calcium channel blocker, spironolactone, and nitrovasodilator, is aimed at managing her hypertension, heart failure symptoms, and arrhythmias. The addition of spironolactone, an aldosterone antagonist, may have helped to reduce her risk of hospitalization and improve her survival.

The patient's low T3 and T4 levels (0.03 pg/dL and 22 ng/L, respectively) may indicate subclinical hypothyroidism, but the TSH level of 1.91 mIU/L is within the normal range, suggesting that the thyroid function is not significantly impaired.

The patient's overall outcome as a survivor can be attributed to the effective management of her hypertension, heart failure symptoms, and arrhythmias, as well as the use of appropriate medications. Additionally, her relatively preserved renal function and lack of severe cardiac dysfunction have also contributed to her survival."
253,253,P0421,"Age: 58
Gender: Male 
Weight: 90 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 11,1
Hemoglobin (g/L): 154.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,51
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 509.0
Protein (g/L): 69
T3 (pg/dL): 0,03
T4 (ng/L): 22
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,5
Urea (mg/dL): 4,99
LVEF (%): 34.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 58-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction, has been managed with a comprehensive treatment plan that includes medications such as beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor. Despite his complex medical history, the patient has survived, which can be attributed to several factors:

1.  Optimal Medication Management: The patient's medication regimen is well-balanced, addressing various aspects of his cardiovascular disease. Beta blockers help reduce the heart rate and contractility, loop diuretics manage fluid overload, spironolactone reduces aldosterone levels, statins lower cholesterol levels, and ACE inhibitors improve heart function and reduce blood pressure.

2.  Control of Hypertension and Diabetes: The patient's blood pressure is well-controlled (110/70 mmHg), and his diabetes is managed with medication. This suggests that the patient's cardiomyopathy may not be significantly exacerbated by these conditions, allowing him to survive.

3.  Regular Monitoring and Follow-up: The patient's condition is closely monitored through regular check-ups and diagnostic tests, including echocardiograms to assess his left ventricular ejection fraction (LVEF), which is 34%. Although the LVEF is low, it is not significantly deteriorating, indicating that the patient's heart function is being preserved.

4.  Presence of Ventricular Extrasystoles and Non-sustained VT: The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which can be a sign of cardiac electrical instability. However, the absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia suggests that these arrhythmias are not life-threatening and do not significantly impact the patient's survival.

5.  Low Troponin Levels: The patient's troponin levels are within normal limits (0.01 ng/mL), indicating that there is no acute myocardial infarction or significant cardiac damage.

6.  Thyroid Function: The patient's TSH level is within the normal range (2.5 mIU/L), indicating that thyroid function is not contributing to his cardiac condition.

7.  Kidney Function: The patient's creatinine level is elevated (106.0 umol/L), but not significantly, suggesting that his kidney function is preserved.

8.  Nutritional Status: The patient's albumin and protein levels are within normal limits, indicating that his nutritional status is not significantly compromised.

Given these factors, the patient's survival can be attributed to the comprehensive management of his cardiovascular disease, regular monitoring, and the absence of significant acute cardiac damage or other life-threatening conditions."
254,254,P0422,"Age: 62
Gender: Male 
Weight: 75 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Other HF etiology
Albumin (g/L): 40
ALT or GPT (IU/L): 35.0
AST or GOT (IU/L): 43.0
Total Cholesterol (mmol/L): 5,9
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 125
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,2
LDL (mmol/L): 4,32
Sodium (mEq/L): 130.0
Pro-BNP (ng/L): 123.0
Protein (g/L): 56
T3 (pg/dL): 0,03
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,3
Urea (mg/dL): 7,15
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient's outcome as a survivor can be attributed to several factors based on the provided data. 

1.  Effective Medications: The patient is on a combination of beta blockers, loop diuretics, and an ACE inhibitor, which are commonly used to manage heart failure (HF) and hypertension. These medications have likely helped to reduce the patient's blood pressure and alleviate symptoms of HF, contributing to their survival.

2.  Early Detection and Management of Heart Failure: The patient has a history of HF and is classified as NYHA Class II, indicating that their symptoms are mild and they can still perform light physical activity without significant discomfort. Early detection and management of HF have likely improved the patient's prognosis.

3.  Low Creatinine Levels: The patient's creatinine level is 71.0 mmol/L, which is within the normal range. This suggests that the patient's kidney function is relatively preserved, which is an important factor in determining the prognosis of patients with HF.

4.  Normal Hemoglobin and Protein Levels: The patient's hemoglobin and protein levels are within the normal range, which indicates that they do not have significant anemia or malnutrition, both of which can negatively impact survival in patients with HF.

5.  Low T3 and T4 Levels: The patient's thyroid hormone levels are within the normal range, which suggests that they do not have hypothyroidism, a condition that can worsen HF.

6.  Normal Electrocardiogram (ECG) Findings: The patient's ECG does not show any signs of sustained ventricular tachycardia, which is a significant risk factor for mortality in patients with HF.

7.  Low Pro-BNP Levels: The patient's Pro-BNP level is 123.0 ng/L, which is within the normal range. Elevated Pro-BNP levels are associated with increased mortality in patients with HF.

8.  Low LVEF: The patient's left ventricular ejection fraction (LVEF) is 20.0%, which is severely reduced. However, the patient's survival despite this low LVEF suggests that they may have a more favorable response to treatment or that their HF is well-managed.

In summary, the combination of effective medications, early detection and management of HF, preserved kidney function, normal hemoglobin and protein levels, normal thyroid hormone levels, normal ECG findings, low Pro-BNP levels, and a low LVEF all contributed to the patient's survival."
255,255,P0424,"Age: 73
Gender: Male 
Weight: 69 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 120/65 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 105.0
AST or GOT (IU/L): 98.0
Total Cholesterol (mmol/L): 3,41
Creatinine (mmol/L): 194.0
Gamma-glutamil transpeptidase (IU/L): 100
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 5,1
LDL (mmol/L): 1,55
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 4846.0
Protein (g/L): 77
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,41
Urea (mg/dL): 19,8
LVEF (%): 37.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient, a 73-year-old male with a history of idiopathic dilated cardiomyopathy, hypertension, and a reduced left ventricular ejection fraction (LVEF) of 37%, is at high risk for cardiac complications. The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG indicates an increased risk of sudden cardiac death. However, the patient's survival can be attributed to several factors:

1.  Optimal Medical Therapy: The patient is on beta blockers, digoxin, loop diuretics, and ACE inhibitors, which are standard treatments for heart failure and arrhythmias. These medications help manage symptoms, reduce morbidity, and potentially improve survival.
2.  Proper Monitoring: The patient's ECG shows signs of arrhythmias, but the presence of a healthcare team and regular monitoring allowed for early detection and management of these issues.
3.  Comprehensive Laboratory Results: Although the patient has elevated liver enzymes (ALT and AST), elevated total cholesterol, and low HDL levels, these are likely secondary to the cardiomyopathy and not a primary cause of the patient's survival. The patient's T4 and TSH levels are within normal limits, indicating no apparent thyroid dysfunction contributing to his cardiac condition.
4.  Kidney Function: The patient's creatinine level is elevated, indicating some degree of renal impairment. However, the patient's urea level is not excessively high, suggesting that the kidneys are still functioning, albeit at a reduced capacity.
5.  Hemoglobin and Electrolytes: The patient's hemoglobin level is within the normal range, and potassium levels are within the normal range, which is crucial for cardiac function.

In conclusion, the combination of optimal medical therapy, proper monitoring, comprehensive laboratory results, relatively preserved kidney function, and normal electrolyte levels likely contributed to the patient's survival, despite the presence of significant cardiac disease and arrhythmias."
256,256,P0425,"Age: 53
Gender: Female 
Weight: 67 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 115/50 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 38
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 51
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 114.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,87
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 775.0
Protein (g/L): 70
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,56
Urea (mg/dL): 4,99
LVEF (%): 43.0
Medications: Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 53-year-old female with a history of idiopathic dilated cardiomyopathy, which is a condition where the heart's left ventricle becomes enlarged and weakened, leading to reduced heart function. Despite having a low left ventricular ejection fraction (LVEF) of 43%, which is below the normal range (50-70%), the patient is on optimal medical therapy with beta blockers, spironolactone, and an ACE inhibitor. These medications are commonly used to manage heart failure and are likely contributing to the patient's survival.

The patient's laboratory results show elevated levels of Pro-BNP (brain natriuretic peptide), which is a biomarker for heart failure, but it is not excessively high (775 ng/L). The patient's kidney function is within normal limits, as indicated by the creatinine level of 80.0 umol/L. 

The ECG findings of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles suggest that the patient has some degree of arrhythmia, but the presence of beta blockers and ACE inhibitors, which are anti-arrhythmic medications, may be helping to manage these arrhythmias.

The patient's blood pressure is within a relatively normal range (115/50 mmHg), and her hemoglobin and potassium levels are within normal limits. The patient's lipid profile shows elevated total cholesterol and LDL levels, but these are being managed with medical therapy.

The patient's TSH level is within the normal range, indicating that her thyroid function is normal, which is important because thyroid disorders can exacerbate heart failure. The patient's troponin level is normal, indicating that there is no acute myocardial infarction.

Considering the patient's overall clinical picture, including her history of idiopathic dilated cardiomyopathy, the presence of optimal medical therapy, and the absence of any acute cardiac events or severe laboratory abnormalities, the patient's survival outcome is likely due to the effectiveness of her current treatment regimen and her overall good clinical condition."
257,257,P0426,"Age: 72
Gender: Male 
Weight: 76 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 125/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 41
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 6,4
Hemoglobin (g/L): 157.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4
LDL (mmol/L): 2,35
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 2598.0
Protein (g/L): 67
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,53
Urea (mg/dL): 11,32
LVEF (%): 10.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Hydralazine
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome is a survivor due to several factors contributing to their improved prognosis. 

Firstly, the patient's blood pressure is well-controlled at 125/70 mmHg, which is within a normal range, reducing the risk of cardiovascular events. The patient's heart function, as indicated by the left ventricular ejection fraction (LVEF) of 10%, is severely impaired, but the patient is still alive, suggesting that they have adapted to their condition.

The patient's medications, including Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, and Hydralazine, are likely contributing to their survival. These medications are standard treatments for heart failure and idiopathic dilated cardiomyopathy, aiming to reduce symptoms, slow disease progression, and improve quality of life.

The patient's laboratory results show elevated levels of Pro-BNP (brain natriuretic peptide), which is a biomarker for heart failure. However, the levels of 2598.0 ng/L are not extremely high, suggesting that the patient's condition is being managed effectively.

The patient's kidney function, as indicated by the creatinine level of 106.0 μmol/L, is slightly elevated, which may be a result of their heart failure. However, it is not severe enough to suggest that the patient is at high risk for kidney failure.

The patient's lipid profile shows elevated total cholesterol and LDL levels, which are being managed with medication. The patient's glucose level is also elevated, but it is not extremely high, and the patient is likely being monitored for diabetes.

The patient's TSH level is within the normal range, indicating that their thyroid function is not contributing to their heart condition.

The patient's ECG shows non-sustained ventricular tachycardia, which is a common finding in patients with heart failure. However, the patient does not have any life-threatening arrhythmias, and their heart rate is within a normal range.

In conclusion, the patient's outcome is a survivor due to a combination of effective medication management, well-controlled blood pressure, and adapted heart function. While the patient has several comorbidities, their condition is being managed, and they are likely to continue living with heart failure."
258,258,P0427,"Age: 77
Gender: Male 
Weight: 61 kg
Height: 152 cm
NYHA Class: II
Blood Pressure: 118/57 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 49.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 101
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,87
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 3993.0
Protein (g/L): 76
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,03
Urea (mg/dL): 6,66
LVEF (%): 25.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient is a 77-year-old male with a history of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipemia. His left ventricular ejection fraction (LVEF) is severely reduced at 25%, indicating a poor heart function. Despite this, he is on optimal medical therapy with beta blockers, loop diuretics, statins, and an ACE inhibitor, which are all standard treatments for heart failure and coronary artery disease.

The patient's high Pro-BNP level (3993.0 ng/L) suggests severe heart failure, but the fact that he is still alive suggests that his medications are effective in managing his symptoms. The presence of ventricular extrasystole, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG indicates that he has significant arrhythmias, but these are likely being managed by his medications.

The patient's laboratory results show mild elevations in liver enzymes (ALT and AST), which may be related to his statin therapy or underlying liver disease. His lipid profile shows a high total cholesterol and LDL level, which is consistent with his history of dyslipemia. His kidney function is impaired, with a creatinine level of 106.0 μmol/L, which may be contributing to his heart failure.

The patient's TSH level is within the normal range, indicating that his thyroid function is not contributing to his heart failure. His hemoglobin level is normal, and his potassium level is slightly low, which may be related to his diuretic therapy.

Given the patient's advanced age, history of heart failure, and significant comorbidities, his survival is a testament to the effectiveness of his current medical therapy. The fact that he is able to survive with a severely reduced LVEF suggests that his medications are well-tolerated and effective in managing his symptoms."
259,259,P0428,"Age: 48
Gender: Female 
Weight: 83 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 115/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,22
Creatinine (mmol/L): 62.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 121.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,02
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 120.0
Protein (g/L): 69
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,91
Urea (mg/dL): 8,49
LVEF (%): 40.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 48-year-old female with a history of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipemia, has been taking beta blockers, statins, and an ACE inhibitor, which are standard medications for managing heart failure and reducing the risk of future cardiovascular events. Her LVEF (Left Ventricular Ejection Fraction) is 40%, indicating mild to moderate left ventricular dysfunction. However, she is still classified as NYHA Class II, which means she experiences some limitations in physical activity but is still able to perform daily tasks without significant symptoms.

The patient's laboratory results show a relatively well-controlled lipid profile, with a total cholesterol level of 4.22 mmol/L and an LDL level of 2.02 mmol/L, which is within the target range for someone with a history of myocardial infarction. Her liver enzymes (ALT and AST) are within normal limits, indicating no significant liver damage. Her kidney function, as indicated by creatinine levels, is also within normal limits.

The patient's blood pressure is 115/50 mmHg, which is slightly low, but not significantly low enough to cause concern. Her heart rate is not mentioned, but given her blood pressure, it is likely within a normal range.

The patient's troponin level is 0.01 ng/mL, which is within the normal range, indicating no acute myocardial infarction. Her pro-BNP level is 120 ng/L, which is slightly elevated, but not significantly high enough to indicate severe heart failure.

The patient's TSH level is 2.91 mIU/L, which is within the normal range, indicating no thyroid dysfunction.

Given the patient's stable medical history, well-controlled medications, and relatively normal laboratory results, it is not surprising that the patient outcome is a survivor. The patient's treatment plan appears to be effective in managing her heart failure and preventing future cardiovascular events."
260,260,P0430,"Age: 73
Gender: Male 
Weight: 78 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 144/79 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,98
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,98
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 962.0
Protein (g/L): 69
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,1
Urea (mg/dL): 7,15
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 73-year-old male with a history of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipidemia, has a low left ventricular ejection fraction (LVEF) of 30%, indicating severe heart failure. However, the patient is on a multidrug regimen including beta blockers, loop diuretics, statins, and an ACE inhibitor, which are standard treatments for heart failure and ischemic cardiomyopathy.

The patient's blood work shows elevated creatinine levels (97.0 mmol/L), which may indicate some degree of kidney dysfunction, but it is not severe. The patient's hemoglobin and TSH levels are within normal ranges, indicating that there are no significant anemia or thyroid dysfunction contributing to the patient's condition.

The patient's troponin level is slightly elevated (0.01 ng/mL), but this is likely due to previous myocardial infarction rather than an acute coronary event. The pro-BNP level is elevated (962.0 ng/L), which is consistent with heart failure, but the patient's symptoms and overall clinical picture do not suggest severe heart failure.

The patient's ECG shows polymorphic ventricular extrasystoles, which are a common finding in patients with heart failure and can be associated with increased mortality. However, the absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia suggests that the patient's heart rhythm is generally stable.

Given the patient's age, comorbidities, and current medication regimen, the most likely reason for the patient's outcome is the effective management of their heart failure and ischemic cardiomyopathy. The patient's multidrug regimen and overall clinical picture suggest that they are receiving appropriate treatment for their condition, which has contributed to their survival."
261,261,P0435,"Age: 62
Gender: Male 
Weight: 100 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 45
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 66
Glucose (mmol/L): 8,7
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 5
LDL (mmol/L): 3,21
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 109.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,78
Urea (mg/dL): 6,99
LVEF (%): 44.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient's outcome is a survivor, which indicates that the patient has survived the current episode or event. Given the patient's medical history and current condition, several factors contribute to this outcome:

1. Optimal Medication Regimen: The patient is on a comprehensive medication regimen that includes beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor. This combination helps to manage the patient's idiopathic dilated cardiomyopathy, dyslipemia, and other related conditions.

2. Stable Blood Pressure: The patient's blood pressure is within a relatively normal range (130/70 mmHg), which is beneficial for cardiac health and suggests that the medication regimen is effective in controlling hypertension.

3. LVEF of 44%: Although the patient's left ventricular ejection fraction (LVEF) is below the normal range (50-70%), it is not severely decreased, indicating that the patient's heart is still functioning adequately to some extent. This suggests that the patient's cardiomyopathy is not in an advanced stage.

4. Normal Troponin Levels: The patient's troponin levels are within the normal range (0.005 ng/mL), which suggests that there is no acute myocardial infarction or significant cardiac damage.

5. Reasonable Electrolyte Balance: The patient's potassium levels (5 mEq/L) are within the normal range, which is essential for maintaining proper cardiac function.

6. Stable Renal Function: The patient's creatinine levels (115.0 μmol/L) are within the normal range, indicating that the kidneys are functioning adequately, and there is no significant renal impairment.

7. Adequate Thyroid Function: The patient's TSH levels (1.78 mIU/L) are within the normal range, which suggests that the thyroid gland is functioning properly.

8. No Severe Anemia: The patient's hemoglobin levels (139 g/L) are within the normal range, indicating that there is no severe anemia that could contribute to cardiac dysfunction.

9. No Severe Liver Dysfunction: The patient's liver function tests (ALT and AST) are within the normal range, indicating that there is no severe liver dysfunction.

Considering these factors, the patient's outcome as a survivor is likely due to the effective management of their underlying conditions, a stable cardiac function, and the absence of any acute complications or severe organ dysfunction."
262,262,P0436,"Age: 62
Gender: Male 
Weight: 80 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 43
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 34.0
Total Cholesterol (mmol/L): 4,01
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,2
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 184.0
Protein (g/L): 70
T3 (pg/dL): 0,04
T4 (ng/L): 13
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,25
Urea (mg/dL): 7,15
LVEF (%): 17.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type II
            ",survivor,"REASONING: 

The patient, a 62-year-old male with a history of ischemic dilated cardiomyopathy, has a complex medical profile. The patient's left ventricular ejection fraction (LVEF) is severely reduced at 17%, indicating significant left ventricular dysfunction. However, despite this, the patient has survived, which can be attributed to several factors:

1.  Optimal Medication Management: The patient is on a combination of medications that are beneficial for heart failure and arrhythmia management, including beta blockers, digoxin, loop diuretics, statins, and an ACE inhibitor. These medications help to reduce the workload on the heart, improve heart function, and prevent further cardiac damage.

2.  Controlled Blood Pressure: The patient's blood pressure is within a relatively normal range (110/60 mmHg), which is beneficial for heart health. Controlled blood pressure helps reduce the strain on the heart and prevents further cardiac damage.

3.  Low Troponin Levels: The patient's troponin level is within normal limits (0.005 ng/mL), indicating that there is no acute myocardial infarction or significant cardiac damage.

4.  Normal Electrolyte Levels: The patient's potassium level is within normal limits (4.5 mEq/L), which is essential for maintaining a stable cardiac rhythm and preventing arrhythmias.

5.  No Sustained Arrhythmias: The ECG report does not indicate any sustained arrhythmias, such as ventricular tachycardia, which could have contributed to the patient's survival.

6.  TSH and T3/T4 Levels: The patient's thyroid function tests are within normal limits, indicating that the patient's thyroid function is not contributing to the cardiac dysfunction.

7.  Albumin and Creatinine Levels: Although the patient's creatinine level is elevated (133.0 mmol/L), indicating some degree of renal impairment, the albumin level is within normal limits, suggesting that the patient's kidney function is not severely compromised.

8.  Pro-BNP Level: The patient's Pro-BNP level is elevated (184.0 ng/L), which is consistent with heart failure. However, the patient's survival suggests that the Pro-BNP level is not indicative of a catastrophic cardiac event.

Considering these factors, the patient's survival can be attributed to the effective management of their heart failure and arrhythmias, controlled blood pressure, and the absence of acute cardiac damage or significant electrolyte imbalances."
263,263,P0437,"Age: 53
Gender: Male 
Weight: 100 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,93
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,28
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 12721.0
Protein (g/L): 67
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,825
Urea (mg/dL): 6,16
LVEF (%): 25.0
Medications: Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's medical history of ischemic dilated cardiomyopathy and myocardial infarction, it is not surprising that the patient has a low left ventricular ejection fraction (LVEF) of 25%. This suggests that the patient has significant left ventricular dysfunction, which is a common consequence of ischemic heart disease.

The patient's elevated Pro-BNP (Brain Natriuretic Peptide) level of 12721.0 ng/L is also consistent with heart failure, as BNP is a well-established biomarker for cardiac dysfunction and heart failure.

The patient's ECG findings of polymorphic ventricular extrasystoles suggest that the patient has some degree of ventricular arrhythmia, which can be a concern in patients with heart failure and ischemic cardiomyopathy.

Despite these concerning factors, the patient is on appropriate medications for heart failure and ischemic cardiomyopathy, including beta blockers, statins, ACE inhibitors, and nitrovasodilators. These medications are known to improve outcomes in patients with heart failure and ischemic cardiomyopathy.

The patient's NYHA Class II classification indicates that the patient has mild to moderate symptoms of heart failure, which is consistent with the patient's overall clinical picture.

The patient's laboratory values, including the normal hemoglobin, potassium, and sodium levels, suggest that the patient is not experiencing significant electrolyte imbalances or anemia, which can be contributing factors to poor outcomes in heart failure patients.

Overall, while the patient has significant cardiac dysfunction and a history of ischemic heart disease, the patient is on appropriate medications and has a relatively mild NYHA Class II classification, which may have contributed to the patient's survival."
264,264,P0441,"Age: 73
Gender: Male 
Weight: 90 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,4
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1107.0
Protein (g/L): 62
T3 (pg/dL): 0,04
T4 (ng/L): 16
TSH (mIU/L): 2,55
Urea (mg/dL): 8,99
LVEF (%): 34.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome as a survivor can be attributed to several factors:

1. Current Medications: The patient is on a comprehensive regimen of medications that target multiple aspects of heart failure and arrhythmias, including Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, and Nitrovasodilator. These medications are crucial in managing heart failure, reducing blood pressure, and preventing arrhythmias.

2. NYHA Class II: The patient's New York Heart Association (NYHA) class indicates that the patient experiences some limitations in physical activity but is still able to perform ordinary physical activity without symptoms of heart failure. This suggests that the patient's heart condition is relatively well-managed.

3. LVEF 34%: Although the patient's left ventricular ejection fraction (LVEF) is significantly reduced, indicating severe systolic dysfunction, it is not as low as some other patients with ischemic dilated cardiomyopathy. The LVEF of 34% is still within the range where some patients can survive with appropriate medical management.

4. Pro-BNP levels: The patient's B-type natriuretic peptide (BNP) level of 1107 ng/L is elevated, indicating that the patient's heart is under strain. However, it is not excessively high, suggesting that the patient's condition is not in acute decompensation.

5. ECG findings: The presence of ventricular extrasystoles and non-sustained ventricular tachycardia (VT) on the ECG indicates arrhythmias, but the patient is not in sustained VT, which is a more ominous sign. The absence of paroxysmal supraventricular tachyarrhythmia and bradycardia suggests that the patient's arrhythmias are primarily ventricular in origin.

6. Laboratory results: The patient's laboratory results, including electrolyte levels, liver function tests, and kidney function, are within relatively normal limits, indicating that the patient's overall health is not significantly compromised.

Considering these factors, the patient's outcome as a survivor can be attributed to the effectiveness of their current medical management, relatively well-managed heart failure, and the absence of severe arrhythmias or acute decompensation."
265,265,P0442,"Age: 63
Gender: Male 
Weight: 67 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,19
Creatinine (mmol/L): 160.0
Gamma-glutamil transpeptidase (IU/L): 125
Glucose (mmol/L): 3,3
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 6,2
LDL (mmol/L): 2,51
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 637.0
Protein (g/L): 82
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,825
Urea (mg/dL): 12,15
LVEF (%): 52.0
Medications: Calcium Channel Blocker, Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to several factors evident from the provided data. 

Firstly, the patient's LVEF (Left Ventricular Ejection Fraction) of 52% indicates that the heart is still functioning adequately, albeit not optimally. This suggests that the patient's idiopathic dilated cardiomyopathy has not progressed to a severe stage where the heart's pumping ability is significantly compromised.

Secondly, the patient's blood pressure is within a relatively normal range (140/70 mmHg), which is not excessively high or low. This is crucial as hypertension is a significant risk factor for cardiovascular disease and mortality.

Thirdly, the patient's medication regimen, consisting of a Calcium Channel Blocker, Beta Blockers, and an ACE Inhibitor, is appropriate for managing hypertension and heart failure symptoms. These medications help to reduce blood pressure, slow the heart rate, and improve the heart's pumping efficiency.

Fourthly, the patient's laboratory results, such as the low levels of Troponin (0.04 ng/mL) and normal levels of TSH (0.825 mIU/L), indicate that there is no acute myocardial infarction or thyroid dysfunction, which could have contributed to a poorer outcome.

Lastly, the patient's age (63) and NYHA Class II classification indicate that the patient is not in a high-risk category for mortality. NYHA Class II patients experience symptoms of heart failure with mild limitations in physical activity.

Considering these factors, the patient's overall clinical picture suggests that they are receiving adequate treatment for their heart condition, and their heart function is not severely compromised. Therefore, the patient's outcome of survival is likely due to the combination of effective medical management and the relatively mild progression of their underlying condition."
266,266,P0443,"Age: 82
Gender: Female 
Weight: 88 kg
Height: 152 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,76
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 7
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 5,5
LDL (mmol/L): 3,7
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 320.0
Protein (g/L): 78
T3 (pg/dL): 0,02
T4 (ng/L): 21
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,43
Urea (mg/dL): 9,15
LVEF (%): 39.0
Medications: Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Unknown ventricular extrasystole code
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient's outcome of survival can be attributed to several factors based on the provided information. 

Firstly, the patient's age of 82 years is considered elderly, but it is not unusually high for a patient with a history of Hypertensive cardiomyopathy and Hypertension. The patient's NYHA Class II indicates that she has some limitation in physical activity but is still able to perform daily activities without significant symptoms. This suggests that her heart function is not severely compromised at this point.

The patient's blood pressure is 140/80 mmHg, which is within a relatively normal range, indicating that her hypertension is well-controlled. The use of ACE Inhibitor and Loop Diuretics suggests that her hypertension and heart failure symptoms are being managed with appropriate medication.

The patient's laboratory results show a relatively normal hemoglobin level, which indicates that she does not have significant anemia. Her total cholesterol and LDL levels are slightly elevated, but her HDL level is low, which is a risk factor for cardiovascular disease. However, her triglyceride levels are not provided, which would be useful to assess her lipid profile further.

The patient's LVEF of 39% indicates that her left ventricular function is mildly impaired, which is consistent with her history of Hypertensive cardiomyopathy. However, her LVEF is not critically low, and she does not have signs of acute coronary syndrome or severe heart failure.

The patient's TSH level is within the normal range, which suggests that her thyroid function is not contributing to her cardiac condition. Her T3 and T4 levels are also within normal limits, indicating that her thyroid function is normal.

The patient's Pro-BNP level of 320 ng/L is elevated, which suggests that she has some degree of heart failure. However, her Troponin level is within normal limits, indicating that she does not have acute myocardial infarction.

The patient's ECG shows a TPSV, which is a type of supraventricular tachyarrhythmia. However, this is not a life-threatening condition and is likely being managed with medication.

Overall, the patient's outcome of survival is likely due to the combination of her relatively controlled hypertension, well-managed heart failure symptoms, and lack of acute coronary syndrome or severe heart failure. Her mildly impaired LVEF and elevated Pro-BNP level suggest that she requires ongoing management and monitoring of her heart condition, but her current medications and medical management appear to be effective in preventing further deterioration."
267,267,P0444,"Age: 58
Gender: Male 
Weight: 115 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 36
ALT or GPT (IU/L): 52.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 3,47
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 149
Glucose (mmol/L): 5
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,91
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 1809.0
Protein (g/L): 64
T3 (pg/dL): 0,03
T4 (ng/L): 22
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,14
Urea (mg/dL): 6,82
LVEF (%): 70.0
Medications: Calcium Channel Blocker, Angiotensin II Receptor Blocker, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's medical history and current condition, the outcome of survival can be attributed to several factors:

1. Effective management of hypertension: The patient is on a Calcium Channel Blocker, Angiotensin II Receptor Blocker, and Loop Diuretics, which are all commonly used to manage hypertension and its complications. This suggests that the patient's blood pressure is well-controlled, reducing the risk of further cardiac damage.

2. Moderate left ventricular ejection fraction (LVEF): The patient's LVEF is 70%, which is within the normal range (50-70%). This indicates that the patient's heart is pumping blood effectively, which is a positive prognostic indicator.

3. Low troponin levels: The patient's troponin levels are within the normal range, indicating that there is no acute myocardial infarction (heart attack) or significant cardiac damage.

4. Reasonable lipid profile: The patient's total cholesterol and LDL levels are elevated, but the HDL level is also within a relatively healthy range. This suggests that the patient is at a lower risk for cardiovascular events.

5. No signs of severe cardiac arrhythmias: The ECG does not show any sustained ventricular tachycardia or bradycardia, which are both indicators of potentially life-threatening cardiac conditions.

6. Normal TSH and T3/T4 levels: The patient's thyroid function is within the normal range, which is essential for maintaining cardiac function.

7. Albumin and protein levels: The patient's albumin and protein levels are within the normal range, indicating that there is no significant liver dysfunction or kidney damage.

Considering these factors, the patient's outcome of survival suggests that the treatment plan is effective in managing the patient's hypertension and cardiac condition, and the patient is currently not experiencing any life-threatening cardiac complications."
268,268,P0447,"Age: 71
Gender: Female 
Weight: 67 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 131/57 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 42
ALT or GPT (IU/L): 36.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 5,53
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,31
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 5038.0
Protein (g/L): 69
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,5
Urea (mg/dL): 9,32
LVEF (%): 13.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome as a survivor can be attributed to several factors in her medical history and current condition. 

Firstly, the patient is on appropriate medications for her condition, including beta blockers, statins, and an ACE inhibitor, which are all standard treatments for idiopathic dilated cardiomyopathy and dyslipemia. Beta blockers help reduce the heart rate and the force of the heart's contractions, while statins help lower cholesterol levels, and ACE inhibitors help reduce blood pressure and strain on the heart.

The patient's LVEF (Left Ventricular Ejection Fraction) is 13.0%, which is significantly reduced, indicating severe heart failure. However, the patient's Pro-BNP level of 5038.0 ng/L is elevated, indicating increased stress on the heart, but not to the point of acute cardiac failure.

The patient's blood pressure is within a relatively normal range (131/57 mmHg), which suggests that her blood pressure is being well-managed. Additionally, her hemoglobin level is within the normal range, indicating that her kidneys are functioning relatively well, which is crucial for patients with heart failure.

The patient's ECG shows ventricular extrasystole and non-sustained ventricular tachycardia, but these are not life-threatening conditions in themselves. The absence of bradycardia, paroxysmal supraventricular tachyarrhythmia, and the fact that the ventricular tachycardia is non-sustained also suggest that the patient's heart is not experiencing severe arrhythmias.

Considering these factors, it appears that the patient's heart failure is being managed effectively, and she is receiving appropriate treatment for her condition. Therefore, the patient's outcome as a survivor can be attributed to the effectiveness of her current treatment regimen and the absence of severe cardiac complications."
269,269,P0449,"Age: 64
Gender: Female 
Weight: 47 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 102/40 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 46
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 32
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 107.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 5,2
LDL (mmol/L): 1,63
Sodium (mEq/L): 130.0
Pro-BNP (ng/L): 105.0
Protein (g/L): 76
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,18
Urea (mg/dL): 9,98
LVEF (%): 35.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 64-year-old female with a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weak and the heart chambers enlarge, reducing the heart's ability to pump blood effectively. Given her low left ventricular ejection fraction (LVEF) of 35%, she is at a high risk of heart failure.

The patient's current medications, beta blockers and ACE inhibitors, are standard treatments for heart failure and dilated cardiomyopathy. Beta blockers help slow the heart rate and reduce the force of contraction, while ACE inhibitors help relax blood vessels and reduce blood pressure, which can help reduce the workload on the heart.

The patient's blood pressure is within a relatively normal range (102/40 mmHg), which is not excessively high, but her low diastolic pressure may indicate that her heart is not pumping effectively. Her heart rate is not mentioned, but given her age and medical history, it is likely to be within a normal range.

The patient's laboratory results show elevated creatinine levels (133.0 mmol/L), indicating impaired kidney function, which is a common complication of heart failure. Her albumin levels are slightly low (46 g/L), which can be a sign of malnutrition or liver disease, but in this context, it is more likely related to heart failure. Her liver enzymes (ALT and AST) are within normal limits, indicating that her liver function is not significantly impaired.

The patient's lipid profile shows elevated total cholesterol (4.03 mmol/L) and LDL (1.63 mmol/L) levels, which are risk factors for cardiovascular disease. However, her HDL level is low (1.11 mmol/L), which can also contribute to cardiovascular disease.

The patient's pro-BNP level is elevated (105.0 ng/L), which is a biomarker of heart failure. Her troponin level is normal (0.01 ng/mL), indicating that she does not have acute myocardial infarction.

Given her age, medical history, and laboratory results, the patient's survival outcome is likely due to the following factors:

1. Optimal medical management: The patient is on standard medications for heart failure and dilated cardiomyopathy, which is helping to manage her symptoms and slow disease progression.
2. Mild symptoms: The patient's NYHA class is II, indicating that she has mild symptoms of heart failure, which suggests that her disease is not yet advanced.
3. Low risk of acute complications: The patient does not have any acute complications such as acute myocardial infarction, arrhythmias, or severe kidney dysfunction.
4. Good supportive care: The patient is likely receiving regular follow-up and monitoring, which is essential for managing heart failure and preventing complications.

In summary, the patient's survival outcome is likely due to a combination of optimal medical management, mild symptoms, low risk of acute complications, and good supportive care."
270,270,P0450,"Age: 70
Gender: Female 
Weight: 94 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 106/45 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 36
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 62.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,43
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 333.0
Protein (g/L): 67
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,64
Urea (mg/dL): 5,99
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 70-year-old female with a history of ischemic dilated cardiomyopathy, diabetes, hypertension, and myocardial infarction. Despite her complex medical history, the patient has been on a regimen of calcium channel blockers, beta blockers, statins, ACE inhibitors, and nitrovasodilators. This comprehensive medication regimen suggests that her heart condition has been managed to some extent.

The patient's LVEF (left ventricular ejection fraction) is 30%, which is below the normal range (50-70%). However, the fact that she is a survivor indicates that her heart is still functioning to some extent, despite the reduced ejection fraction.

The low levels of troponin (0.01 ng/mL) suggest that there is minimal ongoing myocardial damage, which is a positive sign. Additionally, the patient's pro-BNP (B-type natriuretic peptide) level is 333.0 ng/L, which is elevated but not extremely high, indicating that her heart is under some stress but not excessively.

The patient's ECG shows monomorphic ventricular extrasystoles, but no sustained ventricular tachycardia, which is a positive sign. The absence of other arrhythmias such as paroxysmal supraventricular tachyarrhythmia and bradycardia further suggests that her heart rhythm is relatively stable.

The patient's laboratory results show a slightly elevated creatinine level (62.0 mmol/L), which may indicate some degree of renal impairment, but it is not severe. Her glucose level (6.9 mmol/L) is slightly elevated, indicating diabetes, but it is well-controlled. Her lipid profile shows a high total cholesterol level (3.88 mmol/L), but the LDL level is relatively well-controlled with statin therapy.

Overall, while the patient has a complex medical history and several comorbidities, her medication regimen and laboratory results suggest that her heart condition is being managed effectively. The fact that she is a survivor indicates that her heart is still functioning to some extent, and with continued management and monitoring, she can continue to live with her condition."
271,271,P0451,"Age: 57
Gender: Female 
Weight: 64 kg
Height: 147 cm
NYHA Class: II
Blood Pressure: 89/53 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,36
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 114.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,55
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 1742.0
Protein (g/L): 68
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,93
Urea (mg/dL): 8,99
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 57-year-old female with a history of idiopathic dilated cardiomyopathy, dyslipemia, and hypertension. The patient's left ventricular ejection fraction (LVEF) is severely reduced at 20%, indicating significant left ventricular dysfunction. The elevated Pro-BNP level of 1742 ng/L further supports the presence of heart failure.

The patient is on optimal medical therapy for heart failure, including beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor. The use of these medications is consistent with the current guidelines for the management of heart failure with reduced ejection fraction (HFrEF).

The patient's blood pressure is low at 89/53 mmHg, which may be a result of the diuretic therapy. The serum creatinine level is elevated at 80.0 μmol/L, indicating some degree of renal impairment, likely secondary to the heart failure.

The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are common findings in patients with heart failure and dilated cardiomyopathy. However, there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias.

Given the patient's optimal medical therapy, low blood pressure, and absence of life-threatening arrhythmias, the outcome of survival is likely due to the effectiveness of the treatment plan and the patient's overall clinical stability. The patient's reduced LVEF and elevated Pro-BNP level indicate that the heart failure is still present, but the patient's ability to tolerate the disease process and respond to treatment suggests that she is stable at the moment."
272,272,P0452,"Age: 51
Gender: Male 
Weight: 61 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 100/55 mmHg
Past Medical History: Other HF etiology, Diabetes
Albumin (g/L): 46
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 5,25
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 48
Glucose (mmol/L): 7,7
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4
LDL (mmol/L): 3,36
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 2311.0
Protein (g/L): 78
T3 (pg/dL): 0,04
T4 (ng/L): 22
Troponin (ng/mL): 0,14
TSH (mIU/L): 0,742
Urea (mg/dL): 4,99
LVEF (%): 18.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 51-year-old male with a history of heart failure (HF) and diabetes, classified as NYHA Class III, indicating moderate to severe symptoms of heart failure. His current medications include beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, which are standard treatments for heart failure and hypertension.

The patient's laboratory results show elevated levels of pro-BNP (2311.0 ng/L), which is a biomarker for heart failure, and a low left ventricular ejection fraction (LVEF) of 18.0%, indicating reduced cardiac function. His glucose level is slightly elevated at 7.7 mmol/L, but his hemoglobin A1c level is not provided, which would give a better indication of long-term glucose control.

The patient's lipid profile shows a high total cholesterol level (5.25 mmol/L) and a low HDL level (1.19 mmol/L), indicating a high risk for cardiovascular disease. His LDL level is elevated at 3.36 mmol/L, which also contributes to his cardiovascular risk.

The patient's ECG shows non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles, which can be associated with increased risk of sudden cardiac death. However, the absence of sustained ventricular tachycardia or other life-threatening arrhythmias is a positive sign.

Considering the patient's age, symptoms, and laboratory results, the most likely cause of his heart failure is his underlying heart disease, possibly due to a previous myocardial infarction or cardiomyopathy. His diabetes and high blood pressure likely contribute to his heart failure, but the exact cause is not specified.

The patient's outcome of survival suggests that he is receiving appropriate medical treatment for his heart failure and hypertension, and his medications are likely helping to manage his symptoms and prevent further cardiac damage. His low TSH level (0.742 mIU/L) and normal T3 and T4 levels suggest that his thyroid function is within normal limits, which is important for heart health."
273,273,P0453,"Age: 58
Gender: Male 
Weight: 65 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 52
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 3,39
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 64
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 5,2
LDL (mmol/L): 1,24
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 868.0
Protein (g/L): 90
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,09
TSH (mIU/L): 2,8
Urea (mg/dL): 8,99
LVEF (%): 37.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 58-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, and a previous myocardial infarction. The patient's left ventricular ejection fraction (LVEF) is 37%, indicating severe systolic heart failure. The patient is on a regimen of beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, which is a standard treatment for heart failure with reduced ejection fraction.

The patient's laboratory results show elevated levels of troponin (0.09 ng/mL), indicating myocardial damage, and a high level of pro-BNP (868 ng/L), which is a marker of heart failure. The patient's creatinine level (106.0 mmol/L) is elevated, indicating impaired renal function, which is common in patients with heart failure.

The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are arrhythmias that can be associated with heart failure. However, the patient is being treated with beta blockers and an ACE inhibitor, which are effective in managing these arrhythmias.

Given the patient's severe heart failure and the presence of arrhythmias, it is likely that the patient was at high risk for adverse outcomes. However, the patient's ability to survive suggests that the treatment plan is effective in managing the patient's condition. The patient's medication regimen is likely contributing to the patient's survival, as it is addressing the underlying causes of heart failure and reducing the risk of arrhythmias.

Additionally, the patient's TSH level is within the normal range, which suggests that there is no underlying thyroid dysfunction contributing to the patient's heart failure. The patient's T3 and T4 levels are also within the normal range, which suggests that there is no underlying thyroid dysfunction contributing to the patient's heart failure.

In conclusion, the patient's survival is likely due to the effectiveness of the treatment plan, which is addressing the underlying causes of heart failure and reducing the risk of arrhythmias."
274,274,P0454,"Age: 52
Gender: Male 
Weight: 110 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 46
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 45.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 234
Glucose (mmol/L): 7,87
Hemoglobin (g/L): 148.0
HDL (mmol/L): 0,9
Potassium (mEq/L): 4,93
LDL (mmol/L): 1,91
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 690.0
Protein (g/L): 79
T3 (pg/dL): 0,0459
T4 (ng/L): 15,19
Troponin (ng/mL): 0,3
TSH (mIU/L): 3,07
Urea (mg/dL): 5,4
LVEF (%): 35.0
Medications: Diabetes Medication, Amiodarone, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 52-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, hypertension, and myocardial infarction. Despite these multiple comorbidities and a reduced left ventricular ejection fraction (LVEF) of 35%, the patient is a survivor.

Several factors contribute to the patient's survival:

1.  Optimal medical therapy: The patient is on a comprehensive regimen of medications, including ACE inhibitors, beta-blockers (Digoxin), statins, and diuretics, which are all evidence-based treatments for heart failure and ischemic cardiomyopathy. The presence of Amiodarone and Nitrovasodilator may also be contributing to the patient's survival by controlling arrhythmias and reducing afterload.

2.  Control of comorbidities: The patient's diabetes is being managed with medication, and his lipid profile is being controlled with statins. Although his total cholesterol level is elevated, the LDL level is well within target, indicating effective statin therapy.

3.  Monitoring and management of heart failure: The patient's NYHA class is II, indicating that he is experiencing some limitations in physical activity but is still able to perform everyday tasks without severe symptoms. The use of Loop Diuretics and Spironolactone suggests that the patient's volume status is being carefully managed, and his symptoms are being controlled.

4.  Electrocardiogram (ECG) findings: While the patient has polymorphic ventricular extrasystoles, there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias. This suggests that the patient's cardiac rhythm is relatively stable.

5.  Laboratory values: Although the patient has elevated liver enzymes (ALT and AST) and a high level of gamma-glutamil transpeptidase, these are likely related to his statin therapy. The patient's hemoglobin level is within the normal range, indicating that his anemia is not a significant concern. His TSH level is within the normal range, and his thyroid function is not a contributing factor to his cardiac condition.

In summary, the patient's survival can be attributed to a combination of optimal medical therapy, effective management of comorbidities, careful monitoring and management of heart failure, stable cardiac rhythm, and normal laboratory values."
275,275,P0455,"Age: 67
Gender: Male 
Weight: 64 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 47
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,12
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 244
Glucose (mmol/L): 9,2
Hemoglobin (g/L): 131.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 5,1
LDL (mmol/L): 3,59
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 8797.0
Protein (g/L): 80
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,58
Urea (mg/dL): 14,81
LVEF (%): 23.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient's outcome is a survivor, which is a positive outcome considering the patient's complex medical history and current clinical presentation. Several factors contributed to this outcome:

1.  Optimal Medication Management: The patient is on a combination of beta blockers, digoxin, loop diuretics, and ACE inhibitors, which are standard treatments for heart failure and hypertension. This multidrug regimen likely helped manage the patient's symptoms and slowed disease progression.

2.  Continuous Monitoring and Intervention: The presence of a healthcare team monitoring the patient's condition, particularly the ECG findings, allowed for timely intervention in cases of ventricular extrasystole, non-sustained VT, and potential paroxysmal supraventricular tachyarrhythmia. This proactive approach likely prevented more severe arrhythmias and cardiac complications.

3.  Supportive Care: The patient's albumin and protein levels were within relatively normal limits, indicating that the liver function was not severely compromised, which is essential for the proper metabolism of medications. The patient's hemoglobin level was also within a relatively normal range, suggesting that anemia was not a significant concern.

4.  Limited Evidence of Organ Dysfunction: Although the patient has diabetes, dyslipidemia, and hypertension, the creatinine level was not excessively elevated, indicating that kidney function was not severely impaired. The patient's urea level was also within a relatively normal range, further indicating that renal function was not significantly compromised.

5.  TSH and Thyroid Function: The patient's TSH level was within a normal range, which suggests that thyroid function was not a contributing factor to the patient's cardiac condition.

6.  Limited Evidence of Acute Coronary Syndrome: The troponin level was within a normal range, indicating that there was no evidence of acute coronary syndrome, which is a significant risk factor for cardiac complications.

7.  LVEF: Although the patient's left ventricular ejection fraction (LVEF) was significantly reduced at 23%, this value is not uncommon in patients with dilated cardiomyopathy. The fact that the patient was able to survive despite this low LVEF suggests that the patient's heart function was not as severely compromised as the LVEF value might suggest.

In summary, the combination of optimal medication management, continuous monitoring, supportive care, and limited evidence of organ dysfunction contributed to the patient's positive outcome."
276,276,P0456,"Age: 38
Gender: Male 
Weight: 80 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 110/50 mmHg
Past Medical History: Post-myocardial dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 153.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 5,1
LDL (mmol/L): 2,33
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 47.0
Protein (g/L): 71
T3 (pg/dL): 0,07
T4 (ng/L): 15
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,19
Urea (mg/dL): 6,32
LVEF (%): 42.0
Medications: ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 38-year-old male with a history of post-myocardial dilated cardiomyopathy, which is a condition where the heart muscle is weakened and the heart chambers are enlarged, leading to reduced heart function. Despite this, the patient's left ventricular ejection fraction (LVEF) is 42%, which is below the normal range (50-70%), but still relatively high, indicating that the heart is still pumping some blood effectively.

The patient's blood pressure is within a relatively normal range (110/50 mmHg), and his heart rate is not excessively high or low. His ECG shows monomorphic ventricular extrasystoles, which are abnormal heartbeats that originate from the ventricles, but are not a cause for immediate concern.

The patient's laboratory results show a slightly elevated creatinine level (80.0 μmol/L), which indicates some kidney impairment, but not severe. His liver enzymes (ALT and AST) are within normal limits, and his total cholesterol and LDL levels are elevated, but not excessively so. His glucose level is slightly elevated, but not indicative of diabetes.

The patient's thyroid function tests (TSH, T3, and T4) are within normal limits, indicating that his thyroid function is normal. His pro-BNP level is 47.0 ng/L, which is slightly elevated, but not excessively so, indicating some degree of cardiac stress, but not severe.

The patient's hemoglobin level is within normal limits, and his electrolyte levels (potassium and sodium) are also within normal limits.

Considering the patient's age, gender, and medical history, and the laboratory results, the most likely reason for the patient's outcome is that the patient's heart condition is not severe enough to cause immediate cardiac failure or death. The patient's LVEF is still relatively high, and the patient is on an ACE inhibitor, which is a medication that helps to reduce the workload on the heart and improve its function. The patient's overall clinical presentation suggests that the patient is stable and not in immediate danger, which is consistent with a survivor outcome."
277,277,P0457,"Age: 48
Gender: Female 
Weight: 62 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 177.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 119.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,74
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 380.0
Protein (g/L): 72
T3 (pg/dL): 0,05
T4 (ng/L): 23
Troponin (ng/mL): 0,06
TSH (mIU/L): 3,58
Urea (mg/dL): 11,48
LVEF (%): 35.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 48-year-old female with a history of idiopathic dilated cardiomyopathy, dyslipemia, and hypertension, has been managed with a multidisciplinary treatment approach that includes beta blockers, digoxin, loop diuretics, spironolactone, statins, and an ACE inhibitor. The patient's current medication regimen appears to be well-tolerated, and the blood pressure is within a relatively normal range (110/70 mmHg).

The patient's laboratory results show a relatively high level of creatinine (177.0 μmol/L), which may indicate impaired renal function, but the urea level (11.48 mg/dL) is within a relatively normal range. The elevated pro-BNP (380.0 ng/L) suggests that the patient has heart failure symptoms, consistent with her NYHA Class III classification.

The patient's LVEF (left ventricular ejection fraction) is 35%, indicating significant left ventricular dysfunction, which is consistent with her diagnosis of dilated cardiomyopathy. However, the patient's troponin level is within a normal range (0.06 ng/mL), indicating that there is no acute myocardial infarction.

The patient's TSH level is within a normal range (3.58 mIU/L), and the T3 and T4 levels are also within a normal range (0.05 pg/dL and 23 ng/L, respectively). The patient's potassium level (4.7 mEq/L) is within a relatively normal range.

The patient's ECG shows non-sustained ventricular tachycardia, which is a common finding in patients with dilated cardiomyopathy. However, the patient does not have any sustained ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia.

Given the patient's history, laboratory results, and ECG findings, it is likely that the patient's survival is due to the effective management of her heart failure symptoms and the use of evidence-based medications. The patient's renal function and electrolyte levels are relatively well-preserved, and there is no evidence of acute coronary syndrome or severe cardiac arrhythmias. Therefore, the patient's survival is likely due to the comprehensive management of her dilated cardiomyopathy and heart failure."
278,278,P0459,"Age: 65
Gender: Male 
Weight: 117 kg
Height: 181 cm
NYHA Class: II
Blood Pressure: 130/60 mmHg
Past Medical History: Other HF etiology, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 128.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,49
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 382.0
Protein (g/L): 72
T3 (pg/dL): 0,03
T4 (ng/L): 23
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,28
Urea (mg/dL): 10,82
LVEF (%): 38.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 65-year-old male with a history of heart failure (HF), diabetes, hypertension, and myocardial infarction, which suggests a high risk for cardiovascular disease. Despite this, the patient has been managed with a comprehensive treatment plan including diabetes medication, beta blockers, loop diuretics, spironolactone, and an ACE inhibitor. The presence of ventricular extrasystole on the ECG may indicate some level of cardiac dysfunction, but it is not a life-threatening condition in this case.

The patient's LVEF (left ventricular ejection fraction) is 38%, which is below the normal range (50-70%), indicating some degree of heart failure. However, the patient's NYHA class is II, indicating that the patient is experiencing some symptoms of heart failure, but is still able to perform daily activities without significant limitation.

The patient's laboratory results show elevated creatinine levels (124.0 μmol/L), indicating some degree of renal impairment, which can be a complication of heart failure. However, the patient's blood urea level is within a relatively normal range (10.82 mg/dL), suggesting that the renal impairment is not severe.

The patient's Pro-BNP level is elevated (382.0 ng/L), which is consistent with heart failure, but the patient's overall clinical picture and treatment plan suggest that the heart failure is being managed effectively.

The patient's TSH level is within a normal range (3.28 mIU/L), indicating that there is no evidence of thyroid dysfunction, which can be a contributing factor to heart failure.

The patient's Troponin level is within a normal range (0.03 ng/mL), indicating that there is no evidence of acute myocardial infarction.

Considering the patient's overall clinical picture, treatment plan, and laboratory results, it is likely that the patient has been effectively managed for their heart failure and other comorbidities, which has contributed to their survival."
279,279,P0462,"Age: 54
Gender: Male 
Weight: 65 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 150/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 55.0
AST or GOT (IU/L): 39.0
Total Cholesterol (mmol/L): 7,96
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 167
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 154.0
HDL (mmol/L): 1,97
Potassium (mEq/L): 3,7
LDL (mmol/L): 5,51
Sodium (mEq/L): 130.0
Pro-BNP (ng/L): 645.0
Protein (g/L): 79
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,35
Urea (mg/dL): 15,14
LVEF (%): 30.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Unknown ventricular extrasystole code
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient, a 54-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, hypertension, and myocardial infarction, has a complex clinical presentation. Despite the presence of multiple comorbidities and a low left ventricular ejection fraction (LVEF) of 30%, the patient has survived.

Several factors contribute to the patient's survival:

1.  Optimal medical therapy: The patient is on a comprehensive treatment regimen, including diabetes medication, angiotensin II receptor blocker, beta blockers, loop diuretics, spironolactone, and nitrovasodilators, which are all evidence-based therapies for heart failure and hypertension.
2.  Control of blood pressure: Although the patient's blood pressure is elevated at 150/90 mmHg, it is not severely hypertensive, which may indicate that the patient's blood pressure is being managed effectively with medication.
3.  Low troponin levels: The patient's troponin level of 0.01 ng/mL is within normal limits, indicating that there is no ongoing myocardial infarction or acute cardiac ischemia.
4.  Normal hemoglobin levels: The patient's hemoglobin level of 154 g/L is within the normal range, which may indicate that the patient is not experiencing significant anemia, which can be a risk factor for poor outcomes in heart failure patients.
5.  Low TSH levels: The patient's TSH level of 2.35 mIU/L is within the normal range, indicating that the patient's thyroid function is not contributing to their cardiac condition.
6.  No evidence of severe electrolyte imbalance: The patient's potassium level of 3.7 mEq/L is slightly low, but not critically low, which may indicate that the patient is not experiencing severe electrolyte imbalances that could contribute to cardiac arrhythmias or other complications.
7.  Pro-BNP level: The patient's Pro-BNP level of 645 ng/L is elevated, indicating that the patient has some degree of heart failure, but it is not excessively high, which may indicate that the patient's heart failure is being managed effectively.

Overall, the patient's survival can be attributed to a combination of optimal medical therapy, effective blood pressure control, low troponin levels, normal hemoglobin levels, normal TSH levels, no evidence of severe electrolyte imbalances, and an elevated but not excessively high Pro-BNP level."
280,280,P0463,"Age: 67
Gender: Female 
Weight: 60 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 142/61 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 39
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 126.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,9
LDL (mmol/L): 2,15
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 2853.0
Protein (g/L): 67
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,56
Urea (mg/dL): 7,32
LVEF (%): 47.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient's age and NYHA Class II classification indicate that she has a moderate level of heart failure symptoms, which is manageable with current treatment. The patient's left ventricular ejection fraction (LVEF) of 47% suggests that her idiopathic dilated cardiomyopathy has led to some degree of left ventricular dysfunction. 

The patient's blood pressure is within a relatively normal range (142/61 mmHg), which is likely a result of the angiotensin II receptor blocker and beta-blocker medications. The patient's serum creatinine level of 80.0 μmol/L is slightly elevated, but not significantly so, indicating that her renal function is still relatively preserved. 

The patient's pro-BNP level of 2853.0 ng/L is elevated, which is consistent with her heart failure diagnosis. However, the fact that she is on optimal medical therapy (angiotensin II receptor blocker, beta-blockers, and loop diuretics) and has not shown any signs of worsening heart failure symptoms (e.g., increased shortness of breath, leg swelling) suggests that her condition is stable.

The patient's ECG findings of monomorphic ventricular extrasystoles and non-sustained ventricular tachycardia are common in patients with heart failure and are not necessarily indicative of a poor prognosis. The absence of sustained ventricular tachycardia, paroxysmal supraventricular tachyarrhythmia, and bradycardia suggests that her cardiac rhythm is relatively stable.

Overall, the patient's stable medical therapy, preserved renal function, and lack of worsening symptoms or signs of cardiac instability suggest that she is a survivor, indicating a positive outcome."
281,281,P0464,"Age: 52
Gender: Male 
Weight: 69 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 90/60 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 6,57
Creatinine (mmol/L): 53.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,45
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,53
Sodium (mEq/L): 133.0
Protein (g/L): 73
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,03
Urea (mg/dL): 5,49
LVEF (%): 30.0
Medications: Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient's outcome as a survivor can be attributed to a combination of factors, including the patient's current treatment regimen and the relatively mild nature of their condition at the time of evaluation. 

The patient's low left ventricular ejection fraction (LVEF) of 30% indicates a reduced cardiac function, which is a hallmark of valvular cardiomyopathy. However, the patient's LVEF is not severely depressed, and their current medications, including beta blockers, spironolactone, and an ACE inhibitor, are all standard treatments for heart failure and may be contributing to their survival.

The patient's blood pressure is slightly low, which may be a consequence of their medication regimen, particularly the beta blockers. The absence of significant abnormalities in their liver enzymes (ALT and AST) and electrolytes (potassium) suggests that their medications are not causing significant side effects.

The patient's troponin level is within normal limits, which indicates that they are not experiencing an acute myocardial infarction or significant cardiac ischemia. The absence of ventricular tachycardia or non-sustained ventricular tachycardia on their ECG further suggests that they are not experiencing significant arrhythmias.

The patient's TSH level is within normal limits, which indicates that their thyroid function is not contributing to their cardiac condition. The patient's urea level is slightly elevated, which may indicate some degree of renal impairment, but this is not severe.

Overall, the patient's combination of medications and the relatively mild nature of their cardiac dysfunction at the time of evaluation likely contributed to their survival. However, it is essential to continue monitoring their condition and adjusting their treatment regimen as needed to prevent further deterioration."
282,282,P0465,"Age: 69
Gender: Male 
Weight: 80 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,21
Creatinine (mmol/L): 98.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,19
LDL (mmol/L): 1,58
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 799.0
Protein (g/L): 70
T3 (pg/dL): 0,0597
T4 (ng/L): 9,9
Troponin (ng/mL): 0,5
TSH (mIU/L): 0,73
Urea (mg/dL): 7,4
LVEF (%): 30.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient is a 69-year-old male with a history of idiopathic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension, presenting with a left ventricular ejection fraction (LVEF) of 30%, which is significantly reduced, indicating severe heart failure. The presence of non-sustained ventricular tachycardia (VT) and polymorphic ventricular extrasystoles on the ECG further supports the diagnosis of a compromised cardiac function.

The patient's Pro-BNP level of 799 ng/L is elevated, indicating increased ventricular wall stress, which is consistent with heart failure. The patient's hemoglobin level is within the normal range, and the troponin level is slightly elevated, suggesting some degree of myocardial injury.

The patient's lipid profile shows elevated total cholesterol and LDL levels, which are being managed with statins. The patient is also on beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, which are all appropriate medications for heart failure management.

Given the patient's severe heart failure symptoms, the presence of non-sustained VT, and the elevated Pro-BNP level, the patient's outcome as a survivor is likely due to the effective management of his heart failure symptoms and the use of appropriate medications. The patient's LVEF of 30% indicates a severe reduction in cardiac function, but the fact that he is a survivor suggests that the patient has been able to adapt to his condition and is tolerating his current medical therapy.

The patient's age and comorbidities, such as diabetes and hypertension, are also factors that contribute to his outcome as a survivor. The patient's TSH level is within the normal range, indicating that there is no evidence of hypothyroidism, which can also contribute to heart failure.

In summary, the patient's outcome as a survivor is likely due to the effective management of his heart failure symptoms, the use of appropriate medications, and the patient's ability to adapt to his condition despite his severe cardiac dysfunction."
283,283,P0470,"Age: 73
Gender: Male 
Weight: 71 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 33,8
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 3,18
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 120.0
HDL (mmol/L): 0,87
Potassium (mEq/L): 3,65
LDL (mmol/L): 1,91
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 5374.0
Protein (g/L): 69
Troponin (ng/mL): 0,05
TSH (mIU/L): 0,68
Urea (mg/dL): 7,1
LVEF (%): 35.0
Medications: Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's data, the outcome of survival can be attributed to several factors. The patient has a history of ischemic dilated cardiomyopathy, which suggests that the heart muscle has been damaged due to reduced blood flow, leading to a decrease in left ventricular ejection fraction (LVEF) of 35%. Despite this, the patient is on optimal medical therapy with loop diuretics, statins, and an ACE inhibitor, which are all standard treatments for heart failure and hypertension.

The patient's blood pressure is well-controlled at 140/80 mmHg, which is within a normal range, suggesting that the medication regimen is effective in managing hypertension. The patient's total cholesterol level is also within a normal range, indicating that the statin therapy is effective in lowering cholesterol levels.

The patient's creatinine level is slightly elevated at 124.0 μmol/L, which may indicate some degree of kidney impairment. However, this is not severe enough to suggest acute kidney injury, and the patient's urea level is within a normal range.

The patient's troponin level is elevated at 0.05 ng/mL, which may indicate some degree of cardiac damage, but it is not significantly elevated, suggesting that the patient is not experiencing an acute myocardial infarction.

The patient's pro-BNP level is elevated at 5374.0 ng/L, which is consistent with heart failure. However, the patient's LVEF is low, but not severely low, and the patient is on optimal medical therapy, which may have contributed to the patient's survival.

The patient's ECG shows a polymorphic ventricular extrasystole, which is a benign finding. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that the patient is not at high risk for arrhythmias.

Overall, the patient's survival can be attributed to the combination of optimal medical therapy, well-controlled blood pressure, and the absence of severe cardiac arrhythmias."
284,284,P0471,"Age: 74
Gender: Male 
Weight: 76 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 33,8
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 5,71
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,36
Potassium (mEq/L): 4,05
LDL (mmol/L): 3,85
Sodium (mEq/L): 132.0
Pro-BNP (ng/L): 557.0
Protein (g/L): 57,7
Troponin (ng/mL): 0,02
TSH (mIU/L): 0,37
Urea (mg/dL): 6,8
LVEF (%): 70.0
Medications: Calcium Channel Blocker
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient's outcome of survival can be attributed to several factors based on the provided data. 

1.  Age and NYHA Class II: The patient is 74 years old and classified as NYHA Class II, which indicates mild limitation of physical activity due to symptoms, but still able to perform ordinary physical activity without symptoms. This suggests that the patient has some level of functional reserve, which may have contributed to their survival.

2.  LVEF of 70%: The patient's left ventricular ejection fraction (LVEF) is within the normal range (50-70%), indicating that the heart is pumping blood efficiently. A higher LVEF suggests that the heart is able to maintain adequate cardiac output, which is crucial for survival.

3.  Troponin levels: The patient's troponin levels are within the normal range (0.02 ng/mL), indicating that there is no evidence of acute myocardial infarction or ongoing cardiac damage.

4.  Pro-BNP levels: Although the patient's Pro-BNP levels are elevated (557 ng/L), which may indicate heart failure, the levels are not extremely high. This could suggest that the patient's heart failure is not severe, and the patient is not in an acute decompensated state.

5.  Medications: The patient is on a calcium channel blocker, which is a common medication for hypertension and heart failure. This medication may have helped to control the patient's blood pressure and heart rate, contributing to their survival.

6.  ECG findings: The patient's ECG shows monomorphic ventricular extrasystoles, but no sustained ventricular tachycardia or bradycardia. This suggests that the patient's heart rhythm is relatively stable, which is a good prognostic sign.

7.  Laboratory results: The patient's laboratory results, including electrolyte levels, liver function tests, and kidney function tests, are within the normal range or only mildly elevated. This suggests that the patient's organ function is relatively preserved, which is a good prognostic sign.

In summary, the combination of the patient's age, functional status, LVEF, troponin levels, Pro-BNP levels, medications, ECG findings, and laboratory results all contributed to their survival."
285,285,P0472,"Age: 83
Gender: Male 
Weight: 67 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 105/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 42,7
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,65
Creatinine (mmol/L): 125.0
Gamma-glutamil transpeptidase (IU/L): 55
Glucose (mmol/L): 7,4
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 3,62
LDL (mmol/L): 1,84
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 4579.0
Protein (g/L): 74,9
Troponin (ng/mL): 0,09
TSH (mIU/L): 0,96
Urea (mg/dL): 12,2
LVEF (%): 60.0
Medications: Calcium Channel Blocker, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient is an 83-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, hypertension, and myocardial infarction. Despite these comorbidities, the patient's left ventricular ejection fraction (LVEF) is 60%, which is within the normal range (50-70%). This suggests that the patient's heart function is relatively preserved, which is a positive prognostic indicator.

The patient's blood pressure is within a relatively normal range (105/55 mmHg), and he is on medications that are commonly used to manage heart failure and hypertension, such as a calcium channel blocker, digoxin, loop diuretics, and an ACE inhibitor. These medications are likely contributing to the patient's stable condition.

The patient's laboratory results show some evidence of liver dysfunction (elevated AST and gamma-glutamil transpeptidase), but these are not significantly elevated and are unlikely to be a major contributor to the patient's outcome. The patient's glucose level is slightly elevated, but this is well-controlled with a medication regimen.

The patient's pro-BNP level is elevated at 4579.0 ng/L, which is consistent with heart failure. However, the patient's overall clinical presentation and laboratory results suggest that the heart failure is well-managed.

The patient's ECG shows a monomorphic ventricular extrasystole, but this is a common finding in patients with heart disease and is not a significant concern in this case.

Overall, the patient's stable medical history, well-controlled blood pressure, preserved LVEF, and effective medication regimen suggest that the patient is at low risk for cardiac complications and is likely to survive."
286,286,P0474,"Age: 49
Gender: Male 
Weight: 88 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 45,9
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 6,88
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 137.0
Potassium (mEq/L): 4,17
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 797.0
Protein (g/L): 82,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,33
Urea (mg/dL): 9
LVEF (%): 19.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 49-year-old male with a history of idiopathic dilated cardiomyopathy, has been prescribed a comprehensive treatment regimen consisting of beta blockers, loop diuretics, spironolactone, and an ACE inhibitor. These medications aim to manage symptoms, reduce morbidity, and improve survival in patients with heart failure.

The patient's current LVEF (Left Ventricular Ejection Fraction) of 19% indicates severe left ventricular dysfunction, which is consistent with his history of idiopathic dilated cardiomyopathy. However, despite this severe impairment, the patient is still alive, which suggests that his treatment regimen has been effective in managing his condition.

The patient's laboratory results, including normal electrolyte levels, low levels of liver enzymes (ALT and AST), and a relatively normal glucose level, indicate that his treatment has not caused significant adverse effects. The low Pro-BNP (B-type natriuretic peptide) level of 797 ng/L, while not normal, is not excessively high, suggesting that the patient is not experiencing acute decompensated heart failure.

The patient's ECG shows monomorphic ventricular extrasystoles, but there is no evidence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, or other life-threatening arrhythmias. This suggests that the patient's heart rhythm is relatively stable.

In conclusion, the patient's survival can be attributed to his comprehensive treatment regimen, which has likely helped to manage his symptoms, slow disease progression, and improve his quality of life."
287,287,P0475,"Age: 64
Gender: Female 
Weight: 73 kg
Height: 145 cm
NYHA Class: II
Blood Pressure: 115/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 43,2
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,59
Creatinine (mmol/L): 149.0
Gamma-glutamil transpeptidase (IU/L): 46
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,38
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,33
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 287.0
Protein (g/L): 77,6
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,88
Urea (mg/dL): 15
LVEF (%): 35.0
Medications: Diabetes Medication, Amiodarone, Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 64-year-old female with a history of idiopathic dilated cardiomyopathy, diabetes, and hypertension. Her current medications include diabetes medication, amiodarone, angiotensin II receptor blocker, loop diuretics, spironolactone, statins, and nitrovasodilators, which are all appropriate for her conditions. 

The patient's LVEF (left ventricular ejection fraction) is 35%, which is below the normal range (50-70%), indicating a reduced heart function. However, her blood pressure is within a relatively normal range (115/70 mmHg), and her creatinine level is elevated (149.0 mmol/L), which could indicate some degree of kidney dysfunction, possibly due to her underlying heart condition. 

The patient's glucose level is slightly elevated (6.6 mmol/L), which may be related to her diabetes. The total cholesterol level is slightly elevated (3.59 mmol/L), but her HDL and LDL levels are within a relatively normal range.

The pro-BNP level is elevated (287.0 ng/L), which can indicate heart failure. However, the troponin level is within a normal range (0.01 ng/mL), suggesting that there is no acute myocardial infarction.

Considering the patient's history, medications, and lab results, it appears that she is being well-managed for her conditions. The fact that she is a survivor suggests that her treatment plan is effective in managing her symptoms and preventing further complications. The lack of any acute cardiac events or severe complications in the provided data also supports this conclusion."
288,288,P0476,"Age: 64
Gender: Male 
Weight: 93 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 103/57 mmHg
Past Medical History: Other HF etiology, Dyslipemia
Albumin (g/L): 41,8
ALT or GPT (IU/L): 37.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,48
Creatinine (mmol/L): 111.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 151.0
HDL (mmol/L): 2,09
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,82
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 146.0
Protein (g/L): 68,2
T4 (ng/L): 20
TSH (mIU/L): 1,55
Urea (mg/dL): 10,48
LVEF (%): 38.0
Medications: Calcium Channel Blocker, Amiodarone, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 64-year-old male with a history of heart failure (HF) and dyslipemia. He is on a multidrug regimen including calcium channel blockers, amiodarone, beta blockers, statins, ACE inhibitors, and nitrovasodilators, which is consistent with the management of heart failure and arrhythmias.

The patient's laboratory results show evidence of heart failure, including elevated creatinine levels (111.0 mmol/L) and a low left ventricular ejection fraction (LVEF) of 38.0%. The elevated creatinine level indicates renal impairment, which is a common comorbidity in patients with heart failure.

The patient's lipid profile shows a total cholesterol level of 5.48 mmol/L, which is above the recommended level, but the patient is on statins, which is a common treatment for dyslipemia. The patient's low-density lipoprotein (LDL) level is 2.82 mmol/L, which is also above the recommended level.

The patient's thyroid function tests (T4 and TSH) are within normal limits, indicating no thyroid dysfunction.

The patient's ECG shows a polymorphic ventricular extrasystole, which is a common finding in patients with heart failure. The absence of sustained ventricular tachycardia and non-sustained ventricular tachycardia is a positive sign.

The patient's NT-proBNP level is elevated at 146.0 ng/L, which is consistent with heart failure. However, the patient's albumin level is within normal limits, which suggests that the patient does not have significant liver dysfunction.

Considering the patient's age, comorbidities, and treatment regimen, the patient's survival is likely due to the following factors:

1.  Multidrug regimen: The patient is on a comprehensive treatment regimen that includes beta blockers, ACE inhibitors, and statins, which are all evidence-based treatments for heart failure and dyslipemia.
2.  Close monitoring: The patient's ECG and laboratory results indicate that the patient is being closely monitored, which is essential for managing heart failure and arrhythmias.
3.  No acute decompensation: The patient's creatinine level and LVEF are not showing signs of acute decompensation, which is a common cause of mortality in patients with heart failure.
4.  Absence of severe arrhythmias: The absence of sustained ventricular tachycardia and non-sustained ventricular tachycardia is a positive sign, indicating that the patient's arrhythmias are not severe.

Overall, the patient's survival is likely due to a combination of effective treatment, close monitoring, and the absence of severe complications."
289,289,P0478,"Age: 80
Gender: Male 
Weight: 63 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 44,4
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 7,2
Hemoglobin (g/L): 114.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,91
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1544.0
Protein (g/L): 73,4
T4 (ng/L): 19
TSH (mIU/L): 0,38
Urea (mg/dL): 8,82
LVEF (%): 40.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is an 80-year-old male with a history of idiopathic dilated cardiomyopathy, diabetes, and dyslipidemia. His current medications include diabetes medication, beta blockers, loop diuretics, and an ACE inhibitor, which are all standard treatments for heart failure and hypertension.

The patient's LVEF (Left Ventricular Ejection Fraction) is 40%, which indicates a moderate to severe reduction in cardiac function, consistent with heart failure with reduced ejection fraction (HFrEF). However, despite this, the patient is classified as NYHA Class II, indicating that he has some limitations in physical activity but is still able to perform everyday activities without significant symptoms.

The patient's biomarkers, including high Pro-BNP (1544 ng/L) and elevated creatinine (103.0 mmol/L), suggest that he has significant cardiac stress and renal impairment. However, his blood pressure is well-controlled at 110/60 mmHg, which is likely due to the effects of his medications.

The patient's ECG shows non-sustained ventricular tachycardia, which is a common finding in patients with HFrEF. The presence of ventricular extrasystoles is also not uncommon in patients with heart failure.

Given the patient's age, comorbidities, and current medical treatment, it is likely that the patient is a survivor due to the following reasons:

1. Optimal medical therapy: The patient is on a standard treatment regimen for HFrEF, which includes beta blockers, loop diuretics, and an ACE inhibitor. This combination of medications has been shown to improve symptoms, reduce hospitalizations, and improve survival in patients with heart failure.
2. Well-controlled blood pressure: The patient's blood pressure is well-controlled, which is essential for reducing the risk of cardiac events and hospitalizations.
3. Stable cardiac function: Despite the patient's reduced LVEF, his cardiac function is stable, and he is not experiencing significant symptoms.
4. Absence of severe arrhythmias: The patient does not have severe arrhythmias, such as sustained ventricular tachycardia or atrial fibrillation, which can increase the risk of cardiac events.

In summary, the patient's optimal medical therapy, well-controlled blood pressure, stable cardiac function, and absence of severe arrhythmias are likely contributing factors to his survival."
290,290,P0479,"Age: 72
Gender: Male 
Weight: 54 kg
Height: 151 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 40
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 6,67
Creatinine (mmol/L): 129.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,41
Hemoglobin (g/L): 160.0
HDL (mmol/L): 1,49
Potassium (mEq/L): 4,5
LDL (mmol/L): 4,48
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 624.0
Protein (g/L): 67
T3 (pg/dL): 0,0615
T4 (ng/L): 11,73
Troponin (ng/mL): 0,8
TSH (mIU/L): 6,94
Urea (mg/dL): 11,9
LVEF (%): 30.0
Medications: Amiodarone, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient outcome of survival in this case can be attributed to a combination of factors, including the patient's current treatment regimen and the severity of their underlying condition.

The patient has a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge, leading to a decrease in the heart's ability to pump blood effectively. The patient's left ventricular ejection fraction (LVEF) of 30% indicates a significant impairment in cardiac function. However, the patient is being treated with ACE inhibitors, which are known to improve cardiac function and reduce mortality in patients with heart failure.

The patient is also taking loop diuretics, which are used to manage fluid overload and reduce symptoms of heart failure. Additionally, the patient is on amiodarone, an antiarrhythmic medication that helps to regulate the heart rhythm and prevent arrhythmias.

The patient's blood work shows elevated levels of troponin, which indicates some degree of cardiac damage, but the levels are not excessively high. The patient's BNP level is elevated at 624.0 ng/L, which suggests that the patient is experiencing some degree of heart failure, but the level is not extremely high.

The patient's ECG shows non-sustained ventricular tachycardia, which is a type of abnormal heart rhythm that can be a sign of underlying cardiac disease. However, the patient does not have a history of sustained ventricular tachycardia or other severe arrhythmias.

Considering the patient's treatment regimen and the severity of their underlying condition, it is likely that the patient's survival can be attributed to the effectiveness of their current treatment and the relatively mild nature of their symptoms. The patient's NYHA class of II indicates that they have some limitations in their physical activity, but they are still able to perform most daily activities without significant symptoms.

Overall, the combination of the patient's treatment regimen, the relatively mild nature of their symptoms, and the absence of severe arrhythmias or other complications likely contributed to the patient's survival."
291,291,P0484,"Age: 74
Gender: Female 
Weight: 83 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 46
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,98
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 9,4
Hemoglobin (g/L): 118.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,43
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 146.0
Protein (g/L): 77,5
T4 (ng/L): 6
TSH (mIU/L): 34,49
Urea (mg/dL): 6,82
LVEF (%): 35.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 74-year-old female with a history of idiopathic dilated cardiomyopathy, has been managed with beta blockers, loop diuretics, and spironolactone. Despite the presence of a reduced left ventricular ejection fraction (LVEF) of 35%, the patient is classified as NYHA Class II, indicating mild symptoms of heart failure.

Several factors contribute to the patient's survival:

1.  Optimal Medication Management: The patient is on a standard heart failure treatment regimen, which includes beta blockers (to reduce sympathetic tone and improve survival), loop diuretics (to manage fluid overload), and spironolactone (an aldosterone antagonist to reduce mortality and morbidity in patients with heart failure).

2.  Controlled Blood Pressure: The patient's blood pressure is well-managed at 140/80 mmHg, which is within the target range for patients with heart failure.

3.  Low Levels of Liver Enzymes: The patient's liver enzymes (ALT and AST) are within the normal range, indicating no significant liver dysfunction, which is a good prognostic sign.

4.  Normal Kidney Function: The patient's creatinine level is 79.0 mmol/L, which is within the normal range for her age and sex. This suggests that her kidney function is not significantly impaired, which is a good prognostic sign.

5.  Normal Electrolytes: The patient's potassium level is within the normal range (4.4 mEq/L), which is essential for proper cardiac function.

6.  No Signs of Malnutrition: The patient's albumin level is 46 g/L, which is within the normal range, indicating no signs of malnutrition.

7.  No Significant Thyroid Dysfunction: The patient's TSH level is elevated at 34.49 mIU/L, but this is likely due to the use of beta blockers, which can suppress TSH levels. The T4 level is within the normal range, indicating no significant thyroid dysfunction.

8.  No Indications of Electrolyte Imbalance: The patient's sodium level is within the normal range (138.0 mEq/L), which is essential for maintaining proper cardiac function.

9.  No Sustained Ventricular Tachycardia: The ECG shows no signs of sustained ventricular tachycardia, which is a good prognostic sign.

10.  Pro-BNP Level: The patient's pro-BNP level is elevated at 146.0 ng/L, indicating some degree of heart failure, but it is not excessively high, which suggests that the patient's heart failure is not severely decompensated.

Considering these factors, the patient's survival can be attributed to optimal medication management, controlled blood pressure, normal liver and kidney function, normal electrolytes, no signs of malnutrition, no significant thyroid dysfunction, no indications of electrolyte imbalance, no sustained ventricular tachycardia, and a moderate level of heart failure as indicated by the pro-BNP level."
292,292,P0485,"Age: 72
Gender: Male 
Weight: 78 kg
Height: 161 cm
NYHA Class: III
Blood Pressure: 160/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 42,9
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,37
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 106
Glucose (mmol/L): 9,7
Hemoglobin (g/L): 122.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,91
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 903.0
Protein (g/L): 70
T4 (ng/L): 17
TSH (mIU/L): 1,44
Urea (mg/dL): 7,65
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

Given the patient's profile, the outcome of survival can be attributed to several factors:

1. Multi-faceted treatment plan: The patient is on a comprehensive regimen of medications, including beta blockers, digoxin, loop diuretics, spironolactone, statins, ACE inhibitors, and nitrovasodilators. This combination of medications is likely contributing to the stabilization of the patient's condition.

2. Optimal management of heart failure symptoms: The patient's NYHA Class III indicates moderate heart failure symptoms, but the presence of medications like ACE inhibitors, beta blockers, and spironolactone suggests that the patient's symptoms are being managed effectively. This is supported by the patient's LVEF (Left Ventricular Ejection Fraction) of 35%, which is below normal but not critically low.

3. Control of comorbidities: The patient's diabetes and hypertension are being managed with medication, which is crucial in preventing further cardiac damage.

4. Monitoring and management of electrolytes: The patient's potassium levels are within a relatively normal range, which is essential for cardiac function and function of the medications they are taking.

5. Monitoring of liver function: The patient's liver enzymes (ALT and AST) are within normal limits, indicating that the medications are not causing significant liver damage.

6. Close monitoring of renal function: Although the patient's creatinine levels are elevated, they are not severely elevated, indicating that the patient's kidneys are functioning relatively well despite the presence of diabetes.

7. Stable blood pressure: The patient's blood pressure is controlled, which is essential for preventing further cardiac damage.

8. Regular monitoring of cardiac function: The patient's ECG shows no signs of sustained ventricular tachycardia or other severe cardiac arrhythmias, indicating that their cardiac function is relatively stable.

In conclusion, the combination of a comprehensive treatment plan, optimal management of heart failure symptoms, control of comorbidities, and close monitoring of electrolytes, liver function, renal function, blood pressure, and cardiac function have all contributed to the patient's survival."
293,293,P0486,"Age: 68
Gender: Male 
Weight: 83 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 48,1
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 74.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 7,5
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,53
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,79
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 471.0
Protein (g/L): 78,9
T4 (ng/L): 19
TSH (mIU/L): 0,91
Urea (mg/dL): 5,32
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to a combination of factors, including the patient's current medical treatment regimen and the relatively stable nature of their condition.

1. Current Medications: The patient is on a comprehensive medication regimen, including beta blockers, loop diuretics, statins, and an ACE inhibitor. Beta blockers are effective in managing heart rate and reducing the risk of sudden cardiac death. Loop diuretics help manage fluid overload and alleviate symptoms of heart failure. Statins lower cholesterol levels, which is beneficial for patients with dyslipemia and idiopathic dilated cardiomyopathy. ACE inhibitors help reduce blood pressure and alleviate strain on the heart.

2. Stable Blood Pressure: The patient's blood pressure of 140/80 mmHg is within a relatively normal range, indicating that the patient's blood pressure is well-controlled, which is essential for patients with heart failure.

3. LVEF (Left Ventricular Ejection Fraction): Although the patient's LVEF is 40%, which is considered mildly reduced, it is not as low as some patients with more severe heart failure. This suggests that the patient's heart is still functioning relatively well, and the patient is likely experiencing mild symptoms of heart failure.

4. Hemoglobin and Urea Levels: The patient's hemoglobin level of 151 g/L and urea level of 5.32 mg/dL are within relatively normal ranges, indicating that the patient is not experiencing significant anemia or renal impairment.

5. Pro-BNP (N-terminal pro b-type natriuretic peptide): The patient's Pro-BNP level of 471 ng/L is elevated, which is consistent with heart failure. However, it is not extremely high, suggesting that the patient's heart failure is not severe.

6. ECG Findings: The patient's ECG shows non-sustained ventricular tachycardia and ventricular extrasystoles, which are common in patients with heart failure. However, the patient's heart rate is not excessively high, and there is no evidence of severe arrhythmias.

Considering these factors, it is likely that the patient's outcome of survival is due to the effectiveness of their current treatment regimen, relatively stable blood pressure, and mildly reduced LVEF."
294,294,P0488,"Age: 31
Gender: Female 
Weight: 57 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 47,3
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 55.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4
LDL (mmol/L): 3,13
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 391.0
Protein (g/L): 85,5
T4 (ng/L): 14
TSH (mIU/L): 1,84
Urea (mg/dL): 4,82
LVEF (%): 25.0
Medications: Beta Blockers, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 31-year-old female with a history of ischemic dilated cardiomyopathy and myocardial infarction, has been prescribed beta blockers and nitrovasodilators to manage her condition. Her current NYHA Class II classification indicates that she experiences some limitations in physical activity but is still able to carry out daily tasks without significant discomfort.

The patient's laboratory results show elevated creatinine levels (55.0 mmol/L), which may indicate impaired renal function. However, her hemoglobin level is within the normal range (124.0 g/L), suggesting that her kidney function is not severely compromised.

The patient's LVEF (Left Ventricular Ejection Fraction) is 25%, which is significantly reduced, indicating poor heart function. However, her Pro-BNP (Brain Natriuretic Peptide) level is 391.0 ng/L, which is elevated but not excessively high, suggesting that her heart is under strain but not in severe failure.

The patient's lipid profile shows elevated total cholesterol (4.91 mmol/L) and LDL (3.13 mmol/L) levels, which are risk factors for cardiovascular disease. However, her HDL level is within the normal range (1.24 mmol/L), which is beneficial.

The patient's ECG shows non-sustained ventricular tachycardia, which is a common finding in patients with cardiomyopathy. The presence of ventricular extrasystoles and polymorphic ventricular extrasystoles may indicate electrical instability in the heart, but they are not uncommon in patients with cardiomyopathy.

Considering the patient's age, medical history, and laboratory results, her survival can be attributed to the following factors:

1. Early diagnosis and treatment: The patient has been diagnosed and treated for her cardiomyopathy, which has likely slowed the progression of the disease.
2. Medications: The patient is on beta blockers and nitrovasodilators, which are effective in managing symptoms and reducing the risk of complications.
3. Mild renal impairment: The patient's renal function is not severely compromised, which reduces the risk of further complications.
4. Hemoglobin levels within normal range: The patient's hemoglobin level is within the normal range, which suggests that her kidney function is not severely compromised.
5. Regular monitoring: The patient is likely being closely monitored by her healthcare team, which has allowed for early detection and management of any complications.

Overall, the patient's survival can be attributed to a combination of early diagnosis, effective treatment, and regular monitoring."
295,295,P0490,"Age: 74
Gender: Male 
Weight: 85 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 54.0
AST or GOT (IU/L): 34.0
Total Cholesterol (mmol/L): 4,11
Creatinine (mmol/L): 150.0
Gamma-glutamil transpeptidase (IU/L): 155
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 134.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,4
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1375.0
Protein (g/L): 72
T4 (ng/L): 12
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,79
Urea (mg/dL): 11,32
LVEF (%): 32.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to several factors:

1.  Optimal Medication Management: The patient is on a comprehensive regimen of medications, including beta blockers, loop diuretics, spironolactone, ACE inhibitors, and nitrovasodilators. These medications are crucial in managing the patient's ischemic dilated cardiomyopathy, hypertension, and myocardial infarction. Beta blockers help reduce the heart rate and contractility, while loop diuretics alleviate fluid overload. Spironolactone is used for its aldosterone antagonist properties, which can help reduce fibrosis and improve cardiac function. ACE inhibitors are beneficial in reducing afterload and improving cardiac function.

2.  Controlled Blood Pressure: The patient's blood pressure is well-controlled at 140/70 mmHg, which is essential for reducing the strain on the heart and preventing further cardiac damage.

3.  Normal Hemoglobin Levels: The patient's hemoglobin level is within the normal range (134 g/L), which is essential for maintaining adequate oxygen delivery to the tissues and organs, including the heart.

4.  Low Troponin Levels: The patient's troponin level is 0.02 ng/mL, which is within the normal range. This suggests that there is no ongoing myocardial damage or infarction.

5.  Normal TSH Levels: The patient's TSH level is 2.79 mIU/L, which is within the normal range. This suggests that the patient's thyroid function is normal, and there is no evidence of hypothyroidism, which can contribute to cardiac dysfunction.

6.  LVEF of 32%: Although the patient's left ventricular ejection fraction (LVEF) is low at 32%, it is not extremely low, and the patient is on medications that can help improve cardiac function over time.

7.  Absence of Severe Electrocardiogram Abnormalities: The patient's ECG does not show any severe abnormalities such as ventricular tachycardia, non-sustained ventricular tachycardia, or bradycardia, which could indicate a higher risk of cardiac complications.

8.  Albumin and Protein Levels: The patient's albumin and protein levels are within the normal range, which suggests that there is no significant liver dysfunction or malnutrition, both of which can contribute to cardiac dysfunction.

Overall, the combination of optimal medication management, controlled blood pressure, normal hemoglobin levels, low troponin levels, normal TSH levels, and the absence of severe ECG abnormalities all contributed to the patient's outcome of survival."
296,296,P0492,"Age: 40
Gender: Male 
Weight: 73 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 36.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,94
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 575.0
Protein (g/L): 69
T4 (ng/L): 14
Troponin (ng/mL): 0,04
TSH (mIU/L): 2,59
Urea (mg/dL): 4,16
LVEF (%): 31.0
Medications: Calcium Channel Blocker, Diabetes Medication, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's medical history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and myocardial infarction, the patient is at high risk for adverse cardiovascular events. The patient's left ventricular ejection fraction (LVEF) of 31% indicates reduced cardiac function, which is consistent with the diagnosis of dilated cardiomyopathy. 

The patient's blood pressure is within a relatively normal range (100/70 mmHg), and the absence of significant electrolyte imbalances (e.g., potassium 4.4 mEq/L) suggests that the patient is not experiencing acute decompensated heart failure. The patient's troponin level (0.04 ng/mL) is within normal limits, indicating that there is no acute myocardial infarction.

The patient's medication regimen, including a calcium channel blocker, diabetes medication, loop diuretics, statins, and ACE inhibitor, is appropriate for managing their conditions. The use of statins and ACE inhibitor is particularly beneficial for patients with heart failure and diabetes, as they can help to improve cardiac function and reduce the risk of adverse cardiovascular events.

The patient's ECG shows monomorphic ventricular extrasystoles, which are common in patients with cardiomyopathy and are generally not associated with adverse outcomes. The absence of non-sustained ventricular tachycardia, paroxysmal supraventricular tachyarrhythmia, and bradycardia suggests that the patient is not experiencing significant arrhythmias that could compromise cardiac function.

The patient's elevated Pro-BNP level (575 ng/L) indicates that the patient has some degree of heart failure, but it is not indicative of acute decompensated heart failure. The patient's albumin level (45 g/L) is within normal limits, which suggests that the patient does not have significant liver dysfunction or nephrotic syndrome.

Considering the patient's overall clinical presentation and laboratory results, the most likely reason for the patient's survival is the effective management of their underlying conditions with appropriate medication and the absence of acute decompensated heart failure or significant arrhythmias."
297,297,P0493,"Age: 67
Gender: Male 
Weight: 80 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 49.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 75
Glucose (mmol/L): 5
Hemoglobin (g/L): 157.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,56
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 248.0
Protein (g/L): 75
T4 (ng/L): 10
Troponin (ng/mL): 0,09
TSH (mIU/L): 1,87
Urea (mg/dL): 4,16
LVEF (%): 35.0
Medications: Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Unknown ventricular extrasystole code
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient, a 67-year-old male with a history of ischemic dilated cardiomyopathy and myocardial infarction, has a complex medical condition. Despite this, the patient's overall clinical presentation and laboratory results suggest that they have a relatively stable condition, which contributed to their survival.

Several factors support this outcome:

1.  Low troponin levels: The patient's troponin level is 0.09 ng/mL, which is within the normal range. This suggests that there is no current acute myocardial infarction or cardiac damage.
2.  Beta blockers and statins: The patient is on beta blockers and statins, which are medications commonly used to manage heart failure and high cholesterol, respectively. These medications are effective in reducing the risk of cardiac complications and improving survival in patients with heart failure.
3.  LVEF of 35%: Although the patient's left ventricular ejection fraction (LVEF) is low at 35%, it is not extremely low. An LVEF of 35% is still considered a moderate to severe reduction in cardiac function, but it is not a contraindication for survival.
4.  Pro-BNP level: The patient's Pro-BNP level is 248.0 ng/L, which is within the normal range. Elevated Pro-BNP levels are often associated with heart failure, but in this case, the level is not indicative of severe heart failure.
5.  ECG results: The patient's ECG results show no signs of severe cardiac arrhythmias or conduction abnormalities that would suggest a high risk of sudden cardiac death.

However, there are also some factors that may have contributed to the patient's survival:

1.  Age: The patient is 67 years old, which is a relatively advanced age but not extremely old. Older adults are generally more resilient to cardiac disease, and the patient's age may have contributed to their survival.
2.  Good blood pressure: The patient's blood pressure is well-controlled at 130/70 mmHg, which is within the normal range. Good blood pressure control is essential for reducing the risk of cardiac complications.
3.  Low creatinine level: The patient's creatinine level is 71.0 μmol/L, which is within the normal range. Elevated creatinine levels can indicate kidney dysfunction, which can worsen cardiac disease.

In conclusion, the combination of the patient's stable clinical presentation, effective medication management, and favorable laboratory results likely contributed to their survival. However, it is essential to continue monitoring the patient's condition and adjusting their treatment plan as needed to prevent further cardiac complications."
298,298,P0495,"Age: 47
Gender: Male 
Weight: 89 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 42
ALT or GPT (IU/L): 43.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 8,2
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 56
Glucose (mmol/L): 7,5
Hemoglobin (g/L): 163.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,3
LDL (mmol/L): 5,95
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 543.0
Protein (g/L): 79
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,2
Urea (mg/dL): 4,99
LVEF (%): 35.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient's age and gender suggest that he is a middle-aged male, which is a common demographic for idiopathic dilated cardiomyopathy, a condition characterized by a weakened heart muscle that cannot pump blood efficiently. His NYHA Class II classification indicates that he experiences some limitations in physical activity, but is still able to perform daily tasks without significant distress.

The patient's blood pressure is within a relatively normal range, which is beneficial for someone with heart disease. His past medical history of idiopathic dilated cardiomyopathy and dyslipemia (elevated cholesterol levels) is a significant risk factor for cardiovascular disease. The patient's lipid profile shows elevated total cholesterol and LDL levels, which are being managed with statins, but his HDL level is low, which is a negative prognostic factor.

The patient's liver function tests (ALT, AST, GGT) are slightly elevated, suggesting some degree of liver dysfunction, which may be related to his heart disease or other underlying conditions. His creatinine level is elevated, indicating impaired kidney function, which is a common comorbidity in patients with heart failure.

The patient's hemoglobin level is within a normal range, which is beneficial, but his pro-BNP level is elevated at 543 ng/L, indicating increased stress on the heart, which is consistent with heart failure.

The patient's LVEF (Left Ventricular Ejection Fraction) is severely reduced at 35%, indicating significant left ventricular dysfunction, which is a hallmark of heart failure. The patient is on optimal medical therapy with beta blockers, loop diuretics, statins, and ACE inhibitors, which is likely contributing to his survival.

The ECG shows polymorphic ventricular extrasystoles, which are abnormal heart rhythms that can be a sign of underlying cardiac disease. However, the absence of sustained ventricular tachycardia and non-sustained ventricular tachycardia is a positive sign.

Considering the patient's age, comorbidities, and optimal medical therapy, it is likely that the patient's survival is due to the combination of his relatively mild symptoms (NYHA Class II), optimal medical therapy, and the absence of severe complications such as sustained arrhythmias or significant renal impairment. However, the patient's prognosis remains guarded due to the underlying heart disease and comorbidities."
299,299,P0497,"Age: 47
Gender: Male 
Weight: 88 kg
Height: 189 cm
NYHA Class: II
Blood Pressure: 115/70 mmHg
Past Medical History: Toxic dilated cardiomyopathy
Albumin (g/L): 43,4
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,66
Creatinine (mmol/L): 107.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 3,73
LDL (mmol/L): 3,4
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 435.0
Protein (g/L): 69,9
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,72
Urea (mg/dL): 9,2
LVEF (%): 55.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient's outcome as a survivor can be attributed to several factors:

1.  Optimal Medication Regimen: The patient is on a comprehensive medication regimen consisting of beta blockers, digoxin, loop diuretics, and an ACE inhibitor. This combination is effective in managing symptoms of heart failure and improving cardiac function, particularly in a patient with a history of toxic dilated cardiomyopathy.

2.  LVEF (Left Ventricular Ejection Fraction) of 55%: Although the patient's LVEF is below the normal range (60-70%), it is not severely impaired. This suggests that the patient's heart is still functioning relatively well, which contributes to their survival.

3.  Normal Blood Pressure: The patient's blood pressure is within a normal range (115/70 mmHg), which is beneficial for cardiac function. Hypertension can exacerbate heart failure and reduce the patient's survival chances.

4.  Low Troponin Levels: The patient's troponin level is within the normal range (0.01 ng/mL), indicating minimal cardiac damage and reduced risk of acute myocardial infarction.

5.  Normal Hemoglobin Level: The patient's hemoglobin level is within the normal range (117 g/L), which suggests that there is no significant anemia, which can contribute to decreased oxygen delivery to the heart and other organs.

6.  Pro-BNP Level: The patient's pro-BNP level is elevated (435 ng/L), but not excessively high. Elevated pro-BNP levels can indicate heart failure, but the level is not alarmingly high, suggesting that the patient's heart failure is well-managed.

7.  ECG Findings: Although the patient has polymorphic ventricular extrasystoles, there is no evidence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, or bradycardia. This suggests that the patient's cardiac rhythm is generally stable, which contributes to their survival.

8.  Nutritional Status: The patient's albumin level is slightly low (43.4 g/L), but not critically low, indicating that the patient is not severely malnourished, which can contribute to decreased cardiac function.

Overall, the combination of optimal medication management, relatively preserved cardiac function, and stable blood pressure, along with minimal cardiac damage and no significant anemia or malnutrition, contribute to the patient's survival outcome."
300,300,P0502,"Age: 57
Gender: Male 
Weight: 86 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 105/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 41,3
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 6,37
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 60
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 148.0
Potassium (mEq/L): 4,22
Sodium (mEq/L): 140.0
Protein (g/L): 73,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,87
Urea (mg/dL): 6
LVEF (%): 17.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient outcome of survival can be attributed to a combination of factors, including the patient's current medical management and the underlying condition of idiopathic dilated cardiomyopathy.

Firstly, the patient is receiving appropriate medical therapy for heart failure, including beta blockers, loop diuretics, spironolactone, ACE inhibitors, and nitrovasodilators. These medications are aimed at reducing the symptoms of heart failure, improving cardiac function, and preventing further cardiac damage.

The patient's LVEF (Left Ventricular Ejection Fraction) of 17% indicates a severely reduced cardiac function, which is consistent with the diagnosis of dilated cardiomyopathy. However, the fact that the patient is still alive suggests that the current medical management is effective in stabilizing the condition and preventing further deterioration.

The patient's blood pressure is well-controlled at 105/75 mmHg, which is within the normal range. This is likely a result of the beta blockers and ACE inhibitors, which help to reduce blood pressure and heart rate.

The patient's electrolyte levels, including potassium and sodium, are within the normal range, which is essential for maintaining cardiac function. The patient's urea and creatinine levels are also within normal limits, indicating that renal function is preserved.

The absence of ventricular tachycardia and other arrhythmias on the ECG suggests that the patient is not experiencing any acute cardiac complications that would threaten their survival.

Furthermore, the patient's troponin level is within normal limits, which suggests that there is no evidence of acute myocardial infarction or cardiac ischemia.

Overall, the combination of effective medical management, well-controlled blood pressure, preserved electrolyte balance, and the absence of acute cardiac complications have contributed to the patient's survival."
301,301,P0503,"Age: 47
Gender: Male 
Weight: 92 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 130/100 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 46
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 127.0
Gamma-glutamil transpeptidase (IU/L): 63
Glucose (mmol/L): 6,5
Hemoglobin (g/L): 172.0
HDL (mmol/L): 0,71
Potassium (mEq/L): 4,41
LDL (mmol/L): 4
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1129.0
Protein (g/L): 78
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,47
Urea (mg/dL): 13,2
LVEF (%): 17.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to a combination of factors, including the patient's current medical management and the underlying disease state.

1. Optimal Medication Therapy: The patient is on a regimen of beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are all evidence-based treatments for heart failure with reduced ejection fraction (HFrEF) and idiopathic dilated cardiomyopathy. These medications have been shown to improve symptoms, reduce morbidity, and potentially improve survival in patients with heart failure.

2. Stable Blood Pressure: The patient's blood pressure of 130/100 mmHg is not excessively high, which reduces the risk of cardiovascular events such as heart failure exacerbation, myocardial infarction, and stroke.

3. Recent Myocardial Infarction: Although the patient has a history of myocardial infarction, the troponin level is low (0.01 ng/mL), indicating that the myocardial infarction is not recent and the patient's cardiac function has had time to recover.

4. Hemoglobin Level: The patient's hemoglobin level of 172 g/L is within the normal range, which is essential for adequate oxygen delivery to the tissues, including the heart muscle.

5. Low Creatinine Level: The patient's creatinine level of 127.0 mmol/L is elevated, indicating some degree of renal impairment. However, it is not severely elevated, which suggests that the patient's kidneys are still functioning adequately to clear waste products from the blood.

6. Pro-BNP Level: The patient's pro-BNP level of 1129 ng/L is elevated, which is consistent with heart failure with reduced ejection fraction. However, the level is not extremely high, which suggests that the patient's heart failure is not severely decompensated.

7. LVEF: The patient's left ventricular ejection fraction (LVEF) of 17% is severely reduced, indicating significant left ventricular dysfunction. However, the patient's survival suggests that the LVEF has been stable over time, and the patient's heart failure has not progressed to a more severe state.

In conclusion, the combination of optimal medical therapy, stable blood pressure, recent myocardial infarction, adequate hemoglobin level, low creatinine level, elevated pro-BNP level, and stable LVEF have all contributed to the patient's survival."
302,302,P0505,"Age: 79
Gender: Female 
Weight: 78 kg
Height: 158 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43,8
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,44
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,24
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 593.0
Protein (g/L): 76
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,56
Urea (mg/dL): 8,02
LVEF (%): 50.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 79-year-old female with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction, presenting with a New York Heart Association (NYHA) Class III functional classification, indicating moderate symptoms of heart failure. 

Given her past medical history and current medications, which include beta blockers, digoxin, loop diuretics, statins, and a nitrovasodilator, it is likely that the patient is being managed for heart failure with reduced ejection fraction (HFrEF). The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG further supports this, as these are common arrhythmias in patients with heart failure and ischemic cardiomyopathy.

The patient's laboratory results show elevated levels of creatinine (95.0 μmol/L), indicating impaired renal function, which is common in patients with heart failure. Her total cholesterol level is within a relatively safe range (3.44 mmol/L), but her LDL level is slightly elevated (1.24 mmol/L), which may be a concern for further management.

The patient's LVEF is 50%, which is consistent with heart failure with reduced ejection fraction (HFrEF). The elevated Pro-BNP level (593.0 ng/L) supports this diagnosis, as BNP is a marker of heart failure.

Considering her age, comorbidities, and current medications, the patient's outcome as a survivor is likely due to the following factors:

1.  Optimal medical therapy: The patient is on a comprehensive regimen of medications that target her heart failure, hypertension, and dyslipidemia.
2.  Close monitoring and management: Regular follow-up appointments and monitoring of her condition have allowed for timely adjustments to her treatment plan, ensuring that her symptoms and complications are being managed effectively.
3.  Supportive care: The patient's social support system and overall health status have likely contributed to her ability to tolerate her condition and respond to treatment.
4.  Resilience: The patient's age and underlying health conditions may have contributed to her resilience and ability to adapt to her condition.

Overall, the combination of optimal medical therapy, close monitoring, supportive care, and the patient's resilience have likely contributed to her survival outcome."
303,303,P0506,"Age: 71
Gender: Female 
Weight: 63 kg
Height: 145 cm
NYHA Class: II
Blood Pressure: 110/50 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 5,02
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 32
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,59
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 673.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,03
Urea (mg/dL): 7,15
LVEF (%): 65.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient's outcome as a survivor can be attributed to several factors based on the provided data and information. 

Firstly, the patient's left ventricular ejection fraction (LVEF) of 65% is within the normal range (50-70%), indicating that the patient's heart is functioning relatively well despite having idiopathic dilated cardiomyopathy. This suggests that the cardiomyopathy is not severely impacting the patient's cardiac function at this point.

The patient's blood pressure of 110/50 mmHg is within a relatively normal range, and the presence of angiotensin II receptor blocker and beta blockers as part of their medication regimen suggests that the patient's blood pressure is being well-managed. The absence of significant changes in creatinine levels (80.0 mmol/L) and urea levels (7.15 mg/dL) indicates that the patient's kidney function is relatively preserved.

The patient's troponin level of 0.01 ng/mL is within the normal range, indicating that there is no acute myocardial infarction or cardiac damage. The presence of ventricular extrasystoles is a common finding in patients with heart disease, but it is not a predictor of poor outcome in this case.

The patient's TSH level of 2.03 mIU/L is within the normal range, indicating that the patient's thyroid function is normal, which can also contribute to their overall well-being and cardiac function.

The patient's medication regimen, including angiotensin II receptor blocker, beta blockers, and loop diuretics, is appropriate for managing their idiopathic dilated cardiomyopathy, hypertension, and fluid overload.

Considering these factors, the patient's outcome as a survivor is likely due to the effective management of their underlying conditions, preserved cardiac function, and absence of acute cardiac damage."
304,304,P0507,"Age: 45
Gender: Male 
Weight: 90 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 133.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,95
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 89.0
Protein (g/L): 75
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,23
Urea (mg/dL): 7,99
LVEF (%): 55.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome as a survivor can be attributed to several factors based on the provided information. 

Firstly, the patient's left ventricular ejection fraction (LVEF) is 55%, which is within the normal range (50-70%). This indicates that the patient's heart is pumping blood efficiently, and the cardiomyopathy is not significantly impacting the heart's ability to function.

The patient's blood pressure is within the normal range (120/80 mmHg), which is a good sign for someone with hypertension. The use of medications such as beta blockers, ACE inhibitors, and spironolactone is also contributing to the control of blood pressure and heart rate.

The patient's troponin level is within the normal range (0.01 ng/mL), indicating that there is no significant cardiac muscle damage. The absence of ventricular extrasystoles, ventricular tachycardia, and other arrhythmias on the ECG also suggests that the heart is functioning relatively normally.

The patient's albumin level is within the normal range (43 g/L), which indicates that the liver is functioning properly and not contributing to the cardiomyopathy. The patient's creatinine level is also within the normal range (88.0 μmol/L), indicating that the kidneys are functioning properly.

The patient's medications, including beta blockers, loop diuretics, spironolactone, statins, ACE inhibitor, and nitrovasodilator, are all contributing to the management of the patient's heart failure and hypertension. The use of these medications is helping to slow the progression of the cardiomyopathy and improve the patient's overall cardiac function.

Overall, the combination of the patient's relatively preserved LVEF, controlled blood pressure, absence of significant cardiac damage, and effective medication regimen all contribute to the patient's outcome as a survivor."
305,305,P0508,"Age: 66
Gender: Male 
Weight: 77 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 150/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 6,65
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,6
Potassium (mEq/L): 4,62
LDL (mmol/L): 4,32
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 200.0
Protein (g/L): 74,5
T3 (pg/dL): 0,0669
T4 (ng/L): 15,24
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,35
Urea (mg/dL): 5,3
LVEF (%): 35.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient, a 66-year-old male with a history of idiopathic dilated cardiomyopathy, had a low left ventricular ejection fraction (LVEF) of 35%, indicating a reduced heart function. However, the patient was on appropriate medical therapy with a loop diuretic and an ACE inhibitor, which are standard treatments for heart failure.

The patient's laboratory results showed a slightly elevated creatinine level (94.0 μmol/L), indicating mild renal impairment. The elevated pro-BNP (brain natriuretic peptide) level of 200 ng/L suggests that the patient has heart failure with preserved ejection fraction, which is a common condition in patients with dilated cardiomyopathy.

The patient's ECG showed non-sustained ventricular tachycardia (VT), which is a type of abnormal heart rhythm that can be a sign of underlying cardiac disease. However, the patient did not experience any symptoms or complications, and the VT was not sustained.

The patient's other laboratory results, including the liver enzymes, lipid profile, and electrolytes, were within relatively normal limits. The patient's hemoglobin level was slightly low, but not significantly so.

Given the patient's age, medical history, and laboratory results, the most likely reason for the patient's outcome of survival is the effective management of his heart failure symptoms and the absence of severe complications. The patient's low LVEF and non-sustained VT on the ECG suggest that he has underlying cardiac disease, but the patient's overall clinical picture and laboratory results suggest that he is stable and able to tolerate his medical therapy.

The patient's outcome of survival is likely due to the following factors:

1. Effective management of heart failure symptoms with loop diuretics and ACE inhibitors.
2. Absence of severe complications, such as cardiac arrest or significant arrhythmias.
3. Mild renal impairment, which is not significantly impacting the patient's overall prognosis.
4. Presence of a low LVEF, which is a common finding in patients with dilated cardiomyopathy, but not an immediate cause for concern.

Overall, the patient's outcome of survival suggests that he is stable and able to manage his heart failure symptoms with medical therapy, and that his underlying cardiac disease is not currently causing significant complications."
306,306,P0510,"Age: 72
Gender: Female 
Weight: 67 kg
Height: 147 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 41,5
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,37
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,13
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 2207.0
Protein (g/L): 74
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,62
Urea (mg/dL): 10,47
LVEF (%): 22.0
Medications: Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

This patient, a 72-year-old female with a history of idiopathic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension, has been prescribed a comprehensive treatment regimen that includes loop diuretics, spironolactone, statins, and an ACE inhibitor. The patient's current medication regimen is likely aimed at managing her heart failure symptoms, controlling blood pressure, and improving lipid profiles.

The patient's LVEF (Left Ventricular Ejection Fraction) is severely reduced at 22%, indicating significant left ventricular dysfunction. However, the patient has survived, which suggests that her current treatment regimen is effective in managing her heart failure symptoms and preventing further complications.

The patient's Pro-BNP level is elevated at 2207.0 ng/L, which is indicative of heart failure. However, the fact that the patient has survived suggests that her treatment regimen is effective in managing her heart failure symptoms and reducing the risk of adverse outcomes.

The patient's ECG results show polymorphic ventricular extrasystoles, but no sustained ventricular tachycardia or non-sustained ventricular tachycardia. The absence of these arrhythmias suggests that the patient's treatment regimen is effective in managing her arrhythmia risk.

The patient's laboratory results show a slightly elevated glucose level (5.7 mmol/L) and a low HDL cholesterol level (1.37 mmol/L), but these values are not significantly abnormal. The patient's potassium level is within the normal range, and her liver function tests (ALT and AST) are slightly elevated, but not significantly abnormal.

Overall, the patient's survival suggests that her treatment regimen is effective in managing her heart failure symptoms and preventing further complications. However, the patient's severely reduced LVEF and elevated Pro-BNP level indicate that she still requires close monitoring and ongoing treatment to manage her heart failure and prevent adverse outcomes."
307,307,P0511,"Age: 59
Gender: Female 
Weight: 75 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 44,8
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 3,08
Creatinine (mmol/L): 76.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 10,3
Hemoglobin (g/L): 142.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,8
LDL (mmol/L): 1,81
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 1114.0
Protein (g/L): 74
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,61
Urea (mg/dL): 7,35
LVEF (%): 37.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 59-year-old female with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and myocardial infarction. Despite having a reduced left ventricular ejection fraction (LVEF) of 37%, which is a significant indicator of heart failure, the patient has been managed with appropriate medications, including beta blockers, statins, and an ACE inhibitor, which are all standard treatments for heart failure and ischemic cardiomyopathy.

The patient's albumin level is within the normal range (44.8 g/L), which suggests that there is no significant liver dysfunction. The liver enzymes (ALT and AST) are also within normal limits, indicating that the liver is functioning properly. The patient's blood glucose level is slightly elevated (10.3 mmol/L), but it is not significantly high, which is consistent with the patient's diabetes diagnosis.

The patient's pro-BNP level is elevated (1114 ng/L), which is a marker of heart failure. However, the patient's symptoms and clinical presentation are consistent with NYHA Class II, indicating mild to moderate symptoms of heart failure.

The patient's ECG shows a monomorphic ventricular extrasystole, which is a common finding in patients with heart failure. There is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias.

Given the patient's clinical presentation and the management of her medications, it is likely that the patient's outcome is a survivor due to the following reasons:

1. Appropriate medical management: The patient is on standard medications for heart failure and ischemic cardiomyopathy, which has likely helped to slow the progression of the disease.
2. Mild to moderate symptoms: The patient's NYHA Class II symptoms indicate that she has mild to moderate symptoms of heart failure, which is consistent with a better prognosis.
3. No evidence of severe liver dysfunction: The patient's liver enzymes and albumin levels are within normal limits, which suggests that there is no significant liver dysfunction.
4. No evidence of severe electrolyte imbalance: The patient's potassium level is within the normal range (4.8 mEq/L), which is essential for cardiac function.

Overall, the patient's outcome as a survivor is likely due to the effective management of her heart failure and ischemic cardiomyopathy, as well as the absence of severe liver dysfunction and electrolyte imbalance."
308,308,P0512,"Age: 69
Gender: Male 
Weight: 85 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Peripheral vascular disease
Albumin (g/L): 46,3
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,74
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 66
Glucose (mmol/L): 11,3
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,97
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 349.0
Protein (g/L): 90
T3 (pg/dL): 0,06
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,36
Urea (mg/dL): 8,02
LVEF (%): 24.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",survivor,"REASONING: 

The patient's age and gender are 69 and male, respectively, placing him in a higher risk category for cardiovascular events. His past medical history of enolic dilated cardiomyopathy, diabetes, and peripheral vascular disease further increases his risk for adverse outcomes. His New York Heart Association (NYHA) Class II classification indicates that he experiences some limitation in physical activity but is still able to carry on light physical activity without discomfort.

The patient's blood pressure is within a relatively normal range, which is beneficial for his cardiovascular health. However, his elevated Pro-BNP level (349.0 ng/L) suggests that he may have some degree of heart failure.

Laboratory results reveal elevated creatinine levels (95.0 mmol/L), which may indicate impaired renal function, possibly due to his diabetes and peripheral vascular disease. His albumin level is within a relatively normal range, but his total cholesterol and LDL levels are elevated, which may contribute to his cardiovascular risk. His hemoglobin level is within a normal range, and his potassium level is slightly low.

The patient's ECG shows a first-degree atrioventricular block (AVB), which may be a result of his dilated cardiomyopathy. The presence of monomorphic ventricular extrasystoles may also be related to his underlying heart condition.

Despite these findings, the patient is on a comprehensive treatment regimen that includes diabetes medication, beta blockers, loop diuretics, spironolactone, and an ACE inhibitor. These medications are aimed at managing his heart failure, controlling his blood pressure, and reducing his cardiovascular risk.

Given the patient's comprehensive treatment regimen and relatively stable laboratory results, the patient's survival outcome can be attributed to the effectiveness of his current treatment plan and the absence of any acute cardiovascular events. His ability to manage his condition and adhere to his treatment plan has likely contributed to his survival."
309,309,P0514,"Age: 54
Gender: Male 
Weight: 89 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 48,4
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 3,93
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 9,9
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 3,7
LDL (mmol/L): 2,43
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 333.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,36
Urea (mg/dL): 6,45
LVEF (%): 39.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 54-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, hypertension, and myocardial infarction, which are all significant risk factors for cardiac disease. Despite these risk factors, the patient's current LVEF (Left Ventricular Ejection Fraction) is 39%, indicating that the heart is still pumping effectively, albeit not at its optimal level.

The patient's medication regimen, including calcium channel blockers, beta blockers, loop diuretics, statins, and ACE inhibitors, is comprehensive and aimed at managing the patient's hypertension, heart failure symptoms, and lipid profile. The patient's blood pressure is well-controlled at 120/80 mmHg, and his lipid profile is within a relatively normal range.

The patient's troponin level is within normal limits, indicating that there is no current myocardial infarction. The pro-BNP (B-type natriuretic peptide) level of 333 ng/L is elevated, which is consistent with heart failure, but not to an extreme degree. The patient's hemoglobin level is within normal limits, which is important as anemia can exacerbate heart failure symptoms.

The patient's TSH (thyroid-stimulating hormone) level is within normal limits, indicating that the thyroid function is not contributing to the patient's cardiac symptoms. The patient's potassium level is slightly low, which may be due to the diuretic therapy, but not significantly enough to cause cardiac arrhythmias.

The patient's creatinine level is within normal limits, indicating that the kidney function is not significantly impaired. The patient's urea level is also within normal limits.

The patient's ECG shows polymorphic ventricular extrasystoles, which are common in patients with heart failure and may not necessarily indicate a poor prognosis. The patient does not have any sustained ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia.

Considering the patient's overall clinical picture, the presence of a comprehensive treatment plan, and the relatively normal laboratory values, it is likely that the patient will survive and continue to manage their heart failure symptoms with medical therapy."
310,310,P0515,"Age: 50
Gender: Female 
Weight: 83 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 45,8
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 4,81
Creatinine (mmol/L): 87.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,84
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 763.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,14
Urea (mg/dL): 9,8
LVEF (%): 50.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 50-year-old female with a history of hypertensive cardiomyopathy and hypertension, has demonstrated a positive outcome, surviving the condition. Several factors contribute to this outcome:

1.  Appropriate Medication Management: The patient is on loop diuretics and an ACE inhibitor, which are commonly used to manage heart failure and hypertension. These medications likely helped to alleviate symptoms and improve cardiac function.

2.  LVEF of 50%: Although the left ventricular ejection fraction (LVEF) is slightly below the normal range (50-70%), it indicates that the heart is still pumping effectively enough to maintain adequate cardiac output. This suggests that the patient's heart is not severely impaired.

3.  Low Troponin Levels: The troponin level is 0.01 ng/mL, which is within the normal range. Elevated troponin levels indicate cardiac muscle damage, but in this case, the levels are normal, suggesting that there is no significant cardiac muscle damage.

4.  Normal TSH and T3/T4 Levels: The thyroid hormone levels are within the normal range, which is essential for heart function and overall metabolic health.

5.  Albumin and Protein Levels: The albumin and protein levels are within the normal range, indicating that the liver function is adequate, and there is no significant malnutrition.

6.  Blood Pressure: The blood pressure is within the normal range, which is essential for cardiac health.

7.  ECG Results: The ECG results show no signs of arrhythmias, which reduces the risk of sudden cardiac death.

While the patient has a history of hypertensive cardiomyopathy and hypertension, the combination of appropriate medication management, relatively preserved LVEF, and normal laboratory results contributed to a positive outcome. However, the patient should continue to be monitored closely to prevent further cardiac complications."
311,311,P0516,"Age: 49
Gender: Male 
Weight: 97 kg
Height: 175 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 51,3
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,19
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 42
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 156.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,66
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1283.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 24
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,23
Urea (mg/dL): 8,02
LVEF (%): 39.0
Medications: Amiodarone, Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 49-year-old male with a history of enolic dilated cardiomyopathy and dyslipemia, has been prescribed a treatment regimen that includes Amiodarone, Beta Blockers, and an ACE Inhibitor. Despite his compromised left ventricular ejection fraction (LVEF) of 39%, which indicates reduced heart function, the patient has managed to survive.

The presence of enolic dilated cardiomyopathy, characterized by a weakened heart muscle, often results in a decreased LVEF. However, the patient's current LVEF of 39% suggests that the heart is still functioning, albeit inefficiently. The patient's medications, particularly the ACE Inhibitor, which is known to improve heart function and reduce mortality in patients with heart failure, may have contributed to the patient's survival.

The patient's laboratory results show elevated levels of Pro-BNP, which is a biomarker for heart failure. However, the levels are not extremely high, indicating that the patient's heart failure is not severe. Additionally, the patient's hemoglobin and sodium levels are within normal limits, which suggests that there is no significant anemia or fluid overload, which can be contributing factors to mortality in heart failure patients.

The patient's TSH level is within the normal range, which suggests that there is no indication of thyroid dysfunction, which can contribute to heart failure. The patient's T3 and T4 levels are also within normal limits, further supporting the absence of thyroid dysfunction.

The patient's blood pressure is within a relatively normal range, which suggests that the patient's cardiovascular system is not experiencing significant stress or strain. The patient's creatinine level is slightly elevated, which may indicate some degree of kidney impairment, but it is not severe.

Overall, the patient's survival can be attributed to a combination of factors, including the effectiveness of his treatment regimen, the absence of severe heart failure symptoms, and the lack of significant comorbidities that could contribute to mortality."
312,312,P0517,"Age: 41
Gender: Male 
Weight: 84 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44,9
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,93
Creatinine (mmol/L): 90.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,48
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 797.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,26
Urea (mg/dL): 8,69
LVEF (%): 35.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient, a 41-year-old male with a history of idiopathic dilated cardiomyopathy, has been managed with a combination of medications including digoxin, loop diuretics, and an ACE inhibitor. Despite the presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG, the patient's outcome is a survivor. Several factors contribute to this outcome:

1.  Early diagnosis and treatment: The patient has been diagnosed with dilated cardiomyopathy and is receiving appropriate medical management, which includes medications that help to slow the progression of the disease and alleviate symptoms.
2.  Optimal medication regimen: The patient is on a combination of digoxin, loop diuretics, and an ACE inhibitor, which is a standard treatment for heart failure with reduced ejection fraction (HFrEF). This combination helps to improve symptoms, reduce hospitalizations, and improve survival.
3.  Monitoring and management of electrolytes: The patient's potassium level is slightly low (3.9 mEq/L), which may be contributing to the presence of ventricular arrhythmias. However, the patient is not showing signs of severe electrolyte imbalances, and the low potassium level is likely being monitored and managed by the healthcare team.
4.  Normal hemoglobin and urea levels: The patient's hemoglobin and urea levels are within normal limits, indicating that there is no significant anemia or renal impairment, which could contribute to a poorer outcome.
5.  Low T3 and T4 levels: The patient's thyroid function tests are within normal limits, which suggests that hypothyroidism is not contributing to the patient's cardiac condition.
6.  Low troponin levels: The patient's troponin level is within normal limits, indicating that there is no acute myocardial infarction or significant cardiac damage.
7.  Pro-BNP level: The patient's Pro-BNP level is elevated (797 ng/L), which is consistent with heart failure. However, the level is not excessively high, indicating that the patient's heart failure is being managed effectively.

Considering these factors, the patient's outcome as a survivor can be attributed to the early diagnosis and treatment of dilated cardiomyopathy, optimal medication management, and close monitoring of electrolytes and other parameters."
313,313,P0518,"Age: 56
Gender: Male 
Weight: 98 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45,9
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,25
Creatinine (mmol/L): 105.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 145.0
HDL (mmol/L): 0,8
Potassium (mEq/L): 4,8
LDL (mmol/L): 3,34
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 134.0
Protein (g/L): 83
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,88
Urea (mg/dL): 7,12
LVEF (%): 36.0
Medications: ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to a combination of factors, including the current management of his enolic dilated cardiomyopathy and hypertension, as well as the relatively mild severity of his cardiac dysfunction.

The patient's left ventricular ejection fraction (LVEF) of 36% is below the normal range (50-70%), indicating systolic dysfunction, but it is not severely reduced. This suggests that the patient's heart is still able to pump blood effectively, albeit with some compromise. The patient's medication regimen, which includes an ACE inhibitor, is likely helping to manage his hypertension and cardiac function.

The patient's blood pressure is well-controlled at 130/80 mmHg, which is within the normal range. This is a positive sign, as uncontrolled hypertension can exacerbate cardiac dysfunction.

The patient's troponin level of 0.01 ng/mL is within the normal range, indicating that there is no acute myocardial infarction or significant cardiac damage. The patient's pro-BNP level of 134 ng/L is elevated, but not extremely high, which suggests that the patient's heart is under some stress, but not to the point of severe decompensation.

The patient's ECG findings of monomorphic ventricular extrasystoles and paroxysmal supraventricular tachycardia (PSVT) are not uncommon in patients with cardiomyopathy and are not necessarily indicative of a poor prognosis.

Overall, while the patient has significant cardiac dysfunction, his current management and relatively mild symptoms (NYHA Class II) suggest that he is at a relatively low risk for sudden cardiac death or severe cardiac decompensation. Therefore, his outcome of survival is likely due to the combination of his current treatment regimen and the relatively mild severity of his cardiac dysfunction."
314,314,P0519,"Age: 61
Gender: Male 
Weight: 107 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease
Albumin (g/L): 38,7
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 142.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,21
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1035.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 19
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,38
Urea (mg/dL): 8,46
LVEF (%): 23.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient survived despite having a severely impaired left ventricular ejection fraction (LVEF) of 23%, which is indicative of advanced heart failure. The presence of idiopathic dilated cardiomyopathy, diabetes, dyslipemia, and peripheral vascular disease further complicates the patient's condition. However, the patient's current medication regimen, which includes a calcium channel blocker, diabetes medication, angiotensin II receptor blocker, beta blockers, digoxin, loop diuretics, and spironolactone, suggests that the patient is receiving appropriate treatment for heart failure and hypertension.

The elevated Pro-BNP level of 1035.0 ng/L is consistent with heart failure, but the patient's blood pressure is well-controlled at 110/70 mmHg, which may indicate effective management of hypertension. The patient's glucose level of 8.3 mmol/L is also within a relatively controlled range, considering the presence of diabetes.

The absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG suggests that the patient is not experiencing severe arrhythmias. The presence of polymorphic ventricular extrasystoles may be a benign finding in this context.

The patient's TSH level of 1.38 mIU/L is within the normal range, indicating that thyroid function is not contributing to the patient's heart failure. The low T3 level of 0.04 pg/dL may be related to the patient's heart failure, as low T3 levels are often seen in patients with advanced heart failure.

The patient's hemoglobin level of 142.0 g/L is within the normal range, indicating that anemia is not a contributing factor to the patient's heart failure.

Overall, while the patient has multiple comorbidities and a severely impaired LVEF, the patient's current medication regimen and controlled blood pressure and glucose levels suggest that the patient is receiving effective treatment for heart failure and hypertension, which may have contributed to the patient's survival."
315,315,P0521,"Age: 79
Gender: Female 
Weight: 58 kg
Height: 149 cm
NYHA Class: III
Blood Pressure: 110/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 42,5
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 5,64
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 118.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,7
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 6699.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,98
Urea (mg/dL): 12,03
LVEF (%): 23.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

Given the patient's advanced age (79 years) and history of ischemic dilated cardiomyopathy, the patient is at high risk for adverse cardiovascular events. The patient's left ventricular ejection fraction (LVEF) of 23% indicates severe systolic dysfunction, which is a significant predictor of poor prognosis in patients with heart failure.

The patient's NYHA Class III classification indicates that the patient has severe symptoms of heart failure, including shortness of breath and fatigue, even at rest or with minimal exertion. The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG suggests arrhythmia instability, which can increase the risk of sudden cardiac death.

The patient's laboratory results show elevated pro-BNP levels (6699 ng/L), which is a marker of heart failure severity. The patient's creatinine level (119.0 μmol/L) is also elevated, indicating impaired renal function, which is common in patients with heart failure.

The patient is on a regimen of medications that are commonly used to treat heart failure, including beta blockers, loop diuretics, spironolactone, ACE inhibitors, and nitrovasodilators. These medications are intended to reduce symptoms, improve quality of life, and slow disease progression.

Despite the patient's advanced age and comorbidities, the patient's outcome is a survivor, likely due to the aggressive management of heart failure and arrhythmias. The patient's treatment plan, including medications and lifestyle modifications, has helped to stabilize the patient's condition and prevent further deterioration.

However, the patient's outcome is not without risk, and close monitoring and continued management of heart failure and arrhythmias are essential to prevent future complications."
316,316,P0522,"Age: 66
Gender: Male 
Weight: 88 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 140/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 40,9
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,44
Creatinine (mmol/L): 116.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 15,4
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,5
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 277.0
Protein (g/L): 68
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,77
Urea (mg/dL): 10,24
LVEF (%): 39.0
Medications: Diabetes Medication, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type I
            ",survivor,"REASONING: The patient is a 66-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, and a previous myocardial infarction. His current NYHA Class II indicates that he experiences some limitation in his physical activity but is still able to perform daily tasks without significant discomfort.

The patient's blood work shows elevated creatinine levels (116.0 mmol/L), which suggests impaired kidney function, and an elevated glucose level (15.4 mmol/L), indicating poorly controlled diabetes. His total cholesterol level is elevated (3.44 mmol/L), and his LDL level is also elevated (1.5 mmol/L), indicating a need for further management of his dyslipemia.

The patient's LVEF (left ventricular ejection fraction) is 39%, which is below the normal range, indicating left ventricular dysfunction. His Pro-BNP (brain natriuretic peptide) level is elevated at 277.0 ng/L, which is consistent with heart failure.

The ECG findings of polymorphic ventricular extrasystoles, non-sustained ventricular tachycardia, and second-degree AV block (Mobitz type I) indicate underlying cardiac conduction system abnormalities.

Given the patient's complex medical history, multiple comorbidities, and the presence of cardiac dysfunction, it is not surprising that he is a survivor. The patient's medications, including diabetes medication, loop diuretics, spironolactone, statins, and nitrovasodilators, are likely aimed at managing his diabetes, heart failure, and dyslipemia.

The combination of the patient's advanced age, multiple comorbidities, and cardiac dysfunction increases his risk for adverse outcomes. However, the fact that he is still alive suggests that his treatment plan is effective in managing his symptoms and preventing further cardiac deterioration."
317,317,P0523,"Age: 72
Gender: Male 
Weight: 80 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40,4
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,61
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 57
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,54
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 936.0
Protein (g/L): 70
T3 (pg/dL): 0,03
T4 (ng/L): 22
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,368
Urea (mg/dL): 6,91
LVEF (%): 35.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 72-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, hypertension, and myocardial infarction. His current medications include diabetes medication, amiodarone, loop diuretics, statins, ACE inhibitor, and nitrovasodilator, indicating that he is already being managed for his cardiovascular and metabolic conditions.

The patient's LVEF (Left Ventricular Ejection Fraction) is 35%, which is significantly below the normal range (50-70%), indicating severe left ventricular dysfunction. However, his Pro-BNP level is 936.0 ng/L, which is elevated but not excessively high, suggesting that his heart failure symptoms are not as severe as might be expected given his LVEF.

His ECG shows polymorphic ventricular extrasystoles, which can be a sign of increased sympathetic activity or electrical instability in the heart. However, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia suggests that his heart rhythm is relatively stable.

The patient's laboratory results show elevated creatinine (123.0 mmol/L), which may indicate renal impairment, and anemia (Hemoglobin 141.0 g/L), which can be a sign of chronic disease or anemia of chronic disease. His glucose level is 8.5 mmol/L, indicating well-controlled diabetes.

Considering these factors, the patient's outcome as a survivor is likely due to the following reasons:

1.  Effective management of his cardiovascular and metabolic conditions with his current medications.
2.  The presence of a relatively stable heart rhythm, despite the presence of polymorphic ventricular extrasystoles.
3.  The absence of severe heart failure symptoms, as indicated by the relatively low Pro-BNP level.
4.  The patient's overall clinical stability, despite his advanced age and multiple comorbidities.

However, it is essential to note that the patient's outcome as a survivor may also be influenced by other factors not mentioned in the provided data, such as the patient's overall health status, lifestyle, and adherence to his medication regimen."
318,318,P0524,"Age: 66
Gender: Male 
Weight: 68 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 45,8
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 5,46
Creatinine (mmol/L): 117.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 3,8
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,72
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 287.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,06
Urea (mg/dL): 7,12
LVEF (%): 36.0
Medications: Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient, a 66-year-old male with a history of ischemic dilated cardiomyopathy, dyslipemia, peripheral vascular disease, hypertension, and myocardial infarction, has been diagnosed with a left ventricular ejection fraction (LVEF) of 36%, indicating severe heart failure. The patient's ECG shows evidence of ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia, which are all indicators of cardiac arrhythmias.

Despite the presence of these cardiac issues, the patient's blood pressure is within a relatively normal range (120/70 mmHg), and his hemoglobin level is within the normal range (150 g/L). His kidney function, as indicated by the creatinine level, is also relatively preserved (117.0 mmol/L).

The patient is on beta blockers and loop diuretics, which are commonly used to manage heart failure and hypertension. The patient's TSH level is within the normal range, indicating that his thyroid function is not contributing to his cardiac condition.

The patient's Pro-BNP level is elevated at 287 ng/L, which is consistent with heart failure. However, the patient's Troponin level is within the normal range (0.01 ng/mL), indicating that there is no acute myocardial infarction.

Given the patient's history of heart failure, cardiac arrhythmias, and the presence of an elevated Pro-BNP level, the patient's survival outcome can be attributed to the effective management of his condition with beta blockers and loop diuretics. The patient's relatively preserved kidney function and normal hemoglobin level also suggest that his heart failure is being well-managed."
319,319,P0525,"Age: 69
Gender: Male 
Weight: 85 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 145/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40,5
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,22
Creatinine (mmol/L): 182.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 19,3
Hemoglobin (g/L): 120.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,34
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 241.0
Protein (g/L): 64
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,69
Urea (mg/dL): 18,25
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient, a 69-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, peripheral vascular disease, hypertension, and myocardial infarction, has a complex medical profile. Despite the severity of his conditions, the patient's outcome is a survivor, which can be attributed to several factors.

Firstly, the patient's left ventricular ejection fraction (LVEF) is 35%, indicating a reduced ejection fraction, which is a common feature of dilated cardiomyopathy. However, the patient is on medications such as beta blockers and angiotensin II receptor blockers, which are commonly used to manage heart failure and improve LVEF. The fact that the patient is on these medications suggests that his condition is being actively managed.

The patient's blood pressure is elevated at 145/90 mmHg, but it is not excessively high, and his blood glucose level is well-controlled at 19.3 mmol/L. The patient's creatinine level is elevated at 182.0 μmol/L, indicating some degree of renal impairment, but it is not severe.

The patient's ECG shows polymorphic ventricular extrasystoles, which can be a benign finding in some cases, but it may also be a sign of underlying cardiac disease. However, the absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia suggests that the patient's cardiac rhythm is relatively stable.

The patient's TSH level is within the normal range, indicating that his thyroid function is not contributing to his cardiac condition. The low T3 level may be a sign of hypothyroidism, but it is not directly related to the patient's cardiac outcome.

The patient's Pro-BNP level is elevated at 241.0 ng/L, which is consistent with heart failure, but it is not excessively high. The patient's troponin level is normal, indicating that there is no acute myocardial infarction.

In summary, the patient's outcome as a survivor can be attributed to the following factors:

1. Active management of his heart failure with medications such as beta blockers and angiotensin II receptor blockers.
2. Well-controlled blood glucose and blood pressure levels.
3. Presence of a relatively stable cardiac rhythm, despite the presence of polymorphic ventricular extrasystoles.
4. Absence of severe renal impairment.
5. Presence of a multidisciplinary team approach to manage his complex medical conditions.

Overall, the patient's outcome as a survivor is a testament to the effectiveness of his treatment plan and the importance of close monitoring and management of his complex medical conditions."
320,320,P0526,"Age: 71
Gender: Male 
Weight: 69 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 110/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 38,1
ALT or GPT (IU/L): 43.0
AST or GOT (IU/L): 43.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,9
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 318.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,53
Urea (mg/dL): 10,69
LVEF (%): 32.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

Given the patient's extensive medical history, including ischemic dilated cardiomyopathy, myocardial infarction, diabetes, dyslipemia, peripheral vascular disease, and hypertension, it is not surprising that the patient's left ventricular ejection fraction (LVEF) is severely impaired at 32.0%. This suggests that the patient has significant heart failure with reduced ejection fraction (HFrEF), which is a major risk factor for mortality.

The patient's elevated pro-BNP (B-type natriuretic peptide) level of 318.0 ng/L further supports the presence of heart failure, as elevated BNP levels are often associated with increased ventricular wall stress and volume overload.

The patient's medications, including beta blockers, digoxin, loop diuretics, spironolactone, statins, ACE inhibitors, and nitrovasodilators, are all consistent with the management of heart failure and hypertension. The use of these medications suggests that the patient is receiving appropriate treatment for their conditions.

The patient's ECG results show no evidence of ventricular extrasystoles, ventricular tachycardia, or non-sustained ventricular tachycardia, which are all arrhythmias that can be associated with heart failure. However, the ECG impression indicates the presence of an unknown paroxysmal supraventricular tachyarrhythmia and bradycardia, which may require further investigation and management.

The patient's laboratory results, including elevated creatinine and urea levels, suggest impaired renal function, which is common in patients with heart failure. The patient's glucose level of 8.5 mmol/L is also elevated, which is consistent with diabetes.

Despite these risk factors, the patient survived, which may be attributed to the following factors:

1.  The patient's treatment regimen, which includes medications that are known to improve survival and reduce morbidity in patients with heart failure.
2.  The patient's relatively controlled blood pressure, which is 110/85 mmHg, which is within a relatively normal range.
3.  The patient's lack of evidence of acute coronary syndrome or other acute cardiovascular events, such as myocardial infarction or stroke, during the time period leading up to the outcome.

Overall, the patient's survival outcome is likely due to a combination of effective medical management, relatively controlled blood pressure, and the absence of acute cardiovascular events."
321,321,P0527,"Age: 58
Gender: Male 
Weight: 91 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 52,69
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 157.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 3,6
LDL (mmol/L): 2,35
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 825.0
Protein (g/L): 74
T3 (pg/dL): 0,06
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,23
Urea (mg/dL): 5,34
LVEF (%): 34.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient's outcome of being a survivor can be attributed to several factors based on the provided data. 

Firstly, the patient has been managed with a combination of medications that are commonly used in the treatment of heart failure and ischemic cardiomyopathy, including Angiotensin II Receptor Blocker, Beta Blockers, Statins, and Nitrovasodilator. These medications are aimed at reducing the workload on the heart, improving cardiac output, and preventing further cardiac damage.

The patient's LVEF (Left Ventricular Ejection Fraction) of 34% indicates that the patient has significant left ventricular dysfunction, which is consistent with ischemic cardiomyopathy. However, the patient's Pro-BNP level of 825.0 ng/L, while elevated, is not excessively high, suggesting that the patient is not experiencing severe heart failure symptoms at this time.

The patient's blood pressure of 140/90 mmHg is within a relatively normal range, considering the patient's age and medical history. The patient's hemoglobin level of 157.0 g/L is within the normal range, indicating that the patient is not experiencing significant anemia, which can contribute to heart failure symptoms.

The patient's lipid profile shows a Total Cholesterol of 3.9 mmol/L and an LDL of 2.35 mmol/L, which are within the target range for a patient with a history of myocardial infarction and ischemic cardiomyopathy. The patient's HDL level of 1.16 mmol/L is slightly low, but not significantly so.

The patient's TSH level of 1.23 mIU/L is within the normal range, indicating that the patient's thyroid function is not contributing to their cardiac symptoms.

The patient's Troponin level of 0.01 ng/mL is within the normal range, indicating that the patient is not experiencing an acute myocardial infarction at this time.

Overall, while the patient has significant cardiac disease, the combination of their medication regimen, relatively controlled blood pressure, and normal thyroid function, along with their lack of acute cardiac symptoms, contribute to their outcome of being a survivor."
322,322,P0528,"Age: 55
Gender: Male 
Weight: 85 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 41,3
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,19
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 11,6
Hemoglobin (g/L): 103.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,46
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 103.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,04
Urea (mg/dL): 8,02
LVEF (%): 39.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 55-year-old male with a history of hypertensive cardiomyopathy, diabetes, and hypertension. His current medications include diabetes medication, an angiotensin II receptor blocker, and an ACE inhibitor, which are all appropriate for his conditions.

The patient's left ventricular ejection fraction (LVEF) is 39%, indicating reduced left ventricular function, which is consistent with his diagnosis of hypertensive cardiomyopathy. However, his LVEF is not severely decreased, which suggests that his heart function is still relatively preserved.

The patient's blood pressure is controlled at 150/80 mmHg, and his glucose level is within a relatively controlled range (11.6 mmol/L). His lipid profile shows a total cholesterol level of 4.19 mmol/L, with an LDL of 2.46 mmol/L, which is slightly elevated but not severely so.

The patient's kidney function, as indicated by his creatinine level, is within a relatively normal range (91.0 μmol/L). His liver function tests (ALT and AST) are also within normal limits.

The patient's thyroid function is within normal limits, as indicated by his TSH level of 1.04 mIU/L and normal T3 and T4 levels. His electrolyte levels, including potassium and sodium, are also within normal limits.

The patient's ECG shows a monomorphic ventricular extrasystole, which is a common finding in patients with cardiomyopathy. However, there is no evidence of sustained ventricular tachycardia or other significant arrhythmias.

Given the patient's relatively stable medical conditions, controlled medications, and preserved left ventricular function, it is not surprising that the patient survived the event. The patient's outcome is likely due to the combination of his stable medical conditions, appropriate medical management, and lack of severe complications.

It is worth noting that the patient's low LVEF and history of hypertensive cardiomyopathy increase his risk for future cardiac events, and close monitoring and continued medical management are necessary to prevent further complications."
323,323,P0530,"Age: 74
Gender: Female 
Weight: 69 kg
Height: 136 cm
NYHA Class: II
Blood Pressure: 120/75 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 35,4
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 5,9
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 116.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 3,8
LDL (mmol/L): 3,41
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1464.0
Protein (g/L): 68
T3 (pg/dL): 0,03
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,47
Urea (mg/dL): 10,69
LVEF (%): 24.0
Medications: Diabetes Medication, Amiodarone, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 74-year-old female with a history of hypertensive cardiomyopathy, diabetes, dyslipemia, and hypertension. Despite the presence of multiple comorbidities, the patient's current medications, including beta blockers, loop diuretics, statins, and an ACE inhibitor, suggest a multidisciplinary approach to managing her conditions.

The patient's LVEF (Left Ventricular Ejection Fraction) of 24.0% indicates severe left ventricular dysfunction, which is consistent with her diagnosis of hypertensive cardiomyopathy. However, the patient's blood pressure is well-controlled at 120/75 mmHg, which is below the target for someone with hypertension.

The patient's laboratory results show elevated creatinine levels (103.0 mmol/L) and a low hemoglobin level (116.0 g/L), which may indicate underlying renal impairment and anemia. However, the patient's albumin and total protein levels are within normal limits, suggesting that her kidney function is not severely compromised.

The patient's glucose level is within the target range (6.1 mmol/L), indicating good control of her diabetes. Her lipid profile shows a total cholesterol level of 5.9 mmol/L, which is above the target, but her LDL level is well-controlled at 3.41 mmol/L.

The patient's TSH level is within the normal range (3.47 mIU/L), indicating euthyroid status. Her troponin level is within normal limits (0.01 ng/mL), suggesting that there is no acute myocardial infarction.

The patient's Pro-BNP level is elevated at 1464.0 ng/L, which is consistent with heart failure symptoms. However, the patient's ECG shows only monomorphic ventricular extrasystoles, which is a common finding in patients with heart failure.

Considering the patient's overall clinical picture, including her well-controlled blood pressure, good control of her diabetes and lipid profile, and the absence of acute myocardial infarction or severe kidney impairment, it is likely that the patient is a survivor due to the effective management of her comorbidities and the use of appropriate medications."
324,324,P0531,"Age: 53
Gender: Male 
Weight: 95 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 175/100 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43,6
ALT or GPT (IU/L): 95.0
AST or GOT (IU/L): 52.0
Total Cholesterol (mmol/L): 5,53
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 67
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 162.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,52
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 644.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,3
Urea (mg/dL): 10,69
LVEF (%): 45.0
Medications: Calcium Channel Blocker, Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 53-year-old male with a history of ischemic dilated cardiomyopathy, hypertension, dyslipemia, and myocardial infarction, presented with a left ventricular ejection fraction (LVEF) of 45%, indicating reduced cardiac function. The patient's blood pressure is elevated at 175/100 mmHg, and his total cholesterol level is high at 5.53 mmol/L. The patient is on a comprehensive treatment regimen, including calcium channel blockers, angiotensin II receptor blockers, beta blockers, statins, and nitrovasodilators, which suggests that the patient is receiving optimal medical management for his conditions.

The patient's laboratory results show elevated levels of liver enzymes (ALT and AST), which may indicate ongoing liver damage or stress, possibly related to the patient's medication regimen or underlying metabolic issues. The patient's glucose level is slightly elevated at 6.8 mmol/L, which may be a concern for diabetes or insulin resistance.

The patient's troponin level is low at 0.01 ng/mL, indicating minimal cardiac damage. The BNP level is elevated at 644.0 ng/L, suggesting that the patient's heart is experiencing stress, possibly due to the patient's reduced LVEF.

Given the patient's complex medical history and current treatment regimen, the fact that the patient is a survivor suggests that the patient's treatment plan is effective in managing his conditions. The patient's medications are likely helping to control his blood pressure, reduce his cardiac workload, and mitigate the effects of his ischemic dilated cardiomyopathy. Additionally, the patient's low troponin level and minimal cardiac damage suggest that the patient's heart is not experiencing significant acute stress or damage, which is a positive indicator of the patient's overall cardiac health.

Overall, the patient's outcome as a survivor is likely due to the comprehensive treatment plan in place, which is effectively managing his conditions and reducing the risk of cardiac complications."
325,325,P0532,"Age: 74
Gender: Female 
Weight: 78 kg
Height: 148 cm
NYHA Class: III
Blood Pressure: 105/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 122.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,56
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 531.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,51
Urea (mg/dL): 11,36
LVEF (%): 33.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to a combination of factors:

1. Optimal medical management: The patient is on a comprehensive medication regimen consisting of Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, and Nitrovasodilator. These medications are standard treatments for heart failure and ischemic dilated cardiomyopathy, and are likely contributing to the stabilization of the patient's condition.

2. Low Troponin levels: The patient's Troponin level is within normal limits (0.01 ng/mL), indicating minimal cardiac muscle damage, which suggests that the patient's heart is not experiencing significant acute ischemic events.

3. Normal TSH levels: The patient's TSH level is within the normal range (3.51 mIU/L), indicating that the thyroid function is not contributing to the heart failure symptoms.

4. Low Creatinine levels: The patient's Creatinine level is elevated at 115.0 mmol/L, but not excessively high, which suggests that the kidneys are still functioning relatively well, and there is no acute kidney injury that would worsen the patient's prognosis.

5. Pro-BNP levels: The patient's Pro-BNP level is elevated at 531.0 ng/L, indicating that the patient's heart is under stress and likely experiencing heart failure. However, the level is not extremely high, which may indicate that the patient's condition is being managed effectively with medications.

6. LVEF: The patient's LVEF is low at 33%, indicating that the heart is not pumping efficiently. However, the patient's survival suggests that the heart is still able to function adequately despite the low ejection fraction.

7. ECG findings: The patient's ECG shows non-sustained ventricular tachycardia, but no sustained or life-threatening arrhythmias, which may indicate that the patient's heart is not experiencing severe electrical instability.

Overall, the patient's survival can be attributed to a combination of optimal medical management, minimal cardiac muscle damage, and relatively preserved kidney function, despite a low LVEF and elevated Pro-BNP levels."
326,326,P0534,"Age: 73
Gender: Male 
Weight: 94 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 35
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 109.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,35
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1860.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,42
Urea (mg/dL): 9,57
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 73-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, hypertension, and myocardial infarction, has survived despite his complex medical conditions. Several factors contribute to this outcome.

Firstly, the patient's current medications, including beta blockers, statins, and an ACE inhibitor, are all evidence-based treatments for his conditions. Beta blockers help reduce the heart rate and workload on the heart, while statins lower cholesterol levels to reduce the risk of further cardiovascular events. ACE inhibitors also help manage blood pressure and reduce strain on the heart.

Secondly, the patient's blood pressure, although slightly elevated at 140/70 mmHg, is not excessively high, which reduces the risk of further cardiovascular complications.

Thirdly, the patient's LVEF (left ventricular ejection fraction) of 45% indicates that his heart is still pumping blood effectively, albeit not at its optimal level. This suggests that the patient's heart is compensating to some extent for the damage caused by his previous myocardial infarction.

Additionally, the patient's Pro-BNP (brain natriuretic peptide) level of 1860 ng/L is elevated, indicating increased ventricular stretch and potential heart failure, but it is not extremely high, suggesting that the patient's heart is not severely failing at this point.

The patient's troponin level of 0.01 ng/mL is within the normal range, indicating that there is no ongoing myocardial infarction.

The patient's TSH level of 2.42 mIU/L is within the normal range, indicating that his thyroid function is not contributing to his cardiac condition.

Lastly, the patient's overall clinical presentation and laboratory results suggest that he is relatively stable, with no signs of acute decompensation or severe cardiac dysfunction. While he has a history of complex medical conditions, his current medications and relatively stable clinical status have contributed to his survival."
327,327,P0537,"Age: 66
Gender: Male 
Weight: 77 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease
Albumin (g/L): 41,5
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,8
Creatinine (mmol/L): 90.0
Gamma-glutamil transpeptidase (IU/L): 89
Glucose (mmol/L): 8,7
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,88
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 688.0
Protein (g/L): 69
T3 (pg/dL): 0,06
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,867
Urea (mg/dL): 5,34
LVEF (%): 22.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient, a 66-year-old male with a history of idiopathic dilated cardiomyopathy, diabetes, dyslipemia, and peripheral vascular disease, has a complex medical profile that contributes to his outcome as a survivor. 

Several factors suggest a relatively stable and manageable condition:

1.  Medications: The patient is on a comprehensive regimen of medications, including diabetes medication, angiotensin II receptor blocker, beta blockers, loop diuretics, and statins, which are commonly used to manage heart failure, hypertension, and dyslipidemia. This suggests that the patient's condition is being actively managed.

2.  Blood Pressure: The patient's blood pressure is within a relatively normal range (140/70 mmHg), which is a good indicator of controlled hypertension.

3.  LVEF (Left Ventricular Ejection Fraction): Although the patient has a low LVEF of 22%, which indicates significant left ventricular dysfunction, it is not the lowest possible value (which is often associated with more severe outcomes). This suggests that the patient's heart function is still relatively preserved.

4.  Pro-BNP (Brain Natriuretic Peptide): The patient's Pro-BNP level of 688.0 ng/L is elevated, which is often seen in heart failure. However, it is not the highest possible value, indicating that the patient's heart failure is not in an acute decompensated state.

5.  ECG findings: While the patient has ventricular extrasystoles, there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias.

However, the patient also has several risk factors that could have contributed to a poorer outcome:

1.  Diabetes: The patient's glucose level is elevated at 8.7 mmol/L, which indicates poorly controlled diabetes.

2.  Dyslipemia: The patient's total cholesterol and LDL levels are elevated, which increases the risk of cardiovascular events.

3.  Peripheral vascular disease: This condition can further compromise the patient's cardiovascular health.

4.  Low HDL: The patient's HDL level is low, which is a risk factor for cardiovascular disease.

Considering these factors, the patient's outcome as a survivor suggests that his condition is being managed effectively, and he is receiving appropriate treatment for his comorbidities. However, the patient's poorly controlled diabetes and dyslipemia may require closer monitoring and adjustments to his treatment plan to prevent further complications."
328,328,P0538,"Age: 61
Gender: Male 
Weight: 53 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 115/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,23
Creatinine (mmol/L): 85.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 9,8
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,5
LDL (mmol/L): 1,86
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 864.0
Protein (g/L): 67
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,11
Urea (mg/dL): 12,91
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 61-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction. His current NYHA Class II indicates that he experiences some limitation in his physical activity but is still able to perform daily tasks without symptoms. 

His laboratory results show a slightly elevated creatinine level (85.0 mmol/L), which may indicate some degree of kidney impairment. However, his hemoglobin level is within the normal range, and his albumin level is slightly low (42 g/L), which could be related to his kidney function or liver disease. 

The patient's lipid profile shows high total cholesterol (3.23 mmol/L) and LDL (1.86 mmol/L) levels, but his HDL level is low (0.85 mmol/L). His glucose level is elevated (9.8 mmol/L), consistent with his diabetes diagnosis. 

His LVEF (35.0%) is significantly reduced, indicating severe left ventricular dysfunction. However, his Pro-BNP level is elevated (864.0 ng/L), which is often associated with heart failure. 

The ECG findings show polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which may indicate underlying arrhythmia. 

Given his complex medical history and the severity of his cardiac dysfunction, the patient's survival is a positive outcome. The fact that he is on a regimen of beta blockers, statins, ACE inhibitors, and nitrovasodilators suggests that he is receiving optimal medical therapy for his conditions. His ability to survive despite these conditions may be attributed to his current treatment plan and the fact that he does not have any severe complications such as acute heart failure or cardiac arrest."
329,329,P0541,"Age: 61
Gender: Male 
Weight: 74 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 135/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 44,8
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,15
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,8
LDL (mmol/L): 3,54
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1751.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,61
Urea (mg/dL): 12,25
LVEF (%): 40.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to several factors, including the effective management of his chronic conditions and the presence of compensatory mechanisms that have helped him maintain a stable condition despite his severe left ventricular dysfunction.

Firstly, the patient's medications, including beta blockers, statins, and an ACE inhibitor, have likely contributed to his survival. Beta blockers have helped reduce his heart rate and myocardial oxygen demand, while statins have improved his lipid profile and reduced his risk of further cardiovascular events. The ACE inhibitor has helped to reduce his blood pressure and alleviate his heart failure symptoms.

Secondly, the patient's hemoglobin level is within the normal range, which suggests that he has adequate oxygen delivery to his tissues. This is crucial for maintaining cardiac function and overall survival.

Thirdly, the patient's TSH level is within the normal range, indicating that his thyroid function is not contributing to his cardiac dysfunction. Additionally, his T3 and T4 levels are within normal limits, which suggests that his thyroid hormone levels are not contributing to his cardiac dysfunction.

Fourthly, the patient's LVEF (Left Ventricular Ejection Fraction) is 40%, which indicates severe left ventricular dysfunction. However, the patient's Pro-BNP level is elevated, but not excessively high, which suggests that he is not experiencing acute decompensated heart failure.

Lastly, the patient's overall clinical condition, including his blood pressure, heart rate, and respiratory status, suggests that he is stable and not experiencing any acute cardiac events. His absence of ventricular tachycardia, bradycardia, and other arrhythmias on the ECG also suggests that his cardiac rhythm is stable.

In summary, the combination of effective medication management, adequate oxygen delivery, normal thyroid function, and stable cardiac rhythm have all contributed to the patient's survival despite his severe left ventricular dysfunction."
330,330,P0542,"Age: 62
Gender: Male 
Weight: 72 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 135/65 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 51,2
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,33
Creatinine (mmol/L): 107.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 162.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,34
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 358.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,46
Urea (mg/dL): 9,35
LVEF (%): 40.0
Medications: Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to several factors:

1. Optimal Medication Management: The patient is on statins, which help manage dyslipemia, and an ACE inhibitor, which is beneficial for patients with heart failure and hypertension. These medications likely contributed to the stabilization of the patient's cardiac condition.

2. Controlled Blood Pressure: The patient's blood pressure is within a relatively normal range (135/65 mmHg), which reduces the strain on the heart and minimizes the risk of cardiovascular events.

3. Low Troponin Levels: The patient's troponin level is 0.01 ng/mL, which is within normal limits, indicating that there is no acute myocardial infarction or significant cardiac damage.

4. LVEF of 40%: Although the patient has a reduced ejection fraction (LVEF), it is not extremely low, and the patient is still alive, which suggests that the heart is still functioning to some extent.

5. Absence of Severe Arrhythmias: The patient does not have sustained ventricular tachycardia or severe bradycardia, which are both indicators of poor cardiac function.

6. Normal TSH Level: The patient's TSH level is within normal limits, indicating that there is no evidence of thyroid dysfunction, which can contribute to cardiac complications.

7. Pro-BNP Level: The patient's Pro-BNP level is elevated (358.0 ng/L), but not extremely high, which suggests that the patient is experiencing some level of cardiac stress, but not to the point of severe heart failure.

8. Albumin and Protein Levels: The patient's albumin and protein levels are within normal limits, indicating that there is no significant liver dysfunction or malnutrition, which can contribute to cardiac complications.

In summary, the combination of optimal medication management, controlled blood pressure, low troponin levels, relatively preserved LVEF, absence of severe arrhythmias, normal TSH level, and relatively normal laboratory values contributed to the patient's survival."
331,331,P0543,"Age: 63
Gender: Female 
Weight: 82 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 125/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41,4
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,78
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,51
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1726.0
Protein (g/L): 66
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 8,18
Urea (mg/dL): 9,13
LVEF (%): 39.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 63-year-old female with a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack, leading to an enlarged left ventricle. Her left ventricular ejection fraction (LVEF) is 39%, indicating reduced heart function. However, despite this, the patient is a survivor, which suggests that her heart condition has not progressed to a fatal outcome.

Several factors may have contributed to the patient's survival:

1.  Current Medications: The patient is on a combination of beta blockers, loop diuretics, statins, ACE inhibitors, and nitrovasodilators. These medications are commonly used to manage heart failure, high blood pressure, and lipid disorders. Beta blockers, in particular, can help reduce the heart rate and blood pressure, while ACE inhibitors can help reduce the workload on the heart by dilating blood vessels and improving blood flow.

2.  Lifestyle Factors: Although not explicitly mentioned, it is likely that the patient has made lifestyle changes to manage her condition, such as regular exercise, a balanced diet, and stress management. These factors can help improve heart function and overall health.

3.  Low Troponin Levels: The patient's troponin level is 0.01 ng/mL, which is within the normal range. Elevated troponin levels can indicate heart muscle damage, but in this case, the low level suggests that the heart muscle is not experiencing significant damage.

4.  Normal Hemoglobin and Potassium Levels: The patient's hemoglobin and potassium levels are within normal ranges, which suggests that her heart function is not being compromised by anemia or electrolyte imbalances.

5.  Low T3 and T4 Levels: The patient's T3 and T4 levels are within normal ranges, which suggests that her thyroid function is not contributing to her heart condition.

6.  Normal Blood Pressure: The patient's blood pressure is 125/80 mmHg, which is within the normal range, indicating that her hypertension is well-controlled.

7.  Low Creatinine Levels: The patient's creatinine level is 88.0 mmol/L, which is within the normal range, indicating that her kidney function is not compromised.

Overall, the combination of the patient's medications, lifestyle factors, and normal laboratory values have likely contributed to her survival despite her history of ischemic dilated cardiomyopathy."
332,332,P0544,"Age: 61
Gender: Male 
Weight: 92 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 130/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 49
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,59
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 51
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,37
Potassium (mEq/L): 4
LDL (mmol/L): 1,29
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 823.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,37
Urea (mg/dL): 7,57
LVEF (%): 35.0
Medications: Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to a combination of factors. Firstly, the patient's blood pressure is well-controlled at 130/65 mmHg, which is within a relatively normal range, indicating that the patient's hypertension is being effectively managed.

The patient's medication regimen, including an Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Spironolactone, and Nitrovasodilator, suggests that the patient is receiving appropriate treatment for their ischemic dilated cardiomyopathy and hypertension. The use of these medications is aimed at reducing the strain on the heart, improving heart function, and managing fluid overload.

The patient's LVEF (Left Ventricular Ejection Fraction) of 35% is below the normal range, indicating systolic heart failure. However, the patient's Pro-BNP (B-type Natriuretic Peptide) level of 823.0 ng/L is elevated, which is a marker of heart failure. Despite this, the patient's Troponin level of 0.01 ng/mL is within the normal range, indicating that the patient is not experiencing acute myocardial infarction.

The patient's electrolyte levels, including potassium (4 mEq/L) and sodium (140.0 mEq/L), are within the normal range, which is essential for maintaining proper heart function.

The patient's liver enzymes, such as ALT (27.0 IU/L) and AST (22.0 IU/L), are within the normal range, indicating that the patient's liver function is not significantly compromised.

The patient's thyroid function, as indicated by TSH (0.37 mIU/L) and T4 (21 ng/L), is within the normal range, which is essential for maintaining proper heart function.

The patient's renal function, as indicated by creatinine (124.0 mmol/L) and urea (7.57 mg/dL), is within the normal range, indicating that the patient's kidneys are functioning properly.

The patient's ECG shows non-sustained ventricular tachycardia and polymorphic ventricular extrasystole, which are common in patients with heart failure. However, the presence of these arrhythmias does not necessarily indicate a poor prognosis.

In conclusion, the patient's survival can be attributed to the effective management of their hypertension, heart failure, and other comorbidities, as well as the absence of acute myocardial infarction and other life-threatening complications."
333,333,P0546,"Age: 83
Gender: Male 
Weight: 68 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,78
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 74
Glucose (mmol/L): 9,65
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,05
LDL (mmol/L): 3,77
Sodium (mEq/L): 139.0
Protein (g/L): 68
T3 (pg/dL): 0,0375
T4 (ng/L): 21,95
Troponin (ng/mL): 0,1
TSH (mIU/L): 1,15
Urea (mg/dL): 6,5
LVEF (%): 30.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's advanced age (83 years) and history of idiopathic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension, the patient is at a high risk for adverse cardiovascular events. However, despite these risk factors, the patient is classified as NYHA Class II, indicating that they have some limitations in physical activity but are still able to perform light physical activity without symptoms.

The patient's left ventricular ejection fraction (LVEF) is severely reduced at 30%, indicating significant left ventricular dysfunction. However, the patient is on ACE inhibitors, which are known to improve LVEF in patients with heart failure. The patient is also on statins, which can help manage dyslipemia and reduce the risk of cardiovascular events.

The patient's blood pressure is elevated at 160/80 mmHg, which is concerning, but it is not significantly high enough to be a major concern. The patient's potassium level is slightly low at 4.05 mEq/L, which could be a concern for arrhythmias, but it is not significantly low.

The patient's ECG shows polymorphic ventricular extrasystoles, which can be a concern for arrhythmias, but it is not a major concern. The patient does not have any sustained or non-sustained ventricular tachycardia, which is a good sign.

Given the patient's overall clinical picture, the patient's outcome as a survivor is likely due to the following factors:

1. Effective management of heart failure symptoms with ACE inhibitors and loop diuretics.
2. Good control of blood pressure with medication.
3. Effective management of diabetes and dyslipemia with medication.
4. The patient's relatively low TSH level, indicating that the patient's thyroid function is not significantly impaired.
5. The patient's LVEF is not extremely low, indicating that the patient's heart function is not severely impaired.

Overall, the patient's outcome as a survivor is likely due to a combination of effective management of their cardiovascular risk factors, good control of their heart failure symptoms, and relatively preserved cardiac function."
334,334,P0547,"Age: 30
Gender: Female 
Weight: 64 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 7.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 6,65
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,99
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 89.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,44
Urea (mg/dL): 3,83
LVEF (%): 50.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient outcome of survival can be attributed to several factors evident from the provided data. 

Firstly, the patient's age of 30 and NYHA Class II classification indicate that the patient is relatively young and has a mild level of heart failure symptoms, which is a positive prognostic indicator. The patient's ejection fraction (LVEF) of 50% is within the normal range, suggesting that the heart is still functioning adequately. The patient's blood pressure is within the normal range, which is also a good prognostic indicator.

The patient's laboratory results, including normal levels of liver enzymes (ALT, AST, GGT), electrolytes (potassium, sodium), and kidney function (creatinine, urea), suggest that the patient's liver and kidney function are within normal limits. The patient's glucose level is also within the normal range, indicating that the patient does not have diabetes mellitus, which is a significant risk factor for cardiovascular disease.

The patient's lipid profile shows a high total cholesterol level, but the LDL level is also high, indicating a need for lipid-lowering therapy. However, this does not seem to have a significant impact on the patient's outcome.

The patient's thyroid function tests (T3, T4, TSH) are within the normal range, indicating that the patient does not have hypothyroidism, which can contribute to heart failure.

The patient's BNP level is slightly elevated at 89 ng/L, which can indicate heart failure, but the patient's symptoms and LVEF suggest that the heart failure is mild.

The patient's medications, including beta blockers, loop diuretics, and ACE inhibitors, are all appropriate for managing heart failure and hypertension.

The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG suggests that the patient does not have any life-threatening arrhythmias.

In conclusion, the patient's overall clinical picture suggests that they have mild heart failure due to idiopathic dilated cardiomyopathy, but the patient's young age, mild symptoms, and normal LVEF, along with the absence of other significant comorbidities, contribute to a favorable prognosis and the patient's outcome of survival."
335,335,P0548,"Age: 75
Gender: Male 
Weight: 82 kg
Height: 179 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 32.0
Total Cholesterol (mmol/L): 3,28
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 8,4
Hemoglobin (g/L): 164.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 5,2
LDL (mmol/L): 1,03
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 450.0
Protein (g/L): 67
T3 (pg/dL): 0,04
T4 (ng/L): 19
Troponin (ng/mL): 0,13
TSH (mIU/L): 2,29
Urea (mg/dL): 7,15
LVEF (%): 38.0
Medications: Beta Blockers, Digoxin, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient, a 75-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, and myocardial infarction, has a complex clinical presentation. Despite his advanced age and multiple comorbidities, the patient's outcome is a survivor, which can be attributed to several factors.

Firstly, the patient is on a comprehensive medication regimen that includes beta blockers, digoxin, spironolactone, statins, and an ACE inhibitor, which are all evidence-based treatments for heart failure and arrhythmias. These medications are likely contributing to the patient's survival by managing his heart failure symptoms, reducing his heart rate, and preventing further cardiac damage.

The patient's LVEF of 38% is within the range of 30-40%, which indicates that he has a reduced ejection fraction, but not the most severe degree of heart failure. This suggests that his heart is still pumping some blood, albeit inefficiently, which may be sufficient to maintain some level of cardiac output and prevent further decline.

The patient's blood pressure is well-controlled at 110/70 mmHg, which is within a normal range. This is likely due to the effects of his beta blockers and ACE inhibitor, which are both known to lower blood pressure.

The patient's electrolyte levels, including potassium (5.2 mEq/L) and sodium (136 mEq/L), are within normal limits, which is essential for maintaining cardiac function.

The patient's troponin level of 0.13 ng/mL is slightly elevated, but not excessively high, which suggests that he is not experiencing an acute myocardial infarction. His TSH level of 2.29 mIU/L is within the normal range, indicating that his thyroid function is not contributing to his cardiac symptoms.

The patient's Pro-BNP level of 450 ng/L is elevated, which is consistent with heart failure, but not excessively high, suggesting that his heart failure is not in an acute decompensated state.

Overall, the combination of the patient's medication regimen, relatively well-controlled blood pressure, and normal electrolyte levels, along with his slightly elevated but not excessively high troponin and Pro-BNP levels, suggest that he is being managed effectively for his heart failure and arrhythmias. Therefore, his outcome as a survivor is likely due to the effective management of his condition."
336,336,P0549,"Age: 56
Gender: Male 
Weight: 96 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 4,55
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 147.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,59
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 561.0
Protein (g/L): 76
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,2
Urea (mg/dL): 6,32
LVEF (%): 54.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 56-year-old male with a history of ischemic dilated cardiomyopathy, dyslipemia, hypertension, and myocardial infarction. Despite his complex medical history, the patient's current medications, including beta blockers, loop diuretics, spironolactone, statins, ACE inhibitors, and nitrovasodilators, appear to be effective in managing his symptoms and stabilizing his cardiac function.

The patient's LVEF (Left Ventricular Ejection Fraction) is 54%, which is within the mildly reduced range, indicating some degree of left ventricular dysfunction. However, it is not significantly impaired, suggesting that the patient's cardiac function is not severely compromised.

The patient's blood pressure is within a relatively normal range (100/60 mmHg), and his electrolyte levels, including potassium, are within normal limits. His glucose and lipid profiles are also relatively well-managed, with a total cholesterol level of 4.55 mmol/L and an LDL level of 2.59 mmol/L.

The patient's BNP (B-type natriuretic peptide) level is elevated at 561 ng/L, which is consistent with heart failure. However, the fact that the patient is still alive and relatively stable suggests that his heart failure is being effectively managed.

The patient's ECG shows evidence of ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia, but these findings are not uncommon in patients with a history of ischemic cardiomyopathy and are not necessarily indicative of an acute cardiac event.

Overall, the patient's combination of medications and relatively stable cardiac function suggest that he is being effectively managed for his heart failure and other cardiac conditions, which contributed to his survival."
337,337,P0551,"Age: 60
Gender: Male 
Weight: 85 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,65
Creatinine (mmol/L): 177.0
Gamma-glutamil transpeptidase (IU/L): 48
Glucose (mmol/L): 8,1
Hemoglobin (g/L): 137.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,4
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 2239.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 17
TSH (mIU/L): 0,845
Urea (mg/dL): 12,81
LVEF (%): 57.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 60-year-old male with a history of hypertensive cardiomyopathy and hypertension, which suggests that his heart has been under strain due to high blood pressure for a prolonged period. His current NYHA Class II classification indicates that he experiences some limitations in physical activity but is still able to perform everyday activities without significant discomfort.

His blood pressure is well-controlled at 120/70 mmHg, and he is on a combination of medications including a calcium channel blocker, beta blockers, loop diuretics, and an ACE inhibitor, which are all appropriate for managing hypertension and heart failure.

His laboratory results show elevated creatinine levels (177.0 mmol/L), indicating some degree of renal impairment, which is common in patients with hypertensive cardiomyopathy. However, his LVEF (left ventricular ejection fraction) is 57%, which is within the normal range (> 50%), indicating that his heart is still pumping effectively.

His high Pro-BNP (brain natriuretic peptide) level of 2239.0 ng/L suggests that he has some degree of heart failure, but it is not severe. His other laboratory results, including his electrolytes, liver enzymes, and kidney function tests, are within normal limits.

The absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG suggests that he does not have any significant arrhythmias that could be contributing to his condition.

Given the patient's well-controlled blood pressure, stable cardiac function, and absence of severe complications, it is likely that he is a survivor of heart failure, indicating that his heart has adapted to the strain caused by his hypertensive cardiomyopathy and hypertension."
338,338,P0552,"Age: 50
Gender: Female 
Weight: 59 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 41
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,35
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,25
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,62
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 809.0
Protein (g/L): 70
T4 (ng/L): 9
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,04
Urea (mg/dL): 5,99
LVEF (%): 66.0
Medications: Beta Blockers
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's data, the patient is a 50-year-old female with a history of hypertrophic cardiomyopathy (HCM), a condition characterized by thickening of the heart muscle that can lead to impaired cardiac function. Despite this, the patient's left ventricular ejection fraction (LVEF) is 66%, which is within the normal range (50-70%), indicating that the heart is pumping blood efficiently. 

The patient's blood pressure is within the normal range (120/70 mmHg), and her creatinine level is slightly elevated (88.0 μmol/L), which may indicate mild kidney impairment. However, her albumin level is within the normal range (41 g/L), which suggests that the kidney function is not severely compromised.

The patient's lipid profile shows high total cholesterol (5.35 mmol/L) and LDL cholesterol (3.62 mmol/L), which are risk factors for cardiovascular disease. However, her HDL cholesterol level is low (1.25 mmol/L), which is a protective factor against cardiovascular disease.

The patient's Pro-BNP level is elevated (809.0 ng/L), which is a marker of heart failure. However, the patient's symptoms and LVEF suggest that the heart failure is not severe.

The patient is taking beta blockers, which are commonly used to treat HCM and heart failure. The patient's ECG shows monomorphic ventricular extrasystoles, which are common in patients with HCM.

Considering these factors, the patient's outcome as a survivor is likely due to the following reasons:

1. The patient's LVEF is within the normal range, indicating that the heart is pumping blood efficiently.
2. The patient's blood pressure is within the normal range, which reduces the risk of cardiac complications.
3. The patient is taking beta blockers, which are effective in managing HCM and heart failure.
4. The patient's kidney function is not severely compromised, which reduces the risk of cardiac complications.

Overall, the patient's outcome as a survivor is likely due to the combination of these factors, which suggest that the patient's heart condition is well-managed and that the patient is at a lower risk of cardiac complications."
339,339,P0554,"Age: 70
Gender: Female 
Weight: 56 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 147/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 48
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 6,67
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 10,9
Hemoglobin (g/L): 115.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,6
Sodium (mEq/L): 139.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 23
Troponin (ng/mL): 0,005
TSH (mIU/L): 2,39
Urea (mg/dL): 14,48
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 70-year-old female with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and a previous myocardial infarction. Despite her complex medical history, she is currently on a multidrug regimen consisting of diabetes medication, beta blockers, loop diuretics, statins, and an ACE inhibitor. 

The patient's left ventricular ejection fraction (LVEF) is 35%, indicating a reduced ejection fraction, which is consistent with her history of ischemic dilated cardiomyopathy. However, her blood pressure is within a relatively normal range, and her troponin levels are within normal limits, indicating that she is not experiencing an acute myocardial infarction.

The patient's ECG shows monomorphic ventricular extrasystoles, which can be a benign finding in some cases, but it may also be a sign of underlying cardiac disease. However, the absence of other significant arrhythmias, such as ventricular tachycardia or supraventricular tachyarrhythmia, suggests that her cardiac function is not severely compromised.

The patient's laboratory results show elevated creatinine levels, which may indicate renal impairment, but this is not unexpected given her age and history of diabetes. Her lipid profile shows elevated LDL levels, but her statin therapy should help manage this. Her thyroid function tests are within normal limits, which suggests that her hypothyroidism is not contributing to her cardiac condition.

Given the patient's complex medical history and current medication regimen, it is not surprising that she is a survivor. The combination of beta blockers, ACE inhibitors, and statins likely helped to manage her heart failure and reduce her risk of further cardiac events. The loop diuretics may have helped to manage her fluid overload and hypertension. Her diabetes medication may have also helped to control her blood sugar levels, which is important for preventing further cardiac damage.

Overall, the patient's outcome as a survivor suggests that her current treatment regimen is effective in managing her cardiac condition, and she is likely benefiting from her multidrug therapy."
340,340,P0557,"Age: 72
Gender: Female 
Weight: 55 kg
Height: 146 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,61
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 103.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,94
Urea (mg/dL): 8,82
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 72-year-old female with a history of hypertensive cardiomyopathy, dyslipemia, and hypertension. Her left ventricular ejection fraction (LVEF) is significantly reduced at 30%, indicating severe left ventricular dysfunction. However, she is on optimal medical therapy for heart failure, including beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor.

The patient's laboratory results show a slightly elevated total cholesterol level (4.68 mmol/L), but her LDL is within a relatively safe range (2.61 mmol/L), and she is on statins, which are effective in managing dyslipidemia. Her kidney function is also relatively preserved, with a creatinine level of 97.0 mmol/L.

The patient's ECG shows polymorphic ventricular extrasystoles, which can be a sign of electrical instability, but it does not indicate a life-threatening arrhythmia. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia suggests that the patient's heart rate is within a relatively safe range.

The patient's Pro-BNP level is elevated at 103.0 ng/L, which is consistent with heart failure, but it is not excessively high, indicating that the patient's condition is not in acute decompensation.

Considering the patient's age, comorbidities, and the fact that she is on optimal medical therapy, the most likely reason for her survival is the effectiveness of her treatment regimen and her relatively preserved kidney function. The combination of beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor has likely helped to manage her heart failure and prevent further deterioration of her cardiac function.

Additionally, the patient's relatively low TSH level (0.94 mIU/L) suggests that she is not experiencing hypothyroidism, which can contribute to heart failure. Her T3 and T4 levels are also within normal limits, indicating that her thyroid function is well-controlled.

Overall, the patient's survival is likely due to the effectiveness of her medical therapy, her relatively preserved kidney function, and the absence of any life-threatening arrhythmias or other complications."
341,341,P0558,"Age: 65
Gender: Male 
Weight: 98 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 4,09
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 16
Hemoglobin (g/L): 147.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,33
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1649.0
Protein (g/L): 65
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,54
Urea (mg/dL): 6,99
LVEF (%): 27.0
Medications: Digoxin, Loop Diuretics, Hydralazine, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient, a 65-year-old male with a history of ischemic dilated cardiomyopathy and hypertension, has been managed with a multi-drug regimen including digoxin, loop diuretics, hydralazine, ACE inhibitor, and nitrovasodilator. His left ventricular ejection fraction (LVEF) is severely reduced at 27%, indicating significant heart failure.

Despite the presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG, the patient's troponin levels are within normal limits (0.03 ng/mL), indicating minimal myocardial damage. His elevated Pro-BNP levels (1649 ng/L) suggest significant cardiac stress and strain, but his hemodynamic parameters, including blood pressure (140/80 mmHg), are relatively stable.

The patient's laboratory results show mild elevations in liver enzymes (ALT and AST) and a slightly low HDL cholesterol level (0.78 mmol/L), but these are not indicative of significant organ dysfunction. His electrolyte levels, including potassium (4.1 mEq/L), are within normal limits.

The patient's TSH level is slightly low (1.54 mIU/L), which may indicate a mild case of hypothyroidism, but this is not directly related to his cardiac condition.

Considering the patient's overall clinical picture, the presence of a severely reduced LVEF, non-sustained ventricular tachycardia, and elevated Pro-BNP levels, the patient is at high risk for cardiac complications. However, the fact that he is on a multi-drug regimen, including ACE inhibitors and nitrovasodilators, which are known to improve cardiac function and reduce mortality in patients with heart failure, suggests that his condition is being actively managed.

Furthermore, the patient's stable hemodynamic parameters and lack of significant myocardial damage (normal troponin levels) indicate that he is not in acute cardiac failure. Therefore, the patient's outcome of survival is likely due to the effectiveness of his current treatment regimen and the fact that his cardiac condition is being closely monitored and managed.

The patient's NYHA Class III classification indicates that he has severe symptoms of heart failure, but his ability to survive suggests that his condition is being well-managed, and he is receiving adequate treatment."
342,342,P0561,"Age: 38
Gender: Female 
Weight: 58 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 90/50 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 41
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,27
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 8
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,77
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 37.0
Protein (g/L): 75
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,23
Urea (mg/dL): 6,32
LVEF (%): 41.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's medical history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge, it's essential to consider the overall prognosis and the current clinical status of the patient. 

The patient's left ventricular ejection fraction (LVEF) is 41%, which is within the range of heart failure with reduced ejection fraction (HFrEF). However, the patient is on beta-blockers and an ACE inhibitor, which are standard treatments for heart failure and dilated cardiomyopathy. 

The patient's blood pressure is slightly low at 90/50 mmHg, which might be a sign of decreased cardiac output or possibly due to the medications. The serum creatinine level is elevated at 80.0 mmol/L, indicating some degree of renal impairment, which is a common complication in patients with heart failure.

The patient's liver function tests (ALT and AST) are within normal limits, and the total cholesterol and LDL levels are high, which is a known risk factor for cardiovascular disease. However, the HDL level is also low, which might contribute to the high total cholesterol and LDL levels.

The patient's TSH level is slightly elevated at 3.23 mIU/L, but the T4 level is within the normal range. The T3 level is low, which might be a sign of subclinical hypothyroidism or a result of the patient's underlying heart disease.

The pro-BNP level is 37.0 ng/L, which is within the normal range, indicating that the patient is not experiencing acute decompensated heart failure.

Considering the patient's current clinical status, the patient's outcome as a survivor is likely due to the following reasons:

1.  The patient is on optimal medical therapy for heart failure and dilated cardiomyopathy.
2.  The patient's LVEF is within the range of HFrEF, and the patient is not experiencing acute decompensated heart failure.
3.  The patient's renal function is impaired but not severely compromised, which is a common complication in patients with heart failure.
4.  The patient's liver function tests are within normal limits, indicating that the liver is functioning adequately.

In conclusion, the patient's outcome as a survivor is likely due to the combination of optimal medical therapy, the absence of acute decompensated heart failure, and the relatively stable renal and liver function."
343,343,P0562,"Age: 79
Gender: Female 
Weight: 67 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 150/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 27
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,4
Creatinine (mmol/L): 194.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 3,9
Hemoglobin (g/L): 80.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,79
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 4399.0
Protein (g/L): 61
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,4
Urea (mg/dL): 37,27
LVEF (%): 53.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type II
            ",survivor,"REASONING: 

Given the patient's age (79), NYHA Class II, and past medical history of Hypertensive cardiomyopathy, Diabetes, Dyslipemia, and Peripheral vascular disease, the patient is at high risk for cardiovascular complications. The patient's current medications, including Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, and Loop Diuretics, suggest that the patient is being managed for hypertension and heart failure.

The patient's laboratory results show elevated Creatinine levels (194.0 mmol/L), which indicates impaired kidney function, and a low Hemoglobin level (80.0 g/L), which may be indicative of anemia, a common comorbidity in patients with heart failure. The patient's Pro-BNP level is elevated at 4399.0 ng/L, which is consistent with heart failure.

The ECG results show a second-degree AV block (type II), which is a risk factor for heart failure and may be contributing to the patient's symptoms. However, the absence of ventricular tachycardia and non-sustained ventricular tachycardia is a positive sign.

The patient's LVEF (53.0%) is within the normal range, indicating that the patient's heart function is relatively preserved. The patient's Troponin level is normal, which suggests that there is no acute myocardial infarction.

Considering the patient's overall clinical picture, it appears that the patient is being managed for heart failure and hypertension, and the current medications are likely contributing to the patient's survival. The patient's LVEF is preserved, and the absence of acute coronary syndrome or severe arrhythmias suggests that the patient is at low risk for immediate cardiovascular complications.

Therefore, the patient's outcome as a survivor is likely due to the effective management of their heart failure and hypertension, as well as the preserved heart function and lack of acute complications."
344,344,P0564,"Age: 69
Gender: Male 
Weight: 75 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 6,62
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 56
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 147.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,37
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 277.0
Protein (g/L): 74
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,7
Urea (mg/dL): 6,99
LVEF (%): 45.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type II
            ",survivor,"REASONING: 

The patient, a 69-year-old male with a history of ischemic dilated cardiomyopathy, hypertension, and a previous myocardial infarction, has a complex set of risk factors for cardiovascular disease. His ejection fraction (LVEF) of 45% indicates reduced left ventricular function, which is a significant indicator of heart failure.

The patient's laboratory results show elevated levels of creatinine (80.0 mmol/L), indicating impaired renal function, which is a common comorbidity in patients with heart failure. His total cholesterol level is elevated at 6.62 mmol/L, but his LDL level is relatively well-managed with statin therapy. The patient's glucose level is slightly elevated at 4.5 mmol/L, but not significantly high.

The patient's electrocardiogram (ECG) shows a second-degree AV block type II, which is a conduction abnormality that can be a risk factor for heart failure and cardiac arrhythmias. However, the absence of sustained ventricular tachycardia and other arrhythmias on the ECG is reassuring.

The patient's BNP (B-type natriuretic peptide) level is elevated at 277.0 ng/L, which is consistent with heart failure. However, the patient's overall clinical picture and laboratory results suggest that he has well-managed heart failure, likely with the use of beta blockers, statins, and ACE inhibitors.

Given the patient's age, comorbidities, and laboratory results, it is likely that the patient's outcome of survival is due to his relatively well-managed heart failure, the absence of severe cardiac arrhythmias, and the presence of effective medical therapy."
345,345,P0566,"Age: 65
Gender: Male 
Weight: 88 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 170/90 mmHg
Past Medical History: Hypertropic cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,72
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 53
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,98
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 290.0
Protein (g/L): 71
T4 (ng/L): 10
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,46
Urea (mg/dL): 6,66
LVEF (%): 62.0
Medications: Beta Blockers, Digoxin, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient's outcome of survival can be attributed to several factors based on the provided information. 

1. Age and NYHA Class II: Although the patient is 65 years old, their NYHA Class II indicates that they have some limitations in physical activity but are still able to perform everyday tasks without significant symptoms. This suggests that their heart function is not severely compromised.

2. Medications: The patient is on beta blockers, digoxin, and loop diuretics, which are standard medications for managing heart failure and hypertension. These medications are likely contributing to the patient's improved outcome.

3. LVEF (Left Ventricular Ejection Fraction) of 62%: Although not optimal, the patient's LVEF is still within a relatively normal range (50-70%). This indicates that the patient's heart is still pumping efficiently enough to meet their body's needs.

4. Troponin levels: The patient's troponin levels are within the normal range (0.02 ng/mL), indicating that there is no acute myocardial infarction (heart attack) and no significant cardiac damage.

5. Pro-BNP (B-type Natriuretic Peptide) levels: The patient's Pro-BNP levels are elevated at 290 ng/L, which is a marker of heart failure. However, this is not unusually high, and the patient's other symptoms and lab values do not suggest severe heart failure.

6. ECG findings: Although the patient has polymorphic ventricular extrasystoles, this is a relatively benign finding, and there is no evidence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, or bradycardia.

7. Lab values: The patient's lab values, including electrolytes, liver function tests, and kidney function tests, are relatively stable and do not indicate any acute issues that would compromise their survival.

Considering these factors, the patient's outcome of survival is likely due to a combination of their relatively stable heart function, effective medication management, and the absence of acute cardiac damage or severe heart failure."
346,346,P0569,"Age: 83
Gender: Female 
Weight: 58 kg
Height: 154 cm
NYHA Class: III
Blood Pressure: 125/75 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 4,53
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 85.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,84
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 753.0
Protein (g/L): 65
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,83
Urea (mg/dL): 7,15
LVEF (%): 61.0
Medications: Calcium Channel Blocker, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient's age and gender are significant risk factors for cardiovascular disease. However, the patient's blood pressure is within a relatively normal range (125/75 mmHg), which is lower than the typical hypertensive range, suggesting that the patient's hypertensive cardiomyopathy may be well-managed with current medications, including the ACE inhibitor and calcium channel blocker. The patient's LVEF (61%) is also within a relatively normal range, indicating preserved left ventricular function. 

The patient's laboratory results show a slightly elevated Creatinine level (71.0 mmol/L), which may indicate mild renal impairment, but this is not severe enough to significantly impact the patient's cardiovascular outcome. The patient's Glucose level (6.1 mmol/L) is also within a relatively normal range, suggesting that diabetes is not a significant contributing factor to the patient's cardiovascular health.

The patient's Pro-BNP level (753.0 ng/L) is elevated, which is consistent with heart failure, but the patient's LVEF is preserved, and the patient's symptoms are likely well-managed with current medications, including loop diuretics and digoxin.

The ECG results show a ventricular extrasystole, which is a common finding in patients with heart disease, but it is not a significant predictor of adverse cardiovascular outcomes in this case. The patient's TSH level (2.83 mIU/L) is within a normal range, which suggests that hypothyroidism is not a contributing factor to the patient's cardiovascular health.

Overall, the patient's cardiovascular health is relatively stable, and the patient's medications are likely effective in managing their condition. The patient's age and comorbidities are significant risk factors, but the patient's preserved LVEF and well-managed blood pressure suggest that the patient is at relatively low risk for adverse cardiovascular outcomes."
347,347,P0571,"Age: 76
Gender: Male 
Weight: 96 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 115/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 7,7
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 5,1
LDL (mmol/L): 1,89
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1303.0
Protein (g/L): 80
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,71
Urea (mg/dL): 13,48
LVEF (%): 35.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Hydralazine, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient, a 76-year-old male with a history of idiopathic dilated cardiomyopathy, diabetes, and hypertension, has a complex medical condition that requires careful management. Despite his advanced age and reduced left ventricular ejection fraction (LVEF) of 35%, the patient's overall clinical picture suggests that he has been receiving appropriate treatment for his heart failure.

The patient's blood pressure is well-controlled, with a systolic blood pressure of 115 mmHg, and his medications include beta blockers, digoxin, loop diuretics, hydralazine, ACE inhibitors, and nitrovasodilators, which are all standard treatments for heart failure. The patient's serum creatinine level is elevated at 133.0 μmol/L, indicating some degree of renal impairment, but this is not unexpected given his history of diabetes and hypertension.

The patient's troponin level is within normal limits, suggesting that he does not have an acute coronary syndrome. The elevated pro-BNP level of 1303.0 ng/L is consistent with heart failure, but it is not excessively high, indicating that the patient's symptoms are likely well-controlled.

The patient's ECG shows a monomorphic ventricular extrasystole, which is a common finding in patients with heart failure. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that the patient's heart rhythm is relatively stable.

Given the patient's age, comorbidities, and complex medication regimen, it is likely that he requires close monitoring and ongoing medical management to prevent complications and improve his quality of life. However, his current clinical status suggests that he is stable and able to survive with proper care."
348,348,P0572,"Age: 36
Gender: Male 
Weight: 80 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,11
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 58
Glucose (mmol/L): 7,7
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,51
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 32.0
Protein (g/L): 76
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,21
Urea (mg/dL): 4,66
LVEF (%): 53.0
Medications: Calcium Channel Blocker, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient outcome of this 36-year-old male is a survivor due to a combination of several factors that contributed to his successful management of the condition. 

Firstly, the patient's blood pressure is well-controlled, with a systolic pressure of 140 mmHg, which is within a relatively normal range. This suggests that the patient's hypertension is under good control, likely due to the ongoing use of a calcium channel blocker and an ACE inhibitor.

Secondly, the patient's LVEF (Left Ventricular Ejection Fraction) is 53%, which is within the normal range (50-70%). This indicates that the patient's heart function is preserved, despite a history of hypertensive cardiomyopathy. The LVEF is a critical factor in determining the prognosis of patients with heart failure, and a value of 53% suggests that the patient's heart is still functioning relatively well.

Thirdly, the patient's troponin level is 0.01 ng/mL, which is within the normal range. Elevated troponin levels are often associated with myocardial infarction or cardiac damage, so a normal troponin level suggests that the patient's heart muscle is not significantly damaged.

Fourthly, the patient's TSH (Thyroid-Stimulating Hormone) level is 1.21 mIU/L, which is within the normal range. Hypothyroidism can contribute to cardiac dysfunction, but the patient's normal TSH level suggests that his thyroid function is within the normal range.

Lastly, the patient's medications, including calcium channel blockers, beta blockers, digoxin, loop diuretics, and an ACE inhibitor, are all appropriate for managing hypertension, heart failure, and arrhythmias. The presence of these medications suggests that the patient is receiving comprehensive treatment for his cardiac condition.

Considering these factors, the patient's outcome of a survivor is likely due to the effective management of his hypertension, preserved LVEF, normal troponin level, normal TSH level, and comprehensive treatment with appropriate medications."
349,349,P0573,"Age: 46
Gender: Male 
Weight: 85 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 46
ALT or GPT (IU/L): 91.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 50
Glucose (mmol/L): 7,2
Hemoglobin (g/L): 159.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,22
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 172.0
Protein (g/L): 74
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,25
Urea (mg/dL): 5,49
LVEF (%): 22.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient, a 46-year-old male with a history of ischemic dilated cardiomyopathy and myocardial infarction, has been managed with beta blockers, statins, and an ACE inhibitor. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 22%, indicating a compromised cardiac function. 

The patient's blood work reveals elevated liver enzymes (ALT and AST) and a slightly elevated creatinine level, suggesting possible liver and kidney strain. However, the patient's kidney function is still relatively preserved, as indicated by the creatinine level. The patient's lipid profile is concerning, with a high total cholesterol and low HDL level, which is consistent with a history of myocardial infarction.

The patient's troponin level is slightly elevated, but it is not significantly high, indicating that the myocardial infarction may be under control. The patient's TSH level is within the normal range, and the T3 and T4 levels are also within the normal range, indicating that the patient does not have hypothyroidism.

The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are concerning signs of arrhythmias. However, the patient does not have paroxysmal supraventricular tachyarrhythmia or bradycardia.

Considering the patient's age, medical history, and laboratory results, the patient's outcome as a survivor is likely due to the following factors:

1. Optimal medical management: The patient is on beta blockers, statins, and an ACE inhibitor, which are all standard treatments for heart failure and ischemic cardiomyopathy. These medications have likely helped to reduce the patient's symptoms and slow the progression of the disease.
2. Early intervention: The patient has a history of myocardial infarction, which suggests that the patient received prompt medical attention and treatment, potentially preventing further cardiac damage.
3. Regular monitoring: The patient's ECG shows arrhythmias, but the patient is being closely monitored, and the arrhythmias are not life-threatening at this time.
4. Good kidney function: The patient's creatinine level is only slightly elevated, indicating that the patient's kidneys are functioning relatively well, which is important for patients with heart failure.

Overall, the patient's outcome as a survivor is likely due to a combination of optimal medical management, early intervention, regular monitoring, and relatively preserved kidney function."
350,350,P0574,"Age: 76
Gender: Male 
Weight: 76 kg
Height: 153 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 6,08
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 130.0
HDL (mmol/L): 2,61
Potassium (mEq/L): 3,87
LDL (mmol/L): 2,95
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 381.0
Protein (g/L): 73
T3 (pg/dL): 0,0588
T4 (ng/L): 15,24
Troponin (ng/mL): 0,4
TSH (mIU/L): 1,56
Urea (mg/dL): 8,6
LVEF (%): 70.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Second-degree AVB - type II
            ",survivor,"REASONING: 

The patient is a 76-year-old male with a history of hypertensive cardiomyopathy, diabetes, dyslipemia, and hypertension, who presented with a complex ECG showing polymorphic ventricular extrasystoles, non-sustained ventricular tachycardia, non-sustained ventricular tachycardia with a cycle length >10 seconds, paroxysmal supraventricular tachyarrhythmia, and second-degree atrioventricular block type II. 

Despite these significant cardiac conditions, the patient survived, likely due to several factors:

1.  The patient's left ventricular ejection fraction (LVEF) is 70%, which indicates that the heart is still pumping effectively, allowing for adequate blood circulation and oxygen delivery to vital organs.
2.  The patient's medications, including a calcium channel blocker, angiotensin II receptor blocker, loop diuretics, and statins, are likely helping to manage his hypertension, heart failure, and dyslipidemia.
3.  The patient's blood pressure is controlled at 160/80 mmHg, which, although elevated, is not excessively high and may be manageable with his current medication regimen.
4.  The patient's troponin level is 0.4 ng/mL, which is within the normal range, indicating that there is no acute myocardial infarction or significant cardiac damage.
5.  The patient's TSH level is 1.56 mIU/L, which is within the normal range, indicating that his thyroid function is normal, and there is no evidence of hyperthyroidism, which can contribute to cardiac arrhythmias.
6.  The patient's T3 and T4 levels are also within normal ranges, which further supports the absence of thyroid dysfunction.
7.  The patient's electrolyte levels, including potassium and sodium, are within normal ranges, which is essential for maintaining cardiac function and preventing arrhythmias.
8.  The patient's albumin and protein levels are within normal ranges, indicating that there is no significant liver or kidney dysfunction.
9.  The patient's creatinine level is 97.0 umol/L, which is within the normal range, indicating that his kidney function is adequate.
10. The patient's hemoglobin level is 130 g/L, which is within the normal range, indicating that there is no anemia or significant blood loss.

Considering these factors, it is likely that the patient's survival can be attributed to the effectiveness of his current medication regimen, the absence of acute cardiac damage, and the presence of adequate cardiac function and normal laboratory values."
351,351,P0575,"Age: 63
Gender: Female 
Weight: 64 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 90/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 76.0
AST or GOT (IU/L): 52.0
Total Cholesterol (mmol/L): 4,6
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 54
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,53
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,12
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1870.0
Protein (g/L): 72
T4 (ng/L): 3
TSH (mIU/L): 18,75
Urea (mg/dL): 7,32
LVEF (%): 24.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient, a 63-year-old female with ischemic dilated cardiomyopathy, has been prescribed medications that are typically used to manage heart failure and reduce the risk of further cardiac events, including beta blockers, statins, and an ACE inhibitor. Despite the presence of several risk factors, including a low left ventricular ejection fraction (LVEF) of 24%, the patient's current medication regimen and overall condition suggest that she is being effectively managed.

The patient's blood pressure, although slightly low (90/50 mmHg), is not significantly abnormal, and her creatinine level is elevated at 106.0 μmol/L, which may indicate some degree of renal impairment. However, this is not uncommon in patients with heart failure and may be related to the patient's underlying cardiomyopathy.

The patient's liver enzymes (ALT and AST) are elevated, suggesting some degree of liver dysfunction, which could be related to her dyslipemia or other underlying conditions. The total cholesterol level is elevated at 4.6 mmol/L, which is consistent with her dyslipemia diagnosis.

The patient's glucose level is elevated at 5.7 mmol/L, which may be related to her metabolic state or other underlying conditions. The hemoglobin level is within the normal range, and the potassium level is slightly low at 4.7 mEq/L.

The pro-BNP level is elevated at 1870.0 ng/L, which is consistent with heart failure, but the patient's overall clinical picture and medication regimen suggest that she is being effectively managed.

The ECG findings of polymorphic ventricular extrasystoles are not uncommon in patients with heart failure and are not typically associated with poor outcomes.

Given the patient's age, gender, and underlying medical conditions, as well as her current medication regimen and overall clinical picture, it is reasonable to conclude that she is a survivor, indicating that she has been able to manage her condition effectively and is likely to continue to do so with ongoing treatment and management."
352,352,P0577,"Age: 37
Gender: Male 
Weight: 90 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 40.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 7,53
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 107
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,5
LDL (mmol/L): 5,17
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 71.0
Protein (g/L): 72
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,27
Urea (mg/dL): 5,66
LVEF (%): 31.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient's age and sex are 37 years old and male, respectively, which does not necessarily influence the outcome in this case. However, his past medical history is significant for ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and enlarged due to a previous heart attack. This condition can lead to a decreased left ventricular ejection fraction (LVEF), which is supported by the patient's LVEF of 31%. The patient is also on beta blockers, statins, and ACE inhibitors, which are common medications used to manage heart failure and improve outcomes in patients with heart failure.

The patient's current NYHA class is II, indicating that he experiences some limitation in physical activity but is still able to perform daily activities without significant symptoms. His blood pressure is within a normal range, and his glucose level is also within a normal range.

The patient's laboratory results show some abnormalities, including elevated total cholesterol and LDL levels, which are being managed with statins. His liver function tests (ALT and AST) are within a normal range, which suggests that his liver is functioning properly. His creatinine level is elevated, indicating some kidney dysfunction, but it is not significantly high.

The patient's TSH level is within a normal range, which suggests that his thyroid function is normal. His T3 and T4 levels are also within a normal range, which further supports the normal thyroid function.

The patient's Troponin level is low, indicating that there is no acute myocardial infarction at the time of the test. His Pro-BNP level is within a normal range, which suggests that his heart failure symptoms are not severe.

The ECG shows polymorphic ventricular extrasystoles, which are abnormal heartbeats that can be a sign of cardiac dysfunction. However, there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias.

Considering the patient's overall clinical presentation and laboratory results, the most likely reason for the patient's outcome is that he is being effectively managed with his current medications and is not experiencing any acute complications that would lead to a poor outcome. His LVEF of 31% is a significant indicator of heart failure, but it is not a contraindication for survival. With proper management and follow-up, patients with heart failure can live for many years with a good quality of life."
353,353,P0578,"Age: 44
Gender: Male 
Weight: 68 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 41
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 6,8
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 174.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,5
LDL (mmol/L): 5,17
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 628.0
Protein (g/L): 68
T3 (pg/dL): 0,06
T4 (ng/L): 17
Troponin (ng/mL): 0,1
TSH (mIU/L): 1,09
Urea (mg/dL): 4,99
LVEF (%): 43.0
Medications: Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient, a 44-year-old male with a history of idiopathic dilated cardiomyopathy, has a favorable outcome of survival despite having a relatively low left ventricular ejection fraction (LVEF) of 43%. Several factors contribute to this outcome:

1.  Effective management of dyslipidemia: The patient is on statins, which helps to control his total cholesterol level of 6.8 mmol/L and LDL level of 5.17 mmol/L, reducing the risk of further cardiac damage.

2.  Control of blood pressure: His blood pressure is well-managed at 100/70 mmHg, which is within the normal range, reducing the strain on his heart.

3.  ACE Inhibitor therapy: The use of an ACE inhibitor is beneficial for patients with heart failure, as it helps to reduce afterload and improve cardiac function.

4.  Lack of severe electrolyte imbalances: His potassium level is within the normal range (4.5 mEq/L), which is essential for maintaining proper cardiac function.

5.  Normal TSH level: A normal thyroid-stimulating hormone (TSH) level of 1.09 mIU/L indicates that his thyroid function is within the normal range, which is crucial for maintaining cardiac function.

6.  Low troponin level: A troponin level of 0.1 ng/mL is within the normal range, indicating that there is no acute myocardial infarction or significant cardiac damage.

7.  No signs of severe liver dysfunction: His AST and ALT levels are within the normal range, indicating that his liver function is not significantly compromised, which is essential for metabolizing medications and maintaining cardiac health.

8.  No signs of severe kidney dysfunction: His urea level of 4.99 mg/dL is within the normal range, indicating that his kidneys are functioning properly, which is essential for removing waste products and maintaining electrolyte balance.

9.  No signs of severe anemia: His hemoglobin level of 174.0 g/L is within the normal range, which is essential for maintaining adequate oxygen delivery to the tissues.

10.  Low Pro-BNP level: A Pro-BNP level of 628.0 ng/L is elevated, indicating that the patient has some degree of heart failure, but it is not severe. However, the fact that the patient is still alive suggests that the elevation in Pro-BNP is not indicative of an acute decompensation.

Considering these factors, the patient's outcome of survival can be attributed to a combination of effective management of his underlying conditions, well-controlled blood pressure and lipid levels, and the absence of severe electrolyte imbalances, thyroid dysfunction, or severe organ dysfunction."
354,354,P0579,"Age: 73
Gender: Male 
Weight: 98 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 100/58 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,46
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 54
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 3,9
LDL (mmol/L): 3,78
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1083.0
Protein (g/L): 72
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,91
Urea (mg/dL): 7,49
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient, a 73-year-old male with a history of idiopathic dilated cardiomyopathy, hypertension, and dyslipemia, has a complex medical condition. Despite having a low left ventricular ejection fraction (LVEF) of 20%, indicating severe heart failure, the patient's overall outcome is a survivor. This can be attributed to several factors:

1.  Optimal Medical Management: The patient is on a multidrug regimen that includes beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are all evidence-based treatments for heart failure. These medications help reduce symptoms, slow disease progression, and improve survival.

2.  Monitoring and Management of Arrhythmias: The patient has been diagnosed with non-sustained ventricular tachycardia, a common complication in patients with heart failure. The presence of a polymorphic ventricular extrasystole and a non-sustained ventricular tachycardia (CH>10) indicates that the patient's heart is experiencing abnormal electrical activity, but it is not sustained, suggesting that the patient is not experiencing a life-threatening arrhythmia at this time.

3.  TSH and T4 Levels: The patient's thyroid-stimulating hormone (TSH) and free thyroxine (T4) levels are within the normal range, indicating that hypothyroidism, a potential cause of heart failure, is not a contributing factor in this case.

4.  Kidney Function: The patient's creatinine level is slightly elevated at 71.0 μmol/L, indicating some degree of kidney impairment. However, this is not severe enough to significantly impact the patient's overall outcome.

5.  Blood Pressure: The patient's blood pressure is relatively well-controlled at 100/58 mmHg, which is lower than the patient's blood pressure in the past, indicating that the patient's hypertension is being effectively managed.

6.  Lifestyle Factors: While the patient's weight is slightly above average (98 kg), it is not severely elevated, and the patient's height is relatively short, which may not contribute significantly to the patient's heart failure.

7.  Pro-BNP Level: The patient's pro-brain natriuretic peptide (pro-BNP) level is elevated at 1083.0 ng/L, indicating that the patient's heart is under strain. However, this is consistent with the patient's heart failure diagnosis and is not a new development.

Considering these factors, the patient's outcome as a survivor can be attributed to the combination of optimal medical management, effective monitoring and management of arrhythmias, and the absence of any new or severe complications that would contribute to a poor outcome."
355,355,P0580,"Age: 73
Gender: Female 
Weight: 49 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 135/40 mmHg
Past Medical History: Toxic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 23
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,71
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 37
Glucose (mmol/L): 12,4
Hemoglobin (g/L): 126.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,73
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 2932.0
Protein (g/L): 75
T4 (ng/L): 19
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,78
Urea (mg/dL): 9,32
LVEF (%): 29.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 73-year-old female with a history of toxic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension. Despite her complex medical history and multiple comorbidities, the patient has survived, which can be attributed to several factors.

Firstly, her current medications, including beta blockers, digoxin, loop diuretics, statins, and ACE inhibitors, are likely contributing to her survival. Beta blockers and ACE inhibitors are known to improve survival in patients with heart failure, while digoxin can help control heart rate and improve symptoms. Statins are also beneficial in reducing cardiovascular events and mortality in patients with heart failure.

Secondly, the patient's LVEF (Left Ventricular Ejection Fraction) of 29% is relatively low, indicating systolic dysfunction, but it is not the lowest possible value. This suggests that the patient's heart is still able to pump some blood, which is essential for survival.

Thirdly, the patient's Pro-BNP (Brain Natriuretic Peptide) level is elevated at 2932.0 ng/L, which is consistent with heart failure. However, this level is not extremely high, indicating that the patient's heart is not severely failing.

Lastly, the patient's blood pressure is 135/40 mmHg, which is relatively low. This may be a result of the loop diuretics, which can cause hypotension. Despite this, the patient is still able to maintain some level of perfusion to vital organs, which is crucial for survival.

In conclusion, the combination of the patient's medications, relatively low LVEF, moderate Pro-BNP level, and controlled blood pressure have all contributed to her survival. However, the patient's outcome is still guarded, and close monitoring and adjustment of her medications will be necessary to ensure optimal management of her heart failure and other comorbidities."
356,356,P0581,"Age: 45
Gender: Female 
Weight: 73 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 47
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 66
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,17
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 825.0
Protein (g/L): 81
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,06
TSH (mIU/L): 8,69
Urea (mg/dL): 6,82
LVEF (%): 30.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's medical history of ischemic dilated cardiomyopathy and myocardial infarction, it is not surprising that the patient has a reduced left ventricular ejection fraction (LVEF) of 30%. This suggests that the patient's heart is not pumping efficiently, which can lead to symptoms of heart failure. However, the patient's NYHA Class II classification indicates that she is experiencing some symptoms of heart failure, but they are not severe enough to limit her daily activities.

The patient's laboratory results show elevated levels of creatinine (106.0 mmol/L), which suggests impaired renal function. This is consistent with the patient's history of heart failure, as decreased cardiac output can lead to decreased renal perfusion and subsequent kidney damage.

The patient's Pro-BNP level of 825.0 ng/L is elevated, which is consistent with heart failure. BNP is a hormone released by the heart in response to increased ventricular wall stress, which can occur in heart failure.

The patient's medications, including beta blockers, digoxin, loop diuretics, spironolactone, statins, and ACE inhibitor, are all standard treatments for heart failure. These medications are likely helping to manage the patient's symptoms and slow the progression of her heart failure.

The ECG findings of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia suggest that the patient is at risk for arrhythmias, which can be a complication of heart failure. However, the fact that the patient is a survivor suggests that these arrhythmias are not severe enough to cause significant harm.

Overall, the patient's outcome of survivor suggests that her heart failure is being managed effectively with her current treatment regimen, and she is able to tolerate her symptoms and maintain a relatively stable cardiac function."
357,357,P0582,"Age: 74
Gender: Female 
Weight: 72 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 143/76 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 3,7
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,71
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,59
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 2066.0
Protein (g/L): 72
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 6,26
Urea (mg/dL): 7,32
LVEF (%): 28.0
Medications: Amiodarone, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's medical history of ischemic dilated cardiomyopathy, myocardial infarction, and current medications such as amiodarone, loop diuretics, statins, and ACE inhibitor, it is not surprising that the patient is a survivor. The patient's low left ventricular ejection fraction (LVEF) of 28% indicates significant left ventricular dysfunction, which is a common complication of ischemic dilated cardiomyopathy.

The patient's high Pro-BNP level (2066.0 ng/L) also suggests that the patient is experiencing heart failure, which is consistent with the patient's NYHA Class II classification. However, the fact that the patient is still alive and not in NYHA Class III or IV suggests that the patient's heart failure is being well-managed with current medications.

The patient's laboratory results also indicate that the patient's liver function is relatively preserved, as evidenced by normal or near-normal levels of albumin, ALT, AST, and gamma-glutamil transpeptidase. The patient's kidney function is also relatively preserved, as evidenced by a creatinine level of 115.0 μmol/L, which is within the normal range.

The patient's lipid profile shows a high total cholesterol level, but the LDL level is relatively low, which is consistent with the patient's statin therapy. The patient's HDL level is within the normal range, which is a positive prognostic factor.

The patient's blood pressure is within the normal range, which is consistent with the patient's medications, including loop diuretics and ACE inhibitor.

Overall, the patient's survivor outcome is likely due to the effective management of their heart failure and other comorbidities with current medications, as well as the patient's relatively preserved liver and kidney function."
358,358,P0585,"Age: 72
Gender: Male 
Weight: 83 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Valvular cardiomyopathy, Dyslipemia
Albumin (g/L): 45
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,79
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 852.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 21
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,43
Urea (mg/dL): 8,82
LVEF (%): 40.0
Medications: Amiodarone, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient's outcome as a survivor can be attributed to a combination of several factors. 

Firstly, the patient is on a comprehensive medication regimen that includes Amiodarone, Beta Blockers, Statins, and an ACE Inhibitor, which suggests that their treatment plan is well-managed. Amiodarone is an anti-arrhythmic medication that is often used to treat various types of irregular heartbeats, including ventricular extrasystoles. Beta Blockers help to reduce the heart rate and the heart's workload, which is beneficial for a patient with valvular cardiomyopathy and a low left ventricular ejection fraction (LVEF) of 40%. Statins are used to manage dyslipidemia, which can contribute to the progression of heart disease. ACE Inhibitors are used to reduce blood pressure and strain on the heart.

The patient's LVEF of 40% indicates that the heart is still pumping efficiently, despite the presence of valvular cardiomyopathy. The patient's blood pressure of 150/80 mmHg is not excessively high, and their hemoglobin level of 144.0 g/L is within the normal range. The patient's potassium level of 4.8 mEq/L is also within the normal range, which is essential for maintaining proper heart function.

The patient's troponin level of 0.04 ng/mL is within the normal range, indicating that there is no acute myocardial infarction. The patient's TSH level of 0.43 mIU/L is also within the normal range, indicating that their thyroid function is normal.

The patient's creatinine level of 124.0 umol/L is elevated, indicating some degree of kidney dysfunction. However, this is not unexpected in a patient with valvular cardiomyopathy, and it is likely that the patient's kidney function is being monitored closely.

The patient's Pro-BNP level of 852.0 ng/L is elevated, indicating that the patient's heart is under strain. However, this is not unexpected in a patient with valvular cardiomyopathy and a low LVEF.

Overall, the patient's outcome as a survivor can be attributed to a combination of their well-managed treatment plan, their relatively stable cardiac function, and their lack of acute myocardial infarction or other life-threatening complications."
359,359,P0586,"Age: 74
Gender: Male 
Weight: 74 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,2
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 179.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,08
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 493.0
Protein (g/L): 75
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,81
Urea (mg/dL): 8,82
LVEF (%): 23.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient's outcome as a survivor can be attributed to several factors based on the provided data.

1.  Optimal Medication Regimen: The patient is on a comprehensive medication regimen that includes Beta Blockers, Loop Diuretics, Statins, and an ACE Inhibitor. These medications are crucial in managing heart failure, hypertension, and lipid disorders. Beta Blockers help reduce the heart rate and contractility, thereby decreasing the workload on the heart. Loop Diuretics aid in reducing fluid overload, which is common in heart failure. Statins help lower cholesterol levels, reducing the risk of further cardiac damage. ACE Inhibitors, also known as ACEIs, help relax blood vessels and reduce the heart's workload.

2.  Controlled Blood Pressure: The patient's blood pressure is well-controlled at 110/80 mmHg. This is crucial as uncontrolled hypertension can exacerbate heart failure and lead to further cardiac damage.

3.  Reasonable LVEF: Although the patient has a reduced left ventricular ejection fraction (LVEF) of 23%, this is not extremely low. An LVEF of 23% indicates severe heart failure, but the patient is still alive and not in an advanced stage.

4.  Normal Troponin Levels: The troponin level is 0.01 ng/mL, which is within the normal range. Elevated troponin levels often indicate cardiac damage or infarction, which is not the case here.

5.  TSH and T4 Levels: The thyroid function tests (TSH and T4) are within the normal range, indicating no apparent thyroid dysfunction. Thyroid disorders can impact heart function, so this is a positive factor.

6.  Albumin and Protein Levels: The albumin level of 41 g/L is slightly low, but not critically low. Protein levels are within the normal range, which is essential for maintaining fluid balance and cardiac function.

7.  Creatinine Level: The creatinine level of 115.0 mmol/L is elevated, indicating some degree of kidney impairment. However, this is not an immediate life-threatening condition, and the patient is still alive.

Considering these factors, the patient's survival can be attributed to the comprehensive management of their heart failure, hypertension, and lipid disorders, along with a well-controlled blood pressure and relatively stable kidney function."
360,360,P0587,"Age: 58
Gender: Male 
Weight: 97 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 120/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 43
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 2,95
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,47
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 65.0
Protein (g/L): 76
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,93
Urea (mg/dL): 7,82
LVEF (%): 30.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to several factors that are evident from the provided data.

Firstly, the patient's blood pressure is within a relatively normal range (120/75 mmHg), indicating adequate blood pressure control, which is crucial for reducing the strain on the heart. The patient's weight (97 kg) is not significantly high, considering their height (171 cm), which suggests a relatively normal body mass index (BMI).

The patient's medications, including beta blockers, spironolactone, statins, and ACE inhibitors, are all evidence-based treatments for heart failure and idiopathic dilated cardiomyopathy. Beta blockers and ACE inhibitors are particularly effective in reducing morbidity and mortality in patients with heart failure by decreasing afterload and improving cardiac output. Spironolactone is an aldosterone antagonist that helps reduce fluid overload and fibrosis, while statins help lower LDL cholesterol and reduce inflammation.

The patient's laboratory results also indicate that their liver function (ALT and AST) and kidney function (creatinine) are within relatively normal ranges. The low troponin level (0.01 ng/mL) suggests that there is no acute myocardial infarction, and the low pro-BNP level (65.0 ng/L) indicates that the patient is not experiencing significant cardiac stress or strain.

The patient's LVEF (left ventricular ejection fraction) of 30% is significantly reduced, indicating systolic heart failure. However, the patient's symptoms are classified as NYHA Class II, which suggests that they are experiencing mild symptoms of heart failure, such as fatigue and shortness of breath, but are still able to perform daily activities without significant limitation.

The patient's TSH level (1.93 mIU/L) is within the normal range, indicating that their thyroid function is not contributing to their cardiac symptoms. The patient's hemoglobin level (136.0 g/L) is within the normal range, indicating that they are not anemic, which could exacerbate heart failure symptoms.

In summary, the combination of the patient's relatively normal blood pressure, effective medications, and normal laboratory results, along with their mild symptoms of heart failure, contributed to their outcome of survival."
361,361,P0588,"Age: 77
Gender: Male 
Weight: 92 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 135/100 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 10.0
Total Cholesterol (mmol/L): 6,21
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 145.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 4,9
LDL (mmol/L): 4,09
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 514.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,1
TSH (mIU/L): 0,96
Urea (mg/dL): 9,15
LVEF (%): 50.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Unknown ventricular extrasystole code
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 77-year-old male with a history of ischemic dilated cardiomyopathy and myocardial infarction, which indicates a significant cardiac disease burden. His current medications, including digoxin, loop diuretics, ACE inhibitor, and nitrovasodilator, suggest that he is being treated for heart failure symptoms and possibly hypertension.

The patient's NYHA Class II classification indicates that he experiences some limitations in his physical activity, but is still able to perform light physical activity without symptoms. However, his LVEF of 50% suggests that he has significant left ventricular dysfunction, which may contribute to his symptoms.

The patient's laboratory results show an elevated Pro-BNP level of 514.0 ng/L, which is consistent with heart failure. His electrolyte levels, including potassium (4.9 mEq/L) and sodium (139.0 mEq/L), are within normal limits. His liver function tests (ALT and AST) are normal, indicating that his liver is functioning properly.

The patient's lipid profile shows a total cholesterol level of 6.21 mmol/L, which is high, but his HDL level of 1.68 mmol/L is also high, which may help to mitigate the risk of cardiovascular disease. His LDL level of 4.09 mmol/L is also high, which may contribute to his cardiovascular disease risk.

The patient's ECG shows ventricular extrasystole, ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia, which are all consistent with his history of cardiac disease. However, the specific codes for these abnormalities are unknown.

Despite these findings, the patient has survived, which suggests that his current treatment regimen is effective in managing his symptoms and preventing further cardiac complications. His LVEF of 50% and NYHA Class II classification suggest that he has some degree of cardiac dysfunction, but he is still able to tolerate his medications and physical activity without significant symptoms.

Therefore, the patient's survival can be attributed to his current treatment regimen, which includes medications that are effective in managing heart failure symptoms and preventing further cardiac complications. His relatively high HDL level and normal electrolyte levels also suggest that he has a lower risk of cardiovascular disease."
362,362,P0590,"Age: 64
Gender: Female 
Weight: 75 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 135/95 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,72
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 6
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,17
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 667.0
Protein (g/L): 64
T3 (pg/dL): 0,04
T4 (ng/L): 20
Troponin (ng/mL): 0,03
TSH (mIU/L): 4,77
Urea (mg/dL): 12,15
LVEF (%): 32.0
Medications: Amiodarone, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 64-year-old female with a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and enlarged due to a previous heart attack. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 32%, indicating poor heart function. However, the patient has been on optimal medical therapy with amiodarone for arrhythmia management, loop diuretics for fluid management, statins for cholesterol management, and an ACE inhibitor for heart failure management.

The patient's blood pressure is slightly elevated at 135/95 mmHg, but it is not significantly high. The patient's creatinine level is slightly elevated at 106.0 mmol/L, indicating mild kidney dysfunction, which is common in patients with heart failure.

The patient's pro-BNP level is elevated at 667.0 ng/L, which is a marker of heart failure severity. However, the patient's troponin level is within normal limits, indicating no recent myocardial infarction.

The patient's ECG shows a monomorphic ventricular extrasystole, which is a common finding in patients with heart failure. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia suggests that the patient's heart rhythm is relatively stable.

Considering the patient's optimal medical therapy and relatively stable heart rhythm, the patient's ability to survive is likely due to the effectiveness of her treatment regimen and her relatively stable clinical condition. The patient's survival is also influenced by her age, gender, and the fact that she does not have any other life-threatening conditions.

Therefore, the patient's survival is likely due to a combination of her optimal medical therapy, stable heart rhythm, and relatively stable clinical condition."
363,363,P0591,"Age: 62
Gender: Male 
Weight: 72 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 125/90 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,72
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 73
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 120.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,38
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 279.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,18
Urea (mg/dL): 8,32
LVEF (%): 64.0
Medications: Beta Blockers, Digoxin, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient, a 62-year-old male with a history of valvular cardiomyopathy, has a relatively favorable outcome, indicating survival. Several factors contribute to this outcome:

1. Effective management of heart failure symptoms: The patient's NYHA Class II classification indicates that he experiences some limitations in physical activity, but is still able to perform daily tasks without severe symptoms. This suggests that his heart failure symptoms are well-managed.

2. Prescribed medications: The patient is on beta blockers, digoxin, and loop diuretics, which are commonly used to treat heart failure and related conditions. These medications likely help to control symptoms, reduce hospitalizations, and improve survival.

3. Reasonable left ventricular ejection fraction (LVEF): The patient's LVEF is 64%, which is above the threshold for severe heart failure (LVEF < 35-40%). This indicates that his heart is still pumping effectively, contributing to his survival.

4. Normal troponin levels: The patient's troponin level is within normal limits (0.03 ng/mL), indicating that there is no significant myocardial damage or infarction.

5. Normal TSH and T3/T4 levels: The patient's thyroid function is within normal limits, which is essential for maintaining cardiac function and overall health.

6. No evidence of severe electrolyte imbalances: The patient's potassium level is within the normal range (4.2 mEq/L), which is crucial for maintaining cardiac function.

7. Reasonable blood pressure: The patient's blood pressure is controlled, with a systolic pressure of 125 mmHg and a diastolic pressure of 90 mmHg.

8. No indication of severe renal dysfunction: The patient's creatinine level is within normal limits (97.0 μmol/L), indicating that his kidneys are functioning reasonably well.

9. No evidence of significant liver dysfunction: The patient's liver function tests (ALT, AST, and gamma-glutamil transpeptidase) are within normal limits, indicating that his liver is functioning properly.

Overall, the patient's combination of effective medical management, reasonable cardiac function, and absence of severe comorbidities likely contributed to his favorable outcome, indicating survival."
364,364,P0592,"Age: 66
Gender: Male 
Weight: 78 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes
Albumin (g/L): 40
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 85
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 153.0
HDL (mmol/L): 0,54
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,46
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1537.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,13
Urea (mg/dL): 8,65
LVEF (%): 30.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Unknown ventricular extrasystole code
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 66-year-old male with a history of valvular cardiomyopathy and diabetes, which are both significant risk factors for heart failure. The patient's left ventricular ejection fraction (LVEF) is severely impaired at 30%, indicating reduced cardiac function. 

The elevated Pro-BNP level of 1537 ng/L suggests that the patient has heart failure with preserved ejection fraction (HFpEF) or reduced ejection fraction (HFrEF), as Pro-BNP levels are often elevated in heart failure. The patient's blood pressure is within a relatively normal range, and there are no signs of acute coronary syndrome, as indicated by a low troponin level of 0.03 ng/mL.

The patient is on a regimen of beta blockers, digoxin, loop diuretics, spironolactone, and statins, which are all standard treatments for heart failure. The use of beta blockers and ACE inhibitors or ARBs is typically recommended to improve survival in patients with heart failure with reduced ejection fraction.

The patient's ECG shows ventricular extrasystole, but the code is unknown. However, this is a common finding in patients with heart failure and is not typically a cause for concern.

The patient's electrolytes are within a relatively normal range, but the potassium level is slightly elevated at 5.4 mEq/L. The elevated potassium level may be due to the use of spironolactone, which can cause hyperkalemia as a side effect.

Considering the patient's age, comorbidities, and the use of appropriate medications, the patient's survival is likely due to the effective management of heart failure and the use of evidence-based therapies. The patient's LVEF is severely impaired, but the patient is stable and able to survive, which suggests that the patient's cardiac function is being adequately managed."
365,365,P0595,"Age: 69
Gender: Male 
Weight: 68 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 176/92 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 96
Glucose (mmol/L): 7,8
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,53
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 290.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 15
TSH (mIU/L): 0,46
Urea (mg/dL): 7,15
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Diabetes Medication, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's profile, the outcome of survival is attributed to several factors:

1.  Multidisciplinary Management: The patient is on a combination of medications, including a Calcium Channel Blocker, Diabetes Medication, Loop Diuretics, and an ACE Inhibitor, which are commonly used to manage hypertension, diabetes, and heart failure. This multidisciplinary approach has likely helped to control the patient's symptoms and slow the progression of the disease.

2.  Early Detection and Treatment: The patient's LVEF (Left Ventricular Ejection Fraction) is 35%, which indicates that the patient has a reduced ejection fraction, a common indicator of heart failure. However, the patient's Pro-BNP (Brain Natriuretic Peptide) level is 290.0 ng/L, which is elevated but not extremely high. This suggests that the patient's heart failure is not in an advanced stage, and the patient has been receiving appropriate treatment.

3.  No Acute Complications: The ECG impression shows no signs of acute complications such as ventricular tachycardia, non-sustained ventricular tachycardia, or bradycardia, which are all indicators of serious cardiac issues. The presence of monomorphic ventricular extrasystoles is common in patients with heart disease, but it is not a life-threatening condition.

4.  Stable Blood Pressure: Although the patient's blood pressure is elevated (176/92 mmHg), it is not extremely high, and the patient is on medication to control it. The patient's sodium level is within the normal range, which suggests that the patient's blood pressure is not being significantly affected by sodium imbalances.

5.  Minimal Organ Dysfunction: The patient's creatinine level is 88.0 umol/L, which is slightly elevated but not significantly high. The patient's urea level is 7.15 mg/dL, which is within the normal range. These lab results suggest that the patient's kidneys are functioning relatively well, which is a positive prognostic indicator.

6.  No Severe Electrolyte Imbalance: The patient's potassium level is 4.3 mEq/L, which is within the normal range. This suggests that the patient does not have a severe electrolyte imbalance, which can be a life-threatening complication in patients with heart disease.

7.  No Indication of Thyroid Dysfunction: The patient's TSH (Thyroid-Stimulating Hormone) level is 0.46 mIU/L, which is within the normal range. This suggests that the patient does not have thyroid dysfunction, which can be a contributing factor to heart disease.

In summary, the patient's outcome of survival is likely due to the combination of multidisciplinary management, early detection and treatment of heart failure, the absence of acute complications, stable blood pressure, minimal organ dysfunction, no severe electrolyte imbalance, and no indication of thyroid dysfunction."
366,366,P0597,"Age: 74
Gender: Male 
Weight: 83 kg
Height: 164 cm
NYHA Class: III
Blood Pressure: 143/65 mmHg
Past Medical History: Valvular cardiomyopathy, Dyslipemia
Albumin (g/L): 39
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 76
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 137.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4
LDL (mmol/L): 2,9
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1874.0
Protein (g/L): 67
T3 (pg/dL): 0,08
T4 (ng/L): 29
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,09
Urea (mg/dL): 9,32
LVEF (%): 70.0
Medications: Calcium Channel Blocker, Amiodarone, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to a combination of several factors.

Firstly, the patient's left ventricular ejection fraction (LVEF) is 70%, which is within the normal range (> 55%). This indicates that the patient's heart is pumping blood efficiently, which is a positive prognostic factor.

The patient's medication regimen includes a calcium channel blocker, amiodarone, loop diuretics, and a nitrovasodilator, which are all aimed at managing the patient's valvular cardiomyopathy and dyslipemia. The use of these medications suggests that the patient's condition is being actively managed, which may have contributed to their survival.

The patient's blood pressure is 143/65 mmHg, which is within the normal range, indicating that their blood pressure is well-controlled. This is also a positive prognostic factor.

Additionally, the patient's troponin level is 0.03 ng/mL, which is within the normal range, indicating that there is no acute myocardial infarction. This suggests that the patient's heart muscle is not experiencing significant damage.

The patient's TSH level is 0.09 mIU/L, which is within the normal range, indicating that their thyroid function is normal. Hypothyroidism can contribute to heart failure, so this is a positive finding.

The patient's Pro-BNP level is 1874.0 ng/L, which is elevated, but not excessively high. BNP levels can be elevated in patients with heart failure, but a level of 1874 ng/L is not typically associated with a poor prognosis.

The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, but these are not necessarily indicative of a poor prognosis. The presence of these arrhythmias may be a consequence of the patient's valvular cardiomyopathy, but they do not necessarily indicate a high risk of sudden cardiac death.

Overall, the patient's combination of well-managed medications, normal blood pressure, normal LVEF, and normal troponin level, along with the absence of acute myocardial infarction, suggests that their survival is likely due to effective management of their underlying condition."
367,367,P0598,"Age: 50
Gender: Male 
Weight: 65 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,22
Creatinine (mmol/L): 264.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 178.0
HDL (mmol/L): 2,17
Potassium (mEq/L): 4,9
LDL (mmol/L): 1,24
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 8083.0
Protein (g/L): 84
T3 (pg/dL): 0,03
T4 (ng/L): 14
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,33
Urea (mg/dL): 18,47
LVEF (%): 52.0
Medications: Beta Blockers, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 50-year-old male with a history of idiopathic dilated cardiomyopathy and hypertension, presenting with a low left ventricular ejection fraction (LVEF) of 52%. The patient's medication regimen includes beta blockers, digoxin, and an ACE inhibitor, which are standard treatments for heart failure and dilated cardiomyopathy.

The patient's laboratory results show elevated creatinine levels (264.0 mmol/L), which indicates impaired kidney function. However, the patient's albumin levels are within the normal range, suggesting that the kidney impairment is not severe enough to cause significant proteinuria.

The patient's liver function tests (ALT and AST) are within normal limits, indicating that liver function is not significantly impaired. The patient's lipid profile shows a total cholesterol level of 4.22 mmol/L, which is slightly elevated, but the LDL level is low at 1.24 mmol/L.

The patient's thyroid function tests (T3 and T4) are within normal limits, indicating that hypothyroidism is unlikely to be contributing to the patient's heart failure. The patient's TSH level is slightly elevated at 1.33 mIU/L, but this is not significantly abnormal.

The patient's troponin level is slightly elevated at 0.3 ng/mL, indicating some degree of myocardial damage, but this is not severe enough to suggest an acute myocardial infarction.

The patient's pro-BNP level is significantly elevated at 8083.0 ng/L, indicating severe heart failure. However, the patient's LVEF of 52% suggests that the heart failure is not severe enough to cause significant symptoms or mortality.

The patient's ECG shows monomorphic ventricular extrasystoles, which are common in patients with dilated cardiomyopathy. However, there is no evidence of ventricular tachycardia, bradycardia, or other life-threatening arrhythmias.

Overall, the patient's outcome is likely due to the effective management of his heart failure and dilated cardiomyopathy with beta blockers, digoxin, and an ACE inhibitor. The patient's kidney function is impaired, but not severely enough to cause significant proteinuria or mortality. The patient's liver function and thyroid function are within normal limits, and the patient's lipid profile is not significantly abnormal. The patient's troponin level is slightly elevated, but not severe enough to suggest an acute myocardial infarction."
368,368,P0599,"Age: 66
Gender: Female 
Weight: 80 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 48,7
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 4,89
Creatinine (mmol/L): 83.0
Gamma-glutamil transpeptidase (IU/L): 46
Glucose (mmol/L): 9,2
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,38
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 534.0
Protein (g/L): 75,6
T4 (ng/L): 17
TSH (mIU/L): 1,22
Urea (mg/dL): 6,16
LVEF (%): 36.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to several factors:

1. Optimal Medical Management: The patient is on a comprehensive medication regimen, including beta blockers, ACE inhibitors, spironolactone, statins, and a nitrovasodilator, which are all standard treatments for heart failure and ischemic dilated cardiomyopathy. This suggests that the patient has been receiving appropriate care for their condition.

2. Controlled Blood Pressure: The patient's blood pressure is well-controlled at 120/70 mmHg, which is within the target range for a patient with heart failure. This indicates that the patient's blood pressure is not contributing to further strain on the heart.

3. Low Creatinine Levels: The patient's creatinine level of 83.0 mmol/L is within the normal range, suggesting that the kidneys are functioning adequately. This is important because patients with heart failure often have impaired renal function, which can worsen their prognosis.

4. LVEF of 36%: While the patient's left ventricular ejection fraction (LVEF) is low at 36%, it is not the lowest possible value. An LVEF of 36% still allows for some degree of cardiac function, which may be sufficient to sustain life.

5. Absence of Severe Arrhythmias: The ECG does not show any signs of severe arrhythmias such as ventricular tachycardia or non-sustained ventricular tachycardia, which are often associated with a poor prognosis in heart failure patients.

6. Normal TSH and T4 Levels: The patient's thyroid function is within the normal range, which is important because thyroid dysfunction can exacerbate heart failure.

7. Patient's Age and NYHA Class: The patient is 66 years old and has a NYHA Class II heart failure, which is not severe. Patients with NYHA Class III or IV heart failure have a poorer prognosis.

Overall, the combination of optimal medical management, controlled blood pressure, preserved renal function, adequate cardiac function, absence of severe arrhythmias, normal thyroid function, and the patient's age and NYHA Class all contributed to the patient's outcome of survival."
369,369,P0600,"Age: 58
Gender: Female 
Weight: 57 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 44,4
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,53
Creatinine (mmol/L): 68.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,6
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,56
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 828.0
Protein (g/L): 70,9
T4 (ng/L): 18
TSH (mIU/L): 1,93
Urea (mg/dL): 5,99
LVEF (%): 57.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 58-year-old female with a history of ischemic dilated cardiomyopathy and myocardial infarction, has a complex medical history that significantly increases her risk for adverse cardiovascular events. However, her current medication regimen, which includes a calcium channel blocker, beta blockers, loop diuretics, statins, and an ACE inhibitor, suggests that her cardiomyopathy and heart failure symptoms are being managed.

The patient's left ventricular ejection fraction (LVEF) of 57% is within a relatively stable range, indicating that her heart is functioning adequately despite her history of myocardial infarction. Her blood pressure is within a normal range, and her serum creatinine levels are slightly elevated but not indicative of significant kidney dysfunction.

The patient's Pro-BNP level of 828 ng/L is elevated, which is consistent with heart failure, but her albumin levels are within the normal range, and her liver enzymes (ALT and AST) are within the normal range, indicating that her liver function is not significantly compromised.

The patient's lipid profile shows a relatively high total cholesterol level, but her LDL is within the target range for cardiovascular risk reduction. Her HDL level is low, which is a risk factor for cardiovascular disease.

The absence of significant arrhythmias on the ECG and the absence of symptoms such as chest pain, shortness of breath, or fatigue suggest that the patient's current treatment plan is effective in managing her condition.

Given the patient's age, sex, and medical history, her NYHA class II indicates that she has mild to moderate symptoms of heart failure, which is consistent with her current treatment plan and overall clinical presentation. Her ability to survive without significant complications suggests that her current treatment plan is effective in managing her condition.

Therefore, the patient's outcome as a survivor is likely due to the effective management of her heart failure symptoms and her cardiovascular risk factors through her current medication regimen and lifestyle modifications."
370,370,P0601,"Age: 77
Gender: Male 
Weight: 60 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 47,4
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,53
Creatinine (mmol/L): 72.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 145.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,31
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 142.0
Protein (g/L): 74,2
T4 (ng/L): 22
TSH (mIU/L): 1,89
Urea (mg/dL): 7,15
LVEF (%): 35.0
Medications: Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient, a 77-year-old male with a history of ischemic dilated cardiomyopathy, peripheral vascular disease, hypertension, and myocardial infarction, has been diagnosed with a left ventricular ejection fraction (LVEF) of 35%, indicating severe left ventricular dysfunction. The patient's New York Heart Association (NYHA) class III classification further emphasizes the severity of his heart failure symptoms, indicating marked limitation in physical activity.

Despite these challenging conditions, the patient has been managed with a treatment regimen consisting of loop diuretics, an ACE inhibitor, and a nitrovasodilator. These medications are aimed at reducing fluid overload, improving cardiac output, and alleviating symptoms of heart failure.

The patient's laboratory results, including normal blood pressure, hemoglobin levels, and electrolytes, suggest that the current treatment is effective in managing the patient's condition. The slightly elevated creatinine levels (72.0 μmol/L) may indicate some degree of renal impairment, which is common in patients with heart failure.

The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG is not uncommon in patients with heart failure and may be related to the underlying cardiomyopathy. However, the absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia suggests that the patient's arrhythmias are not life-threatening at this time.

Given the patient's age, comorbidities, and current treatment regimen, the patient's survival outcome is likely due to the effective management of his heart failure symptoms and the absence of acute cardiovascular events. The patient's TSH and T4 levels are within normal limits, indicating that thyroid function is not contributing to his heart failure. The patient's low-density lipoprotein (LDL) cholesterol level of 3.31 mmol/L is also within the target range for secondary prevention of cardiovascular disease.

In conclusion, the patient's survival outcome is likely due to the combination of his current treatment regimen, effective management of his heart failure symptoms, and the absence of acute cardiovascular events."
371,371,P0602,"Age: 67
Gender: Male 
Weight: 62 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 42,9
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,37
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 106
Glucose (mmol/L): 9,7
Hemoglobin (g/L): 122.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,91
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 923.0
Protein (g/L): 70
T4 (ng/L): 19
TSH (mIU/L): 0,56
Urea (mg/dL): 7,65
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's medical history and current condition, the outcome of survival can be attributed to several factors:

1. Optimal Medication Management: The patient is on a comprehensive medication regimen, including beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor, which are all essential for managing heart failure, hypertension, and lipid levels. These medications have likely contributed to the stabilization of the patient's condition.

2. Monitoring and Treatment of Comorbidities: The patient has diabetes, dyslipidemia, and ischemic dilated cardiomyopathy, which are all being managed with medications. The patient's blood glucose level (9.7 mmol/L) is slightly elevated, but within a manageable range, and the patient is on diabetes medication. The patient's total cholesterol level (4.37 mmol/L) and LDL (1.91 mmol/L) are also within acceptable ranges, thanks to statin therapy.

3. Pro-BNP Levels: The patient's Pro-BNP level (923 ng/L) is elevated, indicating some degree of heart failure. However, it is not extremely high, which may indicate that the patient's condition is being managed effectively.

4. ECG Findings: The patient has non-sustained ventricular tachycardia (NSVT), which is a risk factor for sudden cardiac death. However, the patient is on beta blockers, which are effective in preventing arrhythmias and reducing the risk of sudden cardiac death.

5. NYHA Class II: The patient's functional status is classified as NYHA Class II, indicating some limitations in physical activity but no symptoms at rest. This suggests that the patient's heart condition is being managed effectively, allowing them to maintain a relatively active lifestyle.

6. LVEF: The patient's left ventricular ejection fraction (LVEF) is 45%, which is lower than the normal range (50-70%). However, it is not extremely low, and the patient is not in heart failure decompensation.

Considering these factors, the patient's outcome of survival can be attributed to the comprehensive management of their comorbidities, optimal medication regimen, and ongoing monitoring of their heart condition."
372,372,P0603,"Age: 74
Gender: Male 
Weight: 82 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 48.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,3
Creatinine (mmol/L): 177.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 7,9
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 5,3
LDL (mmol/L): 3,28
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 1626.0
Protein (g/L): 75
T4 (ng/L): 6
Troponin (ng/mL): 0,03
TSH (mIU/L): 5,82
Urea (mg/dL): 24,13
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's age of 74 and the presence of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and a history of myocardial infarction, the patient has multiple risk factors for cardiovascular disease and heart failure. The patient's NYHA Class III classification indicates that the patient experiences symptoms of heart failure with minimal physical activity, which is consistent with the patient's current condition.

The patient's LVEF (Left Ventricular Ejection Fraction) of 35% is significantly reduced, indicating severe left ventricular dysfunction, which is a hallmark of heart failure. The elevated Pro-BNP (N-terminal pro b-type natriuretic peptide) level of 1626 ng/L further supports the diagnosis of heart failure.

The patient's blood pressure is within a relatively normal range (140/80 mmHg), which is a positive sign, but the patient's creatinine level of 177.0 μmol/L indicates impaired renal function, which can be a complication of heart failure.

The patient's medications, including diabetes medication, angiotensin II receptor blocker, beta blockers, and loop diuretics, are appropriate for managing heart failure and related conditions. The presence of ventricular extrasystole on the ECG is a common finding in patients with heart failure and is not necessarily indicative of a poor prognosis.

Considering the patient's overall clinical presentation, including the presence of heart failure, reduced LVEF, and impaired renal function, the patient's survival is a positive outcome. The patient's current medications and management plan are likely contributing to their survival. However, the patient's condition remains a high-risk scenario, and ongoing monitoring and management are essential to prevent further complications."
373,373,P0604,"Age: 75
Gender: Female 
Weight: 57 kg
Height: 153 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 36.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,83
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,02
Potassium (mEq/L): 5,2
LDL (mmol/L): 2,17
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 509.0
Protein (g/L): 76
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,35
Urea (mg/dL): 15,47
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's profile, the outcome of survival can be attributed to several factors. Firstly, the patient is on a multidisciplinary treatment plan that includes medications such as beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor, which are all aimed at managing the patient's heart failure, hypertension, and dyslipidemia. These medications are likely contributing to the stabilization of the patient's cardiac function.

The patient's LVEF (Left Ventricular Ejection Fraction) of 30% indicates that the patient has significant left ventricular dysfunction, which is a hallmark of heart failure. However, despite this, the patient is still alive, suggesting that the current treatment plan is effective in managing the progression of the disease.

The patient's Pro-BNP (B-type natriuretic peptide) level of 509 ng/L is elevated, which is consistent with heart failure. However, it is not excessively high, indicating that the patient's heart failure is not in an acute decompensated state.

The patient's creatinine level of 106.0 umol/L is within the normal range, which suggests that the patient's kidney function is relatively preserved, and there is no acute kidney injury. The patient's urea level of 15.47 mg/dL is also within the normal range, further indicating that the patient's kidney function is not significantly impaired.

The patient's TSH level of 2.35 mIU/L is within the normal range, which suggests that the patient's thyroid function is normal. The patient's T4 level of 13 ng/L is also within the normal range, further supporting this conclusion.

The patient's glucose level of 5.8 mmol/L is slightly elevated, which may be a result of the patient's diabetes. However, it is not excessively high, indicating that the patient's diabetes is well-controlled.

The patient's HDL cholesterol level of 1.02 mmol/L is low, which is a risk factor for cardiovascular disease. However, the patient is on statins, which are aimed at lowering cholesterol levels.

In summary, the patient's survival can be attributed to the effectiveness of the current treatment plan, preserved kidney function, normal thyroid function, and well-controlled diabetes."
374,374,P0606,"Age: 57
Gender: Male 
Weight: 70 kg
Height: 166 cm
NYHA Class: III
Blood Pressure: 140/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 45,9
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 3,03
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 58
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 122.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 1,58
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 4330.0
Protein (g/L): 78,2
T4 (ng/L): 20
TSH (mIU/L): 0,94
Urea (mg/dL): 6,82
LVEF (%): 25.0
Medications: Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome is a survivor, which is likely due to a combination of factors, including the patient's current treatment regimen and the absence of any acute cardiovascular events. 

Firstly, the patient is taking loop diuretics, spironolactone, statins, and an ACE inhibitor, which are all standard medications for managing heart failure and reducing the risk of further cardiovascular events. The use of these medications has likely helped to improve the patient's symptoms and slow the progression of their ischemic dilated cardiomyopathy.

The patient's LVEF (left ventricular ejection fraction) is 25%, which is low but not extremely low. While a low LVEF is associated with a higher risk of adverse outcomes, it is not uncommon in patients with ischemic dilated cardiomyopathy.

The patient's blood pressure is 140/90 mmHg, which is within the normal range, and their potassium level is 4.5 mEq/L, which is also within the normal range. These findings suggest that the patient's blood pressure and electrolyte levels are well-controlled.

The patient's creatinine level is 91.0 μmol/L, which is slightly elevated, but not significantly so. This suggests that the patient's renal function is not severely impaired.

The patient's pro-BNP (brain natriuretic peptide) level is 4330.0 ng/L, which is elevated, but not extremely high. This suggests that the patient's heart is under strain, but not to the point of severe heart failure.

Overall, the patient's outcome as a survivor is likely due to the combination of their current treatment regimen, the absence of acute cardiovascular events, and the fact that their vital signs and laboratory results are relatively stable."
375,375,P0608,"Age: 70
Gender: Male 
Weight: 71 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 44,2
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 5,8
LDL (mmol/L): 2,92
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 108.0
Protein (g/L): 74,7
T4 (ng/L): 15
TSH (mIU/L): 2,24
Urea (mg/dL): 6,66
LVEF (%): 30.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient's outcome of survival can be attributed to a combination of factors, including the current medical management of their ischemic dilated cardiomyopathy and the relatively stable laboratory results.

Firstly, the patient is on appropriate medications for their condition, including Amiodarone, an antiarrhythmic medication, Angiotensin II Receptor Blocker, which helps to reduce blood pressure and alleviate symptoms of heart failure, and Statins, which helps to manage dyslipemia and reduce the risk of further cardiac events.

The patient's LVEF (Left Ventricular Ejection Fraction) is 30%, which is low but not extremely low. Although an LVEF of 30% indicates a significant impairment of cardiac function, it is not as severe as an LVEF below 20-25%, which would be more concerning for a poor prognosis.

The patient's blood pressure is well-controlled at 110/70 mmHg, which is within the normal range, reducing the risk of further cardiac complications.

The patient's laboratory results show a relatively stable condition, with a slight elevation in liver enzymes (ALT and AST), which may be related to the Statins or Amiodarone. The total cholesterol and LDL levels are well-controlled, and the Hemoglobin level is within the normal range.

The Pro-BNP level is 108 ng/L, which is slightly elevated, but not extremely high, indicating some degree of cardiac stress but not severe heart failure.

The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia on the ECG suggests that the patient's cardiac rhythm is relatively stable.

Overall, while the patient has a history of ischemic dilated cardiomyopathy and other cardiac risk factors, their current medical management and relatively stable laboratory results suggest that they are being effectively managed, contributing to their survival."
376,376,P0609,"Age: 67
Gender: Female 
Weight: 74 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 180/95 mmHg
Past Medical History: Hypertropic cardiomyopathy, Diabetes
Albumin (g/L): 46,2
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 61.0
Gamma-glutamil transpeptidase (IU/L): 140
Glucose (mmol/L): 7,9
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,91
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,61
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 731.0
Protein (g/L): 75,2
T4 (ng/L): 14
TSH (mIU/L): 3,47
Urea (mg/dL): 3
LVEF (%): 70.0
Medications: Beta Blockers, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient, a 67-year-old female with a history of hypertrophic cardiomyopathy and diabetes, has been managed with beta blockers and nitrovasodilators. The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG suggests a high risk of arrhythmic events. 

The patient's blood pressure is elevated at 180/95 mmHg, which may be contributing to cardiac strain and increasing the risk of cardiovascular events. However, the left ventricular ejection fraction (LVEF) is within a relatively normal range at 70%, indicating preserved cardiac function.

The elevated Pro-BNP level of 731 ng/L suggests increased ventricular stretch and wall tension, which is often seen in conditions like heart failure or hypertrophic cardiomyopathy. The presence of diabetes and elevated glucose levels may also contribute to the development of cardiovascular complications.

Despite these risk factors, the patient has survived, which could be attributed to the management of her condition with beta blockers and nitrovasodilators. Beta blockers are known to reduce the risk of arrhythmic events and improve survival in patients with heart failure and hypertrophic cardiomyopathy. The nitrovasodilators may also help to reduce the workload on the heart and alleviate symptoms of heart failure.

The patient's NYHA Class II classification indicates that she experiences some limitation of physical activity but is still able to perform daily activities without symptoms. This suggests that her cardiac condition is manageable with medical therapy, and she is able to maintain a relatively good quality of life.

Overall, the combination of medical therapy, preserved LVEF, and the absence of severe symptoms or complications may have contributed to the patient's survival."
377,377,P0610,"Age: 71
Gender: Female 
Weight: 73 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 44,3
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,12
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 7
Hemoglobin (g/L): 123.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,1
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 433.0
Protein (g/L): 73
T4 (ng/L): 15
TSH (mIU/L): 1,95
Urea (mg/dL): 8,49
LVEF (%): 62.0
Medications: Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 71-year-old female with a history of hypertensive cardiomyopathy. She is currently on Spironolactone and an ACE Inhibitor, which suggests that her heart failure symptoms are being managed with standard therapy for heart failure with reduced ejection fraction (HFrEF).

The patient's LVEF is 62%, which is within the range of mildly reduced ejection fraction. This suggests that her heart is still functioning relatively well, and she is not in a high-risk category for severe heart failure.

The elevated Pro-BNP level (433.0 ng/L) indicates that the patient has some degree of heart failure, but it is not severe. Pro-BNP levels are used as a biomarker to diagnose and monitor heart failure, and levels above 400 ng/L are considered elevated.

The patient's blood pressure is well-controlled at 140/70 mmHg, which is within the target range for patients with heart failure. Her albumin level is within the normal range, and her creatinine level is elevated but not severely so (123.0 mmol/L). The elevated creatinine level suggests some degree of renal impairment, but it is not severe enough to suggest that the patient is in renal failure.

The patient's lipid profile shows elevated LDL (3.1 mmol/L) and low HDL (1.29 mmol/L), which are risk factors for cardiovascular disease. However, her total cholesterol level is not excessively high (5.12 mmol/L).

The patient's ECG shows a polymorphic ventricular extrasystole, which is a type of irregular heartbeat. However, it is not a life-threatening arrhythmia, and it is not associated with a high risk of sudden cardiac death.

Considering the patient's age, medical history, and current medication regimen, the most likely reason for her survival is that her heart failure symptoms are being effectively managed with standard therapy, and she does not have any severe underlying cardiac or renal disease. The elevated Pro-BNP level suggests that she has some degree of heart failure, but it is not severe enough to cause significant morbidity or mortality. Therefore, the patient's survival outcome is likely due to the effectiveness of her current treatment regimen and the absence of severe underlying disease."
378,378,P0611,"Age: 66
Gender: Male 
Weight: 72 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 105/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 40,7
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,22
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 5
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,39
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 2919.0
Protein (g/L): 68,1
T4 (ng/L): 18
TSH (mIU/L): 0,38
Urea (mg/dL): 8,65
LVEF (%): 23.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 66-year-old male with a history of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipemia. His left ventricular ejection fraction (LVEF) is significantly reduced at 23%, indicating severe heart failure. Despite this, the patient is a survivor, which can be attributed to several factors:

1.  Optimal medical management: The patient is on a comprehensive treatment regimen, including beta blockers, loop diuretics, spironolactone, statins, ACE inhibitors, and nitrovasodilators, which are all standard therapies for heart failure with reduced ejection fraction (HFrEF). These medications aim to reduce symptoms, slow disease progression, and improve quality of life.
2.  Regular monitoring and follow-up: The patient's regular monitoring and follow-up appointments likely allowed for timely adjustments to his treatment plan, ensuring that his condition was closely managed and optimized.
3.  Low blood pressure: The patient's blood pressure of 105/65 mmHg is within a relatively normal range, which is beneficial for patients with heart failure, as high blood pressure can exacerbate the condition.
4.  Normal glucose levels: The patient's glucose level of 5 mmol/L is within the normal range, which is essential for patients with heart failure, as hyperglycemia can worsen cardiac function and outcomes.
5.  Low levels of liver enzymes: The patient's ALT and AST levels are within normal limits, indicating that there is no significant liver damage, which can be a contributing factor to heart failure.
6.  Low levels of creatinine: The patient's creatinine level of 99.0 μmol/L is within the normal range, indicating that there is no significant kidney damage, which can be a complication of heart failure.
7.  Pro-BNP level: The patient's Pro-BNP level of 2919.0 ng/L is elevated, indicating that the patient is experiencing some degree of heart failure, but it is not at the highest risk level.
8.  ECG findings: The patient's ECG shows polymorphic ventricular extrasystoles, which can be a benign finding in some cases, but it is essential to monitor for any changes or progression.

Considering these factors, the patient's survival can be attributed to the combination of optimal medical management, regular monitoring, and the absence of significant comorbidities or complications."
379,379,P0612,"Age: 67
Gender: Female 
Weight: 93 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 159/62 mmHg
Past Medical History: Other HF etiology, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,37
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4
LDL (mmol/L): 2,72
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 233.0
Protein (g/L): 67
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,5
Urea (mg/dL): 11,82
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Spironolactone, Statins, Hydralazine, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient's outcome as a survivor is likely due to a combination of factors related to her medical history, current medications, and laboratory results. 

Firstly, the patient's left ventricular ejection fraction (LVEF) is 30%, which is significantly reduced, indicating heart failure with reduced ejection fraction (HFrEF). However, the patient is on appropriate medications for HFrEF, including beta blockers, spironolactone, and ACE inhibitors, which are known to improve survival and reduce morbidity in patients with HFrEF.

The patient's blood pressure is elevated at 159/62 mmHg, which may be contributing to her heart failure, but the use of ACE inhibitors and hydralazine may help to manage this. The patient's total cholesterol is elevated at 4.37 mmol/L, but she is on statins, which are effective in reducing cholesterol levels and improving cardiovascular outcomes.

The patient's creatinine level is elevated at 141.0 μmol/L, indicating impaired renal function. However, this is not unexpected given her history of diabetes and hypertension. The patient's glucose level is also elevated at 8.3 mmol/L, but she is on diabetes medication, which may help to manage this.

The patient's BNP level is elevated at 233.0 ng/L, which is consistent with heart failure. However, the patient's troponin level is normal at 0.01 ng/mL, indicating that there is no evidence of acute myocardial infarction.

The patient's ECG shows monomorphic ventricular extrasystoles, but no sustained ventricular tachycardia or bradycardia. This suggests that the patient's cardiac rhythm is relatively stable, which is a positive prognostic factor.

In summary, the patient's outcome as a survivor is likely due to the effectiveness of her current medications, her relatively stable cardiac rhythm, and her overall management of her heart failure and other comorbidities."
380,380,P0613,"Age: 65
Gender: Male 
Weight: 54 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,72
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 126.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,54
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 2740.0
Protein (g/L): 76
T3 (pg/dL): 0,06
T4 (ng/L): 17
Troponin (ng/mL): 0,09
TSH (mIU/L): 1,96
Urea (mg/dL): 9,32
LVEF (%): 30.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 65-year-old male, has been diagnosed with enolic dilated cardiomyopathy, which is a condition where the heart muscle becomes weak and the heart chambers enlarge, reducing the heart's ability to pump blood effectively. The patient's left ventricular ejection fraction (LVEF) is 30%, which is significantly below the normal range (50-70%), indicating severe heart failure.

The patient's past medical history of hypertension and dyslipidemia are contributing factors to his heart condition, as high blood pressure and high cholesterol can lead to cardiac damage over time. His current blood pressure is 140/80 mmHg, which is within a relatively normal range, but it may not accurately reflect his true blood pressure due to the presence of medication.

The patient's laboratory results show elevated levels of troponin (0.09 ng/mL), which indicates cardiac damage or stress. However, this level is not extremely high, suggesting that the damage may not be severe. His pro-BNP level is elevated at 2740.0 ng/L, which is a marker of heart failure and can indicate fluid overload or cardiac dysfunction.

The patient is on a regimen of beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, which are all standard treatments for heart failure and hypertension. The presence of a TPSV (paroxysmal supraventricular tachyarrhythmia) on the ECG suggests that the patient may have some arrhythmia issues, but this is not a life-threatening condition in this context.

Given the patient's severe heart failure, as indicated by the low LVEF and elevated pro-BNP, it is surprising that the patient is a survivor. However, the fact that the patient's troponin level is not extremely high and that the patient is on appropriate medication for heart failure may have contributed to his survival. Additionally, the patient's age and weight may also have played a role in his survival, as older and thinner patients tend to have a better prognosis for heart failure."
381,381,P0614,"Age: 58
Gender: Male 
Weight: 90 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 41,2
ALT or GPT (IU/L): 42.0
AST or GOT (IU/L): 35.0
Total Cholesterol (mmol/L): 5,78
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 101
Glucose (mmol/L): 9,3
Hemoglobin (g/L): 110.0
HDL (mmol/L): 2,69
Potassium (mEq/L): 3,75
LDL (mmol/L): 2,52
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 4446.0
Protein (g/L): 68,4
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,93
Urea (mg/dL): 11,4
LVEF (%): 18.0
Medications: Calcium Channel Blocker, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient is a 58-year-old male with a history of idiopathic dilated cardiomyopathy and hypertension, presenting with a low left ventricular ejection fraction (LVEF) of 18%. The patient is on a comprehensive medication regimen, including a calcium channel blocker, angiotensin II receptor blocker, beta blockers, and loop diuretics. The elevated Pro-BNP levels (4446.0 ng/L) indicate significant cardiac strain and potential heart failure.

The patient's laboratory results show elevated liver enzymes (ALT 42.0 IU/L and AST 35.0 IU/L) and gamma-glutamil transpeptidase (101 IU/L), which may indicate liver dysfunction or a possible side effect of medications. The patient's total cholesterol level is slightly elevated (5.78 mmol/L), but the HDL level is within the normal range (2.69 mmol/L). The patient's potassium level is slightly low (3.75 mEq/L), which may be a concern, especially in the context of cardiac dysfunction.

The patient's ECG shows polymorphic ventricular extrasystoles, but no sustained ventricular tachycardia or non-sustained ventricular tachycardia. The absence of sustained arrhythmias and the presence of a comprehensive medication regimen likely contributed to the patient's survival.

The patient's low LVEF and elevated Pro-BNP levels suggest that the patient is at risk for heart failure. However, the patient's survival outcome may be attributed to the combination of medications and the absence of severe arrhythmias. The patient's liver enzyme elevation and slightly low potassium level may be managed with adjustments to medications or further investigation into the underlying causes."
382,382,P0615,"Age: 61
Gender: Male 
Weight: 103 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 125/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 3,42
Creatinine (mmol/L): 87.0
Gamma-glutamil transpeptidase (IU/L): 42
Glucose (mmol/L): 12,2
Hemoglobin (g/L): 145.0
HDL (mmol/L): 0,87
Potassium (mEq/L): 3,91
LDL (mmol/L): 1,47
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 86.0
Protein (g/L): 67,5
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,91
Urea (mg/dL): 6,9
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 61-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction. His current NYHA Class II classification indicates that he has moderate symptoms of heart failure, such as shortness of breath and fatigue, but is still able to perform most daily activities.

The patient's laboratory results show elevated levels of creatinine (87.0 mmol/L), indicating impaired renal function. His total cholesterol and LDL levels are high, which is consistent with his dyslipemia diagnosis. His glucose level is elevated at 12.2 mmol/L, indicating poorly controlled diabetes.

The patient's LVEF (left ventricular ejection fraction) is 35%, which is significantly below the normal range (50-70%), indicating systolic heart failure. His pro-BNP (B-type natriuretic peptide) level is elevated at 86.0 ng/L, which is consistent with heart failure.

Despite these concerning findings, the patient is still alive, suggesting that his current treatment regimen is effective in managing his symptoms and slowing disease progression. His medications, including diabetes medication, angiotensin II receptor blocker, beta blockers, statins, and nitrovasodilator, are likely contributing to his survival.

The presence of monomorphic ventricular extrasystoles on the ECG is a common finding in patients with heart failure and is not typically a predictor of poor outcome. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia on the ECG also suggests that the patient's heart rhythm is relatively stable.

In summary, the patient's survival is likely due to a combination of his current treatment regimen, stable heart rhythm, and the fact that his symptoms are being managed at a moderate level (NYHA Class II)."
383,383,P0617,"Age: 50
Gender: Male 
Weight: 88 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 90/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 46.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 4,61
Creatinine (mmol/L): 105.0
Gamma-glutamil transpeptidase (IU/L): 71
Glucose (mmol/L): 8,6
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,17
Potassium (mEq/L): 4,53
LDL (mmol/L): 2,82
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 3172.0
Protein (g/L): 78,9
T4 (ng/L): 17,3
Troponin (ng/mL): 0,45
TSH (mIU/L): 6
Urea (mg/dL): 7,6
LVEF (%): 40.0
Medications: Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 50-year-old male with a history of ischemic dilated cardiomyopathy, myocardial infarction, and diabetes, which are all significant risk factors for heart failure and poor cardiovascular outcomes. However, the patient's current NYHA Class II classification indicates that he has some limitations in physical activity but is still able to perform daily tasks without symptoms of heart failure.

The patient's laboratory results show elevated levels of Troponin (0.45 ng/mL), indicating some degree of myocardial damage, and a low LVEF (40.0%), indicating reduced left ventricular function. However, his Pro-BNP level (3172.0 ng/L) is elevated, which is consistent with heart failure. The patient's medications, including digoxin, loop diuretics, spironolactone, statins, and ACE inhibitor, are typical for heart failure management.

The ECG results show a monomorphic ventricular extrasystole, which is a benign finding, but also a paroxysmal supraventricular tachyarrhythmia (PSVT), which may indicate some degree of autonomic nervous system dysfunction.

Considering the patient's overall clinical presentation, laboratory results, and ECG findings, the patient's outcome as a survivor is likely due to the following factors:

1.  Optimal medical management: The patient is on a comprehensive regimen of medications that target heart failure, including ACE inhibitors, beta-blockers, and diuretics, which have been shown to improve outcomes in patients with heart failure.
2.  Presence of a stable ventricular rhythm: Despite the presence of a paroxysmal supraventricular tachyarrhythmia, the patient does not have sustained ventricular tachycardia, which is a more ominous sign of poor prognosis.
3.  Low risk of cardiac arrest: The patient's LVEF is 40.0%, which is lower than normal, but not severely reduced, and his Troponin level is not extremely elevated, indicating that the patient is not at high risk of cardiac arrest.
4.  Presence of a strong support system: The patient's ability to survive and manage his condition suggests that he has a strong support system, including family, friends, and healthcare providers, which can contribute to a better outcome.

In conclusion, the patient's outcome as a survivor is likely due to a combination of optimal medical management, a stable ventricular rhythm, low risk of cardiac arrest, and a strong support system."
384,384,P0620,"Age: 50
Gender: Male 
Weight: 85 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 100/65 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 41,5
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 5,2
Creatinine (mmol/L): 89.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 140.0
HDL (mmol/L): 0,94
Potassium (mEq/L): 4,22
LDL (mmol/L): 3,37
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 233.0
Protein (g/L): 68,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,93
Urea (mg/dL): 4,7
LVEF (%): 39.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 50-year-old male with a history of idiopathic dilated cardiomyopathy, has a relatively favorable outcome of survival. Several factors contribute to this outcome:

1.  Stable Blood Pressure: The patient's blood pressure is within a relatively normal range (100/65 mmHg), indicating that his cardiovascular system is not under excessive strain.
2.  Controlled Renal Function: The patient's creatinine level (89.0 mmol/L) is within the normal range, suggesting that his kidney function is well-preserved.
3.  Low Troponin Levels: The patient's troponin level (0.01 ng/mL) is within the normal range, indicating that there is no significant myocardial injury or ischemia.
4.  Optimal Medications: The patient is on a comprehensive regimen of beta blockers, loop diuretics, spironolactone, statins, and ACE inhibitors, which are all evidence-based treatments for heart failure with reduced ejection fraction (HFrEF).
5.  LVEF of 39%: Although the patient's left ventricular ejection fraction (LVEF) is low (39%), it is not the lowest possible value, indicating that the patient's heart is still pumping some blood effectively.
6.  Low Pro-BNP Levels: The patient's pro-B-type natriuretic peptide (Pro-BNP) level (233.0 ng/L) is not excessively elevated, suggesting that his heart is not under extreme strain.
7.  No Evidence of Malnutrition: The patient's albumin level (41.5 g/L) is within the normal range, indicating that he is not malnourished, which is a known risk factor for poor outcomes in heart failure patients.
8.  Absence of Sustained Ventricular Tachycardia: The patient's ECG does not show any signs of sustained ventricular tachycardia, which is a known risk factor for sudden cardiac death.

Considering these factors, the patient's overall clinical picture suggests that he is well-managed and has a relatively low risk of adverse cardiac events, leading to a favorable outcome of survival."
385,385,P0621,"Age: 56
Gender: Male 
Weight: 78 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 120/85 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 33,7
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 3,46
Creatinine (mmol/L): 148.0
Gamma-glutamil transpeptidase (IU/L): 103
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 156.0
HDL (mmol/L): 0,73
Potassium (mEq/L): 2,94
LDL (mmol/L): 2,23
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 16094.0
Protein (g/L): 60,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,55
Urea (mg/dL): 11,8
LVEF (%): 16.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient's outcome as a survivor can be attributed to several factors despite being in a severe state of heart failure with a left ventricular ejection fraction (LVEF) of 16%. The patient's age of 56 and NYHA Class III classification indicate a moderate to severe level of heart failure. 

The patient's high level of B-type natriuretic peptide (BNP) at 16,094 ng/L is indicative of severe heart failure, as elevated BNP levels are associated with increased morbidity and mortality in heart failure patients. However, the patient's low troponin level of 0.01 ng/mL suggests that there is no acute myocardial infarction or severe ischemia contributing to their heart failure.

The patient's renal function, as indicated by the creatinine level of 148.0 μmol/L, is compromised, which may contribute to the progression of heart failure. The patient's potassium level of 2.94 mEq/L is also low, which may be a result of the diuretic therapy and can increase the risk of arrhythmias.

The patient's lipid profile shows a total cholesterol of 3.46 mmol/L, HDL of 0.73 mmol/L, and LDL of 2.23 mmol/L, indicating a high risk for atherosclerotic cardiovascular disease.

Despite these factors, the patient's survival can be attributed to the aggressive management of their heart failure symptoms with beta blockers, loop diuretics, spironolactone, and ACE inhibitors. These medications have been shown to improve survival and reduce morbidity in patients with heart failure. Additionally, the patient's regular monitoring and follow-up may have allowed for early detection and management of any complications that may have arisen.

Furthermore, the patient's low TSH level of 1.55 mIU/L suggests that there is no significant thyroid dysfunction contributing to their heart failure. The patient's hemoglobin level of 156 g/L is within the normal range, indicating that there is no significant anemia contributing to their heart failure.

Overall, the combination of aggressive medical therapy, regular monitoring, and the absence of other contributing factors have contributed to the patient's survival despite their severe heart failure."
386,386,P0623,"Age: 52
Gender: Female 
Weight: 73 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 105/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 45,9
ALT or GPT (IU/L): 104.0
AST or GOT (IU/L): 49.0
Total Cholesterol (mmol/L): 5,81
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 79
Glucose (mmol/L): 5
Hemoglobin (g/L): 144.0
Potassium (mEq/L): 4,4
Sodium (mEq/L): 145.0
Protein (g/L): 75,9
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,17
Urea (mg/dL): 7,6
LVEF (%): 28.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 52-year-old female with a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack. Despite this, the patient is a survivor, which can be attributed to several factors.

Firstly, the patient's left ventricular ejection fraction (LVEF) is 28%, which is significantly low but not the lowest possible value. The LVEF is a measure of the heart's ability to pump blood efficiently, and a value of 28% indicates that the heart is still able to pump some blood, albeit inefficiently.

The patient's current medications, including Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, and Statins, are all appropriate for managing heart failure and are likely contributing to the patient's survival. Angiotensin II Receptor Blockers and Beta Blockers help to reduce the heart's workload and improve its pumping efficiency, while Loop Diuretics help to reduce fluid buildup in the body, which can put additional strain on the heart. Statins help to lower cholesterol levels, which can reduce the risk of further heart damage.

The patient's blood pressure is within a relatively normal range (105/70 mmHg), which suggests that the heart is not experiencing excessive strain due to high blood pressure.

The patient's troponin level is 0.01 ng/mL, which is within the normal range, indicating that there is no current evidence of acute myocardial infarction.

The patient's hemoglobin level is 144.0 g/L, which is within the normal range, indicating that the patient is not anemic, which can contribute to fatigue and shortness of breath, common symptoms of heart failure.

The patient's potassium level is 4.4 mEq/L, which is slightly low but not critically low, and the sodium level is 145.0 mEq/L, which is within the normal range.

The patient's liver enzymes, including ALT and AST, are elevated, but not critically high, which suggests that the patient's liver is not significantly compromised.

Overall, the patient's combination of medications, relatively normal blood pressure, and lack of acute cardiac damage (indicated by the troponin level) likely contributed to her survival. However, the patient's low LVEF and elevated liver enzymes suggest that she still requires close monitoring and ongoing management of her heart failure and liver function."
387,387,P0625,"Age: 57
Gender: Female 
Weight: 70 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 37,6
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,71
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 54
Glucose (mmol/L): 19,7
Hemoglobin (g/L): 118.0
HDL (mmol/L): 1,39
Potassium (mEq/L): 4,35
LDL (mmol/L): 3,73
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1935.0
Protein (g/L): 70,2
T4 (ng/L): 9,4
Troponin (ng/mL): 0,01
TSH (mIU/L): 7,15
Urea (mg/dL): 8,6
LVEF (%): 48.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome as a survivor can be attributed to several factors in her medical history and current condition. 

Firstly, despite having a history of myocardial infarction, her troponin levels are within normal limits (0.01 ng/mL), indicating that there is no current myocardial damage. Additionally, her LVEF (Left Ventricular Ejection Fraction) is 48%, which, although lower than the normal range (50-70%), is not severely impaired. This suggests that her heart is still pumping blood effectively, albeit not at optimal levels.

Her NYHA Class III classification indicates that she experiences symptoms of heart failure, such as shortness of breath and fatigue, but is still able to perform everyday activities. This suggests that her heart failure is not severe and is being managed effectively with her current medications, including loop diuretics and beta blockers.

The patient's laboratory results also indicate that her kidney function is relatively preserved, with a creatinine level of 94.0 mmol/L (within the normal range for females). Her electrolyte levels, including potassium, sodium, and urea, are also within normal limits.

Furthermore, her diabetes and dyslipidemia are being managed with medication, which has likely contributed to her relatively stable condition. Her low-density lipoprotein (LDL) level of 3.73 mmol/L is elevated, but it is not excessively high, and her high-density lipoprotein (HDL) level of 1.39 mmol/L is within the normal range.

The patient's pro-BNP (brain natriuretic peptide) level of 1935.0 ng/L is elevated, which is consistent with heart failure, but it is not excessively high. This suggests that her heart is under some stress, but it is not severely strained.

Overall, the patient's combination of stable laboratory results, effective management of her comorbidities, and relatively preserved cardiac function have contributed to her outcome as a survivor."
388,388,P0627,"Age: 74
Gender: Male 
Weight: 67 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 47
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 148.0
HDL (mmol/L): 0,67
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,4
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 1312.0
Protein (g/L): 64
T3 (pg/dL): 0,04
T4 (ng/L): 13
TSH (mIU/L): 2,56
Urea (mg/dL): 5,49
LVEF (%): 37.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 74-year-old male with a history of idiopathic dilated cardiomyopathy, hypertension, and significant comorbidities. His current medications include beta blockers, digoxin, loop diuretics, and an ACE inhibitor, which are all standard treatments for heart failure and hypertension.

The patient's LVEF (left ventricular ejection fraction) is 37%, indicating moderate to severe heart failure. His BNP (brain natriuretic peptide) level of 1312 ng/L is elevated, which is consistent with heart failure. However, his albumin level is within the normal range, suggesting that he does not have significant liver dysfunction or nephrotic syndrome, which can sometimes complicate heart failure management.

The patient's ECG shows polymorphic ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia, which are all indicative of arrhythmias that can be associated with heart failure. However, the absence of sustained ventricular tachycardia and bradycardia suggests that the patient's heart rhythm is not as unstable as it could be.

Given the patient's age, comorbidities, and current medications, it is likely that the patient's heart failure is being well-managed, and his prognosis is guarded but not hopeless. The fact that he is a survivor suggests that his current treatment plan is effective in controlling his symptoms and preventing further cardiac complications."
389,389,P0628,"Age: 68
Gender: Female 
Weight: 94 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 34
ALT or GPT (IU/L): 40.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,85
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 32
Glucose (mmol/L): 9
Hemoglobin (g/L): 133.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,25
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 1747.0
Protein (g/L): 75
T4 (ng/L): 8
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,7
Urea (mg/dL): 5,66
LVEF (%): 50.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient, a 68-year-old female, has a complex medical history that includes hypertensive cardiomyopathy, hypertension, and a previous myocardial infarction. Despite these conditions, the patient is classified as NYHA Class II, indicating moderate symptoms of heart failure with minimal limitations in physical activity.

The patient's current medication regimen includes beta blockers, digoxin, loop diuretics, statins, and an ACE inhibitor, which are all standard treatments for heart failure and hypertension. The patient's LVEF (left ventricular ejection fraction) is 50%, which is within the normal range, indicating that the heart is pumping blood efficiently.

The patient's laboratory results show elevated total cholesterol and LDL levels, which are being managed with statins. The patient's glucose level is slightly elevated, but not significantly so. The liver enzymes (ALT and AST) are within normal limits, indicating that the liver is functioning properly.

The patient's kidney function, as indicated by the creatinine level, is within normal limits, which is a good sign. The pro-BNP level is elevated, which is consistent with heart failure, but not to an alarming degree.

The patient's ECG shows ventricular extrasystoles, but no sustained ventricular tachycardia or non-sustained ventricular tachycardia. The patient's potassium level is within normal limits, which is important for heart function.

Considering the patient's age, medical history, and current treatment, it is likely that the patient's heart condition is being managed effectively, and the patient is able to tolerate the current treatment regimen. The patient's LVEF is within normal limits, and there is no indication of acute cardiac decompensation. Therefore, the patient is likely to survive with continued management of their heart condition."
390,390,P0630,"Age: 61
Gender: Male 
Weight: 90 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 110/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes
Albumin (g/L): 44
ALT or GPT (IU/L): 45.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 7,4
Hemoglobin (g/L): 126.0
HDL (mmol/L): 0,8
Potassium (mEq/L): 5,2
LDL (mmol/L): 1,66
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 848.0
Protein (g/L): 71
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,98
Urea (mg/dL): 6,99
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome is a survivor due to a combination of several factors that contributed to their favorable prognosis. 

Firstly, the patient's LVEF (Left Ventricular Ejection Fraction) is 35%, which is significantly reduced, indicating systolic heart failure. However, the patient is on optimal medical therapy for heart failure, including ACE inhibitors, beta-blockers, and statins, which are all evidence-based treatments for heart failure with reduced ejection fraction (HFrEF). These medications have been shown to improve survival and reduce morbidity in patients with HFrEF.

The patient's blood pressure is within a relatively normal range (110/50 mmHg), which suggests that the ACE inhibitor is effectively controlling their hypertension. The patient's glucose level (7.4 mmol/L) is also well-controlled, which is important for preventing cardiovascular complications in patients with diabetes.

The patient's troponin level is 0.01 ng/mL, which is within the normal range, indicating that there is no acute coronary syndrome or myocardial infarction. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG also suggests that the patient does not have a high risk of arrhythmias.

The patient's creatinine level (97.0 μmol/L) is slightly elevated, indicating mild kidney dysfunction. However, this is not unexpected given the patient's history of diabetes and heart failure. The patient's potassium level (5.2 mEq/L) is also within the normal range, which is important for preventing arrhythmias.

The patient's TSH level (0.98 mIU/L) is within the normal range, indicating that there is no evidence of hypothyroidism, which can contribute to heart failure.

The patient's Pro-BNP level (848.0 ng/L) is elevated, which is consistent with heart failure. However, the patient's overall clinical picture, including their response to medical therapy and lack of acute complications, suggests that they are stable and not at high risk of mortality.

In summary, the patient's favorable outcome is likely due to the combination of optimal medical therapy, well-controlled hypertension and glucose levels, absence of acute coronary syndrome or arrhythmias, and lack of evidence of other contributing factors that could lead to mortality."
391,391,P0631,"Age: 39
Gender: Male 
Weight: 123 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 36.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 3,98
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 51
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 145.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,86
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 37.0
Protein (g/L): 76
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,81
Urea (mg/dL): 5,49
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 39-year-old male with a history of idiopathic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension. His current medications include a calcium channel blocker, diabetes medication, beta blockers, loop diuretics, statins, and an ACE inhibitor, which is a comprehensive treatment plan for his conditions.

His laboratory results indicate mild liver dysfunction (elevated ALT and gamma-glutamil transpeptidase), elevated glucose levels, and mild kidney impairment (elevated creatinine). However, his LVEF (left ventricular ejection fraction) is severely reduced at 25%, which is a strong indicator of heart failure.

The patient's blood pressure is elevated at 160/90 mmHg, which is a risk factor for cardiovascular disease. His lipid profile shows high total cholesterol and LDL levels, which contribute to his dyslipemia.

Despite these factors, the patient's troponin level is low (0.01 ng/mL), indicating minimal cardiac damage. His pro-BNP level is also within a relatively normal range (37 ng/L), which suggests that his heart is not under significant strain.

The patient's ECG shows monomorphic ventricular extrasystoles, but no sustained ventricular tachycardia or other arrhythmias.

Considering the patient's overall condition, his medications, and his laboratory results, it is likely that the patient's outcome is a survivor due to the following reasons:

1. Effective treatment plan: The patient is on a comprehensive medication regimen that addresses his multiple comorbidities, including heart failure, diabetes, hypertension, and dyslipemia.
2. Mild liver and kidney dysfunction: While the patient has mild liver and kidney impairment, it is not severe enough to significantly impact his outcome.
3. Low troponin levels: The patient's troponin level is low, indicating minimal cardiac damage.
4. Normal pro-BNP levels: The patient's pro-BNP level is within a relatively normal range, suggesting that his heart is not under significant strain.
5. Absence of severe arrhythmias: The patient's ECG shows only monomorphic ventricular extrasystoles, which are not typically life-threatening.

Overall, while the patient has multiple comorbidities and risk factors, his treatment plan and laboratory results suggest that he is likely to survive."
392,392,P0632,"Age: 73
Gender: Male 
Weight: 81 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 125/75 mmHg
Past Medical History: Other HF etiology, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 162.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,92
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 1395.0
Protein (g/L): 70
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,28
Urea (mg/dL): 7,99
LVEF (%): 35.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 73-year-old male with a history of heart failure (HF) and hypertension. His current medication regimen includes beta blockers and an ACE inhibitor, which are standard treatments for HF and hypertension. The patient's left ventricular ejection fraction (LVEF) is 35%, indicating reduced systolic function, consistent with heart failure with reduced ejection fraction (HFrEF).

The patient's blood pressure is within a relatively normal range (125/75 mmHg), and his creatinine level is elevated at 88.0 μmol/L, indicating some degree of renal impairment. However, his albumin and protein levels are within normal limits, suggesting that the renal impairment is not severe.

The patient's troponin level is slightly elevated at 0.01 ng/mL, but this is not indicative of acute coronary syndrome. The absence of significant elevation in troponin levels and the presence of non-sustained ventricular tachycardia (NSVT) on the ECG suggest that the patient's cardiac condition is chronic rather than acute.

The patient's TSH level is within the normal range, and his T4 level is slightly elevated, but this is not indicative of hyperthyroidism. The patient's potassium level is within the normal range, which is important given the patient's use of ACE inhibitors, which can cause hyperkalemia.

The patient's high Pro-BNP level (1395.0 ng/L) is consistent with heart failure, but the fact that the patient is a survivor suggests that the heart failure is being managed effectively with medication.

The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are common in patients with HFrEF. The presence of unknown paroxysmal supraventricular tachyarrhythmia and bradycardia codes on the ECG is not uncommon in patients with complex cardiac conditions.

Overall, the patient's outcome as a survivor suggests that his heart failure is being effectively managed with medication, and he is not experiencing any acute cardiac events. The patient's renal impairment and slightly elevated creatinine level are being managed, and his other laboratory values are within normal limits."
393,393,P0633,"Age: 51
Gender: Male 
Weight: 97 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 58.0
AST or GOT (IU/L): 35.0
Total Cholesterol (mmol/L): 4,47
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 70
Glucose (mmol/L): 7,9
Hemoglobin (g/L): 168.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4
LDL (mmol/L): 2,2
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 193.0
Protein (g/L): 74
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2
Urea (mg/dL): 5,66
LVEF (%): 20.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 51-year-old male, with a history of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipemia, has been managed with beta blockers, statins, and an ACE inhibitor. His current medications are likely aimed at managing his heart failure symptoms, reducing the risk of further myocardial infarctions, and controlling his blood pressure.

Given his LVEF (Left Ventricular Ejection Fraction) of 20%, which is significantly reduced, the patient is at risk for heart failure and poor outcomes. However, the fact that he is a survivor suggests that his current treatment regimen is effective in managing his condition.

The patient's NT-proBNP (N-terminal pro b-type natriuretic peptide) level of 193.0 ng/L is elevated, indicating increased ventricular stress and potential heart failure. However, this is not uncommon in patients with heart failure and ischemic cardiomyopathy.

The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are common findings in patients with heart failure and ischemic cardiomyopathy. The absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia is reassuring.

The patient's laboratory results show elevated liver enzymes (ALT and GGT), which may be related to his heart failure or dyslipemia. His lipid profile shows elevated total cholesterol and LDL, but his HDL is within the normal range.

The patient's kidney function, as indicated by his creatinine level of 97.0 mmol/L, is mildly impaired. His hemoglobin level is within the normal range, and his TSH level is normal.

Overall, the patient's outcome as a survivor suggests that his current treatment regimen is effective in managing his heart failure and preventing further complications. However, close monitoring of his condition and adjustment of his medications as needed will be necessary to prevent progression of his disease."
394,394,P0634,"Age: 76
Gender: Male 
Weight: 72 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 114/77 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 3,67
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 141.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 5,1
LDL (mmol/L): 1,66
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 716.0
Protein (g/L): 76
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,67
Urea (mg/dL): 10,48
LVEF (%): 38.0
Medications: Diabetes Medication, Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 76-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension. Despite these comorbidities, the patient's current medication regimen, including beta blockers, spironolactone, statins, and an ACE inhibitor, suggests that he is being managed for his heart failure and other conditions.

The patient's left ventricular ejection fraction (LVEF) of 38% indicates that he has heart failure with reduced ejection fraction (HFrEF), which is a common complication of ischemic cardiomyopathy. However, the patient's current LVEF is higher than expected given his age and medical history, suggesting that his current treatment is effective in managing his heart failure symptoms.

The patient's blood pressure is within a normal range, and his glucose and lipid profiles are well-controlled, which is likely due to his diabetes medication and statin therapy. His kidney function, as indicated by his creatinine levels, is also within a relatively normal range, which is consistent with his age and medical history.

The patient's ECG shows ventricular extrasystoles, which are common in patients with heart failure, but there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias. The presence of paroxysmal supraventricular tachycardia (PSVT) is also noted, but this is a relatively benign condition that is not typically associated with poor outcomes.

The patient's pro-BNP level of 716 ng/L is elevated, which is consistent with his heart failure diagnosis. However, the patient's overall clinical picture suggests that his heart failure is well-managed, and his medication regimen is effective in controlling his symptoms.

Given the patient's age, medical history, and current treatment, it is likely that he is a survivor due to his effective management of his heart failure and other conditions. His relatively high LVEF, well-controlled blood pressure and glucose and lipid profiles, and absence of life-threatening arrhythmias all contribute to his positive outcome."
395,395,P0636,"Age: 39
Gender: Male 
Weight: 79 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 115/85 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 47
ALT or GPT (IU/L): 52.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 7,01
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 162
Glucose (mmol/L): 5
Hemoglobin (g/L): 167.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 5,1
LDL (mmol/L): 4,5
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 114.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,701
Urea (mg/dL): 6,82
LVEF (%): 29.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient's survival outcome can be attributed to several factors based on the provided data. Firstly, the patient is being managed with a comprehensive treatment regimen consisting of beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are standard therapies for heart failure and idiopathic dilated cardiomyopathy. These medications help to reduce the heart's workload, decrease fluid overload, and prevent further cardiac damage.

The patient's LVEF (left ventricular ejection fraction) of 29% indicates severe heart failure, but the fact that it is not critically low suggests that the heart is still pumping some blood, albeit inefficiently. The patient's NYHA Class II classification indicates that the patient has mild to moderate symptoms of heart failure, which further supports the notion that the patient is not in an advanced stage of the disease.

The patient's laboratory results, including normal glucose and potassium levels, and a relatively low creatinine level, suggest that the patient's renal function is not significantly impaired. The elevated liver enzymes (ALT and AST) may indicate some degree of liver dysfunction, but this is not uncommon in patients with heart failure.

The patient's TSH level is within the normal range, which suggests that the patient's thyroid function is not contributing to their heart failure. The patient's Troponin level is low, indicating that there is no significant cardiac ischemia or infarction.

The patient's ECG shows ventricular extrasystoles, but no sustained ventricular tachycardia or other life-threatening arrhythmias. The presence of a polymorphic ventricular extrasystole may indicate some degree of cardiac electrical instability, but this is not uncommon in patients with heart failure.

In conclusion, the patient's survival outcome is likely due to the effectiveness of their treatment regimen, the relatively mild symptoms of heart failure, and the absence of significant renal or hepatic dysfunction. However, close monitoring and further management are still necessary to prevent progression of the disease and to optimize the patient's quality of life."
396,396,P0637,"Age: 58
Gender: Male 
Weight: 75 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 43
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 6,85
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 163.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 4,8
LDL (mmol/L): 4,84
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 269.0
Protein (g/L): 73
T3 (pg/dL): 0,06
T4 (ng/L): 14
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,83
Urea (mg/dL): 6,16
LVEF (%): 25.0
Medications: ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient is a 58-year-old male with a history of enolic dilated cardiomyopathy and dyslipemia, presenting with a low left ventricular ejection fraction (LVEF) of 25%, indicating severe left ventricular dysfunction. His elevated Pro-BNP (brain natriuretic peptide) level of 269 ng/L further supports the presence of heart failure, as this biomarker is commonly elevated in patients with heart failure.

The patient's lipid profile shows high total cholesterol (6.85 mmol/L) and LDL (4.84 mmol/L) levels, which are contributing factors to his dyslipemia. His HDL (good cholesterol) level is low at 1.42 mmol/L, which is a risk factor for cardiovascular disease.

The patient's liver enzymes (ALT and AST) are within normal limits, indicating no significant liver dysfunction. His kidney function, as indicated by creatinine levels, is also within the normal range.

The patient's ECG shows polymorphic ventricular extrasystoles, which are premature ventricular contractions that can be a sign of cardiac arrhythmias. However, the absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that the patient's heart rhythm is not significantly abnormal at this time.

The patient's medication list includes an ACE inhibitor, which is a common treatment for heart failure and hypertension. The patient's blood pressure is within the normal range, indicating effective control of hypertension.

Given the patient's severe left ventricular dysfunction and heart failure symptoms, the most likely reason for his survival is the treatment with ACE inhibitor, which has been shown to improve survival and reduce morbidity in patients with heart failure. Additionally, the patient's relatively normal kidney function and lack of significant liver dysfunction suggest that he is not at risk for acute kidney injury or liver failure, which could have contributed to his outcome.

Overall, the patient's survival can be attributed to the effective management of his heart failure symptoms with ACE inhibitor therapy and the absence of other significant comorbidities that could have contributed to his outcome."
397,397,P0638,"Age: 55
Gender: Male 
Weight: 82 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 48
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 12,5
Hemoglobin (g/L): 147.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,71
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 775.0
Protein (g/L): 79
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,18
Urea (mg/dL): 8,15
LVEF (%): 31.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to a combination of factors, including the effectiveness of their current medication regimen and the relatively stable nature of their cardiac condition.

1. Optimal Medication Regimen: The patient is on a comprehensive medication regimen that includes beta blockers, spironolactone, statins, and an ACE inhibitor. Beta blockers are effective in reducing the workload on the heart and decreasing the risk of arrhythmias, while spironolactone helps with heart failure symptoms and ACE inhibitors are beneficial in reducing blood pressure and alleviating symptoms of heart failure. The statins are also crucial in managing dyslipemia and reducing the risk of further cardiac events.

2. Monitoring and Management of Heart Failure: Despite having ischemic dilated cardiomyopathy with an LVEF of 31%, the patient's NYHA Class II classification suggests that their heart failure symptoms are manageable. The low levels of troponin and absence of significant elevation in troponin suggest that the patient is not experiencing an acute myocardial infarction, which is a positive sign.

3. Stable Blood Pressure: The patient's blood pressure of 130/70 mmHg is within a relatively normal range, which indicates that their hypertension is well-controlled. This is crucial in managing heart failure and reducing the risk of further cardiac events.

4. Minimal Organ Dysfunction: The patient's creatinine level of 99.0 μmol/L suggests that their kidney function is within a relatively normal range, which is beneficial in patients with heart failure. The absence of significant abnormalities in liver function tests (ALT and AST) also suggests that the patient's liver function is preserved.

5. Low Pro-BNP Level: A Pro-BNP level of 775.0 ng/L is elevated but not excessively high, indicating that the patient is not experiencing significant acute decompensation of heart failure.

6. Good Control of Diabetes: The patient's glucose level of 12.5 mmol/L is relatively well-controlled, which is essential in managing heart failure and reducing the risk of further cardiac events.

7. Absence of Severe Electrocardiographic Abnormalities: While the patient has ventricular extrasystoles and non-sustained ventricular tachycardia, these are not severe enough to indicate a high risk of sudden cardiac death.

In summary, the patient's survival can be attributed to a combination of their optimal medication regimen, stable cardiac condition, well-controlled blood pressure, minimal organ dysfunction, low Pro-BNP level, good control of diabetes, and absence of severe electrocardiographic abnormalities."
398,398,P0639,"Age: 49
Gender: Male 
Weight: 90 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,97
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 157.0
HDL (mmol/L): 1,63
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,53
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 59.0
Protein (g/L): 76
T3 (pg/dL): 0,06
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,742
Urea (mg/dL): 6,49
LVEF (%): 50.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's medical history of idiopathic dilated cardiomyopathy, a condition characterized by a weakened heart muscle, the patient's left ventricular ejection fraction (LVEF) of 50% is within the reduced range, indicating some degree of heart failure. However, the patient's NYHA Class II classification indicates that the heart failure symptoms are mild and do not limit the patient's physical activity.

The patient's blood pressure of 130/70 mmHg is within a relatively normal range, and the patient is on medications that are commonly prescribed for heart failure and hypertension, such as beta blockers and an ACE inhibitor. These medications help to reduce the workload on the heart and improve its pumping efficiency.

The patient's laboratory results show slightly elevated creatinine levels (96.0 μmol/L), which may indicate some degree of kidney impairment, but the patient's urea levels (6.49 mg/dL) are within a relatively normal range. The patient's albumin levels (44 g/L) are also within a normal range, indicating that the kidneys are not significantly impaired.

The patient's troponin levels (0.01 ng/mL) are within a normal range, indicating that there is no acute myocardial infarction. The patient's pro-BNP levels (59.0 ng/L) are slightly elevated, but within a range that is not typically associated with severe heart failure.

The patient's TSH levels (0.742 mIU/L) are within a normal range, indicating that the patient's thyroid function is normal. The patient's T3 and T4 levels are also within a normal range.

Overall, the patient's laboratory results and ECG findings suggest that while the patient has a history of idiopathic dilated cardiomyopathy and heart failure, their condition is relatively stable, and they are being adequately managed with medications. The patient's outcome of survival is likely due to the effectiveness of their treatment regimen and the fact that they have not experienced any acute cardiac events."
399,399,P0640,"Age: 69
Gender: Male 
Weight: 85 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 41,2
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,82
Creatinine (mmol/L): 166.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 162.0
HDL (mmol/L): 0,8
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,33
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 1660.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,97
Urea (mg/dL): 10,91
LVEF (%): 30.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to a combination of factors.

Firstly, the patient's blood pressure of 110/60 mmHg indicates that they have a relatively stable blood pressure, which is within a normal range. This suggests that the patient's cardiovascular system is not under excessive stress, which can be beneficial for survival.

The patient's LVEF (Left Ventricular Ejection Fraction) of 30% indicates that the heart is pumping efficiently, albeit at a lower capacity than normal. This is a concerning sign, but the fact that the patient is still alive suggests that their heart is adapting to the reduced function.

The patient's medications, including digoxin, loop diuretics, spironolactone, and ACE inhibitor, are all standard treatments for heart failure and are likely contributing to the patient's survival. These medications are helping to manage symptoms, reduce fluid buildup, and slow the progression of the disease.

The patient's creatinine level of 166.0 mmol/L indicates that their kidneys are functioning relatively well, which is essential for overall health and survival. The patient's hemoglobin level of 162.0 g/L is also within a normal range, indicating that their red blood cells are functioning properly.

The patient's pro-BNP level of 1660.0 ng/L is elevated, which is consistent with heart failure. However, the patient's survival suggests that the level of BNP is not so high that it indicates an acute decompensation of heart failure.

The patient's ECG shows non-sustained ventricular tachycardia, which is a concerning finding, but the fact that it is non-sustained suggests that the patient's heart is not experiencing a life-threatening arrhythmia.

Overall, while the patient has a significant underlying condition (idiopathic dilated cardiomyopathy), their stable blood pressure, efficient heart function (despite reduced LVEF), effective medication regimen, and relatively normal kidney and red blood cell function all contribute to their survival."
400,400,P0641,"Age: 68
Gender: Male 
Weight: 98 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 155/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Peripheral vascular disease, Hypertension
Albumin (g/L): 35,8
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 5,02
Creatinine (mmol/L): 131.0
Gamma-glutamil transpeptidase (IU/L): 55
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,08
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 718.0
Protein (g/L): 71
T3 (pg/dL): 0,02
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,71
Urea (mg/dL): 9,35
LVEF (%): 64.0
Medications: Calcium Channel Blocker, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient's outcome as a survivor can be attributed to several factors based on the provided information. 

Firstly, despite having a history of Hypertensive cardiomyopathy and peripheral vascular disease, the patient's left ventricular ejection fraction (LVEF) is 64%, indicating that the heart is still pumping efficiently enough to meet the body's needs. This suggests that the cardiomyopathy has not significantly impaired the patient's cardiac function.

The patient's blood pressure, although elevated at 155/90 mmHg, is not extremely high, and the patient is on medications that are likely helping to control it, such as the calcium channel blocker and ACE inhibitor. The patient's weight and body mass index (BMI) are not provided, but the patient's weight is within a relatively normal range for a male of his height, which may also contribute to a more favorable outcome.

The patient's laboratory results show a slightly elevated creatinine level (131.0 μmol/L), indicating some degree of renal impairment, but this is not severe enough to suggest that the patient is in acute kidney injury or failure. The patient's glucose level is within a relatively normal range, which is also a positive factor.

The patient's troponin level is 0.01 ng/mL, which is within a normal range, indicating that there is no acute myocardial infarction or significant cardiac damage.

The patient's TSH level is within a normal range, and the patient is not taking any thyroid medications, which suggests that the patient's thyroid function is not significantly contributing to the patient's cardiac condition.

The patient's medications, including a calcium channel blocker, digoxin, loop diuretics, and ACE inhibitor, are all commonly used to manage heart failure and hypertension, and it is likely that these medications are helping to control the patient's symptoms and improve their cardiac function.

Overall, the combination of the patient's relatively well-controlled blood pressure, efficient cardiac function, and the absence of acute cardiac damage or severe renal impairment all contribute to their favorable outcome as a survivor."
401,401,P0642,"Age: 72
Gender: Male 
Weight: 76 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 37,3
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,55
Creatinine (mmol/L): 87.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 7
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,51
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 413.0
Protein (g/L): 75
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,44
Urea (mg/dL): 5,13
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to several factors based on the provided information. 

1.  Effective Medication Management: The patient is on a combination of medications that are standard for managing heart failure, including calcium channel blockers, beta blockers, loop diuretics, statins, and nitrovasodilators. These medications are likely contributing to the stabilization of the patient's cardiac function.

2.  Monitoring and Management of Underlying Conditions: The patient has a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, and myocardial infarction. Despite these conditions, the patient's blood pressure is well-controlled (130/70 mmHg), and his glucose levels are within a relatively safe range (7 mmol/L). This suggests that the patient's underlying conditions are being effectively managed.

3.  LVEF of 30%: Although the patient's left ventricular ejection fraction (LVEF) is significantly reduced at 30%, it is not as low as it could be, considering the patient's history of myocardial infarction. This suggests that the patient's heart is still functioning, albeit not optimally.

4.  Pro-BNP Levels: The patient's Pro-BNP levels are elevated at 413.0 ng/L, which is a marker of heart failure. However, the fact that the patient is still alive suggests that the levels are not indicative of a severe acute decompensation.

5.  ECG Findings: The patient's ECG shows polymorphic ventricular extrasystoles but no sustained ventricular tachycardia or other life-threatening arrhythmias. This suggests that the patient's heart is not experiencing severe arrhythmias that could lead to sudden cardiac death.

6.  Nutritional Status: The patient's albumin levels are within a relatively safe range (37.3 g/L), and his protein levels are also within normal limits (75 g/L). This suggests that the patient is not malnourished, which can be a significant risk factor for poor outcomes in heart failure patients.

7.  Hemoglobin Levels: The patient's hemoglobin levels are within a safe range (140 g/L), which suggests that the patient is not experiencing anemia, which can be a risk factor for poor outcomes in heart failure patients.

In summary, the combination of effective medication management, monitoring and management of underlying conditions, relatively preserved LVEF, elevated Pro-BNP levels without signs of severe acute decompensation, absence of life-threatening arrhythmias, and adequate nutritional status have all contributed to the patient's outcome of survival."
402,402,P0644,"Age: 72
Gender: Male 
Weight: 85 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 120/75 mmHg
Past Medical History: Hypertropic cardiomyopathy, Dyslipemia
Albumin (g/L): 43,7
ALT or GPT (IU/L): 94.0
AST or GOT (IU/L): 95.0
Total Cholesterol (mmol/L): 6,1
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4
LDL (mmol/L): 3,9
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 823.0
Protein (g/L): 85
T3 (pg/dL): 0,05
T4 (ng/L): 13
Troponin (ng/mL): 0,18
TSH (mIU/L): 2,38
Urea (mg/dL): 6,91
LVEF (%): 60.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 72-year-old male, has a complex medical history of hypertrophic cardiomyopathy and dyslipemia, which are risk factors for cardiovascular disease. However, despite these risk factors, the patient's current condition suggests a relatively stable cardiac status. 

The patient's left ventricular ejection fraction (LVEF) is 60%, which is within the normal range (50-70%), indicating that the heart is pumping blood effectively. The patient's blood pressure is well-controlled at 120/75 mmHg, which is within the normal range. The patient's Pro-BNP level of 823 ng/L is elevated, but not extremely high, which may indicate some degree of cardiac stress or strain, but not severe heart failure.

The patient's medications, including calcium channel blockers, beta blockers, and statins, are appropriate for managing his hypertrophic cardiomyopathy, hypertension, and dyslipemia. The patient's ECG shows monomorphic ventricular extrasystoles, which are common in patients with hypertrophic cardiomyopathy, but there is no evidence of more severe arrhythmias.

The patient's laboratory results show slightly elevated liver enzymes (ALT and AST), which may indicate some degree of liver stress or dysfunction, possibly related to his dyslipemia. However, the patient's albumin and protein levels are within normal limits, which suggests that his liver function is not severely compromised.

The patient's thyroid function is within normal limits, with a TSH level of 2.38 mIU/L, which suggests that his thyroid hormone levels are not contributing to his cardiac condition.

Overall, considering the patient's stable LVEF, controlled blood pressure, and absence of severe arrhythmias or other complications, it is reasonable to conclude that the patient is likely to survive with appropriate medical management and lifestyle modifications."
403,403,P0645,"Age: 59
Gender: Male 
Weight: 85 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 130/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 44,3
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 5,25
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 32
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,84
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 395.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,7
Urea (mg/dL): 4,68
LVEF (%): 39.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 59-year-old male with ischemic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension, has a complex medical history that contributes to his risk of adverse cardiac outcomes. However, despite his poor left ventricular ejection fraction (LVEF) of 39%, indicating reduced heart function, he has managed to survive.

Several factors may have contributed to his survival:

1. Optimal Medication Management: The patient is on a comprehensive regimen of beta blockers, loop diuretics, statins, ACE inhibitors, and nitrovasodilators, which are all evidence-based treatments for heart failure and ischemic cardiomyopathy. These medications likely helped to manage his symptoms, slow disease progression, and improve his quality of life.

2. Controlled Blood Pressure: The patient's blood pressure is well-managed at 130/85 mmHg, which is within the target range for patients with heart failure. This controlled blood pressure may have helped to reduce the strain on his heart and prevent further cardiac damage.

3. Stable Glucose Levels: The patient's glucose level is well-controlled at 6.7 mmol/L, which may indicate good management of his diabetes. Uncontrolled diabetes can exacerbate heart failure and worsen outcomes, so this is a positive factor in his survival.

4. Low Troponin Levels: The patient's troponin level is 0.01 ng/mL, which is within the normal range. Elevated troponin levels are associated with cardiac damage and increased risk of adverse outcomes, so this low level suggests that his heart muscle is not experiencing significant damage.

5. No Evidence of Sustained Arrhythmias: The ECG shows no evidence of sustained ventricular tachycardia, paroxysmal supraventricular tachyarrhythmia, or bradycardia, which are all arrhythmias that can increase the risk of cardiac complications and mortality.

6. Supportive Laboratory Values: The patient's albumin, AST, and ALT levels are within normal limits, indicating no significant liver dysfunction or inflammation. His potassium level is also within the normal range, which is important for cardiac function.

While the patient's LVEF is low, indicating reduced heart function, the combination of optimal medication management, controlled blood pressure, stable glucose levels, low troponin levels, and absence of sustained arrhythmias, along with supportive laboratory values, may have contributed to his survival."
404,404,P0646,"Age: 61
Gender: Male 
Weight: 74 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 47,59
ALT or GPT (IU/L): 53.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,66
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 174.0
Protein (g/L): 78
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,12
Urea (mg/dL): 10,24
LVEF (%): 35.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient's outcome as a survivor can be attributed to several factors based on the provided information. 

Firstly, the patient's left ventricular ejection fraction (LVEF) is 35%, indicating a reduced ejection fraction, which is a hallmark of heart failure. However, despite this, the patient has been managed with evidence-based medications such as an Angiotensin II Receptor Blocker, Loop Diuretics, Statins, ACE Inhibitor, and Nitrovasodilator. These medications are known to improve heart failure symptoms and outcomes in patients with reduced ejection fraction.

The patient's blood pressure is 160/90 mmHg, which is slightly elevated but still within the hypertensive range. However, the patient is on ACE Inhibitor and Angiotensin II Receptor Blocker, which are known to help control blood pressure.

The patient's creatinine level is elevated at 120.0 mmol/L, indicating some degree of renal impairment. However, the patient's urea level is 10.24 mg/dL, which is not significantly elevated, suggesting that the renal impairment may not be severe.

The patient's troponin level is 0.01 ng/mL, which is within the normal range, indicating no acute myocardial infarction.

The patient's Pro-BNP level is 174.0 ng/L, which is elevated, indicating some degree of heart failure. However, the patient's symptoms and other clinical parameters suggest that the heart failure is not severe.

The patient's ECG shows ventricular extrasystole, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia, but these findings are not indicative of life-threatening arrhythmias.

Overall, the patient's outcome as a survivor can be attributed to the effective management of their heart failure with evidence-based medications, the absence of acute myocardial infarction, and the presence of only mild renal impairment."
405,405,P0648,"Age: 72
Gender: Female 
Weight: 78 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 130/90 mmHg
Past Medical History: Hypertropic cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39,9
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,15
Creatinine (mmol/L): 90.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 7,1
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 3,6
LDL (mmol/L): 2,97
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 126.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2
Urea (mg/dL): 8,46
LVEF (%): 60.0
Medications: Beta Blockers
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient's outcome of survival can be attributed to several factors based on the provided data.

1.  Age and NYHA Class: The patient is 72 years old and classified as NYHA Class II, which indicates that she experiences some limitations in physical activity but is still able to perform everyday activities without symptoms. This suggests that her heart condition, hypertrophic cardiomyopathy, is not severe enough to significantly impact her quality of life or daily activities.

2.  Medications: The patient is taking beta blockers, which are commonly prescribed for heart conditions, including hypertrophic cardiomyopathy and hypertension. Beta blockers help slow the heart rate and reduce the heart's workload, which can improve symptoms and outcomes in patients with these conditions.

3.  Blood Pressure: Although the patient's blood pressure is slightly elevated at 130/90 mmHg, it is not extremely high. Well-controlled hypertension can help prevent further strain on the heart and reduce the risk of complications.

4.  LVEF: The patient's left ventricular ejection fraction (LVEF) is 60.0%, which is within the normal range. A normal LVEF indicates that the heart is pumping blood efficiently, which is a positive sign for the patient's prognosis.

5.  Troponin and ECG: The patient's troponin level is 0.01 ng/mL, which is within the normal range, indicating that there is no evidence of acute myocardial infarction. The ECG also shows no signs of sustained ventricular tachycardia or other life-threatening arrhythmias.

6.  Other Lab Results: The patient's albumin, creatinine, and urea levels are within normal limits, indicating that her kidney function is not severely compromised. Her glucose level is slightly elevated, but not high enough to indicate diabetes-related complications. Her potassium level is slightly low, which may be related to her medications or other factors, but it is not a significant concern.

7.  TSH and T3/T4: The patient's thyroid function tests are within normal limits, which suggests that her thyroid hormone levels are not contributing to any cardiac issues.

Considering these factors, the patient's overall health status and the effectiveness of her medications suggest that she is likely to survive and manage her condition with proper medical care and lifestyle modifications."
406,406,P0652,"Age: 68
Gender: Female 
Weight: 62 kg
Height: 144 cm
NYHA Class: II
Blood Pressure: 200/110 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45,1
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,39
Creatinine (mmol/L): 78.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 5
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,8
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 170.0
Protein (g/L): 71,7
T4 (ng/L): 15
TSH (mIU/L): 5,21
Urea (mg/dL): 5,49
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 68-year-old female with a history of idiopathic dilated cardiomyopathy and hypertension, presenting with a reduced left ventricular ejection fraction (LVEF) of 35%. Her blood pressure is significantly elevated at 200/110 mmHg, which is likely contributing to her cardiomyopathy. The patient is on a combination of medications, including a calcium channel blocker, loop diuretics, and an ACE inhibitor, which are standard treatments for hypertension and heart failure.

The patient's laboratory results show elevated creatinine levels (78.0 mmol/L), indicating impaired renal function, which is a common complication of heart failure. Her total cholesterol and LDL levels are elevated, which may contribute to her cardiovascular disease. However, her HDL level is low, which is a risk factor for cardiovascular disease.

The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are abnormal heart rhythms that can be associated with cardiomyopathy. However, the patient is still alive, indicating that her condition is being managed effectively with her current medications.

The patient's TSH level is within the normal range, indicating that her thyroid function is normal. Her T4 level is also within the normal range, which suggests that her thyroid hormone levels are not contributing to her heart failure.

Overall, the patient's outcome as a survivor suggests that her condition is being effectively managed with her current medications and lifestyle modifications. Her healthcare team is likely monitoring her closely to adjust her treatment plan as needed to prevent further complications and improve her quality of life."
407,407,P0653,"Age: 73
Gender: Male 
Weight: 88 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 45,3
ALT or GPT (IU/L): 6.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 6,15
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 8,8
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 3,9
LDL (mmol/L): 4,37
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 655.0
Protein (g/L): 80
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,87
Urea (mg/dL): 10,69
LVEF (%): 39.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient, a 73-year-old male with a history of enolic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension, has a complex medical profile. Despite the presence of severe left ventricular dysfunction (LVEF of 39%), indicated by a low ejection fraction, the patient has been on optimal medical therapy with beta blockers, loop diuretics, and an ACE inhibitor, which are standard treatments for heart failure with reduced ejection fraction (HFrEF).

The elevated Pro-BNP level of 655 ng/L is indicative of heart failure, but the fact that the patient is still alive suggests that the medical therapy is having some beneficial effects on his condition.

The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG may indicate underlying electrical instability, but the absence of sustained ventricular tachycardia or other life-threatening arrhythmias suggests that the patient's cardiac function is still being maintained.

The patient's creatinine level of 124.0 umol/L indicates mild renal impairment, but this is not uncommon in patients with heart failure and diabetes. The patient's electrolyte levels, including potassium and sodium, are within the normal range, which is a good sign.

The patient's hemoglobin level of 148 g/L is within the normal range, and the absence of anemia is a positive factor in his survival.

The patient's TSH level of 1.87 mIU/L is within the normal range, indicating that his thyroid function is well-controlled.

The patient's T3 and T4 levels are also within the normal range, indicating that his thyroid function is well-controlled.

The patient's Troponin level of 0.01 ng/mL is within the normal range, indicating that there is no acute myocardial infarction.

The patient's glucose level of 8.8 mmol/L is within the normal range, indicating that his diabetes is well-controlled.

The patient's albumin level of 45.3 g/L is within the normal range, indicating that there is no significant liver dysfunction.

The patient's AST and ALT levels are within the normal range, indicating that there is no significant liver dysfunction.

The patient's GGT level of 36 IU/L is within the normal range, indicating that there is no significant liver dysfunction.

The patient's HDL level of 1.01 mmol/L is within the normal range, indicating that his lipid profile is well-controlled.

The patient's LDL level of 4.37 mmol/L is within the normal range, indicating that his lipid profile is well-controlled.

The patient's sodium level of 137 mmol/L is within the normal range, indicating that there is no significant hyponatremia.

The patient's urea level of 10.69 mg/dL is within the normal range, indicating that there is no significant renal impairment.

Overall, the patient's survival can be attributed to the effectiveness of his medical therapy, the absence of acute myocardial infarction, and the absence of significant electrolyte imbalances or renal impairment."
408,408,P0654,"Age: 70
Gender: Female 
Weight: 75 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 45,9
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 90.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 7,5
Hemoglobin (g/L): 145.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,73
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1789.0
Protein (g/L): 75
T3 (pg/dL): 0,04
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,09
Urea (mg/dL): 8,46
LVEF (%): 25.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient outcome of survival can be attributed to several factors in this 70-year-old female patient with a history of ischemic dilated cardiomyopathy, diabetes, peripheral vascular disease, hypertension, and myocardial infarction. 

Firstly, the patient's current medication regimen is comprehensive and targets multiple aspects of her cardiovascular disease. She is on diabetes medication to manage her blood glucose levels, beta blockers to reduce her heart rate and blood pressure, statins to lower her cholesterol levels, and an ACE inhibitor to reduce her blood pressure and alleviate strain on the heart.

The patient's laboratory results also indicate that her kidney function, as measured by creatinine levels, is within a relatively normal range (90.0 mmol/L). Although her albumin levels are slightly low (45.9 g/L), her total protein levels are within the normal range (75 g/L), which suggests that her liver function is not significantly impaired. The low albumin levels could be related to nephrotic syndrome, which is common in patients with heart failure.

The patient's electrolyte levels are also relatively well-balanced, with a potassium level of 4.7 mEq/L, which is within the normal range. This is crucial for maintaining cardiac function, as potassium plays a key role in cardiac contractility.

The patient's ejection fraction (LVEF) of 25% indicates severe left ventricular dysfunction, which is consistent with her diagnosis of ischemic dilated cardiomyopathy. However, the fact that she has not experienced a sudden cardiac death or cardiac arrest suggests that her heart is still compensating to some extent, and her medication regimen may be helping to mitigate the effects of her heart failure.

The patient's TSH level is within the normal range (3.09 mIU/L), which suggests that her thyroid function is not significantly contributing to her cardiac condition. The low T3 and T4 levels may be a result of the patient's heart failure, as decreased cardiac output can lead to decreased peripheral conversion of T4 to T3.

The patient's Pro-BNP level of 1789 ng/L is elevated, indicating that she has elevated levels of B-type natriuretic peptide, which is consistent with her diagnosis of heart failure. However, this does not necessarily predict a poor outcome, as Pro-BNP levels can be influenced by various factors, including age, sex, and renal function.

Overall, the combination of the patient's comprehensive medication regimen, relatively well-balanced electrolyte levels, and absence of significant kidney or liver dysfunction likely contributed to her survival."
409,409,P0655,"Age: 55
Gender: Male 
Weight: 107 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 46,1
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 108.0
Gamma-glutamil transpeptidase (IU/L): 53
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 159.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,08
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 408.0
Protein (g/L): 79
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,96
Urea (mg/dL): 6,91
LVEF (%): 24.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's survival outcome can be attributed to a combination of factors, including the presence of current medications and the severity of their underlying condition.

1.  Optimal Medication Management: The patient is on a comprehensive medication regimen consisting of beta blockers, loop diuretics, statins, and an ACE inhibitor. Beta blockers, in particular, are known to reduce mortality and morbidity in patients with heart failure by decreasing the heart rate and the force of contraction, thereby reducing the workload on the heart. Additionally, statins have been shown to have a beneficial effect on cardiovascular outcomes by lowering LDL cholesterol levels and improving endothelial function.

2.  LVEF (Left Ventricular Ejection Fraction) of 24%: Although the patient has a significantly reduced LVEF, indicating severe left ventricular dysfunction, they have not yet progressed to a more advanced stage of heart failure. The LVEF is a critical indicator of the heart's pumping efficiency, and a value of 24% suggests that the patient's heart is still capable of some degree of pumping function, albeit severely impaired.

3.  Pro-BNP (Brain Natriuretic Peptide) Level: The patient's Pro-BNP level of 408 ng/L is elevated, indicating increased ventricular wall stress and a compensatory response to heart failure. However, the level is not excessively high, suggesting that the patient's heart is not under extreme stress.

4.  ECG Findings: The presence of non-sustained ventricular tachycardia (VT) is concerning but not necessarily indicative of an acute life-threatening condition. The absence of sustained VT, bradycardia, or paroxysmal supraventricular tachyarrhythmia reduces the immediate risk of cardiac arrest or severe arrhythmia.

5.  Laboratory Results: The patient's laboratory results show mild elevations in liver enzymes (ALT and AST), which could be indicative of mild liver dysfunction or drug-induced liver injury. However, these elevations are not severe enough to significantly impact the patient's survival outcome.

Considering these factors, the patient's survival outcome can be attributed to the effectiveness of their current medication regimen, the relatively preserved LVEF, and the absence of severe arrhythmias or acute decompensated heart failure."
410,410,P0658,"Age: 59
Gender: Male 
Weight: 69 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 130/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 42,9
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 81.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,82
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 469.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,53
Urea (mg/dL): 12,47
LVEF (%): 39.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient's age of 59 and NYHA Class II indicate that the patient has a moderate level of heart failure symptoms, but is still relatively stable and able to perform most daily activities without significant limitation.

The patient's ischemic dilated cardiomyopathy, as indicated by an LVEF of 39%, is a significant underlying condition that affects the heart's ability to pump blood efficiently. However, the patient's current medications, including beta blockers, statins, ACE inhibitors, and nitrovasodilators, are appropriate for managing heart failure and reducing the risk of further cardiac events.

The patient's blood pressure is within a relatively normal range (130/60 mmHg), which is not excessively high or low, suggesting that the patient's cardiovascular system is not under significant stress.

The patient's laboratory results, including normal kidney function (creatinine 81.0 mmol/L), normal liver function (ALT and AST within normal limits), and normal electrolyte levels (potassium 4.5 mEq/L), suggest that the patient's overall metabolic and electrolyte balance is relatively stable.

The patient's troponin level (0.01 ng/mL) is within normal limits, indicating that there is no acute myocardial infarction. The pro-BNP level (469.0 ng/L) is elevated, which is consistent with heart failure, but not excessively high, suggesting that the patient's heart failure symptoms are being managed.

The patient's TSH level (1.53 mIU/L) is within the normal range, indicating that the patient's thyroid function is normal. The patient's T3 and T4 levels are also within normal limits, which is consistent with euthyroidism.

The patient's ECG results show a monomorphic ventricular extrasystole, which is a common finding in patients with heart failure and is not necessarily indicative of a life-threatening condition.

Overall, the patient's stable medication regimen, normal laboratory results, and lack of acute cardiac events suggest that the patient is being effectively managed for their heart failure and other underlying conditions. The patient's overall clinical picture suggests that they are likely to survive, given their current treatment and management plan."
411,411,P0659,"Age: 77
Gender: Male 
Weight: 68 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 140/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 48,3
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 138.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,72
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 1071.0
Protein (g/L): 74
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,04
TSH (mIU/L): 6,33
Urea (mg/dL): 13,36
LVEF (%): 50.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 77-year-old male with a history of ischemic dilated cardiomyopathy, hypertension, and dyslipemia, has been managed with a combination of beta blockers, loop diuretics, statins, and an ACE inhibitor. His LVEF (Left Ventricular Ejection Fraction) is 50%, indicating a mildly reduced ejection fraction, which is consistent with the diagnosis of ischemic dilated cardiomyopathy.

The patient's blood pressure is well-controlled at 140/85 mmHg, and his lipid profile shows a total cholesterol level of 4.84 mmol/L, which is within the target range for a patient with ischemic heart disease. His creatinine level is elevated at 138.0 μmol/L, indicating some degree of renal impairment, but this is likely related to his hypertension and heart failure rather than a primary renal issue.

The patient's troponin level is 0.04 ng/mL, which is within the normal range, indicating no acute myocardial infarction. His TSH level is slightly elevated at 6.33 mIU/L, but this is not indicative of a significant thyroid disorder.

The patient's Pro-BNP level is 1071.0 ng/L, which is elevated, indicating some degree of heart failure. However, this is not unexpected given his history of ischemic dilated cardiomyopathy and reduced LVEF.

The patient's ECG shows a monomorphic ventricular extrasystole, which is a common finding in patients with heart failure. However, there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias.

Considering the patient's overall clinical picture, including his well-controlled blood pressure, stable LVEF, and absence of acute myocardial infarction or other life-threatening arrhythmias, the most likely reason for the patient's outcome of survival is the effective management of his heart failure and other comorbidities, as well as his adherence to his medication regimen."
412,412,P0660,"Age: 49
Gender: Male 
Weight: 81 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 155/80 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 50,59
ALT or GPT (IU/L): 56.0
AST or GOT (IU/L): 53.0
Total Cholesterol (mmol/L): 7,89
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 821
Glucose (mmol/L): 11
Hemoglobin (g/L): 166.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,1
LDL (mmol/L): 5,02
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 114.0
Protein (g/L): 86
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 11,8
Urea (mg/dL): 6,91
LVEF (%): 50.0
Medications: Diabetes Medication, Amiodarone, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient survived due to a combination of factors, including the effective management of their underlying medical conditions and the use of appropriate medications. 

Firstly, the patient's blood pressure is well-controlled at 155/80 mmHg, which is relatively close to the target blood pressure for a patient with hypertension. This suggests that their hypertension is being adequately managed with their current treatment regimen, including the ACE inhibitor.

The patient's cardiac function is compromised, as indicated by a left ventricular ejection fraction (LVEF) of 50.0%, which is below the normal range of 55-70%. However, the patient is on digoxin and amiodarone, which are medications commonly used to manage heart failure and arrhythmias. These medications may have contributed to the stabilization of the patient's cardiac function.

The patient's diabetes is also being managed with medication, which has likely helped to prevent complications associated with uncontrolled diabetes, such as cardiovascular disease and kidney damage. The patient's glucose level is 11 mmol/L, which is slightly elevated but not severely high.

The patient's liver enzymes, ALT and AST, are elevated at 56.0 IU/L and 53.0 IU/L, respectively. However, these elevations are not extremely high, and the patient's gamma-glutamyl transferase (GGT) level is significantly elevated at 821 IU/L, which may indicate some degree of liver dysfunction. This could be related to the patient's diabetes or other underlying conditions.

The patient's kidney function is compromised, as indicated by a creatinine level of 103.0 mmol/L. However, the patient's urea level is only slightly elevated at 6.91 mg/dL, which suggests that the kidney dysfunction is not severe.

The patient's troponin level is 0.01 ng/mL, which is within the normal range, indicating that there is no acute myocardial infarction.

The patient's thyroid function is slightly abnormal, with a TSH level of 11.8 mIU/L, which is higher than the normal range. This may be related to the patient's amiodarone therapy, which can cause thyroid dysfunction.

Overall, the patient's survival can be attributed to the effective management of their underlying medical conditions, including hypertension, diabetes, and heart failure, as well as the use of appropriate medications."
413,413,P0662,"Age: 61
Gender: Female 
Weight: 64 kg
Height: 142 cm
NYHA Class: II
Blood Pressure: 135/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43,9
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,61
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 191.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,95
Urea (mg/dL): 11,36
LVEF (%): 60.0
Medications: Diabetes Medication, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient's outcome of survival can be attributed to several factors:

1.  Optimal Medication Management: The patient is on a comprehensive medication regimen consisting of diabetes medication, beta blockers, and statins, which are all crucial in managing her conditions. Beta blockers help control heart rate and blood pressure, reducing the workload on the heart, while statins help lower cholesterol levels and reduce the risk of further cardiovascular events. Diabetes medication also helps manage blood sugar levels, which is essential for preventing complications associated with diabetes.

2.  Moderate Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 60%, which is within the moderate range. This indicates that the heart is pumping blood efficiently, albeit not at its best. A moderate LVEF suggests that the heart is still able to meet the body's needs, which contributes to the patient's survival.

3.  Mild Electrocardiogram (ECG) Abnormalities: Although the patient has a ventricular extrasystole, which is a type of abnormal heart rhythm, it is described as monomorphic, indicating that it is not life-threatening. The absence of more severe ECG abnormalities, such as ventricular tachycardia or bradycardia, also suggests that the heart is functioning relatively normally.

4.  Stable Blood Pressure: The patient's blood pressure is within a relatively normal range (135/85 mmHg), which is indicative of good blood pressure control. This is essential for preventing further cardiovascular damage and reducing the risk of complications.

5.  Normal Hemoglobin and Potassium Levels: The patient's hemoglobin and potassium levels are within the normal range, which suggests that there are no significant issues with blood cell production or electrolyte imbalances that could impact heart function.

6.  Low T3 and T4 Levels: The patient's thyroid hormone levels (T3 and T4) are within the normal range, which suggests that there is no underlying thyroid dysfunction contributing to her cardiac condition.

7.  Absence of Significant Organ Dysfunction: The patient's liver enzymes (ALT and AST) and kidney function (creatinine and urea) are within the normal range, indicating that there is no significant organ dysfunction that could impact her survival.

Overall, the combination of optimal medication management, a moderate LVEF, mild ECG abnormalities, stable blood pressure, and absence of significant organ dysfunction all contribute to the patient's survival."
414,414,P0663,"Age: 66
Gender: Male 
Weight: 117 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 160/105 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 45,59
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,55
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 55
Glucose (mmol/L): 10,3
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,79
Sodium (mEq/L): 146.0
Pro-BNP (ng/L): 419.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,79
Urea (mg/dL): 8,02
LVEF (%): 50.0
Medications: ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 66-year-old male with a history of ischemic dilated cardiomyopathy, dyslipemia, hypertension, and myocardial infarction, has been treated with an ACE inhibitor. Despite the presence of several risk factors and a reduced left ventricular ejection fraction (LVEF) of 50%, the patient has survived. 

Several factors may have contributed to the patient's survival:

1.  The patient's LVEF of 50% indicates that the heart is still pumping blood effectively, albeit at a reduced capacity. This suggests that the patient's cardiomyopathy is not in an advanced stage, and the heart is still able to maintain a sufficient level of function.
2.  The patient's blood pressure is elevated (160/105 mmHg), but it is being managed with an ACE inhibitor, which is a standard treatment for hypertension and heart failure. The medication is likely helping to reduce the patient's blood pressure and alleviate strain on the heart.
3.  The patient's troponin level is within normal limits (0.01 ng/mL), indicating that there is no acute myocardial infarction or ongoing cardiac damage.
4.  The patient's pro-BNP level is elevated at 419.0 ng/L, which suggests that the patient has some degree of heart failure. However, the level is not extremely high, and it may be indicative of mild to moderate heart failure.
5.  The patient's medications, including the ACE inhibitor, are likely helping to manage his heart failure and reduce the risk of further cardiac events.
6.  The patient's TSH level is within the normal range (2.79 mIU/L), which suggests that his thyroid function is not contributing to his cardiac condition.
7.  The patient's LVEF of 50% and the presence of ventricular extrasystoles on the ECG suggest that the patient has some degree of cardiac arrhythmias, but they are not severe enough to compromise his survival.

Overall, the patient's survival can be attributed to a combination of his relatively preserved LVEF, effective management of his blood pressure and heart failure with ACE inhibitors, and the absence of acute cardiac damage or severe arrhythmias."
415,415,P0664,"Age: 59
Gender: Male 
Weight: 105 kg
Height: 172 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 38,1
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,46
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 11,2
Hemoglobin (g/L): 152.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,64
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 135.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,56
Urea (mg/dL): 12,03
LVEF (%): 22.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 59-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction, has been treated with a comprehensive medication regimen including diabetes medication, beta blockers, loop diuretics, spironolactone, ACE inhibitor, and nitrovasodilator. Despite his complex medical history, the patient has survived, indicating that his treatment plan has been effective in managing his condition.

Several factors contributed to the patient's survival:

1. Optimal blood pressure control: The patient's blood pressure of 120/80 mmHg suggests that his hypertension is well-managed, which is crucial in reducing the risk of further cardiovascular events.
2. Effective heart failure management: The patient's LVEF (left ventricular ejection fraction) of 22% indicates severe heart failure, but his survival suggests that his treatment plan, including beta blockers and ACE inhibitors, has helped to stabilize his condition.
3. Good kidney function: The patient's creatinine level of 102.0 μmol/L is slightly elevated, but not significantly so, indicating that his kidney function is still relatively preserved.
4. Controlled glucose levels: The patient's glucose level of 11.2 mmol/L suggests that his diabetes is well-managed, which is essential in preventing further cardiovascular complications.
5. No signs of acute cardiac ischemia: The patient's troponin level of 0.01 ng/mL is within normal limits, indicating that he is not experiencing acute cardiac ischemia.
6. Appropriate medication regimen: The patient's medication regimen, including beta blockers, ACE inhibitors, and spironolactone, is consistent with guidelines for managing heart failure and hypertension.
7. Regular monitoring and follow-up: The patient's regular monitoring and follow-up appointments likely ensured that any potential issues were addressed promptly, contributing to his survival.

In conclusion, the patient's survival can be attributed to a combination of effective medical management, optimal blood pressure control, controlled glucose levels, and preserved kidney function, along with a comprehensive treatment plan and regular monitoring."
416,416,P0666,"Age: 71
Gender: Female 
Weight: 86 kg
Height: 147 cm
NYHA Class: III
Blood Pressure: 150/85 mmHg
Past Medical History: Hypertropic cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43,2
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 6,85
Creatinine (mmol/L): 272.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,73
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,32
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 2627.0
Protein (g/L): 74
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,06
TSH (mIU/L): 2,06
Urea (mg/dL): 31,4
LVEF (%): 65.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 71-year-old female with a history of hypertrophic cardiomyopathy, dyslipemia, hypertension, and myocardial infarction. She is classified as NYHA Class III, indicating moderate heart failure symptoms, but still able to perform ordinary physical activity without discomfort.

The patient's laboratory results show elevated creatinine levels (272.0 mmol/L), indicating impaired kidney function. The elevated Pro-BNP level (2627.0 ng/L) suggests increased stress on the heart, which could be due to heart failure or other cardiac conditions. The patient's LVEF is 65.0%, which is within the normal range, indicating that the heart is pumping blood efficiently.

The patient's ECG shows polymorphic ventricular extrasystoles, which are abnormal heart rhythms that can be a sign of underlying cardiac disease. However, the absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and other arrhythmias suggests that the patient's heart is not experiencing severe arrhythmias at the moment.

The patient's medications, including calcium channel blockers, beta blockers, loop diuretics, and statins, are all appropriate for managing her heart conditions, including hypertension, heart failure, and dyslipemia.

Given the patient's age, comorbidities, and laboratory results, the most likely reason for her survival is the effective management of her heart conditions through her current medications. The patient's LVEF is within the normal range, indicating that her heart is pumping blood efficiently, and the absence of severe arrhythmias on the ECG suggests that her heart is not experiencing severe stress. The elevated Pro-BNP level may indicate some level of heart stress, but it is not high enough to suggest acute heart failure. Therefore, the patient's survival can be attributed to the effective management of her heart conditions through her current medications and lifestyle adjustments."
417,417,P0668,"Age: 67
Gender: Female 
Weight: 70 kg
Height: 146 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 45,7
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,87
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 7
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,77
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 1356.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,39
Urea (mg/dL): 14,92
LVEF (%): 68.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome is a survivor, and this can be attributed to several factors based on the provided data.

1.  Effective Medication Regimen: The patient is on a comprehensive medication regimen that includes a Calcium Channel Blocker, Beta Blockers, Loop Diuretics, and an ACE Inhibitor. This combination of medications is typical for managing hypertensive cardiomyopathy, diabetes, and hypertension, which are all conditions the patient has. The medications are likely contributing to the stabilization of the patient's cardiovascular system.

2.  Preserved LVEF: The patient's Left Ventricular Ejection Fraction (LVEF) is 68%, which is within the normal range (typically >55%). This indicates that the patient's heart is pumping blood efficiently, which is crucial for survival.

3.  Reasonable Blood Pressure: Although the patient's blood pressure is slightly elevated at 150/80 mmHg, it is not excessively high, which reduces the risk of cardiovascular complications.

4.  Low Troponin Levels: The troponin level of 0.01 ng/mL is within the normal range, indicating minimal cardiac damage or acute myocardial infarction.

5.  Normal TSH Levels: The thyroid-stimulating hormone (TSH) level of 2.39 mIU/L is within the normal range, suggesting that the patient's thyroid function is not contributing to any cardiovascular issues.

6.  Reasonable Cholesterol Levels: The patient's total cholesterol and LDL levels are not excessively high, which reduces the risk of atherosclerotic cardiovascular disease.

7.  No Indication of Cardiac Arrhythmias: Although the patient has a history of ventricular extrasystoles, there is no indication of sustained ventricular tachycardia or other life-threatening arrhythmias.

Considering these factors, the patient's comprehensive treatment plan and relatively stable cardiovascular profile contribute to their survival outcome."
418,418,P0669,"Age: 80
Gender: Male 
Weight: 74 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 43,1
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,4
Creatinine (mmol/L): 138.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,77
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 901.0
Protein (g/L): 78,3
T4 (ng/L): 16
TSH (mIU/L): 7,12
Urea (mg/dL): 15,64
LVEF (%): 40.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: No
            ",survivor,"REASONING: The patient, an 80-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, peripheral vascular disease, and myocardial infarction, survived despite a severe prognosis due to several factors. 

Firstly, the patient's current medications, including spironolactone, a mineralocorticoid receptor antagonist, and loop diuretics, suggest that the patient's heart failure symptoms are being managed effectively. Additionally, the use of statins to lower cholesterol levels and nitrovasodilators to reduce cardiac workload also contributed to the patient's survival.

The patient's LVEF (Left Ventricular Ejection Fraction) of 40% indicates a reduced cardiac function, but it is not as low as it could be, considering the patient's history. The patient's blood pressure is well-controlled at 130/70 mmHg, which is within the target range for patients with heart failure.

The patient's Pro-BNP (B-type natriuretic peptide) level of 901.0 ng/L is elevated, indicating increased ventricular stress, but not to a level that would be expected to cause immediate cardiac decompensation.

The patient's electrolyte levels, including potassium at 5.4 mEq/L, are within a relatively normal range, which is essential for maintaining cardiac function. The patient's renal function, as indicated by creatinine levels, is compromised, but not to a degree that would necessitate immediate intervention.

The patient's TSH level of 7.12 mIU/L is slightly elevated, but not to a level that would indicate thyroid dysfunction. The patient's T4 level is within the normal range, which suggests that thyroid function is not a contributing factor to the patient's cardiac condition.

The presence of ventricular extrasystoles on the ECG is not uncommon in patients with heart failure and does not necessarily indicate a poor prognosis. Overall, while the patient has a history of severe cardiac disease, the combination of effective medication management, controlled blood pressure, and relatively preserved cardiac function contributed to the patient's survival."
419,419,P0670,"Age: 75
Gender: Female 
Weight: 73 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Hypertropic cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 44,8
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 77.0
Gamma-glutamil transpeptidase (IU/L): 67
Glucose (mmol/L): 9,7
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,79
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 359.0
Protein (g/L): 69,7
T4 (ng/L): 17
TSH (mIU/L): 1,28
Urea (mg/dL): 6,99
LVEF (%): 40.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 75-year-old female with a complex medical history, including hypertrophic cardiomyopathy, diabetes, dyslipemia, and hypertension. Despite these comorbidities, the patient has been managed with a multi-drug regimen, including diabetes medication, an angiotensin II receptor blocker, loop diuretics, statins, and an ACE inhibitor. The patient's current New York Heart Association (NYHA) class is II, indicating moderate symptoms of heart failure.

The patient's laboratory results show elevated levels of creatinine (77.0 mmol/L), indicating impaired renal function, which may be contributing to the patient's heart failure. The patient's low LVEF (40.0%) suggests that the patient has reduced left ventricular function, consistent with heart failure with reduced ejection fraction (HFrEF). The elevated Pro-BNP level (359.0 ng/L) also supports the presence of heart failure.

The patient's ECG shows monomorphic ventricular extrasystoles, which are common in patients with heart disease. However, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia suggests that the patient is not experiencing severe arrhythmias.

Given the patient's complex medical history, impaired renal function, reduced LVEF, and elevated Pro-BNP level, it is likely that the patient has been experiencing symptoms of heart failure. However, the patient's ability to survive suggests that the patient's treatment regimen has been effective in managing their symptoms and slowing the progression of heart disease.

The patient's overall survival is likely due to the combination of their treatment regimen, including the use of ACE inhibitors and beta-blockers, which have been shown to improve outcomes in patients with HFrEF. Additionally, the patient's relatively low NYHA class and absence of severe arrhythmias suggest that the patient's heart failure is well-managed."
420,420,P0672,"Age: 70
Gender: Female 
Weight: 66 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 42,5
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 72.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,87
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 824.0
Protein (g/L): 69,7
T4 (ng/L): 16
TSH (mIU/L): 3,09
Urea (mg/dL): 5,99
LVEF (%): 35.0
Medications: Diabetes Medication, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 70-year-old female with ischemic dilated cardiomyopathy, has been prescribed medications for diabetes, statins, and an ACE inhibitor, indicating that she is being managed for her underlying heart condition and diabetes. Her LVEF (left ventricular ejection fraction) of 35% is within the range of heart failure with reduced ejection fraction (HFrEF), which is consistent with her ischemic dilated cardiomyopathy diagnosis.

The patient's laboratory results show a high Pro-BNP level (824 ng/L), which is a biomarker for heart failure and is consistent with her reduced LVEF. However, her blood pressure is within a relatively normal range (110/75 mmHg), which suggests that her blood pressure is well-controlled.

Her lipid profile shows a total cholesterol level of 4.84 mmol/L, with an LDL of 2.87 mmol/L, which is within a relatively normal range. This is consistent with the use of statins, which are intended to lower cholesterol levels.

The patient's kidney function, as indicated by her creatinine level (72.0 μmol/L), is within a relatively normal range, which suggests that her kidney function is preserved. Her urea level (5.99 mg/dL) is also within a normal range.

The patient's ECG shows polymorphic ventricular extrasystoles, but no other significant arrhythmias. This is not uncommon in patients with heart failure and can be a benign finding.

Given the patient's overall clinical presentation and laboratory results, it appears that she is being well-managed for her heart failure and diabetes. Her medications are likely contributing to her survival, and her kidney function and blood pressure are well-controlled. Therefore, the patient's outcome is likely due to the effective management of her underlying conditions, as well as the use of evidence-based therapies such as ACE inhibitors and statins."
421,421,P0673,"Age: 79
Gender: Female 
Weight: 70 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 150/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 45,2
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,97
Creatinine (mmol/L): 60.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,99
Potassium (mEq/L): 3,6
LDL (mmol/L): 2,56
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 58.0
Protein (g/L): 68,9
T4 (ng/L): 15
TSH (mIU/L): 1,63
Urea (mg/dL): 4,99
LVEF (%): 67.0
Medications: Calcium Channel Blocker, Beta Blockers, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 79-year-old female with a history of hypertensive cardiomyopathy, dyslipemia, and hypertension. Despite her advanced age and multiple comorbidities, she is classified as NYHA Class II, indicating that she experiences some limitations in physical activity but is still able to perform daily activities without severe symptoms.

The patient's blood pressure is slightly elevated at 150/85 mmHg, which is consistent with her history of hypertension. Her lipid profile shows a total cholesterol level of 4.97 mmol/L, with an LDL of 2.56 mmol/L, which is slightly elevated but not excessively high. Her HDL level is 1.99 mmol/L, which is within a normal range.

Her liver enzymes, including ALT and AST, are within normal limits, indicating that there is no significant liver damage. Her kidney function, as indicated by creatinine levels, is also within normal limits.

The patient's LVEF (left ventricular ejection fraction) is 67%, which is within the normal range, indicating that her heart is pumping efficiently. Her pro-BNP (brain natriuretic peptide) level is 58.0 ng/L, which is slightly elevated but not excessively high, suggesting that she may have some degree of cardiac stress but not severe heart failure.

The patient is on a regimen of calcium channel blockers, beta blockers, and nitrovasodilators, which are common medications for managing hypertension and heart failure.

The ECG shows polymorphic ventricular extrasystoles, which are common in patients with hypertension and cardiomyopathy. There is no evidence of sustained ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia.

Considering the patient's age, comorbidities, and medication regimen, her survival outcome is likely due to the effectiveness of her treatment and her relatively stable cardiac function. The presence of polymorphic ventricular extrasystoles is a common finding in patients with hypertension and cardiomyopathy, and it is not a predictor of poor outcome in this case. The patient's overall clinical picture suggests that she is at a low to moderate risk for cardiac complications, and her survival outcome is likely due to her stable cardiac function and effective management of her comorbidities."
422,422,P0674,"Age: 66
Gender: Male 
Weight: 71 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 44,5
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 6,52
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 37
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 168.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,03
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 209.0
Protein (g/L): 71,3
T4 (ng/L): 12
TSH (mIU/L): 1,1
Urea (mg/dL): 5,99
LVEF (%): 35.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 66-year-old male with a history of ischemic dilated cardiomyopathy, dyslipemia, hypertension, and myocardial infarction. He is on loop diuretics and ACE inhibitor medications, indicating that he has a history of heart failure and is being managed for it. His LVEF (Left Ventricular Ejection Fraction) is 35%, which is below the normal range (50-70%), indicating that he has heart failure with reduced ejection fraction (HFrEF).

His blood pressure is elevated at 160/90 mmHg, which is consistent with his history of hypertension. His lipid profile shows high total cholesterol and LDL levels, which is consistent with his history of dyslipemia. His creatinine level is elevated at 95.0 mmol/L, indicating some degree of kidney dysfunction, which is common in patients with heart failure.

The patient's Pro-BNP (brain natriuretic peptide) level is elevated at 209.0 ng/L, which is a marker of heart failure. His LVEF and Pro-BNP levels suggest that he has severe heart failure.

However, despite these severe cardiac conditions, the patient has survived, which suggests that his current treatment plan is effective in managing his symptoms and slowing disease progression. His NYHA Class II classification indicates that he has mild to moderate symptoms of heart failure, which is consistent with his ability to survive.

The combination of loop diuretics and ACE inhibitors, which are commonly used in the management of heart failure, may be contributing to his survival. Loop diuretics help reduce fluid overload and alleviate symptoms, while ACE inhibitors help reduce blood pressure and slow disease progression.

The patient's age, weight, and height are not particularly concerning, and his electrolyte levels, including potassium, are within normal limits. His liver enzymes, including ALT and AST, are also within normal limits, indicating that there is no significant liver dysfunction.

In conclusion, the patient's survival can be attributed to the effectiveness of his current treatment plan, which includes loop diuretics and ACE inhibitors, and his relatively mild symptoms of heart failure as indicated by his NYHA Class II classification."
423,423,P0675,"Age: 55
Gender: Male 
Weight: 74 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 140/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,34
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 5,39
Hemoglobin (g/L): 121.0
HDL (mmol/L): 2,4
Potassium (mEq/L): 4,96
LDL (mmol/L): 2,75
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 447.0
Protein (g/L): 69
T3 (pg/dL): 0,03
T4 (ng/L): 12,72
Troponin (ng/mL): 0,3
TSH (mIU/L): 0,38
Urea (mg/dL): 4,2
LVEF (%): 50.0
Medications: Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 55-year-old male with a history of ischemic dilated cardiomyopathy, dyslipemia, hypertension, and myocardial infarction, has survived despite having a compromised left ventricular ejection fraction (LVEF) of 50%. The patient's current medications, including beta blockers, statins, ACE inhibitor, and nitrovasodilator, are consistent with standard therapy for heart failure and coronary artery disease.

Several factors contribute to the patient's survival:

1.  Optimal Medication Management: The patient is on a regimen of beta blockers, statins, ACE inhibitors, and nitrovasodilators, which are all evidence-based treatments for heart failure and coronary artery disease. These medications help reduce symptoms, improve survival, and prevent further cardiac damage.

2.  Controlled Blood Pressure: The patient's blood pressure is within a relatively normal range (140/75 mmHg), which is beneficial for heart health, as high blood pressure is a significant risk factor for cardiovascular disease.

3.  Low Troponin Levels: The patient's troponin level is slightly elevated (0.3 ng/mL), indicating some degree of myocardial damage, but not to the extent that would suggest acute coronary syndrome or severe cardiac ischemia.

4.  Reasonable LVEF: Although the patient's LVEF is reduced at 50%, it is not severely compromised. An LVEF of 50% is still within the range that can be managed with medical therapy and lifestyle modifications.

5.  No Indication of Acute Cardiac Decompensation: The patient's symptoms and laboratory results do not indicate acute cardiac decompensation, such as pulmonary edema, severe dyspnea, or significant changes in renal function.

6.  Low Pro-BNP Levels: The patient's pro-BNP level is 447 ng/L, which is within the range that can be seen in patients with heart failure, but not excessively elevated, suggesting that the patient's heart failure is not severely decompensated.

Given these factors, the patient's survival is likely due to a combination of optimal medical management, controlled blood pressure, and the absence of acute cardiac decompensation."
424,424,P0676,"Age: 67
Gender: Male 
Weight: 79 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 165/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40,9
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,35
Creatinine (mmol/L): 158.0
Gamma-glutamil transpeptidase (IU/L): 50
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,95
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 2034.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,62
Urea (mg/dL): 8,02
LVEF (%): 39.0
Medications: Calcium Channel Blocker, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient is a 67-year-old male with a complex medical history, including ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, hypertension, and a previous myocardial infarction. His current symptoms and clinical presentation are consistent with heart failure, as evidenced by his New York Heart Association (NYHA) Class III classification, elevated natriuretic peptides (Pro-BNP 2034.0 ng/L), and reduced left ventricular ejection fraction (LVEF 39.0%).

Despite his advanced heart failure, the patient's survival is likely due to his current treatment regimen, which includes a calcium channel blocker, loop diuretics, statins, and an ACE inhibitor. These medications are commonly used to manage symptoms and slow disease progression in patients with heart failure.

The patient's blood pressure is well-controlled, with a systolic pressure of 165 mmHg and a diastolic pressure of 85 mmHg, which is not excessively high. His lipid profile is also well-managed, with a total cholesterol level of 5.35 mmol/L and an LDL level of 2.95 mmol/L.

The patient's liver function tests are within normal limits, with an albumin level of 40.9 g/L, AST of 17.0 IU/L, and ALT of 20.0 IU/L. His kidney function is also relatively preserved, with a creatinine level of 158.0 mmol/L.

The patient's ECG shows polymorphic ventricular extrasystoles, which are common in patients with heart failure and may be related to his underlying cardiac disease. However, there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias.

The patient's thyroid function tests are within normal limits, with a TSH level of 1.62 mIU/L and normal T3 and T4 levels. His hemoglobin level is slightly elevated, which may be due to his anemia of chronic disease.

In summary, the patient's survival is likely due to his comprehensive medical treatment regimen and relatively preserved organ function, despite his advanced heart failure."
425,425,P0677,"Age: 60
Gender: Male 
Weight: 78 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,09
LDL (mmol/L): 2,92
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 67.0
Protein (g/L): 68,5
T3 (pg/dL): 0,063
T4 (ng/L): 16,14
Troponin (ng/mL): 0,1
TSH (mIU/L): 1
Urea (mg/dL): 5,2
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 60-year-old male with a history of ischemic dilated cardiomyopathy and myocardial infarction, has a relatively favorable outcome. The patient's left ventricular ejection fraction (LVEF) is 40%, which indicates a reduced cardiac function but is still within the range of moderate heart failure. The patient's NYHA Class II classification indicates that he experiences some symptoms with ordinary physical activity, but is still able to perform daily activities without significant limitation.

The patient's current medications, including beta blockers, loop diuretics, statins, ACE inhibitors, and nitrovasodilators, are appropriate for managing heart failure and reducing the risk of cardiac complications. The presence of polymorphic ventricular extrasystoles on the ECG is a common finding in patients with heart failure, but it does not necessarily indicate a poor prognosis.

The patient's laboratory results show a slightly elevated creatinine level (95.0 μmol/L), which may indicate some degree of renal impairment, but this is not severe. The albumin level is slightly low (43 g/L), which can be seen in patients with heart failure. The lipid profile shows a high total cholesterol level (4.68 mmol/L) and a low HDL level (1.09 mmol/L), which is a risk factor for cardiovascular disease.

The patient's TSH level is within the normal range, which suggests that there is no significant thyroid dysfunction. The pro-BNP level is slightly elevated (67.0 ng/L), which can indicate heart failure, but it is not extremely high.

Considering these factors, the patient's outcome as a survivor is likely due to the following reasons:

1. Effective management of heart failure symptoms with medications.
2. Presence of a relatively well-preserved LVEF.
3. No significant arrhythmias or other cardiac complications.
4. No severe renal impairment.
5. Appropriate lipid management with statins.

However, it is essential to continue monitoring the patient's condition closely, as heart failure can progress over time, and the patient may require adjustments to their medication regimen or other interventions to maintain optimal cardiac function and prevent further complications."
426,426,P0678,"Age: 55
Gender: Male 
Weight: 97 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 127.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 134.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 5,09
LDL (mmol/L): 2,25
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 416.0
Protein (g/L): 69,6
T3 (pg/dL): 0,0435
T4 (ng/L): 13,4
Troponin (ng/mL): 0,1
TSH (mIU/L): 0,63
Urea (mg/dL): 8,2
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

Given the patient's medical history and current condition, the most likely reason for the patient's outcome of being a survivor is the combination of their current treatment regimen and the effectiveness of their current medication management. 

The patient has a history of ischemic dilated cardiomyopathy, myocardial infarction, hypertension, and peripheral vascular disease, all of which are risk factors for heart failure and cardiac complications. However, the patient is currently on a comprehensive treatment regimen that includes beta blockers, loop diuretics, statins, ACE inhibitors, and nitrovasodilators. These medications are commonly used to manage heart failure, hypertension, and dyslipidemia, and are likely contributing to the patient's survival.

The patient's LVEF (Left Ventricular Ejection Fraction) is 40%, which is below the normal range of 50-70%, indicating some degree of heart failure. However, the patient's Pro-BNP (brain natriuretic peptide) level is 416.0 ng/L, which is elevated but not extremely high, suggesting that the patient's heart failure is not severe.

The patient's ECG shows evidence of ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia, which are all potential complications of heart disease. However, the patient's heart rate is not excessively high, and the patient is not experiencing symptoms of acute coronary syndrome or cardiac arrest.

Overall, the patient's current treatment regimen and the absence of severe cardiac complications suggest that the patient is likely to survive, despite their history of cardiac disease."
427,427,P0681,"Age: 79
Gender: Female 
Weight: 55 kg
Height: 142 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 7,21
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 13,4
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,14
LDL (mmol/L): 5,22
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3501.0
Protein (g/L): 66,8
T3 (pg/dL): 0,0522
T4 (ng/L): 14,85
TSH (mIU/L): 2,37
Urea (mg/dL): 7,8
LVEF (%): 25.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 79-year-old female with a history of idiopathic dilated cardiomyopathy and hypertension, presenting with a low left ventricular ejection fraction (LVEF) of 25%. Despite these severe cardiac conditions, the patient's overall outcome is a survivor. Several factors contributed to this outcome:

1.  Optimal medical management: The patient is on a multidrug regimen, including beta blockers, loop diuretics, and an ACE inhibitor, which are standard treatments for heart failure and hypertension. These medications likely helped to manage the patient's symptoms, slow the progression of heart failure, and reduce the risk of adverse cardiac events.

2.  Lack of severe electrolyte imbalances: The patient's potassium level is within the normal range (4.14 mEq/L), which is crucial for maintaining proper cardiac function. Additionally, the sodium level is also within the normal range, indicating that the patient is not experiencing severe dehydration or electrolyte imbalances that could exacerbate cardiac conditions.

3.  Normal liver function: The patient's liver enzymes (AST and ALT) are within the normal range, indicating that the liver is functioning properly and not contributing to the patient's cardiac condition.

4.  Low T4 and TSH levels: The patient's thyroid hormone levels are within the normal range, which is essential for maintaining cardiac function. Hypothyroidism can exacerbate heart failure, so it's essential to monitor and manage thyroid hormone levels in patients with heart failure.

5.  Low BNP levels: The patient's B-type natriuretic peptide (BNP) level is elevated at 3501.0 ng/L, indicating that the patient has heart failure. However, the fact that the patient is a survivor suggests that the BNP level is not extremely high, indicating that the patient's heart failure is not severely decompensated.

6.  Normal hemoglobin levels: The patient's hemoglobin level is within the normal range, indicating that the patient is not experiencing anemia, which can worsen cardiac conditions.

7.  No severe kidney dysfunction: The patient's creatinine level is slightly elevated at 93.0 umol/L, but it is not severely elevated, indicating that the patient's kidney function is not severely impaired. Kidney dysfunction can contribute to the progression of heart failure.

In summary, the patient's optimal medical management, lack of severe electrolyte imbalances, normal liver function, low T4 and TSH levels, low BNP levels, normal hemoglobin levels, and no severe kidney dysfunction all contributed to the patient's favorable outcome."
428,428,P0682,"Age: 59
Gender: Male 
Weight: 83 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 145/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 44,4
ALT or GPT (IU/L): 40.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,43
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 176.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 3,9
LDL (mmol/L): 3,7
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1780.0
Protein (g/L): 70
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,08
Urea (mg/dL): 9,13
LVEF (%): 62.0
Medications: Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient outcome of survival can be attributed to several factors based on the provided data. 

1.  Optimal Medication Regimen: The patient is on a comprehensive medication regimen consisting of beta blockers, statins, and nitrovasodilators. Beta blockers are effective in reducing the heart rate and blood pressure, which can decrease the workload on the heart. Statins help lower LDL cholesterol, reducing the risk of further cardiac damage. Nitrovasodilators can help manage symptoms of heart failure and reduce the risk of hospitalization.

2.  Reasonable LVEF: The patient's left ventricular ejection fraction (LVEF) is 62%, which is within the normal range (50-70%). This suggests that the patient's heart is still pumping blood effectively, which is a positive indicator of the patient's cardiac function.

3.  Low Troponin Levels: The troponin level is 0.01 ng/mL, which is within the normal range. Elevated troponin levels can indicate cardiac damage or acute coronary syndrome. The low troponin level suggests that the patient has not experienced a recent myocardial infarction.

4.  Normal TSH and T3/T4 Levels: The patient's thyroid function is within the normal range, which is essential for overall cardiac health. Abnormal thyroid function can lead to cardiac complications.

5.  No Indications of Acute Cardiac Damage: The absence of non-sustained ventricular tachycardia, paroxysmal supraventricular tachyarrhythmia, and bradycardia on the ECG suggests that the patient does not have acute cardiac damage or arrhythmias that could have led to a poor outcome.

6.  Reasonable Blood Pressure: The patient's blood pressure is 145/80 mmHg, which is within the acceptable range for someone with hypertension. Well-controlled blood pressure reduces the strain on the heart.

7.  Pro-BNP Levels: The Pro-BNP level is 1780.0 ng/L, which is slightly elevated. Elevated Pro-BNP levels can indicate heart failure or cardiac dysfunction. However, the patient's other parameters suggest that the Pro-BNP elevation is not severe.

Considering these factors, the patient's survival can be attributed to a combination of optimal medication management, reasonable cardiac function, and the absence of acute cardiac damage or complications."
429,429,P0683,"Age: 62
Gender: Female 
Weight: 72 kg
Height: 144 cm
NYHA Class: II
Blood Pressure: 130/75 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 46,2
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 7,09
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 8,2
Hemoglobin (g/L): 126.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 3,8
LDL (mmol/L): 4,42
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 2712.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,39
Urea (mg/dL): 8,69
LVEF (%): 70.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient's outcome of survival can be attributed to several factors based on the provided information. 

1. Optimal Medication Management: The patient is on a comprehensive medication regimen, including a diabetes medication, an angiotensin II receptor blocker, beta blockers, statins, and a nitrovasodilator. These medications are commonly used to manage conditions such as hypertension, heart failure, and diabetes, and are likely contributing to the patient's stable condition.

2. Preserved Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 70%, which is within the normal range (>50%). This indicates that the heart is pumping blood efficiently, and the patient's cardiac function is relatively preserved.

3. Mild ECG Abnormalities: Although the patient has some ECG abnormalities, including ventricular extrasystoles and paroxysmal supraventricular tachyarrhythmia, they are not severe or life-threatening. These conditions are often well-managed with medication and lifestyle modifications.

4. Normal Blood Pressure: The patient's blood pressure is within a relatively normal range (130/75 mmHg), which suggests that their hypertension is being effectively managed.

5. No Indication of Acute Coronary Syndrome: The patient's troponin level is within normal limits (0.01 ng/mL), which suggests that there is no indication of acute coronary syndrome or myocardial infarction.

6. Mild Kidney Function Impairment: The patient's creatinine level is elevated (88.0 μmol/L), indicating mild kidney function impairment. However, this is not severe enough to significantly impact the patient's overall outcome.

7. Low Risk Profile: The patient's low T3 and T4 levels, as well as normal TSH, suggest that their thyroid function is within normal limits. This is a positive prognostic indicator.

In summary, the patient's comprehensive treatment plan, preserved cardiac function, and mild ECG abnormalities, combined with their relatively normal blood pressure and lack of acute coronary syndrome, all contribute to their positive outcome."
430,430,P0684,"Age: 71
Gender: Male 
Weight: 76 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 150/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 46
ALT or GPT (IU/L): 57.0
AST or GOT (IU/L): 37.0
Total Cholesterol (mmol/L): 7,84
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 164.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,63
LDL (mmol/L): 5,64
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 78.0
Protein (g/L): 76
T3 (pg/dL): 0,0423
T4 (ng/L): 16,17
TSH (mIU/L): 0,39
Urea (mg/dL): 9,9
LVEF (%): 70.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient survived, which can be attributed to a combination of factors:

1.  Optimal Medication Management: The patient is on a comprehensive regimen of medications, including diabetes medication, an Angiotensin II Receptor Blocker, Loop Diuretics, Statins, and an ACE Inhibitor. These medications effectively manage the patient's hypertension, diabetes, and dyslipidemia, which are all risk factors for cardiovascular disease.

2.  LVEF of 70%: The patient's left ventricular ejection fraction (LVEF) is within the normal range (50-70%), indicating that the heart is pumping blood efficiently. This suggests that the patient's heart is functioning well, despite the presence of hypertensive cardiomyopathy.

3.  No Sustained Ventricular Tachycardia: The ECG findings show no sustained ventricular tachycardia, which is a significant risk factor for cardiac arrest and mortality.

4.  Normal TSH and T4 Levels: The patient's thyroid function is within the normal range, which is essential for maintaining cardiac health.

5.  Pro-BNP of 78.0 ng/L: The patient's B-type natriuretic peptide (BNP) level is within the normal range, which is a marker of heart failure and cardiac stress. A low BNP level suggests that the patient's heart is not under significant stress.

6.  Albumin and Protein Levels: The patient's albumin and protein levels are within the normal range, which indicates that the liver is functioning properly and not contributing to the patient's cardiac condition.

7.  No Indication of Malnutrition: The patient's weight, hemoglobin, and protein levels suggest that they are not malnourished, which is a risk factor for poor cardiac outcomes.

Overall, the combination of optimal medication management, a normal LVEF, absence of sustained ventricular tachycardia, normal thyroid function, low BNP levels, and absence of malnutrition contributed to the patient's survival."
431,431,P0685,"Age: 45
Gender: Male 
Weight: 119 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 42,2
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,72
Creatinine (mmol/L): 83.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 157.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,47
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 403.0
Protein (g/L): 65,9
T4 (ng/L): 22
TSH (mIU/L): 2,25
Urea (mg/dL): 4,66
LVEF (%): 37.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient's outcome is a survivor, which can be attributed to a combination of factors. 

Firstly, the patient's New York Heart Association (NYHA) Class II classification indicates that the patient has mild to moderate symptoms of heart failure, but is still able to perform most physical activities without significant limitation. This suggests that the patient's heart failure is not severe, and the current treatment regimen is effective in managing symptoms.

The patient's ejection fraction (LVEF) of 37% is below the normal range, indicating systolic dysfunction. However, the patient is on beta blockers, which are known to improve LVEF in patients with heart failure. The use of beta blockers, along with other medications such as ACE inhibitors, spironolactone, and loop diuretics, suggests a comprehensive approach to managing the patient's heart failure.

The patient's creatinine level of 83.0 μmol/L is elevated, indicating impaired renal function. However, the urea level is within a relatively normal range, suggesting that the renal impairment is not severe. The patient's potassium level is within a normal range, which is a good sign, as hyperkalemia is a common complication of heart failure.

The patient's pro-BNP level of 403.0 ng/L is elevated, indicating increased ventricular stretch and/or wall tension, which is consistent with heart failure. However, the patient's symptoms and NYHA classification suggest that the heart failure is not severe.

The patient's TSH level is within a normal range, indicating that the patient does not have hyperthyroidism or hypothyroidism, which can exacerbate heart failure.

The patient's hemoglobin level is within a normal range, indicating that the patient does not have significant anemia, which can contribute to heart failure.

In conclusion, the patient's outcome as a survivor can be attributed to the comprehensive treatment regimen, which includes beta blockers, ACE inhibitors, spironolactone, and loop diuretics, and the patient's relatively mild symptoms of heart failure, as indicated by the NYHA Class II classification. The patient's renal function is impaired, but not severely so, and the patient's potassium level is within a normal range. The patient's pro-BNP level is elevated, but not excessively high, indicating that the heart failure is not severe."
432,432,P0686,"Age: 77
Gender: Male 
Weight: 99 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 170/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,22
Creatinine (mmol/L): 136.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 160.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,17
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 686.0
Protein (g/L): 74,9
T3 (pg/dL): 0,0543
T4 (ng/L): 14,54
Troponin (ng/mL): 0,1
TSH (mIU/L): 0,42
Urea (mg/dL): 9,6
LVEF (%): 40.0
Medications: Calcium Channel Blocker, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 77-year-old male with a history of ischemic dilated cardiomyopathy, has a complex medical profile with multiple comorbidities, including hypertension, dyslipemia, peripheral vascular disease, and a previous myocardial infarction. His current medications, including a calcium channel blocker, loop diuretics, statins, and an ACE inhibitor, are aimed at managing these conditions.

The patient's echocardiogram (LVEF of 40%) indicates reduced left ventricular function, which is consistent with his ischemic dilated cardiomyopathy. However, his ejection fraction is not critically low, and he has not had a recent myocardial infarction, which may have contributed to his survival.

The elevated Pro-BNP level (686.0 ng/L) suggests that the patient has some degree of heart failure, but the level is not extremely high, which may indicate that the patient's heart failure is not severe at this point.

The patient's blood pressure is within a relatively controlled range (170/80 mmHg), and his kidney function, as indicated by creatinine levels, is not severely impaired (136.0 μmol/L). His glucose level is within a relatively normal range (4.4 mmol/L), and his lipid profile is being managed with statins.

The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG indicates some degree of arrhythmia, but the patient does not have a history of sustained ventricular tachycardia or other life-threatening arrhythmias.

Given the patient's complex medical profile, it is likely that his survival is due to the following factors:

1.  His relatively well-controlled blood pressure and kidney function, which may have limited the progression of his heart failure and other comorbidities.
2.  The effectiveness of his current medications, which are aimed at managing his hypertension, dyslipemia, and heart failure.
3.  The fact that his ejection fraction is not critically low, which may indicate that his heart is still able to pump blood efficiently enough to meet his body's needs.
4.  The absence of recent acute coronary events or severe arrhythmias, which may have contributed to his survival.

Overall, the patient's survival is likely due to a combination of his relatively well-managed medical conditions, the effectiveness of his medications, and the fact that his heart function is not severely impaired."
433,433,P0687,"Age: 75
Gender: Male 
Weight: 71 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Peripheral vascular disease, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 4,32
Creatinine (mmol/L): 135.0
Gamma-glutamil transpeptidase (IU/L): 82
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 118.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 3,96
LDL (mmol/L): 2,77
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 5751.0
Protein (g/L): 61,3
T3 (pg/dL): 0,0348
T4 (ng/L): 16,95
TSH (mIU/L): 1,31
Urea (mg/dL): 8,1
LVEF (%): 25.0
Medications: Amiodarone, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

This patient, a 75-year-old male with a history of idiopathic dilated cardiomyopathy, peripheral vascular disease, and hypertension, presented with a complex cardiac profile. The patient's left ventricular ejection fraction (LVEF) of 25% indicates severe systolic dysfunction, which is a significant risk factor for mortality.

The patient's elevated Pro-BNP level (5751.0 ng/L) further supports the presence of heart failure, as BNP is a well-established biomarker for cardiac strain. The patient's medication regimen, including Amiodarone, Loop Diuretics, and an ACE Inhibitor, suggests that the patient is being treated for heart failure and arrhythmias.

The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG indicates that the patient is at risk for malignant arrhythmias, which can be life-threatening. However, the fact that the patient is on Amiodarone, a medication that is effective in preventing arrhythmias, may have contributed to the patient's survival.

The patient's laboratory results show mild elevation in liver enzymes (ALT and AST), which may be related to the use of Amiodarone or other medications. The patient's lipid profile shows elevated total cholesterol and LDL, which is a risk factor for cardiovascular disease.

The patient's kidney function, as indicated by the creatinine level, is impaired, which is a common finding in patients with heart failure. The patient's anemia, as indicated by the low hemoglobin level, may be related to the heart failure or other underlying conditions.

The patient's thyroid function tests (T3, T4, and TSH) are within normal limits, which suggests that thyroid dysfunction is unlikely to be contributing to the patient's cardiac condition.

Overall, the patient's complex cardiac profile and multiple comorbidities make him a high-risk patient. However, the fact that the patient is on appropriate medications and has a relatively controlled blood pressure may have contributed to his survival."
434,434,P0691,"Age: 81
Gender: Male 
Weight: 79 kg
Height: 174 cm
NYHA Class: III
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,85
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,07
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 140.0
Protein (g/L): 76
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,26
Urea (mg/dL): 9,65
LVEF (%): 50.0
Medications: Calcium Channel Blocker, Angiotensin II Receptor Blocker, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient's outcome as a survivor can be attributed to a combination of factors. Firstly, the patient's left ventricular ejection fraction (LVEF) of 50% indicates that the heart is still functioning at a moderate level, which is a positive prognostic indicator. The patient's blood pressure is well-controlled at 130/70 mmHg, and they are on a regimen of medications that include a calcium channel blocker, angiotensin II receptor blocker, loop diuretics, statins, and ACE inhibitor, which are all standard treatments for heart failure and hypertension. 

The patient's laboratory results also suggest that their liver function is within normal limits (ALT and AST levels are within normal range), and their kidney function is mildly impaired but not severely compromised (creatinine level is 97.0 mmol/L). The patient's glucose level is slightly elevated at 5.8 mmol/L, but this is not significantly high enough to be a major concern.

The patient's ECG results show a monomorphic ventricular extrasystole, which is a common finding in patients with heart disease, but it is not a life-threatening condition. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia suggests that the patient's heart rhythm is relatively stable.

Furthermore, the patient's TSH level is within the normal range, indicating that their thyroid function is normal. The patient's troponin level is very low, which suggests that there is no acute myocardial infarction or significant cardiac damage.

Overall, while the patient has multiple comorbidities, including idiopathic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension, their current medication regimen and relatively stable vital signs and laboratory results suggest that they are being effectively managed and are at a lower risk of adverse outcomes."
435,435,P0692,"Age: 70
Gender: Female 
Weight: 67 kg
Height: 156 cm
NYHA Class: III
Blood Pressure: 100/66 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 6,13
Creatinine (mmol/L): 248.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 8,4
Hemoglobin (g/L): 126.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 5,4
LDL (mmol/L): 3,62
Sodium (mEq/L): 132.0
Pro-BNP (ng/L): 1048.0
Protein (g/L): 78
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,01
Urea (mg/dL): 32,61
LVEF (%): 25.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome is a survivor due to a combination of factors that indicate a relatively stable and managed condition despite her significant comorbidities. 

Firstly, the patient's LVEF (Left Ventricular Ejection Fraction) of 25% indicates a severely reduced cardiac function, which is often associated with a poor prognosis. However, the fact that she is still alive and on optimal medical therapy, including beta blockers, ACE inhibitors, spironolactone, and statins, suggests that her condition is being managed effectively. The low troponin level of 0.01 ng/mL also indicates that she is not experiencing any acute myocardial infarction, which is a positive sign.

The patient's blood pressure of 100/66 mmHg is within a relatively normal range, and her albumin level of 43 g/L is not indicative of significant liver dysfunction, which could have worsened her cardiac condition. Her hemoglobin level of 126 g/L is also within a normal range, indicating that she is not experiencing significant anemia, which could further compromise her cardiac function.

The patient's pro-BNP level of 1048 ng/L is elevated, which is consistent with her heart failure diagnosis. However, the fact that it is not extremely high suggests that her condition is not rapidly deteriorating. Her TSH level of 5.01 mIU/L is within a normal range, indicating that her thyroid function is not contributing to her cardiac condition.

The patient's medications, including loop diuretics and spironolactone, suggest that she is being adequately managed for her heart failure symptoms. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on her ECG also indicates that her cardiac rhythm is stable.

Overall, while the patient's LVEF is severely reduced, her stable condition, optimal medical therapy, and lack of acute cardiac events suggest that she is a survivor."
436,436,P0693,"Age: 48
Gender: Female 
Weight: 69 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 90/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 6
Creatinine (mmol/L): 72.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,01
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 220.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 11
Troponin (ng/mL): 0,04
TSH (mIU/L): 1,55
Urea (mg/dL): 5,99
LVEF (%): 40.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 48-year-old female with a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge, reducing the heart's ability to pump blood effectively. Despite this, the patient is a survivor, which indicates a favorable outcome.

Several factors contribute to this outcome:

1.  Optimal Medication Management: The patient is on a comprehensive regimen of beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, which are all standard treatments for heart failure and dilated cardiomyopathy. These medications help manage symptoms, improve heart function, and reduce the risk of complications.

2.  Low Blood Pressure: The patient's blood pressure is within a relatively normal range (90/70 mmHg), which is beneficial for heart health. High blood pressure can exacerbate heart failure and dilated cardiomyopathy.

3.  Normal Glucose Levels: The patient's glucose level is within the normal range (5.8 mmol/L), which is essential for preventing the development of diabetes, a significant risk factor for heart disease.

4.  Elevated Hemoglobin: The patient's hemoglobin level is elevated (125 g/L), which may indicate a mild anemia, but it is not severe enough to significantly impact the patient's overall health.

5.  Low Potassium Level: The patient's potassium level is slightly low (4.4 mEq/L), which can be managed with medication and dietary adjustments. Low potassium levels can contribute to arrhythmias and other cardiac complications.

6.  Moderate Creatinine Level: The patient's creatinine level is within a relatively normal range (72.0 μmol/L), indicating that kidney function is not significantly impaired.

7.  Normal Liver Enzymes: The patient's liver enzymes (ALT and AST) are within normal ranges, indicating that liver function is not significantly compromised.

8.  Low Cholesterol: The patient's total cholesterol level is low (6 mmol/L), which can help reduce the risk of cardiovascular disease.

9.  Elevated Pro-BNP: The patient's pro-BNP level is elevated (220 ng/L), which is a marker of heart failure. However, the patient is a survivor, suggesting that the heart failure is being managed effectively.

10.  Low TSH: The patient's TSH level is within a normal range (1.55 mIU/L), indicating that thyroid function is not significantly impaired.

11.  Normal ECG: The ECG does not show any significant abnormalities, such as ventricular tachycardia or bradycardia, which are indicators of cardiac complications.

In conclusion, the patient's favorable outcome can be attributed to optimal medication management, normal blood pressure, normal glucose levels, and a comprehensive approach to managing the patient's dilated cardiomyopathy."
437,437,P0694,"Age: 69
Gender: Male 
Weight: 82 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 140/65 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 48
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 7,7
Hemoglobin (g/L): 164.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,17
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 91.0
Protein (g/L): 81,8
T3 (pg/dL): 0,06
T4 (ng/L): 14,01
Troponin (ng/mL): 0,6
TSH (mIU/L): 1,32
Urea (mg/dL): 6,3
LVEF (%): 65.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 69-year-old male with a history of Hypertensive cardiomyopathy, diabetes, dyslipemia, and hypertension, has a favorable outcome. Several factors contribute to this outcome:

1.  Controlled Blood Pressure: The patient's blood pressure is 140/65 mmHg, which is well-managed considering his history of hypertension. This suggests that his current treatment regimen, including the Calcium Channel Blocker, Angiotensin II Receptor Blocker, Beta Blockers, and Loop Diuretics, is effective in controlling his blood pressure.

2.  Optimal Medications: The patient is on a comprehensive medication regimen that addresses his multiple comorbidities, including diabetes (Diabetes Medication), dyslipemia (Statins), and hypertension (Calcium Channel Blocker, Angiotensin II Receptor Blocker, Beta Blockers, and Loop Diuretics). This suggests that his healthcare provider is actively managing his conditions.

3.  LVEF of 65%: The patient's left ventricular ejection fraction (LVEF) is 65%, which is within the normal range (50-70%). This indicates that his heart is functioning relatively well, despite his history of hypertensive cardiomyopathy.

4.  Reasonable Laboratory Values: Most of the patient's laboratory values are within normal ranges, such as albumin (48 g/L), ALT (26 IU/L), AST (28 IU/L), total cholesterol (3.96 mmol/L), creatinine (1.03 mmol/L), glucose (7.7 mmol/L), HDL (0.88 mmol/L), LDL (2.17 mmol/L), potassium (4.2 mEq/L), sodium (141.0 mEq/L), urea (6.3 mg/dL), and TSH (1.32 mIU/L). However, the patient's troponin level is slightly elevated at 0.6 ng/mL, which may indicate some degree of cardiac stress or injury.

5.  ECG Findings: The patient's ECG shows polymorphic ventricular extrasystoles, which are common in individuals with hypertension and cardiomyopathy. However, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia suggests that the patient's heart rhythm is relatively stable.

6.  Low T3 and T4 Levels: The patient's T3 and T4 levels are within normal ranges, which suggests that his thyroid function is well-managed.

Considering these factors, the patient's favorable outcome can be attributed to the effective management of his comorbidities, optimal medication regimen, and relatively well-preserved cardiac function."
438,438,P0695,"Age: 63
Gender: Male 
Weight: 80 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 135/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,27
Creatinine (mmol/L): 153.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 154.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,4
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 403.0
Protein (g/L): 85
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,27
Urea (mg/dL): 6,66
LVEF (%): 60.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 63-year-old male with a history of ischemic dilated cardiomyopathy and myocardial infarction, has shown a favorable outcome of survival. This can be attributed to several factors:

1. Optimal Medication Management: The patient is on a combination of medications that are commonly used to manage heart failure and coronary artery disease, including a calcium channel blocker, beta blockers, loop diuretics, and statins. These medications have been shown to improve symptoms, slow disease progression, and reduce the risk of adverse outcomes in patients with heart failure.

2. Stable LVEF: The patient's left ventricular ejection fraction (LVEF) is 60%, which is within the normal range. This indicates that the patient's heart is pumping blood effectively, and the cardiomyopathy has not significantly progressed.

3. Normal Blood Pressure: The patient's blood pressure is within the normal range, which is a positive factor for reducing the risk of cardiovascular events.

4. Normal TSH and T4 Levels: The patient's thyroid function is within the normal range, which is essential for maintaining cardiac function and overall health.

5. Low Troponin Levels: The patient's troponin levels are within the normal range, indicating that there is no ongoing myocardial infarction or cardiac damage.

6. Absence of Ventricular Tachycardia: The absence of ventricular tachycardia on the ECG suggests that the patient's heart rhythm is stable, and there is no evidence of life-threatening arrhythmias.

7. Low Pro-BNP Levels: The patient's brain natriuretic peptide (BNP) levels are elevated, but not excessively high, which suggests that the patient's heart is functioning relatively well, and there is no significant fluid overload or cardiac decompensation.

8. No Severe Liver Function Abnormalities: The patient's liver function tests (ALT, AST, and gamma-glutamil transpeptidase) are within the normal range, which is essential for maintaining cardiac health and reducing the risk of liver-related complications.

In summary, the patient's favorable outcome of survival can be attributed to a combination of optimal medication management, stable LVEF, normal blood pressure, normal thyroid function, low troponin levels, absence of ventricular tachycardia, and low Pro-BNP levels."
439,439,P0697,"Age: 49
Gender: Male 
Weight: 109 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 170/110 mmHg
Past Medical History: Other HF etiology, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,61
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,93
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 709.0
Protein (g/L): 71
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,88
Urea (mg/dL): 6,66
LVEF (%): 40.0
Medications: Calcium Channel Blocker, Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient is a 49-year-old male with a history of heart failure (HF), hypertension, dyslipidemia, and other contributing factors to HF. His current blood pressure is elevated at 170/110 mmHg, which is likely contributing to his HF. Despite this, he is being managed with a combination of medications, including a calcium channel blocker, beta blockers, spironolactone, statins, and an ACE inhibitor.

The patient's left ventricular ejection fraction (LVEF) is 40%, which is below the normal range (50-70%), indicating systolic dysfunction. However, his hemoglobin and protein levels are within normal limits, and his troponin levels are low, indicating minimal myocardial damage.

The patient's pro-BNP level is elevated at 709 ng/L, which is consistent with HF, but not excessively high. His TSH level is within the normal range, indicating no thyroid dysfunction.

The ECG shows polymorphic ventricular extrasystoles, which can be a normal finding, but in the context of HF, it may indicate underlying electrical instability. However, there is no evidence of sustained ventricular tachycardia, and the patient is not in a high-risk category for sudden cardiac death.

Given the patient's current medications and the absence of any acute myocardial infarction or severe arrhythmias, the most likely reason for his survival is the effective management of his HF and hypertension, combined with the use of evidence-based medications that have helped to stabilize his cardiac function."
440,440,P0698,"Age: 65
Gender: Female 
Weight: 69 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Peripheral vascular disease
Albumin (g/L): 37
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 3,8
Creatinine (mmol/L): 82.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,68
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 542.0
Protein (g/L): 62
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,58
Urea (mg/dL): 4,16
LVEF (%): 45.0
Medications: Calcium Channel Blocker, Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome as a survivor can be attributed to several factors. 

Firstly, the patient's blood pressure is within a relatively normal range (110/70 mmHg), which is beneficial for cardiovascular health. The use of medications such as Calcium Channel Blocker, Beta Blockers, and ACE Inhibitor suggests that the patient's heart condition is being managed effectively, which has likely contributed to the patient's survival. 

The patient's LVEF (Left Ventricular Ejection Fraction) of 45% indicates that the heart is functioning below the normal range (50-70%), but not severely enough to lead to immediate cardiac failure. The patient's Pro-BNP (B-type Natriuretic Peptide) level of 542.0 ng/L is elevated, which can indicate heart failure or stress on the heart, but the level is not extremely high, suggesting that the patient's heart is not under extreme stress.

Additionally, the patient's kidney function, as indicated by Creatinine (82.0 mmol/L) and Urea (4.16 mg/dL), is within a relatively normal range. This is a good sign, as kidney function is closely linked to heart health, and impaired kidney function can be a marker of heart failure.

The patient's TSH (Thyroid-Stimulating Hormone) level is within a normal range (1.58 mIU/L), which suggests that there is no underlying thyroid disorder that could be contributing to heart failure or other cardiovascular issues.

While the patient has a history of idiopathic dilated cardiomyopathy and peripheral vascular disease, the patient's overall clinical presentation and laboratory results suggest that the condition is being managed effectively, and the patient is not experiencing acute cardiac failure. The patient's outcome as a survivor is likely due to the effective management of their condition and the absence of severe cardiac dysfunction."
441,441,P0699,"Age: 41
Gender: Male 
Weight: 65 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,47
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 158.0
HDL (mmol/L): 1,37
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,69
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 19.0
Protein (g/L): 70
T3 (pg/dL): 0,06
T4 (ng/L): 13
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,2
Urea (mg/dL): 5,16
LVEF (%): 40.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 41-year-old male with a history of hypertrophic cardiomyopathy, has a relatively favorable outcome. The patient's left ventricular ejection fraction (LVEF) is 40%, which is below the normal range (50-70%), indicating some degree of heart failure. However, the patient is on beta blockers and an ACE inhibitor, which are appropriate medications for managing hypertrophic cardiomyopathy and reducing the risk of cardiac complications.

The patient's blood pressure is within a normal range (120/80 mmHg), and his hemoglobin level is within the normal range (158 g/L). The patient's liver function tests (ALT, AST, and GGT) are within normal limits, indicating that there is no significant liver damage.

The patient's lipid profile shows a total cholesterol level of 4.47 mmol/L, which is above the recommended level, but the LDL cholesterol level is 2.69 mmol/L, which is relatively well-controlled. The patient's HDL cholesterol level is 1.37 mmol/L, which is slightly low.

The patient's kidney function is within normal limits, with a creatinine level of 88.0 μmol/L. The patient's glucose level is slightly elevated at 5.7 mmol/L, but it is not significantly high.

The patient's thyroid function tests (T3, T4, and TSH) are within normal limits, indicating that there is no underlying thyroid dysfunction. The patient's troponin level is 0.02 ng/mL, which is within the normal range, indicating that there is no acute myocardial infarction.

The patient's ECG shows monomorphic ventricular extrasystoles, but no ventricular tachycardia or other significant arrhythmias.

Considering these factors, the patient's outcome is likely due to the effective management of his hypertrophic cardiomyopathy with beta blockers and an ACE inhibitor, as well as his relatively normal hemoglobin, liver function, and kidney function. The patient's slightly elevated glucose level and low HDL cholesterol level may require further monitoring and management."
442,442,P0700,"Age: 81
Gender: Male 
Weight: 77 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 160/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 5,1
Creatinine (mmol/L): 129.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 7,46
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,93
LDL (mmol/L): 3,15
Sodium (mEq/L): 146.0
Pro-BNP (ng/L): 1670.0
Protein (g/L): 65
T3 (pg/dL): 0,0483
T4 (ng/L): 12,7
TSH (mIU/L): 3,52
Urea (mg/dL): 11,3
LVEF (%): 25.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome as a survivor can be attributed to a combination of factors, including the presence of a relatively well-managed medical regimen and the patient's overall physiological condition.

Firstly, the patient's blood pressure is controlled, which is crucial in managing heart failure. The use of ACE inhibitors is beneficial in reducing blood pressure and improving cardiac function. The patient's NYHA Class II classification indicates that the patient has some limitations in physical activity but is still able to perform daily tasks without significant symptoms, suggesting that the patient's heart condition is being managed effectively.

The patient's LVEF (Left Ventricular Ejection Fraction) is 25%, which is significantly reduced, indicating a compromised cardiac function. However, the fact that the patient is still alive and has a relatively low creatinine level (129.0 μmol/L) suggests that the kidneys are functioning relatively well, and the patient is not in end-stage renal disease. This is a good prognostic sign.

The patient's electrolyte levels, including potassium (4.93 mEq/L), are within a relatively normal range, which is essential for cardiac function. The patient's TSH level is also within the normal range, indicating that the thyroid function is not contributing to the patient's cardiac condition.

The patient's medication regimen, including digoxin, loop diuretics, and ACE inhibitors, is typical for managing heart failure and is likely contributing to the patient's survival.

The presence of ventricular extrasystoles and non-sustained ventricular tachycardia is concerning, but the fact that the patient is still alive suggests that these arrhythmias are not significantly impacting the patient's cardiac function at this time.

In summary, the patient's outcome as a survivor can be attributed to a combination of effective medical management, relatively well-controlled blood pressure, and a lack of significant kidney dysfunction, which are all contributing factors to the patient's survival."
443,443,P0701,"Age: 76
Gender: Male 
Weight: 65 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 6,23
Creatinine (mmol/L): 108.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 163.0
HDL (mmol/L): 1,84
Potassium (mEq/L): 4,56
LDL (mmol/L): 3,75
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1343.0
Protein (g/L): 76,9
T3 (pg/dL): 0,0531
T4 (ng/L): 11,03
Troponin (ng/mL): 0,1
TSH (mIU/L): 1
Urea (mg/dL): 9,2
LVEF (%): 30.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 76-year-old male with a history of idiopathic dilated cardiomyopathy, dyslipemia, and hypertension, has been managed with a combination of medications including digoxin, loop diuretics, statins, and an ACE inhibitor. The patient's left ventricular ejection fraction (LVEF) of 30% indicates severe left ventricular dysfunction, which is consistent with his dilated cardiomyopathy.

The patient's elevated Pro-BNP level of 1343.0 ng/L suggests significant cardiac stress and potential heart failure symptoms. However, the patient's blood pressure of 130/70 mmHg and hemoglobin level of 163.0 g/L are within relatively normal ranges, indicating that the patient is not experiencing acute cardiac decompensation.

The presence of ventricular extrasystoles on the ECG, while abnormal, is not uncommon in patients with cardiomyopathy and is not typically a predictor of poor outcome. The absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia is also reassuring.

The patient's laboratory results, including normal liver function tests (ALT and AST), normal electrolyte levels, and normal thyroid function (TSH), suggest that the patient is not experiencing acute metabolic or electrolyte disturbances that could compromise cardiac function.

Given the patient's relatively stable clinical presentation and the absence of acute cardiac decompensation or other life-threatening complications, the patient's survival is likely due to the effective management of his cardiomyopathy and other comorbidities with his current medications, as well as his overall resilience as a 76-year-old male."
444,444,P0702,"Age: 54
Gender: Female 
Weight: 80 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 35.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 5,07
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,61
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 666.0
Protein (g/L): 67
T4 (ng/L): 8
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,1
Urea (mg/dL): 5,66
LVEF (%): 38.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 54-year-old female with ischemic dilated cardiomyopathy, has a history of myocardial infarction, dyslipemia, and is on a comprehensive medication regimen including beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor. Her current LVEF (Left Ventricular Ejection Fraction) is 38%, which is below the normal range (50-70%), indicating reduced cardiac function.

Despite her compromised cardiac function, the patient's blood pressure is well-controlled at 120/70 mmHg, which is within the normal range. Her electrolyte levels, including potassium and sodium, are also within normal limits. 

Her laboratory results show elevated creatinine levels (106.0 μmol/L), which may indicate some degree of renal impairment. However, her urea levels are relatively low (5.66 mg/dL), suggesting that her renal function is not severely compromised.

The patient's troponin levels are within normal limits (0.01 ng/mL), indicating that there is no acute myocardial injury. Her TSH levels are within the normal range (1.1 mIU/L), suggesting that her thyroid function is normal.

The patient's LVEF of 38% and her medication regimen suggest that she is being managed for heart failure with reduced ejection fraction (HFrEF). Her Pro-BNP levels are elevated (666.0 ng/L), which is consistent with heart failure.

The presence of ventricular extrasystoles on the ECG is a common finding in patients with heart failure and is not typically a cause for concern.

Overall, the patient's current condition and medication regimen suggest that she is being managed for HFrEF and is likely experiencing some degree of heart failure symptoms, given her NYHA Class III classification. However, her controlled blood pressure, normal electrolytes, and the absence of acute myocardial injury suggest that she is stable and able to survive with appropriate management."
445,445,P0704,"Age: 61
Gender: Male 
Weight: 65 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 133/68 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 37.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 227
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4
LDL (mmol/L): 2,35
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 474.0
Protein (g/L): 80
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,58
Urea (mg/dL): 4,99
LVEF (%): 30.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 61-year-old male with a history of ischemic dilated cardiomyopathy and myocardial infarction, which indicates that he has a compromised heart function. His left ventricular ejection fraction (LVEF) is severely reduced at 30%, indicating that his heart is not pumping efficiently.

Despite his history and compromised heart function, the patient is classified as NYHA Class II, which indicates that he has mild to moderate symptoms of heart failure, such as shortness of breath or fatigue with moderate exertion. However, he is still able to perform most of his daily activities.

The patient's laboratory results show elevated levels of troponin (0.01 ng/mL), which is a marker of cardiac damage. However, it is within the normal range, suggesting that the damage is minimal.

The patient is on beta blockers, statins, and an ACE inhibitor, which are all appropriate medications for a patient with heart failure and a history of myocardial infarction. Beta blockers help slow the heart rate and reduce the force of contraction, while statins help lower cholesterol levels and reduce the risk of future cardiovascular events. ACE inhibitors help reduce blood pressure and alleviate symptoms of heart failure.

The patient's ECG shows a monomorphic ventricular extrasystole, which is a type of abnormal heart rhythm, but it is not life-threatening. He also has a paroxysmal supraventricular tachyarrhythmia (PSVT), which is a type of abnormal heart rhythm that can cause palpitations or shortness of breath.

The patient's Pro-BNP level is elevated at 474.0 ng/L, which is a marker of heart failure. However, it is not extremely high, suggesting that the patient's heart failure is not severe.

Considering the patient's history, laboratory results, and ECG findings, the patient's outcome as a survivor is likely due to the following factors:

1. Appropriate medical management: The patient is on medications that are beneficial for heart failure and myocardial infarction.
2. Mild symptoms: The patient is classified as NYHA Class II, indicating that his symptoms are mild to moderate.
3. Minimal cardiac damage: The patient's troponin level is within the normal range, suggesting that the damage from his myocardial infarction is minimal.
4. No life-threatening arrhythmias: The patient's ECG shows a monomorphic ventricular extrasystole, but it is not life-threatening.

Overall, the patient's outcome as a survivor is likely due to a combination of his medical management, mild symptoms, minimal cardiac damage, and the absence of life-threatening arrhythmias."
446,446,P0705,"Age: 43
Gender: Male 
Weight: 95 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Other HF etiology
Albumin (g/L): 47
ALT or GPT (IU/L): 36.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,66
Creatinine (mmol/L): 86.0
Gamma-glutamil transpeptidase (IU/L): 28
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4
LDL (mmol/L): 4,34
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 12.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,005
TSH (mIU/L): 3,11
Urea (mg/dL): 6,32
LVEF (%): 43.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient outcome of survival can be attributed to a combination of several factors present in the patient's data. 

1. Medication adherence and management: The patient is on a regimen of Beta Blockers, Loop Diuretics, and ACE Inhibitor, which are standard treatments for heart failure (HF) and hypertension. These medications are likely contributing to the patient's improved cardiovascular health and reduced risk of adverse outcomes.

2. NYHA Class II: The patient's New York Heart Association (NYHA) class of II indicates that they have some limitations in their physical activity but are still able to perform most of their daily activities without symptoms. This suggests that their heart failure is not severe, which is a positive prognostic indicator.

3. LVEF of 43%: Although the left ventricular ejection fraction (LVEF) is lower than normal, it is not severely decreased, which may indicate that the patient's heart is still pumping some blood effectively.

4. Normal blood pressure: The patient's blood pressure of 110/70 mmHg is within the normal range, which is another positive indicator for cardiovascular health.

5. Low Pro-BNP levels: A Pro-BNP (N-terminal pro b-type natriuretic peptide) level of 12.0 ng/L is lower than the typical threshold for heart failure diagnosis, which is often considered to be around 400-500 ng/L. This suggests that the patient's heart is not under significant strain, which is a good prognostic sign.

6. Electrocardiogram (ECG) findings: The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia on the ECG suggests that the patient's heart rhythm is relatively stable.

7. Other lab values: The patient's albumin, ALT, AST, total cholesterol, HDL, LDL, potassium, sodium, glucose, hemoglobin, and urea levels are within relatively normal ranges, indicating that there are no significant electrolyte imbalances or organ dysfunction that could contribute to a poor outcome.

In summary, the combination of effective medication management, relatively stable heart function, normal blood pressure, low Pro-BNP levels, and stable ECG findings all contribute to the patient's outcome of survival."
447,447,P0706,"Age: 72
Gender: Male 
Weight: 69 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 5,66
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 166.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,67
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 5545.0
Protein (g/L): 67
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,13
TSH (mIU/L): 1,23
Urea (mg/dL): 7,15
LVEF (%): 25.0
Medications: Beta Blockers, Digoxin, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 72-year-old male with a history of hypertensive cardiomyopathy and hypertension, has a complex cardiac condition. Despite the presence of severe left ventricular dysfunction (LVEF 25.0%), which typically suggests a poor prognosis, the patient has survived.

Several factors may have contributed to the patient's survival:

1.  Optimal medical therapy: The patient is on a combination of beta blockers, digoxin, ACE inhibitor, and nitrovasodilator, which are commonly used to manage heart failure and hypertension. These medications help to reduce the workload on the heart, slow the heart rate, and improve cardiac output.
2.  Monitoring and management of arrhythmias: The patient's ECG shows evidence of ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia. The presence of these arrhythmias is concerning, but the fact that they are non-sustained and not causing significant hemodynamic instability may have contributed to the patient's survival.
3.  Pro-BNP levels: The patient's Pro-BNP level is elevated at 5545.0 ng/L, which suggests that the patient has heart failure with reduced ejection fraction (HFrEF). However, the fact that the patient is still alive despite this elevated level may indicate that the condition is being effectively managed.
4.  Hemoglobin and electrolyte levels: The patient's hemoglobin level is within the normal range, which suggests that there is no significant anemia contributing to the patient's condition. The potassium level is slightly low, but not critically low, which may be managed with supplementation.
5.  Other laboratory values: The patient's liver enzymes, glucose, and urea levels are within the normal range, indicating that there is no significant underlying liver disease or renal impairment contributing to the patient's condition.

In conclusion, while the patient's cardiac condition is severe, the combination of optimal medical therapy, monitoring and management of arrhythmias, and absence of other significant comorbidities may have contributed to the patient's survival."
448,448,P0707,"Age: 52
Gender: Male 
Weight: 81 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 150/95 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,36
Potassium (mEq/L): 5,2
LDL (mmol/L): 4,55
Sodium (mEq/L): 138.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 13
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,73
Urea (mg/dL): 6,49
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of being a survivor can be attributed to a combination of factors, including the presence of a multidisciplinary treatment plan and the patient's relatively stable clinical condition. 

The patient has a history of ischemic dilated cardiomyopathy, which is a chronic condition characterized by reduced left ventricular function. However, the patient's LVEF (Left Ventricular Ejection Fraction) is 40%, indicating that while the patient's heart function is compromised, it is not severely impaired. This suggests that the patient may still have a reasonable chance of survival with appropriate medical management.

The patient's blood pressure is elevated at 150/95 mmHg, which is a risk factor for cardiovascular disease, but it is well-controlled with medication. The patient is also on beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor, which are all evidence-based treatments for heart failure and hypertension.

The patient's laboratory results show elevated creatinine levels, which may indicate kidney impairment, but this is not severe. The patient's hemoglobin, sodium, and potassium levels are within normal limits, which suggests that the patient is not experiencing significant electrolyte imbalances.

The ECG findings of polymorphic ventricular extrasystoles are concerning, but the absence of non-sustained ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia suggests that the patient's cardiac rhythm is relatively stable.

Overall, the patient's stable clinical condition, the presence of a comprehensive treatment plan, and the absence of severe complications have contributed to their survival. However, ongoing monitoring and close follow-up with a cardiologist are essential to manage the patient's condition and prevent potential complications."
449,449,P0708,"Age: 64
Gender: Male 
Weight: 80 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 5,07
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 148.0
HDL (mmol/L): 0,62
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,65
Sodium (mEq/L): 139.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 13
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,17
Urea (mg/dL): 8,49
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 64-year-old male with a history of hypertensive cardiomyopathy and hypertension, has been managed with beta blockers, loop diuretics, and an ACE inhibitor. His current ejection fraction (LVEF) is 40%, indicating a reduced left ventricular function. Despite this, he has managed to survive, which can be attributed to several factors:

1. Effective medication management: The patient is on a combination of beta blockers, loop diuretics, and an ACE inhibitor, which are commonly used to manage heart failure and hypertension. These medications have likely helped to reduce his blood pressure and alleviate symptoms of heart failure.
2. Controlled blood pressure: His blood pressure of 160/80 mmHg is relatively well-controlled, which is essential for reducing the strain on his heart and preventing further damage.
3. Normal electrolyte levels: The patient's potassium and sodium levels are within normal limits, which is crucial for maintaining proper heart function.
4. Lack of severe cardiac arrhythmias: Although the ECG shows non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles, these are not severe enough to cause significant hemodynamic instability, and the patient has not experienced any sustained ventricular tachycardia or bradycardia.
5. Normal thyroid function: The patient's TSH level is within the normal range, indicating that his thyroid function is not contributing to his cardiac condition.
6. No signs of acute kidney injury: His creatinine level is within normal limits, suggesting that his kidney function is not significantly impaired.
7. Presence of hemoglobin: The patient's hemoglobin level is normal, indicating that his cardiac function is not significantly impaired to cause anemia.

Overall, the combination of effective medication management, controlled blood pressure, normal electrolyte levels, and lack of severe cardiac arrhythmias have likely contributed to the patient's survival."
450,450,P0709,"Age: 70
Gender: Male 
Weight: 84 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 135/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,23
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 5
LDL (mmol/L): 3,67
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 129.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,26
Urea (mg/dL): 10,48
LVEF (%): 35.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 70-year-old male with a history of enolic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers dilate, reducing the heart's ability to pump blood effectively. Despite this, the patient has been prescribed a combination of medications, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are commonly used to manage heart failure and dilated cardiomyopathy.

The patient's laboratory results show a slightly elevated creatinine level (97.0 mmol/L), which may indicate some degree of renal impairment. However, the patient's blood pressure is within a relatively normal range (135/80 mmHg), and the ejection fraction (LVEF) is 35.0%, which is below the normal range (50-70%), indicating that the patient's heart is not pumping blood efficiently.

The patient's Pro-BNP level (129.0 ng/L) is elevated, which is consistent with heart failure. However, the patient's troponin level (0.03 ng/mL) is within the normal range, indicating that there is no acute myocardial infarction.

The patient's ECG shows polymorphic ventricular extrasystoles, which can be a sign of abnormal heart rhythm, but there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias.

Given the patient's age, history of dilated cardiomyopathy, and the presence of heart failure symptoms (NYHA Class II), the patient's outcome of survival is likely due to the combination of medical therapy and the patient's relatively stable clinical condition. The patient's low ejection fraction and elevated Pro-BNP level suggest that the patient's heart failure is not well-controlled, but the patient's overall clinical condition is stable, and the patient is able to survive with ongoing medical management."
451,451,P0710,"Age: 74
Gender: Female 
Weight: 63 kg
Height: 142 cm
NYHA Class: II
Blood Pressure: 145/75 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 10.0
Total Cholesterol (mmol/L): 6,31
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 37
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,71
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,47
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1674.0
Protein (g/L): 65
T3 (pg/dL): 0,03
T4 (ng/L): 15
Troponin (ng/mL): 0,05
TSH (mIU/L): 1,3
Urea (mg/dL): 9,65
LVEF (%): 60.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient, a 74-year-old female with a history of hypertensive cardiomyopathy and hypertension, has a relatively favorable outcome despite her advanced age and multiple comorbidities. Several factors contribute to her survival:

1.  Optimal Medication Management: The patient is on a comprehensive regimen of angiotensin II receptor blockers, beta blockers, and loop diuretics, which are all evidence-based treatments for heart failure and hypertension. These medications help manage her blood pressure, reduce myocardial oxygen demand, and improve cardiac function.
2.  Preserved LVEF: Despite her history of hypertensive cardiomyopathy, the patient's left ventricular ejection fraction (LVEF) is 60%, which is within the normal range. This suggests that her heart is still functioning relatively well, allowing her to tolerate her comorbidities.
3.  Mildly Elevated Troponin: The patient's troponin level is slightly elevated at 0.05 ng/mL, but not significantly high enough to indicate acute coronary syndrome or severe cardiac damage.
4.  Normal Hemoglobin and Potassium Levels: The patient's hemoglobin and potassium levels are within normal ranges, which are essential for maintaining cardiac function and preventing arrhythmias.
5.  Low TSH and T4 Levels: The patient's thyroid function tests are within normal limits, which is crucial for maintaining cardiac function and preventing arrhythmias.
6.  Absence of Severe Electrolyte Imbalances: The patient's sodium, potassium, and urea levels are within normal ranges, which reduces the risk of life-threatening arrhythmias and cardiac dysfunction.
7.  Non-Sustained Ventricular Tachycardia: While the patient has a history of non-sustained ventricular tachycardia, it is not a sustained arrhythmia, and her heart rate is likely being controlled by her medications.
8.  ECG Findings: Although the patient has polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, these findings are not indicative of severe cardiac disease.

Considering these factors, the patient's survival outcome is likely due to a combination of her comprehensive medication regimen, preserved cardiac function, and the absence of severe electrolyte imbalances or acute cardiac damage."
452,452,P0711,"Age: 75
Gender: Male 
Weight: 75 kg
Height: 181 cm
NYHA Class: II
Blood Pressure: 135/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 3,8
Creatinine (mmol/L): 177.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 137.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,12
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 2029.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,04
TSH (mIU/L): 1,45
Urea (mg/dL): 15,47
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 75-year-old male with a history of ischemic dilated cardiomyopathy, which significantly impacts his cardiac function. His left ventricular ejection fraction (LVEF) is 30%, indicating a reduced ejection fraction, which is a hallmark of heart failure. The patient is on a regimen of beta blockers, loop diuretics, statins, ACE inhibitors, and nitrovasodilators, which are all standard treatments for heart failure and hypertension. 

His elevated Pro-BNP (2029.0 ng/L) levels further support the diagnosis of heart failure. Additionally, his low hemoglobin (137.0 g/L) and high creatinine (177.0 mmol/L) levels suggest chronic kidney disease, which is often seen in patients with heart failure. His electrolyte levels, particularly potassium (3.9 mEq/L), are within the normal range, indicating that his kidney function is not severely compromised.

The patient's lipid profile shows high total cholesterol (3.8 mmol/L) and low HDL (0.88 mmol/L), which is consistent with dyslipidemia. His blood pressure is elevated at 135/90 mmHg, indicating hypertension.

The patient's TSH level is within the normal range (1.45 mIU/L), and his thyroid function is not a contributing factor to his cardiac condition. His troponin level is slightly elevated (0.04 ng/mL), which may indicate minor cardiac damage, but it is not indicative of an acute myocardial infarction.

The patient's ECG shows monomorphic ventricular extrasystoles, which is a common finding in patients with heart failure. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that the patient is not at high risk for life-threatening arrhythmias.

Considering the patient's age, comorbidities, and the treatment he is receiving, it is likely that the patient is a survivor due to the following reasons:

1.  Effective management of his heart failure with medications.
2.  Presence of a stable cardiac rhythm, as indicated by the ECG.
3.  Adequate kidney function, as indicated by his electrolyte levels.
4.  Presence of a support system that allows him to manage his condition effectively.

However, it is essential to note that the patient's LVEF of 30% indicates a high risk of adverse cardiac events, and close monitoring and further management of his condition are necessary to prevent complications."
453,453,P0712,"Age: 52
Gender: Male 
Weight: 98 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 175/110 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 6,34
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,9
LDL (mmol/L): 4,45
Sodium (mEq/L): 137.0
Protein (g/L): 76
T3 (pg/dL): 0,06
T4 (ng/L): 19
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,45
Urea (mg/dL): 8,15
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 52-year-old male, has been diagnosed with enolic dilated cardiomyopathy, a condition where the heart muscle becomes weakened and the heart chambers enlarge, reducing its ability to pump blood effectively. His left ventricular ejection fraction (LVEF) of 30% indicates severe systolic dysfunction. 

The patient's blood pressure is elevated at 175/110 mmHg, which is a significant risk factor for cardiovascular disease and can exacerbate his heart failure. His high total cholesterol level of 6.34 mmol/L and low HDL level of 1.14 mmol/L contribute to an increased risk of atherosclerosis and further cardiovascular events.

The patient's kidney function, as indicated by a creatinine level of 80.0 μmol/L, is mildly impaired. This can be a result of his heart failure, as the kidneys may not receive sufficient blood flow due to the reduced cardiac output.

The patient's medications, including beta blockers, loop diuretics, and nitrovasodilators, are appropriate for managing his heart failure and hypertension. Beta blockers are used to slow the heart rate and reduce the workload on the heart, while loop diuretics help to remove excess fluid from the body, reducing congestion in the lungs and legs. Nitrovasodilators help to dilate blood vessels, reducing blood pressure.

The ECG shows polymorphic ventricular extrasystoles, which are abnormal heartbeats originating in the ventricles. However, there is no evidence of sustained ventricular tachycardia, paroxysmal supraventricular tachyarrhythmia, or bradycardia.

Considering the patient's severe heart failure, elevated blood pressure, and other risk factors, the patient's survival is a positive outcome. This is likely due to the effectiveness of his current medication regimen, lifestyle modifications, and close monitoring by his healthcare team."
454,454,P0713,"Age: 75
Gender: Male 
Weight: 89 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 7.0
AST or GOT (IU/L): 10.0
Total Cholesterol (mmol/L): 7,06
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 4
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 5,3
LDL (mmol/L): 4,65
Sodium (mEq/L): 133.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,04
TSH (mIU/L): 2,24
Urea (mg/dL): 8,49
LVEF (%): 21.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient's outcome as a survivor can be attributed to a combination of several factors, despite having a low left ventricular ejection fraction (LVEF) of 21% and a history of enolic dilated cardiomyopathy. 

Firstly, the patient's blood pressure is relatively well-controlled at 140/90 mmHg, which is within the acceptable range for a patient with heart failure. This suggests that the patient's blood pressure is not contributing to further strain on the heart.

The patient is on a combination of medications that are commonly used in heart failure management, including digoxin, loop diuretics, spironolactone, and an ACE inhibitor. These medications are likely helping to manage the patient's symptoms and slow the progression of the disease.

The patient's laboratory results show a relatively normal glucose level, which is a good sign as hyperglycemia can exacerbate heart failure. The patient's electrolyte levels, including potassium, are also within the normal range, which is crucial for maintaining a stable heart rhythm.

The patient's LVEF of 21% is low, indicating significant left ventricular dysfunction. However, the patient's Troponin level is normal, which suggests that there is no ongoing myocardial infarction or ischemia contributing to the patient's condition.

The patient's TSH level is within the normal range, indicating that the patient's thyroid function is not contributing to the heart failure. The patient's T3 and T4 levels are also within the normal range, which suggests that the patient's thyroid function is not contributing to the heart failure.

The patient's ECG shows polymorphic ventricular extrasystoles, but no sustained ventricular tachycardia or bradycardia. This suggests that the patient's heart rhythm is relatively stable, despite the presence of ventricular extrasystoles.

Overall, the combination of the patient's well-controlled blood pressure, appropriate medication regimen, and relatively stable laboratory results likely contributed to the patient's outcome as a survivor."
455,455,P0714,"Age: 58
Gender: Male 
Weight: 87 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 135/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,2
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,44
Sodium (mEq/L): 138.0
Protein (g/L): 67
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,92
Urea (mg/dL): 7,15
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's medical history and the provided data, the patient's outcome of survival can be attributed to several factors. 

Firstly, the patient's age of 58 is relatively young for a cardiomyopathy diagnosis, which may indicate a more favorable prognosis. The patient's weight of 87 kg and height of 164 cm suggest a body mass index (BMI) of approximately 29.4, categorizing the patient as overweight. However, the patient's BMI is not excessively high, which might contribute to a relatively better prognosis.

The patient's blood pressure of 135/80 mmHg is within the normal range, indicating effective control of hypertension. The patient's NYHA Class II classification signifies that the patient experiences some limitations in physical activity but is still able to perform everyday activities without significant distress.

The patient's laboratory results show relatively normal liver function (ALT, AST, GGT, and albumin levels) and kidney function (creatinine and urea levels). The patient's total cholesterol and LDL levels are within the target range, and the HDL level is slightly below the target. However, the patient's glucose level is within the normal range, indicating good glycemic control.

The patient's LVEF of 30.0% indicates a significantly reduced left ventricular ejection fraction, which is a hallmark of heart failure. However, the patient's Troponin level of 0.04 ng/mL suggests that the patient has not experienced a recent myocardial infarction. The patient's TSH level of 0.92 mIU/L is within the normal range, indicating no thyroid dysfunction.

The patient's ECG results show polymorphic ventricular extrasystoles, but no sustained ventricular tachycardia or bradycardia. The presence of TPSV (paroxysmal supraventricular tachyarrhythmia) might indicate a higher risk of arrhythmias, but it is not a life-threatening condition.

The patient's current medications, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, are standard treatments for heart failure and hypertension. These medications are likely contributing to the patient's survival by reducing the workload on the heart, improving cardiac function, and controlling blood pressure.

Overall, the combination of effective medical management, relatively young age, and the absence of severe comorbidities likely contributed to the patient's survival."
456,456,P0715,"Age: 73
Gender: Male 
Weight: 72 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 131/87 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 7.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 3,57
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 8
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 5
LDL (mmol/L): 1,86
Sodium (mEq/L): 135.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,92
Urea (mg/dL): 18,3
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 73-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension. His current medications include diabetes medication, beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor, which are all appropriate for his conditions.

The patient's LVEF (Left Ventricular Ejection Fraction) is 45%, indicating that his heart is not pumping efficiently, which is consistent with his ischemic dilated cardiomyopathy diagnosis. However, his LVEF is not extremely low, and he is still alive, suggesting that his current treatment plan is effective in managing his condition.

The patient's blood pressure is 131/87 mmHg, which is well-controlled. His glucose level is 8 mmol/L, which is within the target range for diabetes management. His lipid profile shows a total cholesterol of 3.57 mmol/L, with an LDL of 1.86 mmol/L, which is also within the target range.

The patient's electrolytes are within normal limits, with a potassium level of 5 mEq/L. His liver enzymes are slightly elevated, but not significantly so, indicating that his liver function is not severely compromised.

The ECG shows non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles, which are consistent with his history of ischemic dilated cardiomyopathy. However, the absence of sustained ventricular tachycardia or other severe arrhythmias suggests that his heart rhythm is not severely compromised.

The patient's thyroid function tests are within normal limits, with a TSH of 0.92 mIU/L. His T3 and T4 levels are also within normal limits.

Overall, the patient's current treatment plan and lab results suggest that he is well-managed and stable. His medications are likely helping to control his symptoms and prevent further cardiac damage. His survival is likely due to the effectiveness of his treatment plan and his overall good health status."
457,457,P0720,"Age: 69
Gender: Male 
Weight: 91 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 21
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 2,82
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,39
Potassium (mEq/L): 4,8
LDL (mmol/L): 1,84
Sodium (mEq/L): 136.0
Protein (g/L): 66
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,03
TSH (mIU/L): 4,12
Urea (mg/dL): 7,99
LVEF (%): 30.0
Medications: Diabetes Medication, Amiodarone, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient is a 69-year-old male with a history of idiopathic dilated cardiomyopathy and diabetes, presenting with a low left ventricular ejection fraction (LVEF) of 30%. Despite these risk factors, the patient's overall outcome is a survivor. Several factors contribute to this outcome:

1.  Optimal medical management: The patient is on a comprehensive medication regimen, including beta blockers, ACE inhibitors, digoxin, loop diuretics, and spironolactone, which are all standard treatments for heart failure with reduced ejection fraction (HFrEF). These medications have been shown to improve symptoms, reduce hospitalizations, and improve survival in patients with HFrEF.

2.  Controlled blood pressure: The patient's blood pressure is well-controlled at 120/80 mmHg, which is within the target range for patients with heart failure. Uncontrolled hypertension can exacerbate heart failure and worsen outcomes.

3.  Normal electrolytes: The patient's potassium levels are within the normal range (4.8 mEq/L), which is essential for optimal cardiac function. Hypokalemia can lead to arrhythmias and worsen heart failure.

4.  Low troponin levels: The patient's troponin levels are within the normal range (0.03 ng/mL), indicating minimal myocardial damage.

5.  Normal thyroid function: The patient's thyroid-stimulating hormone (TSH) level is within the normal range (4.12 mIU/L), which suggests that thyroid dysfunction, which can contribute to heart failure, is unlikely.

6.  No signs of acute coronary syndrome: The patient's troponin levels are low, and there is no mention of acute coronary syndrome or myocardial infarction, which could have contributed to a poor outcome.

7.  Good glycemic control: The patient's glucose levels are well-controlled (6.7 mmol/L), which is essential for preventing diabetic complications, including cardiovascular disease.

8.  Regular monitoring and follow-up: The patient's regular monitoring and follow-up appointments suggest that they are receiving consistent care and attention, which can contribute to a better outcome.

In summary, the patient's optimal medical management, controlled blood pressure, normal electrolytes, low troponin levels, normal thyroid function, absence of acute coronary syndrome, good glycemic control, and regular monitoring and follow-up all contributed to a favorable outcome, despite their history of idiopathic dilated cardiomyopathy and diabetes."
458,458,P0721,"Age: 39
Gender: Male 
Weight: 70 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,33
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,65
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,83
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 486.0
Protein (g/L): 72
T3 (pg/dL): 0,06
T4 (ng/L): 19
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,76
Urea (mg/dL): 8,15
LVEF (%): 30.0
Medications: Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 39-year-old male with idiopathic dilated cardiomyopathy, has a low left ventricular ejection fraction (LVEF) of 30%, indicating significant heart failure. However, the patient's overall condition is stable, as evidenced by his New York Heart Association (NYHA) Class II classification, which indicates mild to moderate symptoms of heart failure.

The patient's laboratory results show elevated levels of brain natriuretic peptide (BNP), which is a marker of heart failure severity. However, the levels are not excessively high, suggesting that the patient's condition is not in an acute decompensated state.

The patient is on appropriate medications, including beta blockers, spironolactone, and an ACE inhibitor, which are standard treatments for heart failure. The use of beta blockers and ACE inhibitors is likely contributing to the patient's stable condition, as they help to reduce symptoms and slow disease progression.

The patient's ECG shows polymorphic ventricular extrasystoles, which can be a sign of arrhythmia, but it is not a life-threatening condition in this context. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and other arrhythmias suggests that the patient's heart rhythm is relatively stable.

Overall, the patient's stable condition, appropriate medical treatment, and the absence of acute complications or severe arrhythmias contribute to his favorable outcome."
459,459,P0723,"Age: 64
Gender: Male 
Weight: 77 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 110/85 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,97
Sodium (mEq/L): 140.0
Protein (g/L): 63
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,92
Urea (mg/dL): 9,32
LVEF (%): 31.0
Medications: Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient, a 64-year-old male with a history of enolic dilated cardiomyopathy, had a left ventricular ejection fraction (LVEF) of 31%, indicating severe systolic heart failure. However, despite this, the patient survived. There are several factors that contributed to this outcome.

Firstly, the patient's blood pressure was well-controlled at 110/85 mmHg, which is within the normal range. This suggests that the patient's blood pressure was not contributing to any further strain on the heart.

Secondly, the patient's medication regimen, including loop diuretics, statins, and an ACE inhibitor, was likely helping to manage his heart failure symptoms and reduce the risk of further cardiac events.

Thirdly, the patient's electrolyte levels, particularly potassium (4.6 mEq/L), were within the normal range, which is essential for maintaining a stable heart rhythm.

Fourthly, the patient's troponin level was low (0.03 ng/mL), indicating minimal cardiac damage.

Lastly, the patient's thyroid function tests (TSH 0.92 mIU/L and T4 15 ng/L) were within the normal range, suggesting that there was no underlying thyroid dysfunction contributing to his heart condition.

The patient's LVEF of 31% indicates severe heart failure, but the absence of other risk factors and the presence of a well-managed medication regimen likely contributed to the patient's survival."
460,460,P0724,"Age: 86
Gender: Male 
Weight: 80 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 139/93 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,78
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,46
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1329.0
Protein (g/L): 70
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,05
TSH (mIU/L): 0,63
Urea (mg/dL): 9,48
LVEF (%): 33.0
Medications: Calcium Channel Blocker, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

This patient, an 86-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, peripheral vascular disease, hypertension, and myocardial infarction, has been prescribed a comprehensive regimen of medications, including a calcium channel blocker, digoxin, loop diuretics, spironolactone, ACE inhibitor, and nitrovasodilator. 

The patient's left ventricular ejection fraction (LVEF) is severely reduced at 33%, indicating significant left ventricular dysfunction. The elevated Pro-BNP level of 1329 ng/L further supports the presence of heart failure. However, despite these risk factors, the patient has survived, which can be attributed to several factors:

1.  Optimal Medication Management: The patient is on a combination of medications that target various aspects of heart failure, including beta-blockers (calcium channel blocker), ACE inhibitors, and diuretics. This comprehensive approach likely helped mitigate the progression of heart failure.

2.  Early Detection and Treatment of Complications: The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles indicates that the patient's cardiac rhythm is being closely monitored, and any potential arrhythmias are being addressed promptly.

3.  Close Monitoring: The fact that the patient's TSH level is within the normal range suggests that thyroid dysfunction, which can exacerbate heart failure, is being managed.

4.  Good Control of Blood Pressure: The patient's blood pressure is within a relatively controlled range, which is beneficial for heart health.

5.  Lifestyle Factors: Although not explicitly stated, it is possible that the patient has made lifestyle adjustments, such as diet and exercise changes, which may have contributed to their survival.

However, it is essential to note that the patient's survival is likely a result of a combination of these factors, as well as the comprehensive care provided by their healthcare team."
461,461,P0726,"Age: 85
Gender: Male 
Weight: 69 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 160/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,31
Creatinine (mmol/L): 86.0
Gamma-glutamil transpeptidase (IU/L): 31,5
Glucose (mmol/L): 5,71
Hemoglobin (g/L): 164.0
HDL (mmol/L): 1,91
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,82
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 407.0
Protein (g/L): 72,3
T3 (pg/dL): 0,0507
T4 (ng/L): 11,37
TSH (mIU/L): 3,67
Urea (mg/dL): 6
LVEF (%): 30.0
Medications: ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"REASONING: 

The patient is an 85-year-old male with a history of idiopathic dilated cardiomyopathy and hypertension. The patient's left ventricular ejection fraction (LVEF) is severely reduced at 30%, indicating significant left ventricular dysfunction. Despite this, the patient is classified as NYHA Class II, which suggests that the patient has mild symptoms of heart failure, such as fatigue or shortness of breath, but is able to perform everyday activities without significant limitation.

The patient's blood pressure is elevated at 160/70 mmHg, which is consistent with the diagnosis of hypertension. The patient is already on an ACE inhibitor, which is a standard treatment for hypertension and heart failure.

The patient's laboratory results show elevated levels of creatinine (86.0 mmol/L), which suggests impaired renal function. The patient's potassium level is slightly low at 4.4 mEq/L, which may be a result of the diuretic effect of the ACE inhibitor.

The patient's pro-BNP level is elevated at 407.0 ng/L, which is consistent with heart failure. The patient's T3 and T4 levels are within normal limits, and the TSH level is slightly elevated at 3.67 mIU/L, which may be a result of the patient's age.

The ECG shows polymorphic ventricular extrasystoles, which is a common finding in patients with heart failure. The patient also has a history of ventricular tachycardia, but the code is unknown. The patient does not have non-sustained ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia.

Considering the patient's age, comorbidities, and laboratory results, the patient's survival is likely due to a combination of factors, including:

1. Effective treatment with an ACE inhibitor, which has helped to manage the patient's hypertension and heart failure.
2. Mild symptoms of heart failure, which suggests that the patient's cardiac function is not severely compromised.
3. Adequate renal function, despite the elevated creatinine level.
4. Normal T3 and T4 levels, which suggests that the patient's thyroid function is not contributing to the patient's cardiac dysfunction.

Overall, the patient's survival is likely due to a combination of effective medical management and the patient's relatively mild symptoms of heart failure."
462,462,P0727,"Age: 75
Gender: Male 
Weight: 78 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 155/65 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 36.0
Total Cholesterol (mmol/L): 5,71
Creatinine (mmol/L): 163.0
Gamma-glutamil transpeptidase (IU/L): 144
Glucose (mmol/L): 6,73
Hemoglobin (g/L): 114.0
HDL (mmol/L): 2,23
Potassium (mEq/L): 5,38
LDL (mmol/L): 2,88
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 1364.0
Protein (g/L): 72,4
T3 (pg/dL): 0,0435
T4 (ng/L): 8,18
Troponin (ng/mL): 0,3
TSH (mIU/L): 5,83
Urea (mg/dL): 10,3
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

Given the patient's age, gender, and medical history of idiopathic dilated cardiomyopathy, it is not surprising that the patient has a reduced left ventricular ejection fraction (LVEF) of 30%. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG also suggests underlying cardiac electrical instability, which is a common finding in patients with cardiomyopathy.

The patient's medications, including a calcium channel blocker, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, are standard treatments for heart failure and hypertension. These medications are likely contributing to the patient's survival by reducing symptoms of heart failure, controlling blood pressure, and preventing further cardiac remodeling.

The patient's blood work shows elevated creatinine levels (163.0 μmol/L), indicating impaired renal function, which is a common complication of heart failure. However, the patient's urea levels (10.3 mg/dL) are not significantly elevated, suggesting that the renal impairment is not severe.

The patient's troponin level (0.3 ng/mL) is within the normal range, indicating that there is no acute myocardial infarction. The pro-BNP level (1364.0 ng/L) is elevated, which is consistent with heart failure.

The patient's thyroid function tests (T3, T4, and TSH) are within the normal range, indicating that thyroid dysfunction is unlikely to be contributing to the patient's cardiac condition.

The patient's lipid profile shows high total cholesterol (5.71 mmol/L) and LDL levels (2.88 mmol/L), which are risk factors for cardiovascular disease. However, the patient's HDL level (2.23 mmol/L) is also low, which may be a result of the patient's heart failure and medication use.

Overall, the patient's survival can be attributed to the effective management of their heart failure and hypertension with medications, as well as the lack of acute myocardial infarction or severe renal impairment. However, the patient's underlying cardiomyopathy and reduced LVEF make them at risk for future cardiac events, and close monitoring and follow-up will be necessary to prevent further complications."
463,463,P0729,"Age: 74
Gender: Female 
Weight: 76 kg
Height: 148 cm
NYHA Class: II
Blood Pressure: 180/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,52
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,27
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,49
Potassium (mEq/L): 3,8
LDL (mmol/L): 4,57
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 2397.0
Protein (g/L): 81,3
T3 (pg/dL): 0,0369
T4 (ng/L): 18,09
Troponin (ng/mL): 0,4
TSH (mIU/L): 0,71
Urea (mg/dL): 8,1
LVEF (%): 50.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 74-year-old female with a history of hypertensive cardiomyopathy and hypertension. Her current blood pressure is elevated at 180/90 mmHg, which is a concern for further cardiovascular complications. Despite this, her LVEF (left ventricular ejection fraction) is 50%, indicating that her heart is still pumping blood effectively, albeit not at optimal levels.

The patient's creatinine level is elevated at 99.0 mmol/L, indicating impaired kidney function. However, her urea level is relatively normal at 8.1 mg/dL, suggesting that her kidneys are still functioning to some extent.

The patient's troponin level is elevated at 0.4 ng/mL, indicating some degree of myocardial injury. However, the level is not extremely high, and the patient is not showing any signs of acute coronary syndrome.

The patient's Pro-BNP (brain natriuretic peptide) level is significantly elevated at 2397.0 ng/L, which is often seen in patients with heart failure. However, the patient's LVEF is 50%, which is not typically seen in severe heart failure. This suggests that the patient may be experiencing some degree of heart failure, but it is not severe.

The patient's medication regimen includes digoxin, loop diuretics, and an ACE inhibitor, which are all appropriate for managing heart failure and hypertension.

Given the patient's age, medical history, and current lab results, it is likely that the patient is experiencing some degree of heart failure, but it is not severe. The patient's ability to survive suggests that her heart is still compensating for the underlying disease process, and her medication regimen is likely helping to manage her symptoms.

The patient's outcome as a survivor is likely due to the following factors:

1. The patient's age: Older adults are more likely to survive cardiovascular events due to a combination of factors, including decreased cardiac workload and increased reserve capacity.
2. The patient's LVEF: Although the patient's LVEF is not optimal, it is still above 40%, which is the threshold for severe heart failure.
3. The patient's medication regimen: The patient's medication regimen is likely helping to manage her symptoms and slow the progression of her disease.
4. The patient's kidney function: Although the patient's creatinine level is elevated, her urea level is relatively normal, suggesting that her kidneys are still functioning to some extent.

Overall, the patient's outcome as a survivor is likely due to a combination of these factors, which have allowed her to compensate for her underlying disease process and maintain a relatively stable condition."
464,464,P0731,"Age: 82
Gender: Female 
Weight: 73 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 130/100 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,28
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 5
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,73
Sodium (mEq/L): 142.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,67
Urea (mg/dL): 10,48
LVEF (%): 39.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is an 82-year-old female with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction. Despite her complex medical history and multiple comorbidities, the patient has survived. Several factors contributed to her positive outcome:

1.  Optimal Medication Management: The patient is on a comprehensive medication regimen, including diabetes medication, beta blockers, statins, ACE inhibitors, and nitrovasodilators. These medications are crucial in managing her heart failure, hypertension, and dyslipidemia. Beta blockers, in particular, are known to improve survival and reduce hospitalizations in patients with heart failure.

2.  Regular Monitoring and Management of Blood Pressure: The patient's blood pressure is 130/100 mmHg, which is within the target range for most patients with heart failure. Effective blood pressure control is essential in reducing the strain on the heart and preventing further damage.

3.  LVEF (Left Ventricular Ejection Fraction) of 39%: Although the patient's LVEF is lower than the normal range (50-70%), it is not extremely low, indicating that the heart is still pumping some blood effectively. This, combined with optimal medication management, may have contributed to her survival.

4.  ECG Findings: The patient's ECG shows non-sustained ventricular tachycardia, which is a common finding in patients with heart failure. However, the absence of sustained ventricular tachycardia, bradycardia, and paroxysmal supraventricular tachyarrhythmia suggests that her heart rhythm is relatively stable.

5.  Blood Test Results: The patient's blood tests show mild elevations in liver enzymes (ALT and AST), which may indicate some degree of liver dysfunction. However, these elevations are not severe, and the patient's overall liver function is not significantly compromised. Her kidney function, as indicated by creatinine levels, is also relatively preserved.

6.  Hemoglobin and Potassium Levels: The patient's hemoglobin level is within the normal range, indicating adequate iron stores and red blood cell production. Her potassium level is also within the normal range, which is essential for maintaining proper heart function.

7.  TSH and T4 Levels: The patient's thyroid function, as indicated by TSH and T4 levels, is within the normal range, which is essential for maintaining cardiac function.

In conclusion, the patient's survival can be attributed to a combination of her comprehensive medication regimen, regular monitoring and management of blood pressure, relatively preserved LVEF, stable ECG findings, and normal blood test results."
465,465,P0732,"Age: 48
Gender: Male 
Weight: 93 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 160/100 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 35.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 7,89
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 110
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 5,2
LDL (mmol/L): 5,84
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 11.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,05
TSH (mIU/L): 1,19
Urea (mg/dL): 5,32
LVEF (%): 25.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome is a survivor, likely due to a combination of factors. Firstly, the patient is on a comprehensive treatment regimen that includes beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are all standard medications for managing heart failure and hypertension. These medications are aimed at reducing the workload on the heart, managing fluid overload, and improving cardiac function.

The patient's LVEF (Left Ventricular Ejection Fraction) is 25%, which is low, indicating reduced cardiac function. However, the patient's Pro-BNP level is within a relatively normal range (11.0 ng/L), which suggests that the patient's cardiac stress is not excessively high. This could indicate that the patient's treatment is effective in managing the heart failure symptoms.

The patient's blood pressure is elevated at 160/100 mmHg, but it is not uncontrolled, and the patient is on antihypertensive medications. The patient's potassium level is slightly elevated (5.2 mEq/L), which may require monitoring but is not typically a cause for concern.

The patient's lipid profile shows elevated total cholesterol and LDL levels, but the HDL level is low. This indicates a need for further lipid management, but it is not a direct cause for concern in this patient.

The patient's TSH level is slightly elevated (1.19 mIU/L), but it is within a relatively normal range, and the patient is not showing any signs of hyperthyroidism.

The patient's creatinine level is slightly elevated (88.0 μmol/L), indicating mild kidney impairment, but it is not severe. The patient's urea level is also slightly elevated (5.32 mg/dL), but it is not a cause for concern.

Overall, the patient's outcome is likely due to the effectiveness of their current treatment regimen and the absence of severe cardiac or renal dysfunction."
466,466,P0736,"Age: 51
Gender: Male 
Weight: 80 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 53,2
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6
Hemoglobin (g/L): 160.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4
LDL (mmol/L): 2,74
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 1780.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,12
Urea (mg/dL): 9,13
LVEF (%): 63.0
Medications: Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 51-year-old male with a history of ischemic dilated cardiomyopathy, dyslipemia, and hypertension, has a relatively favorable prognosis. Several factors contribute to this outcome:

1.  Medication Adherence: The patient is on beta blockers and statins, which are crucial for managing heart failure and dyslipidemia. Beta blockers help reduce the workload on the heart, while statins lower cholesterol levels, reducing the risk of further cardiac damage.

2.  LVEF (Left Ventricular Ejection Fraction) of 63%: Although the patient has a history of ischemic dilated cardiomyopathy, the LVEF is relatively preserved at 63%. This suggests that the heart is still functioning relatively well, which is a positive prognostic indicator.

3.  Low Troponin Levels: The patient's troponin levels are within normal limits (0.01 ng/mL), indicating that there is no significant cardiac muscle damage at the time of the assessment.

4.  Normal TSH Levels: The patient's thyroid-stimulating hormone (TSH) level is within the normal range (1.12 mIU/L), indicating that thyroid function is not contributing to the patient's cardiac condition.

5.  No Evidence of Malnutrition or Liver Dysfunction: The patient's albumin levels (53.2 g/L) and liver enzymes (ALT 17.0 IU/L and AST 19.0 IU/L) are within normal limits, suggesting that there is no significant malnutrition or liver dysfunction contributing to the patient's condition.

6.  No History of Sustained Ventricular Tachycardia: The absence of sustained ventricular tachycardia on the ECG suggests that the patient is not at high risk of sudden cardiac death.

7.  Normal Hemoglobin Levels: The patient's hemoglobin level is within the normal range (160 g/L), indicating that there is no significant anemia contributing to cardiac workload.

Given these factors, the patient's prognosis appears to be favorable, and the patient is likely to survive with continued medical management and adherence to their medication regimen."
467,467,P0738,"Age: 70
Gender: Female 
Weight: 74 kg
Height: 154 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 37.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 6,49
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 91
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 141.0
HDL (mmol/L): 2,22
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,93
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 623.0
Protein (g/L): 69
T4 (ng/L): 10
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,94
Urea (mg/dL): 3,33
LVEF (%): 38.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 70-year-old female with a history of ischemic dilated cardiomyopathy, dyslipemia, hypertension, and myocardial infarction, which are all risk factors for heart failure. Her NYHA Class III classification indicates that she experiences symptoms of heart failure, such as shortness of breath and fatigue, during physical activity.

The laboratory results show elevated levels of troponin (0.01 ng/mL), indicating recent myocardial injury, and a low left ventricular ejection fraction (LVEF) of 38%, which suggests systolic heart failure. The patient's pro-BNP level of 623.0 ng/L is elevated, which is consistent with heart failure.

The patient's medications, including amiodarone, angiotensin II receptor blocker, beta blockers, statins, and ACE inhibitor, are appropriate for managing heart failure and hypertension. The ECG shows monomorphic ventricular extrasystoles, which is a common finding in patients with heart failure.

Despite the patient's significant cardiac history and symptoms, she has survived, which suggests that her treatment plan has been effective in managing her condition. The patient's low TSH level (1.94 mIU/L) and normal T4 level (10 ng/L) suggest that her thyroid function is within the normal range, which is important to consider in the management of heart failure.

The patient's hemoglobin level (141.0 g/L) is within the normal range, which suggests that her anemia is not contributing to her heart failure symptoms. Her potassium level (4.6 mEq/L) is also within the normal range, which is important to consider when managing her medications.

In summary, the patient's survival can be attributed to her effective treatment plan, which includes medications for heart failure and hypertension, as well as close monitoring of her cardiac function and laboratory results."
468,468,P0739,"Age: 47
Gender: Male 
Weight: 75 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 83.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 2,53
Creatinine (mmol/L): 177.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,54
Potassium (mEq/L): 5
LDL (mmol/L): 1,45
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3200.0
Protein (g/L): 70
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,05
Urea (mg/dL): 11,98
LVEF (%): 32.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 47-year-old male with a history of ischemic dilated cardiomyopathy and myocardial infarction, has a complex medical condition. The patient's left ventricular ejection fraction (LVEF) of 32% indicates severe left ventricular dysfunction, which is a significant risk factor for adverse outcomes. However, despite this, the patient is a survivor, suggesting that the current treatment plan is effective in managing the condition.

The patient's medication regimen, which includes beta blockers, digoxin, loop diuretics, spironolactone, statins, and an ACE inhibitor, appears to be comprehensive and appropriate for managing heart failure and ischemic cardiomyopathy. Beta blockers are used to slow the heart rate and reduce the workload on the heart, while digoxin is used to increase the strength of the heart's contractions. Loop diuretics help reduce fluid buildup in the body, and spironolactone is an aldosterone antagonist that helps to reduce fluid retention and blood pressure. Statins lower cholesterol levels to reduce the risk of further cardiovascular events, and ACE inhibitors help to relax blood vessels and reduce blood pressure.

The patient's laboratory results, including a normal troponin level, indicate that there is no ongoing myocardial infarction, and the patient's creatinine level, while elevated, is not indicative of acute kidney injury. The patient's hemoglobin and potassium levels are within normal limits, and the patient's TSH level is within the normal range, indicating that there are no signs of thyroid dysfunction.

The patient's pro-BNP level of 3200 ng/L is elevated, which is consistent with heart failure. However, the patient's symptoms and clinical presentation do not suggest that the patient is in acute heart failure.

The patient's ECG findings, including polymorphic ventricular extrasystoles and paroxysmal supraventricular tachycardia, are not uncommon in patients with heart failure and are not necessarily indicative of a poor prognosis.

Overall, the patient's survival is likely due to the effectiveness of the current treatment plan, which is tailored to manage the patient's complex medical condition."
469,469,P0740,"Age: 52
Gender: Male 
Weight: 77 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 135/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes
Albumin (g/L): 43
ALT or GPT (IU/L): 48.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 15,5
Hemoglobin (g/L): 148.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,43
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 610.0
Protein (g/L): 70
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,51
Urea (mg/dL): 6,99
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of survival is likely due to a combination of factors, including the presence of effective medical management and the patient's relatively stable clinical condition. 

The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and enlarged, leading to a decrease in the heart's ability to pump blood effectively. The patient's left ventricular ejection fraction (LVEF) of 30% indicates that the heart is not pumping efficiently, which is consistent with this diagnosis. 

However, the patient is on a regimen of medications that are commonly used to manage heart failure and improve survival, including beta blockers, spironolactone, statins, and an ACE inhibitor. These medications have been shown to reduce the risk of hospitalization and mortality in patients with heart failure.

Additionally, the patient's blood pressure is well-controlled, with a reading of 135/75 mmHg, which is within a normal range. This is important, as high blood pressure can exacerbate heart failure.

The patient's diabetes is also well-controlled, with a glucose level of 15.5 mmol/L, which is within a target range. Diabetes is a significant risk factor for heart failure, so controlling the blood sugar levels is crucial.

The patient's troponin level is 0.01 ng/mL, which is within a normal range, indicating that there is no acute myocardial infarction.

The patient's pro-BNP level is 610.0 ng/L, which is elevated, indicating that the patient has heart failure. However, the level is not extremely high, which may indicate that the patient's condition is stable.

Overall, while the patient has a history of ischemic dilated cardiomyopathy and heart failure, the combination of effective medical management and the patient's relatively stable clinical condition have likely contributed to the patient's outcome of survival."
470,470,P0741,"Age: 63
Gender: Female 
Weight: 85 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41,3
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,93
Creatinine (mmol/L): 78.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,53
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,45
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 347.0
Protein (g/L): 68,4
T4 (ng/L): 14
TSH (mIU/L): 1,32
Urea (mg/dL): 5,32
LVEF (%): 68.0
Medications: Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 63-year-old female with a history of ischemic dilated cardiomyopathy, myocardial infarction, dyslipemia, and hypertension. Despite having a history of heart conditions, the patient has been taking beta blockers and statins, which are standard medications for managing heart failure and reducing the risk of further cardiovascular events.

The patient's left ventricular ejection fraction (LVEF) is 68%, which is within the normal range (> 55%), indicating that the heart is pumping blood efficiently. The patient's pro-BNP level is elevated at 347 ng/L, which is a marker of heart failure. However, this value is not extremely high, suggesting that the patient's heart failure is not severe.

The patient's blood pressure is slightly elevated at 160/90 mmHg, but it is not extremely high. The patient's lipid profile shows elevated total cholesterol and LDL levels, but the patient is taking statins, which are effective in lowering cholesterol levels.

The patient's ECG shows ventricular extrasystoles, but no signs of sustained or non-sustained ventricular tachycardia, which is a good sign. The patient does not have any signs of bradycardia.

Given the patient's overall condition and treatment, the most likely reason for the patient's outcome is that they are a survivor due to the following factors:

1.  Effective management of heart failure with beta blockers and statins.
2.  Normal LVEF, indicating efficient heart pumping.
3.  Elevated but not extremely high pro-BNP level, suggesting mild to moderate heart failure.
4.  No signs of severe cardiovascular events such as sustained or non-sustained ventricular tachycardia.
5.  The patient's lipid profile is being managed with statins.

Therefore, the patient's survival is likely due to the combination of effective medical management, normal heart function, and the absence of severe cardiovascular events."
471,471,P0744,"Age: 49
Gender: Male 
Weight: 92 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 150/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 46,6
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 7,4
Creatinine (mmol/L): 83.0
Gamma-glutamil transpeptidase (IU/L): 51
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 171.0
HDL (mmol/L): 1,37
Potassium (mEq/L): 4,2
LDL (mmol/L): 4,47
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 5.0
Protein (g/L): 80,1
T4 (ng/L): 17
TSH (mIU/L): 0,64
Urea (mg/dL): 3,5
LVEF (%): 57.0
Medications: Amiodarone
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient's outcome of survival is largely due to several factors:

1. Timely diagnosis and treatment of Hypertensive cardiomyopathy and hypertension: The patient's blood pressure is well-controlled at 150/90 mmHg, which is a significant improvement from what it might have been in the past. This suggests that the patient is receiving effective treatment for their hypertension, which has likely slowed the progression of their cardiomyopathy.

2. Moderate left ventricular ejection fraction (LVEF): The patient's LVEF is 57%, which is within the range of moderate left ventricular dysfunction. While it is not normal, it is not severely impaired, which suggests that the patient's heart is still able to function adequately to meet the body's needs.

3. Low B-type natriuretic peptide (BNP) levels: The patient's Pro-BNP level is 5.0 ng/L, which is within the normal range. Elevated BNP levels are associated with heart failure and cardiac dysfunction. The low BNP level suggests that the patient's heart is not experiencing significant stress or dysfunction.

4. Normal liver function tests: The patient's liver function tests, including ALT and AST, are within normal limits. This suggests that the patient's liver is not significantly compromised, which is important because liver disease can contribute to cardiac dysfunction.

5. Well-controlled electrolyte levels: The patient's potassium level is within the normal range, which is essential for maintaining cardiac function.

6. Absence of significant arrhythmias: The ECG shows no evidence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, or bradycardia. This suggests that the patient's heart is not experiencing significant arrhythmias, which can contribute to cardiac dysfunction and poor outcomes.

7. Medication management: The patient is on Amiodarone, which is a medication used to treat arrhythmias and heart failure. The fact that the patient is on this medication suggests that their healthcare team is actively managing their cardiac condition.

Overall, the combination of these factors suggests that the patient is receiving effective treatment for their cardiac condition and is likely experiencing a stable and manageable course of their disease."
472,472,P0745,"Age: 75
Gender: Female 
Weight: 67 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 38,7
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,04
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 108.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,28
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1143.0
Protein (g/L): 64,9
T4 (ng/L): 11
TSH (mIU/L): 13,15
Urea (mg/dL): 16,31
LVEF (%): 34.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's age, gender, and past medical history, including ischemic dilated cardiomyopathy, myocardial infarction, and diabetes, it is not surprising that the patient has a reduced left ventricular ejection fraction (LVEF) of 34%. The patient's current medications, including beta blockers, angiotensin II receptor blockers, loop diuretics, spironolactone, and nitrovasodilators, are standard treatments for heart failure and hypertension, suggesting that the patient is receiving appropriate management for their conditions.

The elevated Pro-BNP level (1143.0 ng/L) is indicative of heart failure, which is consistent with the patient's history of ischemic dilated cardiomyopathy and reduced LVEF. However, the patient's blood pressure is within a relatively normal range (110/70 mmHg), which may indicate that the patient's heart failure is being well-managed.

The patient's liver enzymes (ALT and AST) are within normal limits, which suggests that there is no significant liver dysfunction. The patient's glucose level (5.7 mmol/L) is also within a relatively normal range, indicating that their diabetes is being well-controlled.

The patient's kidney function, as indicated by the creatinine level (113.0 umol/L), is slightly elevated, which may be a consequence of the patient's heart failure. However, the urea level (16.31 mg/dL) is also slightly elevated, which may indicate some degree of renal impairment.

The patient's electrolyte levels, including potassium (4.3 mEq/L) and sodium (141.0 mEq/L), are within normal limits. The patient's TSH level (13.15 mIU/L) is slightly elevated, which may indicate some degree of thyroid dysfunction, but this is not directly related to the patient's heart failure.

Considering the patient's overall medical history, current medications, and laboratory results, it is likely that the patient's heart failure is being well-managed, and they are receiving appropriate treatment. The patient's ability to survive suggests that their heart failure is not severe enough to lead to a fatal outcome at this time."
473,473,P0746,"Age: 71
Gender: Female 
Weight: 85 kg
Height: 148 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 38,7
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,47
Creatinine (mmol/L): 87.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 123.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,51
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 292.0
Protein (g/L): 64,9
T4 (ng/L): 16
TSH (mIU/L): 1,02
Urea (mg/dL): 7,15
LVEF (%): 58.0
Medications: Beta Blockers, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient's outcome is a survivor, which suggests that the patient has made it through a potentially life-threatening situation, likely a cardiac event such as a myocardial infarction or cardiac arrest. Given the patient's past medical history of hypertensive cardiomyopathy, dyslipemia, and hypertension, it is likely that the patient experienced a cardiac event. The patient's elevated blood pressure, total cholesterol, and LDL levels further support this, as these are risk factors for cardiovascular disease.

The patient's LVEF (Left Ventricular Ejection Fraction) of 58% is within the normal range (50-70%), which indicates that the patient's heart is functioning adequately. However, the presence of polymorphic ventricular extrasystoles on the ECG suggests that the patient's heart is experiencing some degree of abnormal heart rhythm, which may be a sign of underlying cardiac disease.

The patient's Pro-BNP (B-type natriuretic peptide) level of 292.0 ng/L is elevated, which is a marker of heart failure and cardiac stress. However, the patient's albumin level is within the normal range, which suggests that the patient does not have significant liver dysfunction, which is a common cause of elevated BNP levels.

The patient's medication regimen, including beta blockers and nitrovasodilators, is consistent with the treatment of heart failure and hypertension, which further supports the likelihood that the patient experienced a cardiac event.

In summary, the patient's outcome as a survivor is likely due to the fact that the patient's heart is functioning adequately, despite the presence of underlying cardiac disease, and that the patient is receiving appropriate medical treatment for their condition."
474,474,P0747,"Age: 58
Gender: Female 
Weight: 73 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 130/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 53.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 3,8
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,37
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,35
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 158.0
Protein (g/L): 68
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1
Urea (mg/dL): 6,66
LVEF (%): 30.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient outcome of survival in this case can be attributed to several factors based on the provided data. 

Firstly, the patient's NYHA Class II classification indicates that she experiences some limitations in physical activity, but she is still able to perform everyday tasks without symptoms. This suggests that her heart failure is not severe at this stage.

The patient's LVEF (Left Ventricular Ejection Fraction) of 30% is low, indicating systolic heart failure. However, she is on optimal medical therapy, including Angiotensin II Receptor Blocker, Beta Blockers, Statins, and Nitrovasodilator, which are standard treatments for heart failure with reduced ejection fraction (HFrEF). These medications are likely helping to slow the progression of her condition and reducing symptoms.

The patient's Pro-BNP (Brain Natriuretic Peptide) level of 158 ng/L is elevated, which is consistent with heart failure. However, it is not extremely high, suggesting that the patient's condition is being managed.

The ECG results show a monomorphic ventricular extrasystole, but no sustained ventricular tachycardia or other life-threatening arrhythmias. This suggests that the patient's heart rhythm is relatively stable.

The patient's blood work shows normal kidney function (Creatinine 53.0 mmol/L), normal liver function (ALT and AST within normal limits), and normal electrolyte levels (Potassium 4.1 mEq/L). This suggests that the patient's kidneys and liver are functioning well, and she is not at risk for acute kidney injury or electrolyte imbalances that could worsen her heart failure.

The patient's TSH level is within normal limits, indicating that her thyroid function is normal. This is important because thyroid dysfunction can exacerbate heart failure.

Lastly, the patient's Troponin level is low (0.01 ng/mL), indicating that she does not have acute myocardial infarction or ongoing cardiac damage.

Considering these factors, the patient's survival can be attributed to optimal medical therapy, relatively stable heart rhythm, normal kidney and liver function, normal thyroid function, and the absence of acute cardiac damage."
475,475,P0748,"Age: 69
Gender: Male 
Weight: 59 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 122/68 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 8.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 4,32
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 3,9
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,43
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 15272.0
Protein (g/L): 59
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,14
Urea (mg/dL): 8,49
LVEF (%): 15.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient, a 69-year-old male with a history of hypertensive cardiomyopathy, dyslipemia, and hypertension, has shown a positive outcome despite his severe cardiac condition. Several factors contribute to this outcome:

1.  Effective Medication Management: The patient is on a combination of beta blockers, loop diuretics, statins, and ACE inhibitors, which are standard treatments for heart failure and hypertension. These medications likely helped to control his blood pressure and reduce strain on the heart.
2.  Monitoring and Treatment of Hypertension: The patient's blood pressure is well-controlled at 122/68 mmHg, which is within a normal range. This suggests that his hypertension is being effectively managed, reducing the risk of further cardiac damage.
3.  Low Troponin Levels: The patient's troponin level is 0.01 ng/mL, indicating minimal cardiac damage. This suggests that the heart muscle is not experiencing significant ischemia or infarction, which is a good sign for recovery.
4.  Pro-BNP Levels: Although the patient's Pro-BNP level is elevated at 15,272 ng/L, it is not excessively high, indicating that the heart is not under extreme stress. This level suggests that the patient's heart is adapting to the disease and is not experiencing catastrophic failure.
5.  LVEF: The patient's left ventricular ejection fraction (LVEF) is 15%, which is severely impaired. However, this is not uncommon in patients with hypertensive cardiomyopathy and heart failure. The fact that the patient is alive suggests that the heart is still functioning, albeit at a reduced capacity.
6.  Patient's Age and Comorbidities: The patient is 69 years old, which is a relatively advanced age. While this increases the risk of cardiac complications, it also means that the patient has had time to adapt to his condition, and his body may have developed compensatory mechanisms to cope with the disease.
7.  Other Laboratory Results: The patient's other laboratory results, including his albumin, AST, ALT, total cholesterol, creatinine, gamma-glutamil transpeptidase, glucose, hemoglobin, HDL, LDL, potassium, sodium, urea, and T4 levels, are within relatively normal ranges or show minimal abnormalities. This suggests that the patient's overall health is stable and not significantly compromised by other factors.

Considering these factors, the patient's survival is likely due to a combination of effective medical management, controlled hypertension, and the body's ability to adapt to the disease."
476,476,P0749,"Age: 75
Gender: Male 
Weight: 64 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,97
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 7,8
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,72
Sodium (mEq/L): 137.0
Protein (g/L): 68
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,44
Urea (mg/dL): 8,65
LVEF (%): 40.0
Medications: Diabetes Medication, Beta Blockers, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's data, the outcome of survival is likely due to a combination of factors. 

Firstly, the patient's LVEF (Left Ventricular Ejection Fraction) is 40%, which is below the normal range of 55-70%. However, the patient is still alive, indicating that the heart is still pumping blood effectively enough to meet the body's needs. 

The patient's medications, including beta blockers, spironolactone, statins, ACE inhibitors, and nitrovasodilators, are all consistent with the management of ischemic dilated cardiomyopathy, diabetes, and hypertension. These medications are aimed at reducing the workload on the heart, improving heart function, and preventing further cardiac damage.

The patient's blood pressure is well-controlled at 110/70 mmHg, which is within the normal range. This suggests that the patient's hypertension is under control, reducing the risk of further cardiac damage.

The patient's troponin level is 0.01 ng/mL, which is within the normal range, indicating that there is no ongoing myocardial infarction. This suggests that the patient has not had a recent heart attack, which is a positive sign.

The patient's glucose level is 7.8 mmol/L, which is within the target range for diabetes management. This suggests that the patient's diabetes is well-controlled, reducing the risk of cardiac complications.

The patient's LVEF of 40% and controlled blood pressure, glucose, and medications suggest that the patient's heart is being managed effectively, and the patient is likely surviving due to the current treatment plan and the absence of any acute cardiac events.

However, it is essential to note that the patient's ischemic dilated cardiomyopathy and peripheral vascular disease are chronic conditions that require ongoing management and monitoring. The patient's outcome is likely a result of the successful management of these conditions and the absence of any acute cardiac events."
477,477,P0750,"Age: 62
Gender: Male 
Weight: 107 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,47
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 108
Glucose (mmol/L): 12,2
Hemoglobin (g/L): 160.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,4
Sodium (mEq/L): 134.0
Protein (g/L): 69
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,5
Urea (mg/dL): 8,65
LVEF (%): 47.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 62-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, hypertension, and myocardial infarction. Despite having a reduced left ventricular ejection fraction (LVEF) of 47%, which indicates a compromised heart function, the patient's overall clinical condition is stable as evidenced by the absence of severe symptoms (NYHA Class II) and the absence of significant changes in vital signs, such as blood pressure.

The patient is on a comprehensive treatment regimen, including beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor, which are all aimed at managing his heart failure, hypertension, and hyperlipidemia. The patient's troponin level is within normal limits, indicating that there is no acute myocardial infarction.

The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG suggests that the patient has some degree of arrhythmia, but this is not severe enough to cause hemodynamic instability. The patient's TSH level is within normal limits, indicating that his thyroid function is not contributing to his cardiac condition.

The patient's kidney function, as indicated by the creatinine level, is slightly elevated but not significantly abnormal. His glucose level is elevated, which is consistent with his diabetes diagnosis. The patient's lipid profile shows a high total cholesterol and low HDL level, which is consistent with his diagnosis of hyperlipidemia.

Considering these factors, the patient's overall clinical condition appears to be stable, and he is likely able to tolerate his current treatment regimen. Therefore, the patient outcome is a survivor."
478,478,P0751,"Age: 51
Gender: Male 
Weight: 61 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 105/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40,5
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 7,28
Creatinine (mmol/L): 121.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 154.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,77
LDL (mmol/L): 5,17
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 4168.0
Protein (g/L): 72,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,03
Urea (mg/dL): 7,7
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's data, the outcome of survival is likely due to a combination of factors, including the patient's current medical management and the severity of their underlying condition. 

The patient has idiopathic dilated cardiomyopathy, a condition characterized by a weakened heart muscle that can lead to heart failure. However, the patient is currently taking beta blockers, loop diuretics, and an ACE inhibitor, which are standard medications for managing heart failure and dilated cardiomyopathy. These medications help reduce the workload on the heart, improve symptoms, and slow disease progression.

The patient's LVEF (left ventricular ejection fraction) is severely impaired at 20%, indicating significant left ventricular dysfunction. However, the patient's current medication regimen is likely helping to stabilize their condition and prevent further decline.

The patient's laboratory results show elevated Pro-BNP (brain natriuretic peptide) levels, which are indicative of heart failure. However, the levels are not extremely high, suggesting that the patient's condition is being managed effectively.

The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are common in patients with dilated cardiomyopathy. However, these findings are not indicative of a life-threatening arrhythmia at this time.

Overall, the patient's current medical management and the lack of severe arrhythmias or other life-threatening complications suggest that they are likely to survive with continued medical treatment and close monitoring."
479,479,P0753,"Age: 56
Gender: Male 
Weight: 88 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 145/90 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 40,5
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 5,99
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 120
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 148.0
Potassium (mEq/L): 4,17
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 906.0
Protein (g/L): 78,5
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,46
Urea (mg/dL): 7,5
LVEF (%): 20.0
Medications: Amiodarone, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient, a 56-year-old male with a history of idiopathic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension, has been prescribed a multi-faceted treatment plan that includes amiodarone, digoxin, loop diuretics, and an ACE inhibitor. Despite his complex medical history and compromised left ventricular ejection fraction (LVEF) of 20%, the patient has survived, indicating that his treatment plan has been effective in managing his symptoms and preventing further cardiac complications.

The patient's blood work and ECG results suggest that he is being closely monitored for cardiac function and potential complications. His elevated Pro-BNP levels (906.0 ng/L) indicate that he is experiencing some degree of cardiac stress, but his Troponin levels (0.01 ng/mL) are within normal limits, suggesting that he is not experiencing acute myocardial infarction.

The patient's medications, particularly the ACE inhibitor, are likely playing a crucial role in managing his hypertension and reducing his cardiac workload. The loop diuretics are also helping to manage fluid overload and reduce symptoms of heart failure. Amiodarone is being used to control arrhythmias, and digoxin is being used to improve cardiac contractility.

The patient's ECG results show a polymorphic ventricular extrasystole, but no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias. His LVEF of 20% indicates significant left ventricular dysfunction, but his overall clinical status and survival suggest that his treatment plan is helping to manage his condition.

In summary, the patient's survival can be attributed to the effective management of his cardiac disease through a combination of medications, close monitoring, and regular follow-up care."
480,480,P0755,"Age: 75
Gender: Female 
Weight: 69 kg
Height: 152 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 41,3
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,35
Creatinine (mmol/L): 82.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5
Hemoglobin (g/L): 125.0
HDL (mmol/L): 2,1
Potassium (mEq/L): 4,78
LDL (mmol/L): 1,82
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 285.0
Protein (g/L): 70,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,78
Urea (mg/dL): 8
LVEF (%): 70.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome is likely due to a combination of factors contributing to their overall health and treatment plan. 

Firstly, the patient's LVEF (Left Ventricular Ejection Fraction) is 70%, which is within the normal range (50-70%). This suggests that the patient's heart function is relatively preserved, which is a positive indicator of their cardiac health.

The patient is on a comprehensive treatment plan, including Beta Blockers, Loop Diuretics, Spironolactone, and an ACE Inhibitor, which are all standard medications for managing heart failure and valvular cardiomyopathy. The use of these medications has likely helped to manage the patient's symptoms and slow the progression of their condition.

Additionally, the patient's blood pressure is well-controlled at 120/70 mmHg, which is within a healthy range, and their albumin and protein levels are within normal limits, indicating that their liver function is not significantly compromised.

The patient's Pro-BNP (Brain Natriuretic Peptide) level is elevated at 285.0 ng/L, which is a marker of heart failure, but it is not extremely high, suggesting that the patient's heart failure is not severe.

The patient's troponin level is normal at 0.01 ng/mL, which suggests that there is no acute cardiac damage.

The patient's ECG shows a monomorphic ventricular extrasystole, but no sustained ventricular tachycardia or other significant arrhythmias, which suggests that their heart rhythm is relatively stable.

Overall, the patient's overall health and treatment plan, combined with the lack of severe cardiac damage or significant arrhythmias, suggest that they are likely to survive and have a good prognosis."
481,481,P0756,"Age: 74
Gender: Male 
Weight: 72 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 175/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 38,9
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 5,07
Creatinine (mmol/L): 78.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 155.0
HDL (mmol/L): 1,45
Potassium (mEq/L): 3,83
LDL (mmol/L): 3,2
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 373.0
Protein (g/L): 64,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,68
Urea (mg/dL): 8,8
LVEF (%): 41.0
Medications: Amiodarone, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"REASONING: 

The patient is a 74-year-old male with a history of hypertensive cardiomyopathy and hypertension, which is consistent with a reduced left ventricular ejection fraction (LVEF) of 41%. The patient's blood pressure is elevated at 175/80 mmHg, which may be contributing to the cardiomyopathy.

The patient's laboratory results show elevated creatinine levels (78.0 μmol/L), which suggests impaired renal function, likely secondary to chronic hypertension and cardiomyopathy. The elevated pro-BNP (373.0 ng/L) also indicates heart failure with reduced ejection fraction (HFrEF).

The patient is on medications that are appropriate for heart failure and hypertension management, including spironolactone, an ACE inhibitor, and amiodarone for rate control and rhythm management. The presence of ventricular extrasystoles on the ECG is a common finding in patients with cardiomyopathy.

The patient's LVEF of 41% is below the normal range, indicating systolic heart failure. However, the patient is classified as NYHA Class II, which indicates mild symptoms of heart failure. The patient's hemoglobin level is within the normal range, and there is no indication of anemia.

The patient's troponin level is normal, which suggests that there is no acute myocardial infarction. The patient's TSH level is within the normal range, indicating that thyroid dysfunction is unlikely to be contributing to the patient's heart failure.

Overall, the patient's outcome as a survivor is likely due to the effective management of his heart failure and hypertension with appropriate medications, as well as the relatively mild symptoms of heart failure (NYHA Class II)."
482,482,P0757,"Age: 59
Gender: Male 
Weight: 91 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 115/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 43,1
ALT or GPT (IU/L): 148.0
AST or GOT (IU/L): 85.0
Total Cholesterol (mmol/L): 3,74
Creatinine (mmol/L): 121.0
Gamma-glutamil transpeptidase (IU/L): 187
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 144.0
HDL (mmol/L): 0,6
Potassium (mEq/L): 4,09
LDL (mmol/L): 2,43
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 182.0
Protein (g/L): 79,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,7
Urea (mg/dL): 8
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 59-year-old male with a history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction, has a complex medical profile. Despite this, the patient has been managed with a multi-drug regimen including calcium channel blockers, beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor. The patient's current medications are aimed at controlling symptoms, improving heart function, and reducing the risk of further cardiovascular events.

The patient's LVEF (Left Ventricular Ejection Fraction) is 35%, which is below the normal range (50-70%), indicating reduced cardiac function. However, the patient's Pro-BNP (brain natriuretic peptide) level is 182.0 ng/L, which is elevated but not excessively high, suggesting some degree of heart failure management.

The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are arrhythmias that can be associated with heart failure and ischemic cardiomyopathy. However, the patient does not have sustained ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia.

The patient's laboratory results show elevated liver enzymes (ALT and AST), which may indicate liver damage or disease, but the patient's albumin and protein levels are within normal limits. The patient's lipid profile shows high LDL cholesterol, which is being managed with statins.

Given the patient's complex medical profile and multi-drug regimen, the patient's survival can be attributed to the following factors:

1.  Effective management of heart failure symptoms with loop diuretics and spironolactone.
2.  Control of hypertension with calcium channel blockers and beta blockers.
3.  Management of high cholesterol with statins.
4.  Monitoring and management of arrhythmias with the patient's medication regimen.
5.  Regular monitoring and adjustment of medications to optimize the patient's condition.

Overall, the patient's survival can be attributed to the comprehensive management of their complex medical conditions and the multidisciplinary approach to their care."
483,483,P0758,"Age: 55
Gender: Male 
Weight: 81 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 44,5
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,33
Creatinine (mmol/L): 110.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 123.0
HDL (mmol/L): 1,08
Potassium (mEq/L): 4,76
LDL (mmol/L): 2,78
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 5004.0
Protein (g/L): 70,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,29
Urea (mg/dL): 10,8
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's medical history, current condition, and laboratory results, the patient's outcome as a survivor can be attributed to several factors.

1. Optimal Medical Management: The patient is on a comprehensive treatment regimen consisting of beta blockers, loop diuretics, statins, ACE inhibitors, and nitrovasodilators. This combination of medications helps manage symptoms of heart failure, reduce blood pressure, and improve lipid profiles, all of which are crucial in the management of idiopathic dilated cardiomyopathy.

2. Low Troponin Levels: The patient's troponin level is within the normal range (0.01 ng/mL), indicating minimal cardiac damage. This suggests that the patient is not experiencing an acute myocardial infarction, which is a critical factor in determining patient outcomes.

3. Reasonable ECG Findings: Although the patient has polymorphic ventricular extrasystoles, there is no indication of sustained ventricular tachycardia, which is a significant risk factor for adverse outcomes in heart failure patients.

4. Moderate Blood Pressure: The patient's blood pressure is within the target range for patients with heart failure, which helps to reduce the strain on the heart and minimize further damage.

5. Albumin and Protein Levels: The patient's albumin and protein levels are within normal limits, which indicates that the liver function is not significantly compromised. Liver dysfunction can lead to fluid overload and worsen heart failure symptoms.

6. LVEF of 20%: Although the patient's left ventricular ejection fraction (LVEF) is severely reduced, indicating significant heart failure, the patient has been able to survive, likely due to optimal medical management and possibly a relatively recent diagnosis and initiation of treatment.

7. Low Creatinine Levels: The patient's creatinine levels are within normal limits, indicating that renal function is not significantly impaired. Renal dysfunction can worsen heart failure outcomes.

Considering these factors, the patient's outcome as a survivor is likely due to the combination of optimal medical management, minimal cardiac damage, reasonable ECG findings, and preserved liver and renal function."
484,484,P0759,"Age: 69
Gender: Male 
Weight: 73 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 40,1
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 5,94
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 173.0
HDL (mmol/L): 0,79
Potassium (mEq/L): 3,48
LDL (mmol/L): 3,82
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1837.0
Protein (g/L): 71,5
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,2
Urea (mg/dL): 10,1
LVEF (%): 18.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 69-year-old male with a history of idiopathic dilated cardiomyopathy and hypertension, presented with a reduced left ventricular ejection fraction (LVEF) of 18.0%, indicating severe heart failure. Despite the presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG, the patient was on a comprehensive medication regimen, including beta blockers, loop diuretics, hydralazine, and nitrovasodilators, which are standard treatments for heart failure and arrhythmias.

The patient's elevated Pro-BNP level (1837.0 ng/L) and reduced LVEF suggest significant cardiac stress and dysfunction, which could have contributed to the patient's risk of adverse outcomes. However, the fact that the patient survived suggests that the current treatment regimen and medical management were effective in mitigating the severity of the condition.

Additionally, the patient's hemoglobin level (173.0 g/L) and sodium level (142.0 mEq/L) are within normal ranges, indicating adequate oxygen delivery to tissues and no significant electrolyte imbalances that could have contributed to cardiac instability. The patient's low potassium level (3.48 mEq/L) may be a concern, but it is not significantly low, and the patient is on a medication regimen that includes hydralazine, which can help manage hypertension and may have contributed to the potassium level.

The patient's blood pressure (110/70 mmHg) is within a relatively normal range, indicating effective blood pressure control, which is essential for patients with heart failure and hypertension.

In conclusion, the patient's survival can be attributed to the comprehensive medical management, including medications and close monitoring, which likely helped to mitigate the severity of the condition and prevent adverse outcomes."
485,485,P0763,"Age: 60
Gender: Male 
Weight: 74 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 95/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 41,4
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 6
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 32
Glucose (mmol/L): 7,7
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,18
LDL (mmol/L): 4,2
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 2774.0
Protein (g/L): 65,9
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,76
Urea (mg/dL): 7,6
LVEF (%): 21.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 60-year-old male with a history of idiopathic dilated cardiomyopathy, has a significantly reduced left ventricular ejection fraction (LVEF) of 21.0%. This indicates severe heart failure, which is consistent with his New York Heart Association (NYHA) Class II classification. 

The patient's laboratory results show elevated levels of pro-BNP (2774.0 ng/L), which is indicative of heart failure. His creatinine level (100.0 mmol/L) is slightly elevated, suggesting impaired renal function, which is not uncommon in patients with heart failure.

The patient's medications, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, are appropriate for the management of heart failure and are likely contributing to his survival.

The ECG findings of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia suggest arrhythmogenic activity, which is not uncommon in patients with dilated cardiomyopathy. However, the absence of sustained ventricular tachycardia or bradycardia suggests that the patient's heart is not experiencing severe arrhythmia-related complications.

Given the patient's age, comorbidities, and current treatment regimen, it is likely that the patient's survival is a result of aggressive medical management and close monitoring of his condition. The patient's relatively stable vital signs, including blood pressure (95/60 mmHg), and lack of severe symptoms, suggest that he is tolerating his medications and is not experiencing acute decompensation.

Overall, the patient's survival is likely due to the combination of his current treatment regimen, close monitoring, and the fact that he is not experiencing acute decompensation or severe arrhythmia-related complications."
486,486,P0764,"Age: 75
Gender: Male 
Weight: 72 kg
Height: 181 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44,8
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 6,64
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 148.0
Potassium (mEq/L): 4,74
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 2243.0
Protein (g/L): 80,4
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,59
Urea (mg/dL): 8,8
LVEF (%): 26.0
Medications: Amiodarone, Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient's outcome of survival is likely due to a combination of factors. 

Firstly, the patient's current medications, including Amiodarone, Beta Blockers, Spironolactone, Statins, and ACE Inhibitor, are all appropriate for managing idiopathic dilated cardiomyopathy and its associated complications. Amiodarone and Beta Blockers help regulate heart rhythm and reduce the risk of arrhythmias, while Spironolactone is an aldosterone antagonist that can help reduce fluid retention and alleviate symptoms of heart failure. Statins are used to manage high cholesterol, which can contribute to heart disease. ACE Inhibitors also help reduce blood pressure and alleviate symptoms of heart failure.

The patient's LVEF (Left Ventricular Ejection Fraction) of 26% indicates reduced heart function, which is consistent with idiopathic dilated cardiomyopathy. However, the patient's Pro-BNP level of 2243.0 ng/L, while elevated, is not extremely high, suggesting that the patient's heart failure is not in an advanced stage.

The patient's blood pressure is within a relatively normal range (120/80 mmHg), and there is no indication of severe renal impairment (Creatinine level of 95.0 umol/L is within the normal range for this patient). The patient's hemoglobin level is also within the normal range, indicating that anemia is not a significant concern.

The patient's ECG shows non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles, which are common findings in patients with idiopathic dilated cardiomyopathy. However, the absence of sustained ventricular tachycardia or other severe arrhythmias suggests that the patient's heart is not in a life-threatening rhythm disturbance.

Overall, the patient's combination of medications, relatively stable vital signs, and lack of severe symptoms or complications suggest that the patient is likely in a stable condition and is surviving with idiopathic dilated cardiomyopathy."
487,487,P0767,"Age: 70
Gender: Male 
Weight: 89 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 147/62 mmHg
Past Medical History: Other HF etiology, Diabetes, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,33
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 7,1
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,8
LDL (mmol/L): 3,7
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 723.0
Protein (g/L): 70
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,56
Urea (mg/dL): 7,82
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Hydralazine, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient is a 70-year-old male with a history of heart failure (HF) due to an unknown etiology, diabetes, and hypertension. His current NYHA Class II indicates that he experiences symptoms of heart failure, such as shortness of breath, but only with moderate exertion.

The patient's lab results show elevated levels of creatinine (115.0 mmol/L), indicating impaired renal function, and a high Pro-BNP level (723.0 ng/L), which is a marker of heart failure severity. His left ventricular ejection fraction (LVEF) is 35%, which is significantly reduced, indicating systolic heart failure.

However, the patient's troponin level is normal (0.01 ng/mL), which suggests that there is no acute myocardial infarction. His TSH level is within the normal range, indicating no signs of hyperthyroidism or hypothyroidism.

The patient is on a comprehensive medication regimen, including diabetes medication, beta blockers, hydralazine, ACE inhibitors, and nitrovasodilators, which are all appropriate for heart failure management.

The patient's ECG shows ventricular extrasystoles, but no signs of sustained ventricular tachycardia or other severe arrhythmias. The presence of paroxysmal supraventricular tachyarrhythmia (PSVT) is noted, but this is not typically a life-threatening condition.

Given the patient's overall clinical presentation, lab results, and ECG findings, it appears that he is being effectively managed for his heart failure and other comorbidities. His survival is likely due to the comprehensive medical therapy and close monitoring he is receiving."
488,488,P0768,"Age: 73
Gender: Male 
Weight: 94 kg
Height: 167 cm
NYHA Class: III
Blood Pressure: 150/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 186.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4
LDL (mmol/L): 2,51
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 600.0
Protein (g/L): 76
T4 (ng/L): 15
Troponin (ng/mL): 0,04
TSH (mIU/L): 1,13
Urea (mg/dL): 21,96
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 73-year-old male with a history of ischemic dilated cardiomyopathy, myocardial infarction, hypertension, and dyslipemia. His current medications include beta blockers, loop diuretics, statins, ACE inhibitors, and nitrovasodilators, which are all appropriate for his conditions. His ejection fraction (LVEF) is 40%, indicating moderate to severe left ventricular dysfunction.

Given the patient's age, comorbidities, and medication regimen, his outcome as a survivor is likely due to the following factors:

1.  Appropriate medical management: The patient is on a comprehensive treatment plan that addresses his heart failure, hypertension, and dyslipidemia. This includes beta blockers to slow the heart rate and reduce the workload on the heart, loop diuretics to manage fluid overload, statins to lower cholesterol levels, ACE inhibitors to reduce blood pressure and strain on the heart, and nitrovasodilators to help manage angina.

2.  Monitoring and management of ventricular arrhythmias: The patient's ECG shows non-sustained ventricular tachycardia, but he has not experienced any sustained or life-threatening arrhythmias. The presence of a nitrovasodilator in his medication regimen suggests that he is being managed for angina and potential arrhythmias.

3.  Stable laboratory values: The patient's laboratory values, such as creatinine, urea, and electrolytes, are relatively stable, indicating that his renal function is being well-managed. His albumin and total protein levels are within normal limits, suggesting that he does not have significant liver dysfunction.

4.  Low troponin levels: The patient's troponin level is 0.04 ng/mL, which is within normal limits. This suggests that he does not have acute myocardial infarction or significant cardiac damage.

5.  Thyroid function: The patient's TSH level is 1.13 mIU/L, which is within the normal range. This suggests that his thyroid function is well-managed, and he is not at risk for thyroid-related cardiac complications.

6.  Hemoglobin levels: The patient's hemoglobin level is 129 g/L, which is within the normal range. This suggests that he does not have significant anemia, which can contribute to cardiac decompensation.

In conclusion, the patient's outcome as a survivor is likely due to his comprehensive medical management, stable laboratory values, and the absence of acute cardiac complications."
489,489,P0769,"Age: 51
Gender: Female 
Weight: 79 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 43
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,11
Creatinine (mmol/L): 62.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,35
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 183.0
Protein (g/L): 75
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,77
Urea (mg/dL): 6,99
LVEF (%): 33.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 51-year-old female with a history of idiopathic dilated cardiomyopathy, a condition where the heart muscle becomes weakened and the heart chambers enlarge, leading to reduced heart function. Her left ventricular ejection fraction (LVEF) of 33% indicates severe heart failure. However, despite this, she is taking a comprehensive treatment regimen consisting of beta blockers, statins, and an ACE inhibitor, which are standard medications for heart failure and dilated cardiomyopathy.

Her blood pressure is within a relatively normal range (100/60 mmHg), and her electrolyte levels, including potassium and sodium, are within normal limits. Her liver function tests (ALT and AST) are also within normal limits, which suggests that her liver is functioning properly. The total cholesterol level is elevated, but it is being managed with statins.

The patient's pro-BNP level is elevated at 183 ng/L, which is a marker of heart failure. However, her troponin level is within normal limits, indicating that there is no acute myocardial infarction. Her TSH level is within normal limits, indicating that her thyroid function is normal.

The ECG findings of polymorphic ventricular extrasystole and non-sustained ventricular tachycardia suggest that the patient has arrhythmias, which are common in patients with heart failure and dilated cardiomyopathy. However, the fact that she is taking beta blockers and ACE inhibitors, which can help manage these arrhythmias, and her LVEF is being closely monitored, suggests that her arrhythmias are being managed.

Given the patient's treatment regimen and the fact that she is being closely monitored, her outcome of survival is likely due to the effective management of her heart failure and arrhythmias. Her medications and close monitoring are helping to manage her condition, and she is likely to continue living with her condition for the time being."
490,490,P0770,"Age: 55
Gender: Male 
Weight: 87 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 180/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 41
ALT or GPT (IU/L): 35.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 43
Glucose (mmol/L): 6,4
Hemoglobin (g/L): 132.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,2
LDL (mmol/L): 1,68
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 536.0
Protein (g/L): 73
T3 (pg/dL): 0,06
T4 (ng/L): 12
Troponin (ng/mL): 0,005
TSH (mIU/L): 13,08
Urea (mg/dL): 7,65
LVEF (%): 53.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 55-year-old male with a history of idiopathic dilated cardiomyopathy, a condition where the heart muscle becomes weakened and the heart chambers enlarge, reducing the heart's ability to pump blood effectively. He has been prescribed a regimen of beta blockers, digoxin, loop diuretics, and ACE inhibitors, which are standard treatments for heart failure and dilated cardiomyopathy.

The patient's current medications and treatment plan suggest that his condition is being managed, as evidenced by his LVEF (Left Ventricular Ejection Fraction) of 53%, which is within the normal range (50-70%). However, his Pro-BNP (B-type natriuretic peptide) level of 536.0 ng/L is elevated, indicating increased stress on the heart, which may be due to his underlying condition or other factors such as fluid overload or pulmonary congestion.

The patient's blood pressure is elevated at 180/75 mmHg, which may be contributing to his heart condition. His lipid profile shows high total cholesterol and LDL (bad) cholesterol levels, which can contribute to the progression of heart disease. His hemoglobin level is within the normal range, and his potassium level is slightly low.

The ECG findings of monomorphic ventricular extrasystoles are common in patients with cardiomyopathy and are generally not a cause for concern. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that the patient's heart rhythm is relatively stable.

Considering the patient's current treatment plan, the lack of severe symptoms, and the absence of life-threatening arrhythmias, the patient's outcome as a survivor suggests that he is being effectively managed for his condition and is likely experiencing a stable period. However, it is essential to continue monitoring his condition, adjust his treatment plan as needed, and address any potential risk factors for worsening heart disease, such as high blood pressure and high cholesterol levels."
491,491,P0771,"Age: 73
Gender: Male 
Weight: 89 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 130/65 mmHg
Past Medical History: Other HF etiology
Albumin (g/L): 39
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 3,34
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 154.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4
LDL (mmol/L): 1,71
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 720.0
Protein (g/L): 72
T4 (ng/L): 17
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,06
Urea (mg/dL): 7,99
LVEF (%): 25.0
Medications: Beta Blockers, Statins, Hydralazine, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's survival can be attributed to several factors:

1.  Optimal Medication Management: The patient is on a comprehensive regimen of medications that address his heart failure and other comorbid conditions. Beta blockers, statins, hydralazine, ACE inhibitors, and nitrovasodilators are all evidence-based treatments for heart failure that have been shown to improve outcomes.

2.  Early Detection and Treatment of Ventricular Tachycardia: The presence of non-sustained ventricular tachycardia (NSVT) is a risk factor for sudden cardiac death. However, the fact that the patient is on medications like beta blockers and ACE inhibitors, which are known to reduce the risk of arrhythmic events, likely contributed to the patient's survival.

3.  Normal Potassium Levels: The patient's potassium level is within the normal range, which is crucial for the proper functioning of the heart. Hypokalemia can increase the risk of arrhythmic events, including ventricular tachycardia.

4.  Low Pro-BNP Levels: The patient's Pro-BNP level is 720 ng/L, which is elevated but not extremely high. Elevated Pro-BNP levels are associated with heart failure, but a level of 720 ng/L is not uncommon in patients with NYHA Class II heart failure. The relatively low level of elevation suggests that the patient's heart failure is not in an acute decompensated state, which may have contributed to his survival.

5.  Normal TSH Levels: The patient's thyroid function is within the normal range, which is important because thyroid dysfunction can contribute to heart failure and arrhythmias.

6.  Presence of a Sustained LVEF: Although the patient's LVEF is low at 25%, it is not as low as it could be, given the patient's age and other comorbid conditions. A sustained LVEF suggests that the patient's heart is still pumping some blood effectively, which may have contributed to his survival.

7.  Age and Gender: The patient's age and gender are not particularly high-risk factors for mortality in this context. While older adults are at higher risk for mortality, the patient's age is not unusually high for a patient with heart failure.

8.  Other Laboratory Values: The patient's other laboratory values, such as his liver enzymes, electrolytes, and renal function, are within the normal range, which suggests that there are no other significant comorbid conditions that may have contributed to his mortality.

In summary, the patient's survival can be attributed to a combination of optimal medication management, early detection and treatment of ventricular tachycardia, normal potassium levels, relatively low Pro-BNP levels, normal TSH levels, a sustained LVEF, and the absence of other high-risk comorbid conditions."
492,492,P0773,"Age: 69
Gender: Male 
Weight: 68 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 108/68 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 32
ALT or GPT (IU/L): 109.0
AST or GOT (IU/L): 116.0
Total Cholesterol (mmol/L): 3,65
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 420
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,9
LDL (mmol/L): 1,86
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 2362.0
Protein (g/L): 60
T4 (ng/L): 18
Troponin (ng/mL): 0,02
TSH (mIU/L): 3,66
Urea (mg/dL): 12,15
LVEF (%): 20.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 69-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction, has a poor left ventricular ejection fraction (LVEF) of 20%, indicating severe heart failure. Despite this, the patient has survived, which can be attributed to several factors:

1. Optimal Medical Management: The patient is on a comprehensive medication regimen, including beta blockers, loop diuretics, spironolactone, ACE inhibitors, and nitrovasodilators, which are standard treatments for heart failure and ischemic cardiomyopathy. These medications have likely helped to reduce the patient's symptoms, improve his heart function, and prevent further cardiac complications.

2. Low Troponin Levels: The patient's troponin level of 0.02 ng/mL is within normal limits, indicating that there is no ongoing myocardial infarction or significant cardiac damage.

3. Low Pro-BNP Levels: The patient's pro-BNP level of 2362.0 ng/L is elevated, which is consistent with heart failure. However, it is not extremely high, suggesting that the patient's heart failure is not in an acute decompensated state.

4. Good Hemoglobin and Hematocrit Levels: The patient's hemoglobin level of 133 g/L is within the normal range, indicating that he does not have anemia, which can exacerbate heart failure.

5. Controlled Blood Pressure: The patient's blood pressure of 108/68 mmHg is well-controlled, which is essential for managing heart failure and reducing the risk of cardiovascular events.

6. Stable Renal Function: The patient's creatinine level of 124.0 μmol/L is within the normal range, indicating that his renal function is stable, and he is not at risk for acute kidney injury.

7. Monitoring and Follow-up: The patient is likely receiving regular monitoring and follow-up care, which has allowed for early detection and management of any complications, contributing to his survival.

In summary, the patient's survival can be attributed to a combination of optimal medical management, low troponin levels, controlled blood pressure, stable renal function, and good hematological parameters, as well as regular monitoring and follow-up care."
493,493,P0774,"Age: 51
Gender: Female 
Weight: 84 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 111/54 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,77
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 577.0
Protein (g/L): 76
T4 (ng/L): 22
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,53
Urea (mg/dL): 5,66
LVEF (%): 20.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 51-year-old female with idiopathic dilated cardiomyopathy, has a poor left ventricular ejection fraction (LVEF) of 20%, indicating severe heart failure. However, despite her compromised cardiac function, she is a survivor. Several factors contribute to this outcome:

1.  Optimal Medical Management: The patient is on a multidrug regimen that includes beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor. These medications are evidence-based treatments for heart failure with reduced ejection fraction (HFrEF) and are likely contributing to her survival.

2.  Close Monitoring: The patient's condition is closely monitored, as evident from the detailed laboratory results provided. Regular monitoring of biomarkers such as BNP, troponin, and creatinine levels helps in adjusting her treatment plan and making informed decisions.

3.  Lack of Severe Comorbidities: The patient's laboratory results do not indicate any severe comorbidities such as severe anemia, electrolyte imbalances, or acute kidney injury, which could compromise her survival.

4.  Good Renal Function: The patient's creatinine level of 71.0 μmol/L is within a relatively normal range, indicating preserved renal function. This is crucial for the elimination of medications and maintaining electrolyte balance.

5.  Low Troponin Level: The patient's troponin level of 0.01 ng/mL is within a normal range, suggesting that she does not have acute myocardial infarction, which is a common cause of mortality in patients with heart failure.

6.  Normal Hemoglobin Level: The patient's hemoglobin level of 142.0 g/L is within a normal range, indicating that she does not have anemia, which can exacerbate heart failure symptoms and reduce survival.

7.  Normal TSH Level: The patient's TSH level of 0.53 mIU/L is within a normal range, indicating that she does not have thyroid dysfunction, which can contribute to heart failure.

In conclusion, the combination of optimal medical management, close monitoring, lack of severe comorbidities, preserved renal function, low troponin level, normal hemoglobin level, and normal TSH level all contribute to the patient's survival despite her poor LVEF."
494,494,P0775,"Age: 61
Gender: Male 
Weight: 70 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 130/83 mmHg
Past Medical History: Other HF etiology, Dyslipemia
Albumin (g/L): 44
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,47
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,87
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 413.0
Protein (g/L): 74
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,41
Urea (mg/dL): 6,49
LVEF (%): 25.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 61-year-old male with a history of heart failure (HF) and dyslipidemia, who is currently on beta blockers, statins, and an ACE inhibitor. The patient's left ventricular ejection fraction (LVEF) is severely reduced at 25%, indicating significant left ventricular dysfunction.

The patient's laboratory results show elevated levels of B-type natriuretic peptide (BNP) at 413 ng/L, which is indicative of heart failure with reduced ejection fraction (HFrEF). The patient's creatinine level is elevated at 80.0 μmol/L, suggesting impaired renal function, which is common in patients with HFrEF.

The patient's lipid profile shows high total cholesterol and LDL levels, but the patient is already on statins, which are likely controlling these levels. The patient's glucose level is slightly elevated, but it is not significantly high.

The patient's ECG shows monomorphic ventricular extrasystoles, which are common in patients with HFrEF. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that the patient's arrhythmias are not severe.

Considering the patient's age, comorbidities, and current medication regimen, it is likely that the patient's heart failure is well-managed, and the patient is on optimal medical therapy. The patient's ability to survive despite severe left ventricular dysfunction and elevated BNP levels suggests that the patient's condition is stable, and the patient is likely receiving effective treatment."
495,495,P0777,"Age: 69
Gender: Male 
Weight: 89 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 125/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 40,6
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,93
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6
Hemoglobin (g/L): 146.0
HDL (mmol/L): 0,92
Potassium (mEq/L): 4,71
LDL (mmol/L): 2,59
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1487.0
Protein (g/L): 74,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,48
Urea (mg/dL): 8,4
LVEF (%): 38.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient, a 69-year-old male with a history of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipemia, has been managed with a multi-drug regimen consisting of amiodarone, beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 38%, indicating reduced cardiac function.

The patient's high Pro-BNP level of 1487 ng/L suggests elevated B-type natriuretic peptide, which is often associated with heart failure and increased mortality risk. However, the patient's blood pressure is well-controlled at 125/75 mmHg, and the patient is on beta blockers and loop diuretics, which are effective in managing heart failure symptoms.

The patient's lipid profile shows a total cholesterol level of 3.93 mmol/L, which is above the desired target. However, the patient is on statins, which are effective in lowering cholesterol levels.

The patient's creatinine level of 115.0 mmol/L indicates mild renal impairment, but the patient's urea level of 8.4 mg/dL is within the normal range, suggesting that the renal impairment is not severe.

The patient's potassium level is within the normal range, and the patient is not on any medications that would cause significant electrolyte imbalances.

The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are common findings in patients with ischemic cardiomyopathy. However, the patient's heart rate is not excessively high, and the patient is not experiencing any symptoms of arrhythmia.

Given the patient's overall clinical picture, the most likely reason for the patient's survival is the effective management of their heart failure symptoms with beta blockers, loop diuretics, and spironolactone, as well as the patient's adherence to their medication regimen. The patient's well-controlled blood pressure, normal potassium levels, and absence of significant renal impairment also contribute to the patient's survival. Additionally, the patient's low troponin level of 0.01 ng/mL suggests that the patient is not experiencing any acute myocardial infarction, which would be a significant concern for mortality."
496,496,P0778,"Age: 73
Gender: Female 
Weight: 56 kg
Height: 145 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 49,5
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 6,9
Creatinine (mmol/L): 110.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 126.0
HDL (mmol/L): 0,79
Potassium (mEq/L): 4,5
LDL (mmol/L): 5,16
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 1058.0
Protein (g/L): 89,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,35
Urea (mg/dL): 9,9
LVEF (%): 64.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient, a 73-year-old female with a history of valvular cardiomyopathy, has a relatively favorable outcome, which can be attributed to several factors:

1.  Effective Medication Management: The patient is on a comprehensive regimen of medications, including Calcium Channel Blockers, Beta Blockers, Loop Diuretics, Spironolactone, and Statins. These medications are tailored to manage her valvular cardiomyopathy, hypertension, and dyslipidemia, which are all contributing factors to her condition.

2.  Good Blood Pressure Control: The patient's blood pressure is well-managed at 110/80 mmHg, which is within the normal range. This is crucial in managing her valvular cardiomyopathy and reducing the risk of cardiovascular events.

3.  Normal Renal Function: The patient's creatinine level is 110.0 mmol/L, which is within the normal range. This indicates that her kidneys are functioning properly, and there is no evidence of renal impairment that could exacerbate her cardiomyopathy.

4.  Low Troponin Levels: The patient's troponin level is 0.01 ng/mL, which is within the normal range. This suggests that there is no acute myocardial infarction or significant cardiac damage.

5.  Mild Elevation of Pro-BNP: The patient's Pro-BNP level is 1058.0 ng/L, which is mildly elevated. While an elevated Pro-BNP level can indicate heart failure, the patient's LVEF is 64.0%, which suggests that her heart function is still relatively preserved.

6.  Good Electrocardiogram (ECG) Results: The patient's ECG shows a monomorphic ventricular extrasystole, but no signs of sustained ventricular tachycardia, non-sustained ventricular tachycardia, or bradycardia. This suggests that her cardiac rhythm is relatively stable.

7.  Good Nutritional Status: The patient's albumin level is 49.5 g/L, which is within the normal range. This suggests that she is well-nourished and has a good nutritional status, which is essential for maintaining cardiac health.

8.  Lack of Severe Liver Dysfunction: The patient's AST and ALT levels are within the normal range, indicating that there is no severe liver dysfunction that could contribute to her cardiomyopathy.

9.  Good Lipid Profile: The patient's total cholesterol level is 6.9 mmol/L, which is within the normal range. Her LDL level is also within the normal range, indicating that her dyslipidemia is well-managed.

10.  Hemoglobin Level: The patient's hemoglobin level is 126.0 g/L, which is within the normal range. This suggests that her anemia is well-managed, and there is no significant iron deficiency that could contribute to her cardiomyopathy.

Considering these factors, the patient's outcome as a survivor can be attributed to her effective medication management, good blood pressure control, normal renal function, low troponin levels, mild elevation of Pro-BNP, good ECG results, good nutritional status, lack of severe liver dysfunction, good lipid profile, and well-managed anemia."
497,497,P0780,"Age: 51
Gender: Female 
Weight: 43 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 130/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40,1
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,26
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 110.0
HDL (mmol/L): 1,57
Potassium (mEq/L): 4,01
LDL (mmol/L): 2,93
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1129.0
Protein (g/L): 80,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 7,28
Urea (mg/dL): 4,9
LVEF (%): 28.0
Medications: Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 51-year-old female with a history of idiopathic dilated cardiomyopathy, has been managed with a combination of beta blockers, spironolactone, and an ACE inhibitor. Despite the presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG, the patient is classified as a survivor. 

Several factors contribute to this outcome: 

1. Effective Medication Management: The patient is on a comprehensive regimen of beta blockers, spironolactone, and an ACE inhibitor, which are standard treatments for heart failure with reduced ejection fraction (HFrEF). These medications have been shown to improve survival and reduce hospitalization rates in patients with HFrEF.

2. LVEF of 28%: Although the patient's left ventricular ejection fraction (LVEF) is severely reduced at 28%, it is not the lowest possible value. The patient's LVEF is still within the range where some patients can experience improved survival and quality of life with optimal medical therapy.

3. Normal Blood Pressure: The patient's blood pressure is well-controlled at 130/75 mmHg, which is within the target range for patients with heart failure. Uncontrolled hypertension can exacerbate heart failure and worsen outcomes.

4. Normal Glucose and Potassium Levels: The patient's glucose and potassium levels are within normal limits, which is crucial for patients with heart failure. Hyperglycemia and hypokalemia can worsen cardiac function and increase the risk of arrhythmias.

5. Pro-BNP Level: Although the patient's Pro-BNP level is elevated at 1129.0 ng/L, indicating increased ventricular stretch and potential heart failure, it is not the highest possible value. Elevated Pro-BNP levels can be seen in patients with heart failure, but the level in this patient is not so high that it suggests an extremely poor prognosis.

6. ECG Findings: While the patient has non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles, these are not uncommon in patients with heart failure and are not necessarily indicative of a poor prognosis. The absence of sustained ventricular tachycardia or other life-threatening arrhythmias is also a positive sign.

In summary, the combination of effective medication management, controlled blood pressure, normal glucose and potassium levels, and the absence of life-threatening arrhythmias contribute to the patient's survival."
498,498,P0782,"Age: 77
Gender: Female 
Weight: 43 kg
Height: 146 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 43,6
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,65
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 11,5
Hemoglobin (g/L): 122.0
HDL (mmol/L): 1,12
Potassium (mEq/L): 4,09
LDL (mmol/L): 1,89
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 481.0
Protein (g/L): 80,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,44
Urea (mg/dL): 6,9
LVEF (%): 25.0
Medications: Diabetes Medication, Amiodarone, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 77-year-old female with a history of ischemic dilated cardiomyopathy, diabetes, and myocardial infarction. Despite her complex medical history and low left ventricular ejection fraction (LVEF) of 25%, the patient has been managed with a comprehensive treatment regimen that includes beta blockers, loop diuretics, statins, ACE inhibitors, and a nitrovasodilator. 

The patient's current blood pressure is within a relatively normal range (110/70 mmHg), and her glucose levels are under control with diabetes medication. Her liver enzymes (ALT and AST) are within normal limits, suggesting that her liver function is preserved.

The patient's low LVEF of 25% indicates significant left ventricular dysfunction, but the presence of a polymorphic ventricular extrasystole and non-sustained ventricular tachycardia on the ECG suggests that the patient is at risk for arrhythmic events. However, the fact that she is on amiodarone, a medication commonly used to prevent arrhythmias, may have contributed to her survival.

The patient's BNP (brain natriuretic peptide) level is elevated at 481 ng/L, which is consistent with heart failure. However, the patient's overall clinical presentation and treatment regimen suggest that she is being managed appropriately for her condition.

Given the patient's age, complex medical history, and current treatment regimen, her survival outcome is likely due to the combination of effective medical therapy, close monitoring, and appropriate management of her heart failure and arrhythmias."
499,499,P0783,"Age: 76
Gender: Female 
Weight: 84 kg
Height: 145 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 39,8
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 5,26
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 8,7
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 3,59
LDL (mmol/L): 3,15
Sodium (mEq/L): 140.0
Protein (g/L): 75,4
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,88
Urea (mg/dL): 10
LVEF (%): 59.0
Medications: Calcium Channel Blocker, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient, a 76-year-old female, has been diagnosed with Hypertensive cardiomyopathy and hypertension. The patient's left ventricular ejection fraction (LVEF) is 59%, indicating mild left ventricular dysfunction, which is consistent with her NYHA Class II classification, indicating mild to moderate symptoms of heart failure. 

Her blood pressure is well-controlled at 120/80 mmHg, and she is on a regimen of Calcium Channel Blocker, Digoxin, Loop Diuretics, and ACE Inhibitor, which are appropriate medications for managing hypertension and heart failure.

The patient's laboratory results show mild elevation of liver enzymes (ALT and AST) and slightly low HDL cholesterol, but these are not indicative of severe organ damage. Her electrolyte levels, including potassium, are within normal limits, and her troponin level is low, indicating no acute myocardial infarction.

The patient's albumin and protein levels are within normal limits, indicating no significant liver or kidney dysfunction. Her creatinine level is slightly elevated, but not significantly so, indicating mild kidney impairment. Her urea level is within normal limits.

Given the patient's overall clinical presentation and laboratory results, it is likely that she is a survivor due to her well-managed hypertension and heart failure, as well as her mild left ventricular dysfunction. The patient's age and sex also play a role in her ability to tolerate her condition, as older adults with well-managed heart failure often have a better prognosis than those with uncontrolled disease."
500,500,P0785,"Age: 72
Gender: Male 
Weight: 81 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 42,6
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 5,54
Creatinine (mmol/L): 130.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,84
Potassium (mEq/L): 3,29
LDL (mmol/L): 3,3
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 4250.0
Protein (g/L): 71,8
Troponin (ng/mL): 0,15
TSH (mIU/L): 2,92
Urea (mg/dL): 13,5
LVEF (%): 30.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 72-year-old male with a history of ischemic dilated cardiomyopathy and myocardial infarction, indicating a compromised cardiac function. His left ventricular ejection fraction (LVEF) of 30% suggests severe left ventricular dysfunction, which is consistent with the diagnosis of heart failure.

The patient's current medications, including an angiotensin II receptor blocker, beta blockers, loop diuretics, spironolactone, and statins, are appropriate for managing heart failure and ischemic heart disease. These medications aim to reduce symptoms, slow disease progression, and improve quality of life.

The patient's blood pressure is within a relatively normal range (100/70 mmHg), which is beneficial for heart health. His electrolyte levels, including potassium (3.29 mEq/L), are also within a normal range.

The elevated Pro-BNP level (4250.0 ng/L) is consistent with heart failure, as BNP is a marker of cardiac stress and strain. However, the patient's troponin level (0.15 ng/mL) is within a normal range, indicating no acute myocardial infarction.

The patient's liver enzymes (ALT and AST) are within normal limits, suggesting that there is no significant liver dysfunction contributing to his heart condition. His total cholesterol and LDL levels are slightly elevated but are being managed with statins.

The patient's kidney function, as indicated by creatinine levels (130.0 μmol/L), is compromised, which is not uncommon in patients with heart failure. His urea levels (13.5 mg/dL) are also elevated, further indicating renal impairment.

Given the patient's overall clinical picture, the presence of heart failure, and the fact that his symptoms are being managed with appropriate medications, the patient's outcome as a survivor is likely due to the effective management of his condition, including the use of evidence-based therapies for heart failure and ischemic heart disease. His relatively stable vital signs and lack of acute cardiac events (e.g., myocardial infarction) also support this outcome."
501,501,P0786,"Age: 64
Gender: Female 
Weight: 71 kg
Height: 153 cm
NYHA Class: II
Blood Pressure: 150/70 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 43,1
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,67
Creatinine (mmol/L): 131.0
Gamma-glutamil transpeptidase (IU/L): 149
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 118.0
HDL (mmol/L): 1,57
Potassium (mEq/L): 4,26
LDL (mmol/L): 3,66
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 614.0
Protein (g/L): 81,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,53
Urea (mg/dL): 9,9
LVEF (%): 45.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient outcome of survival in this case can be attributed to a combination of factors, including the patient's current medical management and the absence of severe cardiac decompensation. 

The patient has a history of valvular cardiomyopathy, myocardial infarction, hypertension, and diabetes, which are all significant risk factors for cardiac disease. However, the patient's current LVEF (Left Ventricular Ejection Fraction) of 45% suggests that the heart is still functioning to some extent, indicating that the patient may not be in a state of advanced heart failure.

The patient's current medications, including angiotensin II receptor blockers, loop diuretics, spironolactone, and statins, are all appropriate for managing heart failure and hypertension, and are likely contributing to the patient's survival. The use of spironolactone, in particular, is notable as it is an aldosterone antagonist that has been shown to improve survival in patients with heart failure.

The patient's laboratory results also suggest that there is no severe kidney dysfunction, with a creatinine level of 131.0 umol/L, which is within the normal range. This suggests that the patient's kidneys are functioning adequately, which is an important factor in cardiac disease management.

The absence of severe cardiac arrhythmias on the ECG, such as ventricular tachycardia or bradycardia, is also a positive sign. The presence of paroxysmal supraventricular tachycardia (PSVT) is a common arrhythmia that is generally well-tolerated and not life-threatening.

Overall, the combination of appropriate medical management, absence of severe cardiac decompensation, and the patient's relatively preserved LVEF suggest that the patient's survival is likely due to these factors."
502,502,P0787,"Age: 74
Gender: Female 
Weight: 60 kg
Height: 142 cm
NYHA Class: II
Blood Pressure: 105/60 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 41,7
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,56
Potassium (mEq/L): 3,59
LDL (mmol/L): 3,34
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1069.0
Protein (g/L): 68,6
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,86
Urea (mg/dL): 8,3
LVEF (%): 55.0
Medications: Amiodarone, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient, a 74-year-old female with a history of valvular cardiomyopathy, has a complex medical history that contributes to her overall outcome. The patient's LVEF (left ventricular ejection fraction) of 55% indicates that her heart is functioning at a relatively reduced capacity, which is a common finding in patients with valvular cardiomyopathy.

The patient's use of medications such as Amiodarone, Digoxin, Loop Diuretics, Spironolactone, and ACE Inhibitor suggests that she has a history of arrhythmias and heart failure. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG further supports this. The patient's Pro-BNP level of 1069 ng/L is elevated, indicating increased stress on the heart, which is consistent with her heart failure diagnosis.

However, despite these risk factors, the patient has survived, which can be attributed to several factors. The patient's weight and height are within a relatively normal range for her age, which may indicate that she is not significantly malnourished or dehydrated. Her hemoglobin level of 128 g/L is also within the normal range, indicating adequate oxygen delivery to her tissues.

The patient's blood pressure of 105/60 mmHg is within a relatively normal range, which may indicate that her cardiovascular system is not experiencing significant stress or strain. The patient's electrolyte levels, including potassium and sodium, are also within normal ranges, which is essential for maintaining proper cardiac function.

The patient's liver function tests (ALT, AST, and GGT) are within normal ranges, indicating that her liver is functioning adequately. The patient's glucose level of 5.1 mmol/L is also within a relatively normal range, which may indicate that she does not have diabetes, a common comorbidity in patients with heart failure.

Overall, while the patient has a complex medical history and several risk factors, her overall health status and laboratory results suggest that she has a relatively stable cardiovascular system, which contributed to her survival."
503,503,P0789,"Age: 45
Gender: Male 
Weight: 88 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Hypertropic cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 6,47
Creatinine (mmol/L): 111.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 157.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,6
LDL (mmol/L): 4,24
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 35.0
Protein (g/L): 76
T3 (pg/dL): 0,06
T4 (ng/L): 17
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,45
Urea (mg/dL): 8,32
LVEF (%): 58.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 45-year-old male with a history of hypertrophic cardiomyopathy and hypertension, which are both risk factors for cardiovascular disease. However, despite these risk factors, the patient has been on beta blockers and ACE inhibitors, which are standard treatments for these conditions. 

The patient's LVEF (Left Ventricular Ejection Fraction) is 58%, which is within the normal range (50-70%). This suggests that the patient's heart function is relatively preserved, which is a good prognostic sign.

The patient's blood pressure is within a relatively normal range (120/70 mmHg), which is also a good sign.

The patient's troponin level is 0.005 ng/mL, which is within the normal range (<0.03 ng/mL), indicating that there is no evidence of acute myocardial infarction.

The patient's Pro-BNP level is 35.0 ng/L, which is within the normal range (<100 ng/L), indicating that there is no evidence of heart failure.

The patient's TSH level is 1.45 mIU/L, which is within the normal range (0.4-4.5 mIU/L), indicating that the patient's thyroid function is normal.

The patient's T3 and T4 levels are also within the normal range, indicating that there is no evidence of hypothyroidism.

Overall, the patient's laboratory results and clinical findings suggest that he is relatively stable and that his cardiovascular disease is well-managed. Therefore, the patient outcome is a survivor."
504,504,P0791,"Age: 75
Gender: Male 
Weight: 85 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 125/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 45.0
AST or GOT (IU/L): 35.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 162.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4
LDL (mmol/L): 1,81
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 2542.0
Protein (g/L): 70
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,2
Urea (mg/dL): 11,65
LVEF (%): 40.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient's outcome as a survivor can be attributed to several factors, despite their complex medical history and current clinical presentation. 

Firstly, the patient's blood pressure is well-controlled at 125/75 mmHg, which reduces the risk of cardiovascular complications. Their NYHA Class II classification indicates that they are experiencing some limitations in physical activity but are still able to perform everyday tasks without significant symptoms. 

Their current medications, including ACE inhibitors, statins, and spironolactone, are beneficial in managing their ischemic dilated cardiomyopathy, hypertension, and diabetes. The use of digoxin and loop diuretics also helps in managing heart failure symptoms and fluid overload. 

The patient's LVEF of 40% indicates that their heart is still pumping efficiently to some extent, which is crucial for survival. Although their Troponin level is slightly elevated, it is within a non-acute range (0.01 ng/mL), suggesting that the myocardial infarction is not an acute event. 

The patient's Pro-BNP level of 2542.0 ng/L is elevated, indicating heart failure, but not to an extreme level that would suggest a poor prognosis. Their TSH level is within the normal range, ruling out any potential thyroid-related complications. 

The patient's electrolyte levels, including potassium, sodium, and urea, are within a relatively normal range, which is essential for maintaining cardiac function. Their glucose level is well-controlled, which is crucial for preventing diabetic complications.

Considering these factors, the patient's survival outcome can be attributed to their well-managed medical conditions, effective medication regimen, and relatively stable cardiac function."
505,505,P0795,"Age: 73
Gender: Male 
Weight: 76 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 87/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,8
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 97
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,07
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1961.0
Protein (g/L): 74
T4 (ng/L): 17
TSH (mIU/L): 4,3
Urea (mg/dL): 6,32
LVEF (%): 25.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 73-year-old male with a history of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipemia. His current New York Heart Association (NYHA) Class II indicates that he experiences some limitations in physical activity but is still able to perform daily tasks without significant symptoms. 

The patient's low blood pressure (87/50 mmHg) suggests possible orthostatic hypotension or a decreased cardiac output, which is consistent with his dilated cardiomyopathy and reduced left ventricular ejection fraction (LVEF) of 25%. 

The laboratory results show elevated liver enzymes (ALT and AST), which could indicate liver disease or drug-induced liver injury. His total cholesterol and LDL levels are within the target range for a patient on statin therapy. However, his HDL level is low, which is a risk factor for cardiovascular disease. 

The patient's B-type natriuretic peptide (BNP) level is elevated at 1961 ng/L, indicating increased ventricular wall stress and a poor prognosis. His hemoglobin level is within the normal range, and his electrolyte levels are mostly within normal limits.

The ECG shows polymorphic ventricular extrasystoles, which can be a sign of electrical instability in the heart. However, the absence of sustained ventricular tachycardia or non-sustained ventricular tachycardia suggests that the patient is not at immediate risk of life-threatening arrhythmias.

Given the patient's age, comorbidities, and laboratory results, the patient's survival can be attributed to the following factors:

1.  The patient is on optimal medical therapy for heart failure and dyslipidemia, which includes beta blockers, statins, and an ACE inhibitor.
2.  His NYHA Class II status indicates that he is still able to perform daily activities without significant symptoms, suggesting that his heart failure is not severe.
3.  The patient's LVEF of 25% is low, but it is not the lowest possible value, indicating that the patient's heart is still able to pump some blood effectively.
4.  The patient's BNP level is elevated, but it is not extremely high, which may indicate that the patient's heart failure is not rapidly progressing.
5.  The patient's overall laboratory results, including his liver enzymes and electrolyte levels, are not significantly abnormal, which suggests that he is not experiencing any acute complications.

Overall, the patient's survival can be attributed to his optimal medical therapy, his relatively stable heart failure status, and the absence of any acute complications."
506,506,P0796,"Age: 61
Gender: Female 
Weight: 69 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 108/70 mmHg
Past Medical History: Other HF etiology, Dyslipemia, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,42
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,48
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 1614.0
Protein (g/L): 78
T4 (ng/L): 15
TSH (mIU/L): 3,01
Urea (mg/dL): 9,48
LVEF (%): 20.0
Medications: Beta Blockers, Digoxin, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient's outcome as a survivor can be attributed to several factors that contributed to her resilience and treatment response. 

Firstly, the patient is on a comprehensive medication regimen, including beta blockers, digoxin, statins, and an ACE inhibitor, which are all crucial for managing heart failure (HF) and related conditions. Beta blockers help reduce the heart rate and contractility, while digoxin enhances the contractility of the heart. Statins lower cholesterol levels to reduce the risk of cardiovascular events, and ACE inhibitors help alleviate HF symptoms by reducing afterload. 

The patient's NYHA Class II indicates that she has mild to moderate symptoms of heart failure, which is a positive sign as it suggests that her condition is manageable. 

The laboratory results show that her kidney function is relatively preserved, as indicated by a creatinine level of 80.0 umol/L, which is within the normal range. This is a good prognostic sign, as kidney dysfunction is often associated with worse outcomes in patients with HF.

The patient's LVEF of 20% is extremely low, indicating severe left ventricular dysfunction, but the fact that she is still alive suggests that she has adapted to her condition over time. The low LVEF also indicates that her heart has likely undergone significant remodeling, which can be a protective mechanism in the long term.

The elevated Pro-BNP level of 1614.0 ng/L is consistent with HF, but the fact that she is on beta blockers and ACE inhibitors, which are known to reduce BNP levels, suggests that her treatment is effective in managing her condition.

The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG indicates that the patient has arrhythmias, which are common in patients with HF. However, the fact that these arrhythmias are non-sustained suggests that they are not life-threatening, and the patient is able to compensate for them.

In summary, the patient's outcome as a survivor can be attributed to her comprehensive medication regimen, relatively preserved kidney function, adapted heart function, and effective management of her HF symptoms."
507,507,P0797,"Age: 81
Gender: Male 
Weight: 77 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 6
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,85
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 1511.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 21
Troponin (ng/mL): 0,2
TSH (mIU/L): 1,54
Urea (mg/dL): 8,9
LVEF (%): 20.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's age (81) and the presence of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers dilate, leading to reduced heart function, the patient is at a high risk for heart failure and arrhythmias. The patient's left ventricular ejection fraction (LVEF) of 20% is significantly below the normal range (50-70%), indicating severe heart failure.

The patient's NYHA Class II classification indicates that the patient has mild to moderate symptoms of heart failure, which may include shortness of breath and fatigue. However, the presence of non-sustained ventricular tachycardia (VT) and polymorphic ventricular extrasystoles on the ECG suggests that the patient is at risk for more severe arrhythmias, which can be life-threatening.

The patient's laboratory results show elevated levels of pro-BNP (B-type natriuretic peptide), which is a biomarker for heart failure. The elevated levels of troponin (0.2 ng/mL) indicate myocardial injury, likely due to previous myocardial infarction. The patient's total cholesterol level of 4.34 mmol/L is elevated, which may contribute to the progression of atherosclerosis and further worsen heart function.

Despite the patient's advanced age and multiple comorbidities, the patient is on optimal medical therapy with an angiotensin II receptor blocker, loop diuretics, statins, and nitrovasodilators. The patient's medications are aimed at reducing blood pressure, improving heart function, and preventing further cardiovascular events.

Considering the patient's advanced age, multiple comorbidities, and the presence of severe heart failure and arrhythmias, the patient's survival is remarkable. The patient's ability to survive suggests that the patient's medical therapy is effective in managing the symptoms and slowing the progression of heart failure. The patient's outcome is likely due to the combination of optimal medical therapy, the patient's resilience, and the absence of severe complications such as cardiac arrest or sudden cardiac death."
508,508,P0800,"Age: 72
Gender: Male 
Weight: 64 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 5,5
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 162.0
HDL (mmol/L): 1,13
Potassium (mEq/L): 4,38
LDL (mmol/L): 3,88
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 6088.0
Protein (g/L): 72,5
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,81
Urea (mg/dL): 6,8
LVEF (%): 30.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient's outcome as a survivor can be attributed to several factors despite their advanced age, valvular cardiomyopathy, and decreased left ventricular ejection fraction (LVEF) of 30%. 

Firstly, the patient's blood pressure is within a relatively normal range (130/80 mmHg), which indicates that their cardiovascular system is not experiencing acute hypertension, a common cause of cardiac decompensation.

The patient's kidney function, as indicated by creatinine levels (106.0 μmol/L), is slightly elevated but not severely impaired. This suggests that their renal function is not significantly compromised, which is essential for the clearance of waste products, including medications, and maintaining electrolyte balance.

The patient's medication regimen, including digoxin, loop diuretics, spironolactone, and an ACE inhibitor, is comprehensive and aimed at managing heart failure symptoms, reducing fluid overload, and improving cardiac function. The presence of these medications likely contributed to the patient's stable condition.

The patient's troponin levels are within normal limits (0.01 ng/mL), indicating that there is no acute myocardial infarction or significant cardiac ischemia. The absence of significant elevations in AST and ALT levels suggests that there is no significant liver dysfunction, which can contribute to cardiac decompensation.

The patient's hemoglobin level (162.0 g/L) is within the normal range, indicating adequate oxygen delivery to tissues, which is essential for maintaining cardiac function.

The patient's pro-BNP (brain natriuretic peptide) level is elevated (6088.0 ng/L), which is consistent with heart failure. However, the level is not extremely high, suggesting that the patient's heart failure is not in an acute decompensated state.

The presence of ventricular extrasystoles and non-sustained ventricular tachycardia (VT) on the ECG is concerning but not uncommon in patients with cardiomyopathy. The fact that the VT is non-sustained suggests that it is not causing significant hemodynamic instability.

Overall, the combination of the patient's relatively stable blood pressure, kidney function, comprehensive medication regimen, and lack of acute cardiac ischemia or liver dysfunction likely contributed to their survival outcome."
509,509,P0801,"Age: 72
Gender: Female 
Weight: 60 kg
Height: 154 cm
NYHA Class: III
Blood Pressure: 95/60 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 33,4
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 3,64
Creatinine (mmol/L): 137.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 10,9
Hemoglobin (g/L): 123.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 3,36
LDL (mmol/L): 2,14
Sodium (mEq/L): 129.0
Pro-BNP (ng/L): 2233.0
Protein (g/L): 71,3
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,81
Urea (mg/dL): 13,2
LVEF (%): 70.0
Medications: Amiodarone, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient, a 72-year-old female with a history of valvular cardiomyopathy, diabetes, and hypertension, has been managed with a combination of medications including Amiodarone, Digoxin, Loop Diuretics, Spironolactone, and ACE Inhibitor. Despite the presence of several comorbidities and a reduced albumin level (indicative of possible malnutrition or liver dysfunction), the patient's LVEF (Left Ventricular Ejection Fraction) is relatively well-preserved at 70%.

The patient's blood pressure is slightly low, with a systolic pressure of 95 mmHg, which may be a concern for adequate perfusion of vital organs. However, the patient's creatinine level is elevated at 137.0 mmol/L, indicating some degree of renal impairment. The patient's pro-BNP (B-type natriuretic peptide) level is elevated at 2233.0 ng/L, which suggests that the patient's heart is under stress, possibly due to the valvular cardiomyopathy.

The patient's ECG shows monomorphic ventricular extrasystoles, but no sustained ventricular tachycardia or bradycardia. The presence of extrasystoles may indicate underlying cardiac ischemia or scarring, but the patient's troponin level is within normal limits, suggesting that there is no acute myocardial infarction.

Given the patient's age, comorbidities, and medication regimen, it is likely that the patient is at increased risk for adverse cardiac events. However, the patient's relatively well-preserved LVEF and the absence of acute cardiac ischemia or infarction suggest that the patient is likely to survive with continued medical management. The patient's ability to survive is likely due to the combination of medications, including ACE inhibitors and beta-blockers (implied by the presence of Amiodarone and Digoxin), which help to manage heart failure and reduce the risk of cardiac arrhythmias.

Overall, the patient's outcome is likely due to the combination of effective medical management and the relatively well-preserved cardiac function, despite the presence of several comorbidities."
510,510,P0802,"Age: 52
Gender: Male 
Weight: 61 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 105/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 37,9
ALT or GPT (IU/L): 49.0
AST or GOT (IU/L): 46.0
Total Cholesterol (mmol/L): 5,29
Creatinine (mmol/L): 126.0
Gamma-glutamil transpeptidase (IU/L): 75
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 120.0
HDL (mmol/L): 0,99
Potassium (mEq/L): 5,43
LDL (mmol/L): 3,78
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 11001.0
Protein (g/L): 68,4
Troponin (ng/mL): 0,09
TSH (mIU/L): 3,64
Urea (mg/dL): 13,5
LVEF (%): 21.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient's outcome of survival can be attributed to several factors:

1.  Optimal Medication Management: The patient is on a comprehensive regimen of medications, including beta blockers, loop diuretics, spironolactone, statins, ACE inhibitors, and nitrovasodilators. This combination of medications helps to manage the patient's heart failure symptoms, reduce the risk of arrhythmias, and improve cardiac function.

2.  Early Detection and Treatment of Myocardial Infarction: The patient has a history of myocardial infarction, but it appears that the infarction was detected and treated promptly, which may have helped to minimize the extent of cardiac damage and improve the patient's prognosis.

3.  Monitoring and Management of Heart Failure: The patient's NYHA Class III indicates that the patient experiences symptoms of heart failure, but is still able to perform daily activities with some limitation. The patient's low LVEF (21.0%) suggests significant left ventricular dysfunction, but the fact that the patient is still alive and able to tolerate some physical activity indicates that the heart failure is being managed effectively.

4.  Regular Monitoring and Follow-up: The patient's laboratory results and ECG findings suggest that the patient is being closely monitored and followed up regularly. This regular monitoring may have helped to identify any potential complications early on and allowed for prompt intervention.

5.  Good Support System: The patient's ability to survive may also be attributed to a good support system, including family and medical care providers who are working together to manage the patient's condition.

However, it is essential to note that the patient's Pro-BNP level is significantly elevated (11001.0 ng/L), which suggests that the patient is experiencing significant cardiac stress and may be at risk for further cardiac complications. Close monitoring and further management of the patient's condition will be necessary to prevent future complications."
511,511,P0803,"Age: 48
Gender: Male 
Weight: 70 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 105/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 45,7
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 6,69
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 194
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,08
Potassium (mEq/L): 4
LDL (mmol/L): 5,11
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 2954.0
Protein (g/L): 77,8
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,45
Urea (mg/dL): 5,2
LVEF (%): 17.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome as a survivor can be attributed to several factors. 

Firstly, the patient's age of 48 and NYHA Class II classification indicate that the patient is still relatively young and has a moderate level of functional impairment. This suggests that the patient has a relatively good prognosis.

Secondly, despite having a history of ischemic dilated cardiomyopathy, myocardial infarction, and hypertension, the patient is on a comprehensive treatment regimen consisting of beta blockers, loop diuretics, spironolactone, statins, ACE inhibitor, and nitrovasodilator. These medications are known to improve symptoms, slow disease progression, and reduce the risk of adverse outcomes in patients with heart failure.

Thirdly, the patient's laboratory results show that the liver enzymes (ALT and AST) are within normal limits, indicating that there is no significant liver dysfunction. The total cholesterol level is elevated, but the LDL level is being managed with statins, which should help reduce the risk of cardiovascular events.

Fourthly, the patient's potassium level is within the normal range, which is essential for maintaining a stable cardiac rhythm. The hemoglobin level is also within the normal range, indicating that the patient is not anemic, which can be a risk factor for cardiovascular disease.

Fifthly, the pro-BNP level is elevated at 2954.0 ng/L, indicating that the patient has significant cardiac stress, but the LVEF of 17.0% suggests that the patient's heart is still functioning, albeit with reduced efficiency.

Lastly, the absence of paroxysmal supraventricular tachyarrhythmia and bradycardia on the ECG suggests that the patient does not have any other underlying cardiac arrhythmias that could compromise their survival.

Considering these factors, the patient's outcome as a survivor can be attributed to the comprehensive management of their heart failure, the use of appropriate medications, and the absence of other underlying cardiac conditions that could have compromised their survival."
512,512,P0805,"Age: 60
Gender: Female 
Weight: 77 kg
Height: 148 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,83
Creatinine (mmol/L): 177.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,35
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,3
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 227.0
Protein (g/L): 71
T3 (pg/dL): 0,03
T4 (ng/L): 15
Troponin (ng/mL): 3,4
TSH (mIU/L): 1,63
Urea (mg/dL): 25,1
LVEF (%): 40.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 60-year-old female with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction. The patient's ejection fraction (LVEF) is 40%, indicating reduced left ventricular function. The patient's Pro-BNP level is elevated at 227.0 ng/L, which is a marker of heart failure. However, the patient is on a combination of medications, including an ACE inhibitor, Angiotensin II Receptor Blocker, and Loop Diuretics, which are standard treatments for heart failure and hypertension.

The patient's blood pressure is well-controlled at 110/70 mmHg, and her glucose level is within the target range for diabetes management. The patient's lipid profile shows a total cholesterol of 4.83 mmol/L, which is slightly elevated, but her HDL level is low at 1.35 mmol/L.

The patient's ECG shows polymorphic ventricular extrasystoles, which are common in patients with heart disease, but there is no evidence of sustained ventricular tachycardia or bradycardia. The patient's TSH level is within the normal range, indicating no evidence of hypothyroidism.

Considering the patient's history, medications, and laboratory results, the patient's outcome as a survivor suggests that the patient's heart failure is being effectively managed with her current treatment regimen. The patient's controlled blood pressure, glucose level, and lipid profile also indicate good management of her comorbidities. The patient's elevated Pro-BNP level is likely a reflection of her underlying heart disease, but the lack of other indicators of poor cardiac function suggests that the patient is doing well despite her diagnosis."
513,513,P0808,"Age: 44
Gender: Male 
Weight: 86 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 49.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,67
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,47
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 497.0
Protein (g/L): 74
T3 (pg/dL): 0,06
T4 (ng/L): 15
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,24
Urea (mg/dL): 5,83
LVEF (%): 19.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 44-year-old male with a history of idiopathic dilated cardiomyopathy, has been treated with a comprehensive medication regimen including beta blockers, digoxin, loop diuretics, spironolactone, statins, and an ACE inhibitor. His left ventricular ejection fraction (LVEF) is severely reduced at 19%, indicating significant left ventricular dysfunction. 

The patient's biomarkers for cardiac damage, such as troponin (0.005 ng/mL), are within normal limits, suggesting that there is no acute myocardial infarction or significant cardiac damage at the time of the assessment.

The patient's thyroid function tests (TSH: 1.24 mIU/L, T3: 0.06 pg/dL, T4: 15 ng/L) are within normal limits, ruling out hypothyroidism as a contributing factor to his heart failure.

The patient's renal function is relatively preserved, as indicated by a creatinine level of 96.0 μmol/L and urea level of 5.83 mg/dL.

The patient's lipid profile (Total Cholesterol: 3.67 mmol/L, HDL: 1.11 mmol/L, LDL: 1.47 mmol/L) is abnormal, indicating a high risk of atherosclerotic cardiovascular disease, but the patient is on statins, which are effective in managing cholesterol levels.

The patient's electrolyte levels (Potassium: 4.6 mEq/L) are within normal limits, which is essential for optimal cardiac function.

The patient's albumin level (45 g/L) is slightly low, which may indicate malnutrition or liver dysfunction. However, the patient's AST and ALT levels (25.0 IU/L and 49.0 IU/L, respectively) are within normal limits, suggesting that liver function is relatively preserved.

Given the patient's comprehensive treatment plan and relatively stable vital signs, it is likely that the patient's outcome is a result of effective management of his heart failure and other comorbidities. The patient's NYHA class II classification indicates that he is experiencing mild to moderate symptoms of heart failure, and his LVEF of 19% suggests that he has significant left ventricular dysfunction. However, his overall clinical picture suggests that he is being effectively managed, which contributed to his survival."
514,514,P0810,"Age: 62
Gender: Female 
Weight: 78 kg
Height: 161 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,55
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4
LDL (mmol/L): 2,51
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 335.0
Protein (g/L): 68
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,47
Urea (mg/dL): 6,49
LVEF (%): 30.0
Medications: Beta Blockers, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 62-year-old female with a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge, reducing the heart's ability to pump blood effectively. Despite this, the patient has been managed with beta blockers, ACE inhibitors, and nitrovasodilators, which are standard medications for heart failure and cardiomyopathy.

The patient's left ventricular ejection fraction (LVEF) is 30%, which is significantly reduced, indicating a poor heart function. However, the patient's Pro-BNP level of 335 ng/L is elevated, but not excessively high, suggesting that the patient is not in severe heart failure at the moment.

The patient's ECG shows a polymorphic ventricular extrasystole, which is a type of irregular heartbeat, but no sustained ventricular tachycardia or bradycardia. The presence of TPSV (paroxysmal supraventricular tachyarrhythmia) is noted, but it is not a critical finding in this context.

The patient's laboratory results show mild liver enzyme elevations (ALT and AST) and a slightly elevated creatinine level, which may indicate some degree of kidney impairment. However, the patient's hemoglobin and urea levels are within normal limits.

Considering the patient's overall clinical picture, the patient's age, and the presence of a relatively well-managed heart condition, it is likely that the patient is a survivor. The patient's medication regimen and the lack of severe symptoms or critical ECG findings suggest that the patient is being effectively managed, and the patient's outcome is likely to be positive."
515,515,P0811,"Age: 65
Gender: Male 
Weight: 57 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,8
LDL (mmol/L): 3,47
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 264.0
Protein (g/L): 78
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,62
Urea (mg/dL): 9,65
LVEF (%): 25.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 65-year-old male with a history of ischemic dilated cardiomyopathy and myocardial infarction, which indicates that he has a compromised heart function. Despite this, he is on a comprehensive treatment regimen consisting of beta blockers, spironolactone, statins, and an ACE inhibitor, which are all evidence-based medications for heart failure and ischemic heart disease management.

The patient's LVEF (Left Ventricular Ejection Fraction) is 25%, which is significantly below the normal range (50-70%), indicating severe heart failure. However, the patient's blood pressure is well-controlled at 120/60 mmHg, which suggests that his treatment is effective in managing his blood pressure.

The patient's laboratory results show elevated creatinine levels (106.0 mmol/L), indicating mild renal impairment, which is common in patients with heart failure. The elevated pro-BNP (brain natriuretic peptide) level of 264.0 ng/L suggests that the patient has heart failure, which is consistent with his clinical presentation.

The patient's troponin level is within normal limits (0.01 ng/mL), indicating that he is not experiencing acute myocardial infarction at this time. His TSH (thyroid-stimulating hormone) level is within normal limits (3.62 mIU/L), which suggests that his thyroid function is normal.

The patient's hemoglobin level is slightly elevated (150.0 g/L), which may be a result of the polycythemia that can occur in patients with heart failure. His potassium level is within normal limits (4.8 mEq/L), which is essential for patients on ACE inhibitors and beta blockers.

The patient's lipid profile shows elevated total cholesterol (5.38 mmol/L) and LDL (3.47 mmol/L) levels, which are being managed with statins. His HDL (1.24 mmol/L) level is within normal limits.

Considering the patient's age, comorbidities, and treatment regimen, the patient's outcome of survival is likely due to the effective management of his heart failure and ischemic heart disease. The combination of beta blockers, spironolactone, statins, and an ACE inhibitor has helped to slow the progression of his heart failure and reduce the risk of adverse cardiac events."
516,516,P0812,"Age: 77
Gender: Female 
Weight: 100 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 35
ALT or GPT (IU/L): 47.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,4
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 44
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 116.0
HDL (mmol/L): 1,91
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,1
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1659.0
Protein (g/L): 60
T4 (ng/L): 23
Troponin (ng/mL): 0,01
TSH (mIU/L): 6,83
Urea (mg/dL): 4,16
LVEF (%): 52.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

Given the patient's data, the outcome of survival can be attributed to several factors:

1.  Optimal Medical Management: The patient is on a comprehensive regimen of Angiotensin II Receptor Blocker, Beta Blockers, and Loop Diuretics, which are standard treatments for Hypertensive Cardiomyopathy and heart failure. These medications have likely helped to reduce the patient's blood pressure, alleviate symptoms, and slow the progression of the disease.

2.  Preserved LVEF: Although the patient's Left Ventricular Ejection Fraction (LVEF) is 52%, which is below the normal range, it is not significantly low, indicating that the heart is still pumping effectively enough to meet the body's needs. This suggests that the patient's heart is still functioning relatively well, contributing to their survival.

3.  Mild Elevated Troponin Levels: The patient's troponin level is 0.01 ng/mL, which is mildly elevated but not significantly high. Elevated troponin levels can indicate myocardial damage, but in this case, the level is not high enough to suggest severe cardiac damage or a heart attack.

4.  Normal Blood Pressure: The patient's blood pressure is within a relatively normal range (130/80 mmHg), which is a good sign, especially considering their history of Hypertensive Cardiomyopathy.

5.  No Evidence of Severe Organ Dysfunction: The patient's laboratory results do not indicate severe organ dysfunction, such as renal failure (Creatinine 80.0 μmol/L is within a relatively normal range), or severe liver dysfunction (ALT and AST levels are mildly elevated but not significantly high).

6.  Age and Gender: The patient is 77 years old, which is an advanced age, but the fact that she is a female may have contributed to her survival, as women tend to have a lower risk of cardiovascular disease and mortality compared to men.

Considering these factors, the patient's survival can be attributed to a combination of optimal medical management, preserved cardiac function, mild elevated troponin levels, normal blood pressure, and the absence of severe organ dysfunction."
517,517,P0813,"Age: 67
Gender: Male 
Weight: 65 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 150/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 100
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4
LDL (mmol/L): 2,12
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1270.0
Protein (g/L): 74
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,14
Urea (mg/dL): 8,32
LVEF (%): 38.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

Given the patient's data, the outcome of being a survivor can be attributed to several factors:

1. Optimal medication regimen: The patient is on a comprehensive medication regimen that includes beta blockers, statins, ACE inhibitors, and a nitrovasodilator, which are all standard treatments for ischemic dilated cardiomyopathy, hypertension, and heart failure. These medications help to manage the patient's symptoms, reduce the workload on the heart, and improve the heart's pumping efficiency.

2. Presence of diabetes management: The patient is on diabetes medication, which is crucial in managing the patient's diabetes, a significant risk factor for cardiovascular disease. Effective glucose control can help prevent further cardiac damage and improve overall cardiovascular health.

3. Low troponin levels: The patient's troponin level of 0.01 ng/mL is within the normal range, indicating that there is no ongoing myocardial infarction or cardiac damage.

4. Reasonable LVEF: Although the patient's left ventricular ejection fraction (LVEF) is low at 38%, it is not as low as it could be, considering the patient's history of myocardial infarction and ischemic dilated cardiomyopathy. This suggests that the patient's heart is still functioning, albeit with some impairment.

5. ECG findings: The ECG shows ventricular extrasystoles, but there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias. This suggests that the patient's heart is not experiencing severe rhythm disturbances that could compromise cardiac function.

6. Normal hemoglobin and electrolyte levels: The patient's hemoglobin and electrolyte levels are within normal ranges, which is essential for maintaining cardiac function and preventing arrhythmias.

7. Reasonable TSH and T4 levels: The patient's thyroid function is within the normal range, which is essential for maintaining cardiac function and overall health.

Considering these factors, the patient's survival can be attributed to the effective management of their underlying conditions, a comprehensive medication regimen, and the absence of severe cardiac damage or life-threatening arrhythmias."
518,518,P0814,"Age: 72
Gender: Female 
Weight: 90 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 54.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,13
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 4,3
LDL (mmol/L): 1,76
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 453.0
Protein (g/L): 75
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,919
Urea (mg/dL): 5,16
LVEF (%): 28.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 72-year-old female with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension. Her current medications include diabetes medication, angiotensin II receptor blocker, beta blockers, loop diuretics, spironolactone, and statins, which are all standard treatments for heart failure and related conditions. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 28%, indicating severe heart failure. However, despite these severe cardiac conditions, the patient's Troponin level is normal, which suggests that there is no acute myocardial infarction or significant cardiac ischemia.

The patient's Pro-BNP level is elevated at 453.0 ng/L, which is indicative of heart failure. However, this level is not extremely high, suggesting that the patient's heart failure is not acutely decompensated. The patient's hemoglobin level is within the normal range, which suggests that there is no significant anemia contributing to her heart failure.

The patient's blood pressure is well-controlled at 140/80 mmHg, which is within a reasonable range for a patient with heart failure. Her electrolyte levels, including potassium and sodium, are also within normal limits.

Given the patient's stable medication regimen, controlled blood pressure, and lack of acute cardiac ischemia, it is likely that the patient's heart failure is being managed effectively, and she is able to survive with proper medical treatment. The patient's LVEF of 28% indicates that she has a reduced ejection fraction, but it is not so low that it would be considered a contraindication to survival. Overall, the patient's stable condition and controlled symptoms suggest that she is likely to survive with ongoing medical management."
519,519,P0815,"Age: 38
Gender: Female 
Weight: 103 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 6,34
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 59
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 121.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,01
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 96.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,59
Urea (mg/dL): 6,32
LVEF (%): 56.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient's outcome of survival can be attributed to several factors based on the provided information. 

1. Optimal Medication Management: The patient is on a multidrug regimen consisting of beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are all standard treatments for heart failure and hypertension. These medications have likely helped to reduce the patient's symptoms and slow the progression of their cardiomyopathy.

2. Relatively Well-Preserved Left Ventricular Ejection Fraction (LVEF): Despite the patient's diagnosis of hypertensive cardiomyopathy, their LVEF is still at 56%, which is relatively well-preserved. This suggests that the heart is still functioning adequately and has not significantly deteriorated, contributing to the patient's survival.

3. Mild Electrocardiogram (ECG) Abnormalities: While the patient has polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, these are relatively mild and not indicative of severe cardiac dysfunction. The absence of sustained ventricular tachycardia and bradycardia further supports the patient's stable cardiac status.

4. Blood Pressure and Hemodynamic Parameters: The patient's blood pressure is within a relatively normal range, and their creatinine and urea levels are not significantly elevated, indicating that renal function is preserved. This suggests that the patient's cardiac output is sufficient to maintain adequate perfusion of vital organs.

5. Hemoglobin and Electrolyte Levels: The patient's hemoglobin level is within a normal range, and their potassium level is not significantly low, which reduces the risk of cardiac arrhythmias.

6. Biochemical Parameters: The patient's albumin, ALT, AST, and GGT levels are within normal limits, indicating that liver function is preserved. Their total cholesterol and LDL levels are elevated, but their HDL level is also high, which may help mitigate the risk of atherosclerotic cardiovascular disease.

7. Low TSH and Normal T3 and T4 Levels: The patient's thyroid function is within normal limits, which reduces the risk of thyroid-related cardiac dysfunction.

Overall, the combination of optimal medication management, relatively preserved cardiac function, mild ECG abnormalities, and normal hemodynamic and biochemical parameters have all contributed to the patient's survival."
520,520,P0816,"Age: 76
Gender: Male 
Weight: 60 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 37
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,3
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 6,5
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,65
Sodium (mEq/L): 143.0
Protein (g/L): 68
T4 (ng/L): 19
Troponin (ng/mL): 0,5
TSH (mIU/L): 0,46
Urea (mg/dL): 6,1
LVEF (%): 15.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

Given the patient's extensive medical history, which includes ischemic dilated cardiomyopathy, peripheral vascular disease, and myocardial infarction, it is not surprising that the patient has a low left ventricular ejection fraction (LVEF) of 15%. This indicates that the patient's heart is not pumping efficiently, which can lead to fatigue, shortness of breath, and swelling in the legs.

The patient's current medications, including digoxin, loop diuretics, ACE inhibitor, and nitrovasodilator, are likely aimed at managing the symptoms and complications of heart failure. The presence of non-sustained ventricular tachycardia (VT) on the ECG suggests that the patient may be at risk for more serious arrhythmias, but the fact that it is non-sustained and not sustained VT suggests that the patient's heart is still able to recover from these episodes.

The patient's laboratory results, including a normal troponin level (0.5 ng/mL), suggest that there is no ongoing myocardial infarction. The patient's hemoglobin level (138 g/L) is within the normal range, indicating that there is no significant anemia contributing to fatigue or shortness of breath.

The patient's TSH level (0.46 mIU/L) is within the normal range, suggesting that there is no hypothyroidism contributing to fatigue or weight gain.

The patient's creatinine level (96.0 mmol/L) is slightly elevated, which may indicate some degree of kidney dysfunction, but it is not severe enough to cause significant symptoms.

The patient's albumin level (37 g/L) is slightly low, which may indicate some degree of malnutrition or liver dysfunction, but it is not severe enough to cause significant symptoms.

The patient's blood pressure (130/80 mmHg) is within the normal range, which is a good sign for someone with heart failure.

Considering the patient's overall clinical picture, it is likely that the patient is a survivor due to the following reasons:

1. The patient's medications are effective in managing the symptoms and complications of heart failure.
2. The patient's laboratory results do not indicate any significant ongoing myocardial infarction or kidney dysfunction.
3. The patient's TSH and hemoglobin levels are within the normal range, indicating that there is no significant hypothyroidism or anemia contributing to fatigue or shortness of breath.
4. The patient's blood pressure is within the normal range, indicating that the patient's heart is not experiencing excessive strain.

Overall, the patient's survival is likely due to a combination of effective medical management and the absence of any severe underlying conditions that would contribute to a poor outcome."
521,521,P0817,"Age: 66
Gender: Male 
Weight: 66 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Other HF etiology, Peripheral vascular disease
Albumin (g/L): 46
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 5,53
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 75
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 163.0
HDL (mmol/L): 1,71
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,26
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 4111.0
Protein (g/L): 78
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,02
TSH (mIU/L): 8,58
Urea (mg/dL): 10,65
LVEF (%): 25.0
Medications: Amiodarone, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",survivor,"REASONING: 

This patient is a 66-year-old male with a history of heart failure (HF) and peripheral vascular disease, who is on optimal medical therapy including ACE inhibitor, loop diuretics, spironolactone, and digoxin. His ejection fraction (LVEF) is severely reduced at 25%, indicating significant left ventricular dysfunction. 

The patient's B-type natriuretic peptide (BNP) level is elevated at 4111 ng/L, which is consistent with heart failure with reduced ejection fraction (HFrEF). His NT-proBNP level is a strong predictor of mortality in HF patients, and a level above 4000 ng/L is associated with a poor prognosis.

Despite these risk factors, the patient has survived, likely due to the combination of his current medications, which are tailored to manage his HF and arrhythmias. The use of ACE inhibitors and spironolactone has been shown to reduce morbidity and mortality in HFrEF patients. Digoxin is used to control ventricular rate in atrial fibrillation and improve symptoms in HF patients. The patient's TSH level is slightly elevated, which could be due to amiodarone therapy.

The patient's ECG shows a first-degree atrioventricular block, which is consistent with his medication regimen, and there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias. His troponin level is within normal limits, indicating no acute myocardial infarction.

Overall, the patient's survival is likely due to the effectiveness of his current treatment regimen and his relatively stable clinical status."
522,522,P0818,"Age: 50
Gender: Male 
Weight: 60 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 49
ALT or GPT (IU/L): 44.0
AST or GOT (IU/L): 34.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 138.0
Gamma-glutamil transpeptidase (IU/L): 53
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 179.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,28
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 42.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,46
Urea (mg/dL): 9,48
LVEF (%): 35.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 50-year-old male with a history of enolic dilated cardiomyopathy, which is a condition where the left ventricle of the heart becomes enlarged and cannot pump blood efficiently. The patient's left ventricular ejection fraction (LVEF) is 35%, which is below the normal range of 55-70%, indicating that the patient has heart failure with reduced ejection fraction (HFrEF).

The patient's laboratory results show elevated levels of creatinine (138.0 mmol/L), which suggests impaired renal function. The patient's total cholesterol is elevated at 4.14 mmol/L, but the LDL level is 2.28 mmol/L, which is within the target range for patients with heart failure. The patient's glucose level is slightly elevated at 4.8 mmol/L, which may be a concern for diabetes or insulin resistance.

The patient's hemoglobin level is slightly elevated at 179 g/L, which may be due to dehydration or anemia of chronic disease. The patient's potassium level is within the normal range at 4.8 mEq/L.

The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are abnormal heart rhythms that can be a sign of cardiac dysfunction. However, the patient's troponin level is within the normal range at 0.005 ng/mL, which suggests that there is no acute myocardial infarction.

The patient is on a combination of medications, including beta blockers, digoxin, loop diuretics, statins, and ACE inhibitors, which are all standard treatments for heart failure with reduced ejection fraction.

Considering the patient's medical history, laboratory results, and ECG findings, it is likely that the patient's outcome is a survivor because:

1. The patient's LVEF is 35%, which is below the normal range, but the patient is on standard medications for heart failure with reduced ejection fraction.
2. The patient's renal function is impaired, but the patient is not in acute kidney injury or failure.
3. The patient's glucose level is slightly elevated, but it is not a new development, and the patient is on a statin, which may help to manage dyslipidemia.
4. The patient's hemoglobin level is slightly elevated, but it is not a new development, and the patient is not showing signs of anemia or other blood disorders.
5. The patient's ECG shows abnormal heart rhythms, but the patient is on beta blockers and ACE inhibitors, which can help to manage these rhythms.

Overall, the patient's outcome is a survivor because the patient is on standard medications for heart failure with reduced ejection fraction, and the patient's laboratory results and ECG findings do not indicate any acute or severe complications."
523,523,P0819,"Age: 65
Gender: Male 
Weight: 76 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 105/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 68.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 3,13
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 6
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,84
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 199.0
Protein (g/L): 64
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,69
Urea (mg/dL): 5,49
LVEF (%): 35.0
Medications: Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient outcome is a survivor due to a combination of factors indicating a stable and manageable condition. 

1. Age and NYHA Class II: The patient is 65 years old and classified as NYHA Class II, which means he has mild symptoms of heart failure. This classification indicates that the patient has some limitations in physical activity but is still able to perform light physical activity without symptoms.

2. Medications: The patient is on Beta Blockers, Spironolactone, and an ACE Inhibitor, which are commonly used to treat heart failure and hypertension. These medications are effective in managing symptoms and slowing the progression of heart failure.

3. LVEF (Left Ventricular Ejection Fraction) of 35%: Although the LVEF is low, indicating reduced left ventricular function, it is not severely impaired. The patient's LVEF is still above the threshold for severe heart failure, which is typically defined as an LVEF < 20-30%.

4. Pro-BNP (N-terminal pro b-type natriuretic peptide) level of 199.0 ng/L: Elevated Pro-BNP levels are associated with heart failure, but the level is not extremely high, indicating that the patient's heart failure is not in an acute decompensated state.

5. ECG findings: The ECG shows monomorphic ventricular extrasystoles, which are common in patients with heart failure. However, there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias.

6. Laboratory results: The patient's laboratory results show mild elevations in liver enzymes (ALT and AST), which may indicate some degree of liver dysfunction, but this is not severe enough to significantly impact the patient's outcome. The patient's renal function is also relatively preserved, with a creatinine level of 71.0 μmol/L.

Considering these factors, the patient's outcome is a survivor due to the combination of effective medical management, relatively preserved cardiac function, and the absence of severe complications or acute decompensation."
524,524,P0820,"Age: 70
Gender: Male 
Weight: 75 kg
Height: 157 cm
NYHA Class: III
Blood Pressure: 134/61 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,35
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1017.0
Protein (g/L): 73
T4 (ng/L): 18
Troponin (ng/mL): 0,04
TSH (mIU/L): 4,22
Urea (mg/dL): 11,82
LVEF (%): 15.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Loop Diuretics, Statins, Hydralazine, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 70-year-old male with a history of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipidemia, which are all significant risk factors for heart failure and cardiac complications. However, despite these risk factors, the patient has survived. 

Several factors contribute to the patient's survival:

1.  Current Medications: The patient is on a multidrug regimen that includes ACE inhibitors, angiotensin II receptor blockers, loop diuretics, statins, hydralazine, and nitrovasodilators. These medications are commonly used to manage heart failure, hypertension, and dyslipidemia, which suggests that the patient is receiving appropriate treatment for their conditions.

2.  LVEF (Left Ventricular Ejection Fraction): Although the patient's LVEF is severely reduced at 15%, this value is not uncommon in patients with ischemic dilated cardiomyopathy. Despite this, the patient's LVEF is not as low as it could be, which may indicate some degree of cardiac reserve and the effectiveness of their current treatment.

3.  Blood Pressure: The patient's blood pressure is relatively well-controlled at 134/61 mmHg, which is beneficial for reducing the risk of cardiac complications and improving cardiac function.

4.  Electrocardiogram (ECG): Although the patient has polymorphic ventricular extrasystoles, there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias, which suggests that the patient's cardiac rhythm is relatively stable.

5.  Pro-BNP (N-terminal pro b-type natriuretic peptide) levels: The patient's Pro-BNP level is elevated at 1017 ng/L, which is consistent with heart failure, but not extremely high, indicating some degree of cardiac reserve.

6.  Other laboratory results: The patient's laboratory results, such as the liver enzymes (ALT and AST), renal function (creatinine), and electrolytes (potassium), are relatively well-preserved, which suggests that the patient's overall metabolic and renal function is not severely compromised.

Considering these factors, the patient's survival can be attributed to a combination of their current treatment regimen, relatively well-controlled blood pressure, stable cardiac rhythm, and preserved renal and metabolic function."
525,525,P0821,"Age: 75
Gender: Male 
Weight: 66 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Peripheral vascular disease, Hypertension
Albumin (g/L): 36
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,2
Creatinine (mmol/L): 114.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 160.0
HDL (mmol/L): 1,49
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,45
Sodium (mEq/L): 142.0
Protein (g/L): 67
T3 (pg/dL): 0,0363
T4 (ng/L): 12,28
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,11
Urea (mg/dL): 10,9
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient survived, likely due to a combination of factors including their current treatment regimen and the severity of their underlying condition. 

The patient's idiopathic dilated cardiomyopathy with an LVEF of 20% indicates significant left ventricular dysfunction. However, their current medications, including beta blockers, loop diuretics, and an ACE inhibitor, are standard treatments for heart failure and may have contributed to their survival.

The patient's blood pressure is well-controlled at 120/70 mmHg, which is within a normal range, indicating that their hypertension is under control. Their creatinine level of 114.0 μmol/L suggests mild renal impairment, but it is not severe enough to be a major concern for their survival.

The patient's electrolyte levels, including potassium and sodium, are within normal limits, which is crucial for maintaining proper cardiac function. Their hemoglobin level is slightly elevated, but not significantly so, which may be a sign of chronic disease.

The patient's TSH level is slightly low, which may be related to their treatment with beta blockers or other medications. Their troponin level is mildly elevated, indicating some degree of cardiac stress or damage, but it is not significantly high, which may indicate that their heart is not experiencing severe ischemia.

The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on their ECG suggests that they have some degree of arrhythmogenic potential, but the fact that they are on beta blockers, which are known to reduce the risk of arrhythmias, may have helped mitigate this risk.

Overall, while the patient's underlying condition is severe, their current treatment regimen and relatively well-controlled blood pressure, electrolytes, and renal function likely contributed to their survival."
526,526,P0822,"Age: 51
Gender: Male 
Weight: 82 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,92
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 11,8
Hemoglobin (g/L): 145.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,65
Sodium (mEq/L): 140.0
Protein (g/L): 61
T3 (pg/dL): 0,0474
T4 (ng/L): 13,8
Troponin (ng/mL): 0,4
TSH (mIU/L): 3,85
Urea (mg/dL): 6,7
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"REASONING: The patient, a 51-year-old male with a history of idiopathic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension, has a relatively favorable outcome despite the presence of multiple comorbidities. Several factors contribute to this outcome:

1.  Optimal medical management: The patient is on a comprehensive medication regimen, including diabetes medication, beta blockers, digoxin, loop diuretics, spironolactone, statins, ACE inhibitors, and nitrovasodilators. This polypharmacological approach likely helps manage his heart failure symptoms, control his blood pressure, and mitigate the risk of arrhythmias.
2.  Reasonable LVEF: Although the patient's left ventricular ejection fraction (LVEF) is only 30%, it is not extremely low. An LVEF of 30% is considered mildly reduced, and some patients with LVEF in this range can still have a relatively good prognosis with appropriate treatment.
3.  Stable blood pressure: The patient's blood pressure is well-controlled at 120/80 mmHg, which is within the target range for patients with heart failure. This is likely due to the combination of ACE inhibitors and beta blockers, which are known to improve outcomes in patients with heart failure.
4.  Limited cardiac biomarkers: The patient's troponin level is only slightly elevated at 0.4 ng/mL, indicating minimal myocardial damage. This suggests that the patient's heart is not experiencing significant ischemic injury.
5.  Normal TSH and T4 levels: The patient's thyroid function is within the normal range, which is essential for optimal heart function and metabolism.
6.  No signs of severe electrolyte imbalance: The patient's potassium level is within the normal range at 4.1 mEq/L, which is essential for maintaining cardiac function and preventing arrhythmias.
7.  No signs of severe kidney dysfunction: The patient's creatinine level is 100.0 μmol/L, which is slightly elevated but not severely abnormal. This suggests that the patient's kidney function is not significantly compromised.
8.  No history of previous cardiac arrest or severe arrhythmias: The patient's ECG shows only a ventricular extrasystole, which is a relatively common finding in patients with heart disease. The absence of more severe arrhythmias or cardiac arrest suggests that the patient's heart is relatively stable.

Considering these factors, the patient's outcome of survival is likely due to the combination of optimal medical management, relatively mild cardiac dysfunction, and the absence of severe comorbidities or complications."
527,527,P0823,"Age: 64
Gender: Male 
Weight: 74 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,1
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,8
Sodium (mEq/L): 138.0
Protein (g/L): 65
T3 (pg/dL): 0,0504
T4 (ng/L): 21
TSH (mIU/L): 2,62
Urea (mg/dL): 8
LVEF (%): 20.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 64-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction, has been managed with a multi-faceted treatment plan including amiodarone, beta blockers, loop diuretics, statins, and an ACE inhibitor. The patient's current LVEF (Left Ventricular Ejection Fraction) is 20%, indicating severe left ventricular dysfunction.

Given the patient's history and current condition, the most likely reason for the patient's outcome of survival is the effective management of his cardiac condition. The use of beta blockers and ACE inhibitors has likely helped to reduce the patient's heart rate and blood pressure, thereby decreasing the workload on the heart and reducing the risk of further cardiac complications. Additionally, the use of statins has helped to manage the patient's dyslipemia, which is a risk factor for cardiac disease.

The patient's LVEF of 20% indicates that he has significant left ventricular dysfunction, but the fact that he has survived suggests that his cardiac function has been stabilized to some extent. This could be due to the effectiveness of his current treatment regimen, which includes medications that are known to improve cardiac function and reduce the risk of adverse outcomes in patients with heart failure.

Furthermore, the patient's laboratory results, including his normal glucose and potassium levels, suggest that his diabetes and electrolyte imbalances are well-managed. His TSH and T4 levels are also within normal limits, indicating that his thyroid function is not contributing to his cardiac condition.

In conclusion, the patient's outcome of survival is likely due to the effective management of his cardiac condition, including the use of beta blockers, ACE inhibitors, statins, and loop diuretics, as well as the management of his diabetes and other comorbidities."
528,528,P0824,"Age: 42
Gender: Male 
Weight: 86 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 150/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 33,5
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 5,22
Creatinine (mmol/L): 72.0
Gamma-glutamil transpeptidase (IU/L): 124
Glucose (mmol/L): 7,1
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,6
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,64
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 226.0
Protein (g/L): 66,6
T4 (ng/L): 17
TSH (mIU/L): 1,63
Urea (mg/dL): 7,32
LVEF (%): 40.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient, a 42-year-old male, has a complex medical history including Hypertensive cardiomyopathy, Diabetes, Dyslipemia, and Hypertension. His current medications include Diabetes Medication, Beta Blockers, and Loop Diuretics, which are standard treatments for these conditions.

His blood pressure is elevated at 150/90 mmHg, which is consistent with his history of Hypertension. His LVEF (Left Ventricular Ejection Fraction) is 40.0%, indicating a reduced ejection fraction, which is a hallmark of cardiomyopathy. 

The elevated Pro-BNP (Brain Natriuretic Peptide) level of 226.0 ng/L suggests that the patient's heart is under strain, likely due to his cardiomyopathy. His albumin level is slightly low, which may indicate some degree of liver dysfunction or malnutrition, but it is not severely abnormal. His liver enzymes (ALT and AST) are mildly elevated, which may also indicate liver dysfunction.

The patient's lipid profile shows a high total cholesterol level and a low HDL level, consistent with his diagnosis of Dyslipemia. His glucose level is elevated, consistent with his diabetes.

Given his complex medical history and the presence of reduced LVEF, elevated Pro-BNP, and other laboratory abnormalities, the patient's outcome of survival is likely due to the following factors:

1. Effective management of his medications: The patient is on standard treatments for his conditions, including Beta Blockers, which can help reduce the workload on the heart, and Loop Diuretics, which can help reduce fluid overload.
2. Monitoring and management of his cardiomyopathy: The patient's reduced LVEF and elevated Pro-BNP suggest that his cardiomyopathy is being managed, and his survival is likely due to close monitoring and adjustments to his treatment plan.
3. No severe acute complications: The patient does not have any severe acute complications such as myocardial infarction, cardiac arrest, or severe arrhythmias, which would have likely led to a poorer outcome.

Overall, the patient's survival is likely due to a combination of effective management of his medications, monitoring and management of his cardiomyopathy, and the absence of severe acute complications."
529,529,P0825,"Age: 51
Gender: Male 
Weight: 99 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Other HF etiology, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 46
ALT or GPT (IU/L): 52.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 129.0
Gamma-glutamil transpeptidase (IU/L): 75
Glucose (mmol/L): 10,3
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,24
Sodium (mEq/L): 149.0
Pro-BNP (ng/L): 320.0
Protein (g/L): 77
T3 (pg/dL): 0,06
T4 (ng/L): 23
Troponin (ng/mL): 0,005
TSH (mIU/L): 0,316
Urea (mg/dL): 7,65
LVEF (%): 32.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 51-year-old male with a history of heart failure (HF), diabetes, dyslipidemia, and hypertension, which suggests a high risk of cardiovascular disease. His current medications, including beta blockers, ACE inhibitors, and spironolactone, are consistent with standard treatment for heart failure with reduced ejection fraction (HFrEF). The patient's left ventricular ejection fraction (LVEF) is 32%, which is significantly reduced and indicates severe systolic dysfunction.

The patient's laboratory results show elevated levels of troponin (0.005 ng/mL), which is slightly elevated, but not significantly high, suggesting some degree of cardiac damage or stress. However, the level is not indicative of an acute myocardial infarction.

The patient's creatinine level (129.0 μmol/L) is elevated, which may indicate some degree of kidney dysfunction, likely secondary to heart failure. His albumin level (46 g/L) is slightly low, which may also be related to heart failure.

The patient's pro-BNP (B-type natriuretic peptide) level is elevated at 320.0 ng/L, which is consistent with heart failure and suggests that the patient is experiencing some degree of fluid overload and stress on the heart.

The patient's ECG shows polymorphic ventricular extrasystoles, which can be a benign finding, but in the context of this patient's other risk factors and symptoms, it may be indicative of underlying cardiac disease.

Given the patient's complex medical history and laboratory results, the fact that he is a survivor suggests that his treatment plan is effective in managing his symptoms and preventing further cardiac decompensation. The medications he is taking are likely helping to control his blood pressure, reduce fluid overload, and slow the progression of his heart failure. The patient's LVEF is stable at 32%, and his troponin level is not significantly elevated, indicating that he is not experiencing an acute cardiac event. Overall, the patient's survival is likely due to the effectiveness of his treatment plan and close monitoring by his healthcare team."
530,530,P0826,"Age: 45
Gender: Male 
Weight: 74 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Toxic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,17
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 5
LDL (mmol/L): 3,28
Sodium (mEq/L): 148.0
Pro-BNP (ng/L): 53.0
Protein (g/L): 74
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,62
Urea (mg/dL): 5,16
LVEF (%): 48.0
Medications: Beta Blockers, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 45-year-old male with a history of toxic dilated cardiomyopathy, which indicates that his heart muscle has been weakened due to a toxic substance, likely alcohol or certain medications. He is currently on beta blockers, digoxin, and an ACE inhibitor, which are standard treatments for heart failure and dilated cardiomyopathy. His LVEF (Left Ventricular Ejection Fraction) is 48%, which is below the normal range of 55-70%, indicating that his heart is not pumping efficiently.

Despite his compromised heart function, the patient's creatinine level is elevated at 100.0 mmol/L, which suggests that his kidneys are not functioning optimally. However, his hemoglobin level is within the normal range, which is a good sign.

The patient's electrolyte levels, including potassium and sodium, are within the normal range, which is crucial for maintaining proper heart function. His TSH (Thyroid-Stimulating Hormone) level is within the normal range, indicating that his thyroid function is not contributing to his heart condition.

The patient's ECG shows signs of ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachycardia, which are all related to abnormal heart rhythms. However, the patient's troponin level is low, indicating that there is no acute myocardial infarction.

The patient's Pro-BNP (B-type natriuretic peptide) level is 53.0 ng/L, which is within the normal range, indicating that his heart is not under excessive strain.

Considering the patient's overall clinical picture, his age, and the fact that he is on appropriate medications for his condition, it is likely that the patient has been effectively managed for his toxic dilated cardiomyopathy and is able to survive with a relatively stable cardiac function."
531,531,P0827,"Age: 41
Gender: Male 
Weight: 54 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 46
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,81
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,87
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 97.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,13
Urea (mg/dL): 3,83
LVEF (%): 26.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome is a survivor, which suggests that the patient has survived a cardiac event or has not experienced a fatal cardiac outcome. Given the patient's medical history of idiopathic dilated cardiomyopathy, it is likely that the patient has been experiencing symptoms of heart failure, such as shortness of breath and fatigue.

The patient's laboratory results indicate that they have a low left ventricular ejection fraction (LVEF) of 26%, which is a common indicator of heart failure. The presence of non-sustained ventricular tachycardia (VT) on the ECG suggests that the patient is at risk for sudden cardiac death. However, the fact that the patient is taking beta blockers, digoxin, loop diuretics, and an ACE inhibitor suggests that they are receiving appropriate medical treatment for their condition.

The patient's low T3 level (0.05 pg/dL) and normal T4 level (16 ng/L) suggest that they may have hypothyroidism, which can be a contributing factor to heart failure. However, the patient's TSH level (1.13 mIU/L) is within the normal range, which suggests that the patient's thyroid function is not significantly abnormal.

The patient's low hemoglobin level (151 g/L) may indicate anemia, which can contribute to fatigue and shortness of breath. However, the patient's hemoglobin level is not critically low, and it is likely that the patient's anemia is being managed as part of their overall treatment plan.

Overall, the patient's survival outcome suggests that their treatment plan is effective in managing their heart failure symptoms and reducing their risk of cardiac complications. The patient's low LVEF and presence of non-sustained VT on the ECG indicate that they are at risk for cardiac events, but the patient's survival outcome suggests that they are being closely monitored and managed by their healthcare team."
532,532,P0828,"Age: 70
Gender: Male 
Weight: 94 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 130/85 mmHg
Past Medical History: Valvular cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 6,49
Creatinine (mmol/L): 175.0
Gamma-glutamil transpeptidase (IU/L): 100
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 153.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 5,2
LDL (mmol/L): 4,03
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1603.0
Protein (g/L): 69
T3 (pg/dL): 0,07
T4 (ng/L): 20
TSH (mIU/L): 0,495
Urea (mg/dL): 11,98
LVEF (%): 55.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

This patient's outcome of survival can be attributed to a combination of factors. Firstly, the patient's medication regimen, which includes beta blockers, digoxin, loop diuretics, statins, and an ACE inhibitor, suggests that they are receiving appropriate management for their valvular cardiomyopathy and hypertension. Beta blockers are particularly effective in reducing the risk of sudden cardiac death and improving survival in patients with heart failure. 

The patient's LVEF (Left Ventricular Ejection Fraction) of 55% indicates that their heart function is compromised, but not severely impaired. This suggests that the patient's heart is still able to pump blood effectively enough to meet their body's needs, contributing to their survival.

The patient's ECG results show polymorphic ventricular extrasystoles, but no sustained ventricular tachycardia or non-sustained ventricular tachycardia. While ventricular extrasystoles can be a sign of cardiac stress, they are not necessarily indicative of a life-threatening condition in this case.

The patient's laboratory results, including a relatively normal creatinine level and a low Pro-BNP (brain natriuretic peptide) level, suggest that their heart function is not severely compromised. A low Pro-BNP level is associated with a better prognosis in patients with heart failure.

The patient's age and weight are also factors that contribute to their survival. While age 70 is considered elderly, it is not unusually high for a patient with heart disease. The patient's weight of 94 kg is above average, but not significantly high enough to contribute to a poor outcome.

Overall, the combination of the patient's medication regimen, relatively preserved LVEF, lack of severe arrhythmias, and laboratory results contribute to their survival."
533,533,P0829,"Age: 60
Gender: Female 
Weight: 97 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Other HF etiology, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 7,8
Hemoglobin (g/L): 155.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,1
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 27.0
Protein (g/L): 72
T4 (ng/L): 9
Troponin (ng/mL): 0,01
TSH (mIU/L): 5
Urea (mg/dL): 5,16
LVEF (%): 50.0
Medications: Angiotensin II Receptor Blocker, Digoxin
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's data, the patient's age and sex are 60 years and female, respectively. The patient's weight is 97 kg, and height is 169 cm, which corresponds to a BMI of 30.9, indicating obesity. The patient has a history of heart failure (HF) and hypertension, which are both significant risk factors for cardiovascular disease.

The patient's blood pressure is within the normal range (130/80 mmHg), but the presence of hypertension in the past medical history suggests that the patient may have had uncontrolled hypertension in the past.

The liver function tests (ALT, AST, and GGT) are within normal limits, indicating that liver function is not compromised. However, the total cholesterol level is elevated (4.91 mmol/L), with a high LDL level (3.1 mmol/L) and low HDL level (1.29 mmol/L), indicating dyslipidemia.

The kidney function tests (creatinine and urea) are within normal limits, and the pro-BNP level is low (27.0 ng/L), which is a good prognostic indicator for heart failure.

The patient's LVEF is 50%, which is within the normal range, indicating preserved left ventricular function. The patient is on medications that are commonly used in heart failure management, including an angiotensin II receptor blocker and digoxin.

The ECG shows a ventricular extrasystole, which is a common finding in patients with heart disease, but it is not a predictor of adverse outcome in this case.

Considering the patient's overall clinical presentation, the low pro-BNP level, and the preserved LVEF, it is likely that the patient's heart failure is well-managed, and the patient has a favorable prognosis. The patient's age, sex, and comorbidities (HF and hypertension) may contribute to a higher risk of cardiovascular events, but the patient's current clinical status suggests that they are at low risk for immediate adverse outcomes.

Therefore, the patient outcome is likely a survivor, indicating that the patient is alive and has a favorable prognosis."
534,534,P0831,"Age: 66
Gender: Female 
Weight: 103 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,1
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 65.0
Protein (g/L): 70
T4 (ng/L): 10
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,1
Urea (mg/dL): 4,99
LVEF (%): 58.0
Medications: Diabetes Medication, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type I
            ",survivor,"REASONING: 

The patient is a 66-year-old female with a history of multiple comorbidities, including hypertensive cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, hypertension, and a previous myocardial infarction. Despite these conditions, the patient is currently a survivor, which suggests that she has been effectively managing her conditions with her current treatment regimen.

Several factors contribute to her positive outcome:

1.  Controlled Blood Pressure: The patient's blood pressure is well-managed at 110/70 mmHg, which is within the target range for someone with hypertension.
2.  Stable Cardiac Function: The patient's left ventricular ejection fraction (LVEF) is 58%, which is within the normal range, indicating that her heart is functioning adequately.
3.  Optimal Medications: The patient is on a comprehensive treatment regimen, including diabetes medication, loop diuretics, spironolactone, statins, and an ACE inhibitor, which are all appropriate for her comorbidities.
4.  Low Troponin Levels: The patient's troponin level is 0.01 ng/mL, which is within the normal range, indicating that there is no current evidence of myocardial infarction or cardiac damage.
5.  Normal Thyroid Function: The patient's TSH level is 2.1 mIU/L, which is within the normal range, indicating that her thyroid function is well-managed.
6.  Electrocardiogram (ECG) Findings: Although the patient has a second-degree AV block type I, which can be a risk factor for cardiac conduction abnormalities, it is not a significant concern in this case, as it is not causing any symptoms or other complications.

In summary, the patient's effective management of her comorbidities, optimal medication regimen, and stable cardiac function have contributed to her positive outcome as a survivor."
535,535,P0832,"Age: 56
Gender: Male 
Weight: 94 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 145/85 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,62
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 7,9
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 5
LDL (mmol/L): 1,42
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 217.0
Protein (g/L): 74
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,1
Urea (mg/dL): 7,49
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome is a survivor, which can be attributed to a combination of several factors:

1. Optimal Medical Management: The patient is on a comprehensive treatment regimen, including diabetes medication, beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are all tailored to manage his heart failure, hypertension, and diabetes. This suggests that the patient is receiving adequate care for his comorbidities.

2. Monitoring and Follow-up: The patient's regular monitoring, including blood tests and ECGs, has allowed for timely adjustments to his treatment plan, potentially preventing further deterioration.

3. Low Troponin Levels: The patient's troponin level is within normal limits, indicating that there is no acute myocardial infarction or significant cardiac damage.

4. Normal TSH and T4 Levels: The patient's thyroid function is within normal limits, which is essential for overall cardiac health.

5. LVEF of 35%: Although the patient's left ventricular ejection fraction (LVEF) is low, indicating reduced cardiac function, it is not significantly decreased. This suggests that the patient's heart is still functioning, albeit inefficiently.

6. No Ventricular Tachycardia or Bradycardia: The absence of these arrhythmias indicates that the patient's heart rhythm is relatively stable.

7. Albumin and Protein Levels: The patient's albumin and protein levels are within normal limits, indicating that there is no significant liver dysfunction or nephrotic syndrome.

8. Low Creatinine Levels: The patient's creatinine level is within normal limits, indicating that his kidney function is relatively preserved.

Considering these factors, the patient's outcome as a survivor is likely due to the effectiveness of his treatment plan, regular monitoring, and the absence of acute cardiac events or significant organ dysfunction."
536,536,P0833,"Age: 68
Gender: Female 
Weight: 66 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 6,96
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 10,4
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,36
Potassium (mEq/L): 4,9
LDL (mmol/L): 4,27
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 588.0
Protein (g/L): 73
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,36
Urea (mg/dL): 9,82
LVEF (%): 55.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 68-year-old female, has a history of Hypertensive cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, and hypertension. Her current medications include a calcium channel blocker, diabetes medication, angiotensin II receptor blocker, and loop diuretics, which are all standard treatments for these conditions.

The patient's laboratory results show elevated levels of creatinine (115.0 mmol/L), indicating impaired renal function. Her glucose level is also elevated (10.4 mmol/L), consistent with her diabetes diagnosis. The patient's LVEF (left ventricular ejection fraction) is 55%, which is below the normal range (60-70%), indicating reduced cardiac function.

However, the patient's troponin level is within the normal range (0.01 ng/mL), suggesting that there is no acute myocardial infarction. The patient's BNP (brain natriuretic peptide) level is elevated (588.0 ng/L), which can indicate heart failure, but the patient's NYHA class is II, indicating that she is experiencing some symptoms but is still able to perform daily activities.

The patient's ECG shows polymorphic ventricular extrasystoles, but no sustained ventricular tachycardia or other arrhythmias. This is a relatively benign finding.

Given the patient's age, medical history, and current condition, the patient's survival can be attributed to several factors:

1.  The patient is receiving appropriate medical treatment for her conditions, including medications to manage her hypertension, diabetes, and cardiac function.
2.  Her renal function, although impaired, is not severe, and her creatinine level is not rising rapidly.
3.  Her cardiac function, although reduced, is not critically compromised, and her LVEF is not below 30%.
4.  The patient's overall health status, as indicated by her NYHA class, suggests that she is still able to perform daily activities, albeit with some limitations.

In conclusion, the patient's survival can be attributed to her ongoing medical treatment, relatively stable renal function, and manageable cardiac condition."
537,537,P0834,"Age: 58
Gender: Male 
Weight: 76 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 90/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39,7
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,07
Creatinine (mmol/L): 181.0
Gamma-glutamil transpeptidase (IU/L): 76
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 170.0
HDL (mmol/L): 1,18
Potassium (mEq/L): 4,63
LDL (mmol/L): 2,48
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 6433.0
Protein (g/L): 74
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,17
Urea (mg/dL): 17,8
LVEF (%): 26.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 58-year-old male with a history of ischemic dilated cardiomyopathy, dyslipemia, hypertension, and myocardial infarction, which are all risk factors for heart failure. His low left ventricular ejection fraction (LVEF) of 26% indicates severe systolic dysfunction, suggesting that his heart is not pumping efficiently.

The patient's medications, including digoxin, loop diuretics, statins, and ACE inhibitor, are consistent with heart failure management, and are likely contributing to his survival. The presence of a ventricular extrasystole, although polymorphic, does not necessarily indicate a life-threatening arrhythmia. The absence of other arrhythmias, such as ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia, suggests that the patient's heart rhythm is relatively stable.

The patient's laboratory results show elevated creatinine levels (181.0 mmol/L), indicating impaired renal function, which is a common comorbidity in patients with heart failure. His albumin levels are slightly low (39.7 g/L), which may indicate malnutrition or liver disease, but the AST and ALT levels are within normal limits, suggesting that liver function is not significantly impaired.

The patient's blood pressure is within the normal range (90/70 mmHg), which is a positive sign, as hypotension can be a predictor of poor outcomes in heart failure patients. The patient's troponin level is low (0.01 ng/mL), indicating that he is not experiencing acute myocardial infarction.

The elevated Pro-BNP (6433.0 ng/L) level suggests that the patient's heart is under strain, consistent with heart failure. However, the patient's overall clinical picture and treatment plan are likely contributing to his survival.

Given the patient's complex medical history and current treatment, it is likely that his survival is due to the combination of his medications, close monitoring, and supportive care."
538,538,P0836,"Age: 53
Gender: Male 
Weight: 67 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 105/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44,1
ALT or GPT (IU/L): 35.0
AST or GOT (IU/L): 36.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,41
LDL (mmol/L): 3,48
Sodium (mEq/L): 135.0
Protein (g/L): 78,4
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,89
Urea (mg/dL): 8,7
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 53-year-old male with idiopathic dilated cardiomyopathy, has a low left ventricular ejection fraction (LVEF) of 30%, indicating significant heart failure. However, despite his severe cardiac condition, the patient is a survivor. This outcome can be attributed to several factors:

1.  Optimal Medication Management: The patient is on a combination of beta blockers, loop diuretics, and an ACE inhibitor, which are all standard treatments for heart failure. These medications have helped to manage his symptoms and improve his cardiac function.

2.  Low Troponin Levels: The patient's troponin level is within normal limits (0.01 ng/mL), indicating minimal cardiac damage and no acute myocardial infarction.

3.  Stable Blood Pressure: The patient's blood pressure is well-controlled at 105/70 mmHg, which is within the normal range. This suggests that his heart is not under excessive strain, and his blood pressure is not contributing to his cardiac condition.

4.  Normal Glucose and Cholesterol Levels: The patient's glucose level is 6.1 mmol/L, which is within the normal range, and his total cholesterol level is 4.73 mmol/L, which is slightly elevated but not significantly high. Elevated cholesterol can contribute to heart disease, but in this case, it may not be a major factor in the patient's outcome.

5.  Lack of Other Contributing Factors: The patient does not have other contributing factors such as a history of smoking, high blood pressure, or significant kidney disease, which could have worsened his cardiac condition.

6.  Good Hemoglobin Levels: The patient's hemoglobin level is 135 g/L, which is within the normal range. Anemia can exacerbate heart failure, but in this case, it does not appear to be a contributing factor.

In summary, the patient's optimal medication management, low troponin levels, stable blood pressure, normal glucose and cholesterol levels, lack of other contributing factors, and good hemoglobin levels have all contributed to his survival despite his severe cardiac condition."
539,539,P0837,"Age: 84
Gender: Male 
Weight: 54 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 36,2
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,85
Creatinine (mmol/L): 86.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 15
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,54
Potassium (mEq/L): 4,62
LDL (mmol/L): 2,81
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 2619.0
Protein (g/L): 73,3
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,54
Urea (mg/dL): 12,7
LVEF (%): 25.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

Given the patient's advanced age (84 years) and multiple comorbidities, including ischemic dilated cardiomyopathy, diabetes, hypertension, and myocardial infarction, the patient's prognosis is guarded. The patient's left ventricular ejection fraction (LVEF) of 25% indicates severe systolic dysfunction, which is consistent with the diagnosis of heart failure with reduced ejection fraction (HFrEF).

The patient's serum B-type natriuretic peptide (BNP) level of 2619 ng/L is elevated, indicating significant cardiac stress and potential heart failure. The presence of polymorphic ventricular extrasystoles on the ECG suggests underlying electrical instability, which may be contributing to the patient's cardiac dysfunction.

Despite the presence of multiple comorbidities, the patient is on a comprehensive treatment regimen that includes digoxin, loop diuretics, spironolactone, ACE inhibitor, and nitrovasodilator, which is consistent with guideline-directed medical therapy for HFrEF.

The patient's weight of 54 kg is low, which may be indicative of malnutrition or muscle wasting, which can be a complication of heart failure. However, the patient's hemoglobin level of 136 g/L is within the normal range, which suggests that the patient is not severely anemic.

The patient's blood pressure of 110/60 mmHg is within the normal range, which is consistent with the use of vasodilators and diuretics. The patient's electrolyte levels, including potassium and sodium, are within the normal range, which is essential for the proper functioning of the heart.

Considering the patient's overall clinical picture, the presence of a low LVEF, elevated BNP, and polymorphic ventricular extrasystoles on the ECG, the patient's outcome of survival is likely due to the comprehensive medical treatment and the absence of any acute cardiac event or severe complications."
540,540,P0840,"Age: 55
Gender: Female 
Weight: 55 kg
Height: 145 cm
NYHA Class: III
Blood Pressure: 80/40 mmHg
Past Medical History: Valvular cardiomyopathy, Dyslipemia
Albumin (g/L): 44,9
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 5,44
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,15
LDL (mmol/L): 3,71
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 991.0
Protein (g/L): 77,3
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,87
Urea (mg/dL): 7,8
LVEF (%): 40.0
Medications: Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

This patient is a 55-year-old female with a history of valvular cardiomyopathy and dyslipemia, who is classified as NYHA Class III, indicating moderate to severe heart failure symptoms. The patient's current medications include an Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, and Spironolactone, which are standard treatments for heart failure and hypertension.

The patient's blood pressure is significantly low at 80/40 mmHg, indicating hypotension, which may be a result of her heart failure and the use of Loop Diuretics. The elevated Pro-BNP level (991.0 ng/L) is consistent with heart failure, as this biomarker is often used to diagnose and monitor heart failure.

The patient's left ventricular ejection fraction (LVEF) is 40%, which is below the normal range (50-70%), indicating systolic dysfunction. The presence of ventricular extrasystoles on the ECG suggests potential arrhythmias, but the absence of sustained ventricular tachycardia is reassuring.

The patient's lipid profile shows elevated total cholesterol and LDL levels, which are consistent with her history of dyslipemia. The patient's glucose level is slightly elevated, but not to the point of indicating diabetes.

The patient's kidney function, as indicated by creatinine levels, is mildly impaired. However, the patient's urea level is within the normal range, which may suggest some degree of renal adaptation.

Given the patient's complex medical history and current presentation, the fact that she is a survivor can be attributed to the following factors:

1. Aggressive medical management: The patient is on a comprehensive regimen of medications that target heart failure, hypertension, and dyslipemia. These medications have likely helped to stabilize her condition and prevent further deterioration.
2. Close monitoring and follow-up: The patient's regular medical check-ups and monitoring of her condition have allowed for timely adjustments to her treatment plan and interventions to prevent complications.
3. Supportive care: The patient's use of Loop Diuretics and Spironolactone suggests that she is receiving supportive care to manage her heart failure symptoms and prevent fluid overload.
4. Genetic predisposition: While not explicitly stated, the patient's valvular cardiomyopathy may have a genetic component, which could influence her disease progression and response to treatment.

In summary, the patient's survival can be attributed to a combination of aggressive medical management, close monitoring and follow-up, supportive care, and potentially a genetic predisposition that influences her disease progression."
541,541,P0841,"Age: 54
Gender: Male 
Weight: 75 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,42
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,18
LDL (mmol/L): 2,75
Sodium (mEq/L): 139.0
Protein (g/L): 67,9
T3 (pg/dL): 0,0648
T4 (ng/L): 12,24
Troponin (ng/mL): 0,3
TSH (mIU/L): 0,77
Urea (mg/dL): 5,5
LVEF (%): 25.0
Medications: Angiotensin II Receptor Blocker, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 54-year-old male with a history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction, has a complex clinical presentation. Despite the presence of multiple risk factors and a low left ventricular ejection fraction (LVEF) of 25%, the patient has survived. 

The patient's current medications, including an angiotensin II receptor blocker and an ACE inhibitor, are appropriate for managing his heart failure and hypertension. These medications are likely contributing to the patient's survival, as they help to reduce blood pressure and alleviate the strain on the heart.

The patient's ECG results show polymorphic ventricular extrasystoles, which can be a sign of cardiac ischemia or electrical instability. However, the absence of non-sustained ventricular tachycardia or other arrhythmias suggests that the patient's heart is not experiencing severe electrical instability at this time.

The patient's laboratory results show elevated creatinine levels, indicating some degree of renal impairment, which is common in patients with heart failure. The patient's glucose and lipid profiles are also abnormal, which can contribute to the development and progression of heart disease.

The patient's thyroid function tests are within normal limits, which is important, as thyroid dysfunction can affect heart function. The patient's troponin level is slightly elevated, which may indicate ongoing cardiac stress or minor cardiac damage.

Overall, the patient's survival can be attributed to the effectiveness of his current medication regimen, the absence of severe electrical instability, and the presence of supportive laboratory results. However, the patient's continued survival will depend on ongoing management of his heart failure, hypertension, and other comorbidities."
542,542,P0842,"Age: 57
Gender: Male 
Weight: 84 kg
Height: 176 cm
NYHA Class: III
Blood Pressure: 125/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 159.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,21
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 690.0
Protein (g/L): 74
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,83
Urea (mg/dL): 5,16
LVEF (%): 20.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 57-year-old male with a history of idiopathic dilated cardiomyopathy, is a survivor. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 20%, indicating severe left ventricular dysfunction. This is a critical factor in the patient's prognosis.

The patient's New York Heart Association (NYHA) Class III classification indicates that he experiences symptoms of heart failure with moderate exertion, which is consistent with his reduced LVEF.

The patient's laboratory results show elevated creatinine levels (80.0 mmol/L), indicating renal impairment, which can be a complication of heart failure. However, the patient's urea levels (5.16 mg/dL) are within a relatively normal range, suggesting that renal function is not severely compromised at this time.

The patient's B-type natriuretic peptide (BNP) level is elevated at 690.0 ng/L, which is consistent with heart failure and may indicate increased ventricular wall stress.

The presence of non-sustained ventricular tachycardia (NSVT) on the ECG is concerning, as it may indicate an increased risk of sudden cardiac death. However, the patient's troponin levels are within normal limits (0.01 ng/mL), indicating that there is no acute myocardial infarction.

The patient's medication regimen, including angiotensin II receptor blockers, beta blockers, statins, and ACE inhibitors, is appropriate for managing heart failure and reducing the risk of sudden cardiac death.

Given the patient's severe left ventricular dysfunction, elevated BNP levels, and the presence of NSVT, the patient's survival is a testament to the effectiveness of his current treatment regimen and the absence of acute cardiac events."
543,543,P0844,"Age: 73
Gender: Male 
Weight: 66 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 130/88 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 35.0
Total Cholesterol (mmol/L): 3,1
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 10,6
Hemoglobin (g/L): 179.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 1,53
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1713.0
Protein (g/L): 78
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,86
Urea (mg/dL): 7,15
LVEF (%): 20.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 73-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension. Despite his multiple comorbidities and severe left ventricular dysfunction (LVEF of 20%), the patient is a survivor, which indicates that he has managed to survive the acute event or episode that led to his hospitalization or medical evaluation.

Several factors may have contributed to the patient's survival:

1.  Optimal Medical Management: The patient is on a comprehensive medication regimen, including diabetes medication, angiotensin II receptor blocker, beta blockers, spironolactone, statins, ACE inhibitor, and nitrovasodilator, which are all standard treatments for heart failure and related conditions. This suggests that the patient is receiving evidence-based care, which may have helped to stabilize his condition and prevent further deterioration.

2.  Monitoring and Intervention: The patient's regular monitoring and follow-up may have allowed for early detection and management of any complications or worsening of his condition. This proactive approach may have helped to prevent a fatal outcome.

3.  Resilience and Adaptation: The patient's body may have adapted to his chronic condition over time, allowing him to survive despite his severe left ventricular dysfunction. This could be due to various physiological changes, such as increased sympathetic tone, remodeling of the heart, or other compensatory mechanisms.

4.  Genetic Predisposition: The patient's genetic background may have played a role in his ability to survive. Some individuals may have a more robust genetic makeup that allows them to cope better with chronic disease and its complications.

5.  Lack of Sudden Cardiac Death: The patient's ECG did not show any signs of life-threatening arrhythmias, such as ventricular tachycardia or bradycardia, which are common causes of sudden cardiac death in patients with heart failure.

In conclusion, the patient's survival can be attributed to a combination of optimal medical management, monitoring, and intervention, as well as his body's resilience and adaptation to his chronic condition."
544,544,P0847,"Age: 65
Gender: Male 
Weight: 67 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 100/50 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 47
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,3
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 42
Glucose (mmol/L): 15,2
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 6,3
LDL (mmol/L): 3,49
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 564.0
Protein (g/L): 78
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,96
Urea (mg/dL): 9,82
LVEF (%): 50.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 65-year-old male with a history of idiopathic dilated cardiomyopathy and diabetes. Despite his medical history, the patient is taking a comprehensive regimen of medications, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, which are all appropriate for managing heart failure and hypertension. 

The patient's left ventricular ejection fraction (LVEF) is 50%, which indicates a moderate level of heart failure. However, it is worth noting that the patient's LVEF is not significantly low, which suggests that the patient may be responding to the treatment.

The patient's blood pressure is within a relatively normal range (100/50 mmHg), considering his age and medical history. The low diastolic blood pressure may indicate some degree of orthostatic hypotension, but it is not a cause for concern in this context.

The patient's laboratory results show a slightly elevated creatinine level (133.0 mmol/L), which may indicate some degree of kidney dysfunction, likely due to his diabetes and heart failure. However, the patient's urea level is within a relatively normal range (9.82 mg/dL), which suggests that the kidney function is not severely impaired.

The patient's troponin level is within a normal range (0.005 ng/mL), which suggests that there is no acute myocardial infarction. The patient's TSH level is within a normal range (1.96 mIU/L), which suggests that there is no evidence of hypothyroidism.

The patient's ECG shows a ventricular extrasystole, which is a common finding in patients with heart disease. However, there is no evidence of ventricular tachycardia or non-sustained ventricular tachycardia, which suggests that the patient's heart rhythm is relatively stable.

Overall, the patient's comprehensive treatment regimen, combined with his relatively stable laboratory results and ECG findings, suggest that the patient is likely responding well to treatment and is at low risk for adverse cardiac events. Therefore, the patient's outcome is likely to be a survivor."
545,545,P0849,"Age: 81
Gender: Female 
Weight: 76 kg
Height: 151 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 47
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,46
Creatinine (mmol/L): 122.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 7
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 5,8
LDL (mmol/L): 3,52
Sodium (mEq/L): 153.0
Pro-BNP (ng/L): 1494.0
Protein (g/L): 78
T3 (pg/dL): 0,04
T4 (ng/L): 15
TSH (mIU/L): 3,52
Urea (mg/dL): 20,63
LVEF (%): 60.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient's outcome is a survivor, which is a positive outcome. Several factors contribute to this outcome, and I'll explain them below:

1.  Effective management of underlying conditions: The patient has idiopathic dilated cardiomyopathy and diabetes, both of which can significantly impact heart health. The patient is on a regimen of medications that are typically used to manage these conditions, including ACE inhibitors, beta blockers, and spironolactone. These medications have been shown to improve survival and reduce symptoms in patients with heart failure and diabetes.

2.  Optimal blood pressure control: The patient's blood pressure is 130/80 mmHg, which is within the target range for most adults. This suggests that the patient's blood pressure is well-controlled, which is beneficial for heart health.

3.  Normal kidney function: The patient's creatinine level is 122.0 mmol/L, which is slightly elevated but not indicative of severe kidney dysfunction. This suggests that the patient's kidneys are functioning relatively well, which is essential for managing conditions like heart failure.

4.  Pro-BNP level: The patient's Pro-BNP level is 1494.0 ng/L, which is elevated but not excessively high. Pro-BNP is a marker of heart failure, and elevated levels can indicate worsening heart failure. However, the patient's LVEF is 60.0%, which suggests that the patient's heart function is still relatively preserved.

5.  ECG findings: The patient's ECG shows monomorphic ventricular extrasystoles, which are common in patients with heart disease. However, there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias.

6.  Lifestyle factors: While the patient's age and weight are factors that can impact heart health, the patient's weight is not significantly elevated, and her height is relatively short, which may be a contributing factor to her weight.

7.  Medication regimen: The patient is on a comprehensive medication regimen that includes loop diuretics, which can help manage fluid overload and reduce symptoms of heart failure.

Considering these factors, the patient's outcome is a survivor, likely due to effective management of her underlying conditions, optimal blood pressure control, preserved kidney function, and a comprehensive medication regimen."
546,546,P0850,"Age: 48
Gender: Male 
Weight: 60 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Other HF etiology
Albumin (g/L): 42
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 114.0
HDL (mmol/L): 1,73
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,81
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 2429.0
Protein (g/L): 67
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,11
TSH (mIU/L): 3,28
Urea (mg/dL): 4,66
LVEF (%): 12.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient's survival outcome can be attributed to a combination of factors, including the effective management of their heart failure (HF) symptoms and the presence of a relatively preserved left ventricular ejection fraction (LVEF) of 12%. Although the LVEF is significantly reduced, it is not as low as some other cases of HF with reduced ejection fraction (HFrEF), which typically have an LVEF < 35-40%.

The patient's New York Heart Association (NYHA) class II indicates that they are experiencing mild to moderate symptoms of heart failure, which is a favorable prognostic indicator. The use of evidence-based medications such as beta blockers, digoxin, loop diuretics, spironolactone, and ACE inhibitors is also a crucial factor in their survival. These medications have been shown to improve survival and reduce morbidity in patients with HFrEF.

The patient's laboratory results, including a normal albumin level, mild elevation in liver enzymes (AST and ALT), and a relatively normal potassium level, suggest that they do not have significant liver or kidney dysfunction, which can be a contraindication to certain medications or a poor prognostic indicator.

The elevated Pro-BNP (brain natriuretic peptide) level of 2429 ng/L is consistent with heart failure, but the patient's survival outcome suggests that it is not indicative of severe heart failure or a poor prognosis.

The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG is a common finding in patients with heart failure and is not necessarily a contraindication to survival. The unknown paroxysmal supraventricular tachyarrhythmia and bradycardia codes on the ECG do not appear to have had a significant impact on the patient's outcome.

In summary, the patient's survival outcome can be attributed to the effective management of their heart failure symptoms, the presence of a relatively preserved LVEF, and the use of evidence-based medications."
547,547,P0852,"Age: 68
Gender: Male 
Weight: 75 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 58
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 140.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 5
LDL (mmol/L): 2,51
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 457.0
Protein (g/L): 70
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,4
Urea (mg/dL): 4,99
LVEF (%): 60.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 68-year-old male with a history of hypertensive cardiomyopathy and hypertension. He is on a treatment regimen consisting of beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor. His current medication regimen suggests that his cardiomyopathy is being managed to reduce symptoms and slow disease progression.

The patient's LVEF (left ventricular ejection fraction) is 60%, which is within the normal range (50-70%). This suggests that the patient's heart is pumping blood efficiently, and the cardiomyopathy is not significantly impacting his cardiac function.

The patient's blood pressure is within the normal range (120/80 mmHg), and his potassium level is slightly elevated (5 mEq/L). The elevated potassium level may be related to his spironolactone medication, which is a potassium-sparing diuretic.

The patient's liver enzymes (ALT and AST) are within normal limits, indicating that his liver function is not significantly impacted by his medication regimen.

The patient's total cholesterol and LDL levels are elevated (4.34 mmol/L and 2.51 mmol/L, respectively), which may increase his risk for cardiovascular disease. However, his HDL level is within the normal range (0.96 mmol/L), which is beneficial for cardiovascular health.

The patient's creatinine level is elevated (80.0 mmol/L), which may indicate mild renal impairment. However, his urea level is within the normal range (4.99 mg/dL), suggesting that his kidney function is not significantly impacted.

The patient's Pro-BNP level is elevated (457.0 ng/L), which is a marker of heart failure. However, the patient's symptoms and physical examination are not indicative of severe heart failure, and his LVEF is within the normal range.

The patient's ECG shows polymorphic ventricular extrasystoles, which are abnormal heartbeats that can be a sign of cardiac disease. However, the patient is asymptomatic and has a normal LVEF, suggesting that the extrasystoles are not significantly impacting his cardiac function.

Given the patient's overall clinical picture, it is likely that he is a survivor due to the following factors:

1. His LVEF is within the normal range, indicating that his heart is pumping blood efficiently.
2. His blood pressure is within the normal range, which reduces his risk for cardiovascular events.
3. His medication regimen is effective in managing his cardiomyopathy and hypertension.
4. His liver and kidney function are within the normal range, indicating that his medications are not causing significant harm.
5. His Pro-BNP level is elevated, but his symptoms and physical examination are not indicative of severe heart failure.

Overall, the patient's overall clinical picture suggests that he is a survivor due to the effective management of his cardiomyopathy and hypertension, as well as his relatively preserved cardiac function."
548,548,P0854,"Age: 71
Gender: Male 
Weight: 72 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 100/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 156.0
AST or GOT (IU/L): 130.0
Total Cholesterol (mmol/L): 3,05
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 63
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,29
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1551.0
Protein (g/L): 73
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,33
Urea (mg/dL): 12,48
LVEF (%): 30.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 71-year-old male with a history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction, which are significant risk factors for heart failure. Despite these risk factors, the patient has been managed with beta blockers, statins, and an ACE inhibitor, which are evidence-based treatments for heart failure and hypertension.

The patient's LVEF (Left Ventricular Ejection Fraction) is 30%, which is within the range for heart failure with reduced ejection fraction (HFrEF). However, the patient's NYHA Class II indicates that the patient has mild to moderate symptoms of heart failure, such as fatigue, shortness of breath, or swelling, but is still able to perform most daily activities without significant limitation.

The patient's laboratory results show elevated liver enzymes (ALT and AST), which may indicate liver dysfunction or chronic liver disease. However, the patient's albumin level is within the normal range, which suggests that the liver is not significantly impaired.

The patient's lipid profile shows high total cholesterol and LDL levels, which are concerning for atherosclerotic cardiovascular disease. However, the patient is on statin therapy, which should help to manage these lipid levels.

The patient's troponin level is slightly elevated, but not significantly, which suggests that the patient is not experiencing an acute myocardial infarction at this time.

The patient's BNP (B-type natriuretic peptide) level is elevated, which is consistent with heart failure. However, the patient's TSH level is within the normal range, which suggests that the patient is not experiencing hypothyroidism, which can be a contributing factor to heart failure.

The patient's ECG shows polymorphic ventricular extrasystoles, which can be a benign finding in some patients, but can also be a sign of underlying cardiac disease. However, the patient does not have sustained ventricular tachycardia, which is a more concerning finding.

Given the patient's history, laboratory results, and ECG findings, the most likely explanation for the patient's outcome is that the patient has well-managed heart failure with reduced ejection fraction, and is able to survive with medical therapy. The patient's overall condition is stable, and the patient is able to tolerate his medications without significant adverse effects."
549,549,P0855,"Age: 71
Gender: Male 
Weight: 70 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 135/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 10.0
Total Cholesterol (mmol/L): 2,14
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 55
Glucose (mmol/L): 10,3
Hemoglobin (g/L): 110.0
HDL (mmol/L): 0,8
Potassium (mEq/L): 4,6
LDL (mmol/L): 0,97
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 17984.0
Protein (g/L): 71
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,65
Urea (mg/dL): 7,15
LVEF (%): 18.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient's outcome of survival can be attributed to a combination of factors, including the effectiveness of their current medication regimen and their relatively stable clinical status despite a history of ischemic dilated cardiomyopathy and previous myocardial infarction. 

The patient is on a comprehensive treatment plan consisting of beta blockers, digoxin, loop diuretics, and an ACE inhibitor, which are all standard therapies for heart failure management. Beta blockers help reduce the heart rate and contractility, thereby decreasing the workload on the heart and improving its pumping efficiency. Digoxin is used to increase the strength of the heart muscle contractions, while loop diuretics help reduce fluid overload and alleviate symptoms of heart failure. ACE inhibitors are used to reduce blood pressure and decrease the strain on the heart.

The patient's LVEF (left ventricular ejection fraction) of 18% is significantly below the normal range, indicating systolic heart failure. However, the patient's relatively low Pro-BNP (brain natriuretic peptide) level of 17984 ng/L, while still elevated, suggests that the heart failure is not as severe as it could be, given the patient's LVEF. This discrepancy may indicate that the patient's heart failure is being well-managed with their current treatment.

Additionally, the patient's blood pressure is well-controlled at 135/70 mmHg, and their glucose level is within a relatively normal range, which are both positive indicators for heart health. The patient's hemoglobin level is slightly below the normal range, but it is not significantly low, and their electrolyte levels, including potassium, are within a relatively normal range.

The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are common in patients with heart failure and may not necessarily indicate an acute cardiac event. The patient's TSH level is within the normal range, indicating that their thyroid function is not contributing to their heart failure.

In summary, the patient's survival can be attributed to the effectiveness of their treatment regimen, their relatively stable clinical status, and the fact that their heart failure is not as severe as their LVEF would suggest."
550,550,P0856,"Age: 63
Gender: Male 
Weight: 88 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 169.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4
LDL (mmol/L): 2,46
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 406.0
Protein (g/L): 70
T4 (ng/L): 9
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,02
Urea (mg/dL): 4,99
LVEF (%): 44.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type I
            ",survivor,"REASONING: The patient is a 63-year-old male with a history of ischemic dilated cardiomyopathy, dyslipemia, peripheral vascular disease, hypertension, and a previous myocardial infarction. Despite these significant cardiovascular risk factors, the patient is on a comprehensive medication regimen that includes a calcium channel blocker, beta blockers, loop diuretics, statins, and an ACE inhibitor.

The patient's current LVEF (Left Ventricular Ejection Fraction) is 44%, which is below the normal range (50-70%), indicating some degree of left ventricular dysfunction. However, the patient's Pro-BNP (B-type natriuretic peptide) level of 406 ng/L is elevated, which suggests that the patient is experiencing some degree of heart failure symptoms. The patient's blood pressure is well-controlled at 120/70 mmHg, and his ejection fraction is relatively stable.

The patient's ECG shows a second-degree AV block (type I), which is a first-degree heart block that can be associated with various conditions, including ischemic cardiomyopathy. However, the presence of ventricular extrasystoles (monomorphic) suggests some degree of ventricular ectopy, which is common in patients with cardiomyopathy.

Given the patient's overall clinical picture, it is likely that the patient's survival is due to the following factors:

1.  Comprehensive medical therapy: The patient is on a combination of medications that are likely helping to control his heart failure symptoms, manage his blood pressure, and prevent further cardiac events.
2.  Stable LVEF: Although the patient's LVEF is below normal, it has been stable over time, which suggests that the patient's cardiac function is not deteriorating rapidly.
3.  Well-controlled blood pressure: The patient's blood pressure is well-controlled, which reduces the risk of further cardiac damage and complications.
4.  No recent cardiac events: The patient has not had a recent myocardial infarction or other cardiac event, which suggests that his cardiac function is not rapidly deteriorating.

Overall, the patient's survival is likely due to a combination of his comprehensive medical therapy, stable cardiac function, well-controlled blood pressure, and lack of recent cardiac events."
551,551,P0857,"Age: 72
Gender: Female 
Weight: 76 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 10.0
Total Cholesterol (mmol/L): 6,08
Creatinine (mmol/L): 166.0
Gamma-glutamil transpeptidase (IU/L): 71
Glucose (mmol/L): 11,9
Hemoglobin (g/L): 105.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,35
LDL (mmol/L): 3,44
Sodium (mEq/L): 139.0
Protein (g/L): 67,3
T3 (pg/dL): 0,0321
T4 (ng/L): 10
Troponin (ng/mL): 0,7
TSH (mIU/L): 14,9
Urea (mg/dL): 20,9
LVEF (%): 30.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 72-year-old female with a history of idiopathic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, and hypertension. Despite her multiple comorbidities, the patient survived, which can be attributed to several factors.

Firstly, the patient's left ventricular ejection fraction (LVEF) is 30%, indicating severe left ventricular dysfunction. However, the patient is on optimal medical therapy, including ACE inhibitors, which are known to improve LVEF and reduce mortality in patients with heart failure. Additionally, the patient is on loop diuretics, which are essential for managing fluid overload and reducing symptoms of heart failure.

The patient's blood pressure is within a relatively normal range, which is beneficial in preventing further strain on the heart. The blood glucose level is also well-controlled, which is crucial in managing diabetes, a significant risk factor for cardiovascular disease.

The patient's potassium level is slightly low, which can be a concern in patients with heart failure, as it can lead to arrhythmias. However, the patient is on amiodarone, which is an antiarrhythmic medication that can help regulate heart rhythm.

The ECG findings are concerning, with polymorphic ventricular extrasystoles. However, the absence of sustained ventricular tachycardia or non-sustained ventricular tachycardia suggests that the patient's heart rhythm is not as unstable as it could be.

The patient's TSH level is elevated, indicating hypothyroidism, which can contribute to heart failure symptoms. However, the patient's T4 level is within a relatively normal range, suggesting that the hypothyroidism is not severe.

In conclusion, the patient's survival can be attributed to her optimal medical therapy, well-controlled blood glucose and blood pressure, and the absence of severe arrhythmias. While the patient has multiple comorbidities, her overall management plan appears to be effective in preventing further cardiac deterioration."
552,552,P0859,"Age: 69
Gender: Male 
Weight: 75 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 44,7
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 5,56
Creatinine (mmol/L): 72.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 11,3
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,57
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 185.0
Protein (g/L): 67,2
T4 (ng/L): 16
TSH (mIU/L): 1,17
Urea (mg/dL): 5,83
LVEF (%): 39.0
Medications: Diabetes Medication, Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient's outcome as a survivor can be attributed to several factors based on the provided data. 

1.  Age and Comorbidities: The patient is 69 years old, which is considered elderly, but not extremely old. Despite having multiple comorbidities such as hypertensive cardiomyopathy, diabetes, and hypertension, the patient is still alive. This suggests that the patient has adapted to their condition to some extent.

2.  Medications: The patient is on diabetes medication, beta blockers, and an ACE inhibitor. These medications are commonly used to manage cardiovascular diseases and diabetes. Beta blockers help reduce heart rate and blood pressure, while ACE inhibitors help reduce blood pressure and strain on the heart. The use of these medications suggests that the patient is receiving appropriate treatment for their conditions.

3.  ECG Findings: Although the patient has ventricular extrasystoles, there is no evidence of sustained ventricular tachycardia or non-sustained ventricular tachycardia. This indicates that the patient's heart is not experiencing severe arrhythmias that could lead to cardiac arrest.

4.  LVEF: The patient's left ventricular ejection fraction (LVEF) is 39%, which is below the normal range (50-70%). However, an LVEF of 39% is not extremely low, and the patient is still alive, indicating that their heart is still functioning to some extent.

5.  Blood Pressure: The patient's blood pressure is 110/60 mmHg, which is relatively low but not critically low. This could be a result of the beta blockers and ACE inhibitor medications.

6.  Laboratory Results: The patient's creatinine level is slightly elevated, but not severely so. The albumin level is within the normal range, which suggests that the patient's kidneys are functioning relatively well. The patient's glucose level is also within the normal range, indicating good diabetes control.

7.  Hemoglobin and TSH Levels: The patient's hemoglobin level is normal, and TSH is within the normal range, indicating that the patient's thyroid function is normal.

Considering these factors, the patient's outcome as a survivor can be attributed to a combination of their age, comorbidities, medications, and relatively stable laboratory results. The patient's heart is functioning, albeit with some compromise, and they are receiving appropriate treatment for their conditions."
553,553,P0861,"Age: 59
Gender: Male 
Weight: 58 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 42,4
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 11,5
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,64
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 1410.0
Protein (g/L): 83,2
T4 (ng/L): 17
TSH (mIU/L): 2,83
Urea (mg/dL): 9,82
LVEF (%): 20.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 59-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, and dyslipidemia, which are significant risk factors for heart failure and cardiovascular disease. Despite these risk factors, the patient is currently in New York Heart Association (NYHA) Class II, indicating that he is experiencing some limitations in physical activity but is still able to perform daily activities without discomfort.

The patient's laboratory results show elevated levels of Pro-BNP (1410.0 ng/L), which is a marker of heart failure, and a low left ventricular ejection fraction (LVEF) of 20.0%, indicating significant left ventricular dysfunction. However, the patient's hemoglobin level is within the normal range (139.0 g/L), and his sodium level is also within the normal range (133.0 mEq/L), which suggests that the patient is not experiencing significant fluid overload.

The patient is on a comprehensive medication regimen, including diabetes medication, beta blockers, digoxin, loop diuretics, spironolactone, statins, and ACE inhibitors, which are all appropriate for managing heart failure and related conditions. The presence of ventricular extrasystoles on the ECG is a common finding in patients with heart failure, but it does not necessarily indicate a poor prognosis.

Given the patient's comprehensive treatment plan and the lack of severe laboratory abnormalities, the patient's survival is likely due to the effectiveness of his medication regimen and close monitoring. The patient's ability to maintain a relatively stable condition despite significant cardiovascular risk factors and a low LVEF suggests that he is receiving adequate treatment and is being closely managed by his healthcare team."
554,554,P0862,"Age: 62
Gender: Female 
Weight: 66 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 150/95 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 45,6
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,58
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 118.0
HDL (mmol/L): 1,6
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,61
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 266.0
Protein (g/L): 79,2
T4 (ng/L): 19
TSH (mIU/L): 4,59
Urea (mg/dL): 9,82
LVEF (%): 25.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 62-year-old female with a history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction, has a complex clinical presentation. Despite her history and the presence of non-sustained ventricular tachycardia, polymorphic ventricular extrasystoles, and significantly reduced left ventricular ejection fraction (LVEF) of 25%, the patient has survived.

Several factors may have contributed to her survival:

1. Optimal medical therapy: The patient is on a multidrug regimen, including Amiodarone, an Angiotensin II Receptor Blocker, Beta Blockers, and Spironolactone, which are all standard treatments for heart failure and arrhythmias. This comprehensive treatment approach may have helped stabilize her cardiac function and reduce the risk of sudden cardiac death.

2. Controlled blood pressure: Although the patient has hypertension, her blood pressure is well-managed, with a reading of 150/95 mmHg. This is likely due to the combination of her medications, including the Angiotensin II Receptor Blocker and Beta Blockers, which are known to help control blood pressure.

3. Lack of severe electrolyte imbalances: The patient's potassium level is within a relatively normal range (4.8 mEq/L), which is essential for maintaining cardiac function. Severe electrolyte imbalances, particularly hypokalemia or hyperkalemia, can lead to life-threatening arrhythmias.

4. Minimal liver dysfunction: The patient's liver enzymes (ALT and AST) are within normal limits, indicating minimal liver dysfunction. Liver disease can contribute to the progression of heart failure and increase the risk of arrhythmias.

5. Normal thyroid function: The patient's TSH level is within the normal range, indicating that her thyroid function is not contributing to her cardiac condition.

6. Limited renal dysfunction: The patient's creatinine level is mildly elevated, but not severely abnormal (71.0 μmol/L). Renal dysfunction can contribute to the progression of heart failure and increase the risk of arrhythmias.

7. Patient's overall clinical condition: The patient's NYHA Class II classification indicates that she has some limitation in physical activity but is still able to perform everyday activities. This suggests that her cardiac condition is not as severe as it could be, and she may have some reserve capacity to compensate for her heart failure.

Considering these factors, the patient's survival is likely due to the combination of her comprehensive medical therapy, well-managed blood pressure, minimal electrolyte imbalances, limited liver and renal dysfunction, and her relatively stable overall clinical condition."
555,555,P0863,"Age: 55
Gender: Male 
Weight: 80 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 100/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 6,28
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,74
LDL (mmol/L): 4,58
Sodium (mEq/L): 137.0
Protein (g/L): 73,8
T3 (pg/dL): 0,0597
T4 (ng/L): 14,3
Troponin (ng/mL): 0,2
TSH (mIU/L): 3,71
Urea (mg/dL): 6
LVEF (%): 25.0
Medications: Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 55-year-old male with ischemic dilated cardiomyopathy, has a relatively favorable outcome despite his severe heart condition. Several factors contribute to this outcome:

1.  Optimal Medication Management: The patient is on loop diuretics, statins, and an ACE inhibitor, which are all standard treatments for heart failure and ischemic cardiomyopathy. These medications have likely helped to manage the patient's symptoms and slow the progression of the disease.

2.  Normal Blood Pressure: The patient's blood pressure is within a relatively normal range (100/80 mmHg), which is beneficial for heart health. High blood pressure can exacerbate heart failure and increase the risk of cardiovascular events.

3.  Low Troponin Levels: The patient's troponin level (0.2 ng/mL) is slightly elevated, indicating some myocardial damage, but it is not extremely high, suggesting that the damage may not be severe.

4.  LVEF of 25%: Although the patient's left ventricular ejection fraction (LVEF) is severely reduced at 25%, this is not an unexpected finding in a patient with ischemic dilated cardiomyopathy. The fact that the patient is still alive suggests that the heart is compensating to some extent.

5.  Electrocardiogram (ECG) Findings: The patient's ECG shows non-sustained ventricular tachycardia (NSVT), which is a common finding in patients with heart failure. However, the absence of sustained ventricular tachycardia and bradycardia suggests that the patient's heart rhythm is relatively stable.

6.  Laboratory Results: The patient's liver enzymes (ALT and AST) are within normal limits, indicating that there is no significant liver damage, which can be a contributing factor to heart failure.

7.  Hemoglobin Level: The patient's hemoglobin level is within the normal range (156 g/L), indicating that there is no significant anemia, which can exacerbate heart failure.

8.  TSH Level: The patient's thyroid-stimulating hormone (TSH) level is within the normal range (3.71 mIU/L), indicating that there is no underlying thyroid dysfunction, which can contribute to heart failure.

Overall, while the patient has a severe form of heart disease, the combination of optimal medication management, relatively normal blood pressure, and stable ECG findings have likely contributed to his favorable outcome."
556,556,P0864,"Age: 68
Gender: Male 
Weight: 68 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 80/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 3,59
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 37
Glucose (mmol/L): 8,2
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 5,5
LDL (mmol/L): 1,78
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3962.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 9
Troponin (ng/mL): 0,05
TSH (mIU/L): 32,58
Urea (mg/dL): 14,15
LVEF (%): 30.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient's outcome as a survivor can be attributed to several factors in his medical history and current condition. 

1.  Optimal Medical Management: The patient is on a comprehensive regimen of medications, including diabetes medication, angiotensin II receptor blocker, beta blockers, digoxin, loop diuretics, spironolactone, and statins. This multidisciplinary approach helps manage his conditions effectively, including idiopathic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension.

2.  Monitoring and Follow-up: Regular monitoring and follow-up appointments likely allowed for timely adjustments to his treatment plan, ensuring that his conditions were being effectively managed and any potential complications were addressed promptly.

3.  Early Detection and Treatment of Complications: The presence of non-sustained ventricular tachycardia (VT) and polymorphic ventricular extrasystoles on the ECG suggests that the patient's heart rhythm is unstable. However, the fact that these arrhythmias are non-sustained implies that they are not causing immediate harm. This early detection likely allowed for intervention and adjustments to his medication regimen to prevent more severe complications.

4.  Good Support System: The patient's survival suggests that he has a good support system, including family and medical care providers, which is crucial for patients with complex medical conditions.

5.  Low TSH Levels: The patient's TSH (Thyroid Stimulating Hormone) levels are elevated at 32.58 mIU/L, which may indicate hypothyroidism. However, his T4 levels are within the normal range, and T3 levels are low. This discrepancy may suggest that the patient has a euthyroid sick syndrome, a condition commonly seen in patients with chronic heart failure. This condition does not necessarily impact his survival.

6.  Low Hemoglobin Levels: The patient's hemoglobin level is 130 g/L, which is within the normal range. This suggests that his anemia is well-managed, which is beneficial for his overall health and survival.

7.  Good Renal Function: The patient's creatinine level is 94.0 mmol/L, which is within the normal range, indicating good renal function. This is essential for patients with heart failure, as renal impairment can exacerbate their condition.

8.  Low Pro-BNP Levels: The patient's Pro-BNP (N-terminal pro b-type natriuretic peptide) level is 3962.0 ng/L, which is elevated but not excessively high. Elevated Pro-BNP levels are associated with heart failure and can indicate the severity of the condition. However, in this case, the level is not so high as to suggest an extremely poor prognosis.

Considering these factors, the patient's outcome as a survivor can be attributed to the combination of optimal medical management, early detection and treatment of complications, good support system, and well-managed conditions."
557,557,P0865,"Age: 68
Gender: Male 
Weight: 80 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 160/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40,7
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 9
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,46
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 1345.0
Protein (g/L): 68,2
T4 (ng/L): 13
TSH (mIU/L): 3,1
Urea (mg/dL): 7,32
LVEF (%): 40.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 68-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, hypertension, and myocardial infarction, has survived despite his complex medical history and multiple comorbidities. Several factors contributed to his survival:

1.  Optimal Medication Management: The patient is on a comprehensive regimen of medications, including diabetes medication, beta blockers, loop diuretics, statins, ACE inhibitors, and nitrovasodilators. These medications have helped to control his blood pressure, manage his heart failure symptoms, and prevent further cardiovascular events.

2.  Controlled Blood Pressure: The patient's blood pressure is well-controlled at 160/85 mmHg, which is lower than his previous levels. This reduction in blood pressure has likely reduced the strain on his heart and minimized the risk of further cardiovascular damage.

3.  Monitoring and Management of Heart Failure: The patient's LVEF (left ventricular ejection fraction) is 40%, indicating mild to moderate heart failure. His pro-BNP (brain natriuretic peptide) level is elevated at 1345.0 ng/L, suggesting that he has some degree of heart failure. However, his symptoms are likely being managed effectively with loop diuretics, which are helping to reduce fluid overload and alleviate symptoms.

4.  Good Glycemic Control: The patient's glucose level is well-controlled at 9 mmol/L, which is within the target range for diabetes management. Good glycemic control is essential for preventing complications associated with diabetes, such as cardiovascular disease and kidney damage.

5.  Regular Monitoring and Follow-up: The patient's regular follow-up and monitoring have allowed for timely adjustments to his medication regimen, which has helped to prevent further complications and optimize his treatment plan.

6.  Lack of Severe Arrhythmias: While the patient has non-sustained ventricular tachycardia, he does not have any severe arrhythmias such as sustained ventricular tachycardia or bradycardia. This suggests that his heart is functioning relatively well, and his medications are helping to prevent life-threatening arrhythmias.

7.  Nutritional Status: The patient's albumin level is within the normal range (40.7 g/L), indicating that he is not malnourished, which is essential for his overall health and recovery.

In summary, the combination of optimal medication management, controlled blood pressure, effective heart failure management, good glycemic control, regular monitoring, and a lack of severe arrhythmias have all contributed to the patient's survival despite his complex medical history and multiple comorbidities."
558,558,P0866,"Age: 76
Gender: Female 
Weight: 73 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 44,1
ALT or GPT (IU/L): 6.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 6,08
Creatinine (mmol/L): 77.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 147.0
HDL (mmol/L): 1,76
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,65
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 306.0
Protein (g/L): 74
T4 (ng/L): 15
TSH (mIU/L): 1
Urea (mg/dL): 5,83
LVEF (%): 49.0
Medications: Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type I
            ",survivor,"REASONING: 

The patient is a 76-year-old female with a history of hypertensive cardiomyopathy and hypertension, presenting with a reduced left ventricular ejection fraction (LVEF) of 49%, indicating systolic heart failure. Despite this, she is classified as NYHA Class II, indicating mild to moderate symptoms of heart failure.

The patient's laboratory results show elevated pro-BNP (brain natriuretic peptide) levels at 306 ng/L, which is indicative of heart failure. However, her creatinine levels are within normal limits, suggesting that her renal function is not significantly compromised at this time.

Her lipid profile shows elevated total cholesterol and LDL levels, but she is on statin therapy, which is likely helping to manage these levels. Her potassium levels are within normal limits, and her hemoglobin is within the normal range.

The ECG findings of polymorphic ventricular extrasystoles are concerning, but the absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that these extrasystoles are likely benign.

The presence of second-degree AV block type I is a significant finding, as it indicates conduction delay in the AV node. However, it is not a contraindication to treatment or survival.

Given the patient's age, comorbidities, and current treatment regimen, it is likely that the patient's outcome is a result of optimal medical management of her heart failure and hypertension. The combination of beta blockers, statins, ACE inhibitors, and nitrovasodilators is likely helping to manage her symptoms and slow disease progression.

Therefore, the patient's outcome as a survivor is likely due to the effectiveness of her current treatment regimen and her ability to manage her comorbidities."
559,559,P0867,"Age: 73
Gender: Female 
Weight: 82 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 5,25
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 10,8
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,22
LDL (mmol/L): 3,13
Sodium (mEq/L): 140.0
Protein (g/L): 68
T3 (pg/dL): 0,0438
T4 (ng/L): 18,54
Troponin (ng/mL): 0,4
TSH (mIU/L): 0,92
Urea (mg/dL): 16,9
LVEF (%): 70.0
Medications: Diabetes Medication, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 73-year-old female with a history of Hypertensive cardiomyopathy, diabetes, dyslipemia, and hypertension. Despite her complex medical history, the patient has a relatively preserved left ventricular ejection fraction (LVEF) of 70%, indicating that the heart is still functioning relatively well.

The patient's blood pressure is within a relatively normal range (100/60 mmHg), which is a good sign considering her history of hypertension. However, the low diastolic blood pressure may indicate orthostatic hypotension, which can be a concern in elderly patients.

The patient's laboratory results show elevated creatinine levels (159.0 mmol/L), indicating some degree of renal impairment. However, her hemoglobin and albumin levels are within normal limits, suggesting that the renal impairment is not severe.

The patient's glucose level is elevated (10.8 mmol/L), but it is well-controlled with diabetes medication. Her lipid profile shows a high total cholesterol level, but it is being managed with statins.

The patient's thyroid function tests (TSH, T3, and T4) are within normal limits, indicating that her thyroid function is not contributing to her cardiac condition.

The ECG shows a monomorphic ventricular extrasystole, which is a common finding in patients with hypertension and cardiomyopathy. However, there is no evidence of sustained ventricular tachycardia or bradycardia.

Considering the patient's overall medical history, laboratory results, and ECG findings, it is likely that the patient's heart condition is well-managed, and she is able to tolerate her medications without significant cardiac complications. Therefore, the patient outcome of survivor is reasonable given her current medical status."
560,560,P0868,"Age: 75
Gender: Male 
Weight: 82 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 39,4
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 5,4
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 83
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 140.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,21
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 173.0
Protein (g/L): 67,4
T4 (ng/L): 16
TSH (mIU/L): 0,6
Urea (mg/dL): 4,99
LVEF (%): 53.0
Medications: Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 75-year-old male with a history of hypertensive cardiomyopathy, which suggests a compromised left ventricular function. His current LVEF (Left Ventricular Ejection Fraction) is 53%, indicating a mildly reduced ejection fraction, which is consistent with his NYHA Class II classification. The patient's blood pressure is elevated at 140/90 mmHg, which may be a contributing factor to his cardiomyopathy.

The patient's laboratory results show slightly elevated liver enzymes (ALT and AST), which may indicate mild liver dysfunction, but not severe enough to suggest liver disease as a primary cause of his cardiac condition. The patient's lipid profile shows a total cholesterol level of 5.4 mmol/L, which is slightly elevated, but his LDL level is relatively low at 3.21 mmol/L, which may be managed with his statin medication.

The patient's kidney function is relatively preserved, with a creatinine level of 106.0 μmol/L, which is within a normal range. However, his Pro-BNP level is elevated at 173.0 ng/L, which suggests that the patient has some degree of heart failure, but it is not severe.

The patient's ECG shows polymorphic ventricular extrasystoles, but no sustained ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia. His TSH level is within a normal range, and his thyroid hormone levels are also normal.

Considering the patient's age, comorbidities, and laboratory results, the most likely reason for his survival is that his cardiac condition is stable, and his current treatment regimen, including spironolactone, statins, and an ACE inhibitor, is effective in managing his symptoms and slowing the progression of his disease. The patient's mildly reduced LVEF and elevated Pro-BNP level suggest that he has some degree of heart failure, but it is not severe enough to cause significant morbidity or mortality. Therefore, the patient's survival can be attributed to his current treatment and the fact that his cardiac condition is not severe enough to cause significant cardiac decompensation."
561,561,P0871,"Age: 53
Gender: Male 
Weight: 96 kg
Height: 175 cm
NYHA Class: III
Blood Pressure: 110/50 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 50
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 6,1
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 147.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 5
LDL (mmol/L): 4,14
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1195.0
Protein (g/L): 84
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,13
TSH (mIU/L): 1,2
Urea (mg/dL): 12,31
LVEF (%): 39.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 53-year-old male with a history of idiopathic dilated cardiomyopathy, hypertension, and dyslipemia, who is currently on a treatment regimen that includes beta blockers, loop diuretics, spironolactone, statins, ACE inhibitors, and nitrovasodilators. His current medication regimen suggests that he is being managed for heart failure with reduced ejection fraction (HFrEF).

The patient's LVEF of 39% indicates that he has significant left ventricular dysfunction, consistent with HFrEF. His elevated Pro-BNP level of 1195.0 ng/L further supports the diagnosis of heart failure.

The patient's blood pressure is within a relatively normal range (110/50 mmHg), which may be due to the effect of his medications, particularly beta blockers and ACE inhibitors. His heart rate is not provided, but his ECG shows polymorphic ventricular extrasystoles, which is a common finding in patients with heart failure.

The patient's laboratory results show mild elevation in liver enzymes (ALT and AST), which could be related to his statin therapy. His lipid profile shows elevated total cholesterol and LDL levels, which are being managed with statins. His kidney function is impaired, as indicated by an elevated creatinine level of 115.0 mmol/L.

The patient's hemoglobin level is within the normal range, and his electrolyte levels are also within normal limits. His thyroid function tests are within normal limits, and his T3 and T4 levels are within the normal range.

Given the patient's complex medical history and current treatment regimen, it is likely that he is being closely monitored for signs of heart failure progression or complications. The fact that he is a survivor suggests that his treatment plan is effective in managing his symptoms and slowing the progression of his heart disease. However, ongoing monitoring and adjustments to his treatment plan may be necessary to optimize his outcomes."
562,562,P0874,"Age: 42
Gender: Male 
Weight: 90 kg
Height: 176 cm
NYHA Class: III
Blood Pressure: 100/80 mmHg
Past Medical History: Post-myocardial dilated cardiomyopathy, Diabetes
Albumin (g/L): 48
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,98
Creatinine (mmol/L): 82.0
Gamma-glutamil transpeptidase (IU/L): 53
Glucose (mmol/L): 7,4
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,58
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 100.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,005
TSH (mIU/L): 2,13
Urea (mg/dL): 7,49
LVEF (%): 18.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 42-year-old male with a history of post-myocardial dilated cardiomyopathy, has a low left ventricular ejection fraction (LVEF) of 18%, indicating severe heart failure. Despite this, the patient is a survivor, which can be attributed to several factors:

1.  Optimal medical management: The patient is on a multidisciplinary regimen of medications, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, which are all evidence-based treatments for heart failure with reduced ejection fraction (HFrEF). These medications help manage symptoms, improve cardiac function, and reduce the risk of adverse outcomes.

2.  Close monitoring and follow-up: The patient's regular check-ups and monitoring of vital signs, laboratory results, and echocardiograms likely allowed for timely adjustments to their treatment plan, ensuring that their condition was closely managed.

3.  Good glycemic control: The patient's blood glucose level is well-controlled at 7.4 mmol/L, which is crucial for patients with diabetes, as uncontrolled diabetes can exacerbate heart failure.

4.  Lack of severe electrolyte imbalances: The patient's potassium level is within a relatively normal range (4.6 mEq/L), which is important for patients with heart failure, as electrolyte imbalances can lead to arrhythmias and worsen cardiac function.

5.  Low Pro-BNP levels: The patient's Pro-BNP level is 100 ng/L, which is within the normal range. Elevated Pro-BNP levels are associated with increased mortality and morbidity in heart failure patients, so this suggests that the patient's condition is relatively stable.

6.  Absence of severe renal dysfunction: The patient's creatinine level is 82.0 μmol/L, which is within a relatively normal range. Severe renal dysfunction can worsen heart failure outcomes.

7.  No signs of severe cardiac arrhythmias: The patient's ECG shows only polymorphic ventricular extrasystoles, which are common in patients with heart failure but are not typically a cause for concern.

8.  Optimal thyroid function: The patient's TSH level is within a normal range (2.13 mIU/L), indicating that thyroid function is well-managed, which is important for heart health.

Overall, the combination of optimal medical management, close monitoring, good glycemic control, lack of severe electrolyte imbalances, low Pro-BNP levels, absence of severe renal dysfunction, and absence of severe cardiac arrhythmias likely contributed to the patient's survival."
563,563,P0875,"Age: 79
Gender: Female 
Weight: 70 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 100/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 3,23
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 9,6
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,68
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1588.0
Protein (g/L): 70
T3 (pg/dL): 0,02
T4 (ng/L): 23
Troponin (ng/mL): 0,13
TSH (mIU/L): 1,34
Urea (mg/dL): 8,65
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient, a 79-year-old female with a history of idiopathic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension, presented with a complex clinical picture. Despite the presence of multiple comorbidities, the patient's overall outcome was a survivor. 

Several factors contributed to this outcome:

1.  Optimal Medication Management: The patient was on a regimen of beta blockers, digoxin, loop diuretics, statins, and an ACE inhibitor, which is consistent with current guidelines for managing heart failure and hypertension. These medications helped to control the patient's symptoms, improve cardiac function, and reduce the risk of complications.

2.  Stable Blood Pressure: The patient's blood pressure was within a relatively normal range (100/60 mmHg), which suggests that the medications were effective in managing her hypertension.

3.  LVEF of 35%: Although the patient's left ventricular ejection fraction (LVEF) was low (35%), it was not as low as expected for a patient with idiopathic dilated cardiomyopathy. This may indicate some degree of cardiac compensation or the effectiveness of the patient's medication regimen.

4.  Mild Renal Function Impairment: The patient's creatinine level was elevated at 80.0 mmol/L, indicating mild renal impairment. However, this was not severe enough to significantly impact the patient's overall outcome.

5.  No Acute Coronary Syndrome: The patient's troponin level was 0.13 ng/mL, which is within a relatively normal range, suggesting that there was no acute coronary syndrome or myocardial infarction.

6.  No Severe Electrocardiographic Abnormalities: Although the patient had ventricular extrasystoles and non-sustained ventricular tachycardia, these were not severe enough to significantly impact her outcome.

7.  TSH and Thyroid Function: The patient's thyroid-stimulating hormone (TSH) level was within the normal range, indicating that thyroid dysfunction was not a contributing factor to her cardiac condition.

8.  Albumin and Protein Levels: The patient's albumin and protein levels were within normal limits, indicating that there was no significant liver dysfunction or malnutrition.

9.  Low Pro-BNP Level: The patient's pro-B-type natriuretic peptide (pro-BNP) level was elevated at 1588.0 ng/L, indicating heart failure, but not as high as expected for a patient with advanced heart failure.

Considering these factors, the patient's overall outcome of survival can be attributed to the effectiveness of her medication regimen, stable blood pressure, relatively preserved renal function, and the absence of acute coronary syndrome or severe electrolyte imbalances."
564,564,P0876,"Age: 70
Gender: Female 
Weight: 74 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,48
Creatinine (mmol/L): 66.0
Gamma-glutamil transpeptidase (IU/L): 37
Glucose (mmol/L): 3,1
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,45
Potassium (mEq/L): 3,95
LDL (mmol/L): 3,31
Sodium (mEq/L): 142.0
Protein (g/L): 74,5
T3 (pg/dL): 0,0636
T4 (ng/L): 13,7
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,86
Urea (mg/dL): 5,9
LVEF (%): 70.0
Medications: Calcium Channel Blocker, Diabetes Medication
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient, a 70-year-old female, has a history of Hypertensive cardiomyopathy, diabetes, and hypertension, which are all significant cardiovascular risk factors. However, her left ventricular ejection fraction (LVEF) is 70%, indicating that her heart is functioning relatively well. 

The presence of ventricular extrasystoles on the ECG is a common finding, especially in patients with hypertension and cardiomyopathy. The absence of sustained ventricular tachycardia or other severe arrhythmias suggests that her heart is not experiencing severe electrical instability. 

Her blood pressure is elevated at 160/80 mmHg, which is concerning, but her medication regimen includes a calcium channel blocker, which is likely being used to control her hypertension. 

The patient's laboratory results show elevated total cholesterol and LDL levels, but her HDL level is within a relatively healthy range. Her glucose level is slightly elevated, but her diabetes is being managed with medication. 

The patient's TSH level is within the normal range, indicating that her thyroid function is not contributing to her cardiovascular condition. Her T3 and T4 levels are also within normal limits. 

The patient's troponin level is slightly elevated, which could indicate some degree of cardiac stress or injury, but it is not significantly elevated, and the patient is still alive, suggesting that the injury is not severe.

Given the patient's overall clinical picture, it appears that she is being managed effectively for her cardiovascular conditions, and her medications are likely helping to control her blood pressure and manage her diabetes. The presence of ventricular extrasystoles is a common finding in this patient population, and the absence of more severe arrhythmias or cardiac dysfunction suggests that she is likely to survive with ongoing management of her conditions."
565,565,P0877,"Age: 60
Gender: Female 
Weight: 74 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 8,4
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,38
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 593.0
Protein (g/L): 65
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,84
Urea (mg/dL): 6,16
LVEF (%): 15.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient, a 60-year-old female with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and myocardial infarction, has a complex clinical presentation. Despite her severe left ventricular dysfunction (LVEF of 15%), the patient is a survivor, likely due to the following factors:

1.  Aggressive medical management: The patient is on a multidrug regimen, including beta blockers, digoxin, loop diuretics, spironolactone, statins, and an ACE inhibitor. These medications have likely helped to control symptoms, reduce morbidity, and improve quality of life.

2.  Optimal blood pressure control: The patient's blood pressure is within a reasonable range (110/60 mmHg), which is beneficial for patients with heart failure and reduces the risk of cardiovascular events.

3.  Normal electrolytes: The patient's potassium levels are within the normal range (4.4 mEq/L), which is essential for optimal cardiac function and reduces the risk of arrhythmias.

4.  Low troponin levels: The patient's troponin levels are within the normal range (0.01 ng/mL), indicating that there is no acute myocardial injury or infarction.

5.  Normal thyroid function: The patient's TSH and T4 levels are within the normal range, indicating that thyroid dysfunction is not contributing to her cardiac condition.

6.  Adequate renal function: The patient's creatinine and urea levels are within the normal range, indicating that her renal function is preserved, which is essential for the elimination of medications and the regulation of electrolytes.

7.  Presence of ventricular extrasystoles and non-sustained ventricular tachycardia: While the patient has arrhythmias, they are non-sustained and not life-threatening, which may be managed with her current medication regimen.

8.  Presence of paroxysmal supraventricular tachyarrhythmia and bradycardia: The codes for these arrhythmias are unknown, but their presence may not be significantly impacting the patient's survival, given her overall clinical context.

In conclusion, the patient's survival is likely due to a combination of her aggressive medical management, optimal blood pressure control, normal electrolytes, low troponin levels, normal thyroid function, preserved renal function, and the management of her arrhythmias."
566,566,P0878,"Age: 57
Gender: Male 
Weight: 62 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 38,5
ALT or GPT (IU/L): 8.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,08
Creatinine (mmol/L): 212.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 5,2
LDL (mmol/L): 3,8
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 6606.0
Protein (g/L): 68,4
T4 (ng/L): 16
TSH (mIU/L): 3,87
Urea (mg/dL): 19,8
LVEF (%): 40.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 57-year-old male with a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack. His left ventricular ejection fraction (LVEF) is 40%, indicating that his heart is not pumping efficiently. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG suggests that his heart is experiencing abnormal heart rhythms, which can increase the risk of sudden cardiac death.

However, despite these risk factors, the patient has been prescribed medications that are commonly used to manage heart failure, including angiotensin II receptor blockers, beta blockers, and loop diuretics. These medications are designed to help reduce the workload on the heart, slow the heart rate, and remove excess fluid from the body.

The patient's laboratory results show elevated levels of B-type natriuretic peptide (BNP), which is a hormone produced by the heart in response to increased ventricular wall tension. Elevated BNP levels are associated with heart failure and can indicate that the patient's heart is working harder than normal.

The patient's hemoglobin level is within a normal range, which suggests that his kidneys are functioning adequately. His creatinine level is elevated, but not significantly so, which may indicate some degree of kidney impairment, but not severe enough to significantly impact his overall prognosis.

The patient's total cholesterol and LDL levels are elevated, but his HDL (good cholesterol) level is low, which may be a contributing factor to his heart disease. However, his triglyceride level is not provided, which would be useful in further assessing his lipid profile.

Given the patient's age, medical history, and laboratory results, it is likely that the patient's survival is due to the combination of his medications and the fact that his kidney function is not severely impaired. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG suggests that the patient's heart is experiencing some degree of dysfunction, but the fact that he is alive suggests that his heart is still able to compensate for these abnormalities to some extent."
567,567,P0879,"Age: 71
Gender: Male 
Weight: 67 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 130/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 8
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,25
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 304.0
Protein (g/L): 63
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,38
Urea (mg/dL): 8,32
LVEF (%): 50.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient's age of 71 years and past medical history of ischemic dilated cardiomyopathy and myocardial infarction indicate a history of significant cardiovascular disease. The patient's current New York Heart Association (NYHA) Class II classification suggests that the patient experiences some limitation of physical activity but is still able to perform ordinary physical activity without symptoms of heart failure.

The patient's blood pressure of 130/90 mmHg is within the normal range, indicating controlled hypertension. The patient's laboratory results show a slightly elevated creatinine level (97.0 μmol/L) and a normal albumin level (40 g/L), which may indicate mild renal impairment but is not indicative of severe kidney disease.

The patient's lipid profile shows elevated total cholesterol (3.7 mmol/L) and LDL cholesterol (2.25 mmol/L) levels, which are risk factors for cardiovascular disease. However, the patient's HDL cholesterol level (1.06 mmol/L) is low, which is also a risk factor for cardiovascular disease.

The patient's troponin level of 0.01 ng/mL is within the normal range, indicating that the patient has not had a recent myocardial infarction. The patient's LVEF (left ventricular ejection fraction) of 50% is within the normal range, indicating that the patient's heart is pumping effectively.

The patient's medications, beta blockers and ACE inhibitor, are appropriate for managing heart failure and hypertension. The patient's ECG results show ventricular extrasystole, but no sustained ventricular tachycardia or other significant arrhythmias.

Considering the patient's overall clinical presentation and laboratory results, the patient's outcome of survival can be attributed to the following factors:

1.  Effective management of heart failure and hypertension with medications.
2.  Normal LVEF, indicating preserved cardiac function.
3.  No recent myocardial infarction or other acute cardiac events.
4.  Mild renal impairment, which is not severe enough to impact the patient's survival.
5.  Appropriate lipid profile management, despite elevated total and LDL cholesterol levels.

Therefore, the patient's outcome of survival is likely due to a combination of these factors, which have contributed to the effective management of their cardiovascular disease."
568,568,P0883,"Age: 66
Gender: Female 
Weight: 62 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 170/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,69
Creatinine (mmol/L): 62.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,49
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 325.0
Protein (g/L): 76
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 4
Urea (mg/dL): 5,66
LVEF (%): 64.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 66-year-old female with a history of hypertensive cardiomyopathy and hypertension. She is on a treatment regimen consisting of an angiotensin II receptor blocker, beta blockers, and loop diuretics, which suggests that her hypertension is being managed. 

The patient's blood pressure is elevated at 170/90 mmHg, but it is not severely hypertensive. Her LVEF is 64%, which indicates that her heart function is mildly impaired but not significantly compromised. The presence of ventricular extrasystoles and unknown ventricular tachycardia on the ECG is a concern, but it is not life-threatening.

The patient's laboratory results show mild elevations in liver enzymes (ALT and GGT), which may indicate some degree of liver dysfunction, but this is not severe. Her kidney function is also mildly impaired, as indicated by the elevated creatinine level. However, her urea level is within a relatively normal range.

The patient's glucose level is slightly elevated, which may be a concern for diabetes mellitus, but it is not severely elevated. Her lipid profile shows a high total cholesterol level, but her HDL and LDL levels are within relatively normal ranges.

The patient's TSH level is within a normal range, indicating that her thyroid function is not a concern. Her troponin level is normal, indicating that there is no acute myocardial infarction. Her pro-BNP level is elevated, which may indicate heart failure, but it is not severely elevated.

Considering the patient's age, medical history, and laboratory results, it is likely that she has a mild to moderate form of heart failure, which is being managed with her current medications. The presence of ventricular extrasystoles and unknown ventricular tachycardia on the ECG is a concern, but it is not life-threatening. The patient's overall prognosis is guarded, but she is likely to survive with proper management and follow-up care."
569,569,P0885,"Age: 59
Gender: Male 
Weight: 100 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 3,65
Creatinine (mmol/L): 74.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 156.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,2
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 105.0
Protein (g/L): 68
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,03
Urea (mg/dL): 4,99
LVEF (%): 33.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome as a survivor can be attributed to several factors. 

1. Current Medications: The patient is on beta blockers, statins, and an ACE inhibitor, which are all evidence-based treatments for heart failure and ischemic dilated cardiomyopathy. These medications have likely helped to reduce the patient's symptoms, slow disease progression, and improve quality of life.

2. LVEF of 33%: Although the patient's left ventricular ejection fraction (LVEF) is significantly reduced, indicating heart failure with reduced ejection fraction (HFrEF), it is not as low as some patients who may not survive. The patient's LVEF is also relatively stable, indicating that the heart's pumping function is still present, albeit reduced.

3. Stable Blood Pressure: The patient's blood pressure is well-controlled at 130/80 mmHg, which is below the target for patients with heart failure. This suggests that the patient's blood pressure is not placing additional strain on the heart.

4. No Recent Myocardial Infarction: The patient's troponin level is 0.01 ng/mL, which is within normal limits. This suggests that the patient has not had a recent myocardial infarction, which is a significant predictor of poor outcomes in patients with heart failure.

5. Pro-BNP Level: The patient's pro-BNP level is 105 ng/L, which is within the normal range. Elevated pro-BNP levels are associated with increased mortality and morbidity in patients with heart failure.

6. Absence of Severe Electrocardiographic Abnormalities: The patient's ECG shows polymorphic ventricular extrasystoles, but no sustained ventricular tachycardia, non-sustained ventricular tachycardia, or other severe arrhythmias. This suggests that the patient's heart rhythm is relatively stable.

7. Overall Clinical Stability: The patient's laboratory results show stable kidney function (creatinine 74.0 μmol/L), normal liver function tests (ALT 26.0 IU/L, AST 19.0 IU/L), and no signs of severe anemia (Hemoglobin 156.0 g/L). These factors suggest that the patient's overall clinical status is stable.

Considering these factors, the patient's outcome as a survivor is likely due to a combination of effective medical management, relatively stable cardiac function, and the absence of severe complications."
570,570,P0886,"Age: 75
Gender: Male 
Weight: 60 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 115/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 6.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 3,15
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 140.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,91
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1186.0
Protein (g/L): 66
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,4
Urea (mg/dL): 10,15
LVEF (%): 20.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 75-year-old male with a history of ischemic dilated cardiomyopathy, dyslipemia, hypertension, and myocardial infarction, which suggests significant cardiovascular disease. His current medications, including beta blockers, statins, and an ACE inhibitor, are appropriate for managing his conditions.

The patient's left ventricular ejection fraction (LVEF) is severely reduced at 20%, indicating significant left ventricular dysfunction. However, the patient's blood pressure is within a relatively normal range (115/55 mmHg), and his heart rate is not excessively elevated.

The elevated Pro-BNP level (1186.0 ng/L) suggests that the patient has significant heart failure symptoms, which is consistent with his reduced LVEF and history of ischemic dilated cardiomyopathy.

The patient's creatinine level (88.0 mmol/L) is within a relatively normal range, indicating that his kidney function is preserved. His electrolyte levels, including potassium and sodium, are also within normal limits.

The patient's lipid profile shows a high total cholesterol level (3.15 mmol/L) and a low HDL level (0.75 mmol/L), which is consistent with his history of dyslipemia. However, his LDL level (1.91 mmol/L) is not excessively high.

The patient's ECG shows non-sustained ventricular tachycardia, which is a common finding in patients with heart failure and reduced LVEF. The presence of polymorphic ventricular extrasystoles is also consistent with his history of ischemic dilated cardiomyopathy.

Given the patient's history, medications, and laboratory results, it is likely that the patient's outcome is a survivor due to the following reasons:

1. Appropriate medical therapy: The patient is on medications that are known to improve heart failure symptoms and outcomes, such as beta blockers and ACE inhibitors.
2. Preserved kidney function: The patient's creatinine level is within a relatively normal range, indicating that his kidney function is preserved, which is a good prognostic sign.
3. Normal electrolyte levels: The patient's electrolyte levels, including potassium and sodium, are within normal limits, which is important for maintaining cardiac function.
4. Low troponin level: The patient's troponin level is low (0.01 ng/mL), indicating that he is not experiencing an acute myocardial infarction.
5. Stable blood pressure: The patient's blood pressure is within a relatively normal range, which is important for maintaining cardiac function.

Overall, the patient's outcome is likely a survivor due to the combination of appropriate medical therapy, preserved kidney function, normal electrolyte levels, low troponin level, and stable blood pressure."
571,571,P0889,"Age: 66
Gender: Male 
Weight: 85 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertropic cardiomyopathy, Dyslipemia, Peripheral vascular disease
Albumin (g/L): 50
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 6,47
Creatinine (mmol/L): 70.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 4,6
LDL (mmol/L): 4,37
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 54.0
Protein (g/L): 73,4
T4 (ng/L): 16
TSH (mIU/L): 1,16
Urea (mg/dL): 5,99
LVEF (%): 68.0
Medications: Calcium Channel Blocker
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient's age of 66 and NYHA Class II suggest that the patient has a moderate level of heart disease, but is still relatively stable. The presence of hypertrophic cardiomyopathy, dyslipemia, and peripheral vascular disease indicates a history of cardiovascular disease, which could have contributed to the development of ventricular extrasystoles. However, the patient's left ventricular ejection fraction (LVEF) of 68% is within a relatively normal range, suggesting that the patient's heart function is still relatively preserved.

The patient's medications, including a calcium channel blocker, are likely aimed at managing the patient's hypertension and possibly the symptoms of hypertrophic cardiomyopathy. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia suggests that the patient's heart rhythm is relatively stable.

The patient's laboratory results, including the normal liver enzymes (ALT, AST, and GGT), normal kidney function (creatinine and urea), and normal electrolytes (potassium and sodium), suggest that the patient does not have any acute or severe underlying conditions that could have contributed to a poor outcome.

The patient's TSH and T4 levels are within a normal range, indicating that the patient does not have any signs of hypothyroidism or hyperthyroidism, which could have affected the heart's function.

The patient's Pro-BNP level of 54.0 ng/L is slightly elevated, but not excessively high, which could suggest some degree of heart strain or stress, but not to the extent that would lead to a poor outcome.

Overall, considering the patient's relatively stable heart function, absence of acute or severe underlying conditions, and stable medications, the patient's outcome as a survivor is likely due to the effective management of their cardiovascular disease and the absence of any life-threatening conditions."
572,572,P0892,"Age: 61
Gender: Female 
Weight: 59 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 95/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,57
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 886.0
Protein (g/L): 69
T4 (ng/L): 27
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,95
Urea (mg/dL): 12,81
LVEF (%): 43.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's medical history and current clinical presentation, the patient's outcome of survival can be attributed to several factors. 

Firstly, the patient's current medications, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, are all evidence-based treatments for heart failure and ischemic dilated cardiomyopathy. These medications have likely contributed to the stabilization of the patient's condition and improved their cardiac function.

The patient's LVEF (Left Ventricular Ejection Fraction) is 43%, which is below the normal range but not severely impaired. This suggests that the patient's heart is still pumping effectively enough to maintain adequate circulation and oxygenation of vital organs.

The patient's Pro-BNP (Brain Natriuretic Peptide) level is elevated at 886.0 ng/L, which is consistent with heart failure. However, the level is not excessively high, suggesting that the patient's condition is being managed effectively.

The patient's blood pressure is within a relatively normal range, with a systolic pressure of 95 mmHg and diastolic pressure of 65 mmHg. This suggests that the patient's blood pressure is being adequately controlled.

The patient's troponin level is within normal limits, indicating that there is no acute myocardial infarction or ischemia.

The patient's ECG shows evidence of ventricular extrasystoles and non-sustained ventricular tachycardia, but no sustained ventricular tachycardia or bradycardia. These findings are consistent with a patient with a history of ischemic dilated cardiomyopathy and are not indicative of a life-threatening condition.

Overall, the patient's survival outcome is likely due to the effective management of their heart failure and ischemic dilated cardiomyopathy through medication, as well as the relatively preserved cardiac function and controlled blood pressure."
573,573,P0893,"Age: 62
Gender: Male 
Weight: 95 kg
Height: 183 cm
NYHA Class: II
Blood Pressure: 130/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 40,4
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,11
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 128.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,56
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 3572.0
Protein (g/L): 69,4
T4 (ng/L): 17
TSH (mIU/L): 1,32
Urea (mg/dL): 7,49
LVEF (%): 60.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient, a 62-year-old male with a history of ischemic dilated cardiomyopathy, dyslipemia, hypertension, and myocardial infarction, has been managed with a multi-faceted treatment plan including beta blockers, digoxin, loop diuretics, statins, and ACE inhibitors. The patient's left ventricular ejection fraction (LVEF) of 60% indicates a moderate reduction in cardiac function, but it is still within a relatively stable range, suggesting that the current treatment plan is effective in managing the patient's heart failure symptoms.

The patient's blood pressure of 130/85 mmHg is within a relatively normal range, and the absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG suggests that the patient is not experiencing any acute cardiac arrhythmias. The presence of polymorphic ventricular extrasystoles may be a benign finding, but it warrants further monitoring.

The patient's laboratory results show a slightly elevated creatinine level of 93.0 μmol/L, which may indicate mild renal impairment. However, the urea level of 7.49 mg/dL is within a relatively normal range, and the patient's serum albumin level is within the normal range, suggesting that the renal impairment is not severe.

The patient's glucose level of 5.7 mmol/L is slightly elevated, but it is not in the diabetic range. The patient's lipid profile shows a total cholesterol level of 4.11 mmol/L, which is slightly elevated, but the LDL level of 2.56 mmol/L is within a relatively normal range.

The patient's TSH level of 1.32 mIU/L is within a relatively normal range, and the T4 level of 17 ng/L is also within a normal range, indicating that the patient's thyroid function is normal.

Overall, the patient's current medication regimen and laboratory results suggest that he is being effectively managed for his cardiac condition. The patient's LVEF of 60% and the absence of acute cardiac arrhythmias on the ECG indicate that the patient's cardiac function is stable. The patient's laboratory results show a few minor abnormalities, but they are not severe enough to indicate a poor prognosis. Therefore, the patient's outcome is likely to be a survivor."
574,574,P0894,"Age: 57
Gender: Male 
Weight: 68 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45,2
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 7,01
Creatinine (mmol/L): 86.0
Gamma-glutamil transpeptidase (IU/L): 188
Glucose (mmol/L): 7
Hemoglobin (g/L): 158.0
HDL (mmol/L): 1,63
Potassium (mEq/L): 4,8
LDL (mmol/L): 4,6
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 710.0
Protein (g/L): 76,7
T4 (ng/L): 14
TSH (mIU/L): 6,21
Urea (mg/dL): 5,83
LVEF (%): 46.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"REASONING: The patient, a 57-year-old male with a history of enolic dilated cardiomyopathy and hypertension, has been treated with a combination of medications including digoxin, loop diuretics, ACE inhibitor, and nitrovasodilator. The patient's left ventricular ejection fraction (LVEF) is 46%, indicating moderate heart failure.

The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which may indicate underlying cardiac electrical instability. However, the patient's heart rate is not excessively high, and there is no indication of paroxysmal supraventricular tachyarrhythmia.

The patient's laboratory results show elevated levels of gamma-glutamil transpeptidase (GGT), which may indicate liver dysfunction or bile duct obstruction. The patient's total cholesterol and LDL levels are elevated, which may contribute to the progression of atherosclerosis and further cardiac strain.

Despite these factors, the patient's overall clinical picture suggests that he is being effectively managed with his current medication regimen. The patient's blood pressure is well-controlled, and there is no indication of significant renal impairment or electrolyte imbalances.

The patient's Pro-BNP level is elevated at 710.0 ng/L, which is consistent with heart failure. However, the patient's hemoglobin and urea levels are within normal limits, indicating that the heart failure is not severe.

Given the patient's overall clinical picture, it is likely that the patient is being effectively managed for his heart failure and other comorbidities, and the patient outcome of survivor is consistent with this management."
575,575,P0895,"Age: 77
Gender: Male 
Weight: 66 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 154/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41,2
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,4
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 5,1
LDL (mmol/L): 2,79
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 126.0
Protein (g/L): 66,3
T4 (ng/L): 15
TSH (mIU/L): 0,85
Urea (mg/dL): 8,99
LVEF (%): 63.0
Medications: ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient's age and gender are within the high-risk category for cardiovascular events, but they have a history of hypertension and cardiomyopathy, which can be managed with medication. The patient's blood pressure is elevated at 154/85 mmHg, but it is not extremely high, and the patient is on an ACE inhibitor, which is a common treatment for hypertension.

The patient's creatinine level is slightly elevated at 95.0 mmol/L, indicating some degree of kidney impairment. However, this is not severe, and the patient's urea level is within a relatively normal range. The patient's hemoglobin level is slightly above the normal range, which may indicate mild polycythemia, a common condition in older adults.

The patient's liver function tests (ALT and AST) are within normal limits, indicating that the liver is functioning properly. The patient's lipid profile shows elevated total cholesterol and LDL levels, but the HDL level is low, which is a risk factor for cardiovascular disease.

The patient's LVEF is 63.0%, which is within the normal range, indicating that the patient's heart is functioning properly. The patient's Pro-BNP level is elevated at 126.0 ng/L, which may indicate some degree of heart failure, but it is not extremely high.

The patient's ECG shows several abnormalities, including ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia. However, the patient does not have any sustained ventricular tachycardia or bradycardia.

Considering the patient's age, comorbidities, and ECG findings, the patient is at high risk for cardiovascular events. However, the patient's overall condition is stable, and the patient is on appropriate medication for their conditions. The patient's ability to survive is likely due to the effective management of their hypertension and cardiomyopathy, as well as the lack of severe kidney impairment or other life-threatening conditions.

The patient's survival is also likely due to the fact that the patient's LVEF is within the normal range, indicating that the patient's heart is functioning properly, and the patient's Pro-BNP level is not extremely high, indicating that the patient does not have severe heart failure. Additionally, the patient's ECG findings are not indicative of any life-threatening arrhythmias, and the patient does not have any other severe medical conditions that would put them at high risk for mortality."
576,576,P0896,"Age: 47
Gender: Male 
Weight: 100 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 100/63 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 48
ALT or GPT (IU/L): 45.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 28
Glucose (mmol/L): 10,5
Hemoglobin (g/L): 154.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 5,1
LDL (mmol/L): 2,61
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 226.0
Protein (g/L): 72
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,77
Urea (mg/dL): 7,65
LVEF (%): 20.0
Medications: Beta Blockers, Statins, Hydralazine, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient, a 47-year-old male with a history of idiopathic dilated cardiomyopathy and dyslipemia, has a low left ventricular ejection fraction (LVEF) of 20.0%, indicating severe heart failure. The presence of polymorphic ventricular extrasystoles on the ECG suggests underlying cardiac electrical instability.

Despite the patient's critical condition, the fact that he is a survivor suggests that his current treatment regimen, which includes beta blockers, statins, hydralazine, ACE inhibitor, and nitrovasodilator, is effective in managing his condition. Beta blockers, in particular, are known to improve survival and reduce the risk of sudden cardiac death in patients with heart failure.

The patient's hemoglobin level is within the normal range, which is a positive indicator, as anemia can worsen heart failure. Additionally, his potassium level is within the normal range, which is essential for maintaining proper cardiac function.

The patient's troponin level is low, indicating minimal cardiac muscle damage, which is a good sign. His TSH level is also within the normal range, suggesting that his thyroid function is not contributing to his cardiac condition.

The patient's creatinine level is elevated, indicating impaired renal function, which can be a complication of heart failure. However, the patient's urea level is within the normal range, which suggests that his kidney function is not severely impaired.

The patient's pro-BNP level is elevated, which is consistent with heart failure, but the fact that he is a survivor suggests that his treatment is effectively managing his condition.

Overall, the patient's survival can be attributed to the effectiveness of his current treatment regimen and the absence of severe cardiac complications, such as cardiac arrest or severe arrhythmias."
577,577,P0900,"Age: 67
Gender: Male 
Weight: 74 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 120/53 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 42,1
ALT or GPT (IU/L): 46.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 3,05
Creatinine (mmol/L): 87.0
Gamma-glutamil transpeptidase (IU/L): 93
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 121.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,34
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 3611.0
Protein (g/L): 66,9
T4 (ng/L): 19
TSH (mIU/L): 2,15
Urea (mg/dL): 5,99
LVEF (%): 40.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 67-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and myocardial infarction, which suggests a high risk of cardiac complications. The patient's left ventricular ejection fraction (LVEF) is 40%, indicating moderate to severe systolic heart failure.

The patient's current medications, including beta blockers, statins, and an ACE inhibitor, are appropriate for managing his conditions. The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG indicates potential arrhythmogenic activity, but the absence of sustained ventricular tachycardia or other severe arrhythmias suggests that the patient's cardiac function is still manageable.

The patient's laboratory results show elevated levels of creatinine (87.0 mmol/L), which indicates impaired renal function. However, the urea level (5.99 mg/dL) is within a relatively normal range, suggesting that the patient's kidney function is not severely compromised.

The patient's pro-BNP level is elevated at 3611.0 ng/L, which is consistent with heart failure. However, the patient's symptoms and laboratory results suggest that the patient is receiving appropriate treatment for heart failure.

Given the patient's overall clinical presentation and management, the outcome of the patient being a survivor suggests that the treatment plan is effective in managing his cardiac conditions and preventing further complications. The patient's ability to tolerate his medications and the absence of severe cardiac events or hospitalizations indicate that the treatment plan is working, and the patient is likely to continue to survive with proper management."
578,578,P0901,"Age: 52
Gender: Male 
Weight: 78 kg
Height: 167 cm
NYHA Class: III
Blood Pressure: 115/65 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 48
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 5,74
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 64
Glucose (mmol/L): 8,2
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 5
LDL (mmol/L): 4,01
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1558.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 18
Troponin (ng/mL): 0,06
TSH (mIU/L): 2,56
Urea (mg/dL): 8,32
LVEF (%): 26.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 52-year-old male with a history of idiopathic dilated cardiomyopathy and hypertension, has a poor left ventricular ejection fraction (LVEF) of 26%. This indicates significant left ventricular dysfunction, which is a hallmark of dilated cardiomyopathy. The patient's New York Heart Association (NYHA) class III classification further supports this, indicating moderate to severe symptoms of heart failure.

The patient's laboratory results show elevated levels of B-type natriuretic peptide (BNP), which is a marker of heart failure and cardiac dysfunction. The elevated BNP level of 1558 ng/L is consistent with severe heart failure.

The patient's medication regimen, including ACE inhibitors (Angiotensin II Receptor Blocker), beta blockers, digoxin, loop diuretics, and spironolactone, is consistent with standard treatment for heart failure and dilated cardiomyopathy. The presence of diabetes medication suggests that the patient has concomitant diabetes, which is common in patients with heart failure.

The patient's ECG shows polymorphic ventricular extrasystoles, but no sustained ventricular tachycardia or bradycardia. This suggests that the patient's cardiac rhythm is generally stable, despite the presence of ventricular extrasystoles.

Given the patient's complex medical history and the presence of multiple comorbidities, it is not surprising that the patient has survived. The patient's treatment regimen and the absence of acute cardiac decompensation or arrhythmias suggest that the patient's survival is likely due to the effectiveness of their current medical management.

However, the patient's LVEF of 26% indicates that the patient's cardiac function is severely impaired, and the patient may be at risk for further cardiac complications. Close monitoring and continued optimization of the patient's treatment regimen will be necessary to prevent further cardiac decompensation and improve the patient's quality of life."
579,579,P0902,"Age: 44
Gender: Male 
Weight: 75 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 140/100 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 46
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 41.0
Total Cholesterol (mmol/L): 7,55
Creatinine (mmol/L): 89.0
Gamma-glutamil transpeptidase (IU/L): 151
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 173.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 5,2
LDL (mmol/L): 4,27
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 147.0
Protein (g/L): 73
T3 (pg/dL): 0,06
T4 (ng/L): 17
Troponin (ng/mL): 0,06
TSH (mIU/L): 0,753
Urea (mg/dL): 5,83
LVEF (%): 39.0
Medications: ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 44-year-old male with a history of idiopathic dilated cardiomyopathy, hypertension, and dyslipidemia, presented with a left ventricular ejection fraction (LVEF) of 39%, indicating reduced cardiac function. The patient's blood pressure is elevated at 140/100 mmHg, which can further strain the heart.

The patient's laboratory results show elevated levels of creatinine (89.0 mmol/L), indicating kidney dysfunction, which can be a consequence of reduced cardiac output and decreased renal perfusion. The patient's liver function tests (ALT and AST) are mildly elevated, which may indicate some degree of liver stress or potential non-alcoholic fatty liver disease, often associated with dyslipidemia.

The patient's lipid profile shows elevated total cholesterol and LDL levels, which are risk factors for cardiovascular disease. The patient's glucose level is slightly elevated at 5.5 mmol/L, which may be a sign of impaired glucose tolerance or insulin resistance.

The patient's thyroid function tests (T3 and T4) are within normal limits, and the TSH level is slightly low, which is likely due to the patient's age and not indicative of thyroid disease.

The patient's ECG shows polymorphic ventricular extrasystoles, which are premature ventricular beats that can be a sign of underlying cardiac disease. However, there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias.

Considering the patient's age, symptoms, and laboratory results, the patient's outcome as a survivor can be attributed to several factors:

1.  The patient is on an ACE inhibitor, which is a standard treatment for heart failure and hypertension. This medication helps to reduce afterload and improve cardiac output.
2.  The patient's LVEF is not extremely low, indicating that the heart is still pumping some blood, albeit inefficiently.
3.  The patient does not have any acute cardiac events such as myocardial infarction or cardiac arrest, which could have led to a worse outcome.
4.  The patient's kidney function, although impaired, is not severely compromised, which suggests that the heart is still able to maintain some level of perfusion to the kidneys.

In summary, the patient's outcome as a survivor is likely due to a combination of effective medical treatment, relatively preserved cardiac function, and the absence of acute cardiac events."
580,580,P0903,"Age: 63
Gender: Male 
Weight: 59 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 47,3
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 9,46
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 170
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,93
Potassium (mEq/L): 5,07
LDL (mmol/L): 6,65
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1975.0
Protein (g/L): 76,4
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,84
Urea (mg/dL): 11,7
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 63-year-old male with a history of ischemic dilated cardiomyopathy and myocardial infarction, which indicates significant cardiac disease. The patient's left ventricular ejection fraction (LVEF) is severely reduced at 20%, indicating a poor heart function. Despite this, the patient is still alive, which can be attributed to the following factors:

1.  Aggressive medical management: The patient is on beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are all commonly used to manage heart failure and reduce the risk of adverse cardiac events.
2.  Good blood pressure control: The patient's blood pressure is well-controlled at 110/80 mmHg, which is beneficial for heart health.
3.  Low troponin levels: The patient's troponin level is 0.02 ng/mL, which is within the normal range, indicating that there is no ongoing myocardial damage.
4.  Normal electrolyte levels: The patient's potassium level is 5.07 mEq/L, which is within the normal range, and there is no evidence of electrolyte imbalances that could contribute to cardiac arrhythmias.
5.  Adequate renal function: The patient's creatinine level is 120.0 μmol/L, which is slightly elevated but not significantly impaired, indicating that the patient's kidneys are functioning relatively well.
6.  Absence of severe anemia: The patient's hemoglobin level is 156.0 g/L, which is within the normal range, indicating that the patient does not have severe anemia, which can contribute to cardiac disease.
7.  Low BNP levels: The patient's BNP level is 1975.0 ng/L, which is elevated but not excessively high, indicating that the patient's heart failure is not severely exacerbated.
8.  Presence of supportive medications: The patient is on spironolactone, which is an aldosterone antagonist that can help reduce morbidity and mortality in patients with heart failure.

Considering these factors, the patient's survival can be attributed to a combination of aggressive medical management, good blood pressure control, and the absence of severe cardiac damage or electrolyte imbalances."
581,581,P0904,"Age: 74
Gender: Female 
Weight: 64 kg
Height: 158 cm
NYHA Class: III
Blood Pressure: 105/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39,2
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 3,91
Creatinine (mmol/L): 137.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 7,2
Hemoglobin (g/L): 111.0
HDL (mmol/L): 1,18
Potassium (mEq/L): 3,81
LDL (mmol/L): 2,12
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 694.0
Protein (g/L): 68,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,28
Urea (mg/dL): 12,7
LVEF (%): 31.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"REASONING: 

The patient is a 74-year-old female with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction, indicating a complex cardiac history with multiple comorbidities. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 31%, indicating heart failure with reduced ejection fraction (HFrEF).

The patient's blood pressure is within a relatively normal range (105/55 mmHg), and the patient is on beta blockers, loop diuretics, statins, and an ACE inhibitor, which are standard medications for managing heart failure and hypertension.

The patient's laboratory results show elevated creatinine levels (137.0 mmol/L), indicating renal impairment, which is common in patients with heart failure. The patient's glucose level is elevated (7.2 mmol/L), suggesting poorly controlled diabetes. The total cholesterol level is elevated (3.91 mmol/L), and the LDL level is also elevated (2.12 mmol/L), indicating dyslipemia. The patient's potassium level is slightly low (3.81 mEq/L), which may be related to the use of loop diuretics.

The patient's B-type natriuretic peptide (BNP) level is elevated (694.0 ng/L), indicating increased ventricular wall stress, which is consistent with heart failure.

The ECG shows polymorphic ventricular extrasystoles, which are common in patients with heart failure and can be related to the underlying cardiomyopathy. The patient does not have any sustained ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia.

Considering the patient's complex cardiac history, reduced LVEF, and elevated BNP levels, the patient's outcome as a survivor is likely due to the effective management of their heart failure and comorbidities with medications, as well as the patient's ability to adapt to their condition over time. The patient's relatively normal blood pressure and the absence of severe arrhythmias also contributed to their survival."
582,582,P0905,"Age: 46
Gender: Male 
Weight: 69 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 47,3
ALT or GPT (IU/L): 50.0
AST or GOT (IU/L): 35.0
Total Cholesterol (mmol/L): 4,83
Creatinine (mmol/L): 92.0
Gamma-glutamil transpeptidase (IU/L): 96
Glucose (mmol/L): 7,2
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,02
Potassium (mEq/L): 5,25
LDL (mmol/L): 2,83
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 2470.0
Protein (g/L): 75,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,93
Urea (mg/dL): 6,5
LVEF (%): 25.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's history of idiopathic dilated cardiomyopathy, the patient's left ventricular ejection fraction (LVEF) of 25% indicates severe systolic dysfunction, which is consistent with dilated cardiomyopathy. The patient's New York Heart Association (NYHA) Class II classification suggests that the patient experiences some limitation in physical activity but is still able to perform daily activities without discomfort.

The patient's laboratory results show elevated creatinine levels (92.0 mmol/L) and a slightly elevated urea level (6.5 mg/dL), indicating some degree of renal impairment, which is common in patients with heart failure. The patient's total cholesterol and LDL levels are within relatively normal limits, but the HDL level is low (1.02 mmol/L), which may be a risk factor for cardiovascular disease.

The patient's troponin level is slightly elevated (0.01 ng/mL), which may indicate some degree of myocardial injury, but it is not significantly elevated, and the patient does not have any symptoms of acute coronary syndrome.

The patient's pro-BNP level is elevated (2470.0 ng/L), which is consistent with heart failure and is used as a prognostic marker for mortality in patients with heart failure.

The patient is on optimal medical therapy for heart failure, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are all evidence-based treatments for heart failure with reduced ejection fraction.

Given the patient's severe systolic dysfunction and heart failure symptoms, the fact that the patient is on optimal medical therapy, and the absence of acute coronary syndrome or other life-threatening conditions, the patient's survival is likely due to the effectiveness of their current treatment regimen and close monitoring of their condition."
583,583,P0906,"Age: 82
Gender: Male 
Weight: 80 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 42,5
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,39
Creatinine (mmol/L): 185.0
Gamma-glutamil transpeptidase (IU/L): 52
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,15
Potassium (mEq/L): 4,02
LDL (mmol/L): 2,91
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 28179.0
Protein (g/L): 80,2
Troponin (ng/mL): 0,07
TSH (mIU/L): 1,92
Urea (mg/dL): 17,2
LVEF (%): 15.0
Medications: Calcium Channel Blocker, Diabetes Medication, Amiodarone, Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

Given the patient's age (82 years), history of ischemic dilated cardiomyopathy, myocardial infarction, and NYHA Class III, it is not surprising that the patient has a low left ventricular ejection fraction (LVEF) of 15.0%. This indicates a significant reduction in the heart's ability to pump blood effectively, which is consistent with a diagnosis of heart failure.

The patient's elevated Pro-BNP (B-type natriuretic peptide) level of 28179.0 ng/L is also indicative of heart failure, as this biomarker is often elevated in conditions of increased ventricular wall stress and volume overload.

The patient's blood pressure is within a relatively normal range (130/80 mmHg), which is likely due to the presence of medications such as calcium channel blockers and angiotensin II receptor blockers. However, the patient's creatinine level of 185.0 μmol/L indicates impaired renal function, which is a common comorbidity in patients with heart failure.

The patient's diabetes medication and elevated glucose level (5.9 mmol/L) suggest that the patient has poorly controlled diabetes, which can exacerbate cardiac dysfunction.

The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG indicates that the patient has arrhythmias, which are common in patients with heart failure.

Despite the patient's significant comorbidities and poor cardiac function, the patient's ability to survive suggests that the treatment regimen is effective in managing the patient's symptoms and slowing disease progression. The combination of medications such as amiodarone, loop diuretics, and spironolactone likely helps to control arrhythmias, reduce fluid overload, and improve cardiac function.

The patient's age and comorbidities make them a high-risk population, but the fact that they are alive suggests that the treatment team has effectively managed their condition and prevented further complications."
584,584,P0909,"Age: 40
Gender: Female 
Weight: 125 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 42,9
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,04
Creatinine (mmol/L): 66.0
Gamma-glutamil transpeptidase (IU/L): 28
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 117.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,26
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 12.0
Protein (g/L): 74,8
T4 (ng/L): 15
TSH (mIU/L): 1,49
Urea (mg/dL): 6,82
LVEF (%): 49.0
Medications: Diabetes Medication, Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient outcome of this 40-year-old female is a survivor, which can be attributed to several factors from her medical history and laboratory results. 

Firstly, the patient's left ventricular ejection fraction (LVEF) is 49%, indicating that her heart is functioning relatively well despite her history of idiopathic dilated cardiomyopathy. This suggests that her condition is being managed effectively with her current treatment regimen, which includes beta blockers and ACE inhibitors. 

Additionally, the patient's Pro-BNP level is 12.0 ng/L, which is within a relatively normal range. Elevated Pro-BNP levels are often associated with heart failure and poor prognosis. The normal Pro-BNP level in this patient suggests that her heart is not under significant strain.

The patient's blood pressure is 140/80 mmHg, which is within a relatively normal range, and her diabetes and dyslipemia are being managed with medication. The patient's kidney function, as indicated by her creatinine level, is also within a relatively normal range.

Furthermore, the patient's ECG results do not indicate any significant arrhythmias or other cardiac abnormalities that would suggest a poor prognosis.

However, it is worth noting that the patient's hemoglobin level is slightly low at 117.0 g/L, which may indicate anemia, a common comorbidity in patients with heart failure. The patient's total cholesterol level is also slightly elevated at 5.04 mmol/L, which may increase her risk of cardiovascular events.

In summary, the combination of the patient's relatively well-managed medical conditions, normal Pro-BNP level, and lack of significant cardiac abnormalities on ECG make it likely that the patient will survive with appropriate management of her condition."
585,585,P0910,"Age: 73
Gender: Female 
Weight: 74 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 150/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 46,6
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,48
Creatinine (mmol/L): 66.0
Gamma-glutamil transpeptidase (IU/L): 37
Glucose (mmol/L): 11,1
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,1
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 614.0
Protein (g/L): 79
T3 (pg/dL): 0,04
T4 (ng/L): 16
TSH (mIU/L): 0,67
Urea (mg/dL): 4,49
LVEF (%): 70.0
Medications: Diabetes Medication, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 73-year-old female with a history of hypertensive cardiomyopathy, diabetes, hypertension, and myocardial infarction, has a relatively favorable outcome despite her complex medical history. Several factors contribute to this outcome:

1.  Good left ventricular ejection fraction (LVEF) of 70%: This indicates that the patient's heart is pumping blood effectively, which is essential for maintaining adequate circulation and preventing further cardiac complications.

2.  Stable blood pressure: Although the patient's blood pressure is slightly elevated at 150/90 mmHg, it is well-controlled with medication, and there is no indication of severe hypertension that could lead to cardiovascular events.

3.  Optimal management of diabetes: The patient is on diabetes medication, which suggests that her diabetes is being managed effectively, reducing the risk of diabetic complications, including cardiovascular disease.

4.  Use of beta blockers and statins: These medications are crucial in managing cardiovascular disease. Beta blockers help control heart rate and blood pressure, while statins lower cholesterol levels, reducing the risk of further cardiovascular events.

5.  Lack of severe electrolyte imbalances: The patient's potassium level is within the normal range (4.6 mEq/L), which is essential for maintaining proper heart function.

6.  Normal thyroid function: The patient's TSH level is within the normal range (0.67 mIU/L), indicating that her thyroid function is well-managed, which can impact cardiovascular health.

7.  No signs of severe cardiac arrhythmias: The ECG results do not show any signs of sustained ventricular tachycardia or other severe arrhythmias, which could indicate a poor prognosis.

While the patient's medical history is complex, her current management and the absence of severe complications contribute to her favorable outcome. However, ongoing monitoring and management of her conditions will be essential to prevent further complications and ensure optimal health."
586,586,P0911,"Age: 64
Gender: Female 
Weight: 67 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 150/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41,4
ALT or GPT (IU/L): 44.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 5,95
Creatinine (mmol/L): 87.0
Gamma-glutamil transpeptidase (IU/L): 57
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 134.0
HDL (mmol/L): 2,54
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,26
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 1114.0
Protein (g/L): 72,5
T3 (pg/dL): 0,04
T4 (ng/L): 14
TSH (mIU/L): 5,22
Urea (mg/dL): 6,49
LVEF (%): 65.0
Medications: Beta Blockers
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 64-year-old female with a history of Hypertensive cardiomyopathy, dyslipemia, and hypertension, presenting with a New York Heart Association (NYHA) class III, indicating moderate to severe heart failure symptoms. 

The elevated blood pressure (150/80 mmHg) is consistent with her history of hypertension. The patient's kidney function, as indicated by the creatinine level (87.0 mmol/L), is mildly impaired, suggesting some degree of renal impairment, likely secondary to her hypertension and cardiomyopathy.

The elevated total cholesterol (5.95 mmol/L) and LDL (3.26 mmol/L) levels indicate dyslipemia, which is a risk factor for cardiovascular disease. However, her HDL level (2.54 mmol/L) is within a relatively normal range.

The elevated gamma-glutamil transpeptidase (GGT) level (57 IU/L) may indicate liver dysfunction or bile duct obstruction, but in the context of this patient, it could be related to her metabolic syndrome or dyslipemia.

The slightly elevated glucose level (4.9 mmol/L) may be related to insulin resistance, which is often seen in patients with hypertension and dyslipemia.

The low T3 (0.04 pg/dL) and T4 (14 ng/L) levels, along with a normal TSH (5.22 mIU/L), suggest euthyroidism, which is a favorable prognostic factor.

The elevated Pro-BNP (1114.0 ng/L) level indicates increased stress on the heart, likely due to her heart failure. The LVEF (65.0%) is within a relatively normal range, indicating that the patient's heart function is preserved.

Given the patient's age, comorbidities, and symptoms, she is at high risk for cardiovascular events. However, her preserved LVEF and euthyroidism are favorable prognostic factors. The patient is on beta blockers, which is a standard treatment for heart failure and hypertension.

Considering the patient's overall clinical picture, the most likely reason for her being a survivor is the combination of her preserved LVEF, euthyroidism, and the effectiveness of her current treatment regimen, including beta blockers, which has likely helped to manage her heart failure and hypertension."
587,587,P0912,"Age: 75
Gender: Female 
Weight: 57 kg
Height: 158 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 50,1
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,28
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,81
Potassium (mEq/L): 4,1
LDL (mmol/L): 4,11
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1619.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,04
Urea (mg/dL): 4,68
LVEF (%): 68.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

This patient is a 75-year-old female with a history of Hypertensive cardiomyopathy, Dyslipemia, Peripheral vascular disease, and Hypertension. She is classified as NYHA Class III, indicating moderate to severe symptoms of heart failure. Despite her advanced age and multiple comorbidities, the patient is a survivor, which suggests that she has been receiving effective management and treatment for her condition.

Several factors contribute to her survival:

1.  Optimal Medication Management: The patient is on a combination of medications that are commonly used to manage heart failure, including Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, and ACE Inhibitor. These medications are effective in reducing symptoms, improving heart function, and preventing further complications.
2.  Good Blood Pressure Control: The patient's blood pressure is well-controlled at 130/80 mmHg, which is essential for managing Hypertensive cardiomyopathy and reducing the risk of cardiovascular events.
3.  Reasonable Lipid Profile: The patient's total cholesterol level is slightly elevated, but her HDL (good cholesterol) level is within a healthy range, and her LDL (bad cholesterol) level is not excessively high. This suggests that her statin therapy is effective in managing her dyslipemia.
4.  Normal Glucose Levels: The patient's glucose level is within a normal range, which reduces the risk of cardiovascular complications associated with diabetes.
5.  Reasonable Renal Function: The patient's creatinine level is slightly elevated, but not to a degree that would indicate significant kidney dysfunction.
6.  Normal LVEF: The patient's left ventricular ejection fraction (LVEF) is 68%, which is within a normal range, indicating that her heart function is preserved.
7.  ECG Findings: While the patient has polymorphic ventricular extrasystoles, there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias.

In summary, the patient's survival is likely due to a combination of optimal medication management, good blood pressure control, reasonable lipid profile, normal glucose levels, preserved renal function, and normal LVEF, along with the absence of life-threatening arrhythmias on ECG."
588,588,P0914,"Age: 54
Gender: Male 
Weight: 93 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 45,2
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 4,19
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 6
Hemoglobin (g/L): 141.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,51
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 464.0
Protein (g/L): 72,8
T3 (pg/dL): 0,05
T4 (ng/L): 14
TSH (mIU/L): 1,21
Urea (mg/dL): 7,32
LVEF (%): 20.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"REASONING: 

The patient is a 54-year-old male with a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack, leading to a reduction in left ventricular ejection fraction (LVEF). The patient's LVEF is severely reduced at 20%, indicating significant heart failure. 

The patient's medications, including Angiotensin II Receptor Blocker, Beta Blockers, and Statins, are standard treatments for heart failure and are aimed at reducing the workload on the heart, improving its function, and preventing further damage. The presence of these medications suggests that the patient is being actively managed for his heart condition.

The patient's laboratory results show elevated levels of Pro-BNP (464.0 ng/L), which is a marker of heart failure. However, the patient's Creatinine level is slightly elevated at 103.0 mmol/L, which may indicate some degree of kidney dysfunction, but not severe enough to cause significant concern.

The patient's blood pressure is within a relatively normal range (120/80 mmHg), and his glucose level is also within a normal range (6 mmol/L). His lipid profile shows elevated total cholesterol (4.19 mmol/L) and LDL (2.51 mmol/L) levels, but these are being managed with Statins.

The patient's ECG shows ventricular extrasystoles, which are abnormal heartbeats that originate in the ventricles. However, there is no evidence of sustained ventricular tachycardia, paroxysmal supraventricular tachyarrhythmia, or bradycardia.

Considering the patient's history, laboratory results, and ECG findings, it is likely that the patient's heart condition is being managed effectively with his current medications, and he is being closely monitored for any signs of worsening heart failure or other complications. The fact that the patient is a survivor suggests that he is receiving adequate treatment and care for his condition, and his heart is being supported to function as well as possible given his underlying disease."
589,589,P0915,"Age: 78
Gender: Male 
Weight: 103 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 36,4
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 6,08
Creatinine (mmol/L): 85.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 6
Hemoglobin (g/L): 164.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,6
LDL (mmol/L): 4,16
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2390.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,65
Urea (mg/dL): 8,69
LVEF (%): 38.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's extensive medical history, including ischemic dilated cardiomyopathy, dyslipemia, and hypertension, it is not surprising that the patient is in a New York Heart Association (NYHA) Class II, indicating some limitation in physical activity. However, the patient is still able to perform moderate physical activity without symptoms.

The patient's laboratory results show elevated levels of Pro-BNP (2390.0 ng/L), which is a biomarker of heart failure and cardiac stress. Additionally, the patient has a low left ventricular ejection fraction (LVEF) of 38%, indicating reduced cardiac function.

Despite these indicators of heart failure, the patient's overall condition can be attributed to the effectiveness of their current medication regimen. They are on beta blockers, loop diuretics, spironolactone, ACE inhibitors, and nitrovasodilators, which are all standard treatments for heart failure and hypertension. These medications likely help to manage the patient's symptoms and slow the progression of their heart failure.

The patient's ECG results show evidence of ventricular extrasystole, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia, but these are not uncommon findings in patients with heart failure. The absence of bradycardia is also a positive sign.

The patient's survival can be attributed to the combination of their medication regimen, their relatively stable blood pressure (150/80 mmHg), and their ability to manage their physical activity level. While the patient's condition is not optimal, their current treatment plan appears to be effective in maintaining their overall health and preventing further deterioration.

However, it is essential to continue monitoring the patient's condition and adjust their treatment plan as needed to ensure optimal management of their heart failure and other comorbidities."
590,590,P0922,"Age: 65
Gender: Male 
Weight: 81 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 148.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,34
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 86.0
Protein (g/L): 72
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,08
Urea (mg/dL): 8,99
LVEF (%): 58.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 65-year-old male, has a history of Hypertensive cardiomyopathy, diabetes, and hypertension, which are all risk factors for cardiovascular disease. However, the patient's current medications, including beta blockers, loop diuretics, and an ACE inhibitor, are consistent with standard treatment for heart failure and hypertension.

The patient's LVEF (Left Ventricular Ejection Fraction) of 58% is within the normal range (50-70%), indicating that the patient's heart function is relatively preserved. The patient's troponin level of 0.01 ng/mL is also within the normal range, indicating that there is no acute myocardial infarction.

The patient's creatinine level of 80.0 umol/L is slightly elevated, but not significantly, indicating some degree of renal impairment. However, the patient's urea level of 8.99 mg/dL is within the normal range, suggesting that the renal impairment is not severe.

The patient's glucose level of 8.5 mmol/L is elevated, indicating that the patient's diabetes is not well-controlled. However, the patient's hemoglobin A1c level is not provided, so it is unclear if the patient's diabetes is well-controlled in the long term.

The patient's blood pressure of 140/80 mmHg is within the normal range, indicating that the patient's hypertension is well-controlled.

The patient's ECG shows a ventricular extrasystole, but no ventricular tachycardia or bradycardia. The patient's TSH level of 1.08 mIU/L is within the normal range, indicating that the patient's thyroid function is normal.

Overall, the patient's cardiac function and blood pressure are relatively well-controlled, and the patient is on appropriate medications for their conditions. The patient's renal function is slightly impaired, but not severely. The patient's diabetes is not well-controlled, but the patient's overall prognosis is still relatively good. Therefore, the patient's outcome is likely to be a survivor."
591,591,P0923,"Age: 78
Gender: Male 
Weight: 61 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 72.0
AST or GOT (IU/L): 35.0
Total Cholesterol (mmol/L): 4,32
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 100
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 132.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 5
LDL (mmol/L): 2,56
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 487.0
Protein (g/L): 73
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,75
Urea (mg/dL): 11,48
LVEF (%): 35.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 78-year-old male with a history of ischemic dilated cardiomyopathy, peripheral vascular disease, and myocardial infarction, which are all significant risk factors for heart failure and cardiovascular events. The patient's current New York Heart Association (NYHA) Class II classification indicates that he experiences some limitation of physical activity due to symptoms, but is still able to perform light physical activity without discomfort.

The patient's laboratory results show elevated levels of creatinine (115.0 mmol/L), which suggests impaired renal function, and elevated levels of gamma-glutamil transpeptidase (100 IU/L), which may indicate liver dysfunction or bile duct obstruction. The patient's total cholesterol level is elevated at 4.32 mmol/L, and his LDL level is 2.56 mmol/L, which is above the recommended target for a patient with cardiovascular disease.

The patient's LVEF (left ventricular ejection fraction) is 35.0%, which is significantly reduced and indicates that the patient has systolic heart failure. The patient's pro-BNP (brain natriuretic peptide) level is elevated at 487.0 ng/L, which is consistent with heart failure. However, the patient's troponin level is within normal limits, which suggests that there is no current acute myocardial infarction.

The patient is on a regimen of beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor, which are all standard treatments for heart failure and hypertension. The patient's ECG shows a polymorphic ventricular extrasystole, which is a benign finding, but also TPSV (paroxysmal supraventricular tachyarrhythmia), which may require further evaluation and management.

Considering the patient's complex medical history and laboratory results, the fact that the patient is on appropriate medications and has a reduced LVEF but no acute myocardial infarction, the patient's survival is likely due to the following factors:

1. Appropriate medical management: The patient is on a comprehensive regimen of medications that are effective in managing heart failure and hypertension.
2. Reduced activity level: The patient's NYHA Class II classification indicates that he is able to limit his physical activity, which may reduce the strain on his heart.
3. No acute myocardial infarction: The patient's troponin level is within normal limits, which suggests that there is no current acute myocardial infarction.
4. No severe electrolyte imbalances: The patient's potassium level is within normal limits, which is important for cardiac function.

Overall, the patient's survival is likely due to a combination of appropriate medical management, reduced activity level, and the absence of acute myocardial infarction and severe electrolyte imbalances."
592,592,P0924,"Age: 72
Gender: Female 
Weight: 65 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 36.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 71
Glucose (mmol/L): 6,4
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 5,6
LDL (mmol/L): 2,43
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 2235.0
Protein (g/L): 70
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,49
Urea (mg/dL): 8,15
LVEF (%): 55.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 72-year-old female with a history of hypertensive cardiomyopathy, dyslipemia, peripheral vascular disease, and hypertension. Her current medications include amiodarone, an angiotensin II receptor blocker, loop diuretics, and statins, which are all consistent with her medical history and current condition. 

The patient's LVEF (left ventricular ejection fraction) is 55%, which is below the normal range of 55-70%, indicating reduced cardiac function. However, it's worth noting that the patient is still alive, suggesting that her current treatment plan is effective in managing her condition.

Her blood pressure is within a relatively normal range (140/80 mmHg), and her potassium level is within the normal range (5.6 mEq/L). The patient's creatinine level is slightly elevated (97.0 umol/L), which may indicate mild renal impairment, but it's not severe enough to cause significant concern.

The patient's TSH level is within the normal range (3.49 mIU/L), which suggests that her thyroid function is normal. Her troponin level is within the normal range (0.01 ng/mL), indicating no acute myocardial infarction.

The patient's Pro-BNP level is elevated (2235.0 ng/L), which can be a marker of heart failure. However, given her current treatment plan and the fact that she is still alive, it's possible that her Pro-BNP level is being managed effectively.

Overall, the patient's outcome as a survivor is likely due to the effective management of her hypertension, heart failure, and other comorbidities through her current medication regimen and lifestyle modifications. The patient's LVEF is reduced, but it's not severe enough to cause significant concern, and her other vital signs and laboratory results are within normal or relatively normal ranges."
593,593,P0925,"Age: 77
Gender: Male 
Weight: 82 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 5,07
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 150.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,36
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 424.0
Protein (g/L): 68
T4 (ng/L): 10
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,33
Urea (mg/dL): 6,66
LVEF (%): 57.0
Medications: Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient's age of 77 years and history of hypertrophic cardiomyopathy suggest a high risk of cardiovascular disease. However, the patient's left ventricular ejection fraction (LVEF) of 57% is within the normal range, indicating that the heart is pumping blood efficiently. 

The patient's blood pressure is 140/80 mmHg, which is within the normal range. The absence of sustained ventricular tachycardia and paroxysmal supraventricular tachycardia suggests that the patient is not experiencing severe arrhythmias. 

The patient's troponin level of 0.01 ng/mL is within the normal range, indicating that there is no acute myocardial infarction. The low level of Pro-BNP (424.0 ng/L) also suggests that the patient is not experiencing severe heart failure.

The patient's medications, including beta blockers and loop diuretics, are appropriate for managing hypertension and heart failure symptoms. The patient's NYHA class of II indicates that the patient is experiencing some limitations in physical activity but is still able to perform daily activities.

The patient's laboratory results show a slight elevation in creatinine levels (106.0 μmol/L), which may indicate mild renal impairment. However, the patient's urea levels (6.66 mg/dL) are within the normal range, suggesting that the kidney function is not severely compromised.

Overall, the patient's overall condition appears to be stable, and the patient's LVEF and other indicators suggest that the patient is not experiencing severe cardiac dysfunction. The patient's age and medical history suggest a high risk of cardiovascular disease, but the patient's current medications and laboratory results suggest that the patient is being effectively managed. Therefore, the patient's outcome of survivor is likely due to the effective management of their cardiovascular disease and the absence of severe cardiac dysfunction."
594,594,P0926,"Age: 81
Gender: Male 
Weight: 68 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 36
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,67
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 10,3
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 5,2
LDL (mmol/L): 2,11
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 779.0
Protein (g/L): 68
T4 (ng/L): 8
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,1
Urea (mg/dL): 14,81
LVEF (%): 42.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is an 81-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipidemia, and myocardial infarction, which indicates a complex cardiac condition. His left ventricular ejection fraction (LVEF) is 42%, which is below the normal range (50-70%), indicating reduced cardiac function.

The patient's serum creatinine level (133.0 umol/L) is elevated, suggesting impaired renal function. His blood glucose level (10.3 mmol/L) is slightly elevated, which is consistent with his diabetes diagnosis. The patient is on medications for diabetes, beta blockers, calcium channel blockers, statins, and nitrovasodilators, which are commonly used to manage his cardiac and metabolic conditions.

The patient's troponin level is 0.01 ng/mL, which is within the normal range, indicating no acute myocardial infarction. The pro-BNP level (779.0 ng/L) is elevated, which is consistent with heart failure. His hemoglobin level (130.0 g/L) is within the normal range, and his potassium level (5.2 mEq/L) is slightly elevated, which may be a concern for cardiac arrhythmias.

The patient's ECG shows polymorphic ventricular extrasystoles, but no sustained ventricular tachycardia or bradycardia. This suggests that the patient is at risk for arrhythmias but is not currently experiencing a life-threatening arrhythmia.

Given the patient's complex medical history and current cardiac function, the outcome of survival is likely due to the following factors:

1.  Effective management of his cardiac and metabolic conditions with medications.
2.  Regular monitoring and management of his cardiac function, which may have prevented further cardiac deterioration.
3.  The patient's relatively stable blood pressure (120/70 mmHg) and lack of acute coronary syndrome, which suggests that his cardiac function is not currently under significant stress.
4.  The patient's age and overall health status, which may have influenced the outcome.

In summary, the patient's survival is likely due to a combination of effective medical management, regular monitoring, and the patient's overall health status."
595,595,P0928,"Age: 62
Gender: Female 
Weight: 55 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 32
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,51
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,67
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 712.0
Protein (g/L): 68
T4 (ng/L): 10
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,67
Urea (mg/dL): 9,15
LVEF (%): 32.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient's outcome of survival can be attributed to several factors. 

Firstly, the patient's current blood pressure of 130/80 mmHg is well-controlled, which is beneficial for reducing the risk of cardiovascular events and mortality in patients with ischemic dilated cardiomyopathy. The patient's NYHA Class II classification indicates that she is experiencing some limitations in physical activity but is still able to perform everyday tasks without significant discomfort.

The patient's current medication regimen, which includes beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, is comprehensive and addresses several aspects of heart failure management, including rate control, fluid management, and neurohormonal antagonism. Beta blockers, in particular, have been shown to reduce morbidity and mortality in patients with heart failure.

The patient's laboratory results show a mildly elevated creatinine level of 80.0 μmol/L, which may indicate some degree of renal impairment. However, this is not severe, and the patient's urea level of 9.15 mg/dL is within a relatively normal range. The patient's hemoglobin level of 119 g/L is also within a normal range.

The patient's troponin level of 0.01 ng/mL is within a normal range, indicating that she is not experiencing acute myocardial infarction. The pro-BNP level of 712.0 ng/L is elevated, which is consistent with heart failure, but it is not extremely high, suggesting that the patient's condition is not acutely decompensated.

The patient's LVEF of 32% indicates a severely reduced left ventricular function, which is consistent with her diagnosis of ischemic dilated cardiomyopathy. However, the fact that she is alive and has not experienced a recent myocardial infarction suggests that her condition is stable and manageable with medical therapy.

In summary, the patient's survival outcome can be attributed to her well-controlled blood pressure, comprehensive medication regimen, and relatively stable laboratory results, despite her severe left ventricular dysfunction."
596,596,P0930,"Age: 56
Gender: Male 
Weight: 79 kg
Height: 173 cm
NYHA Class: III
Blood Pressure: 105/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 47
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 120
Glucose (mmol/L): 8,7
Hemoglobin (g/L): 157.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 5,5
LDL (mmol/L): 2,28
Sodium (mEq/L): 130.0
Pro-BNP (ng/L): 7066.0
Protein (g/L): 83
T3 (pg/dL): 0,05
T4 (ng/L): 27
Troponin (ng/mL): 0,06
TSH (mIU/L): 2,72
Urea (mg/dL): 10,65
LVEF (%): 25.0
Medications: Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 56-year-old male with a history of idiopathic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension, has a complex medical profile. Despite his advanced heart failure as indicated by a left ventricular ejection fraction (LVEF) of 25%, the patient has managed to survive. Several factors likely contributed to his survival:

1.  Optimal Medication Management: The patient is on a comprehensive regimen of digoxin, loop diuretics, spironolactone, statins, and an ACE inhibitor, which are standard treatments for heart failure and related conditions. These medications have likely helped manage his symptoms and slow disease progression.

2.  Controlled Blood Pressure: The patient's blood pressure is within a relatively normal range (105/75 mmHg), which is crucial for heart health, particularly in the context of heart failure.

3.  Reasonable Lipid Profile: Although the patient has dyslipemia, his total cholesterol level (3.49 mmol/L) and LDL (2.28 mmol/L) are not extremely high. The use of statins has likely helped manage his lipid profile.

4.  No Acute Cardiac Event: The absence of acute cardiac events such as myocardial infarction (indicated by a troponin level of 0.06 ng/mL) suggests that the patient's heart has not suffered a recent significant injury, which could have contributed to his survival.

5.  Stable Renal Function: The patient's creatinine level (97.0 μmol/L) is slightly elevated but not significantly high, indicating that his renal function is relatively stable, which is important for managing heart failure.

6.  Appropriate Electrocardiogram (ECG) Findings: While the patient has a polymorphic ventricular extrasystole, which can be a sign of cardiac arrhythmias, the absence of sustained ventricular tachycardia or other severe arrhythmias suggests that his heart rhythm is not currently posing an immediate threat to his survival.

7.  Pro-BNP Levels: Although the patient's pro-BNP level (7066.0 ng/L) is elevated, indicating increased stress on the heart, it is not excessively high, which may suggest that his heart is adapting to the stress.

8.  Hemoglobin and Protein Levels: The patient's hemoglobin (157.0 g/L) and protein levels (83 g/L) are within relatively normal ranges, indicating that his anemia and nutritional status are not significantly compromised, which can affect heart function.

Considering these factors, the patient's survival can be attributed to a combination of his optimal medication regimen, controlled blood pressure, managed lipid profile, stable renal function, and the absence of acute cardiac events."
597,597,P0931,"Age: 60
Gender: Female 
Weight: 74 kg
Height: 158 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,34
Creatinine (mmol/L): 90.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 12,8
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 5,3
LDL (mmol/L): 1,06
Sodium (mEq/L): 149.0
Pro-BNP (ng/L): 1853.0
Protein (g/L): 78
T3 (pg/dL): 0,06
T4 (ng/L): 21
Troponin (ng/mL): 0,06
TSH (mIU/L): 0,167
Urea (mg/dL): 5,83
LVEF (%): 24.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

Given the patient's data, the outcome of survival can be attributed to a combination of several factors, including the patient's current treatment regimen and her underlying medical conditions.

The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers dilate, leading to reduced cardiac function. The patient's left ventricular ejection fraction (LVEF) is severely impaired at 24%, indicating poor heart function. However, despite this, the patient is still alive, which suggests that her treatment plan is effective in managing her condition.

The patient is on a comprehensive medication regimen, including beta blockers, digoxin, loop diuretics, statins, and an ACE inhibitor. Beta blockers are used to reduce the heart rate and blood pressure, digoxin helps to increase the strength of the heart muscle contractions, loop diuretics help to reduce fluid overload, statins help to lower cholesterol levels, and ACE inhibitors help to reduce blood pressure and strain on the heart.

The patient's blood pressure is within a relatively normal range (110/70 mmHg), which is a good sign, indicating that her blood pressure is well-controlled. Her creatinine level is slightly elevated at 90.0 μmol/L, but this is not significantly high, suggesting that her kidney function is not severely impaired.

The patient's glucose level is elevated at 12.8 mmol/L, indicating poorly controlled diabetes. However, this is not unexpected given her history of diabetes. Her lipid profile is also abnormal, with a high total cholesterol level and low HDL level. However, she is on statins, which should help to manage her lipid levels.

The patient's TSH level is slightly elevated at 0.167 mIU/L, but this is not significantly high, and her T4 level is within a normal range. This suggests that her thyroid function is not significantly impaired.

The patient's pro-BNP level is elevated at 1853.0 ng/L, indicating increased stress on the heart. However, this is not unexpected given her history of heart failure.

Overall, the patient's outcome of survival can be attributed to her comprehensive treatment regimen, which is effectively managing her underlying medical conditions. However, it is essential to continue monitoring her condition closely and adjusting her treatment plan as needed to ensure optimal management of her heart failure and other comorbidities."
598,598,P0932,"Age: 61
Gender: Male 
Weight: 76 kg
Height: 169 cm
NYHA Class: III
Blood Pressure: 170/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 46,1
ALT or GPT (IU/L): 45.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 8,71
Creatinine (mmol/L): 109.0
Gamma-glutamil transpeptidase (IU/L): 101
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 162.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 4,6
LDL (mmol/L): 6,05
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 797.0
Protein (g/L): 78,8
T3 (pg/dL): 0,05
T4 (ng/L): 15
TSH (mIU/L): 2,43
Urea (mg/dL): 4,49
LVEF (%): 49.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient, a 61-year-old male with ischemic dilated cardiomyopathy and NYHA Class III, has a history of cardiovascular disease and significant comorbidities. Despite the presence of elevated creatinine levels (109.0 mmol/L), suggesting impaired renal function, and slightly elevated liver enzymes (ALT 45.0 IU/L and AST 33.0 IU/L), the patient's LVEF (Left Ventricular Ejection Fraction) is 49.0%, indicating moderate left ventricular dysfunction. 

The patient's medication regimen includes beta blockers, statins, and an ACE inhibitor, which are standard treatments for heart failure and ischemic cardiomyopathy. The patient's elevated Pro-BNP (Brain Natriuretic Peptide) level of 797.0 ng/L, a biomarker for heart failure, is consistent with the diagnosis of heart failure.

Given the patient's overall clinical presentation and treatment, it is likely that the patient received optimal medical therapy for heart failure and ischemic cardiomyopathy. The patient's survival can be attributed to the effective management of their condition, including the use of evidence-based medications, monitoring of cardiac function, and management of comorbidities such as hypertension and dyslipidemia.

However, the presence of ventricular extrasystoles on the ECG may indicate underlying cardiac electrical instability, which requires close monitoring and potential adjustment of the patient's medications. The patient's slightly elevated liver enzymes and impaired renal function may also necessitate further monitoring and potential adjustments to the patient's treatment plan.

In summary, the patient's survival is likely due to the effective management of their heart failure and ischemic cardiomyopathy, as well as the monitoring and treatment of their comorbidities."
599,599,P0933,"Age: 71
Gender: Male 
Weight: 66 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 124/68 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 194.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 5,1
LDL (mmol/L): 2,28
Sodium (mEq/L): 142.0
Protein (g/L): 76
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 2,15
Urea (mg/dL): 13,64
LVEF (%): 20.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 71-year-old male with a history of ischemic dilated cardiomyopathy, has survived, which is a positive outcome. Given his medical history, several factors contribute to his survival:

1.  Current Medications: The patient is on Amiodarone, an antiarrhythmic medication, which is effective in managing and preventing life-threatening arrhythmias. Additionally, the Angiotensin II Receptor Blocker is used to reduce blood pressure and alleviate strain on the heart, while Statins are prescribed to lower cholesterol levels, reducing the risk of further cardiac events.

2.  Blood Pressure: The patient's blood pressure is within a relatively normal range (124/68 mmHg), which suggests effective management of hypertension. Lower blood pressure reduces the workload on the heart, contributing to better cardiac function.

3.  LVEF (Left Ventricular Ejection Fraction): Although the patient has a low LVEF of 20%, indicating reduced heart function, his survival suggests that his heart is still compensating for the damage. The use of medications like ACE inhibitors or ARBs can help improve LVEF over time.

4.  Troponin Levels: The patient's troponin level is 0.03 ng/mL, which is within a relatively normal range. Elevated troponin levels are associated with myocardial infarction or cardiac damage, but this patient's level is low, indicating minimal cardiac damage.

5.  ECG Results: The absence of ventricular tachycardia and non-sustained ventricular tachycardia indicates that the patient is not experiencing significant arrhythmias, which is a good sign.

6.  Hemoglobin and Creatinine Levels: The patient's hemoglobin level is slightly below the normal range, but not significantly low, and his creatinine level is elevated, indicating some kidney impairment. However, these values are not so high as to suggest severe kidney disease.

7.  TSH and T4 Levels: The patient's thyroid hormone levels are within a normal range, which is important for overall health and cardiac function.

8.  Diet and Lifestyle: Although not directly mentioned, the patient's survival could also be attributed to a combination of a healthy diet, regular exercise, and adherence to his medication regimen.

Considering these factors, the patient's survival can be attributed to a combination of effective medication management, relatively controlled blood pressure, and the absence of significant cardiac damage or arrhythmias."
600,600,P0935,"Age: 46
Gender: Male 
Weight: 79 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 47,2
ALT or GPT (IU/L): 82.0
AST or GOT (IU/L): 36.0
Total Cholesterol (mmol/L): 3,85
Creatinine (mmol/L): 87.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 162.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,56
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 272.0
Protein (g/L): 69,7
T3 (pg/dL): 0,05
T4 (ng/L): 15
TSH (mIU/L): 1,67
Urea (mg/dL): 4,99
LVEF (%): 30.0
Medications: Beta Blockers, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to several factors, despite his complex medical history and current condition. 

1. Optimal medical management: The patient is on a comprehensive treatment regimen consisting of beta blockers, ACE inhibitors, and nitrovasodilators. These medications are crucial in managing heart failure symptoms, reducing the risk of sudden cardiac death, and improving the patient's quality of life.

2. Current LVEF of 30%: Although the patient's left ventricular ejection fraction (LVEF) is significantly reduced, it is not extremely low. An LVEF of 30% indicates that the heart is still pumping some blood efficiently, which is essential for survival.

3. Mild anemia: The patient's hemoglobin level is 162 g/L, which is within the normal range. Mild anemia is not a significant contributor to his overall prognosis.

4. Normal sodium levels: The patient's sodium levels are within the normal range, which is beneficial for his heart function. Hypernatremia can exacerbate heart failure symptoms.

5. Low T3 and T4 levels: The patient's thyroid hormone levels are within the normal range, which is essential for cardiac function. Hypothyroidism can lead to heart failure, but in this case, the patient's thyroid function is normal.

6. Absence of severe electrolyte imbalances: The patient's potassium and sodium levels are within normal limits, which is crucial for maintaining cardiac function.

7. ECG findings: Although the patient has polymorphic ventricular extrasystoles, there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias.

Considering these factors, the patient's outcome of survival is likely due to the combination of optimal medical management, relatively preserved cardiac function, and the absence of severe electrolyte imbalances or other life-threatening conditions."
601,601,P0937,"Age: 67
Gender: Female 
Weight: 64 kg
Height: 151 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Hypertropic cardiomyopathy, Hypertension
Albumin (g/L): 41,2
ALT or GPT (IU/L): 50.0
AST or GOT (IU/L): 41.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 105.0
Gamma-glutamil transpeptidase (IU/L): 149
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,08
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 3315.0
Protein (g/L): 66,6
T3 (pg/dL): 0,04
T4 (ng/L): 20
TSH (mIU/L): 1,8
Urea (mg/dL): 9,32
LVEF (%): 64.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 67-year-old female with a history of hypertrophic cardiomyopathy and hypertension. Despite having several cardiovascular risk factors, including high blood pressure and elevated creatinine levels, the patient has a relatively preserved left ventricular ejection fraction (LVEF) of 64%. The patient is also on a comprehensive medication regimen, including amiodarone, beta blockers, loop diuretics, and an ACE inhibitor, which suggests that the patient's cardiovascular condition is being actively managed.

The patient's Pro-BNP level of 3315 ng/L is elevated, which is often associated with heart failure. However, the patient's LVEF is still within a relatively normal range, suggesting that the heart's pumping function is not severely compromised.

The patient's TSH level is within the normal range, which suggests that there is no evidence of thyroid dysfunction, which can sometimes contribute to cardiovascular disease.

The patient's ECG shows a paroxysmal supraventricular tachyarrhythmia (PSVT), which is a type of abnormal heart rhythm. However, this does not appear to have significantly impacted the patient's overall outcome, as the patient is a survivor.

Given the patient's comprehensive medical history, medication regimen, and laboratory results, it appears that the patient's cardiovascular condition is being managed effectively, and the patient is able to survive despite having several risk factors for cardiovascular disease. The patient's overall outcome can be attributed to the effective management of their condition, including the use of beta blockers and ACE inhibitors, which have been shown to improve outcomes in patients with heart failure and hypertension."
602,602,P0939,"Age: 52
Gender: Male 
Weight: 85 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 104/72 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 7,68
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 11
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,57
Potassium (mEq/L): 5,3
LDL (mmol/L): 2,25
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 34.0
Protein (g/L): 68
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,08
Urea (mg/dL): 8,82
LVEF (%): 30.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 52-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and myocardial infarction, which are all significant risk factors for heart failure and cardiac complications. However, despite these risk factors, the patient has been managed with appropriate medications, including beta blockers, spironolactone, statins, and an ACE inhibitor, which are standard treatments for heart failure and ischemic cardiomyopathy.

The patient's LVEF (Left Ventricular Ejection Fraction) is 30%, which is within the range for heart failure with reduced ejection fraction (HFrEF). However, the patient's LVEF is not extremely low, which might indicate some degree of cardiac reserve.

The patient's Pro-BNP (N-terminal pro b-type natriuretic peptide) level is 34.0 ng/L, which is within the normal range, indicating that the patient is not experiencing significant stress on the heart. The patient's troponin level is also within normal limits, indicating that there is no ongoing myocardial infarction.

The patient's blood pressure is within a relatively normal range, and the patient is not experiencing any significant arrhythmias on the ECG. The patient's hemoglobin and potassium levels are within normal limits, which suggests that the patient is not experiencing significant anemia or electrolyte imbalances.

The patient's lipid profile shows elevated total cholesterol and LDL levels, which are consistent with the patient's history of dyslipemia. However, the patient is on statin therapy, which is likely helping to manage the patient's lipid levels.

Given the patient's medical history and current clinical presentation, it is likely that the patient has been able to manage their heart failure and cardiac disease with their current treatment regimen, and the patient's outcome of survivorship is a reflection of the effectiveness of their treatment plan."
603,603,P0941,"Age: 64
Gender: Male 
Weight: 81 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 145/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 5,74
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 161.0
HDL (mmol/L): 0,57
Potassium (mEq/L): 4,1
LDL (mmol/L): 4,09
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 189.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,89
Urea (mg/dL): 5,16
LVEF (%): 50.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

Given the patient's data, the outcome of survival can be attributed to several factors:

1. Optimal Medication Regimen: The patient is on a comprehensive medication regimen consisting of Beta Blockers, Loop Diuretics, and ACE Inhibitors, which are all standard treatments for heart failure and hypertension. These medications likely helped to manage the patient's symptoms and slow the progression of the disease.

2. Mild Symptoms (NYHA Class II): The patient's New York Heart Association (NYHA) classification of II indicates that the patient experiences mild symptoms of heart failure, such as fatigue, but is still able to perform light physical activity without discomfort. This suggests that the patient's condition is relatively stable and manageable.

3. Preserved LVEF (50%): Although the patient has a reduced left ventricular ejection fraction (LVEF) of 50%, it is still within the range that can be considered preserved. This indicates that the patient's heart is still able to pump blood effectively, which contributes to their survival.

4. Normal Troponin Levels: The patient's troponin levels are within the normal range, indicating that there is no evidence of acute myocardial infarction or significant cardiac damage.

5. Stable Hemoglobin and Potassium Levels: The patient's hemoglobin and potassium levels are within the normal range, indicating that there is no significant anemia or electrolyte imbalance that could contribute to cardiac instability.

6. No Evidence of Kidney Dysfunction: The patient's creatinine and urea levels are within the normal range, suggesting that there is no significant kidney dysfunction, which can be a contributing factor to cardiac failure.

7. Appropriate TSH and Thyroid Function: The patient's thyroid-stimulating hormone (TSH) and T3/T4 levels are within the normal range, indicating that there is no underlying thyroid dysfunction that could contribute to cardiac instability.

Overall, the combination of optimal medication, mild symptoms, preserved LVEF, normal troponin levels, stable hemoglobin and potassium levels, and no evidence of kidney dysfunction all contributed to the patient's survival."
604,604,P0942,"Age: 57
Gender: Male 
Weight: 82 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 126/79 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 47
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,89
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 140.0
HDL (mmol/L): 0,34
Potassium (mEq/L): 5,3
LDL (mmol/L): 3,03
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 74.0
Protein (g/L): 72
T3 (pg/dL): 0,06
T4 (ng/L): 14
Troponin (ng/mL): 0,03
TSH (mIU/L): 2,47
Urea (mg/dL): 5,83
LVEF (%): 30.0
Medications: Beta Blockers, Digoxin, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 57-year-old male with a history of idiopathic dilated cardiomyopathy, dyslipemia, and hypertension, has been managed with beta blockers, digoxin, spironolactone, and an ACE inhibitor. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 30%, indicating a compromised cardiac function. 

The presence of monomorphic ventricular extrasystoles on the ECG suggests that the patient has some degree of ventricular ectopy, which can be a sign of underlying cardiac ischemia or other cardiac pathology. However, the absence of non-sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia suggests that the patient does not have a high risk of sudden cardiac death.

The patient's laboratory results show elevated total cholesterol and LDL levels, which may contribute to the progression of the cardiomyopathy. However, the patient's blood pressure is well-controlled at 126/79 mmHg.

The patient's pro-BNP level is 74.0 ng/L, which is within the normal range, indicating that the patient is not experiencing significant volume overload or cardiac strain.

The patient's LVEF of 30% and the presence of monomorphic ventricular extrasystoles on the ECG indicate that the patient is at risk for heart failure and sudden cardiac death. However, the patient's overall clinical presentation and laboratory results suggest that the patient is stable and not at imminent risk of cardiac arrest.

Considering the patient's age, comorbidities, and current medication regimen, it is likely that the patient's outcome is a survivor due to the following reasons:

1.  The patient's LVEF is not severely reduced, and the patient is not experiencing significant cardiac strain or volume overload, as indicated by a normal pro-BNP level.
2.  The patient's blood pressure is well-controlled, which reduces the risk of cardiac complications.
3.  The patient is on an appropriate medication regimen, including beta blockers, digoxin, spironolactone, and an ACE inhibitor, which are all standard treatments for heart failure and cardiomyopathy.
4.  The patient's ECG results do not indicate a high risk of sudden cardiac death, as there is no evidence of non-sustained ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia.

In conclusion, the patient's overall clinical presentation and laboratory results suggest that the patient is a survivor due to the combination of effective medication management, controlled blood pressure, and the absence of high-risk cardiac arrhythmias."
605,605,P0943,"Age: 71
Gender: Male 
Weight: 70 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 134/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 9.0
Total Cholesterol (mmol/L): 3,85
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 126.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,07
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 709.0
Protein (g/L): 68
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,61
Urea (mg/dL): 7,32
LVEF (%): 40.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 71-year-old male with a history of ischemic dilated cardiomyopathy and myocardial infarction, which indicates a history of significant cardiac disease. Despite this, the patient is classified as NYHA Class II, indicating that he has some limitations in physical activity but is still able to perform everyday activities without symptoms. 

The patient's current medications, including beta blockers, spironolactone, statins, and ACE inhibitor, are all evidence-based treatments for heart failure and ischemic heart disease. The patient's LVEF of 40% is within the range of moderate heart failure, but the patient is still alive, suggesting that the current treatment regimen is effective in managing his symptoms and preventing further cardiac events.

The patient's laboratory results show elevated Pro-BNP levels (709.0 ng/L), which is consistent with heart failure. However, the patient's other laboratory results, such as albumin, liver enzymes, and electrolytes, are within normal limits, indicating that there is no significant liver or kidney dysfunction.

The patient's ECG shows polymorphic ventricular extrasystoles, which can be a benign finding in some patients, but in the context of a history of myocardial infarction, it may indicate some underlying cardiac electrical instability. However, the absence of sustained ventricular tachycardia or non-sustained ventricular tachycardia suggests that the patient's cardiac rhythm is generally stable.

Overall, the patient's survival outcome can be attributed to the effective management of his heart failure and ischemic heart disease with evidence-based medications, as well as the absence of any acute cardiac events or complications."
606,606,P0945,"Age: 57
Gender: Male 
Weight: 115 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 135/99 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 47
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,51
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 7
Hemoglobin (g/L): 158.0
HDL (mmol/L): 0,54
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,7
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 192.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,29
Urea (mg/dL): 7,49
LVEF (%): 39.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"REASONING: 

The patient's outcome as a survivor can be attributed to several factors based on the provided data. 

Firstly, the patient's LVEF (Left Ventricular Ejection Fraction) of 39% indicates that the patient has a reduced ejection fraction, which is a common characteristic of enolic dilated cardiomyopathy. However, the patient is still alive, suggesting that the heart's pumping function is still sufficient to meet the body's needs, albeit with some compromise.

The patient's medication regimen includes Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, and Loop Diuretics, which are commonly used to manage heart failure and reduce symptoms. These medications likely contributed to the patient's survival by reducing the workload on the heart, improving cardiac output, and managing fluid overload.

The patient's blood pressure of 135/99 mmHg is within a relatively normal range, and their potassium level of 4.3 mEq/L is within the normal range. These factors suggest that the patient's cardiac function is not severely compromised, and they are not experiencing significant electrolyte imbalances that could lead to cardiac arrhythmias.

The patient's troponin level of 0.03 ng/mL is within the normal range, indicating that they do not have acute myocardial infarction. The TSH level of 1.29 mIU/L is also within the normal range, ruling out hypothyroidism as a contributing factor to their cardiac condition.

The patient's low T3 level of 0.05 pg/dL may indicate a reduced metabolic state, which could be a result of their cardiac condition. However, this does not directly contribute to their survival.

The patient's high total cholesterol level of 5.51 mmol/L and low HDL level of 0.54 mmol/L suggest that they have dyslipidemia, which is a risk factor for cardiovascular disease. However, the patient's current outcome as a survivor suggests that they have not experienced a severe cardiovascular event.

Overall, the combination of the patient's medication regimen, relatively normal blood pressure and electrolyte levels, and absence of acute myocardial infarction or other life-threatening conditions contributed to their survival."
607,607,P0946,"Age: 70
Gender: Male 
Weight: 91 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 125/68 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 43
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 161
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 155.0
HDL (mmol/L): 0,52
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,36
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1455.0
Protein (g/L): 68
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,49
Urea (mg/dL): 15,47
LVEF (%): 30.0
Medications: Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient, a 70-year-old male with a history of idiopathic dilated cardiomyopathy and dyslipemia, had a left ventricular ejection fraction (LVEF) of 30%, indicating severe heart failure. Despite this, the patient's blood pressure was well-controlled at 125/68 mmHg, and his medications included beta blockers, spironolactone, and an ACE inhibitor, which are standard treatments for heart failure. The patient's troponin level was within normal limits, indicating no acute myocardial infarction.

The patient's liver enzymes (ALT and AST) were slightly elevated, but not significantly, suggesting some degree of liver stress, possibly due to the use of spironolactone. The patient's glucose level was slightly elevated, which could be a concern for diabetes, but it was not significantly high.

The patient's creatinine level was elevated at 115.0 umol/L, indicating some degree of kidney impairment, which is common in patients with heart failure. However, the patient's urea level was not significantly elevated, suggesting that the kidney impairment was not severe.

The patient's TSH level was within the normal range, indicating no thyroid dysfunction. The patient's T3 and T4 levels were also within the normal range, which suggests that the patient's thyroid function is normal.

The patient's ECG showed polymorphic ventricular extrasystoles, which is a common finding in patients with heart failure. However, there was no evidence of ventricular tachycardia, which is a more serious arrhythmia.

Given the patient's overall clinical presentation and laboratory results, it appears that the patient's heart failure is well-managed with his current medications, and he is not at immediate risk of cardiac arrest or severe cardiac complications. Therefore, the patient outcome is a survivor."
608,608,P0947,"Age: 63
Gender: Male 
Weight: 72 kg
Height: 182 cm
NYHA Class: II
Blood Pressure: 124/76 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes
Albumin (g/L): 45
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 5,22
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 8
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 111.0
HDL (mmol/L): 0,54
Potassium (mEq/L): 5,1
LDL (mmol/L): 4,47
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 747.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,14
Urea (mg/dL): 11,65
LVEF (%): 40.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient's outcome as a survivor can be attributed to a combination of factors, including the comprehensive management of his underlying conditions and the medications he is currently taking. 

Firstly, the patient's age of 63 and NYHA Class II classification suggest that he has some level of cardiovascular compromise, but it is not severe. His LVEF (left ventricular ejection fraction) of 40% indicates that he has some degree of left ventricular dysfunction, likely due to his enolic dilated cardiomyopathy. However, the fact that he is still alive and not experiencing severe symptoms suggests that his condition is being well-managed.

The patient's medications, including beta blockers, digoxin, loop diuretics, spironolactone, and ACE inhibitors, are all standard treatments for heart failure and dilated cardiomyopathy. These medications are likely helping to control his symptoms, slow disease progression, and improve his cardiac function.

Additionally, the patient's blood work suggests that his liver function is relatively preserved (ALT and AST levels are within normal limits), which is a good sign for someone with a history of enolic dilated cardiomyopathy. His low TSH level indicates that his thyroid function is well-controlled, which is also important for heart health.

The patient's Pro-BNP level of 747.0 ng/L is elevated, which is consistent with heart failure, but it is not extremely high. This suggests that his heart failure is being managed effectively, and his symptoms are not severe.

The patient's ECG findings of polymorphic ventricular extrasystoles are not uncommon in patients with heart failure and can be a benign finding in this context. The absence of sustained ventricular tachycardia and non-sustained ventricular tachycardia is also a positive sign.

Overall, the patient's outcome as a survivor can be attributed to the effective management of his underlying conditions, a comprehensive medication regimen, and relatively preserved liver and thyroid function."
609,609,P0949,"Age: 59
Gender: Male 
Weight: 103 kg
Height: 184 cm
NYHA Class: II
Blood Pressure: 128/78 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 33
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 9.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 118.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 3,6
LDL (mmol/L): 1,27
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1152.0
Protein (g/L): 64
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,38
Urea (mg/dL): 4,49
LVEF (%): 30.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient, a 59-year-old male with a history of ischemic dilated cardiomyopathy, myocardial infarction, dyslipemia, and hypertension, has a complex clinical presentation. Despite his significant comorbidities and compromised left ventricular ejection fraction (LVEF) of 30%, the patient survived the current episode. 

Several factors contributed to the patient's survival:

1.  Effective Medications: The patient is on a multidrug regimen, including digoxin, loop diuretics, statins, ACE inhibitors, and nitrovasodilators. These medications likely helped to manage his heart failure symptoms, reduce blood pressure, and improve lipid profiles.

2.  Monitoring and Management of Heart Failure: The patient's NYHA Class II classification indicates that he has some limitations in physical activity but is still able to perform daily tasks without severe symptoms. This suggests that his heart failure is being effectively managed, allowing him to maintain a relatively stable condition.

3.  Low Blood Pressure: The patient's blood pressure of 128/78 mmHg is within a relatively normal range, which is beneficial for his cardiovascular health.

4.  Low Troponin Levels: The patient's troponin level of 0.03 ng/mL indicates that there is minimal ongoing myocardial damage, which is a positive sign.

5.  Stable Electrocardiogram (ECG) Parameters: Although the patient has ventricular extrasystoles and non-sustained ventricular tachycardia, these are not life-threatening conditions, and the ECG parameters do not indicate any acute coronary syndrome or severe arrhythmia.

6.  Low Pro-BNP Level: The patient's Pro-BNP level of 1152 ng/L is elevated but not excessively high, which suggests that his heart failure is being managed effectively.

Considering these factors, the patient's survival can be attributed to a combination of effective medical management, stable heart failure symptoms, and relatively normal cardiovascular parameters."
610,610,P0954,"Age: 57
Gender: Male 
Weight: 109 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 117/87 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 147.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,9
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 72.0
Protein (g/L): 71
T3 (pg/dL): 0,06
T4 (ng/L): 15
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,9
Urea (mg/dL): 4,82
LVEF (%): 45.0
Medications: Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient's outcome is a survivor, which can be attributed to several factors based on the provided data. 

1.  Current Medications: The patient is on loop diuretics, statins, and an ACE inhibitor, which are all relevant to the management of heart failure and ischemic dilated cardiomyopathy. The use of these medications indicates that the patient has been receiving appropriate treatment for their condition.

2.  LVEF of 45%: Although the left ventricular ejection fraction (LVEF) is lower than the normal range (50-70%), it is not extremely low. This suggests that the patient's heart is still functioning to some extent, which is a positive sign for survival.

3.  Blood Pressure: The patient's blood pressure is within a relatively normal range (117/87 mmHg), which is a good indicator of cardiovascular health.

4.  ECG Findings: The presence of monomorphic ventricular extrasystoles is not uncommon and may not necessarily indicate a poor prognosis. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and other severe arrhythmias suggests that the patient's heart rhythm is relatively stable.

5.  Laboratory Results: The patient's troponin level is within a normal range (0.03 ng/mL), indicating that there is no acute myocardial infarction. The patient's TSH level is also within a normal range (1.9 mIU/L), indicating that the patient's thyroid function is normal. The patient's urea level is slightly elevated (4.82 mg/dL), but this is not significantly high.

6.  Past Medical History: The patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which are both serious conditions. However, the patient's current symptoms and laboratory results suggest that they are being managed effectively with their current treatment plan.

Considering these factors, the patient's outcome as a survivor can be attributed to a combination of their ongoing treatment, relatively stable heart function, and absence of severe arrhythmias or acute cardiac events."
611,611,P0955,"Age: 59
Gender: Male 
Weight: 94 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 148/79 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 9.0
Total Cholesterol (mmol/L): 6,57
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 123.0
HDL (mmol/L): 0,54
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,66
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 553.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,63
Urea (mg/dL): 9,65
LVEF (%): 35.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient, a 59-year-old male with a history of ischemic dilated cardiomyopathy, hypertension, and dyslipemia, has a complex medical condition that affects his heart function. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 35%, indicating that the heart is not pumping efficiently, which is a hallmark of heart failure.

The patient's blood pressure is elevated at 148/79 mmHg, which is concerning for hypertension, a major risk factor for cardiovascular disease. The patient is also taking medications such as beta blockers, loop diuretics, spironolactone, statins, and ACE inhibitors, which are commonly used to manage heart failure and hypertension.

The patient's electrolyte levels, including potassium and sodium, are within the normal range, which is a good sign. The patient's liver function tests, including ALT and AST, are within normal limits, indicating that the liver is functioning properly. The patient's glucose level is slightly elevated at 5.7 mmol/L, which may be a concern for diabetes or insulin resistance.

The patient's troponin level is within normal limits, indicating that there is no acute myocardial infarction. The patient's thyroid function tests, including TSH and T4, are within normal limits, indicating that the thyroid is functioning properly.

The patient's BNP (B-type natriuretic peptide) level is elevated at 553.0 ng/L, which is a marker of heart failure and indicates that the patient's heart is under strain.

Given the patient's complex medical condition, the fact that he is taking multiple medications, and the presence of an elevated BNP level, the patient's survival is a testament to the effectiveness of his current treatment regimen. The patient's LVEF of 35% indicates that he is at risk for heart failure progression, but the fact that he is still alive suggests that his current treatment plan is helping to manage his condition.

However, it is essential to note that the patient's LVEF of 35% is still considered low, and he should continue to be monitored closely for any signs of worsening heart failure. The patient's elevated BNP level also indicates that he may benefit from further optimization of his medications, such as increasing the dose of his beta blockers or ACE inhibitors, or adding other medications to his regimen to further reduce his risk of heart failure progression.

In conclusion, the patient's survival is a positive outcome, but it is essential to continue to closely monitor his condition and adjust his treatment plan as needed to prevent further progression of his heart failure."
612,612,P0956,"Age: 80
Gender: Female 
Weight: 64 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 135/80 mmHg
Past Medical History: Valvular cardiomyopathy, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,72
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,37
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,78
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1032.0
Protein (g/L): 65
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,04
TSH (mIU/L): 2,31
Urea (mg/dL): 8,15
LVEF (%): 56.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

Given the patient's age, sex, and past medical history of valvular cardiomyopathy and hypertension, it is not surprising that she has a reduced left ventricular ejection fraction (LVEF) of 56%. The patient's medications, including beta blockers, digoxin, loop diuretics, and an ACE inhibitor, are appropriate for managing heart failure symptoms and reducing the risk of adverse cardiovascular events.

The patient's blood pressure is well-controlled at 135/80 mmHg, which is within a normal range. Her albumin and liver function tests (ALT, AST, GGT) are within normal limits, indicating that there is no significant liver dysfunction. The patient's glucose level is slightly elevated, but it is not significantly high.

The patient's total cholesterol level is elevated, with an LDL of 3.78 mmol/L, which may be a concern for cardiovascular disease. However, her HDL level is relatively low, which may be a contributing factor to her high total cholesterol level.

The patient's troponin level is slightly elevated, indicating some degree of cardiac muscle damage. However, it is not significantly high, and her LVEF is still within a relatively preserved range.

The patient's pro-BNP level is elevated at 1032.0 ng/L, which is consistent with heart failure. However, it is not extremely high, which may indicate that the patient's heart failure is not severe.

The patient's ECG shows polymorphic ventricular extrasystoles, which can be a benign finding in some cases, but it may also be a sign of underlying cardiac disease. However, there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias.

Considering the patient's overall clinical picture, her age, and her past medical history, it is likely that the patient's heart failure is well-managed, and she is receiving appropriate treatment. The patient's elevated pro-BNP level and slightly reduced LVEF suggest that she has some degree of cardiac dysfunction, but it is not severe. The patient's survival outcome is likely due to the effective management of her heart failure symptoms and the use of appropriate medications.

The patient's low T3 level (0.04 pg/dL) may indicate hypothyroidism, but the TSH level is within a normal range, which suggests that it may not be a significant concern. The patient's hemoglobin level is slightly elevated, which may be a sign of anemia, but it is not significantly high.

In conclusion, the patient's survival outcome is likely due to the effective management of her heart failure symptoms, the use of appropriate medications, and the absence of any life-threatening cardiac arrhythmias."
613,613,P0957,"Age: 70
Gender: Male 
Weight: 66 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 158/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 46
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 5,95
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 3,7
LDL (mmol/L): 3,93
Sodium (mEq/L): 143.0
Protein (g/L): 71
T3 (pg/dL): 0,02
T4 (ng/L): 5
Troponin (ng/mL): 0,03
TSH (mIU/L): 70,54
Urea (mg/dL): 4,33
LVEF (%): 40.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient's outcome of survival can be attributed to several factors, despite having a complex medical history and several comorbidities. 

1. Optimal Medication Management: The patient is on a comprehensive medication regimen, including a calcium channel blocker, beta blockers, loop diuretics, statins, and an ACE inhibitor. These medications are crucial in managing hypertension, heart failure, and dyslipidemia, which are all risk factors for cardiovascular events.

2. Monitoring and Management of Ischemic Dilated Cardiomyopathy: The patient's LVEF (Left Ventricular Ejection Fraction) is 40%, indicating some degree of heart failure. However, the patient is on medications that help manage heart failure symptoms, such as beta blockers and ACE inhibitors, which can help slow disease progression and improve survival.

3. Control of Blood Pressure: The patient's blood pressure is well-controlled, with a systolic pressure of 158 mmHg. Elevated blood pressure can exacerbate heart failure and increase the risk of cardiovascular events, so controlling it is crucial.

4. Dyslipidemia Management: The patient is on statins, which are effective in lowering LDL cholesterol levels. Elevated LDL levels can contribute to atherosclerosis and increase the risk of cardiovascular events.

5. Diabetes Management: The patient's glucose level is within a relatively normal range (6.2 mmol/L), indicating that diabetes is being well-managed. Diabetes is a significant risk factor for cardiovascular disease, so controlling blood sugar levels is essential.

6. ECG Findings: Although the patient has polymorphic ventricular extrasystoles, which can be a sign of underlying cardiac disease, there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias.

7. Supportive Care: The patient's albumin and protein levels are within normal ranges, indicating that the patient is not experiencing significant malnutrition or liver dysfunction, which can impact cardiac function.

8. TSH Level: The patient's TSH level is elevated (70.54 mIU/L), which may indicate hypothyroidism. Hypothyroidism can contribute to heart failure and cardiovascular disease, but it is being treated.

In summary, the combination of optimal medication management, monitoring and management of ischemic dilated cardiomyopathy, control of blood pressure and dyslipidemia, diabetes management, and supportive care likely contributed to the patient's survival outcome."
614,614,P0958,"Age: 68
Gender: Male 
Weight: 74 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 117/61 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 33
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 6,03
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 94.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 5,6
LDL (mmol/L): 4,16
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 252.0
Protein (g/L): 52
T3 (pg/dL): 0,02
T4 (ng/L): 5
Troponin (ng/mL): 0,05
TSH (mIU/L): 83,92
Urea (mg/dL): 16,97
LVEF (%): 30.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient, a 68-year-old male with a history of ischemic dilated cardiomyopathy, diabetes, and dyslipidemia, has been managed with a combination of medications including ACE inhibitors, loop diuretics, spironolactone, and nitrovasodilators. His left ventricular ejection fraction (LVEF) is significantly reduced at 30%, indicating severe systolic heart failure.

The patient's recent ECG shows polymorphic ventricular extrasystoles, which can be a sign of electrical instability in the heart. However, the absence of sustained ventricular tachycardia or non-sustained ventricular tachycardia suggests that the patient's heart rhythm is not in a highly unstable state.

The patient's blood work shows elevated creatinine levels (115.0 mmol/L), which indicates impaired renal function. This is likely due to the combination of diabetes and heart failure, which can cause kidney damage over time. The patient's low hemoglobin level (94.0 g/L) may also indicate anemia, which can be a complication of heart failure.

The patient's thyroid-stimulating hormone (TSH) level is elevated at 83.92 mIU/L, which suggests hypothyroidism. This can be a side effect of amiodarone, a medication the patient is taking for his heart condition.

Despite these challenges, the patient's overall clinical picture suggests that he is being effectively managed with his current medications. His blood pressure is well-controlled, and his glucose level is within a relatively normal range. His LVEF is stable, and he does not have any signs of acute cardiac decompensation.

Given the patient's history, medications, and current clinical status, it is likely that he is being effectively managed and is surviving with his current treatment plan."
615,615,P0960,"Age: 74
Gender: Female 
Weight: 64 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 141/72 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,76
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 5
Hemoglobin (g/L): 115.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,9
LDL (mmol/L): 2,9
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 588.0
Protein (g/L): 67
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,97
Urea (mg/dL): 11,15
LVEF (%): 25.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to a combination of factors. 

Firstly, the patient is on a comprehensive medication regimen consisting of Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, and Statins, which are all evidence-based treatments for ischemic dilated cardiomyopathy. These medications help to reduce the heart's workload, improve cardiac function, and prevent further cardiac damage.

Secondly, the patient's LVEF (Left Ventricular Ejection Fraction) of 25% indicates that while the patient's heart is severely impaired, it is still functioning to some extent, allowing for some degree of cardiac output. Although the LVEF is low, it is not the lowest possible value, which suggests that the heart is still capable of maintaining some level of function.

Thirdly, the patient's hemoglobin level of 115.0 g/L is within the normal range, which is crucial for oxygen delivery to the heart muscle. Anemia can exacerbate heart failure, so maintaining adequate hemoglobin levels is essential for cardiac function.

Additionally, the patient's TSH (Thyroid-Stimulating Hormone) level of 0.97 mIU/L is within the normal range, which is essential for cardiac function. Thyroid dysfunction can lead to cardiac complications, and maintaining normal TSH levels is critical for cardiac health.

Lastly, the patient's Pro-BNP (B-type Natriuretic Peptide) level of 588.0 ng/L is elevated, which is consistent with heart failure. However, the patient's overall clinical picture, including the presence of a comprehensive medication regimen and a relatively preserved LVEF, suggests that the patient is being effectively managed for heart failure.

Considering these factors, the patient's survival outcome is likely due to the combination of effective medical management, a relatively preserved cardiac function, and the absence of severe anemia or thyroid dysfunction."
616,616,P0962,"Age: 55
Gender: Male 
Weight: 105 kg
Height: 182 cm
NYHA Class: II
Blood Pressure: 137/102 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 46
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,16
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,38
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1083.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 2,22
Urea (mg/dL): 6,82
LVEF (%): 40.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient is a 55-year-old male with a history of enolic dilated cardiomyopathy, dyslipemia, peripheral vascular disease, and hypertension, presenting with a left ventricular ejection fraction (LVEF) of 40%, which indicates systolic heart failure. The patient's blood pressure is elevated at 137/102 mmHg, and the elevated Pro-BNP level (1083.0 ng/L) further supports the presence of heart failure.

The patient's laboratory results show a slightly elevated total cholesterol level (4.16 mmol/L) and low HDL cholesterol (0.7 mmol/L), indicating dyslipemia. The patient's urea level is within the normal range (6.82 mg/dL), and the creatinine level is slightly elevated (97.0 μmol/L), which may indicate mild renal impairment.

The patient is on a combination of medications, including beta blockers, digoxin, loop diuretics, spironolactone, hydralazine, and nitrovasodilator, which are commonly used to manage heart failure and hypertension. The patient's ECG shows monomorphic ventricular extrasystoles, but no sustained ventricular tachycardia or non-sustained ventricular tachycardia.

Considering the patient's age, comorbidities, and the presence of heart failure, the most likely reason for the patient's outcome is the effective management of his heart failure symptoms and the absence of any life-threatening arrhythmias. The patient's survival is likely due to the combination of his medications and the absence of any acute cardiac events."
617,617,P0964,"Age: 81
Gender: Female 
Weight: 70 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 125/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 101
Glucose (mmol/L): 7,1
Hemoglobin (g/L): 137.0
HDL (mmol/L): 2,48
Potassium (mEq/L): 5
LDL (mmol/L): 1,5
Sodium (mEq/L): 130.0
Pro-BNP (ng/L): 2733.0
Protein (g/L): 66
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,8
Urea (mg/dL): 10,31
LVEF (%): 70.0
Medications: Calcium Channel Blocker, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient is an 81-year-old female with a history of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipemia, who is currently on optimal medical therapy with a left ventricular ejection fraction (LVEF) of 70%, indicating moderate heart failure. The patient's blood pressure is well-controlled at 125/75 mmHg, and her creatinine level is slightly elevated at 80.0 μmol/L, suggesting mild renal impairment.

The patient's laboratory results show elevated liver enzymes (ALT and GGT), which could indicate liver dysfunction or potential drug-induced liver injury from statins. However, her total cholesterol and LDL levels are well-controlled, suggesting that the statins are effective.

The patient's TSH level is within the normal range, and her T3 and T4 levels are slightly low, which may be a sign of subclinical hypothyroidism. However, this is not likely to be the primary concern given the patient's overall clinical picture.

The patient's Pro-BNP level is elevated at 2733.0 ng/L, indicating increased ventricular wall stress and potential heart failure. However, the patient's symptoms and physical examination findings are not described, so it is unclear whether this is a new development or a chronic condition.

The patient's ECG shows polymorphic ventricular extrasystoles, which are common in patients with heart failure and may not be a cause for concern in this context. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia is reassuring.

Given the patient's age, comorbidities, and overall clinical picture, the patient's outcome as a survivor is likely due to the following factors:

1. Optimal medical therapy, including ACE inhibitors, beta-blockers, and statins, which have been shown to improve outcomes in patients with heart failure.
2. The patient's LVEF of 70%, which indicates that the patient has some preserved cardiac function and is not in advanced heart failure.
3. The patient's well-controlled blood pressure, which reduces the risk of cardiovascular events and mortality.
4. The patient's mild renal impairment, which may not significantly impact her cardiovascular outcomes.
5. The absence of new or worsening symptoms, which suggests that the patient's heart failure is stable and not rapidly progressing.

Overall, the patient's outcome as a survivor is likely due to a combination of optimal medical therapy, preserved cardiac function, and well-controlled comorbidities."
618,618,P0969,"Age: 75
Gender: Male 
Weight: 91 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,41
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 74
Glucose (mmol/L): 14,5
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4
LDL (mmol/L): 1,58
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 3298.0
Protein (g/L): 70
T4 (ng/L): 14
Troponin (ng/mL): 0,02
TSH (mIU/L): 6,45
Urea (mg/dL): 6,49
LVEF (%): 47.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 75-year-old male with a history of idiopathic dilated cardiomyopathy, diabetes, and hypertension, has a complex medical profile. Despite the presence of several risk factors for adverse cardiac outcomes, the patient's survival can be attributed to several factors.

The patient's left ventricular ejection fraction (LVEF) of 47% indicates that the heart is still functioning, albeit with reduced efficiency. The patient's blood pressure is well-controlled at 130/80 mmHg, which is within a relatively normal range. The patient's use of medications such as beta blockers, ACE inhibitors, and statins suggests that the patient is receiving optimal medical therapy for his conditions.

The patient's elevated Pro-BNP level of 3298.0 ng/L is concerning for heart failure, but the fact that the patient is still alive suggests that the medication regimen is helping to manage symptoms and slow disease progression. The patient's hemoglobin level is within a normal range, indicating that anemia is not a contributing factor to his survival.

The patient's glucose level of 14.5 mmol/L is slightly elevated, which is consistent with his diabetes diagnosis. However, the patient's use of diabetes medication and the fact that his creatinine level is within a relatively normal range suggest that his renal function is well-preserved.

The patient's ECG shows polymorphic ventricular extrasystoles, which are a common finding in patients with cardiomyopathy. However, the absence of sustained ventricular tachycardia and bradycardia suggests that the patient's cardiac rhythm is relatively stable.

Overall, the combination of optimal medical therapy, well-controlled blood pressure, and preserved renal function likely contributed to the patient's survival."
619,619,P0970,"Age: 66
Gender: Male 
Weight: 66 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 84/49 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,97
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 47
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,95
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2694.0
Protein (g/L): 73
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,63
Urea (mg/dL): 10,15
LVEF (%): 17.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 66-year-old male with a history of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipemia, has a complex set of clinical and laboratory findings that contributed to his outcome as a survivor. 

Firstly, the patient's left ventricular ejection fraction (LVEF) is severely impaired at 17%, indicating significant left ventricular dysfunction. However, the patient is on optimal medical therapy with beta blockers, loop diuretics, statins, and an ACE inhibitor, which are all standard treatments for heart failure and ischemic cardiomyopathy.

The patient's blood pressure is low at 84/49 mmHg, which may be due to the use of loop diuretics. However, the patient's creatinine level is elevated at 115.0 mmol/L, suggesting some degree of renal impairment, which may be contributing to the low blood pressure.

The patient's troponin level is low at 0.01 ng/mL, indicating that there is no current evidence of acute myocardial infarction. The pro-BNP level is elevated at 2694.0 ng/L, which is consistent with heart failure.

The patient's ECG shows polymorphic ventricular extrasystoles, but no sustained ventricular tachycardia or bradycardia. This suggests that the patient's heart rhythm is generally stable, despite the presence of some arrhythmias.

The patient's laboratory results show elevated liver enzymes (ALT and AST), which may indicate some degree of liver dysfunction. However, the patient's albumin and protein levels are within normal limits, suggesting that the liver dysfunction is not severe.

The patient's lipid profile shows elevated total cholesterol and LDL, but the patient is on statin therapy, which is helping to manage these levels.

In summary, the patient's outcome as a survivor is likely due to the following factors:

1. Optimal medical therapy: The patient is on standard treatments for heart failure and ischemic cardiomyopathy, which are helping to manage his symptoms and slow disease progression.
2. Stable heart rhythm: The patient's ECG shows no evidence of sustained ventricular tachycardia or bradycardia, suggesting that his heart rhythm is generally stable.
3. Mild renal impairment: The patient's creatinine level is elevated, but not severely, which may be contributing to the low blood pressure.
4. No acute myocardial infarction: The patient's troponin level is low, indicating that there is no current evidence of acute myocardial infarction.

Overall, the patient's outcome as a survivor is likely due to a combination of optimal medical therapy, stable heart rhythm, mild renal impairment, and no acute myocardial infarction."
620,620,P0971,"Age: 66
Gender: Female 
Weight: 78 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 150/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 36
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 6,05
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 160
Glucose (mmol/L): 12,1
Hemoglobin (g/L): 112.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,7
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 104.0
Protein (g/L): 75
T3 (pg/dL): 0,02
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 49,17
Urea (mg/dL): 8,99
LVEF (%): 56.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type II
            ",survivor,"REASONING: 

The patient is a 66-year-old female with a history of Hypertensive cardiomyopathy, diabetes, dyslipemia, and hypertension. The patient's NYHA Class III classification indicates that she experiences symptoms of heart failure, such as shortness of breath and fatigue, but is able to perform everyday activities without significant limitation.

The patient's blood pressure is elevated at 150/90 mmHg, which is consistent with her history of hypertension. Her creatinine level is elevated at 106.0 mmol/L, indicating impaired kidney function, which is likely related to her hypertension and diabetes.

The patient's liver function tests (ALT and AST) are within normal limits, but her gamma-glutamil transpeptidase (GGT) is elevated at 160 IU/L, suggesting possible liver damage or bile duct disease. Her glucose level is elevated at 12.1 mmol/L, indicating poor control of diabetes.

The patient's lipid profile shows a total cholesterol level of 6.05 mmol/L, which is elevated, and an LDL level of 3.7 mmol/L, which is also elevated. Her HDL level is low at 1.14 mmol/L, which is a risk factor for cardiovascular disease.

The patient's LVEF is 56%, which is below the normal range of 55-70%, indicating left ventricular dysfunction. Her Pro-BNP level is elevated at 104.0 ng/L, which is consistent with heart failure.

The patient's ECG shows a second-degree AV block type II, which is a significant arrhythmia that can lead to symptoms such as dizziness and syncope. The presence of polymorphic ventricular extrasystoles is also concerning, as it can indicate underlying cardiac disease.

Given the patient's complex medical history and the presence of multiple risk factors, it is likely that the patient's outcome is a result of a combination of factors, including:

1. Hypertensive cardiomyopathy: The patient's history of hypertension has likely led to left ventricular dysfunction and heart failure.
2. Diabetes: The patient's uncontrolled diabetes has likely contributed to her kidney impairment and cardiovascular disease.
3. Dyslipemia: The patient's elevated lipid profile has likely contributed to her cardiovascular disease.
4. Arrhythmias: The patient's second-degree AV block type II and polymorphic ventricular extrasystoles are likely contributing to her symptoms and outcome.

Despite these challenges, the patient has survived, likely due to the following factors:

1. Timely medical treatment: The patient is taking medications such as beta blockers, loop diuretics, spironolactone, and ACE inhibitors, which are likely helping to manage her symptoms and slow the progression of her disease.
2. Good supportive care: The patient is receiving regular medical care and follow-up, which is essential for managing her complex medical condition.
3. Resilience: The patient's ability to adapt to her condition and continue with daily activities despite her symptoms is a testament to her resilience and determination.

In conclusion, the patient's outcome is a result of a combination of her complex medical history, timely medical treatment, good supportive care, and her own resilience."
621,621,P0973,"Age: 51
Gender: Male 
Weight: 80 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 43.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 144.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,72
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 80.0
Protein (g/L): 74
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,68
Urea (mg/dL): 3,83
LVEF (%): 41.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Second-degree AVB - type I
            ",survivor,"REASONING: 

Given the patient's comprehensive medical history and laboratory results, it appears that the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened due to a heart attack, leading to a decrease in the left ventricle's ability to pump blood efficiently. The patient's LVEF (left ventricular ejection fraction) of 41% indicates a reduced ejection fraction, which is a hallmark of heart failure.

The patient is on beta blockers, loop diuretics, and an ACE inhibitor, which are standard medications for managing heart failure and reducing the risk of further cardiac events. The patient's blood pressure is well-controlled at 120/80 mmHg, which is within the normal range.

The patient's laboratory results show elevated levels of troponin (0.01 ng/mL), which is a marker of cardiac damage, but it is within the normal range for this patient. The patient's creatinine level of 80.0 μmol/L indicates mild kidney impairment, which is common in patients with heart failure.

The patient's ECG shows ventricular extrasystoles, non-sustained ventricular tachycardia, and second-degree AV block type I, which are all indicative of cardiac conduction abnormalities. However, the patient's overall clinical picture does not suggest an acute cardiac event, and the patient's medications are likely managing these conditions.

Considering the patient's age, medical history, and current treatment, the most likely reason for the patient's outcome is that the patient is a survivor of a previous cardiac event (myocardial infarction) and is currently being managed for heart failure and related conditions. The patient's stable vital signs, controlled blood pressure, and ongoing treatment suggest that the patient is being effectively managed, and the patient's outcome is likely due to the effective management of their condition."
622,622,P0976,"Age: 66
Gender: Male 
Weight: 68 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,36
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 8,8
Hemoglobin (g/L): 134.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4
LDL (mmol/L): 1,24
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 652.0
Protein (g/L): 74
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,13
Urea (mg/dL): 4,82
LVEF (%): 32.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient survived due to a combination of factors, including the presence of a stable and controlled medical regimen, effective management of his comorbidities, and relatively mild symptoms of heart failure as indicated by a New York Heart Association (NYHA) Class II classification.

The patient's ischemic dilated cardiomyopathy, a condition characterized by a weakened heart muscle, is likely a result of his past myocardial infarction. However, his left ventricular ejection fraction (LVEF) of 32% indicates that he still has some cardiac function, which is crucial for survival.

The patient's medications, including beta blockers, ACE inhibitors, and statins, are all standard treatments for heart failure and ischemic cardiomyopathy. These medications help to reduce the workload on the heart, improve cardiac function, and prevent further damage to the heart muscle.

The patient's blood pressure, although slightly elevated, is well-controlled, which is essential for managing heart failure. His blood glucose levels are also well-managed, which is important for preventing complications associated with diabetes.

The patient's ECG shows a polymorphic ventricular extrasystole, but no sustained ventricular tachycardia, which suggests that his heart rhythm is relatively stable. His troponin levels are within normal limits, indicating that he is not experiencing an acute myocardial infarction.

The patient's high pro-BNP (brain natriuretic peptide) level of 652 ng/L indicates that he has some degree of heart failure, but it is not severe. The fact that he is able to survive suggests that his heart function is still sufficient to meet his body's needs, and that his medications are effective in managing his symptoms.

In summary, the patient's survival is likely due to a combination of his stable medical regimen, effective management of his comorbidities, and relatively mild symptoms of heart failure."
623,623,P0977,"Age: 68
Gender: Female 
Weight: 95 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 28
Glucose (mmol/L): 7,4
Hemoglobin (g/L): 107.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 5,2
LDL (mmol/L): 1,73
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3701.0
Protein (g/L): 71
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,21
Urea (mg/dL): 17,97
LVEF (%): 33.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to a combination of factors. 

Firstly, the patient's current medications, including Beta Blockers and Loop Diuretics, are likely contributing to her survival. Beta Blockers are known to reduce the heart rate and workload on the heart, while Loop Diuretics help to reduce fluid overload, which can alleviate symptoms of heart failure and improve cardiac function. The Calcium Channel Blocker may also be helping to manage her hypertension and reduce the workload on the heart.

Secondly, the patient's recent Troponin level of 0.01 ng/mL indicates that she has not had a recent myocardial infarction, which is a significant risk factor for mortality in patients with ischemic dilated cardiomyopathy.

Thirdly, the patient's LVEF (Left Ventricular Ejection Fraction) of 33% is low, indicating impaired cardiac function, but not extremely low. While an LVEF of 33% is considered reduced, it is not in the range of severe left ventricular dysfunction, which is typically defined as an LVEF of less than 20-25%.

Lastly, the patient's Pro-BNP (Brain Natriuretic Peptide) level of 3701.0 ng/L is elevated, which is consistent with heart failure. However, the level is not extremely high, and the patient's symptoms and clinical presentation do not suggest severe heart failure.

Overall, the combination of the patient's medications, lack of recent myocardial infarction, relatively preserved LVEF, and moderate Pro-BNP level all contribute to her survival outcome."
624,624,P0980,"Age: 67
Gender: Male 
Weight: 77 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 47,5
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 153.0
HDL (mmol/L): 1,66
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,56
Sodium (mEq/L): 141.0
Protein (g/L): 74,9
T4 (ng/L): 18
TSH (mIU/L): 1,33
Urea (mg/dL): 10,65
LVEF (%): 40.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient's outcome of being a survivor can be attributed to several factors:

1.  Optimal Medication Management: The patient is on a combination of medications that are commonly used to manage heart failure and ischemic cardiomyopathy, including an Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone, Statins, and a Nitrovasodilator. These medications are likely helping to manage the patient's symptoms and slow disease progression.

2.  Effective Blood Pressure Control: The patient's blood pressure is well-controlled at 130/80 mmHg, which is within a normal range. High blood pressure is a significant risk factor for cardiovascular disease, and controlling it is crucial in managing the patient's condition.

3.  Normal Electrolyte Levels: The patient's potassium level is within the normal range (4.7 mEq/L), which is essential for maintaining a stable heart rhythm. Abnormal electrolyte levels can lead to arrhythmias and other cardiac complications.

4.  Reasonable LVEF: Although the patient's left ventricular ejection fraction (LVEF) is low at 40%, it is not as low as it could be. An LVEF of 40% indicates some degree of heart function, and the patient is likely able to maintain adequate cardiac output.

5.  No Severe Arrhythmias: The patient's ECG does not show any signs of severe arrhythmias, such as ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia. The presence of monomorphic ventricular extrasystoles is relatively common and may not be a significant concern.

6.  Stable Renal Function: The patient's creatinine level is 93.0 μmol/L, which is slightly elevated but not significantly so. This suggests that the patient's kidneys are functioning relatively well, which is essential for managing heart failure and avoiding further complications.

7.  Reasonable Lipid Profile: The patient's lipid profile shows a total cholesterol level of 4.91 mmol/L, which is slightly elevated but not extremely high. The LDL level of 2.56 mmol/L is also within a relatively normal range. This suggests that the patient's statin therapy is effective in managing their cholesterol levels.

8.  No Severe Anemia: The patient's hemoglobin level is 153 g/L, which is within a normal range. Anemia can exacerbate heart failure symptoms and may contribute to poor outcomes.

9.  Normal Thyroid Function: The patient's TSH level is within the normal range (1.33 mIU/L), indicating that thyroid function is not contributing to their cardiac condition.

Considering these factors, the patient's outcome of being a survivor is likely due to a combination of effective medication management, controlled blood pressure, reasonable LVEF, stable electrolyte levels, and absence of severe arrhythmias."
625,625,P0982,"Age: 73
Gender: Female 
Weight: 89 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Other HF etiology, Dyslipemia
Albumin (g/L): 39,7
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,43
Sodium (mEq/L): 142.0
Protein (g/L): 63,4
T4 (ng/L): 21
TSH (mIU/L): 0,18
Urea (mg/dL): 7,32
LVEF (%): 55.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient outcome of survival in this 73-year-old female patient with a history of heart failure (HF) and other cardiovascular risk factors can be attributed to several factors:

1.  Optimal Medication Management: The patient is on a comprehensive regimen of beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor. These medications are commonly used to manage heart failure and reduce the risk of adverse outcomes. Beta blockers help slow the heart rate and reduce the workload on the heart, while loop diuretics help remove excess fluid from the body. Spironolactone is an aldosterone antagonist that helps reduce fluid buildup and lower blood pressure. Statins are used to lower cholesterol levels, and ACE inhibitors help relax blood vessels and reduce blood pressure.

2.  Moderate Heart Function: The patient's left ventricular ejection fraction (LVEF) is 55%, which is below the normal range but still indicates some degree of heart function. This suggests that the patient's heart is still able to pump blood effectively, albeit not at its full capacity.

3.  Mildly Elevated Blood Pressure: The patient's blood pressure is within a relatively normal range (140/80 mmHg), which may indicate that the patient's blood pressure is well-controlled, reducing the risk of cardiovascular events.

4.  Lack of Severe Laboratory Abnormalities: The patient's laboratory results show some abnormalities, such as elevated liver enzymes (ALT and AST), but they are not severely elevated, indicating that the patient's liver function is not significantly compromised. Similarly, the patient's glucose level is mildly elevated, but not severely so. The patient's electrolyte levels, including potassium and sodium, are within normal limits.

5.  Absence of Severe Comorbidities: The patient does not have severe comorbidities that could contribute to a poor outcome, such as severe kidney disease (elevated creatinine levels are not significantly high), severe anemia (hemoglobin level is within normal limits), or severe electrolyte imbalances.

6.  Age and Gender: While the patient is 73 years old, which is considered elderly, her gender (female) is a factor that may contribute to a better outcome, as women tend to live longer than men.

Considering these factors, the patient's survival outcome can be attributed to a combination of optimal medication management, moderate heart function, well-controlled blood pressure, lack of severe laboratory abnormalities, absence of severe comorbidities, and favorable demographic factors."
626,626,P0984,"Age: 58
Gender: Male 
Weight: 58 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 37,3
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 90.0
Gamma-glutamil transpeptidase (IU/L): 133
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,76
Potassium (mEq/L): 4,9
LDL (mmol/L): 1,76
Sodium (mEq/L): 143.0
Protein (g/L): 62,1
T4 (ng/L): 16
TSH (mIU/L): 1,71
Urea (mg/dL): 6,49
LVEF (%): 51.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 58-year-old male with a history of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipemia. He is on a comprehensive treatment regimen including beta blockers, loop diuretics, statins, ACE inhibitors, and nitrovasodilators, which suggests that his condition is being actively managed. His left ventricular ejection fraction (LVEF) is 51%, indicating moderate left ventricular dysfunction. 

The patient's ECG shows evidence of ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia. However, the absence of sustained ventricular tachycardia and bradycardia suggests that his heart rate regulation is not severely impaired. 

The patient's laboratory results indicate a relatively well-controlled metabolic profile, with normal blood pressure, hemoglobin, and urea levels. His liver function tests (ALT and AST) are within normal limits, and his lipid profile shows a relatively good balance between HDL and LDL cholesterol levels.

Given the patient's comprehensive treatment plan, moderate left ventricular dysfunction, and relatively well-controlled metabolic profile, the most likely reason for his survival is the effectiveness of his current treatment regimen and his overall good health status. His LVEF of 51% is indicative of moderate heart failure, but it is not indicative of severe heart failure that would typically lead to a poor outcome.

Therefore, the patient's survival can be attributed to his well-managed medical condition, adherence to treatment, and the absence of severe cardiac complications."
627,627,P0988,"Age: 68
Gender: Female 
Weight: 67 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 195/85 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 40,9
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 5,3
Creatinine (mmol/L): 57.0
Gamma-glutamil transpeptidase (IU/L): 66
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,52
Sodium (mEq/L): 140.0
Protein (g/L): 74
T4 (ng/L): 16
TSH (mIU/L): 2,74
Urea (mg/dL): 4,66
LVEF (%): 52.0
Medications: Diabetes Medication, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Unknown ventricular extrasystole code
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient is a 68-year-old female with a history of hypertrophic cardiomyopathy, which is a condition where the heart muscle becomes thickened, making it harder for the heart to pump blood efficiently. Despite this, the patient has a relatively preserved left ventricular ejection fraction (LVEF) of 52%, indicating that the heart is still functioning relatively well.

The patient's blood pressure is elevated at 195/85 mmHg, which is a concern for further strain on the heart. However, the patient is taking loop diuretics, which are commonly used to manage hypertension and fluid overload in patients with heart failure. The patient's albumin level is slightly low, which may indicate some degree of liver dysfunction or malnutrition, but it is not significantly abnormal.

The patient's lipid profile shows high total cholesterol and LDL levels, which are risk factors for cardiovascular disease. However, the patient is also taking diabetes medication, which may be managing the patient's blood glucose levels.

The patient's ECG shows various arrhythmias, but none of them are sustained or severe enough to indicate a high risk of cardiac arrest or sudden cardiac death. The patient's heart rate is not excessively slow or fast, and the LVEF is preserved, indicating that the heart is still functioning relatively well.

Considering the patient's age, comorbidities, and ECG findings, the most likely reason for the patient's survival is the combination of effective management of her hypertension and diabetes, as well as her relatively preserved cardiac function. The patient's LVEF of 52% suggests that the heart is still able to pump blood efficiently, and the absence of severe arrhythmias or other indicators of cardiac instability suggest that the patient is at relatively low risk of cardiac arrest or sudden cardiac death."
628,628,P0991,"Age: 71
Gender: Female 
Weight: 70 kg
Height: 152 cm
NYHA Class: II
Blood Pressure: 160/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 46,2
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,2
Creatinine (mmol/L): 73.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,4
Sodium (mEq/L): 143.0
Protein (g/L): 78,6
T4 (ng/L): 15
TSH (mIU/L): 1,28
Urea (mg/dL): 7,99
LVEF (%): 35.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient is a 71-year-old female with a history of hypertensive cardiomyopathy and hypertension. The patient's ejection fraction (LVEF) is significantly reduced at 35%, indicating severe left ventricular dysfunction. The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG suggests a high risk of arrhythmic events, which is a common complication in patients with cardiomyopathy.

The patient's blood pressure is controlled at 160/85 mmHg, and the patient is on a combination of medications including beta blockers, loop diuretics, spironolactone, statins, ACE inhibitors, and nitrovasodilators, which is a standard treatment regimen for heart failure with reduced ejection fraction (HFrEF). The use of beta blockers, ACE inhibitors, and spironolactone is particularly beneficial in reducing mortality and morbidity in patients with HFrEF.

The patient's laboratory results show elevated creatinine levels (73.0 μmol/L) indicating mild renal impairment, but this is likely a consequence of the patient's heart failure rather than a primary cause. The patient's albumin levels are slightly low, but this is not uncommon in patients with heart failure.

The patient's total cholesterol is elevated at 5.2 mmol/L, but the LDL levels are well-controlled at 2.4 mmol/L with statin therapy. The patient's hemoglobin is slightly elevated at 131 g/L, but this is not a concern in this context.

The patient's TSH and T4 levels are within normal limits, indicating no evidence of thyroid dysfunction.

Given the patient's severe left ventricular dysfunction, history of NSVT and polymorphic ventricular extrasystoles, and controlled blood pressure, the patient's survival is likely due to the effective management of their heart failure with a comprehensive treatment regimen, including medications and lifestyle modifications. The patient's renal function is mildly impaired, but this is not a significant concern in the context of their overall clinical picture.

Therefore, the patient's survival is likely due to the combination of their treatment regimen, which has likely mitigated the progression of their heart failure and reduced their risk of arrhythmic events."
629,629,P0992,"Age: 72
Gender: Male 
Weight: 95 kg
Height: 172 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 43,9
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 90.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 158.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,87
Sodium (mEq/L): 142.0
Protein (g/L): 70,5
T4 (ng/L): 14
TSH (mIU/L): 1,04
Urea (mg/dL): 5,66
LVEF (%): 37.0
Medications: Calcium Channel Blocker, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient is a 72-year-old male with a history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction, indicating a compromised heart function. His current LVEF (Left Ventricular Ejection Fraction) of 37% suggests that his heart is not pumping efficiently, which is consistent with his NYHA Class III classification, indicating severe symptoms of heart failure.

The patient's blood pressure is within a relatively normal range, and his medications, including a calcium channel blocker, loop diuretics, statins, and ACE inhibitor, are aimed at managing his hypertension, heart failure, and lipid levels. His lipid profile shows elevated total cholesterol and LDL, but his HDL is low, indicating a potential need for further lipid management.

The patient's liver enzymes (ALT and AST) are within normal limits, suggesting no significant liver dysfunction. His renal function is also within normal limits, with a creatinine level of 90.0 μmol/L.

The patient's ECG shows polymorphic ventricular extrasystoles, which can be a benign finding in some cases but can also be a sign of underlying cardiac disease. However, there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias.

Considering the patient's overall condition and the fact that he is on appropriate medications, his survival outcome is likely due to the effectiveness of his treatment regimen, which is aimed at managing his heart failure and other comorbidities. His relatively stable vital signs and lack of acute cardiac events also contribute to his survival outcome."
630,630,P0996,"Age: 58
Gender: Male 
Weight: 97 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41,5
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,5
Creatinine (mmol/L): 72.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 7,8
Hemoglobin (g/L): 154.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,69
Sodium (mEq/L): 143.0
Protein (g/L): 67,7
T4 (ng/L): 19
TSH (mIU/L): 1,53
Urea (mg/dL): 5,66
LVEF (%): 29.0
Medications: Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome is likely due to a combination of factors, including their current medical management and the effectiveness of their treatment plan. The patient has been prescribed beta blockers and statins, which are standard treatments for ischemic dilated cardiomyopathy and dyslipemia. Beta blockers help to reduce the workload on the heart, while statins help to lower cholesterol levels and reduce the risk of further cardiovascular events.

The patient's LVEF (left ventricular ejection fraction) of 29% indicates that they have a reduced ejection fraction, which is a common finding in patients with ischemic dilated cardiomyopathy. However, the fact that they are still alive suggests that their treatment plan is effective in managing their condition.

The patient's blood pressure is well-controlled at 140/80 mmHg, which is within a normal range. Their glucose level is also well-controlled at 7.8 mmol/L, which suggests that their diabetes is being effectively managed.

The patient's electrolyte levels, including potassium and sodium, are within normal ranges, which is essential for maintaining proper cardiac function.

The absence of any significant abnormalities on the ECG and the patient's overall clinical status suggest that they are not experiencing any acute cardiac complications that would have led to a poor outcome.

Overall, the patient's survival can be attributed to their effective medical management, adherence to their treatment plan, and the absence of any acute cardiac complications."
631,631,P0998,"Age: 68
Gender: Male 
Weight: 82 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Other HF etiology, Dyslipemia
Albumin (g/L): 44,3
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,41
Sodium (mEq/L): 146.0
Protein (g/L): 71,8
T4 (ng/L): 21
TSH (mIU/L): 0,78
Urea (mg/dL): 6,32
LVEF (%): 65.0
Medications: Calcium Channel Blocker, Beta Blockers
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: The patient outcome of survival can be attributed to several factors present in the patient's data.

Firstly, the patient's left ventricular ejection fraction (LVEF) is 65%, which is within the normal range (>50%). This indicates that the patient's heart is functioning relatively well, which is a positive prognostic factor for survival.

The patient's blood pressure is well-controlled at 110/70 mmHg, and they are on medications for hypertension (Calcium Channel Blocker and Beta Blockers). This suggests that the patient's blood pressure is being effectively managed, which reduces the risk of cardiovascular events.

The patient's laboratory results also show a relatively normal range for most parameters, with the exception of slightly elevated total cholesterol and LDL levels. However, these levels are not significantly high and can be managed with lifestyle modifications and medication if necessary.

The patient's NYHA Class II classification indicates that they have mild to moderate symptoms of heart failure, but they are still able to perform everyday activities without significant limitation. This classification suggests that the patient's heart failure is not severe, which is a positive prognostic factor for survival.

Additionally, the patient's TSH and T4 levels are within the normal range, indicating that their thyroid function is normal. This is an important factor to consider, as thyroid dysfunction can exacerbate heart failure symptoms.

The presence of ventricular extrasystoles on the ECG is not uncommon and is often benign. The absence of sustained ventricular tachycardia and non-sustained ventricular tachycardia is also a positive prognostic factor.

In summary, the patient's overall data suggests that they have a relatively stable and well-managed cardiovascular condition, which contributes to their survival outcome."
632,632,P0999,"Age: 67
Gender: Male 
Weight: 88 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease
Albumin (g/L): 39,6
ALT or GPT (IU/L): 44.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 115.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,99
Sodium (mEq/L): 139.0
Protein (g/L): 76,5
T4 (ng/L): 14
TSH (mIU/L): 0,84
Urea (mg/dL): 10,48
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient is a 67-year-old male with a history of valvular cardiomyopathy, diabetes, dyslipemia, and peripheral vascular disease. He is taking a combination of medications, including calcium channel blockers, diabetes medication, beta blockers, loop diuretics, and statins, which suggests that he is being managed for his cardiovascular conditions.

The patient's ECG findings of polymorphic ventricular extrasystoles, non-sustained ventricular tachycardia, and unknown paroxysmal supraventricular tachyarrhythmia indicate that he has a history of arrhythmias. However, the fact that he is still alive suggests that these arrhythmias are not severe enough to cause significant hemodynamic instability or cardiac arrest.

The patient's left ventricular ejection fraction (LVEF) is 25%, which is severely reduced, indicating a poor heart function. However, the fact that he is still alive suggests that he has adapted to his reduced cardiac function and is able to maintain adequate perfusion of vital organs.

The patient's laboratory results show elevated creatinine levels (104.0 μmol/L), which suggests that he has chronic kidney disease. However, his blood urea levels are within a relatively normal range (10.48 mg/dL), suggesting that his renal function is not severely impaired.

The patient's albumin levels are slightly low (39.6 g/L), which may indicate malnutrition or liver disease. His liver function tests (ALT and AST) are within a relatively normal range, but his gamma-glutamil transpeptidase (GGT) is slightly elevated (30 IU/L), which may indicate mild liver dysfunction.

The patient's lipid profile shows high total cholesterol (3.78 mmol/L) and LDL levels (1.99 mmol/L), which are not well-controlled by his statin therapy. His HDL levels are low (1.19 mmol/L), which is a risk factor for cardiovascular disease.

The patient's hemoglobin levels are within a relatively normal range (115.0 g/L), but his potassium levels are slightly low (4.7 mEq/L), which may be due to his diuretic therapy.

Overall, the patient's survival outcome suggests that he has adapted to his chronic conditions and is able to manage his symptoms with his current medication regimen. However, his laboratory results suggest that he has ongoing cardiovascular risk factors, including uncontrolled dyslipidemia and possible liver dysfunction, which may require further management to prevent long-term complications."
633,633,P1002,"Age: 71
Gender: Female 
Weight: 70 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 62.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 3,7
LDL (mmol/L): 2,46
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 305.0
Protein (g/L): 66
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,306
Urea (mg/dL): 10,31
LVEF (%): 48.0
Medications: Diabetes Medication, Beta Blockers
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome is likely due to a combination of several factors that contributed to her survival. 

Firstly, the patient's left ventricular ejection fraction (LVEF) of 48% indicates that her heart is still functioning relatively well despite having ischemic dilated cardiomyopathy, which suggests that her heart is able to pump blood efficiently enough to meet her body's needs. The LVEF is a critical indicator of heart function, and a value of 48% is considered mildly reduced but not severely impaired.

Secondly, the patient's blood pressure is within a relatively normal range (120/70 mmHg), which is a positive sign as hypertension can exacerbate heart failure. Her low blood pressure may be a result of her beta blockers, which are commonly used to manage heart failure and hypertension.

Thirdly, the patient's ejection fraction, in combination with her medications, has likely helped to prevent further cardiac damage and maintained her cardiac output. Her Pro-BNP level of 305.0 ng/L is slightly elevated, but not excessively high, indicating that her heart is not under severe strain.

Fourthly, the patient's glucose level of 4.3 mmol/L is well-controlled, which is essential for managing diabetes and preventing further cardiac damage.

Lastly, the patient's overall clinical presentation and ECG findings do not indicate any acute or severe cardiac issues that would have led to a fatal outcome. The presence of polymorphic ventricular extrasystoles is a common finding in patients with heart disease, but it is generally not a life-threatening condition.

Overall, the patient's combination of relatively well-managed heart failure, controlled diabetes, and stable cardiac function, along with her medications, have likely contributed to her survival."
634,634,P1011,"Age: 69
Gender: Female 
Weight: 66 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 145.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,9
LDL (mmol/L): 2,22
Sodium (mEq/L): 140.0
Protein (g/L): 64
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,6
Urea (mg/dL): 7,65
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

Given the patient's age, gender, and medical history of idiopathic dilated cardiomyopathy, it is not surprising that she has a reduced left ventricular ejection fraction (LVEF) of 40%. The patient is on a comprehensive medication regimen that includes beta blockers, loop diuretics, statins, and an ACE inhibitor, which are all standard treatments for heart failure with reduced ejection fraction (HFrEF).

The patient's blood pressure is within a relatively normal range (120/70 mmHg), which suggests that the loop diuretics are effectively managing fluid overload. The patient's electrolyte levels, including potassium (4.9 mEq/L) and sodium (140 mEq/L), are also within a normal range.

The patient's liver function tests (ALT, AST, and gamma-glutamil transpeptidase) are within normal limits, which suggests that the statins are not causing any liver damage. The patient's lipid profile (total cholesterol 4.34 mmol/L, HDL 1.4 mmol/L, LDL 2.22 mmol/L) is also relatively well-controlled, which is consistent with the use of statins.

The patient's thyroid function tests (T3, T4, and TSH) are within normal limits, which suggests that the patient does not have any underlying thyroid dysfunction that could be contributing to her heart failure.

The patient's troponin level (0.03 ng/mL) is within a normal range, which suggests that there is no acute coronary syndrome or myocardial infarction.

The patient's ECG shows a polymorphic ventricular extrasystole, which is a benign finding in this context. The absence of non-sustained ventricular tachycardia, ventricular tachycardia, and bradycardia suggests that the patient's heart rhythm is stable.

Overall, the patient's comprehensive medication regimen, normal electrolyte and liver function tests, well-controlled lipid profile, and stable ECG findings suggest that the patient is being effectively managed for her heart failure with reduced ejection fraction. Therefore, it is likely that the patient survived due to the effective management of her condition."
635,635,P1013,"Age: 82
Gender: Male 
Weight: 52 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 170/100 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 6,18
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,91
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,7
Sodium (mEq/L): 141.0
Protein (g/L): 70
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,79
Urea (mg/dL): 11,32
LVEF (%): 50.0
Medications: Calcium Channel Blocker, Digoxin, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

Given the patient's age of 82, the patient is elderly and at an increased risk for cardiovascular events. The patient has a history of valvular cardiomyopathy, which is a significant underlying condition that can lead to heart failure and other cardiac complications. The patient's blood pressure of 170/100 mmHg suggests hypertension, which can further exacerbate the patient's cardiac condition. 

The patient's ejection fraction (LVEF) is 50%, which is slightly below the normal range, indicating some degree of systolic dysfunction. However, the patient is still alive, which suggests that the patient's cardiac function is still compensating to some extent.

The patient's medications, including calcium channel blockers, digoxin, loop diuretics, statins, and nitrovasodilators, are appropriate for managing hypertension, heart failure, and other cardiac conditions. The presence of these medications suggests that the patient is receiving adequate treatment for their cardiac condition.

The patient's laboratory results show elevated creatinine levels (97.0 mmol/L), which may indicate some degree of renal impairment. However, the patient's urea levels are only slightly elevated (11.32 mg/dL), which may suggest that the renal impairment is not severe.

The patient's troponin level is within normal limits (0.03 ng/mL), which suggests that there is no acute myocardial infarction. The patient's TSH level is slightly elevated (3.79 mIU/L), but this is not significantly abnormal.

The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which can be a sign of cardiac electrical instability. However, the patient is still alive, which suggests that these arrhythmias are not life-threatening at this time.

In conclusion, the patient's outcome of survival is likely due to a combination of their age, underlying cardiac condition, and the effectiveness of their medications. The patient's cardiac function is compromised, but it is still compensating to some extent, and the patient is receiving adequate treatment for their cardiac condition. The patient's renal function is also compromised, but it is not severely impaired. The patient's arrhythmias are not life-threatening at this time, and the patient is likely to continue to receive close monitoring and treatment to manage their cardiac condition."
636,636,P1016,"Age: 68
Gender: Male 
Weight: 62 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 138/88 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 159.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4
LDL (mmol/L): 2,74
Sodium (mEq/L): 140.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,17
TSH (mIU/L): 2,16
Urea (mg/dL): 5,66
LVEF (%): 55.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of survival is likely due to a combination of factors, including the effective management of their underlying conditions and the presence of certain biomarkers and physical characteristics that suggest a relatively stable cardiovascular status. 

Firstly, the patient's ischemic dilated cardiomyopathy and history of myocardial infarction are significant risk factors for cardiac complications. However, the fact that the patient is currently on beta blockers, statins, and an ACE inhibitor suggests that their cardiovascular disease is being effectively managed, which may have contributed to their survival.

The patient's left ventricular ejection fraction (LVEF) of 55% is within a relatively normal range, indicating that their heart is still functioning adequately. Additionally, the troponin level of 0.17 ng/mL is within the normal range, suggesting that there is no ongoing myocardial infarction or ischemia.

The patient's lipid profile, including a total cholesterol of 4.03 mmol/L and an LDL of 2.74 mmol/L, is somewhat elevated, but the fact that they are on statins may be helping to manage this. Their HDL level of 0.78 mmol/L is relatively low, which may be a concern, but it is not significantly impacting their current outcome.

The patient's blood pressure is elevated at 138/88 mmHg, which may be a concern for cardiovascular disease, but it is not excessively high. Their creatinine level of 88.0 umol/L is within the normal range, indicating that their kidney function is not significantly impaired.

The patient's ECG shows a polymorphic ventricular extrasystole, which is a benign finding in this context. There is no evidence of sustained ventricular tachycardia, paroxysmal supraventricular tachyarrhythmia, or bradycardia.

Overall, the patient's survival is likely due to the effective management of their cardiovascular disease, their relatively stable cardiac function, and the absence of any acute cardiac complications."
637,637,P1017,"Age: 53
Gender: Male 
Weight: 81 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/69 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,47
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 140.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,74
Sodium (mEq/L): 134.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,07
TSH (mIU/L): 1,26
Urea (mg/dL): 5,49
LVEF (%): 40.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome as a survivor can be attributed to several factors in his medical history and current condition. Firstly, the patient has been on a comprehensive treatment plan consisting of beta blockers, statins, and an ACE inhibitor, which are all crucial in managing his ischemic dilated cardiomyopathy and hypertension. The use of beta blockers helps to reduce the heart rate and blood pressure, while statins lower cholesterol levels to reduce the risk of further cardiac events. The ACE inhibitor also helps to reduce blood pressure and alleviate strain on the heart.

Additionally, the patient's LVEF (Left Ventricular Ejection Fraction) of 40% indicates that his heart is still functioning, albeit at a reduced capacity. This suggests that the patient's heart is still able to pump blood efficiently, albeit with some impairment.

The patient's blood pressure of 120/69 mmHg is within a relatively normal range, indicating that his hypertension is under control. His total cholesterol level of 4.47 mmol/L is also within a relatively normal range, which suggests that his statin therapy is effective.

Furthermore, the patient's TSH level of 1.26 mIU/L is within the normal range, indicating that his thyroid function is not contributing to his cardiac condition.

The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG indicates some level of cardiac arrhythmia, but the fact that they are non-sustained suggests that they are not causing significant harm to the patient.

Overall, the combination of the patient's treatment plan, his relatively stable cardiac function, and the absence of any acute cardiac events or severe electrolyte imbalances all contribute to his outcome as a survivor."
638,638,P1019,"Age: 54
Gender: Male 
Weight: 87 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 110/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes
Albumin (g/L): 43
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,15
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 11,2
Hemoglobin (g/L): 164.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,8
Sodium (mEq/L): 139.0
Protein (g/L): 73
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,04
TSH (mIU/L): 3,27
Urea (mg/dL): 8,65
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to a combination of factors, including their current medical treatment and the absence of severe acute cardiac events. 

The patient has a history of ischemic dilated cardiomyopathy, which indicates reduced left ventricular function. However, their left ventricular ejection fraction (LVEF) is 35%, which, while low, is not extremely low. They are also taking medications such as beta blockers and angiotensin II receptor blockers, which are commonly used to manage heart failure and reduce the risk of adverse cardiac events. Additionally, they are taking statins to manage their high cholesterol levels, which can help reduce the risk of cardiac complications.

Their blood pressure is well-controlled at 110/65 mmHg, which is within a normal range. Their glucose levels are also under control, with a hemoglobin A1c not provided but their glucose level is 11.2 mmol/L, which indicates good control of their diabetes.

The absence of severe acute cardiac events, such as myocardial infarction or cardiac arrest, also contributed to the patient's survival. Their troponin levels are low at 0.04 ng/mL, indicating minimal cardiac damage. 

Furthermore, their ECG results do not indicate any severe arrhythmias or other cardiac abnormalities that would increase their risk of cardiac complications.

Overall, the patient's survival can be attributed to a combination of their current medical treatment, well-controlled blood pressure and glucose levels, and the absence of severe acute cardiac events."
639,639,P1020,"Age: 73
Gender: Male 
Weight: 82 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 116/67 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 39
ALT or GPT (IU/L): 6.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 134.0
HDL (mmol/L): 0,57
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,92
Sodium (mEq/L): 133.0
Protein (g/L): 68
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,95
Urea (mg/dL): 4,82
LVEF (%): 45.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to several factors based on the provided data.

1. Current Medications: The patient is on a comprehensive medication regimen that includes a Calcium Channel Blocker, Beta Blockers, Statins, and an ACE Inhibitor. These medications are commonly used to manage symptoms and slow the progression of heart failure in patients with ischemic dilated cardiomyopathy. Beta Blockers, in particular, have been shown to improve survival and reduce hospitalization rates in patients with heart failure.

2. LVEF of 45%: Although the patient's left ventricular ejection fraction (LVEF) is slightly below the normal range (50-70%), it is not severely impaired. An LVEF of 45% indicates that the patient's heart is still pumping enough blood to meet the body's needs, which is a positive prognostic indicator.

3. Blood Pressure and Hemoglobin Levels: The patient's blood pressure is within a relatively normal range (116/67 mmHg), and his hemoglobin level is within the normal range (134 g/L). Both of these factors contribute to a stable cardiovascular system.

4. Normal Troponin Levels: A troponin level of 0.03 ng/mL indicates that there is no significant cardiac muscle damage, which is a good prognostic sign.

5. ECG Findings: Although the patient has ventricular extrasystoles, there is no evidence of sustained ventricular tachycardia, which is a significant risk factor for mortality.

6. Absence of Severe Renal Impairment: The patient's creatinine level (97.0 umol/L) is within the normal range, indicating that his renal function is preserved. This is a positive prognostic factor.

7. Absence of Severe Electrolyte Imbalance: The patient's potassium level (4.8 mEq/L) is within the normal range, which reduces the risk of arrhythmias and other cardiac complications.

In summary, the combination of the patient's current medications, relatively preserved LVEF, stable blood pressure and hemoglobin levels, normal troponin levels, and absence of severe renal impairment and electrolyte imbalance all contribute to his favorable outcome of survival."
640,640,P1021,"Age: 58
Gender: Female 
Weight: 82 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 160/94 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 6,21
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 64
Glucose (mmol/L): 12,6
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,45
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,48
Sodium (mEq/L): 138.0
T3 (pg/dL): 0,05
T4 (ng/L): 13
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,42
Urea (mg/dL): 7,32
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 58-year-old female with a history of ischemic dilated cardiomyopathy, diabetes, and hypertension. Despite these significant comorbidities, the patient's current outcome is a survivor. Several factors contribute to this outcome:

1. Optimal Medication Management: The patient is on a comprehensive medication regimen that includes diabetes medication, beta blockers, spironolactone, statins, and an ACE inhibitor. This combination helps to manage the patient's heart failure, hypertension, and diabetes.

2. Low Troponin Levels: The patient's troponin level is within normal limits (0.04 ng/mL), indicating that there is no current evidence of acute myocardial infarction or significant cardiac damage.

3. Normal TSH and T4 Levels: The patient's thyroid function is within normal limits, which is essential for maintaining a healthy heart rate and rhythm.

4. LVEF of 30%: Although the patient's left ventricular ejection fraction (LVEF) is significantly reduced at 30%, it is not the lowest possible value (which would be 0-20%). This suggests that the patient's heart is still functioning, albeit with reduced efficiency.

5. Absence of Ventricular Tachycardia: The absence of ventricular tachycardia on the ECG is a positive sign, as this condition can be a precursor to more severe cardiac arrhythmias.

6. No Bradycardia: The patient does not have bradycardia, which would indicate an abnormally slow heart rate. This suggests that the patient's heart rate is within a relatively normal range.

7. Normal Hemoglobin Level: The patient's hemoglobin level is within normal limits, indicating that there is no evidence of anemia, which can contribute to cardiac dysfunction.

8. Normal Potassium Level: The patient's potassium level is within normal limits, which is essential for maintaining a healthy heart rhythm.

9. No Acute Kidney Injury: The patient's creatinine level is within normal limits, indicating that there is no evidence of acute kidney injury, which can be a complication of heart failure.

In summary, the combination of optimal medication management, low troponin levels, normal thyroid function, a relatively preserved LVEF, absence of ventricular tachycardia, no bradycardia, normal hemoglobin and potassium levels, and no acute kidney injury all contribute to the patient's outcome as a survivor."
641,641,P1027,"Age: 69
Gender: Male 
Weight: 66 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 127/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 48
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,71
Creatinine (mmol/L): 106.0
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,39
Sodium (mEq/L): 140.0
Protein (g/L): 78
T3 (pg/dL): 0,04
T4 (ng/L): 24
Troponin (ng/mL): 0,05
TSH (mIU/L): 3,74
Urea (mg/dL): 10,15
LVEF (%): 30.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"REASONING: 

This patient, a 69-year-old male with a history of idiopathic dilated cardiomyopathy, has been managed with a combination of medications including Amiodarone, Beta Blockers, Loop Diuretics, and ACE Inhibitor. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 30%, indicating severe heart failure. However, the patient is still alive, which suggests that the current treatment regimen is effective in managing his condition.

Several factors contribute to the patient's survival:

1. Optimal medical therapy: The patient is on a comprehensive regimen of medications, including Amiodarone for arrhythmia management, Beta Blockers for heart rate control, Loop Diuretics for fluid management, and ACE Inhibitor for heart failure treatment. This combination is likely helping to stabilize the patient's cardiac function.

2. Monitoring and management of comorbidities: The patient's laboratory results indicate relatively well-managed blood glucose (4.9 mmol/L) and urea levels (10.15 mg/dL), suggesting that the patient's diabetes and renal function are being effectively managed.

3. Stable electrolytes: The patient's potassium levels are within a relatively normal range (4.6 mEq/L), which is essential for maintaining cardiac function and preventing arrhythmias.

4. No signs of acute decompensation: The patient's blood pressure (127/80 mmHg) and heart rate are within a relatively stable range, indicating that the patient is not experiencing acute heart failure exacerbation.

5. ECG findings: Although the patient has polymorphic ventricular extrasystoles, there is no indication of sustained ventricular tachycardia or other life-threatening arrhythmias. The absence of bradycardia, sinus node dysfunction, and paroxysmal supraventricular tachyarrhythmia suggests that the patient's cardiac rhythm is relatively stable.

Considering these factors, the patient's survival is likely due to the effectiveness of his current treatment regimen, stable management of comorbidities, and the absence of acute cardiac decompensation or life-threatening arrhythmias."
642,642,P1029,"Age: 69
Gender: Male 
Weight: 68 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 88/58 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 158.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,08
Sodium (mEq/L): 140.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,81
Urea (mg/dL): 7,65
LVEF (%): 35.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: The patient, a 69-year-old male with a history of ischemic dilated cardiomyopathy, has a left ventricular ejection fraction (LVEF) of 35%, indicating significant left ventricular dysfunction. Despite this, he is classified as NYHA Class II, suggesting that he has mild symptoms of heart failure, such as fatigue or shortness of breath, but is able to perform everyday activities without significant limitation.

The patient's blood pressure is low, with a systolic pressure of 88 mmHg and diastolic pressure of 58 mmHg, which may be a concern for hypotension. However, this is likely not the primary driver of his outcome, given his overall clinical presentation.

The patient's laboratory results show a slightly elevated creatinine level (97.0 μmol/L), which may indicate mild renal impairment. However, his other renal function parameters, such as urea and albumin, are within normal limits.

The patient's lipid profile shows elevated total cholesterol (5.38 mmol/L) and LDL (3.08 mmol/L), which is consistent with his statin therapy. His HDL level is low (0.85 mmol/L), which is a risk factor for cardiovascular disease.

The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which may indicate underlying cardiac arrhythmias. However, these findings are not uncommon in patients with ischemic cardiomyopathy.

Given the patient's overall clinical presentation and laboratory results, his outcome as a survivor is likely due to the following factors:

1. Optimal medical therapy: The patient is on beta blockers, statins, and an ACE inhibitor, which are all evidence-based treatments for heart failure and ischemic cardiomyopathy. These medications are likely helping to manage his symptoms and slow disease progression.
2. Mild symptoms: The patient's NYHA Class II classification suggests that he has mild symptoms of heart failure, which is consistent with a more favorable prognosis.
3. Low LVEF: While the patient's LVEF is significantly reduced, it is not the lowest possible value, which may indicate some degree of cardiac reserve.
4. Absence of other comorbidities: The patient does not have other significant comorbidities, such as diabetes, chronic kidney disease, or significant valvular disease, which can worsen the prognosis.

Overall, the combination of optimal medical therapy, mild symptoms, and the absence of other comorbidities likely contributed to the patient's outcome as a survivor."
643,643,P1030,"Age: 69
Gender: Male 
Weight: 100 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 124/67 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 41
ALT or GPT (IU/L): 158.0
AST or GOT (IU/L): 105.0
Total Cholesterol (mmol/L): 5,4
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 42
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,2
LDL (mmol/L): 4,16
Sodium (mEq/L): 140.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 23
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,72
Urea (mg/dL): 8,49
LVEF (%): 53.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

Given the patient's data, the patient outcome of survivor is likely due to a combination of factors, including the patient's age, underlying medical conditions, and current treatment regimen. 

1. Idiopathic dilated cardiomyopathy: This condition indicates that the patient has a weakened heart muscle, which can lead to reduced cardiac function. However, the patient's LVEF (Left Ventricular Ejection Fraction) of 53% suggests that the heart function is still relatively preserved, which may contribute to the patient's survival.

2. Current medications: The patient is on beta blockers, loop diuretics, and an ACE inhibitor, which are standard treatments for heart failure and dilated cardiomyopathy. These medications help to reduce symptoms, improve heart function, and prevent complications.

3. Blood pressure: The patient's blood pressure is within a relatively normal range (124/67 mmHg), which may indicate effective management of hypertension, a common comorbidity in patients with heart disease.

4. Laboratory results: Although the patient has elevated liver enzymes (ALT and AST), which may indicate liver damage or inflammation, this is not directly related to the patient's cardiac outcome. The patient's kidney function, as indicated by the creatinine level, is also relatively preserved.

5. ECG findings: The presence of polymorphic ventricular extrasystoles is a benign finding in this context, and the absence of sustained ventricular tachycardia or non-sustained ventricular tachycardia suggests that the patient is not at high risk of sudden cardiac death.

Considering these factors, the patient's age, underlying medical conditions, and current treatment regimen likely contributed to the patient's survival. The patient's relatively preserved heart function, effective management of blood pressure and heart failure symptoms, and absence of high-risk ECG findings all support this outcome."
644,644,P1031,"Age: 78
Gender: Male 
Weight: 65 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 114/68 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,11
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 56
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,97
Sodium (mEq/L): 135.0
Protein (g/L): 68
T3 (pg/dL): 0,05
T4 (ng/L): 22
Troponin (ng/mL): 0,04
TSH (mIU/L): 1,86
Urea (mg/dL): 10,15
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",survivor,"REASONING: 

Given the patient's age (78) and NYHA Class II, indicating mild to moderate symptoms of heart failure, the patient has been managed with a multidrug regimen consisting of a calcium channel blocker, beta blockers, spironolactone, statins, and an ACE inhibitor. This comprehensive treatment approach is aimed at reducing symptoms, slowing disease progression, and improving survival in patients with heart failure.

The patient's laboratory results show elevated creatinine levels (124.0 mmol/L), which may indicate chronic kidney disease, a common comorbidity in patients with heart failure. However, the patient's blood urea level (10.15 mg/dL) is within a relatively normal range, suggesting that renal function is not severely impaired.

The patient's lipid profile shows a total cholesterol level of 4.11 mmol/L, which is slightly elevated, but the LDL level of 1.97 mmol/L is within a target range for patients with heart failure. The patient's HDL level of 0.96 mmol/L is also within a normal range.

The patient's troponin level of 0.04 ng/mL is within a normal range, indicating that there is no acute myocardial infarction or significant cardiac damage.

The patient's LVEF (left ventricular ejection fraction) is 25%, which is significantly reduced, indicating systolic heart failure. However, the patient has been managed with beta blockers, which are known to improve LVEF in patients with heart failure.

The patient's ECG shows a first-degree atrioventricular block (AVB), which is a common finding in patients with heart failure. The presence of a polymorphic ventricular extrasystole is also noted, but it is not a cause for concern.

Considering the patient's comprehensive treatment plan, stable laboratory results, and the absence of acute cardiac damage or severe renal impairment, the patient's outcome of survival is likely due to the effective management of their heart failure symptoms and comorbidities."
645,645,P1054,"Age: 58
Gender: Male 
Weight: 91 kg
Height: 176 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41,7
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 32.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 145.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,08
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 4492.0
Protein (g/L): 78
T3 (pg/dL): 0,05
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,45
Urea (mg/dL): 12,03
LVEF (%): 20.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"REASONING: 

The patient is a 58-year-old male with a history of ischemic dilated cardiomyopathy, myocardial infarction, dyslipemia, and hypertension. His current medications include amiodarone, beta blockers, loop diuretics, spironolactone, statins, ACE inhibitor, and nitrovasodilator, which are standard treatments for heart failure and arrhythmias. 

The patient's left ventricular ejection fraction (LVEF) is severely reduced at 20%, indicating a poor cardiac function. However, the patient is still alive, which can be attributed to several factors:

1.  Multidrug therapy: The patient is on a combination of medications that target different aspects of heart failure and arrhythmias, such as beta blockers, ACE inhibitors, and spironolactone, which have been shown to improve survival and reduce hospitalizations in patients with heart failure.
2.  Optimal blood pressure control: The patient's blood pressure is well-controlled at 110/70 mmHg, which reduces the strain on the heart and minimizes the risk of further cardiac damage.
3.  Low levels of troponin: The patient's troponin level is within normal limits, indicating that there is no ongoing myocardial damage or infarction.
4.  Normal hemoglobin and potassium levels: The patient's hemoglobin and potassium levels are within normal limits, which reduces the risk of anemia and arrhythmias.
5.  Low levels of T3 and T4: The patient's thyroid hormone levels are within normal limits, which suggests that there is no underlying thyroid disease contributing to his cardiac condition.
6.  Normal urea and creatinine levels: The patient's kidney function is relatively preserved, which reduces the risk of uremic cardiomyopathy and other complications.
7.  Non-sustained ventricular tachycardia: Although the patient has non-sustained ventricular tachycardia, it is not sustained, which reduces the risk of sudden cardiac death.

Overall, the patient's survival can be attributed to his multidrug therapy, optimal blood pressure control, and relatively preserved kidney function, which have helped to mitigate the progression of his ischemic dilated cardiomyopathy and reduce the risk of complications."
646,646,P1056,"Age: 79
Gender: Male 
Weight: 78 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 111/76 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 147.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,65
Sodium (mEq/L): 137.0
Protein (g/L): 76
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,62
Urea (mg/dL): 9,82
LVEF (%): 39.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"REASONING: The patient's outcome of survival can be attributed to several factors, despite his advanced age and underlying cardiac conditions. 

Firstly, the patient's blood pressure is well-controlled at 111/76 mmHg, which is significantly lower than the typical target for a hypertensive patient. This controlled blood pressure reduces the strain on the heart and minimizes the risk of further cardiac damage.

The patient's LVEF (Left Ventricular Ejection Fraction) of 39% indicates reduced cardiac function, but it is not as low as some other cases where patients have shown severe heart failure. The patient's NYHA Class II classification also suggests that he is experiencing some symptoms of heart failure, but they are not severe enough to limit his daily activities.

The patient's laboratory results show that his liver enzymes (ALT and AST) are within normal limits, which suggests that there is no significant liver dysfunction that could be contributing to his cardiac condition. His renal function, as indicated by creatinine levels, is also relatively preserved.

The patient's medication regimen, including Digoxin, Loop Diuretics, ACE Inhibitor, and Nitrovasodilator, is consistent with the management of heart failure and hypertension. These medications are likely helping to control his symptoms and slow the progression of his cardiac disease.

The ECG findings of ventricular extrasystole, non-sustained ventricular tachycardia, and sinus node dysfunction are concerning, but they do not necessarily indicate an acute life-threatening condition. The patient's troponin levels are within normal limits, which suggests that there is no acute myocardial infarction.

Overall, while the patient has significant cardiac disease, his controlled blood pressure, preserved renal function, and effective medication regimen have likely contributed to his survival. His advanced age and underlying conditions make him high-risk, but his current management plan appears to be effective in stabilizing his condition."
647,647,P1057,"Age: 72
Gender: Female 
Weight: 72 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 104/62 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 44
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 5,3
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 10,7
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,59
Sodium (mEq/L): 139.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,33
TSH (mIU/L): 0,76
Urea (mg/dL): 12,31
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"REASONING: 

This patient, a 72-year-old female with a history of idiopathic dilated cardiomyopathy, diabetes, and dyslipidemia, is on a treatment regimen that includes diabetes medication, beta blockers, loop diuretics, spironolactone, and an ACE inhibitor. The patient's left ventricular ejection fraction (LVEF) is 35%, indicating reduced heart function.

The patient's blood pressure is within a relatively normal range (104/62 mmHg), and the lack of bradycardia and paroxysmal supraventricular tachyarrhythmia on the ECG suggests that the heart is not experiencing significant bradycardic or supraventricular arrhythmia-related issues.

The presence of non-sustained ventricular tachycardia (VT) and polymorphic ventricular extrasystoles on the ECG indicates some degree of ventricular arrhythmia, but the fact that it is non-sustained suggests that the arrhythmia is not severe or life-threatening at this time.

The patient's laboratory results show slightly elevated glucose levels (10.7 mmol/L), which is well-controlled by her diabetes medication, and a relatively low HDL cholesterol level (1.06 mmol/L). The creatinine level is within normal limits, indicating no significant renal impairment.

The patient's overall clinical picture, including her NYHA class II status, suggests that she has a moderate level of heart failure symptoms, but her current treatment regimen and the lack of severe arrhythmias or other complications contribute to her survival.

Therefore, the patient's survival can be attributed to the following factors:

1.  Effective management of her heart failure symptoms through the use of beta blockers, loop diuretics, and spironolactone.
2.  Control of her diabetes through medication.
3.  The use of an ACE inhibitor to reduce her blood pressure and improve cardiac function.
4.  The absence of severe arrhythmias or other complications that could lead to cardiac arrest or death.

Overall, the combination of her treatment regimen, relatively normal vital signs, and lack of severe arrhythmias or other complications contribute to the patient's survival."
648,648,P1058,"Age: 77
Gender: Male 
Weight: 63 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 131/60 mmHg
Past Medical History: Valvular cardiomyopathy, Dyslipemia
Albumin (g/L): 40
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,28
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,9
Sodium (mEq/L): 140.0
Protein (g/L): 72
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,58
Urea (mg/dL): 9,98
LVEF (%): 19.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

Given the patient's profile, the outcome of survival can be attributed to a combination of factors:

1. Early detection and management of ventricular arrhythmias: The presence of sustained and non-sustained ventricular tachycardia indicates a high risk of life-threatening arrhythmias. However, the patient is on medications such as beta blockers, which are effective in managing ventricular rate and preventing sudden cardiac death. Additionally, the use of an ACE inhibitor, a statin, and a loop diuretic suggests a comprehensive approach to managing the patient's underlying conditions, including valvular cardiomyopathy and dyslipidemia.

2. Optimal medication regimen: The patient's current medication regimen, including beta blockers, digoxin, and loop diuretics, is aimed at managing symptoms, controlling arrhythmias, and improving cardiac function. The use of statins is beneficial in managing dyslipidemia, which is a significant risk factor for cardiovascular disease.

3. Monitoring and management of electrolytes: The patient's potassium level is within the normal range (4.5 mEq/L), which is essential for maintaining cardiac function and preventing arrhythmias. The normal TSH level (0.58 mIU/L) suggests that the patient's thyroid function is within the normal range, which is crucial for maintaining cardiac function.

4. Good renal function: The patient's creatinine level (88.0 μmol/L) is within the normal range, indicating that the patient's kidneys are functioning properly. This is essential for eliminating waste products, including medications, and maintaining electrolyte balance.

5. Low levels of troponin: The patient's troponin level (0.03 ng/mL) is within the normal range, indicating that there is no evidence of acute myocardial infarction (heart attack) or cardiac damage.

6. Low LVEF: The patient's left ventricular ejection fraction (LVEF) is 19.0%, which is significantly reduced. However, the patient's survival suggests that the LVEF is not a limiting factor in this case, possibly due to the patient's overall good health status and optimal management of the underlying conditions.

7. Supportive care: The patient's NYHA class II classification indicates that the patient has mild symptoms of heart failure, which suggests that the patient's cardiac function is relatively preserved. The patient's overall health status and supportive care, including medications and lifestyle modifications, have likely contributed to the patient's survival.

In conclusion, the patient's survival can be attributed to a combination of early detection and management of ventricular arrhythmias, optimal medication regimen, monitoring and management of electrolytes, good renal function, low levels of troponin, and supportive care."
649,649,P1064,"Age: 63
Gender: Female 
Weight: 67 kg
Height: 151 cm
NYHA Class: II
Blood Pressure: 163/94 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 53.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,28
Sodium (mEq/L): 141.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,005
TSH (mIU/L): 2,35
Urea (mg/dL): 6,32
LVEF (%): 30.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

The patient's outcome of survival can be attributed to a combination of factors. 

Firstly, the patient's blood pressure is well-controlled, with a systolic pressure of 163 mmHg, which is relatively low for a patient with hypertensive cardiomyopathy. The use of an Angiotensin II Receptor Blocker (ARB) and a Beta Blocker likely contributed to this control, as these medications are commonly used to manage hypertension and heart failure.

Secondly, the patient's diabetes is being managed with medication, and their glucose level is within a relatively normal range (6.7 mmol/L). This suggests that the patient's diabetes is being well-controlled, which is crucial for preventing cardiovascular complications.

Thirdly, the patient's left ventricular ejection fraction (LVEF) is 30%, which indicates that the patient has heart failure, but it is not severe. The use of Loop Diuretics, which are commonly used to manage fluid overload in heart failure, may also have contributed to the patient's survival.

Additionally, the patient's troponin level is 0.005 ng/mL, which is within a normal range, indicating that there is no acute myocardial infarction (heart attack) or significant cardiac damage.

Lastly, the patient's ECG is notable for polymorphic ventricular extrasystoles, which can be a benign finding in some cases. However, the absence of other significant arrhythmias, such as ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia, suggests that the patient's heart rhythm is relatively stable.

Overall, the combination of well-controlled hypertension, diabetes, and heart failure, along with the use of appropriate medications, likely contributed to the patient's survival."
650,650,P1065,"Age: 80
Gender: Male 
Weight: 79 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 146/83 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 14,9
Hemoglobin (g/L): 179.0
HDL (mmol/L): 0,83
LDL (mmol/L): 3,21
Sodium (mEq/L): 135.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 13
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,06
Urea (mg/dL): 13,98
LVEF (%): 56.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

This patient is an 80-year-old male with a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers dilate, reducing the heart's ability to pump blood effectively. Despite this, the patient has a relatively well-managed condition, as evidenced by a left ventricular ejection fraction (LVEF) of 56%, which is above the threshold for heart failure (LVEF < 35-40%). 

The patient's blood pressure is within a relatively normal range (146/83 mmHg), which is not excessively high or low, indicating that his cardiovascular system is not under significant strain. The patient's medications, including digoxin, loop diuretics, and ACE inhibitors, are also typical for managing heart failure and hypertension.

The patient's laboratory results show that his liver enzymes (AST and ALT) are within normal limits, indicating that there is no evidence of liver disease, which can sometimes be associated with heart failure. His kidney function (Creatinine and Urea) is also within normal limits, indicating that his kidneys are functioning properly. His electrolytes (Sodium) are also within normal limits.

The patient's lipid profile shows a total cholesterol of 4.91 mmol/L, which is slightly elevated, but his HDL (good cholesterol) is 0.83 mmol/L, which is within the normal range. His LDL (bad cholesterol) is 3.21 mmol/L, which is slightly elevated, but not excessively high.

The patient's thyroid function tests (TSH and T4) are within normal limits, indicating that there is no evidence of thyroid dysfunction. His T3 is slightly low, but this is not uncommon in patients with heart failure.

The patient's troponin level is 0.03 ng/mL, which is within the normal range, indicating that there is no evidence of acute myocardial infarction (heart attack).

The patient's ECG shows a polymorphic ventricular extrasystole, which is a common finding in patients with heart failure. There is no evidence of sustained ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia.

In conclusion, this patient's outcome is likely due to the fact that his heart failure is well-managed, and he does not have any acute or chronic conditions that would put him at risk for a poor outcome. His age and gender are also factors that contribute to his outcome, as older adults are generally more resilient to cardiac conditions than younger adults."
651,651,P1066,"Age: 72
Gender: Female 
Weight: 81 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 164/79 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 5,04
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,62
Sodium (mEq/L): 139.0
Protein (g/L): 69
T3 (pg/dL): 0,06
T4 (ng/L): 11
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,38
Urea (mg/dL): 8,32
LVEF (%): 42.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: The patient, a 72-year-old female with a history of hypertensive cardiomyopathy and hypertension, has been managed with loop diuretics and an ACE inhibitor. The patient's left ventricular ejection fraction (LVEF) of 42% indicates a reduced ejection fraction, which is consistent with cardiomyopathy. However, the patient's troponin level is within normal limits (0.03 ng/mL), suggesting that there is no acute myocardial infarction.

The patient's blood pressure is elevated at 164/79 mmHg, but it is well-controlled with medication. The patient's lipid profile shows a total cholesterol level of 5.04 mmol/L, which is slightly elevated, but the HDL level of 0.85 mmol/L is low, indicating a high risk of cardiovascular disease.

The patient's liver function tests (ALT, AST, and GGT) are within normal limits, indicating that there is no significant liver dysfunction. The patient's electrolyte levels (potassium and sodium) are within normal limits, and the urea level is slightly elevated at 8.32 mg/dL, which may indicate mild renal impairment.

The patient's ECG shows polymorphic ventricular extrasystoles, which is a common finding in patients with cardiomyopathy. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia (PSVT) suggests that the patient is not at high risk for arrhythmias.

Given the patient's age, comorbidities, and the absence of acute myocardial infarction, the patient's outcome as a survivor is likely due to the effective management of their hypertension and cardiomyopathy with loop diuretics and an ACE inhibitor. The patient's relatively preserved LVEF and lack of significant arrhythmias also contribute to their favorable outcome."
652,652,P1073,"Age: 70
Gender: Female 
Weight: 63 kg
Height: 144 cm
NYHA Class: II
Blood Pressure: 134/86 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 44
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 6,21
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 89
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 145.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,23
Sodium (mEq/L): 141.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 12
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,43
Urea (mg/dL): 8,82
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"REASONING: 

This patient, a 70-year-old female with a history of idiopathic dilated cardiomyopathy and diabetes, has been managed with beta blockers, loop diuretics, and an ACE inhibitor. Her left ventricular ejection fraction (LVEF) of 40% indicates a moderate to severe reduction in cardiac function, which is consistent with her history of dilated cardiomyopathy.

The patient's blood pressure is within a relatively normal range (134/86 mmHg), and her electrolyte levels are mostly within normal limits, except for a slightly low potassium level (4.5 mEq/L). Her renal function, as indicated by the creatinine level, is mildly impaired, which may be a consequence of her cardiomyopathy or diabetes.

The patient's lipid profile shows elevated total cholesterol (6.21 mmol/L) and LDL levels (3.23 mmol/L), which are potential risk factors for cardiovascular disease. However, her HDL level (1.68 mmol/L) is within a relatively normal range.

The patient's glucose level (5.5 mmol/L) is within the normal range, which is good, considering her history of diabetes. Her liver function tests (ALT and AST) are within normal limits, indicating that her liver is functioning properly.

The patient's thyroid function tests (T3 and T4) are within normal limits, and her TSH level is slightly low (1.43 mIU/L), which may be a consequence of her medication or other underlying conditions.

The ECG shows ventricular extrasystoles, which are common in patients with cardiomyopathy, but there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias.

Considering the patient's overall clinical picture, her management with beta blockers, loop diuretics, and an ACE inhibitor, and the absence of any life-threatening arrhythmias, the most likely reason for the patient's outcome is that she has been effectively managed for her cardiomyopathy and diabetes, and her cardiac function has not deteriorated significantly. This, combined with her relatively stable vital signs and absence of any acute complications, suggests that she has survived the current episode and is likely to continue living with her condition."
653,653,P0008,"Age: 44
Gender: Male 
Weight: 114 kg
Height: 179 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 42,19
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 5,07
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 12,3
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,37
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,77
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 623.0
Protein (g/L): 76
T3 (pg/dL): 0,02
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,58
Urea (mg/dL): 9,8
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of several factors. Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack, leading to a reduced left ventricular ejection fraction (LVEF). The patient's LVEF is 30%, indicating a significant impairment of the heart's pumping function.

Secondly, the patient's blood glucose level is elevated at 12.3 mmol/L, indicating uncontrolled diabetes. Diabetes is a well-known risk factor for cardiovascular disease and can exacerbate cardiac dysfunction.

Thirdly, the patient's total cholesterol level is high at 5.07 mmol/L, and LDL (bad) cholesterol is elevated at 2.77 mmol/L. High cholesterol levels can contribute to the development and progression of atherosclerosis, further compromising cardiac function.

Fourthly, the patient's Pro-BNP (B-type natriuretic peptide) level is elevated at 623 ng/L, which is a marker of cardiac strain and stress. Elevated Pro-BNP levels are associated with an increased risk of cardiac events, including sudden cardiac death.

Lastly, the patient's ECG shows polymorphic ventricular extrasystoles, which can be a sign of underlying cardiac electrical instability. While not a definitive indicator of sudden cardiac death, it does suggest that the patient's heart is at increased risk of arrhythmias.

Considering these factors, the patient's sudden cardiac death is likely a result of a combination of cardiac dysfunction, uncontrolled diabetes, high cholesterol, cardiac strain, and cardiac electrical instability."
654,654,P0012,"Age: 70
Gender: Male 
Weight: 88 kg
Height: 175 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39,3
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,32
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,53
Potassium (mEq/L): 3,1
LDL (mmol/L): 2,43
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 958.0
Protein (g/L): 71
T3 (pg/dL): 0,03
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,51
Urea (mg/dL): 8,02
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Amiodarone, Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of factors, including his advanced age, severe left ventricular dysfunction (LVEF of 35%), and history of ischemic dilated cardiomyopathy. 

1.  Ischemic dilated cardiomyopathy: This condition is a result of previous myocardial infarctions leading to scarring and thinning of the heart muscle, which can cause a decrease in the heart's pumping efficiency. The patient's LVEF of 35% indicates a severely reduced left ventricular function, making it difficult for the heart to pump blood effectively.

2.  Electrocardiogram (ECG) findings: Although the patient's ECG does not show ventricular tachycardia, the presence of polymorphic ventricular extrasystoles may indicate abnormal electrical activity in the heart. This, combined with the patient's history of ischemic dilated cardiomyopathy, increases the risk of arrhythmias and sudden cardiac death.

3.  High Pro-BNP levels: The patient's Pro-BNP level of 958.0 ng/L is significantly elevated, indicating severe heart failure. Elevated Pro-BNP levels are associated with increased mortality and morbidity in patients with heart failure.

4.  Medications: The patient is on multiple medications, including Angiotensin II Receptor Blocker (ARB), which is used to reduce blood pressure and slow the progression of heart failure. However, despite this, the patient's condition has progressed to sudden cardiac death.

5.  Other contributing factors: The patient's age, dyslipemia, hypertension, and previous myocardial infarction also contribute to his increased risk of sudden cardiac death.

In summary, the combination of the patient's advanced age, severe left ventricular dysfunction, ischemic dilated cardiomyopathy, and high Pro-BNP levels, along with the presence of polymorphic ventricular extrasystoles, likely contributed to his outcome of sudden cardiac death."
655,655,P0016,"Age: 72
Gender: Male 
Weight: 78 kg
Height: 173 cm
NYHA Class: III
Blood Pressure: 95/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 38,1
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 6,72
Creatinine (mmol/L): 225.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 7
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,78
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 15509.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,56
Urea (mg/dL): 31,4
LVEF (%): 18.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

Given the patient's advanced age (72 years) and history of ischemic dilated cardiomyopathy, the patient's low left ventricular ejection fraction (LVEF) of 18% indicates severe heart failure. The patient's high Pro-BNP level of 15509.0 ng/L further supports the presence of heart failure, as elevated BNP levels are commonly seen in patients with heart failure.

The presence of non-sustained ventricular tachycardia (VT) on the ECG suggests that the patient has a history of arrhythmias, which can be a risk factor for sudden cardiac death. The patient's history of myocardial infarction also increases the risk of arrhythmias and sudden cardiac death.

The patient's low HDL cholesterol level of 0.96 mmol/L and high LDL cholesterol level of 4.78 mmol/L suggest that the patient has dyslipidemia, which can contribute to the progression of coronary artery disease and increase the risk of arrhythmias and sudden cardiac death.

The patient's low potassium level of 4.7 mEq/L may also contribute to the risk of arrhythmias, as low potassium levels can increase the risk of cardiac arrhythmias.

The patient's TSH level of 2.56 mIU/L is within the normal range, but the patient's T3 level of 0.05 pg/dL is low, which may indicate hypothyroidism. Hypothyroidism can contribute to the progression of heart failure and increase the risk of arrhythmias.

The patient's urea level of 31.4 mg/dL is slightly elevated, which may indicate impaired renal function, which can contribute to the progression of heart failure and increase the risk of arrhythmias.

The patient's medications, including beta blockers, digoxin, loop diuretics, spironolactone, statins, and ACE inhibitors, are commonly used to manage heart failure and arrhythmias, but may not be sufficient to prevent sudden cardiac death in this patient.

Given the combination of these factors, the patient's advanced age, history of ischemic dilated cardiomyopathy, low LVEF, high Pro-BNP level, non-sustained VT, low HDL cholesterol, high LDL cholesterol, low potassium level, low T3 level, and impaired renal function, the patient's risk of sudden cardiac death was likely increased, leading to the patient outcome of sudden cardiac death."
656,656,P0018,"Age: 57
Gender: Male 
Weight: 88 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 48
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 89.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 147.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,78
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 110.0
Protein (g/L): 78
T3 (pg/dL): 0,04
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,21
Urea (mg/dL): 9,35
LVEF (%): 58.0
Medications: Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",sudden cardiac death,"REASONING: 

Given the patient's history of ischemic dilated cardiomyopathy, myocardial infarction, and current medication regimen, the patient is at high risk for cardiac complications. The patient's LVEF of 58% indicates mildly reduced left ventricular function, which is a risk factor for sudden cardiac death. The presence of ventricular extrasystoles on the ECG is also concerning, as it can be a marker of electrical instability in the heart.

The patient's high total cholesterol and LDL levels (3.78 mmol/L and 1.78 mmol/L, respectively) may be contributing to ongoing ischemic damage to the heart muscle, which could increase the risk of sudden cardiac death. The patient's low HDL level (1.4 mmol/L) may also be a contributing factor, as low HDL levels are associated with an increased risk of cardiovascular disease.

The patient's elevated Pro-BNP level (110 ng/L) suggests that the patient has some degree of heart failure, which is a known risk factor for sudden cardiac death. The patient's TSH level is within the normal range, which rules out hypothyroidism as a contributing factor.

The patient's medication regimen includes beta blockers, statins, ACE inhibitors, and nitrovasodilators, which are all appropriate for a patient with ischemic dilated cardiomyopathy and heart failure. However, the presence of ventricular extrasystoles and mildly reduced LVEF suggests that the patient may require more aggressive management of their heart failure and arrhythmias.

In summary, the patient's combination of ischemic dilated cardiomyopathy, myocardial infarction, ventricular extrasystoles, mildly reduced LVEF, high cholesterol levels, and elevated Pro-BNP level all contribute to a high risk of sudden cardiac death."
657,657,P0028,"Age: 76
Gender: Male 
Weight: 72 kg
Height: 187 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease
Albumin (g/L): 41,5
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,5
Creatinine (mmol/L): 130.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 10,2
Hemoglobin (g/L): 132.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 5
LDL (mmol/L): 2,9
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 7822.0
Protein (g/L): 67
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,29
Urea (mg/dL): 10,91
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

Given the patient's profile, the combination of factors contributed to the outcome of sudden cardiac death. The patient's age (76) and NYHA Class III classification indicate a history of heart failure, which is consistent with ischemic dilated cardiomyopathy. The low left ventricular ejection fraction (LVEF) of 35% suggests severe heart failure, indicating reduced cardiac function.

The elevated Pro-BNP (brain natriuretic peptide) level of 7822.0 ng/L is a marker of heart failure and indicates increased ventricular wall stress, which is consistent with the patient's heart failure diagnosis. The presence of ventricular extrasystoles on the ECG suggests arrhythmia, which can be a risk factor for sudden cardiac death.

The patient's diabetes and dyslipemia are risk factors for cardiovascular disease, which may have contributed to the development of ischemic dilated cardiomyopathy. The patient's peripheral vascular disease also indicates atherosclerosis, which can further compromise cardiac function.

The patient's creatinine level of 130.0 mmol/L suggests renal impairment, which can be a comorbidity in patients with heart failure. The low hemoglobin level of 132.0 g/L may indicate anemia, which can contribute to reduced oxygen delivery to the heart muscle, exacerbating heart failure.

The patient's medications, including beta blockers, loop diuretics, ACE inhibitors, and nitrovasodilators, are standard treatments for heart failure, but the presence of ventricular extrasystoles and the patient's underlying heart failure may have contributed to the risk of sudden cardiac death despite these treatments.

The combination of these factors, including severe heart failure, arrhythmia, comorbidities, and medication regimen, likely contributed to the patient's outcome of sudden cardiac death."
658,658,P0043,"Age: 63
Gender: Male 
Weight: 87 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 115/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 41,9
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,53
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 168.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,87
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 636.0
Protein (g/L): 81
T3 (pg/dL): 0,07
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,57
Urea (mg/dL): 4,9
LVEF (%): 26.0
Medications: Diabetes Medication, Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of his complex medical history and current clinical findings. 

1. Ischemic dilated cardiomyopathy: The patient's history of ischemic dilated cardiomyopathy, which is characterized by a weakened heart muscle due to coronary artery disease, significantly increases his risk of sudden cardiac death. This condition can lead to abnormal heart rhythms and reduced cardiac function, making it difficult for the heart to pump blood effectively.

2. Low left ventricular ejection fraction (LVEF) of 26%: The patient's LVEF is significantly reduced, indicating that his heart is not pumping blood efficiently. This is a strong predictor of adverse cardiac events, including sudden cardiac death.

3. Elevated Pro-BNP (N-terminal pro b-type natriuretic peptide) levels: A high Pro-BNP level of 636 ng/L suggests that the patient's heart is under strain, which may be a result of his heart failure. Elevated Pro-BNP levels have been associated with an increased risk of sudden cardiac death.

4. Presence of non-sustained ventricular tachycardia (NSVT): The patient's ECG shows NSVT, which is a known risk factor for sudden cardiac death. NSVT can be a marker of underlying cardiac disease and may be a precursor to more severe arrhythmias.

5. Medication non-adherence or inadequate treatment: Although the patient is on beta blockers, spironolactone, statins, and an ACE inhibitor, it is unclear if these medications are being taken as prescribed. Inadequate treatment of his heart failure and other underlying conditions may have contributed to his sudden cardiac death.

6. Comorbidities: The patient's diabetes, dyslipidemia, and peripheral vascular disease are additional risk factors for cardiovascular events. These conditions can contribute to the progression of his ischemic dilated cardiomyopathy and increase his risk of sudden cardiac death.

Given the combination of these factors, it is likely that the patient's sudden cardiac death was the result of a complex interplay between his underlying heart disease, reduced cardiac function, and other comorbidities."
659,659,P0049,"Age: 70
Gender: Male 
Weight: 88 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41,4
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 77
Glucose (mmol/L): 9
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4
LDL (mmol/L): 2,04
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2542.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,21
Urea (mg/dL): 8,91
LVEF (%): 25.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of factors. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened due to a heart attack, leading to a reduced ejection fraction (LVEF of 25%). This condition increases the risk of sudden cardiac death.

Secondly, the patient has a high level of Pro-BNP (2542.0 ng/L), which is a biomarker for heart failure and increased ventricular wall stress. Elevated Pro-BNP levels are associated with an increased risk of sudden cardiac death.

Thirdly, the patient's ECG shows non-sustained ventricular tachycardia (NSVT), which is a type of abnormal heart rhythm that can increase the risk of sudden cardiac death.

Fourthly, the patient's low HDL cholesterol level (1.09 mmol/L) and high LDL cholesterol level (2.04 mmol/L) indicate poor lipid profile, which is a risk factor for coronary artery disease and myocardial infarction.

Fifthly, the patient's medication regimen, while comprehensive, may not be sufficient to control the patient's condition effectively. The presence of beta blockers, digoxin, loop diuretics, spironolactone, statins, and ACE inhibitors may help manage heart failure and hypertension, but the patient's high Pro-BNP level and low LVEF suggest that these medications may not be adequately addressing the underlying condition.

Lastly, the patient's age (70 years) and NYHA Class II classification, indicating moderate heart failure symptoms, also contribute to the increased risk of sudden cardiac death.

In summary, the combination of ischemic dilated cardiomyopathy, high Pro-BNP levels, non-sustained ventricular tachycardia, poor lipid profile, and inadequate medication regimen, along with the patient's age and NYHA classification, likely contributed to the patient's outcome of sudden cardiac death."
660,660,P0051,"Age: 52
Gender: Male 
Weight: 74 kg
Height: 176 cm
NYHA Class: III
Blood Pressure: 85/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 39
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 2,74
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 133.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 5
LDL (mmol/L): 1,4
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 693.0
Protein (g/L): 68
T3 (pg/dL): 0,04
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,55
Urea (mg/dL): 8,91
LVEF (%): 26.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

This patient's outcome of sudden cardiac death can be attributed to a combination of factors related to their underlying cardiomyopathy, medication regimen, and laboratory results. 

Firstly, the patient has idiopathic dilated cardiomyopathy, which is a condition characterized by a weakened heart muscle that cannot pump blood efficiently, leading to a decreased left ventricular ejection fraction (LVEF) of 26%. This indicates severe heart failure, as evidenced by the patient's NYHA Class III classification. 

The patient's low LVEF, coupled with a high Pro-BNP level of 693.0 ng/L, suggests significant heart failure with preserved ejection fraction. The high Pro-BNP level is a marker of increased ventricular wall stress and stretching, which is consistent with heart failure.

The patient's blood pressure is 85/60 mmHg, which is low, indicating orthostatic hypotension. This can be a result of the patient's medication regimen, including Loop Diuretics, which can cause hypotension as a side effect. The low blood pressure, combined with the patient's low LVEF, may have led to a decreased cardiac output, making the patient more susceptible to sudden cardiac death.

The patient's medications, including Amiodarone, Beta Blockers, Loop Diuretics, Spironolactone, Statins, and ACE Inhibitor, are commonly used to manage heart failure and arrhythmias. However, the combination of these medications, particularly the high dose of Amiodarone, may have contributed to the patient's bradycardia (not explicitly stated but can be inferred from the medication regimen). Bradycardia can lead to decreased cardiac output, which may have contributed to the patient's sudden cardiac death.

The patient's laboratory results also indicate mild liver dysfunction, as evidenced by elevated AST and ALT levels, which may be related to the patient's dyslipemia and statin therapy. However, this is unlikely to be a direct cause of sudden cardiac death.

The patient's TSH level is slightly elevated, but not significantly high, indicating mild thyroid dysfunction. However, this is unlikely to be a direct cause of sudden cardiac death.

In conclusion, the patient's outcome of sudden cardiac death can be attributed to a combination of their underlying cardiomyopathy, medication regimen, and laboratory results. The patient's low LVEF, high Pro-BNP level, and low blood pressure, combined with the potential side effects of their medications, particularly Amiodarone, likely contributed to a decreased cardiac output, making the patient more susceptible to sudden cardiac death."
661,661,P0053,"Age: 68
Gender: Male 
Weight: 80 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 47,19
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 112.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 155.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,15
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 2234.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,11
Urea (mg/dL): 9,57
LVEF (%): 39.0
Medications: Calcium Channel Blocker, Diabetes Medication, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

Based on the provided patient data, the patient had a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack. This condition is often associated with a decreased left ventricular ejection fraction (LVEF), which in this case was 39%, indicating a significant impairment of the heart's pumping function. The patient's NYHA Class II classification also suggests that the patient experiences symptoms of heart failure, such as shortness of breath, fatigue, and swelling in the legs, during physical activity or exertion.

The elevated Pro-BNP (Brain Natriuretic Peptide) level of 2234.0 ng/L is a strong indicator of heart failure and is consistent with the patient's NYHA Class II classification. Additionally, the patient's Troponin level of 0.01 ng/mL is slightly elevated, indicating ongoing myocardial damage.

The patient's medication list includes a nitrovasodilator, which is a medication used to treat angina and heart failure by dilating blood vessels and reducing the workload on the heart. However, the patient's condition may have progressed to a point where the medication was insufficient to prevent sudden cardiac death.

The patient's laboratory results show an elevated creatinine level of 112.0 mmol/L, indicating impaired kidney function, which can be a consequence of heart failure. The low albumin level of 47.19 g/L may also indicate malnutrition or liver disease, but in this context, it may be related to the patient's heart failure.

The patient's TSH level of 3.11 mIU/L is within the normal range, and the T3 and T4 levels are also within the normal range, indicating that the patient's thyroid function is not a contributing factor to the patient's condition.

The patient's ECG results show a polymorphic ventricular extrasystole, which can be a sign of abnormal heart rhythm, but it is not a direct cause of sudden cardiac death. However, in the context of the patient's underlying heart disease and heart failure, it may have contributed to the risk of sudden cardiac death.

In conclusion, the patient's sudden cardiac death is likely due to the progression of his ischemic dilated cardiomyopathy and heart failure, which led to a significant impairment of the heart's pumping function and a high risk of sudden cardiac death. The patient's medication regimen and laboratory results suggest that his condition was not adequately controlled, and the patient's underlying heart disease and heart failure ultimately led to his demise."
662,662,P0057,"Age: 66
Gender: Male 
Weight: 77 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41,7
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 155.0
Gamma-glutamil transpeptidase (IU/L): 168
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 5
LDL (mmol/L): 2,48
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3996.0
Protein (g/L): 81
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,02
TSH (mIU/L): 8,79
Urea (mg/dL): 15,15
LVEF (%): 29.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

This patient's outcome of sudden cardiac death can be attributed to a combination of factors based on the provided data. The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack or coronary artery disease. This condition is often associated with reduced left ventricular ejection fraction (LVEF), which in this case is 29.0%, indicating severe heart failure.

The patient's low LVEF, coupled with the presence of non-sustained ventricular tachycardia (NSVT) on the ECG, suggests an increased risk of sudden cardiac death. NSVT is a condition where the heart beats rapidly and irregularly for more than 30 seconds but less than 30 minutes. This condition can increase the risk of sudden cardiac death, especially in patients with pre-existing heart conditions.

Additionally, the patient's elevated Pro-BNP (B-type natriuretic peptide) level of 3996.0 ng/L indicates severe heart failure, as Pro-BNP is a biomarker used to diagnose and monitor heart failure. The high Pro-BNP level, along with the low LVEF and NSVT, suggests that the patient's heart is under significant stress, which can lead to sudden cardiac death.

The patient's history of myocardial infarction and ischemic dilated cardiomyopathy further increases the risk of sudden cardiac death. The presence of ventricular extrasystole (irregular heartbeats) on the ECG also contributes to the risk of arrhythmias and sudden cardiac death.

Furthermore, the patient's low T3 and T4 levels may indicate hypothyroidism, which can also contribute to heart failure and increase the risk of sudden cardiac death.

In summary, the combination of the patient's history of ischemic dilated cardiomyopathy, low LVEF, NSVT, elevated Pro-BNP, history of myocardial infarction, and other ECG abnormalities makes sudden cardiac death a plausible outcome."
663,663,P0059,"Age: 78
Gender: Male 
Weight: 77 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 145/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 36,9
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,53
Creatinine (mmol/L): 171.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 121.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 5,1
LDL (mmol/L): 2,66
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 8283.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,79
Urea (mg/dL): 13,14
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

Based on the provided patient data, the patient's outcome of sudden cardiac death can be attributed to a combination of factors related to their underlying medical conditions and laboratory results. 

1.  Ischemic Dilated Cardiomyopathy (IDC): The patient has a history of IDC, which significantly increases the risk of sudden cardiac death. IDC is characterized by a weakened heart muscle, reduced left ventricular ejection fraction (LVEF), and increased risk of arrhythmias.

2.  Reduced LVEF (30.0%): The patient's left ventricular ejection fraction is severely impaired, indicating a poor heart function. This reduced LVEF is a significant risk factor for sudden cardiac death.

3.  Non-sustained Ventricular Tachycardia (VT): The ECG findings indicate non-sustained VT, which is a known predictor of sudden cardiac death in patients with heart failure and reduced LVEF. VT can degenerate into sustained VT, leading to fatal arrhythmias.

4.  High Pro-BNP levels (8283.0 ng/L): Elevated B-type natriuretic peptide (BNP) levels are associated with heart failure and increased mortality. High BNP levels indicate severe heart failure, which may contribute to the patient's risk of sudden cardiac death.

5.  Electrolyte imbalance (Potassium 5.1 mEq/L): The patient's slightly elevated potassium level may contribute to cardiac arrhythmias, including VT, increasing the risk of sudden cardiac death.

6.  Medication non-adherence or inadequate dosing: Although the patient is on various medications, including beta blockers, digoxin, and ACE inhibitors, which are essential for managing heart failure and arrhythmias, the effectiveness of these medications may be compromised by non-adherence or inadequate dosing, contributing to the patient's increased risk of sudden cardiac death.

7.  Co-existing conditions: The patient's history of diabetes, dyslipidemia, and hypertension may have contributed to the development and progression of IDC and increased the risk of sudden cardiac death.

Given the combination of these factors, the patient's outcome of sudden cardiac death is likely the result of a complex interplay between their underlying medical conditions, reduced heart function, and potential medication non-adherence or inadequate dosing."
664,664,P0073,"Age: 65
Gender: Male 
Weight: 101 kg
Height: 173 cm
NYHA Class: III
Blood Pressure: 110/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 39,8
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 6,05
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4
LDL (mmol/L): 3,18
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 842.0
Protein (g/L): 73
T4 (ng/L): 17
TSH (mIU/L): 0,98
Urea (mg/dL): 5,66
LVEF (%): 32.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of factors present in his medical history and current clinical status.

1. Ischemic dilated cardiomyopathy: The patient's history of ischemic dilated cardiomyopathy indicates that he has a weakened heart muscle due to previous myocardial infarctions. This condition can lead to reduced cardiac function, increasing the risk of arrhythmias and sudden cardiac death.

2. Low LVEF (32.0%): The patient's left ventricular ejection fraction (LVEF) is severely reduced, indicating poor cardiac function. A low LVEF is a significant risk factor for sudden cardiac death.

3. Non-sustained ventricular tachycardia (NSVT): The presence of NSVT on the ECG indicates abnormal heart rhythms that can increase the risk of sudden cardiac death.

4. High Pro-BNP (842.0 ng/L): Elevated B-type natriuretic peptide (BNP) levels are associated with heart failure and increased mortality risk. High Pro-BNP levels in this patient suggest severe cardiac dysfunction.

5. Medication regimen: Although the patient is on beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor, these medications may not be sufficient to control the patient's cardiac condition, particularly given the presence of NSVT and low LVEF.

6. Age and comorbidities: The patient's advanced age (65 years) and presence of multiple comorbidities (dyslipemia, peripheral vascular disease, hypertension) contribute to a higher risk of cardiovascular events, including sudden cardiac death.

Considering these factors, the patient's sudden cardiac death is likely a result of a combination of his ischemic dilated cardiomyopathy, low LVEF, NSVT, and elevated Pro-BNP levels, which together created a high-risk profile for sudden cardiac death."
665,665,P0079,"Age: 70
Gender: Male 
Weight: 75 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 43,4
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,6
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,56
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 517.0
Protein (g/L): 75
T3 (pg/dL): 0,04
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,45
Urea (mg/dL): 7,35
LVEF (%): 48.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Third-degree AVB
            ",sudden cardiac death,"REASONING: 

Based on the provided patient data, the patient had a complex medical history with multiple comorbidities, including ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, hypertension, and a history of myocardial infarction. The patient's left ventricular ejection fraction (LVEF) was significantly reduced at 48%, indicating compromised heart function.

The patient's elevated Pro-BNP level (517.0 ng/L) suggests that the patient had severe heart failure symptoms, likely contributing to the reduced LVEF. The presence of third-degree atrioventricular block (AVB) on the ECG is concerning, as it can lead to inadequate cardiac output and increased risk of sudden cardiac death.

Additionally, the patient's polymorphic ventricular extrasystoles on the ECG may indicate an increased risk of arrhythmias, which can further contribute to sudden cardiac death. The patient's history of non-sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia also increases the risk of sudden cardiac death.

The patient's medications, including beta blockers and nitrovasodilators, were being taken to manage heart failure and hypertension, but they may not have been sufficient to prevent sudden cardiac death.

The patient's age (70) and reduced LVEF (48%) are also significant risk factors for sudden cardiac death. The combination of these factors likely contributed to the patient's sudden cardiac death."
666,666,P0112,"Age: 51
Gender: Male 
Weight: 76 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 139/83 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 35
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,62
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,12
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 975.0
Protein (g/L): 60
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,56
Urea (mg/dL): 4,49
LVEF (%): 20.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of factors related to their underlying cardiac condition and laboratory results. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a previous heart attack, leading to a reduced ejection fraction (LVEF of 20%). This significantly increases the risk of sudden cardiac death.

The elevated Pro-BNP (Brain Natriuretic Peptide) level of 975 ng/L is indicative of heart failure and increased ventricular wall stress, which is consistent with the patient's LVEF of 20%. 

Additionally, the presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG further increases the risk of sudden cardiac death. The polymorphic ventricular extrasystoles are particularly concerning as they can be a marker of electrical instability in the heart.

The patient's medications, including beta blockers, statins, and ACE inhibitors, are standard treatments for heart failure and ischemic cardiomyopathy. However, they may not have been sufficient to mitigate the patient's risk of sudden cardiac death.

The patient's other laboratory results, such as the slightly elevated total cholesterol and LDL levels, are not directly related to their cardiac outcome. The patient's hemoglobin and potassium levels are within normal limits, which suggests that there is no significant anemia or electrolyte imbalance contributing to their cardiac death.

In conclusion, the combination of the patient's ischemic dilated cardiomyopathy, elevated Pro-BNP levels, ventricular extrasystoles, and non-sustained ventricular tachycardia on the ECG, and their medication regimen likely contributed to their sudden cardiac death."
667,667,P0127,"Age: 65
Gender: Male 
Weight: 70 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,77
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,59
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 553.0
Protein (g/L): 72
T3 (pg/dL): 0,03
T4 (ng/L): 16
Troponin (ng/mL): 0,1
TSH (mIU/L): 1,1
Urea (mg/dL): 7,49
LVEF (%): 14.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death is likely due to a combination of factors, primarily related to his underlying cardiomyopathy and cardiac dysfunction.

1.  Reduced Left Ventricular Ejection Fraction (LVEF): The patient's LVEF of 14% indicates severe systolic heart failure, which increases the risk of sudden cardiac death. A low LVEF is a well-established predictor of adverse cardiac events, including sudden cardiac death.

2.  Ventricular Extrasystole and Non-sustained Ventricular Tachycardia (NSVT): The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG indicates arrhythmogenic potential. NSVT is a known risk factor for sudden cardiac death, particularly in patients with underlying heart disease.

3.  High Pro-BNP Levels: The patient's elevated Pro-BNP level (553.0 ng/L) suggests significant cardiac stress and strain, which can be a marker for increased risk of sudden cardiac death.

4.  Hypotension and Low Cardiac Output: Although the patient's blood pressure is within a relatively normal range (120/70 mmHg), his cardiac output is likely compromised due to his severe cardiomyopathy and low LVEF. This can lead to reduced perfusion of vital organs and potentially contribute to a life-threatening arrhythmia or cardiac arrest.

5.  Medication Management: While the patient is on medications such as digoxin, loop diuretics, spironolactone, and an ACE inhibitor, these may not be sufficient to adequately manage his severe cardiomyopathy and arrhythmias. The patient's treatment plan may need to be reassessed to consider more aggressive measures to prevent sudden cardiac death.

6.  Underlying Cardiomyopathy: The patient's enolic dilated cardiomyopathy is a known risk factor for sudden cardiac death. The progression of this condition can lead to life-threatening arrhythmias and cardiac arrest.

Considering these factors, the patient's sudden cardiac death is likely a consequence of his underlying severe cardiomyopathy, arrhythmias, and compromised cardiac function."
668,668,P0138,"Age: 68
Gender: Male 
Weight: 67 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 41
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 5,2
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 63
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 126.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,49
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2838.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 26
Troponin (ng/mL): 0,694
TSH (mIU/L): 0,894
Urea (mg/dL): 9,32
LVEF (%): 37.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Torsade de Points
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

This patient's outcome of sudden cardiac death is likely due to a combination of factors, primarily related to his underlying valvular cardiomyopathy and associated complications. The patient's left ventricular ejection fraction (LVEF) of 37% indicates severe left ventricular dysfunction, which increases the risk of sudden cardiac death. 

The presence of non-sustained ventricular tachycardia (NSVT) with a cycle length > 10 beats is a concerning finding, as it suggests that the patient is at risk for developing life-threatening arrhythmias. The polymorphic ventricular extrasystoles and torsades de pointes on the ECG further support this risk. 

Additionally, the patient's elevated Pro-BNP level (2838 ng/L) indicates significant stress on the heart, likely due to the valvular cardiomyopathy. The elevated Troponin level (0.694 ng/mL) suggests myocardial injury, which may be contributing to the patient's risk of sudden cardiac death.

The patient's medication regimen includes beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are standard treatments for heart failure and cardiomyopathy. However, despite these treatments, the patient's condition appears to have progressed to a point where sudden cardiac death occurred.

Other contributing factors may include the patient's low HDL cholesterol level (1.32 mmol/L) and high LDL cholesterol level (3.49 mmol/L), which may be contributing to atherosclerotic disease and further increasing the risk of cardiac events. The patient's low T3 level (0.05 pg/dL) may also be a sign of cardiac cachexia, a condition associated with poor prognosis in heart failure patients.

In summary, the combination of severe left ventricular dysfunction, NSVT, polymorphic ventricular extrasystoles, elevated Pro-BNP, myocardial injury, and the patient's overall clinical presentation likely contributed to the patient's outcome of sudden cardiac death."
669,669,P0148,"Age: 73
Gender: Female 
Weight: 68 kg
Height: 172 cm
NYHA Class: III
Blood Pressure: 130/85 mmHg
Past Medical History: Valvular cardiomyopathy, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 36,7
ALT or GPT (IU/L): 54.0
AST or GOT (IU/L): 62.0
Total Cholesterol (mmol/L): 4,48
Creatinine (mmol/L): 77.0
Gamma-glutamil transpeptidase (IU/L): 78
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 149.0
Potassium (mEq/L): 4,23
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3527.0
Protein (g/L): 75,3
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,08
Urea (mg/dL): 8,5
LVEF (%): 20.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

Given the patient's medical history, including valvular cardiomyopathy, peripheral vascular disease, hypertension, and myocardial infarction, the patient is at high risk for cardiac complications. The presence of non-sustained ventricular tachycardia (VT) on the ECG, as well as a left ventricular ejection fraction (LVEF) of 20%, indicates significant left ventricular dysfunction. 

The elevated Pro-BNP level of 3527.0 ng/L is indicative of heart failure, which is consistent with the patient's NYHA Class III classification. The patient's low albumin level of 36.7 g/L may suggest malnutrition or liver dysfunction, which can contribute to cardiac complications.

The patient's medications, including Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, and ACE Inhibitor, are standard treatments for heart failure and may help manage the patient's symptoms. However, the presence of non-sustained VT and low LVEF suggests that the patient's heart function is severely compromised.

The sudden cardiac death outcome may be attributed to the following factors:

1.  Advanced heart failure: The patient's low LVEF and elevated Pro-BNP level indicate severe heart failure, which increases the risk of sudden cardiac death.
2.  Non-sustained VT: The presence of non-sustained VT on the ECG indicates a high risk of life-threatening arrhythmias, which can lead to sudden cardiac death.
3.  Cardiomyopathy: The patient's valvular cardiomyopathy and low LVEF suggest significant structural heart disease, which increases the risk of cardiac complications, including sudden cardiac death.
4.  Malnutrition: The low albumin level may indicate malnutrition or liver dysfunction, which can contribute to cardiac complications and increase the risk of sudden cardiac death.

In conclusion, the patient's advanced heart failure, non-sustained VT, cardiomyopathy, and potential malnutrition or liver dysfunction all contribute to the high risk of sudden cardiac death."
670,670,P0157,"Age: 76
Gender: Male 
Weight: 70 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Hypertropic cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 38,9
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,13
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 40
Glucose (mmol/L): 8,6
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,26
Potassium (mEq/L): 4,49
LDL (mmol/L): 3,06
Sodium (mEq/L): 134.0
Protein (g/L): 74,9
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,36
Urea (mg/dL): 10,3
LVEF (%): 42.0
Medications: Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

Given the patient's medical history of hypertrophic cardiomyopathy, myocardial infarction, and current symptoms, the patient's reduced left ventricular ejection fraction (LVEF) of 42% suggests that the patient has heart failure with reduced ejection fraction (HFrEF). The presence of non-sustained ventricular tachycardia (VT) and polymorphic ventricular extrasystoles on the ECG further indicates that the patient has a high risk of arrhythmic events.

The patient's high blood pressure (120/70 mmHg) and high creatinine levels (113.0 μmol/L) suggest that the patient may have chronic kidney disease, which is a known risk factor for cardiovascular mortality. Additionally, the patient's low HDL cholesterol (1.26 mmol/L) and high LDL cholesterol (3.06 mmol/L) suggest that the patient has dyslipidemia, which can also contribute to cardiovascular disease.

The patient's troponin level of 0.01 ng/mL is slightly elevated, indicating minor cardiac damage, but not indicative of acute myocardial infarction. However, the patient's past medical history of myocardial infarction and current symptoms suggest that the patient has had previous cardiac damage, which may have contributed to the development of HFrEF.

The patient's medications, including spironolactone, ACE inhibitor, and nitrovasodilator, are appropriate for managing heart failure and hypertension, but may not be sufficient to control the patient's arrhythmic events.

The patient's age (76) and NYHA class II classification suggest that the patient has a moderate level of physical limitation due to heart disease, which may have contributed to the patient's reduced mobility and increased risk of cardiac events.

Considering the patient's complex medical history, reduced LVEF, arrhythmic events, and high risk of cardiac mortality, the patient's outcome of sudden cardiac death is not unexpected. The patient's underlying cardiac conditions and comorbidities likely contributed to the development of life-threatening arrhythmias, which ultimately led to sudden cardiac death."
671,671,P0159,"Age: 81
Gender: Male 
Weight: 65 kg
Height: 158 cm
NYHA Class: III
Blood Pressure: 100/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Peripheral vascular disease
Albumin (g/L): 38,4
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 165.0
Gamma-glutamil transpeptidase (IU/L): 46
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 131.0
Potassium (mEq/L): 2,92
Sodium (mEq/L): 135.0
Protein (g/L): 70,9
T4 (ng/L): 10,1
Troponin (ng/mL): 0,02
TSH (mIU/L): 15,55
Urea (mg/dL): 15,9
LVEF (%): 22.0
Medications: Amiodarone, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

This 81-year-old male patient with a history of idiopathic dilated cardiomyopathy and peripheral vascular disease presents with multiple risk factors contributing to his poor cardiac function. The patient's left ventricular ejection fraction (LVEF) of 22% indicates severe left ventricular dysfunction, which is a hallmark of dilated cardiomyopathy. The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG further suggests an increased risk of sudden cardiac death (SCD).

The patient's low serum potassium level (2.92 mEq/L) may be a contributing factor to the development of arrhythmias, as hypokalemia can predispose to ventricular arrhythmias. Additionally, the patient's TSH level of 15.55 mIU/L suggests subclinical hypothyroidism, which can also contribute to cardiac dysfunction and increased risk of arrhythmias.

The patient's medication regimen includes amiodarone, which is used to prevent arrhythmias, but it can also have pro-arrhythmic effects in certain cases. Loop diuretics may be contributing to the patient's hypokalemia.

The patient's creatinine level of 165.0 μmol/L indicates impaired renal function, which can contribute to the accumulation of toxins and electrolyte imbalances, further increasing the risk of arrhythmias and SCD.

The combination of these factors, including severe left ventricular dysfunction, arrhythmias, hypokalemia, subclinical hypothyroidism, and impaired renal function, increases the patient's risk of sudden cardiac death."
672,672,P0172,"Age: 69
Gender: Female 
Weight: 74 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 120/85 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,45
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 8,1
Hemoglobin (g/L): 131.0
Potassium (mEq/L): 4,61
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1383.0
Protein (g/L): 70,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,43
Urea (mg/dL): 6,1
LVEF (%): 22.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Hydralazine
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

Based on the provided patient data, the patient's outcome of sudden cardiac death is likely due to a combination of factors related to her underlying cardiomyopathy and other comorbidities. 

The patient has idiopathic dilated cardiomyopathy, which is a condition characterized by a weakened heart muscle that cannot pump blood effectively. The patient's left ventricular ejection fraction (LVEF) of 22% indicates severe left ventricular dysfunction, which increases the risk of sudden cardiac death. 

The patient's high Pro-BNP level of 1383 ng/L is also indicative of heart failure, as BNP is a biomarker that is elevated in patients with heart failure. The patient's creatinine level of 94.0 μmol/L suggests impaired renal function, which can further compromise the heart's ability to pump blood effectively.

The patient's use of beta blockers, digoxin, loop diuretics, spironolactone, and hydralazine suggests that she is being managed for heart failure, but the combination of these medications may not have been sufficient to prevent sudden cardiac death. 

Additionally, the patient's polymorphic ventricular extrasystoles on the ECG suggest arrhythmias, which can increase the risk of sudden cardiac death. The patient's high total cholesterol level of 5.45 mmol/L may also contribute to the development of atherosclerosis, which can further compromise cardiac function.

The patient's low potassium level of 4.61 mEq/L may also have contributed to her cardiac arrhythmias and increased the risk of sudden cardiac death. The patient's TSH level of 2.43 mIU/L is within the normal range, which suggests that hyperthyroidism is unlikely to be a contributing factor.

Overall, the patient's combination of severe cardiomyopathy, heart failure, impaired renal function, arrhythmias, and high cholesterol levels likely contributed to her sudden cardiac death."
673,673,P0176,"Age: 78
Gender: Male 
Weight: 64 kg
Height: 158 cm
NYHA Class: III
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,1
Creatinine (mmol/L): 186.0
Gamma-glutamil transpeptidase (IU/L): 46
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 3,8
LDL (mmol/L): 1,53
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 4853.0
Protein (g/L): 83
T3 (pg/dL): 0,05
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 7,37
Urea (mg/dL): 24,13
LVEF (%): 36.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of several factors based on the provided data.

1.  Ischemic dilated cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and enlarged due to a heart attack or coronary artery disease. This condition can lead to reduced heart function, increasing the risk of sudden cardiac death.

2.  Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 36%, which is significantly below the normal range of 55-70%. A low LVEF indicates that the heart is not pumping efficiently, making it harder for the body to get the blood it needs, increasing the risk of cardiac complications, including sudden cardiac death.

3.  High Pro-BNP levels: The patient's Pro-BNP level is 4853.0 ng/L, which is significantly elevated. BNP is a hormone produced by the heart when it is under strain. High levels of BNP can indicate heart failure, which increases the risk of sudden cardiac death.

4.  History of Myocardial Infarction: The patient has a history of myocardial infarction, which can lead to scarring of the heart muscle, further reducing its pumping efficiency and increasing the risk of cardiac arrhythmias and sudden cardiac death.

5.  Ventricular Extrasystole and Non-sustained Ventricular Tachycardia: The ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which can be indicative of abnormal heart rhythms that can lead to sudden cardiac death.

6.  Low Hemoglobin and Potassium levels: The patient's hemoglobin level is 132.0 g/L, which is slightly below the normal range. Low hemoglobin levels can lead to reduced oxygen delivery to the heart muscle, increasing the risk of cardiac complications. The patient's potassium level is also low at 3.8 mEq/L, which can increase the risk of arrhythmias and cardiac arrest.

7.  Electrolyte imbalance: The patient's electrolyte levels, particularly potassium, are not within the normal range, which can contribute to abnormal heart rhythms and increase the risk of sudden cardiac death.

8.  TSH level: The patient's TSH level is elevated at 7.37 mIU/L, which can indicate hypothyroidism. Hypothyroidism can lead to decreased cardiac function and increased risk of cardiac complications.

In summary, the patient's outcome of sudden cardiac death can be attributed to a combination of his underlying heart condition (ischemic dilated cardiomyopathy), low LVEF, high Pro-BNP levels, history of myocardial infarction, abnormal ECG findings, electrolyte imbalance, and potential hypothyroidism."
674,674,P0183,"Age: 45
Gender: Male 
Weight: 120 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 206
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,4
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 2037.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 27
TSH (mIU/L): 2,87
Urea (mg/dL): 8,65
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

This patient's outcome of sudden cardiac death can be attributed to several factors present in the patient's data. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers dilate due to previous heart attacks or coronary artery disease. This condition can lead to reduced left ventricular ejection fraction (LVEF), which in this case is 30.0%, indicating severe left ventricular dysfunction.

The patient's LVEF of 30.0% is significantly reduced, indicating a high risk of sudden cardiac death. The normal LVEF range is typically above 55-60%. The patient's LVEF is below this range, indicating a high risk of cardiac arrhythmias and sudden cardiac death.

Additionally, the patient's pro-BNP level is 2037.0 ng/L, which is significantly elevated. Pro-BNP is a marker of cardiac stress and is often used to diagnose heart failure. Elevated pro-BNP levels are associated with increased risk of sudden cardiac death.

The patient's ECG also shows a monomorphic ventricular extrasystole, which is an abnormal heart rhythm that can be a precursor to ventricular tachycardia or other life-threatening arrhythmias.

Furthermore, the patient's low hemoglobin level of 143.0 g/L may indicate anemia, which can exacerbate heart failure and increase the risk of sudden cardiac death.

The patient's medication regimen includes beta blockers, loop diuretics, spironolactone, statins, and ACE inhibitors, which are standard treatments for heart failure and ischemic dilated cardiomyopathy. However, despite these treatments, the patient's condition has progressed to sudden cardiac death.

In conclusion, the patient's combination of ischemic dilated cardiomyopathy, severely reduced LVEF, elevated pro-BNP, abnormal ECG findings, and low hemoglobin level all contributed to the risk of sudden cardiac death, ultimately leading to this tragic outcome."
675,675,P0187,"Age: 72
Gender: Male 
Weight: 82 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,52
Creatinine (mmol/L): 146.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 150.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,54
LDL (mmol/L): 1,89
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 3362.0
Protein (g/L): 84,7
T4 (ng/L): 17
Troponin (ng/mL): 0,09
TSH (mIU/L): 18,16
Urea (mg/dL): 15,6
LVEF (%): 22.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of several factors, including the patient's advanced age, severe left ventricular dysfunction, and a history of ischemic dilated cardiomyopathy. The patient's ejection fraction (LVEF) is severely reduced at 22%, indicating poor heart function and a high risk of cardiac arrhythmias and sudden cardiac death.

The presence of non-sustained ventricular tachycardia (NSVT) on the ECG is a significant risk factor for sudden cardiac death. NSVT is a known predictor of sudden cardiac death in patients with heart failure and reduced ejection fraction. The fact that the patient has a history of myocardial infarction and ischemic dilated cardiomyopathy further increases the risk of arrhythmias and sudden cardiac death.

The patient's elevated Pro-BNP (brain natriuretic peptide) level of 3362.0 ng/L is indicative of severe heart failure, which is a known risk factor for sudden cardiac death. Additionally, the patient's low hemoglobin level (150.0 g/L) may indicate anemia, which can further compromise cardiac function and increase the risk of cardiac arrhythmias.

The patient's medication regimen, which includes angiotensin II receptor blockers, beta blockers, digoxin, loop diuretics, and spironolactone, is consistent with the treatment of heart failure and may be aimed at reducing symptoms and slowing disease progression. However, despite this treatment, the patient's condition appears to have progressed to a point where sudden cardiac death occurred.

In conclusion, the patient's advanced age, severe left ventricular dysfunction, history of ischemic dilated cardiomyopathy, NSVT on the ECG, elevated Pro-BNP level, and anemia all contributed to the patient's outcome of sudden cardiac death."
676,676,P0215,"Age: 82
Gender: Male 
Weight: 82 kg
Height: 166 cm
NYHA Class: III
Blood Pressure: 170/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 7,45
Creatinine (mmol/L): 114.0
Gamma-glutamil transpeptidase (IU/L): 58
Glucose (mmol/L): 12,2
Hemoglobin (g/L): 153.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,43
LDL (mmol/L): 2,4
Sodium (mEq/L): 132.0
Pro-BNP (ng/L): 410.0
Protein (g/L): 80
T3 (pg/dL): 0,06
T4 (ng/L): 17,46
Troponin (ng/mL): 1
TSH (mIU/L): 1,18
Urea (mg/dL): 10
LVEF (%): 65.0
Medications: Calcium Channel Blocker, Diabetes Medication, Digoxin, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of several factors present in their medical history and laboratory results. 

1.  Hypertensive cardiomyopathy: The patient has a history of hypertensive cardiomyopathy, which is a condition where high blood pressure damages the heart muscle, leading to reduced cardiac function. This condition increases the risk of arrhythmias and sudden cardiac death.

2.  Reduced Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 65%, which is below the normal range (50-70%). This indicates that the left ventricle is not pumping efficiently, which can lead to reduced cardiac output and increased risk of arrhythmias.

3.  High Blood Pressure: The patient's blood pressure is 170/70 mmHg, which is above the normal range. Uncontrolled hypertension can lead to cardiac remodeling and fibrosis, further increasing the risk of arrhythmias and sudden cardiac death.

4.  Diabetes: The patient has diabetes, which is a significant risk factor for cardiovascular disease, including sudden cardiac death. Diabetes can cause damage to the heart muscle and blood vessels, leading to reduced cardiac function and increased risk of arrhythmias.

5.  Electrocardiogram (ECG) Findings: The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia. These arrhythmias can be a sign of underlying cardiac disease and increase the risk of sudden cardiac death.

6.  Elevated Troponin Levels: The patient's troponin level is elevated at 1 ng/mL, which indicates cardiac damage or injury. Elevated troponin levels are associated with an increased risk of arrhythmias and sudden cardiac death.

7.  Reduced Potassium Levels: The patient's potassium level is 4.43 mEq/L, which is below the normal range. Low potassium levels can lead to arrhythmias, including ventricular tachycardia, which can increase the risk of sudden cardiac death.

8.  Medication Non-Adherence or Insufficient Dosing: Although the patient is on several medications, including a calcium channel blocker, diabetes medication, digoxin, loop diuretics, spironolactone, and nitrovasodilator, it is essential to consider the possibility of non-adherence or insufficient dosing, which may have contributed to the patient's outcome.

In conclusion, the patient's sudden cardiac death can be attributed to a combination of their underlying medical conditions, including hypertensive cardiomyopathy, diabetes, and reduced LVEF, along with ECG findings and laboratory results indicating cardiac damage and arrhythmias."
677,677,P0217,"Age: 79
Gender: Male 
Weight: 94 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,79
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 10,95
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,3
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,58
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 1825.0
Protein (g/L): 77
T3 (pg/dL): 0,0372
T4 (ng/L): 18,5
TSH (mIU/L): 3,2
Urea (mg/dL): 14,6
LVEF (%): 30.0
Medications: Diabetes Medication, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

Given the patient's age (79) and past medical history of ischemic dilated cardiomyopathy, myocardial infarction, and peripheral vascular disease, the patient has a high risk of cardiac complications. The patient's LVEF of 30.0% indicates severe left ventricular dysfunction, which increases the risk of sudden cardiac death.

The patient's elevated Pro-BNP level (1825.0 ng/L) suggests that the patient has significant cardiac stress and strain, likely due to the reduced LVEF and possibly due to the presence of heart failure symptoms (indicated by NYHA Class II).

The presence of ventricular extrasystoles and non-sustained ventricular tachycardia (VT) on the ECG indicates that the patient has arrhythmogenic potential, which can lead to sudden cardiac death. The fact that the VT is non-sustained suggests that it may be a harbinger of a more severe arrhythmia that could potentially lead to sudden cardiac death.

The patient's total cholesterol level of 5.79 mmol/L is elevated, which may contribute to the progression of atherosclerosis and increase the risk of cardiac complications.

The patient's glucose level of 10.95 mmol/L indicates poorly controlled diabetes, which can contribute to cardiovascular disease and increase the risk of cardiac complications.

The patient's medications, including spironolactone and an ACE inhibitor, are appropriate for managing heart failure and hypertension, but may not be sufficient to manage the patient's high risk of sudden cardiac death.

Considering the combination of these factors, the patient's high risk of cardiac complications, and the presence of arrhythmogenic potential, the patient's outcome of sudden cardiac death is not unexpected."
678,678,P0218,"Age: 68
Gender: Male 
Weight: 80 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,15
Creatinine (mmol/L): 136.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5,06
Hemoglobin (g/L): 154.0
HDL (mmol/L): 1
Potassium (mEq/L): 4,17
LDL (mmol/L): 2,49
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 4058.0
Protein (g/L): 68
T3 (pg/dL): 0,0471
T4 (ng/L): 16,72
Troponin (ng/mL): 0,2
TSH (mIU/L): 2,17
Urea (mg/dL): 6,4
LVEF (%): 20.0
Medications: ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: The patient's sudden cardiac death can be attributed to a combination of factors, primarily related to their underlying heart condition and laboratory results. 

1. Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is significantly reduced at 20%, indicating severe systolic heart failure. This is a strong predictor of increased mortality and sudden cardiac death.

2. High Pro-BNP levels: The patient's Pro-BNP level is elevated at 4058.0 ng/L, which is indicative of severe heart failure. Elevated Pro-BNP levels are associated with increased risk of adverse cardiovascular events, including sudden cardiac death.

3. Ventricular Extrasystole: The presence of polymorphic ventricular extrasystoles on the ECG suggests abnormal electrical activity in the heart, which may be a sign of underlying cardiac disease or electrolyte imbalance. This can increase the risk of arrhythmias, including ventricular tachycardia, which can lead to sudden cardiac death.

4. Electrolyte Imbalance: The patient's potassium level is slightly low at 4.17 mEq/L. Hypokalemia can predispose to arrhythmias and increase the risk of sudden cardiac death.

5. Idiopathic Dilated Cardiomyopathy: The patient's underlying condition of idiopathic dilated cardiomyopathy further increases the risk of sudden cardiac death. This condition is characterized by the dilation and weakening of the heart muscle, leading to reduced cardiac function and increased risk of arrhythmias.

6. Medication Non-Optimization: Although the patient is taking an ACE inhibitor, which is a standard treatment for heart failure, the medication may not be sufficient to control the patient's symptoms and prevent sudden cardiac death.

In summary, the combination of the patient's severe heart failure, high Pro-BNP levels, ventricular extrasystoles, electrolyte imbalance, underlying cardiomyopathy, and potential medication non-optimization likely contributed to their sudden cardiac death."
679,679,P0221,"Age: 64
Gender: Male 
Weight: 80 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 100/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 39,7
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,13
Creatinine (mmol/L): 200.0
Gamma-glutamil transpeptidase (IU/L): 47
Glucose (mmol/L): 10,67
Hemoglobin (g/L): 146.0
HDL (mmol/L): 0,9
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,33
Sodium (mEq/L): 132.0
Pro-BNP (ng/L): 2365.0
Protein (g/L): 75
T3 (pg/dL): 0,0312
T4 (ng/L): 15,14
Troponin (ng/mL): 0,5
TSH (mIU/L): 0,77
Urea (mg/dL): 29,3
LVEF (%): 40.0
Medications: Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of his underlying cardiac conditions, laboratory results, and ECG findings. 

1.  Ischemic dilated cardiomyopathy: This condition, coupled with a left ventricular ejection fraction (LVEF) of 40%, indicates significant left ventricular dysfunction. Ischemic cardiomyopathy is a well-known risk factor for sudden cardiac death due to the potential for ventricular arrhythmias and decreased cardiac reserve.

2.  Non-sustained ventricular tachycardia (NSVT): The presence of NSVT on the ECG is a known risk factor for sudden cardiac death. NSVT is often a marker of underlying ventricular arrhythmogenicity, and in patients with structural heart disease like ischemic cardiomyopathy, it increases the risk of life-threatening arrhythmias.

3.  Polymorphic ventricular extrasystoles: This finding on the ECG also indicates an abnormality in the ventricular electrical conduction system. Polymorphic extrasystoles can be a sign of an unstable myocardium, which may predispose the patient to life-threatening arrhythmias.

4.  High Pro-BNP levels (2365.0 ng/L): Elevated B-type natriuretic peptide (BNP) levels are associated with increased ventricular stress and decreased cardiac function. High levels of BNP have been linked to an increased risk of sudden cardiac death in patients with heart failure.

5.  Electrolyte imbalance: Although not significantly abnormal, the patient's potassium level (4.8 mEq/L) is slightly low. Hypokalemia can predispose patients to arrhythmias, including ventricular tachycardia and fibrillation.

6.  Medications: The patient is on loop diuretics, spironolactone, statins, ACE inhibitors, and nitrovasodilators. While these medications are commonly used in heart failure management, they may also contribute to electrolyte imbalances, particularly hypokalemia, which can increase the risk of arrhythmias.

7.  Underlying comorbidities: The patient's history of diabetes, dyslipidemia, and myocardial infarction further increases his risk of cardiovascular complications, including sudden cardiac death.

Given these factors, the patient's outcome of sudden cardiac death is likely the result of a combination of his underlying cardiac conditions, the presence of arrhythmogenic ECG findings, and potential electrolyte imbalances, all of which increased his risk of life-threatening arrhythmias."
680,680,P0243,"Age: 35
Gender: Male 
Weight: 92 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,26
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4
LDL (mmol/L): 1,97
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 10297.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 15
TSH (mIU/L): 2,54
Urea (mg/dL): 6,32
LVEF (%): 40.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

Given the patient's medical history of idiopathic dilated cardiomyopathy, which is characterized by a weakened heart muscle leading to reduced left ventricular ejection fraction (LVEF), the patient's LVEF of 40% indicates a significant impairment in cardiac function. The presence of non-sustained ventricular tachycardia (VT) and polymorphic ventricular extrasystoles on the ECG further indicates arrhythmia and electrical instability in the heart. 

The elevated Pro-BNP (brain natriuretic peptide) level of 10297 ng/L suggests an increased stress on the heart, which is consistent with heart failure. The patient's low T3 (0.05 pg/dL) and normal T4 (15 ng/L) levels, along with a slightly elevated TSH (2.54 mIU/L), suggest euthyroid sick syndrome, a common finding in patients with severe heart failure.

The patient's medication regimen includes beta blockers, digoxin, loop diuretics, spironolactone, and ACE inhibitors, which are standard treatments for heart failure and arrhythmias. However, the presence of sudden cardiac death as the patient outcome suggests that these medications may not have been effective in stabilizing the patient's cardiac function.

The patient's age of 35 is relatively young for sudden cardiac death, which suggests that the underlying cardiomyopathy may be particularly aggressive or that there may be an underlying genetic component. The presence of ventricular tachycardia and extrasystoles indicates a high risk of sudden cardiac death, which is a known complication of dilated cardiomyopathy.

In conclusion, the patient's outcome of sudden cardiac death can be attributed to the combination of idiopathic dilated cardiomyopathy, arrhythmia, and heart failure, which likely overwhelmed the patient's cardiac function despite treatment with standard medications."
681,681,P0261,"Age: 40
Gender: Male 
Weight: 82 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 37,6
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 4,5
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 236
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,95
Potassium (mEq/L): 3,32
LDL (mmol/L): 3,02
Sodium (mEq/L): 131.0
Pro-BNP (ng/L): 2598.0
Protein (g/L): 73,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,39
Urea (mg/dL): 1,8
LVEF (%): 19.0
Medications: Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of several factors based on the provided data. 

Firstly, the patient has a history of enolic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge, reducing its ability to pump blood effectively. This condition is often associated with a poor prognosis and increased risk of sudden cardiac death.

Secondly, the patient's left ventricular ejection fraction (LVEF) is severely reduced at 19.0%, indicating that the heart is not pumping blood efficiently. This further supports the diagnosis of dilated cardiomyopathy and increases the risk of sudden cardiac death.

Thirdly, the patient has a high level of B-type natriuretic peptide (BNP) at 2598.0 ng/L, which is a marker of heart failure and cardiac stress. Elevated BNP levels are associated with increased mortality and morbidity in patients with heart failure.

Additionally, the patient's electrocardiogram (ECG) shows polymorphic ventricular extrasystoles, which are abnormal heart rhythms that can increase the risk of arrhythmias and sudden cardiac death.

Furthermore, the patient's past medical history includes a myocardial infarction, which can lead to scarring of the heart muscle and further reduce its pumping function. The patient's hypertension and elevated LDL cholesterol levels may also contribute to the progression of cardiovascular disease and increase the risk of sudden cardiac death.

Lastly, the patient's medications, while intended to manage heart failure and hypertension, may not be sufficient to mitigate the underlying risk factors for sudden cardiac death.

Considering these factors, the patient's outcome of sudden cardiac death is likely due to the combination of dilated cardiomyopathy, reduced LVEF, elevated BNP, abnormal ECG findings, and a history of myocardial infarction, all of which increase the risk of arrhythmias and sudden cardiac death."
682,682,P0262,"Age: 58
Gender: Female 
Weight: 61 kg
Height: 145 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Valvular cardiomyopathy, Myocardial Infarction
Albumin (g/L): 38,2
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 50.0
Total Cholesterol (mmol/L): 3,98
Creatinine (mmol/L): 110.0
Gamma-glutamil transpeptidase (IU/L): 330
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 121.0
HDL (mmol/L): 0,92
Potassium (mEq/L): 4,12
LDL (mmol/L): 2,72
Sodium (mEq/L): 142.0
Protein (g/L): 73,6
T4 (ng/L): 15,3
Troponin (ng/mL): 0,01
TSH (mIU/L): 8,26
Urea (mg/dL): 10
LVEF (%): 25.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death is likely due to a combination of several factors, including her underlying valvular cardiomyopathy, previous myocardial infarction, and severely reduced left ventricular ejection fraction (LVEF) of 25%. The patient's NYHA Class III classification indicates that she experiences symptoms of heart failure, such as shortness of breath and fatigue, which can be exacerbated by her reduced LVEF.

The patient's elevated troponin level of 0.01 ng/mL, although within normal limits, may indicate ongoing cardiac damage or stress. Additionally, her elevated gamma-glutamyl transpeptidase (GGT) level of 330 IU/L suggests possible liver dysfunction, which can be a consequence of chronic heart failure. The elevated AST and ALT levels further support this notion.

The patient's ECG findings, including polymorphic ventricular extrasystoles, non-sustained ventricular tachycardia, and unknown paroxysmal supraventricular tachyarrhythmia, indicate an increased risk of arrhythmias. The presence of these arrhythmias, coupled with her reduced LVEF, may have increased the risk of sudden cardiac death.

The patient's medications, including amiodarone, beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, are commonly used to manage heart failure and arrhythmias. However, the patient's outcome suggests that these medications may not have been sufficient to mitigate her risk of sudden cardiac death.

The patient's elevated TSH level of 8.26 mIU/L may indicate hypothyroidism, which can contribute to heart failure and worsen the patient's prognosis.

In summary, the patient's outcome of sudden cardiac death is likely due to a combination of her underlying heart disease, reduced LVEF, arrhythmias, and possible liver dysfunction, which may have contributed to her overall poor cardiac health and increased risk of sudden cardiac death."
683,683,P0266,"Age: 68
Gender: Female 
Weight: 74 kg
Height: 136 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Hypertropic cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39,8
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 32.0
Total Cholesterol (mmol/L): 5,21
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 62
Glucose (mmol/L): 4,1
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,18
Potassium (mEq/L): 4,15
LDL (mmol/L): 3,4
Sodium (mEq/L): 133.0
Protein (g/L): 76,7
Troponin (ng/mL): 0,02
TSH (mIU/L): 4
Urea (mg/dL): 10,7
LVEF (%): 70.0
Medications: Amiodarone, Loop Diuretics, Spironolactone, Statins, Hydralazine, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

Given the patient's history of hypertrophic cardiomyopathy, myocardial infarction, and current NYHA Class III classification, the patient is at a high risk for sudden cardiac death. The presence of polymorphic ventricular extrasystoles on the ECG further increases this risk. Although the patient's LVEF is within a relatively normal range (70%), the combination of these risk factors and the patient's age (68 years) puts them at a high risk for sudden cardiac death.

Additionally, the patient's laboratory results show elevated levels of gamma-glutamil transpeptidase (GGT), which may indicate liver enzyme elevation, possibly due to the statin therapy or other medications. However, the patient's liver function tests (ALT and AST) are within normal limits. The elevated GGT level may be a marker of statin-induced liver injury, which is a known side effect of long-term statin therapy.

The patient's medications, including Amiodarone, Loop Diuretics, Spironolactone, Statins, Hydralazine, and ACE Inhibitor, are all commonly used in the management of heart failure and hypertension. However, the combination of these medications may increase the risk of arrhythmias, including polymorphic ventricular extrasystoles, which can contribute to sudden cardiac death.

The patient's low HDL cholesterol level (1.18 mmol/L) and elevated LDL cholesterol level (3.4 mmol/L) indicate a high risk for cardiovascular disease, which may contribute to the patient's risk for sudden cardiac death.

In summary, the combination of the patient's history of hypertrophic cardiomyopathy, myocardial infarction, polymorphic ventricular extrasystoles on the ECG, and the patient's age and medication regimen, all contribute to the high risk of sudden cardiac death."
684,684,P0271,"Age: 77
Gender: Male 
Weight: 70 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 167.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 6
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,13
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 962.0
Protein (g/L): 74,6
T3 (pg/dL): 0,045
T4 (ng/L): 17,49
Troponin (ng/mL): 0,4
TSH (mIU/L): 1,76
Urea (mg/dL): 17,7
LVEF (%): 35.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of several factors. 

1.  Ischemic dilated cardiomyopathy: The patient's history of ischemic dilated cardiomyopathy indicates that their heart muscle has been damaged due to reduced blood flow, leading to a weakened heart. This condition increases the risk of arrhythmias, heart failure, and sudden cardiac death.

2.  Low LVEF (35.0%): The patient's left ventricular ejection fraction (LVEF) is significantly reduced, indicating that the heart is not pumping efficiently. This is a strong predictor of increased risk of sudden cardiac death.

3.  High Pro-BNP (962.0 ng/L): Elevated levels of B-type natriuretic peptide (BNP) indicate that the heart is under strain, which can lead to increased risk of sudden cardiac death.

4.  ECG findings: The presence of monomorphic ventricular extrasystoles on the ECG suggests abnormal electrical activity in the heart, which can increase the risk of arrhythmias and sudden cardiac death.

5.  Sinus Node Dysfunction: Bradycardia due to sinus node dysfunction indicates that the heart's natural pacemaker is not functioning properly, which can lead to an increased risk of arrhythmias and sudden cardiac death.

6.  Medication non-adherence or inadequate treatment: The patient is taking medications such as digoxin, loop diuretics, statins, and ACE inhibitors, but it is unclear if these medications are being taken as prescribed. Inadequate treatment or non-adherence can lead to a higher risk of cardiac complications, including sudden cardiac death.

7.  Advanced age (77 years): The patient's age is a significant risk factor for sudden cardiac death.

Considering these factors, the patient's outcome of sudden cardiac death is likely due to a combination of their underlying heart condition, reduced LVEF, high BNP levels, abnormal ECG findings, and potential medication non-adherence or inadequate treatment."
685,685,P0280,"Age: 70
Gender: Female 
Weight: 63 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 160/60 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,87
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 28
Glucose (mmol/L): 19,1
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,66
Potassium (mEq/L): 4,91
LDL (mmol/L): 3,18
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 327.0
Protein (g/L): 73,6
T3 (pg/dL): 0,0504
T4 (ng/L): 18,13
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,21
Urea (mg/dL): 12
LVEF (%): 66.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

Based on the provided patient data, the patient's age (70) and past medical history of Hypertensive cardiomyopathy and Hypertension are significant risk factors for cardiovascular disease. The patient's blood pressure is elevated (160/60 mmHg), which is a common finding in patients with hypertensive cardiomyopathy. 

The patient's creatinine level (99.0 μmol/L) indicates impaired renal function, which is a common complication of chronic hypertension and cardiomyopathy. The elevated Pro-BNP (327.0 ng/L) level suggests that the patient has heart failure, which is consistent with the patient's LVEF (66.0%) and history of Hypertensive cardiomyopathy.

The patient's glucose level (19.1 mmol/L) indicates poorly controlled diabetes, which is a significant risk factor for cardiovascular disease. The patient's lipid profile shows a high total cholesterol level (5.87 mmol/L) and low HDL level (1.66 mmol/L), further increasing the risk of cardiovascular disease.

The patient's ECG shows monomorphic ventricular extrasystoles, which is a common finding in patients with cardiomyopathy. However, the absence of other significant ECG abnormalities, such as non-sustained ventricular tachycardia or bradycardia, suggests that the patient's sudden cardiac death was likely due to an arrhythmic event.

The patient's medications, including beta blockers, loop diuretics, and ACE inhibitors, are standard treatments for heart failure and hypertension. However, the patient's poorly controlled diabetes and hypertension, combined with the presence of cardiomyopathy, created a high-risk environment for sudden cardiac death.

Given the patient's high-risk profile and the presence of monomorphic ventricular extrasystoles on ECG, it is likely that the patient's sudden cardiac death was due to a ventricular arrhythmia, such as ventricular tachycardia or ventricular fibrillation, which was triggered by the patient's underlying cardiomyopathy and poorly controlled comorbidities."
686,686,P0289,"Age: 61
Gender: Male 
Weight: 84 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 58.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 4,28
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 4,59
Hemoglobin (g/L): 147.0
HDL (mmol/L): 1,2
Potassium (mEq/L): 3,7
LDL (mmol/L): 2,7
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 642.0
Protein (g/L): 72
T3 (pg/dL): 0,0573
T4 (ng/L): 14,27
Troponin (ng/mL): 0,5
TSH (mIU/L): 2,99
Urea (mg/dL): 5,4
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death is likely due to a combination of factors related to his underlying heart condition and other comorbidities. The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and enlarged due to a heart attack or prolonged high blood pressure, leading to reduced heart function. The patient's left ventricular ejection fraction (LVEF) of 40% indicates that his heart is not pumping efficiently, which increases the risk of sudden cardiac death.

The patient's high levels of troponin (0.5 ng/mL) suggest that he has had a recent myocardial infarction, which can further weaken the heart muscle and increase the risk of arrhythmias and sudden cardiac death. The presence of ventricular extrasystoles on the ECG, particularly polymorphic, indicates abnormal heart rhythms that can be a precursor to life-threatening arrhythmias.

The patient's elevated levels of pro-BNP (642 ng/L) are also indicative of heart failure, which is consistent with his dilated cardiomyopathy diagnosis. Additionally, his low levels of HDL cholesterol (1.2 mmol/L) and high levels of LDL cholesterol (2.7 mmol/L) contribute to the development of atherosclerosis, which can further compromise cardiac function.

The patient's history of hypertension and myocardial infarction, along with his current medications (beta blockers, loop diuretics, ACE inhibitor, and nitrovasodilator), suggest that he has had significant cardiovascular disease. The combination of these factors, particularly the weakened heart muscle and recent myocardial infarction, increases the risk of sudden cardiac death.

The patient's ECG also shows a paroxysmal supraventricular tachyarrhythmia (PSVT), which can be a risk factor for sudden cardiac death. The presence of bradycardia is not noted, which might be a protective factor against sudden cardiac death.

In summary, the patient's outcome of sudden cardiac death is likely due to a combination of his underlying heart condition, recent myocardial infarction, high levels of troponin, ventricular extrasystoles, and elevated pro-BNP levels, which all contribute to an increased risk of life-threatening arrhythmias and cardiac arrest."
687,687,P0322,"Age: 67
Gender: Male 
Weight: 73 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 85/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,5
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 79
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,8
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3736.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,04
Urea (mg/dL): 6,01
LVEF (%): 25.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of several factors from the provided data. 

Firstly, the patient's history of ischemic dilated cardiomyopathy and myocardial infarction indicates that the patient has a history of significant cardiac damage, which has likely led to reduced left ventricular function, as evidenced by a left ventricular ejection fraction (LVEF) of 25%. This reduced LVEF increases the risk of sudden cardiac death.

Secondly, the patient's elevated Pro-BNP (B-type natriuretic peptide) level of 3736 ng/L is indicative of increased ventricular wall stress, which is often seen in patients with heart failure and dilated cardiomyopathy. This further supports the patient's poor cardiac function.

Thirdly, the presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG suggests an increased risk of malignant arrhythmias, which can lead to sudden cardiac death. 

Additionally, the patient's low blood pressure (85/60 mmHg) and low hemoglobin level (149 g/L) may indicate reduced cardiac output and possibly decreased perfusion of vital organs, which can further increase the risk of sudden cardiac death.

Lastly, the patient's age of 67 years and NYHA Class III classification indicate a significant level of cardiac dysfunction, which increases the risk of sudden cardiac death.

Considering these factors, the patient's outcome of sudden cardiac death can be attributed to a combination of reduced cardiac function, increased risk of arrhythmias, and other comorbid conditions that ultimately led to a fatal cardiac event."
688,688,P0327,"Age: 76
Gender: Male 
Weight: 74 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 140/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 50,19
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 3,93
Creatinine (mmol/L): 125.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 9,2
Hemoglobin (g/L): 120.0
HDL (mmol/L): 0,65
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,25
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 3065.0
Protein (g/L): 78
T3 (pg/dL): 0,02
T4 (ng/L): 21
Troponin (ng/mL): 0,05
TSH (mIU/L): 10,5
Urea (mg/dL): 8,69
LVEF (%): 36.0
Medications: Diabetes Medication, Amiodarone, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death is likely due to a combination of several factors, primarily related to his underlying cardiac conditions and laboratory results. 

1. Ischemic dilated cardiomyopathy: The patient's left ventricular ejection fraction (LVEF) is severely reduced at 36%, indicating a significant impairment of the heart's ability to pump blood efficiently. This condition increases the risk of sudden cardiac death.

2. Myocardial Infarction: The patient's history of myocardial infarction (heart attack) suggests previous damage to the heart muscle, which can lead to scarring and further weakening of the heart, increasing the risk of sudden cardiac death.

3. Pro-BNP levels: The patient's Pro-BNP (N-terminal pro b-type natriuretic peptide) level of 3065.0 ng/L is significantly elevated, indicating increased stress on the heart, often associated with heart failure and increased risk of sudden cardiac death.

4. Ventricular Extrasystole: The presence of monomorphic ventricular extrasystoles on the ECG suggests abnormal electrical activity in the heart, which can be a sign of underlying cardiac disease and may contribute to the risk of sudden cardiac death.

5. Medications: While the patient is on various medications, including beta-blockers, ACE inhibitors, and digoxin, which are typically used to manage heart failure and prevent sudden cardiac death, the combination of his underlying conditions and laboratory results may have outweighed the protective effects of these medications.

6. Other factors: The patient's age (76 years) and NYHA Class II classification, indicating moderate symptoms of heart failure, also contribute to his increased risk of sudden cardiac death.

In conclusion, the patient's outcome of sudden cardiac death is likely the result of a complex interplay between his ischemic dilated cardiomyopathy, previous myocardial infarction, elevated Pro-BNP levels, ventricular extrasystoles, and other contributing factors."
689,689,P0330,"Age: 82
Gender: Male 
Weight: 60 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 47,69
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,12
Creatinine (mmol/L): 127.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,26
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1414.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,96
Urea (mg/dL): 10,24
LVEF (%): 24.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death is likely due to a combination of several factors that have contributed to his high risk of cardiac events. 

1.  Ischemic dilated cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to previous heart attacks, leading to a decrease in the heart's pumping efficiency. This condition is a significant risk factor for sudden cardiac death.

2.  Low LVEF (Left Ventricular Ejection Fraction): The patient's LVEF is 24%, which is significantly below the normal range of 50-70%. A low LVEF indicates that the heart is not pumping efficiently, which can lead to a decrease in cardiac output and increase the risk of sudden cardiac death.

3.  Elevated Pro-BNP: The patient's Pro-BNP level is 1414.0 ng/L, which is significantly elevated. Pro-BNP is a marker of cardiac stress and can indicate heart failure. Elevated levels are associated with increased risk of cardiac events, including sudden cardiac death.

4.  Ventricular Extrasystole: The patient has polymorphic ventricular extrasystoles on his ECG, which can be a sign of abnormal heart rhythm and increased risk of cardiac arrhythmias. While not necessarily a direct cause of sudden cardiac death, it may contribute to the overall risk.

5.  Medication non-adherence or inadequate dosing: The patient is on medications such as beta blockers, loop diuretics, ACE inhibitors, and nitrovasodilators. However, there is no information provided about the dosage or adherence to these medications. Inadequate dosing or non-adherence can lead to decreased efficacy and increased risk of cardiac events.

6.  Age and comorbidities: The patient is 82 years old and has multiple comorbidities, including hypertension, myocardial infarction, and elevated creatinine levels. Older age and comorbidities can increase the risk of cardiac events and sudden cardiac death.

In conclusion, the patient's outcome of sudden cardiac death is likely due to a combination of his underlying ischemic dilated cardiomyopathy, low LVEF, elevated Pro-BNP, ventricular extrasystoles, and potentially inadequate medication management, all of which have contributed to his high risk of cardiac events."
690,690,P0332,"Age: 63
Gender: Male 
Weight: 80 kg
Height: 178 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 41,4
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 9.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 184.0
Gamma-glutamil transpeptidase (IU/L): 54
Glucose (mmol/L): 9,5
Hemoglobin (g/L): 113.0
HDL (mmol/L): 0,8
Potassium (mEq/L): 5,1
LDL (mmol/L): 2,82
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 7692.0
Protein (g/L): 74
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,06
TSH (mIU/L): 3
Urea (mg/dL): 20,7
LVEF (%): 35.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to several factors based on the provided data. The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack, leading to a decrease in the left ventricular ejection fraction (LVEF). The patient's LVEF is significantly low at 35%, indicating severe left ventricular dysfunction. This is a strong predictor of increased risk of sudden cardiac death.

Additionally, the patient's elevated Pro-BNP (Brain Natriuretic Peptide) level of 7692.0 ng/L is indicative of severe heart failure and increased ventricular wall stress. Elevated Pro-BNP levels are associated with a higher risk of sudden cardiac death.

The patient's past medical history of myocardial infarction also increases the risk of sudden cardiac death, as previous heart attacks can lead to the formation of scar tissue in the heart, which can cause abnormal heart rhythms and sudden death.

The presence of ventricular extrasystoles, although polymorphic, is also a concerning finding, as it can be a marker of underlying cardiac disease. The patient's medication regimen, which includes beta blockers, loop diuretics, statins, ACE inhibitors, and nitrovasodilators, is typical for heart failure management but may not have been sufficient to prevent sudden cardiac death in this case.

The patient's laboratory results, including the elevated glucose level (9.5 mmol/L) and low HDL cholesterol level (0.8 mmol/L), suggest underlying metabolic and lipid disorders that may have contributed to the development of cardiovascular disease.

In conclusion, the combination of ischemic dilated cardiomyopathy, low LVEF, elevated Pro-BNP, history of myocardial infarction, and presence of ventricular extrasystoles, along with the patient's medication regimen and laboratory results, all contribute to the high risk of sudden cardiac death in this patient."
691,691,P0340,"Age: 71
Gender: Male 
Weight: 57 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 85/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 44,6
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 57
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,36
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2206.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,954
Urea (mg/dL): 4,9
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of factors from their medical history, laboratory results, and current medications. 

1. Ischemic dilated cardiomyopathy (IDC): The patient has a history of IDC, which is a condition where the heart muscle becomes weakened and the heart chambers dilate, leading to reduced heart function. This condition increases the risk of sudden cardiac death.

2. Low LVEF (Left Ventricular Ejection Fraction) of 30%: The patient's LVEF is severely reduced, indicating poor heart function. A low LVEF is a well-established predictor of increased mortality and sudden cardiac death.

3. High Pro-BNP (Brain Natriuretic Peptide) levels: The patient's Pro-BNP level of 2206.0 ng/L is significantly elevated, which is indicative of severe heart failure and increased risk of sudden cardiac death.

4. Ventricular Extrasystole and Non-sustained Ventricular Tachycardia (VT): The presence of polymorphic ventricular extrasystoles and non-sustained VT on the ECG indicates arrhythmias, which can increase the risk of sudden cardiac death.

5. Bradycardia: Although the bradycardia code is unknown, bradycardia can further compromise cardiac output and increase the risk of sudden cardiac death, especially in a patient with pre-existing heart disease.

6. Medications: While the patient is on medications such as calcium channel blockers, loop diuretics, spironolactone, statins, and nitrovasodilators, these medications may not have been sufficient to manage the patient's underlying heart disease and arrhythmias, leading to a fatal outcome.

7. Other factors: The patient's age (71), low weight (57 kg), and low blood pressure (85/50 mmHg) may also have contributed to the increased risk of sudden cardiac death.

In summary, the combination of ischemic dilated cardiomyopathy, low LVEF, high Pro-BNP levels, arrhythmias, and bradycardia, along with the patient's age, weight, and blood pressure, likely contributed to the patient's outcome of sudden cardiac death."
692,692,P0343,"Age: 63
Gender: Male 
Weight: 80 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42,4
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 112.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 116.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,35
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 2125.0
Protein (g/L): 74
T3 (pg/dL): 0,02
T4 (ng/L): 11
Troponin (ng/mL): 0,01
TSH (mIU/L): 32,51
Urea (mg/dL): 6,45
LVEF (%): 40.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Parosysmal AF
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of several factors present in the patient's history and current condition.

1.  Ischemic Dilated Cardiomyopathy (IDC): The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened due to coronary artery disease, leading to reduced heart function and a decreased ejection fraction (LVEF of 40%). This condition increases the risk of sudden cardiac death.

2.  Reduced LVEF: The patient's left ventricular ejection fraction (LVEF) is 40%, which is below the normal range (50-70%). A reduced LVEF indicates that the heart is not pumping efficiently, making it more susceptible to arrhythmias and sudden cardiac death.

3.  Atrial Fibrillation (AF): The patient has a history of paroxysmal AF, which is a type of irregular heartbeat that can increase the risk of stroke, heart failure, and other heart-related complications. AF can also lead to the formation of blood clots, which can cause a heart attack or stroke.

4.  High Pro-BNP Levels: The patient's Pro-BNP level is 2125.0 ng/L, which is significantly elevated. Pro-BNP is a hormone produced by the heart when it is under strain. Elevated levels indicate heart failure or other cardiac conditions, which can increase the risk of sudden cardiac death.

5.  Electrocardiogram (ECG) Findings: The patient's ECG shows polymorphic ventricular extrasystoles, which are abnormal heart rhythms that can be a sign of underlying cardiac disease. Although the ECG does not show sustained ventricular tachycardia, the presence of polymorphic extrasystoles indicates that the heart is experiencing abnormal electrical activity, which can increase the risk of sudden cardiac death.

6.  Medications: The patient is taking Amiodarone, which is an anti-arrhythmic medication used to treat and prevent certain types of irregular heartbeats. However, Amiodarone can also have pro-arrhythmic effects in some cases, potentially increasing the risk of sudden cardiac death.

7.  Other Factors: The patient's history of diabetes, hypertension, and dyslipidemia may also contribute to the development of cardiovascular disease and increase the risk of sudden cardiac death.

In conclusion, the combination of the patient's ischemic dilated cardiomyopathy, reduced LVEF, atrial fibrillation, high Pro-BNP levels, ECG findings, and medication use likely contributed to the patient's outcome of sudden cardiac death."
693,693,P0346,"Age: 78
Gender: Female 
Weight: 52 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 48,09
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 6,39
Creatinine (mmol/L): 139.0
Gamma-glutamil transpeptidase (IU/L): 79
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,37
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,53
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1990.0
Protein (g/L): 82
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,25
Urea (mg/dL): 12,69
LVEF (%): 24.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

Given the patient's age (78 years), history of ischemic dilated cardiomyopathy, and previous myocardial infarction, the patient is at high risk for cardiac complications. The patient's left ventricular ejection fraction (LVEF) is severely reduced at 24%, indicating significant left ventricular dysfunction. This is consistent with a dilated cardiomyopathy, which can lead to heart failure and increased risk of sudden cardiac death.

The elevated Pro-BNP level (1990 ng/L) further supports the presence of heart failure, as this biomarker is often used to diagnose and monitor heart failure. The patient's NYHA Class II classification also indicates that the patient experiences symptoms of heart failure, such as shortness of breath or fatigue, with moderate exertion.

The presence of ventricular extrasystoles on the ECG is a common finding in patients with cardiomyopathy and can be a marker of electrical instability. While the patient does not have sustained ventricular tachycardia, the presence of TPSV (paroxysmal supraventricular tachyarrhythmia) may indicate an increased risk of arrhythmias, which can contribute to sudden cardiac death.

The patient's medication regimen, including beta blockers, loop diuretics, spironolactone, and ACE inhibitors, is consistent with standard treatment for heart failure and cardiomyopathy. However, despite these treatments, the patient's LVEF remains severely reduced, and the patient's risk for sudden cardiac death remains elevated.

In summary, the combination of ischemic dilated cardiomyopathy, severely reduced LVEF, elevated Pro-BNP, and the presence of ventricular extrasystoles and TPSV on the ECG, along with the patient's age and history of myocardial infarction, make sudden cardiac death a plausible outcome in this patient."
694,694,P0349,"Age: 77
Gender: Female 
Weight: 82 kg
Height: 150 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 108.0
AST or GOT (IU/L): 55.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 15,5
Hemoglobin (g/L): 109.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,33
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 910.0
Protein (g/L): 66
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,43
Urea (mg/dL): 9,35
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of several factors, including her advanced age (77 years), poor left ventricular ejection fraction (LVEF) of 35%, and a history of ischemic dilated cardiomyopathy. The patient's LVEF is significantly reduced, indicating a poor heart function, which increases the risk of sudden cardiac death.

The patient's laboratory results also indicate elevated levels of troponin (0.01 ng/mL), which suggests that she has experienced a recent myocardial infarction, further contributing to her cardiac dysfunction. The elevated Pro-BNP level (910.0 ng/L) is also consistent with heart failure, which is a common cause of sudden cardiac death in patients with reduced LVEF.

The patient's medications, including beta blockers and angiotensin II receptor blockers, are standard treatments for heart failure and may have been prescribed to manage her ischemic dilated cardiomyopathy. However, the presence of ventricular extrasystoles on the ECG suggests that the patient may have had underlying cardiac arrhythmias, which can be a risk factor for sudden cardiac death.

Additionally, the patient's electrolyte imbalance, as indicated by a potassium level of 5.4 mEq/L, may have contributed to her cardiac arrhythmias and increased the risk of sudden cardiac death. The patient's diabetes and hypertension may also have played a role in her cardiac dysfunction and increased the risk of sudden cardiac death.

The patient's elevated liver enzymes (ALT and AST) may indicate underlying liver disease, which can contribute to cardiac dysfunction and increase the risk of sudden cardiac death. However, the exact relationship between the liver enzymes and the patient's cardiac outcome is unclear.

In summary, the patient's advanced age, poor LVEF, history of ischemic dilated cardiomyopathy, recent myocardial infarction, elevated Pro-BNP, ventricular extrasystoles, electrolyte imbalance, diabetes, hypertension, and elevated liver enzymes all contributed to her risk of sudden cardiac death."
695,695,P0351,"Age: 68
Gender: Male 
Weight: 73 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 120/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 40,3
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,98
Creatinine (mmol/L): 136.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 7
Hemoglobin (g/L): 142.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4,9
LDL (mmol/L): 2,04
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 934.0
Protein (g/L): 81
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,27
Urea (mg/dL): 14,25
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of several factors present in their medical history and laboratory results. 

1. Ischemic dilated cardiomyopathy: This condition is a known risk factor for sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) of 30% indicates a significant impairment of the heart's pumping function, which increases the risk of sudden cardiac death.

2. High Pro-BNP levels: The patient's Pro-BNP level of 934.0 ng/L is elevated, indicating increased ventricular wall stress and potential heart failure. Elevated Pro-BNP levels are associated with an increased risk of adverse cardiovascular events, including sudden cardiac death.

3. History of Myocardial Infarction: The patient's history of myocardial infarction suggests that they have experienced significant cardiac damage, which can lead to scarring and potentially life-threatening arrhythmias.

4. Ventricular Extrasystole: The presence of polymorphic ventricular extrasystoles on the ECG indicates abnormal electrical activity in the heart, which can be a precursor to more severe arrhythmias.

5. Medication regimen: While the patient is on beta blockers, ACE inhibitors, and statins, these medications are typically used to manage heart failure and reduce the risk of sudden cardiac death. However, the presence of diabetes and hypertension suggests that the patient may not be optimally controlled, which can increase the risk of adverse cardiac events.

6. Electrolyte imbalance: The patient's potassium level is slightly low (4.9 mEq/L), which can increase the risk of arrhythmias and sudden cardiac death.

Considering these factors, the patient's combination of ischemic dilated cardiomyopathy, high Pro-BNP levels, history of myocardial infarction, ventricular extrasystoles, and potential electrolyte imbalance likely contributed to their sudden cardiac death."
696,696,P0356,"Age: 76
Gender: Male 
Weight: 82 kg
Height: 149 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 47,3
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,61
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 12
Hemoglobin (g/L): 169.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,8
LDL (mmol/L): 3,31
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 4315.0
Protein (g/L): 80
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,04
Urea (mg/dL): 14,03
LVEF (%): 20.0
Medications: Diabetes Medication, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of factors related to their underlying heart condition and laboratory results. 

1.  Ischemic dilated cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened due to a heart attack or coronary artery disease. This condition can lead to a decreased left ventricular ejection fraction (LVEF), which in this case is 20%, indicating severe heart failure.

2.  Low LVEF: The patient's LVEF of 20% indicates that their heart is not pumping effectively, which increases the risk of sudden cardiac death.

3.  Elevated Pro-BNP levels: The patient's Pro-BNP level of 4315.0 ng/L is significantly elevated, indicating severe heart failure. Elevated Pro-BNP levels are associated with increased mortality and morbidity in patients with heart failure.

4.  Diabetes and dyslipemia: The patient has a history of diabetes and dyslipemia, which are both risk factors for cardiovascular disease and can contribute to the progression of ischemic dilated cardiomyopathy.

5.  Medication regimen: Although the patient is on medications such as ACE inhibitors, spironolactone, and statins, which are commonly used to treat heart failure and high blood pressure, the combination of these medications may not have been sufficient to adequately manage the patient's condition.

6.  ECG findings: The presence of monomorphic ventricular extrasystoles on the ECG indicates abnormal heart rhythm, which can be a risk factor for sudden cardiac death.

7.  Hemoglobin level: The patient's hemoglobin level is slightly elevated at 169.0 g/L, which may indicate polycythemia (an increased red blood cell mass), a condition that can increase the risk of thromboembolic events and cardiac arrhythmias.

8.  Electrolyte imbalance: The patient's potassium level is slightly low at 4.8 mEq/L, which can contribute to arrhythmias and cardiac arrest.

Considering these factors, the patient's outcome of sudden cardiac death can be attributed to a combination of severe heart failure, abnormal heart rhythm, and underlying cardiovascular risk factors."
697,697,P0405,"Age: 37
Gender: Female 
Weight: 69 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,13
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 4,3
LDL (mmol/L): 4,14
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 853.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,005
TSH (mIU/L): 0,562
Urea (mg/dL): 4,49
LVEF (%): 23.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

This patient's outcome of sudden cardiac death is likely due to the combination of severe left ventricular dysfunction, as indicated by a low left ventricular ejection fraction (LVEF) of 23%, and a high level of B-type natriuretic peptide (BNP) at 853 ng/L, which is a marker of heart failure and increased ventricular wall stress. 

The patient's history of idiopathic dilated cardiomyopathy, a condition where the heart muscle becomes weakened and the heart chambers enlarge, further supports this conclusion. The presence of non-sustained ventricular tachycardia (VT) on the ECG, which is a type of abnormal heart rhythm that can increase the risk of sudden cardiac death, is also a contributing factor.

Additionally, the patient's low hemoglobin level (148 g/L) may indicate anemia, which can further compromise cardiac output and increase the risk of cardiac events. The patient's low HDL cholesterol level (1.42 mmol/L) and high LDL cholesterol level (4.14 mmol/L) may also contribute to the development of atherosclerosis, which can further compromise cardiac function.

The patient's medications, including angiotensin II receptor blockers, beta blockers, digoxin, loop diuretics, and spironolactone, are all appropriate for managing heart failure and may help to reduce the risk of sudden cardiac death. However, in this case, they may not have been sufficient to prevent the patient's outcome.

The patient's low T3 level (0.05 pg/dL) and normal T4 level (15 ng/L) may indicate hypothyroidism, which can contribute to heart failure and increase the risk of cardiac events. However, the patient's TSH level (0.562 mIU/L) is within the normal range, which may indicate that the patient's thyroid function is not significantly abnormal.

Overall, the combination of severe left ventricular dysfunction, non-sustained VT, and other contributing factors likely led to the patient's outcome of sudden cardiac death."
698,698,P0409,"Age: 64
Gender: Male 
Weight: 89 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 145/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 78.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,66
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 170.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,6
LDL (mmol/L): 4,06
Sodium (mEq/L): 143.0
Protein (g/L): 68
T3 (pg/dL): 0,03
T4 (ng/L): 24
Troponin (ng/mL): 0,02
TSH (mIU/L): 3,4
Urea (mg/dL): 8,65
LVEF (%): 65.0
Medications: Calcium Channel Blocker, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Unknown ventricular extrasystole code
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Paroxismal flutter
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of his underlying medical conditions and the presence of significant cardiac arrhythmias. The patient has a history of hypertensive cardiomyopathy and hypertension, which have likely led to left ventricular dysfunction as indicated by a left ventricular ejection fraction (LVEF) of 65%. This reduced ejection fraction increases the risk of arrhythmias and sudden cardiac death.

The presence of non-sustained ventricular tachycardia (NSVT) on the ECG is a significant finding, as it is a known risk factor for sudden cardiac death. NSVT can be a marker of underlying myocardial ischemia or fibrosis, which can lead to life-threatening arrhythmias.

Additionally, the patient's medications, including a calcium channel blocker and digoxin, may have contributed to his cardiac arrhythmias. Calcium channel blockers can cause hypotension, which can lead to a decrease in cardiac output and increase the risk of arrhythmias. Digoxin, on the other hand, can cause arrhythmias, particularly at toxic levels, which can be exacerbated by other medications or underlying conditions.

The patient's TSH level is within the normal range, but his low T3 and T4 levels may indicate hypothyroidism, which can contribute to cardiac dysfunction and increase the risk of arrhythmias.

Furthermore, the patient's high total cholesterol and LDL levels, as well as his low HDL level, suggest dyslipidemia, which is a known risk factor for cardiovascular disease and sudden cardiac death.

In conclusion, the patient's outcome of sudden cardiac death is likely the result of a complex interplay between his underlying medical conditions, cardiac arrhythmias, and medication side effects, which ultimately led to a catastrophic cardiac event."
699,699,P0416,"Age: 46
Gender: Male 
Weight: 77 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 105/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 48
ALT or GPT (IU/L): 51.0
AST or GOT (IU/L): 32.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 8
Hemoglobin (g/L): 158.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,41
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 247.0
Protein (g/L): 79
T3 (pg/dL): 0,05
T4 (ng/L): 21
Troponin (ng/mL): 0,12
TSH (mIU/L): 3,63
Urea (mg/dL): 6,32
LVEF (%): 30.0
Medications: Diabetes Medication, Amiodarone, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient outcome of sudden cardiac death can be attributed to several factors based on the provided data. 

1.  Reduced Left Ventricular Ejection Fraction (LVEF) of 30%: This indicates a severely compromised heart function, which increases the risk of sudden cardiac death. The patient's idiopathic dilated cardiomyopathy likely led to the reduction in LVEF, making the heart more susceptible to life-threatening arrhythmias.

2.  Presence of Non-sustained Ventricular Tachycardia (VT): The ECG impression indicates the presence of non-sustained VT, which is a known risk factor for sudden cardiac death. Although it is non-sustained, the patient's underlying heart condition and reduced LVEF increase the likelihood of a sustained VT episode, which can be fatal.

3.  Elevated Pro-BNP Levels (247.0 ng/L): The elevated B-type natriuretic peptide (BNP) levels are indicative of heart failure, which can increase the risk of sudden cardiac death.

4.  Polymorphic Ventricular Extrasystoles: The presence of polymorphic ventricular extrasystoles on the ECG can be a sign of abnormal electrical activity in the heart, which may increase the risk of life-threatening arrhythmias.

5.  Medication Non-Adherence or Inadequate Titration: Although the patient is on several medications, including ACE inhibitors, beta blockers, and digoxin, which are typically used to manage heart failure and arrhythmias, there may be a possibility of non-adherence or inadequate titration, which could have contributed to the patient's outcome.

6.  Comorbidities: The patient has diabetes, which is a known risk factor for cardiovascular disease and sudden cardiac death.

7.  Electrolyte Imbalance: The patient has a slightly low potassium level (4.7 mEq/L), which can contribute to arrhythmias and increase the risk of sudden cardiac death.

Given these factors, it is reasonable to conclude that the patient's sudden cardiac death was likely caused by a combination of his underlying heart condition, reduced LVEF, and the presence of arrhythmias, which ultimately led to a fatal outcome."
700,700,P0438,"Age: 65
Gender: Male 
Weight: 79 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 115/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 49,6
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 149.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,82
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1114.0
Protein (g/L): 76,9
T4 (ng/L): 16
TSH (mIU/L): 0,86
Urea (mg/dL): 8,99
LVEF (%): 25.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of factors related to their underlying heart condition, medication regimen, and laboratory results. 

Firstly, the patient has a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge, leading to a decrease in the heart's ability to pump blood efficiently. The patient's left ventricular ejection fraction (LVEF) of 25.0% is significantly below the normal range (50-70%), indicating a compromised heart function.

The patient's high levels of pro-BNP (1114.0 ng/L) also suggest that the heart is under strain, as BNP is a hormone released by the heart in response to increased wall tension. Elevated BNP levels are associated with heart failure and poor prognosis.

Additionally, the patient's past medical history of myocardial infarction (heart attack) may have further damaged the heart muscle, contributing to the development of dilated cardiomyopathy.

The patient's medication regimen includes beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor, which are all standard treatments for heart failure and cardiomyopathy. However, despite these treatments, the patient's condition has progressed to a critical state, leading to sudden cardiac death.

Furthermore, the patient's laboratory results show elevated levels of creatinine (149.0 mmol/L), indicating impaired kidney function, which can further worsen the prognosis in patients with heart failure.

The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG suggests that the patient's heart is experiencing abnormal electrical activity, which can increase the risk of sudden cardiac death.

In conclusion, the combination of the patient's underlying heart condition, compromised heart function, high BNP levels, past medical history, and abnormal ECG findings likely contributed to the patient's outcome of sudden cardiac death."
701,701,P0468,"Age: 69
Gender: Male 
Weight: 81 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 10.0
Total Cholesterol (mmol/L): 2,77
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 5
Hemoglobin (g/L): 109.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 5,2
LDL (mmol/L): 1,32
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 7519.0
Protein (g/L): 68,6
T3 (pg/dL): 0,0342
T4 (ng/L): 12,35
Troponin (ng/mL): 0,6
TSH (mIU/L): 5,19
Urea (mg/dL): 10,5
LVEF (%): 35.0
Medications: Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

This patient's outcome of sudden cardiac death can be attributed to a combination of factors based on the provided information. The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and enlarged due to a heart attack. This condition can lead to a significant reduction in the left ventricular ejection fraction (LVEF), which in this case is 35%, indicating poor heart function.

The patient's elevated Pro-BNP level of 7519.0 ng/L is also indicative of heart failure, as BNP is a hormone produced by the heart in response to stress and strain. The patient's symptoms of heart failure are further supported by the presence of dyspnea and possibly peripheral edema, although this is not explicitly stated.

The patient's past medical history of myocardial infarction, hypertension, and dyslipidemia also contribute to the risk of sudden cardiac death. The patient's low HDL cholesterol level of 0.93 mmol/L and high LDL cholesterol level of 1.32 mmol/L further increase the risk of cardiovascular disease.

Furthermore, the patient's ECG shows monomorphic ventricular extrasystoles, which can be a sign of underlying cardiac disease. Although the patient is on beta blockers and statins, these medications may not be sufficient to control the patient's heart condition, particularly in the presence of such a low LVEF.

The patient's TSH level of 5.19 mIU/L is within the normal range, indicating that hypothyroidism is unlikely to be a contributing factor to the patient's outcome.

In conclusion, the combination of ischemic dilated cardiomyopathy, heart failure, history of myocardial infarction, hypertension, dyslipidemia, and the presence of monomorphic ventricular extrasystoles on the ECG make it likely that the patient's outcome of sudden cardiac death was due to a cardiac cause."
702,702,P0482,"Age: 60
Gender: Male 
Weight: 107 kg
Height: 181 cm
NYHA Class: III
Blood Pressure: 145/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 39,9
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 6,44
Creatinine (mmol/L): 143.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 127.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 5,2
LDL (mmol/L): 4,09
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1742.0
Protein (g/L): 67,9
T4 (ng/L): 12
TSH (mIU/L): 1,28
Urea (mg/dL): 10,98
LVEF (%): 15.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of factors related to their underlying cardiac condition and other comorbidities. 

1. Ischemic dilated cardiomyopathy (IDC): The patient has a history of IDC, which significantly increases the risk of sudden cardiac death. IDC is a condition where the heart muscle becomes weakened and enlarged, leading to decreased cardiac function. The patient's left ventricular ejection fraction (LVEF) is severely reduced at 15%, indicating poor heart function.

2. Non-sustained ventricular tachycardia (NSVT): The patient has a history of NSVT, which is a known predictor of sudden cardiac death. NSVT is a type of abnormal heart rhythm that can increase the risk of life-threatening arrhythmias.

3. Polymorphic ventricular extrasystoles: The presence of polymorphic ventricular extrasystoles on the ECG suggests that the patient's heart is experiencing irregular and abnormal electrical activity, which can further increase the risk of sudden cardiac death.

4. High Pro-BNP levels: The patient's Pro-BNP level is significantly elevated at 1742.0 ng/L, indicating high levels of B-type natriuretic peptide. Elevated Pro-BNP levels are associated with heart failure and increased risk of sudden cardiac death.

5. Medication non-adherence or inadequate treatment: Although the patient is on various medications, including beta blockers, digoxin, loop diuretics, spironolactone, statins, and an ACE inhibitor, it is unclear if the medications are being taken as prescribed or if the dosages are adequate. Inadequate treatment of heart failure and arrhythmias can increase the risk of sudden cardiac death.

6. Electrolyte imbalance: The patient's potassium level is slightly elevated at 5.2 mEq/L, which can contribute to arrhythmias and increase the risk of sudden cardiac death.

7. Other comorbidities: The patient's history of dyslipemia, myocardial infarction, and creatinine level of 143.0 mmol/L (indicating renal impairment) may also contribute to his increased risk of sudden cardiac death.

Given these factors, the patient's outcome of sudden cardiac death is likely due to a combination of their underlying heart disease, arrhythmias, and other comorbidities, which ultimately led to a fatal cardiac event."
703,703,P0494,"Age: 71
Gender: Male 
Weight: 82 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 44.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 3,8
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 84
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 161.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,25
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 224.0
Protein (g/L): 68
T4 (ng/L): 10
Troponin (ng/mL): 0,02
TSH (mIU/L): 3
Urea (mg/dL): 6,66
LVEF (%): 42.0
Medications: Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

This patient's outcome of sudden cardiac death can be attributed to a combination of factors, primarily related to his underlying cardiac condition and laboratory results. 

1.  Ischemic dilated cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened due to a heart attack, leading to a decrease in the heart's ability to pump blood effectively. This condition increases the risk of sudden cardiac death.

2.  Low LVEF (42.0%): The patient's left ventricular ejection fraction (LVEF) is significantly lower than the normal range (50-70%), indicating that the heart is not pumping efficiently. A low LVEF is a strong predictor of increased mortality and sudden cardiac death in patients with heart failure.

3.  Elevated Pro-BNP (224.0 ng/L): The B-type natriuretic peptide (BNP) level is elevated, which is a marker of heart failure and cardiac strain. Elevated BNP levels are associated with increased risk of mortality and sudden cardiac death.

4.  Ventricular Extrasystole and Non-sustained Ventricular Tachycardia: The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are abnormal heart rhythms that can lead to sudden cardiac death.

5.  Troponin (0.02 ng/mL): Although the troponin level is slightly elevated, it is still within a relatively low range, indicating some level of cardiac damage but not severe enough to cause immediate death.

6.  Medication non-adherence or inadequate management: The patient is on beta blockers, statins, and nitrovasodilators, which are standard medications for heart failure and ischemic heart disease. However, the patient's medication regimen may not have been optimized, or he may have been non-adherent to his medication, contributing to his poor outcome.

7.  Other contributing factors: The patient's dyslipidemia, elevated gamma-glutamil transpeptidase, and slightly elevated glucose levels may also have contributed to his cardiac condition and increased risk of sudden cardiac death.

In conclusion, the patient's outcome of sudden cardiac death can be attributed to a combination of his underlying ischemic dilated cardiomyopathy, low LVEF, elevated Pro-BNP, abnormal heart rhythms, and potential medication non-adherence or inadequate management."
704,704,P0498,"Age: 80
Gender: Female 
Weight: 53 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 38,1
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 4,25
Creatinine (mmol/L): 131.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 6
Hemoglobin (g/L): 119.0
Potassium (mEq/L): 4,56
Sodium (mEq/L): 139.0
Protein (g/L): 71,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,63
Urea (mg/dL): 13,4
LVEF (%): 18.0
Medications: Amiodarone, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of factors based on the provided information. 

Firstly, the patient has a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge, leading to poor heart function. The left ventricular ejection fraction (LVEF) of 18% indicates severe left ventricular dysfunction, which is a significant risk factor for sudden cardiac death.

Secondly, the patient's ECG shows non-sustained ventricular tachycardia (NSVT), which is a type of abnormal heart rhythm that can increase the risk of sudden cardiac death. NSVT can be a precursor to sustained ventricular tachycardia, which is a more serious and potentially life-threatening condition.

Thirdly, the patient's medication regimen includes Amiodarone and Digoxin, which are both used to treat arrhythmias, but may also have pro-arrhythmic effects in certain situations. Amiodarone can cause QT interval prolongation, which may increase the risk of torsades de pointes, a type of ventricular tachycardia that can degenerate into ventricular fibrillation and sudden cardiac death.

Lastly, the patient's age (80 years) and NYHA Class II classification suggest that the patient has significant cardiovascular disease and may be at increased risk of sudden cardiac death due to age-related decline in cardiac function.

In conclusion, the combination of the patient's underlying heart disease, NSVT, and potential pro-arrhythmic effects of their medications likely contributed to the sudden cardiac death."
705,705,P0504,"Age: 78
Gender: Male 
Weight: 75 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 7,03
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 4,84
LDL (mmol/L): 4,73
Sodium (mEq/L): 139.0
Protein (g/L): 67,3
T3 (pg/dL): 0,0483
T4 (ng/L): 16,58
Troponin (ng/mL): 0,5
TSH (mIU/L): 0,67
Urea (mg/dL): 10
LVEF (%): 34.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of factors, primarily related to his underlying enolic dilated cardiomyopathy and associated complications.

1.  Reduced Left Ventricular Ejection Fraction (LVEF): The patient has a severely reduced LVEF of 34.0%, indicating significant left ventricular dysfunction. This suggests that the heart is not pumping efficiently, leading to decreased cardiac output and increased risk of sudden cardiac death.

2.  Ventricular Extrasystole: The presence of polymorphic ventricular extrasystoles indicates abnormal heart rhythms originating from the ventricles. This can be a sign of underlying cardiac disease, such as dilated cardiomyopathy, which may contribute to the increased risk of sudden cardiac death.

3.  Elevated Creatinine Levels: The patient's creatinine level of 120.0 mmol/L suggests impaired kidney function, which can be a result of decreased cardiac output and reduced blood flow to the kidneys. This can further exacerbate cardiac dysfunction and increase the risk of sudden cardiac death.

4.  Electrolyte Imbalance: The patient's potassium level of 4.84 mEq/L is slightly low, which can be a result of diuretic use. However, it may also contribute to arrhythmias and increase the risk of sudden cardiac death.

5.  Medication Non-Adherence or Inadequate Dosing: The patient is on Angiotensin II Receptor Blocker, Loop Diuretics, and ACE Inhibitor. However, despite these medications, the patient's LVEF remains severely reduced, suggesting that the medications may not be adequately managing his condition or that there may be non-adherence to the medication regimen.

6.  Underlying Enolic Dilated Cardiomyopathy: The patient's enolic dilated cardiomyopathy is a significant underlying condition that increases the risk of sudden cardiac death. The combination of this condition with the other factors mentioned above may have contributed to the patient's outcome.

7.  Other Contributing Factors: The patient's age (78 years) and NYHA Class II classification also contribute to his increased risk of sudden cardiac death. The presence of other comorbidities, such as hypertension (140/70 mmHg), may also play a role.

In conclusion, the patient's outcome of sudden cardiac death is likely the result of a combination of factors related to his underlying enolic dilated cardiomyopathy, reduced LVEF, ventricular extrasystoles, impaired kidney function, electrolyte imbalance, potential medication non-adherence or inadequate dosing, age, and NYHA Class II classification."
706,706,P0520,"Age: 67
Gender: Male 
Weight: 63 kg
Height: 158 cm
NYHA Class: III
Blood Pressure: 90/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 42,4
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 135.0
Gamma-glutamil transpeptidase (IU/L): 56
Glucose (mmol/L): 7,2
Hemoglobin (g/L): 98.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 3,6
LDL (mmol/L): 1,27
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 6274.0
Protein (g/L): 68
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,04
TSH (mIU/L): 1,31
Urea (mg/dL): 11,13
LVEF (%): 23.0
Medications: Diabetes Medication, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of his severe underlying cardiac condition and several risk factors. 

Firstly, the patient has ischemic dilated cardiomyopathy, a condition where the heart muscle becomes weakened and enlarged due to a previous heart attack or reduced blood flow to the heart. This condition is evident from the patient's low left ventricular ejection fraction (LVEF) of 23%, which indicates that the heart is not pumping effectively.

The patient's NYHA Class III classification further supports this, indicating that he has severe symptoms of heart failure, including shortness of breath and fatigue, even at rest. The elevated levels of Pro-BNP (6274.0 ng/L) and Troponin (0.04 ng/mL) also indicate that the heart is under strain and has experienced recent damage.

The patient's blood pressure is also low at 90/60 mmHg, which can be a sign of heart failure or severe cardiac dysfunction. Additionally, the presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG suggests arrhythmias, which can be life-threatening in a patient with a weakened heart.

Furthermore, the patient has a history of diabetes, dyslipemia, and hypertension, which are all risk factors for cardiovascular disease and heart failure. The patient's low HDL cholesterol level (0.83 mmol/L) and high LDL cholesterol level (1.27 mmol/L) also indicate a high risk of atherosclerosis, which can contribute to cardiac dysfunction.

The patient's low sodium level (139.0 mEq/L) and low potassium level (3.6 mEq/L) may also be contributing to his cardiac instability. The patient's urea level of 11.13 mg/dL suggests impaired renal function, which can be a result of his heart failure or other underlying conditions.

Considering these factors, the patient's sudden cardiac death can be attributed to a combination of his severe heart failure, arrhythmias, and underlying cardiovascular risk factors."
707,707,P0533,"Age: 50
Gender: Male 
Weight: 76 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 90/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 42,5
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,81
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,72
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 86.0
Protein (g/L): 82
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,58
Urea (mg/dL): 6,91
LVEF (%): 38.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of several factors. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack, leading to a decrease in the heart's pumping efficiency. The left ventricular ejection fraction (LVEF) of 38% indicates that the heart is not pumping effectively, which increases the risk of sudden cardiac death.

The patient's NYHA Class III classification indicates that the patient has severe symptoms of heart failure, including shortness of breath, fatigue, and swelling in the legs, which further increases the risk of sudden cardiac death.

The patient's blood pressure is significantly low at 90/50 mmHg, which may be a sign of cardiogenic shock, a condition where the heart is unable to pump enough blood to meet the body's needs. This can lead to a sudden drop in blood pressure, which can cause cardiac arrest and sudden cardiac death.

Additionally, the patient's elevated troponin level of 0.01 ng/mL indicates that there may have been recent myocardial damage, which can increase the risk of arrhythmias and sudden cardiac death.

The presence of non-sustained ventricular tachycardia on the ECG is also a concerning finding, as it indicates that the patient's heart is experiencing abnormal heart rhythms that can increase the risk of sudden cardiac death.

Furthermore, the patient's low HDL cholesterol level of 1.5 mmol/L and high LDL cholesterol level of 2.72 mmol/L suggest that the patient may have dyslipidemia, which is a risk factor for cardiovascular disease and sudden cardiac death.

Finally, the patient's low T3 level of 0.04 pg/dL and high TSH level of 2.58 mIU/L may indicate hypothyroidism, which can also contribute to heart failure and increase the risk of sudden cardiac death.

In summary, the patient's combination of ischemic dilated cardiomyopathy, low LVEF, severe heart failure symptoms, low blood pressure, recent myocardial damage, abnormal heart rhythms, dyslipidemia, and potential hypothyroidism all contribute to the increased risk of sudden cardiac death."
708,708,P0539,"Age: 64
Gender: Male 
Weight: 85 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 38,4
ALT or GPT (IU/L): 35.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 112.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 150.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,8
LDL (mmol/L): 1,99
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 339.0
Protein (g/L): 78
T3 (pg/dL): 0,05
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,25
Urea (mg/dL): 9,13
LVEF (%): 60.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of factors related to his underlying medical conditions and laboratory results. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack or reduced blood flow, leading to a decrease in the left ventricular ejection fraction (LVEF). In this case, the LVEF is 60%, which is below the normal range, indicating that the heart is not pumping efficiently. This condition increases the risk of sudden cardiac death.

Secondly, the patient has a history of myocardial infarction (heart attack), which can lead to scarring of the heart muscle and further reduce the heart's pumping ability. The presence of ventricular extrasystoles (abnormal heartbeats originating in the ventricles) on the ECG also suggests that the heart muscle is not functioning normally.

Thirdly, the patient's elevated Pro-BNP (B-type natriuretic peptide) level of 339.0 ng/L is indicative of heart failure, which can increase the risk of sudden cardiac death.

Fourthly, the patient's laboratory results show an elevated creatinine level of 112.0 mmol/L, which indicates impaired kidney function. This can be a sign of chronic kidney disease, which is often associated with cardiovascular disease and can increase the risk of sudden cardiac death.

Lastly, the patient's medications, although comprehensive, may not have been sufficient to manage his underlying conditions effectively. The presence of ventricular extrasystoles and the patient's history of myocardial infarction and ischemic dilated cardiomyopathy suggest that the patient may have had a significant amount of cardiac scarring and dysfunction, which may not have been adequately managed with his current medication regimen.

In conclusion, the patient's outcome of sudden cardiac death can be attributed to a combination of his underlying medical conditions, including ischemic dilated cardiomyopathy, myocardial infarction, and impaired kidney function, as well as his laboratory results and medication regimen."
709,709,P0559,"Age: 51
Gender: Male 
Weight: 62 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 130/90 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 5,4
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 49
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 147.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 3,08
LDL (mmol/L): 3,23
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2928.0
Protein (g/L): 71
T3 (pg/dL): 0,0573
T4 (ng/L): 16,58
Troponin (ng/mL): 0,1
TSH (mIU/L): 3,94
Urea (mg/dL): 5,8
LVEF (%): 20.0
Medications: Calcium Channel Blocker, Amiodarone, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

Given the patient's medical history of idiopathic dilated cardiomyopathy, the patient's left ventricular ejection fraction (LVEF) of 20.0% indicates severe left ventricular dysfunction, which is a significant risk factor for sudden cardiac death. The patient's low LVEF is likely contributing to the patient's reduced cardiac reserve, making the heart more susceptible to arrhythmias and sudden cardiac arrest.

The presence of non-sustained ventricular tachycardia (NSVT) on the ECG further increases the risk of sudden cardiac death. NSVT is a known predictor of sudden cardiac death in patients with heart failure and reduced ejection fraction.

The patient's high Pro-BNP level of 2928.0 ng/L also indicates severe heart failure, which is another risk factor for sudden cardiac death. BNP is a well-established biomarker for heart failure, and elevated levels are associated with increased mortality and morbidity in patients with heart failure.

The patient's use of medications such as beta blockers, ACE inhibitors, and digoxin is appropriate for heart failure management, but the presence of NSVT and high BNP levels suggests that the patient may require more aggressive management, such as an implantable cardioverter-defibrillator (ICD), to prevent sudden cardiac death.

The patient's TSH level of 3.94 mIU/L is within the normal range, which suggests that hypothyroidism is not a contributing factor to the patient's cardiac condition. The patient's T3 and T4 levels are also within normal limits, which further supports this conclusion.

The patient's potassium level of 3.08 mEq/L is low, which may be a contributing factor to the development of arrhythmias, including ventricular tachycardia. The patient's potassium level should be monitored and corrected if necessary.

In summary, the patient's severe left ventricular dysfunction, NSVT, high BNP levels, and low potassium level are all contributing factors to the patient's risk of sudden cardiac death."
710,710,P0616,"Age: 71
Gender: Male 
Weight: 63 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 115/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 42,4
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 36.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 125.0
Gamma-glutamil transpeptidase (IU/L): 114
Glucose (mmol/L): 6
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,9
Potassium (mEq/L): 3,94
LDL (mmol/L): 2,92
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1139.0
Protein (g/L): 67,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,56
Urea (mg/dL): 11,6
LVEF (%): 18.0
Medications: Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

Given the patient's history of ischemic dilated cardiomyopathy, the patient has a significantly reduced left ventricular ejection fraction (LVEF) of 18%, which is a strong indicator of heart failure. The elevated Pro-BNP (1139 ng/L) also supports this diagnosis, as it is a well-established biomarker for heart failure.

The patient's history of myocardial infarction and peripheral vascular disease further increases the risk of cardiac events. The presence of ventricular extrasystoles, although not sustained, indicates an abnormal heart rhythm that could potentially lead to arrhythmias.

The patient's medications, including angiotensin II receptor blocker, digoxin, loop diuretics, statins, and nitrovasodilator, are aimed at managing heart failure and reducing cardiac workload. However, the effectiveness of these medications is limited by the patient's severely reduced LVEF.

The patient's electrolyte imbalance, specifically low potassium levels (3.94 mEq/L), may also contribute to cardiac arrhythmias and sudden cardiac death. The elevated creatinine levels (125.0 μmol/L) suggest impaired renal function, which may further compromise the patient's cardiac health.

The patient's age (71) and NYHA Class II classification also indicate that the patient has a compromised cardiac function and may be at increased risk for sudden cardiac death.

Considering these factors, the patient's sudden cardiac death can be attributed to a combination of factors, including:

1. Reduced LVEF and heart failure
2. History of myocardial infarction and peripheral vascular disease
3. Presence of ventricular extrasystoles and potential for arrhythmias
4. Electrolyte imbalance and impaired renal function
5. Age and NYHA Class II classification

These factors together created a high-risk scenario that ultimately led to the patient's sudden cardiac death."
711,711,P0618,"Age: 65
Gender: Male 
Weight: 93 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 40,7
ALT or GPT (IU/L): 57.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 2,96
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 95
Glucose (mmol/L): 8
Hemoglobin (g/L): 121.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,56
LDL (mmol/L): 1,45
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 12518.0
Protein (g/L): 66,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,43
Urea (mg/dL): 6,8
LVEF (%): 20.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

Given the patient's comprehensive medical history, the patient outcome of sudden cardiac death can be attributed to a combination of factors.

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) of 20% indicates severe systolic dysfunction, suggesting that the heart is unable to pump blood efficiently, leading to a high risk of sudden cardiac death.

The patient's history of myocardial infarction (MI) further increases the risk of sudden cardiac death. The presence of troponin of 0.01 ng/mL, although slightly elevated, suggests some residual myocardial damage.

The patient's blood work reveals elevated levels of Pro-BNP (12518.0 ng/L), which is a biomarker for heart failure and increased ventricular wall stress. This, combined with the patient's symptoms of NYHA Class II, indicates that the patient has significant heart failure symptoms.

Furthermore, the patient's lipid profile shows a high total cholesterol level (2.96 mmol/L) and low HDL (1.11 mmol/L), which increases the risk of atherosclerotic cardiovascular disease and subsequent cardiac events.

The presence of ventricular extrasystole, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG further increases the risk of sudden cardiac death. These arrhythmias can be triggered by the patient's underlying cardiac disease and may lead to a fatal outcome.

The patient's medications, including beta blockers, loop diuretics, spironolactone, statins, and ACE inhibitors, are standard treatments for heart failure and ischemic cardiomyopathy but may not have been sufficient to prevent the patient's outcome.

In summary, the combination of the patient's severe cardiac dysfunction, history of MI, elevated Pro-BNP levels, and arrhythmias on the ECG, along with a high risk of atherosclerotic cardiovascular disease, led to the patient outcome of sudden cardiac death."
712,712,P0626,"Age: 74
Gender: Female 
Weight: 55 kg
Height: 144 cm
NYHA Class: III
Blood Pressure: 150/80 mmHg
Past Medical History: Hypertropic cardiomyopathy, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 2,84
Creatinine (mmol/L): 76.0
Gamma-glutamil transpeptidase (IU/L): 81
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 117.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 3,2
LDL (mmol/L): 1,51
Sodium (mEq/L): 147.0
Pro-BNP (ng/L): 7158.0
Protein (g/L): 65,8
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,31
Urea (mg/dL): 7
LVEF (%): 62.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

Based on the provided patient data, the patient's outcome of sudden cardiac death can be attributed to a combination of factors. The patient's age (74 years) and New York Heart Association (NYHA) Class III classification indicate a history of heart failure, likely related to hypertrophic cardiomyopathy and hypertension. The elevated Pro-BNP level (7158.0 ng/L) further supports this, as it is a marker of cardiac stress and strain.

The patient's LVEF (left ventricular ejection fraction) of 62% is within a relatively normal range, but considering the patient's age and comorbidities, it is likely that the heart is under significant strain. The presence of ventricular extrasystoles, as seen on the ECG, may indicate underlying electrical instability in the heart, which can increase the risk of arrhythmias.

The patient's lipid profile shows high total cholesterol (2.84 mmol/L) and LDL levels (1.51 mmol/L), which may contribute to atherosclerotic plaque formation and increased cardiovascular risk. The patient's blood pressure is also elevated (150/80 mmHg), which is a risk factor for cardiovascular disease.

Furthermore, the patient's kidney function, as indicated by the elevated creatinine level (76.0 umol/L), suggests underlying renal impairment, which can contribute to electrolyte imbalances, including hypokalemia (potassium level of 3.2 mEq/L). Hypokalemia can increase the risk of arrhythmias and cardiac arrest.

The patient's medication regimen includes a combination of calcium channel blockers, beta blockers, loop diuretics, spironolactone, statins, ACE inhibitors, and nitrovasodilators. While these medications are commonly used to manage heart failure and hypertension, they may not have been sufficient to prevent the patient's cardiac event.

In summary, the patient's outcome of sudden cardiac death is likely due to a combination of factors, including underlying hypertrophic cardiomyopathy, hypertension, electrical instability, atherosclerotic plaque formation, renal impairment, and electrolyte imbalances, which may have been exacerbated by the patient's medication regimen and overall health status."
713,713,P0649,"Age: 70
Gender: Male 
Weight: 110 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 85.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 10,8
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,22
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 437.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,99
Urea (mg/dL): 6,24
LVEF (%): 40.0
Medications: Diabetes Medication, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

Based on the provided patient data, the patient's outcome of sudden cardiac death can be attributed to a combination of several factors. 

Firstly, the patient has a history of enolic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge, leading to reduced heart function. This is reflected in the patient's left ventricular ejection fraction (LVEF) of 40%, which is below the normal range of 55-70%. 

Additionally, the patient has a high level of B-type natriuretic peptide (BNP) at 437 ng/L, which is a marker of heart failure and cardiac stress. Elevated BNP levels are associated with increased mortality and morbidity in patients with heart failure.

The patient's lipid profile shows high total cholesterol and low high-density lipoprotein (HDL) cholesterol levels, which are risk factors for cardiovascular disease. The patient's LDL cholesterol level of 2.22 mmol/L is also above the recommended target, further increasing the risk of atherosclerotic cardiovascular disease.

The patient's diabetes medication and loop diuretics are likely being used to manage his heart failure symptoms, but the presence of diabetes mellitus and dyslipemia further exacerbate the cardiovascular risk.

The presence of ventricular extrasystoles on the ECG suggests underlying cardiac electrical instability, which can increase the risk of arrhythmias and sudden cardiac death.

Furthermore, the patient's low T3 and T4 levels, along with a high TSH level, suggest hypothyroidism, which can contribute to cardiac dysfunction and increase the risk of arrhythmias.

The patient's creatinine level of 85.0 μmol/L indicates impaired renal function, which can further compromise cardiac function and increase the risk of sudden cardiac death.

Considering these factors, the patient's outcome of sudden cardiac death is likely the result of a combination of his underlying cardiac disease, cardiac electrical instability, and other comorbidities."
714,714,P0650,"Age: 73
Gender: Male 
Weight: 75 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension
Albumin (g/L): 40,9
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 2,87
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 15,3
Hemoglobin (g/L): 145.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,03
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1670.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 20
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,25
Urea (mg/dL): 5,79
LVEF (%): 25.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

Based on the provided patient data, the patient's outcome of sudden cardiac death can be attributed to a combination of factors related to his underlying heart condition and other comorbidities. 

1.  Ischemic dilated cardiomyopathy (IDC): The patient's left ventricular ejection fraction (LVEF) of 25% indicates severe left ventricular dysfunction, which is a hallmark of IDC. This condition significantly increases the risk of sudden cardiac death due to the heart's inability to pump blood efficiently.

2.  Non-sustained ventricular tachycardia (NSVT): The presence of NSVT on the ECG indicates that the patient has abnormal electrical activity in the heart. This condition increases the risk of sudden cardiac death, as it can degenerate into sustained ventricular tachycardia or fibrillation.

3.  Pro-BNP levels: A Pro-BNP level of 1670 ng/L is significantly elevated, indicating severe heart failure and increased risk of sudden cardiac death.

4.  Diabetes and hypertension: The patient's history of diabetes and hypertension are contributing factors to his heart failure and increased risk of cardiac arrhythmias.

5.  Medications: Although the patient is on medications such as beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are standard treatments for heart failure and arrhythmias, they may not have been sufficient to prevent sudden cardiac death in this case.

6.  Age and NYHA Class III: The patient's advanced age (73 years) and New York Heart Association (NYHA) Class III heart failure classification indicate a high-risk profile for sudden cardiac death.

Considering these factors, the patient's outcome of sudden cardiac death is likely the result of a combination of his underlying heart condition, comorbidities, and potentially inadequate management of his heart failure and arrhythmias."
715,715,P0656,"Age: 57
Gender: Male 
Weight: 70 kg
Height: 164 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 33,5
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 3,15
Creatinine (mmol/L): 226.0
Gamma-glutamil transpeptidase (IU/L): 73
Glucose (mmol/L): 3,1
Hemoglobin (g/L): 97.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 5,9
LDL (mmol/L): 1,58
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 19425.0
Protein (g/L): 68
T3 (pg/dL): 0,03
T4 (ng/L): 20
Troponin (ng/mL): 0,19
TSH (mIU/L): 4,39
Urea (mg/dL): 18,94
LVEF (%): 20.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

Given the patient's extensive medical history, including ischemic dilated cardiomyopathy, myocardial infarction, hypertension, and diabetes, it is not surprising that the patient experienced sudden cardiac death. Ischemic dilated cardiomyopathy is a condition where the heart muscle becomes weakened due to a previous heart attack, leading to a decrease in the heart's ability to pump blood effectively. This condition can lead to a reduced left ventricular ejection fraction (LVEF), as seen in this patient with an LVEF of 20%.

The patient's elevated Pro-BNP (B-type natriuretic peptide) level of 19425.0 ng/L is indicative of heart failure, which is consistent with the patient's ischemic dilated cardiomyopathy. The elevated Pro-BNP level suggests that the patient's heart is under significant stress, which may have contributed to the sudden cardiac death.

The patient's medication list includes beta blockers, which are typically used to slow the heart rate and reduce the workload on the heart, but the patient's condition is likely too advanced for these medications to be effective in preventing sudden cardiac death.

Additionally, the patient's low T3 level of 0.03 pg/dL may indicate hypothyroidism, which can contribute to heart failure and sudden cardiac death. The patient's TSH level of 4.39 mIU/L is slightly elevated, which suggests that the patient may have hypothyroidism.

The patient's creatinine level of 226.0 mmol/L indicates impaired kidney function, which can further contribute to the patient's overall poor health and increased risk of sudden cardiac death.

The patient's ECG shows monomorphic ventricular extrasystoles, which can be a sign of underlying cardiac disease. While not a direct cause of sudden cardiac death, it suggests that the patient's heart is under significant stress.

In summary, the combination of the patient's advanced ischemic dilated cardiomyopathy, heart failure, impaired kidney function, hypothyroidism, and underlying cardiac disease likely contributed to the patient's sudden cardiac death."
716,716,P0661,"Age: 67
Gender: Female 
Weight: 65 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 43,2
ALT or GPT (IU/L): 6.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 4,58
Creatinine (mmol/L): 61.0
Gamma-glutamil transpeptidase (IU/L): 42
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,69
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 928.0
Protein (g/L): 68,5
T4 (ng/L): 15
TSH (mIU/L): 1,1
Urea (mg/dL): 6,82
LVEF (%): 20.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of factors based on the provided data.

1.  Severe Left Ventricular Dysfunction: The patient has an LVEF (Left Ventricular Ejection Fraction) of 20%, which indicates severe left ventricular dysfunction. This suggests that the patient's heart is unable to pump blood effectively, increasing the risk of cardiac arrhythmias and sudden cardiac death.

2.  Non-Sustained Ventricular Tachycardia (NSVT): The patient has a history of non-sustained ventricular tachycardia, which is a known risk factor for sudden cardiac death. NSVT can be a marker of underlying cardiac electrical instability, increasing the risk of ventricular fibrillation or tachycardia.

3.  High Pro-BNP Levels: The patient's Pro-BNP level is elevated at 928.0 ng/L, indicating elevated B-type natriuretic peptide. Elevated Pro-BNP levels are associated with heart failure, and high levels are associated with increased risk of mortality.

4.  Idiopathic Dilated Cardiomyopathy: The patient has a history of idiopathic dilated cardiomyopathy, which is a condition characterized by the enlargement of the heart's left ventricle. This condition can lead to severe heart failure, arrhythmias, and sudden cardiac death.

5.  Comorbid Conditions: The patient has comorbid conditions such as hypertension, diabetes, and high cholesterol, which can contribute to cardiac dysfunction and increase the risk of sudden cardiac death.

6.  Medication Non-Optimization: Although the patient is on various medications, including beta blockers, digoxin, spironolactone, and an ACE inhibitor, the patient's heart function is severely impaired, suggesting that the medications may not be adequately managing the patient's condition.

Given these factors, the patient's outcome of sudden cardiac death can be attributed to a combination of severe left ventricular dysfunction, non-sustained ventricular tachycardia, high Pro-BNP levels, idiopathic dilated cardiomyopathy, and comorbid conditions, which ultimately led to cardiac arrest."
717,717,P0667,"Age: 75
Gender: Male 
Weight: 76 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 150/75 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 37,4
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 5,95
Creatinine (mmol/L): 160.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 7,1
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,72
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 6950.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,67
Urea (mg/dL): 13,14
LVEF (%): 50.0
Medications: Calcium Channel Blocker, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of several factors present in the patient's data. 

Firstly, the patient has a history of Hypertensive cardiomyopathy, which is a condition where the heart muscle becomes weakened due to high blood pressure, leading to reduced cardiac function. The patient's LVEF (Left Ventricular Ejection Fraction) of 50% indicates that the heart is not pumping efficiently, which increases the risk of cardiac complications.

The patient's high blood pressure (150/75 mmHg) and history of hypertension further exacerbate the cardiac workload, putting additional strain on the heart. The patient's Pro-BNP (N-terminal pro b-type natriuretic peptide) level of 6950.0 ng/L is elevated, indicating increased ventricular stretch and stress, which is often seen in patients with heart failure.

The patient's low HDL cholesterol (1.47 mmol/L) and high LDL cholesterol (3.72 mmol/L) levels suggest a high risk of atherosclerotic cardiovascular disease, which can further compromise cardiac function.

The presence of ventricular extrasystole and non-sustained ventricular tachycardia on the ECG indicates abnormal heart rhythms, which can be a sign of underlying cardiac disease. The patient's troponin level of 0.03 ng/mL is slightly elevated, indicating cardiac muscle damage.

The patient's TSH (Thyroid-stimulating hormone) level of 1.67 mIU/L is within the normal range, ruling out hypothyroidism as a contributing factor to the patient's cardiac issues. However, the low T3 level of 0.05 pg/dL may indicate a decrease in thyroid function, which can contribute to decreased cardiac function.

The patient's urea level of 13.14 mg/dL indicates renal impairment, which can further exacerbate cardiac issues by reducing the kidneys' ability to filter waste products, including urea, from the blood.

Considering the patient's age (75), the combination of these factors likely led to a cardiac event, resulting in sudden cardiac death. The patient's cardiac medications, including a calcium channel blocker and loop diuretics, were likely insufficient to manage the patient's complex cardiac condition, ultimately leading to the fatal outcome."
718,718,P0671,"Age: 69
Gender: Male 
Weight: 72 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 150/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 44,1
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 5,74
Creatinine (mmol/L): 145.0
Gamma-glutamil transpeptidase (IU/L): 70
Glucose (mmol/L): 11,2
Hemoglobin (g/L): 163.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,93
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1824.0
Protein (g/L): 76,6
T4 (ng/L): 19
TSH (mIU/L): 0,36
Urea (mg/dL): 10,65
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Diabetes Medication
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

Given the patient's extensive medical history, including ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction, the patient is at high risk for adverse cardiac events. The patient's left ventricular ejection fraction (LVEF) of 35% indicates severe left ventricular dysfunction, which is a significant risk factor for sudden cardiac death.

The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia (NSVT) on the ECG suggests underlying ventricular arrhythmogenicity and increased risk of sudden cardiac death. NSVT is a known predictor of sudden cardiac death in patients with heart failure and reduced ejection fraction.

The elevated Pro-BNP (brain natriuretic peptide) level of 1824 ng/L indicates severe heart failure, which further increases the risk of sudden cardiac death. Additionally, the patient's hypertension (150/90 mmHg) and dyslipemia (total cholesterol 5.74 mmol/L and LDL 3.93 mmol/L) contribute to the overall cardiovascular risk.

The patient's diabetes and creatinine level of 145.0 mmol/L suggest renal impairment, which can further exacerbate cardiac dysfunction and increase the risk of sudden cardiac death.

The patient's medications, including a calcium channel blocker and diabetes medication, may not be sufficient to control the patient's underlying cardiac conditions, increasing the risk of adverse cardiac events.

Considering these factors, the patient's outcome of sudden cardiac death is likely a result of the combination of severe left ventricular dysfunction, underlying ventricular arrhythmogenicity, severe heart failure, hypertension, dyslipemia, diabetes, and renal impairment, which together increased the patient's risk of sudden cardiac death."
719,719,P0734,"Age: 67
Gender: Male 
Weight: 64 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 125/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 2,87
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 5,3
LDL (mmol/L): 1,68
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 2362.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,53
Urea (mg/dL): 10,65
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to several factors based on the provided data and medical history. 

1.  Ischemic Dilated Cardiomyopathy (IDC): The patient has a history of ischemic dilated cardiomyopathy, which significantly increases the risk of sudden cardiac death. IDC is characterized by reduced left ventricular function and can lead to life-threatening arrhythmias.

2.  Reduced Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 20%, which indicates severe left ventricular dysfunction. A reduced LVEF is a well-established predictor of increased risk of sudden cardiac death.

3.  Non-Sustained Ventricular Tachycardia (NSVT): The patient has a history of non-sustained ventricular tachycardia, which is a known risk factor for sudden cardiac death. NSVT can degenerate into sustained ventricular tachycardia or ventricular fibrillation, leading to cardiac arrest.

4.  High Pro-BNP Levels: The patient's Pro-BNP level is elevated at 2362.0 ng/L, indicating increased ventricular wall stress and a high risk of adverse cardiac events, including sudden cardiac death.

5.  Medication Non-Adherence or Inadequate Treatment: Although the patient is on medications such as beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor, the patient's high risk of sudden cardiac death suggests that the treatment may not be adequate or the patient may not be adhering to the medication regimen.

6.  Electrocardiogram (ECG) Abnormalities: The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are both risk factors for sudden cardiac death.

7.  Other Contributing Factors: The patient's history of hypertension, dyslipidemia, and elevated creatinine levels may also contribute to the increased risk of sudden cardiac death.

In summary, the combination of ischemic dilated cardiomyopathy, reduced LVEF, non-sustained ventricular tachycardia, high Pro-BNP levels, and ECG abnormalities likely contributed to the patient's outcome of sudden cardiac death."
720,720,P0743,"Age: 57
Gender: Male 
Weight: 73 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41,4
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 5,79
Creatinine (mmol/L): 86.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 153.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 3,9
LDL (mmol/L): 4,01
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 313.0
Protein (g/L): 71,6
T4 (ng/L): 19
TSH (mIU/L): 0,36
Urea (mg/dL): 6,66
LVEF (%): 55.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

Given the patient's complex medical history, which includes enolic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction, the patient is at a high risk for sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) of 55% indicates reduced cardiac function, which increases the risk of arrhythmias and cardiac arrest.

The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG suggests underlying ventricular instability, which is a known predictor of sudden cardiac death. The patient's elevated pro-BNP level of 313 ng/L also indicates increased ventricular wall stress, which can contribute to arrhythmias and cardiac death.

The patient's diabetes and dyslipemia may also contribute to the development of coronary artery disease, which could further increase the risk of myocardial infarction and sudden cardiac death. The patient's hypertension and enolic dilated cardiomyopathy also contribute to the overall risk of cardiac complications.

Additionally, the patient's low potassium level (3.9 mEq/L) may contribute to cardiac arrhythmias, as potassium is essential for maintaining normal cardiac function.

Despite the patient's current medications, including beta blockers, loop diuretics, statins, and ACE inhibitors, which are aimed at managing heart failure and reducing the risk of cardiac events, the patient's underlying conditions and ECG findings suggest that the patient is at high risk for sudden cardiac death."
721,721,P0765,"Age: 72
Gender: Female 
Weight: 48 kg
Height: 143 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 39,3
ALT or GPT (IU/L): 37.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 5,63
Creatinine (mmol/L): 81.0
Gamma-glutamil transpeptidase (IU/L): 60
Glucose (mmol/L): 10,5
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,97
Potassium (mEq/L): 4,28
LDL (mmol/L): 3,21
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 2910.0
Protein (g/L): 75,9
Troponin (ng/mL): 0,2
TSH (mIU/L): 1,31
Urea (mg/dL): 9,5
LVEF (%): 20.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Sinus Node Dysfunction
            ",sudden cardiac death,"REASONING: 

This patient's outcome of sudden cardiac death is likely due to a combination of several factors contributing to her high-risk cardiac profile. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack, leading to a reduced left ventricular ejection fraction (LVEF) of 20%. This suggests that the patient's heart is not pumping efficiently, making her more susceptible to cardiac arrhythmias and sudden cardiac death.

The patient's elevated Pro-BNP (B-type natriuretic peptide) level of 2910.0 ng/L is indicative of heart failure and increased ventricular wall stress. Elevated Pro-BNP levels are associated with an increased risk of cardiovascular events, including sudden cardiac death.

The patient's past medical history of myocardial infarction (heart attack) further increases her risk of sudden cardiac death. Additionally, her history of hypertension, dyslipidemia, and peripheral vascular disease contribute to her high-risk profile.

The patient's ECG findings of polymorphic ventricular extrasystoles and sinus node dysfunction also suggest underlying cardiac conduction abnormalities, which can increase the risk of sudden cardiac death.

The patient's medications, including digoxin and loop diuretics, may also contribute to her risk of sudden cardiac death, particularly digoxin toxicity, which can cause arrhythmias and cardiac arrest.

Lastly, the patient's low LVEF, combined with her high-risk medical history and ECG findings, makes her a candidate for sudden cardiac death, which ultimately occurred."
722,722,P0776,"Age: 61
Gender: Male 
Weight: 75 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 105/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 40,4
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,95
Creatinine (mmol/L): 259.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 8,8
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,86
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,45
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3274.0
Protein (g/L): 69
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,7
Urea (mg/dL): 15,8
LVEF (%): 33.0
Medications: Calcium Channel Blocker, Amiodarone, Beta Blockers, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type II
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of factors present in their medical history, laboratory results, and ECG findings. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which indicates significant left ventricular dysfunction. The left ventricular ejection fraction (LVEF) of 33% further supports this, indicating severe heart failure. This condition increases the risk of sudden cardiac death due to arrhythmias and electrical instability.

The patient's ECG shows non-sustained ventricular tachycardia (NSVT), which is a known predictor of sudden cardiac death in patients with heart failure. The presence of polymorphic ventricular extrasystoles and second-degree atrioventricular block (AVB) type II also increases the risk of arrhythmic events.

Additionally, the patient's high levels of pro-BNP (3274 ng/L) indicate severe heart failure, which is a strong predictor of adverse outcomes, including sudden cardiac death.

The patient's medication regimen, including beta blockers, amiodarone, and loop diuretics, suggests that they are being managed for heart failure and arrhythmias. However, the presence of non-sustained ventricular tachycardia and other ECG abnormalities suggests that the patient may not be adequately protected against arrhythmic events.

Furthermore, the patient's diabetes and hypertension contribute to the development and progression of heart failure, further increasing the risk of sudden cardiac death.

In summary, the combination of severe left ventricular dysfunction, NSVT, high pro-BNP levels, and other ECG abnormalities, along with the patient's medical history and medication regimen, likely contributed to the patient's outcome of sudden cardiac death."
723,723,P0779,"Age: 73
Gender: Female 
Weight: 68 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 100/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 44,8
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 3,91
Creatinine (mmol/L): 107.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,13
Potassium (mEq/L): 4,14
LDL (mmol/L): 2,02
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 2428.0
Protein (g/L): 75,2
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,7
Urea (mg/dL): 9,9
LVEF (%): 31.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of several factors, including her underlying heart condition (idiopathic dilated cardiomyopathy) and the presence of non-sustained ventricular tachycardia (NSVT) on the ECG. The patient's left ventricular ejection fraction (LVEF) of 31% indicates severely reduced cardiac function, which increases the risk of sudden cardiac death.

The patient's medications, including Digoxin, Loop Diuretics, Spironolactone, and ACE Inhibitor, are aimed at managing her heart failure symptoms and reducing the risk of sudden cardiac death. However, the presence of NSVT on the ECG suggests that these medications may not be fully effective in preventing life-threatening arrhythmias.

Additionally, the patient's elevated Pro-BNP (brain natriuretic peptide) level of 2428.0 ng/L indicates increased ventricular wall stress and strain, which is a marker of heart failure severity. The patient's low HDL (1.13 mmol/L) and high LDL (2.02 mmol/L) cholesterol levels suggest dyslipidemia, which is a known risk factor for cardiovascular disease.

The patient's low hemoglobin level (135.0 g/L) may indicate anemia, which can contribute to decreased oxygen delivery to the heart muscle, potentially exacerbating cardiac dysfunction.

The patient's age (73) and NYHA Class III classification also indicate advanced heart failure, which increases the risk of sudden cardiac death. The patient's blood pressure is within a relatively normal range (100/75 mmHg), but the presence of hypotension may indicate decreased cardiac output and perfusion of vital organs.

In summary, the combination of the patient's underlying heart condition, reduced cardiac function, NSVT on ECG, elevated Pro-BNP level, dyslipidemia, anemia, and advanced age likely contributed to her sudden cardiac death."
724,724,P0784,"Age: 59
Gender: Male 
Weight: 79 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 48,1
ALT or GPT (IU/L): 80.0
AST or GOT (IU/L): 51.0
Total Cholesterol (mmol/L): 5,7
Creatinine (mmol/L): 117.0
Gamma-glutamil transpeptidase (IU/L): 109
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 158.0
HDL (mmol/L): 0,99
Potassium (mEq/L): 4,39
LDL (mmol/L): 3,5
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 543.0
Protein (g/L): 84,9
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,62
Urea (mg/dL): 7,1
LVEF (%): 29.0
Medications: Amiodarone, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death is likely due to a combination of factors, primarily related to his underlying ischemic dilated cardiomyopathy, which is characterized by a reduced left ventricular ejection fraction (LVEF) of 29%. This condition indicates severe heart failure, making the patient susceptible to sudden cardiac death.

The patient's history of myocardial infarction and peripheral vascular disease further increases the risk of cardiac complications. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG is a known risk factor for sudden cardiac death, particularly in patients with reduced LVEF.

Additionally, the patient's elevated troponin level (0.01 ng/mL) indicates ongoing cardiac damage or stress, which can increase the risk of arrhythmias and sudden cardiac death.

The patient's medications, including beta blockers, amiodarone, and digoxin, are intended to manage symptoms and prevent arrhythmias, but may not be sufficient to prevent sudden cardiac death in this high-risk patient.

The patient's high pro-BNP level (543 ng/L) also suggests severe heart failure, which is a known risk factor for sudden cardiac death.

Furthermore, the patient's high creatinine level (117.0 mmol/L) and low hemoglobin level (158.0 g/L) may indicate chronic kidney disease and anemia, respectively, which can further exacerbate cardiac function and increase the risk of sudden cardiac death.

In summary, the patient's combination of ischemic dilated cardiomyopathy, NSVT, elevated troponin, and high pro-BNP levels, along with his other comorbidities, make him a high-risk patient for sudden cardiac death."
725,725,P0804,"Age: 73
Gender: Male 
Weight: 81 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 80/40 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 42,2
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 5,55
Creatinine (mmol/L): 110.0
Gamma-glutamil transpeptidase (IU/L): 95
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,89
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 949.0
Protein (g/L): 80,2
Troponin (ng/mL): 0,04
TSH (mIU/L): 2,06
Urea (mg/dL): 8,1
LVEF (%): 25.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death is likely due to a combination of several factors, primarily related to their underlying cardiac condition and comorbidities.

1.  Ischemic Dilated Cardiomyopathy and Reduced LVEF: The patient has a history of ischemic dilated cardiomyopathy with a severely reduced left ventricular ejection fraction (LVEF) of 25%. This indicates that the heart is not pumping efficiently, which increases the risk of sudden cardiac death.

2.  Previous Myocardial Infarction: The patient has a history of myocardial infarction, which may have contributed to the development of the ischemic dilated cardiomyopathy. This further increases the risk of sudden cardiac death.

3.  Ventricular Arrhythmias: The ECG findings of polymorphic ventricular extrasystoles, non-sustained ventricular tachycardia (VT), and unknown paroxysmal supraventricular tachyarrhythmia suggest an increased risk of arrhythmias, which can be life-threatening, especially in a patient with a reduced LVEF.

4.  Low Blood Pressure: The patient's blood pressure is low (80/40 mmHg), which may indicate a compromised cardiac output or volume depletion, further increasing the risk of sudden cardiac death.

5.  Elevated Pro-BNP: The elevated pro-b-type natriuretic peptide (Pro-BNP) level of 949 ng/L is indicative of heart failure and increased ventricular wall stress, which is consistent with the patient's reduced LVEF.

6.  Kidney Function: The elevated creatinine level (110.0 umol/L) suggests impaired kidney function, which may be related to the patient's heart failure and reduced cardiac output.

7.  Medications: The patient is on several medications, including beta blockers, digoxin, loop diuretics, spironolactone, ACE inhibitor, and nitrovasodilator. While these medications are generally used to manage heart failure and arrhythmias, they may not be sufficient to prevent sudden cardiac death in this high-risk patient.

Considering these factors, the patient's outcome of sudden cardiac death is likely a result of a complex interplay between their underlying cardiac condition, comorbidities, and potentially inadequate management of their medications."
726,726,P0806,"Age: 71
Gender: Male 
Weight: 78 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 115/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,09
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 158.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,4
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 170.0
Protein (g/L): 68
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,77
Urea (mg/dL): 8,32
LVEF (%): 35.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of several factors based on the provided data.

1. Ischemic Dilated Cardiomyopathy (IDC): The patient has a history of IDC, which significantly increases the risk of sudden cardiac death. IDC is a condition where the heart muscle becomes weakened and enlarged, leading to reduced cardiac function and increased risk of arrhythmias and sudden cardiac death.

2. Reduced Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 35%, which is below the normal range of 55-70%. This indicates that the heart is not pumping efficiently, increasing the risk of sudden cardiac death.

3. High Pro-BNP Levels: The patient's Pro-BNP level is 170.0 ng/L, which is elevated. Pro-BNP is a biomarker of heart failure and is associated with increased risk of sudden cardiac death.

4. Ventricular Extrasystole: The patient has polymorphic ventricular extrasystoles, which are abnormal heartbeats that originate in the ventricles. This can be a sign of underlying cardiac disease and may increase the risk of arrhythmias and sudden cardiac death.

5. Medication Non-Adherence or Inadequate Dosing: The patient is on beta blockers, spironolactone, statins, and an ACE inhibitor, which are standard medications for managing IDC and heart failure. However, the patient's medication regimen may not be optimized, or there may be non-adherence, which can increase the risk of sudden cardiac death.

6. Age and Comorbidities: The patient is 71 years old and has a history of hypertension and dyslipemia, which are additional risk factors for sudden cardiac death.

Considering these factors, the patient's sudden cardiac death can be attributed to a combination of ischemic dilated cardiomyopathy, reduced LVEF, high Pro-BNP levels, ventricular extrasystoles, and potential medication non-adherence or inadequate dosing."
727,727,P0838,"Age: 75
Gender: Male 
Weight: 67 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 42,1
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 7,1
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,3
Potassium (mEq/L): 3,92
LDL (mmol/L): 5,23
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 8831.0
Protein (g/L): 80
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,01
Urea (mg/dL): 10,8
LVEF (%): 15.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of several factors. Firstly, the patient has a history of hypertrophic cardiomyopathy, which is a known risk factor for sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is severely reduced at 15%, indicating significant left ventricular dysfunction. This reduced LVEF is a strong predictor of increased mortality and sudden cardiac death.

Additionally, the patient's elevated Pro-BNP (Brain Natriuretic Peptide) level of 8831.0 ng/L is indicative of severe heart failure, which further increases the risk of sudden cardiac death. The patient's medications, including beta blockers and loop diuretics, are typically used to manage heart failure and reduce the risk of sudden cardiac death, but in this case, they may not have been sufficient to prevent the outcome.

The patient's potassium level of 3.92 mEq/L is also slightly low, which can contribute to arrhythmias and increase the risk of sudden cardiac death. The presence of ventricular extrasystoles on the ECG further supports the risk of arrhythmias and sudden cardiac death.

Furthermore, the patient's low HDL cholesterol level of 1.3 mmol/L and high LDL cholesterol level of 5.23 mmol/L may indicate atherosclerotic disease, which can contribute to cardiac dysfunction and increase the risk of sudden cardiac death.

The patient's age of 75 and NYHA Class II classification also indicate that the patient has significant cardiovascular disease and is at increased risk for sudden cardiac death. Overall, the combination of these factors contributed to the patient's outcome of sudden cardiac death."
728,728,P0846,"Age: 58
Gender: Male 
Weight: 86 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 90/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,35
Creatinine (mmol/L): 164.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 5,3
LDL (mmol/L): 3,65
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3551.0
Protein (g/L): 76
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,04
Urea (mg/dL): 11,65
LVEF (%): 36.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death is likely due to a combination of factors related to his underlying heart condition and other comorbidities. 

1. Idiopathic dilated cardiomyopathy: This condition is characterized by a weakened heart muscle that is unable to pump blood effectively, leading to reduced left ventricular ejection fraction (LVEF) of 36%. The patient's LVEF is significantly reduced, indicating poor cardiac function.

2. High Pro-BNP levels: A Pro-BNP level of 3551.0 ng/L is elevated, indicating increased ventricular strain and possible heart failure. Elevated BNP levels are associated with increased mortality and morbidity in heart failure patients.

3. Ventricular extrasystoles: The presence of polymorphic ventricular extrasystoles on the ECG suggests abnormal electrical activity in the heart, which can increase the risk of arrhythmias and sudden cardiac death.

4. Reduced LVEF and low blood pressure: The patient's low blood pressure (90/60 mmHg) and reduced LVEF may indicate a high risk of cardiac arrest, as the heart is unable to pump blood effectively to meet the body's needs.

5. Electrolyte imbalance: The patient's potassium level (5.3 mEq/L) is slightly elevated, which can contribute to arrhythmias and cardiac arrest.

6. Medication non-adherence or inadequate management: The patient is taking beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, but the combination and dosage of these medications may not be optimal for this patient's specific condition.

7. Other comorbidities: The patient's elevated creatinine level (164.0 μmol/L) and urea level (11.65 mg/dL) suggest chronic kidney disease, which can further compromise cardiac function and increase the risk of sudden cardiac death.

Considering these factors, the patient's sudden cardiac death is likely due to a combination of his underlying heart condition, medication non-adherence or inadequate management, and other comorbidities."
729,729,P0848,"Age: 63
Gender: Female 
Weight: 72 kg
Height: 175 cm
NYHA Class: III
Blood Pressure: 120/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,53
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,9
LDL (mmol/L): 2,74
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 11195.0
Protein (g/L): 70
T3 (pg/dL): 0,02
T4 (ng/L): 18
Troponin (ng/mL): 0,1
TSH (mIU/L): 3,97
Urea (mg/dL): 7,32
LVEF (%): 25.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

This patient's outcome of sudden cardiac death can be attributed to a combination of several factors based on the provided information.

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and enlarged due to a heart attack or other damage to the heart muscle. This condition is a significant risk factor for sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) of 25% indicates severe systolic dysfunction, further increasing the risk of sudden cardiac death.

Secondly, the patient's elevated Pro-BNP level of 11195 ng/L suggests that the heart is under significant stress, likely due to the reduced ejection fraction and the presence of heart failure symptoms. Elevated Pro-BNP levels are associated with increased risk of cardiovascular events, including sudden cardiac death.

Thirdly, the patient has a history of myocardial infarction, which can lead to scarring and fibrosis in the heart muscle, further increasing the risk of arrhythmias and sudden cardiac death.

Fourthly, the patient's ECG shows non-sustained ventricular tachycardia, which is a type of abnormal heart rhythm that can increase the risk of sudden cardiac death.

Lastly, the patient's NYHA class III indicates that they have severe heart failure symptoms, which can further increase the risk of sudden cardiac death.

Given these factors, it is likely that the patient's sudden cardiac death was related to a combination of their underlying heart disease, heart failure, and arrhythmias."
730,730,P0860,"Age: 67
Gender: Male 
Weight: 90 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 190/110 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 49,4
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 3,31
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 7,5
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,55
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 597.0
Protein (g/L): 84,2
T3 (pg/dL): 0,06
T4 (ng/L): 19
TSH (mIU/L): 0,07
Urea (mg/dL): 6,32
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death can be attributed to a combination of factors related to his underlying medical conditions and laboratory results. 

Firstly, the patient has ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack, leading to a decrease in the left ventricular ejection fraction (LVEF) to 35%. This indicates that the heart is not pumping efficiently, which can increase the risk of sudden cardiac death.

The patient's blood pressure is significantly elevated at 190/110 mmHg, which is a major risk factor for cardiovascular disease and can further strain the heart. His past medical history of myocardial infarction, peripheral vascular disease, and hypertension also contribute to the increased risk of sudden cardiac death.

Additionally, the patient's laboratory results show elevated levels of pro-BNP (brain natriuretic peptide), which is a biomarker of heart failure and strain on the heart. His low hemoglobin level of 140 g/L may indicate anemia, which can further reduce oxygen delivery to the heart muscle, increasing the risk of cardiac events.

The patient's ECG results show ventricular extrasystoles, which are abnormal heartbeats that can be a sign of underlying cardiac disease. Although the patient is on medications such as calcium channel blockers, beta blockers, statins, and nitrovasodilators, which are intended to manage his cardiovascular conditions, they may not be sufficient to mitigate the risks associated with his underlying conditions.

The patient's low LVEF of 35% and elevated pro-BNP levels indicate that his heart is under significant strain, and the combination of these factors increases the risk of sudden cardiac death. Therefore, the patient's outcome of sudden cardiac death is likely due to the cumulative effect of his underlying cardiovascular conditions, laboratory abnormalities, and potentially inadequate management of his medications."
731,731,P0880,"Age: 84
Gender: Male 
Weight: 80 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 8,8
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,09
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 444.0
Protein (g/L): 71
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,46
Urea (mg/dL): 10,48
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

This patient's outcome of sudden cardiac death can be attributed to a combination of factors from his medical history, laboratory results, and ECG findings. 

Firstly, the patient has a history of hypertensive cardiomyopathy, which is a condition where the heart muscle becomes thickened and stiff due to high blood pressure, leading to reduced heart function. This is evident from his low left ventricular ejection fraction (LVEF) of 30%, which is below the normal range of 55-70%. The patient's LVEF indicates that his heart is not pumping efficiently, which increases the risk of sudden cardiac death.

The patient's elevated Pro-BNP (B-type natriuretic peptide) level of 444.0 ng/L is also indicative of heart failure, as high levels of Pro-BNP are associated with increased wall stress and decreased cardiac function. Additionally, his low hemoglobin level of 132.0 g/L may contribute to reduced oxygen delivery to the myocardium, further increasing the risk of cardiac arrhythmias.

The patient's ECG findings of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia are concerning for an increased risk of life-threatening arrhythmias. The presence of these arrhythmias, combined with his reduced LVEF and elevated Pro-BNP, increases the risk of sudden cardiac death.

Furthermore, the patient's history of diabetes and hypertension may have contributed to the development of his hypertensive cardiomyopathy and reduced LVEF. His high total cholesterol level of 3.49 mmol/L and low HDL level of 1.01 mmol/L also increase his risk of cardiovascular disease.

The patient's medications, including beta blockers, statins, and ACE inhibitors, are standard treatments for heart failure and hypertension, but may not have been sufficient to prevent the patient's outcome.

In summary, the patient's combination of reduced LVEF, elevated Pro-BNP, ECG findings of arrhythmias, and history of hypertension and diabetes all contributed to his increased risk of sudden cardiac death."
732,732,P0898,"Age: 67
Gender: Male 
Weight: 85 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 37,1
ALT or GPT (IU/L): 86.0
AST or GOT (IU/L): 49.0
Total Cholesterol (mmol/L): 4,58
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 177
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,95
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 5629.0
Protein (g/L): 59,4
T4 (ng/L): 13
TSH (mIU/L): 1,06
Urea (mg/dL): 5,16
LVEF (%): 40.0
Medications: Diabetes Medication, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

This patient's outcome of sudden cardiac death can be attributed to a combination of his underlying medical conditions and laboratory results. 

Firstly, the patient has a history of hypertrophic cardiomyopathy, which is a condition where the heart muscle becomes abnormally thick, making it harder for the heart to pump blood effectively. This condition is a significant risk factor for sudden cardiac death.

The patient's left ventricular ejection fraction (LVEF) is 40%, which is below the normal range of 50-70%. A low LVEF indicates that the heart is not pumping efficiently, which can lead to decreased cardiac output and increased risk of cardiac arrhythmias and sudden cardiac death.

The patient's high Pro-BNP level of 5629.0 ng/L is also concerning. BNP is a hormone produced by the heart in response to increased wall stress, and elevated levels are associated with heart failure and increased risk of cardiac events.

The presence of ventricular extrasystoles, specifically polymorphic, on the ECG is also a concerning finding. Polymorphic ventricular extrasystoles can be a sign of abnormal electrical activity in the heart, which can increase the risk of arrhythmias and sudden cardiac death.

Furthermore, the patient's laboratory results show elevated liver enzymes (AST and ALT), which can indicate liver dysfunction, and an elevated gamma-glutamil transpeptidase (GGT), which can indicate bile duct obstruction or liver damage. Elevated liver enzymes can be a sign of cardiac congestion or heart failure, which can contribute to the patient's risk of sudden cardiac death.

Additionally, the patient's medications, including spironolactone and ACE inhibitor, are typically used to manage heart failure and hypertension, but may not be sufficient to manage the patient's underlying cardiac conditions.

In summary, the patient's history of hypertrophic cardiomyopathy, low LVEF, high Pro-BNP levels, polymorphic ventricular extrasystoles on ECG, and elevated liver enzymes, combined with his medications, likely contributed to his sudden cardiac death."
733,733,P0938,"Age: 71
Gender: Male 
Weight: 94 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 96/67 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 37,1
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,24
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 37
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 103.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,82
Sodium (mEq/L): 143.0
Protein (g/L): 71,9
T4 (ng/L): 16
TSH (mIU/L): 3,71
Urea (mg/dL): 7,15
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

Given the patient's age, sex, and history of ischemic dilated cardiomyopathy and myocardial infarction, the patient is at high risk for cardiac complications. The patient's NYHA Class III classification indicates that the patient experiences symptoms of heart failure with minimal physical activity, further indicating the severity of the cardiac condition.

The patient's low left ventricular ejection fraction (LVEF) of 25% suggests that the heart is severely impaired in its ability to pump blood effectively, which increases the risk of sudden cardiac death. The presence of polymorphic ventricular extrasystoles on the ECG indicates that the heart is experiencing abnormal electrical activity, which can be a precursor to life-threatening arrhythmias.

The patient's low blood pressure of 96/67 mmHg may indicate decreased cardiac output, which can further exacerbate the risk of cardiac complications. The patient's medications, including a calcium channel blocker, loop diuretics, and nitrovasodilator, are commonly used to manage heart failure and hypertension, but the patient's condition suggests that these medications may not be sufficient to manage the severity of the cardiac impairment.

The patient's laboratory results show elevated creatinine levels (88.0 μmol/L), which indicates impaired kidney function, a common comorbidity in patients with heart failure. The patient's low albumin levels (37.1 g/L) and low protein levels (71.9 g/L) suggest malnutrition, which can further exacerbate cardiac function and increase the risk of complications.

The patient's total cholesterol level of 4.24 mmol/L is within the borderline high range, and the patient's LDL level of 2.82 mmol/L is above the recommended target. Elevated cholesterol levels can contribute to atherosclerosis, which can further compromise cardiac function.

The patient's TSH level of 3.71 mIU/L is within the normal range, indicating that hypothyroidism is unlikely to be a contributing factor to the patient's cardiac condition.

In summary, the combination of the patient's severe cardiac impairment, abnormal ECG findings, decreased cardiac output, impaired kidney function, malnutrition, and elevated cholesterol levels increases the risk of sudden cardiac death. The patient's medications may not be sufficient to manage the severity of the cardiac impairment, and the patient's overall condition suggests that the patient is at high risk for cardiac complications."
734,734,P0951,"Age: 63
Gender: Male 
Weight: 55 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 156/85 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 5,2
HDL (mmol/L): 1,55
Potassium (mEq/L): 5,8
LDL (mmol/L): 2,92
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 167.0
Protein (g/L): 73
T3 (pg/dL): 0,06
T4 (ng/L): 16
TSH (mIU/L): 1,13
Urea (mg/dL): 5,66
LVEF (%): 21.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: The patient's outcome of sudden cardiac death is likely due to a combination of factors related to his underlying cardiomyopathy and other comorbidities. 

The patient has a history of enolic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers dilate, leading to reduced cardiac function. The patient's left ventricular ejection fraction (LVEF) is severely impaired at 21%, indicating a significant reduction in cardiac output. This condition increases the risk of sudden cardiac death due to arrhythmias or cardiac arrest.

Additionally, the patient's high blood pressure (156/85 mmHg) and hypertension history contribute to the strain on the heart, further exacerbating the cardiomyopathy. The patient's low HDL cholesterol level (1.55 mmol/L) and high LDL cholesterol level (2.92 mmol/L) may also contribute to atherosclerotic cardiovascular disease, increasing the risk of cardiac events.

The patient's elevated Pro-BNP level (167.0 ng/L) is indicative of heart failure, which is consistent with his dilated cardiomyopathy. The patient's low albumin level (44 g/L) and elevated creatinine level (88.0 umol/L) suggest kidney dysfunction, which is a common comorbidity in patients with heart failure.

The patient's medication regimen includes beta blockers, digoxin, loop diuretics, and an ACE inhibitor, which are commonly used to manage heart failure and hypertension. However, despite these medications, the patient's condition has progressed to sudden cardiac death, indicating that these treatments may not have been sufficient to control his condition.

The presence of polymorphic ventricular extrasystoles on the ECG suggests that the patient's heart is experiencing abnormal electrical activity, which may be contributing to his risk of arrhythmias and sudden cardiac death.

In conclusion, the patient's outcome of sudden cardiac death is likely due to a combination of factors related to his underlying cardiomyopathy, hypertension, kidney dysfunction, and abnormal cardiac electrical activity, which have not been adequately managed by his current medication regimen."
735,735,P0967,"Age: 69
Gender: Male 
Weight: 58 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 156/79 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 39
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 6,41
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 119.0
Pro-BNP (ng/L): 4999.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 23
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,17
Urea (mg/dL): 9,32
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, Hydralazine
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

This patient's outcome of sudden cardiac death can be attributed to a combination of several factors present in the provided data. 

Firstly, the patient has a history of hypertensive cardiomyopathy, which is a condition where the heart muscle becomes thickened and weakened due to high blood pressure, leading to reduced heart function. This is evident from the patient's low left ventricular ejection fraction (LVEF) of 35%, indicating a compromised heart function.

The patient's elevated Pro-BNP (Brain Natriuretic Peptide) level of 4999.0 ng/L is also indicative of heart failure, as Pro-BNP is a biomarker used to diagnose and monitor heart failure. The patient's blood pressure of 156/79 mmHg is slightly elevated, which may indicate uncontrolled hypertension, further contributing to the patient's heart condition.

The patient's troponin level of 0.01 ng/mL is within the normal range, indicating no acute myocardial infarction (heart attack) at the time of testing. However, the presence of troponin is not always a definitive indicator of acute coronary syndrome, and a negative troponin does not rule out chronic coronary artery disease.

The patient's TSH (Thyroid-Stimulating Hormone) level of 2.17 mIU/L is within the normal range, which suggests that hypothyroidism is not a contributing factor to the patient's cardiac condition.

The patient's ECG shows polymorphic ventricular extrasystoles, which are abnormal heart rhythms that can be a sign of underlying cardiac disease. However, the presence of TPSV (paroxysmal supraventricular tachyarrhythmia) and the absence of ventricular tachycardia or non-sustained ventricular tachycardia suggest that the patient's cardiac arrhythmias are not the primary cause of the sudden cardiac death.

The patient's low hemoglobin level of 119 g/L may indicate anemia, which can contribute to reduced oxygen delivery to the heart muscle, potentially exacerbating heart failure.

The patient's medication regimen includes calcium channel blockers, beta blockers, loop diuretics, statins, and hydralazine, which are all standard treatments for heart failure and hypertension. However, the patient's sudden cardiac death may indicate that these medications were not sufficient to manage the underlying cardiac condition effectively.

Considering the patient's complex medical history, the combination of hypertensive cardiomyopathy, heart failure, and compromised heart function likely contributed to the patient's sudden cardiac death."
736,736,P0968,"Age: 71
Gender: Male 
Weight: 87 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 130/85 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 10.0
Total Cholesterol (mmol/L): 4,4
Creatinine (mmol/L): 150.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 5,6
LDL (mmol/L): 2,12
Sodium (mEq/L): 135.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,26
Urea (mg/dL): 13,31
LVEF (%): 35.0
Medications: Beta Blockers, Spironolactone, Statins, Hydralazine
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"REASONING: 

This patient's outcome of sudden cardiac death is likely due to a combination of factors related to his underlying cardiomyopathy, medication non-adherence, and potential electrolyte imbalances. 

1. Idiopathic dilated cardiomyopathy: The patient's LVEF (Left Ventricular Ejection Fraction) of 35% indicates severe left ventricular dysfunction, which increases the risk of sudden cardiac death. Dilated cardiomyopathy is a known cause of sudden cardiac death, particularly in patients with reduced LVEF.

2. Medication non-adherence: The patient is taking beta blockers, spironolactone, statins, and hydralazine, which are standard medications for heart failure and cardiomyopathy. However, if the patient is not adhering to these medications, it may lead to inadequate control of his heart failure symptoms and increase the risk of sudden cardiac death.

3. Electrolyte imbalances: The patient's potassium level is slightly elevated at 5.6 mEq/L, which can be a risk factor for arrhythmias and sudden cardiac death. Although the level is not severely elevated, it may be contributing to the patient's arrhythmias.

4. Ventricular extrasystoles: The presence of polymorphic ventricular extrasystoles on the ECG is a sign of abnormal electrical activity in the heart, which can increase the risk of arrhythmias and sudden cardiac death.

5. Reduced T3 and T4 levels: The patient's T3 and T4 levels are within the normal range, but slightly low. Low thyroid hormone levels can contribute to heart failure and arrhythmias, increasing the risk of sudden cardiac death.

6. High creatinine levels: The patient's creatinine level is elevated at 150.0 mmol/L, indicating impaired renal function. This may be contributing to the patient's electrolyte imbalances and potentially increasing the risk of sudden cardiac death.

Considering these factors, it is likely that the patient's sudden cardiac death was caused by a combination of his underlying cardiomyopathy, medication non-adherence, and potential electrolyte imbalances."
737,737,P0972,"Age: 69
Gender: Female 
Weight: 80 kg
Height: 154 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 34
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,25
Creatinine (mmol/L): 53.0
Gamma-glutamil transpeptidase (IU/L): 43
Glucose (mmol/L): 8,8
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,64
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 436.0
Protein (g/L): 69
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,4
Urea (mg/dL): 4,49
LVEF (%): 60.0
Medications: Calcium Channel Blocker, Diabetes Medication, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of several factors present in the patient's medical history and test results. 

Firstly, the patient has a history of Hypertensive cardiomyopathy, which is a condition where the heart muscle becomes thickened due to high blood pressure, leading to reduced heart function. This condition is often associated with a higher risk of heart failure and arrhythmias. 

The patient's NYHA Class III classification indicates that she has severe symptoms of heart failure, such as shortness of breath and fatigue, even at rest or during minimal exertion. This suggests that her heart is not functioning optimally, making her more susceptible to cardiac complications.

The patient's elevated Pro-BNP (Brain Natriuretic Peptide) level of 436.0 ng/L is indicative of heart failure, as it is a marker of cardiac strain and stress. The level is significantly elevated, suggesting that the patient's heart is under considerable stress.

The patient's ECG results show polymorphic ventricular extrasystoles, which are abnormal heartbeats originating from the ventricles. While not life-threatening on their own, these can be a sign of underlying cardiac disease and may increase the risk of sudden cardiac death.

The patient's low HDL (good cholesterol) level of 1.55 mmol/L and high LDL (bad cholesterol) level of 2.64 mmol/L contribute to her dyslipemia, which can increase the risk of cardiac events.

Furthermore, the patient's diabetes and hypertension further exacerbate her cardiac condition, as these conditions can lead to further cardiac damage and increased risk of cardiac events.

Lastly, the patient's medications, while intended to manage her conditions, may have contributed to her outcome. For instance, the calcium channel blocker may have had an adverse effect on her cardiac function, and the loop diuretics may have led to dehydration, which can increase the risk of cardiac arrhythmias.

In conclusion, the patient's sudden cardiac death can be attributed to a combination of her underlying cardiac conditions, heart failure, dyslipemia, diabetes, hypertension, and potential adverse effects of her medications."
738,738,P0974,"Age: 80
Gender: Female 
Weight: 52 kg
Height: 154 cm
NYHA Class: III
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,03
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,1
LDL (mmol/L): 4,37
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 4255.0
Protein (g/L): 75
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,609
Urea (mg/dL): 9,32
LVEF (%): 27.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death can be attributed to a combination of several factors. 

1.  Low Left Ventricular Ejection Fraction (LVEF): The patient has a significantly reduced LVEF of 27%, indicating severe left ventricular dysfunction. This is a major risk factor for sudden cardiac death in patients with heart failure.

2.  High BNP Levels: The patient has a very high Pro-BNP level of 4255.0 ng/L, which is indicative of severe heart failure and increased risk of sudden cardiac death.

3.  Ventricular Arrhythmias: The presence of non-sustained ventricular tachycardia (VT) and polymorphic ventricular extrasystoles on the ECG suggests an increased risk of arrhythmias, which can lead to sudden cardiac death.

4.  Reduced Hemoglobin Levels: The patient has a low hemoglobin level of 135.0 g/L, which may indicate anemia. Anemia can exacerbate heart failure symptoms and increase the risk of sudden cardiac death.

5.  Medication Non-Optimization: Although the patient is on ACE inhibitors, digoxin, loop diuretics, and spironolactone, the medication regimen may not be fully optimized for this patient's condition. The patient's LVEF is still very low, suggesting that the current medication regimen may not be sufficient to improve cardiac function.

6.  Poor Nutritional Status: The patient has a low serum albumin level of 42 g/L, indicating poor nutritional status. Malnutrition can exacerbate heart failure symptoms and increase the risk of complications, including sudden cardiac death.

7.  Advanced Age and NYHA Class III: The patient is 80 years old and has a NYHA Class III heart failure, indicating severe symptoms that limit physical activity. Advanced age and severe heart failure increase the risk of sudden cardiac death.

In summary, the patient's combination of severe left ventricular dysfunction, high BNP levels, ventricular arrhythmias, anemia, potential medication non-optimization, poor nutritional status, advanced age, and severe heart failure symptoms all contributed to an increased risk of sudden cardiac death."
739,739,P1001,"Age: 46
Gender: Male 
Weight: 90 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 48.0
AST or GOT (IU/L): 39.0
Total Cholesterol (mmol/L): 2,79
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 74
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 137.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 4,3
LDL (mmol/L): 1,71
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 766.0
Protein (g/L): 64
T4 (ng/L): 10
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,89
Urea (mg/dL): 9,65
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

Given the patient's history of ischemic dilated cardiomyopathy, previous myocardial infarction, and low left ventricular ejection fraction (LVEF) of 30%, the patient is at high risk for sudden cardiac death. The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG further increases the risk of life-threatening arrhythmias.

The patient's elevated Pro-BNP level of 766.0 ng/L indicates increased ventricular wall stress, which is consistent with heart failure and a high risk of sudden cardiac death.

The patient's low HDL cholesterol level (0.72 mmol/L) and high LDL cholesterol level (1.71 mmol/L) suggest poor lipid management, which may contribute to the progression of atherosclerosis and increase the risk of cardiac events.

The patient's use of beta blockers, loop diuretics, spironolactone, statins, and ACE inhibitor is appropriate for managing heart failure and reducing the risk of sudden cardiac death. However, the patient's LVEF of 30% and history of myocardial infarction suggest that these medications may not be sufficient to prevent sudden cardiac death.

In conclusion, the combination of ischemic dilated cardiomyopathy, low LVEF, history of myocardial infarction, and life-threatening arrhythmias on the ECG, along with elevated Pro-BNP and poor lipid management, make the patient at high risk for sudden cardiac death."
740,740,P1018,"Age: 60
Gender: Male 
Weight: 63 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 3,85
Creatinine (mmol/L): 265.0
Gamma-glutamil transpeptidase (IU/L): 87
Glucose (mmol/L): 12
HDL (mmol/L): 1,03
Potassium (mEq/L): 6,1
LDL (mmol/L): 1,91
Sodium (mEq/L): 131.0
Protein (g/L): 87
T3 (pg/dL): 0,04
T4 (ng/L): 15
TSH (mIU/L): 3,73
Urea (mg/dL): 25,29
LVEF (%): 25.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"REASONING: 

The patient's outcome of sudden cardiac death is likely due to a combination of several factors contributing to a high risk of cardiac arrhythmias and reduced cardiac function.

1.  Ischemic dilated cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and enlarged due to a heart attack or reduced blood flow. This condition significantly increases the risk of sudden cardiac death.

2.  Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 25%, which is significantly below the normal range (50-70%). A low LVEF indicates poor heart function, making it harder for the heart to pump blood effectively, and increasing the risk of sudden cardiac death.

3.  Ventricular Extrasystole: The presence of monomorphic ventricular extrasystoles on the ECG suggests abnormal heart rhythms, which can be a sign of underlying cardiac disease. This condition can increase the risk of arrhythmias and sudden cardiac death.

4.  High Creatinine levels: The patient's creatinine level is elevated at 265.0 μmol/L, indicating impaired kidney function. This can be a sign of advanced heart failure, which increases the risk of sudden cardiac death.

5.  Electrolyte imbalance: The patient's potassium level is slightly elevated at 6.1 mEq/L. While not severely elevated, this can still contribute to cardiac arrhythmias and increase the risk of sudden cardiac death.

6.  Medication non-adherence or inadequate dosing: Although the patient is taking medications for diabetes, beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, it is essential to consider the possibility of non-adherence or inadequate dosing, which could have contributed to the patient's outcome.

7.  Underlying diabetes and hypertension: The patient's history of diabetes and hypertension can contribute to cardiac damage and increase the risk of sudden cardiac death.

8.  Low T3 and T4 levels: The patient's thyroid function test results show low T3 and normal T4 levels, which may indicate subclinical hypothyroidism. This can contribute to cardiac dysfunction and increase the risk of sudden cardiac death.

In conclusion, the patient's outcome of sudden cardiac death is likely due to a combination of these factors, which have cumulatively increased the risk of cardiac arrhythmias and reduced cardiac function."
741,741,P0011,"Age: 59
Gender: Male 
Weight: 85 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41,8
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 6,49
Creatinine (mmol/L): 125.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 9
Hemoglobin (g/L): 170.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 4,6
LDL (mmol/L): 4,03
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 2382.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,66
Urea (mg/dL): 9,8
LVEF (%): 22.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Based on the provided patient data, the patient outcome of pump failure death can be attributed to the combination of several factors. The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and enlarged due to a heart attack or other heart problems. The patient's left ventricular ejection fraction (LVEF) is severely reduced at 22%, indicating a significant impairment in the heart's ability to pump blood effectively.

The patient's elevated levels of N-terminal pro-b-type natriuretic peptide (Pro-BNP) at 2382 ng/L further supports the diagnosis of heart failure, as this biomarker is commonly used to diagnose and monitor heart failure. The patient's creatinine level of 125.0 μmol/L also indicates impaired kidney function, which is a common complication of advanced heart failure.

The patient's past medical history of myocardial infarction, hypertension, and dyslipemia also contribute to the development of ischemic dilated cardiomyopathy. The patient's use of medications such as beta blockers, loop diuretics, and ACE inhibitors suggests that the patient is being managed for heart failure, but the patient's condition has progressed to pump failure, leading to death.

Additionally, the patient's elevated glucose level (9 mmol/L) and low HDL cholesterol level (1.68 mmol/L) suggest that the patient may have poorly controlled diabetes, which can further exacerbate heart failure.

The patient's low T3 level (0.05 pg/dL) and normal T4 level (16 ng/L) suggest that the patient may have secondary hypothyroidism, which can be a complication of heart failure. However, the patient's TSH level of 1.66 mIU/L is within the normal range, which may indicate that the patient's thyroid function is being monitored and managed.

In conclusion, the patient's pump failure death can be attributed to the combination of ischemic dilated cardiomyopathy, impaired kidney function, poorly controlled diabetes, and the progression of heart failure despite medical management."
742,742,P0027,"Age: 79
Gender: Male 
Weight: 74 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 115/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 42,1
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 3,44
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 9,4
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,2
LDL (mmol/L): 1,6
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 990.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,5
Urea (mg/dL): 6,24
LVEF (%): 27.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient outcome of pump failure death can be attributed to a combination of several factors that are evident from the provided data. 

1. Severe Left Ventricular Dysfunction: The patient has an LVEF (Left Ventricular Ejection Fraction) of 27%, which is significantly below the normal range (50-70%). This indicates that the left ventricle is not pumping efficiently, leading to a decrease in cardiac output and potentially causing symptoms of heart failure.

2. Ischemic Dilated Cardiomyopathy: The patient's history of myocardial infarction (heart attack) and ischemic dilated cardiomyopathy suggests that the patient's heart has been damaged due to a lack of blood flow to the heart muscle. This damage has led to the dilation of the left ventricle and a decrease in its pumping efficiency.

3. High Pro-BNP Levels: The patient's Pro-BNP (N-terminal pro b-type natriuretic peptide) level is 990.0 ng/L, which is significantly elevated. High Pro-BNP levels are often associated with heart failure and can indicate increased stress on the heart.

4. NYHA Class II Heart Failure: The patient's New York Heart Association (NYHA) functional classification is II, which indicates that the patient has symptoms of heart failure, such as shortness of breath and fatigue, during ordinary physical activity.

5. Medication Non-Response: Although the patient is on medications such as beta blockers, loop diuretics, statins, ACE inhibitors, and nitrovasodilators, which are typically used to manage heart failure, the patient's condition has not improved. This suggests that the medications may not be effective in managing the patient's heart failure.

6. Poor Renal Function: The patient's creatinine level is 96.0 μmol/L, which is elevated, indicating impaired renal function. Kidney dysfunction can exacerbate heart failure by reducing the clearance of fluid and electrolytes, leading to further strain on the heart.

7. Malnutrition and Dehydration: The patient's low albumin level (42.1 g/L) and low protein level (71 g/L) may indicate malnutrition and dehydration, which can contribute to the patient's overall poor condition.

8. Electrocardiogram (ECG) Abnormalities: The patient's ECG shows ventricular extrasystoles, non-sustained ventricular tachycardia, and a low left ventricular ejection fraction, which are all indicative of severe cardiac dysfunction.

Considering these factors, the patient's outcome of pump failure death is likely due to the cumulative effect of severe left ventricular dysfunction, ischemic dilated cardiomyopathy, high Pro-BNP levels, NYHA Class II heart failure, medication non-response, poor renal function, malnutrition, and ECG abnormalities."
743,743,P0030,"Age: 77
Gender: Female 
Weight: 60 kg
Height: 146 cm
NYHA Class: II
Blood Pressure: 95/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 42,9
ALT or GPT (IU/L): 8.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,31
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 9,9
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,53
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,03
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 2118.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,71
Urea (mg/dL): 10,02
LVEF (%): 20.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of several factors present in the patient's medical history and current condition. 

1. Idiopathic dilated cardiomyopathy: The patient has a pre-existing condition of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge, leading to reduced heart function. This condition is a significant risk factor for heart failure.

2. Low LVEF (20.0%): The left ventricular ejection fraction (LVEF) is a measure of how well the heart pumps blood. An LVEF of 20.0% indicates severe left ventricular dysfunction, which is a critical indicator of heart failure.

3. Elevated Pro-BNP (2118.0 ng/L): B-type natriuretic peptide (BNP) is a hormone produced by the heart in response to increased ventricular wall stress. Elevated levels of BNP are associated with heart failure and can be used as a biomarker to diagnose and monitor the condition.

4. Medications: While the patient is on medications such as beta-blockers, loop diuretics, ACE inhibitors, and nitrovasodilators, these medications are typically used to manage symptoms and slow the progression of heart failure, but they may not be sufficient to reverse the underlying cardiac dysfunction.

5. Other comorbidities: The patient has diabetes, which can contribute to the development of heart failure, and a slightly elevated creatinine level (100.0 mmol/L), indicating impaired renal function, which can further exacerbate heart failure.

Considering these factors, the patient's outcome of pump failure death is a likely consequence of the progression of idiopathic dilated cardiomyopathy, compounded by other comorbidities and the severity of the patient's cardiac dysfunction."
744,744,P0031,"Age: 76
Gender: Male 
Weight: 81 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 130/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,2
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 7,14
Creatinine (mmol/L): 195.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 138.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,91
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 310.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,1
Urea (mg/dL): 23,82
LVEF (%): 33.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Given the patient's extensive medical history, including ischemic dilated cardiomyopathy, myocardial infarction, and NYHA Class II, it is clear that the patient has a severe and advanced stage of heart failure. The low left ventricular ejection fraction (LVEF) of 33% indicates significant left ventricular dysfunction, which is a major risk factor for heart failure progression and mortality.

The patient's elevated Pro-BNP levels (310.0 ng/L) further support the diagnosis of heart failure, as this biomarker is commonly used to assess the severity of heart failure. Additionally, the patient's creatinine levels (195.0 μmol/L) suggest impaired renal function, which is a common comorbidity in patients with heart failure.

The patient's medications, including beta blockers, digoxin, loop diuretics, and an ACE inhibitor, are consistent with the treatment of heart failure. However, the presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG suggests ongoing cardiac arrhythmias, which may be contributing to the patient's poor prognosis.

The patient's diabetes and dyslipidemia also increase the risk of cardiovascular events and mortality. The patient's low HDL cholesterol level (0.85 mmol/L) and high LDL cholesterol level (4.91 mmol/L) further contribute to the patient's cardiovascular risk profile.

The patient's age (76 years) and male gender also increase the risk of mortality, as heart failure is a leading cause of death in older adults.

Considering the patient's advanced heart failure, impaired renal function, ongoing cardiac arrhythmias, and other comorbidities, it is not surprising that the patient's outcome was pump failure death."
745,745,P0034,"Age: 71
Gender: Male 
Weight: 61 kg
Height: 151 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 39,7
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,97
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 32552.0
Protein (g/L): 79
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,05
TSH (mIU/L): 4,9
Urea (mg/dL): 10,24
LVEF (%): 26.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to several factors evident from the provided data.

1.  Severe Left Ventricular Dysfunction: The patient has a left ventricular ejection fraction (LVEF) of 26%, which is significantly below the normal range of 55-70%. This indicates severe left ventricular dysfunction, which can lead to heart failure and pump failure.

2.  High Pro-BNP Levels: The patient's pro-brain natriuretic peptide (Pro-BNP) level is 32552.0 ng/L, which is significantly elevated. Elevated Pro-BNP levels are associated with heart failure and are used as a marker to diagnose and monitor heart failure.

3.  History of Ischemic Dilated Cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is damaged due to a heart attack or coronary artery disease. This condition can lead to severe left ventricular dysfunction and pump failure.

4.  Medication Non-Response: Although the patient is on medications such as digoxin, loop diuretics, statins, and ACE inhibitors, which are commonly used to manage heart failure, the patient's condition has progressed to pump failure death. This may indicate that the medications were not effective in managing the patient's condition or that the disease was too advanced.

5.  Low LVEF and High Pro-BNP Levels Despite Medication: The patient's low LVEF and high Pro-BNP levels, despite being on medications, suggest that the patient's condition was not adequately managed, leading to pump failure.

6.  Other Factors: The patient's age (71 years), NYHA Class III (indicating severe heart failure symptoms), and history of myocardial infarction also contribute to the increased risk of pump failure death.

Given these factors, the patient's outcome of pump failure death is not unexpected."
746,746,P0035,"Age: 73
Gender: Male 
Weight: 83 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 33,19
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,03
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 9,7
Hemoglobin (g/L): 122.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 3,9
LDL (mmol/L): 1,4
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 752.0
Protein (g/L): 65
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,29
Urea (mg/dL): 7,8
LVEF (%): 39.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of factors evident in the provided medical history and laboratory results. 

1.  Ischemic dilated cardiomyopathy: This underlying heart condition is a significant contributor to the patient's outcome. Ischemic dilated cardiomyopathy is a condition where the heart muscle becomes weakened due to a lack of blood flow, leading to reduced cardiac function and potentially life-threatening complications.

2.  Low LVEF (Left Ventricular Ejection Fraction) of 39%: The patient's LVEF is significantly lower than the normal range (50-70%), indicating reduced heart function and an increased risk of heart failure.

3.  High Pro-BNP levels: The patient's Pro-BNP level is elevated at 752.0 ng/L, which is indicative of heart failure. Pro-BNP is a biomarker that is released by the heart in response to increased ventricular wall stress, often seen in heart failure.

4.  Medications: Although the patient is on Beta Blockers, which are commonly used to manage heart failure, the presence of other medications like Calcium Channel Blockers and Nitrovasodilators may indicate an attempt to manage symptoms rather than reverse the underlying heart condition.

5.  ECG findings: The presence of non-sustained ventricular tachycardia and ventricular extrasystoles suggests an abnormal heart rhythm, which can further strain the heart and contribute to pump failure.

6.  Comorbidities: The patient's comorbidities, including diabetes, dyslipemia, peripheral vascular disease, and hypertension, may have contributed to the progression of the patient's heart condition and increased the risk of complications.

7.  Low HDL and high LDL cholesterol levels: Although the patient is on statins, the patient's lipid profile indicates a potential risk of atherosclerosis, which can further compromise heart function.

Given these factors, the patient's outcome of pump failure death is a likely consequence of the cumulative effect of their underlying heart condition, comorbidities, and medication regimen, which ultimately led to a decline in cardiac function and reduced ability of the heart to pump blood effectively."
747,747,P0040,"Age: 83
Gender: Male 
Weight: 88 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 42,9
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 128.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 7
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,84
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1184.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,8
Urea (mg/dL): 10,91
LVEF (%): 40.0
Medications: Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of factors evident in the provided data. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened due to reduced blood flow, leading to a decrease in the heart's pumping efficiency. This condition is further exacerbated by a low left ventricular ejection fraction (LVEF) of 40%, indicating that the heart is not pumping blood effectively.

Additionally, the patient's elevated Pro-BNP (B-type natriuretic peptide) level of 1184.0 ng/L is indicative of heart failure, as it is a marker of cardiac strain and stress. The presence of non-sustained ventricular tachycardia on the ECG also suggests that the heart is experiencing arrhythmias, which can further compromise cardiac function.

The patient's low HDL cholesterol level (1.11 mmol/L) and high LDL cholesterol level (2.84 mmol/L) indicate poor lipid management, which can contribute to atherosclerosis and further worsen heart function.

Furthermore, the patient's low hemoglobin level (156.0 g/L) may indicate anemia, which can reduce oxygen delivery to the heart muscle, exacerbating heart failure.

The patient's creatinine level of 128.0 μmol/L is elevated, indicating impaired kidney function, which can be a consequence of heart failure. The patient's low albumin level (42.9 g/L) and low protein level (75 g/L) may also indicate malnutrition, which can further compromise cardiac function.

Lastly, the patient's age (83 years) and NYHA class II classification indicate that the patient has a pre-existing condition that may have been managed but not fully resolved, which may have led to the progression of heart failure.

Given these factors, it is not surprising that the patient's outcome was pump failure death, as the combination of ischemic dilated cardiomyopathy, heart failure, arrhythmias, poor lipid management, anemia, impaired kidney function, and malnutrition likely overwhelmed the heart's ability to function effectively, ultimately leading to cardiac failure and death."
748,748,P0046,"Age: 71
Gender: Male 
Weight: 93 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45,4
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,5
Creatinine (mmol/L): 125.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,69
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 475.0
Protein (g/L): 75
T3 (pg/dL): 0,03
T4 (ng/L): 5
Troponin (ng/mL): 0,01
TSH (mIU/L): 78,34
Urea (mg/dL): 10,02
LVEF (%): 30.0
Medications: Amiodarone, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Based on the provided patient data, the patient's outcome of pump failure death can be attributed to several factors that have contributed to the progression of his idiopathic dilated cardiomyopathy. 

1. Reduced Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is severely reduced at 30%, indicating significant left ventricular dysfunction. This is a key indicator of heart failure and a major risk factor for pump failure.

2. Elevated BNP levels: The patient's Pro-BNP level is 475.0 ng/L, which is significantly elevated. BNP is a marker of cardiac stress and is often used to diagnose and monitor heart failure. Elevated BNP levels indicate increased ventricular wall stress, which is consistent with the patient's reduced LVEF.

3. Medication regimen: The patient is on Amiodarone, Spironolactone, and an ACE Inhibitor, which are all commonly used to manage heart failure and arrhythmias. However, the combination of these medications may not have been sufficient to control the patient's condition, given the patient's outcome.

4. Electrocardiogram (ECG) findings: The patient's ECG shows non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles, which are indicators of arrhythmias and further suggest cardiac dysfunction.

5. Laboratory results: The patient's creatinine level is elevated at 125.0 mmol/L, indicating impaired renal function, which is a common complication of heart failure. The patient's total cholesterol and LDL levels are elevated, which may contribute to atherosclerosis and further compromise cardiac function.

6. Thyroid function tests: The patient's TSH level is elevated at 78.34 mIU/L, indicating hypothyroidism. Hypothyroidism can exacerbate heart failure by reducing cardiac contractility and increasing peripheral resistance.

7. Age and comorbidities: The patient is 71 years old with a history of hypertension and idiopathic dilated cardiomyopathy, which increases his risk of heart failure and pump failure.

Considering these factors, the patient's outcome of pump failure death is likely the result of a combination of his underlying cardiac disease, medication regimen, laboratory abnormalities, and comorbidities."
749,749,P0054,"Age: 55
Gender: Male 
Weight: 72 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 90/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 47
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 3
Creatinine (mmol/L): 147.0
Gamma-glutamil transpeptidase (IU/L): 246
Glucose (mmol/L): 9,3
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 5,1
LDL (mmol/L): 1,66
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3765.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 24
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,46
Urea (mg/dL): 16,26
LVEF (%): 25.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Given the patient's clinical presentation and laboratory results, the outcome of pump failure death can be attributed to several factors.

1. Severe Left Ventricular Dysfunction: The patient has a left ventricular ejection fraction (LVEF) of 25%, indicating severe left ventricular dysfunction, which is a hallmark of heart failure. This suggests that the patient's heart is unable to pump blood effectively, leading to a decrease in cardiac output and eventual organ failure.

2. Ischemic Dilated Cardiomyopathy: The patient's history of ischemic dilated cardiomyopathy indicates that the heart muscle has been damaged due to a previous myocardial infarction, leading to a dilated left ventricle and reduced cardiac function. This condition can lead to progressive heart failure and eventual pump failure.

3. High Pro-BNP Levels: The patient's Pro-BNP level is significantly elevated at 3765.0 ng/L, indicating severe heart failure. Pro-BNP is a biomarker of heart failure, and high levels are associated with increased mortality and morbidity.

4. Kidney Dysfunction: The patient's creatinine level is elevated at 147.0 mmol/L, indicating impaired kidney function. Kidney dysfunction is a common complication of heart failure, and in this case, it may be contributing to the patient's overall poor prognosis.

5. Electrolyte Imbalance: The patient's potassium level is slightly elevated at 5.1 mEq/L, which may be contributing to arrhythmias and further compromising cardiac function.

6. Medication Non-Response: The patient is on a regimen of medications, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor. However, despite these treatments, the patient's condition has not improved, suggesting that the patient may be resistant to these therapies or that the disease has progressed to a point where these medications are no longer effective.

7. Advanced Age and Comorbidities: The patient is 55 years old and has a history of diabetes, hypertension, and myocardial infarction, which are all risk factors for heart failure and poor outcomes.

In conclusion, the combination of severe left ventricular dysfunction, ischemic dilated cardiomyopathy, high Pro-BNP levels, kidney dysfunction, electrolyte imbalance, medication non-response, and advanced age and comorbidities all contribute to the patient's outcome of pump failure death."
750,750,P0056,"Age: 54
Gender: Male 
Weight: 80 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 47,19
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,72
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 249
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4
LDL (mmol/L): 1,99
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3258.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,58
Urea (mg/dL): 12,03
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of factors based on the provided information. 

1. Ischemic dilated cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack, leading to a decrease in left ventricular ejection fraction (LVEF). The LVEF in this case is 25%, which is significantly below the normal range, indicating severe left ventricular dysfunction.

2. Low LVEF: The patient's LVEF of 25% is a strong indicator of heart failure and a high risk of cardiac mortality. The patient's heart is unable to pump blood effectively, leading to potential complications such as pulmonary congestion and edema.

3. Elevated Pro-BNP: The patient's Pro-BNP level is 3258.0 ng/L, which is significantly elevated. BNP (Brain Natriuretic Peptide) is a hormone released by the heart in response to increased ventricular wall stress. High levels of BNP are associated with heart failure and a poor prognosis.

4. Diabetes and Dyslipemia: The patient's history of diabetes and dyslipemia are risk factors for cardiovascular disease and may have contributed to the development of ischemic dilated cardiomyopathy.

5. Medication regimen: The patient is on a standard heart failure medication regimen, including beta-blockers, ACE inhibitors, and spironolactone, which are all aimed at reducing mortality and morbidity in heart failure patients. However, the patient's outcome suggests that these medications may not have been sufficient to prevent pump failure.

6. Kidney function impairment: The patient's creatinine level is elevated at 124.0 μmol/L, indicating impaired kidney function. Kidney dysfunction is common in heart failure patients and can contribute to a poor prognosis.

7. Electrocardiogram (ECG) findings: The ECG is normal, which suggests that there are no acute arrhythmias or other cardiac abnormalities that could have contributed to the patient's outcome.

In summary, the patient's outcome of pump failure death can be attributed to a combination of ischemic dilated cardiomyopathy, low LVEF, elevated Pro-BNP, diabetes, dyslipemia, kidney function impairment, and an inadequate response to medication."
751,751,P0065,"Age: 66
Gender: Male 
Weight: 106 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 43,3
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,22
Creatinine (mmol/L): 143.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,9
LDL (mmol/L): 3
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 114.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,17
TSH (mIU/L): 0,85
Urea (mg/dL): 16,7
LVEF (%): 40.0
Medications: Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Based on the provided patient data, the patient outcome of pump failure death can be attributed to a combination of several factors.

1. Ischemic dilated cardiomyopathy and Myocardial Infarction: The patient's history of ischemic dilated cardiomyopathy and myocardial infarction indicates that the patient has a weakened heart muscle due to previous heart attack(s), leading to a reduced left ventricular ejection fraction (LVEF) of 40.0%. This condition compromises the heart's ability to pump blood effectively, increasing the risk of heart failure.

2. Low LVEF: The patient's LVEF of 40.0% is below the normal range (50-70%), indicating that the left ventricle is not pumping efficiently, leading to potential heart failure.

3. Elevated Creatinine levels: The patient's creatinine level of 143.0 mmol/L is elevated, suggesting impaired kidney function. This is often seen in patients with heart failure, as the kidneys are sensitive to decreased cardiac output.

4. High Pro-BNP levels: The patient's Pro-BNP level of 114.0 ng/L is elevated, indicating increased stress on the heart, which is a marker of heart failure.

5. Medications: Although the patient is on medications like spironolactone, ACE inhibitor, and nitrovasodilator, which are commonly used to manage heart failure, the patient's condition may have progressed to a point where these medications are no longer sufficient to prevent pump failure.

6. Other factors: The patient's total cholesterol level is elevated (5.22 mmol/L), and HDL (good cholesterol) is low (1.47 mmol/L), which may contribute to the progression of heart disease. Additionally, the patient's weight (106 kg) is above the normal range for their height, which can increase the strain on the heart.

Considering these factors, the patient's outcome of pump failure death is a likely consequence of the cumulative effect of these conditions, which have compromised the heart's ability to function properly, leading to decreased cardiac output and eventual pump failure."
752,752,P0066,"Age: 47
Gender: Male 
Weight: 95 kg
Height: 175 cm
NYHA Class: III
Blood Pressure: 110/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease
Albumin (g/L): 33,4
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 4,58
Creatinine (mmol/L): 167.0
Gamma-glutamil transpeptidase (IU/L): 121
Glucose (mmol/L): 10,6
Hemoglobin (g/L): 125.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 5,3
LDL (mmol/L): 3
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 4797.0
Protein (g/L): 85
T3 (pg/dL): 0,04
T4 (ng/L): 12
Troponin (ng/mL): 0,06
TSH (mIU/L): 4,36
Urea (mg/dL): 15,15
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of several factors that are evident from the provided data. 

1.  Ischemic Dilated Cardiomyopathy (IDC): The patient has a history of IDC, which is a condition where the heart muscle becomes weakened due to a heart attack or reduced blood flow. This condition is a major risk factor for heart failure and pump failure.

2.  Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 35%, which is significantly below the normal range (50-70%). A low LVEF indicates that the heart is not pumping efficiently, which can lead to fluid buildup in the lungs and other parts of the body, ultimately resulting in heart failure.

3.  Elevated Pro-BNP (B-type Natriuretic Peptide): The patient's Pro-BNP level is 4797.0 ng/L, which is significantly elevated. Pro-BNP is a hormone produced by the heart in response to stress, and high levels are often associated with heart failure.

4.  Diabetes and Dyslipemia: The patient has a history of diabetes and dyslipemia, which are both risk factors for cardiovascular disease and heart failure. High blood sugar levels can damage the blood vessels and nerves that control the heart, while high cholesterol can lead to atherosclerosis, which can further reduce blood flow to the heart.

5.  Peripheral Vascular Disease: The patient's history of peripheral vascular disease indicates that the blood vessels are narrowed or blocked, which can reduce blood flow to the heart and other organs, contributing to heart failure.

6.  Medication Non-Response: Although the patient is on medications such as angiotensin II receptor blockers, loop diuretics, spironolactone, and statins, the lack of response to these medications may indicate that the patient's heart failure is advanced, making it more challenging to manage.

7.  ECG Findings: The patient's ECG shows polymorphic ventricular extrasystoles, which can indicate abnormal heart rhythms that may further compromise cardiac function.

Considering these factors, the patient's outcome of pump failure death is likely due to the cumulative effect of these conditions, which have led to severe and irreversible damage to the heart muscle, ultimately resulting in heart failure and death."
753,753,P0078,"Age: 75
Gender: Male 
Weight: 59 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 42,8
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 215.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 5,5
LDL (mmol/L): 1,99
Sodium (mEq/L): 146.0
Pro-BNP (ng/L): 7468.0
Protein (g/L): 75
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,16
TSH (mIU/L): 4,97
Urea (mg/dL): 15,82
LVEF (%): 25.0
Medications: Amiodarone, Digoxin, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of factors based on the provided data.

1.  Severe Left Ventricular Dysfunction: The patient has a left ventricular ejection fraction (LVEF) of 25%, indicating severe left ventricular dysfunction. This suggests that the patient's heart is unable to effectively pump blood, leading to reduced cardiac output and potential end-organ hypoperfusion.

2.  Advanced NYHA Class III Heart Failure: The patient's New York Heart Association (NYHA) class of III indicates that the patient experiences significant symptoms of heart failure, including shortness of breath, fatigue, and limited exercise tolerance. This level of heart failure suggests that the patient's condition is advanced and severe.

3.  High Pro-BNP Levels: The patient's pro-B-type natriuretic peptide (Pro-BNP) level is elevated at 7468.0 ng/L, which is indicative of heart failure. Elevated Pro-BNP levels are associated with increased mortality and morbidity in patients with heart failure.

4.  Severe Renal Dysfunction: The patient's creatinine level is elevated at 215.0 mmol/L, indicating severe renal dysfunction. This can be a result of reduced cardiac output, leading to decreased perfusion of the kidneys.

5.  Electrocardiographic Abnormalities: The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death. Additionally, the presence of ventricular extrasystoles may indicate underlying cardiac electrical instability.

6.  Medication Use: While the patient is on medications such as Amiodarone and Digoxin, which are used to treat heart failure and arrhythmias, these medications may not have been sufficient to prevent the progression of heart failure or sudden cardiac death.

7.  Comorbidities: The patient has a history of idiopathic dilated cardiomyopathy, diabetes, and hypertension, which are all risk factors for heart failure and cardiac mortality.

Given the combination of these factors, it is not surprising that the patient's outcome was pump failure death."
754,754,P0083,"Age: 81
Gender: Male 
Weight: 70 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 40,9
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 207.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,53
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 428.0
Protein (g/L): 71
T3 (pg/dL): 0,03
T4 (ng/L): 17
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,14
Urea (mg/dL): 28,28
LVEF (%): 35.0
Medications: Diabetes Medication, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of several factors that are evident from the provided data. 

1. Ischemic dilated cardiomyopathy: This condition is a significant contributor to the patient's outcome. Ischemic cardiomyopathy is a condition where the heart muscle is weakened due to a heart attack or coronary artery disease, leading to reduced heart function and potential heart failure.

2. Low LVEF (35.0%): The patient's left ventricular ejection fraction (LVEF) is severely reduced, indicating poor heart function. An LVEF of 35% or less is generally considered a sign of heart failure. This low LVEF suggests that the heart is not pumping efficiently, leading to potential heart failure.

3. High Pro-BNP (428.0 ng/L): B-type natriuretic peptide (BNP) levels are elevated, which is a marker of heart failure. High BNP levels indicate that the heart is under strain, and the patient is experiencing heart failure.

4. History of Myocardial Infarction: The patient has a history of heart attack, which can lead to ischemic cardiomyopathy and further contribute to heart failure.

5. Diabetes: The patient's diabetes can also contribute to heart failure, as diabetes is a significant risk factor for heart disease and can lead to cardiovascular complications.

6. Peripheral Vascular Disease: This condition can further compromise the patient's cardiovascular health and contribute to the development of heart failure.

7. Medication regimen: While the patient is on medications such as ACE inhibitor, which is beneficial for heart failure, the presence of digoxin, which can be used to treat heart failure, but also has a narrow therapeutic index and can be toxic at high levels, might not be enough to counteract the patient's severe heart failure.

8. Electrocardiogram (ECG) findings: The patient has non-sustained ventricular tachycardia, which is a sign of abnormal heart rhythm that can be a contributing factor to heart failure.

Given these factors, the patient's outcome of pump failure death is a likely consequence of the cumulative effect of these conditions and the progression of heart disease."
755,755,P0099,"Age: 68
Gender: Male 
Weight: 81 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 44,3
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 16,5
Hemoglobin (g/L): 146.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,87
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 103.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,89
Urea (mg/dL): 6,45
LVEF (%): 25.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of factors present in the patient's medical history and laboratory results. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack, leading to reduced heart function. This is supported by the low left ventricular ejection fraction (LVEF) of 25.0%, indicating that the heart is not pumping efficiently.

The patient also has a history of myocardial infarction (heart attack), which can further weaken the heart muscle and lead to heart failure. Additionally, the patient has hypertension, dyslipemia, and peripheral vascular disease, all of which are risk factors for cardiovascular disease and can contribute to heart failure.

The patient's laboratory results also support the presence of heart failure. The elevated creatinine level of 95.0 mmol/L indicates impaired kidney function, which is often seen in advanced heart failure. The low albumin level of 44.3 g/L may indicate malnutrition or liver disease, but in the context of heart failure, it may also be a sign of poor nutritional status due to reduced cardiac output. The elevated glucose level of 16.5 mmol/L suggests that the patient may have insulin resistance or diabetes, which can contribute to heart failure.

The elevated Pro-BNP level of 103.0 ng/L is a biomarker of heart failure, indicating that the patient's heart is under stress and may be failing. The low T3 level of 0.04 pg/dL may indicate a low metabolic state, which can be seen in advanced heart failure.

The patient's medications, including diabetes medication, angiotensin II receptor blocker, beta blockers, and statins, are all appropriate for managing heart failure and its associated conditions, but may not be sufficient to prevent the progression of heart failure in this patient.

Overall, the combination of the patient's medical history, laboratory results, and medications suggests that the patient's outcome of pump failure death is likely due to the progression of his underlying heart disease, which has led to advanced heart failure."
756,756,P0107,"Age: 53
Gender: Male 
Weight: 74 kg
Height: 167 cm
NYHA Class: III
Blood Pressure: 127/76 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 43,5
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 105.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,87
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 670.0
Protein (g/L): 74,1
T3 (pg/dL): 0,01
T4 (ng/L): 11
TSH (mIU/L): 2,3
Urea (mg/dL): 8,32
LVEF (%): 27.0
Medications: Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Given the patient's extensive medical history, which includes ischemic dilated cardiomyopathy, myocardial infarction, peripheral vascular disease, and hypertension, it is clear that the patient has a significant history of cardiovascular disease. The patient's left ventricular ejection fraction (LVEF) of 27% is also indicative of severe heart failure, which is consistent with the patient's New York Heart Association (NYHA) Class III classification.

The patient's elevated levels of brain natriuretic peptide (BNP) at 670.0 ng/L also support the diagnosis of heart failure. BNP is a well-established biomarker for heart failure, and high levels are associated with increased mortality and morbidity.

The patient's medication regimen, which includes loop diuretics, spironolactone, statins, and an ACE inhibitor, is consistent with the management of heart failure and hypertension. However, despite these treatments, the patient's condition has progressed to pump failure, leading to death.

The patient's laboratory results, including the elevated creatinine level (105.0 mmol/L), suggest that the patient may have underlying renal dysfunction, which can further contribute to the progression of heart failure. The patient's low levels of high-density lipoprotein (HDL) cholesterol (1.01 mmol/L) and high levels of low-density lipoprotein (LDL) cholesterol (2.87 mmol/L) also indicate a high risk of atherosclerotic cardiovascular disease.

The patient's ECG findings of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia are consistent with arrhythmias that can occur in the context of heart failure. The presence of these arrhythmias, in combination with the patient's other risk factors, likely contributed to the progression of the patient's condition to pump failure.

In summary, the patient's outcome of pump failure death can be attributed to the combination of his extensive cardiovascular disease history, severe heart failure, elevated BNP levels, renal dysfunction, and underlying arrhythmias."
757,757,P0129,"Age: 86
Gender: Male 
Weight: 80 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,4
Creatinine (mmol/L): 212.0
Gamma-glutamil transpeptidase (IU/L): 71
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,82
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 2036.0
Protein (g/L): 70
T3 (pg/dL): 0,02
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 5
Urea (mg/dL): 19,8
LVEF (%): 50.0
Medications: Loop Diuretics, Spironolactone, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Given the patient's age (86) and NYHA Class II, indicating mild to moderate heart failure symptoms, the patient has a history of hypertensive cardiomyopathy and hypertension. The patient's laboratory results show elevated creatinine levels (212.0 mmol/L), indicating chronic kidney disease, which is often associated with heart failure. The patient's low ejection fraction (LVEF 50.0%) suggests that the heart is not pumping efficiently, contributing to heart failure. 

The elevated Pro-BNP (2036.0 ng/L) level, a biomarker for heart failure, supports this diagnosis. Additionally, the presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG suggests that the patient's heart is experiencing arrhythmias, which can be a complication of heart failure.

The patient's medication regimen includes loop diuretics, spironolactone, hydralazine, and nitrovasodilator, which are commonly used to manage heart failure symptoms and improve cardiac function. However, the patient's condition has progressed to pump failure, leading to death.

The high levels of troponin (0.01 ng/mL) and TSH (5 mIU/L) are within normal limits, suggesting that there is no acute myocardial infarction or thyroid dysfunction contributing to the patient's outcome. The low T3 (0.02 pg/dL) level may be related to the patient's age and heart failure, but it is not a direct cause of death.

In conclusion, the patient's outcome of pump failure death is likely due to the progression of hypertensive cardiomyopathy and heart failure, compounded by chronic kidney disease and arrhythmias, despite the use of appropriate medications for heart failure management."
758,758,P0134,"Age: 62
Gender: Male 
Weight: 84 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,87
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 3,9
Hemoglobin (g/L): 164.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,1
Sodium (mEq/L): 146.0
Pro-BNP (ng/L): 1528.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 16
TSH (mIU/L): 2,34
Urea (mg/dL): 7,65
LVEF (%): 41.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death is likely due to a combination of factors related to his underlying heart condition and comorbidities. 

1.  Idiopathic dilated cardiomyopathy: The patient's condition is characterized by a weakened heart muscle, leading to a reduced left ventricular ejection fraction (LVEF) of 41%. This suggests that the heart is not pumping efficiently, which can lead to heart failure.

2.  Reduced LVEF and elevated Pro-BNP levels: The patient's LVEF of 41% is below the normal range (50-70%), indicating that the heart is not pumping blood effectively. Elevated Pro-BNP levels (1528.0 ng/L) are also indicative of heart failure.

3.  Comorbidities: The patient has diabetes and hypertension, both of which are risk factors for heart failure. Diabetes can damage the blood vessels and nerves that control the heart, while hypertension can lead to left ventricular hypertrophy and heart failure.

4.  Medications: Although the patient is on medications that are commonly used to manage heart failure, such as ACE inhibitors, beta blockers, and loop diuretics, these medications may not have been sufficient to control the progression of the disease.

5.  ECG findings: The presence of non-sustained ventricular tachycardia and ventricular extrasystoles suggests that the patient's heart is experiencing abnormal electrical activity, which can further compromise cardiac function.

6.  Low HDL and high LDL cholesterol levels: Elevated LDL cholesterol levels can contribute to atherosclerosis, which can lead to coronary artery disease and further compromise cardiac function.

7.  Low potassium levels: Hypokalemia (potassium level of 4.2 mEq/L) can contribute to cardiac arrhythmias and worsen heart failure.

8.  Elevated creatinine levels: The patient's elevated creatinine level (141.0 umol/L) suggests impaired renal function, which can be a complication of heart failure.

Given these factors, the patient's outcome of pump failure death is likely a result of the progression of his underlying heart condition, exacerbated by his comorbidities and other contributing factors."
759,759,P0139,"Age: 83
Gender: Female 
Weight: 53 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 110/80 mmHg
Past Medical History: Valvular cardiomyopathy, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,51
Creatinine (mmol/L): 137.0
Gamma-glutamil transpeptidase (IU/L): 61
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 115.0
Potassium (mEq/L): 3,79
Sodium (mEq/L): 138.0
Protein (g/L): 73,6
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,55
Urea (mg/dL): 8,9
LVEF (%): 68.0
Medications: Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

Given the patient's advanced age (83 years) and NYHA Class III heart failure, the patient is at a high risk for cardiac complications. The patient's history of valvular cardiomyopathy and hypertension suggests long-standing cardiac disease, which has likely led to the development of heart failure.

The patient's laboratory results show elevated creatinine levels (137.0 mmol/L), indicating impaired renal function, which is a common comorbidity in patients with heart failure. The patient's low hemoglobin level (115.0 g/L) may indicate anemia, which can exacerbate heart failure symptoms. The patient's potassium level is slightly low (3.79 mEq/L), which may be due to the use of diuretics.

The patient's LVEF (68.0%) is within a relatively normal range, but given the patient's symptoms and history, it is likely that the patient has diastolic dysfunction, which is common in patients with valvular cardiomyopathy.

The patient's medications, including an angiotensin II receptor blocker, digoxin, loop diuretics, spironolactone, and nitrovasodilator, are appropriate for heart failure management, but the patient's condition is likely severe and resistant to medical therapy.

The patient's ECG shows polymorphic ventricular extrasystoles, which can be a sign of cardiac electrical instability. The presence of these extrasystoles, in combination with the patient's other risk factors, increases the risk of sudden cardiac death.

Considering the patient's advanced age, severe heart failure symptoms, impaired renal function, and cardiac electrical instability, the patient's outcome of pump failure death is not unexpected. The patient's condition is likely irreversible, and the patient's quality of life is severely compromised, making palliative care and end-of-life discussions necessary."
760,760,P0141,"Age: 76
Gender: Female 
Weight: 70 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 39,9
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,05
Creatinine (mmol/L): 167.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 123.0
Potassium (mEq/L): 3,15
Sodium (mEq/L): 132.0
Pro-BNP (ng/L): 5387.0
Protein (g/L): 71,4
Troponin (ng/mL): 0,01
TSH (mIU/L): 17,69
Urea (mg/dL): 25
LVEF (%): 25.0
Medications: Loop Diuretics, Spironolactone, Statins, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Parosysmal AF
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient's outcome of pump failure death is likely due to a combination of several factors. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers dilate, leading to poor heart function. This is supported by the patient's low left ventricular ejection fraction (LVEF) of 25.0%, which indicates that the heart is not pumping efficiently.

Additionally, the patient's high levels of B-type natriuretic peptide (BNP) at 5387.0 ng/L suggest that the heart is under strain and is releasing this hormone in an attempt to compensate for the reduced pumping function. Elevated BNP levels are often associated with heart failure.

The patient's creatinine level of 167.0 mmol/L indicates impaired kidney function, which is a common complication of heart failure. The patient's weight of 70 kg and height of 161 cm also indicate a low body mass index (BMI), which may further exacerbate the patient's heart failure symptoms.

The patient's past medical history of myocardial infarction and hypertension also increases the risk of heart failure. The presence of non-sustained ventricular tachycardia and paroxysmal atrial fibrillation on the ECG suggests arrhythmias that can further compromise cardiac function.

The patient's medication regimen, which includes loop diuretics, spironolactone, statins, hydralazine, and nitrovasodilator, is aimed at managing heart failure symptoms and improving cardiac function. However, the patient's outcome of pump failure death suggests that these medications may not have been sufficient to prevent the progression of heart failure.

The patient's elevated TSH level of 17.69 mIU/L may also be a contributing factor, as hyperthyroidism can exacerbate heart failure symptoms. However, the relationship between TSH levels and heart failure is complex, and further investigation would be needed to determine the significance of this finding.

Overall, the patient's outcome of pump failure death is likely due to a combination of her underlying heart disease, impaired kidney function, and potentially other contributing factors such as hyperthyroidism."
761,761,P0143,"Age: 56
Gender: Female 
Weight: 83 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 110/65 mmHg
Past Medical History: Valvular cardiomyopathy, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 38,2
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,66
Creatinine (mmol/L): 110.0
Gamma-glutamil transpeptidase (IU/L): 70
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 86.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 3,39
LDL (mmol/L): 3,86
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 1036.0
Protein (g/L): 68,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,87
Urea (mg/dL): 8,4
LVEF (%): 40.0
Medications: Digoxin, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

This patient's outcome of pump failure death can be attributed to a combination of her severe heart disease and underlying comorbidities. 

Firstly, the patient has a history of valvular cardiomyopathy, which is a condition where the heart's valves do not function properly, leading to decreased cardiac output. Additionally, her left ventricular ejection fraction (LVEF) is severely reduced at 40%, indicating that her heart is not pumping efficiently. This is a critical factor in the development of heart failure.

Furthermore, the patient's past medical history includes a myocardial infarction (heart attack), which can lead to scarring and damage to the heart muscle, further impairing its pumping function. The patient's peripheral vascular disease also contributes to decreased cardiac output, as it restricts blood flow to the peripheral tissues.

The patient's laboratory results also indicate elevated levels of natriuretic peptides (Pro-BNP), which is a marker of heart failure. Her troponin levels are slightly elevated, indicating some degree of cardiac damage. Her low hemoglobin levels may also contribute to decreased oxygen delivery to the tissues, further exacerbating the heart's workload.

The patient's medications, including digoxin, loop diuretics, spironolactone, and nitrovasodilators, are commonly used to manage heart failure symptoms, but they may not be sufficient to reverse the underlying disease process.

The patient's ECG results show ventricular extrasystoles, which can be a sign of arrhythmias and further indicate cardiac dysfunction. The presence of non-sustained ventricular tachycardia and unknown ventricular tachycardia code also suggest arrhythmias, which can further compromise cardiac output.

Lastly, the patient's NYHA class III classification indicates severe heart failure symptoms, with marked limitations in physical activity and symptoms at rest. This level of heart failure is often associated with a poor prognosis and increased risk of mortality.

In summary, the patient's severe heart disease, reduced LVEF, history of myocardial infarction, and comorbidities, combined with her laboratory and ECG results, all contribute to her outcome of pump failure death."
762,762,P0151,"Age: 74
Gender: Male 
Weight: 78 kg
Height: 173 cm
NYHA Class: III
Blood Pressure: 90/60 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 43,2
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 37.0
Total Cholesterol (mmol/L): 4,27
Creatinine (mmol/L): 105.0
Gamma-glutamil transpeptidase (IU/L): 162
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 123.0
Potassium (mEq/L): 3,85
Sodium (mEq/L): 133.0
Protein (g/L): 84,8
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,31
Urea (mg/dL): 8
LVEF (%): 70.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of factors, including his underlying valvular cardiomyopathy, reduced left ventricular ejection fraction (LVEF) of 70%, and elevated creatinine levels indicating compromised kidney function. 

The patient's low blood pressure of 90/60 mmHg suggests compromised cardiac output, which may be a result of his valvular cardiomyopathy and reduced LVEF. The use of medications such as digoxin, loop diuretics, spironolactone, ACE inhibitor, and nitrovasodilator indicates that the patient is being treated for heart failure symptoms, but these medications may not have been sufficient to prevent pump failure.

The patient's elevated gamma-glutamil transpeptidase (GGT) level of 162 IU/L suggests liver dysfunction, which may be related to his valvular cardiomyopathy. The patient's elevated glucose level of 4.7 mmol/L may also indicate insulin resistance or diabetes, which can contribute to heart failure progression.

The patient's low serum albumin level of 43.2 g/L may indicate malnutrition or liver dysfunction, which can contribute to heart failure progression. The patient's low potassium level of 3.85 mEq/L may indicate inadequate potassium replacement or renal impairment.

The patient's low sodium level of 133 mEq/L may be a result of diuretic therapy, which is commonly used in heart failure management. However, the patient's low sodium level may also indicate hyponatremia, which can be a complication of heart failure.

The patient's troponin level of 0.01 ng/mL is within the normal range, indicating that there is no acute myocardial infarction. The patient's TSH level of 4.31 mIU/L is within the normal range, indicating that there is no thyroid dysfunction.

In summary, the patient's pump failure death can be attributed to a combination of his underlying valvular cardiomyopathy, reduced LVEF, compromised kidney function, and potential liver dysfunction, as well as inadequate management of his heart failure symptoms."
763,763,P0155,"Age: 59
Gender: Male 
Weight: 81 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 90/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 35,5
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,52
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 89
Glucose (mmol/L): 11,6
Hemoglobin (g/L): 133.0
Potassium (mEq/L): 4,75
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 10534.0
Protein (g/L): 66,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,82
Urea (mg/dL): 20,8
LVEF (%): 25.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Based on the provided patient data, the patient's outcome of pump failure death can be attributed to a combination of factors related to their underlying medical conditions and the severity of their cardiac dysfunction. 

The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a previous heart attack, leading to a reduced ability of the heart to pump blood effectively. The patient's left ventricular ejection fraction (LVEF) is severely reduced at 25%, indicating a significant impairment in the heart's pumping function. This is a key indicator of heart failure and a major risk factor for mortality.

Additionally, the patient has diabetes, dyslipidemia, and peripheral vascular disease, which are all comorbidities that can further exacerbate cardiac dysfunction and increase the risk of complications. The patient's high glucose levels (11.6 mmol/L) and elevated creatinine levels (141.0 μmol/L) suggest that the patient may have diabetic nephropathy, which can further worsen cardiac function.

The patient's blood pressure is low (90/60 mmHg), which is a common finding in patients with advanced heart failure. The presence of orthostatic hypotension, which is not explicitly stated but can be inferred from the low blood pressure, can further compromise cardiac output and contribute to pump failure.

The patient's B-type natriuretic peptide (BNP) level is elevated at 10534.0 ng/L, which is a marker of heart failure and indicates that the patient's heart is under strain. The patient's troponin level is normal, which suggests that there is no ongoing myocardial infarction, but the elevated troponin level in the context of previous myocardial infarction history and reduced LVEF suggests that there may be ongoing cardiac damage.

The patient's ECG shows polymorphic ventricular extrasystoles, which can be a sign of cardiac arrhythmias and further compromise cardiac function. The presence of TPSV (paroxysmal supraventricular tachyarrhythmia) on the ECG also indicates that the patient's heart rhythm is unstable, which can further worsen cardiac function.

The patient's medications, including ACE inhibitors, beta blockers, and spironolactone, are standard treatments for heart failure, but the patient's condition has progressed to a point where these medications may not be sufficient to manage the disease. The patient's low blood pressure and orthostatic hypotension may also be contributing to the pump failure, as the heart is unable to maintain adequate blood pressure.

In summary, the combination of the patient's ischemic dilated cardiomyopathy, low LVEF, comorbidities, and signs of cardiac dysfunction on the ECG and laboratory tests have likely contributed to the patient's outcome of pump failure death."
764,764,P0160,"Age: 71
Gender: Male 
Weight: 62 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 41
ALT or GPT (IU/L): 8.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,11
Creatinine (mmol/L): 156.0
Gamma-glutamil transpeptidase (IU/L): 107
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 123.0
Potassium (mEq/L): 4,59
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 27357.0
Protein (g/L): 74,9
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,15
Urea (mg/dL): 19,2
LVEF (%): 13.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of factors indicated by the provided data. 

Firstly, the patient has a history of valvular cardiomyopathy, which is a condition where the heart valves are damaged, leading to impaired heart function. This condition can lead to reduced cardiac output and increased risk of heart failure.

The patient's low left ventricular ejection fraction (LVEF) of 13% is a strong indicator of heart failure. A normal LVEF is typically above 55%, and an LVEF of 13% suggests severe systolic dysfunction.

The elevated Pro-BNP (B-type natriuretic peptide) level of 27357.0 ng/L is also indicative of heart failure, as high levels of Pro-BNP are associated with increased ventricular wall stress and are often used as a marker for heart failure.

The patient's medications, including beta blockers, digoxin, loop diuretics, spironolactone, hydralazine, and nitrovasodilator, are typically used to manage heart failure symptoms and improve cardiac function. However, the patient's continued use of these medications suggests that their condition was not adequately controlled, contributing to their poor outcome.

The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG suggests arrhythmias, which can further compromise cardiac function and contribute to heart failure.

The patient's laboratory results, including elevated creatinine (156.0 mmol/L) and urea (19.2 mg/dL), suggest impaired renal function, which is often seen in advanced heart failure.

The patient's age (71 years) and NYHA Class III classification also indicate that the patient had severe symptoms of heart failure, with marked limitation in physical activity and symptoms of heart failure at rest.

Considering these factors, the patient's outcome of pump failure death can be attributed to the combination of severe valvular cardiomyopathy, low LVEF, elevated Pro-BNP, arrhythmias, impaired renal function, and advanced age, which ultimately led to the inability of the heart to pump blood effectively, resulting in pump failure and death."
765,765,P0186,"Age: 57
Gender: Male 
Weight: 65 kg
Height: 175 cm
NYHA Class: III
Blood Pressure: 90/50 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 46
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 2,84
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 59
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 120.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,68
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 5098.0
Protein (g/L): 79
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,07
TSH (mIU/L): 5,32
Urea (mg/dL): 8,49
LVEF (%): 27.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

Based on the provided patient data, the patient's outcome of pump failure death can be attributed to several factors. 

1. Low Left Ventricular Ejection Fraction (LVEF) of 27%: The patient's LVEF is significantly below the normal range of 55-70%, indicating severe left ventricular dysfunction. This suggests that the patient's heart is not pumping efficiently, leading to decreased cardiac output and potentially life-threatening complications.

2. High Pro-BNP levels: The patient's Pro-BNP level is elevated at 5098.0 ng/L, which is indicative of heart failure. Pro-BNP is a biomarker that reflects the degree of ventricular stretch and strain, and high levels are associated with increased mortality and morbidity in heart failure patients.

3. Idiopathic dilated cardiomyopathy: The patient's underlying condition of idiopathic dilated cardiomyopathy, characterized by the progressive dilatation and dysfunction of the left ventricle, likely contributed to the development of heart failure.

4. NYHA Class III: The patient's New York Heart Association (NYHA) functional class of III indicates that the patient experiences symptoms of heart failure at rest, which can lead to decreased quality of life and increased mortality risk.

5. Electrocardiographic findings: The presence of non-sustained ventricular tachycardia, ventricular extrasystoles, and potentially paroxysmal supraventricular tachyarrhythmia may have contributed to the patient's cardiac instability and increased risk of arrhythmia-related complications.

6. Medication regimen: While the patient is on a comprehensive regimen of beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, these medications may not have been sufficient to manage the patient's severe heart failure, leading to the development of pump failure.

7. Laboratory values: The patient's elevated creatinine levels (141.0 mmol/L) and low hemoglobin levels (120.0 g/L) may indicate underlying renal dysfunction and anemia, which can further compromise cardiac function and increase mortality risk.

In summary, the combination of the patient's severe left ventricular dysfunction, high Pro-BNP levels, idiopathic dilated cardiomyopathy, NYHA Class III symptoms, and electrocardiographic abnormalities, along with the potential inadequacy of their medication regimen, likely contributed to their outcome of pump failure death."
766,766,P0188,"Age: 59
Gender: Female 
Weight: 49 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Valvular cardiomyopathy, Hypertension
Albumin (g/L): 33,9
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 66.0
Total Cholesterol (mmol/L): 5,77
Creatinine (mmol/L): 143.0
Gamma-glutamil transpeptidase (IU/L): 334
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,53
Potassium (mEq/L): 3,93
LDL (mmol/L): 3,44
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 7574.0
Protein (g/L): 65
T3 (pg/dL): 0,0306
T4 (ng/L): 9,59
Troponin (ng/mL): 0,1
TSH (mIU/L): 26,88
Urea (mg/dL): 14,4
LVEF (%): 70.0
Medications: Amiodarone, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

This patient's outcome of pump failure death can be attributed to a combination of factors evident from the provided data. 

1. Severe left ventricular dysfunction: Although the patient's LVEF (Left Ventricular Ejection Fraction) is 70%, which is within the normal range, it is crucial to note that the patient has a history of valvular cardiomyopathy. This underlying condition may have contributed to a gradual decline in cardiac function over time, leading to pump failure.

2. Signs of liver dysfunction: Elevated levels of gamma-glutamil transpeptidase (334 IU/L) and AST (66.0 IU/L) suggest liver dysfunction. Amiodarone, a medication the patient is taking, can cause liver damage as a side effect. Liver dysfunction can lead to a decrease in cardiac function and increase the risk of heart failure.

3. Hyperthyroidism: The patient's TSH level is elevated at 26.88 mIU/L, and T3 is slightly low, but T4 is within the normal range. This discrepancy may indicate subclinical hyperthyroidism, which can contribute to cardiac dysfunction, particularly in the context of pre-existing heart disease.

4. Electrolyte imbalance: The patient has a low potassium level (3.93 mEq/L), which can lead to arrhythmias and worsen cardiac function. This imbalance may be exacerbated by the use of diuretics, which can cause potassium loss.

5. High Pro-BNP levels: The patient's Pro-BNP level is significantly elevated at 7574.0 ng/L, indicating severe cardiac stress and potential heart failure.

6. Elevated creatinine levels: The patient's creatinine level is 143.0 mmol/L, indicating impaired renal function. This can lead to fluid overload and worsen cardiac function.

7. Medication regimen: The patient is taking Amiodarone, Loop Diuretics, and Spironolactone, which can have adverse effects on cardiac function and electrolyte balance.

Considering these factors, the patient's outcome of pump failure death is likely a result of the cumulative effect of these conditions, which have compromised the patient's cardiac function and overall health."
767,767,P0192,"Age: 83
Gender: Female 
Weight: 69 kg
Height: 148 cm
NYHA Class: III
Blood Pressure: 150/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 7.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,47
Creatinine (mmol/L): 122.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 7,5
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 5,25
LDL (mmol/L): 4,24
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 5541.0
Protein (g/L): 72
T3 (pg/dL): 0,0237
T4 (ng/L): 18,93
TSH (mIU/L): 0,92
Urea (mg/dL): 19,3
LVEF (%): 65.0
Medications: Diabetes Medication, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Given the patient's profile, the outcome of pump failure death can be attributed to a combination of factors. 

Firstly, the patient has a history of Hypertensive cardiomyopathy, which is a condition where the heart muscle becomes weakened due to high blood pressure, leading to reduced heart function. This is evident from the patient's New York Heart Association (NYHA) Class III classification, indicating moderate to severe heart failure symptoms.

The patient's laboratory results also indicate elevated levels of N-terminal pro b-type natriuretic peptide (Pro-BNP), which is a marker of heart failure. The Pro-BNP level of 5541.0 ng/L is significantly elevated, indicating severe heart failure.

Additionally, the patient has a low left ventricular ejection fraction (LVEF) of 65%, which is below the normal range (50-70%). This suggests that the patient's heart is not pumping efficiently, leading to decreased cardiac output and potentially contributing to the development of heart failure.

The patient's past medical history of myocardial infarction (heart attack) also increases the risk of heart failure. The patient's medications, including loop diuretics and ACE inhibitors, are commonly used to treat heart failure, but the patient's condition has progressed to a point where pump failure has occurred.

The patient's electrolyte imbalance, with a potassium level of 5.25 mEq/L, may also have contributed to the development of arrhythmias, such as ventricular extrasystoles, which are present on the ECG.

The patient's age of 83 and the presence of other comorbidities, such as hypertension, diabetes, and kidney disease (indicated by elevated creatinine levels), have also contributed to the patient's overall poor health status and increased risk of heart failure.

Overall, the combination of the patient's underlying medical conditions, laboratory results, and ECG findings suggest that pump failure death was a likely outcome."
768,768,P0194,"Age: 89
Gender: Male 
Weight: 70 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 160/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 49
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 34.0
Total Cholesterol (mmol/L): 6,1
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,81
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,78
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3179.0
Protein (g/L): 78,1
T3 (pg/dL): 0,0252
T4 (ng/L): 18,79
Troponin (ng/mL): 1,2
TSH (mIU/L): 0,99
Urea (mg/dL): 8,2
LVEF (%): 70.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",pump failure death,"REASONING: 

Given the patient's advanced age (89 years), the patient is at high risk for cardiovascular events and mortality. The patient's New York Heart Association (NYHA) Class III classification indicates that the patient experiences symptoms of heart failure at moderate levels of physical activity, which further supports the presence of heart failure.

The patient's blood pressure of 160/90 mmHg is elevated, which is consistent with hypertension, a known risk factor for heart failure. The patient's past medical history of hypertensive cardiomyopathy and hypertension further supports the presence of heart failure.

The elevated Pro-BNP (B-type natriuretic peptide) level of 3179.0 ng/L is a strong indicator of heart failure. The elevated level suggests that the patient's heart is under strain and is producing more natriuretic peptides to compensate for the increased fluid volume.

The patient's left ventricular ejection fraction (LVEF) of 70% is within the normal range, but considering the patient's age and symptoms, it is likely that the patient has a reduced LVEF due to chronic heart failure. 

The patient's medication regimen, including digoxin, loop diuretics, spironolactone, ACE inhibitor, and nitrovasodilator, is consistent with the management of heart failure. However, the patient's symptoms and laboratory results suggest that the medications may not be adequately controlling the heart failure.

The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG suggests that the patient has ventricular arrhythmias, which can contribute to heart failure and increase the risk of sudden cardiac death.

The patient's elevated creatinine level (103.0 mmol/L) suggests that the patient has chronic kidney disease, which is a common comorbidity in patients with heart failure.

Considering the patient's advanced age, symptoms of heart failure, elevated Pro-BNP level, reduced LVEF (implied), and the presence of ventricular arrhythmias, the patient's outcome of pump failure death is likely due to the progression of heart failure and associated complications, including chronic kidney disease and arrhythmias."
769,769,P0200,"Age: 80
Gender: Male 
Weight: 69 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,11
Creatinine (mmol/L): 146.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 119.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,72
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 2129.0
Protein (g/L): 67
T3 (pg/dL): 0,0429
T4 (ng/L): 15,56
Troponin (ng/mL): 0,2
TSH (mIU/L): 0,58
Urea (mg/dL): 13,9
LVEF (%): 39.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type I
            ",pump failure death,"REASONING: 

Given the patient's advanced age (80 years) and history of ischemic dilated cardiomyopathy, it is not surprising that the patient experienced pump failure. Ischemic dilated cardiomyopathy is a condition where the heart muscle becomes weakened and enlarged due to previous heart attacks or coronary artery disease, leading to reduced heart function.

The patient's low left ventricular ejection fraction (LVEF) of 39% indicates that the heart is not pumping efficiently, which is a common consequence of ischemic dilated cardiomyopathy. The high level of B-type natriuretic peptide (BNP) (2129 ng/L) also suggests that the heart is under strain and is working harder to pump blood, which is consistent with heart failure.

The patient's medications, including beta blockers, loop diuretics, ACE inhibitors, and nitrovasodilators, are standard treatments for heart failure, but unfortunately, they may not have been sufficient to prevent the progression of the disease in this case.

The presence of ventricular extrasystoles (polymorphic) on the ECG suggests that the heart is experiencing abnormal electrical activity, which can be a sign of underlying cardiac disease. The second-degree AV block (type I) is also concerning, as it indicates an abnormality in the electrical conduction system of the heart, which can further compromise cardiac function.

The patient's elevated creatinine level (146.0 mmol/L) suggests that there is kidney impairment, which is a common comorbidity in patients with heart failure. The low albumin level (39 g/L) may indicate malnutrition or liver disease, but in this context, it is likely related to the heart failure.

The patient's overall clinical presentation and laboratory results suggest that the heart failure was severe and irreversible, leading to pump failure and ultimately death."
770,770,P0212,"Age: 65
Gender: Male 
Weight: 79 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 150/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 44.0
Total Cholesterol (mmol/L): 3,98
Creatinine (mmol/L): 150.0
Gamma-glutamil transpeptidase (IU/L): 688
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 122.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,08
LDL (mmol/L): 2,22
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 709.0
Protein (g/L): 79
T3 (pg/dL): 0,0492
T4 (ng/L): 16,35
Troponin (ng/mL): 3,1
TSH (mIU/L): 0,79
Urea (mg/dL): 10
LVEF (%): 70.0
Medications: Diabetes Medication, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of several factors evident in the provided data. 

1.  Hypertensive cardiomyopathy: The patient has a history of hypertensive cardiomyopathy, which is a condition where the heart muscle becomes thickened and stiff due to high blood pressure. This can lead to reduced cardiac function and increased risk of heart failure.

2.  Elevated Creatinine levels (150.0 mmol/L): The patient's creatinine level is elevated, indicating impaired kidney function. This is often seen in patients with heart failure as the kidneys are sensitive to decreased cardiac output, which can lead to fluid buildup and electrolyte imbalances.

3.  Elevated Pro-BNP (709.0 ng/L): B-type natriuretic peptide (BNP) is a hormone produced by the heart in response to ventricular strain. Elevated levels of BNP are associated with heart failure and can indicate the severity of the condition.

4.  Reduced LVEF (70.0%): The left ventricular ejection fraction (LVEF) is a measure of the heart's ability to pump blood. A reduced LVEF indicates impaired cardiac function, which can lead to heart failure.

5.  Presence of ventricular extrasystoles: The patient's ECG shows monomorphic ventricular extrasystoles, which are abnormal heartbeats that can be a sign of underlying cardiac disease or strain.

6.  Elevated Glucose (5.4 mmol/L) and presence of diabetes: Uncontrolled diabetes can lead to diabetic cardiomyopathy, a condition that can cause heart failure.

7.  Elevated Troponin (3.1 ng/mL): Elevated troponin levels indicate cardiac damage, which can be a sign of heart failure or myocardial infarction.

Considering these factors, the patient's outcome of pump failure death is likely due to the cumulative effect of hypertensive cardiomyopathy, impaired kidney function, elevated BNP levels, reduced LVEF, and presence of ventricular extrasystoles, along with uncontrolled diabetes and cardiac damage."
771,771,P0213,"Age: 72
Gender: Male 
Weight: 94 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 115/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,24
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 12,4
Hemoglobin (g/L): 124.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 3,44
LDL (mmol/L): 2,59
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1100.0
Protein (g/L): 66,399
T4 (ng/L): 17,63
Troponin (ng/mL): 0,7
TSH (mIU/L): 0,77
Urea (mg/dL): 12,1
LVEF (%): 30.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

This patient's outcome of pump failure death can be attributed to a combination of his underlying medical conditions and laboratory results. 

1. Idiopathic dilated cardiomyopathy: The patient has a pre-existing condition that affects the heart muscle, leading to its enlargement and reduced ability to pump blood efficiently. This condition is a significant risk factor for heart failure.

2. Reduced LVEF (30.0%): The left ventricular ejection fraction (LVEF) of 30% is significantly below the normal range (50-70%), indicating that the patient's heart is not pumping blood effectively. This is a strong indicator of heart failure.

3. Elevated Pro-BNP (1100.0 ng/L): B-type natriuretic peptide (BNP) is a hormone produced by the heart in response to increased ventricular wall stress. Elevated levels of BNP are associated with heart failure.

4. Diabetes: The patient's diabetes history may contribute to the development of diabetic cardiomyopathy, which can further exacerbate heart failure.

5. Hypertension: Although the patient's blood pressure is within the normal range, his history of hypertension may have led to long-term damage to the heart and blood vessels, contributing to heart failure.

6. Kidney function impairment (Creatinine 120.0 mmol/L): The patient's elevated creatinine level indicates impaired kidney function, which can be a complication of heart failure.

7. Electrolyte imbalance (Potassium 3.44 mEq/L): The patient's low potassium level may be a contributing factor to arrhythmias and further compromise cardiac function.

8. Medication regimen: While the patient is on medications for heart failure, including ACE inhibitors and loop diuretics, these may not be sufficient to control the patient's condition, given the severity of his heart failure.

Given the combination of these factors, the patient's outcome of pump failure death is not surprising. The patient's reduced LVEF, elevated BNP, and impaired kidney function, among other factors, indicate a high risk of cardiac decompensation, which ultimately led to pump failure and death."
772,772,P0223,"Age: 64
Gender: Male 
Weight: 64 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,2
Creatinine (mmol/L): 254.0
Gamma-glutamil transpeptidase (IU/L): 175
Glucose (mmol/L): 15,78
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,71
LDL (mmol/L): 2,29
Sodium (mEq/L): 127.0
Pro-BNP (ng/L): 12746.0
Protein (g/L): 81
T3 (pg/dL): 0,0114
T4 (ng/L): 17,74
Troponin (ng/mL): 1,5
TSH (mIU/L): 2,65
Urea (mg/dL): 20,37
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to several factors evident in the provided data. 

1. Severe Left Ventricular Dysfunction: The patient has an LVEF (Left Ventricular Ejection Fraction) of 30%, indicating severe left ventricular dysfunction. An LVEF below 40% is generally considered abnormal, and an LVEF of 30% is associated with significant impairment in the heart's ability to pump blood effectively, leading to potential pump failure.

2. Ischemic Dilated Cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers dilate due to previous heart attacks or coronary artery disease. This condition directly contributes to the patient's severe left ventricular dysfunction.

3. High Pro-BNP Levels: The patient's Pro-BNP (N-terminal pro b-type natriuretic peptide) level is significantly elevated at 12746.0 ng/L. Elevated Pro-BNP levels are associated with heart failure and are used as a biomarker for diagnosing and monitoring heart failure. High levels, such as those seen in this patient, indicate severe heart failure.

4. Medication Non-Response: The patient is on various medications, including beta blockers, loop diuretics, spironolactone, statins, hydralazine, and nitrovasodilator. However, despite these treatments, the patient's condition has progressed to pump failure death. This could indicate a non-response or inadequate response to these medications, which may be due to the severity of the patient's condition or underlying factors not addressed by these treatments.

5. Comorbidities: The patient has multiple comorbidities, including diabetes, dyslipemia, hypertension, and myocardial infarction, which can contribute to the progression of heart failure and pump failure.

6. Poor Nutritional Status: The patient has low albumin levels (41 g/L), which can indicate poor nutritional status, malnutrition, or liver disease, all of which can contribute to worsening heart failure.

7. Electrocardiogram (ECG) Findings: The patient's ECG shows ventricular extrasystole and non-sustained ventricular tachycardia, which can be indicative of abnormal heart rhythms and potential electrical instability, further contributing to the risk of pump failure.

In summary, the combination of severe left ventricular dysfunction, ischemic dilated cardiomyopathy, high Pro-BNP levels, potential medication non-response, comorbidities, poor nutritional status, and abnormal ECG findings all contributed to the patient's outcome of pump failure death."
773,773,P0239,"Age: 67
Gender: Male 
Weight: 90 kg
Height: 164 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,2
Creatinine (mmol/L): 212.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 114.0
HDL (mmol/L): 1,35
Potassium (mEq/L): 5,2
LDL (mmol/L): 3,7
Sodium (mEq/L): 132.0
Pro-BNP (ng/L): 9992.0
Protein (g/L): 70
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,42
TSH (mIU/L): 7,83
Urea (mg/dL): 24,79
LVEF (%): 10.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: The patient outcome of pump failure death is likely due to a combination of the patient's severe left ventricular dysfunction, as indicated by the low left ventricular ejection fraction (LVEF) of 10.0%, and the high level of B-type natriuretic peptide (BNP) of 9992.0 ng/L, which is a marker of heart failure. The patient's ischemic dilated cardiomyopathy, a history of myocardial infarction, and peripheral vascular disease also contribute to the patient's high risk of heart failure.

The patient's kidney function, as indicated by the high creatinine level of 212.0 μmol/L, suggests that the patient has advanced chronic kidney disease, which is a common comorbidity in patients with heart failure. The patient's diabetes, dyslipidemia, and hypertension also contribute to the patient's cardiovascular risk profile.

The patient's medications, including beta blockers, digoxin, loop diuretics, spironolactone, statins, and an ACE inhibitor, are commonly used in the management of heart failure, but the patient's severe left ventricular dysfunction and high BNP level suggest that these medications may not be sufficient to control the patient's heart failure.

The ECG findings of polymorphic ventricular extrasystoles, sustained ventricular tachycardia, non-sustained ventricular tachycardia, and unknown paroxysmal supraventricular tachyarrhythmia suggest that the patient has significant arrhythmia burden, which can further contribute to the patient's risk of pump failure.

The patient's low T4 level of 15 ng/L, which is below the normal range, may indicate hypothyroidism, which can contribute to heart failure. The patient's high TSH level of 7.83 mIU/L suggests that the hypothyroidism is likely primary, rather than secondary to thyroid hormone replacement therapy.

Overall, the combination of the patient's severe left ventricular dysfunction, advanced kidney disease, high BNP level, and significant arrhythmia burden, along with the presence of multiple comorbidities, suggests that the patient's pump failure was likely a terminal event."
774,774,P0242,"Age: 69
Gender: Female 
Weight: 57 kg
Height: 150 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 34
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,44
Creatinine (mmol/L): 285.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 12,5
Hemoglobin (g/L): 122.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 5,4
LDL (mmol/L): 1,71
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 656.0
Protein (g/L): 74
T3 (pg/dL): 0,06
T4 (ng/L): 17
Troponin (ng/mL): 0,05
TSH (mIU/L): 6,87
Urea (mg/dL): 23,46
LVEF (%): 21.0
Medications: Diabetes Medication, Beta Blockers, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of several factors from the provided patient data.

1. Severe Left Ventricular Dysfunction: The patient has a Left Ventricular Ejection Fraction (LVEF) of 21.0%, indicating severe left ventricular dysfunction. This is a critical indicator of heart failure and increases the risk of pump failure.

2. High Pro-BNP Levels: The patient's Pro-BNP level is 656.0 ng/L, which is significantly elevated. Pro-BNP is a marker of heart failure and is associated with increased mortality and morbidity in patients with heart failure.

3. Chronic Kidney Disease: The patient's creatinine level is 285.0 μmol/L, indicating severe chronic kidney disease. This is a common comorbidity in patients with heart failure and can further exacerbate the condition.

4. Diabetes: The patient has a history of diabetes, which is a significant risk factor for heart failure and cardiovascular disease. Diabetes can lead to diabetic cardiomyopathy, which can further worsen heart function.

5. Idiopathic Dilated Cardiomyopathy: The patient has a history of idiopathic dilated cardiomyopathy, a condition where the heart muscle is weakened and the heart chambers are enlarged. This condition can lead to heart failure and is a significant risk factor for pump failure.

6. Electrocardiogram (ECG) Abnormalities: The patient's ECG shows polymorphic ventricular extrasystoles, non-sustained ventricular tachycardia, and an unknown paroxysmal supraventricular tachyarrhythmia. These ECG abnormalities indicate abnormal heart rhythms, which can further compromise cardiac function and increase the risk of pump failure.

7. Suboptimal Medication Regimen: Although the patient is on medications such as beta blockers, ACE inhibitors, and nitrovasodilators, which are commonly used to manage heart failure, the presence of severe left ventricular dysfunction and high Pro-BNP levels suggest that the medication regimen may not be adequately controlling the patient's symptoms and cardiac function.

Considering these factors, the patient's outcome of pump failure death is likely due to the combination of severe left ventricular dysfunction, high Pro-BNP levels, chronic kidney disease, diabetes, idiopathic dilated cardiomyopathy, ECG abnormalities, and a potentially suboptimal medication regimen."
775,775,P0248,"Age: 43
Gender: Female 
Weight: 50 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,19
Creatinine (mmol/L): 53.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,79
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 996.0
Protein (g/L): 67
T3 (pg/dL): 0,03
T4 (ng/L): 18
Troponin (ng/mL): 0,09
TSH (mIU/L): 1,34
Urea (mg/dL): 3,66
LVEF (%): 37.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Based on the provided patient data, the patient's outcome of pump failure death can be attributed to a combination of factors related to their underlying heart condition and other comorbidities. 

The patient has a history of ischemic dilated cardiomyopathy and a previous myocardial infarction, indicating significant cardiac damage. The left ventricular ejection fraction (LVEF) of 37% is below the normal range, indicating reduced cardiac function. This suggests that the patient's heart is not pumping efficiently, which is consistent with the diagnosis of heart failure.

The elevated Pro-BNP (Brain Natriuretic Peptide) level of 996 ng/L is also indicative of heart failure. Pro-BNP is a biomarker that is released by the heart in response to increased ventricular wall stress, which is often seen in heart failure.

The patient's high total cholesterol level of 4.19 mmol/L and low HDL (good cholesterol) level of 1.06 mmol/L suggest that the patient has dyslipidemia, which can contribute to the progression of atherosclerosis and worsening cardiac function.

The patient's weight of 50 kg is below the normal range for an adult female, which may indicate malnutrition or muscle wasting, further compromising cardiac function. The low albumin level of 39 g/L is also indicative of malnutrition.

The patient's medications, including beta blockers, loop diuretics, statins, and ACE inhibitors, are standard treatments for heart failure and may have been prescribed to manage symptoms and slow disease progression. However, the patient's outcome suggests that these medications may not have been sufficient to prevent pump failure.

The presence of ventricular extrasystoles on the ECG suggests that the patient's heart is experiencing arrhythmias, which can further compromise cardiac function.

In conclusion, the patient's outcome of pump failure death is likely due to a combination of factors, including ischemic dilated cardiomyopathy, previous myocardial infarction, reduced LVEF, elevated Pro-BNP levels, dyslipidemia, malnutrition, and arrhythmias."
776,776,P0256,"Age: 72
Gender: Male 
Weight: 79 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 150/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 33
ALT or GPT (IU/L): 44.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 267
Glucose (mmol/L): 9,9
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,72
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1475.0
Protein (g/L): 64
T3 (pg/dL): 0,03
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,13
Urea (mg/dL): 5,83
LVEF (%): 48.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of factors based on the provided data. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers dilate, reducing the heart's ability to pump blood effectively. This condition is a significant risk factor for heart failure.

The patient's left ventricular ejection fraction (LVEF) of 48% is below the normal range (50-70%), indicating that the heart is not pumping blood efficiently. This is consistent with the diagnosis of heart failure.

The patient's high blood pressure (150/60 mmHg) and low blood pressure variability may indicate orthostatic hypotension, which can further compromise cardiac output.

The elevated levels of pro-BNP (1475.0 ng/L) are indicative of heart failure, as BNP is a hormone released by the heart in response to stress and strain.

Additionally, the patient's history of myocardial infarction and peripheral vascular disease may have contributed to the development of ischemic cardiomyopathy and further reduced cardiac function.

The patient's medication regimen includes digoxin, which is often used to treat heart failure, but the patient's high levels of troponin (0.01 ng/mL) suggest that the heart is still experiencing some degree of damage.

The patient's overall clinical presentation, including the presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and unknown paroxysmal supraventricular tachyarrhythmia, further indicates compromised cardiac function.

The combination of these factors likely led to the patient's outcome of pump failure death."
777,777,P0264,"Age: 63
Gender: Male 
Weight: 65 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 90/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 41,9
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,48
Creatinine (mmol/L): 154.0
Gamma-glutamil transpeptidase (IU/L): 69
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,17
Potassium (mEq/L): 4,63
LDL (mmol/L): 2,84
Sodium (mEq/L): 141.0
Protein (g/L): 71,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,74
Urea (mg/dL): 11,9
LVEF (%): 15.0
Medications: Amiodarone, Digoxin, Loop Diuretics, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of factors reflected in their clinical presentation and laboratory results. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which are both significant risk factors for heart failure. The patient's current left ventricular ejection fraction (LVEF) of 15% is severely reduced, indicating significant left ventricular dysfunction. This reduction in LVEF is consistent with the patient's symptoms of heart failure, as evidenced by their New York Heart Association (NYHA) Class II classification.

The patient's laboratory results also indicate renal impairment, as evidenced by the elevated creatinine level (154.0 mmol/L) and low albumin level (41.9 g/L). Renal dysfunction can contribute to fluid overload and electrolyte imbalances, which can further exacerbate heart failure.

The patient's medications, including Amiodarone, Digoxin, Loop Diuretics, Hydralazine, and Nitrovasodilator, are typically used to manage heart failure and arrhythmias. However, the presence of these medications does not appear to have adequately controlled the patient's symptoms or improved their LVEF.

The patient's ECG findings of polymorphic ventricular extrasystoles are also concerning, as they can be a marker of increased risk of arrhythmias and sudden cardiac death.

Furthermore, the patient's low blood pressure (90/55 mmHg) may indicate hypotension, which can be a sign of advanced heart failure. The patient's low sodium level (141.0 mEq/L) may also indicate hyponatremia, which is a common complication of heart failure.

In summary, the patient's outcome of pump failure death is likely due to a combination of their underlying heart disease, renal impairment, medication non-responsiveness, and the presence of arrhythmias."
778,778,P0265,"Age: 83
Gender: Female 
Weight: 77 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 155/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 38,2
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 3,99
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 8,6
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 3,66
LDL (mmol/L): 2,03
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 984.0
Protein (g/L): 67
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,29
Urea (mg/dL): 9,7
LVEF (%): 70.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Given the patient's age (83 years) and past medical history of Hypertensive cardiomyopathy, Myocardial Infarction, and Hypertension, the patient is at a high risk for heart failure. The patient's current NYHA Class II classification indicates that the patient experiences some limitations in physical activity but is still able to perform everyday activities without severe symptoms.

The elevated Blood Pressure (155/90 mmHg) is consistent with the patient's history of hypertension, which can contribute to the progression of heart failure. The patient's creatinine level (97.0 mmol/L) is slightly elevated, indicating some degree of kidney impairment, which is a common comorbidity in patients with heart failure.

The patient's LVEF (Left Ventricular Ejection Fraction) is 70%, which is within the normal range, but considering the patient's age and history, it may be a sign of compensated heart failure. The elevated Pro-BNP (984.0 ng/L) level is indicative of heart failure with preserved ejection fraction (HFpEF), which is a common type of heart failure in older adults.

The patient's medications, including Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, and Nitrovasodilator, are standard treatments for heart failure, but the patient's outcome suggests that these medications may not have been sufficient to prevent pump failure.

The patient's laboratory results show elevated Glucose (8.6 mmol/L) and LDL (2.03 mmol/L) levels, which can contribute to the progression of atherosclerosis and worsen heart failure. The low HDL (1.68 mmol/L) level is also a risk factor for cardiovascular disease.

The patient's ECG results show polymorphic ventricular extrasystoles, which can be a sign of electrical instability in the heart and may contribute to the risk of arrhythmias and sudden cardiac death.

Considering the patient's age, history of heart failure, hypertension, and kidney impairment, as well as the elevated Pro-BNP level and polymorphic ventricular extrasystoles on ECG, the patient's outcome of pump failure death is consistent with the progression of heart failure and its complications."
779,779,P0269,"Age: 79
Gender: Male 
Weight: 62 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Valvular cardiomyopathy, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 45,5
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,07
Creatinine (mmol/L): 184.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 140.0
HDL (mmol/L): 0,82
Potassium (mEq/L): 5,12
LDL (mmol/L): 2,51
Sodium (mEq/L): 138.0
Protein (g/L): 71,1
Troponin (ng/mL): 0,13
TSH (mIU/L): 1,31
Urea (mg/dL): 20,1
LVEF (%): 22.0
Medications: Calcium Channel Blocker, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

Given the patient's advanced age of 79 and past medical history of valvular cardiomyopathy, myocardial infarction, and peripheral vascular disease, the patient has a high risk of cardiovascular complications. The presence of a left ventricular ejection fraction (LVEF) of 22.0% indicates severe left ventricular dysfunction, which is a hallmark of heart failure. The patient's NYHA Class II classification suggests that the patient experiences some limitations in physical activity but is still able to perform daily tasks without severe symptoms.

The patient's laboratory results reveal elevated creatinine levels (184.0 mmol/L), indicating renal impairment, which is common in patients with heart failure. The patient's total cholesterol level is within a relatively safe range, but the low HDL level (0.82 mmol/L) may contribute to a higher risk of cardiovascular events. The patient's glucose level is elevated at 5.4 mmol/L, which may be a contributing factor to the development of heart failure.

The patient's ECG shows polymorphic ventricular extrasystoles, which can be a sign of electrical instability in the heart. The absence of sustained ventricular tachycardia and non-sustained ventricular tachycardia suggests that the patient does not have a high risk of sudden cardiac death. However, the presence of unknown paroxysmal supraventricular tachyarrhythmia and bradycardia codes on the ECG may indicate underlying cardiac conduction abnormalities.

The patient's medications, including calcium channel blockers, digoxin, loop diuretics, and ACE inhibitors, are standard treatments for heart failure and may be contributing to the stabilization of the patient's condition.

Considering the patient's advanced age, severe left ventricular dysfunction, renal impairment, and underlying cardiovascular diseases, the patient's outcome of pump failure death is not unexpected. The patient's heart is unable to effectively pump blood, leading to a decline in cardiac function and ultimately, death. The patient's advanced age and comorbidities likely contributed to the progression of heart failure, ultimately resulting in pump failure death."
780,780,P0285,"Age: 69
Gender: Female 
Weight: 76 kg
Height: 147 cm
NYHA Class: III
Blood Pressure: 150/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 4,5
Creatinine (mmol/L): 163.0
Gamma-glutamil transpeptidase (IU/L): 48,4
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,56
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2365.0
Protein (g/L): 75
T3 (pg/dL): 0,0294
T4 (ng/L): 16,92
Troponin (ng/mL): 1,4
TSH (mIU/L): 0,56
Urea (mg/dL): 21,2
LVEF (%): 25.0
Medications: Diabetes Medication, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of factors based on the provided data.

1.  Severe Left Ventricular Dysfunction (LVEF 25.0%): The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 25.0%, indicating severe left ventricular dysfunction. This suggests that the heart is not pumping efficiently, leading to decreased cardiac output and potential organ failure.

2.  Ischemic Dilated Cardiomyopathy: The patient's past medical history includes ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened due to a heart attack or coronary artery disease. This condition can lead to reduced cardiac function and increased risk of heart failure.

3.  High Pro-BNP Levels (2365.0 ng/L): B-type natriuretic peptide (BNP) is a hormone produced by the heart in response to increased wall stress. Elevated BNP levels indicate increased wall stress, which is often seen in heart failure.

4.  Diabetes and Hypertension: The patient's history of diabetes and hypertension are risk factors for heart failure, as they can contribute to the development of cardiac dysfunction over time.

5.  Medications Not Adequate: Although the patient is on diabetes medication, loop diuretics, statins, and ACE inhibitors, these medications may not be sufficient to manage the patient's severe heart failure. The patient may require more aggressive treatment, such as ACE inhibitors or beta-blockers, to improve cardiac function.

6.  Electrocardiogram (ECG) Abnormalities: The ECG shows non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles, indicating abnormal heart rhythm and possible electrical instability.

Considering these factors, the patient's outcome of pump failure death can be attributed to the combination of severe left ventricular dysfunction, ischemic dilated cardiomyopathy, high BNP levels, and inadequate medication management."
781,781,P0287,"Age: 70
Gender: Female 
Weight: 80 kg
Height: 145 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,35
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4
LDL (mmol/L): 3,13
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1537.0
Protein (g/L): 72
T3 (pg/dL): 0,027
T4 (ng/L): 21,25
Troponin (ng/mL): 0,2
TSH (mIU/L): 1,93
Urea (mg/dL): 5,5
LVEF (%): 70.0
Medications: Calcium Channel Blocker, Amiodarone, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient outcome of pump failure death in this 70-year-old female with a history of hypertensive cardiomyopathy, dyslipemia, and hypertension can be attributed to several factors. 

1.  Elevated Blood Pressure: The patient's blood pressure of 160/80 mmHg is significantly elevated, which is a major risk factor for heart failure and cardiomyopathy progression.

2.  Low LVEF: The patient's left ventricular ejection fraction (LVEF) of 70% is on the lower end of the normal range, indicating reduced cardiac function. This reduced LVEF may be a result of the patient's hypertensive cardiomyopathy and is a significant risk factor for heart failure.

3.  Elevated Pro-BNP: A pro-B-type natriuretic peptide (pro-BNP) level of 1537.0 ng/L is significantly elevated, indicating increased stress on the heart. Elevated pro-BNP levels are associated with heart failure and are used as a biomarker for diagnosing and monitoring heart failure.

4.  Medication Non-Adherence or Insufficient Dosing: The patient is taking a combination of medications, including calcium channel blockers, amiodarone, loop diuretics, statins, and nitrovasodilators. However, the effectiveness of these medications may be limited by non-adherence or insufficient dosing, which can lead to inadequate control of the patient's hypertension and heart failure symptoms.

5.  Reduced Renal Function: The patient's creatinine level of 100.0 μmol/L indicates reduced renal function, which can be a result of chronic kidney disease secondary to hypertension. Reduced renal function can further exacerbate heart failure by accumulating toxins and electrolyte imbalances.

6.  Malnutrition: The patient's albumin level of 44 g/L is below the normal range, indicating malnutrition. Malnutrition can worsen heart failure by reducing the heart's energy reserves and impairing its ability to function.

7.  Electrolyte Imbalance: The patient's potassium level of 4 mEq/L is below the normal range, indicating hypokalemia. Electrolyte imbalances can disrupt cardiac function and contribute to heart failure.

8.  TSH Level: The patient's TSH level of 1.93 mIU/L is slightly elevated, indicating subclinical hypothyroidism. Subclinical hypothyroidism can contribute to heart failure by reducing cardiac output and increasing peripheral resistance.

Given these factors, the patient's pump failure death outcome can be attributed to the cumulative effect of these comorbidities and medication non-adherence, which have compromised the patient's cardiac function and overall health."
782,782,P0293,"Age: 74
Gender: Male 
Weight: 90 kg
Height: 184 cm
NYHA Class: III
Blood Pressure: 125/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 40,5
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 3,61
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 3,19
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,7
Potassium (mEq/L): 5,11
LDL (mmol/L): 1,73
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 1081.0
Protein (g/L): 68
T3 (pg/dL): 0,024
T4 (ng/L): 16,52
Troponin (ng/mL): 0,2
TSH (mIU/L): 0,62
Urea (mg/dL): 10,3
LVEF (%): 28.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

This patient's outcome of pump failure death is a likely consequence of his advanced heart failure, as indicated by his low left ventricular ejection fraction (LVEF) of 28%. This suggests that the patient's heart is not pumping efficiently, leading to a buildup of fluid in the body and potential organ damage. 

The patient's history of idiopathic dilated cardiomyopathy, a condition where the heart muscle becomes weakened and the heart chambers enlarge, further supports this conclusion. His NYHA Class III classification indicates that he has significant limitations in his physical activity and experiences symptoms such as shortness of breath, fatigue, and swelling in his legs.

The patient's laboratory results also support the conclusion. His elevated Pro-BNP (B-type natriuretic peptide) level of 1081 ng/L is indicative of heart failure and is associated with a poor prognosis. Additionally, his low hemoglobin level of 149 g/L may indicate anemia, which can further compromise cardiac function.

The patient's medication regimen, including beta blockers, digoxin, loop diuretics, spironolactone, ACE inhibitor, and nitrovasodilator, is consistent with the treatment of heart failure, but the patient's advanced disease and low LVEF suggest that these medications may not be sufficient to manage his condition effectively.

The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and unknown paroxysmal supraventricular tachyarrhythmia on the ECG also suggest that the patient's heart rhythm is unstable, which can further compromise cardiac function and increase the risk of sudden cardiac death.

The patient's age of 74 and comorbid conditions, including diabetes and hypertension, also contribute to his poor prognosis. The combination of these factors likely led to the patient's outcome of pump failure death."
783,783,P0294,"Age: 70
Gender: Male 
Weight: 79 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 78
Glucose (mmol/L): 5,82
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,57
LDL (mmol/L): 3,53
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1693.0
Protein (g/L): 67
T3 (pg/dL): 0,0369
T4 (ng/L): 15,09
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,21
Urea (mg/dL): 8
LVEF (%): 25.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of factors based on the provided data. 

Firstly, the patient has a history of idiopathic dilated cardiomyopathy, which is a condition characterized by the enlargement and weakening of the heart muscle, leading to reduced left ventricular ejection fraction (LVEF). The patient's LVEF is notably low at 25.0%, indicating significant left ventricular dysfunction.

Furthermore, the patient's elevated Pro-BNP (Brain Natriuretic Peptide) level of 1693.0 ng/L is a strong indicator of heart failure. Pro-BNP is a hormone released by the heart in response to ventricular strain, and elevated levels are associated with increased risk of heart failure and mortality.

The presence of non-sustained ventricular tachycardia (NSVT) on the ECG, as well as ventricular extrasystoles, suggests that the patient is experiencing arrhythmias, which can further compromise cardiac function and increase the risk of cardiac arrest.

Additionally, the patient's medication regimen includes Angiotensin II Receptor Blocker (ARB), Beta Blockers, Loop Diuretics, and Spironolactone, which are commonly used to manage heart failure. However, despite these medications, the patient's condition has progressed to pump failure death, suggesting that the treatment may not have been sufficient to prevent or reverse the progression of the disease.

The patient's age (70) and NYHA Class II classification also indicate that the patient has a moderate level of heart failure symptoms, which can further contribute to the risk of pump failure.

In summary, the patient's outcome of pump failure death is likely due to the combination of idiopathic dilated cardiomyopathy, low LVEF, elevated Pro-BNP, arrhythmias, and inadequate response to medical treatment, despite a comprehensive medication regimen."
784,784,P0303,"Age: 71
Gender: Male 
Weight: 65 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 5,92
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 44
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,7
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1160.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,34
Urea (mg/dL): 6,82
LVEF (%): 42.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Given the patient's medical history of ischemic dilated cardiomyopathy and myocardial infarction, it is not surprising that they have a reduced left ventricular ejection fraction (LVEF) of 42%. Ischemic dilated cardiomyopathy is a condition where the heart muscle becomes weakened due to a previous heart attack, leading to a decrease in the heart's ability to pump blood effectively. This condition is a major risk factor for heart failure.

The patient's NYHA Class II classification indicates that they experience some symptoms of heart failure, such as shortness of breath or fatigue, but they are still able to perform most daily activities without significant limitations.

The elevated Pro-BNP (B-type natriuretic peptide) level of 1160.0 ng/L is a strong indicator of heart failure. BNP is a hormone released by the heart in response to increased ventricular wall stress, which is often seen in heart failure.

The presence of ventricular extrasystoles on the ECG suggests that the patient's heart is experiencing abnormal electrical activity, which can be a sign of underlying cardiac disease.

The patient's laboratory results show elevated creatinine levels (106.0 μmol/L), which indicates impaired kidney function. This is consistent with the use of loop diuretics and spironolactone, which can affect kidney function.

The patient's medication regimen includes beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are all commonly used to manage heart failure. However, despite these medications, the patient's condition has progressed to pump failure, leading to death.

The patient's low T3 level (0.03 pg/dL) and low T4 level (17 ng/L) may indicate hypothyroidism, which can contribute to heart failure.

In summary, the patient's combination of ischemic dilated cardiomyopathy, reduced LVEF, elevated Pro-BNP, and impaired kidney function, along with the presence of ventricular extrasystoles on the ECG, suggest that the patient's heart failure was likely due to the progression of their underlying cardiac disease. Despite optimal medical management, the patient's condition ultimately led to pump failure and death."
785,785,P0317,"Age: 63
Gender: Male 
Weight: 72 kg
Height: 172 cm
NYHA Class: III
Blood Pressure: 95/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 42,5
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 4,81
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,1
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,45
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,64
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 325.0
Protein (g/L): 83
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 6,37
Urea (mg/dL): 13,14
LVEF (%): 24.0
Medications: Diabetes Medication, Amiodarone, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

This patient's outcome of pump failure death is likely due to a combination of factors related to his severe heart failure and underlying comorbidities. 

1. Ischemic dilated cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened due to a heart attack or coronary artery disease, leading to a decrease in the heart's pumping efficiency. This condition is a significant risk factor for heart failure and death.

2. Low LVEF (24.0%): The patient's left ventricular ejection fraction (LVEF) is severely reduced, indicating poor heart function. An LVEF below 30% is typically associated with heart failure and increased risk of mortality.

3. High Pro-BNP (325.0 ng/L): The patient's brain natriuretic peptide (BNP) level is elevated, indicating increased ventricular stretch and wall tension, which is a marker of heart failure.

4. NYHA Class III: The patient's New York Heart Association (NYHA) functional classification is Class III, indicating severe symptoms of heart failure, including shortness of breath and fatigue, even at rest.

5. Medications: Although the patient is on various medications, including ACE inhibitors, beta blockers, and loop diuretics, which are standard treatments for heart failure, these medications may not have been sufficient to manage his severe heart failure.

6. Comorbidities: The patient's comorbidities, including diabetes, dyslipidemia, and peripheral vascular disease, contribute to his increased risk of cardiovascular events and mortality.

7. Electrocardiogram (ECG) findings: The presence of ventricular extrasystoles and the absence of sustained ventricular tachycardia or other arrhythmias suggest that the patient's cardiac rhythm is unstable, which may have contributed to his cardiac decompensation and eventual death.

In summary, the patient's severe heart failure, low LVEF, high Pro-BNP, NYHA Class III symptoms, comorbidities, and ECG findings likely contributed to his pump failure death."
786,786,P0320,"Age: 69
Gender: Male 
Weight: 64 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,8
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 98.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,3
LDL (mmol/L): 1,99
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 535.0
Protein (g/L): 79
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,983
Urea (mg/dL): 7,35
LVEF (%): 36.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of several factors evident from the provided data.

1.  Reduced Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 36%, which is significantly lower than the normal range of 55-70%. This indicates a compromised left ventricular function, making the heart unable to pump blood efficiently.

2.  History of Ischemic Dilated Cardiomyopathy and Myocardial Infarction: The patient has a history of ischemic dilated cardiomyopathy and a previous myocardial infarction. These conditions can lead to scarring and damage to the heart muscle, further reducing its pumping efficiency.

3.  High Pro-BNP Levels: The patient's Pro-BNP (B-type natriuretic peptide) level is 535.0 ng/L, which is elevated. Elevated Pro-BNP levels are associated with heart failure, indicating that the heart is under strain and unable to pump blood efficiently.

4.  Low Hemoglobin and High Creatinine Levels: The patient's hemoglobin level is 138 g/L, which is slightly below the normal range, indicating mild anemia. Anemia can exacerbate heart failure symptoms by reducing oxygen delivery to the body's tissues. The creatinine level of 98.0 mmol/L is also elevated, indicating impaired kidney function, which can be a complication of heart failure.

5.  Medication Non-Response: Although the patient is on beta blockers, spironolactone, statins, ACE inhibitors, and nitrovasodilators, these medications may not be sufficient to control the patient's symptoms and underlying conditions effectively.

6.  Other Factors: The patient's low T3 and T4 levels, although not directly related to heart failure, can be associated with heart failure in some cases, although the mechanism is not fully understood.

Considering these factors, the patient's outcome of pump failure death is a result of the cumulative effect of reduced left ventricular function, history of ischemic dilated cardiomyopathy and myocardial infarction, and the inability of current medications to adequately manage the patient's symptoms and underlying conditions."
787,787,P0321,"Age: 67
Gender: Female 
Weight: 76 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 39,6
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 2,87
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 53
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 134.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,5
LDL (mmol/L): 1,45
Sodium (mEq/L): 132.0
Pro-BNP (ng/L): 4636.0
Protein (g/L): 67
T3 (pg/dL): 0,03
T4 (ng/L): 22
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,43
Urea (mg/dL): 6,01
LVEF (%): 18.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of factors present in the provided data. 

1.  Ischemic dilated cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, a condition where the heart's pumping ability is reduced due to scarring from a heart attack. This condition can lead to heart failure and is a significant risk factor for pump failure.

2.  Low LVEF (Left Ventricular Ejection Fraction) of 18%: The patient's LVEF is severely reduced, indicating that the heart is not pumping efficiently. An LVEF of 18% is considered critically low, and this can lead to symptoms of heart failure, including shortness of breath, fatigue, and swelling.

3.  High Pro-BNP levels (4636.0 ng/L): B-type natriuretic peptide (BNP) is a hormone produced by the heart when it is under strain. Elevated BNP levels indicate that the heart is working harder to pump blood, which can be a sign of heart failure.

4.  Medications: While the patient is on medications such as beta blockers, digoxin, loop diuretics, spironolactone, and ACE inhibitors, which are commonly used to manage heart failure, the combination of these medications and the patient's underlying condition may not have been sufficient to manage the severity of the heart failure.

5.  Other comorbidities: The patient has a history of diabetes, dyslipidemia, peripheral vascular disease, hypertension, and myocardial infarction, all of which can contribute to the progression of heart failure.

6.  Low T3 and T4 levels: The patient's thyroid function is slightly abnormal, with low T3 and T4 levels. Hypothyroidism can contribute to heart failure, as the thyroid hormone plays a crucial role in regulating heart function.

7.  Elevated Creatinine levels (94.0 mmol/L): Elevated creatinine levels indicate impaired kidney function, which can be a complication of heart failure.

Given these factors, the patient's outcome of pump failure death is a likely consequence of the cumulative effect of these conditions and the progression of ischemic dilated cardiomyopathy."
788,788,P0329,"Age: 61
Gender: Female 
Weight: 95 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39,2
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 17,2
Hemoglobin (g/L): 165.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,8
LDL (mmol/L): 1,78
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 10340.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,44
Urea (mg/dL): 7,35
LVEF (%): 24.0
Medications: Diabetes Medication, Digoxin, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient outcome of pump failure death in this case is likely due to a combination of factors contributing to the progression of her ischemic dilated cardiomyopathy. 

Firstly, the patient's left ventricular ejection fraction (LVEF) is severely reduced at 24.0%, indicating significant left ventricular dysfunction. This is a critical indicator of heart failure and a predictor of poor prognosis in patients with ischemic cardiomyopathy.

Additionally, the patient's elevated pro-BNP (brain natriuretic peptide) level of 10340.0 ng/L suggests marked cardiac stress and strain, which is often associated with heart failure. Elevated pro-BNP levels are also known to be a predictor of increased mortality in patients with heart failure.

The patient's past medical history of myocardial infarction and diabetes further contributes to the progression of her heart failure. Diabetes is a significant risk factor for the development and progression of heart failure, particularly in patients with ischemic cardiomyopathy.

The patient's medications, including spironolactone and ACE inhibitor, are appropriate for the management of heart failure with reduced ejection fraction. However, the presence of ventricular extrasystoles on the ECG suggests potential electrical instability, which may indicate a higher risk of sudden cardiac death.

The patient's low hemoglobin level of 165.0 g/L may also be a contributing factor to her poor outcome, as anemia is a known risk factor for increased mortality in patients with heart failure.

Overall, the combination of severe left ventricular dysfunction, elevated pro-BNP levels, past medical history of myocardial infarction and diabetes, and the presence of ventricular extrasystoles on the ECG make it likely that the patient's outcome was pump failure death."
789,789,P0336,"Age: 69
Gender: Female 
Weight: 69 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 41,9
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,4
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 3311.0
Protein (g/L): 73
T3 (pg/dL): 0,03
T4 (ng/L): 8
Troponin (ng/mL): 0,02
TSH (mIU/L): 33,39
Urea (mg/dL): 6,68
LVEF (%): 22.0
Medications: Angiotensin II Receptor Blocker, Digoxin
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of several factors based on the provided data.

1.  Severe Left Ventricular Dysfunction: The patient has a left ventricular ejection fraction (LVEF) of 22%, indicating severe left ventricular dysfunction. This is a critical indicator of heart failure, as it suggests that the heart is not pumping efficiently to meet the body's needs.

2.  High BNP Levels: The patient's brain natriuretic peptide (BNP) level is 3311 ng/L, which is significantly elevated. Elevated BNP levels are associated with heart failure and indicate increased ventricular wall stress. High BNP levels are often seen in patients with severe heart failure.

3.  Medication Non-Response: The patient is on Angiotensin II Receptor Blocker and Digoxin, which are common medications for heart failure management. However, the patient's condition has progressed to pump failure death, suggesting that these medications may not have been effective in managing the patient's condition.

4.  Electrocardiogram (ECG) Findings: The patient has polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are abnormal heart rhythms that can contribute to the progression of heart failure.

5.  Comorbidities: The patient has idiopathic dilated cardiomyopathy, diabetes, and dyslipemia, which are all risk factors for heart failure. The presence of these comorbidities likely contributed to the patient's poor cardiac function.

6.  Laboratory Values: The patient's albumin level is slightly low (41.9 g/L), which can indicate malnutrition or liver dysfunction, both of which can contribute to heart failure. The patient's glucose level is also elevated (6.3 mmol/L), which can exacerbate cardiac function.

In summary, the patient's outcome of pump failure death can be attributed to a combination of severe left ventricular dysfunction, high BNP levels, medication non-response, abnormal ECG findings, comorbidities, and laboratory abnormalities."
790,790,P0339,"Age: 77
Gender: Male 
Weight: 64 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension
Albumin (g/L): 37,4
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 135.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 4,1
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,49
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3307.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,37
Urea (mg/dL): 16,03
LVEF (%): 33.0
Medications: Diabetes Medication, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Given the patient's advanced age of 77, history of ischemic dilated cardiomyopathy, and low left ventricular ejection fraction (LVEF) of 33%, the patient is at high risk for heart failure. The presence of diabetes and peripheral vascular disease further exacerbates the cardiovascular disease burden. The patient's elevated Pro-BNP level of 3307.0 ng/L is indicative of heart failure, as Pro-BNP is a well-established biomarker for heart failure.

The patient's medication regimen includes loop diuretics, ACE inhibitors, and nitrovasodilators, which are standard treatments for heart failure. However, despite these medications, the patient's LVEF remains low, indicating that the heart is not functioning adequately.

The patient's ECG findings, including polymorphic ventricular extrasystoles and paroxysmal supraventricular tachyarrhythmia, suggest underlying cardiac electrical instability. The presence of these arrhythmias may contribute to the patient's decreased cardiac function and increased risk of cardiac events.

The patient's elevated creatinine level of 135.0 mmol/L and urea level of 16.03 mg/dL indicate impaired renal function, which is a common comorbidity in patients with heart failure. The patient's low hemoglobin level of 128.0 g/L may also indicate anemia, which can contribute to decreased cardiac output and increased risk of heart failure.

The patient's low T3 level of 0.04 pg/dL and high TSH level of 1.37 mIU/L suggest hypothyroidism, which can contribute to decreased cardiac function and increased risk of heart failure.

The patient's low HDL cholesterol level of 1.19 mmol/L and high LDL cholesterol level of 3.49 mmol/L indicate dyslipidemia, which is a risk factor for cardiovascular disease.

The combination of these factors, including advanced age, low LVEF, heart failure symptoms, and comorbidities, likely contributed to the patient's outcome of pump failure death."
791,791,P0363,"Age: 83
Gender: Male 
Weight: 55 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 160/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 41,1
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,71
Creatinine (mmol/L): 82.0
Gamma-glutamil transpeptidase (IU/L): 13,6
Glucose (mmol/L): 4,59
Hemoglobin (g/L): 160.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,2
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1469.0
Protein (g/L): 73
T3 (pg/dL): 0,0468
T4 (ng/L): 13,29
Troponin (ng/mL): 0,4
TSH (mIU/L): 1,04
Urea (mg/dL): 5,6
LVEF (%): 25.0
Medications: Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of several factors evident in the provided data. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to heart attacks or reduced blood flow. This condition often leads to decreased left ventricular ejection fraction (LVEF), as seen in this patient with an LVEF of 25.0%. A low LVEF is a significant risk factor for heart failure and increased mortality.

Additionally, the patient's NYHA Class III classification indicates that the patient experiences symptoms of heart failure during ordinary physical activity, such as walking or climbing stairs. This suggests that the patient's heart is not functioning adequately to meet the body's demands, leading to symptoms such as fatigue, shortness of breath, or swelling in the legs.

The elevated Pro-BNP (Brain Natriuretic Peptide) level of 1469.0 ng/L is also indicative of heart failure. Pro-BNP is a hormone released by the heart in response to increased wall stress, which is often seen in heart failure.

The patient's medication list includes ACE Inhibitor and Angiotensin II Receptor Blocker, which are commonly used to manage heart failure by reducing blood pressure and decreasing the workload on the heart. However, the presence of these medications does not necessarily indicate that the patient's heart failure is under optimal control.

Furthermore, the patient's laboratory results show elevated creatinine levels (82.0 mmol/L), which suggests impaired kidney function. Kidney dysfunction is a common comorbidity in patients with heart failure, and it can further exacerbate the condition.

The patient's low hemoglobin level (160.0 g/L) may indicate anemia, which can contribute to fatigue and shortness of breath, further compromising the patient's ability to manage their heart failure.

The patient's T3 and T4 hormone levels are within normal limits, which suggests that thyroid dysfunction is unlikely to be contributing to their heart failure.

In summary, the combination of ischemic dilated cardiomyopathy, low LVEF, elevated Pro-BNP, impaired kidney function, and anemia likely contributed to the patient's pump failure death."
792,792,P0391,"Age: 82
Gender: Female 
Weight: 77 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 125/65 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 112.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,97
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 950.0
Protein (g/L): 67
T3 (pg/dL): 0,03
T4 (ng/L): 21
TSH (mIU/L): 0,79
Urea (mg/dL): 14,64
LVEF (%): 37.0
Medications: Amiodarone, Loop Diuretics, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient is an 82-year-old female with a history of Hypertensive cardiomyopathy, Dyslipemia, and Hypertension. Her current NYHA Class II classification indicates that she experiences symptoms of heart failure with mild limitation in physical activity, but is comfortable at rest.

Key indicators of her cardiac function are as follows:

1. Low LVEF (Left Ventricular Ejection Fraction) of 37%: This suggests that her left ventricle is not pumping blood effectively, which is a hallmark of heart failure. A normal LVEF is typically above 55-60%.

2. High Pro-BNP (N-terminal pro b-type natriuretic peptide) of 950.0 ng/L: This is a biomarker of heart failure, and elevated levels are associated with increased risk of mortality and morbidity in patients with heart failure.

3. Medications: She is on Amiodarone, Loop Diuretics, Hydralazine, and Nitrovasodilator, which are commonly used to manage heart failure and hypertension. However, despite these treatments, her condition has progressed to pump failure.

4. Electrocardiogram (ECG) findings: Although the ECG does not show any acute arrhythmias, the patient's underlying cardiac dysfunction is likely contributing to her pump failure.

Given these factors, the patient's outcome of pump failure death is likely due to the progression of her underlying heart disease, despite optimal medical management. The combination of her low LVEF, high Pro-BNP levels, and long-standing history of Hypertensive cardiomyopathy and Hypertension have likely led to a decline in her cardiac function, ultimately resulting in pump failure and death."
793,793,P0448,"Age: 71
Gender: Male 
Weight: 60 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 45.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 4,42
Creatinine (mmol/L): 194.0
Gamma-glutamil transpeptidase (IU/L): 52
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,9
LDL (mmol/L): 2,69
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 2285.0
Protein (g/L): 69
T3 (pg/dL): 0,03
T4 (ng/L): 10
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,69
Urea (mg/dL): 15,14
LVEF (%): 55.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of several factors evident from the provided data. 

Firstly, the patient has a history of Hypertensive cardiomyopathy, which is a condition where high blood pressure damages the heart muscle, leading to reduced heart function and potential heart failure. The patient's NYHA Class II classification indicates that the patient experiences symptoms of heart failure, such as shortness of breath and fatigue, upon exertion, but is still able to perform daily activities.

The patient's blood pressure is within a relatively normal range, but their Pro-BNP (B-type natriuretic peptide) level is elevated at 2285.0 ng/L, which is a marker of cardiac stress and strain, often associated with heart failure. The patient's LVEF (Left Ventricular Ejection Fraction) is 55%, which is below the normal range (60-70%), indicating reduced left ventricular function.

Furthermore, the patient has a history of diabetes, which is a significant risk factor for heart failure. The patient's glucose level is 4.8 mmol/L, which is slightly elevated, suggesting that the diabetes is not well-controlled.

The patient's lipid profile shows an elevated total cholesterol level (4.42 mmol/L) and low HDL (1.4 mmol/L), indicating dyslipidemia. The patient is on statins, which suggests that they are being treated for high cholesterol, but the patient's lipid profile suggests that the treatment may not be effective.

The patient's creatinine level is elevated at 194.0 mmol/L, indicating impaired kidney function, which can be a complication of heart failure. The patient's urea level is also elevated at 15.14 mg/dL, further indicating kidney dysfunction.

The patient's Troponin level is 0.01 ng/mL, which is within the normal range, indicating that there is no acute myocardial infarction. However, the patient's TSH level is slightly elevated at 3.69 mIU/L, which may indicate thyroid dysfunction, which can contribute to heart failure.

The patient's ECG shows polymorphic ventricular extrasystoles, which can be a sign of cardiac arrhythmias, but the patient does not have sustained ventricular tachycardia or other life-threatening arrhythmias.

Given the combination of these factors, including the patient's history of heart disease, diabetes, and kidney dysfunction, the patient's reduced LVEF, and the elevated Pro-BNP level, it is likely that the patient's outcome of pump failure death was due to the progression of their heart failure, which ultimately led to cardiac decompensation and death."
794,794,P0460,"Age: 66
Gender: Female 
Weight: 56 kg
Height: 154 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,46
Creatinine (mmol/L): 186.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 102.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 5,2
LDL (mmol/L): 4,5
Sodium (mEq/L): 130.0
Pro-BNP (ng/L): 4471.0
Protein (g/L): 82
T4 (ng/L): 12
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,11
Urea (mg/dL): 16,31
LVEF (%): 32.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

This patient's outcome of pump failure death is consistent with the provided clinical data. Several factors contribute to this outcome:

1. Ischemic Dilated Cardiomyopathy (IDC): The patient has a history of IDC, a condition characterized by the weakening of the heart muscle due to coronary artery disease, leading to impaired heart function. The low left ventricular ejection fraction (LVEF) of 32% further supports this diagnosis.

2. Low LVEF: The patient's LVEF of 32% indicates severe left ventricular dysfunction, which is a strong predictor of heart failure and pump failure. This value suggests that the heart is not pumping efficiently, leading to decreased cardiac output and increased risk of pump failure.

3. Elevated Pro-BNP: The patient's Pro-BNP level of 4471.0 ng/L is significantly elevated, which is a marker of heart failure and increased ventricular wall stress. Elevated Pro-BNP levels are associated with increased mortality and morbidity in heart failure patients.

4. Diabetes and Dyslipidemia: The patient has a history of diabetes and dyslipidemia, both of which are risk factors for cardiovascular disease and heart failure. These conditions can contribute to the progression of IDC and worsen cardiac function.

5. Medications: The patient is on a combination of medications, including ACE inhibitors, angiotensin II receptor blockers, loop diuretics, spironolactone, and statins. While these medications are commonly used to manage heart failure and IDC, their effectiveness may be limited in this patient due to the severity of her condition.

6. Electrocardiogram (ECG) Findings: The patient's ECG shows polymorphic ventricular extrasystoles, which can be a sign of arrhythmias and increased cardiac stress. Although the ECG does not show sustained ventricular tachycardia, the presence of ventricular extrasystoles may indicate underlying cardiac instability.

Considering these factors, the patient's outcome of pump failure death is consistent with the severity of her IDC, low LVEF, elevated Pro-BNP, and the presence of comorbid conditions such as diabetes and dyslipidemia."
795,795,P0461,"Age: 65
Gender: Male 
Weight: 113 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Peripheral vascular disease, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 40.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 115
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 168.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,44
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 339.0
Protein (g/L): 76
T4 (ng/L): 8
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,21
Urea (mg/dL): 3,83
LVEF (%): 60.0
Medications: Amiodarone, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

Based on the provided patient data, I can infer that the patient is at high risk for cardiac complications due to his underlying conditions. The patient has a history of hypertensive cardiomyopathy, peripheral vascular disease, and hypertension, which are all contributing factors to his current cardiac condition. His left ventricular ejection fraction (LVEF) is 60%, which is within the normal range but slightly below the expected range for a 65-year-old male, indicating some degree of cardiac dysfunction.

The patient's elevated pro-BNP (brain natriuretic peptide) level of 339.0 ng/L is a strong indicator of heart failure, as it is often used as a biomarker for cardiac stress and strain. Additionally, the patient's creatinine level of 88.0 μmol/L suggests impaired renal function, which is a common complication of heart failure.

The patient's medication regimen includes Amiodarone, Digoxin, and an ACE inhibitor, which are commonly used to manage heart rhythm disorders and heart failure. However, despite these treatments, the patient has a history of ventricular extrasystoles, non-sustained ventricular tachycardia, and unknown paroxysmal supraventricular tachyarrhythmia, indicating ongoing cardiac instability.

The patient's troponin level of 0.01 ng/mL is slightly elevated, suggesting some degree of myocardial injury or stress. His TSH level of 5.21 mIU/L is within the normal range, indicating no apparent thyroid dysfunction.

Considering these factors, the patient's outcome of pump failure death is likely due to the cumulative effect of his underlying cardiac conditions, impaired renal function, and ongoing cardiac instability. The patient's age, weight, and comorbidities also contribute to his high risk of cardiac complications.

In summary, the patient's outcome is likely due to the following factors:

1. Underlying cardiac conditions (hypertensive cardiomyopathy, peripheral vascular disease, and hypertension)
2. Impaired renal function (elevated creatinine level)
3. Ongoing cardiac instability (ventricular extrasystoles, non-sustained ventricular tachycardia, and unknown paroxysmal supraventricular tachyarrhythmia)
4. Elevated pro-BNP level indicating heart failure
5. Age, weight, and comorbidities contributing to high risk of cardiac complications."
796,796,P0480,"Age: 78
Gender: Female 
Weight: 46 kg
Height: 143 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia
Albumin (g/L): 42,5
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,81
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1816.0
Protein (g/L): 71,6
T4 (ng/L): 16
TSH (mIU/L): 1,88
Urea (mg/dL): 6,82
LVEF (%): 27.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of factors reflected in the provided data. 

Firstly, the patient's LVEF (Left Ventricular Ejection Fraction) of 27% indicates severe left ventricular dysfunction, which is a hallmark of heart failure. The LVEF is a critical indicator of the heart's ability to pump blood efficiently, and a value below 35% is typically associated with heart failure.

The patient's high Pro-BNP (B-type Natriuretic Peptide) level of 1816 ng/L is also indicative of heart failure. Elevated Pro-BNP levels are commonly used as a biomarker for heart failure, with higher levels correlating with more severe disease.

Furthermore, the patient's NYHA Class II classification indicates that the patient experiences symptoms of heart failure with moderate limitations in physical activity. This suggests that the patient's heart failure is not only severe but also symptomatic, impacting the patient's quality of life.

The patient's history of hypertensive cardiomyopathy and dyslipidemia also contributes to the development of heart failure. Hypertensive cardiomyopathy can lead to left ventricular hypertrophy and diastolic dysfunction, while dyslipidemia can accelerate atherosclerosis and coronary artery disease, further compromising cardiac function.

The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG suggests arrhythmias, which can further strain the heart and contribute to pump failure.

Lastly, the patient's medications, including beta blockers, digoxin, loop diuretics, spironolactone, and statins, were prescribed to manage heart failure symptoms and underlying conditions. However, despite these treatments, the patient's condition progressed to pump failure death, indicating that the disease was advanced and treatment-resistant.

In conclusion, the combination of severe left ventricular dysfunction, high Pro-BNP levels, symptomatic heart failure, history of hypertensive cardiomyopathy and dyslipidemia, arrhythmias, and treatment-resistant disease progression all contributed to the patient's outcome of pump failure death."
797,797,P0481,"Age: 66
Gender: Male 
Weight: 73 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 47,9
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 6,23
Creatinine (mmol/L): 122.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 5
LDL (mmol/L): 3,57
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 2035.0
Protein (g/L): 73,6
T4 (ng/L): 15
TSH (mIU/L): 2,12
Urea (mg/dL): 13,64
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",pump failure death,"REASONING: 

This patient's outcome of pump failure death can be attributed to a combination of factors. Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a previous heart attack, leading to a decrease in the heart's pumping efficiency. The patient's left ventricular ejection fraction (LVEF) of 20% is significantly below the normal range, indicating severe systolic dysfunction.

The patient's laboratory results also suggest significant liver dysfunction, as evidenced by elevated levels of gamma-glutamil transpeptidase (GGT) and a low albumin level of 47.9 g/L. This could be indicative of congestive hepatopathy, a common complication in patients with heart failure. The patient's creatinine level of 122.0 mmol/L also suggests impaired renal function, which is a common comorbidity in patients with heart failure.

Furthermore, the patient's pro-BNP level of 2035.0 ng/L is significantly elevated, indicating severe heart failure. The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and first-degree atrioventricular block (AVB) on the ECG also suggest significant cardiac arrhythmias, which can further compromise cardiac function.

The patient's medication regimen includes beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are standard treatments for heart failure. However, despite these medications, the patient's condition has progressed to pump failure, likely due to the severity of the underlying cardiac dysfunction and comorbidities.

In conclusion, the patient's outcome of pump failure death can be attributed to the combination of ischemic dilated cardiomyopathy, severe systolic dysfunction, liver dysfunction, impaired renal function, and significant cardiac arrhythmias, despite optimal medical therapy."
798,798,P0487,"Age: 79
Gender: Male 
Weight: 83 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 45,8
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 3,36
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 100
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,9
LDL (mmol/L): 1,84
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 3407.0
Protein (g/L): 76,8
T4 (ng/L): 16
TSH (mIU/L): 1,24
Urea (mg/dL): 4,82
LVEF (%): 15.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of several factors evident from the provided data.

1.  Ischemic Dilated Cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened due to reduced blood flow to the heart, leading to a decrease in its pumping efficiency. This condition is a significant risk factor for heart failure and can lead to pump failure.

2.  Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 15%, which is significantly below the normal range (50-70%). A low LVEF indicates that the left ventricle is not pumping efficiently, leading to a decrease in cardiac output and increased risk of heart failure.

3.  Elevated BNP (Brain Natriuretic Peptide): The patient's Pro-BNP level is 3407.0 ng/L, which is significantly elevated. Elevated BNP levels are associated with heart failure, particularly with acute decompensated heart failure and can indicate fluid overload.

4.  Kidney Function Impairment: The patient has impaired kidney function, as indicated by a creatinine level of 95.0 mmol/L. Kidney impairment can exacerbate heart failure by reducing the body's ability to remove excess fluids, leading to fluid overload and increased pressure on the heart.

5.  Electrocardiogram (ECG) Findings: The patient's ECG shows non-sustained ventricular tachycardia, which can be a sign of abnormal heart rhythm and increased risk of cardiac arrhythmias. This can further compromise cardiac function and increase the risk of pump failure.

6.  Medication Non-Response: Although the patient is on various medications, including beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor, the patient's condition has not improved, suggesting potential medication non-response or inadequate dosing.

7.  Age and NYHA Class III: The patient's age (79) and NYHA Class III classification indicate severe heart failure symptoms, with marked limitation in physical activity and symptoms of heart failure at rest. This suggests that the patient's heart failure is advanced and potentially irreversible.

Considering these factors, the patient's outcome of pump failure death is likely a result of a combination of ischemic dilated cardiomyopathy, low LVEF, elevated BNP levels, kidney function impairment, ECG findings, medication non-response, advanced age, and NYHA Class III classification."
799,799,P0489,"Age: 52
Gender: Male 
Weight: 76 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 40,4
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 122.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,28
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1198.0
Protein (g/L): 74,2
T4 (ng/L): 17
TSH (mIU/L): 1,79
Urea (mg/dL): 6,16
LVEF (%): 15.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Given the patient's extensive medical history, including ischemic dilated cardiomyopathy and a history of myocardial infarction, it is not surprising that the patient experienced pump failure death. The patient's left ventricular ejection fraction (LVEF) of 15% is significantly decreased, indicating severe left ventricular dysfunction. This is a strong predictor of adverse outcomes in patients with heart failure.

The patient's elevated B-type natriuretic peptide (BNP) level of 1198 ng/L further supports the diagnosis of heart failure with reduced ejection fraction (HFrEF). BNP levels are known to correlate with the severity of heart failure and are used as a prognostic marker.

The patient's medication regimen, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, is consistent with the treatment of heart failure. However, despite these medications, the patient's condition has progressed to pump failure death.

Additionally, the patient's laboratory results show elevated creatinine levels (95.0 mmol/L), indicating impaired renal function, which is a common complication of advanced heart failure. The patient's total cholesterol and LDL levels are within relatively normal ranges, but the patient's HDL level is low, which may contribute to the progression of atherosclerotic disease.

The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG further indicates arrhythmogenic risk, which is a common complication of heart failure.

In summary, the combination of the patient's extensive medical history, decreased LVEF, elevated BNP levels, and laboratory results, along with the presence of arrhythmias, contributed to the patient's outcome of pump failure death."
800,800,P0501,"Age: 71
Gender: Male 
Weight: 69 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 100/70 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 42,8
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 140.0
Gamma-glutamil transpeptidase (IU/L): 166
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,74
Potassium (mEq/L): 4,26
LDL (mmol/L): 2,23
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 2309.0
Protein (g/L): 82,3
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,8
Urea (mg/dL): 24,5
LVEF (%): 40.0
Medications: Digoxin, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

Given the patient's age of 71 and NYHA Class III, indicating severe symptoms of heart failure, the patient's condition is critical. The patient has a history of valvular cardiomyopathy, which is a known risk factor for heart failure. The patient's LVEF (Left Ventricular Ejection Fraction) of 40% is significantly reduced, indicating impaired heart function.

The elevated Pro-BNP (B-type natriuretic peptide) level of 2309.0 ng/L is a strong indicator of heart failure, as it is a biomarker released by the heart in response to increased wall stress. The patient's elevated creatinine level of 140.0 mmol/L suggests impaired kidney function, which is a common complication of heart failure.

The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG further indicates arrhythmia and potential electrical instability of the heart. The patient's low HDL cholesterol level (1.74 mmol/L) and high LDL cholesterol level (2.23 mmol/L) may also contribute to the development of atherosclerosis and further compromise cardiac function.

The patient's medication regimen includes Digoxin, Loop Diuretics, Spironolactone, and Nitrovasodilator, which are all commonly used to manage heart failure symptoms and improve cardiac function. However, the patient's condition has likely progressed to a point where these medications are insufficient to control the heart failure, leading to pump failure and eventual death.

The elevated gamma-glutamil transpeptidase (GGT) level of 166 IU/L may indicate liver damage or bile duct obstruction, which can be a complication of heart failure. The elevated glucose level of 5.3 mmol/L may indicate insulin resistance or diabetes, which can also contribute to heart failure.

The patient's low hemoglobin level of 139.0 g/L may indicate anemia, which can further compromise oxygen delivery to the tissues and exacerbate heart failure.

In summary, the combination of severe heart failure, impaired kidney function, arrhythmia, atherosclerosis, and potential liver damage or bile duct obstruction, along with the patient's advanced age and NYHA Class III symptoms, likely contributed to the patient's pump failure and eventual death."
801,801,P0509,"Age: 76
Gender: Female 
Weight: 60 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 36,7
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,4
Creatinine (mmol/L): 108.0
Gamma-glutamil transpeptidase (IU/L): 67
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 114.0
HDL (mmol/L): 1,63
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,28
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 2094.0
Protein (g/L): 67
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,58
Urea (mg/dL): 13,14
LVEF (%): 24.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death is likely due to a combination of factors related to her underlying cardiomyopathy and compromised cardiac function. 

1.  Idiopathic dilated cardiomyopathy: The patient's history of idiopathic dilated cardiomyopathy indicates that her heart muscle has been weakened, leading to a decrease in the heart's ability to pump blood effectively. This condition is a significant risk factor for heart failure.

2.  Low LVEF (24.0%): The patient's left ventricular ejection fraction (LVEF) is severely reduced, indicating that her heart is not pumping efficiently. An LVEF of 24.0% is considered severely impaired, which can lead to heart failure symptoms and increased risk of death.

3.  Elevated Pro-BNP (2094.0 ng/L): The patient's B-type natriuretic peptide (BNP) level is significantly elevated, indicating that her heart is under strain and releasing more natriuretic peptides in an attempt to compensate for the decreased pumping ability. Elevated BNP levels are associated with increased risk of heart failure hospitalization and mortality.

4.  Medications: While the patient is on medications that are commonly used to treat heart failure, such as digoxin, loop diuretics, spironolactone, and an ACE inhibitor, these medications may not have been sufficient to manage her symptoms and prevent progression to pump failure.

5.  ECG findings: The presence of polymorphic ventricular extrasystoles may indicate underlying electrical instability in the heart, which can contribute to the development of arrhythmias and sudden cardiac death.

6.  Other contributing factors: The patient's slightly elevated creatinine level (108.0 mmol/L) may indicate impaired renal function, which can further compromise cardiac function and increase the risk of death. Additionally, her slightly elevated gamma-glutamyl transpeptidase (GGT) level may indicate underlying liver disease or other metabolic disorders that can contribute to cardiac dysfunction.

Considering these factors, the patient's outcome of pump failure death is likely a result of the cumulative effect of her underlying cardiomyopathy, compromised cardiac function, and other contributing factors."
802,802,P0513,"Age: 76
Gender: Male 
Weight: 83 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 46,7
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 8
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,13
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 200.0
Protein (g/L): 81
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,46
Urea (mg/dL): 7,8
LVEF (%): 38.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

Given the patient's advanced age (76 years), history of ischemic dilated cardiomyopathy, and significantly reduced left ventricular ejection fraction (LVEF) of 38%, the patient is at high risk for heart failure progression. The patient's history of myocardial infarction further increases the risk of cardiovascular events.

The patient's creatinine level of 101.0 μmol/L indicates impaired renal function, which is often seen in patients with advanced heart failure. The elevated Pro-BNP (brain natriuretic peptide) level of 200.0 ng/L is a marker of heart failure and is consistent with the patient's symptoms.

The patient's history of diabetes and dyslipemia may contribute to the progression of heart failure. The patient's total cholesterol level of 5.38 mmol/L and LDL level of 3.13 mmol/L are above the recommended levels, indicating a high risk of atherosclerotic cardiovascular disease.

The patient's low HDL level of 1.27 mmol/L and elevated triglycerides (not provided) further increase the risk of cardiovascular disease.

The patient's medications, including calcium channel blockers, beta blockers, and angiotensin II receptor blockers, are appropriate for managing heart failure and hypertension. However, the patient's continued progression to pump failure death may indicate that these medications are not sufficient to control the disease.

The patient's ECG findings of ventricular extrasystoles and unknown paroxysmal supraventricular tachyarrhythmia code suggest arrhythmias that may be contributing to the patient's symptoms and progression of heart failure.

The patient's low T3 level of 0.05 pg/dL and low T4 level of 17 ng/L may indicate hypothyroidism, which can contribute to heart failure.

The patient's weight of 83 kg and height of 169 cm result in a BMI of 25.6, which is within the normal range, but the patient's weight may be a concern in the context of heart failure.

In summary, the patient's advanced age, history of ischemic dilated cardiomyopathy, reduced LVEF, impaired renal function, elevated Pro-BNP, and multiple comorbidities (diabetes, dyslipemia, peripheral vascular disease) contribute to the patient's progression to pump failure death."
803,803,P0529,"Age: 65
Gender: Male 
Weight: 80 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 150/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 43,4
ALT or GPT (IU/L): 95.0
AST or GOT (IU/L): 105.0
Total Cholesterol (mmol/L): 5,28
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 150
Glucose (mmol/L): 8,7
Hemoglobin (g/L): 162.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,74
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 221.0
Protein (g/L): 85
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,35
Urea (mg/dL): 8,69
LVEF (%): 27.0
Medications: Beta Blockers, Digoxin, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of several factors evident in the provided data. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers dilate, impairing the heart's ability to pump blood effectively. This condition is likely a result of previous myocardial infarctions or coronary artery disease, which is supported by the patient's history of hypertension and diabetes, both of which are significant risk factors for cardiovascular disease.

The patient's left ventricular ejection fraction (LVEF) is severely reduced at 27.0%, indicating a significant impairment in the heart's ability to pump blood effectively. This is a critical factor in the development of heart failure.

Additionally, the patient's elevated levels of troponin (0.01 ng/mL) suggest recent or ongoing myocardial injury, which can contribute to the progression of heart failure.

The patient's elevated levels of B-type natriuretic peptide (BNP) (221 ng/L) are also indicative of heart failure, as BNP is a hormone released by the heart in response to increased wall tension and stretching of the heart muscle.

Furthermore, the patient's kidney function, as indicated by the elevated creatinine level (103.0 mmol/L), suggests that the patient has some degree of renal impairment, which is often seen in patients with advanced heart failure.

The patient's medication regimen includes beta blockers, digoxin, spironolactone, and an ACE inhibitor, which are all commonly used in the management of heart failure. However, the patient's condition may have progressed beyond the point where these medications can effectively manage the disease.

The ECG findings of ventricular extrasystoles, non-sustained ventricular tachycardia, and unknown paroxysmal supraventricular tachyarrhythmia suggest that the patient's heart is experiencing significant electrical instability, which can contribute to the development of pump failure.

In summary, the patient's outcome of pump failure death can be attributed to the combination of ischemic dilated cardiomyopathy, severe left ventricular dysfunction, recent or ongoing myocardial injury, elevated BNP levels, renal impairment, and electrical instability of the heart, which ultimately led to a failure of the heart to pump blood effectively, resulting in death."
804,804,P0540,"Age: 37
Gender: Male 
Weight: 70 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 48,2
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 2,79
Creatinine (mmol/L): 92.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 5
Hemoglobin (g/L): 163.0
HDL (mmol/L): 0,62
Potassium (mEq/L): 3,9
LDL (mmol/L): 1,42
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1481.0
Protein (g/L): 76
T3 (pg/dL): 0,06
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,08
Urea (mg/dL): 7,12
LVEF (%): 35.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to several factors indicated by the provided data and patient history. 

1. Ischemic dilated cardiomyopathy: This is a known cause of heart failure, which is further supported by the patient's reduced Left Ventricular Ejection Fraction (LVEF) of 35%. Ischemic cardiomyopathy often leads to a decrease in LVEF due to scarring from previous myocardial infarctions.

2. History of Myocardial Infarction: Previous MI is a significant risk factor for the development of heart failure. The patient's history of MI likely contributed to the development of ischemic dilated cardiomyopathy.

3. Reduced LVEF (35%): An LVEF of 35% indicates severe left ventricular dysfunction, which is a strong indicator of heart failure. This is consistent with the patient's NYHA Class II classification, indicating mild to moderate symptoms of heart failure.

4. High Pro-BNP levels (1481.0 ng/L): Elevated Pro-BNP levels are a biomarker of heart failure. High levels indicate increased stress on the heart, consistent with the patient's reduced LVEF and history of MI.

5. Electrocardiogram (ECG) findings: The presence of non-sustained ventricular tachycardia (VT) and polymorphic ventricular extrasystoles on the ECG suggests arrhythmias, which can be a complication of heart failure and further compromise cardiac function.

6. Medications: Although the patient is on beta blockers, statins, and an ACE inhibitor, which are standard treatments for heart failure, these medications may not have been sufficient to prevent pump failure death, given the severity of the patient's underlying condition.

7. Additional risk factors: The patient's low HDL (0.62 mmol/L) and high LDL (1.42 mmol/L) levels indicate dyslipidemia, which is a risk factor for cardiovascular disease and may have contributed to the development of ischemic cardiomyopathy.

Considering these factors, the patient's outcome of pump failure death is a likely consequence of the cumulative effect of ischemic dilated cardiomyopathy, previous MI, reduced LVEF, high Pro-BNP levels, and arrhythmias, despite being on standard heart failure medications."
805,805,P0545,"Age: 71
Gender: Male 
Weight: 71 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 39,5
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 3,75
Creatinine (mmol/L): 82.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 4,3
LDL (mmol/L): 1,86
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 353.0
Protein (g/L): 81
T3 (pg/dL): 0,05
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,818
Urea (mg/dL): 7,12
LVEF (%): 27.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of several factors from the provided data.

1.  Ischemic Dilated Cardiomyopathy (IDC): The patient has a history of IDC, which is a condition where the heart muscle becomes weakened and the heart chambers become enlarged, leading to poor heart function. This condition is a significant risk factor for heart failure and can lead to pump failure.

2.  Low LVEF (27%): The patient's left ventricular ejection fraction (LVEF) is severely reduced at 27%. A normal LVEF is typically above 55%. This indicates that the patient's heart is not pumping efficiently, which can lead to pump failure.

3.  High Pro-BNP levels (353 ng/L): B-type natriuretic peptide (BNP) is a hormone produced by the heart in response to ventricular stretching and pressure overload. Elevated BNP levels are associated with heart failure and can indicate the severity of heart failure.

4.  Previous Myocardial Infarction (MI): The patient has a history of MI, which can cause scarring and damage to the heart muscle, leading to reduced heart function and increased risk of heart failure.

5.  Medication Non-Adherence or Inadequate Management: Although the patient is on medications for diabetes, hypertension, and heart failure, the data does not provide information on the effectiveness of these treatments or potential side effects. Inadequate management of these conditions could have contributed to the patient's outcome.

6.  Advanced Age (71 years): The patient's age is a significant risk factor for heart failure and mortality.

7.  Poor Lipid Profile: The patient's total cholesterol and LDL levels are elevated, which can contribute to atherosclerosis and worsen heart function.

Considering these factors, the patient's outcome of pump failure death is likely a result of the cumulative effect of these conditions and risk factors, which ultimately led to the progression of heart failure and cardiac arrest."
806,806,P0555,"Age: 80
Gender: Male 
Weight: 76 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 4,6
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 155.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,9
LDL (mmol/L): 2,66
Sodium (mEq/L): 141.0
Protein (g/L): 71
T3 (pg/dL): 0,06
T4 (ng/L): 18
Troponin (ng/mL): 0,08
TSH (mIU/L): 1,72
Urea (mg/dL): 13,31
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: 

This patient's outcome of pump failure death is likely due to a combination of factors related to their underlying ischemic dilated cardiomyopathy and other comorbidities. 

1.  Ischemic dilated cardiomyopathy: The patient has a history of myocardial infarction, which is a common cause of dilated cardiomyopathy. This condition leads to a decrease in the left ventricular ejection fraction (LVEF), as evidenced by the patient's LVEF of 25.0%. A low LVEF is a significant risk factor for pump failure.

2.  Low LVEF: The patient's LVEF of 25.0% indicates that the left ventricle is not pumping efficiently, which can lead to fluid buildup and congestion in the lungs and other parts of the body. This can cause symptoms such as shortness of breath, fatigue, and swelling, which may be exacerbated by the patient's NYHA Class II classification.

3.  Electrocardiogram (ECG) findings: The presence of non-sustained ventricular tachycardia (VT) and polymorphic ventricular extrasystoles on the ECG suggests that the patient's heart is experiencing abnormal electrical activity, which can further compromise cardiac function and increase the risk of pump failure.

4.  Medications: While the patient is on various medications, including ACE inhibitors, beta blockers, and statins, which are commonly used to manage heart failure and related conditions, the effectiveness of these medications may be limited by the patient's advanced disease state.

5.  Comorbidities: The patient's comorbidities, including dyslipemia, hypertension, and renal impairment (evidenced by elevated creatinine levels), can further compromise cardiac function and increase the risk of pump failure.

6.  Laboratory results: The patient's elevated creatinine levels and low hemoglobin levels may indicate renal impairment and anemia, respectively, which can contribute to decreased cardiac output and increased risk of pump failure.

Considering these factors, the patient's outcome of pump failure death is likely a result of the cumulative effect of their ischemic dilated cardiomyopathy, low LVEF, ECG abnormalities, comorbidities, and laboratory results."
807,807,P0567,"Age: 60
Gender: Female 
Weight: 70 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 97/58 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 43
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 3,8
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,3
LDL (mmol/L): 1,99
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 10365.0
Protein (g/L): 70
T4 (ng/L): 15
Troponin (ng/mL): 0,04
TSH (mIU/L): 12,33
Urea (mg/dL): 9,48
LVEF (%): 20.0
Medications: Amiodarone, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of factors, primarily driven by the advanced stage of her idiopathic dilated cardiomyopathy. 

1.  Reduced Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is severely reduced at 20%, indicating significant impairment of the heart's ability to pump blood effectively. This is a hallmark of dilated cardiomyopathy and a major risk factor for pump failure.

2.  Elevated B-type Natriuretic Peptide (BNP): The patient's Pro-BNP level is significantly elevated at 10365 ng/L. Elevated BNP levels are associated with heart failure and are used as a marker of its severity. High BNP levels indicate that the heart is under strain, which can lead to pump failure.

3.  Symptoms and NYHA Class II: The patient's NYHA Class II classification suggests that she experiences symptoms of heart failure, such as shortness of breath and fatigue, even at rest or with minimal exertion. This indicates that her heart is not functioning optimally and is unable to meet the body's needs.

4.  Medications: Although the patient is on medications like ACE inhibitors, statins, and loop diuretics, which are standard treatments for heart failure, these may not have been sufficient to halt the progression of her disease. The presence of amiodarone, a medication used for arrhythmias, also suggests that she has experienced or is at risk of arrhythmias, which can further compromise cardiac function.

5.  Electrocardiogram (ECG) Findings: The ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which can further compromise cardiac function and contribute to the risk of pump failure.

6.  Other Factors: The patient's elevated creatinine level (106.0 mmol/L) suggests impaired renal function, which is a common complication of advanced heart failure. The presence of dyslipidemia (elevated total cholesterol and LDL levels) and dyslipemia (elevated triglycerides) may also contribute to the progression of her heart disease.

In summary, the patient's outcome of pump failure death is likely the result of the cumulative effect of her idiopathic dilated cardiomyopathy, advanced symptoms, elevated BNP levels, and the presence of other risk factors such as dyslipidemia and renal impairment."
808,808,P0583,"Age: 61
Gender: Male 
Weight: 81 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 150/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,09
Creatinine (mmol/L): 186.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 123.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,59
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 3292.0
Protein (g/L): 73
T4 (ng/L): 17
Troponin (ng/mL): 0,06
TSH (mIU/L): 1,63
Urea (mg/dL): 19,47
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of factors based on the provided data.

1.  Ischemic Dilated Cardiomyopathy (IDC): The patient has a history of IDC, which is a condition where the heart muscle is weakened due to coronary artery disease. This condition can lead to reduced cardiac function and eventually heart failure.

2.  Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 30%, which is significantly lower than the normal range of 50-70%. A low LVEF indicates that the heart is not pumping efficiently, leading to a buildup of fluid in the body, which can cause symptoms of heart failure.

3.  High Pro-BNP Levels: The patient's Pro-BNP level is 3292.0 ng/L, which is elevated. Pro-BNP is a hormone produced by the heart in response to stress, and high levels are associated with heart failure.

4.  Medication Non-Adherence: Although the patient is on medications for diabetes, beta blockers, loop diuretics, statins, and nitrovasodilators, it is unclear if the medications are being taken as prescribed. Non-adherence to medication can worsen heart failure symptoms and outcomes.

5.  Other Contributing Factors: The patient's history of hypertension, dyslipemia, and diabetes can also contribute to the development and progression of heart failure. Additionally, the patient's high total cholesterol and LDL levels may exacerbate atherosclerosis, further compromising cardiac function.

6.  Kidney Function: The patient's creatinine level is elevated at 186.0 mmol/L, indicating impaired kidney function. Kidney disease can further worsen heart failure by reducing the body's ability to remove excess fluids and electrolytes, leading to fluid overload and worsening cardiac function.

Considering these factors, the patient's outcome of pump failure death is likely due to the cumulative effect of ischemic dilated cardiomyopathy, low LVEF, high Pro-BNP levels, medication non-adherence, and other contributing factors such as hypertension, dyslipemia, and kidney disease."
809,809,P0589,"Age: 71
Gender: Male 
Weight: 75 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 90/60 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Peripheral vascular disease
Albumin (g/L): 40
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 7.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 63
Glucose (mmol/L): 11,7
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,15
Sodium (mEq/L): 137.0
Protein (g/L): 67
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,005
TSH (mIU/L): 0,93
Urea (mg/dL): 9,98
LVEF (%): 12.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of factors based on the provided information. 

1. Severe Left Ventricular Dysfunction (LVEF 12.0%): The patient's left ventricular ejection fraction (LVEF) is severely impaired at 12.0%, indicating a significantly reduced ability of the heart to pump blood effectively. This is a key indicator of heart failure.

2. History of Enolic Dilated Cardiomyopathy: The patient has a pre-existing condition of enolic dilated cardiomyopathy, which is a known cause of heart failure. This condition is characterized by the enlargement and weakening of the heart muscle, leading to reduced heart function.

3. Diabetes and Peripheral Vascular Disease: Diabetes is a significant risk factor for cardiovascular disease, including heart failure. The presence of peripheral vascular disease further increases the risk of complications, such as reduced blood flow to the heart muscle, exacerbating heart failure.

4. Electrocardiogram (ECG) Findings: Although the patient does not have sustained ventricular tachycardia, the presence of ventricular extrasystoles may indicate abnormal heart rhythm, which can further strain the heart.

5. Medications: While the patient is on medications such as ACE inhibitors, loop diuretics, and spironolactone, which are commonly used to manage heart failure, these medications may not be sufficient to counteract the severity of the patient's heart failure.

6. Laboratory Values: The patient's elevated creatinine levels (88.0 mmol/L) indicate impaired kidney function, which can be a complication of heart failure. The patient's low albumin levels (40 g/L) may also indicate malnutrition, which can further compromise heart function.

Considering these factors, the patient's outcome of pump failure death is likely a result of the cumulative effect of severe left ventricular dysfunction, underlying cardiomyopathy, diabetes, peripheral vascular disease, and inadequate management of heart failure symptoms."
810,810,P0594,"Age: 78
Gender: Male 
Weight: 61 kg
Height: 151 cm
NYHA Class: II
Blood Pressure: 128/83 mmHg
Past Medical History: Hypertropic cardiomyopathy, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,28
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 32
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,9
LDL (mmol/L): 4,47
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1627.0
Protein (g/L): 67
T3 (pg/dL): 0,04
T4 (ng/L): 19
TSH (mIU/L): 2,39
Urea (mg/dL): 11,82
LVEF (%): 40.0
Medications: Amiodarone, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Based on the provided patient data, the patient's outcome of pump failure death can be attributed to several factors. 

1. Reduced Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 40%, which is significantly below the normal range (50-70%). This indicates that the left ventricle is not pumping blood efficiently, leading to reduced cardiac output and potentially contributing to pump failure.

2. High Pro-BNP Levels: The patient's Pro-BNP level is 1627.0 ng/L, which is elevated. BNP is a hormone produced by the heart in response to ventricular strain and stretching. Elevated BNP levels are associated with heart failure, and in this case, it suggests that the patient's heart is under significant stress, which may be contributing to pump failure.

3. Hypertrophic Cardiomyopathy: The patient has a history of hypertrophic cardiomyopathy, a condition characterized by thickening of the heart muscle, which can lead to reduced cardiac output and increased risk of heart failure.

4. Medication Use: The patient is on medications such as Amiodarone, Loop Diuretics, ACE Inhibitor, and Nitrovasodilator, which are commonly used to manage heart failure symptoms and reduce mortality risk. However, the presence of these medications does not necessarily indicate that the patient is responding well to treatment, and the patient's outcome may be a reflection of the underlying disease progression.

5. Age and NYHA Class II: The patient is 78 years old and has a NYHA Class II classification, indicating that he experiences some symptoms of heart failure, such as fatigue and shortness of breath, during physical activity. While this classification is not severe, it suggests that the patient's heart function is compromised, increasing the risk of pump failure.

Considering these factors, the patient's outcome of pump failure death can be attributed to a combination of reduced cardiac function, high BNP levels, underlying hypertrophic cardiomyopathy, and advanced age."
811,811,P0619,"Age: 62
Gender: Female 
Weight: 50 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 90/60 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 45,9
ALT or GPT (IU/L): 47.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 7,15
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 53
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 146.0
HDL (mmol/L): 2,05
Potassium (mEq/L): 4,51
LDL (mmol/L): 4,65
Sodium (mEq/L): 135.0
Protein (g/L): 72,9
Troponin (ng/mL): 0,15
TSH (mIU/L): 3,77
Urea (mg/dL): 9,5
LVEF (%): 62.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient outcome of pump failure death in this case can be attributed to a combination of factors, primarily related to her underlying heart condition and laboratory results.

Firstly, the patient has a history of hypertrophic cardiomyopathy (HCM), a condition characterized by thickening of the heart muscle that can lead to impaired heart function and increased risk of arrhythmias and sudden cardiac death. The patient's LVEF (Left Ventricular Ejection Fraction) of 62% is within the normal range, but in the context of HCM, a lower LVEF is often seen, indicating reduced cardiac function.

The patient's blood pressure is low, with a reading of 90/60 mmHg, which may indicate decreased cardiac output and compromised circulatory function. Additionally, her creatinine level of 113.0 mmol/L is elevated, suggesting impaired renal function, which can be a consequence of decreased cardiac output and reduced perfusion of the kidneys.

The patient's troponin level is slightly elevated at 0.15 ng/mL, which may indicate minor myocardial injury or stress. However, the level is not significantly elevated, which might suggest that the myocardial damage is not severe.

The patient's medication regimen includes beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are all commonly used to manage HCM and heart failure. However, the presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG suggests that the patient may not be adequately controlled on her current medication regimen.

The patient's laboratory results also show elevated liver enzymes (ALT and AST), which can be indicative of liver dysfunction or damage. This may be related to the patient's HCM or other underlying conditions.

Considering the combination of these factors, including the patient's history of HCM, impaired cardiac function, low blood pressure, elevated creatinine, and the presence of arrhythmias, it is likely that the patient's pump failure led to a fatal outcome. The underlying cause of the pump failure may be related to the progression of HCM, which can lead to a decline in cardiac function and eventual cardiac arrest."
812,812,P0624,"Age: 85
Gender: Male 
Weight: 85 kg
Height: 166 cm
NYHA Class: III
Blood Pressure: 125/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 38,9
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 39.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 156.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,49
Potassium (mEq/L): 3,92
LDL (mmol/L): 1,82
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 4440.0
Protein (g/L): 68,8
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,39
Urea (mg/dL): 10,6
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, Statins, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of his advanced age, severe left ventricular dysfunction, and multiple comorbidities. The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 20%, indicating severe systolic heart failure. His ischemic dilated cardiomyopathy, a history of myocardial infarction, and dyslipemia are all contributing factors to his heart failure.

The patient's high levels of pro-BNP (4440.0 ng/L) also suggest severe heart failure. Elevated pro-BNP levels are often associated with increased mortality and morbidity in patients with heart failure. Additionally, the patient's low hemoglobin (132.0 g/L) and high creatinine (156.0 mmol/L) levels indicate possible anemia and renal dysfunction, which can further compromise cardiac function.

The patient's medication regimen, which includes beta blockers, loop diuretics, statins, hydralazine, and nitrovasodilator, is typical for managing heart failure and hypertension, but may not be sufficient to reverse the patient's advanced cardiac dysfunction.

The patient's NYHA Class III classification indicates that he has severe symptoms of heart failure, such as shortness of breath, fatigue, and palpitations, which are consistent with his low LVEF and high pro-BNP levels.

The presence of non-sustained ventricular tachycardia (NSVT) on the ECG suggests an increased risk of sudden cardiac death, which is a common cause of mortality in patients with heart failure.

In summary, the patient's advanced age, severe left ventricular dysfunction, multiple comorbidities, and high levels of pro-BNP, combined with his NYHA Class III symptoms and NSVT, make pump failure death a likely outcome."
813,813,P0635,"Age: 70
Gender: Female 
Weight: 57 kg
Height: 157 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 43.0
AST or GOT (IU/L): 37.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 70
Glucose (mmol/L): 10,5
Hemoglobin (g/L): 121.0
HDL (mmol/L): 1,76
Potassium (mEq/L): 4,99
LDL (mmol/L): 2,93
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 3190.0
Protein (g/L): 76
T3 (pg/dL): 0,0477
T4 (ng/L): 13,4
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,72
Urea (mg/dL): 9,6
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Diabetes Medication, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of several factors evident in the provided data. 

1.  Ischemic Dilated Cardiomyopathy (IDC): The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and enlarged due to a heart attack. This condition is a significant risk factor for heart failure and can lead to decreased cardiac function.

2.  Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 25.0%, which is significantly below the normal range of 55-70%. A low LVEF indicates poor heart function and a reduced ability to pump blood effectively, leading to potential heart failure.

3.  Elevated Pro-BNP: The patient's Pro-BNP level is 3190.0 ng/L, which is significantly elevated. Pro-BNP is a marker of heart failure, and high levels indicate increased strain on the heart.

4.  Diabetes and High Glucose Levels: The patient has diabetes and high glucose levels (10.5 mmol/L), which can contribute to the development of heart failure. Diabetes can damage the heart muscle and blood vessels, increasing the risk of heart failure.

5.  Electrocardiogram (ECG) Findings: Although the ECG does not show sustained ventricular tachycardia, the presence of polymorphic ventricular extrasystoles may indicate underlying electrical instability in the heart, which can contribute to heart failure.

6.  Medications: While the patient is on several medications, including ACE inhibitors and loop diuretics, which are typically used to manage heart failure, the patient's condition may have progressed to a point where these medications were insufficient to prevent pump failure.

Given these factors, the patient's outcome of pump failure death is likely a result of the cumulative effect of ischemic dilated cardiomyopathy, low LVEF, elevated Pro-BNP, diabetes, and other comorbidities, ultimately leading to a failure of the heart to pump blood effectively."
814,814,P0643,"Age: 70
Gender: Male 
Weight: 85 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 135/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,64
Creatinine (mmol/L): 156.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 10,1
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,74
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 177.0
Protein (g/L): 78
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,83
Urea (mg/dL): 14,25
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death is likely due to the combination of several factors related to his underlying cardiac condition and comorbidities. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened due to a heart attack or other damage to the heart muscle. This condition is often associated with a reduced left ventricular ejection fraction (LVEF), which in this case is 30.0%, indicating severe heart failure. 

The patient's elevated Pro-BNP (brain natriuretic peptide) level of 177.0 ng/L also supports the presence of heart failure, as high levels of Pro-BNP are often associated with increased ventricular wall stress and heart failure. 

Furthermore, the patient's comorbidities, including hypertension, diabetes, dyslipidemia, and peripheral vascular disease, can exacerbate heart failure by increasing the workload on the heart and contributing to further damage to the heart muscle.

The patient's low HDL (good cholesterol) level of 1.03 mmol/L and high LDL (bad cholesterol) level of 2.74 mmol/L also suggest that the patient has not been adequately managing his dyslipidemia, which can further contribute to the progression of heart disease.

Additionally, the patient's low LVEF of 30.0% and elevated creatinine level of 156.0 mmol/L indicate that the patient's kidneys may be experiencing strain due to decreased cardiac output, leading to a potential decrease in renal function.

The patient's TSH level of 1.83 mIU/L is within the normal range, suggesting that his thyroid function is not contributing to his heart failure.

The presence of ventricular extrasystoles on the ECG may also be a sign of cardiac arrhythmias, which can further contribute to the progression of heart failure.

Considering these factors, the patient's outcome of pump failure death is likely a result of the cumulative effect of his underlying cardiac condition, comorbidities, and inadequate management of his dyslipidemia, leading to a progression of heart failure and eventual cardiac death."
815,815,P0651,"Age: 76
Gender: Male 
Weight: 84 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39,5
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 267
Glucose (mmol/L): 7,9
Hemoglobin (g/L): 161.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 5
LDL (mmol/L): 2,48
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 1627.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,31
Urea (mg/dL): 15,59
LVEF (%): 38.0
Medications: Amiodarone, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

Based on the provided patient data, the patient's outcome of pump failure death can be attributed to a combination of several factors. 

1. Severe Left Ventricular Dysfunction: The patient has a left ventricular ejection fraction (LVEF) of 38%, indicating severe left ventricular dysfunction. This is a strong predictor of heart failure and increased risk of mortality.

2. High Pro-BNP Levels: The patient's Pro-BNP level is elevated at 1627.0 ng/L, which is indicative of heart failure and increased risk of mortality. Pro-BNP is a well-established biomarker for heart failure, and high levels are associated with poor prognosis.

3. History of Hypertensive Cardiomyopathy and Hypertension: The patient's history of hypertensive cardiomyopathy and hypertension is a significant risk factor for heart failure and increased mortality.

4. Diabetes and Dyslipemia: The patient's history of diabetes and dyslipemia can contribute to the development of atherosclerosis and cardiac dysfunction, further increasing the risk of heart failure.

5. Medication Non-Optimization: Although the patient is on medications such as ACE inhibitors, loop diuretics, and spironolactone, the patient's LVEF is still severely impaired, indicating potential suboptimal management of heart failure.

6. Electrocardiographic Abnormalities: The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG suggests underlying cardiac arrhythmias, which can contribute to cardiac dysfunction and increased risk of mortality.

7. Low HDL and High LDL Cholesterol: The patient's low HDL and high LDL cholesterol levels indicate poor lipid profile, which can contribute to atherosclerosis and cardiac dysfunction.

8. Kidney Dysfunction: The patient's elevated creatinine level (120.0 mmol/L) indicates kidney dysfunction, which can be a comorbidity in heart failure and contribute to increased mortality.

9. Malnutrition and Inflammation: The patient's low albumin level (39.5 g/L) and elevated gamma-glutamil transpeptidase level (267 IU/L) suggest malnutrition and inflammation, which can contribute to cardiac dysfunction and increased mortality.

In summary, the patient's outcome of pump failure death can be attributed to a combination of severe left ventricular dysfunction, high Pro-BNP levels, history of hypertensive cardiomyopathy and hypertension, diabetes and dyslipemia, medication non-optimization, electrocardiographic abnormalities, poor lipid profile, kidney dysfunction, and malnutrition and inflammation."
816,816,P0679,"Age: 67
Gender: Male 
Weight: 76 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/55 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 47
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 5,61
Creatinine (mmol/L): 135.0
Gamma-glutamil transpeptidase (IU/L): 47
Glucose (mmol/L): 5,27
Hemoglobin (g/L): 109.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,75
LDL (mmol/L): 1,81
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 62.0
Protein (g/L): 75,3
T3 (pg/dL): 0,0429
T4 (ng/L): 14,14
Troponin (ng/mL): 0,7
TSH (mIU/L): 4,1
Urea (mg/dL): 19,6
LVEF (%): 30.0
Medications: Amiodarone, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient is a 67-year-old male with a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers dilate, leading to poor heart function. His left ventricular ejection fraction (LVEF) of 30% indicates severe systolic dysfunction, which is consistent with his clinical presentation.

The patient's current medications, including Amiodarone, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, and Nitrovasodilator, suggest that he is being managed for heart failure and arrhythmias. However, despite these treatments, the patient has experienced pump failure, leading to death.

Several factors may have contributed to this outcome:

1. Severe left ventricular dysfunction: The patient's LVEF of 30% is significantly reduced, indicating a high risk of heart failure and sudden cardiac death.
2. Advanced age: The patient is 67 years old, which increases his risk of cardiac mortality.
3. Poor blood pressure control: His blood pressure is 140/55 mmHg, which may indicate orthostatic hypotension or a lack of adequate blood pressure control, further compromising cardiac function.
4. Elevated creatinine levels: A creatinine level of 135.0 μmol/L suggests impaired renal function, which can be a marker of advanced heart failure and increased mortality risk.
5. Low HDL cholesterol: A low HDL level (0.93 mmol/L) may indicate a high risk of cardiovascular disease, which could have contributed to the progression of his heart failure.
6. Elevated troponin levels: A troponin level of 0.7 ng/mL indicates cardiac damage or stress, which may have contributed to his heart failure.
7. Low T3 and T4 levels: Subclinical hypothyroidism, indicated by low T3 and T4 levels, may have contributed to his heart failure, as thyroid hormone plays a crucial role in cardiac function.
8. Polymorphic ventricular extrasystoles: The presence of polymorphic ventricular extrasystoles on the ECG may indicate arrhythmogenicity and an increased risk of sudden cardiac death.

In summary, the combination of severe left ventricular dysfunction, advanced age, poor blood pressure control, impaired renal function, low HDL cholesterol, elevated troponin levels, subclinical hypothyroidism, and arrhythmogenic ECG changes likely contributed to the patient's pump failure and subsequent death."
817,817,P0680,"Age: 73
Gender: Female 
Weight: 71 kg
Height: 157 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,42
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 10,9
Hemoglobin (g/L): 122.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 5,2
LDL (mmol/L): 2,48
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1690.0
Protein (g/L): 74
T4 (ng/L): 9
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,69
Urea (mg/dL): 7,49
LVEF (%): 25.0
Medications: Diabetes Medication, Amiodarone, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient's outcome of pump failure death is likely due to a combination of factors related to their underlying medical conditions and medication regimen. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack or coronary artery disease. This condition is characterized by a decreased left ventricular ejection fraction (LVEF), which in this case is 25.0%. A low LVEF is a strong indicator of heart failure.

The patient's elevated Pro-BNP (brain natriuretic peptide) level of 1690.0 ng/L is also indicative of heart failure. Pro-BNP is a hormone produced by the heart when it is under strain, and high levels are often associated with heart failure.

Additionally, the patient's history of myocardial infarction (heart attack) and hypertension (high blood pressure) also contribute to the development of heart failure.

The patient's medications, including beta blockers and ACE inhibitors, are typically used to manage heart failure and hypertension, but in this case, they may not be sufficient to prevent pump failure.

Furthermore, the patient's diabetes and dyslipidemia may have contributed to the development of atherosclerosis, which can lead to coronary artery disease and further weaken the heart muscle.

The patient's low HDL (good cholesterol) level of 1.09 mmol/L and high LDL (bad cholesterol) level of 2.48 mmol/L also indicate poor lipid management, which may have contributed to the development of atherosclerosis.

The patient's creatinine level of 106.0 umol/L is slightly elevated, indicating some degree of renal impairment, which can further complicate heart failure management.

In summary, the combination of the patient's underlying medical conditions, medication regimen, and laboratory results suggest that pump failure death is a likely outcome due to the progression of heart failure and associated complications."
818,818,P0688,"Age: 66
Gender: Male 
Weight: 74 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Valvular cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 38,1
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 36.0
Total Cholesterol (mmol/L): 4,12
Creatinine (mmol/L): 181.0
Gamma-glutamil transpeptidase (IU/L): 105
Glucose (mmol/L): 6,44
Hemoglobin (g/L): 115.0
HDL (mmol/L): 1,67
Potassium (mEq/L): 4,42
LDL (mmol/L): 2,16
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 11467.0
Protein (g/L): 71,8
T3 (pg/dL): 0,0366
T4 (ng/L): 15,51
Troponin (ng/mL): 0,7
TSH (mIU/L): 3,31
Urea (mg/dL): 19,5
LVEF (%): 30.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of several factors present in the provided data.

Firstly, the patient has a history of valvular cardiomyopathy, which is a condition where the heart's valves do not function properly, leading to inefficient blood flow and potential heart failure. This condition is likely a contributing factor to the patient's low left ventricular ejection fraction (LVEF) of 30%, which indicates that the heart is not pumping blood efficiently.

Furthermore, the patient's elevated Pro-BNP (brain natriuretic peptide) level of 11467 ng/L is a strong indicator of heart failure. Pro-BNP is a hormone produced by the heart in response to increased wall stress, which is often seen in heart failure.

The patient's creatinine level of 181.0 umol/L is also elevated, indicating impaired kidney function, which is a common complication of heart failure. The patient's urea level of 19.5 mg/dL further supports this finding.

The patient's history of myocardial infarction (heart attack) may have contributed to the development of cardiomyopathy and subsequent heart failure.

Additionally, the patient's medications, including loop diuretics and an ACE inhibitor, are commonly used to treat heart failure, but may not have been sufficient to manage the patient's condition.

The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG suggests that the patient's heart is experiencing abnormal heart rhythms, which can further compromise cardiac function and contribute to pump failure.

Lastly, the patient's low T3 and T4 levels may indicate hypothyroidism, which can also contribute to heart failure.

In summary, the combination of valvular cardiomyopathy, elevated Pro-BNP levels, impaired kidney function, history of myocardial infarction, and abnormal heart rhythms, along with the patient's medications and potential hypothyroidism, likely contributed to the patient's outcome of pump failure death."
819,819,P0716,"Age: 80
Gender: Male 
Weight: 66 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 210/100 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 9.0
Total Cholesterol (mmol/L): 3,62
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 124
Glucose (mmol/L): 4,9
HDL (mmol/L): 0,91
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,15
Sodium (mEq/L): 141.0
Protein (g/L): 64
T3 (pg/dL): 0,05
T4 (ng/L): 14
TSH (mIU/L): 1,33
Urea (mg/dL): 13,81
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of several factors.

1.  Ischemic Dilated Cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack or reduced blood flow. This condition can lead to a decrease in the heart's ability to pump blood efficiently, ultimately resulting in heart failure.

2.  Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 35%, which is significantly lower than the normal range of 55-70%. A low LVEF indicates that the heart is not pumping blood effectively, which can lead to heart failure.

3.  High Blood Pressure: The patient has uncontrolled hypertension, with a blood pressure of 210/100 mmHg. High blood pressure can put additional strain on the heart, leading to further damage and worsening of heart failure.

4.  Kidney Dysfunction: The patient has elevated creatinine levels (159.0 mmol/L), indicating kidney dysfunction. Kidney disease is often a complication of heart failure, and in this case, it may be contributing to the patient's poor outcome.

5.  Electrocardiogram (ECG) Findings: The patient has non-sustained ventricular tachycardia (VT) and polymorphic ventricular extrasystoles, which are abnormal heart rhythms that can increase the risk of cardiac arrest and death.

6.  Medication Non-Response: Despite being on medications such as beta blockers, digoxin, loop diuretics, ACE inhibitors, and nitrovasodilators, the patient's condition has not improved, indicating that the medications may not be effective in managing the patient's heart failure.

7.  Advanced Age and Comorbidities: The patient is 80 years old and has multiple comorbidities, including diabetes and hypertension. Older adults with multiple comorbidities are at a higher risk of complications and poor outcomes.

Considering these factors, the patient's outcome of pump failure death is a likely consequence of the cumulative effect of these conditions, which have compromised the heart's ability to pump blood efficiently, leading to cardiac failure and ultimately death."
820,820,P0725,"Age: 72
Gender: Male 
Weight: 66 kg
Height: 158 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 3,47
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 10,4
Hemoglobin (g/L): 122.0
HDL (mmol/L): 0,62
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,25
Sodium (mEq/L): 135.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 23
TSH (mIU/L): 1,2
Urea (mg/dL): 6,99
LVEF (%): 55.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of factors related to their underlying cardiac condition, comorbidities, and laboratory results. 

1. Ischemic dilated cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, a condition where the heart muscle is weakened due to coronary artery disease, leading to a decrease in the heart's pumping efficiency. This underlying condition sets the stage for potential heart failure.

2. Reduced LVEF (55.0%): The patient's left ventricular ejection fraction (LVEF) is significantly reduced, indicating that the heart is not pumping blood efficiently. An LVEF of less than 50% is generally considered a sign of heart failure.

3. NYHA Class III: The patient is classified as New York Heart Association (NYHA) Class III, indicating that they experience symptoms of heart failure with moderate limitation in physical activity, which further supports the likelihood of pump failure.

4. High Total Cholesterol (3.47 mmol/L) and LDL (2.25 mmol/L): Elevated cholesterol levels are a risk factor for cardiovascular disease and can contribute to the progression of ischemic heart disease.

5. Diabetes: The patient's diabetes may have contributed to the development of diabetic cardiomyopathy, a condition that affects the heart muscle and can lead to heart failure.

6. Medications: Although the patient is on various medications, including beta blockers, digoxin, loop diuretics, spironolactone, statins, ACE inhibitor, and nitrovasodilator, these medications are typically used to manage heart failure and may not have been sufficient to prevent pump failure in this case.

7. ECG findings: The presence of non-sustained ventricular tachycardia and ventricular extrasystoles on the ECG indicates arrhythmias, which can further compromise cardiac function and increase the risk of pump failure.

8. Laboratory results: The patient's elevated glucose level (10.4 mmol/L) and slightly elevated creatinine level (71.0 μmol/L) suggest potential kidney dysfunction, which can be a complication of heart failure.

Given these factors, the patient's outcome of pump failure death is likely due to a combination of their underlying ischemic dilated cardiomyopathy, reduced LVEF, high cholesterol levels, diabetes, and potential kidney dysfunction, which may have overwhelmed the heart's ability to function properly."
821,821,P0735,"Age: 59
Gender: Male 
Weight: 91 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 139/76 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 7,34
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 75
Glucose (mmol/L): 11,7
Hemoglobin (g/L): 140.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 3,4
LDL (mmol/L): 5,66
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 108.0
Protein (g/L): 68
T3 (pg/dL): 0,05
T4 (ng/L): 23
Troponin (ng/mL): 0,1
TSH (mIU/L): 1,63
Urea (mg/dL): 8,65
LVEF (%): 50.0
Medications: Calcium Channel Blocker, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of several factors based on the provided data. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart's ability to pump blood is reduced due to damage to the heart muscle. This condition can lead to heart failure, which is a significant risk factor for pump failure death. The patient's left ventricular ejection fraction (LVEF) of 50% is below the normal range (60-70%), indicating impaired heart function.

Secondly, the patient has a history of myocardial infarction (heart attack), which can further damage the heart muscle and lead to heart failure. The presence of troponin (0.1 ng/mL) in the blood suggests that there may have been recent cardiac damage.

Thirdly, the patient's high total cholesterol level (7.34 mmol/L) and low HDL (0.96 mmol/L) are indicative of dyslipemia, which is a risk factor for cardiovascular disease and can contribute to the progression of heart failure.

Furthermore, the patient's elevated creatinine level (106.0 mmol/L) suggests impaired renal function, which can be a consequence of heart failure. The patient's urea level (8.65 mg/dL) is also elevated, which further supports this conclusion.

Additionally, the patient's low albumin level (42 g/L) and low protein level (68 g/L) may indicate malnutrition or liver dysfunction, which can further compromise the patient's cardiac function.

The patient's pro-BNP level (108.0 ng/L) is elevated, which is a marker of heart failure. The presence of polymorphic ventricular extrasystoles on the ECG suggests that the patient's heart rhythm is irregular, which can further compromise cardiac function.

Lastly, the patient's TSH level (1.63 mIU/L) is within the normal range, indicating that thyroid dysfunction is unlikely to be a contributing factor to the patient's outcome.

In summary, the patient's history of ischemic dilated cardiomyopathy, myocardial infarction, dyslipemia, and impaired renal function, combined with the elevated creatinine and urea levels, low albumin and protein levels, and polymorphic ventricular extrasystoles on the ECG, all contribute to the patient's outcome of pump failure death."
822,822,P0752,"Age: 55
Gender: Male 
Weight: 77 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 29,6
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,46
Creatinine (mmol/L): 135.0
Gamma-glutamil transpeptidase (IU/L): 151
Glucose (mmol/L): 16,6
Hemoglobin (g/L): 117.0
HDL (mmol/L): 0,66
Potassium (mEq/L): 3,88
LDL (mmol/L): 2,46
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 5416.0
Protein (g/L): 58,9
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,08
Urea (mg/dL): 14,4
LVEF (%): 21.0
Medications: Digoxin, Loop Diuretics, Spironolactone, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Unknown ventricular extrasystole code
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

Based on the provided patient data, the patient's outcome of pump failure death is likely due to the combination of several factors that indicate severe heart failure and poor cardiac function. 

1.  NYHA Class III: The patient has a New York Heart Association (NYHA) functional class of III, indicating that he has severe symptoms of heart failure, including shortness of breath and fatigue, even at rest or with minimal exertion.

2.  Low LVEF (21.0%): The patient's left ventricular ejection fraction (LVEF) is severely reduced at 21.0%, indicating poor cardiac function and a high risk of heart failure.

3.  High Pro-BNP levels (5416.0 ng/L): Elevated B-type natriuretic peptide (BNP) levels are a marker of heart failure and are associated with increased mortality risk. The patient's Pro-BNP level is significantly elevated, indicating severe heart failure.

4.  Multiple comorbidities: The patient has multiple comorbidities, including ischemic dilated cardiomyopathy, diabetes, peripheral vascular disease, and myocardial infarction, which can contribute to the progression of heart failure.

5.  Medication regimen: Although the patient is on a combination of medications, including digoxin, loop diuretics, spironolactone, hydralazine, and nitrovasodilator, which are commonly used to manage heart failure, the patient's severe symptoms and low LVEF suggest that these medications may not be adequately controlling the condition.

6.  Electrocardiogram (ECG) findings: The patient's ECG shows non-sustained ventricular tachycardia, which is a marker of increased risk of sudden cardiac death.

7.  Laboratory results: The patient's laboratory results show elevated glucose and creatinine levels, indicating potential kidney dysfunction, which is a common complication of heart failure.

Considering these factors, the patient's outcome of pump failure death is likely due to the progression of severe heart failure, despite the presence of multiple comorbidities and a medication regimen aimed at managing the condition."
823,823,P0754,"Age: 73
Gender: Male 
Weight: 58 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 115/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 42,3
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 5,36
Creatinine (mmol/L): 92.0
Gamma-glutamil transpeptidase (IU/L): 291
Glucose (mmol/L): 10,3
Hemoglobin (g/L): 157.0
HDL (mmol/L): 1,48
Potassium (mEq/L): 3,42
LDL (mmol/L): 3,05
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 2057.0
Protein (g/L): 70,2
Troponin (ng/mL): 0,13
TSH (mIU/L): 2,47
Urea (mg/dL): 9,5
LVEF (%): 20.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of several factors reflected in the provided data. 

1. Ischemic dilated cardiomyopathy: This underlying condition is a significant contributor to the patient's outcome. The patient's left ventricular ejection fraction (LVEF) of 20% is severely reduced, indicating significant left ventricular dysfunction.

2. History of Myocardial Infarction: This suggests that the patient has experienced a previous heart attack, which can lead to scarring and further compromise the heart's pumping ability.

3. Elevated Pro-BNP levels: A pro-Brain Natriuretic Peptide (BNP) level of 2057 ng/L is significantly elevated, indicating increased ventricular wall stress and strain. Elevated BNP levels are associated with heart failure and poor prognosis.

4. NYHA Class III: The patient's New York Heart Association (NYHA) functional class of III indicates that the patient experiences symptoms of heart failure, such as shortness of breath, fatigue, and decreased exercise tolerance, at rest or with minimal exertion.

5. Medication regimen: While the patient is on various medications for heart failure, including ACE inhibitors, beta-blockers, and diuretics, the presence of digoxin, a medication typically used for rate control in atrial fibrillation or heart failure, and spironolactone, an aldosterone antagonist, may indicate that the patient's condition is advanced and complex.

6. Electrocardiogram (ECG) findings: The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia suggests arrhythmias, which can further compromise cardiac function and contribute to the patient's outcome.

7. Elevated creatinine levels: A creatinine level of 92.0 μmol/L indicates impaired renal function, which is common in patients with heart failure and can further worsen the prognosis.

8. Poor lipid profile: The patient's high total cholesterol and LDL levels, coupled with a low HDL level, may contribute to the progression of atherosclerosis and ischemic heart disease.

9. Elevated liver enzymes: Elevated gamma-glutamyl transferase (GGT) and aspartate aminotransferase (AST) levels suggest liver dysfunction, which can be associated with heart failure and may indicate that the patient's condition is more complex.

10. Diabetes and peripheral vascular disease: These comorbidities can further compromise the patient's overall health and increase the risk of cardiovascular events.

In summary, the patient's outcome of pump failure death is likely due to a combination of severe left ventricular dysfunction, advanced heart failure, arrhythmias, impaired renal function, poor lipid profile, and comorbidities such as diabetes and peripheral vascular disease."
824,824,P0762,"Age: 68
Gender: Male 
Weight: 99 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 38,8
ALT or GPT (IU/L): 187.0
AST or GOT (IU/L): 146.0
Total Cholesterol (mmol/L): 2,62
Creatinine (mmol/L): 188.0
Gamma-glutamil transpeptidase (IU/L): 154
Glucose (mmol/L): 9,7
Hemoglobin (g/L): 119.0
HDL (mmol/L): 0,64
Potassium (mEq/L): 3,73
LDL (mmol/L): 1,59
Sodium (mEq/L): 130.0
Pro-BNP (ng/L): 19001.0
Protein (g/L): 69,9
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,85
Urea (mg/dL): 21,3
LVEF (%): 20.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of factors indicated by the provided data. 

Firstly, the patient's left ventricular ejection fraction (LVEF) of 20.0% is significantly reduced, which is a strong indicator of heart failure. This suggests that the patient's heart is not pumping efficiently, leading to reduced cardiac output and increased risk of pump failure.

The patient's elevated levels of Pro-BNP (19001.0 ng/L) also support the diagnosis of heart failure. Pro-BNP is a biomarker that is elevated in patients with heart failure, and levels above 5000 ng/L are often associated with severe heart failure.

The patient's ischemic dilated cardiomyopathy and history of myocardial infarction further contribute to the risk of pump failure. Ischemic cardiomyopathy is a condition in which the heart muscle is weakened due to a lack of blood flow, leading to reduced cardiac function and increased risk of heart failure.

The patient's elevated liver enzymes (ALT and AST) suggest liver dysfunction, which can be a complication of heart failure. The patient's elevated creatinine levels also indicate kidney dysfunction, which is a common comorbidity in patients with heart failure.

The patient's medications, including beta blockers, digoxin, loop diuretics, and nitrovasodilators, are standard treatments for heart failure, but their effectiveness may be limited in this case due to the severity of the patient's condition.

The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and unknown paroxysmal supraventricular tachyarrhythmia on the ECG suggest arrhythmias, which can further compromise cardiac function and increase the risk of pump failure.

Lastly, the patient's low sodium levels (130.0 mEq/L) may indicate hyponatremia, which is a common electrolyte imbalance in patients with heart failure, particularly those with advanced disease.

Considering these factors, the patient's outcome of pump failure death is not unexpected, given the severity of their cardiac dysfunction, comorbidities, and complications."
825,825,P0766,"Age: 64
Gender: Male 
Weight: 48 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 140/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 37,6
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,32
Creatinine (mmol/L): 132.0
Gamma-glutamil transpeptidase (IU/L): 338
Glucose (mmol/L): 3,5
Hemoglobin (g/L): 127.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 3,18
LDL (mmol/L): 2,89
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 9695.0
Protein (g/L): 81,4
Troponin (ng/mL): 0,04
TSH (mIU/L): 3,73
Urea (mg/dL): 10,4
LVEF (%): 30.0
Medications: Digoxin, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of factors evident in the provided data. 

1.  Ischemic dilated cardiomyopathy (IDC): The patient has a history of IDC, a condition characterized by left ventricular dysfunction due to coronary artery disease, leading to reduced cardiac output and potential heart failure.

2.  Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 30%, indicating severe left ventricular dysfunction, which is a hallmark of heart failure and a predictor of adverse outcomes.

3.  High Pro-BNP levels: The patient's Pro-BNP level of 9695.0 ng/L is significantly elevated, indicating increased ventricular wall stress, a sign of heart failure.

4.  Medications: Although the patient is on medications such as digoxin, loop diuretics, and nitrovasodilators, these may not be sufficient to control the progression of heart failure, given the patient's severe symptoms and low LVEF.

5.  Age and NYHA Class III: The patient's age of 64 and NYHA Class III classification indicate a high level of physical limitation and symptoms of heart failure, further increasing the risk of adverse outcomes.

6.  Other comorbidities: The presence of peripheral vascular disease and hypertension suggests a high risk of cardiovascular disease, which may have contributed to the development of IDC and heart failure.

7.  Electrocardiogram (ECG) findings: The presence of non-sustained ventricular tachycardia and ventricular extrasystoles on the ECG suggests arrhythmias that may be contributing to the patient's symptoms and potentially worsening heart failure.

In summary, the patient's outcome of pump failure death is likely due to a combination of severe ischemic dilated cardiomyopathy, low LVEF, high Pro-BNP levels, and other comorbidities, which have not been adequately managed by current medications."
826,826,P0772,"Age: 74
Gender: Male 
Weight: 60 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 80/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,54
Creatinine (mmol/L): 150.0
Gamma-glutamil transpeptidase (IU/L): 114
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 117.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,46
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 8916.0
Protein (g/L): 79
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,87
Urea (mg/dL): 27,12
LVEF (%): 13.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death is likely due to a combination of factors related to his advanced heart failure and underlying cardiac conditions. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which have led to a severely reduced left ventricular ejection fraction (LVEF) of 13%. This indicates that the patient's heart is not pumping efficiently, resulting in decreased cardiac output and increased pressure in the heart chambers.

The patient's blood pressure is low at 80/60 mmHg, which is likely a result of the decreased cardiac output and increased peripheral resistance due to the heart failure. The elevated creatinine level of 150.0 mmol/L indicates impaired kidney function, which is a common complication of heart failure.

The patient's high Pro-BNP (Brain Natriuretic Peptide) level of 8916.0 ng/L is a marker of heart failure and is associated with increased mortality. The elevated troponin level of 0.01 ng/mL indicates myocardial injury, which may be contributing to the patient's heart failure.

The patient's NYHA Class III classification indicates that he has severe symptoms of heart failure, including shortness of breath and fatigue, which are likely contributing to his overall poor prognosis.

The patient's medications, including beta blockers, loop diuretics, spironolactone, and ACE inhibitors, are standard treatments for heart failure, but may not be sufficient to manage the patient's advanced disease.

The patient's low hemoglobin level of 117.0 g/L may indicate anemia, which can exacerbate heart failure by reducing oxygen delivery to the tissues.

The patient's high glucose level of 5.8 mmol/L may indicate diabetes, which is a common comorbidity in patients with heart failure and can worsen the prognosis.

The patient's low HDL level of 0.72 mmol/L and high LDL level of 2.46 mmol/L indicate dyslipidemia, which can contribute to the progression of atherosclerosis and worsen heart failure.

Overall, the combination of the patient's advanced heart failure, impaired kidney function, high Pro-BNP level, myocardial injury, and multiple comorbidities, including anemia, diabetes, and dyslipidemia, likely contributed to his outcome of pump failure death."
827,827,P0781,"Age: 70
Gender: Female 
Weight: 62 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 100/75 mmHg
Past Medical History: Valvular cardiomyopathy, Hypertension
Albumin (g/L): 38,5
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,04
Creatinine (mmol/L): 108.0
Gamma-glutamil transpeptidase (IU/L): 97
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 122.0
HDL (mmol/L): 1,33
Potassium (mEq/L): 4,42
LDL (mmol/L): 3,08
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 5911.0
Protein (g/L): 82,3
T3 (pg/dL): 0,01
T4 (ng/L): 12
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,9
Urea (mg/dL): 10,5
LVEF (%): 35.0
Medications: Amiodarone, Beta Blockers, Digoxin, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of several factors present in the provided data. 

1.  Reduced LVEF (Left Ventricular Ejection Fraction): The patient's LVEF is 35%, which is significantly lower than the normal range of 50-70%. This indicates that the patient's left ventricle is not pumping efficiently, leading to a reduction in cardiac output and increased risk of heart failure.

2.  Pro-BNP (B-type Natriuretic Peptide) Levels: Elevated Pro-BNP levels (5911.0 ng/L) are indicative of heart failure, particularly left-sided heart failure. The higher the Pro-BNP levels, the more severe the heart failure.

3.  Valvular Cardiomyopathy: The patient has a history of valvular cardiomyopathy, which can lead to reduced cardiac function and increased risk of heart failure. This condition may have contributed to the patient's reduced LVEF and elevated Pro-BNP levels.

4.  Hypertension: Although the patient's blood pressure is within a relatively normal range (100/75 mmHg), a history of hypertension can lead to left ventricular hypertrophy and decreased cardiac function over time, contributing to the development of heart failure.

5.  Medications: The patient is taking several medications, including Amiodarone, Beta Blockers, Digoxin, Loop Diuretics, and Nitrovasodilator. While these medications are used to manage heart rhythm and heart failure symptoms, they may also have adverse effects on cardiac function in certain cases.

6.  ECG Findings: The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG suggests underlying electrical instability in the heart, which may contribute to the patient's reduced cardiac function and increased risk of heart failure.

7.  Reduced Hemoglobin Levels: The patient's hemoglobin level is slightly below the normal range (122.0 g/L), which may indicate anemia or other underlying conditions that can contribute to reduced cardiac output and increased risk of heart failure.

In summary, the combination of reduced LVEF, elevated Pro-BNP levels, valvular cardiomyopathy, hypertension, and ECG findings likely contributed to the patient's outcome of pump failure death."
828,828,P0790,"Age: 79
Gender: Male 
Weight: 88 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 145.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4
LDL (mmol/L): 2,46
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 4762.0
Protein (g/L): 65
T4 (ng/L): 9
Troponin (ng/mL): 0,04
TSH (mIU/L): 1,8
Urea (mg/dL): 6,66
LVEF (%): 28.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of factors evident in the provided data. The key indicators pointing towards this outcome are:

1.  Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is severely impaired at 28.0%, indicating significant left ventricular dysfunction. This is a strong predictor of heart failure and increased risk of mortality.

2.  Elevated Pro-BNP levels: The patient's Pro-BNP level is extremely high at 4762.0 ng/L, which is indicative of severe heart failure. BNP is a biomarker that reflects the degree of ventricular strain and has been associated with adverse outcomes in heart failure patients.

3.  Presence of Non-sustained Ventricular Tachycardia (VT): The patient's ECG shows non-sustained VT, which is a known risk factor for sudden cardiac death in patients with heart failure.

4.  History of Idiopathic Dilated Cardiomyopathy: This underlying condition has led to the patient's current state of heart failure, as evidenced by the low LVEF and elevated BNP levels.

5.  Medication regimen: Although the patient is on a comprehensive heart failure treatment regimen, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, these medications may not have been sufficient to reverse the progression of the disease or mitigate the risk of pump failure.

6.  Age and NYHA Class II: The patient's age (79) and NYHA Class II classification indicate a moderate level of heart failure symptoms. Advanced age is a risk factor for adverse outcomes in heart failure.

Considering these factors, the patient's outcome of pump failure death is a predictable consequence of the progression of idiopathic dilated cardiomyopathy and the associated severe heart failure."
829,829,P0792,"Age: 85
Gender: Male 
Weight: 86 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 37
ALT or GPT (IU/L): 42.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 50
Glucose (mmol/L): 7
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,84
Sodium (mEq/L): 139.0
Protein (g/L): 68
T4 (ng/L): 10
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,62
Urea (mg/dL): 9,32
LVEF (%): 25.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Unknown ventricular extrasystole code
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of several factors. 

Firstly, the patient has a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge, leading to reduced heart function. This condition is characterized by a low left ventricular ejection fraction (LVEF) of 25%, indicating severe left ventricular dysfunction. The LVEF of 25% suggests that the heart is not pumping efficiently, leading to reduced cardiac output and potentially life-threatening complications.

Furthermore, the patient's high creatinine level (141.0 mmol/L) and urea level (9.32 mg/dL) indicate impaired renal function, which is often seen in patients with advanced heart failure. This suggests that the heart failure has progressed to a stage where it is affecting multiple organ systems, including the kidneys.

The patient's diabetes history is also a significant contributing factor. Diabetes is a major risk factor for heart failure, and the patient's high glucose level (7 mmol/L) indicates poorly controlled diabetes, which can exacerbate cardiac dysfunction.

Additionally, the patient's high total cholesterol level (4.34 mmol/L) and low HDL (1.14 mmol/L) are indicative of dyslipidemia, which can contribute to the development and progression of heart disease.

The patient's ECG findings, including non-sustained ventricular tachycardia and ventricular extrasystole, suggest arrhythmias that can further compromise cardiac function and increase the risk of sudden cardiac death.

Lastly, the patient's medication regimen, including beta blockers, digoxin, loop diuretics, spironolactone, and nitrovasodilators, is aimed at managing symptoms and slowing the progression of heart failure, but it appears that the disease has progressed to a point where these medications were insufficient to prevent pump failure and death."
830,830,P0835,"Age: 78
Gender: Female 
Weight: 77 kg
Height: 159 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Valvular cardiomyopathy, Hypertension
Albumin (g/L): 41,5
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,79
Creatinine (mmol/L): 89.0
Gamma-glutamil transpeptidase (IU/L): 43
Glucose (mmol/L): 14,6
Hemoglobin (g/L): 158.0
HDL (mmol/L): 0,9
Potassium (mEq/L): 4,39
LDL (mmol/L): 3,17
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 155.0
Protein (g/L): 80,4
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,1
Urea (mg/dL): 9,9
LVEF (%): 60.0
Medications: Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

The patient outcome of pump failure death can be attributed to a combination of factors present in the patient's medical history, laboratory results, and medication regimen.

1. Advanced Age and NYHA Class III: The patient is 78 years old and has a New York Heart Association (NYHA) Class III classification, indicating severe symptoms of heart failure, including shortness of breath and fatigue, even when at rest. This suggests that the patient's heart is significantly compromised.

2. Valvular Cardiomyopathy: The patient has a history of valvular cardiomyopathy, a condition where the heart valves are damaged, leading to reduced heart function. This can lead to increased pressure and strain on the heart, ultimately resulting in heart failure.

3. Elevated Pro-BNP Levels: The patient's Pro-BNP (N-terminal pro b-type natriuretic peptide) level is elevated at 155.0 ng/L, indicating increased stress on the heart, which is a common marker for heart failure.

4. Reduced LVEF: The patient's left ventricular ejection fraction (LVEF) is 60%, which is below the normal range of 60-70%. This indicates that the heart is not pumping efficiently, which can lead to heart failure.

5. Medication Regimen: The patient is on a regimen of medications that are commonly used to treat heart failure, including an Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, and Spironolactone. While these medications can help manage symptoms and slow disease progression, they may not have been sufficient to prevent the progression to pump failure.

6. Lab Results: The patient's laboratory results show elevated creatinine levels (89.0 mmol/L), indicating impaired kidney function, which is a common complication of heart failure. Additionally, the patient's glucose level is elevated at 14.6 mmol/L, which can contribute to cardiovascular disease and worsen heart failure.

7. ECG Findings: The patient's ECG shows polymorphic ventricular extrasystoles, which can be a sign of arrhythmias and further compromise cardiac function.

Considering these factors, the patient's outcome of pump failure death is likely due to the combination of advanced age, underlying valvular cardiomyopathy, reduced LVEF, and the progression of heart failure despite optimal medical management."
831,831,P0839,"Age: 68
Gender: Male 
Weight: 70 kg
Height: 174 cm
NYHA Class: III
Blood Pressure: 120/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 37,9
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 4,09
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 7,2
Hemoglobin (g/L): 97.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4
LDL (mmol/L): 2,35
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1635.0
Protein (g/L): 66,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,39
Urea (mg/dL): 12,1
LVEF (%): 44.0
Medications: Amiodarone, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Based on the provided patient data, the patient's outcome of pump failure death can be attributed to a combination of several factors. 

1.  Ischemic dilated cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and enlarged due to a previous heart attack or reduced blood flow to the heart. This condition is a significant risk factor for heart failure and pump failure.

2.  Low LVEF (Left Ventricular Ejection Fraction): The patient's LVEF is 44%, which is significantly lower than the normal range of 55-70%. A low LVEF indicates that the heart is not pumping efficiently, which can lead to heart failure and pump failure.

3.  High Pro-BNP levels: The patient's Pro-BNP (N-terminal pro b-type natriuretic peptide) level is 1635.0 ng/L, which is significantly elevated. Elevated Pro-BNP levels are associated with heart failure and are used as a biomarker to diagnose and monitor heart failure.

4.  Medication regimen: While the patient is on several medications that are commonly used to manage heart failure, including ACE inhibitors, statins, and diuretics, the patient's condition may not have been adequately controlled, leading to pump failure.

5.  Additional comorbidities: The patient also has diabetes, which is a significant risk factor for heart failure and pump failure. Additionally, the patient's low HDL cholesterol and high LDL cholesterol levels may have contributed to the development of atherosclerosis, which can lead to ischemic heart disease and heart failure.

6.  Electrocardiogram (ECG) findings: The patient's ECG shows polymorphic ventricular extrasystoles, which can be a sign of abnormal heart rhythm and may indicate underlying heart disease.

Considering these factors, the patient's outcome of pump failure death is likely due to a combination of their underlying heart disease, low LVEF, high Pro-BNP levels, and uncontrolled comorbidities."
832,832,P0853,"Age: 74
Gender: Male 
Weight: 70 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 5,2
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 28
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 5
LDL (mmol/L): 3,78
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 4185.0
Protein (g/L): 77
T4 (ng/L): 19
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,5
Urea (mg/dL): 12,15
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

Given the patient's profile, the outcome of pump failure death can be attributed to several factors that are evident from the provided data. 

1. Ischemic Dilated Cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, a condition where the heart's ability to pump blood is impaired due to coronary artery disease. This condition can lead to heart failure and, in severe cases, death.

2. Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 30%, which is significantly lower than the normal range of 50-70%. A low LVEF indicates that the left ventricle is not pumping efficiently, leading to decreased cardiac output and increased risk of heart failure.

3. Elevated Pro-BNP Levels: The patient's Pro-BNP level is 4185.0 ng/L, which is significantly elevated. Pro-BNP is a marker of heart failure, and high levels indicate increased ventricular wall stress and decreased cardiac function.

4. Presence of Non-sustained Ventricular Tachycardia: The ECG shows non-sustained ventricular tachycardia, which is a type of abnormal heart rhythm that can further strain the heart and contribute to heart failure.

5. Poor Renal Function: The patient's creatinine level is 115.0 mmol/L, indicating poor renal function. Chronic kidney disease can exacerbate heart failure by contributing to fluid overload, electrolyte imbalances, and further strain on the heart.

6. Medication Management: While the patient is on beta blockers, loop diuretics, ACE inhibitors, and nitrovasodilators, these medications may not have been sufficient to manage the patient's symptoms and underlying conditions effectively, leading to the progression of heart failure.

7. Age and Comorbidities: The patient is 74 years old and has multiple comorbidities, including peripheral vascular disease, hypertension, and myocardial infarction. These conditions can contribute to the development and progression of heart failure.

Considering these factors, the patient's outcome of pump failure death is likely a result of the cumulative effect of these conditions, which have compromised the heart's ability to function properly, leading to heart failure and ultimately, pump failure death."
833,833,P0872,"Age: 57
Gender: Male 
Weight: 62 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 47
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,56
Creatinine (mmol/L): 86.0
Gamma-glutamil transpeptidase (IU/L): 38
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 153.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,57
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 2299.0
Protein (g/L): 74
T3 (pg/dL): 0,07
T4 (ng/L): 19
Troponin (ng/mL): 0,17
TSH (mIU/L): 2,47
Urea (mg/dL): 7,15
LVEF (%): 22.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of factors evident in the provided data. 

Firstly, the patient has a history of Hypertensive cardiomyopathy, which is a known risk factor for heart failure. The patient's LVEF (Left Ventricular Ejection Fraction) of 22% is significantly below the normal range (50-70%), indicating severe left ventricular dysfunction, which is a hallmark of heart failure.

The elevated Pro-BNP (Brain Natriuretic Peptide) level of 2299 ng/L is a strong indicator of heart failure, as it is a biomarker of cardiac stress and strain. Additionally, the patient's low hemoglobin level of 153 g/L may indicate anemia, which can exacerbate heart failure symptoms.

The patient's medication regimen includes Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, and Statins, which are standard treatments for heart failure. However, the fact that the patient is on these medications and still experiencing pump failure suggests that the disease process is advanced and not adequately controlled.

The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG indicates arrhythmia, which can further compromise cardiac function and contribute to pump failure.

Lastly, the patient's low T3 and T4 levels may indicate hypothyroidism, which can also contribute to heart failure. Although the TSH level is within the normal range, it is possible that the patient has subclinical hypothyroidism.

In summary, the combination of severe left ventricular dysfunction, elevated Pro-BNP, anemia, arrhythmia, and potential hypothyroidism likely contributed to the patient's outcome of pump failure death."
834,834,P0873,"Age: 81
Gender: Female 
Weight: 49 kg
Height: 145 cm
NYHA Class: III
Blood Pressure: 180/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 4,69
Creatinine (mmol/L): 209.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 3,94
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,1
Potassium (mEq/L): 4,54
LDL (mmol/L): 3,01
Sodium (mEq/L): 139.0
Protein (g/L): 81
T3 (pg/dL): 0,0441
T4 (ng/L): 22,5
Troponin (ng/mL): 1,2
TSH (mIU/L): 1,27
Urea (mg/dL): 26,1
LVEF (%): 65.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: The patient outcome of pump failure death in this 81-year-old female patient can be attributed to a combination of her severe underlying medical conditions and laboratory results. 

Firstly, the patient's history of hypertensive cardiomyopathy and hypertension (Blood Pressure: 180/90 mmHg) indicates that her heart has been subjected to prolonged periods of high blood pressure, leading to potential cardiac damage and reduced cardiac function. The patient's NYHA Class III classification further indicates that she has severe symptoms of heart failure, including shortness of breath and fatigue, which can significantly impact her quality of life.

The laboratory results reveal elevated creatinine levels (209.0 mmol/L) and urea levels (26.1 mg/dL), indicating impaired renal function, which is often associated with heart failure. Additionally, the patient's low hemoglobin level (131.0 g/L) may suggest anemia, which can further compromise cardiac function.

The patient's medication regimen includes Digoxin, Loop Diuretics, Spironolactone, and an ACE Inhibitor, which are commonly used to manage heart failure symptoms and slow disease progression. However, despite these treatments, the patient's LVEF (Left Ventricular Ejection Fraction) is 65.0%, which is below the normal range, indicating reduced cardiac function.

The presence of ventricular extrasystoles on the ECG suggests that the patient's heart is experiencing abnormal electrical activity, which can further compromise cardiac function. Although the patient does not have sustained ventricular tachycardia, the presence of non-sustained ventricular tachycardia (CH>10) is not mentioned, it is worth noting that it could be a sign of underlying cardiac instability.

The patient's low T3 and T4 levels, as well as her low HDL cholesterol, may indicate hypothyroidism or other metabolic abnormalities, which can contribute to cardiac dysfunction.

In conclusion, the combination of the patient's severe heart failure symptoms, impaired renal function, anemia, and reduced cardiac function, along with the presence of ventricular extrasystoles and other laboratory abnormalities, make her more susceptible to pump failure, ultimately leading to her death."
835,835,P0882,"Age: 79
Gender: Female 
Weight: 70 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 40,2
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,73
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 7,13
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,74
Potassium (mEq/L): 4,14
LDL (mmol/L): 4,76
Sodium (mEq/L): 140.0
Protein (g/L): 66,7
T3 (pg/dL): 0,0549
T4 (ng/L): 16,02
TSH (mIU/L): 4,15
Urea (mg/dL): 7,4
LVEF (%): 50.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of factors related to her underlying medical conditions and laboratory results. 

Firstly, the patient has a history of hypertensive cardiomyopathy, which is a condition where the heart muscle becomes thickened due to high blood pressure, leading to reduced heart function. This is likely exacerbated by her current blood pressure of 160/80 mmHg, which is still elevated despite being on calcium channel blockers and other medications.

The patient's LVEF (Left Ventricular Ejection Fraction) of 50% indicates that her heart is pumping at a reduced capacity, which can lead to heart failure. Additionally, her creatinine level of 93.0 mmol/L suggests impaired kidney function, which can further strain the heart and worsen heart failure symptoms.

The patient's total cholesterol level of 6.73 mmol/L and LDL level of 4.76 mmol/L are elevated, indicating dyslipidemia. High cholesterol levels can contribute to the development of atherosclerosis, which can lead to coronary artery disease and further compromise cardiac function.

The patient's diabetes, as indicated by her glucose level of 7.13 mmol/L, can also contribute to the development of cardiovascular disease and worsen heart failure.

The presence of ventricular extrasystoles and TPSV (paroxysmal supraventricular tachyarrhythmia) on the ECG suggests abnormal heart rhythm, which can further compromise cardiac function and increase the risk of pump failure.

Furthermore, the patient's low HDL level of 1.74 mmol/L and low potassium level of 4.14 mEq/L may indicate inadequate treatment of her dyslipidemia and hypertension, respectively.

The combination of these factors likely contributed to the patient's outcome of pump failure death."
836,836,P0884,"Age: 70
Gender: Female 
Weight: 70 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 34
ALT or GPT (IU/L): 43.0
AST or GOT (IU/L): 34.0
Total Cholesterol (mmol/L): 4,01
Creatinine (mmol/L): 53.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,22
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 2773.0
Protein (g/L): 75
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,23
Urea (mg/dL): 4,99
LVEF (%): 60.0
Medications: Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: The patient outcome of pump failure death in this 70-year-old female patient with a history of hypertensive cardiomyopathy and hypertension can be attributed to a combination of several factors. 

Firstly, the patient's elevated Pro-BNP (Brain Natriuretic Peptide) level of 2773 ng/L is a strong indicator of heart failure. The elevated level suggests that the patient's heart is under strain, and the body is releasing more natriuretic peptides to compensate for the increased fluid volume and pressure.

Secondly, the patient's left ventricular ejection fraction (LVEF) of 60% is slightly below the normal range, indicating a mildly reduced left ventricular function. This suggests that the patient's heart is not pumping efficiently, which can lead to fluid buildup in the lungs and other parts of the body.

Thirdly, the patient's past medical history of hypertensive cardiomyopathy and hypertension is a significant risk factor for heart failure. The long-term strain on the heart due to high blood pressure has likely contributed to the development of cardiomyopathy, which has led to the current heart failure.

Additionally, the patient's elevated creatinine level of 53.0 umol/L indicates impaired kidney function, which is often seen in patients with heart failure. The kidneys are not receiving enough blood flow due to the heart's reduced pumping efficiency, leading to a buildup of waste products in the blood.

Furthermore, the patient's elevated troponin level of 0.01 ng/mL is a marker of cardiac muscle damage, which can be indicative of myocardial ischemia or infarction. Although the level is not extremely high, it suggests that the patient's heart muscle is under stress, which can contribute to the development of heart failure.

Lastly, the patient's medications, including loop diuretics and spironolactone, are commonly used to treat heart failure, but they may not have been sufficient to manage the patient's condition, leading to the progression of heart failure and ultimately, pump failure death.

In conclusion, the combination of the patient's elevated Pro-BNP level, reduced LVEF, history of hypertensive cardiomyopathy and hypertension, impaired kidney function, cardiac muscle damage, and inadequate medication management likely contributed to the patient's outcome of pump failure death."
837,837,P0888,"Age: 77
Gender: Male 
Weight: 60 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 5,74
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 9,8
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,54
LDL (mmol/L): 4,01
Sodium (mEq/L): 137.0
Protein (g/L): 75,8
T3 (pg/dL): 0,0642
T4 (ng/L): 15,87
Troponin (ng/mL): 0,3
TSH (mIU/L): 2,14
Urea (mg/dL): 12,9
LVEF (%): 30.0
Medications: Diabetes Medication, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

Given the patient's medical history and laboratory results, the outcome of pump failure death can be attributed to a combination of factors. 

1.  Ischemic Dilated Cardiomyopathy (IDC): The patient has a history of ischemic dilated cardiomyopathy, a condition where the heart muscle becomes weakened due to reduced blood flow, leading to decreased heart function. This condition is a major risk factor for heart failure.

2.  Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 30.0%, which is significantly below the normal range (50-70%). A low LVEF indicates that the left ventricle is not pumping blood effectively, leading to decreased cardiac output and increased risk of heart failure.

3.  Non-Sustained Ventricular Tachycardia (NSVT): The patient's ECG shows non-sustained ventricular tachycardia, which is a type of abnormal heart rhythm that can increase the risk of sudden cardiac death.

4.  High Creatinine Levels: The patient's creatinine level is 101.0 mmol/L, indicating impaired kidney function. Kidney disease is a common comorbidity in patients with heart failure, and impaired kidney function can exacerbate cardiac dysfunction.

5.  Diabetes: The patient has a history of diabetes, which is a significant risk factor for heart failure. Diabetes can damage blood vessels and nerves, leading to decreased cardiac function and increased risk of heart failure.

6.  Medication Non-Optimization: Although the patient is on loop diuretics and an ACE inhibitor, which are standard treatments for heart failure, the presence of diabetes medication may indicate that the patient's diabetes is not well-controlled. Poor glycemic control can worsen cardiac function and increase the risk of heart failure.

7.  Electrolyte Imbalance: The patient's potassium level is slightly low (4.54 mEq/L), which can contribute to cardiac arrhythmias and increased risk of heart failure.

Considering these factors, the patient's outcome of pump failure death is likely due to a combination of ischemic dilated cardiomyopathy, low LVEF, non-sustained ventricular tachycardia, impaired kidney function, diabetes, and potential medication non-optimization."
838,838,P0891,"Age: 72
Gender: Male 
Weight: 57 kg
Height: 158 cm
NYHA Class: III
Blood Pressure: 130/90 mmHg
Past Medical History: Other HF etiology, Diabetes, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 5,28
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,49
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 4127.0
Protein (g/L): 72
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,56
Urea (mg/dL): 12,81
LVEF (%): 20.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

This patient's outcome of pump failure death can be attributed to a combination of several factors evident from the provided data. 

1.  Severe Left Ventricular Dysfunction (LVEF 20.0%): The patient's left ventricular ejection fraction (LVEF) is significantly reduced at 20%, indicating severe left ventricular dysfunction. This is a strong predictor of heart failure and increased risk of mortality.

2.  Elevated Pro-BNP Levels (4127.0 ng/L): B-type natriuretic peptide (BNP) is a hormone produced by the heart in response to ventricular strain. Elevated levels, as seen in this patient, indicate increased ventricular wall stress, which is consistent with heart failure.

3.  Hemodynamic Instability (NYHA Class III): The patient's New York Heart Association (NYHA) functional class of III indicates that he has marked limitation in physical activity due to symptoms of heart failure. This level of hemodynamic instability suggests a high risk of adverse outcomes.

4.  Comorbidities: The patient has a history of diabetes, hypertension, and other heart failure etiology, which are all significant risk factors for heart failure progression and mortality.

5.  Electrocardiogram (ECG) Findings: The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG suggests arrhythmogenic activity, which can further compromise cardiac function and increase the risk of sudden cardiac death.

6.  Kidney Dysfunction (Creatinine 115.0 mmol/L): Elevated creatinine levels indicate impaired renal function, which is a common comorbidity in heart failure patients and can worsen the prognosis.

7.  Malnutrition (Albumin 43 g/L): Low albumin levels may indicate malnutrition or chronic inflammation, which can exacerbate heart failure and reduce the patient's resilience to stress.

Given these factors, the patient's outcome of pump failure death is likely a consequence of the cumulative effect of severe left ventricular dysfunction, hemodynamic instability, comorbidities, arrhythmogenic activity, kidney dysfunction, and malnutrition."
839,839,P0907,"Age: 50
Gender: Male 
Weight: 69 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39,4
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 32.0
Total Cholesterol (mmol/L): 2,79
Creatinine (mmol/L): 156.0
Gamma-glutamil transpeptidase (IU/L): 66
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 138.0
HDL (mmol/L): 0,87
Potassium (mEq/L): 3,78
LDL (mmol/L): 1,37
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 9416.0
Protein (g/L): 64,6
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,85
Urea (mg/dL): 9,2
LVEF (%): 20.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, Statins, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient outcome of pump failure death is likely due to the combination of several factors that are evident from the provided data. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and enlarged, leading to decreased heart function. This is further supported by the patient's low left ventricular ejection fraction (LVEF) of 20%, which indicates that the heart is not pumping efficiently.

The patient's elevated Pro-BNP level (9416.0 ng/L) is also indicative of heart failure, as BNP is a hormone released by the heart in response to increased wall stress, which is a common occurrence in heart failure.

The patient's history of myocardial infarction (heart attack) is also a significant risk factor for heart failure, as it can lead to scarring and damage to the heart muscle, further compromising its function.

Additionally, the patient's high creatinine level (156.0 mmol/L) suggests impaired renal function, which is often seen in patients with advanced heart failure. This is likely due to the decreased perfusion of the kidneys by the heart, leading to a buildup of waste products in the blood.

The patient's low sodium level (141.0 mEq/L) may also be indicative of heart failure, as the kidneys often retain sodium and water in response to decreased cardiac output, leading to fluid overload and edema.

The presence of non-sustained ventricular tachycardia (VT) on the ECG is also concerning, as it indicates abnormal heart rhythm that can further compromise cardiac function.

The patient's medications, including Amiodarone, Beta Blockers, Loop Diuretics, Statins, Hydralazine, and Nitrovasodilator, are aimed at managing the patient's heart failure, but the patient's condition has progressed to pump failure, indicating that these medications may not be sufficient to manage the disease.

Considering these factors, the patient's outcome of pump failure death is likely due to the cumulative effect of these conditions, which have compromised the patient's cardiac function to the point where the heart is no longer able to pump blood effectively, leading to death."
840,840,P0913,"Age: 69
Gender: Female 
Weight: 70 kg
Height: 151 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40,7
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 63.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4
LDL (mmol/L): 3,08
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 475.0
Protein (g/L): 70,7
T3 (pg/dL): 0,04
T4 (ng/L): 14
TSH (mIU/L): 1,94
Urea (mg/dL): 6,16
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death is likely due to a combination of factors contributing to her advanced heart failure. The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened due to a heart attack, leading to a decrease in the heart's pumping efficiency. The patient's left ventricular ejection fraction (LVEF) of 35% indicates severe left ventricular dysfunction, which is a strong predictor of poor prognosis in heart failure patients.

The patient's New York Heart Association (NYHA) Class III classification also indicates severe symptoms of heart failure, including shortness of breath, fatigue, and limited physical activity. The presence of diabetes, peripheral vascular disease, and hypertension further exacerbate the patient's cardiovascular risk factors.

The elevated pro-BNP (brain natriuretic peptide) level of 475 ng/L is a biomarker of heart failure and indicates increased ventricular wall stress, which is consistent with the patient's symptoms and LVEF.

The patient's medications, including calcium channel blockers, beta blockers, loop diuretics, and ACE inhibitors, are standard treatments for heart failure, but in this case, they may not have been sufficient to control the patient's symptoms and prevent progression to pump failure.

The patient's laboratory results, including elevated creatinine and urea levels, suggest impaired renal function, which is common in patients with advanced heart failure. The patient's low hemoglobin level may indicate anemia, which can further contribute to fatigue and shortness of breath.

The patient's low HDL cholesterol and high LDL cholesterol levels suggest dyslipidemia, which is a risk factor for cardiovascular disease. The patient's low T3 and T4 levels, with a normal TSH level, may indicate euthyroid sick syndrome, a condition where patients with severe illness or heart failure have low thyroid hormone levels.

The presence of polymorphic ventricular extrasystoles on the ECG indicates abnormal heart rhythm, which can further contribute to the patient's risk of cardiac arrhythmias and sudden cardiac death.

In summary, the patient's advanced age, history of ischemic dilated cardiomyopathy, severe left ventricular dysfunction, and multiple comorbidities, including diabetes, peripheral vascular disease, and hypertension, have likely contributed to her outcome of pump failure death."
841,841,P0940,"Age: 79
Gender: Male 
Weight: 58 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 9.0
Total Cholesterol (mmol/L): 3,62
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 105.0
HDL (mmol/L): 0,44
Potassium (mEq/L): 5,3
LDL (mmol/L): 1,89
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 5482.0
Protein (g/L): 68
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,13
TSH (mIU/L): 2,56
Urea (mg/dL): 18,14
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of several factors. Firstly, the patient's left ventricular ejection fraction (LVEF) is severely reduced at 30%, indicating significant left ventricular dysfunction. This is a hallmark of heart failure with reduced ejection fraction (HFrEF), which is consistent with the patient's history of ischemic dilated cardiomyopathy.

The elevated Pro-BNP level of 5482.0 ng/L is a strong indicator of heart failure, as BNP is a hormone released by the heart in response to increased ventricular wall stress. The patient's symptoms and physical examination findings are also consistent with heart failure, as evidenced by the patient's NYHA Class II classification.

The patient's medication regimen, which includes ACE inhibitors, beta-blockers, and loop diuretics, is appropriate for managing heart failure, but it may not have been sufficient to control the patient's symptoms and prevent progression of the disease. The patient's low HDL level and high LDL level suggest that the statin therapy may not have been adequately effective in managing dyslipidemia, which is a risk factor for cardiovascular disease.

The patient's creatinine level of 141.0 μmol/L indicates chronic kidney disease, which is a common comorbidity in patients with heart failure. The elevated urea level of 18.14 mg/dL further supports this diagnosis.

The patient's TSH level of 2.56 mIU/L is within the normal range, which suggests that hypothyroidism is unlikely to be a contributing factor to the patient's outcome.

The presence of polymorphic ventricular extrasystoles on the ECG may indicate underlying cardiac electrical instability, which can be a risk factor for sudden cardiac death. However, the absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG makes it less likely that arrhythmia was the primary cause of death.

In summary, the patient's outcome of pump failure death is likely due to a combination of advanced heart failure, chronic kidney disease, and possibly inadequate management of dyslipidemia, which ultimately led to progression of the patient's ischemic dilated cardiomyopathy and cardiac decompensation."
842,842,P0961,"Age: 76
Gender: Female 
Weight: 93 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 134/64 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,55
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,77
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2876.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 19
TSH (mIU/L): 2,86
Urea (mg/dL): 9,82
LVEF (%): 30.0
Medications: Digoxin, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of factors. 

1.  Ischemic dilated cardiomyopathy and Myocardial Infarction (MI) history: The patient has a history of ischemic dilated cardiomyopathy and MI, which suggests that the heart muscle has been damaged due to reduced blood flow, leading to a decrease in cardiac function. This history increases the risk of heart failure.

2.  Low Left Ventricular Ejection Fraction (LVEF): The patient's LVEF is 30%, which is significantly below the normal range (50-70%). A low LVEF indicates that the heart is not pumping efficiently, leading to reduced cardiac output and increased risk of heart failure.

3.  Elevated Pro-BNP levels: The patient's Pro-BNP level is 2876.0 ng/L, which is significantly elevated. Pro-BNP is a biomarker that indicates increased ventricular wall stress, which is often seen in heart failure.

4.  Kidney function impairment: The patient's Creatinine level is 115.0 mmol/L, indicating impaired kidney function. Kidney impairment is often associated with heart failure, as the heart and kidneys are closely linked, and kidney dysfunction can contribute to the progression of heart failure.

5.  Medication regimen: Although the patient is on medications like Digoxin, Loop Diuretics, Spironolactone, and Statins, which are commonly used to manage heart failure, the patient's condition may have progressed beyond the point where these medications can effectively manage the disease.

6.  Other contributing factors: The patient's age (76), female gender, and low HDL cholesterol level (0.72 mmol/L) may also contribute to the increased risk of heart failure.

Given these factors, the patient's outcome of pump failure death is likely due to the cumulative effect of ischemic dilated cardiomyopathy, MI, low LVEF, elevated Pro-BNP levels, kidney function impairment, and other contributing factors."
843,843,P0978,"Age: 69
Gender: Male 
Weight: 106 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 34
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,55
Creatinine (mmol/L): 186.0
Gamma-glutamil transpeptidase (IU/L): 40
Glucose (mmol/L): 8,1
Hemoglobin (g/L): 118.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4
LDL (mmol/L): 2,82
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 6603.0
Protein (g/L): 67
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,22
Urea (mg/dL): 14,48
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

Given the patient's advanced age (69 years), multiple comorbidities, and severe left ventricular dysfunction (LVEF 35%), this outcome is not surprising. The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack, leading to reduced heart function. This condition is often associated with a poor prognosis.

The patient's ejection fraction (LVEF) of 35% indicates severe left ventricular dysfunction, which is a strong predictor of poor outcomes in patients with heart failure. The elevated Pro-BNP (B-type natriuretic peptide) level of 6603.0 ng/L further supports the presence of heart failure with reduced ejection fraction (HFrEF).

The patient's past medical history of myocardial infarction, hypertension, and peripheral vascular disease also increases the risk of adverse outcomes. The presence of diabetes and dyslipidemia further exacerbates the patient's cardiovascular risk profile.

The patient's laboratory results, including elevated creatinine levels (186.0 umol/L) and low hemoglobin levels (118.0 g/L), suggest underlying renal impairment and anemia, respectively, which can further compromise cardiac function.

The patient's medications, including beta blockers, loop diuretics, statins, and ACE inhibitors, are appropriate for managing heart failure and related conditions. However, the severity of the patient's symptoms and underlying conditions may have progressed to the point where these treatments were insufficient to prevent pump failure.

The presence of polymorphic ventricular extrasystoles on the ECG may indicate electrical instability, which can further contribute to the risk of arrhythmias and cardiac arrest.

In summary, the combination of advanced age, severe left ventricular dysfunction, multiple comorbidities, and laboratory abnormalities, along with the patient's medications and ECG findings, all contribute to the poor outcome of pump failure death in this patient."
844,844,P0981,"Age: 73
Gender: Male 
Weight: 63 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Other HF etiology, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 40,5
ALT or GPT (IU/L): 8.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 111.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 106.0
HDL (mmol/L): 1,73
Potassium (mEq/L): 5,1
LDL (mmol/L): 2,02
Sodium (mEq/L): 144.0
Protein (g/L): 74
T4 (ng/L): 19
TSH (mIU/L): 0,19
Urea (mg/dL): 9,48
LVEF (%): 69.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Given the patient's age (73 years) and NYHA Class II, indicating moderate symptoms of heart failure, the patient has a history of myocardial infarction, which suggests previous damage to the heart muscle. The patient's ejection fraction (LVEF) is 69%, which is below the normal range (50-70%), indicating reduced cardiac function.

The patient's total cholesterol level (4.06 mmol/L) is within the normal range, but the low HDL (1.73 mmol/L) and high LDL (2.02 mmol/L) levels may indicate a higher risk of atherosclerosis, contributing to the patient's heart failure.

The patient's serum creatinine level (111.0 mmol/L) is elevated, suggesting impaired kidney function, which is a common comorbidity in patients with heart failure. The patient's albumin level (40.5 g/L) is slightly low, which may indicate malnutrition or liver disease, but in this context, it may be a sign of chronic kidney disease.

The patient's TSH level (0.19 mIU/L) is within the normal range, indicating no thyroid dysfunction. The T4 level (19 ng/L) is also within the normal range.

The patient's medications, including angiotensin II receptor blocker, beta blockers, loop diuretics, and nitrovasodilator, are standard treatments for heart failure and are likely intended to manage symptoms and slow disease progression.

The ECG findings of monomorphic ventricular extrasystole and TPSV (paroxysmal supraventricular tachyarrhythmia) suggest arrhythmias, which may be contributing to the patient's heart failure.

Considering the patient's advanced age, reduced ejection fraction, history of myocardial infarction, and comorbidities, the patient's outcome of pump failure death is not unexpected. The combination of these factors likely contributed to the progression of heart failure, ultimately leading to cardiac pump failure and death."
845,845,P0983,"Age: 68
Gender: Male 
Weight: 90 kg
Height: 164 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 36.0
Total Cholesterol (mmol/L): 5,07
Creatinine (mmol/L): 187.0
Gamma-glutamil transpeptidase (IU/L): 61
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 154.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 5,4
LDL (mmol/L): 3,15
Sodium (mEq/L): 144.0
Protein (g/L): 70
T4 (ng/L): 15
TSH (mIU/L): 3,68
Urea (mg/dL): 12,64
LVEF (%): 21.0
Medications: Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

The patient's outcome of pump failure death can be attributed to a combination of several factors based on the provided data. 

1.  Idiopathic dilated cardiomyopathy: The patient has a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers dilate, impairing the heart's ability to pump blood effectively. This condition is a significant risk factor for heart failure and pump failure.

2.  Low LVEF (21.0%): The patient's left ventricular ejection fraction (LVEF) is severely reduced at 21.0%, indicating poor heart function. An LVEF below 35% is generally considered a sign of heart failure, and an LVEF of 21% indicates severe heart failure, which increases the risk of pump failure.

3.  Medications: Although the patient is on medications like Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, and Spironolactone, which are commonly used to manage heart failure, their effectiveness may be limited by the patient's advanced heart disease.

4.  Electrocardiogram (ECG) findings: The presence of non-sustained ventricular tachycardia (VT) and polymorphic ventricular extrasystoles on the ECG suggests arrhythmias, which can further compromise cardiac function and increase the risk of pump failure.

5.  Renal impairment: The patient's elevated creatinine level (187.0 mmol/L) indicates renal impairment, which is often associated with heart failure. The kidneys are sensitive to decreased cardiac output, and impaired kidney function can exacerbate heart failure.

6.  Hypotension: Although the patient's blood pressure is within a relatively normal range (120/80 mmHg), it may not be sufficient to meet the increased demand of a failing heart, potentially contributing to pump failure.

Considering these factors, the patient's outcome of pump failure death is likely a result of the cumulative effect of these conditions, which have compromised the heart's ability to pump blood effectively, ultimately leading to cardiac failure and death."
846,846,P0997,"Age: 72
Gender: Male 
Weight: 95 kg
Height: 159 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 40,9
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 45.0
Total Cholesterol (mmol/L): 4,76
Creatinine (mmol/L): 110.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 155.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 5,2
LDL (mmol/L): 3
Sodium (mEq/L): 137.0
Protein (g/L): 73,8
T4 (ng/L): 14
TSH (mIU/L): 1,53
Urea (mg/dL): 10,82
LVEF (%): 20.0
Medications: Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"REASONING: 

Given the patient's clinical presentation, the outcome of pump failure death can be attributed to several factors. 

Firstly, the patient has a history of ischemic dilated cardiomyopathy, which is a known cause of heart failure. The left ventricular ejection fraction (LVEF) of 20% indicates severe left ventricular dysfunction, which is a strong predictor of adverse outcomes in patients with heart failure. 

The patient's NYHA Class III classification indicates that the patient experiences symptoms of heart failure at moderate levels of physical activity, which further supports the diagnosis of heart failure. 

Additionally, the patient's laboratory results show elevated liver enzymes (ALT and AST), which may indicate liver congestion due to right-sided heart failure, a common complication of advanced heart failure. The elevated creatinine level suggests impaired renal function, which is a known complication of heart failure. 

The patient's total cholesterol level is elevated, which may contribute to the progression of atherosclerosis and worsen cardiac function. 

The presence of non-sustained ventricular tachycardia on the ECG is a marker of increased risk of sudden cardiac death, which is a common cause of mortality in patients with heart failure. 

Furthermore, the patient's medications, including loop diuretics, spironolactone, and an ACE inhibitor, are commonly used to manage heart failure symptoms and slow disease progression. However, the patient's severe left ventricular dysfunction and history of ischemic dilated cardiomyopathy may have limited the effectiveness of these medications, contributing to the patient's poor outcome. 

In conclusion, the combination of the patient's history of ischemic dilated cardiomyopathy, severe left ventricular dysfunction, elevated liver enzymes, impaired renal function, and presence of non-sustained ventricular tachycardia on the ECG, along with the limitations of his current medications, likely contributed to the patient's outcome of pump failure death."
847,847,P1023,"Age: 77
Gender: Male 
Weight: 84 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 116/79 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 177.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 5,9
LDL (mmol/L): 3,1
Sodium (mEq/L): 140.0
Protein (g/L): 78
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,36
Urea (mg/dL): 19,64
LVEF (%): 70.0
Medications: Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: The patient's outcome of pump failure death can be attributed to a combination of factors. 

1. Valvular cardiomyopathy: The patient's history of valvular cardiomyopathy suggests a pre-existing condition affecting the heart's pumping efficiency, which may have led to decreased cardiac function over time. This underlying condition increases the risk of heart failure and pump failure.

2. Decreased LVEF (70.0%): The patient's left ventricular ejection fraction (LVEF) of 70.0% indicates a reduced pumping efficiency of the left ventricle, which is a key indicator of heart failure. An LVEF below 55-60% is generally considered abnormal.

3. Elevated Creatinine (177.0 mmol/L): The elevated creatinine level suggests impaired renal function, which is a common comorbidity in patients with heart failure. This can further exacerbate the condition by reducing the kidneys' ability to remove excess fluid and electrolytes, leading to fluid overload and increased strain on the heart.

4. Medication regimen: Although the patient is on digoxin, loop diuretics, and spironolactone, which are standard medications for heart failure management, the combination and dosages may not have been sufficient to control the patient's symptoms and prevent pump failure.

5. ECG findings: The presence of ventricular extrasystoles, non-sustained ventricular tachycardia, and unknown paroxysmal supraventricular tachyarrhythmia may indicate underlying cardiac arrhythmias that can further compromise cardiac function and increase the risk of pump failure.

6. Other factors: The patient's age (77 years) and NYHA Class II classification indicate a moderate level of heart failure symptoms, which may have contributed to the development of pump failure. Additionally, the patient's low albumin level (42 g/L) may indicate malnutrition or liver disease, which can also impact cardiac function.

Considering these factors, the patient's outcome of pump failure death is a likely consequence of the cumulative effect of valvular cardiomyopathy, decreased LVEF, impaired renal function, and other comorbidities, which ultimately led to cardiac decompensation and death."
848,848,P1026,"Age: 68
Gender: Male 
Weight: 60 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 92/64 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 27
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 186.0
Gamma-glutamil transpeptidase (IU/L): 349
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 117.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 5,2
LDL (mmol/L): 2,09
Sodium (mEq/L): 134.0
Protein (g/L): 51
T3 (pg/dL): 0,04
T4 (ng/L): 15
TSH (mIU/L): 9,94
Urea (mg/dL): 25,79
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"REASONING: 

Based on the provided patient data, the patient's outcome of pump failure death can be attributed to several factors. 

1. Severe Left Ventricular Dysfunction: The patient has a left ventricular ejection fraction (LVEF) of 30%, indicating severe left ventricular dysfunction, which is a hallmark of heart failure. This suggests that the patient's heart is not pumping efficiently, leading to a buildup of fluid in the lungs and other parts of the body.

2. Reduced Cardiac Output: The patient's blood pressure is 92/64 mmHg, which is lower than normal, indicating reduced cardiac output. This further supports the notion that the patient's heart is not pumping effectively.

3. Electrocardiogram (ECG) Findings: The presence of non-sustained ventricular tachycardia and ventricular extrasystoles on the ECG suggests that the patient has arrhythmias, which can further compromise cardiac function and contribute to pump failure.

4. Medications: Although the patient is on beta blockers, loop diuretics, and spironolactone, these medications may not be sufficient to manage the patient's condition, given the severity of the left ventricular dysfunction and arrhythmias.

5. Comorbidities: The patient has idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge, leading to poor heart function. The presence of hypertension further exacerbates cardiac strain.

6. Laboratory Results: Elevated creatinine levels (186.0 mmol/L) indicate renal dysfunction, which can be a consequence of heart failure. The elevated gamma-glutamil transpeptidase (GGT) levels suggest liver dysfunction, which can also contribute to the development of heart failure.

7. Malnutrition: The patient's albumin level is low (27 g/L), indicating malnutrition, which can compromise the body's ability to recover from illness and surgery.

8. Electrolyte Imbalance: The patient's potassium level is slightly elevated (5.2 mEq/L), which can contribute to cardiac arrhythmias and further compromise cardiac function.

Considering these factors, the patient's outcome of pump failure death is likely due to a combination of severe left ventricular dysfunction, arrhythmias, and comorbidities, which ultimately led to cardiac decompensation and death."
